<SEC-DOCUMENT>0001628280-24-015671.txt : 20240411
<SEC-HEADER>0001628280-24-015671.hdr.sgml : 20240411
<ACCEPTANCE-DATETIME>20240410193749
ACCESSION NUMBER:		0001628280-24-015671
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20240411
DATE AS OF CHANGE:		20240410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LENZ Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001815776
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				844867570
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278393
		FILM NUMBER:		24836880

	BUSINESS ADDRESS:	
		STREET 1:		445 MARINE VIEW AVE SUITE 320
		CITY:			DEL MAR
		STATE:			CA
		ZIP:			92014
		BUSINESS PHONE:		858-925-7000

	MAIL ADDRESS:	
		STREET 1:		445 MARINE VIEW AVE SUITE 320
		CITY:			DEL MAR
		STATE:			CA
		ZIP:			92014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Graphite Bio, Inc.
		DATE OF NAME CHANGE:	20210312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Integral Medicines, Inc.
		DATE OF NAME CHANGE:	20200622
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>lenztherapeutics424b3.htm
<DESCRIPTION>424B3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1421"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROSPECTUS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filed Pursuant to Rule 424(b)(3)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registration Statement No. 333-278393</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">1,297,411 Shares of Common Stock </font></div><div style="text-align:center"><img alt="lenztherapeuticslogo1a.jpg" src="lenztherapeuticslogo1a.jpg" style="height:74px;margin-bottom:5pt;vertical-align:text-bottom;width:288px"></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.314%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a &#8220;selling securityholder&#8221; and, collectively, the &#8220;selling securityholders&#8221;) of 1,297,411 shares of common stock, par value $0.00001 per share (the &#8220;Common Stock&#8221;) issued in the PIPE Financing. This prospectus also covers any additional securities that may become issuable by reason of stock splits, stock dividends or other similar transactions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are registering the offer and sale of these securities to satisfy certain registration rights we have granted. We will not receive any of the proceeds from the sale of the securities by the selling securityholders. We will pay the expenses associated with registering the sales by the selling securityholders, as described in more detail in the section titled &#8220;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1448" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Proceeds</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; appearing elsewhere in this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selling securityholders may sell the securities described in this prospectus in a number of different ways and at varying prices. We provide more information about how the selling securityholders may sell their securities in the section titled &#8220;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1481" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Plan of Distribution</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; appearing elsewhere in this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selling securityholders may sell any, all or none of the securities and we do not know when or in what amount the selling securityholders may sell their securities hereunder following the effective date of this registration statement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Stock is listed on The Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;LENZ.&#8221; On April 10, 2024, the last quoted sale price for our Common Stock as reported on Nasdaq was $21.03.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for future filings.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in the section titled &#8220;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2220" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factors</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221; beginning on page&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2220" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">6</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> of this prospectus. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">You should rely only on the information contained in this prospectus or any prospectus supplement or amendment hereto. We have not authorized anyone to provide you with different information. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neither the Securities Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.314%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The date of this prospectus is April 10, 2024.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1424"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1427" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">About This Prospectus</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1427" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ii</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1430" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Market and Industry Data</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1430" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ii</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1433" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trademarks</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1433" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ii</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2748" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Prospectus Summary</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2748" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2220" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Risk Factors</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2220" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1445" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cautionary Note Regarding Forward-Looking Statements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1445" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1448" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Use of Proceeds</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1448" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1451" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Market Price of and Dividends on the Registrant&#8217;s Common Equity and Related Stockholder Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1451" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">64</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1189" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Unaudited Pro Forma Condensed Combined Financials</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1189" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">65</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1399" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1399" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">76</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2727" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Business</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2727" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">89</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1463" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Management</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1463" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">120</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1466" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Executive Compensation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1466" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">127</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1469" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Relationships, Related Party and Other Transactions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1469" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">149</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1472" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Principal Securityholders</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1472" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">154</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1475" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Selling Securityholders</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1475" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">156</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1478" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description of Securities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1478" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">158</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1481" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Plan of Distribution</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1481" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">161</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1484" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Matters</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1484" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">163</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1487" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Experts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1487" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">163</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1490" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Where You Can Find Additional Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1490" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">164</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_872" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Index to Financial Statements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_872" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_872" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should rely only on the information contained in this prospectus or in any free writing prospectus prepared by us or on our behalf. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1427"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABOUT THIS PROSPECTUS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus is part of a registration statement on Form&#160;S-1 that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the selling securityholders hereunder may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such selling securityholders of the securities offered by them described in this prospectus. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither we nor the selling securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the selling securityholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the selling securityholders will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Where You Can Find Additional Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1430"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET AND INDUSTRY DATA</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained the industry and market data used throughout this prospectus from our own internal estimates and research, as well as from independent market research, industry and general publications and surveys, governmental agencies, publicly available information and research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In addition, while we believe the industry and market data included in this prospectus is reliable and based on reasonable assumptions, such data involve material risks and other uncertainties and are subject to change based on various factors, including those discussed in the section entitled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1433"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRADEMARKS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This document contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the&#160;&#174;&#160;or&#160;TM&#160;symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of it by, any other companies.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_2748"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS SUMMARY </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This summary highlights information contained in greater detail elsewhere in this prospectus. This summary is not complete and does not contain all of the information you should consider in making your investment decision. You should read the entire prospectus carefully before making an investment in our Common Stock. You should carefully consider, among other things, our consolidated financial statements and the related notes and the sections titled &#8220;Risk Factors,&#8221; &#8220;Business,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this prospectus. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Our initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45. In the United States, the estimated addressable population who suffer from this condition, known as presbyopes, is 128&#160;million, almost four times the number of individuals suffering from dry eye disease and three times the number of individuals suffering from childhood myopia, macular degeneration, diabetic retinopathy and glaucoma combined. We believe that a once-daily pharmacological eye drop that can effectively and safely improve near vision throughout the full workday, without the need for reading glasses, will be a highly attractive commercial product with an estimated U.S. market opportunity in excess of $3&#160;billion. It is our goal to develop and commercialize such a product, and we have assembled an executive team with extensive clinical and commercial experience to execute this goal and become the category leader.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate LNZ100 is a preservative-free,&#160;single-use,&#160;once-daily eye drop containing aceclidine. We believe our product candidate is differentiated based on rapid onset, degree and duration of near vision improvement, as well as its ability to be used across the full age range of presbyopes, from their&#160;mid-40s&#160;to well into their&#160;mid-70s,&#160;as well as the broadest refractive range. Aceclidine&#8217;s pupil-selective mechanism of action was demonstrated in our clinical trials where near vision improved while avoiding blurry distance vision. Our product candidate was well-tolerated in clinical trials, and its active ingredient aceclidine has a favorable tolerability profile that have been well-established empirically. LNZ100 has patent protection until 2039 in the United States, at a minimum, due to a robust intellectual property portfolio underpinned by issued patents. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the safety and efficacy trials (&#8220;CLARITY 1 and 2&#8221;) of our Phase 3 study, LNZ100 achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (&#8220;BCDVA&#8221;) at near, without losing one or more lines in distance visual acuity. In the vehicle-controlled CLARITY 2 trial, the day 1 results showed (all p&#60;0.0001)&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Rapid onset</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; 71% achieved three-lines or greater improvement at 30 minutes.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Primary endpoint</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; 71% achieved three-lines or greater improvement at 3 hours. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Long duration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  40% achieved three-lines or greater improvement at 10 hours.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Near vision improvement was reproducible and consistent across both CLARITY 1 and 2 throughout the four-week study periods. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNZ100 was well-tolerated with no serious treatment-related adverse events observed in the over 30,000 treatment days including the six-week safety study period in CLARITY 1 and 2 and the six-month period in the CLARITY 3 Phase 3 long-term safety trial (collectively, the &#8220;CLARITY study&#8221;). For more details, see the section entitled &#8220;CLARITY Phase 3 Clinical Trials (the &#8220;CLARITY Study&#8221;)&#8221; in this prospectus in the section titled &#8220;Business&#8221; beginning on page </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2727" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">89</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other product candidate LNZ101, a preservative-free eye drop containing aceclidine and brimonidine, showed similar results, including achieving primary and secondary endpoints in both CLARITY 1 and 2, but did not show superiority to LNZ100. Based on these results, we selected LNZ100 as our lead product candidate, for which we plan to submit a New Drug Application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in mid-2024 with a launch target date in the&#160;second half of 2025. We believe that LNZ100, if approved, could be the </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first aceclidine-based product approved by the FDA and would then be eligible for five years of new chemical entity (&#8220;NCE&#8221;) exclusivity in the United&#160;States.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is estimated that there are 1.8&#160;billion presbyopes globally and 128&#160;million presbyopes in the United States. As people age, the crystalline lens in their eyes gradually hardens, resulting in a loss of lens elasticity that reduces the ability of the lens to increase its curvature and refractive power to focus incoming light for near vision onto the retina, known as accommodation. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their&#160;mid-40s,&#160;when reading glasses or other corrective aids are suddenly necessary to read text or conduct&#160;close-up&#160;work. Presbyopia is typically self-diagnosed and self-managed with&#160;over-the-counter&#160;reading glasses, or managed, after evaluation by an eye care professional (ECP), with prescription reading or bifocal glasses or multifocal contact lenses. Currently, the only approved and marketed pharmaceutical treatment for presbyopia is marketed by AbbVie under the brand Vuity.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on data collected in a third-party study commissioned by us in early 2023 that is further described in the section &#8220;Market Opportunity&#8221; in this prospectus in the section titled &#8220;Business&#8221; beginning on page </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2727" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">89</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we found that presbyopes have high willingness to use a daily prescription eye drop that improves their near vision throughout the full workday. We expect that there will be a wide range of presbyopes that will be interested in using the eye drops at least four times a week. The large initial demand seen for Vuity during its launch in late 2021 and early 2022 corroborates the market demand for a pharmaceutical option for the treatment of presbyopia. However, despite a promising initial launch, Vuity&#8217;s user uptake has been limited by reportedly lower-than-expected efficacy and duration of effect across users. Additionally, Vuity use is associated with some side effects, including retinal tears and detachments, induced by the stimulation of the ciliary muscle. These limitations on efficacy and safety subsequently resulted in lower than anticipated prescription refill rates and a label amendment reflecting the risk of retinal tears and detachment specifically associated with Vuity. We believe that our once-daily eye drop, if approved, could become the leading brand for presbyopes, by improving near vision throughout the full workday.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate LNZ100 is formulated with aceclidine, a miotic, and designed to achieve optimal pupil diameter without impacting distance vision, a key limitation of other miotics. Miotics are compounds that cause pupil constriction, or miosis, creating a pinhole effect that enables better focus of incoming light from near objects onto the retina. Research has shown that a pupil diameter below two millimeters (2 mm) is optimal for presbyopia treatment and results in clinically meaningful improvement in near vision. Unlike other miotics such as pilocarpine and carbachol, aceclidine&#8217;s mechanism of action is pupil-selective, meaning it can activate the iris sphincter muscle and cause miosis of the pupil to a diameter below 2 mm without overstimulating the ciliary muscles that can cause a myopic shift and impair distance vision. As a result, aceclidine does not require any remaining accommodation to improve near vision, broadening its benefits to older presbyopes whose lens has lost this capacity. Therefore, we expect that users may be able to benefit from treatment even as they age from&#160;mid-40s&#160;to well into their&#160;mid-70s&#160;and across a broader range of refractive errors, as demonstrated in clinical testing to date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While aceclidine is new to the United States, it has a long-established history outside the United States having been approved in Europe since the 1970s for the treatment of glaucoma, and marketed by Merck under the brand Glaucostat, at higher concentrations than in LENZ&#8217;s product candidates and up to four times a day. Given the known favorable tolerability profile of the active ingredient, which has been used for decades, and the unique mechanism of action of aceclidine, we believe LNZ100 has the potential to treat the broadest population of presbyopes and become the category leader. Based on the positive Phase 3 topline results, we selected LNZ100 as our lead product candidate, for which we plans to submit a New Drug Application (NDA) in mid-2024, with a launch target date in the&#160;second half of 2025. If approved, we believe that LNZ100 could be the first aceclidine-based product approved by the U.S. Food and Drug Administration (FDA) and would then be eligible for five years of new chemical entity (NCE) exclusivity in the United&#160;States.Given our goal to develop and commercialize the leading, once-daily eye drop for presbyopia that can effectively and safely improve near vision throughout the full workday, we continue to build a robust commercial strategy in the United States to be launch-ready upon expected timing of FDA approval. We retain the flexibility to not only seek commercialization of LNZ100, but to also remain opportunistic in&#160;developing,&#160;in-licensing&#160;or partnering other products or product candidates to further leverage our commercial infrastructure to drive growth and operating leverage. LNZ100 has patent protection until 2039, at a minimum, in the United States due to a robust intellectual property portfolio underpinned by issued patents. As of March 21, 2024, we had at least 18 issued U.S. patents, at least 25 issued patents outside the United States and at least 74 pending </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applications globally. If approved, we believe that LNZ100 could be the first&#160;FDA-approved&#160;aceclidine-based product and would then be eligible for five years of NCE exclusivity in the United States. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute our vision, we have assembled a team with extensive experience building successful life science and consumer product companies. Our team has helped launch and commercialize over a dozen ophthalmic products and therapies, including Acuvue, Alphagan P, Combigan, Dailies AquaComfort Plus, Durysta, Latisse, Lumigan, Pred Forte, Refresh, Restasis, Truetear, and Vuity, as well as major consumer-focused brands such as Botox, Herbalife and&#160;Ray-Ban.&#160;Members of our management team have held senior positions at Alcon, Allergan, Alvotech, Avanir, Bausch + Lomb, Herbalife, Hospira, Johnson&#160;&#38; Johnson, Pfenex, Pfizer, VISX and others. We have also engaged a strong team of medical advisors across the ophthalmology and optometry fields. Our team is further supported by a strong group of investors that share our commitment to helping the millions of people experiencing symptoms of presbyopia in the United States and globally.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investor relations website is located at https&#58;&#47;&#47;ir.lenz-tx.com&#47;. We use our investor relations website to post important information for investors, including news releases, analyst presentations, and supplemental financial information, and as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor our investor relations website, in addition to following press releases, SEC filings and public conference calls and webcasts. We also make available, free of charge, on our investor relations website under &#8220;SEC Filings,&#8221; our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to these reports as soon as reasonably practicable after electronically filing or furnishing those reports to the SEC. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE INFORMATION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2024 (the &#8220;Closing Date&#8221;), LENZ Therapeutics, Inc., a Delaware corporation (previously named Graphite Bio, Inc., a Delaware corporation and our predecessor company (&#8220;Graphite&#8221;)), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of November 14, 2023 (the &#8220;Merger Agreement&#8221;), by and among Graphite, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Graphite (&#8220;Generate Merger Sub&#8221;) and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation (&#8220;LENZ OpCo&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, on the Closing Date, (i) Graphite effected a reverse stock split of Graphite&#8217;s issued common stock at a ratio of 1&#58;7, (ii) Graphite changed its name to &#8220;LENZ Therapeutics, Inc.&#8221;, and (iii) Generate Merger Sub merged with and into LENZ OpCo (the &#8220;Merger&#8221;), with LENZ OpCo as the surviving company in the Merger and, after giving effect to such Merger, LENZ OpCo becoming a wholly-owned subsidiary of LENZ Therapeutics, Inc. (together with its consolidated subsidiary, &#8220;New LENZ&#8221; or &#8220;LENZ&#8221;). As of the open of trading on March 22, 2024, the Common Stock of the Company, formerly those of Graphite, began trading on The Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;LENZ.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 445 Marine View Ave., Ste. #320, Del Mar, California 92014, and our telephone number is (858) 925-7000. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is https&#58;&#47;&#47;lenz-tx.com&#47;. The information on, or that can be accessed through, our website is not part of this prospectus, and you should not consider information contained on our website in deciding whether to purchase shares of our Common Stock. We have included our website address in this prospectus solely as an inactive textual reference.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the LENZ logo and other marks as trademarks in the United States and other countries. This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without a trademark symbol, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). We will remain an emerging growth company until the earliest to occur of&#58; the last day of the fiscal year in which we have more than $1.235&#160;billion in annual revenues&#59; the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700&#160;million of equity securities held by non-affiliates&#59; the issuance, in any three-year period, by us of more than $1.0&#160;billion in non-convertible debt securities&#59; and the last day of the fiscal year ending after the fifth anniversary of Graphite&#8217;s initial public offering (i.e., December 31, 2026). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with certain other public companies difficult or impossible because of the potential differences in accounting standards used. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may continue to be a smaller reporting company in any given year if either (i) the market value of our stock held by non-affiliates is less than $250 million as of June 30th in the most recently completed fiscal year, or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million as of June 30th in the most recently completed fiscal year</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless expressly indicated or the context requires otherwise, the terms &#8220;LENZ,&#8221; &#8220;New LENZ,&#8221; the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this prospectus refer to LENZ Therapeutics, Inc., the parent entity formerly named Graphite Bio, Inc., after giving effect to the Merger, and as renamed LENZ Therapeutics, Inc., and where appropriate, our wholly-owned subsidiaries (including LENZ OpCo). </font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1439"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 36.00pt 36.00pt"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Offering</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Common Stock Offered Hereunder</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are registering the resale by the selling securityholders named in this prospectus, or their permitted transferees, of an aggregate of 1,297,411 shares of Common Stock issued in the PIPE Financing.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Use of Proceeds</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We will not receive any proceeds from the sale of our shares of common stock offered by the selling securityholders under this prospectus (the &#8220;Securities&#8221;). See the section titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; appearing elsewhere in this prospectus for more information.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Outstanding</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,534,458 shares of Common Stock as of March 21, 2024.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See the section titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our Common Stock.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq symbol</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;LENZ&#8221; for our Common Stock.</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of Common Stock outstanding is based on 25,534,458 shares of Common Stock as of March 21, 2024 and excludes the following, in each case as of March 21, 2024&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">164,676 shares of our Common Stock issuable upon the exercise of warrants to purchase shares of our Common Stock outstanding as of March 21, 2024, with an exercise price of $10.64 per share&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,590,018 shares of our Common Stock issuable upon the exercise of outstanding options under the LENZ OpCo 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), which were assumed by the Company in connection with the Merger, with a weighted average exercise price of $4.24 per share&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">15,791 shares of our Common Stock issuable upon the exercise of outstanding options under the LENZ Therapeutics, Inc. (f&#47;k&#47;a Graphite Bio, Inc.) 2020 Stock Option and Grant Plan, with a weighted average exercise price of $1.42 per share&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">343,068 shares of our Common Stock issuable upon the exercise of outstanding options under the LENZ Therapeutics, Inc. (f&#47;k&#47;a Graphite Bio, Inc.) 2021 Stock Option and Incentive Plan, with a weighted average exercise price of $10.84 per share&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,325,800 shares of our Common Stock issuable upon the exercise of outstanding options under the LENZ Therapeutics, Inc. 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), with an exercise price of $15.05 per share&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,686,148 shares of our Common Stock reserved for future issuance under our 2024 Plan, as well as any automatic increases in the number of shares of Common Stock reserved for future issuance under this plan&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">250,995 shares of our Common Stock reserved for future issuance under our 2024 Employee Stock Purchase Plan (the &#8220;2024 ESPP&#8221;), as well as any automatic increases in the number of shares of Common Stock reserved for future issuance under this plan.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_2220"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our Common Stock involves a high degree of risk. In addition to the risk and uncertainties described under the section titled &#8220;Cautionary Note Regarding Forward-Looking Statements,&#8221; you should consider carefully the risks and uncertainties described below, together with all of the other information contained in this prospectus, including our consolidated financial statements and related notes, before deciding to invest in our Common Stock. If any of the following events occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of our Common Stock could decline, and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business or results of operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company, as more fully described below. The principal factors and uncertainties that make investing in our company risky include, among others&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a late-stage biopharmaceutical company with limited operating history. We have incurred significant losses and negative cash flows from operations since our formation, and we anticipate that we will continue to incur losses for the foreseeable future. We have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business depends entirely on the development and commercialization of LNZ100, and we do not have additional product candidates in our current development pipeline. If we are unable to successfully complete our clinical development program for LNZ100 and obtain the marketing approvals necessary to commercialize LNZ100, or experience significant delays in doing so, or if after obtaining marketing approvals, we fail to commercialize LNZ100, our business will be materially harmed. We currently generate no revenues from sales of any products and may never generate revenue or be profitable.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. The outcome of preclinical testing and earlier clinical trials may not be predictive of the success of later clinical trials. The results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidate. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if LNZ100 or any other product candidate receives marketing approval, they may fail to achieve market acceptance by ECPs and patients, and the market opportunity for these products, if approved, may be smaller than we estimate. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates on acceptable terms, we may be unable to successfully commercialize our product candidates that obtain regulatory approval.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain sufficient intellectual property protection for our technology and products and product candidates we may develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully develop and, if approved, commercialize our product candidates may be adversely affected. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted. Our product candidates may, if approved, also face competition from existing branded, generic and off-label products.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We contract with third parties for the manufacture of our product candidates for our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have relied, and expect to continue to rely on third parties, including independent clinical investigators and CROs, to conduct, supervise and monitor certain aspects of our clinical trials and any future preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An active trading market for our common stock may never develop or be sustained.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Limited Operating History, Development and Commercialization of Our Product Candidates </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a late-stage biopharmaceutical company with limited operating history. We have incurred significant losses and negative cash flows from operations since our formation, and we anticipate that we will continue to incur losses for the foreseeable future. We have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage biopharmaceutical company with limited operating history. Our operations to date have been limited to organizing the company, raising capital, developing our product candidates and beginning to prepare for commercialization, including building our commercial strategy, supply chain and distribution network. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. If LNZ100 is approved by the FDA, we will need to further expand our commercialization infrastructure to successfully launch such product. We have not yet demonstrated our ability to successfully obtain marketing approvals, complete arrangements for third parties to manufacture the commercial-scale product on our behalf, or conduct sales and marketing activities necessary for successful product commercialization, and we may not be successful in such a transition. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any products approved for sale, we have not generated any revenue from the sale of products, we have incurred significant net losses since the company&#8217;s formation and have funded our operations primarily from the sale and issuance of redeemable convertible preferred stock, and recently the Merger and PIPE Financing. Our net losses were $10.8 million and $70.0 million for the years ended December 31, 2022 and 2023, respectively. As of December 31, 2023, we had an accumulated deficit of $95.2 million. Additionally, the net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indicator of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue incurring significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional clinical and other studies for our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change or add additional manufacturers or suppliers, some of which may require additional permits or other governmental approvals&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify, acquire, and develop additional product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates and technologies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make milestone or other payments in connection with the development or approval of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, protect, and expand our intellectual property portfolio&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter issues with any of the above.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and ability to achieve and maintain profitability. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business depends entirely on the development and commercialization of LNZ100, and we do not have additional product candidates in our current development pipeline. If we are unable to successfully complete our clinical development program for LNZ100 and obtain the marketing approvals necessary to commercialize LNZ100, or experience significant delays in doing so, or if after obtaining marketing approvals, we fail to commercialize LNZ100, our business will be materially harmed. We currently generate no revenues from sales of any products and may never generate revenue or be profitable.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted a significant portion of our financial resources and business efforts to the development of LNZ100 and LNZ101, both of which include aceclidine as an active ingredient, for the treatment of presbyopia. Based on the results of our Phase 3 CLARITY trials, we selected LNZ100 as our lead product candidate, for which we plan to submit a New Drug Application (&#8220;NDA&#8221;) in mid-2024. We do not currently have other product candidates in our development pipeline, and our success depends entirely on LNZ100. We have no products approved for commercial sale and do not anticipate generating any revenue unless LNZ100 receives the regulatory approval necessary for commercialization. Our ability to generate revenues from product sales will depend on us obtaining marketing approval for and commercializing LNZ100, and we cannot accurately predict when or if LNZ100 will be determined by the Food and Drug Administration (&#8220;FDA&#8221;) to be effective in humans for the proposed indication or whether it will receive marketing approval. Our ability to generate revenue and achieve profitability also depends significantly on our ability, or any future collaborator&#8217;s ability, to achieve a number of objectives, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful and timely completion of clinical development of  LNZ100 and any other future product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effective investigational new drug applications (&#8220;INDs&#8221;) from the FDA or comparable foreign applications that allow the commencement of our clinical trials or future clinical trials for such product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of clinical studies in compliance with the FDA&#8217;s current Good Clinical Practices (&#8220;GCPs&#8221;) with positive results&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse events experienced with any of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining relationships with contract research organizations (&#8220;CROs&#8221;) and clinical sites for the clinical development, both in the United States and internationally, of our product candidates, including LNZ100 and any other future product candidates&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development for their intended uses&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making any required post-marketing approval commitments to applicable regulatory authorities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate products and services, in both amount and quality, to support clinical development and meet the market demand for product candidates that we develop, if approved&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether in-house or with one or more collaborators&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining compliance with regulatory requirements, including the FDA&#8217;s current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile both prior to and following any marketing approval of our product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercial acceptance of our product candidates by patients and the medical community&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, assessing and developing new product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting our rights in our intellectual property portfolio&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defending against third-party interference or infringement claims, if any&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining favorable terms in any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our existing or acquired product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing therapies and technological and market developments&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring and retaining qualified personnel.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never be successful in achieving our objectives and, even if we are successful, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we fail to become and remain profitable, the value of our company could decrease. This could impair our ability to maintain or expand our research and development efforts, raise necessary additional capital, grow our business, and continue our operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current product candidate, LNZ100, is based on an active pharmaceutical ingredient (&#8220;API&#8221;) that has been previously approved and marketed outside of the United States, which exposes us to additional risks. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The API in LNZ100, aceclidine, was previously approved by the European Medicines Agency (&#8220;EMA&#8221;) as a therapeutic for glaucoma by decreasing interocular pressure and had been marketed in more than 12 countries throughout Europe. Although we expect to obtain new chemical entity (&#8220;NCE&#8221;) exclusivity in the United States if we are the first to obtain FDA approval of a product candidate containing aceclidine as an API, such determination is only made at the time of approval. Accordingly, no regulatory authority, including the FDA, has established or provided any confirmation that our product candidate will in fact be regarded as an NCE, and there can be no assurance that LNZ100 will be the first product containing aceclidine to be approved by the FDA. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we anticipate that manufacturers in Europe could make and sell aceclidine in generic form in the future, which could compete with our ability to commercialize in Europe. Previously, aceclidine was used as a treatment for glaucoma at concentrations higher than the concentrations used in LNZ100. It is possible that if aceclidine is used again in Europe, it could be used at the wrong dosage and increase the possibility that patients experience adverse side effects related to aceclidine. Any adverse side effects that arise from the use of any form of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aceclidine could prevent or inhibit the commercialization of LNZ100 and seriously harm our business. Furthermore, if manufacturer demand for aceclidine increases in the future, particularly as a result of generic forms of aceclidine becoming available, we may not be able to continue to obtain aceclidine on commercially reasonable terms, which would seriously harm our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any approved or commercial drug product having the same API, including off-label use of such approved drug products, such as Glaucostat and other generic forms of the API, could reduce the profitability of LNZ100 even if we obtain marketing approval from FDA or regulatory authorities outside of the United States. Any commercially available drug product having the same API could prevent us from or limit our ability to commercialize or to establish market share in the same jurisdiction even if we were to obtain marketing authorization in such jurisdiction.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. The outcome of preclinical testing and earlier clinical trials may not be predictive of the success of later clinical trials. The results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidate. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development of pharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized. The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Product candidates in later stages of clinical trials may fail to show the desired safety, efficacy and durability profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Failure can occur at any time during the clinical trial process. Even if our ongoing and any future clinical trials are completed as planned, we cannot be certain that our results will support the safety and effectiveness of our product candidates for their targeted indications or support continued clinical development of such product candidates. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy data or meet endpoints despite having progressed through preclinical and clinical studies. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of our preclinical and clinical studies of product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of subjects may not be predictive of those obtained in another. In some instances, there can be significant variability in safety, efficacy or durability results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. For example, although we have sought and received feedback from FDA on the designs of our clinical trials, FDA may ultimately disagree that our Phase 3 trials support approval for LNZ100. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available, to conduct additional trials in support of potential approval of LNZ100 or any future product candidates. Even if we secure regulatory approval for any of our product candidates, the terms of such approval may limit the scope and use of the product candidate, which may also limit its commercial potential. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also experience issues in conducting our clinical trials that would delay or prevent us from satisfying the applicable requirements of the FDA and other regulatory authorities, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation of clinical trials for any future product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement with the FDA or other regulatory authorities as to the design or implementation of our clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining regulatory authorization to commence a clinical trial&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching, or failure to reach, agreement on acceptable terms with clinical trial sites or prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining institutional review board (&#8220;IRB&#8221;) approval at each trial site&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruiting suitable patients to participate in a clinical trial&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">having patients complete a clinical trial or return for post-treatment follow-up&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspections of clinical trial sites or operations by applicable regulatory authorities, or the imposition of a clinical hold&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites, CROs or other third parties deviating from trial protocol or dropping out of a trial&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to perform in accordance with applicable regulatory requirements, including the FDA&#8217;s GCP requirements, or applicable regulatory requirements in other countries&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing patient safety concerns that arise during the course of a trial, including occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adding a sufficient number of clinical trial sites&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing sufficient quantities of product candidate for use in clinical trials&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspensions or terminations by IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board (&#8220;DSMB&#8221;), for such trial or by the FDA or other regulatory authorities due to a number of factors, including those described above.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have completed our Phase 3 CLARITY trials, we may experience numerous unforeseen events during, or as a result of, any future clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements or guidance, or receiving feedback from regulatory authorities, that requires us to modify the design of our clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon development programs&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate and we may not have funds to cover the costs&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of LNZ100 beyond our Phase 3 CLARITY trials, if we are unable to successfully complete clinical trials of any future product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur unplanned costs&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for LNZ100 or any future product candidates or not obtain marketing approval at all&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain marketing approval in some countries and not in others&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain marketing approval for indications or patient populations that are not as broad as intended or desired&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings or a Risk Evaluation Mitigation Strategy (&#8220;REMS&#8221;)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to changes in the way the product is administered&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have regulatory authorities withdraw or suspend their approval of the product.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that any future clinical trials will be successful. For example, use of LNZ100 requires the patient to follow a prescribed technique to administer the eye drops. In our Phase 2 clinical trial, patients were dosed by clinical staff in the office while in our Phase 3 clinical trials the product was self-administered by patients on the vast majority of days. While under our current trial design patients are only measured for efficacy on days they are in the office during the trial, during which they will be dosed by clinical staff, failure to properly administer the eye drops by the patient or inappropriate technique demonstration by the eye care professional (&#8220;ECP&#8221;), may adversely affect the outcome of LNZ100 in demonstrating safety or efficacy in one or more clinical trials. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if LNZ100 or any other product candidate receives marketing approval, they may fail to achieve market acceptance by ECPs and patients, and the market opportunity for these products, if approved, may be smaller than we estimate. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If LNZ100 or any other product candidate we develop receives marketing approval, they may nonetheless fail to gain sufficient market acceptance by ECPs, patients, and others in the medical community. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses. LNZ100, if approved, would require a prescription by an ECP, which would require a visit to an ECP, which can be perceived to be more burdensome to an individual who has never previously visited an ECP and limit the number of prescriptions that are written. Some ECPs may also be deterred by the potential loss of revenue from the sale of contact lenses and glasses or feel uncomfortable prescribing a new product.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there is only one pharmacologic option for presbyopia marketed by AbbVie under the brand Vuity. Despite an initial strong commercial launch with over 120,000 prescriptions filled in 2022, the refill rate for Vuity has lagged due to a variety of reasons. Based on a survey of 40 ECPs in a study we commissioned, the majority of ECPs reported that the barrier to Vuity adoption was that the product either did not work or did not work long enough. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional survey of 18 optometrists indicated that 66% of their patients did not see duration past four hours despite one of the Vuity clinical trial results showing some effectiveness to the sixth hour. While the reported patient experience at three hours post-treatment aligns with the primary endpoint of Vuity efficacy at three hours in both Phase 3 trials, the limited functional benefit of Vuity at and beyond three hours was reportedly not sufficient to drive continued usage by patients. In fact, the ECPs and their patients identified both the low rate of effectiveness and the short duration of effectiveness as the key factors for discontinuing use. Because Vuity&#8217;s clinical success did not translate to commercial success, it is possible that prior users of Vuity may be reluctant to try another miotic as a result of their negative experiences with Vuity. Similarly, even if we believe that the clinical data supporting LNZ100 may offer advantages over Vuity, the products have not been evaluated head-to-head, and LNZ100 may not, in fact, provide meaningful advantages resulting in greater adoption or acceptance by ECPs and patients, even if LNZ100 obtains marketing authorization.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Vuity is marketed by AbbVie, a much larger pharmaceutical company with established brand recognition. As a result, even if LNZ100 demonstrates promising or superior clinical results, including the treatment of presbyopia, it is possible that ECPs may continue to rely on these treatments rather than LNZ100 or any other product candidate we develop, even if approved for marketing by the FDA. In addition, if generic versions of any products that compete with any of our product candidates are approved for marketing by the FDA, they would likely be offered at a substantially lower price than we expect to offer for our product candidates, if approved. As a result, ECPs, patients and others may choose to rely on such products rather than our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If LNZ100 or any other product candidate does not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of LNZ100 or any other product candidate that we develop, if approved for commercial sale, will depend on a number of factors, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages of our product candidates compared to alternative treatments, including the existing standard of care&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer products for sale at competitive prices, particularly in light of the lower cost of alternative treatments&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which the product is approved&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of ECPs to prescribe these therapies&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of our marketing and distribution support&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of competitive products&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for our competitors to limit our access to the market through anti-competitive contracts or other arrangements&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assessment of the potential market opportunity for LNZ100 and other product candidates is based on industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties, some of which we commissioned. Industry publications and third-party research, surveys and studies generally indicate that our information has been obtained from sources believed to be reliable, although we do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and fail to accurately reflect market opportunities. Further, we have commissioned a number of market studies that are specific to us and to our product candidates and used the results of these studies to help assess our market opportunity. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for LNZ100 or any other product candidates we may develop may be smaller than we expect, and as a result our product revenue may be limited and we may be more difficult for us to achieve or maintain profitability.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, initial, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, preliminary or top-line data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their condition. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, preliminary and top-line data should be viewed with caution until the final data are available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and could have a material adverse effect on the success of our business. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, results of operations, prospects or financial condition. Further, disclosure of interim, top-line or preliminary data by us or by our competitors could result in volatility in the price of our common stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment and&#47;or retention of subjects in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. While we have completed our three Phase 3 clinical trials for LNZ100, if we are required to conduct additional trials, we may not be able to initiate or continue such clinical trials if we are unable to locate and enroll a sufficient number of subjects to participate in these trials to such trial&#8217;s conclusion as required by the FDA, EMA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment may be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and subjects who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment for any of our future clinical trials may be affected by other factors, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">size and nature of the patient population, and process for identifying patients&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">severity and difficulty of diagnosing the condition under investigation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability and efficacy of approved drugs and other competing therapeutic candidates for the condition under investigation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility and exclusion criteria for the trial in question as defined in the protocol&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the clinical trial&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived risks and benefits of the product candidate under study&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ECPs&#8217; and participants&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efforts to facilitate timely enrollment in clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">participant referral practices of ECPs&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to monitor participants adequately during and after treatment&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical trial sites for prospective trial subjects&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued enrollment of prospective subjects by clinical trial sites&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that subjects enrolled in clinical trials will drop out of the trials before completion.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of subjects for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance. Even if we are able to enroll a sufficient number of subjects for our clinical trials, we may have difficulty maintaining enrollment of such subjects in our clinical trials.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted. Our product candidates may, if approved, also face competition from existing branded, generic and off-label products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to LNZ100 and will face competition with respect to any other product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. As LNZ100 is for the treatment of presbyopia, we may face competition from a variety of companies developing or marketing other pharmaceutical presbyopia therapies, including AbbVie (formerly Allergan), Bausch &#38; Lomb, Eyenovia, Glaukos, Johnson &#38; Johnson, Orasis, OSRX Pharmaceuticals (an affiliate of Ocular Science), Viatris (through licensing of Ocuphire&#8217;s presbyopia products), Visus Therapeutics and Vyluma. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses. LNZ100, if approved, would require a prescription by an ECP, which would require a visit to an ECP, which can be perceived to be more burdensome to an individual who has never previously visited an ECP and limit the number of prescriptions that are written. Some ECPs may also be deterred by the potential loss of revenue from the sale of contact lenses and glasses or feel uncomfortable prescribing a new product.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNZ100 may not demonstrate sufficient additional clinical benefits to ECPs, patients or payors to justify a higher price compared to using glasses, which are potentially just a one-time purchase.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than LNZ100, if approved, or any other products we develop that are approved. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for LNZ100 or any other products, which could result in our competitors establishing a strong market position before we are able to enter the market.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future have substantially greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates on acceptable terms, we may be unable to successfully commercialize our product candidates that obtain regulatory approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to use the proceeds of the Merger and the PIPE Financing, in part, to continue to build the sales and marketing infrastructure required to successfully commercialize LNZ100, subject to FDA approval. As of March 21, 2024, we have substantially completed hiring of all senior leadership roles in the commercial team, including adding industry veterans with extensive experience in the pharmaceutical space. We plan to launch with our own sales organization in the United States, which we envision expanding to a substantially larger number of individuals, focused on partnering with ECPs, while also deploying, in parallel, a highly targeted consumer strategy. In order to achieve these commercialization goals for LNZ100, if approved, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell and market LNZ100. We may not be successful in accomplishing these required tasks.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishing and building out an internal sales and marketing team with technical expertise and supporting distribution capabilities to commercialize LNZ100, if approved, will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of LNZ100 or any other product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize LNZ100 or any other product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial strategy is focused on targeting and partnering with the estimated 15,000 ECPs that prescribed over 85% of the pharmaceutical presbyopia prescriptions in the United States in 2022. If we are unable to obtain access to these ECPs or successfully demonstrate the clinical benefits of our products to adequate numbers of ECPs, if approved, our efforts to commercialize such products will be severely inhibited, which would have a material adverse effect on our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, a direct-to-consumer (&#8220;DTC&#8221;) strategy can potentially be extremely costly. We intend to deploy a targeted, cost-effective, digitally focused DTC strategy, but if we are unable to be sufficiently effective with a limited budget and are required to spend more than anticipated, we may need to raise more capital, divert resources from other strategies or just fail to reach the intended market. As a result, a DTC strategy that is not sufficiently cost-effective can have a material adverse effect on our business.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional funds to pursue regulatory approval of LNZ100 and any future product candidates and to continue the development of LNZ100 and any future product candidates. Our future capital requirements will depend upon a number of factors, including&#58; the number and timing of future product candidates in the pipeline&#59; progress with and results from preclinical testing and clinical trials&#59; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials&#59; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims&#59; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could, for example, through the sale of common stock or securities convertible or exchangeable into common stock, significantly dilute our stockholders&#8217; ownership interests or inhibit our ability to achieve our business objectives. If we raise additional funds through public or private equity offerings, the terms of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs, or grant licenses on terms that may not be favorable to us. Even if we were to obtain funding, there can be no assurance that it will be available on terms acceptable to us or our stockholders.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products, if approved.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If LNZ100 or any future product candidates are approved for marketing, such claims could still result in an FDA, EMA or other regulatory authority investigation of the safety and effectiveness of such products, our manufacturing processes and facilities or our marketing programs. These investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in injury to our reputation, withdrawal of clinical trial participants, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates and decreased demand for our product candidates, if approved for commercial sale. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing LNZ100, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business and cause our stock price to decline. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to maintain or obtain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses, including those caused by product liability claims.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing regulatory strategies for LNZ100 outside the United States and, accordingly, we expect that we or our partners would seek regulatory approval of our product candidates outside of the United States. As such, we expect that we will be subject to additional risks related to operating in foreign countries if we or such partners obtain the necessary approvals, including&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements and drug pricing regimes in foreign countries&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential issues due to aceclidine having been previously marketed and sold in Europe as a treatment for glaucoma, including, but not limited to potential competition from or for manufacturers and suppliers, and potential assumptions, concerns or biases resulting from the limited efficacy of the prior marketed products&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties staffing and managing foreign operations&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability under the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) or comparable foreign regulations&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our international operations or those of any applicable international partners may materially adversely affect our ability to attain or maintain profitable operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, there is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-border operations. The U.S. government has made and continues to make significant additional changes in U.S. trade policy and may continue to take future actions that could negatively impact U.S. trade. For example, legislation has been introduced in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or provided by select Chinese biotechnology companies, and others in Congress have advocated for the use of existing executive branch authorities to limit those Chinese service providers&#8217; ability to engage in business in the U.S. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation. If we are unable to obtain or use services from existing service providers or become unable to export or sell our products to any of our customers or service providers, our business, liquidity, financial condition, and&#47;or results of operations would be materially and adversely affected.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our technology and products and product candidates we may develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully develop and, if approved, commercialize our product candidates may be adversely affected. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to our development programs and product candidates. Our success depends in part on our ability to obtain and maintain patent protection in the United States and other countries with respect to LNZ100 or any future product candidates. If we are unable to obtain or maintain patent protection with respect to LNZ100 or any future product candidates, and their uses, our business, financial condition, resultant operations and prospects could be materially harmed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to LNZ100, any of our future product candidates, our development programs, product candidates and novel discoveries that are important to our business, as appropriate. Our pending and future patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties, including generics. The patent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patents and patent applications that we own may fail to result in issued patents with claims that protect LNZ100 or any future product candidate in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover LNZ100 or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, the scope and coverage of such patents may be so narrow that a third party could successfully design around our patents without materially impacting the therapeutic effectiveness of the resulting drug product. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO requires us to disclose all material references to the Patent Examiner during prosecution of our patent applications at the USPTO, and failure to do so could result in a third party successfully challenging our ability to enforce a patent against an infringer&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications may not result in any patents being issued&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">granted patents may not have a claim scope that covers LNZ100 or any future product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for treatments of diseases or conditions that prove successful, as a matter of public policy regarding worldwide health concerns&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is also expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications or maintain and&#47;or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. We may not be able to obtain or maintain patent applications and patents due to the subject matter claimed in such patent applications and patents being in disclosures in the public domain. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, if we choose to license certain patent rights in the future from third parties, we may not have the right to control the preparation, filing, and prosecution of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such patent applications, or to maintain the patents, directed to technology that we license from those third parties. We may also require the cooperation of our future licensor, if any, in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, any licensed patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by any of our future licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the patent applications we hold or may in-license in the future with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for LNZ100 or any future product candidate, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to commercialize LNZ100 or future product candidates. Any such outcome could have a materially adverse effect on our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, many countries restrict the patentability of methods of treatment of the human body. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. For example, the America Invents Act created new administrative post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings that allow third parties to challenge the validity of issued patents. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending patents or enforcing proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our owned and licensed patents and patent applications may be challenged in the courts or patent offices in the United States and abroad. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. An adverse decision in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay incurred by the USPTO in examining the patent application (patent term adjustment). The scope of patent protection may also be limited.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that the claims in patents or our pending patent applications directed to LNZ100 or any of our future product candidates will be considered patentable by the USPTO, by patent offices in foreign countries, by the courts, or by other relevant authority. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#8220;prior art,&#8221; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim relevant to our business. There is no assurance that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our products that may be approved in the future, or impair our competitive position. Even if the patents do issue based on the patent applications we own, co-own or exclusively license, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent, trademark, trade secret and other intellectual property protection in the discovery, development, manufacturing and sale of LNZ100 and any future product candidates. In particular, patent protection is important in the development and eventual commercialization of LNZ100 or any of our future product candidates. Patents covering LNZ100 or any of our future product candidates normally provide market exclusivity, which is important in order for LNZ100 or any of our future product candidates to become profitable.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent rights are of limited duration. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Various extensions may be available, but the life of a patent, and the protection it affords is limited. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. Upon issuance in the United States, the term of a patent can be increased by patent term adjustment, which is based on certain delays caused by the USPTO, but this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prosecution. The term of a U.S. patent may also be shortened if the patent is terminally disclaimed over an earlier-filed patent.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA marketing approval of LNZ100 and future product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during drug development and the FDA regulatory review process, which is limited to the approved indication (or any additional indications approved during the period of extension). This extension is based on the first approved use of a product and is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. Such patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA&#59; (2) such patent has expired&#59; (3) the date on which such patent expires&#59; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. We cannot guarantee that a patent that may cover LNZ100 or a future product candidate can or will be appropriately listed in the Orange Book.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws governing analogous patent term extension (&#8220;PTE&#8221;) in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain PTE or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and&#47;or patent applications will be due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of our patents and patent applications. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. We employ reputable law firms and other professionals to help us comply with these provisions. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. If we or any of our licensors fail to maintain the patents and patent applications covering LNZ100 or any future product candidate, our competitors may be able to enter the market, which would have an adverse effect on our business, financial conditions, results of operations and growth prospects.  We do not have granted patents in certain major markets, including Europe, and cannot guarantee that we will obtain patent coverage in such markets that cover LNZ100 or any future product candidate.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the biopharmaceutical industry expands and more patents are issued, the risk increases that LNZ100 or any of our future product candidates may be subject to claims of infringement of the patent rights of third parties. There can be no assurance that our operations do not, or will not in the future, infringe, misappropriate or otherwise violate existing or future third-party patents or other intellectual property rights. Identification of third-party patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot provide any assurances that third-party patents do not exist which might be enforced against our existing products or current technology, including our research programs, LNZ100, any of our future product candidates, their respective methods of use, and manufacture thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and&#47;or other forms of compensation to third parties, which could be significant. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our current and future product candidates in any jurisdiction.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. We do not always conduct independent reviews of pending patent applications and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These patent applications may later result in issued patents, or the revival of previously abandoned patents, that may be infringed by the manufacture, use or sale of our product candidates or will prevent, limit or otherwise interfere with our ability to make, use or sell our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. For example, we may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any patent in the United States or abroad that we consider relevant may be incorrect, and our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in third-party claims of intellectual property infringement, which may delay or prevent the development and commercialization of LNZ100 and any future product candidate. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to develop, manufacture, market and sell LNZ100 and any future product candidates, while avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation, and administrative law proceedings, inter partes review, and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights who allege that our product candidates, uses and&#47;or other proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current and future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future product candidates may infringe.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third parties may obtain patent rights in the future and claim that use of our technologies infringes upon their rights. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process, methods of treating certain diseases or conditions that we are pursuing with our product candidates, our formulations including combination therapies, or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our current and future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents or other intellectual property rights, or the patents or other intellectual property rights of any licensors, which could be expensive, time consuming, and unsuccessful, and could result in a court or administrative body finding our patents to be invalid or unenforceable.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may challenge, infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter challenges, infringement or unauthorized use or misappropriations, we or any future licensors may be required to file or defend legal claims, which can be expensive and time-consuming. In addition, in such a proceeding, a court may decide that one or more patent of ours or any of our current or future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and&#47;or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness (inventive step), non-enablement, insufficient written description, or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours or any future licensors is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that it or any future licensors&#8217; patent claims do not cover the invention, or decide that the other party&#8217;s use of our or any future licensors&#8217; patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). An adverse outcome in a litigation or proceeding involving our or any future licensors&#8217; patents could limit our ability to assert our own or any future licensors&#8217; patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive position, and our business, financial condition, results of operations and prospects. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For any patents and patent applications that we may license from third parties in the future, we may have limited or no right to participate in the defense of such licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to prevent, alone or with our licensees, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our patents, any patents that may be issued as a result of our future patent applications, or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents relating to LNZ100 and any future product candidates. Obtaining, defending, maintaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents, and may diminish our ability to protect our inventions, obtain, maintain, enforce and protect our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our future owned and licensed patents. The United States has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, the complexity and uncertainty of European patent laws have also increased in recent years. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, a new unitary patent system took effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (the &#8220;UPC&#8221;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC over the first seven years of the court&#8217;s existence and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. We may decide to opt out our future European patents from the UPC, but doing so may preclude us from realizing the benefits of the UPC. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC, our future European patents could remain under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents and allow for the possibility of a competitor to obtain pan-European injunction. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates due to increased competition and, resultantly, on our business, financial condition, prospects and results of operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world, which could impair our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are of national or regional effect, and filing, prosecuting, and defending patents covering LNZ100 and any future product candidate throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our or any future licensors&#8217; inventions in all countries outside the United States, even in jurisdictions where we or any future licensors do pursue patent protection, or from selling or importing products made using our or any future licensors&#8217; inventions in and into the United States or other jurisdictions. Competitors may use our or any future licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may have or obtain patent protection, but where patent enforcement is not as strong as that in the United States. These competitors&#8217; products may compete with our products in such jurisdictions and take away our market share where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize LNZ100 or any of our future product candidates in all of our expected significant foreign markets.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. As a result, the patent owner may have limited remedies in certain circumstances, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Accordingly, our efforts to protect or enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize LNZ100 or any of our future product candidates in all of our expected significant foreign markets.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. As such, we do not know the degree of future protection that we will have on our technologies, products and product candidates. While we will endeavor to try to protect our technologies, products and product candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and unpredictable.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, geo-political actions in the United States and in foreign countries (such as the Russia and Ukraine conflict) could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws within the United States. We may need to share our trade secrets and proprietary know-how with current or future partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. In addition, some courts inside and outside the United States are sometimes less willing or unwilling to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. Even if we are successful, these types of lawsuits may consume our time and other resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we may seek to rely on trade secret protection to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by our patents. We may not be able to meaningfully protect our trade secrets. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed to our competitors or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws within the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we expect to rely on third parties to manufacture LNZ100 and any future product candidates, and we expect to collaborate with third parties on the continuing development of LNZ100 and any future product candidates, we must, at times, share trade secrets with them. We also expect to conduct R&#38;D programs that may require us to share trade secrets under the terms of our partnerships or agreements with CROs. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations, including material transfer agreements, consulting agreements, manufacturing and supply agreements, confidentiality agreements or other similar agreements with our advisors, employees, contractors, CMOs, CROs, other service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors CMOs, CROs, other service providers and consultants to publish data potentially relating to our trade secrets, although such agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover such trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monitoring unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. For example, significant elements of our products, including confidential aspects of sample preparation, methods of manufacturing, and related processes and software, are based on unpatented trade secrets. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies, or at research institutions, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals have or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Further, although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators, and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. An inability to incorporate such technologies or features would harm our business and may prevent us from successfully commercializing our technologies or product candidates. In addition, we may lose personnel as a result of such claims and any such litigation, or the threat thereof, may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our technologies or product candidates, which could adversely affect our </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business, financial condition, results of operations and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may also be subject to claims that former employers, consultants or other third parties have an ownership interest in our patents or patent applications as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and&#47;or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such challenges may also result in our inability to develop, manufacture or commercialize our technologies and product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future technologies and product candidates. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Any of the foregoing could adversely affect our business, financial condition, results of operations and prospects.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our future trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an opportunity to respond to such rejections, we may be unable to overcome them. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any proprietary name we propose to use with our current or future product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make formulations or compositions that are the same as or similar to our current and future product candidates, but that are not covered by the pending patent applications or patents that we own or any pending patent applications or patents that we may in-license in the future&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make product that is similar to our current and future product candidates that we intend to commercialize and that is not covered by the patents that we exclusively licensed and have the right to enforce&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, any of our future licensors or collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or may in-license in the future&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future licensors might not have been the first to file patent applications covering certain of its or those licensors&#8217; inventions&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing or otherwise violating our owned intellectual property rights or any patent applications that we may license in the future&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications or those that we may own or license in the future will not lead to issued patents&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we either own or that we may license in the future may be revoked, modified or held valid or unenforceable, as a result of legal challenges by our competitors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we either own or that we may license in the future may not provide us with any competitive advantages&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may have access to the same intellectual property rights licensed to us in the future on a non-exclusive basis&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot predict the scope of protection of any patent issuing based on our or any future licensors&#8217; patent applications, including whether the patent applications that we own, or, in the future, in-licenses will result in issued patents with claims directed to our product candidates or uses thereof in the United States or in other foreign countries&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if enforced, a court may not hold that our patents are valid, enforceable or infringed&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may need to initiate litigation or administrative proceedings to enforce and&#47;or defend our patent rights which will be costly whether we win or lose&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to adequately protect and police our trademarks and trade secrets&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patent applications.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any collaboration or partnership arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in our strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our current and future product candidates&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future product candidates or that results in costly litigation or arbitration that diverts management attention and resources&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator's sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under any license, collaboration or other agreements, such agreements may be terminated, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future license or otherwise acquire development or commercialization rights to current and future product candidates or data from third parties. If any future licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize future product candidates that may be subject of such licensed rights could </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be adversely affected. In spite of our efforts, any future licensors might conclude that we are in material breach of obligations under our license agreements. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. If such in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, our competitors will have the freedom to seek regulatory approval of, and to market, products identical to our product candidates and the licensors to such in-licenses could prevent us from developing or commercializing product candidates that rely upon the patents or other intellectual property rights which were the subject matter of such terminated agreements. Any of these events could adversely affect our business, financial condition, results of operations, and prospects. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">either party&#8217;s financial or other obligations under the license agreement&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to sublicense patents and other rights under our collaborative development relationships to third parties&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our right to transfer or assign the license&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by any of our licensors and us and our partners&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we license prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our current or future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we or our current or future licensors, if any, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, ownership, claim scope, or requests for patent term adjustments. If such defects are identified in a granted patent, we may reissue the granted patent, which would require us to relinquish the patent, and subject the patent to subsequent reissue patent examination. During reissue examination, there is no guarantee that a similar scope of claim would again be granted or that any claim would be granted at all. In addition, if defects in ownership or assignment of rights are identified, there is no guarantee that we would be able to perfect such ownership or assignment of rights.  If our current or future licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and&#47;or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where we have the right to control patent prosecution of patents and patent applications under a license from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquired technologies and current or future licensed technology may be subject to retained rights. Our predecessors or licensors may retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or future licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are limited in our ability to utilize acquired technologies or current or future licensed technologies, or if we lose our rights to critical acquired or in-licensed technology, we may be unable to successfully develop, out-license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of acquired technologies, and current or future licensed technology, into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our product candidate.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to license or acquire new or necessary intellectual property rights or technology from third parties. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. Further, other parties, including our competitors, may have patents and have filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these patents, we may find it necessary or prudent to obtain licenses to such patents from such parties. The licensing or acquisition of intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. No assurance can be given that we will be successful in licensing any additional rights or technologies from third parties. Our inability to license the rights and technologies that we have identified, or that we may in the future identify, could have a material adverse impact on our ability to complete the development of our product candidates or to develop additional product candidates. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. Failure to obtain any necessary rights or licenses may detrimentally affect our planned development of our current or future product candidates could be impacted and costs could increase, extending timelines associated with the development of such other product candidates if we fail to acquire necessary rights or licenses. We may even have to abandon the development of the relevant program or product candidate. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into license agreements in the future with others to advance our existing or future research or allow commercialization of our existing or future product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. In that event, we may be required to expend significant time and resources to redesign our product candidates, or the methods for manufacturing them, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current manufacturing methods, product candidates, or future methods or product candidates resulting in either an injunction prohibiting their manufacture or future </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales, or, with respect to their future sales, an obligation on our part to pay royalties and&#47;or other forms of compensation to third parties, which could be significant.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Regulatory Approval and Other Legal Compliance Matters </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates, including LNZ100 and any future product candidates we may seek to develop, and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. Before we can commercialize any of our product candidates, we must obtain marketing approval. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining approval by the FDA and other comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. Further, securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize any drug product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval for our product candidates, the FDA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested or may impose other prescribing limitations or warnings that limit the product&#8217;s commercial potential. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or after approval, or may object to elements of our clinical development programs. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our product candidates will ever obtain regulatory approval. Further, development of our product candidates or regulatory approval may be delayed for reasons beyond our control.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applications for LNZ100 or any future product candidates could fail to receive regulatory approval for many reasons, including the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or other comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the population studied in the clinical trials may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the FDA or other comparable foreign regulatory authorities that our product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval or resulting in delays in their regulatory approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of drugs in development, only a small percentage successfully complete the FDA or comparable foreign regulatory approval processes and are commercialized. The lengthy approval processes as well as the unpredictability of future clinical trial results may result in us failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in us failing to obtain regulatory approval to market LNZ100 or any future product candidates, which would significantly harm our business, results of operations and prospects. In addition, even if we obtain approval of LNZ100 or any future product candidates, regulatory authorities may approve any of such product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a risk evaluation and mitigation strategy (&#8220;REMS&#8221;). In addition, the FDA or comparable foreign regulatory authorities may change its policies, issue additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval of LNZ100 or any future product candidates on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current or future product candidates may fail to demonstrate substantial evidence of their safety and efficacy or cause significant adverse events or other undesirable side effects may be identified during the development of our product candidates, which could prevent, delay or limit the scope of regulatory approval of our product candidates, prevent market acceptance, limit our commercial potential or result in significant negative consequences.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe and effective for use in each target indication. Preclinical studies and clinical trials are expensive and time-consuming, and their outcomes are inherently uncertain. Failures can occur at any time during the development process. Product candidates often fail to demonstrate safety or efficacy of the product candidate studied for the target indication, and most product candidates that begin clinical trials are never approved.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe our Phase 3 CLARITY trials were completed successfully, we may fail to demonstrate with substantial evidence from adequate and well-controlled trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that LNZ1000 or any future product candidates are safe and effective for their intended uses.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are associated with undesirable side effects or have unexpected characteristics in nonclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs, we may decide or be required to perform additional clinical studies or to interrupt, delay or abandon our development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the clinical trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or maintaining market acceptance of the affected product candidate and may harm our business, financial condition, and prospects significantly. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition, and prospects significantly. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in our clinical trials may in the future suffer significant adverse events or other side effects not observed in our nonclinical studies or previous clinical trials. Some of our product candidates may be used as chronic therapies or be used in populations for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if our product candidates are used in combination with other therapies, our product candidates may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing separate treatments which can cause side effects or adverse events that are unrelated to our product candidates, but may still impact the success of our clinical trials, including, for example, by interfering with the effects of our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our clinical trials, or we may be required to abandon the clinical trials or our development efforts of that product candidate altogether. We, the FDA or other comparable regulatory authorities, or an IRE may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such clinical trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage clinical trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition, and prospects.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if any of our product candidates obtains marketing approval, and we or others later identify adverse events or other side effects associated with such products, a number of potentially negative consequences could result, including&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend, withdraw or limit approvals of that product, or seek an injunction against its manufacture or distribution&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide to remove the product from the market&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to conduct post-marketing studies or change the way the product is administered&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be sued and held liable for harm caused to subjects or patients&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, injunctions or the imposition of criminal penalties&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation and physician or patient acceptance of our products may suffer. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any foreign regulatory agency in a timely manner or at all. Moreover, any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of the affected product, if approved by applicable regulatory authorities.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional time may be required to develop and obtain regulatory approval for LNZ100 because we expect they will be regulated as a drug-device combination product. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect LNZ100 to be regulated as a drug-device combination product that will require coordination within the FDA and comparable foreign regulatory authorities and notified bodies for review of its drug and device components. Although the FDA and comparable foreign regulatory authorities and notified bodies have systems in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">place for the review and approval of drug-device combination products such as LNZ100, we may experience delays in the development, approval and commercialization of LNZ100 due to regulatory timing constraints and uncertainties in the product development and approval process. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and pricing of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, the pricing of a prescription drug candidate is subject to regulatory approval before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our potential product candidates will be harmed.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of LNZ100 or any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory oversight, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain any regulatory approval for LNZ100 or any future product candidates, such product candidates will be subject to ongoing regulatory requirements applicable to manufacturing, labeling, packaging, storage, advertising, promoting, sampling, record-keeping and submission of safety or other post-market information, among other things. Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS, limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or requirements that we conduct potentially costly post-market testing and surveillance studies, including Phase 4 trials and surveillance to monitor the quality, safety and efficacy of the drug. An unsuccessful post-marketing study or failure to complete such a study could result in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any new legislation addressing drug safety issues could result in delays in our product development or commercialization, or increased costs to assure compliance. We will also have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drug products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we will not be allowed to promote our products for indications or uses for which they do not have approval, commonly known as off-label promotion. The holder of an approved NDA must submit new or supplemental applications and obtain prior approval for certain changes to the approved product, product labeling, or manufacturing process. A company that is found to have improperly promoted off-label uses of its products may be subject to significant civil, criminal and administrative penalties. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the NDA or foreign marketing application. If we, the FDA or a comparable foreign regulatory authority, discover previously unknown problems with our product candidates, such as adverse events of unanticipated severity or frequency, or problems with the facility where the drug is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure by us to comply with applicable regulatory requirements following approval of any product candidates, may result in, among other things&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a REMS, which may include distribution or use restrictions&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to conduct additional post-market clinical trials to assess the safety of the product&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of fines, untitled letters, warning letters or holds on clinical trials&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. We also cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. It is difficult to predict how current and future legislation, executive actions, and litigation, including the executive orders, will be implemented, and the extent to which they will impact our business, our clinical development, and the FDA&#8217;s and other agencies&#8217; ability to exercise their regulatory authority, including FDA&#8217;s pre-approval inspections and timely review of any regulatory filings or applications we submit to the FDA. To the extent any executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA, the Securities and Exchange Commission, and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown or other disruption occurs, or if global health or other concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities in a timely manner, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, the FDA announced its intention to postpone most inspections of foreign and domestic manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities, if a prolonged government shutdown occurs, either for global health related reasons or other reasons, preventing the FDA or other regulatory authorities from conducting business as usual or conducting inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material effect on our business.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to our manufacturing arrangements&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or modifications to product labeling&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recall or discontinuation of our products&#59; or </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional record-keeping requirements, if any such changes were to be imposed on us, could adversely affect the operation of our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNZ100, if approved, will be directed to the out-of-pocket, cash-pay market in the United States, which we believe makes the market less sensitive to changes in insurance coverage and reimbursement. That said, changes in healthcare legislation and healthcare cost containment measures could impact the pricing of other products and procedures that compete with LNZ100, which can indirectly impact our pricing strategy and profitability. If a competitor treatment is covered by health plans or has more favorable pricing for consumers, the pricing of LNZ100 may be negatively impacted, which could have a material adverse effect on our ability to generate revenue and to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attain profitability. Additionally, the out-of-pocket, cash-pay market for our patient population may be negatively impacted by other price increases and market conditions, including rising costs of other consumer goods, which patients may prioritize over any product candidates we may commercialize. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;), was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA contained provisions that may reduce the profitability of drug products through, among other things, increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. In August 2022, Congress passed the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. HHS has and will continue to issue and update guidance as these programs are implemented. On August 29, 2023, CMS announced the list of the first ten drugs that will be subject to price negotiations. However, various industry stakeholders, including pharmaceutical companies, the U.S. Chamber of Commerce, and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA are unconstitutional. The impact of these judicial challenges as well as future legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the government on our company and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. In February 2023, HHS also issued a proposal in response to an October 2022 executive order from President Biden that includes a proposed prescription drug pricing model that will test whether targeted Medicare payment adjustments will sufficiently incentivize manufacturers to complete confirmatory trials for drugs approved through FDA&#8217;s accelerated approval pathway. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control prescription drug pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare or impose price controls may adversely affect&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for our product candidates, if we obtain regulatory approval&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a competitive price that we believe is fair for our products&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of cost containment measures or other healthcare reforms may lower the pricing of competitor products or procedures, which in turn may constrain the pricing of our product candidates, if approved, and prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure to what extent the trajectory of these legislative and regulatory proposals will be implemented by the federal and state governments, whether additional legislative changes will be enacted, whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens, and diminished profits and future earnings. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect that LNZ100, if approved, will be directed to the out-of-pocket, cash-pay market in the United States, our current and future arrangements with healthcare professionals, clinical investigators, CROs, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws that may affect our ability to operate include, but are not limited to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the False Claims Act (&#8220;FCA&#8221;), which can be enforced through civil &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty laws, impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent&#59; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government&#59; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, created under the ACA and its implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others), and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection, and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources&#59; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities&#59; state and local laws requiring the registration of pharmaceutical sales representatives&#59; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities, including our advisory board arrangements with physicians, some of whom receive stock or stock options as compensation for services provided, and any sales and marketing activities after a product candidate has been approved for marketing in the United States, could be subject to legal challenge and enforcement actions. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers, and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers&#8217; compensation insurance to cover our company for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations and can face serious consequences for violations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We plan to engage third parties for clinical trials or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Reliance on Third Parties </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contracted with third parties for the manufacture of our product candidates for our clinical trials for LNZ100, and expect to continue to do so for any additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of LNZ100 or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have the infrastructure or internal capability to manufacture supplies of LNZ100 for use in development and commercialization. We relied on third-party manufacturers for the production of our product candidates for our clinical trials under the guidance of members of our organization, and would expect to continue to do so for any additional clinical trials. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier. For any future clinical trials, if we were to experience an unexpected loss of supply of LNZ100 or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any such clinical trials.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to continue to rely on third-party manufacturers for the commercial supply of LNZ100 if we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of the third party to manufacture LNZ100 according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over the supply of LNZ100 or otherwise do not satisfactorily perform according to the terms of the agreements between us and them&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the breach by the third-party contractors of their agreements with us&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of third-party contractors to comply with applicable regulatory requirements&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of the third party to manufacture LNZ100 according to our specifications&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mislabeling of clinical supplies for any future clinical trials we conduct, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical supplies not being delivered to clinical sites on time for any future clinical trials we conduct,, leading to clinical trial interruptions, or drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the misappropriation of our proprietary information, including our trade secrets and know-how.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or others, we will not be able to secure and&#47;or maintain marketing approval for our manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of LNZ100 or any future product candidates we may seek to develop, or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for, or market LNZ100 or any such product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. Our current and anticipated future dependence upon others for the manufacture of LNZ100 may adversely affect our future profit margins and our ability to commercialize LNZ100, if approved, on a timely and competitive basis.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of LNZ100 for patients, if approved, could be delayed or prevented. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity, potency, and stability. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could adversely harm our business. If our manufacturers are unable to produce sufficient quantities for any future clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied, and expect to continue to rely on third parties, including independent clinical investigators and CROs, to conduct, supervise and monitor certain aspects of our clinical trials and any future preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our prior preclinical studies and clinical trials and to monitor and manage data for our ongoing clinical programs and any future preclinical studies or clinical trials. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on these parties for execution of our trials, and generally do not control their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable clinical investigation plan and protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply or, with respect to completed clinical trials, complied with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, these investigators and CROs are not our employees and we are not able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. If any of our relationships with these third parties terminate, we may not be able to timely enter into arrangements with alternative third parties or to do so on commercially reasonable terms, if at all. Switching or adding CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We entered into a collaboration agreement with Ji Xing and depend on Ji Xing to develop and commercialize its products within Greater China. We have limited control over how Ji Xing will conduct development and commercialization activities for LNZ100 or LNZ101. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into the Ji Xing License, pursuant to which we granted Ji Xing an exclusive license to certain of our intellectual property rights to develop, use, import, and sell products containing LNZ100 or LNZ101 (&#8220;LNZ Products&#8221;) for the treatment of presbyopia in humans in mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan (collectively, &#8220;Greater China&#8221;) and the first right of negotiation for Ji Xing to license any other product that we develop or commercialize containing aceclidine or brimonidine for uses outside of the treatment of presbyopia in Greater China. Under the terms of the Ji Xing License, we shall refrain from developing or commercializing any competing product, or knowingly enabling a third party to develop or commercialize a product containing aceclidine or brimonidine that would reasonably be expected to result in off-label sales of such products, for the treatment of presbyopia in humans in Greater China. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Ji Xing License Agreement, we are dependent upon Ji Xing for the development, regulatory, and commercialization activities for LNZ Products in Greater China, and we have limited control over the amount and timing of resources that Ji Xing devotes to such activities. In addition, payments associated with development, regulatory and commercial milestones that we may be eligible to receive, as well as royalties, will be dependent upon further advancement of LNZ Products by Ji Xing. If these milestones are not met and no LNZ Products are commercialized in Greater China, we will not receive future revenues from the collaboration. Ji Xing may fail to develop or effectively commercialize any LNZ Product for a variety of reasons and the Ji Xing License Agreement subjects us to a number of risks, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ji Xing may not commit sufficient resources to the development, regulatory approval, marketing, or distribution of any LNZ Product&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ji Xing may be unable to successfully complete the clinical development of any LNZ Product or obtain all necessary approvals from foreign regulatory agencies in any of the Greater China territories required to market any LNZ Product&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ji Xing may develop or commercialize (or attempt to develop or commercialize) an LNZ Product in a manner that may adversely impact our development or commercialization of either such product candidate and&#47;or future product candidates outside of such collaboration, including for example (1) the risk that any clinical trials conducted by Ji Xing may result in unfavorable safety or efficacy results that negatively impact our ability to obtain regulatory approval of our products in jurisdictions outside Greater China and (2) the risk that, if approved and commercialized, patients report that the products developed by Ji Xing are not effective, or not effective for long enough, and it negatively impacts our ability to market any products outside Greater China, if approved&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ji Xing may not properly maintain our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ji Xing may terminate its agreement with us prior to completing development or commercialization of any LNZ Product under the collaboration, in whole or in part, adversely impacting the potential approval and our revenue from the licensed product&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ji Xing may fail to manufacture any applicable LNZ Product in compliance with requirements of applicable foreign regulatory agencies and in commercial quantities sufficient to meet market demand&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be disputes between us and Ji Xing, including disagreements regarding the Ji Xing License Agreement, that may result in (1) the delay or prevention of the achievement of development, regulatory and commercial objectives that would result in milestone payments, (2) the delay or termination of the development or commercialization of any LNZ Product in Greater China, costly litigation or arbitration that diverts our management&#8217;s attention and resources and&#47;or termination of the underlying agreement&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ji Xing may not comply with applicable regulatory guidelines with respect to developing or commercializing any LNZ Product, which could adversely impact the development of or sales thereof, either in Greater China or (depending on the scope of the noncompliant activities) by us in other jurisdictions, and could result in administrative or judicially imposed sanctions, including warning letters, civil and criminal penalties, injunctions, product seizures or detention, product recalls, total or partial suspension of production and refusal to approve any new drug applications&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ji Xing may experience financial difficulties&#59; and </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business combinations or significant changes in the business strategy of Ji Xing may also adversely affect its ability to perform its obligations under its license agreement with us. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Ji Xing does not perform in the manner we expect or fulfill its responsibilities in a timely manner, or at all, the development, regulatory approval, and commercialization efforts related to an LNZ Product in Greater China could be delayed and it may be necessary for us to either assume the responsibility at our own expense for the development of LNZ100 or LNZ101 in Greater China or seek out a different collaboration partner for such efforts. In that event, our potential to generate future revenues from the Greater China region could be significantly reduced and our business could be materially and adversely harmed.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business Operations </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To succeed, we must recruit, retain, manage and motivate qualified executives as we build out the management team, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and need to add executives with operational and commercialization experience as we plan for commercialization of our product candidates and build out a leadership team that can manage our operations as a public company. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could, in the future, have difficulty attracting experienced personnel and may be required to expend significant financial resources in employee recruitment and retention efforts.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in acquisitions, in-licensing or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased operating expenses and cash requirements&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the assumption of indebtedness or contingent liabilities&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of equity securities which would result in dilution to our stockholders&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of management&#8217;s attention from our existing product candidates and initiatives in pursuing such an acquisition or strategic partnership&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to generate revenue from acquired intellectual property, technology and&#47;or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we undertake such a transaction, we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to significantly expand our organization, including building sales and marketing capability and creating additional infrastructure to support our operations as a public company, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of sales and marketing and finance and accounting. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and our limited experience in managing such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert or stretch our management and business development resources in a way that we may not anticipate. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to securities class action litigation, which is expensive and could divert management attention. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business, operating results, or financial condition.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our computer systems, as well as those of our contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including hurricanes), terrorism, war and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development programs. For example, the loss of preclinical study or clinical trial data from completed, ongoing or planned trials could result in delays in regulatory approval efforts and significantly increase costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, or breached due to employee error, a technical vulnerability, malfeasance or other disruptions. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay clinical development of our product candidates.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may never develop or be sustained.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, there was no public trading market for LENZ OpCo common stock. Although our common stock is listed on the Nasdaq Global Select Market, if an active trading market does not develop, or develops but is not maintained, you may have difficulty selling any of our common stock due to the limited public float. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. Accordingly, we cannot assure you of your ability to sell your shares of our common stock when desired or at prices at or above the price you paid for your shares or at all.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock is expected to be volatile, and the market price of the common stock may drop following the Merger. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of our common stock to fluctuate include&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price and volume fluctuations in the overall stock market from time to time&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and results of clinical trials for LNZ100 and any future product candidates that we may develop&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approvals for LNZ100 any any future product candidates that we may develop, and any delays or failures to obtain such approvals</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement or termination of collaborations for our product development and research programs&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to achieve development, regulatory or commercialization milestones under our collaborations&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure or discontinuation of any of our product development and research programs&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our research programs, clinical development programs or product candidates that we may develop&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to develop additional product candidates or products&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions with respect to our products or those of our competitors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announced or completed acquisitions of businesses, products or intellectual property by us or our competitors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in the financial projections or development timelines we may provide to the public or our failure to meet those projections or timelines&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the biotechnology, pharmaceutical and ophthalmology sectors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of shares of our common stock by us or our stockholders, or expectations that such sales may occur, and the expiration of market stand-off or lock-up agreements&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public&#8217;s reaction to our press releases, other public announcements, and filings with the SEC&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rumors and market speculation involving us or other companies in our industry&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the trading volume of our shares or the size of our public float&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes or fluctuations in our results of operations&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated developments in our business, our competitors&#8217; businesses, or changes in the market valuations of similar companies and the competitive landscape generally&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of securities analysts to maintain coverage of us, changes in actual or future expectations of investors or securities analysts, or our failure to meet these estimates or the expectations of investors&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation involving us, our industry or both&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governmental or regulatory actions or audits&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic conditions and trends&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or expectation of additional financing efforts&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of securities by us or our securityholders in the future&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we do not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards, policies, guidelines, interpretations, or principles.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results, financial condition and cash flows.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our board of directors is authorized to issue and designate shares of our convertible preferred stock in additional series without stockholder approval. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation authorizes our board of directors, without the approval of our stockholders, to issue shares of convertible preferred stock, subject to limitations prescribed by applicable law, rules and regulations and the provisions of our amended and restated certificate of incorporation, as shares of convertible preferred stock in series, to establish from time to time the number of shares to be included in each such series and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions thereof. The powers, preferences and rights of these additional series of convertible preferred stock may be senior to or on parity with our common stock, which may reduce its value.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to be an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company, as defined in the JOBS Act enacted in April 2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements, and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of Graphite&#8217;s initial public offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which requires, among other things, that the market value of our common stock that is held by non-affiliates to exceed $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act (if we are also a non-accelerated filer at that time) and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. It cannot be predicted if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. It is expected that we will elect to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance, or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Once we are no longer an emerging growth company, a smaller reporting company or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results and cash flows. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial condition as well as other disclosure and corporate governance requirements. However, as an emerging growth company, we may take advantage of exemptions from various requirements such as an exemption from the requirement to have our independent auditors attest to our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002 as well as an exemption from the &#8220;say on pay&#8221; voting requirements pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. We will no longer qualify as an emerging growth company after December 31, 2026 (or upon such earlier time as we no longer meet the other applicable requirements). After we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule 12b-2 under the Exchange Act, which may allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and in our periodic reports and proxy statements. Once we are no longer an emerging growth company or a smaller reporting company or otherwise no longer qualifies for these exemptions, we will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If we are not able to comply with the requirements in a timely manner or at all, our financial condition or the market price of our common stock may be harmed. For example, if we or our independent auditor identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, we could face additional costs to remedy those deficiencies, the market price of our stock could decline or we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K filing for that year, as required by Section 404 of the Sarbanes-Oxley Act. As a private company, LENZ OpCo was not required to test its internal controls within a specified period. Doing so will require that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors will be responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create a classified board of directors whose members serve staggered three-year terms&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that special meetings of our stockholders can be called only by our board of directors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholder action by written consent&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that our directors may be removed (i) only for cause and (ii) only by the affirmative vote of the holders of 75% or more of the outstanding shares of capital stock then entitled to vote at an election of directors&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expressly authorize our board of directors to make, alter, amend or repeal our amended and restated bylaws&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated bylaws&#59; however, if our board of directors recommends that the stockholders approve the amendment at a meeting of stockholders, the amendment shall only require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between us and our stockholders, which could limit stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceedings under Delaware statutory or common law&#58; (i) any derivative action or proceeding brought on the company&#8217;s behalf&#59; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or employees to the company or its stockholders&#59; (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our bylaws (including their interpretation, validity or enforceability)&#59; or (iv) any action asserting a claim governed by the internal affairs doctrine. Unless we consent in writing to the selection of an alternate forum, the United States federal district courts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. In addition, our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to these exclusive forum provisions. The forum selection provisions in our bylaws may limit our stockholders&#8217; ability to litigate disputes with us in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against the company and its directors, officers and employees, even though an action, if successful, might benefit the company&#8217;s stockholders. In addition, these forum selection provisions may impose additional litigation costs for stockholders who determine to pursue any such lawsuits against the company or its directors, officers or employees.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation and bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section 145 of the Delaware General Corporation Law, our bylaws and the indemnification agreements that we plan to enter into with our directors and officers provide that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, at our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are not obligated pursuant to our bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents, and to obtain insurance to indemnify such persons&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees, and agents.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in our business.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transfers of our securities utilizing Rule 144 of the Securities Act may be limited. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our securities are restricted from immediate resale. Holders should be aware that transfers of our securities pursuant to Rule 144 may be limited as Rule 144 is not available, subject to certain exceptions, for the resale of securities initially issued by shell companies (other than business combination related </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shell companies) or issuers that have been at any time previously a shell company. The disposal of Graphite&#8217;s historical assets and operations in connection with the Merger made Graphite subject to the SEC requirements applicable to reporting shell company business combinations. Following the Merger, we are no longer a shell company. As a result, we anticipate that holders will not be able to sell their restricted securities pursuant to Rule 144 without registration until one year after March 22, 2024, the date that we filed the Current Report on Form 8-K following the closing that includes the required Form 10 information that reflects we are no longer a shell company. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The disposal of Graphite&#8217;s historical assets and operations in connection with the Merger made us subject to the SEC requirements applicable to reporting shell company business combinations. As a result, we will be subject to more stringent reporting requirements, offering limitations, and resale restrictions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to SEC guidance, the requirements applicable to reporting shell company business combinations apply to any company that sells or otherwise disposes of its historical assets or operations in connection with or as part of a plan to combine with a non-shell private company in order to convert the private company into a public one. Prior to the completion of the Merger, Graphite had no remaining ongoing development programs and disposed of its legacy technology and intellectual property. As such, we are subject to the SEC requirements applicable to reporting shell company business combinations, which are as follows&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we were required to file a Form 8-K to report the Form 10 type information after closing of the Merger with the SEC reflecting our status as an entity that is not a shell company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will not be eligible to use a Form S-3 until 12 full calendar months after closing of the Merger&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will need to wait at least 60 calendar days after closing of the Merger to file a Form S-8&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will be an &#8220;ineligible issuer&#8221; for three years following the closing of the Merger, which will prevent us from (i) incorporating by reference in our Form S-1 filings, (ii) using a free writing prospectus, or (iii) taking advantage of the well-known seasoned issuer (WKSI) status regardless of our public float&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investors who (i) were affiliates of LENZ OpCo or Graphite at the time the Merger was submitted for the vote or consent of the respective company&#8217;s stockholders, (ii) received securities in the Merger (i.e., Rule 145(c) securities) and (iii) publicly offer or sell such securities will be deemed to be engaged in a distribution of such securities, and therefore to be underwriters with respect to resales of those securities, and accordingly such securities may not be included in any resale registration statement unless such securities are sold only in a fixed price offering in which such investors are named as underwriters in the prospectus&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Rule 144(i)(2) will limit the ability to publicly resell Rule 145(c) securities per Rule 145(d), as well as any other &#8220;restricted&#8221; or &#8220;control&#8221; securities per Rule 144 until one year after the Form 10 information is filed with the SEC.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing SEC requirements will increase our time and cost of raising capital, offering stock to under equity plans, and compliance with securities laws. Further, such requirements will add burdensome restrictions on the resale of our shares by affiliates and any holders of &#8220;restricted&#8221; or &#8220;control&#8221; securities.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect to not provide research coverage of our common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts cease coverage of us or fail to publish reports on us regularly, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or our stockholders. For example, the United States recently enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) eliminated the option to deduct research and development expenditures and required taxpayers to amortize them generally over five (for R&#38;D performed in the United States) or fifteen years (for R&#38;D performed outside the United States). We will assess the impact of various tax reform proposals in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we will make about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. Such changes, among others, may adversely affect our effective tax rate, results of operation, and general business condition.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and other tax attributes may be limited, including those obtained as a result of the Merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, LENZ OpCo had federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $18.1 million and $17.9 million, respectively. The federal NOL carryforwards of $18.1 million may be carried forward indefinitely. State NOL carryforwards totaling $17.2 million begin to expire in 2040, unless previously utilized, and $0.6 million that carryforward indefinitely. In addition, LENZ OpCo also had federal and state R&#38;D credit carryforwards totaling $6.5 million and $0.5 million, respectively. The federal R&#38;D credit carryforwards will begin to expire in 2040 unless previously utilized. $0.1 million of the state R&#38;D credit carryforwards will begin to expire in 2037 unless previously utilized, and the remaining carryforward indefinitely.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023, Graphite had U.S. federal net operating loss carryforwards of $146.5 million and minimal state net operating loss carryforwards. The federal NOL carryforwards may be carried forward indefinitely. In addition, Graphite also had federal and state R&#38;D credit carryforwards totaling $6.4 million and $4.7 million, respectively. The federal R&#38;D credit carryforwards will begin to expire in 2041 unless previously utilized. The state R&#38;D credit carryforward indefinitely.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under current law, U.S. federal net operating loss carryforwards generated in taxable periods beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income for taxable periods beginning after December 31, 2020. Many state jurisdictions conform to federal law for this purpose or have similar provisions that limit the deductibility of state net operating loss carryfowards in a taxable period. In addition, under Sections 382 and 383 of the Code, U.S. federal net operating loss carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points (by value) over their lowest ownership percentage within a rolling three-year period. We may have experienced such ownership changes in the past, and in connection with the Merger and the PIPE Financing. To the extent we have or will experience an ownership change(s), our ability to utilize our net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Merger and the PIPE Financing or other transactions. Similar rules may apply under state tax laws. If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations, or cash flows.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1445"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements in this prospectus may constitute &#8220;forward-looking statements&#8221; for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including those relating to the Transactions and their expected benefits&#59; our performance following the Transactions&#59; our plans relating to the clinical development of our product candidates, including the size, number and areas to be evaluated&#59; our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and strategy&#59; and our ability to obtain funding for its operations.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements include statements relating to our management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the Merger and related transactions. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include, but are not limited to, the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates to the satisfaction of the FDA, and other positive results&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope and likelihood of regulatory filings and approvals for LNZ100&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of LNZ100&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the development of LNZ100&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the market opportunity for LNZ100, including our estimates of the size of the affected population and potential adoption rate&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing LNZ100, if approved, including the geographic areas of focus and sales strategy&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position and the success of competing therapies that are or may become available&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of LNZ100&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel and our ability to attract and retain such personnel&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development and manufacturing of LNZ100 and any future product candidates&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of LNZ100 and any other product candidates we may develop&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of existing laws and regulations and regulatory developments in the United States and other jurisdictions&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering LNZ100, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct any additional clinical trials of LNZ100 or any future product candidates, and for the manufacture of our product candidates for any such trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to the Merger&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recognize the anticipated benefits of the Merger&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will remain an emerging growth company under the JOBS Act&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of our existing resources and the proceeds from the Transactions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1448"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">USE OF PROCEEDS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Securities offered by the selling securityholders pursuant to this prospectus will be sold by the selling securityholders for their respective accounts. We will not receive any of the proceeds from the sale of the Securities hereunder. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the registration of shares of our Common Stock offered by the selling securityholders pursuant to this prospectus, the selling securityholders will pay any underwriting discounts and commissions and expenses incurred by them for brokerage, accounting, tax or legal services or any other expenses incurred by them in disposing of the Securities. We will bear all other costs, fees and expenses incurred in effecting the registration of the Securities covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees, and fees of our counsel and our independent registered public accountants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1451"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT&#8217;S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information and Holders </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Stock is currently listed on The Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;LENZ.&#8221; Prior to the consummation of the Merger, our Common Stock was historically quoted on The Nasdaq Global Market under the symbol &#8220;GRPH.&#8221; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 21, 2024, there were 25,534,458 shares of Common Stock issued and outstanding held of record by approximately 103 holders. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the consummation of the Merger, the Graphite board of directors&#160;declared a special cash dividend to its stockholders (the &#8220;Special Dividend&#8221;), which was paid on March 21, 2024. The Special Dividend was in the amount of $1.03 per share of Graphite&#8217;s common stock and was payable in cash to the stockholders of record of Graphite as of March&#160;18, 2024 that continued to hold their shares through the ex-dividend date of March 22, 2024.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to retain all available funds and any future earnings to fund the growth and development of our business. Other than the Special Dividend, we have never declared or paid any cash dividends on our capital stock. We do not intend to pay cash dividends to our stockholders in the foreseeable future. Investors should not purchase our common stock with the expectation of receiving cash dividends.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1189"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1225"></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merger</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2023, Graphite Bio, Inc., a Delaware corporation (&#8220;Graphite&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) by and between Graphite, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Graphite (&#8220;Merger Sub&#8221;), and Lenz Therapeutics, Inc., a Delaware corporation (&#8220;LENZ&#8221;), pursuant to which, Merger Sub merged with and into LENZ, with LENZ continuing as a wholly owned subsidiary of Graphite and the surviving corporation of the merger. On March 21, 2024, Graphite, Merger Sub and LENZ consummated the transactions contemplated by the Merger Agreement, Merger Sub was merged with and into LENZ and LENZ became a wholly owned subsidiary of Graphite (the &#8220;merger&#8221;). On March 21, 2024, in connection with the transactions contemplated by the Merger Agreement, Graphite (i) effected a reverse stock split of Graphite&#8217;s common stock, par value $0.00001 per share (&#8220;Graphite common stock&#8221;), at a ratio of 1&#58;7 (the &#8220;reverse stock split&#8221;). Unless otherwise noted, the reverse stock split has not been reflected in the historical share and per share disclosures of Graphite. Defined terms used in this &#8220;Unaudited Pro Forma Condensed Combined Financial Information&#8221; section shall be used as defined in this section. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the effective time of the merger (the &#8220;effective time&#8221;), </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">each then-outstanding share of LENZ&#8217;s common stock, par value $0.001 per share (&#8220;LENZ common stock&#8221;), was converted into the right to receive a number of shares of Graphite&#8217;s common stock, par value $0.00001 per share (&#8220;Graphite common stock&#8221;), based on a ratio calculated in accordance with the Merger Agreement (the &#8220;exchange ratio&#8221;), </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">each then-outstanding share of LENZ&#8217;s preferred stock, par value $0.001 per share (&#8220;LENZ preferred stock&#8221;), was converted into the right to receive a number of shares of Graphite common stock equal to the exchange ratio multiplied by the aggregate number of LENZ common stock into which each share of LENZ preferred stock is then convertible, </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">each then-outstanding option to purchase LENZ common stock was assumed by Graphite, subject to adjustment as set forth in the Merger Agreement and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">each then-outstanding warrant to purchase shares of LENZ common stock or LENZ preferred stock was converted into a warrant to purchase shares of Graphite common stock, subject to adjustment as set forth in the Merger Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the closing of the merger, LENZ completed a private placement with certain investors to purchase 3,559,565 shares of LENZ common stock at a price per share of $15.03 per share for an aggregate gross purchase price of $53.5 million. Upon the closing of the merger and in accordance with the terms and conditions of the Merger Agreement, the shares sold in the private placement have the right to receive a number of shares of Graphite common stock based on the exchange ratio. In connection with the private placement, LENZ entered into a registration rights agreement with the private placement investors, pursuant to which LENZ agreed to use commercially reasonably efforts to prepare and file a registration statement with the SEC as soon as practicable following the closing of the merger but in no event later than the 10th day following such closing to register the resale of the shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately after the effective time, pre-merger LENZ stockholders owned approximately 65% of the combined company on a fully-diluted basis and pre-merger Graphite stockholders owned approximately 35% of the combined company on a fully-diluted basis (prior to giving effect to the private placement, any exercised options, and excluding any shares reserved for future grants under the 2024 Plan and the 2024 ESPP). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unexercised and outstanding Graphite stock options at the effective time of the merger with an exercise price per share of equal to or greater than $3.00 (prior to giving effect to the special cash dividend and reverse stock split) accelerated in full as of immediately prior to the effective time and each such stock option not exercised as of immediately prior to the effective time were cancelled at the effective time for no consideration. All Graphite stock options with an exercise price per share of less than $3.00 (prior to giving effect to the special cash dividend and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reverse stock split) will continue to be subject to the same terms and conditions after the effective time as were applicable to such stock option as of immediately prior to the effective time.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the closing, Graphite declared a cash dividend to the pre-merger Graphite stockholders of $60.0 million in the aggregate (the &#8220;special cash dividend&#8221;).</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Pro Forma Condensed Combined Financial Statements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma condensed combined financial information gives effect to the merger, which has been accounted for as a reverse recapitalization under U.S. generally accepted accounting principles (&#8220;GAAP&#8221;), as well as the private placement and special cash dividend. Graphite only held cash and some nominal assets at the closing. LENZ is considered the accounting acquirer for financial reporting purposes. This determination is based on the facts that, immediately following the merger&#58; (i) LENZ stockholders owned a substantial majority of the voting rights of the combined company&#59; (ii) LENZ designated a majority (five of seven) of the initial members of the board of directors of the combined company&#59; and (iii) LENZ&#8217;s senior management held all key positions in senior management of the combined company. The transaction is accounted for as a reverse recapitalization of Graphite by LENZ similar to the issuance of equity for the net assets of Graphite, which is primarily cash, short-term investments, and other non-operating assets. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of LENZ being treated as the accounting acquirer, LENZ&#8217;s assets and liabilities will be recorded at their pre-combination carrying amounts. Graphite&#8217;s assets and liabilities will be measured and recognized at their fair values as of the effective time, which approximate the carrying value of the acquired cash and other non-operating assets. Any difference between the consideration transferred and the fair value of the net assets of Graphite following determination of the actual purchase consideration for Graphite is reflected as an adjustment to additional paid-in capital. Upon consummation of the merger, the historical financial statements of LENZ became the historical consolidated financial statements of the combined company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The historical financial information has been adjusted to give effect to pro forma events that are&#58; (1)&#160;directly attributable to the merger, (2)&#160;factually supportable, and (3)&#160;with respect to the unaudited Pro Forma Statement of Operations, expected to have a continuing impact on the combined results. The unaudited pro forma condensed combined balance sheet data assumes that the merger, private placement, and special cash dividend took place on December 31, 2023 and combines the historical balance sheets of Graphite and LENZ as of such date. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2023 assumes that the merger private placement, and special cash dividend took place as of January 1, 2023 and combines the historical results of Graphite and LENZ for the year ended December 31, 2023. The unaudited pro forma condensed combined financial information was prepared pursuant to the rules and regulations of Article 11 of SEC Regulation S-X.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma condensed combined financial information is provided for illustrative purposes only, does not necessarily reflect what the actual consolidated results of operations and financial position would have been had the acquisition occurred on the dates assumed and may not be useful in predicting the future consolidated results of operations or financial position.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, progress or changes in product development and strategies, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial information, including the notes thereto, should be read in conjunction with the separate historical financial statements of Graphite and LENZ, and their respective management&#8217;s discussion and analysis of financial condition and results of operations included elsewhere in, or incorporated by reference to, this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of Graphite may materially vary from those of LENZ. During preparation of the unaudited pro forma condensed combined financial information, management has performed a preliminary analysis and is not aware of any material differences, and accordingly, this unaudited pro forma condensed combined financial information assumes no material differences in accounting policies. Following the merger, management will conduct a final review of Graphite&#8217;s accounting policies in order to determine if differences in accounting policies require adjustment or reclassification of Graphite&#8217;s results of operations or reclassification of assets or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities to conform to LENZ&#8217;s accounting policies and classifications. As a result of this review, management may identify differences that, when conformed, could have a material impact on these unaudited pro forma condensed combined financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1208"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Pro Forma Condensed Combined Balance Sheets </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Graphite Bio, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lenz Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transaction Accounting Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma Combined</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,259&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,140&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,462&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">A</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,870&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,991)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,654&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,654&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,116)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188,021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,244</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,645)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">243,620</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL ASSETS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188,456</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,376</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,645)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">247,187</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES, CONVERTIBLE PREFERRED AND COMMON STOCK, AND STOCKHOLDERS' EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,961&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">B</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,803&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">B</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,065&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">D</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,288&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,418&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">E</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,797&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,514&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,288&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,599&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock warrants liability</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(871)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">J</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,874&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,698&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,417&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,989&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMMITMENTS AND CONTINGENCIES</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible Preferred and Common Stock&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A convertible preferred stock</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,621&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,621)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A-1 convertible preferred stock</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,893&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,893)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B convertible preferred stock</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,976&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,976)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B convertible common stock</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,900)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible preferred and common stock</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,390&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,390)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Graphite Bio, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lenz Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transaction Accounting Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma Combined</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">A</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">K</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,635&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,462&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">A</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,127&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292,487)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">L</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367,054)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,245)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,480&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">M</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,935)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,116)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,582&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,712)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,328&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,198&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LIABILITIES, CONVERTIBLE PREFERRED AND COMMON STOCK, AND STOCKHOLDERS' EQUITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188,456</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,376</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,645)</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">247,187</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1249"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Pro Forma Condensed Combined Statements of Operations </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Year Ended December 31, 2023</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Graphite Bio, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lenz Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Historical</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transaction Accounting Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pro Forma Combined</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,137&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,504&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,012&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,973&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,925&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,752&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,418&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">E</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">F</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and impairment costs</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,081&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,081&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135,191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,429</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,225</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">216,845</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(135,191)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(72,429)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,225)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(216,845)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">J</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,949&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,138&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income (expense), net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,540</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,282</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(123)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,699</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before income taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(124,651)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(70,147)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,348)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(204,146)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(124,651)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(69,968)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,348)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(203,967)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments in marketable securities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"><div style="text-align:right"><font><br></font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(123,603)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(69,962)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,348)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(202,913)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share, basic and diluted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.19)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.22)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N&#47;A</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.18)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average shares of common stock outstanding, basic and diluted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,015,159</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,689,045</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,235,427</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,924,472</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1268"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1287"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Description of the Transaction</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Graphite, Merger Sub and LENZ have entered into the Merger Agreement, pursuant to which the Merger Sub merged with and into LENZ, with LENZ being the surviving company. As a result of the merger, LENZ is a wholly owned subsidiary of Graphite. Upon the effective time of the merger, all shares of LENZ capital stock outstanding immediately prior to the effective time, after giving effect to the preferred stock conversion and excluding any shares held in treasury stock by LENZ or owned by Graphite or any subsidiary of Graphite or LENZ and any dissenting shares, were converted into 13,654,408 shares of Graphite common stock in the aggregate, based on an exchange ratio of 0.2022, after giving effect to the reverse stock split. Graphite assumed outstanding and unexercised stock options and warrants to purchase shares of LENZ capital stock, and in connection with the merger they were converted into options and warrants to purchase shares of Graphite common stock based on the exchange ratio. On March 21, 2024, in connection with the transactions contemplated by the Merger Agreement, Graphite effected a reverse stock split of Graphite&#8217;s common stock, par value $0.00001 per share at a ratio of 1&#58;7.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the effective time of the merger, LENZ&#8217;s stockholders owned or held rights to acquire 65% of the combined company and Graphite stockholders owned or held rights to acquire 35% of the combined company, in each case, on a fully-diluted basis and, in the case of Graphite, using the treasury stock method (prior to giving effect to the private placement, any exercised options, and excluding any shares reserved for future grants under the 2024 Plan and the 2024 ESPP). </font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1308"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Basis of Pro Forma Presentation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of SEC Regulation S-X. The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2023, gives effect to the merger and other events as if it had been consummated on January 1, 2023 and combine the historical statements of operations of Graphite and LENZ for the period then ended.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma condensed combined balance sheet as of December 31, 2023 gives effect to the merger and other events and combines the historical balance sheets of Graphite and LENZ as of such date. Based on LENZ&#8217;s preliminary review of LENZ&#8217;s and Graphite&#8217;s summary of significant accounting policies and preliminary discussions between management teams of LENZ and Graphite, the nature and amount of any adjustments to the historical financial statements of Graphite to conform its accounting policies to those of LENZ are not expected to be material. Following completion of the merger, further review of Graphite&#8217;s accounting policies may result in additional revisions to Graphite&#8217;s accounting policies and classifications to conform to those of LENZ.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of these pro forma financial statements, the estimated purchase price consideration consists of the following&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated number of shares of the combined company to be owned by Graphite's stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,429,509&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the estimate fair value of Graphite's common stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.61&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (in thousands)</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,591&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated fair value of assumed Graphite equity awards based on pre-combination&#160;service (in thousands)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total estimated purchase price (in thousands)</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,848&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10.46pt">Reflects the number of shares of common stock of the combined company that Graphite equity holders owned as of the effective time of the merger pursuant to the Merger Agreement. This amount is calculated, for purposes of this unaudited pro forma condensed combined financial information, based on shares of Graphite common stock outstanding at December 31, 2023 as effected by the reverse stock-split, and contemplation of equity instruments that are in-the-money and expected to be net exercised using the treasury stock method.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Reflects the price per share of Graphite common stock, which is the closing bid price of Graphite common stock as reported by Nasdaq on March 18, 2024, as effected by the reverse stock split (See Note F).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.02pt">Reflects the estimated acquisition-date fair value of the assumed Graphite equity awards attributable to pre-merger service outstanding as of the effective time of the merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, LENZ is considered to be the acquiring company and the merger is accounted for as a reverse recapitalization of Graphite by LENZ because on the merger date, the pre-combination assets of Graphite are primarily cash, short-term investments, and other non-operating assets.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under reverse recapitalization accounting, the assets and liabilities of Graphite were recorded, as of the completion of the merger, at their fair value, which is expected to approximate the carrying value of the pre-combination assets. The difference between the final fair value of the consideration transferred and the fair value of the net assets of Graphite following determination of the actual purchase price consideration for Graphite was reflected as an adjustment to additional paid-in capital. The subsequent financial statements of LENZ will reflect the combined operations of LENZ as the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the stockholders of the legal acquirer, Graphite, immediately prior to the effective time, and a recapitalization of the equity of the accounting acquirer, LENZ.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited pro forma condensed combined financial information is derived from the historical financial statements of Graphite and LENZ, and include adjustments to give pro forma effect to reflect the accounting for the merger and other events in accordance with GAAP. The historical financial statements of LENZ shall become the historical financial statements of the combined company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LENZ and Graphite may incur significant costs associated with integrating the operations of LENZ and Graphite after the merger. The unaudited pro forma condensed combined financial information does not reflect the costs of any integration activities or benefits that may result from realization of future cost savings from operating efficiencies expected to result from the merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma condensed combined financial information may differ from the final recapitalization accounting for a number of reasons, including the fact that the estimate of the fair value of Graphite&#8217;s net assets at closing is preliminary. The differences that may occur between the preliminary estimate and the final purchase accounting could have a material impact on the accompanying unaudited pro forma condensed combined financial information.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1327"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Shares of Graphite Common Stock Issued to LENZ Stockholders upon Closing of the Merger</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the merger, (i) each then-outstanding share of LENZ common stock was converted into the right to receive a number of shares of Graphite common stock equal to the exchange ratio, (ii) each then-outstanding share of LENZ preferred stock was converted into a number of shares of Graphite common stock equal to the exchange ratio multiplied by the aggregate number of shares of LENZ common stock into which each such share of LENZ preferred stock is then convertible, and (iii) each then-outstanding warrant to purchase LENZ preferred stock was converted into a warrant to purchase a number of shares of Graphite common stock equal to the exchange ratio multiplied by the number of shares of LENZ common stock issuable upon the conversion of the shares of LENZ preferred stock subject to the unexercised portion of such warrant. The exchange ratio for purposes of the unaudited pro forma condensed combined financial information of 0.2022 was derived on a fully-diluted basis using the treasury stock method for Graphite as of March 21, 2024 using a negotiated value of LENZ of approximately $231.6 million and of Graphite of approximately $126.7 million. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of Graphite common stock that Graphite expects to issue to LENZ&#8217;s stockholders (ignoring rounding of fractional shares) as of March 21, 2024 is determined as follows&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of LENZ common stock issued</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,838,624&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of LENZ Class B common stock and preferred stock outstanding</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,691,195&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,529,819&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange Ratio</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2022&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Graphite common stock expected to be issued to Lenz upon closing</font></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,654,408&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1346"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Adjustments to Unaudited Pro Forma Condensed Combined Financial Statements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments included in the column under the heading &#8220;Transaction Accounting Adjustments&#8221; reflect the application of the required accounting to the merger, private placement, and special cash dividend, applying the effects of the merger to LENZ&#8217;s and Graphite&#8217;s historical financial information. Further analysis will be performed after the completion of the merger to confirm these estimates or make adjustments in the final purchase price allocation, as necessary.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both LENZ and Graphite have a history of net operating losses and each maintains a full valuation allowance against their net deferred tax assets, and management has not identified any changes to the income tax positions due to the merger that would result in an incremental tax expense or benefit. Accordingly, management assumed a statutory tax rate of 0% and no tax-related adjustments have been reflected for the pro forma adjustments.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma adjustments included in the unaudited pro forma condensed combined financial information are as follows&#58;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Accounting Adjustments&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.28pt">To reflect the sale and issuance of approximately 3,559,565 shares of Graphite&#8217;s common stock with a par value of $0.00001, at a per share price of $15.03, by Graphite as a result of the Graphite private placement that occurred substantially concurrently with the closing of the merger for $53.5 million in gross proceeds, less an estimated $4.0 million in issuance costs.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.84pt">To reclassify $1.5 million from accrued compensation to accrued expenses to conform Graphite&#8217;s balance sheet presentation to LENZ&#8217;s.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.84pt">To derecognize $1.1 million of Graphite&#8217;s prepaid expenses including $0.7 million of prepaid directors&#8217; and officers&#8217; insurance and $0.4 million of research and development tax credits that cannot be utilized upon closing of the merger (See Note K).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.28pt">To reflect preliminary estimated transaction costs of $1.9 million, not yet reflected in the historical financial statements, that are expected to be incurred by LENZ in connection with the merger, such as legal fees, accounting expenses and consulting fees, as an increase in accrued liabilities and a reduction to additional paid-in capital in the unaudited pro forma condensed combined balance sheet. As the merger is accounted for as a reverse recapitalization equivalent to the issuance of equity for the net assets, primarily cash and short-term investments, of Graphite, these direct and incremental costs are treated as a reduction of the net proceeds received within additional paid-in capital (See Note L).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.4pt">To reflect preliminary estimated transaction costs of $7.4 million, not yet reflected in the historical financial statements, which are expected to be incurred by Graphite in connection with the merger, such as adviser fees, legal, and directors&#8217; and officers&#8217; liability insurance expenses, as an increase in other current liabilities and accumulated deficit in the unaudited pro forma condensed combined balance sheet and as selling, general and administrative expense in the unaudited pro forma condensed combined statement of operations (See Note K).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt">To reflect (1) $0.3 million of consideration transferred related to pre-combination service of replacement awards and (2) the post-combination share-based compensation expense of $0.7 million as an increase in additional paid-in-capital and accumulated deficit related to the acceleration of vesting upon the change of control and termination of employment for certain awards (See Note L).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.28pt">Reclassification of $143.3 million to additional paid-in-capital, related to LENZ preferred stock, and reflecting the conversion of 52,947,011 shares of LENZ preferred stock and 2,744,184 shares of LENZ Class B common stock into LENZ common stock immediately prior to the merger to be exchanged for 11,260,672 shares of Graphite common stock at an exchange ratio of 0.2022.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.28pt">Reclassification of $64,000 from LENZ common stock to additional paid-in-capital related to LENZ common stock outstanding as of December 31, 2023, after giving effect to the conversion of LENZ </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preferred stock and Class B common stock discussed in Note G, that convert into Graphite common stock at an exchange ratio of 0.2022. The par value of LENZ common stock is $0.001 while the par value of Graphite common stock is $0.00001, which has been reflected as a decrease to the par value of LENZ common stock.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">Concurrent with the closing of the merger, a special cash dividend of $60.0 million will be paid to Graphite stockholders.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.61pt">Represents the conversion of LENZ&#8217;s preferred warrants into warrants to purchase Graphite common stock upon the closing of the merger, resulting in a reduction in the warrant liability of $0.9 million. Also represents the elimination of other income (loss) of $0.1 million as these warrants were recorded at fair value, and subsequently adjusted to their current fair value at each reporting period with changes reflected in earnings, for warrants that convert upon consummation of the merger.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.28pt">To reflect the elimination of Graphite&#8217;s historical net equity, which represents the net assets acquired in the reverse capitalization&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Footnote to eliminate Historical Graphite net equity and net assets</font></div><div style="margin-bottom:9pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:83.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-combination Graphite additional paid-in Capital&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Historical Graphite additional paid-in capital</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550,635)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-combination Graphite accumulated deficit&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Historical Graphite accumulated deficit</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,054&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Graphite transaction costs (Note E)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,418&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derecognition of Graphite prepaid expenses (Note C)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pre-combination Graphite accumulated deficit</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,588&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Graphite common stock</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustment to historical equity (net assets of Graphite)</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,048)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.4pt">The pro forma adjustments recorded in additional paid-in capital as noted include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjustments to Additional Paid-in Capital</font></div><div style="margin-bottom:9pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:83.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of pre-combination Graphite additional paid-in capital (Note K)</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550,635)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Record acquisition of Graphite historical net assets (Note K)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,048&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected transaction costs of LENZ (Note D)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,870)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense related to Graphite's acceleration of options upon a change-in-control (Note F)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividend paid to Graphite's shareholders upon a change-in-control (Note I)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,991)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of LENZ preferred stock into LENZ common stock (Note G)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,334&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of historical LENZ common stock issued at December 31, 2023 (Note H)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of LENZ preferred warrants into Graphite common warrants (Note J)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments to additional paid-in capital</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292,487)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.61pt">The pro forma adjustments recorded to accumulated deficit as noted include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjustments to accumulated deficit</font></div><div style="margin-bottom:9pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:83.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elimination of historical Graphite accumulated deficit (Note K)</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,054&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense related to Graphite's acceleration of options upon a change-in-control (Note F)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derecognition of Graphite prepaid expenses (Notes C)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustment to accumulated deficit</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,480&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.28pt">The pro forma basic and diluted earnings per share have been adjusted to reflect the pro forma net loss for the year ended December 31, 2023. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the total number of shares of common stock of the combined company for the respective periods including the 1&#58;7 reverse stock split that was effected by Graphite on its common shares. For the year ended December 31, 2023, the pro forma weighted average shares outstanding has been calculated as follows&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:83.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:9pt;padding-right:14.25pt;text-indent:18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LENZ weighted-average shares of common stock outstanding</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,689,045&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of LENZ convertible preferred and Class B common stock assuming conversion as of January 1, 2023</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,691,195&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,380,240&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Application of the exchange ratio to historical LENZ weighted-average shares outstanding</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2022&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted LENZ weighted-average shares outstanding</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,219,884&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in the Graphite private placement</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,559,565&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Historical Graphite weighted-average shares of common stock outstanding</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,145,023&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total pro forma weighted-average shares outstanding</font></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,924,472&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1399"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis provides information that our management believes is relevant to an assessment and understanding of LENZ&#8217; consolidated results of operations and financial condition. The discussion should be read together with the audited financial statements and related notes and unaudited pro forma condensed financial information that are included elsewhere or incorporated by reference in this prospectus. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. LENZ&#8217;s actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; as set forth in this prospectus. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise indicated or the context otherwise requires, references in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section to &#8220;LENZ OpCo,&#8221; &#8220;LENZ,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to the business and operations of LENZ OpCo prior to the Merger and to New LENZ and its consolidated subsidiary following the Merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of the financial condition and results of operation of LENZ OpCo as of and for the year ended December 31, 2023 is set forth below.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the legal acquirer in the Merger was Graphite, for financial accounting and reporting purposes under U.S. GAAP, LENZ OpCo was the accounting acquirer and the Merger was accounted for as a &#8220;reverse recapitalization.&#8221; A reverse recapitalization (i.e., a capital transaction involving the issuance of stock by Graphite for LENZ OpCo&#8217;s stock) does not result in a new basis of accounting, and the consolidated financial statements of the combined entity represent the continuation of the consolidated financial statements of LENZ OpCo in many respects. Accordingly, the consolidated assets, liabilities and results of operations of LENZ OpCo became the historical consolidated financial statements of the combined company, and Graphite&#8217;s assets, liabilities and results of operations were consolidated with those of LENZ OpCo beginning on the acquisition date. Operations prior to the Merger will be presented as those of LENZ OpCo in future reports. Graphite&#8217;s assets and liabilities will be measured and recognized at their fair values as of the effective time.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Our initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45. In the United States, the estimated addressable population who suffer from this condition, known as presbyopes, is 128&#160;million, almost four times the number of individuals suffering from dry eye disease and three times the number of individuals suffering from childhood myopia, macular degeneration, diabetic retinopathy and glaucoma combined. We believe that a once-daily pharmacological eye drop that can effectively and safely improve near vision throughout the full workday, without the need for reading glasses, will be a highly attractive commercial product with an estimated U.S. market opportunity in excess of $3&#160;billion. It is our goal to develop and commercialize such a product, and we have assembled an executive team with extensive clinical and commercial experience to execute this goal and become the category leader.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate LNZ100 is a preservative-free,&#160;single-use,&#160;once-daily eye drop containing aceclidine. We believe our product candidate is differentiated based on rapid onset, degree and duration of near vision improvement, as well as its ability to be used across the full age range of presbyopes, from their&#160;mid-40s&#160;to well into their&#160;mid-70s,&#160;as well as the broadest refractive range. Aceclidine&#8217;s pupil-selective mechanism of action was demonstrated in our clinical trials where near vision improved while avoiding blurry distance vision. Our product candidate was well-tolerated in clinical trials, and its active ingredient aceclidine has a favorable tolerability profile that have been well-established empirically. LNZ100 has patent protection until 2039 in the United States, at a minimum, due to a robust intellectual property portfolio underpinned by issued patents. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the safety and efficacy trials (&#8220;CLARITY 1 and 2&#8221;) of our Phase 3 study, LNZ100 achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corrected Distance Visual Acuity (&#8220;BCDVA&#8221;) at near, without losing one or more lines in distance visual acuity. In the vehicle-controlled CLARITY 2 trial, the day 1 results showed (all p&#60;0.0001)&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Rapid onset</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; 71% achieved three-lines or greater improvement at 30 minutes.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Primary endpoint</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; 71% achieved three-lines or greater improvement at 3 hours. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Long duration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  40% achieved three-lines or greater improvement at 10 hours.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Near vision improvement was reproducible and consistent across both CLARITY 1 and 2 throughout the four-week study periods. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNZ100 was well-tolerated with no serious treatment-related adverse events observed in the over 30,000 treatment days including the six-week safety study period in CLARITY 1 and 2 and the six-month period in the CLARITY 3 Phase 3 long-term safety trial (collectively, the  &#8220;CLARITY study&#8221;). For more details, see the section entitled &#8220;CLARITY Phase 3 Clinical Trials (the &#8220;CLARITY Study&#8221;)&#8221; in this prospectus in the section titled &#8220;Business&#8221; beginning on page </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_2727" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">89</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had $65.8 million of cash, cash equivalents and short-term investments. Based on our current plans, we believe our existing cash, cash equivalents and short-term investments, together with the proceeds from the Merger and the PIPE Financing, will allow the company to continue to build infrastructure and commercialize LNZ100, subject to the NDA submission and FDA approval. We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for LNZ100. We have incurred net losses in each year since inception, and as of December 31, 2023, we had an accumulated deficit of $95.2 million. These losses have resulted principally from costs incurred in connection with research and development activities and selling, general and administrative costs associated with our operations. We expect to continue to incur significant expenses and operating losses for the foreseeable future due to the cost of research and development, including conducting clinical trials, the regulatory approval process and preparation for and the commercial launch of LNZ100, subject to FDA approval, including expenses related to product sales, marketing and distribution, and additional costs associated with being a public company, including audit, legal, regulatory and tax-related services associated with maintaining compliance with an exchange listing and SEC requirements. As a result of these and other factors, it is possible that we may require additional financing to fund our operations and planned growth.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the completion of the Merger, LENZ OpCo financed its operations primarily through private placements of its common stock and convertible preferred stock, including the following financings during the periods presented&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2023, LENZ OpCo issued and sold an aggregate of 28,019,181 shares of Series B preferred stock at a purchase price of $2.9801 per share for an aggregate purchase price of approximately $83.5 million.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2022, LENZ OpCo issued and sold an aggregate of 9,899,340 shares of Series A Preferred Stock at a purchase price of $2.15 per share for an aggregate purchase price of approximately $21.3 million as part of a milestone closing of the 2021 Series A Preferred Stock financing.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2022, LENZ OpCo issued and sold an aggregate of 2,950,548 shares of Series A-1 Preferred Stock at a purchase price of $3.3892 per share for an aggregate purchase price of approximately $10.0 million.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate significant revenue from sales of LNZ100, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourself.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ji Xing License and Collaboration Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a License and Collaboration Agreement with Ji Xing Pharmaceuticals Hong Kong Limited (&#8220;Ji Xing&#8221;) granting Ji Xing an exclusive license (the &#8220;Ji Xing License&#8221;) to certain of our intellectual property rights to develop, use, import, and sell products containing LNZ100 or LNZ101 (&#8220;Products&#8221;) for the treatment of presbyopia in humans in mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan (collectively, &#8220;Greater China). We also granted Ji Xing (i) the right to negotiate in good faith and enter into agreements to purchase Products from us for clinical and commercial uses at cost plus a negotiated percentage and (ii) the right of first negotiation to obtain a regional license from us on other products we might develop outside of the field of presbyopia for commercialization in Greater China.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received nonrefundable, non-creditable upfront payments totaling $15.0 million as initial consideration under the Ji Xing License. In addition, we are also eligible to receive (i) up to $95.0 million in regulatory and sales milestone payments, (ii) tiered, escalating royalties in the range of 5% to 15% on net sales of Products in Greater China by Ji Xing, its affiliates and sublicensees, and (iii) tiered, deescalating royalties in the range of 15% to 5% of sublicensing income received by Ji Xing prior to the regulatory approval of the first Product in Greater China.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $15.0 million upfront payments allocated to that single performance obligation was recognized on execution of the Ji Xing License in the year ended December 31, 2022. No additional amounts under the Ji Xing License were received during the year ended December 31, 2022.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Ji Xing License, RTW Investments, LP (&#8220;RTW&#8221;), a significant investor in Ji Xing, through three funds managed or advised by RTW, invested approximately $10.0 million in exchange for 2,950,548 shares of LENZ OpCo's Series A-1 Preferred Stock at a purchase price of $3.3892 per share.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Trends and Factors Affecting Comparability Between Periods</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Ji Xing License was signed in April 2022, and we recorded $15.0 million of revenue for the year ended December 31, 2022. We did not generate any revenue related to the Ji Xing License or from other sources for the year ending December 31, 2023.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to build out our research and development team and our research and development costs increased in 2023, relative to 2022, as a result of significant expenses related to the CLARITY trials. See the section of this prospectus titled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Business&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information about the CLARITY trials.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have built a cross-functional commercial team consisting of marketing, market access and commercial operations and will continue to strategically build our sales and our commercial infrastructure with capabilities designed to scale when necessary to support a commercial launch if approval is received. These expenses increased in 2023 as compared to 2022.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Following the Merger, the combined company&#8217;s expenses will increase from those that we incurred in prior years as a privately held company, including (i) costs to comply with the rules and regulations of the SEC and those of Nasdaq, (ii) legal, accounting and other professional services, (iii) insurance, (iv) investor relations activities, and (v) other administrative and professional services.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Merger and PIPE Financing</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2023, we entered into the Merger Agreement with Graphite and Generate Merger Sub, pursuant to which LENZ OpCo merged with and into Generate Merger Sub at the Effective Time on March 21, 2024, with LENZ OpCo continuing after the Merger as the surviving company and a wholly-owned subsidiary of Graphite. At the Effective Time, each outstanding share of LENZ OpCo capital stock was converted into the right to receive shares of Graphite common stock, par value $0.00001, as set forth in the Merger Agreement. Upon closing of the Merger, the combined company was named &#8220;LENZ Therapeutics, Inc.&#8221; and will continue to be listed on the Nasdaq.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the exchange ratio formula in the Merger Agreement, immediately following the Effective Time, the LENZ OpCo securityholders owned approximately 65% of the outstanding shares of the combined company&#8217;s common stock on a fully-diluted basis and securityholders of Graphite as of immediately prior to the Effective Time owned approximately 35% of the outstanding shares of the combined company&#8217;s common stock on a fully-diluted basis (prior to giving effect to the PIPE Financing and excluding shares reserved for future grants under the 2024 Plan and the 2024 ESPP).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Merger Agreement, Graphite entered into the subscription agreement with the PIPE Investors, pursuant to which, immediately following the Effective Time, the PIPE Investors subscribed for and purchased an aggregate of 3,559,565 shares of Common Stock at a price of $15.0299 per share for aggregate gross proceeds of approximately $53.5 million. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described and provides information that management believes is relevant for an assessment and understanding of the balance sheets and statements of operations and comprehensive loss presented herein. The following discussion and analysis are based on our audited financial statements and related notes thereto, which we have prepared in accordance with GAAP. You should read the discussion and analysis together with such audited financial statements and the related notes thereto.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Statements of Operations and Comprehensive Loss</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no products approved for sale, and we have not generated any revenue from product sales to date. We have generated revenue related to the Ji Xing License, and in the future may generate revenue from payments received under licenses or collaboration agreements we may enter into with respect to our product candidates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded $15.0 million of license revenue related to the Ji Xing License for the year ended December 31, 2022.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not generate any revenue related to the Ji Xing License or from other sources for the year ended December 31, 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses, which consist primarily of costs associated with our product research and development efforts, are expensed as incurred. Research and development expenses consist primarily of&#58; (i) employee related costs, including salaries, benefits and share-based compensation expense for employees engaged in research and development activities&#59; (ii) third-party contract costs relating to research, formulation, manufacturing, nonclinical studies and clinical trial activities&#59; (iii) external costs of outside consultants who assist with technology development, regulatory affairs, clinical development and quality assurance&#59; and (iv) allocated facility-related costs. We track research and development costs collectively for LNZ100 or LNZ101 because expenses incurred are interrelated and disaggregation would not be meaningful.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for certain activities, such as manufacturing, nonclinical studies and clinical trials are generally recognized based on the evaluation of the progress of completion of specific tasks using information and data provided by our vendors and collaborators. Research and development activities are central to our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to build out our research and development team and we expect our research and development costs will decrease in 2024, relative to 2023, given the completion of the CLARITY trials in April 2024.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and related benefits, including share-based compensation, related to our executive, finance, business development, sales and marketing, and other corporate functions. Other general and administrative expenses include professional fees for legal, auditing, tax and business consulting services, insurance costs, intellectual property and patent costs, facility costs and travel costs. We expect that selling, general and administrative expenses will increase in the future as we expand our operating activities. Additionally, we expect that the combined company will incur significant additional expenses associated with being a public company that LENZ OpCo did not incur as a privately-held company, including (i) costs to comply with the rules and regulations of the SEC and those of Nasdaq, (ii) legal, accounting and other professional services, (iii) insurance, (iv) investor relations activities, and (v) other administrative and professional services.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net consists of the change in fair value of preferred stock warrants liability and interest income earned on cash, cash equivalents and short-term investments.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) consists of U.S. federal and state income taxes.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Year Ended December 31, 2022 and 2023</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the results of operations for the periods indicated (amounts in thousands, except percentages)&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue </font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,000)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,125&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,504&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,379&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,483&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,429&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,946&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,483)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,429)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,946)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,625&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,282&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,911&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,464)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,147)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,683)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,811)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,968)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,157)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we recognized $15.0 million of license revenue related to the Ji Xing License. This revenue was recognized upon completion of the related performance obligation. We did not recognize any revenue for the year ended December 31, 2023.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our research and development expenses incurred for the years ended December 31, 2022 and 2023 were related to the development of LNZ100 and LNZ101, which were both included together in our INSIGHT and CLARITY trials.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a detailed breakdown of our research and development expenses for the periods indicated (in thousands)&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract clinical research expense</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,598&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,949&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,006&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,339&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract nonclinical research expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,835&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract regulatory consulting expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee salaries and related expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,131&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,125&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,504&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $38.4 million, or 182%, from $21.1 million for the year ended December 31, 2022 to $59.5 million for the year ended December 31, 2023. The increase was primarily driven by a $26.4 million increase in contract research expense for our clinical trials, a $2.3 million increase in contract manufacturing expenses for clinical drug product manufacturing, a $5.6 million increase in contract nonclinical research expense, and a $2.3 million increase in employee salaries and related expenses. These increases were primarily related to our CLARITY trials and preparation for our potential NDA filing.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $8.6 million, or 197%, from $4.4 million for the year ended December 31, 2022 to $12.9 million for the year ended December 31, 2023. The increase was primarily driven by a $4.6 million increase in legal and other professional services (principally related to legal fees incurred in connection with our abandoned initial public offering), a $2.2 million increase in employee salaries and related expenses due to increased headcount, and a $1.4 million increase in sales infrastructure and marketing expenses.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net for the year ended December 31, 2022, was $19,000, compared to $2.3 million for the year ended December 31, 2023. The change was primarily driven by a $2.2 million increase in interest income and a reduction in fair value of preferred stock warrants liability of $0.1 million.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we recognized income tax expense $0.3 million due to the requirement to capitalize research and development expenses under the Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;), compared to an income tax benefit of $0.2 million for the year ended December 31, 2023 primarily due to our income derived in foreign markets, which is subject to a lower tax rate as a result of the foreign-derived intangible income deduction that was introduced as part of the TCJA. The TCJA requires taxpayers to capitalize and amortize research and development expenditures under section 174 for tax years beginning after December 31, 2021. This rule became effective for us during the year ended December 31, 2022 resulting in a gross deferred tax asset for capitalized research and development expenditures of approximately $66.0 million as of December 31, 2023. We will continue to amortize these costs for tax purposes over 5 years for R&#38;D performed in the U.S. and over 15&#160;years for R&#38;D performed outside the U.S.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had $65.8 million of cash, cash equivalents and marketable securities. Based on our current operating plans, we believe our existing cash, cash equivalents and short-term investments will be sufficient to fund our planned operations into 2025. Further, based on our current operating plans, we believe our cash, cash equivalents, and short-term investments as of December 31, 2023, together with the proceeds from the merger and the Graphite private placement, will be sufficient to fund our planned operations through several anticipated value-creating milestones and through at least 2026, and will allow us to continue to build infrastructure and commercialize our lead product candidate, subject to successful completion of the ongoing Phase 3 trials, NDA submission and FDA approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses in each year since inception and as of December 31, 2023, we had an accumulated deficit of $95.2 million. Our net losses were $10.8 million and $70.0 million for the years ended December 31, 2022 and 2023, respectively. These losses have resulted principally from costs incurred in connection with research and development activities and selling, general and administrative costs associated with our operations. We expect to continue to incur significant expenses and operating losses for the foreseeable future due to the cost of research and development, the regulatory approval process for LNZ100, and the commercial launch of LNZ100, if approved.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through December 31, 2023, we received funding of $13.0 million from our initial seed financing, $47.0 million from the sale of Series A Convertible Preferred Stock, $10.0 million from the sale of Series&#160;A-1 Convertible Preferred Stock, and gross proceeds of $83.5 million from the sale of Series B Convertible Preferred Stock.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into 2025. Further, based on our current operating plans, we believe our existing cash, cash equivalents, and short-term investments, together with the proceeds from the Merger and the PIPE Financing, will be sufficient to fund our planned operations through several anticipated value-creating milestones and through at least 2026, and will allow us to continue to build infrastructure and commercialize LNZ100, subject to NDA submission and FDA approval. This belief is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than expected. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than currently anticipated, and we may need to seek additional funds sooner than planned.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including but not limited to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results, costs, and timing of any additional clinical trials we are required to complete for LNZ100&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of manufacturing for LNZ100 and commercial manufacturing if LNZ100 is approved&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with establishing a sales, marketing, and distribution infrastructure to commercialize LNZ100 if we obtain marketing approval&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of LNZ100&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the legal costs of obtaining, maintaining, and enforcing our patents and other intellectual property rights&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of establishing and maintaining licenses and other similar arrangements&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve sufficient market acceptance and adequate market share and revenue for LNZ100. if approved&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with any products or technologies that we may in-license or otherwise acquire or develop.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, LENZ OpCo funded its operations primarily through the sale and issuance of convertible preferred stock and it is possible that, following the Merger, we may require additional financing. We intend to evaluate financing opportunities from time to time, and our ability to obtain financing will depend, among other things, on our development efforts, business plans, operating performance and the condition of the capital markets at the time we seek financing. We cannot assure you that additional financing will be available to us on favorable terms when required, or at all. If we raise additional funds through the issuance of equity or equity-linked securities, those securities may have rights, preferences or privileges senior to the rights of our Common Stock, and our stockholders may experience dilution. If we raise additional funds through the incurrence of indebtedness, then we may be subject to increased fixed payment obligations and could be subject to restrictive covenants, such as limitations on our ability to incur additional debt, and other operating restrictions that could adversely impact our ability to conduct our business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the years presented (amounts in thousands)&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,091)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,380)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,621)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,700&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,134&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,301)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net cash used in operating activities primarily results from our net loss adjusted for non-cash expenses, changes in working capital components, amounts due to contract research organizations to conduct our clinical programs, manufacturing of drug product and employee-related expenditures for research and development and selling, general and administrative activities. Our cash flows from operating activities will continue to be affected by spending to develop and pursue regulatory approval for LNZ100 and commercialization activities, if approval is obtained. Our cash flows will also be affected by other operating and general administrative activities, including operating as a public company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, cash used in operating activities was $4.1 million and resulted from (i) our net loss of $10.8 million plus a $2.1 million increase in operating assets, offset by (ii) a $8.2 million increase in accounts payable and accrued liabilities and $0.7 million in non-cash adjustments primarily related to share-based compensation expense.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, cash used in operating activities was $60.4 million and resulted from (i) our net loss of $70.0 million, plus $1.1 million in amortization of premiums and discounts on marketable securities, offset by (ii) an $8.6 million increase in accounts payable and accrued liabilities, $1.3 million of share-based compensation expense, and a $0.8 million decrease in operating assets.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Investing Activities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the year ended December 31, 2022 was $37,000 and related to the purchase of property and equipment.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, cash used in investing activities was $29.6 million and related primarily to the purchase of marketable securities of $52.1 million offset by proceeds from maturities of marketable securities of $22.5 million.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the year ended December 31, 2022 includes $20.2 million in net cash proceeds from the sale by LENZ OpCo of Series A Convertible Preferred Stock, $9.9 million in net cash proceeds from the sale by LENZ OpCo of Series A-1 Convertible Preferred Stock, and $0.1 million in net cash proceeds from the exercise of LENZ OpCo stock options.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, cash provided by financing activities was $80.7 million and consisted of $83.0 million in net cash proceeds from the sale by LENZ OpCo of Series B Convertible Preferred Stock, and $0.2 million in net cash proceeds from the exercise of LENZ OpCo stock options, offset by an increase in deferred offering costs of $2.5 million.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Cash Requirements from Contractual Obligations</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we entered into a lease for 2,930 square feet of office space in Del Mar, California. In March 2023, we entered into a lease amendment for a 647 square feet expansion of our office space at the same facility. The term of the lease, as amended, is forty-eight months from the original commencement date, terminating March 31, 2026, unless terminated sooner.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recorded on a straight-line basis. Rent expense related to the Del Mar lease was $0.1 million for the years ended December 31, 2022 and 2023, respectively. See Note 6 to our audited financial statements for details related to future lease payments.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have contracts with various organizations to conduct research and development activities, including clinical trial organizations to manage clinical trial activities and manufacturing companies to manufacture the drug product used in the clinical trials. The scope of the services under these research and development contracts can be modified and the contracts cancelled by us upon written notice. In the event of a cancellation, the company would be liable for the cost and expenses incurred to date as well as any close out costs of the service arrangement.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of the financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of our financial statements requires us to make certain estimates, judgements and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We believe that the estimates, judgments and assumptions are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected. Historically, revisions to our estimates have not resulted in a material change to our financial statements.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our financial statements, we believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our financial statements.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Accrued Research and Development Expenses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our financial statements, we are required to estimate our prepaid and accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our prepaid and accrued research and development </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at the time.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates and amounts actually incurred.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock Warrants Liability</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LENZ OpCo had freestanding warrants to purchase shares of Series A convertible preferred stock, referred to herein as the Series A Warrants. Upon certain change in control events that were outside of LENZ OpCo's control, including liquidation, sale or transfer of control, holders of the preferred stock could cause redemption of such warrants. The Series A Warrants are revalued at each subsequent balance sheet date, with fair value changes recognized as increases or reductions to other income (expense), net in the accompanying statements of operations. See Note 3 to our audited financial statements for information concerning certain of the specific assumptions we used in determining the value of the Series A Warrants at each reporting period. Upon completion of the Merger, the Series A Warrants became exercisable into shares of the Common Stock and will no longer continue to be remeasured at each reporting date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. We estimate the fair value of equity awards using the Black-Scholes option pricing model and recognize forfeitures as they occur. Estimating the fair value of equity awards as of the grant date using valuation models, such as the Black-Scholes option pricing model, is affected by assumptions regarding a number of variables, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield and the fair value of the underlying common stock on the date of grant. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop. See Note 10 to our audited financial statements for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted, if any, during the years ended December 31, 2022 and 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Valuations</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LENZ OpCo was required to estimate the fair value of the common stock underlying its equity awards when performing fair value calculations. The fair value of the common stock underlying such equity awards was determined on the grant date by the LENZ OpCo board of directors considering the most recently available third-party valuations of LENZ OpCo common stock and the LENZ OpCo board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the grant. All options were intended to be granted with an exercise price per share no less than the fair value per share of common stock underlying those options on the date of grant, based on the information known to the LENZ OpCo board of directors on the date of grant. In the absence of a public trading market for the LENZ OpCo common stock prior to the Merger, on each grant date LENZ OpCo developed an estimate of the fair value of our common stock in order to determine an exercise price for the option grants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The various objective and subjective factors the LENZ OpCo board of directors considered, along with input from management, to determine the fair value of the LENZ OpCo common stock, included&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">valuations of the LENZ OpCo common stock performed by independent third-party valuation specialists&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LENZ OpCo's stage of development and business strategy, including the status of research and development efforts of its platforms, programs and product candidates, and the material risks related to its business and industry&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LENZ OpCo's results of operations and financial position, including levels of available capital resources&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed mergers and acquisitions of peer companies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of marketability of the LENZ OpCo common stock as a private company&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prices of LENZ OpCo convertible preferred stock sold to investors in arm&#8217;s length transactions and the rights, preferences, and privileges of LENZ OpCo convertible preferred stock relative to those of LENZ OpCo common stock&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of achieving a liquidity event for the holders of LENZ OpCo common stock, such as an initial public offering or a sale of the company, given prevailing market conditions&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trends and developments in LENZ OpCo's industry&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external market conditions affecting the life sciences and biotechnology industry sectors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, determinations of the fair value of LENZ OpCo common stock have included the consideration by the LENZ OpCo board of directors of valuations prepared by an independent third-party valuation specialist using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide&#58; Valuation of Privately Held Company Equity Securities Issued as Compensation (the &#8220;Practice Aid&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Practice Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to the LENZ OpCo common stock. The cost approach establishes the value of an enterprise based on the cost of reproducing or replacing the property less depreciation and functional or economic obsolescence, if present. The income approach establishes the value of an enterprise based on the present value of future cash flows that are reasonably reflective of LENZ OpCo's future operations, discounting to the present value with an appropriate risk adjusted discount rate or capitalization rate. The market approach is based on the assumption that the value of an asset is equal to the value of a substitute asset with the same characteristics. Each valuation methodology was considered in LENZ OpCo's valuations.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Practice Aid also identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, the LENZ OpCo board of directors considered the following methods&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Probability-weighted expected return method (&#8220;PWERM&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The PWERM is a scenario-based analysis that estimates the fair value of common stock based upon an analysis of future values for the business, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible forecasted outcomes as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at a non-marketable indication of value for the common stock.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Option Pricing Method (&#8220;OPM&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the OPM, shares are valued by creating a series of call options, representing the present value of the expected future returns to the stockholders, with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are inferred by analyzing these options.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Hybrid Return Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The hybrid return method is a blended approach using aspects of both the PWERM and OPM, in which the equity value in one of the scenarios is calculated using an OPM.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LENZ OpCo generally estimated the enterprise value of its business using a market approach. For each of the valuations conducted as of October 30, 2020, May 1, 2022 and October 31, 2022, LENZ OpCo used the precedent transaction method (one of the three general methodologies of the market approach) to determine enterprise value. The precedent transaction method considers the sale price of shares in a recent financing and then back- solves using an option pricing model that gives consideration to the company's capitalization structure and rights of the preferred and common stockholders as well as an assumption for a discount for lack of marketability (&#8220;DLOM&#8221;). For the March 6, 2023, June 30, 2023, and September 6, 2023 valuations, LENZ OpCo examined two scenarios to estimate enterprise value&#58; (1) the &#8220;IPO Scenario,&#8221; which represents the future value of LENZ OpCo common stock upon an initial public offering, based on certain assumptions, and then risk-adjusts to estimate the present value of LENZ OpCo's common stock excluding any DLOM, and (2) the &#8220;Stay Private Scenario,&#8221; in which LENZ OpCo would remain an independent and private company and for which it used the precedent transaction method including a DLOM. We then probability weighted the valuations for the IPO Scenario and the Stay Private Scenario to estimate enterprise value.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the uncertainty associated with both the timing and type of any future exit scenario, and based on LENZ OpCo's stage of development and other relevant factors, for the valuations conducted as of October 30, 2020, May&#160;1, 2022, and October 31, 2022, LENZ OpCo concluded that the OPM was most appropriate for allocating enterprise value. LENZ OpCo believed the OPM was the most appropriate given the expectation of various potential liquidity outcomes and the difficulty of selecting and supporting appropriate enterprise values given LENZ OpCo's early stage of development. Under the OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of LENZ OpCo's preferred stock and common stock are inferred by analyzing these options. For the valuations conducted as of March 6, 2023, June 30, 2023, and September 6, 2023, LENZ OpCo determined to allocate enterprise value using the hybrid return method, which is a hybrid between PWERM and OPM and estimates the probability weighted value across multiple scenarios but uses the OPM to estimate the allocation of value within one or more of those scenarios. The hybrid method is useful when certain discrete future outcomes can be predicted, but also accounts for uncertainty regarding the timing or likelihood of specific alternative exit events.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions underlying these valuations represented LENZ OpCo management&#8217;s best estimates, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if LENZ OpCo had used significantly different assumptions or estimates, the fair value of LENZ OpCo's common stock and LENZ OpCo's stock-based compensation expense could have been materially different. Following the closing of the Merger, our board of directors will determine the fair value of our common stock based on our closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Company Information</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jumpstart Our Business Startups Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be an emerging growth company, as defined in the JOBS Act, and we may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the initial public offering of Graphite&#8217;s common stock. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company disclosure and reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. In particular, we have provided only two years of audited financial statements and have not included all of the executive compensation-related information that would be required if we were not an emerging growth company. Accordingly, the information contained herein may not be comparable with the information stockholders receive from other public companies in which they may hold stock.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Prior to the Merger, Graphite has elected to use, and we intend to continue to use, this extended transition period for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complying with certain or new or revised accounting standards until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the closing of Graphite's initial public offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th, (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period, or (iii) if we affirmatively and irrevocably opt out of the extended transition period provided by the JOBS Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also be a &#8220;smaller reporting company&#8221; because the market value of Graphite&#8217;s stock held by non-affiliates was less than $700 million as of June 30, 2023 and its annual revenue was less than $100&#160;million during the fiscal year ended December 31, 2022. We may continue to be a smaller reporting company after the Merger in any given year if either (i) the market value of our stock held by non-affiliates is less than $250 million as of June 30 in the most recently completed fiscal year or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million as of June 30 in the most recently completed fiscal year. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to our audited financial statements included elsewhere in this prospectus for a discussion of recent accounting pronouncements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_2727"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Our initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45. In the United States, the estimated addressable population who suffer from this condition, known as presbyopes, is 128 million, almost four times the number of individuals suffering from dry eye disease and three times the number of individuals suffering from childhood myopia, macular degeneration, diabetic retinopathy and glaucoma combined. We believe that a once-daily pharmacological eye drop that can effectively and safely improve near vision throughout the full workday, without the need for reading glasses, will be a highly attractive commercial product with an estimated U.S. market opportunity in excess of $3 billion. It is our goal to develop and commercialize such a product, and we have assembled an executive team with extensive clinical and commercial experience to execute this goal and become the category leader.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. We believe our product candidate is differentiated based on rapid onset, degree and duration of near vision improvement, as well as its ability to be used across the full age range of presbyopes, from their mid-40s to well into their mid-70s, as well as the broadest refractive range. Aceclidine&#8217;s pupil-selective mechanism of action was demonstrated in our clinical trials where near vision improved while avoiding blurry distance vision. LNZ100 was well-tolerated in clinical trials and its active ingredient aceclidine has a favorable tolerability profile. LNZ100 has patent protection until 2039 in the United States, at a minimum, due to a robust intellectual property portfolio underpinned by issued patents. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the safety and efficacy trials of our Phase 3 study (&#8220;CLARITY 1 and 2&#8221;), LNZ100 achieved the primary endpoints and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (&#8220;BCDVA&#8221;) at near, without losing one or more lines in distance visual acuity. In the vehicle-controlled CLARITY 2 trial, the day 1 results showed (all p&#60;0.0001)&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Rapid onset&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 71% achieved three-lines or greater improvement at 30 minutes.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Primary endpoint&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 71% achieved three-lines or greater improvement at 3 hours. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Long duration&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  40% achieved three-lines or greater improvement at 10 hours.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Near vision improvement was reproducible and consistent across both CLARITY 1 and 2 throughout the four-week study periods. LNZ100 was well-tolerated with no serious treatment-related adverse events observed in the over 30,000 treatment days, including the six-week safety study period in CLARITY 1 and 2, and the six-month period in the CLARITY 3 Phase 3 long-term safety trial (collectively, the &#8220;CLARITY study&#8221;). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other product candidate LNZ101,a preservative-free eye drop containing aceclidine and brimonidine, showed similar results, including achieving primary and secondary endpoints in both CLARITY 1 and 2, but did not show superiority to LNZ100. Based on these results, we selected LNZ100 as our lead product candidate. We plan to submit a New Drug Application (&#34;NDA&#34;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for LNZ100 in mid-2024 with a launch target date in the second half of 2025 assuming approval. We believe that LNZ100, if approved, could be the first aceclidine-based product approved by the FDA and would then be eligible for five years of new chemical entity (&#8220;NCE&#8221;) exclusivity in the United States.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is estimated that there are 1.8 billion presbyopes globally and 128 million presbyopes in the United States. As people age, the crystalline lens in their eyes gradually hardens, resulting in a loss of lens elasticity that reduces the ability of the lens to increase its curvature and refractive power to focus incoming light for near vision onto the retina, known as accommodation. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an eye care professional (&#8220;ECP&#8221;), with prescription reading or bifocal glasses or multifocal contact lenses. Currently, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the only approved and marketed pharmaceutical treatment for presbyopia is marketed by AbbVie under the brand Vuity.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on data collected in a third-party study commissioned by us in early 2023 that is further described in the section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Market Opportunity,&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we found that presbyopes have high willingness to use a daily prescription eye drop that improves their near vision throughout the full workday. We expect that there will be a wide range of presbyopes that will be interested in using the eye drops at least four times a week. The large initial demand seen for Vuity during its launch in late 2021 and early 2022 corroborates the market demand for a pharmaceutical option for the treatment of presbyopia. However, despite a promising initial launch, Vuity&#8217;s user uptake has been limited by reportedly lower-than-expected efficacy and duration of effect across users. Additionally, Vuity use is associated with some side effects, including retinal tears and detachments, induced by the stimulation of the ciliary muscle. These limitations on efficacy and safety subsequently resulted in lower than anticipated prescription refill rates and a label amendment reflecting the risk of retinal tears and detachment specifically associated with Vuity. We believe that our once-daily eye drop, if approved, could become the leading brand for presbyopes, by improving near vision throughout the full workday.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNZ100 is formulated with aceclidine, a miotic, and is designed to achieve optimal pupil diameter without impacting distance vision, a key limitation of other miotics. Miotics are compounds that cause pupil constriction, or miosis, creating a pinhole effect that enables better focus of incoming light from near objects onto the retina. Research has shown that a pupil diameter below two millimeters (2 mm) is optimal for presbyopia treatment and results in clinically meaningful improvement in near vision. Unlike other miotics such as pilocarpine and carbachol, aceclidine's mechanism of action is pupil-selective, meaning it can activate the iris sphincter muscle and cause miosis of the pupil to a diameter below 2 mm without overstimulating the ciliary muscles that can cause a myopic shift and impair distance vision. As a result, aceclidine does not require any remaining accommodation to improve near vision, broadening its benefits to older presbyopes whose lens has lost this capacity. Therefore, we expect that users may be able to benefit from treatment even as they age from mid-40s to well into their mid-70s and across a broader range of refractive errors, as demonstrated in clinical testing to date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While aceclidine is new to the United States, it has a long-established history outside of the United States, having been approved in Europe since the 1970s for the treatment of glaucoma and marketed by Merck under the brand Glaucostat, at higher concentrations than in LNZ100 and up to four times a day. Given the known favorable tolerability profile of aceclidine, LNZ100&#8217;s sole active ingredient, its decades-long use, and unique mechanism of action, we believe LNZ100 has the potential to treat the broadest population of presbyopes and become the category leader.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our goal to develop and commercialize the leading, once-daily eye drop for presbyopia that can effectively and safely improve near vision throughout the full workday, we continue to build a robust commercial strategy in the United States to be launch-ready upon expected timing of FDA approval. We retain the flexibility to not only seek commercialization of our product candidates, but to also remain opportunistic in developing, in-licensing or partnering other products or product candidates to further leverage our commercial infrastructure to drive growth and operating leverage. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute our vision, we have assembled a team with extensive experience in building successful life science and consumer product companies. Our team has helped launch and commercialize over a dozen ophthalmic products and therapies, including Acuvue, Alphagan P, Combigan, Dailies AquaComfort Plus, Durysta, Latisse, Lumigan, Pred Forte, Refresh, Restasis, Truetear, and Vuity, as well as major consumer-focused brands such as Botox, Herbalife and Ray-Ban. Members of our management team have held senior positions at Alcon, Allergan, Alvotech, Avanir, Bausch + Lomb, Herbalife, Hospira, Johnson &#38; Johnson, Pfenex, Pfizer, VISX and others. We have also engaged a strong team of medical advisors across the ophthalmology and optometry fields. Our team is further supported by a strong group of investors that share our commitment to helping the millions of people experiencing symptoms of presbyopia in the United States and globally.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LENZ Strategy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Our goal is to develop and commercialize the leading, once-daily eye drop for presbyopia that can effectively and safely improve near vision throughout the full workday. We intend to achieve this goal by pursuing the following key strategic objectives&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Capitalize on the unique characteristics of aceclidine through LNZ100.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A key part of our strategy was the selection and development of aceclidine as a miotic agent for the treatment of presbyopia. As the only known pupil-selective miotic, aceclidine has a unique mechanism of action that we believe should allow for development as a category leading eye drop for presbyopia. We have since demonstrated our ability to enable rapid onset, degree and duration of near vision improvement with minimal risk of impact to distance vision in multiple clinical trials. Furthermore, we believe that aceclidine can address both a wider age range of presbyopes from mid-40s to well into their mid-70s, as well as broader refractive range, relative to currently available eye drops.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pursue approval and commercialization of LNZ100.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on our positive Phase 3 results, we selected LNZ100 as our lead product candidate. We plan to submit an NDA for LNZ100 in mid-2024 with a launch target date in the second half of 2025. We believe that LNZ100, if approved, could be the first aceclidine-based product approved by the FDA and would then be eligible for five years of NCE exclusivity in the United States. If approved by FDA, our objective is to best create loyalty and value based on an &#34;all eyes, all day&#34; brand mission.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pursue our focused commercial strategy across U.S. ECPs and presbyopes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are focused on targeting and partnering with the estimated 15,000 ECPs who prescribed over 85% of the pharmaceutical presbyopia prescriptions in the United States in 2022 to enable efficient commercialization and rapid adoption of our product. We are currently educating ECPs on the importance of pupil-selective miotics that have a clinical profile that reduces pupil diameter below 2 mm without overstimulating the ciliary muscles. If approved, we plan to communicate the efficacy profile of the approved product and highlight the value proposition of an alternative treatment option for presbyopia for ECPs. In parallel, our commercial team will deploy a cost-effective, highly targeted and digitally-focused consumer strategy to identify, target, and build loyalty among presbyopes in the United States. We expect to commercialize through the self-pay healthcare market (without third-party reimbursement), which is strategically advantageous in the United States and enables immediate patient access and volume-based pricing strategies.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Continue to build an experienced commercial team with the capabilities of a leading consumer-focused company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have built a leadership team with extensive experience across successful life science and consumer product companies who have launched and commercialized over a dozen ophthalmic products and therapies and well-known consumer-focused brands. Our leadership team is complemented by a team of leading medical advisors across the ophthalmology and optometry fields. To ensure immediate commercialization upon the potential approval of LNZ100, we are timing the expansion of our existing commercial capabilities and the development of a sales organization of 100 to 150 individuals to coincide with the expected timing of any such approval.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Continue to strengthen our intellectual property portfolio.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have developed and continue to expand a strong portfolio of intellectual property for the treatment of presbyopia with aceclidine-based eye drops. We have patent protection until 2039, at a minimum, in the United States due to a robust intellectual property portfolio underpinned by issued patents. If LNZ100 is approved, we believe that it could be the first FDA-approved aceclidine-based product and would then be eligible for five years of NCE exclusivity in the United States. We plan to actively seek to obtain, where appropriate, the broadest intellectual property protection possible by filing for additional patents or other applicable intellectual property protection covering new or enhanced proprietary technology, including new methods of use, formulations, and dosing regimens. We also rely on regulatory frameworks, trademarks, trade secrets, know-how, and continuing technological innovation and may consider in-licensing opportunities to develop and maintain our proprietary position.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Opportunistically evaluate strategic and commercial opportunities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are focused on commercializing in the United States on our own. In addition, we have entered into a license and collaboration agreement with Ji Xing to develop product candidates in Greater China and are developing regulatory strategies and intend to opportunistically seek partnerships for Europe, Canada, and other markets. For more details, see the subsection entitled &#34;License and Collaboration Agreement with Ji Xing Pharmaceuticals Hong Kong Limited.&#34; We believe our presbyopia program, if approved and successful, can serve as a cornerstone for building a suite of ophthalmology biopharmaceuticals. As a result, we may acquire other products or product candidates that we believe can make a substantial impact on vision and yield high user satisfaction. We may seek to maximize the commercial infrastructure and relationships with ECPs that we are currently building for our presbyopia program, to potentially offer a broad portfolio of ophthalmology biopharmaceuticals to our users to drive growth and operating leverage.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Presbyopia</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presbyopia is the inevitable loss of near vision associated with aging. It impacts the daily lives of nearly all people over 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over age 50 lose on average 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses. Currently, the only approved pharmaceutical treatment for presbyopia is marketed by AbbVie under the brand Vuity.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As illustrated in the figure below, contraction of the ciliary muscle allows the flexible lens in a healthy eye (center panel) to increase its curvature and refractive power and focus incoming light for near vision onto the retina in a process known as accommodation. As the lens hardens with age, the presbyopic lens (right panel) loses its flexibility and ability to accommodate and, despite contraction of the ciliary muscles, the incoming light for near vision no longer focuses on the surface of the retina, resulting in blurry near vision.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business1a.jpg" src="business1a.jpg" style="height:299px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Opportunity</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presbyopia impacts an estimated 1.8 billion people globally and 128 million people in the United States, which makes it the most prevalent ophthalmology indication, outside latent refractive errors. On an addressable population basis, presbyopia is almost four times greater than dry eye disease and three times greater than childhood myopia, macular degeneration, diabetic retinopathy and glaucoma combined. Furthermore, the market opportunity for presbyopia is growing due to the aging of the general population. As people continue working and stay active longer, they will require effective treatment for presbyopia for near vision acuity in their daily lives.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business2a.jpg" src="business2a.jpg" style="height:277px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presbyopia is a consumer-driven and cash pay market that requires intense focus on the needs and desires of presbyopes. We believe that the likely demand for a pharmaceutical option is driven by multiple factors, most notably presbyopes seeking to have a functional visual benefit in their day-to-day life, as well as those that want the cosmetic benefit of not requiring reading glasses. From a functional and cosmetic perspective, we see many similarities to the market dynamics between contact lenses and glasses. The contact lens market has grown to approximately $17 billion globally and approximately $6 billion in the United States in 2022. Contact lens users tend to have strong brand loyalty and the market has shown they are willing to spend out of pocket as an alternative to glasses for a variety of factors, including convenience, a more natural field of vision, enabling an active lifestyle and the ability to look younger. Similarly, over 10 million individuals have elected to complete laser vision correction, such as LASIK, which demonstrates a willingness to undergo elective surgical procedures to improve vision. Additionally, global sales of Botox injections for non-therapeutic applications, such as for cosmetic purposes, were $2.6 billion in 2022, demonstrating a high willingness to pay out of pocket for differentiated pharmaceutical brands. Currently, as people begin to develop presbyopia, they often have to stop using contact lenses, which seldom allow for simultaneous effective distance and near vision correction. A prescription eye drop that can be used in combination with distance correcting lenses can allow patients to stay in their contact lenses longer.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that there will be a wide range of presbyopes that will be interested in using the eye drops at least four times a week as well as a smaller group that will use them on a more episodic basis. In early 2023, we commissioned a third-party consultant to conduct a market research study of at least 1,000 presbyopes in the United States, ranging from ages 45 to 74, through a 15-minute online survey. The third-party consultant contacted and screened individuals who self-identified to be open to online surveys to ensure the participants satisfied the pre-specified age and near vision acuity requirements and that the group of respondents were balanced in gender and household income. Of the individuals screened, 1,358 individuals were qualified and completed the survey, and approximately 95% indicated they would &#34;consider&#34; using a once-daily prescription eye drop for up to 10 hours of near vision improvement, including 60% who indicated they would &#8220;seriously consider&#8221; using such eye drop. Of the respondents who also indicated that they would either &#8220;seriously consider&#8221; or &#8220;might consider&#8221; such eye drops, 79% </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indicated they would use such eye drops at least four times a week, including 58% who indicated they would use such eye drop six to seven times a week.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business3a.jpg" src="business3a.jpg" style="height:292px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, presbyopes indicated potential demand across multiple age cohorts across the following stages, including those adapting early (ages 45 to 54), busy midlife (ages 55 to 64) and active aging (ages 65+). 68% of respondents ages 45 to 54 (n&#61;452) would &#8220;seriously consider&#8221; and another 31% &#8220;might consider&#8221; such eye drop, of which 80% (of those who would consider such eye drops) would use such eye drop at least four times a week. For respondents ages 55 to 64 (n&#61;448), 62% would &#8220;seriously consider&#8221; and another 31% &#8220;might consider&#8221; such eye drop, of which 79% would use such eye drop at least four times a week, and for respondents ages 65 to 74 (n&#61;458), 51% would &#8220;seriously consider&#8221; and another 42% &#8220;might consider&#8221; such eye drop, of which 79% would use such eye drop at least four times a week. This market survey aligns with our patient reported outcomes from our CLARITY Phase 3 study, where 75% of the 223 participants surveyed on the 28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of receiving LNZ100 indicated interest in continuing to use the eye drops after the study, of which 81% would use the drops at least four times a week.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business4a.jpg" src="business4a.jpg" style="height:278px;margin-bottom:5pt;vertical-align:text-bottom;width:623px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is high demand for prescription eye drop-based treatments. In 2022 alone, more than 120,000 unique users paid out-of-pocket for a prescription for Vuity, the first miotic-based eye drop approved by the FDA in late 2021. Furthermore, the market opportunity for presbyopia is growing due to the aging of the general population and as people continue working and stay active longer they will require effective treatment for presbyopia for near vision acuity in their daily lives. Assuming a 6% adoption rate of the addressable presbyope patient population in the United States, we estimate there are eight million potential users in the United States for LNZ100, if approved and marketed, well below our estimate of the number of users of other out-of-pocket products such as LASIK. Using existing market price for Vuity of $79 per prescription and assuming a 42% refill rate (or five refills in a twelve-month period), we estimate a U.S. market opportunity in excess of $3 billion.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business5a.jpg" src="business5a.jpg" style="height:219px;margin-bottom:5pt;vertical-align:text-bottom;width:623px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approaches to Manage or Treat Presbyopia and Their Limitations</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the primary options available for the management of presbyopia are limited to reading glasses or multi-focal glasses and contact lenses. The only currently FDA-approved pharmaceutical treatment for presbyopia is marketed by AbbVie under the brand Vuity.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glasses and Contact Lenses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over-the-counter or prescription reading glasses (&#8220;readers&#8221;), prescription bifocal glasses and lenses (&#8220;bifocals&#8221;), graduated glasses (&#8220;transitions&#8221;), and multifocal contact lenses are commonly used to correct for presbyopia by focusing near objects on the retina. The additional refractive power that these types of corrective lenses offer can also be combined with other vision corrections in the same prescription lenses. However, users often report dissatisfaction with the inconvenience caused by having to wear and carry glasses or insert and remove contact lenses. There are also undesirable cultural connotations associated with the use of glasses, especially reading glasses, as they can be associated with aging. Additionally, these products require a trade-off between near vision and distance vision, either removing the readers, or looking at different areas of the bifocals.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eye Drops</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eye drops can be an attractive method of treatment for presbyopia, especially when they only need to be administered once daily and effectively improve near vision throughout the full workday. Such an option can obviate the need to carry and wear reading glasses.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Miotics are pharmacological agents that are being developed and commercialized for the treatment of presbyopia. Miotic agents treat presbyopia by creating a pinhole effect to increase the depth of focus and thus improve the ability to see up-close. The pinhole effect is based on an optical effect whereby the depth of focus is inversely correlated with the size of the opening that light travels through. When light passes through a small pinhole or pupil, the rays that hit the outer areas of the eye and would need the most refraction to be focused on one point of the retina are blocked, leaving only the center rays which require minimal refraction to land on the retina to form a clear image. In presbyopes who have minimal accommodation or refraction ability left in their lens, this pinhole effect improves their ability to clearly see objects that are up-close. Because some miotics are historically </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">known to negatively impact distance vision caused by a potential myopic shift associated with stimulation of the ciliary muscle, the FDA has indicated that the clinical endpoint for the approval of eye drops for the treatment of presbyopia is showing three-lines or greater (15 letters) of improvement in near visual acuity as a result of the reduction of the pupil diameter without losing one or more line (5 letters) in distance visual acuity.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business6a.jpg" src="business6a.jpg" style="height:233px;margin-bottom:5pt;vertical-align:text-bottom;width:528px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Independent, peer-reviewed, academic studies conducted by third parties and summarized by W. Neil Charman in a published editorial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have shown that pupil diameter is highly correlated with the depth of focus and that reducing pupil diameters below 2 mm is correlated with a dramatic increase in depth of focus (left graphic below). Similarly, in another independent, peer-reviewed, academic study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of near vision improvement conducted by a third party across a variety of lighting conditions, pupil diameters below 2 mm were correlated with two- to five-lines or greater improvement in near visual acuity (right graphic below).</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business7a.jpg" src="business7a.jpg" style="height:224px;margin-bottom:5pt;vertical-align:text-bottom;width:528px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparison of Miotics</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNZ100 is designed and formulated with aceclidine, a unique miotic, to achieve the below 2 mm pupil diameter without impacting distance vision, a key limitation seen by other miotics. Unlike other miotics such as pilocarpine and carbachol, aceclidine&#8217;s mechanism of action is pupil-selective, meaning it can activate the iris sphincter muscle and cause miosis without overstimulating the ciliary muscles that can cause a myopic shift and impair distance vision. Due to its pupil-selectivity and its ability to reduce the pupil diameter below 2 mm, aceclidine does not </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Charman, W.N. (2019), Pinholes and presbyopia&#58; solution or sideshow&#63;. Ophthalmic Physiol Opt, 39&#58; 1-10&#59; Ciuffreda, K.J., Rosenfield, M., Mordi, J., Chen, HW. (2000). Accommodation, age and presbyopia. In&#58; Franz&#233;n, O., Richter, H., Stark, L. (eds) Accommodation and Vergence Mechanisms in the Visual System. Birkh&#228;user, Basel.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Xu, R, Gil, D, Dibas, M, Hare, W, and Bradley, A, The Effect of Light Level and Small Pupils on Presbyopic Reading Performance. Investigative Ophthalmology &#38; Visual Science October 2016, Vol.57, 5656-5664.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require any remaining accommodation to improve near vision, broadening its benefit to older presbyopes whose lens has lost this capacity.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potency of a miotic towards the iris sphincter muscle or ciliary muscles can be expressed by EC50, the drug concentration required to produce 50% of its maximal effect, and its degree of pupil-selectivity can be expressed by the independence ratio, the ratio of the EC50 for the ciliary muscles to EC50 for the iris sphincter muscle. Based on a third-party, independent, peer-reviewed, academic study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the selectivity of certain miotics on human intraocular muscles, the independence ratio of aceclidine between the longitudinal ciliary muscle and the iris sphincter muscle can be calculated to be 28, and between the circular ciliary muscle and iris sphincter muscle to be 22, compared to 1.9 and 1.6, respectively, for pilocarpine and 5.4 and 5.3, respectively, for carbachol. The 11 to 17 times higher independence ratio of aceclidine compared to pilocarpine reflects its pupil-selectivity.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business8a.jpg" src="business8a.jpg" style="height:282px;margin-bottom:5pt;vertical-align:text-bottom;width:576px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the independence ratio, another independent, peer-reviewed, academic in vivo study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> looked at the correlation of pupil diameter and visual distortion caused by the myopic shift of various miotics, including aceclidine at a concentration different from LNZ100, which contains 1.75% aceclidine. The distortion is expressed in diopters (&#34;D&#34;), a measurement of focusing strength and distance used widely by ECPs to measure vision. Less change in diopter strength equates to lower disruption to distance vision. The results show that, among 40- to 60-year-old patients, treatment with 2% aceclidine results in reducing the pupil diameter below 2 mm with a negligible myopic shift as compared to 2% pilocarpine and 3% carbachol which drive respectively a -1.3D and -1.15D of myopic shift, respectively. A 1.0D myopic shift changes 20&#47;20 vision to 20&#47;50 distance vision, which can be measured as a decrease of four lines of vision in an eye exam. 20&#47;20 visual acuity means that a person can see at 20 feet what should normally be seen at that distance. 20&#47;50 visual acuity means that a person needs to be at 20 feet to see what a normal person can see at 50 feet. A minimum of 20&#47;40 vision is required to complete a driver&#8217;s test, so the &#62;1.0D</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> H Ishikawa, L DeSantis, PN Patil, Selectivity of muscarinic agonists including (+&#47;-)-aceclidine and antimuscarinics on the human intraocular muscles, J Ocul Pharmacol Ther. 1998 Aug&#59;14(4)&#58;363-73</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> J. Fran&#231;ois&#59; F. Goes, Ultrasonographic Study of the Effect of Different Miotics on the Eye Components, Ophthalmologica (1977) 175 (6)&#58; 328&#8211;338.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> myopic shift caused by pilocarpine and carbachol is enough to make an otherwise able driver now unfit to drive.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business9a.jpg" src="business9a.jpg" style="height:287px;margin-bottom:5pt;vertical-align:text-bottom;width:597px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When using non-pupil selective miotics, a trade-off is required between improvement in near vision and reduction in distance vision. Because aceclidine is a pupil-selective miotic and can reduce pupil diameter below 2 mm without overstimulating the ciliary muscles, no such compromise is needed. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, contraction of the ciliary muscle by drugs such as carbachol and pilocarpine pulls on a critical area of the eye where these muscle fibers connect to the retina. This constant tugging or pulling by the stimulated ciliary muscle can lead to retinal traction, vitreous detachments, secondary retinal pathology, and in severe cases, retinal detachments. Besides being described in peer-reviewed literature on chronic pilocarpine use for glaucoma, retinal detachments have also been reported by Vuity users. In August 2022, Vuity&#8217;s label was amended by the FDA to include a warning related to cases of retinal tears and detachments being reported with Vuity specifically, as opposed to miotics in general. In addition, the revised label advises having ECPs examine the retina of all patients prior to initiation of therapy. Despite the potential severity, concerns related to the risk of retinal tears and detachments ranked third behind low efficacy and low duration of efficacy among reasons why survey participants discontinued treatment with Vuity. Given that aceclidine has minimal effect on the ciliary muscle, we believe that the risk of side effects caused by activating the ciliary muscle are also reduced.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the only approved pharmaceutical treatment for presbyopia is an eye drop using pilocarpine as the active ingredient that is marketed by AbbVie under the brand Vuity. Despite an initial strong commercial launch with over 120,000 unique user prescriptions filled in 2022, the refill rate has lagged, primarily due to lower-than-expected efficacy and duration. Based on our commissioned survey of 40 ECPs, a majority reported that the barrier to Vuity adoption was that the product either did not work or did not work long enough. An additional survey of 18 optometrists indicated that 66% of their patients did not see duration past four hours despite one of the Vuity clinical trial results showing some effectiveness to the sixth hour. While this aligns with the primary endpoint of at three hours in both Phase 3 trials, the functional benefit was not sufficient enough to support patient needs. The ECPs and their patients identified the low effectiveness and short duration of effectiveness as the key factors for discontinuing use. To resolve the duration issue, AbbVie tested a twice-a-day dosing of the same formulation following initial approval of Vuity and achieved FDA approval for this updated dosing frequency in March 2023. The updated Vuity label now recommends that a second dose may be administered three to six hours after the first dose. Nonetheless, we believe users are looking for a once-daily solution that can last the full workday, which is further supported by the lack of increased Vuity uptake thus far following FDA approval of this label amendment. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, Vuity was primarily tested in younger presbyopes ranging from ages 40 to 55 with the average age of 50 in each of its Phase 3 GEMINI trials. Therefore, we expect that older users may experience even less effect as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they have little or no remaining accommodation to be activated to improve near vision, and Vuity has not been shown to reduce pupil diameter below 2 mm. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, the current treatment paradigm for presbyopia leaves much to be desired and is largely limited to symptom management or insufficiently effective pharmaceutical options. Evidence from patient surveys on their experience demonstrates patient appetite for a longer-lasting and holistic solution to the treatment of presbyopia.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Solution&#58; LNZ100 </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate LNZ100 is a single-use eye drop being developed to restore loss of near vision associated with presbyopia. LNZ100 contains 1.75% aceclidine as the sole active ingredient and is designed to be a once-daily dose that can potentially provide at least 10 hours of improved near vision. LNZ100 is preservative-free enabling it to be single-use, which is a more convenient delivery method for eye drops for users, and further differentiates us from Vuity. In our CLARITY 1 and CLARITY 2 Phase 3 trials, LNZ100 achieved its pre-specified primary endpoint of three-lines or greater improvement in BCDVA at near without losing one or more lines in distance visual acuity at three hours post-treatment, with a response rate of 71% (p&#60;0.0001) compared to 8% for vehicle. Based on these positive results in our Phase 3 trial, we selected LNZ100 as our lead product candidate and plan to submit an NDA to the FDA in mid-2024 with a launch target date in the second half of 2025.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business10a.jpg" src="business10a.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aceclidine</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We selected aceclidine, the key ingredient in LNZ100, for presbyopia because of its pupil-selective mechanism of action. The formulation was specifically designed to achieve a below 2 mm pupil diameter without impacting distance vision, a key limitation seen with other miotic agents, such as pilocarpine and carbachol. As evidenced above in the independence ratio and degree of myopic shift, aceclidine as an agent has robust clinical evidence to support the mechanism of action in achieving the key measures to both improve vision in normal and low light, while avoiding a myopic shift that impairs distance vision. Additionally, due to this pupil-selective mechanism of action, aceclidine does not require any remaining accommodation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, aceclidine has also been used in Europe since the 1970s as an eye drop for treatment of glaucoma and was marketed by Merck under the brand name Glaucostat. Aceclidine was previously marketed in at least twelve European countries, during which time over 400 million doses were administered up to four times a day and at higher concentrations than proposed for LNZ100, and it was well-tolerated with no known reports of tachyphylaxis, which is a sudden decrease in drug response. Aceclidine&#8217;s pupil-selective mechanism of action and reduced effect on the ciliary muscles made it a less desirable glaucoma treatment because it did not lower pressure as much as other marketed miotics. For the same reasons, it is potentially a better treatment for presbyopia than those other miotics. Though it has been used extensively throughout Europe, aceclidine was never commercialized in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States, reportedly because the lyophilized, or freeze-dried, nature of the glaucoma product presented complex supply chain issues. Nonetheless, given aceclidine&#8217;s broad safety profile, documented through decades of commercial use in Europe, and unique mechanism of action, we believe LNZ100 has the potential to treat a broad population of presbyopes globally as they are ready-to-use, stable liquid formulations of aceclidine.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLARITY Phase 3 Clinical Trials (the &#8220;CLARITY Study&#8221;)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, we reported topline results from the CLARITY study, a Phase 3 multi-center, double-masked, randomized, controlled, efficacy and safety study for LNZ100 and LNZ101 for the treatment of presbyopia. The CLARITY study is comprised of three Phase 3 trials&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">CLARITY 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;NCT05656027&#8221;) is a six-week, multi-center, double-masked, randomized trial that evaluated the efficacy and safety of LNZ100 and LNZ101. CLARITY 1 enrolled 469 participants, who were randomized to receive LNZ100, LNZ101 or brimonidine (at a 1&#58;1&#58;1 ratio) bilaterally. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">CLARITY 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;NCT05728944&#8221;) is also a six-week, multi-center, double-masked, randomized, Phase 3 evaluation of the efficacy and safety of LNZ100 and LNZ101 for the treatment of presbyopia. CLARITY 2 enrolled 229 participants, who were randomized to receive LNZ100, LNZ101 or vehicle (at a 1&#58;1&#58;1 ratio) bilaterally. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">CLARITY 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;NCT05753189&#8221;) is a six-month multi-center, double-masked, randomized, Phase 3 long-term safety study of LNZ100 and LNZ101 for the treatment of presbyopia. CLARITY 3 enrolled 361 participants, who were randomized to receive LNZ100, LNZ101 or vehicle (at a 2&#58;2&#58;1 ratio) bilaterally.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business11b.jpg" src="business11b.jpg" style="height:289px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trials enrolled a total of 1,059 participants ranging from ages 45 to 75, and a refractive range of -4.0D SE to +1.0D SE with a baseline near visual acuity of 20&#47;50 or worse. Some participants had previously undergone prior vision correction, such as LASIK, or cataract extraction with lens implant (referred to as &#34;pseudophakia&#34;). At the first visit, the participants were randomly assigned to one of three cohorts, which determined whether the participant would be treated with LNZ100, LNZ101 or the control, which was brimonidine for CLARITY 1 and vehicle for CLARITY 2 and 3. Participants used their assigned treatment agent every day once-daily. An aggregate of 234 participants in CLARITY 1 and 2 combined were assigned to use LNZ100 over the 42-day safety study period and in CLARITY 3, 144 participants assigned to use LNZ100 over the 180-day period, resulting in more than 30,000 LNZ100 treatment days across all three CLARITY trials. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary efficacy endpoint in both CLARITY 1 and 2 is the percentage of participants who achieve three-lines or greater improvement in BCDVA at near without losing one-line or more (5 letters or more of distance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vision) at three hours post-treatment relative to control. BCDVA in this context refers to the best possible distance vision that an individual&#8217;s eye can see using corrective lenses. BCDVA is a standard used in ophthalmology and optometry to determine the refractive state of the eye (nearsighted vs. farsighted). Having subjects use appropriate corrective lenses to see well at distance allows assessment of near vision deficits and comparisons across participants who may have different distance visual acuity. Additionally, we believe that using BCDVA provides the most accurate representation of the impact of the product candidate as it is intended to be used together with any distance corrective lenses that a user may need.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each participant was monitored and visual acuity was measured by a standardized eye test at certain timepoints from 30 minutes to 10 hours post-treatment, provided that on Day 15, efficacy in CLARITY 1 and 2 was measured over shorter period of 3 hours and on Day 42, only safety parameters were measured. We also measured the impact on distance vision in normal and low light at various timepoints. Participants also completed on Day 28 a patient-reported outcome questionnaire, and other assessments and measurements, such as the pupil diameter, which is considered a biomarker for near vision improvement, were also taken. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary Trial Results</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the figure below (with all p-value &#60;0.0001), both LNZ100 and LNZ101 achieved the primary endpoint of three-lines or greater improvement in near visual acuity at three hours post-treatment, without losing one or more lines in BCDVA, in both CLARITY 1 and CLARITY 2. In the vehicle-controlled CLARITY 2, 71% (p&#60;0.0001) and 91% (p&#60;0.0001) of participants receiving our lead product candidate LNZ100 achieved three- and two-lines or greater improvement, respectively, compared to 12% and 22% for vehicle on Day 1. For the brimonidine-controlled CLARITY 1, 64% (p&#60;0.0001) and 83% (p&#60;0.0001) of participants receiving LNZ100 achieved three- and two-lines or greater improvement, respectively.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business12a.jpg" src="business12a.jpg" style="height:198px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the description of the results of our clinical trials herein, p or p-values represent the probability that random chance caused the result (e.g., p&#60;0.0001 means that there is less than a 0.01% probability that the difference between the vehicle and the treatment groups is due to random chance). A p-value &#8804; 0.05 is a commonly used criterion for statistical significance and is usually considered supportive of a finding of efficacy by regulatory authorities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other product candidate LNZ101 showed similar results, including achieving primary and secondary endpoints in both CLARITY 1 and 2, but did not show superiority to LNZ100.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LNZ100&#58; Vehicle-controlled CLARITY 2 Efficacy Results</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNZ100 showed rapid onset with response rates of 71% (p&#60;0.0001), at 30 minutes post-treatment, the earliest timepoint measured, and LNZ100 maintained statistical significance of three-lines or greater improvement in near visual acuity compared to vehicle for all timepoints measured. At 10 hours post-treatment, the last measured </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timepoint, 40% (p&#60;0.0001) of users dosed with LNZ100 maintained a three-lines or greater improvement in near visual acuity compared with 5% of users dosed with vehicle. </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business13a.jpg" src="business13a.jpg" style="height:351px;margin-bottom:5pt;vertical-align:text-bottom;width:576px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the clinical benefit of LNZ100 is consistent, robust and reproducible. As shown in the figure below, participants experienced similar near vision improvement across the four-week study period with 81% (p&#60;0.0001) and 82% (p&#60;0.0001) response on Day 15 and Day 28, respectively, at 30 minutes post-treatment compared to 71% (p&#60;0.0001) on Day 1, with 78% (p&#60;0.0001) and 78% (p&#60;0.0001) response on Day 15 and Day 28, respectively, at three hours post-treatment compared to 71% (p&#60;0.0001) on Day 1, and 35% (p&#60;0.0001) on Day 28 at ten hours post-treatment compared to 40% (p&#60;0.0001) on Day 1. On Day 15, no measurements were taken beyond 3 hours post-treatment.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business14a.jpg" src="business14a.jpg" style="height:299px;margin-bottom:5pt;vertical-align:text-bottom;width:508px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNZ100 also achieved the pre-specified secondary endpoint of two-lines or greater improvement in BCDVA at near without losing one or more lines in distance visual acuity at three hours post-treatment, with a response rate of 91% (p&#60;0.0001) compared to 24% for vehicle. LNZ100 also showed rapid onset with response rates of 91% (p&#60;0.0001) compared to 22% for vehicle at 30 minutes post-treatment, the earliest timepoint measured, and maintained statistical significance of two-lines or greater improvement in near visual acuity compared to vehicle for all timepoints measured. At 10 hours post-treatment, the last measured timepoint, 69% (p&#60;0.0001) of users dosed with LNZ100 maintained a two-lines or greater improvement, compared to 21% of users dosed with vehicle. Standard clinical practice considers two-lines or greater improvement in near visual acuity to be clinically meaningful.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business15a.jpg" src="business15a.jpg" style="height:290px;margin-bottom:5pt;vertical-align:text-bottom;width:492px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNZ100 had no adverse impact on distance vision across all timepoints measured including 30 minutes and 1, 3, 5, 7, 8, 9 and 10 hours post-treatment in normal light conditions and 1, 3 and 10 hours in low light conditions. In fact, at normal light, there was statistically significant improvement of two to four letters of distance vision at all time points. We believe these improvements are due to pupil constriction which block the peripheral light that is most likely to travel across aberrations, or nuanced distortions within the eye&#8217;s structure, and cause blurry vision. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the reduction in distance vision observed in the placebo group is due to progressive eye fatigue across multiple assessments for each timepoint measurement. </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="picture16.jpg" src="picture16.jpg" style="height:308px;margin-bottom:5pt;vertical-align:text-bottom;width:528px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LNZ100&#58; Pooled Safety Analysis </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all three CLARITY trials, an aggregate of 378 participants received LNZ100. LNZ100 was well tolerated with no drug-related serious adverse events in the more than 30,000 treatment days across all CLARITY trials. The only reported adverse events with an incidence at 5% or more were instillation site pain, visual impairment, hyperemia and headaches. 95% of all the adverse events experienced were mild.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business17a.jpg" src="business17a.jpg" style="height:339px;margin-bottom:5pt;vertical-align:text-bottom;width:556px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LNZ100&#58; Patient Reported Outcomes in CLARITY 1 and 2</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On Day 28, each participant in CLARITY 1 and 2 completed a patient-reported outcome questionnaire regarding their experience across the prior 30 days.  90% of participants who received LNZ100 and were surveyed (n&#61;223) indicated that they noticed improvement in near vision and 75% wished to continue to use drops after the study, of which 81% indicated that they were likely to use the drops at least four times a week.</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="business18a.jpg" src="business18a.jpg" style="height:267px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Having successfully completed all three CLARITY trials, we plan to submit an NDA for LNZ100 to the FDA in mid-2024 with a launch target date in the second half of 2025.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currently Marketed Eye Drops</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vuity was approved as the first pharmaceutical treatment for presbyopia in October 2021. Despite enthusiasm for the concept of an eye drop improving near vision throughout the full workday, Vuity&#8217;s reportedly lower than expected efficacy, duration and adverse event profile, contributed to lower than anticipated prescription refill rates. To resolve the duration issue, AbbVie tested a twice a day dosing of the same formulation following initial approval of Vuity and achieved FDA approval for this updated dosing frequency in March 2023. In addition, Vuity&#8217;s label was amended to include a warning and precaution related to rare cases of retinal detachment and retinal tears reported with miotics, including Vuity.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vuity&#8217;s FDA approval in October 2021 was based on results from two 30-day pivotal, Phase 3, randomized, double-masked, vehicle-controlled trials, GEMINI 1 and GEMINI 2. A total of 750 participants aged 40 to 55 with presbyopia with best distance correction inclusion criteria of sphere ranging from -4.00D to +1.00D (inclusive) and cylinder &#8804; &#177;2.00D were randomized in these two trials and patients were instructed to administer one drop of Vuity or vehicle daily in each eye. In both trials, a statistically significant but minority portion of participants (31% of patients in GEMINI 1 and 26% of patients in GEMINI 2) showed three-lines or greater improvement in Distance Corrected Near Visual Acuity (&#8220;DCNVA&#8221;) which is equivalent to BCDVA measured at 40 centimeters, without losing more than 1 line of Corrected Distance Visual Acuity (&#8220;CDVA&#8221;) at three hours post-treatment (the last statistically significant timepoint in GEMINI 2) on Day 30. The peak response rate at 1 hour post-treatment relative to vehicle in GEMINI 2 is 25%.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our CLARITY trials focused on enrolling presbyopes from ages of 45 to 75, the GEMINI trials enrolled a younger patient population ranging from ages 40 to 55 with an average age of 50 in each trial and predominantly emmetropic subjects (76% were emmetropes with sphere ranging from &#8211;0.50 D to +0.75 D and cylinder&#58; &#8804;0.75 D). Moreover, data from the GEMINI 1 trial demonstrated that Vuity could not achieve a pupil diameter below 2 mm at any timepoint over the course of 10 hours post-treatment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective is to commercialize a product that we believe will most effectively meet the needs of the widest range of presbyopes and best create loyalty and value based on an &#8220;all eyes, all day&#8221; brand mission. Based on the Phase 3 CLARITY results, we selected LNZ100 as our lead product candidate and intend to submit an NDA in mid-2024 prepare for commercialization and a launch target date in the second half of 2025. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on commercializing in the United States on our own. In addition, we are developing regulatory strategies and intend to opportunistically seek partnerships for Europe, Canada, and other markets. We have recently entered into a license and collaboration agreement with Ji Xing to develop product candidates and products containing aceclidine and brimonidine for the treatment of patients with presbyopia in Greater China. For more details, see the subsection entitled &#8220;License and Collaboration Agreement with Ji Xing Pharmaceuticals Hong Kong Limited.&#8221; We are continuing to evaluate potential partnerships to pursue regulatory and commercialization in other markets.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Experienced Commercial Team</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to use the cash and cash equivalents from the Merger and the PIPE Financing, in part, to continue to build the sales and marketing infrastructure required to successfully commercialize our lead product candidate in anticipation of FDA approval. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have substantially completed hiring of all senior leadership roles in the commercial team, including adding industry veterans with extensive experience in the pharmaceutical space. Our commercialization effort is led by our Chief Commercial Officer Shawn Olsson, who manages a team of seasoned sales and marketing executives, who have helped launch and commercialize over a dozen ophthalmic products and therapies, including Acuvue, Alphagan P, Combigan, Dailies AquaComfort Plus, Durysta, Lumigan, Pred Forte, Refresh, Restasis, Truetear, and Vuity, as well as major user-focused brands such as Botox, Herbalife and Ray-Ban. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To ensure immediate commercialization upon the potential approval of our lead product candidate, we are timing the expansion of our existing commercial capabilities and the development of a sales organization of 100 to 150 individuals to coincide with the expected timing of such potential approval. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proactive Execution of Commercial Strategy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial team has already made substantial progress in executing on our foundational commercial strategy, including selection and submission of a proprietary name, selection of an advertising agency, development of sales organization size and design, ECP segmentation and targeting, selection of a sampling vendor, selection of an e-pharmacy partner, selection of our third-party logistics (&#8220;3PL&#8221;) provider, obtaining relevant state licensures, and setting up a customer relationship management system.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ECP-Focused Sales Strategy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to launch with our own sales organization in the United States, which we envision will expand to 100 to 150 individuals. Our strategy involves initially targeting and partnering with the estimated 15,000 ECPs who prescribed over 85% of the pharmaceutical presbyopia prescriptions in the United States in 2022. Additionally, we will expand beyond the initial set of high-prescribing ECPs by demonstrating the unique value proposition of providing a treatment for presbyopia. We will leverage our strong relationships with key opinion leaders to facilitate awareness regarding the importance of reducing the pupil diameter below 2 mm and using a pupil-selective miotic to avoid overstimulating the ciliary muscle. Our sales strategy will empower ECPs to be actively involved in the diagnosis and treatment of presbyopia for the aging population, including a consumer sampling program described in &#8220;Consumer Sampling Strategy.&#8221; If our product is approved, we expect to see more ECPs begin to prescribe prescription-based eye drops, which will drive more patients requesting prescriptions who otherwise may not have sought appointments with ECPs for other eye conditions. If we elect to expand our product offerings in the future, we will be able to leverage a larger community of prescribing ECPs to support product uptake.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumer Focused Strategy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the NDA is approved, we also plan to deploy, in parallel, a cost-effective, highly targeted and digitally-focused consumer strategy designed to efficiently target the early adopters among the estimated 128 million presbyopes in the United States. This will drive user awareness and interest through digital, offline, and social marketing to create brand awareness, develop brand loyalty, and eventually enable long-term brand durability and recognition. Our strategy involves driving consumer awareness of an effective treatment of presbyopia with prescription eye drops and creating an emotional connection to returning to life prior to presbyopia. A key component to consumer experience is our sampling program that will provide a free option for potential users to try as described in &#8220;Consumer Sampling Strategy&#8221;. To meet the long-term usage needs of young and old presbyopes, we plan to offer both retail access and collaborate with e-pharmacy vendors to provide easy and convenient prescription fulfillment and home delivery. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumer Sampling Strategy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the NDA is approved, we intend to establish a consumer sampling program that will be a key component to the consumer experience and reduce barriers to trial and adoption. We believe LNZ100 is highly suitable for a consumer sampling program as users in our clinical trials have experienced rapid onset and noticeable near vision improvement after a single dose. Our commercial team has already engaged with vendors for storage and distribution of samples to support both field representative delivery and mail delivery to ECPs. With in-office samples, a potential customer can try the product at the ECP&#8217;s offices or at home without having to fill a prescription. The sampling program is a strategy for potential customers to experience near vision improvement of the product at no-cost, which can accelerate customer acceptance and desire to use the product.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Pay</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the NDA is approved, we intend to commercialize our product through the self-pay healthcare marketplace, without third-party reimbursement. We believe pursuing a non-reimbursed product strategy will allow for strategic advantages in the United States, including immediate user access without having to negotiate with formularies and insurers, pricing and marketing flexibility, and without being subject to the Inflation Reduction Act of 2022. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our LNZ100 product candidate is a ready-to-use, self-administered, once-daily eye drop that is a formulation of aceclidine hydrochloride together with commonly used excipients. LNZ100 is delivered via a single-use Blow-Fill-Seal (&#8220;BFS&#8221;) container and is preservative-free.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate facilities for manufacturing, storing, distributing or testing our product candidates and products. We currently use different contract manufacturing organizations (&#8220;CMOs&#8221;) to supply our active pharmaceutical ingredient (&#8220;API&#8221;), aceclidine hydrochloride, and formulate and fill LNZ100, our investigational drug product (&#8220;DP&#8221;). All of our CMOs, including analytical and distribution chain partners, have been inspected by the FDA for compliance with current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulatory guidelines. A Drug Master File (&#8220;DMF&#8221;) is on file with the FDA for the API. Commercial supply agreements have been secured with our API suppliers with commercially reasonable terms to meet our planned clinical and commercial activities, and we are continuing to negotiate and enter additional contracts for secondary supply. Similarly, we have secured both clinical and commercial-scale supply. Our manufacturing and testing processes are common to the pharmaceutical and ophthalmic industry, and we have identified and are working with additional API suppliers for aceclidine hydrochloride  and identified secondary DP manufacturers with similar equipment for additional commercial supply. We have initiated process transfer activities for both the API suppliers and DP manufacturers.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in negotiations to secure our 3PL provider. We expect that the 3PL provider will support cold storage commercial warehousing and distribution activities, the drug product will ship directly from the DP CMO via a qualified shipping vendor at controlled cold storage temperature to the 3PL provider, and the 3PL provider will maintain inventory and comply with the Drug Supply Chain Security Act (&#8220;DSCSA&#8221;) requirements for product serialization and track and trace capabilities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology, pharmaceutical, and ophthalmology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property. We believe that our product candidates, intellectual property portfolio, business strategy, internal capabilities, and experience provide us with competitive advantages. However, we face competition from many different sources, including large and specialty pharmaceutical, biotechnology and ophthalmology companies, academic research institutions and governmental agencies, and public and private research institutions. Any product candidate we develop and commercialize will have to compete with existing therapies as well as therapies currently in development and that may be developed in the future. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, convenience, cost, level of promotional activity devoted to them and intellectual property protection. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As LNZ100 is being developed for the treatment of presbyopia, we may face competition from a variety of companies developing or marketing other pharmaceutical presbyopia therapies, including AbbVie (formerly Allergan), Bausch &#38; Lomb, Eyenovia, Glaukos, Johnson &#38; Johnson, Orasis, OSRX Pharmaceuticals (an affiliate of Ocular Science), Viatris (through licensing of Ocuphire&#8217;s presbyopia products), Visus Therapeutics, and Vyluma. A large majority of the new pharmaceutical drops are miotic. Other than Visus which is developing a carbachol-based eye drop, most of the drops in clinical development are based on pilocarpine, similar to Vuity. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our current or potential competitors, either alone or with their collaboration partners, have substantially greater financial resources and may have greater expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and ophthalmology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be strong competitors, particularly through collaborative arrangements with large and established companies. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies and intellectual property complementary to, or necessary for, our product candidates. Because of the size of the ophthalmology and vision correction markets and the high growth profile of such markets, we anticipate that companies will dedicate substantial resources to developing competing products. We believe that the principal competitive factors in these markets will include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improved outcomes for users and other product quality attributes&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product innovation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by ECPs&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ease of use and reliability&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory status and speed to market&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">marketing and product price.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that any such treatment options that are successfully developed could eventually be available both within and outside the United States. Consolidations and mergers and acquisitions in the pharmaceutical, medical device, and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective, safer, or less costly than our current or future products, or obtain regulatory approval for their products more rapidly than we may obtain approval for our products. Our success will also be based in part on our ability to identify, develop and manage a portfolio of products that are safer and more effective than competing therapies.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and continue to expand our patent portfolio for the treatment of presbyopia with LNZ100. As of March 21, 2024, we hold at least 43 issued patents. 18 of these patents are in the United States, and 25 of these </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents are in other countries throughout the world. We have at least 25 granted patents in Australia, Brazil, Canada, China, India, Japan, Mexico, and Singapore. These patents are expected to expire between 2034 and 2041. Our patents cover compositions for and methods of treating presbyopia with LNZ100. We also have at least 74 pending applications filed in Argentina, Australia, Bolivia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, Korea, Macao, Mexico, Singapore, Taiwan, the United States, Uruguay, and the Patent Cooperation Treaty system. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents related to LNZ100 may be eligible for patent term extensions in certain jurisdictions, including up to five years in both the United States and Europe, if granted, upon approval of commercial use of the corresponding product by a regulatory agency in the jurisdiction where the patent was granted.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No drug product containing aceclidine, an active pharmaceutical agent of LNZ100, has yet been approved in the United States under section 505(b) of the Federal Food, Drug and Cosmetic Act, for any indication. Therefore, we believe LNZ100, if approved, could be eligible for five years of New Chemical Entity (NCE) exclusivity in the United States upon such approval so long as no other drug product containing aceclidine is approved by the FDA before approval of such product candidate. Further, as LNZ100 has not previously been approved in Europe for any indication, LNZ100 may be eligible for eight years of data exclusivity, as well as two years of market exclusivity upon approval in Europe. In Europe, an additional one year of exclusivity may be obtained if LNZ100 is approved for a new indication that provides a significant clinical benefit. In addition to patent protection, we rely on trade secret protection and know-how to expand our proprietary position around our chemistry, technology, and other discoveries and inventions that we consider important to our business. We also seek to protect our intellectual property in part by entering into confidentiality agreements with companies with whom we share proprietary and confidential information in the course of business discussions, and by having confidentiality terms in our agreements with employees, consultants, scientific advisors, clinical investigators, and other contractors. We also require our employees, commercial contractors, and certain consultants and investigators, to enter into invention assignment agreements that grant us ownership of any discoveries or inventions made by them while in our employ.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Collaboration Agreement with Ji Xing Pharmaceuticals Hong Kong Limited</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a License and Collaboration Agreement with Ji Xing Pharmaceuticals Hong Kong Limited (Ji Xing). Under this agreement, we granted Ji Xing (i) an exclusive (even as to us), royalty-bearing, nontransferable license, with the right to grant sublicenses (our prior written consent is required for sublicenses for commercialization purposes), under the technology we control including know-how and patents for Ji Xing to develop, use, import and sell pharmaceutical products containing aceclidine and brimonidine for the treatment of presbyopia in humans in mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan (collectively, &#8220;Greater China&#8221;), (ii) a non-exclusive, nontransferable license, with the right to grant sublicenses, under the same technology we control to manufacture the same products for the same use in Greater China, and (iii) a first right of negotiation for Ji Xing to license any other product that we develop or commercialize containing aceclidine or brimonidine for uses outside of the treatment of presbyopia in Greater China. We retain the rights to use the same technology to perform our obligations in the agreement and the non-exclusive right to manufacture and have manufactured such products in Greater China. The agreement provides that we shall refrain from developing or commercializing any competing product, or knowingly enabling a third party to develop or commercialize a product containing aceclidine or brimonidine that would reasonably be expected to result in off-label sales of such products, for the treatment of presbyopia in humans in Greater China. Under the terms of the agreement, we received an upfront, non-refundable payment of $15.0 million, and an investment from three funds managed or advised by RTW Investments, LP for an aggregate purchase price of approximately $10.0&#160;million in exchange for shares of our Series A-1 preferred stock. We are also eligible to receive an additional up to $15.0 million in development milestone payments, $80.0 million in sales milestone payments, tiered, escalating royalties in the range of 5% to 15% on net sales of such products by Ji Xing, its affiliates or sublicensees in Greater China during the royalty term, and tiered, deescalating royalties in the range of 15% to 5% of Ji Xing&#8217;s sublicensing income prior to the regulatory approval of the first such product in Greater China. Royalties are subject to adjustment if no valid claim of a patent is covering such product, if a generic product exceeds 10% of the market share on a volume basis, or if a third-party license is necessary to manufacture or sell such products. The royalty term in each region is on a product-by-product basis and the longer of (a) expiration of the last valid claim of a patent covering such product in such region, (b) expiration of regulatory exclusivity for such product in such region, and (c) ten years from the date of first commercial sale of such product in such region. Ji Xing may terminate the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement in its entirety at any time upon 180 days&#8217; prior written notice. Either party may terminate the agreement for the other&#8217;s uncured and material breach, subject to a disputed breach resolution mechanism. Either party may also terminate the agreement upon the other party&#8217;s insolvency. We may terminate the agreement upon 60-days&#8217; prior written notice if Ji Xing or its affiliates or sublicensees challenge the validity, enforceability, or scope of any licensed patent.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and operations are subject to extensive regulation by the Food and Drug Administration (&#8220;FDA&#8221;) and other federal and state authorities in the United States, as well as comparable authorities in other countries. For example, our current product candidate, LNZ100, which is ophthalmic pharmaceutical product delivered through a single-use eye dropper device, is subject to regulation as drug-device combination products in the United States. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other federal, state, local, and foreign authorities regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and combination products. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review, and approved by the regulatory authority.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Drug Development</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. Drug products and substances are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate and any future small molecule product candidates must be approved by the FDA through the new drug application (&#8220;NDA&#8221;) process before they may be legally marketed in the United States. The process generally involves the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completion of extensive preclinical studies in accordance with applicable regulations, including the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) requirements&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission to the FDA of an investigational new drug (&#8220;IND&#8221;) application, which must become effective before clinical trials may begin&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approval by an independent institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical trial site before each trial may be initiated&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, good clinical practice (&#8220;GCP&#8221;) requirements and other clinical trial-related regulations to establish the safety and efficacy of an investigational product for each proposed indication&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preparation and submission to the FDA of an NDA&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A determination by the FDA within 60 days of its receipt of an NDA to file the application for review&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug product will be produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;), requirements to assure that the facilities, methods and controls are adequate to preserve the drug identity, strength, quality, and purity&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential FDA audit of the preclinical study and&#47;or clinical trial sites that generated the data in support of the NDA&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), and the potential requirement to conduct post-approval studies.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Studies</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preclinical and clinical testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical tests generally involve laboratory evaluations of drug chemistry, formulation, and stability, as well as studies to evaluate toxicity in animals, including pharmacology, pharmacokinetics, toxicokinetic, and metabolism studies that support subsequent clinical testing in humans. The results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, are submitted to the FDA as part of the Investigational New Drug (IND) application. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before clinical trials may begin. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The central focus of an IND submission is the general investigation plan and the protocol(s) for human studies. An IND must become effective before clinical trials may begin. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each successive clinical trial conducted with the investigational drug, a separate, new protocol submission to an existing IND must be made, along with any subsequent changes to the investigational plan. Sponsors are also subject to ongoing reporting requirements, including submission of IND safety reports for any serious adverse experiences associated with use of the investigational drug or findings from preclinical studies suggesting a significant risk for human subjects, as well as IND annual reports on the progress of the investigations conducted under the IND.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical studies involve the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with Good Clinical Practice (GCP) requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, each clinical trial must be reviewed and approved by an Institutional Review Board (IRB) for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries, including the website maintained by the U.S. National Institutes of Health, ClinicalTrials.gov.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA. The FDA will generally accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials in the United States generally are conducted in three phases, known as Phase 1, Phase 2, and Phase 3. Although the phases are usually conducted sequentially, they may overlap or be combined.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2 clinical trials typically involve studies in a limited population of disease-affected patients to determine possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to evaluate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit&#47;risk relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and&#47;or other comparator treatments.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical study investigators. Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing that suggest a significant risk for human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1, Phase 2, and Phase 3 clinical trials may not be successfully completed within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal safety studies and also must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of our product candidates. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their labeled shelf life. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NDA Review</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA, along with proposed labeling, chemistry, and manufacturing information in a request for approval to market the drug for one or more specified indications. The application must include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of an NDA must be obtained before a drug may be marketed in the United States.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, as amended (&#8220;PDUFA&#8221;), each NDA must be accompanied by an application user fee. FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for each marketed human drug. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a qualifying small business.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews all submitted NDAs before it accepts them for filing to determine if they are sufficiently complete to permit a substantive review, and the FDA may request additional information rather than accepting the NDA for filing. In this event, the application must be resubmitted with the additional information and is subject to payment of additional user fees. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA. Under PDUFA, the FDA has agreed to certain performance goals in the review of NDAs through a two-tiered classification system, standard review and priority review. According to PDUFA performance goals, the FDA endeavors to review applications subject to standard review within ten months, whereas the FDA&#8217;s goal is to review priority review applications within six months. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer applications for novel drug products or products which present difficult questions of safety or efficacy to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA typically will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. The FDA also closely analyzes the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates an NDA and conducts inspections of manufacturing facilities, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data, including the potential requirement to conduct additional pivotal Phase 3 clinical trial(s) and&#47;or other significant and time-consuming requirements related to clinical trials, or to conduct </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional preclinical studies or manufacturing changes. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new product, the product is subject to continuing regulation by the FDA, including, among other things, requirements relating to facility registration and drug listing monitoring and record-keeping adverse event and other periodic reporting, product sampling and distribution, and product promotion and advertising. The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After approval, if there are any changes to the approved product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved NDA. In addition, quality control, drug manufacture, packaging, and labeling products must continue to conform to cGMP requirements after approval. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. Manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violative conditions, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, its manufacturer or the NDA holder, including recalls.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also place other conditions on approvals including the requirement for a REMS, to assure the safe use of the product. If the FDA concludes that a REMS is needed, the NDA sponsor must submit a proposed REMS. The FDA will not approve the product without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw approval of a product if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Corrective action could delay drug distribution and require significant time and financial expenditures. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information&#59; imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market, or product recalls&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters, or holds on clinical trials&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or revocation of product approvals&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated modifications of promotional materials and labeling and the issuance of corrective information&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product&#59; or injunctions or the imposition of civil or criminal penalties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, known as &#8220;off-label use,&#8221; industry-sponsored scientific and educational activities, and promotional activities involving the internet and social media.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require post-approval studies and clinical trials if the FDA finds that scientific data, including information regarding related drugs, deem it appropriate. The purpose of such studies would be to assess a known serious risk or signals of serious risk related to the drug or to identify an unexpected serious risk when available data indicate the potential for a serious risk. The FDA may also require a labeling change if it becomes aware of new safety information that it believes should be included in the labeling of a drug.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the applicable regulatory requirements at any time during the product development process, approval process or after approval may subject an applicant or manufacturer to, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Regulation of Drug&#47;Device Combination Products</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect LNZ100 to be subject to regulation in the United States as a combination product comprised of a drug product candidate and a device delivery system. A combination product is the combination of two or more regulated components, such as a drug&#47;device, that are combined or mixed and produced as a single entity, packaged together in a single package or a drug or device packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug or device where both are required to achieve the intended use, indication or effect. If marketed individually, each component would be subject to different regulatory pathways and would require approval of independent marketing applications by the FDA &#8211; one for the device component and one for the drug component of the combination.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A combination product, however, is assigned to a center within FDA that will have primary jurisdiction over its regulation based on a determination of the combination product&#8217;s primary mode of action, which is the single mode of action that provides the most important therapeutic action. To determine which FDA center or centers will review a combination product candidate submission, companies may submit a request for assignment to the FDA. Those requests may be handled formally or informally. In some cases, jurisdiction may be determined informally based on FDA experience with similar products. However, informal jurisdictional determinations are not binding on the FDA. Companies also may submit a formal Request for Designation to the FDA Office of Combination Products. The Office of Combination Products will review the request and make its jurisdictional determination within 60 days of receiving a Request for Designation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For LNZ100, which is an ophthalmic pharmaceutical product prefilled and packaged in a single-use eye dropper device, the mechanism of action and the pharmacological effect are attributable to the drug component of the drug-device combination product. Consistent with our communications with FDA to date and the regulatory pathway for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other ophthalmic pharmaceutical products, we plan to seek FDA approval of LNZ100 through the NDA pathway, and we do not expect that the FDA will require a separate marketing authorization for the device component. However, each component of LNZ100 will need to meet the applicable quality and manufacturing standards set by FDA, meaning the drug product must be manufactured in accordance with GMPs for drugs, and the device component must be manufactured in a manner consistent with the device GMPs set forth in FDA&#8217;s Quality System Regulation, or QSR.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Patent-Term Restoration and Marketing Exclusivity</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA approval of any of our future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. Application for patent extension must be filed with the USPTO within 60 days of FDA approval of the drug product even if the product cannot be commercially marketed at that time. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent term restoration period is generally one-half the time between the effective date of an IND or the issue date of the patent, whichever is later, and the submission date of an NDA plus the time between the submission date of an NDA or the issue date of the patent, whichever is later, and the approval of the NDA application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve an abbreviated new drug application (&#8220;ANDA&#8221;), or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Such three-year and five-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other U.S. Regulatory Matters</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect any of our products, if approved, would be covered by any government healthcare programs or other third-party payors, we may still be subject to state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including self-pay patients&#59; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers&#59; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value made to physicians and other healthcare providers or marketing expenditures&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">state and local laws requiring the registration of pharmaceutical sales representatives&#59; and state and foreign laws governing the collection, export, privacy, use, protection and security of biological materials and health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, see the section titled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8220;Risk Factors&#8212;Risks Related to Our Regulatory Approval and Other Legal Compliance Matters&#8212; we may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions or safe harbors, it is possible that some of our activities could be subject to challenge under one or more of such laws. The growth of our business and sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. The risk of us being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to various interpretations. Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties, including significant civil, criminal and administrative penalties, including damages, fines, disgorgement, individual imprisonment, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Healthcare Reform</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect any of our products, if approved, would be covered by any government healthcare programs or other third-party payors, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the regulatory approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent regulatory approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. For more information, see the section titled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Risk Factors&#8212;Risks Related to Our Regulatory Approval and Other Legal Compliance Matters&#8212;we may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.&#8221; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, different pricing and reimbursement schemes exist in other countries. In the European Community, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may be marketed only once a reimbursement price has been agreed upon. Some of these countries may require, as condition of obtaining reimbursement or pricing approval, the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. For more information, see the section titled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Risk Factors&#8212;Risks Related to Our Company&#8212;we may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Regulation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our product candidates to the extent we choose to develop or sell any product candidates outside of the United States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Resources</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 21, 2024, we had 28 employees, 16 of whom were engaged in research and development activities. We also engage contractors and consultants. None of our employees are represented by a labor union or covered under a collective bargaining agreement. We have not experienced any work stoppages due to employee disputes, and we consider our relationship with our employees to be good.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facilities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located in Del Mar, California, and consists of 3,577 square feet of office space pursuant to a lease that expires in March 2026.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease all of our facilities and do not own any real property. We believe that our existing facilities are adequate and suitable for our current needs and that, should it be needed, suitable additional or alternative space will be available as and when needed.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger Proceedings</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, one complaint was filed in the United States District Court for the Northern District of California captioned Glen Chew v. Graphite Bio, Inc. et al., Case No. 3&#58;24-cv-00613 (filed February 1, 2024) (the &#8220;Chew Complaint&#8221;) and one complaint was filed in the United States District Court for the District of Delaware captioned Kevin Turner v. Graphite Bio, Inc. et al., Case No. 1&#58;24-cv-00241-UNA (filed February 22, 2024) (the &#8220;Turner Complaint&#8221; and collectively, the &#8220;Complaints&#8221;). The Complaints generally allege that the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">definitive proxy statement&#47;prospectus (the &#8220;Proxy Statement&#47;Prospectus&#8221;) included in Graphite&#8217;s Registration Statement on Form S-4 (File No. 333-275919), filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">misrepresents and&#47;or omits certain purportedly material information relating to LENZ&#8217;s financial projections, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">analyses performed by the financial advisor to Graphite&#8217;s Board of Directors in connection with the Merger, potential conflicts of interest of the financial advisor to Graphite&#8217;s Board of Directors, potential conflicts of interest of Graphite&#8217;s officers, and Graphite&#8217;s liquidation analysis. The Complaints assert violations of Section 14(a) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Rule 14a-9 promulgated thereunder against all defendants (Graphite, its Board of Directors and certain officers) and violations of Section 20(a) of the Exchange Act against Graphite&#8217;s directors and officers. The Complaints seek orders rescinding the Merger or awarding rescissory damages, as well as costs, including attorneys&#8217; and experts&#8217; fees. On March 22, 2024, the Chew Complaint was voluntarily dismissed.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Graphite also received twelve demand letters by purported Graphite stockholders from December 14, 2023 to March 20, 2024 seeking additional disclosures in the Proxy Statement&#47;Prospectus (the &#8220;Demands&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the outcome of any litigation or the Demands. The Company and the individual defendants intend to vigorously defend against the Turner Complaint, the Demands, and any subsequently filed similar actions. It is possible additional lawsuits may be filed or additional demand letters may be received arising out of the Merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the disclosures set forth in the Proxy Statement&#47;Prospectus comply fully with all applicable laws, and deny the allegations in the Complaints and Demands described above. Nevertheless, in order to moot plaintiffs&#8217; disclosure claims, avoid nuisance and possible expense and business delays, and provide additional information to its stockholders, Graphite voluntarily supplemented certain disclosures in the Proxy Statement&#47;Prospectus on March 5, 2024 (the &#8220;Supplemental Disclosures&#8221;). Nothing in the Supplemental Disclosures shall be deemed an admission of the legal merit of the Complaints or the Demands described above, or of the necessity or materiality under applicable laws of any of the disclosures set forth herein. To the contrary, we specifically deny all allegations in the Complaints and the Demands that any additional disclosure was or is required or is material.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Proceedings</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be subject to legal proceedings and claims arising in the ordinary course of our business. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1463"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers and Directors </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the names, ages, and positions of our executive officers and directors as of March 29, 2024&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Executive Officers</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evert Schimmelpennink</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President, Secretary, and Director</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shawn Olsson</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Commercial Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Odrich</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Chevallard</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Non-Employee Directors</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frederic Guerard</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James McCollum</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zach Scheiner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shelley Thunen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeff George</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberlee C. Drapkin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of the audit committee.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of the compensation committee.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of the nominating and corporate governance committee.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evert Schimmelpennink</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as our President and Chief Executive Officer and a member of our board of directors since March 2024. Mr. Schimmelpennink served as LENZ OpCo&#8217;s President and Chief Executive Officer and a member of its board of directors from March 2021 through the closing of the Merger. Previously, from August 2017 to October 2020, Mr.&#160;Schimmelpennink served as President and Chief Executive Officer and a member of the board of directors of publicly listed Pfenex, Inc., a biopharmaceutical company, until its acquisition by Ligand Pharmaceuticals&#160;Inc. (Nasdaq&#58; LGND) in late 2020. From November&#160;2019 until its sale, Mr.&#160;Schimmelpennink also served as the acting Principal Financial Officer and Principal Accounting Officer of Pfenex&#160;Inc. From October 2015 to August 2017, Mr.&#160;Schimmelpennink served as Chief Executive Officer of Alvotech, a biopharmaceutical company. Prior to that, Mr.&#160;Schimmelpennink held senior positions at Pfizer&#160;Inc. (NYSE&#58; PFE) and Hospira,&#160;Inc. within their global specialty injectables businesses, as well as Synthon BV.&#160;Mr. Schimmelpennink currently serves on the board of directors of iBio, Inc. (NYSE&#58; IBIO) and Pipeline Therapeutics. Mr.&#160;Schimmelpennink holds a M.Sc. in Bioprocess Engineering from the University of Wageningen in the Netherlands and a business degree from the Arnhem Business School.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Mr.&#160;Schimmelpennink is qualified to serve on our board of directors because of his knowledge of our business and his extensive leadership and operational experience within the pharmaceutical and biotech industries.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shawn Olsson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as our Chief Commercial Officer since March 2024. Mr. Olsson served as LENZ OpCo&#8217;s Chief Commercial Officer from April 2021 through the closing of the Merger. Previously, from March&#160;2018 to April 2021, Mr.&#160;Olsson served as Vice President of North American Marketing and Global Portfolio and Vice President of North American Marketing at Xellia Pharmaceuticals, a pharmaceuticals and life sciences company. From September 2015 to March 2018, Mr.&#160;Olsson served as Director, Global Sterile Injectables on Market Strategy Lead and Commercial Lead, Opioids and Syringe Technology Portfolio at Pfizer (NYSE&#58; PFE), a multinational pharmaceutical and biotechnology company. Mr.&#160;Olsson holds a B.S. in Mechanical Engineering from Purdue University, a M.S. in Mechanical Engineering from University of Michigan and an M.B.A. in Strategic Management and Finance from University of Chicago.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marc Odrich, M.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as our Chief Medical Officer since March 2024. Dr. Odrich served as LENZ OpCo&#8217;s Chief Medical Officer from July 2021 through the closing of the Merger and provided consulting services to LENZ OpCo from March 2018 to July 2021. Since June 2017, Dr.&#160;Odrich has served as an Associate Professor of Ophthalmology at the University of Virginia, where he specializes in Refractive Surgery and Ocular Surface Disease. Since March 2016, Dr.&#160;Odrich has served as a consultant to TearSolutions, Inc., an early stage clinical ophthalmology company specializing in Ocular Surface Disease. Dr.&#160;Odrich is also a consultant to Johnson&#160;&#38; Johnson Vision Care and is a member of the board of directors of Epion Therapeutics. Dr.&#160;Odrich previously served as the Medical Director for Visx Incorporated, a developer of technology and systems for laser vision correction, where he led the clinical team in bringing the excimer laser into commercialization worldwide. Dr.&#160;Odrich has been involved with group, private and academic ophthalmic practices since 1990. Dr.&#160;Odrich holds a B.A. in Ancient History from Columbia University in the City of New York and an M.D. from Columbia University&#8217;s College of Physicians and Surgeons. Dr.&#160;Odrich completed an internship in internal medicine at Yale&#8217;s Danbury Hospital before pursuing his residency at Columbia University&#8217;s Harkness Eye Institute. Dr.&#160;Odrich then completed a two-year fellowship focused on cornea and external disease at Harvard&#8217;s Massachusetts Eye and Ear Infirmary.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daniel Chevallard</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Chief Financial Officer since March 2024. From July 2019 to March 2024, Mr. Chevallard served as Chief Financial Officer, Treasurer and Secretary of Viracta Therapeutics, Inc. (NASDAQ&#58; VIRX), a biotechnology company, and served as its Chief Operating Officer from March 2021 to March 2024. Previously, Mr.&#160;Chevallard served as the Chief Financial Officer and principal financial officer at Regulus Therapeutics (NASDAQ&#58; RGLS) from May 2017 to July 2019. Mr.&#160;Chevallard joined Regulus Therapeutics in December 2012 as Vice President, Accounting and Financial Reporting and served as Vice President, Finance from May 2013 to April 2017. Prior to joining Regulus Therapeutics, Mr.&#160;Chevallard held various senior roles in corporate finance, accounting and financial reporting including Controller and Senior Director, Finance of Prometheus Laboratories Inc. (acquired by Nestl&#233; Health Science in July 2011). Prior to joining Prometheus, Mr.&#160;Chevallard spent approximately five years in public accounting at Ernst&#160;&#38; Young, LLP in their assurance services practice. Mr. Chevallard received his Bachelor of Accountancy from the University of San Diego and is a Certified Public Accountant (inactive) in the state of California.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Directors</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Frederic Guerard, Pharm.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as a member of our board of directors since March 2024 and served on the LENZ OpCo board of directors from September 2021 through the closing of the Merger. Since October 2023, Dr.&#160;Guerard has served as Chief Executive Officer of Opthea Limited (Nasdaq&#58; OPT&#59; ASX&#58; OPT), a biopharmaceutical company. Dr.&#160;Guerard served as the President and Chief Executive Officer of Graybug Vision, Inc. from February 2019 until March 2023. From 1999 to February 2019, Dr.&#160;Guerard held key leadership roles at Novartis AG, a multinational pharmaceutical company, including Worldwide Business Franchise Head of Ophthalmology from April 2016 to February 2019, Global Franchise Head of Pharmaceuticals at Alcon Laboratories, a Novartis company, from May 2015 to April 2016, Managing Director of the United&#160;Kingdom and Ireland from July 2012 to April 2015, and Country President and Managing Director of Australia and New Zealand from April 2009 to July 2012, among others. Dr.&#160;Guerard currently serves on the board of directors of CalciMedica, Inc. (Nasdaq&#58; CALC). Dr.&#160;Guerard holds a Pharm.D. and a Master of Biological and Medical Sciences from the University of Rouen, France and a Master of Marketing from HEC Paris.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Dr.&#160;Guerard is qualified to serve on our board of directors because of his extensive drug development experience and his experience serving in various leadership positions in biotechnology companies.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">James McCollum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as a member of our board of directors since March 2024. Mr. McCollum co-founded LENZ OpCo and served on LENZ OpCo&#8217;s board of directors from July 2013 through the closing of the Merger. From September 2016 to March 2021, Mr.&#160;McCollum served as LENZ&#8217;s President and Chief Executive Officer. From September 2014 to September 2016, Mr.&#160;McCollum served as President and Chief Executive Officer of Eye Therapies, LLC, an ocular pharmaceutical company co-founded by Mr.&#160;McCollum. Previously, Mr.&#160;McCollum served as the President and Chief Executive Officer of Restoration Robotics, a medical robotics company, President and Chief Executive Officer of Vision Membrane Technologies, an intraocular lens medical device company, and President and Chief Executive Officer of Argus Biomedical, an artificial cornea medical device company. Earlier in his career, Mr.&#160;McCollum held the position of Senior Vice President of Worldwide </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing and Sales at VISX, Incorporated, a developer of technology and systems for laser vision correction. Mr.&#160;McCollum holds a B.A. in Business from North Carolina State University.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Mr.&#160;McCollum is qualified to serve on our board of directors because of his deep knowledge of our business and strategy, his extensive executive leadership and operational experience.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zach Scheiner, Ph.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as a member of our board of directors since March 2024. Dr. Scheiner served as a member of LENZ OpCo&#8217;s board of directors from October 2020 through the closing of the Merger. Dr.&#160;Scheiner joined RA Capital Management, L.P., an investment manager, in April&#160;2015 as an associate, became an analyst in April 2017, and has been a principal since December 2017. Prior to joining RA Capital, Dr.&#160;Scheiner was a Science Officer at the California Institute for Regenerative Medicine (CIRM), where he worked from September 2008 to March 2015. Dr.&#160;Scheiner currently serves on the board of directors of Nkarta Therapeutics, Inc. (Nasdaq&#58; NKTX) and several private biotechnology companies. Dr.&#160;Scheiner holds a B.S. in Molecular Biophysics and Biochemistry from Yale University and a Ph.D. in Neurobiology and Behavior from the University of Washington.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Dr.&#160;Scheiner is qualified to serve on our board of directors because of his experience in the life sciences industry and his investing experience.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelley Thunen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as a member of our board of directors since March 2024. Ms. Thunen served as a member of LENZ OpCo&#8217;s board of directors from November 2023 through the closing of the Merger. Since February 2017, Ms.&#160;Thunen has served as Chief Financial Officer of RxSight, Inc. (Nasdaq&#58; RXST), an ophthalmic medical technology company, and served as RxSight&#8217;s Chief Administrative Officer from January 2016 to February 2017. From January 2013 to October 2015, Ms.&#160;Thunen served as the Chief Financial Officer of Endologix, Inc. (Nasdaq&#58; ELGX), a medical device company. From August 2010 to December 2012, Ms.&#160;Thunen served as Associate General Manager of Alcon LenSx, Inc., a medical device company. Prior to Alcon&#8217;s (NYSE&#58; ALC) acquisition of LenSx, Inc. in August 2010, Ms.&#160;Thunen served as a board member and chair of the audit committee from April 2008 to August 2010, as well as Chief Financial Officer and Vice President, Operations from November 2009 to August 2010. Ms.&#160;Thunen joined IntraLase Corp. (Nasdaq&#58; ILSE), a laser technology company, in May 2001 and was its Chief Financial Officer and later Executive Vice President&#160;&#38; Chief Financial Officer until its acquisition by Advanced Medical Optics, Inc. (NYSE&#58; EYE) in April 2007. Ms.&#160;Thunen serves on the board of directors and as audit committee chair of AEON Biopharma, Inc. (NYSE&#58; AEON). Ms.&#160;Thunen holds a B.A. in economics and an M.B.A. from the University of California, Irvine.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Ms.&#160;Thunen is qualified to serve on our board of directors because of her extensive experience in the biotechnology industry and her leadership experience as a senior financial executive.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeff George</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as a member of our board of directors and as Chair since March 2024. Since January 2017, Mr. George has served as the Managing Partner of Maytal Capital, a healthcare-focused private equity investment and advisory firm he founded. Between 2008 and 2016, Mr. George served on the Executive Committee of Novartis Group AG, a pharmaceutical company, first as Division Head and CEO of Sandoz, Novartis&#8217; generic pharmaceuticals and biosimilars subsidiary, and then as Division Head and CEO of Alcon, Novartis&#8217; then eye care subsidiary. Mr. George previously headed Emerging Markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharmaceuticals and served as Vice President and Head of Western and Eastern Europe for Novartis Vaccines. Prior to this, Mr. George held leadership roles at Gap Inc. and McKinsey &#38; Co. Mr. George serves on the boards of directors of Amneal Pharmaceuticals, Inc. (Nasdaq&#58; AMRX), a generics and specialty pharmaceuticals company, 908 Devices (Nasdaq&#58; MASS), a pioneer in life science diagnostics, Dorian Therapeutics, a cellular senescence biotech spun out of Stanford University, and MAPS PBC, a late-stage CNS-focused private biopharma company where he serves as chairman of the board. Mr. George also currently serves on several non-profit boards and previously served as the Chairman of Education Opens Doors. Mr. George has also served as an Operating Partner at Revival Healthcare Capital, a medical device-focused private equity firm. Mr. George holds an M.B.A. from Harvard Business School, an M.A. from Johns Hopkins University&#8217;s School of Advanced International Studies, and a B.A. from Carleton College.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Mr. George is qualified to serve on our board of directors because of his extensive industry background and experience in the life sciences industry.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kimberlee C. Drapkin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served a member of our board of directors since July 2023. Ms. Drapkin served as our president and chief executive officer from August 2023 through the closing of the Merger. Ms. Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Most recently, Ms. Drapkin was the Chief Financial Officer at Jounce Therapeutics, Inc., a position she held from August 2015 until the company&#8217;s acquisition by Concentra Biosciences, LLC in May 2023, playing a key role in building Jounce&#8217;s financial infrastructure. Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early-stage biotechnology companies. Previously, she was the Chief Financial Officer at EPIX Pharmaceuticals, Inc. and also spent ten years in roles of increasing responsibility within the finance organization at Millennium Pharmaceuticals, Inc. Her career began in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Ms. Drapkin served as a member of the board of directors of Proteostasis Therapeutics, Inc. until the completion of the merger of Proteostasis and Yumanity Therapeutics, Inc., at which point she became a member of the Yumanity board of directors. Ms. Drapkin then served on the board of directors of Yumanity through the completion of its reverse merger with Kineta, Inc. She currently serves on the board of directors of Acumen Pharmaceuticals, Inc. (Nasdaq&#58; ABOS), Imugene Limited (ASX&#58; IMU) and Kineta, Inc. (Nasdaq&#58; KA), where she is a member of audit committee at all three companies. Ms. Drapkin holds a B.S. in accounting from Babson College.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Ms. Drapkin is qualified to serve on our board of directors because of her role as our chief executive officer prior to the Merger.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Family Relationships</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships among any of our directors and executive officers.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Composition of the Board of Directors </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and affairs are organized under the direction of the board of directors. Our board of directors currently consists of seven (7) members. Mr. George serves as Chair of our board of directors. The primary responsibilities of the board of directors are to provide oversight, strategic guidance, counseling and direction to our management. The board of directors will meet on a regular basis and additionally as required. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of our Certificate of Incorporation and our Bylaws, our board of directors is divided into three staggered classes of directors, Class I, Class II and Class III, with members of each class serving staggered three-year terms. Our board of directors is divided into the following classes&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class I, which consists of Frederic Guerard and James McCollum, whose terms expire at our annual meeting of stockholders in 2025&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class II, which consists of Jeff George, Shelley Thunen, and Evert Schimmelpennink, whose terms expire at our annual meeting of stockholders in 2026&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class III, which consists of Kimberlee C. Drapkin and Zach Scheiner, whose terms expire at our annual meeting of stockholders in 2024 (or 2025 if no annual meeting of stockholders is held in 2024).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election and until their successors are duly elected and qualified. This classification of the board of directors may have the effect of delaying or preventing changes in our control or management. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has determined that each of our directors other than Mr. Schimmelpennink qualify as independent directors, as defined under the rules of the Nasdaq listing standards, and our board of directors consists of a majority of &#8220;independent directors,&#8221; as defined under the rules of the SEC and Nasdaq relating to the membership, qualifications, and operations of the audit committee, as discussed below. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Role of Our Board of Directors in Risk Oversight</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the key functions of our board of directors is informed oversight of the risk management process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit committee has the responsibility to consider and discuss major financial risk exposures and the steps our management takes to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. Our compensation committee is responsible for overseeing the management of risks relating to executive compensation plans and arrangements. The compensation committee also assesses and monitors whether compensation plans, policies and programs comply with applicable legal and regulatory requirements.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committees of the Board of Directors</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has three standing committees&#58; an audit committee, a compensation committee, and a nominating and corporate governance committee.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our audit committee are Shelley Thunen, Frederic Guerard and Zach Scheiner, and Ms. Thunen serves as the chairperson of the audit committee. Under the Nasdaq listing rules and applicable SEC rules, we are required to have at least three members of the audit committee. The rules of Nasdaq and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be composed solely of independent directors for audit committee purposes, and each member qualifies as an independent director for audit committee purposes under applicable rules. Each of Shelley Thunen, Frederic Guerard and Zach Scheiner is financially literate and each of Shelley Thunen and Frederic Guerard qualifies as an &#8220;audit committee financial expert&#8221; as defined in applicable SEC rules.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functions of our audit committee include, among other things&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">select, retain, compensate, evaluate, oversee and, where appropriate, terminate our independent registered public accounting firm&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review and approve the scope and plans for the audits and the audit fees and approve all non-audit and tax services to be performed by the independent auditor&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluate the independence and qualifications of our independent registered public accounting firm&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review our financial statements, and discuss with management and our independent registered public accounting firm the results of the annual audit and the quarterly reviews&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review and discuss with management and our independent registered public accounting firm the quality and adequacy of our internal controls and our disclosure controls and procedures&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discuss with management our procedures regarding the presentation of our financial information, and review earnings press releases and guidance&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">oversee the design, implementation and performance of our internal audit function, if any&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">set hiring policies with regard to the hiring of employees and former employees of our independent auditor and oversee compliance with such policies&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review, approve and monitor related party transactions&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adopt and oversee procedures to address complaints regarding accounting, internal accounting controls and auditing matters, including confidential, anonymous submissions by our employees of concerns regarding questionable accounting or auditing matters&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review and discuss with management and our independent auditor the adequacy and effectiveness of our legal, regulatory and ethical compliance programs&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review and discuss with management and our independent auditor our guidelines and policies to identify, monitor and address enterprise risks, including the oversight of risks from cybersecurity threats.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our compensation committee are Frederic Guerard, Kimberlee C. Drapkin and Shelley Thunen, and Dr. Guerard serves as the chairperson of the compensation committee. Our board of directors has determined that each of the members of the compensation committee is a non-employee director, as defined in Rule 16b-3 promulgated under the Exchange Act and satisfies the independence requirements of Nasdaq. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functions of our compensation committee include, among other things&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review, approve or make recommendations to our board of directors regarding the compensation for our executive officers, including our chief executive officer&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review, approve and administer our employee benefit and equity incentive plans&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and review the compensation plans and programs of our employees, and ensure that they are consistent with our general compensation strategy&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determine or make recommendations to our board of directors regarding non-employee director compensation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitor compliance with any stock ownership guidelines&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approve or make recommendations to our board of directors regarding the creation or revision of any clawback policy.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nominating and Corporate Governance Committee</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our nominating and corporate governance committee are Jeff George, Kimberlee C. Drapkin, and Zach Scheiner, and Mr. George serves as the chair of the nominating and corporate governance committee. Our board of directors has determined that each of the members of our nominating and corporate governance committee satisfy the independence requirements of Nasdaq. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functions of our nominating and corporate governance committee include, among other things&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review and assess and make recommendations to our board of directors regarding desired qualifications, expertise and characteristics sought of board members&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify, evaluate, select or make recommendations to our board of directors regarding nominees for election to our board of directors&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop policies and procedures for considering stockholder nominees for election to our board of directors&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review our succession planning process for our chief executive officer and any other members of our executive management team&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review and make recommendations to our board of directors regarding the composition, organization and governance our board of directors and its committees&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review and make recommendations to our board directors regarding our corporate governance guidelines and corporate governance framework&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">oversee director orientation for new directors and continuing education for our directors&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">oversee the evaluation of the performance of our board of directors and its committees&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review and monitor compliance with our code of business conduct and ethics, and review conflicts of interest of our board members and officers other than related party transactions reviewed by our audit committee&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">administer policies and procedures for communications with the non-management members of our board of directors. Our nominating and corporate governance committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Director Compensation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors or our compensation committee will determine the annual compensation to be paid to the members of our board of directors.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kimberlee C. Drapkin, a member of our compensation committee, served as Graphite&#8217;s President, interim Chief Executive Officer and director prior to the Merger. None of our executive officers currently serve, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more executive officers that serves as a member of the board of directors or our compensation committee. See the section titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Relationships, Related Party and Other Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for information about related party transactions involving members of our compensation committee or their affiliates.&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1466"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits program to attract, retain, incentivize and reward deeply talented and qualified executives who share our philosophy and desire to work towards achieving these goals.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our compensation program should promote the success of the company and align executive incentives with the long-term interests of our stockholders. As our needs evolve, we intend to continue to evaluate our philosophy and compensation programs as circumstances require.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section provides an overview of our and LENZ OpCo&#8217;s executive compensation programs, including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. This section also sets forth information relating to the compensation earned by Graphite&#8217;s named executive officers for the fiscal years ended December 31, 2023 and 2022, as well as certain information regarding equity awards granted to Graphite&#8217;s named executive officers that remained outstanding as of December 31, 2023. Unless otherwise indicated, as used in this section, &#8220;LENZ,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to LENZ OpCo prior to the closing of the Merger and New LENZ after the closing of the Merger. Upon the closing of the Merger, the executive officers of LENZ OpCo became executive officers of New LENZ.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors, with input from our Chief Executive Officer, has historically determined the compensation for our named executive officers. For the years ended December 31, 2023 and 2022, LENZ OpCo&#8217;s named executive officers were&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evert Schimmelpennink, Chief Executive Officer, President, and Secretary</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Shawn Olsson, Chief Commercial Officer </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Marc Odrich, Chief Medical Officer</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, Graphite&#8217;s named executive officers were&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Kimberlee Drapkin, Graphite&#8217;s interim President and Chief Executive Officer&#8224;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Josh Lehrer, M.D., Graphite Bio&#8217;s former President and Chief Executive Officer+</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Alethia Young, Graphite&#8217;s former Chief Financial Officer*</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Kimberlee Drapkin served as Graphite&#8217;s interim President and Chief Executive Officer from August 21, 2023 through the closing of the Merger. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;&#160;&#160;&#160;Josh Lehrer served as Graphite&#8217;s President and Chief Executive Officer through August 21, 2023.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;Alethia Young served as Graphite&#8217;s Chief Financial Officer through June 30, 2023. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table for the Fiscal Year Ended December 31, 2023</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the compensation earned by LENZ OpCo&#8217;s named executive officers for the fiscal years ended December 31, 2023 and 2022.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and principal position</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">awards</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All other</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">compensation</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evert Schimmelpennink</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537,438&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,898&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,630,871&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517,407&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,250&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,950&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,246&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,150,646&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shawn Olsson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Commercial Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,997&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,936&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,887&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,200&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795,020&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,063&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,143&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,087&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597,493&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Marc Odrich</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Medical Officer</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,750&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,213&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,163&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,127&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,886&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,550&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,650&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amounts reported represent discretionary bonuses paid in 2023 and 2024 based upon the achievement of LENZ OpCo goals for the years ended December&#160;31, 2022 and 2023, as determined by the LENZ OpCo board of directors. For additional information regarding these amounts, see the section of this prospectus below titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Narrative Disclosure to Summary Compensation Table for the Fiscal Year Ended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">December 31, 2023.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221; </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock option awards granted during 2022 and 2023, computed in accordance with FASB ASC Topic 718, Compensation&#8212;Stock Compensation. The assumptions used in calculating the grant date fair value of the awards disclosed in this column are set forth in Note 10 to LENZ&#8217;s audited financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amounts reported represent matching contributions under LENZ&#8217;s 401(k) plan. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amount reported reflects the total salary earned by Mr. Schimmelpennink in 2023. Mr. Schimmelpennink&#8217;s annual base salary was $513,000 from January 1, 2023 until January 31, 2023 and was increased to an annual base salary of $538,500 on February 1, 2023. </font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amount reported reflects the total salary earned by Mr. Olsson in 2023. Mr. Olsson&#8217;s annual base salary was $344,500 from January&#160;1, 2023 until January 31, 2023 and was increased to an annual base salary of $361,725 on February 1, 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the compensation earned by Graphite&#8217;s named executive officers for the fiscal years ended December 31, 2023 and 2022, as applicable&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:23.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Principal Position</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Awards</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-equity </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incentive </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation ($)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Compensation</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberlee Drapkin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:19pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Interim President, Chief Executive Officer and Director</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,521&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,148&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,669&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Josh Lehrer, M.D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Former President, Chief Executive Officer and Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,778&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,446&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491,253&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903,477&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,705,285&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,750&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,490,535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alethia R. Young</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Former Chief Financial Officer</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,950&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,164&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,114&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212,715&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,350&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986,839&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amounts reported represent the aggregate grant date fair value of the stock options granted to Graphite&#8217;s named executive officers during the applicable fiscal year, calculated in accordance with FASB ASC Topic 718. Such grant date fair values do not take into account </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in notes 2 and 11 to Graphite&#8217;s financial statements included herein for the year ended December 31, 2023. The amounts reported in this column reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by Graphite&#8217;s named executive officers upon the exercise of the stock options or any sale of the underlying shares of common stock.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Ms. Drapkin commenced employment with Graphite on August 21, 2023. Her 2023 annual base salary is pro-rated based on her employment commencement date.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Dr. Lehrer resigned as Chief Executive Officer on August 21, 2023 and transitioned to serve as a consultant to Graphite on such date. His 2023 annual base salary is pro-rated based on his resignation date. Dr. Lehrer did not receive any cash compensation for his services as a consultant to Graphite.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes an aggregate grant date fair value of $918,480 for Dr. Lehrer&#8217;s 2023 option grants as well as an incremental fair value of $131,966, in each case calculated in accordance with FASB ASC Topic 718, related to the modification of the Dr. Lehrer&#8217;s outstanding options to provide for the extension of their post-termination exercise periods.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes a payment equal to $286,000 pursuant to the Lehrer Retention Agreement, as well as severance payments in the amount of $190,667 in base salary continuation and $14,586 in COBRA premium reimbursements, made to Dr. Lehrer pursuant to the Lehrer Separation Agreement.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Ms. Young resigned as Chief Financial Officer, effective June 30, 2023.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes an aggregate grant date fair value of $336,776 for Ms. Young&#8217;s 2023 option grants as well as an incremental fair value of $48,388, in each case calculated in accordance with FASB ASC Topic 718, related to the modification of Ms. Young&#8217;s outstanding options to provide for the extension of their post-termination exercise periods.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes reimbursements for relocation housing assistance paid to Ms. Young for the first quarter of the fiscal year ended December 31, 2023.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Narrative Disclosure to LENZ OpCo&#8217;s Summary Compensation Table for the Fiscal Year Ended December 31, 2023</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Base Salary</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the footnotes to the Summary Compensation Table for the Fiscal Year Ended December 31, 2023 above for information on the base salaries of LENZ OpCo&#8217;s named executive officers in effect during fiscal years ended 2023 and 2022.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Annual Cash Bonuses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of LENZ OpCo&#8217;s named executive officers is eligible to participate in an annual cash incentive compensation program which provides participants with an opportunity to earn variable cash incentive compensation based on individual and company performance. For 2023, Mr. Schimmelpennink&#8217;s target bonus was 50% of his base salary, Mr. Olsson&#8217;s target bonus was 35% of his base salary, and Dr. Odrich&#8217;s target bonus was 30% of his base salary.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the 2023 bonus amount was discretionary based on the LENZ OpCo&#8217;s board of directors assessment of company performance against corporate goals.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actual annual cash bonuses awarded to each named executive officer for 2023 performance are set forth above in the &#8220;Bonus&#8221; column of the Summary Compensation Table for the Fiscal Year Ended December 31, 2023.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End December 31, 2023</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding equity awards granted to LENZ OpCo&#8217;s named executive officers that remained outstanding as of December 31, 2023. The number of shares subject to each award </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, where applicable, the exercise price per share, reflect all changes as a result of our capitalization adjustments in connection with the Merger.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock Awards</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grant Date</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">securities </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">underlying </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">unexercised </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">options</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(#) exercisable</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">securities </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">underlying </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">unexercised </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">options</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(#) unexercisable</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise price</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">expiration date</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">shares or units </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of stock that </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">have not vested</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(#)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value of </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">shares of units of </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">stock that have </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">not vested</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">($)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evert Schimmelpennink</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;8&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266,135&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,970&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.04&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;7&#47;2031</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#47;24&#47;2022</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,871&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,851&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.05&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#47;23&#47;2032</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#47;20&#47;2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315,864&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.04&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#47;19&#47;2033</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shawn Olsson</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#47;19&#47;2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,316&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,658&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.08&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#47;18&#47;2031</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#47;24&#47;2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,310&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,155&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.05&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#47;23&#47;2032</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#47;20&#47;2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,915&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.04&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#47;19&#47;2033</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marc Odrich</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#47;19&#47;2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,568&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184,844&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#47;24&#47;2022</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,855&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149,773&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#47;20&#47;2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,472&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.04&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#47;19&#47;2033</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">All of the outstanding stock option awards were granted under and subject to the terms of the LENZ OpCo 2020 Equity Incentive Plan.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock option awards were granted with a per share exercise price equal to the fair market value of one share of LENZ OpCo common stock on the date of grant, as determined in good faith by its board of directors based on third party valuations of its common stock.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Twenty-five percent of the shares subject to the option vested on March 8, 2022, and 1&#47;36th of the remaining shares subject to the award shall vest each month thereafter on the same day of the month, subject to Mr. Schimmelpennink continuing to be a service provider to LENZ through each such date. All of the shares underlying the option are subject to an early exercise provision pursuant to which Mr. Schimmelpennink may exercise the option for shares of restricted stock subject to LENZ&#8217;s right to repurchase such shares that lapses on the same vesting schedule as would have applied to such shares under the option. Additionally, the option is subject to certain equity acceleration benefits provided for in the Severance Policy. For a summary of the material terms of the Severance Policy, please see the section of this prospectus below titled &#8220;Potential Payments Upon Termination or Change of Control.&#8221;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Twenty-five percent of the shares subject to the option shall vest on March 6, 2024, and 1&#47;36th of the remaining shares subject to the award shall vest each month thereafter on the same day of the month, subject to the named executive officer continuing to be a service provider to LENZ through each such date. All of the shares underlying the option are subject to an early exercise provision pursuant to which such named executive officer may exercise the option for shares of restricted stock subject to LENZ&#8217;s right to repurchase such shares that lapses on the same vesting schedule as would have applied to such shares under the option. Additionally, the option is expected to be subject to certain equity acceleration benefits provided for in the Severance Policy. For a summary of the material terms of the Severance Policy, please see the section of this prospectus below titled &#8220;Potential Payments Upon Termination or Change of Control.&#8221;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Twenty-five percent of the shares subject to the option vested on April 26, 2022, and 1&#47;36th of the remaining shares subject to the award shall vest each month thereafter on the same day of the month, subject to Mr. Olsson continuing to be a service provider to LENZ through each such date. All of the shares underlying the option are subject to an early exercise provision pursuant to which Mr. Olsson may exercise the option for shares of restricted stock subject to LENZ&#8217;s right to repurchase such shares that lapses on the same vesting schedule as would have applied to such shares under the option. Additionally, the option is expected to be subject to certain equity acceleration benefits provided for in the Severance Policy. For a summary of the material terms of the Severance Policy, please see the section of this prospectus below titled &#8220;Potential Payments Upon Termination or Change of Control.&#8221;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents restricted stock obtained on January 28, 2022 upon exercise of an early exercise option. Twenty-five percent of the shares subject to the option vested on July 1, 2022, and 1&#47;36th of the remaining shares subject to the award shall vest monthly in equal installments on the 1st of each month, through July 1, 2025. Additionally, the option is expected to be subject to certain equity acceleration benefits provided for in the Severance Policy. For a summary of the material terms of the Severance Policy, please see the section of this prospectus below titled &#8220;Potential Payments Upon Termination or Change of Control.&#8221;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">This amount reflects the fair market value of LENZ OpCo&#8217;s common stock based on the determination of the fair market value by the LENZ OpCo board of directors as of the most proximate date multiplied by the amount shown in the column for the number of shares or units of stock that have not vested.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents restricted stock obtained on December 30, 2022 upon exercise of an early exercise option. Twenty-five percent of the shares subject to the option vested on July 1, 2022, and 1&#47;36th of the remaining shares subject to the award shall vest monthly in equal installments on the 1st of each month, through July 1, 2025. Additionally, the option is expected to be subject to certain equity acceleration benefits provided for in the Severance Policy. For a summary of the material terms of the Severance Policy, please see the section of this prospectus below titled &#8220;Potential Payments Upon Termination or Change of Control.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding equity awards granted to Graphite&#8217;s named executive officers that remained outstanding as of December 31, 2023. The number of shares subject to each award and the exercise price per share are each reported as of December 31, 2023 and do not reflect any changes as a result </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Graphite&#8217;s capitalization adjustments in connection with the Merger, the reverse stock split or the Special Dividend.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option Awards</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stock Awards</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Grant Date</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vesting Commencement Date</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Securities Underlying Unexercised Options (#) Exercisable</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Securities Underlying Unexercised Options (#) Unexercisable</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option Exercise Price</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Option Expiration Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Shares or Units of Stock That Have Not Vested (#)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market Value of Shares or Units of Stock That Have Not Vested </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">($)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kimberlee C. Drapkin</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#47;28&#47;2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#47;28&#47;2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,555&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,445&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.52&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#47;27&#47;2033</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Josh Lehrer</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#47;20&#47;2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#47;20&#47;2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,867&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,372&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#47;20&#47;2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#47;20&#47;2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,095&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,829&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#47;13&#47;2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#47;20&#47;2020</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,168&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)(5)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,660&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;17&#47;2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;17&#47;2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546,697&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248,499&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;16&#47;2031</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;17&#47;2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;17&#47;2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234,298&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)(7)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#47;16&#47;2031</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#47;16&#47;2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#47;1&#47;2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311,458&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338,542&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.02&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#47;15&#47;2032</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#47;21&#47;2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#47;1&#47;2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.18&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#47;20&#47;2033</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alethia R. Young</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#47;1&#47;2022</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#47;1&#47;2022</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109,375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#47;3&#47;2024</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#47;21&#47;2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#47;1&#47;2023</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#47;3&#47;2024</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Each equity award is subject to the terms of Graphite&#8217;s 2020 Stock Option and Grant Plan, as amended (the &#8220;2020 Graphite Plan&#8221;), or Graphite&#8217;s 2021 Stock Option and Incentive Plan, as amended (the &#8220;2021Graphite Plan&#8221;). Grants made subsequent to June 24, 2021 are subject to the terms of the 2021 Graphite Plan. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Based on the closing price of a share of the Graphite common stock on December 29, 2023, the last business day of the most recently completed fiscal year, which was $2.62.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The shares of common stock underlying the option vest in 36 equal monthly installments following the vesting commencement date, subject to the named executive officer&#8217;s continuous service relationship with Graphite through each applicable vesting date. Notwithstanding the foregoing, in connection with the consummation of the Merger, all unvested shares immediately vested and became exercisable. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The shares of restricted stock vest as follows&#58; 25% of the shares on the first anniversary of the vesting commencement date and the remaining 75% in 36 equal monthly installments thereafter, subject to the named executive officer&#8217;s continuous service relationship with Graphite through each applicable vesting date, including his continuous service relationship as a consultant to Graphite. During his post-employment consulting period, Dr. Lehrer&#8217;s outstanding equity awards continued to vest in accordance with the foregoing terms.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The named executive officer received an early exercisable stock option award, which the named executive officer early exercised in its entirety. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The shares of Graphite common stock underlying the option vest in 48 equal monthly installments following the vesting commencement date, subject to the named executive officer&#8217;s continuous service relationship with Graphite through each applicable vesting date. Notwithstanding the foregoing, during his post-employment consulting period, Dr. Lehrer&#8217;s outstanding equity awards continued to vest in accordance with the foregoing terms.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The option was granted subject to the achievement by Graphite of performance vesting criteria. On June 29, 2021, the performance vesting criteria was met such that the option became subject to time-based vesting in accordance with the vesting schedule described in footnote (6) above. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The shares of common stock underlying the option vest in 48 equal monthly installments following the vesting commencement date, subject to the named executive officer&#8217;s continuous service relationship with the Company through each applicable vesting date. Notwithstanding the foregoing, pursuant to the separation and release agreement entered into between Graphite and Dr. Lehrer, 50% of the unvested shares underlying such option accelerated upon his termination with Graphite (i.e., August 21, 2023), and the remaining unvested shares continued to vest during his post-employment consulting period in accordance with the foregoing vesting terms.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The shares of common stock underlying the option vest in 48 equal monthly installments following the vesting commencement date, subject to Ms. Young&#8217;s continuous service relationship with the Company through each applicable vesting date. Notwithstanding the foregoing, upon Ms. Young&#8217;s resignation, fifty percent (50%) of the unvested shares underlying such option accelerated and the remaining unvested shares of Graphite common stock were forfeited. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Arrangements with Named Executive Officers</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evert Schimmelpennink</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the Transactions, LENZ entered into a confirmatory employment letter with Mr. Schimmelpennink, its Chief Executive Officer. The confirmatory employment letter has no specific term and provides that Mr. Schimmelpennink is an at-will employee. The confirmatory employment letter supersedes all pre-existing agreements and understandings that Mr. Schimmelpennink may have entered into concerning his employment relationship with LENZ. Prior to the Closing, Mr. Schimmelpennink&#8217;s annual base salary was $538,500 and he was eligible for an annual target cash bonus opportunity equal to&#160;50% of his base salary. As of the Closing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date, pursuant to the confirmatory employment letter, Mr. Schimmelpennink&#8217;s annual base salary was increased to $630,000 and he is eligible for a target annual cash bonus opportunity equal to 55% of his annual base salary.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marc Odrich</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the Transactions, LENZ entered into a confirmatory employment letter with Dr. Odrich, its Chief Medical Officer. The confirmatory employment letter has no specific term and provides that Dr. Odrich is an at-will employee. The confirmatory employment letter supersedes all pre-existing agreements and understandings that Dr. Odrich may have entered into concerning his employment relationship with LENZ. Prior to the Closing, Dr. Odrich&#8217;s annual base salary was $410,000 and he was eligible for an annual target cash bonus opportunity equal to 30% of his base salary. As of the Closing Date, pursuant to the confirmatory employment letter, Dr. Odrich&#8217;s annual base salary was increased to $485,000 and he is eligible for a target annual cash bonus opportunity equal to 40% of his annual base salary.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shawn Olsson</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the Transactions, LENZ entered into a confirmatory employment letter with Mr. Olsson, its Chief Commercial Officer. The confirmatory employment letter has no specific term and provides that Mr. Olsson is an at-will employee. The confirmatory employment letter supersedes all pre-existing agreements and understandings that Mr. Olsson may have entered into concerning his employment relationship with LENZ. Prior to the Closing, Mr. Olsson&#8217;s annual base salary was $361,725 and he was eligible for an annual target cash bonus opportunity equal to 35% of his base salary. As of the Closing Date, pursuant to the confirmatory employment letter, Mr. Olsson&#8217;s annual base salary was increased to $433,000 and he is eligible for a target annual cash bonus opportunity equal to 40% of his annual base salary.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Based Incentive Awards</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity-based incentive awards are designed to more closely align our interests and those of our stockholders with those of our employees and consultants, including our named executive officers. Our board of directors is responsible for approving equity grants to our employees and consultants, including our named executive officers. In 2023, stock option awards were the only form of equity awards LENZ OpCo granted to its named executive officers. LENZ OpCo granted equity incentive awards under the terms of its 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), which was terminated in connection with the Merger. The terms of the 2020 Plan are described below under&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LENZ OpCo 2020 Equity Incentive Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All options under the 2020 Plan were granted with an exercise price per share that was no less than the fair market value of a share of LENZ OpCo common stock on the date of grant of such award, as determined in good faith by the LENZ OpCo board of directors. Our stock option awards generally vest over a four-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Outstanding Equity Awards at Fiscal 2023 Year-End December 31, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Grants</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2024, New LENZ&#8217;s board of directors granted (i) Mr. Schimmelpennink an option to purchase 475,000 shares of Common Stock, (ii) Marc Odrich an option to purchase 105,000 shares of Common Stock, and (iii) Shawn Olsson an option to purchase 105,000 shares of Common Stock. Each of the options were granted under the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;) and the form of option agreement thereunder and has a per share exercise price of $15.05. Twenty-five percent (25%) of the shares subject to the option shall vest on March 21, 2025, and one thirty-sixth (1&#47;36th) of the remaining shares subject to the option shall vest each month thereafter, subject to such individual continuing to be a service provider to us through each such date.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Potential Payments Upon Termination or Change of Control</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of the manner in which an officer&#8217;s service terminates, that officer is entitled to receive amounts earned during his or her term of service, including unpaid salary and unused vacation, as applicable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of Mr. Schimmelpennink, Mr. Odrich and Mr. Olsson holds stock options granted subject to the general terms of the 2020 Plan and the 2024 Plan. A description of the termination and change in control provisions in the 2020 Plan and applicable to the stock options granted to such officers under the 2020 Plan is provided below in the section titled &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LENZ OpCo 2020 Equity Incentive Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and a description of such provisions applicable to the 2024 Plan and stock options granted under such plan are provided below in the section titled &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Equity Incentive Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Closing, New LENZ adopted an executive change in control and severance policy (the &#8220;Severance Policy&#8221;) for eligible employees of New LENZ, including the executive officers and other key employees, effective as of the Closing. The Severance Policy is designed to be an &#8220;employee welfare benefit plan&#8221; (as defined in Section 3(1) of the Employee Retirement Income Security Act of 1974, as amended). The compensation committee of the board of directors of New LENZ will administer the Severance Policy, and designate individuals as eligible to participate in the Severance Policy, whether individually or by position or category of position. Each participant in the Severance Policy must execute a participation agreement (each an &#8220;Eligible Employee&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Severance Policy, upon a termination of an Eligible Employee&#8217;s employment (x)&#160;by New LENZ without Cause (as such term is defined in the Severance Policy) (excluding by reason of the Eligible Employee&#8217;s death or disability) or (y)&#160;by the Eligible Employee for Good Reason (as such term is defined in the Severance Policy) (such termination, a &#8220;Qualified Termination&#8221;), in either case, outside of the period beginning 3 months prior to a Change in Control (as such term is defined in the Severance Policy) and ending 12&#160;months following a Change in Control (the &#8220;Change in Control Period&#8221;), (the &#8220;Non-CIC Qualified Termination&#8221;), Eligible Employees will be eligible to receive (i)&#160;a lump sum payment equal to (A)&#160;12 months of annualized base salary with respect to New LENZ&#8217;s Chief Executive Officer, (B)&#160;9 months of annualized base salary with respect to New LENZ&#8217;s Senior Vice Presidents and Executive Officers other than New LENZ&#8217;s Chief Executive Officer, and (C)&#160;3 months plus 2 weeks per year of continuous service of annualized base salary with respect to New LENZ&#8217;s Vice Presidents, and (ii)&#160;subject to a valid election under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;COBRA&#8221;), the cost of such continuation coverage for the Eligible Employee and any of the Eligible Employee&#8217;s eligible dependents that were covered under New LENZ&#8217;s health care plans immediately prior to the date of his or her Non-CIC Qualified Termination until the earliest of the date which the Eligible Employee or their eligible dependents become covered under similar plans, the date which the Eligible Employee ceases to be eligible for coverage under COBRA, or (A)&#160;12 months following the Non-CIC Qualified Termination with respect to New LENZ&#8217;s Chief Executive Officer, (B)&#160;9 months following the Non-CIC Qualified Termination with respect to New LENZ&#8217;s Senior Vice Presidents and Executive Officers other than New LENZ&#8217;s Chief Executive Officer, and (C)&#160;3 months plus 2 weeks per year of continuous service following the Non-CIC Qualified Termination with respect to New LENZ&#8217;s Vice Presidents. Any unvested portion of the Eligible Employee&#8217;s then-outstanding equity awards will remain outstanding until the earlier of (A) 3 months following the Non-CIC Qualified Termination or (B) the occurrence of a Change in Control, provided that, if no Change in Control occurs within the 3 months following a Non-CIC Qualified Termination, any unvested portion of the Eligible Employee&#8217;s equity awards automatically and permanently will be forfeited on the 3-month anniversary following such termination date without having vested.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a Qualified Termination occurs during a Change in Control Period (the &#8220;CIC Qualified Termination&#8221;), the Eligible Employee will be entitled to receive (i)&#160;a lump sum payment equal to (A)&#160;18 months of annualized base salary with respect to New LENZ&#8217;s Chief Executive Officer, (B)&#160;12 months of annualized base salary with respect to New LENZ&#8217;s Senior Vice Presidents and Executive Officers other than New LENZ&#8217;s Chief Executive Officer, and (C)&#160;6 months of annualized base salary with respect to New LENZ&#8217;s Vice Presidents, (ii)&#160;subject to a valid election under COBRA, the cost of such continuation coverage for the Eligible Employee and any of the Eligible Employee&#8217;s eligible dependents that were covered under New LENZ&#8217;s health care plans immediately prior to the date of his or her CIC Qualified Termination until the earliest of the date which the Eligible Employee or their eligible dependents become covered under similar plans, the date which the Eligible Employee ceases to be eligible for coverage under COBRA, or (A)&#160;18 months following the CIC Qualified Termination with respect to New LENZ&#8217;s Chief Executive Officer, (B)&#160;12 months following the CIC Qualified Termination with respect to New LENZ&#8217;s Senior Vice Presidents and Executive Officers other than New LENZ&#8217;s Chief Executive Officer, and (C)&#160;6 months following the CIC Qualified Termination with respect to New LENZ&#8217;s Vice Presidents, (iii)&#160;a lump-sum payment equal to a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">percentage of the Eligible Employee&#8217;s target bonus in effect for the fiscal year which the CIC Qualified Termination occurs in, which such percentage is (A)&#160;150% with respect to New LENZ&#8217;s Chief Executive Officer, (B)&#160;100% with respect to New LENZ&#8217;s Senior Vice Presidents and Executive Officers other than New LENZ&#8217;s Chief Executive Officer, and (C)&#160;50% with respect to New LENZ&#8217;s Vice Presidents, and (iv)&#160;acceleration of vesting as to 100% of the then-unvested shares or rights subject to all of the Eligible Employee&#8217;s equity awards. In the case of an equity award subject to performance-based vesting conditions, unless otherwise specified in the applicable equity award agreement governing the award, all performance goals and other vesting criteria will be deemed achieved at target.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Severance Policy further provides that if any payment or benefit that an Eligible Employee would receive from New LENZ or any other party (the &#8220;Payment&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code, and (ii)&#160;be subject to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;Excise Tax&#8221;), then such Payment will be equal to the Best Results Amount. The &#8220;Best Results Amount&#8221; will be either (x)&#160;the full amount of such Payment or (y)&#160;such lesser amount as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employment taxes, income taxes and the Excise Tax, results in the Eligible Employee&#8217;s receipt, on an after-tax basis, of the greater amount notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The receipt of payments and benefits under the Severance Policy is subject to the Eligible Employee signing and not revoking a separation agreement and release of claims no later than the sixtieth (60th)&#160;day following the Eligible Employee&#8217;s termination.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the Severance Policy, for the avoidance of doubt, Mr.&#160;Schimmelpennink will participate at the level of benefits provided to New LENZ&#8217;s Chief Executive officer, and Mr.&#160;Olsson and Dr.&#160;Odrich will participate at the level of benefits provided to New LENZ&#8217;s Senior Vice Presidents and Executive Officers other than New LENZ&#8217;s Chief Executive Officer.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Incentive Compensation Plan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board approved an Employee Incentive Compensation Plan (the &#8220;Incentive Compensation Plan&#8221;) to provide periodic incentive bonus opportunities to our employees, effective upon Closing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Incentive Compensation Plan allows the plan&#8217;s administrator to grant incentive awards, generally payable in cash, to employees selected by the compensation committee, including the executive officers of the Company, based upon performance goals established by the compensation committee.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Incentive Compensation Plan, the plan&#8217;s administrator will determine the performance goals, if any, applicable to any award, which goals may include, without limitation, goals related to&#58; attainment of research and development milestones&#59; sales bookings&#59; business divestitures and acquisitions&#59; capital raising&#59; cash flow&#59; cash position&#59; contract awards or backlog&#59; corporate transactions&#59; customer renewals&#59; customer retention rates from an acquired company, subsidiary, business unit or division&#59; earnings (which may include any calculation of earnings, including but not limited to earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation and amortization and net taxes)&#59; earnings per share&#59; expenses&#59; financial milestones&#59; gross margin&#59; growth in stockholder value relative to the moving average of the S&#38;P 500 Index or another index&#59; internal rate of return&#59; leadership development or succession planning&#59; license or research collaboration arrangements&#59; market share&#59; net income&#59; net profit&#59; net sales&#59; new product or business development&#59; new product invention or innovation&#59; number of customers&#59; operating cash flow&#59; operating expenses&#59; operating income&#59; operating margin&#59; overhead or other expense reduction&#59; patents&#59; procurement&#59; product defect measures&#59; product release timelines&#59; productivity&#59; profit&#59; regulatory milestones or regulatory-related goals&#59; retained earnings&#59; return on assets&#59; return on capital&#59; return on equity&#59; return on investment&#59; return on sales&#59; revenue&#59; revenue growth&#59; sales results&#59; sales growth&#59; savings&#59; stock price&#59; time to market&#59; total stockholder return&#59; working capital&#59; unadjusted or adjusted actual contract value&#59; unadjusted or adjusted total contract value&#59; and individual objectives such as peer reviews or other subjective or objective criteria. As determined by the administrator, the performance goals may be based on U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) or non GAAP results and any actual results may be adjusted by the administrator for one-time items or unbudgeted or unexpected items and&#47;or payments of actual awards under the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incentive Compensation Plan when determining whether the performance goals have been met. The performance goals may be based on any factors the administrator determines relevant, including without limitation on an individual, divisional, portfolio, project, business unit, segment or company-wide basis. Any criteria used may be measured on such basis as the administrator determines, including without limitation&#58; (a) in absolute terms, (b) in combination with another performance goal or goals (for example, but not by way of limitation, as a ratio or matrix), (c) in relative terms (including, but not limited to, results for other periods, passage of time and&#47;or against another company or companies or an index or indices), (d) on a per-share basis, (e) against the performance of the Company as a whole or a segment of the Company and&#47;or (f) on a pre-tax or after-tax basis. The performance goals may differ from participant to participant and from award to award. The administrator also may determine that a target award (or portion thereof) will not have a performance goal associated with it but instead will be granted (if at all) as determined by the administrator.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee of the board of directors will administer the Incentive Compensation Plan and may, in its sole discretion and at any time prior to payment of an actual award, increase, reduce or eliminate a participant&#8217;s actual award, and&#47;or increase, reduce or eliminate the amount allocated to the bonus pool for a particular performance period. The actual award may be below, at or above a participant&#8217;s target award, as determined by the administrator. The administrator may determine the amount of any increase, reduction or elimination on the basis of such factors as it deems relevant, and it will not be required to establish any allocation or weighting with respect to the factors it considers.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual awards generally will be paid in cash (or its equivalent) in a single lump sum only after they are earned, and, unless otherwise determined by the administrator, to earn an actual award a participant must be employed by us through the date the actual award is paid. The administrator of the Incentive Compensation Plan may reserve the right to settle an actual award with a grant of an equity award, which equity award may have such terms and conditions, including vesting, as the administrator determines. Payment of awards will occur as soon as practicable after the end of the performance period to which the award relates and after the actual award is approved by the administrator, but no later than the dates set forth in the Incentive Compensation Plan.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards under the Incentive Compensation Plan will be subject to the clawback policy of the Company. The administrator also may impose such other clawback, recovery or recoupment provisions with respect an award under the Incentive Compensation Plan as the administrator determines necessary or appropriate, including, without limitation, a reacquisition right in respect of previously acquired cash, stock or other property provided with respect to an award. Certain participants may be required to reimburse us for certain amounts paid under an award under the Incentive Compensation Plan in connection with certain accounting restatements we may be required to prepare due to our material noncompliance with any financial reporting requirements under applicable securities laws, as a result of misconduct.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The administrator will have the authority to amend, suspend or terminate the Incentive Compensation Plan, provided such action does not alter or impair the existing rights of any participant with respect to any earned awards.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Benefits and Perquisites</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide benefits to our executive officers on the same basis as provided to all of our employees, including health, dental and vision insurance&#59; life insurance&#59; accidental death and dismemberment insurance&#59; short-and long-term disability insurance&#59; a flexible spending account&#59; and a tax-qualified Section 401(k) plan. We do not maintain any executive-specific benefit or perquisite programs.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retirement Benefits</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a 401(k) retirement savings plan, which is intended to be a tax qualified defined contribution plan under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), for the benefit of our employees, including certain of our named executive officers, who satisfy certain eligibility requirements. Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a pre-tax (traditional) or post-tax (Roth) basis, through contributions to the 401(k) plan. As a tax-qualified retirement plan, pre-tax contributions to the 401(k) plan and earnings on those pre-tax contributions are not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 401(k) plan authorizes employer safe harbor matching contributions and discretionary profit-sharing contributions. We make matching contributions under the 401(k) plan on behalf of our employees who are eligible to participate in the 401(k) plan. Matching contributions follow certain safe harbor provisions, pursuant to which we make a matching contribution equal to 100% of an eligible employee&#8217;s contributions which do not exceed 3% of such employee&#8217;s compensation, plus 50% of an eligible employee&#8217;s contributions which exceed 3% but not 5% of such employee&#8217;s compensation. We also may choose to make profit-sharing contributions to our employees who are eligible to participate in the 401(k) plan. Profit-sharing contributions may be provided at our sole discretion, and may be allocated so that each participant receives a different amount of profit-sharing as long as the contributions comply with IRS nondiscrimination requirements. Participants are always 100% immediately vested in safe harbor matching and profit sharing contributions under the 401(k) plan. LENZ OpCo did not make any profit sharing contributions under the 401(k) plan during 2023. The matching contributions made to our named executive officers in 2023 are set forth in the &#8220;All Other Compensation&#8221; column of the Summary Compensation Table for the Fiscal Year Ended December 31, 2023.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LENZ OpCo 2020 Equity Incentive Plan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan allowed LENZ OpCo to provide incentive stock options, within the meaning of Section 422 of the Code, nonstatutory stock options, stock appreciation rights, restricted stock awards and restricted stock units (each, an &#8220;award&#8221; and the recipient of such award, a &#8220;participant&#8221;) to any of LENZ OpCo&#8217;s eligible employees, directors, and consultants of and any parent or subsidiary of LENZ OpCo. The 2020 Plan was terminated in connection with the closing of the Merger and we will not grant any additional awards under the 2020 Plan. However, the 2020 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under the 2020 Plan and assumed by us at the closing of the Merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 21, 2024, and after giving effect to the closing of the Merger, stock options covering 1,590,018 shares of Common Stock were outstanding under the 2020 Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Authorized&#160;Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the adjustment provisions in the 2020 Plan, the maximum aggregate number of shares of LENZ OpCo Common Stock that could have been granted under the 2020 Plan prior to the consummation of the Merger was 11,385,409 shares of LENZ OpCo Common&#160;Stock (prior to giving effect to the Merger or the impact of the exchange ratio). The shares eligible for grant could have been authorized, but unissued, or reacquired Common Stock.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plan Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2020 Plan is administered by the board of directors or a committee of the board of directors, or a combination thereof, as determined by the board of directors. Any committee appointed by the board of directors to administer the 2020 Plan may, from time to time, be increased by the board of directors, which may appoint additional members or remove members of the committee with or without cause, including removing all members and directly administering the 2020 Plan.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the provisions of the 2020 Plan, the administrator will have the power to administer the 2020 Plan, including but not limited to&#58; the power to determine the fair market value of the Common Stock in accordance with the provisions of the 2020 Plan&#59; select the employees and consultants (including directors) to whom awards may from time to time be granted&#59; determine whether and to what extent awards are granted&#59; determine the number of shares of Common Stock covered by each award&#59; approve forms of award agreements for use under the 2020 Plan&#59; determine the terms and conditions not inconsistent with the terms of the 2020 Plan of any award granted, which terms and conditions include but are not limited to the exercise or purchase price, the time or times when awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, any pro rata adjustment to vesting as a result of a holder of an award&#8217;s transitioning from full-to part-time service (or vice versa), and any restriction or limitation regarding any stock option, optioned stock, stock right or restricted stock, based in each case on such factors as the administrator determines&#59; determine whether and under what circumstances a stock option may be settled in cash under the provisions of the 2020 Plan instead of Common Stock&#59; implement a program approved by the administrator of the 2020 Plan where outstanding stock options can be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exchanged for stock options with a lower exercise price or amended to decrease the exercise price on such terms and conditions as the administrator in its discretion deems appropriate, provided that no amendment or adjustment to a stock option that would materially and adversely affect the rights of a holder of a stock option shall be made without the prior written consent of the holder of that stock option&#59; adjust the vesting of a stock option held by an employee, director or consultant as a result of a change in the terms or conditions under which such person is providing services to LENZ&#59; construe and interpret the terms of the 2020 Plan and awards granted under it&#59; without amending the 2020 Plan, modify grants of stock options or stock rights to any holder of stock options or stock rights who are foreign nationals or employed outside of the United States in order to recognize differences in local law, tax policies, or customs. The administrator&#8217;s constructions, interpretations, and decisions will be final and binding on all participants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2020 permitted the grant of stock options. Incentive stock options may be granted only to employees, including employees who are also directors. Each stock option shall be designated in an option agreement as either an incentive stock option or a nonstatutory stock option. Prior to the consummation of the Merger, the maximum number of shares of Common Stock with respect to which incentive stock options could have been granted under the 2020 Plan was 11,385,409.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of each stock option shall be the term stated in the applicable option agreement&#59; provided that the term shall be no more than ten years from the date of grant, or such shorter term as may be provided in the option agreement. In the case of an incentive stock option granted to a person who at the time of such grant owns more than ten percent of the voting power of all classes of LENZ&#8217;s outstanding stock, the term of the stock option shall be five years from the date of grant or such shorter term as may be provided in the applicable option agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The per share exercise price of options granted under the 2020 Plan will be a price determined by the administrator that is set forth in the applicable option agreement. In the case of incentive stock options granted to an employee who at the time of grant, owns more than ten percent of the voting power of all classes of LENZ&#8217;s outstanding stock, the term of an incentive stock option granted to such participant must not exceed five years and the exercise price must equal at least one-hundred ten percent of the fair market value of Common Stock on the grant date. In the case of nonstatutory stock options granted on any date on which its Common Stock is not a security of LENZ&#8217;s that is listed or approved for listing on a national securities exchange or designated or approved for designation as a national market system security on an interdealer quotation system by the Financial Industry Regulatory Authority, Inc. (a &#8220;Listed Security&#8221;), the per&#160;share exercise price will be the price determined by the Administrator&#59; or granted on any date on which the Common Stock is a Listed Security to any eligible person, the per share exercise price shall be a price determined by the administrator based on the closing price of LENZ&#8217;s Common Stock for the applicable date. No nonstatutory stock option will be granted with a per share exercise price less than one-hundred percent of the fair market value on the date of grant unless the administrator explicitly designates such as a discounted option with terms intended to avoid additional taxes under Section&#160;409A of the Code.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The administrator determines the consideration to be paid for shares issued upon exercise of a stock option, including the methods of payment (in the case of incentive stock options this will be determined at the time of grant), which may include cash, check, delivery of a promissory note having recourse, interest, security and redemption provisions determined by the administrator, other shares that have a fair market value on the date of surrender equal to the aggregate exercise price of the shares to which the stock option is exercised (provided that in the case of shares provided directly or indirectly by LENZ, the shares must have been owned for more than six months on the date of surrender (or such period as may be required for securities law purposes to avoid LENZ incurring an adverse accounting charge)&#59; by net exercise or by a cashless exercise method, including a broker-assisted cashless exercise&#59; any combination thereof&#59; or any other consideration or method of payment acceptable to the administrator, to the extent permitted by applicable law.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The administrator will establish in the applicable option agreement the terms and conditions in which a stock option will remain exercisable, if at all, following termination of a participant. Unless the administrator provides in the applicable option agreement, if an option holder does not exercise their stock option to the extent they are entitled to do so within the time specified in their option agreement, the stock option will terminate and the optioned stock underlying the unexercised portion of the stock option will revert to the 2020 Plan. If an employee, director or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consultant is terminated other than for death, disability or for cause, the option holder may exercise their option for ninety days following their termination to the extent they are vested in the optioned stock (they may exercise their stock option for twelve months in the event of termination due to disability or death). If terminated for cause, a participant&#8217;s stock options will immediately terminate in their entirety.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2020 Plan permitted the grant of stock rights. A stock right is the right to acquire Common Stock pursuant to the 2020 Plan. The administrator will advise a participant in writing of the terms, conditions and restrictions related to the stock right, including the number of shares that the participant will be entitled to acquire, the price to be paid, and the time within which the participant must accept such offer. The offer to purchase shares subject to a stock right will be accepted by execution of a restricted stock agreement in the form determined by the administrator. The restricted stock agreement will grant LENZ a repurchase option exercisable upon the voluntary or involuntary termination of the participant&#8217;s employment or other service arrangement with LENZ for any reason (including death or disability), unless determined otherwise by the administrator.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the participant is terminated for cause, LENZ will have the right to repurchase from the participant any vested shares derived from a stock right prior to the date, if any, upon which LENZ&#8217;s Common Stock becomes a Listed Security. LENZ&#8217;s right to repurchase such shares upon termination of such participant&#8217;s service for cause shall be made at the lower of (A)&#160;the participant&#8217;s original cost for the shares and (B)&#160;the fair market value of the shares as of the date of termination, and shall be effected pursuant to such terms and conditions, and at such time, as the administrator shall determine.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Transferability&#160;of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2020 Plan generally does not allow stock options, stock rights or shares issued upon the exercise of either to be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than by will, or by the laws of descent or distribution, except as set forth in the 2020 Plan. The administrator may, in its discretion, grant nonstatutory stock options that may be transferred by instrument to an inter vivos or testamentary trust in which the stock options are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift or pursuant to domestic relations orders to immediate family members of the holder of the stock option.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to any action required under applicable law, in the event of a stock split, reverse stock split, stock dividend, combination, recapitalization or reclassification of LENZ&#8217;s Common Stock, or any other increase or decrease in the number of issued shares without receipt of consideration by LENZ, a proportionate adjustment will be made in the number of shares covered by each outstanding award, and the number of shares that have been authorized for issuance under the 2020 Plan but as to which no awards have yet been granted or that have been returned to the 2020 Plan upon cancellation or expiration of an award, as well as the price per share covered by each such outstanding award. The adjustment will be made by the administrator, whose determination will be final, binding and conclusive.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dissolution or Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event of LENZ&#8217;s liquidation or dissolution, each stock option or stock right will terminate immediately prior to the consummation of such event, unless determined otherwise by the administrator.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2020 Plan provides that in the event of a change of control, as defined under the plan, the LENZ board of directors or a committee appointed by its board of directors may provide for&#58; (1)&#160;the acceleration in part or whole of the right to exercise a stock option or the vesting of any award&#59; (2)&#160;the assumption or substitution of, or adjustment to, each outstanding stock option by the successor corporation or a parent or subsidiary of the successor corporation&#59; (3)&#160;the termination of any stock option not exercised within a specified period of notice of such termination&#59; and&#47;or (4)&#160;termination of stock options as a result of the change of control on such other terms and conditions as it deems appropriate, including providing for the cancellation of stock options for a cash payment to the participant. The plan&#8217;s administrator does not have to provide for identical treatment of each outstanding award in connection with a merger or change in control.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of any distribution to LENZ stockholders of securities of any other entity or other assets (other than dividends payable in cash or stock of the company) without receipt of consideration by LENZ, the administrator </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may, in its discretion, adjust the price per share of LENZ&#8217;s Common Stock covered by each outstanding stock option or stock right to reflect the effect of such distribution.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendment and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As noted above, in connection with the closing of the Merger, the 2020 Plan terminated and we will not grant any additional awards under the 2020 Plan.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024 Equity Incentive Plan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following paragraphs summarize the key features of the 2024 Plan and its operation. However, this summary is not a complete description of all of the provisions of the 2024 Plan and is qualified in its entirety by the specific language of the 2024 Plan.&#160;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 21, 2024, stock options covering 1,325,800 shares of Common Stock were outstanding under the 2024 Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purposes of the 2024 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purposes of the 2024 Plan are to attract and retain personnel for positions with the combined company&#59; to provide additional incentive to employees, directors, and consultants&#59; and to promote the success of the combined company&#8217;s business. These incentives are provided through the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, or performance awards.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2024 Plan will provide for the grant of incentive stock options, within the meaning of Section&#160;422 of the Code, to employees of LENZ and any member of the company group, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance awards to the combined company&#8217;s employees, directors and consultants and any member of the company group. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Authorized Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to adjustment upon certain changes in the Company&#8217;s capitalization as described in the 2024 Plan, the maximum number of shares of common stock that will be available for issuance under the 2024 Plan will be 3,011,948&#160;shares of common stock, plus (i)&#160;any shares subject to awards granted under the 2020 Plan (including, but not limited to, awards granted under the 2020 Plan that were assumed in the Merger), Graphite&#8217;s 2021 Stock Option and Incentive Plan and Graphite&#8217;s 2020 Stock Option and Grant Plan) that, on or after the effective date of the merger, expire or terminate without having been exercised in full, are tendered to or withheld for payment of an exercise price or for tax withholding obligations, are forfeited or repurchased due to failure to vest, with a maximum number of shares that may be added to the 2024 Plan equal to 1,607,930 shares, plus (ii)&#160;any shares that become available for issuance due to the automatic share reserve increase or share reserve return (as described below) will be reserved for issuance under the 2024 Plan.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares available for issuance under the 2024 Plan will include an annual increase on the first day of each fiscal year beginning with the 2025 fiscal year, equal to the least of&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">4,517,922&#160;shares.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a number of lesser shares as determined by the 2024 Plan&#8217;s administrator.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The automatic share reserve increase will operate only until the tenth anniversary of the earlier of the board or stockholder approval of the 2024 Plan.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an award of options or stock appreciation rights expire or become unexercisable without having been exercised in full, is surrendered pursuant to an exchange program, or, with respect to restricted stock, restricted stock units, or stock-settled performance awards, are reacquired by the combined company due to failure to vest or forfeited to the combined company, the unpurchased or unissued shares will become available for future issuance under the 2024 Plan (unless the 2024 Plan has terminated). With respect to stock appreciation rights, only the net shares actually issued will cease to be available under the 2024 Plan and all remaining shares of common stock subject to the stock appreciation right will remain available for future issuance under the 2024 Plan (unless the 2024 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan has terminated). Shares that have actually been issued under the 2024 Plan will not be returned to the 2024 Plan. Shares used to pay the exercise price of an award or satisfy the tax withholding obligations related to an award will become available for future issuance under the 2024 Plan. To the extent an award is paid out in cash rather than shares, such cash payment will not result in a reduction in the number of shares available for issuance under the 2024 Plan.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plan Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The combined company&#8217;s board of directors or a committee appointed by the board of directors will administer the 2024 Plan. The combined company&#8217;s board of directors or the committee appointed by them may delegate to one or more subcommittees or officers of the combined company, the authority to grant awards to employees of the combined company, if this delegation complies with applicable laws this delegation can be revoked by the combined company&#8217;s board of directors or the committee they appointed. Different administrators may administer the 2024 Plan with respect to different groups of employees, directors, and consultants. The combined company&#8217;s board of directors may retain the authority to administer the 2024 Plan along with a committee and may revoke delegation of some or all of the authority delegated to that committee. The combined company&#8217;s compensation committee will initially administer the 2024 Plan. Subject to the provisions of the 2024 Plan, the administrator has the power to administer the 2024 Plan and make all determinations deemed necessary or advisable for administering the 2024 Plan, including but not limited to, the power to determine the fair market value of the combined company&#8217;s common stock, select the service providers to whom awards may be granted, determine the number of shares covered by each award, approve forms of award agreements for use under the 2024 Plan, determine the terms and conditions of awards (including, but not limited to, the exercise price, the time or times at which awards may be exercised, any vesting acceleration or waiver or forfeiture restrictions and any restriction or limitation regarding any award or the shares relating thereto), construe and interpret the terms of the 2024 Plan and awards granted under it, establish, amend and rescind rules relating to the 2024 Plan, including adopting&#160;sub-plans,&#160;interpret, modify or amend each award, including but not limited to the discretionary authority to extend the post-termination exercisability period of awards, and allow a participant to defer the receipt of payment of cash or the delivery of shares that would otherwise be due to such participant under an award. The administrator also has the authority to allow participants the opportunity to transfer outstanding awards to a financial institution or other person or entity selected by the administrator and to institute an exchange program by which outstanding awards may be surrendered or cancelled in exchange for awards of the same type, which may have a higher or lower exercise price and&#47;or different terms, awards of a different type, and&#47;or cash or by which the exercise price of an outstanding award is increased or reduced. The administrator&#8217;s decisions, determinations, and interpretations are final and binding on all participants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Stock options may be granted under the 2024 Plan. The exercise price of options granted under the 2024 Plan must generally be at least equal to the fair market value of the combined company&#8217;s common stock on the date of grant. The term of an option may not exceed ten years. With respect to any participant who owns more than 10% of the voting power of all classes of the combined company&#8217;s (or any parent or subsidiary of the combined company&#8217;s) outstanding stock, the term of an incentive stock option granted to such participant must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date. The administrator will determine the methods of payment of the exercise price of an option, which may include cash, shares or other property acceptable to the administrator, as well as other types of consideration permitted by applicable law. After the termination of service of an employee, director, or consultant (except for termination as a result of death or disability), he or she may exercise his or her option for a period of thirty days or such longer period of time stated in his or her option agreement. If termination is due to death or disability, the option will remain exercisable for six months following the termination of service or such longer period of time as specified in the participant&#8217;s award agreement. Subject to the provisions of the 2024 Plan, the administrator determines the other terms of options.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Stock appreciation rights may be granted under the 2024 Plan. Stock appreciation rights allow the recipient to receive the appreciation in the fair market value of the combined company&#8217;s common stock between the exercise date and the date of grant. The administrator of the 2024 Plan will determine the number of shares of common stock subject to a stock appreciation right, its exercise price a, the expiration date of a stock appreciation right, and other terms and conditions, which will be set forth in an award agreement. The per share exercise price for the shares to be issued pursuant to the exercise of a stock appreciation right will be no less than 100% of the fair market value per share on the date of grant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock may be granted under the 2024 Plan. Restricted stock awards are grants of shares of the combined company&#8217;s common stock that vest in accordance with terms and conditions established by the administrator. The administrator will determine the number of shares subject an award of restricted stock and will determine the terms and conditions of such awards. Unless determined otherwise by the administer, shares of restricted stock will be held in escrow while unvested. Recipients of restricted stock awards generally may exercise full voting rights with respect to such shares while unvested, unless the administrator provides otherwise. An award recipient of restricted stock will not be entitled to receive dividends or other distributions paid with respect to the shares underlying the restricted stock award while those shares are unvested, unless the administrator provides otherwise. If the administrator provides that dividends and distributions will be received and any such dividends or distributions are paid in cash they will be subject to the same provisions regarding forfeitability as the shares of common stock underlining the restricted stock award with respect to which they were paid and if dividends or distributions are paid in shares, the shares will be subject to the same restrictions on transferability and forfeitability as the shares with respect to which they were paid and, unless the administrator determines otherwise, the Company will hold such dividends until the restrictions on the shares with respect to which they were paid have lapsed. The administrator may impose (prior to grant) or remove (at any time) any restrictions on shares covered by an award of restricted stock.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Restricted stock units may be granted under the 2024 Plan. Restricted stock units are bookkeeping entries representing an amount equal to the fair market value of one share of the combined company&#8217;s common stock. Subject to the provisions of the 2024 Plan, the administrator determines the terms and conditions of restricted stock units, including the vesting criteria (if any), the number of restricted stock units paid out and the form and timing of payment, which will be set out in the applicable award agreement. The administrator may set vesting criteria based upon the achievement of company-wide, divisional, business unit or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws or any other basis determined by the administrator in its sole discretion. The administrator may settle earned restricted stock units in the form of cash, in shares or in some combination thereof. In addition, the administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Performance awards may be granted under the 2024 Plan. Performance awards are awards that will result in a payment to a participant only if performance objectives established by the administrator are achieved or the awards otherwise vest. The administrator will specify any time period during which any performance objectives or other vesting provisions, if any, will be measured, and such other terms, as specified in the applicable award agreement. The administrator may set performance objectives based on the achievement of company-wide, divisional, business unit or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws or any other basis determined by the administrator in its discretion. After the grant of a performance award, the administrator, may reduce or waive any performance objectives or other vesting provisions for such performance awards. Performance awards will have an initial value established by the administrator on or prior to the grant date. The administrator, in its sole discretion, may pay out earned performance awards in cash, shares, or in some combination thereof.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outside Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All outside&#160;(non-employee)&#160;directors will be eligible to receive all types of awards (except for incentive stock options) under the 2024 Plan. To provide a maximum limit on the cash retainer fees and equity awards that can be made to outside directors, the 2024 Plan provides that in any given fiscal year, an outside director will not be granted cash retainer fees and equity awards with an aggregate value greater than $750,000 (increased to $1,000,000 in the fiscal year in connection with his or her initial service as an outside director), with the value of each equity award based on its grant date fair value as determined according to GAAP for purposes of this limit. Any cash compensation paid, or awards granted to an individual for his or her services as an employee or consultant (other than as an outside director) will not count toward this limit.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Transferability&#160;of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unless the administrator provides otherwise, or otherwise required by applicable laws, an award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the participant, only by the participant. If the administrator makes an award transferable, the award will be limited by any additional terms and conditions imposed by the administrator. Any unauthorized transfer of an award will be void.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any extraordinary dividend or other extraordinary distribution (whether in cash, shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, reclassification, repurchase, or exchange of shares or other securities of the combined company, other change in the corporate structure of the combined company affecting the shares of common stock, or any similar equity restructuring transaction, as that term is used in Statement of FASB ASC 718 (or any of its successors) affecting the shares of common stock occurs, to prevent diminution or enlargement of the benefits or potential benefits available under the 2024 Plan, the administrator will adjust the number and class of shares that may be delivered under the 2024 Plan and&#47;or the number, class and price of shares covered by each outstanding award and the numerical share limits set forth in the 2024 Plan.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dissolution or Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the event of the combined company&#8217;s proposed liquidation or dissolution, the administrator will notify participants prior to the effective date of the proposed transaction and, to the extent not previously exercised, all awards will terminate immediately prior to the consummation of such proposed action.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merger or Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2024 Plan provides that in the event of a merger or change in control, as defined under the 2024 Plan, each outstanding award will be treated as the administrator determines, without a participant&#8217;s consent, including providing that awards be continued by the successor corporation or a parent or subsidiary of the successor corporation (or an affiliate thereof) or that the vesting of any such awards may accelerate automatically upon consummation of a transaction. The administrator is not required to treat all awards, all awards held by a participant or all awards of the same type similarly. The administrator may take different actions with respect to the vested and unvested portions of an award. The administrator has the authority to modify awards in connection with a change in control or merger in a manner that causes the awards to lose their tax-preferred status, to terminate any right a participant has to exercise an option prior to vesting in the shares of common stock subject to the option, so that following the closing of the transaction the option may only be exercised to the extent it is vested&#59; to reduce the exercise price subject to the award in a manner that is disproportionate to the increase in the number of shares of common stock subject to the award, as long as the amount that would be received upon exercise of the award immediately before and immediately following the closing of the transaction is equivalent and the adjustment complies with applicable laws&#59; and to suspend a participant&#8217;s right to exercise an option during a limited period of time preceding and or following the closing of the transaction without participant&#8217;s consent if such suspension is administratively necessary or advisable to permit the closing of the transaction.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a successor corporation does not continue an award, or some portion of such award, then the participant will fully vest in and have the right to exercise all of his or her outstanding options and stock appreciation rights, all restrictions on restricted stock and restricted stock units will lapse, and for awards with performance-based vesting, unless specifically provided for otherwise under the applicable award agreement or other agreement or policy applicable to the participant, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and all other terms and conditions met. If an option or stock appreciation right is not assumed or substituted in the event of a change in control, the administrator will notify the participant in writing or electronically that such option or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion and the option or stock appreciation right will terminate upon the expiration of such period. For awards granted to an outside director, in the event of a change in control, the outside director will fully vest in and have the right to exercise all of his or her outstanding options and stock appreciation rights, all restrictions on restricted stock and restricted stock units will lapse and, for awards with performance-based vesting, unless specifically provided for otherwise under the applicable award agreement or other agreement or policy applicable to the participant, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and all other terms and conditions met.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All awards under the 2024 Plan will be subject to recoupment under any clawback policy that the combined company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the combined company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable laws. The administrator may impose other clawback, recovery or recoupment provisions in an award agreement as the administrator determines necessary or appropriate, including without limitation to any reacquisition right regarding previously acquired shares of the combined company&#8217;s common stock or other cash or property. The administrator may specify in an award agreement that a participant&#8217;s rights, payments, and benefits with respect to an award will be subject to reduction, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cancellation, forfeiture, or recoupment upon the occurrence of specified events, in addition to any otherwise applicable vesting or performance conditions of an award.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Date&#59; Amendment&#59; Termination</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2024 Plan became effective date on March 21, 2024. The administrator, in its sole discretion, has the authority to amend, alter, suspend or terminate the 2024 Plan, or any part thereof, at any time and for any reason, provided that a participant&#8217;s rights will not be materially impaired without signed, written agreement authorized by the administrator between the participant and the Company. The Company will obtain stockholder approval of any plan amendment to the extent necessary or desirable to comply with applicable laws. Termination of the 2024 Plan will not affect the administrator&#8217;s ability to exercise the powers granted to it regarding awards granted under the 2024 Plan prior to such termination. The 2024 Plan will continue in effect until terminated pursuant its terms, but (i)&#160;no incentive stock options may be granted after 10 years from the earlier of the Graphite board or stockholder approval of the 2024 Plan and (ii)&#160;the automatic share reserve increase will operate only until the tenth anniversary of the earlier of the Graphite board or stockholder approval of the 2024 Plan.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024 Employee Stock Purchase Plan </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal features of our 2024 Employee Stock Purchase Plan (the &#8220;2024 ESPP&#8221;) and its operation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purpose.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The purpose of the 2024 ESPP is to provide eligible employees with an opportunity to purchase shares of the combined company&#8217;s common stock through accumulated contributions, which generally will be made through payroll deductions. The 2024 ESPP permits the administrator (as discussed below) to grant purchase rights that qualify for preferential tax treatment under Section&#160;423 of the Code. In addition, the 2024 ESPP authorizes the grant of purchase rights that do not qualify under Code Section&#160;423 pursuant to rules, procedures or&#160;sub-plans&#160;adopted by the administrator that are designed to achieve desired tax or other objectives.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Authorized Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Subject to adjustment upon certain changes in the Company&#8217;s capitalization as described in the 2024 ESPP, the maximum number of shares of common stock that will be available for issuance under the 2024 ESPP will be 250,995 shares. The shares may be authorized, but unissued, or reacquired common stock. The number of shares of common stock available for issuance under the 2024 ESPP will be increased on the first day of each fiscal year beginning for the fiscal year following the fiscal year in which the first enrollment date under the 2024 ESPP (if any) occurs, in an amount equal to the least of (i)&#160;376,493 shares, (ii)&#160;one percent (1%)&#160;of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii)&#160;an amount determined by the administrator.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are unable to determine how long this share reserve may last because the number of shares that will be issued in any year or offering period depends on a variety of factors that cannot be predicted with certainty, including, for example, the number of employees who elect to participate in the 2024 ESPP, the level of contributions made by participants and the future price of shares of common stock.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plan Administration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The board of directors or a committee appointed by the board of directors will administer the 2024 ESPP. The compensation committee will initially administer the 2024 ESPP. Subject to the terms of the 2024 ESPP, the administrator will have full and exclusive discretionary authority to construe, interpret and apply the terms of the 2024 ESPP, to delegate ministerial duties to any of the combined company&#8217;s employees, to designate separate offerings under the 2024 ESPP, to designate subsidiaries and affiliates as participating in the Section&#160;423 Component and the&#160;Non-Section&#160;423 Component, to determine eligibility, to adjudicate all disputed claims filed under the 2024 ESPP and to establish such procedures that it deems necessary or advisable for the administration of the 2024 ESPP. The administrator is authorized to adopt rules and procedures in order to&#58; determine eligibility to participate, determine the definition of compensation for the purposes of contributions to the 2024 ESPP, handle contributions to the 2024 ESPP, coordinate the making of contributions to the 2024 ESPP, establish bank or trust accounts to hold contributions to the 2024 ESPP, effect the payment of interest, effect the conversion of local currency, satisfy obligations to pay payroll tax, determine beneficiary designation requirements, implement and determine withholding procedures and determine procedures for the handling of stock certificates that vary with applicable local requirements. The administrator will also be authorized to determine that, to the extent permitted by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable law, the terms of a purchase right granted under the 2024 ESPP or an offering to citizens or residents of a&#160;non-U.S.&#160;jurisdiction will be less favorable than the terms of options granted under the 2024 ESPP or the same offering to employees that reside solely in the United States. Every finding, decision and determination made by the administrator will, to the full extent permitted by law, be final and binding upon all parties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Eligibility.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Generally, all of the combined company&#8217;s employees will be eligible to participate if they are customarily employed by us, or any participating subsidiary or affiliate, for at least 20 hours per week and more than five months in any calendar year, or any lesser number of hours per week and&#47;or number of months in any calendar year established by the administrator (if required under applicable local law) for purposes of any separate offering or the Non-Section&#160;423 component. The administrator, in its discretion, on a uniform and nondiscriminatory basis, may, prior to an enrollment date, for all options to be granted on such enrollment date in an offering, determine that an employee who (i)&#160;has not completed at least two years of service (or a lesser period of time determined by the administrator) since his or her last hire date, (ii)&#160;customarily works not more than 20 hours per week (or a lesser period of time determined by the administrator), (iii)&#160;customarily works not more than five months per calendar year (or a lesser period of time determined by the administrator), (iv)&#160;is a highly compensated employee within the meaning of Section&#160;414(q) of the Code, or (v)&#160;is a highly compensated employee within the meaning of Section&#160;414(q) of the Code with compensation above a certain level or is an officer or subject to disclosure requirements under Section&#160;16(a) of the Exchange Act, is or is not eligible to participate in such offering period.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, an employee may not be granted rights to purchase shares of the combined company&#8217;s common stock under the 2024 ESPP if such employee&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">immediately after the grant would own capital stock and&#47;or hold outstanding options to purchase such stock possessing 5% or more of the total combined voting power or value of all classes of capital stock of ours or of any parent or subsidiary of ours&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">holds rights to purchase shares of the combined company&#8217;s common stock under all employee stock purchase plans of ours or any parent or subsidiary of ours that accrue at a rate that exceeds $25,000 worth of shares of the combined company&#8217;s common stock for each calendar year in which such rights are outstanding at any time.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Offering Periods</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2024 ESPP will include a component that allows the Company to make offerings intended to qualify under Section&#160;423 of the Code and a component that allows the Company to make offerings not intended to qualify under Section&#160;423 of the Code to designated companies, as described in the 2024 ESPP. Offering periods will begin and end on such dates as established by the administrator (including the commencement and termination dates thereof) without stockholder approval if such change is announced prior to an enrollment date for all purchase rights to be granted on such enrollment date. No offering period may last more than 27 months.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contributions.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 ESPP will permit participants to purchase shares of the combined company&#8217;s common stock through contributions (in the form of payroll deductions or otherwise to the extent permitted by the administrator) of up to 15% of their eligible compensation, a measure to be determined by the administrator, or such other limit established by the administrator from time to time in its discretion and on a uniform and nondiscretionary basis for all options to be granted on an enrollment date in an offering.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise of Purchase Right</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A participant&#8217;s option for the purchase of shares of common stock will be exercised automatically on each exercise date, unless a participant withdraws from the 2024 ESPP (or participant&#8217;s participation is terminated), and the maximum number of full shares of the combined company&#8217;s common stock subject to the option will be purchased for such participant at the applicable purchase price with the accumulated contributions from his or her account. No fractional shares of common stock will be purchased. Any contributions accumulated in a participant&#8217;s account, which are not sufficient to purchase a full share will be retained in the participant&#8217;s account for the next purchase period or offering period and will be subject to earlier withdrawal by the participant. Any other funds left over in a participant&#8217;s account after the exercise date will be returned to the participant. The Administrator may, for future offering periods, increase or decrease, in its absolute discretion, the maximum number of shares of common stock that an eligible employee may purchase during each purchase period and&#47;or offering period, as applicable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Termination of Participation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Participation in the 2024 ESPP generally will terminate when a participating employee&#8217;s employment with the combined company or a designated company ceases for any reason, the employee withdraws from the 2024 ESPP or the combined company&#8217;s board terminates or amends the 2024 ESPP such that the employee no longer is eligible to participate. An employee may withdraw his or her participation in the 2024 ESPP at any time in accordance with procedures, and prior to any applicable deadline, specified by the administrator. Upon withdrawal from the 2024 ESPP, in general the employee will receive all amounts credited to his or her account without interest (unless otherwise required under applicable law) and his or her payroll withholdings or contributions under the 2024 ESPP will cease.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Transferability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Neither contributions credited to a participant&#8217;s account nor rights to purchase shares of common stock and any other rights and interests under the 2024 ESPP may be assigned, transferred, pledged or otherwise disposed of (other than by will, the laws of descent and distribution or beneficiary designation in the event of death). Any attempt at such prohibited disposition will be without effect, except that the combined company may treat such act as an election to withdraw participation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Transactions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the event that any extraordinary dividend or other extraordinary distribution (whether in cash, shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation,&#160;split-up,&#160;spin-off,&#160;combination, reclassification, repurchase, or exchange of shares of common stock or other securities, or other change in the combined company&#8217;s corporate structure affecting the common stock or any similar equity restructuring transaction, as that term is used in Statement of FASB ASC Topic 718 (or any of its successors) affecting the shares of common stock occurs, the administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the 2024 ESPP in such manner it may deem equitable, will adjust the number and class of common stock that may be delivered under the 2024 ESPP, the purchase price per share, the number of shares of common stock covered by each purchase right under the 2024 ESPP that has not yet been exercised, and the numerical limits of the 2024 ESPP.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of the Company&#8217;s proposed dissolution or liquidation, any ongoing offering periods will be shortened and will terminate immediately before consummation of the proposed dissolution or liquidation following the purchase of shares of common stock under the shortened offering periods, unless provided otherwise by the administrator. Prior to the new exercise date, the administrator will notify participants regarding the new exercise date and the exercise to occur on such date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a merger or &#8220;change in control&#8221; (as defined in the 2024 ESPP), each outstanding option under the 2024 ESPP will be assumed or substituted for by the successor corporation or its parent or subsidiary. In the event that options are not assumed or substituted for, the offering period will be shortened by setting a new exercise date on which the offering period will end, which will occur prior to the closing of the merger or change in control. Prior to the new exercise date, the administrator will notify participants regarding the new exercise date and the exercise to occur on such date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendment&#59; Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The administrator will have the authority to amend, suspend or terminate the 2024 ESPP. The 2024 ESPP will continue in effect for a term of 20 years, unless terminated sooner. If the administrator determines that the ongoing operation of the 2024 ESPP may result in unfavorable financial accounting consequences, the administrator may modify, amend or terminate the 2024 ESPP to reduce or eliminate such accounting consequence. If the 2024 ESPP is terminated, the administrator in its discretion may terminate all outstanding offering periods either immediately or after consummation of the purchase of shares of common stock under the 2024 ESPP (which may be adjusted to occur sooner than originally scheduled), or in accordance with their terms. If options are terminated prior to their expiration, then all amounts credited to participants that have not been used to purchase shares of common stock will be returned, without interest (unless otherwise required under applicable law), as soon as administratively practicable.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, LENZ OpCo had no formal policy under which non-employee directors received compensation for their service on the LENZ OpCo board of directors or its committees. LENZ OpCo&#8217;s policy was to reimburse non-employee directors for reasonable and necessary out-of-pocket expenses incurred in connection with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attending board and committee meetings or performing other services in their capacities as non-employee directors, and LENZ OpCo occasionally granted stock options to non-employee directors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Compensation Table</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the compensation of each person who served as a LENZ OpCo non-employee director for the year ended December 31, 2023. Evert Schimmelpennink, LENZ OpCo&#8217;s Chief Executive Officer, did not receive any additional compensation for his service as a director in 2023. The compensation of Mr. Schimmelpennink as a LENZ OpCo named executive officer is set forth above in this section in the Summary Compensation Table.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and principal position</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option awards ($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total ($)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frederic Guerard, PharmaD.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,706&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,706&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James McCollum</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clare Ozawa, Ph.D.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zach Scheiner, Ph.D.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chris Dimitropoulos</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stefan Larson, Ph.D.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shelley Thunen</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock option awards granted during 2023, computed in accordance with FASB ASC Topic 718, Compensation&#8212;Stock Compensation. The assumptions used in calculating the grant date fair value of the awards disclosed in this column are set forth in Note 10 to LENZ&#8217;s audited financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by the non-employee director upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists all outstanding option awards held by non-employee directors as of December&#160;31, 2023. None of LENZ OpCo&#8217;s non-employee directors held any outstanding stock awards as of December&#160;31, 2023.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of Shares Underlying Outstanding Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frederic Guerard, Pharm.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,468&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James McCollum</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,034&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clare Ozawa, Ph.D.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zach Scheiner, Ph.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chris Dimitropoulos</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stefan Larson, Ph.D.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shelley Thunen</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The number of shares subject to each award reflect all changes as a result of our capitalization adjustments in connection with the Merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Stock Option Grants </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2024, pursuant to the Outside Director Compensation Policy (as defined below), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each individual who was a non-employee director as of such date, was granted an award of stock options to purchase 27,000 shares of Common Stock. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the options were granted under the 2024 Equity Incentive Plan and the form of option agreement thereunder and has a per share exercise price of $15.05. The shares subject to the option vest</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in equal monthly installments over the thirty-six (36)&#160;months following March 21, 2024, on the same day of each relevant month, in each case subject to the non-employee director continuing to be a non-employee director through the applicable vesting date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Compensation Policy</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors expects to review director compensation periodically to ensure that director compensation remains competitive such that we are able to recruit and retain qualified directors. In 2023, the compensation committee of the LENZ OpCo board of directors retained Aon, a third-party compensation consultant, to provide the LENZ OpCo board of directors and its compensation committee with an analysis of publicly available market data regarding practices and compensation levels at comparable companies and assistance in determining compensation to be provided to New LENZ&#8217;s non-employee directors. Based on the discussions with and assistance from the compensation consultant, in connection with the Merger, our board of directors adopted an Outside Director Compensation Policy that provides for certain compensation to our non-employee directors. The Outside Director Compensation Policy became effective as of the Closing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Compensation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Outside Director Compensation Policy provides for the following cash compensation program for our non-employee directors&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$40,000 per year for service as a non-employee director&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$30,000 per year for service as non-employee chair of our board of directors&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$15,000 per year for service as chair of our audit committee&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$7,500 per year for service as a member of our audit committee&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$12,000 per year for service as chair of our compensation committee&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$6,000 per year for service as a member of our compensation committee&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$10,000 per year for service as chair of our nominating and corporate governance committee&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$5,000 per year for service as a member of our nominating and corporate governance committee.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each non-employee director who serves as a committee chair of our board of directors receives the cash retainer fee as the chair of the committee but not the cash retainer fee as a member of that committee, provided that the non-employee director who serves as the non-employee chair of our board of directors receives the annual retainer fees for such role as well as the annual retainer fee for service as a non-employee director. These fees to our non-employee directors are paid quarterly in arrears on a prorated basis. The above-listed fees for service as non-employee chair of our board of directors or a chair or member of any committee are payable in addition to the non-employee director retainer. Under our Outside Director Compensation Policy, we also reimburse our non-employee directors for reasonable travel expenses to attend meetings of our board of directors and its committees.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Compensation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Transactions, pursuant to the Outside Director Compensation Policy, each individual who was a non-employee director as of the effective date of the policy was granted an award of stock options to purchase 27,000 shares of Common Stock (the &#8220;Merger Award&#8221;). The Merger Award was granted automatically on March 21, 2024. Each Merger Award is scheduled to vest in equal monthly installments over the next thirty-six (36)&#160;months on the same day of each relevant month as the applicable vesting date, in each case subject to the non-employee director continuing to be a non-employee director through the applicable vesting date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Outside Director Compensation Policy also provides that, each individual who first becomes a non-employee director following the effective date of the policy and who does not receive a Merger Award will be granted an award of stock options to purchase 27,000 shares of Common Stock, with such number of shares subject to equitable adjustment by the board of directors in the event of a capitalization adjustment (the &#8220;Initial Award&#8221;). The Initial Award will be granted automatically on the first trading day on or after the date on which such individual first becomes a non-employee director (the first date as a non-employee director, the &#8220;Initial Start Date&#8221;), whether </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through election by LENZ stockholders or appointment by the board of directors to fill a vacancy. Each Initial Award will be scheduled to vest in equal monthly installments over the next thirty-six (36)&#160;months following the Initial Start Date on the same day of each relevant month as the applicable Initial Start Date, in each case subject to the non-employee director continuing to be a non-employee director through the applicable vesting date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the first trading day immediately following each annual meeting of our stockholders following the Merger (each, an &#8220;Annual Meeting&#8221;), each non-employee director automatically will be granted an award of stock options (an &#8220;Annual Award&#8221;) to purchase 13,500 shares of Common Stock, with such number of shares subject to equitable adjustment by the board of directors in the event of a capitalization adjustment&#59; provided that the first Annual Award granted to an individual who first becomes a non-employee director following the effective date of the policy will cover a number of shares equal to the product of (A)&#160;13,500 multiplied by (B)&#160;a fraction, (i)&#160;the numerator of which is the number of fully completed months between the applicable Initial Start Date and the date of the first Annual Meeting to occur after such individual first becomes a non-employee director, and (ii)&#160;the denominator of which is twelve (12), subject to equitable adjustment by the board of directors in the event of a capitalization adjustment. Each Annual Award will be scheduled to vest in full on the first anniversary of the date on which the Annual Award is granted, in each case subject to the non-employee director continuing to be a non-employee director through the applicable vesting date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a change in control, each non-employee director will fully vest in his or her outstanding equity awards granted under the contemplated policy as of immediately prior to the change in control, including any Merger Awards, Initial Awards and Annual Awards, provided that the non-employee director continues to be a non-employee director through the date of the change in control.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any&#160;non-employee&#160;director of the combined company for services as a director in a calendar year period will not exceed $1,000,000 in the first calendar year such individual becomes a&#160;non-employee&#160;director and $750,000 in any other calendar year.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company will reimburse all reasonable&#160;out-of-pocket&#160;expenses incurred by directors for their attendance at meetings of the board or any committee thereof.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee directors of the company will not receive any additional compensation for their service as a director.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1469"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTAIN RELATIONSHIPS, RELATED PARTY AND OTHER TRANSACTIONS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Described below are any transactions occurring since January 1, 2022 and any currently proposed transactions to which we or either of Graphite or LENZ OpCo was a party and in which&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our, Graphite or LENZ OpCo&#8217;s total assets, as applicable, at year-end for the last two completed fiscal years&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a director, executive officer, holder of more than 5% of the outstanding capital stock of us, Graphite or LENZ OpCo, or any member of such person&#8217;s immediate family had or will have a direct or indirect material interest.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Relationships and Related Person Transactions&#8212;Graphite</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Option to Acquire Nula-Cel Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;4, 2023, Graphite entered into a license and option agreement (&#8220;LOA&#8221;) with Kamau Therapeutics, Inc. (&#8220;Kamau&#8221;) pursuant to which it exclusively licensed to Kamau, and granted Kamau, an option to acquire certain intellectual property and materials related to its nula-cel program and related pre-clinical platform assets. The option includes rights to assume the License Agreement and the First Option Agreement with Stanford, as well as the IDT License Agreement, among other agreements. Exercise of the option is contingent on Kamau raising a minimum of $10 million in funds no later than August&#160;4,&#160;2024 (the &#8220;Financing Milestone&#8221;), which contingency may be waived by Graphite. All rights to the intellectual property and materials will revert to Graphite if the milestone is not achieved or if Kamau elects not to exercise the option. In return for this license and option, Graphite received an equity interest in Kamau representing 20% of all outstanding shares on a fully diluted basis subject to dilution protection until the Financing Milestone. The LOA includes customary representations and warranties, limitations of liability and indemnification obligations for a transaction of this nature. The LOA automatically expires upon the first to occur of&#58; (1) Kamau&#8217;s exercise of the option, (2) Kamau&#8217;s failure to exercise the option within a specified exercise period following achievement of the financing milestone, or (3) Kamau&#8217;s failure to achieve the financing milestone by a pre-agreed deadline. In addition, either party has the right to terminate the LOA for the uncured material breach or insolvency of the other party, and Graphite has the right to terminate the LOA if Kamau challenges any of the patent rights that are subject to the option. As a result of the 20% equity interest, Graphite has the ability to exert significant influence over Kamau and accounts for the interest as an equity method investment. Graphite records its proportionate share of investee&#8217;s equity in earnings or losses based on the most recently available financial information. Dr. Porteus, a director and stockholder of Graphite, is the founder and chief executive officer of Kamau.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2023, Graphite and Kamau entered into an amendment to the LOA, under which Graphite agreed to assign certain contracts to Kamau prior to exercise of the option. On March 20, 2024, Kamau and Graphite executed a Patent and Trademark Assignment agreement reflecting Kamau&#8217;s exercise of the option.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 20% equity interest in the counterparty had minimal value upon execution of the LOA and Graphite did not record any amount related to the equity interest as of September 30, 2023. As of December 31, 2023, Kamau has not achieved the financial milestone and does not have the right to exercise the option.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Non-Genotoxic Targeted Conditioning Technology Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;1, 2023, Graphite entered into an asset purchase agreement (&#8220;APA&#8221;) with Maro Bio Inc. (&#8220;Maro&#8221;) pursuant to which Graphite sold to Maro, concurrently with the execution of the APA, certain assets related to its non-genotoxic conditioning technology in exchange for upfront consideration of $0.5 million. Maro was formed by Samsara BioCapital and funds affiliated with Versant Ventures, both of which are greater than 5% stockholders of Graphite. Additional consideration included certain contingent milestone payments totaling up to approximately $1.0 million in the aggregate, and potential fees upon the completion of certain transactions by the acquirer. The APA also provided for reimbursement of certain research and development amounts incurred prior to closing of approximately $0.6&#160;million as well as certain transition services to be provided by Graphite to Maro. Under the APA, Maro will also pay us a sub single digit percentage cash royalty of worldwide net sales of certain products </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporating the acquired technology. The royalty term will terminate on a product-by-product and country-by-country basis on the latest of (i)&#160;the ten (10) year anniversary of the first commercial sale of such product in such country, (ii)&#160;the expiration of the last-to-expire valid claim of a transferred patent that covers such product in such country, and (iii) the expiration of regulatory exclusivity with respect to such product in such country. The APA also includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disposal of certain assets sold pursuant to the APA was accounted for as a deconsolidation of a subsidiary or group of assets in accordance with ASC 810. During the three and nine months ended September&#160;30, 2023, Graphite recognized a loss on disposal of $0.1&#160;million, which was recorded in other income. Graphite will record amounts related to the contingent milestone payments, royalties, and potential transaction fees when contingencies are resolved and amounts are due in accordance with ASC&#160;450. No contingencies were resolved and recorded as of September&#160;30, 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PIPE Financing</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;14, 2023, in connection with the execution of the Merger Agreement, Graphite entered into the Subscription Agreement with the PIPE Investors. Pursuant to the Subscription Agreement, immediately following the Effective Time, the PIPE investors subscribed for and purchased an aggregate of 3,559,565 shares of Common Stock at a price of $15.0299 per share for aggregate gross proceeds of approximately $53.5 million. The table below sets forth the number of shares of Common Stock purchased by related party holders in the PIPE Financing&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Participant</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of Common Stock</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Purchase Price ($)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with RA Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998,009&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999,975.48&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Wave Ventures II, LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,209&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,499,991.45&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sectoral Asset Management Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,999,996.84&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McCollum Living Trust</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,633&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,992.33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Zach Scheiner, a member of the LENZ board of directors, is an affiliate of RA Capital.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Chris Dimitropoulos, a member of LENZ OpCo&#8217;s board of directors until immediately prior to the Effective Time, is an affiliate of Alpha Wave Ventures II, LP.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Stefan Larson, a member of LENZ OpCo&#8217;s board of directors until immediately prior to the Effective Time, is a partner at Sectoral Asset Management Inc.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">James McCollum, a member of the LENZ board of directors, is the trustee of the McCollum Living Trust.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Subscription Agreement, Graphite entered into a registration rights agreement, contemporaneously with the sale of shares pursuant to the PIPE Financing, with the PIPE investors pursuant to which Graphite agreed to prepare and file a registration statement with the SEC within 10 days after the closing of the PIPE Financing for the purposes of registering the resale of the shares. Graphite also agreed, among other things, to indemnify the PIPE Investors, their officers, directors, members, employees and agents, successors and assigns under the registration statement from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incidents to Graphite&#8217;s obligations under the registration rights agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Support Agreements Under the Merger</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Merger Agreement, (i)&#160;certain Graphite stockholders entered into the Graphite Support Agreements with Graphite and LENZ to vote all of their shares of Graphite common stock in favor of the proposals relating to the Transactions, and (ii)&#160;certain LENZ OpCo stockholders entered into the LENZ Op Co Support Agreements with LENZ OpCo and to vote all of their shares of LENZ OpCo capital stock in favor of the Merger Agreement and the related contemplated transactions and against any alternative acquisition proposals. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lock-Up Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Merger Agreement, certain executive officers, directors and stockholders of Graphite and LENZ OpCo entered into the Lock-Up Agreements with Graphite, pursuant to which such parties </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreed not to, except in limited circumstances, sell or transfer their shares of Graphite common stock, for the 90-day period following the closing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Graphite Indemnification Agreements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Graphite has entered into agreements, and in the future plans to enter into, agreements to indemnify its directors and executive officers. These agreements, among other things, require Graphite to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in Graphite&#8217;s right, on account of any services undertaken by such person on behalf of Graphite or that person&#8217;s status as a member of the Graphite board of directors to the maximum extent allowed under Delaware law.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Relationships and Related Person Transactions&#8212;LENZ OpCo </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placements of Securities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock Financing</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, LENZ OpCo issued and sold an aggregate of 814,495 shares of its Series A Preferred Stock at a purchase price of $2.15 per share for an aggregate purchase price of approximately $1.75 million, including $0.25 million pursuant to the conversion of convertible notes. In October 2020, LENZ OpCo issued warrants to purchase 814,495 shares of its Series A Preferred Stock with an exercise price of $2.15 per share (the &#8220;Series A Warrants&#8221;). In April 2021, LENZ OpCo issued and sold an aggregate of 11,263,447 shares of its Series A Preferred Stock at a purchase price of $2.15 per share for an aggregate purchase price of approximately $24.22&#160;million. In October 2022, LENZ issued and sold an aggregate of 9,899,340 additional shares of its Series A Preferred Stock at a purchase price of $2.15 per share for an aggregate purchase price of approximately $21.28 million.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchasers of LENZ OpCo&#8217;s Series A Preferred Stock included certain of its directors and holders of more than 5% of its capital stock at the time of the financing (or subsequent closings of such financing). The following table presents the number of shares and the total purchase price paid by these entities.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investor</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;of&#160;Series</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">A&#160;Preferred</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Purchase</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series&#160;A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McCollum Living Trust</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,521&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,920&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,521&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with RA Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,697,674&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,837&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Versant Ventures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,697,674&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,837&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">James McCollum, a member of the LENZ board of directors, is the trustee of the McCollum Living Trust.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Zach Scheiner, a member of the LENZ board of directors, is an affiliate of RA Capital.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Clare Ozawa, a member of LENZ OpCo&#8217;s board of directors until immediately prior to the Effective Time, is an affiliate of Versant Ventures.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares and purchase price per share set forth above are prior to giving effect to the exchange in accordance with the Merger Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series B Preferred Stock Financing</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, LENZ issued and sold an aggregate of 28,019,181 shares of its Series&#160;B&#160;Preferred Stock at a purchase price of $2.9801 per share for an aggregate purchase price of approximately $83.5&#160;million.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchasers of LENZ&#8217;s Series B Preferred Stock included certain of its directors and holders of more than 5% of its capital stock at the time of the financing. The following table presents the number of shares and the total purchase price paid by these entities&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investor</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;of&#160;Series</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">B&#160;Preferred</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Purchase</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Wave Ventures II, LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,422,368</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,999,999&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Point72 Biotech Private Investments,&#160;LLC-Series&#160;LT</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033,388</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with RA Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033,388</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Versant Ventures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,779</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,998&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McCollum Living Trust</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,779</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,998&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with RTW</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,779</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,998&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Chris Dimitropoulos, a member of the LENZ board of directors, is an affiliate of Alpha Wave Ventures II, LP.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Zach Scheiner, a member of the LENZ board of directors, is an affiliate of RA Capital.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Clare Ozawa, a member of the LENZ board of directors, is an affiliate of Versant Ventures.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">James McCollum, a member of the LENZ board of directors, is the trustee of the McCollum Living Trust.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares and purchase price per share set forth above are prior to giving effect to the exchange in accordance with the Merger Agreement.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investors&#8217; Rights Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LENZ OpCo was a party to an amended and restated investors&#8217; rights agreement with certain holders of its capital stock, including Alpha Wave Ventures II, LP, Point72 Biotech Private Investments, LLC-Series LT, entities affiliated with Versant Ventures and entities affiliated with RA Capital. Under LENZ OpCo&#8217;s amended and restated investors&#8217; rights agreement, certain holders of its capital stock had the right to demand that LENZ OpCo file a registration statement or request that their shares of LENZ OpCo capital stock be covered by a registration statement that LENZ OpCo was otherwise filing. LENZ OpCo&#8217;s amended and restated investors&#8217; rights agreement terminated in connection with the closing.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voting Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LENZ OpCo was a party to an amended and restated voting agreement, as amended, with certain holders of its capital stock, including, among others, Evert Schimmelpennink, its President, Chief Executive Officer and a member of its board of directors, Shawn Olsson, its Chief Commercial Officer, James McCollum, a member of its board of directors, Marc Odrich, its Chief Medical Officer, Alpha Wave Ventures II, LP, Point72 Biotech Private Investments, LLC-Series LT, entities affiliated with Versant Ventures and entities affiliated with RA Capital. The parties to the voting agreement agreed, subject to certain conditions, to vote the shares of LENZ OpCo capital stock held by them so as to maintain the size of the board of directors at eight (8)&#160;and to elect certain nominees to the board of directors. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the Closing, the obligations of the parties to the voting agreement to vote their shares so as to elect these nominees, as well as the other rights and obligations under this agreement, terminated and none of the LENZ OpCo stockholders have any special rights regarding the nomination, election or designation of members of the board of directors of New LENZ pursuant to such agreement. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LENZ OpCo Indemnification Agreements and Insurance</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LENZ OpCo has entered, and intends to continue to enter, into separate indemnification agreements with each of its directors and executive officers, in addition to the indemnification provided for in its certificate of incorporation and bylaws. The indemnification agreements and its certificate of incorporation and bylaws generally require LENZ to indemnify its directors, executive officers and certain controlling persons to the fullest extent permitted by Delaware law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LENZ OpCo Policies for Approval of Related Party Transactions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LENZ OpCo did not have a written policy regarding the review and approval of related person transactions. Nevertheless, with respect to such transactions, it had been the practice of the LENZ OpCo board of directors to consider the nature of and business reasons for such transactions, how the terms of such transactions compared to those which might be obtained from unaffiliated third parties and whether such transactions were otherwise fair to and in the best interests of, or not contrary to, LENZ OpCo&#8217;s best interests.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Policies and Procedures for Related Party Transactions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has adopted a written Related Person Transactions Policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of &#8220;related person transactions.&#8221; For purposes of our policy only, a &#8220;related person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we or any of our subsidiaries are participants involving an amount that exceeds $120,000, in which any &#8220;related person&#8221; has a material interest.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions involving compensation for services provided to us as an employee, consultant or director will not be considered related person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than 5% of any class of our voting securities (including our Common Stock), including any of their immediate family members and affiliates, including entities owned or controlled by such persons.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the policy, the related person in question or, in the case of transactions with a holder of more than 5% of any class of our voting securities, an officer with knowledge of a proposed transaction, must present information regarding the proposed related person transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another independent body of our board of directors) for review. To identify related person transactions in advance, we will rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related person transactions, our audit committee will take into account the relevant available facts and circumstances, which may include, but are not limited to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks, costs, and benefits to us&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on a director&#8217;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of the transaction&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of other sources for comparable services or products&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms available to or from, as the case may be, unrelated third parties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee will approve only those transactions that it determines are fair to us and in our best interests. All of the transactions described above were entered into prior to the adoption of such policy.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1472"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL SECURITYHOLDERS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding the beneficial ownership of Common Stock as of March 21, 2024 by&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each person known by New LENZ to be the beneficial owner of more than 5% of New LENZ&#8217;s outstanding Common Stock immediately following the consummation of the Merger&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of New LENZ&#8217;s executive officers and directors&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all of New LENZ&#8217;s executive officers and directors as a group after the consummation of the Merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that the individual or entity has the right to acquire, such as through the exercise of stock options, within 60 days of March 21, 2024. Shares subject to warrants and options that are currently exercisable or exercisable within 60 days of March 21, 2024 are considered outstanding and beneficially owned by the person holding such options for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where applicable, based on the information provided to New LENZ, New LENZ believes that the persons and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially owned by them. Unless otherwise noted, the business address of each of the directors and executive officers of New LENZ is </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445 Marine View Ave., Ste. #320, Del Mar, CA 92014</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The percentage of beneficial ownership of New LENZ is calculated based on 25,534,458 shares of Common Stock outstanding as of March 21, 2024.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Beneficial Owners</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Greater than 5% Stockholders</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Wave Ventures II, LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612,211&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Point72 Asset Management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882,693&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with RA Capital Management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,249,356&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Versant Management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,612,684&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Executive Officers and Directors</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evert Schimmelpennink</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785,693&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shawn Olsson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,355&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marc Odrich</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,071&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Chevallard</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frederic Guerard</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,772&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James McCollum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,842&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zach Scheiner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,249,356&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shelley Thunen</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeff George</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kimberlee C. Drapkin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,714&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All directors and executive officers as a group (10 persons)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,989,803&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Less than 1%</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 2,714,002 shares of Common Stock received by Alpha Wave Ventures II, LP in the Merger as an equityholder of record of LENZ OpCo, and (ii) 898,209 shares of Common Stock purchased by Alpha Wave Ventures II, LP in the PIPE Financing. Alpha Wave Ventures GP, Ltd is the general partner of Alpha Wave Ventures II, LP and therefore may be deemed to have beneficial ownership over these shares. The address of Alpha Wave Ventures GP, Ltd is 667 Madison Ave, 19th Floor, New York, New York 10065.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 1,017,751 shares of Common Stock received by Point72 Biotech Private Investments, LLC &#8211; Series LT (&#8220;Point72 Biotech&#8221;) in the Merger as an equityholder of LENZ OpCo, and (ii) 864,942 shares of Common Stock purchased by Point72 Associates, LLC (&#8220;Point72 Associates&#8221;) in the PIPE Financing. Differentiated Ventures Investments, LLC (&#8220;Differentiated Ventures&#8221;), a Delaware limited </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">liability company, is the managing member of Point72 Biotech and may be deemed to share beneficial ownership of the shares held by Point72 Biotech. 72 Investment Holdings, LLC (&#8220;72 Investment Holdings&#8221;), a Delaware limited liability company, is the sole member of Differentiated Ventures and may be deemed to share beneficial ownership of the shares of which Differentiated Ventures may be deemed to share beneficial ownership. Steven A. Cohen (&#8220;Mr. Cohen&#8221;) is the sole member of 72 Investment Holdings and may be deemed to share beneficial ownership of the shares of which 72 Investment Holdings may be deemed to share beneficial ownership. Each of Differentiated Ventures, 72 Investment Holdings, and Mr. Cohen disclaims beneficial ownership of the shares held by Point72 Biotech. Pursuant to an investment management agreement, Point72 Asset Management, L.P. (&#8220;Point72 Asset Management&#8221;), a Delaware limited partnership, maintains investment and voting power with respect to the shares held by Point72 Associates and therefore may be deemed to share beneficial ownership of such shares. Point72 Capital Advisors, Inc. (&#8220;Point72 Capital Advisors&#8221;) a Delaware corporation, is the general partner of Point72 Asset Management and may be deemed to share beneficial ownership of the shares of which Point72 Asset Management may be deemed to share beneficial ownership. Mr. Cohen is the sole member of Point72 Capital Advisors and may be deemed to share beneficial ownership of the shares of which Point72 Capital Advisors may be deemed to share beneficial ownership. Each of Point72 Asset Management, Point72 Capital Advisors and Mr. Cohen disclaims beneficial ownership of the shares held by Point72 Associates. The address for these entities and individuals is c&#47;o Point72, L.P., 72 Cummings Point Road, Stamford, CT 06902.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 2,386,301 shares of Common Stock received by RA Capital Healthcare Fund, L.P. (&#8220;RACHF&#8221;) in the Merger as an equityholder of LENZ OpCo, (ii) 629,784 shares of Common Stock received by RA Capital Nexus Fund II, L.P. (&#8220;Nexus II&#8221;) in the Merger as an equityholder of LENZ OpCo, (iii) 164,729 shares of Common Stock received by a separately managed account (the &#8220;Account,&#8221; and together with RACHF and Nexus II, the &#8220;RA Funds&#8221;) in the Merger as an equityholder of LENZ OpCo, (iv) 54,582 shares of Common Stock subject to warrants to purchase shares of Common Stock held by RACHF as an equityholder of LENZ OpCo, (v) 10,580 shares of Common Stock subject to warrants to purchase shares of Common Stock held by Nexus II as an equityholder of LENZ OpCo, (vi) 5,371 shares of Common Stock subject to warrants to purchase shares of Common Stock held by the Account as an equityholder of LENZ OpCo, (vii) 933,038 shares of Common Stock purchased by RACHF in the PIPE Financing, and (viii) 64,971 shares of Common Stock purchased by Nexus II in the PIPE Financing. RA Capital Management, L.P. is the investment manager for the RA Funds. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC, of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. Each of RA Capital Management, L.P., RA Capital Management GP, LLC, Mr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the securities held by the RA Funds. RA Capital Management, L.P., RA Capital Management GP, LLC, Mr. Kolchinsky and Mr. Shah disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The principal business address of the persons and entities listed above is 200 Berkeley Street, 18th Floor, Boston, MA 02116.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 598,203 shares of Common Stock received by Versant Vantage II, L.P. (&#8220;Versant Vantage II&#8221;) in the Merger as an equityholder of LENZ OpCo, (ii) 1,598,789 shares of Common Stock received by Versant Venture Capital VII, L.P. (&#8220;Versant VII&#8221;) in the Merger as an equityholder of LENZ OpCo, (iii) 70,534 shares of Common Stock subject to warrants to purchase shares of Common Stock held by Versant VII as an equityholder of LENZ OpCo, (iv) 2,101,199 shares of Common Stock held by Versant Venture Capital VI, LP (&#8220;Versant Capital VI&#8221;), and (v) 243,959 shares of Common Stock held by Versant Vantage II. Versant Vantage II GP-GP is the general partner of Versant Vantage II GP, which is the general partner of Versant Vantage II. Each of Versant Vantage II GP and Versant Vantage II GP-GP share voting and dispositive power with respect to the shares held by Versant Vantage II. Versant Ventures VI GP-GP, LLC (&#8220;Versant Ventures VI GP-GP&#8221;) is the general partner of Versant Ventures VI GP, L.P. (&#8220;Versant Ventures VI GP&#8221;), which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP share voting and dispositive power with respect to the shares held by Versant VI. Versant Ventures VII GP-GP is the general partner of Versant Ventures VII GP, which is the general partner of Versant VII. Each of Versant Ventures VII GP and Versant Ventures VII GP-GP share voting and dispositive power with respect to the securities held by Versant VII. The address for each of the entities mentioned in this footnote is One Sansome Street, Suite 1650, San Francisco, CA 94104.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of shares of Common Stock subject to options held by Mr. Schimmelpennink exercisable within 60 days of March 21, 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of shares of Common Stock subject to options held by Mr. Olsson exercisable within 60 days of March 21, 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 99,599 shares of Common Stock received by Dr. Odrich in the Merger as an equityholder of LENZ OpCo, and (ii) 66,472 shares&#160;of Common Stock subject to options held by Dr. Odrich exercisable within 60 days of March 21, 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of shares of Common Stock subject to options held by Dr. Guerard exercisable within 60 days of March 21, 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of&#160;(i) 95,034 shares of Common Stock received by James McCollum in the Merger as an equityholder of LENZ OpCo, (ii) 477,600 shares of Common Stock received by the McCollum Living Trust in the Merger as an equityholder of LENZ OpCo, (iii) 6,575 shares of Common Stock subject to warrants to purchase shares of Common Stock held by the McCollum Living Trust as an equityholder of LENZ OpCo, and (iv) 16,633&#160;shares of common stock purchased by the McCollum Living Trust in the PIPE Financing. Mr. McCollum is a trustee of the McCollum Living Trust and as such has voting and investment control over the shares held by the McCollum Living Trust.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of the shares of Common Stock set forth in footnote 3 above. Dr. Scheiner is employed as a principal at RA Capital Management, L.P. Dr. Scheiner disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of shares of Common Stock subject to options held by Ms. Drapkin exercisable within 60 days of March 21, 2024.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of (i) 4,867,689 shares of Common Stock beneficially owned by our executive officers and directors, (ii) 1,045,006 shares of Common Stock subject to options held our executive officers and directors and exercisable within 60 days of March 21, 2024, and (iii) 77,108 shares of Common Stock subject to warrants beneficially owned by our executive officers and directors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the sections titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party and Other Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; appearing elsewhere in this prospectus for information regarding material relationships with our principal securityholders within the past two years. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1475"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLING SECURITYHOLDERS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus relates to the resale by the selling securityholders from time to time of up to an aggregate of 1,297,411 shares of Common Stock that were issued to certain PIPE Investors in the PIPE Financing. The selling securityholders may from time to time offer and sell any or all of the shares of Common Stock set forth below pursuant to this prospectus and any accompanying prospectus supplement. When we refer to the &#8220;selling securityholders&#8221; in this prospectus, we mean the persons listed in the table below and their permitted transferees who later come to hold any of the selling securityholders&#8217; interest in the Common Stock in accordance with the terms of the applicable agreements governing their respective registration rights, other than through a public sale.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, as of March 21, 2024 (after giving effect to the Merger), the names of the selling securityholders, the aggregate number of shares of Common Stock beneficially owned by the selling securityholders, the aggregate number of shares of Common Stock that the selling securityholders may offer pursuant to this prospectus and the number of shares of Common Stock that would be beneficially owned by the selling securityholders after the sale of the shares of Common Stock offered hereby assuming that the selling securityholders sell all of the shares of Common Stock covered by this prospectus. The percentage of beneficial ownership after the offered shares of Common Stock are sold is calculated based on 25,534,458 shares of Common Stock outstanding as of March 21, 2024 (after giving effect to the Merger).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined beneficial ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the tables have sole voting and sole investment power with respect to the shares of Common Stock set forth below, subject to community property laws where applicable.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot advise you as to whether the selling securityholders will in fact sell any or all of such Common Stock. In addition, the selling securityholders may sell, transfer or otherwise dispose of, at any time and from time to time, the Common Stock in transactions exempt from the registration requirements of the Securities Act after the date of this prospectus. For purposes of this table, we have assumed that the selling securityholders will have sold all of the shares of Common Stock covered by this prospectus upon the completion of the offering.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling securityholder information for each additional selling securityholder, if any, will be set forth by a prospectus supplement to the extent required prior to the time of any offer or sale of such selling securityholder&#8217;s shares pursuant to this prospectus. Any prospectus supplement may add, update, substitute, or change the information contained in this prospectus, including the identity of each selling securityholder and the number of shares registered on its behalf. A selling securityholder may sell or otherwise transfer all, some or none of such shares in this offering. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plan of Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr style="height:60pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Selling Securityholder</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beneficially</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Owned</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prior to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Offering </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Being</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Offered </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beneficially</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Owned&#160;After&#160;the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Offered Shares</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">are Sold </font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alyeska Master Fund, LP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,602&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,602&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RTW Biotech Opportunities, Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,351&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,387&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,964&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RTW Innovation Master Fund, Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,880&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,902&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,978&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RTW Master Fund, Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,158&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,578&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,580&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Point72 Associates, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882,693&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864,942&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017,751&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Shares</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945,684&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,411&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648,273&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Less than 1%</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Alyeska Investment Group, L.P., the investment manager of Alyeska Master Fund, L.P. (the &#8220;Selling Securityholder&#8221;), has voting and investment control of the shares held by the Selling Securityholder. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to be the beneficial owner of such shares. Mr. Parekh, however, disclaims any beneficial ownership of the shares held by the Selling Securityholder. The registered address of Alyeska Master Fund, L.P. is at c&#47;o Maples Corporate Services Limited, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, KY1-1104, Cayman Islands. Alyeska Investment Group, L.P. is located at 77 W. Wacker, Suite 700, Chicago IL 60601.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">RTW Investments, LP (&#8220;RTW&#8221;), in its capacity as the investment manager of RTW Biotech Opportunities, Ltd., RTW Innovation Master Fund, Ltd., and RTW Master Fund, Ltd. (collectively, the &#8220;RTW Funds&#8221;), has the power to vote and the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The address and principal office of RTW Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong and each of the RTW Funds is c&#47;o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Point72 Asset Management, L.P. maintains investment and voting power with respect to the securities held by certain investment funds it manages, including Point72 Associates, LLC. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, L.P. Mr. Steven A. Cohen controls each of Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. By reason of the provisions of Rule 13d-3 of the Exchange Act, each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr. Cohen may be deemed to beneficially own the securities directly held by Point72 Associates reflected herein. Each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr. Cohen disclaims beneficial ownership of any such securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the sections titled &#8220;Certain Relationships, Related Party and Other Transactions&#8221; appearing elsewhere in this prospectus for information regarding material relationships with our selling securityholders within the past two years.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1478"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF SECURITIES</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our capital stock and provisions of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws are summaries and are qualified by reference to our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and applicable provisions of Delaware corporate law. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized Capital Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our authorized capital stock consists of 300,000,000 shares of common stock, par value $0.00001 per share and 10,000,000 shares of preferred stock, par value $0.00001 per share.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our common stock are entitled to one vote for each share of common stock held of record for the election of directors and on all matters submitted to a vote of stockholders. Except as described under &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Takeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of Incorporation and Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below, a majority vote of the holders of our common stock is generally required to take action under our Certificate of Incorporation and Bylaws.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of common stock are entitled to receive dividends ratably, if any, as may be declared by our board of directors out of legally available funds, subject to any preferential dividend rights of any preferred stock then outstanding.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions on Liquidation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon our dissolution, liquidation or winding up, holders of our common stock are entitled to share ratably in our net assets legally available after the payment of all of our debts and other liabilities, subject to the preferential rights of any preferred stock then outstanding.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Rights</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our common stock have no preemptive, subscription, redemption or conversion rights and no sinking fund provisions are applicable to our common stock. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors is authorized, without action by the stockholders, to designate and issue up to an aggregate of 10,000,000 shares of preferred stock in one or more series. Our board of directors can designate the rights, preferences and privileges of the shares of each series and any of its qualifications, limitations or restrictions. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect of restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying, deferring or preventing a change in control of the Company, which might harm the market price of our common stock. Our board of directors will make any determination to issue such shares based on its judgment as to our best interests and the best interests of our stockholders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Takeover Effects of Delaware Law and Provisions of our Amended and Restated Certificate of Incorporation and Bylaws</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the DGCL and of our Certificate of Incorporation and Bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of our Company. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and, as a consequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions are also designed in part to encourage anyone seeking to acquire control of us to first negotiate with our board of directors. These provisions might also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests. However, we believe that the advantages gained by protecting our ability to negotiate with any unsolicited and potentially unfriendly acquirer outweigh the disadvantages of discouraging such proposals, including those priced above the then-current market value of our common stock, because, among other reasons, the negotiation of such proposals could improve their terms.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware Takeover Statute</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the provisions of Section&#160;203 of the DGCL. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">before the stockholder became interested, the Graphite board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at or after the time the stockholder became interested, the business combination was approved by the Graphite board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least&#160;two-thirds&#160;of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section&#160;203 defines a business combination to include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent for our Common Stock is Equiniti Trust Company, LLC.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Listing </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Stock is listed on Nasdaq under the symbol &#8220;LENZ.&#8221; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1481"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PLAN OF DISTRIBUTION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selling securityholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling securityholders as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selling securityholders may use any one or more of the following methods when disposing of shares or interests therein&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exchange distribution in accordance with the rules of the applicable exchange&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">privately negotiated transactions&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">short sales&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broker-dealers may agree with the selling securityholders to sell a specified number of such shares at a stipulated price per share&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a combination of any such methods of sale&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other method permitted by applicable law.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selling securityholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), amending the list of selling securityholders to include the pledgee, transferee or other successors in interest as selling securityholders under this prospectus. The selling securityholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling securityholders for purposes of this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of our common stock or interests therein, the selling securityholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling securityholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling securityholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate proceeds to the selling securityholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling securityholders </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selling securityholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements of the Securities Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selling securityholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be &#8220;underwriters&#8221; within the meaning of Section 2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling securityholders who are &#8220;underwriters&#8221; within the meaning of Section 2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent required, the shares of our common stock to be sold, the names of the selling securityholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have advised the selling securityholders that the anti-manipulation rules of Regulation M under the Securities Exchange Act of 1934, as amended, may apply to sales of shares in the market and to the activities of the selling securityholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling securityholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreed to indemnify the selling securityholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreed with the selling securityholders to use commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with such registration statement or (2) (B) the date that all the shares covered by this prospectus cease to be Registrable Securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">162</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1484"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL MATTERS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The validity of the Securities offered hereby has been passed upon for us by Wilson Sonsini Goodrich&#160;&#38; Rosati, Professional Corporation. Certain members of, and investment partnerships comprised of members of, and persons associated with, Wilson Sonsini Goodrich &#38; Rosati, Professional Corporation, directly or indirectly own less than 0.1% of the outstanding shares of our common stock.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1487"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPERTS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of Lenz Therapeutics, Inc. as of December 31, 2022 and 2023, and for the years then ended, included in this Prospectus and Registration Statement </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been audited by Ernst &#38; Young LLP, an independent registered public accounting firm, as stated in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of Graphite Bio, Inc. as of December 31, 2023 and 2022, and for each of the two years in the period ended December 31, 2023, included in this prospectus </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been audited by Deloitte &#38; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given their authority as experts in accounting and auditing.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Certifying Accountant</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Dismissal of Independent Registered Accounting Firm</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2024, the audit committee of the board of directors approved a resolution dismissing Deloitte &#38; Touche LLP (&#8220;Deloitte&#8221;), Graphite&#8217;s independent registered public accounting firm prior to the Merger, as New LENZ&#8217;s independent registered public accounting firm.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reports of Deloitte on Graphite&#8217;s financial statements as of and for the most fiscal years ending December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainties, audit scope or accounting principles.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During Graphite&#8217;s fiscal years ending December 31, 2023 and 2022 and the subsequent interim period through March 21, 2024, there were no disagreements between Graphite and Deloitte on any matter of accounting principles or practices, financial disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Deloitte, would have caused it to make reference to the subject matter of the disagreements in its reports on Graphite&#8217;s financial statements for such year.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During Graphite&#8217;s fiscal years ending December 31, 2023 and 2022 and the subsequent interim period through March 21, 2024, there were no &#8220;reportable events&#8221; (as defined in Item 304(a)(1)(v) of Regulation S-K under the Exchange Act).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New LENZ provided Deloitte with a copy of the foregoing disclosures and has requested that Deloitte furnish New LENZ with a letter addressed to the SEC stating whether it agrees with the statements made by New LENZ set forth above. A copy of Deloitte&#8217;s letter, dated March 21, 2024, is filed as an exhibit hereto.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:6.34pt">Engagement of New Independent Registered Accounting Firm</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2024, the audit committee of the board of directors approved a resolution appointing Ernst &#38; Young LLP (&#8220;EY&#8221;) as New LENZ's independent registered public accounting firm to audit New LENZ's consolidated financial statements for the fiscal year ending December 31, 2024. EY served as the independent registered public accounting firm of LENZ OpCo prior to the Merger. During the fiscal years ending December 31, 2023 and 2022 and the subsequent interim period through March 21, 2024, neither New LENZ, nor any party on behalf of New LENZ, consulted with EY with respect to either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of the audit opinion that might be rendered with respect to New LENZ&#8217;s consolidated financial statements, and no written report or oral advice was provided to New LENZ by EY that was an important factor considered by New LENZ in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii) any matter that was subject to any disagreement (as that term is defined </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1490"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WHERE YOU CAN FIND ADDITIONAL INFORMATION </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed with the SEC a registration statement on Form S-1 under the Securities Act that registers the shares of our Common Stock to be sold in this offering. The registration statement, including the attached exhibits and schedules, contains additional relevant information about us and our capital stock. The rules and regulations of the SEC allow us to omit from this prospectus certain information included in the registration statement. For further information about us and the Securities, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the informational reporting requirements of the Exchange Act. We file reports, proxy statements and other information with the SEC under the Exchange Act. Our SEC filings are available over the Internet at the SEC&#8217;s website at http&#58;&#47;&#47;www.sec.gov. Our website address is https&#58;&#47;&#47;lenz-tx.com&#47;. The information on, or that can be accessed through, our website is not part of this prospectus. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_872"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Graphite Bio, Inc. </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audited Financial Statements as of and for the Years Ended December 31, 2023 and 2022&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_879" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Report of Independent Registered Public Accounting Firm</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_879" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_879" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_886" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Balance Sheets</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_886" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_886" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_898" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Statements of Operations and Comprehensive Loss</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_898" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_898" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_905" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Statements of Stockholders&#8217; Equity</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_905" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_905" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_912" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Statements of Cash Flows</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_912" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_912" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_919" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notes to Financial Statements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_919" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_919" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">7</a></font></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lenz Therapeutics, Inc. </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audited Financial Statements as of and for the Years Ended December 31, 2023 and 2022&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Report of Independent Registered Public Accounting</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> Firm</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID No. 42)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_1" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">33</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_99" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Balance Sheet</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_99" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">s</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_99" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_99" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">34</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_30" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Statements of Operations and Comprehensive Loss </a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_30" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_30" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">35</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_44" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Statements of </a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_44" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Convertible Preferred and Common Stock an</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_44" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">d </a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_44" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stockholders&#8217; </a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_44" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Deficit</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_44" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_44" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_56" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Statements of Cash Flows</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_56" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_56" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">37</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_68" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notes to Financial Statements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_68" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-</a><a href="#i53d6782078384f7ab44e5c29cf9c0dbd_68" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">38</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1073"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_879"></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the shareholders and the Board of Directors of Graphite Bio, Inc. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Graphite Bio, Inc. (the &#34;Company&#34;) as of December 31, 2023 and 2022, the related statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows, for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#34;financial statements&#34;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Francisco, California </font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 27, 2024 </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2021.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_886"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Graphite Bio, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data) </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,259&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,730&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,499&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,136&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,021&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,365&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,322&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,630&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,580&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,456&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,902&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,797&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,043&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long- term liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,819&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,874&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,611&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $0.00001 par value, 10,000,000 shares authorized as of December 31, 2023 and 2022&#59; and no shares issued and outstanding as of December 31, 2023 and 2022</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.00001 par value, 300,000,000 shares authorized as of December 31, 2023 and 2022&#59; 58,008,396 and 58,221,760 shares issued and outstanding as of December 31, 2023 and 2022, respectively</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,635&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,741&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,048)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367,054)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242,403)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,582&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,291&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,456&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,902&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_898"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Graphite Bio, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations and Comprehensive Loss </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data) </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended <br>December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,137&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,787&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,973&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,852&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and impairment costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,081&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,191&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,639&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,191)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,639)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,949&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,587&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,540&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,587&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,651)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,052)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments in marketable securities</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,048)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,603)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,100)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212;basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.19)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.84)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share&#8212;basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,015,159</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,873,675</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_905"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Graphite Bio, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Stockholders&#8217; Equity</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data) </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.166%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common<br>Stock</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br>Paid-In<br>Capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217; </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity </font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,010,823</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,400&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,351)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,050&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issued upon exercise of options</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,196</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issued under ESPP</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,155</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised shares</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of unvested early exercised shares</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189,414)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,534&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,534&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments in marketable securities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,048)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,048)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,052)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,052)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,221,760</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,741&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,048)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242,403)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,291&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued upon exercise of options</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,900</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued under ESPP</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,222</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised shares</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of founders' shares</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,694)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of unvested early exercised shares</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227,792)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,574&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,574&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments in marketable securities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,651)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,651)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,008,396</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,635&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367,054)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,582&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_912"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Graphite Bio, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows </font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands) </font></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended <br>December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,651)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,052)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amortization of premiums and discounts on investments in marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,600)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,407&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,352&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,289&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,994&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,574&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,534&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on ROU asset abandonment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,638)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale&#47; disposal of assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,621&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets and other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,676&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,211)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,358)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,265)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(720)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities and other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,362)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,482)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,007)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,980)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,856)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,594)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments in marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,129)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(405,519)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,427&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,250&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,346&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,863)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock upon exercise of vested stock options</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from employee stock purchase plan</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of unvested early exercised shares and founders' shares</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,529&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329,246)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, at beginning of period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,446&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,692&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, at end of period</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,975&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,446&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash to statement of financial position&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,259&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,730&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash in statement of financial position</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,975&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,446&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash investing and financing information&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment purchases in accounts payable and accrued expenses</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessor funded lease incentive additions included in property and equipment</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,193&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,920&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to ROU assets from new operating lease liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,974&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised stock options</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of unvested early exercised shares included in accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_919"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Graphite Bio, Inc. </font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements </font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_926"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Description of Business, Organization and Liquidity </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Business </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Graphite Bio, Inc. (the &#8220;Company&#8221;) has historically been a clinical-stage, next-generation gene editing company. In January 2023, the Company announced a voluntary pause of its Phase 1&#47;2 CEDAR study of nulabeglogene autogedtemcel (&#34;nula-cel&#34;), the Company&#8217;s lead product candidate for sickle cell disease (&#8220;SCD&#8221;), due to a serious adverse event in the first patient dosed, which the Company concluded is likely related to study treatment. Nula-cel was designed to provide a highly differentiated approach with the potential to directly correct the mutation that causes SCD and restore normal adult hemoglobin expression.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in Ontario, Canada in June 2017 as Longbow Therapeutics Inc., and was reincorporated in the State of Delaware in October 2019. In February 2020, the Company changed its name to Integral Medicines, Inc., and again in August 2020, changed the name to Graphite Bio, Inc. Research and development of the Company&#8217;s initial technology ceased at the end of 2018, and the Company did not have any significant operations or any research and development activities in 2019. In March 2020, the Company identified new gene editing technology which the Company sought to further develop, and the Company licensed the related intellectual property rights from The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;) in December 2020 (Note 6). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company announced its decision to discontinue the development of nula-cel and initiate a process to explore strategic alternatives (the &#8220;Restructuring Plan&#8221;). As a result of this decision, the Company conducted a corporate restructuring that resulted in an approximately 50% reduction in force in February 2023 and additional reductions in August 2023 that resulted in a total reduction in force of 78.1%. In August 2023, the Company subleased some of its facilities to recover a portion of the total costs. Together, these restructuring actions are intended to reduce the Company's operational cash burn in an effort to maximize its strategic optionality.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had previously disclosed its intention to continue research activities associated with its pre-clinical non-genotoxic conditioning program, with the goal of advancing toward one or more potential development candidates. In August, the Company entered into an asset purchase agreement pursuant to which the Company transferred to Maro Bio, Inc. (&#8220;Maro&#8221;) its pre-clinical non-genotoxic conditioning program, including its technology and intellectual property. Also in August 2023, the Company entered into a license and option agreement (the &#8220;LOA&#8221;), pursuant to which it granted another third-party an option to acquire certain of the Company&#8217;s technology and intellectual property related to its nula-cel program and related pre-clinical platform assets. On September 12, 2023, the Company and Kamau Therapeutics, Inc. (&#8220;Kamau&#8221;) entered into an amendment to the LOA, under which we agreed to assign certain contracts to Kamau prior to exercise of the option, and as of December 31, 2023, these contracts have been assigned to Kamau.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Company entered into an amendment to the master lease, with Bayside Area Development, which provided for an accelerated termination of the lease. The amendment to the master lease also provided for a release of liabilities under the master lease, as well as under the new sublease entered into for a portion of the facility leased to it by Bayside Area Development in October 2023, upon payment of a lump sum at the time of signing. Following this transaction, the Company is no longer obligated for any rent payments under its master lease with Bayside Area Development. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a comprehensive review of strategic alternatives, including identifying and reviewing potential candidates for a strategic transaction, on November 14, 2023, the Company entered into the Merger Agreement with LENZ, pursuant to which a wholly-owned subsidiary of the Company will merge with and into LENZ, with LENZ surviving as the Company&#8217;s wholly-owned subsidiary. The merger was unanimously approved by the Company&#8217;s board of directors, and the board resolved to recommend approval of the Merger Agreement to the stockholders. The closing of the merger is subject to approval by the Company and LENZ&#8217;s stockholders, as well as other customary closing conditions, including the effectiveness of a registration statement filed with the SEC in connection with the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction and Nasdaq&#8217;s approval of the listing of the shares of the Graphite common stock to be issued in connection with the transaction. If the merger is completed, the business of LENZ will continue as the business of the combined company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From its inception in 2017, the Company&#8217;s primary activities have been to perform research and development, undertake preclinical studies and enable manufacturing activities in support of its product development efforts, organize and staff the Company, establish its intellectual property portfolio, and raise capital to support and expand such activities. The Company&#8217;s future operations are highly dependent on the success of the merger and there can be no assurances that the merger will be successfully consummated. There can be no assurance that the strategic review process or any transaction relating to a specific asset, including the merger or any asset sale, will result in the Company pursuing such a transaction(s), or that any transaction(s), if pursued, will be completed on terms favorable to the Company and its stockholders. If the strategic review process is unsuccessful, its board of directors may decide to pursue a dissolution and liquidation of the Company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity Matters</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred significant operating losses since inception and has primarily relied on private equity and convertible debt financings to fund its operations. As of December 31, 2023, the Company had an accumulated deficit of $367.1 million. The Company expects to continue to incur substantial losses. The Company may never achieve profitability, and unless and until then, the Company will need to continue to raise additional capital. Management expects that the existing cash and cash equivalents of $184.3 million as of December 31, 2023 will be sufficient to fund the Company&#8217;s current operating plan for at least the next 12 months from the date of issuance of these financial statements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, the Company filed a shelf registration statement on Form S-3 (the &#8220;2022 Shelf&#8221;) with the SEC in relation to the registration of up to an aggregate offering price of $300.0 million of common stock, preferred stock, debt securities, warrants and units or any combination thereof. The Company also simultaneously entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald &#38; Co. (the &#8220;Sales Agent&#8221;), to provide for the offering, issuance and sale by the Company of up to an aggregate of $75.0 million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the 2022 Shelf and subject to the limitations thereof (the &#8220;Sales Agreement&#8221;). The Company will pay to the Sales Agent cash commissions of up to 3.0 percent of the gross proceeds of sales of common stock under the Sales Agreement. The Company has not issued any shares or received any proceeds from any offerings under the 2022 Shelf through December 31, 2023.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_933"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. Summary of Significant Accounting Policies </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the marketable securities, stock-based compensation expense, accruals for research and development costs, lease assets and liabilities, the valuation of deferred tax assets, uncertain income tax positions, and impairment of long-lived assets. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses entities for consolidation based on the specific facts and circumstances surrounding that entity. The Company first considers whether an entity is considered a variable interest entity (&#8220;VIE&#8221;) and therefore whether to apply the consolidation guidance under the VIE model. Entities that do not qualify as VIEs are assessed for consolidation as voting interest entities (&#8220;VOE&#8221;) under the voting interest model.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An entity is considered to be a VIE if any of the following conditions exist&#58; (i) the equity investment at risk is not sufficient to finance the activities of the entity without additional subordinated financial support, (ii) as a group, the holders of the equity investment at risk lack the power to direct the activities that most significantly impact the entity&#8217;s economic performance or the obligation to absorb the expected losses or right to receive the expected residual returns, and (iii) the voting rights of some holders of the equity investment at risk are disproportionate to their obligation to absorb losses or right to receive returns, and substantially all of the activities are conducted on behalf of the holder of equity investment at risk with disproportionately few voting rights.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates all VIEs in which it is the primary beneficiary. An entity is determined to be the primary beneficiary if it holds a controlling financial interest in a VIE. The consolidation guidance requires an analysis to determine (i) whether an entity in which the Company holds a variable interest is a VIE and (ii) whether the Company&#8217;s involvement, through holding interest directly or indirectly in the entity or contractually through other variable interests, would give it a controlling financial interest. Performance of that analysis requires judgment. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with major financial institution and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institution in which the cash and cash equivalents are held. The Company has not experienced any losses on deposits of cash and cash equivalents. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on the future financial position or results of operations&#58; the timing of, and the Company&#8217;s ability to advance its current and future product candidates into and through clinical development&#59; costs and timelines associated with the manufacture of clinical supplies of the Company&#8217;s product candidates&#59; regulatory approval and market acceptance of, and reimbursement for its product candidates&#59; performance of third-party CROs and CMOs&#59; competition from pharmaceutical companies with greater financial resources or expertise&#59; protection of the intellectual property&#59; litigation or claims against the Company based on intellectual property or other factors&#59; and its ability to attract and retain employees necessary to support its growth. Disruption from CROs&#8217;, CMOs&#8217; or suppliers&#8217; operations would likely have a negative impact on the Company&#8217;s business, financial position and results of operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographical Information </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates and manages its business as one reportable and operating segment. The chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of the Company&#8217;s long-lived assets are based in the United States. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2023 and 2022, cash and cash equivalents consisted of cash, money market funds, and commercial paper. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash of $0.1 million and $1.7&#160;million as of December 31, 2023 and 2022, respectively, represented security deposits in the form of letters of credit issued in connection with the Company's leases. A lease amendment was executed in October 2023 for the Company's intended headquarters at 233 E. Grand Ave, whereby the Company did not have any further rent obligations to the landlord following the effective date. As of December 31, 2023, the letter of credit of $1.6&#160;million is expected to be returned within a year and is presented as Restricted cash, current on the balance sheet. The remaining letter of credit is related to the Company's former headquarters at 201 Haskins Way, which will be returned upon lease termination.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities are accounted for as available-for-sale and recorded at fair value with the related unrealized gains and losses included in accumulated other comprehensive gain (loss). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its investment portfolio to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of financial instruments, including restricted cash, prepaid expenses and other current assets, accounts payable, accrued compensation, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. The cash invested in money-market funds are carried at fair value. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, the Company adopted ASC Topic 842, Leases (&#8220;ASC 842&#8221;) using the optional transition method and applied the standard only to leases that existed at that date. Under the optional transition method, the Company does not need to restate the comparative periods in transition and will continue to present financial information and disclosures for periods before January 1, 2021 in accordance with ASC Topic 840. The Company has elected the package of practical expedients allowed under ASC Topic 842, which permits the Company to account for its existing operating leases as operating leases under the new guidance, without reassessing the Company&#8217;s prior conclusions about lease identification, lease classification and initial direct cost. As a result of the adoption of the new lease accounting guidance on January 1, 2021, the Company recognized no cumulative adjustment to accumulated deficit since the Company had only one operating lease with a term of less than 12 months and no plans to extend the lease.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable&#59; otherwise, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed lease expense for operating leases is recognized on a straight-line basis, unless the right-of-use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the statements of operations and comprehensive loss. Variable lease expenses are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses in the statements of operations and comprehensive loss.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases for which the right-of-use assets have been impaired, the Company will recognize the amortization of the right-of-use assets on a straight-line basis over the remaining respective lease term with lease expense included in operating expenses in the statements of operations and comprehensive loss. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to maintenance, insurance and taxes, which varies based on future outcomes and is thus recognized in lease expense when incurred.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Acquisitions </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (&#8220;IPR&#38;D&#8221;) with no alternative future use is charged to research and development expense at the acquisition date. Please refer to Note 6 for more details on asset acquisition.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. During the year ended December 31, 2023, the Company recognized $54.1 million related to the impairment of its leases and long- lived assets. There were no such impairments of long-lived assets in the year ended December 31, 2022. Please refer to Note 13 for more details on impairment.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation, and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, CROs and investigative sites that conduct preclinical studies, other supplies and costs associated with product development efforts, preclinical activities, and regulatory operations. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically entered into various agreements with outsourced vendors, CROs and CMOs. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued research costs on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between estimates of such expenses and the amounts actually incurred. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Credit Receivable </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible for federal and California research and development credits for its research and development activities performed within the United States and California, respectively. The credits are, generally, available to offset federal and California income tax liabilities as applicable. The Company has applied $0.3 million of federal research and development credits to offset its federal payroll tax expenses as of the year ended December 31, 2023 due to its small business status. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the ability to recover deferred income tax assets, the Company considers all available positive and negative evidence, including operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize deferred income tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2023 and 2022, the Company has recorded a full valuation allowance on deferred tax assets. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based equity awards include restricted stock awards and stock options that are granted to employees and consultants that are accounted at fair value on the award grant date. Stock-based compensation expense is recognized over the awards&#8217; vesting period on a straight-line basis and recorded as either research and development or general and administrative expenses in the statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As there was no public market for the Company&#8217;s common stock prior to the initial public offering of its common stock in June 2021, the estimated fair value of common stock was determined by the Company&#8217;s board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock, as well as the Company&#8217;s board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant, and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation. Following the closing of the initial public offering, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of common stock. The Company also lacks company&#8209;specific historical and implied volatility information for its stock. The Company estimates its expected stock price volatility and expected term based on the historical volatility and expected term of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The risk&#8209;free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. There is no expected dividend yield since the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based expense related to shares issued pursuant to its Employee Stock Purchase Plan (&#8220;ESPP&#8221;) on a straight-line basis over the offering period, which is typically 6 months. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a 15 percent discount on the lower price of either (i) the offering period begin date or (ii) the purchase date. The Company estimates the fair value of shares to be issued under the ESPP using the Black-Scholes option-pricing model. There are no employees enrolled in the ESPP as of December 31, 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity of a business during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes net loss as well as other changes in stockholders&#8217; deficit which includes certain changes in equity that are excluded from net loss. The Company&#8217;s only element of other comprehensive loss is unrealized gains and losses on marketable securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, common stock subject to repurchase, restricted common shares issued, and stock options are considered to be potentially dilutive securities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. Restricted shares issued to the founders and upon early exercise of stock options also participate in dividends from the issuance date and are considered participating securities. Participating securities do not have a contractual obligation to share in losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted and Recent Accounting Pronouncements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a smaller reporting company and an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Thus, the Company has elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) the Company is no longer an emerging growth company or (ii) the Company affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. However, the Company may early adopt certain accounting standards, as the JOBS Act does not preclude an emerging growth company from adopting a new or revised accounting standard earlier than the time that such standard applies to private companies to the extent early adoption is permitted. </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280)&#58; Improvements to Reportable Segment Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2023-07&#8221;). This update requires entities to disclose significant segment expenses by reportable segment if they are regularly provided to the Chief Operating Decision Maker and included in each reported measure of segment profit or loss and requires disclosure of other segment items by reportable segment and a description of its composition. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. ASU 2023-07 should be applied retrospectively to all prior periods presented in the financial statements. The Company operates and discloses its operations as a single segment and does not expect the adoption of this standard to have a material impact on its annual and interim disclosures.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)&#58; Improvements to Income Tax Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2023-00&#8221;). This update requires entities to consistently categorize and provide greater disaggregation of information in the rate reconciliation and to further disaggregate income taxes paid by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. ASU 2023-07 may be applied retrospectively or prospectively. The Company is currently evaluating the planned adoption date and the impact of this standard on its annual and interim disclosures. </font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_940"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Fair Value Measurements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows&#58;</font></div><div style="margin-bottom:9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date&#59; </font></div><div style="margin-bottom:9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities&#59; and </font></div><div style="margin-bottom:9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. An assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. The Company recognizes transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, Level 1 securities consist of U.S. Treasury and money market funds, for which the carrying amounts are based on the quoted market prices in active markets. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, Level 2 securities consist of highly rated commercial paper, U.S. agency securities, and asset-backed securities, for which fair value is determined through the use of models or other valuation methodologies. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented, the Company did not have any Level 3 securities. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2023 and 2022 (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair<br>Value</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,259&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,259&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,259&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,259&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair<br>Value</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,739&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,739&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,730&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,739&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,391&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,391&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,061&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,061&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,455&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,455&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,821&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,391&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,430&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,551&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,130&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,421&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included within cash and cash equivalents on the balance sheet. </font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included within investments in marketable securities, current and investments in marketable securities, non-current on the balance sheet. </font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_947"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Marketable Securities </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not hold any marketable securities as of December 31, 2023. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company&#8217;s marketable securities by major security type as of December 31, 2022 are summarized in the table below (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br>Cost Basis</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br>Gains</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br>Losses </font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br>Value</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale securities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasuries</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,807&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(416)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,391&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,381&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,061&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,767&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,455&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,869&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,076)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,821&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost of available-for-sale securities is adjusted for amortization of premiums and accretion of discounts to maturity. As of December 31, 2023, the Company did not hold any securities in an unrealized loss with remaining maturities of less than one year. As a result, the Company determined it did not hold any investments with a credit loss at December 31, 2023.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were minimal realized gains (losses) recognized on the sale or maturity of available-for-sale securities during year ended December 31, 2023, and as a result, there was a reclassification out of accumulated other comprehensive gain (loss) for the same period. There were no realized gains or losses recognized on the sale or maturity of available-for-sale securities during year ended December 31, 2022, and as a result, there were no reclassifications out of accumulated other comprehensive gain (loss) for the same period.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not hold any marketable securities as of December 31, 2023.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_954"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. Balance Sheet Components </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets as of December 31, 2023 and 2022 consisted of the following (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances to suppliers</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,486&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,307&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,136&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net as of December 31, 2023 and 2022 consisted of the following (in thousands)&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and network equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,521&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,440&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,837&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; accumulated depreciation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,207)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,630&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $2.4 million for each of the years ended December 31, 2023 and 2022. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the modification of our leases (see Note 8), we disposed of leasehold improvements, computer equipment, lab and office equipment, and furniture and fixtures and recorded a $0.1 million loss within Loss on disposal of assets and $11.3 million within Restructuring and impairment costs on the statement of operations and comprehensive loss during the year ended December 31, 2023. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Expenses </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses as of December 31, 2023 and 2022 consisted of the following (in thousands)&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early exercise liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee termination benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,728&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_961"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. Significant Agreements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stanford Exclusive License Agreement </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into an exclusive license agreement (the &#8220;License Agreement&#8221;) with The Board of Trustees of the Leland Stanford Junior University (Stanford), pursuant to which Stanford granted the Company a worldwide license to specified technology and patent rights to develop, manufacture and commercialize human prophylactic and therapeutic products. Other than with respect to specified, broadly applicable assays and procedures and subject to retained rights by Stanford, the license is exclusive with respect to human prophylactic and therapeutic products for the treatment of SCD, XSCID and beta thalassemia. The license is non-exclusive with respect to those broadly applicable assays and procedures and with respect to all human prophylactic and therapeutic products other than for the treatment of SCD, XSCID and beta thalassemia. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the License Agreement, the Company paid an upfront license fee of $50.0 thousand and as additional consideration for the license, the Company agreed to issue to Stanford approximately 0.6 million shares of common stock. As of December 31, 2020, the Company recorded its obligations to issue Stanford shares of common stock at an estimated fair value of $2.8 million to additional paid in capital. The shares of common stock were expected to be issued when Stanford provided the inventors&#8217; names for allocation of the shares. Stanford also received an option to purchase up to 10% of newly issued shares in the future private financings at the price paid by other participating investors. During the year ended December 31, 2021, the Company entered into an amendment to the License Agreement, pursuant to which it extended the time when the shares would be issued to May 7, 2021. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the Company issued an aggregate of 640,861 shares of the Company&#8217;s common stock to Stanford and certain individuals designated by Stanford in consideration for rights granted to the Company under the Company&#8217;s exclusive license agreement. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, the Company exercised its right to repurchase an aggregate of 624,845 shares from each founder and investor under the Stanford Adjustment Repurchase Right as described below.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of the exclusive license, including patent rights and know-how, and clinical supplies was accounted for as an asset acquisition and as the acquired technology and inventories did not have an alternative use, the total consideration of $2.8 million was recorded as research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2020.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the License Agreement, the Company reimbursed Stanford $0.2 million for previously incurred patent costs, which were recorded in general and administrative expenses for the year ended December 31, 2020 and in addition, is obligated to reimburse future patent costs. The Company is also obligated to pay annual maintenance fees as follows&#58; $5.0 thousand in the first year, $10.0 thousand in each year 2 and 3, $25.0 thousand in each year 3 through 6, $50.0 thousand each subsequent year until first commercial sale and $200.0 thousand each subsequent year after the first commercial sale. No fees were recorded during the year ended December 31, 2023. The Company did not record any patent fees during the year ended December 31, 2023.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to make future development and regulatory milestone payments in total of up to $5.3 million, sales based milestone payments of up to $7.5 million and royalties on future sales at percentage rates ranging in the low single digits. In addition, if the Company receives any sublicense income, it is required to share it with Stanford as a certain percentage defined for each milestone in the License Agreement. The Company will record the maintenance fees, when payable, and will record milestones when contingencies are resolved and milestones are due. No milestones were achieved and recorded as of December 31, 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into a license and option agreement (the &#8220;LOA&#8221;), pursuant to which the Company granted a third party an option to acquire certain of the Company&#8217;s technology and intellectual property related to its nula-cel program and related pre-clinical platform assets. The License Agreement is included in the assets that are subject to the LOA and may be assigned to this third party if and when it exercises the option.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Option Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an option agreement (the &#8220;First Option Agreement&#8221;) with Stanford, pursuant to which Stanford granted the Company the right to obtain a license to specified patent rights relating to human prophylactic and therapeutic products. The Company may exercise the option in whole or in part to obtain a license under one or more of the optioned patent rights.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the Company&#8217;s exercise of the option under the First Option Agreement and its execution of an amendment to the License Agreement that incorporates the optioned patent rights and any optioned technology, the Company has agreed to issue to Stanford 132,137 shares of its common stock and pay a license execution fee of $10.0 thousand .</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the First Option Agreement expires 18 months after its effective date, subject to the Company&#8217;s right to extend such expiration date by up to an additional one year upon notice to Stanford and by another additional one year upon the reasonable agreement of Stanford. The First Option Agreement will terminate if the License Agreement terminates. On June 23, 2022, the Company exercised its right to extend the term of the First Option Agreement for an additional year. On June 6, 2023, the Company and Stanford agreed to extend the term of the First Option Agreement for another additional year. As of December 31, 2023, the Company had not exercised the option under the First Option Agreement and no fees have been paid for the First Option Agreement. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into the LOA, pursuant to which it granted a third party an option to acquire certain of the Company&#8217;s technology and intellectual property related to its nula-cel program and related preclinical platform assets. The First Option Agreement is included in the assets that are subject to the LOA and may be assigned to this third party if and when it exercises the option.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Option Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into an option agreement (the &#8220;Second Option Agreement&#8221;) with Stanford to negotiate the license for additional technologies from Stanford. Pursuant to the Second Option Agreement, the Company agreed to pay Stanford option fees in an aggregate amount of $30.0 thousand over the term of the option. On April 13, 2022, the Company entered into an amendment to the Second Option Agreement which extended the term for an additional year. On March 8, 2023, the Company terminated the Second Option Agreement without exercising the option to negotiate a license for additional technologies from Stanford. No maintenance fees were paid during the year ended December 31, 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LCGM Service Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company entered into a Master Manufacturing and Service Agreement with the Laboratory for Cell &#38; Gene Medicine at Stanford (&#8220;LCGM MSA&#8221;). Pursuant to the LCGM MSA, LCGM will conduct clinical manufacturing, release testing, and product release for nula-cel in the Company&#8217;s Phase 1&#47;2 CEDAR clinical trial to treat SCD. During 2021, the Company entered into various Statements of Work under the LCGM MSA under which it received technology transfer and related services for HBB Beta-Globin Gene Variant for SCD, manufacturing engineer test runs, the exclusive use of a manufacturing suite at the LCGM facility, and Phase 1&#47;2 CEDAR clinical development and manufacturing of the HBB Variant for SCD. During the years ended </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023 and 2022, the Company has recognized $1.7 and $6.1 millions in research and development expense in connection with the LCGM MSA. As of December 31, 2023, the LCGM MSA has been terminated and Graphite does not expect to incur any additional expenses. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IDT License Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2021, the Company entered into a License Agreement (&#8220;IDT License Agreement&#8221;) with Integrated DNA Technologies, Inc. (&#8220;IDT&#8221;). Pursuant to the IDT License Agreement, IDT granted the Company and its affiliates a worldwide, non-exclusive, sublicensable license to research and develop products incorporating HiFi Cas9 protein variants for use in human therapeutic applications for SCD, XSCID and Gaucher disease (the &#8220;Field&#8221;) and a worldwide, exclusive, sublicensable license to commercialize such products in the Field. The Company has also been granted the right to expand the licensed Field to include human therapeutic applications in the additional fields of beta thalassemia disorder and lysosomal storage disorders upon the payment of an exercise fee in the amount of $0.5 million per additional field or $1.0 million for both additional fields. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the licenses and rights granted to the Company under the IDT License Agreement, the Company agreed to pay to IDT an upfront payment in the amount of $3.0 million and up to $5.3 million (or $8.8 million if the Company elects to expand the Field as described above to include both the beta thalassemia and lysosomal storage disorders fields) in total regulatory milestone payments. Each regulatory milestone payment is payable once on an indication-by-indication basis. In addition, the Company has agreed to pay IDT a low single-digit royalty on the net sales of products, subject to reductions in specified circumstances. As the acquisition of the license was accounted for as an asset acquisition and as the acquired technology did not have an alternative use, the total consideration of $3.0 million was recorded as research and development expense in the statement of operations and comprehensive loss during the year ended December 31, 2021. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IDT License Agreement remains in effect on a country-by-country and product-by-product basis until the expiration of the royalty term for such product in such jurisdiction. The Company and IDT each have the right to terminate the IDT License Agreement for the other party&#8217;s material breach of its obligations under the IDT License Agreement, subject to specified rights to cure. Additionally, the Company may terminate the IDT License Agreement for any reason upon written notice.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company has not recognized any research and development expense in connection with the IDT License Agreement. There are no milestones probable as of December 31, 2023&#59; therefore, no milestone payments have been recognized in the year ended December 31, 2023. As of December 31, 2023, the Company does not expect to incur any additional expenses associated with the IDT License Agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into the LOA, pursuant to which it granted a third party an option to acquire certain of the Company&#8217;s technology and intellectual property related to its nula-cel program and related preclinical platform assets. The IDT License Agreement is included in the assets that are subject to the LOA and may be assigned to this third party if and when it exercises the option.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Non-Genotoxic Targeted Conditioning Technology Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2023, the Company entered into an asset purchase agreement (the &#8220;APA&#8221;) with a third party pursuant to which the Company sold to the counterparty, concurrently with the execution of the APA, certain assets related to the Company&#8217;s non-genotoxic conditioning technology in exchange for upfront consideration of $0.5 million. Additional consideration included certain contingent milestone payments totaling up to approximately $1.0 million in the aggregate as well as royalties on net sales by the acquirer of certain products incorporating the acquired technology, and potential fees upon the completion of certain transactions by the acquirer. The APA also provided for reimbursement of certain research and development amounts incurred prior to closing of approximately $0.6 million.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disposal of certain assets sold pursuant to the APA was accounted for as a deconsolidation of a subsidiary or group of assets in accordance with ASC 810. During the year ended December 31, 2023, the Company recognized a loss on disposal of $0.1 million, which was recorded in other expense. The Company will record amounts related to the contingent milestone payments, royalties, and potential transaction fees when contingencies </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are resolved and amounts are due in accordance with ASC 450. No contingencies were resolved and recorded as of December 31, 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Option to Acquire Nula-Cel Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2023, the Company entered into an LOA with a third party pursuant to which the Company exclusively licensed to the counterparty, and granted the counterparty, an option to acquire certain intellectual property and materials related to the Company&#8217;s nula-cel program and related pre-clinical platform assets. Exercise of the option is contingent on the counterparty timely achieving a financing milestone, and all rights to the intellectual property and materials will revert to the Company if the milestone is not achieved or if the counterparty elects not to exercise the option. In return for this license and option, the Company received an equity interest in the counterparty representing 20% of all outstanding shares on a fully diluted basis. As a result of the 20% equity interest, the Company has the ability to exert significant influence over the counterparty and accounts for the interest as an equity method investment. The Company records its proportionate share of investee&#8217;s equity in earnings or losses based on the most recently available financial information.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the entity under the VIE model to assess whether to apply the consolidation guidance in accordance with ASC 810. The Company holds variable interests in the entity, and the entity was determined to be a VIE which is not consolidated as it is determined the Company lacks the power to direct the activities that most significantly impact the entity&#8217;s economic performance. The balance sheet does not contain assets and liabilities related to the Company&#8217;s interest in the non-consolidated VIE. Additionally, the Company&#8217;s maximum exposure to loss is limited to the carrying value of the equity interest in the counterparty. No arrangements exist where additional financial support would need to be provided by the Company. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 20% equity interest in the counterparty had minimal value upon execution of the LOA and the Company did not record any amount related to the equity interest as of December 31, 2023. As of December 31, 2023, the counterparty has not achieved the financial milestone and does not have the right to exercise the option.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_973"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. Commitments and Contingencies </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Agreements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with CROs for clinical trials, with CMOS or other vendors for preclinical studies, supplies and other services and products for operating purposes. These contracts generally provide for termination on notice or may have a potential termination fee if a purchase order is cancelled within a specified time. As of December 31, 2023 and 2022, there were no amounts accrued related to termination and cancellation charges as the Company does not expect to incur any additional expenses associated with termination and cancellation charges.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into license agreements (Note 6), pursuant to which the Company may acquire or license other patents, patent applications or know-how from various third parties to access intellectual property covering product candidates that the Company is developing. Under these acquisitions or licensing agreements, the Company may be liable for certain diligence obligations and payments, which are contingent upon achieving various development, regulatory and commercial milestones. Also, pursuant to the terms of some of these license agreements, when and if commercial sales of a product commence, the Company may be obligated to pay royalties to such third parties on net sales of the respective products. No such milestones were achieved or probable as of December 31, 2023 and 2022. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in legal proceedings arising from the ordinary course of business. The Company records a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by the Company is required to determine both </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probability and the estimated amount. Management is currently not aware of any legal matters that could have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. Its exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at a request in such capacity. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of December 31, 2023 and 2022, the Company did not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities. </font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_980"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. Operating Leases</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the current and non-current portions of the total liability for operating leases was $0.3 million and $0.1 million, respectively. As of December 31, 2023 and 2022, the weighted average remaining lease term on the operating lease was 15 and 19 months, respectively. As of December 31, 2023 and 2022, the weighted average incremental borrowing rate used to determine the operating lease liabilities included on the balance sheets was 9.0% and 8.5%, respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility leases</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">South San Francisco</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2021, the Company entered into a new lease agreement for office and lab space in South San Francisco, California that included two office suites. The lease terms for the two office suites commenced during July and August 2021, respectively. The term of the lease is 44 months for the first office suite and 43 months for the second office suite with an option to extend the term for an additional two years on the same terms and conditions. This option to extend the lease term was not determined to be reasonably certain and therefore has not been included in the Company&#8217;s calculation of the associated operating lease liability under ASC 842. The corresponding right-of-use assets and lease liabilities related to the two office suites were recorded on the Company&#8217;s balance sheet upon the lease commencement date, which was the date the Company was deemed to have obtained control of the premises.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company subleased one of its office suites in the South San Francisco lease for 20 months starting from August 2023 for aggregate sublease payments of $0.5 million. The sublease income, while it reduces the rent expense, is not considered in the value of the right-of-use assets or lease liabilities. The Company&#8217;s sublease income was $0.1 million for the year ended December 31, 2023. The Company did not have any sublease income during the year ended December 31, 2022.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company subleased its second office suite in the South San Francisco lease through the end of the lease term in March 2025. The third party agreed to assume all of the Company&#8217;s obligations under the head lease, including the obligation to make rent payments, as well as all of the Company&#8217;s obligations under the services agreement associated with the head lease, and to indemnify the Company for all obligations under the head lease and the associated services agreement, in exchange for the Company&#8217;s payment to the third party of approximately $1.4 million. As the Company was relieved of its primary obligations under the head lease, the Company accounted for the sublease as a lease termination, recording a loss on lease termination of $0.1 million, calculated as the carrying value of the lease liability on the date of termination, net of the payment made to the subtenant for assuming the lease. Additionally, following the sublease, the Company no longer has use of the related leasehold improvements. Therefore, the Company accounted for these assets as abandoned, recording a loss on abandonment of $0.1 million included in restructuring and impairment expenses on the statement of operations and comprehensive loss.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayside</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the Company entered into a lease agreement with Bayside Area Development, LLC (&#8220;Bayside&#8221;) for 85,165 square feet of office and laboratory space in South San Francisco, CA. The lease for the office and laboratory space commenced in April 2023. The term of the lease was 120 months with the option to extend the term up to an additional ten years. This option to extend the lease term was not determined to be reasonably certain and therefore was not included in the Company&#8217;s calculation of the associated operating lease liability. During the second quarter of 2023, the Company took possession of the lease and recognized a $32.0 million right-of-use asset and corresponding lease liability upon the lease commencement date. In addition, the Company recognized $27.2 million in leasehold improvements. Bayside provided a tenant improvement allowance of up to $14.9 million, which was fully utilized and recorded in lease liability. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company recognized an impairment in conjunction with its restructuring activities related to its Bayside lease (Note 13).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Company subleased approximately 32,113 square feet of space in the Bayside premises. The term of the sublease commenced on October 26, 2023 and expires on December 31, 2024. Pursuant to the sublease, the subtenant agreed to make rent payments directly to Bayside. The subtenant assumed all rights and obligations of the Bayside lease relative to the subleased premises.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in October 2023, the Company entered into an amendment to the Bayside lease to adjust the timeline for certain payments under the lease and to effect the acceleration of the termination date of the Bayside lease to terminate on December 31, 2024, subject to that the ability of Bayside to accelerate the termination date for the premises at its discretion. The Company prepaid all amounts payable during the amended term of the Bayside lease, in an amount equal to $15.9 million, as well as a lease termination payment of $20.8 million. Concurrent with the amendment, the Company sold all furniture, fixtures and equipment residing at the Bayside premises to the landlord for a nominal amount. Following the amendment and sublease, the Company no longer has use of any of the Bayside premises and has no further obligation thereunder.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the amendment to the Bayside lease as a lease modification, remeasuring the lease liability equal to the present value of the remaining lease payments over the amended term. Additionally, as the subtenant assumed all remaining rights and obligations under the head lease, there is no right-of-use asset or lease liability associated with the subleased space on the Company&#8217;s balance sheet. In November, the Company determined that it had no use of the Bayside premises and accounted for the remeasured right-of-use asset and related leasehold improvements as abandoned. In the aggregate, the Company recorded a net loss on modification, abandonment and sale of fixed assets of $10.8 million.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company&#8217;s only operating lease with an associated right-of-use asset and lease liability related to the South San Francisco lease that was subleased without relieving the Company of its primary obligation under the head lease. As of December 31, 2023, the Company had an operating lease right-of-use asset of $0.3 million and operating lease liability of $0.4 million recorded on its balance sheet.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Embedded leases </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its vendor contracts to identify embedded leases, if any, and determined that two agreements with contract manufacturing suppliers constituted a lease under ASC 842 as the Company has the right to substantially all of the economic benefits from the use of the asset and can direct the use of the asset.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2021 and August 30, 2021, the Company and LCGM entered into the LCGM MSA and Statement of Work #3 (&#8220;SOW #3&#8221;), respectively, for the exclusive use of a manufacturing suite at the LCGM facility. Pursuant to the terms of SOW #3, LCGM agreed to provide the Company with certain dedicated space for the clinical manufacturing, release testing, and product release in the Company&#8217;s Phase 1&#47;2 CEDAR clinical trial to treat sickle cell disease. The Company concluded that the agreement contained an embedded lease as the Company controlled the use of a dedicated manufacturing suite and the equipment therein. The agreement included fixed lease payments of $5.6 million from inception of lease through April&#160;30, 2023, the expiration date of SOW #3. As of December 31, 2023, the Company does not have any remaining obligations related to SOW #3.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Explora BioLabs, Inc. (&#8220;Explora&#8221;) entered into a License Service Agreement and Master Services Agreement (together, the &#8220;Explora Agreements&#8221;) on November 17, 2021 and December 16, 2021, respectively. Pursuant to the terms of the Explora Agreements, Explora agreed to provide a certain dedicated space to perform in vitro or in vivo studies, obtain or house research animals, and provide scientific or technical consultation to the Company. The Company concluded that the Explora Agreements contained an embedded lease as the Company controlled the use of a dedicated manufacturing suite and the equipment therein. The Explora Agreements contained fixed lease payments of $0.7 million from inception of lease through November 2023. As of December 31, 2023, the Company does not have any remaining obligations related to the Explora embedded lease.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company did not have any operating lease right-of-use assets and operating lease liabilities related to the embedded leases recorded on its balance sheet.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the future minimum lease payments for the Company&#8217;s operating leases for each of the years ending December 31 were as follows (in thousands)&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount </font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net lease liabilities</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense was $7.3 million and $6.7 million for the years ended December 31, 2023 and 2022, respectively.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the remaining lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for operating leases were $2.2 million and $1.3 million for the years ended December 31, 2023 and 2022, respectively, including non-lease components such as common area maintenance fees, taxes, and insurance.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information represents supplemental disclosure for the statement of cash flows related to the operating leases (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows under operating leases</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,123&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_992"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. Common Stock </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company was authorized to issue 300,000,000 shares of its common stock with $0.00001 par value per share. Each share of the Company&#8217;s common stock is entitled to one vote. In connection with the IPO in June 2021, all outstanding shares of redeemable convertible preferred stock were converted into 30,761,676 shares of common stock. The IPO closed on June 29, 2021, pursuant to which the Company issued and sold 14,000,000 shares of its common stock at a public offering price of $17.00 per share.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, the underwriters also exercised their option to purchase an additional 2,100,000 shares of common stock at the IPO price, less the underwriting discounts and commissions. The closing of the offering of the additional shares occurred on July 2, 2021. The Company issued and sold 2,100,000 shares of its common stock at a public offering price of $17.00 per share.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company reserved common stock for future issuances as follows&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock option awards</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,376,373&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,755,303&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future stock option grants</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,798,817&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,382,907&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares available for future grants</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253,729&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,951&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shares reserved for future issuance</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,428,919&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,893,161&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Founders&#8217; and Investor&#8217;s Restricted Common Stock </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Board approved and in April 2020, the Company issued 6,081,413 shares of its common stock to its founders and 2,467,104 shares of its common stock to its investor at the purchase price of $0.00002 per share. As of December 31, 2020, the investor&#8217;s shares were fully vested and a portion of the shares issued were subject to the Company&#8217;s option to repurchase per the Stanford Adjustment Repurchase Right, as described below. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company&#8217;s common stock issued to its founders for their services as an employee, advisor, or consultant vest monthly over four years with one year cliff from the vesting commencement date. The vesting commencement date was the date of the initial closing of the Series A preferred stock financing or June 24, 2020. Pursuant to the restricted stock purchase agreements with each of the founders, the vesting of the founders&#8217; common stock shares could be accelerated upon the occurrence of certain events, including signing of the term sheet for the license with Stanford, a change in control, or if the founder&#8217;s service is terminated by the Company without cause. The Company signed the term sheet with Stanford in June 2020, and as a result, an aggregate of 912,212 shares of founders&#8217; common stock vested pursuant to the acceleration terms. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a founder terminates the service relationship with the Company during the vesting period, the Company may repurchase any unvested restricted common stock at the price per share equal to the lower of (i) the original purchase price, subject to adjustment in the event of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split, or (ii) the current fair market value as of the date the Company elects to exercise its Stanford Adjustment Repurchase Right, as described below. The repurchase right lapses in 180 days after the termination of the founder&#8217;s service or employment. During the vesting term, holders of founders&#8217; common stock awards are deemed to be common stockholders and have the right to receive dividends and voting rights. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The founders&#8217; shares of common stock are also subject to the Company&#8217;s option to repurchase per the Stanford Adjustment Repurchase Right, as described below. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for shares issued to founders as equity compensation awards and the estimated fair value at the grant date was minimal. During the year ended December 31, 2023, the Company repurchased 152,694 shares of founders' common stock awards. 431,863 and 1,938,430 shares of founders&#8217; common stock awards were unvested and expected to vest in 0.5 years and 1.5 years as of December 31, 2023 and 2022, respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stanford Adjustment Repurchase Right</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the issuance of shares of common stock to Stanford pursuant to the License Agreement, as discussed in Note 5, the Company has a right to repurchase from each founder and an investor a number of shares of common stock equal to the number of shares issued to Stanford multiplied by the applicable number of shares issued to the founder or investor, as applicable, divided by 7,273,848 shares (a fully diluted number of shares of the Company at the end of March 2020, after the founders&#8217; and the investors&#8217; shares were approved by the board of directors). The Stanford Adjustment Repurchase Right may be exercised by the Company within six months following the date of the issuance of the shares of common stock to Stanford. The repurchase price per share is equal to the lower of (i) the purchase price, subject to adjustment in the event of any reorganization, recapitalization, reclassification, etc., or (ii) the current fair market value as of the date the Company elects to exercise its Stanford Adjustment Repurchase Right. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the Company issued an aggregate of 640,861 shares of the Company&#8217;s common stock to Stanford and certain individuals designated by Stanford in consideration for rights granted to the Company under the Company&#8217;s exclusive license agreement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, the Company exercised its right to repurchase an aggregate of 624,845 shares from each founder and investor under the Stanford Adjustment Repurchase Right. As of December 31, 2023, the Company has not exercised the right to purchase the remaining 16,016 shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for the founders and investors&#8217; shares of restricted common stock as equity share-based awards.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_999"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Equity Incentive Plans </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Grant Plan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the effectiveness of the registration statement on Form S-1 (File No. 333-256838) for its IPO, the Company granted share-based awards under the 2020 Stock Option and Grant Plan, as amended (the &#8220;2020 Plan&#8221;). The Company was authorized to grant under the 2020 Plan incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units and other share-based awards to the Company&#8217;s officers, employees, directors and consultants. Options under the 2020 Plan could be granted for periods of up to 10 years and at prices no less than 100.0% of the estimated fair value of the shares on the date of grant as determined by the Board, provided, however, that the exercise price of an incentive stock option granted to a 10.0% stockholder shall not be less than 110.0% of the estimated fair value of the shares on the date of grant and the option is not exercisable after the expiration of five years from the date of grant. Options generally vest monthly over four years with or without one year cliff vesting. Per the 2020 Plan, granted options may be early exercised prior to vesting and the Company will issue shares of restricted stock upon the early exercise with vesting terms consistent with the original grant. Upon completion of the Company&#8217;s IPO, the remaining shares available for issuance under the 2020 Plan were retired, and the Company no longer grants awards pursuant to the 2020 Plan.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Stock Option and Incentive Plan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company&#8217;s board of directors approved the 2021 Stock Option and Incentive Plan (the &#8220;2021 Plan&#8221;) that became effective immediately prior to the date when the Company&#8217;s prospectus was declared effective by the SEC on June 24, 2021. The Company initially reserved 5,636,000 shares of common stock for issuance of awards under the 2021 Plan. The 2021 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by 5% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Company&#8217;s compensation committee. On January 1, 2022 and 2023, the number of shares of common stock available under the 2021 Plan increased by 2,900,541 shares and 2,911,088 shares, respectively, pursuant to the evergreen provision of the 2021 Plan. The option exercise price of each option will be determined by the Company&#8217;s compensation committee but generally may not be less than 100% of the fair market value of the Company&#8217;s common stock on the date of grant. The term of each option will be fixed by the Company&#8217;s compensation committee and may not exceed ten years from the date of grant. The grant date fair value of all awards made under the 2021 Plan and all other cash compensation paid by the Company to any non-employee director for services as a non-employee director in any calendar year may not exceed $1.0 million for the first year of service and $750.0 thousand for each year of service thereafter.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, there were 10,798,817 shares available for future issuance under the 2021 Plan. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company issued 832,983 shares as restricted stock awards under the 2020 Plan. The purchase price of the restricted common stock awards was fair value as determined by the Board at the issuance date. The shares vest monthly over four years with the one-year cliff vesting from the grant date. Upon termination of employment, the Company has the right to repurchase any unvested restricted shares. The repurchase price for unvested shares of common stock will be the lower of (i) the fair market value on the date of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">repurchase or (ii) their original purchase price. There were no shares issued during the years ended December 31, 2023 and 2022.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for restricted stock awards as early exercised options and recognized a liability in other liabilities when cash was received for the purchase of shares of restricted stock awards. As shares of restricted stock awards vest, the Company reclassified the liability to common stock and additional paid in capital. As of December 31, 2023 and 2022, the Company recorded a minimal liability for restricted stock awards included in accrued expenses and other current liabilities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 163,830 and 5,140 shares of restricted stock award shares canceled and repurchased as of December 31, 2023 and 2022, respectively. There were 751,758 and 553,443 shares of restricted stock vested as of December 31, 2023 and 2022, respectively.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company&#8217;s board of directors and stockholders approved the 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) which became effective upon the IPO. Pursuant to the ESPP, certain employees of the Company, excluding consultants and non-employee directors, are eligible to purchase common stock of the Company at a reduced rate during offering periods. The ESPP permits participants to purchase common stock using funds contributed through payroll deductions, subject to a calendar year limit of $25,000 and at a purchase price of 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period. The ESPP has two annual purchase periods extending from June to November and December to May.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, no employees were enrolled in the ESPP and the Company did not record a liability for ESPP in accrued liabilities as of December 31, 2023. The Company had $0.1&#160;million in accrued liabilities as of December 31, 2022. The Company issued 65,222 shares and 333,155 shares under the ESPP during the years ended December 31, 2023 and 2022, respectively.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022 and 2023, the number of shares of common stock available under the 2021 ESPP increased by 564,000 shares pursuant to the evergreen provision of the 2021 ESPP.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.00% - 79.00% </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.00% - 75.00%</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65% - 5.44%</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10% - 4.65%</font></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Stock Options and Nonqualified Stock Options </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued under the 2020 Plan and 2021 Plan, generally, vest over a four-year period and expire ten years from the date of grant. Certain options provide for accelerated vesting if there is a change in control, as defined in the individual award agreements. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes option pricing model to estimate stock-based compensation expense for stock option awards granted during the periods presented, with the following assumptions.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.00% - 79.00% </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.00% - 75.00% </font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.97- 6.01</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% - 4.12%</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91% - 4.23% </font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the 2020 Plan and the 2021 Plan during the year ended December 31, 2023 is as follows&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br>Options </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br>Average<br>Exercise<br>Price Per<br>Share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br>Average<br>Remaining<br>Contractual<br>Term<br>(in years)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br>Intrinsic<br>Value<br>(in thousands)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,755,303&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.47&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted - 2021 Plan</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.22&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,900)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.98&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,500,430)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.79&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,376,373&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.58&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812,992&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2023</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,376,373&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.58&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the difference between the fair value of the underlying common stock and the exercise price as of December 31, 2023. The weighted-average grant date fair value of options granted during the December 31, 2023 was $1.56 per share. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of the stock options exercised was $0.1 and $0.2 million for the years ended December 31, 2023 and 2022, respectively.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercise of Stock Options </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the 2020 Plan permit the exercise of options granted prior to vesting, subject to required approvals. The unvested shares are subject to the repurchase right upon termination of employment at the original purchase price. The repurchase right lapses in 180 days after the termination of the employee&#8217;s employment. Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as other liabilities on the balance sheet and is reclassified to common stock and additional paid-in capital as such shares vest. During the years ended December 31, 2023 and 2022, the Company repurchased 227,792 and 189,414 shares that were previously early exercised.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023 and 2022, 68,868 and 554,695 shares, respectively, remained subject to the right of repurchase as a result of the early exercised stock options. The remaining liability related to early exercised shares as of December 31, 2023 and 2022 was minimal and was recorded in accrued expenses and other current liabilities in the balance sheets. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of stock-based compensation expense for the Company&#8217;s stock-based awards for the periods presented (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards and founders&#8217; common stock awards</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,471&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,132&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,574&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,534&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above stock-based compensation expense also includes the expenses of $2.6 million and $2.2 million related to stock options issued to non-employees during the years ended December 31, 2023 and 2022, respectively.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the classification of stock-based compensation expense for the Company&#8217;s stock-based awards for the periods presented (in thousands)&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,317&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,670&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,217&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,574&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,534&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the years ended December 31, 2023 and 2022, there was $7.4 million and $31.0 million, respectively, of unrecognized stock-based compensation expense related to the employee and non-employee awards, which is expected to be recognized over a weighted-average period of 1.5 years and 2.6 years , respectively. </font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1011"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. Net Loss Per Share Attributable to Common Stockholders </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders, which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share amounts)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,651)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,052)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,046,553&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,111,437&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; weighted-average unvested restricted shares and shares subject to repurchase</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,031,394)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,237,762)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share attributable to common stockholders</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,015,159&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,873,675&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders &#8212; basic and diluted&#58;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.19)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.84)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-dilutive Outstanding Shares or Equivalents</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding options, unvested shares, and ESPP shares were excluded (as common stock equivalents) from the computation of diluted net loss per common share for the periods presented as their effect would have been antidilutive (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,376,373&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,755,303&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock subject to vesting or repurchase</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,667&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,767,526&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan shares</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,080&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942,040&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,690,909&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1018"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. Income Taxes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No provision for income taxes was recorded for the years ended December 31, 2023 and 2022. The Company has incurred net operating losses only in the United States since its inception. The Company has not reflected any benefit of such net operating loss carryforwards in the financial statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate was as follows&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory income tax rate ate</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.01)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease Modification</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.52)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.97)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.69)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.55)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets and liabilities consisted of the following (in thousands)&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses - non-current</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,820&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,940&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&#38;D</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,493&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,815&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credit - non-current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,201&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,699&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease termination costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,621&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,161&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,699&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,285&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,626)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,110)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset basis</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,175)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,175)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credit carryforwards were as follows as of December 31, 2023 (dollars in thousands)&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31, 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expiration Years</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal (starting from January 1, 2018)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146,450&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, state</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039 - 2043</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits, federal</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,395&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2041 - 2043</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits, state</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,716&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the net operating loss carryforwards and research credit carryforwards may be subject to an annual limitation due to the ownership percentage change limitations provided by the Internal Revenue Code, as amended, (&#8220;IRC&#8221;), and similar state provisions. Annual limitations may result in the expiration of the net operating losses and tax credit carryforwards before they are utilized. The Company did not perform an IRC Section 382 analysis and any previous ownership changes may result in a limitation that will reduce the total amount of net operating loss and tax credit carryforwards disclosed that can be utilized. Subsequent ownership changes may affect the limitation in future years. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023 and 2022, the Company recorded a full valuation allowance on federal and state deferred balances since management does not forecast the Company to be in a profitable position in the near future. Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2023 and 2022 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards and were as follows (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,110&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,332&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Increases recorded to income tax provision</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,516&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,778&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,626&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,110&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. federal and state income tax returns are generally subject to tax examinations for the tax years from inception through December 31, 2022. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,701&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to current year</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction for prior period positions</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefit-December 31</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,558&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,701&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entire amount of the unrecognized tax benefits would not impact the Company&#8217;s effective tax rate if recognized. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision. The Company has elected to include interest and penalties as a component of tax expense. During the years ended December 31, 2023 and 2022, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly increase or decrease during the next 12 months.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1030"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. Restructuring Activities </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company's board of directors approved a restructuring plan (the &#8220;First Restructuring Plan&#8221;) to reduce the Company&#8217;s operating costs and better align its workforce with the needs of its business. The First Restructuring Plan eliminated approximately 50% of the Company&#8217;s workforce.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees affected by the First Restructuring Plan obtained involuntary termination benefits that are provided pursuant to a one-time benefit arrangement. For employees who were notified of their termination in February 2023 and had no requirements to provide future service, the Company recognized the liability for the termination benefits in full at fair value in February 2023. For employees who were required to render services beyond a minimum retention period to receive their one-time termination benefits, the Company recognized the termination benefits ratably over their future service periods. The service periods began in February 2023 and ended at various dates </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through June 2023. The Company has incurred approximately $3.4 million of employee termination benefits expense to implement the First Restructuring Plan and does not have any remaining obligations as of December 31, 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company's board of directors approved a second restructuring plan (the &#8220;Second Restructuring Plan&#8221;&#59; together with the First Restructuring Plan, the &#34;Restructuring Plans&#34;) to further reduce the Company's operating costs and align its workforce with the needs of its business. The Second Restructuring Plan eliminated approximately an additional 33.1% of its total workforce, and in aggregate, 78.1% of its total workforce. Employees affected by the Second Restructuring Plan obtained involuntary termination benefits that are provided to an ongoing benefit arrangement. Accordingly, the Company recognized termination benefits upon announcement of termination to all employees. The Company has incurred approximately $3.5 million and has a remaining liability of $1.0 of employee termination benefits expense to implement the Second Restructuring Plan.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that it had set a precedence for providing terminated employees with severance benefits, and accordingly, it had a de facto severance plan. In September 2023, the Company determined that it was reasonably likely to incur additional employee termination benefits expense for its remaining employees within the next twelve months. It recognized termination benefits for the remaining employees totaling $1.0 million, of which $0.6 million was paid during the year ended December 31, 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restructuring liability that is included in accrued expenses and other current liabilities in the accompanying balance sheet&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2023 </font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Accrued employee termination benefits beginning balance</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Employee termination benefits charges incurred during the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Amounts paid or otherwise settled during the period</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,565)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Accrued employee termination benefits as of December 31, 2023</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the board of directors determined that it was in the best interests of the Company and its stockholders to put in place arrangements designed to provide that the Company will have the continued dedication and commitment of those employees, including executives, determined to be key to the Company&#8217;s planned go-forward operations. In March 2023, the Board approved, and management implemented, a retention program for certain employees staying with the Company which includes cash retention bonuses totaling $4.2 million for certain retained employees provided that they remain within the Company through the requisite service period, which is the earlier of March 1, 2024 or the termination date upon a Restructuring Plan. As a result, these cash retention bonuses are being accrued over the requisite service period, with $3.7 million recognized during the year ended December 31, 2023 and included within general and administrative and research and development expenses in the statements of operations. During the year ended December 31, 2023, the Company paid $3.2 million in retention bonuses to employees for fulfilling their requisite service periods.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company committed to a plan to sell certain of its lab equipment associated with the Restructuring Plan. During the year ended December 31, 2023, the Company implemented a plan to sell its remaining lab equipment as well as other fixed assets not transferred to the Bayside lease. As of December 31, 2023, the Company disposed of all of its assets previously meeting the criteria of held for sale. These assets were recognized at the lower of cost or fair value less cost to sell using market approach. The fair value of these assets were classified as Level 3 in the fair value hierarchy due to a mix of unobservable inputs utilized such as independent research in the market as well as actual quotes from market participants. Subsequent changes to the estimated selling price of assets held for sale are recorded as gains or losses to the statements of operations and comprehensive loss wherein the recognition of subsequent gains is limited to the cumulative loss previously recognized. During the year ended December 31, 2023, the Company recorded impairment charges and loss on disposal of assets, which was included in restructuring and impairment costs in the statements of operations and comprehensive loss, of $7.0 million. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Restructuring Plans, the Company has determined that it will not utilize the Bayside and South San Francisco leases for purposes of its own operations. In August 2023, the Company subleased one of its office suites in the South San Francisco lease for 20 months starting from August 2023 for aggregate sublease payments of $0.5 million. In October 2023, the Company entered into a sublease agreement and amendment to the original master lease with the landlord to accelerate the termination date of the Bayside lease and in November 2023, the Company entered into an amendment to the original lease agreement to reassign the second suite of the South San Francisco lease (Note 8). The Company performed a recoverability test by comparing the future cash flows attributable to the asset group to the carrying value of the long-lived assets. Future cash flows were estimated using comparable laboratory and office facilities discounted at a market discount rate over the remaining term of the Company's lease. During the year ended December 31, 2023, the Company recorded a non-cash impairment of $46.9 million, to the right-of-use asset and related leasehold improvement, which was included in restructuring and impairment costs in the statements of operations and comprehensive loss.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into an asset purchase agreement with Maro pursuant to which the Company sold to the counterparty, concurrently with the execution of the APA, certain assets related to the Company&#8217;s non-genotoxic conditioning technology in exchange for upfront consideration of $0.5 million. Additional consideration included certain contingent milestone payments totaling up to approximately $1.0 million in the aggregate, as well as royalties on net sales by Maro of certain products incorporating the acquired technology, and potential fees upon the completion of certain transactions by Maro. The APA also provided for reimbursement of certain research and development amounts incurred prior to closing of approximately $0.6 million.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company also entered into an LOA with Kamau Therapeutics, Inc. (&#8220;Kamau&#8221;) pursuant to which the Company exclusively licensed to Kamau, and granted the counterparty an option to acquire, certain intellectual property and materials related to the Company&#8217;s nulabeglogene autogedtemcel (nula-cel) program and related pre-clinical platform assets. Exercise of the option is contingent on Kamau timely achieving a financing milestone, and all rights to the intellectual property and materials will revert to the Company if the milestone is not achieved or if the counterparty elects not to exercise the option. In return for this license and option, the Company received an equity interest in the counterparty representing 20% of all outstanding shares on a fully diluted basis.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1037"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. Subsequent Events </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated all subsequent events that occurred after the date of the accompanying financial statements and determined that there were no events or transactions during this subsequent event reporting period which require recognition or disclosure in our financial statements other than those disclosed elsewhere within this Form 10-K.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1127"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_1"></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Shareholders and the Board of Directors of Lenz Therapeutics, Inc.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Lenz Therapeutics, Inc. (the Company) as of December 31, 2022 and 2023, the related statements of operations and comprehensive loss, convertible preferred and common stock and stockholders' deficit and cash flows for the years then ended and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2023, and the results of its operations and its cash flows for each of the years then ended in conformity with U.S. generally accepted accounting principles.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2022.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 21, 2024 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_99"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LENZ THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except for shares and par value)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,441&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,140&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,654&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,641&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,244&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security deposit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,951&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,376&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, convertible preferred and common stock and stockholders&#8217; deficit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,755&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,803&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,499&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,514&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock warrants liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,706&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,698&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred and common stock&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A convertible preferred stock, par value of $0.001 per share&#59; 22,791,777 shares authorized, 21,977,282 shares issued and outstanding at December&#160;31, 2022 and 2023, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,621&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,621&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A-1 convertible preferred stock, par value of $0.001 per share&#59; 2,950,548 shares authorized, and 2,950,548 issued and outstanding at December&#160;31, 2022 and 2023, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,893&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,893&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B convertible preferred stock, par value of $0.001 per share&#59; 28,019,181 shares authorized, no shares and 28,019,181 issued and outstanding at December&#160;31, 2022 and 2023, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,976&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B convertible common stock, par value of $0.001 per share&#59; 2,744,184 shares authorized, and 2,744,184 shares issued and outstanding at December&#160;31, 2022 and 2023, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible preferred and common stock</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,414&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,390&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' deficit&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value of $0.001 per share&#59; 79,218,247 Class A shares authorized, and 9,915,013 shares issued at December&#160;31, 2022 and 2023, respectively, and 9,629,171 and 9,739,818 shares outstanding at December&#160;31, 2022 and 2023, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,277)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,245)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,169)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,712)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities, convertible preferred and common stock and stockholders&#8217; deficit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,951&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,376&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_30"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LENZ THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except share and per share data)</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,125&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,504&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,483&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,429&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,483)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,429)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,282&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,464)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,147)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,811)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,968)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,811)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,962)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to Class A common stockholders, basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.22)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average Class A common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,455,393</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,689,045</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_44"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LENZ THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF CONVERTIBLE PREFERRED AND COMMON STOCK AND STOCKHOLDERS&#8217; DEFICIT </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except share data)</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Convertible Preferred and Common Stock</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stockholders' Deficit</font></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series A Convertible Preferred Stock</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series A-1 Convertible Preferred Stock</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible Preferred Stock</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class B Convertible Common Stock</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Class A Common Stock</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-in Capital</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stockholders' Deficit</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,077,942&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,381&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,744,184&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,900&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,357,145&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,466)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,214)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Series A convertible preferred stock (Tranche 3), net of issuance costs</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,899,340&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,240&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Series A-1 convertible preferred stock, net of issuance costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,950,548&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,893&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272,026&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,811)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,811)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,977,282&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,621&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,950,548&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,893&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,744,184&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,900&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,629,171&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,098&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,277)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,169)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Series B convertible preferred stock, net of issuance costs</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,019,181&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,976&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of early exercised stock options</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,647&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,343&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,343&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69,968)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69,968)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December&#160;31, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,977,282&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,621&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,950,548&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,893&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,019,181&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,976&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,744,184&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,900&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,739,818&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,517&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95,245)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92,712)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_56"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LENZ THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF CASH FLOWS </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,811)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,968)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,057)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of preferred stock warrants</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,112)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,295&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,858&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security deposit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,091)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,380)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,091)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,621)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of Series A, Series A-1, and Series B convertible preferred stock, net of issuance costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,133&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,976&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,479)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,262&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,700&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,134&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,301)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the year</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,307&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,441&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,441&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,140&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing information</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred offering costs included in accounts payable and accrued expenses</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_68"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LENZ THERAPEUTICS, INC.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS </font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_142"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Organization and Liquidity </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of the Business</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lenz Therapeutics, Inc. (Lenz Therapeutics or the Company), previously known as Presbyopia Therapies, Inc., became a corporation in Delaware on October 28, 2020, upon the filing of a Certificate of Conversion to convert Presbyopia Therapies, LLC, a Delaware limited liability company (formed in September 2013) to a Delaware corporation. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lenz Therapeutics is headquartered in Del Mar, California. The Company is a late-stage clinical company developing innovative ophthalmic pharmaceutical products.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Merger Transaction</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2024, Graphite Bio, Inc., a Delaware corporation (&#8220;Graphite&#8221;) and the Company completed a merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) dated November 14, 2023, pursuant to which, among other matters, Generate Merger Sub, Inc., a wholly-owned subsidiary of Graphite (&#8220;Merger Sub&#8221;), merged with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly-owned subsidiary of Graphite (&#8220;the Merger&#8221;). Additionally, Graphite changed its name to &#8220;LENZ Therapeutics, Inc.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, Graphite concurrently entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with certain institutional investors (the &#8220;PIPE investors&#8221;) pursuant to which, among other things, Graphite agreed to issue to the PIPE investors shares of Graphite common stock immediately following the Merger in a private placement transaction for an aggregate purchase price of $53.5&#160;million, which amount may be increased to up to $125&#160;million through additional subscriptions under the Subscription Agreement from additional PIPE investors (the &#8220;Graphite private placement&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Graphite assumed each outstanding and unexercised option to purchase the Company&#8217;s common stock, whether vested or not vested, and each outstanding and unexercised warrant to purchase the Company&#8217;s common stock or preferred stock, which became options and warrants to purchase shares of Graphite common stock. Subsequently, at the effective time of the Merger, each outstanding share of the Company&#8217;s common stock and preferred stock, and options and warrants to purchase the Company&#8217;s common stock was converted into the right to receive or purchase 0.2022 shares of Graphite&#8217;s common stock, which resulted in the issuance by Graphite of an aggregate of 15,409,184 shares of, and options and warrants to purchase, Graphite common stock to the stockholders, option holders, and warrant holders of the Company. Immediately following the consummation of the Merger and Graphite private placement, the Company, Graphite stockholders, and the PIPE investors collectively owned approximately 56%, 31%, and 13% of the combined company, respectively, on a fully diluted basis.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses and negative cash flows from operations since inception and as of December&#160;31, 2023, had an accumulated deficit of $95.2 million. The Company incurred net losses of $10.8 million and $70.0&#160;million during the years ended December&#160;31, 2022 and 2023, respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to incur additional losses in the future as it continues its research and development efforts, advances its product candidates through clinical development, seeks regulatory approval, prepares for commercialization, hires additional personnel, protects its intellectual property, and grows its business. The Company may need to raise additional capital to support its continuing operations and pursue its long-term business plan, including the development and commercialization of its product candidates, if approved. Such activities are subject to significant risks and uncertainties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company had cash, cash equivalents, and marketable securities of $65.8 million, which is available to fund future operations. In connection with the Merger, the Company completed the Graphite </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private placement for gross proceeds of $53.5&#160;million and received approximately $115.0&#160;million from the Merger in March 2024. The Company believes that its existing cash, cash equivalents, and marketable securities as of December&#160;31, 2023 in addition to the funds received in connection with the Merger, will be sufficient to support operations for at least the next 12 months from the date these financial statements were available to be issued.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_161"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates used in preparing the accompanying financial statements include, but are not limited to, estimates related to the research and development accruals, preferred stock warrants liability, share-based compensation, and the valuation of deferred tax assets and liabilities. Although actual results could differ from those estimates, management does not believe that such differences would be material. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in a traditional checking and savings accounts with a financial institution and does not have restricted cash.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies marketable securities as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all marketable securities with maturity dates beyond three months at the date of purchase as current assets in the accompanying balance sheets. As of December&#160;31, 2023, the Company had no intent to sell any marketable securities prior to maturity. Marketable securities classified as available-for-sale are carried at fair value with the unrealized gains and losses included in other comprehensive income as a component of stockholders&#8217; deficit until realized. Any premium or discount arising at purchase is amortized and&#47;or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Realized gains and losses are calculated using the specific identification method and recorded as interest income or expense.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For available-for-sale securities in an unrealized loss position, the Company first assesses whether it intends to sell, or if it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">making this assessment, the Company considers the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive income on the statements of operations and comprehensive loss. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excludes the applicable accrued interest from both the fair value and amortized costs basis of its available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded within prepaid expenses and other current assets on the balance sheets. The Company&#8217;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which the Company considers to be in the period in which it determines the accrued interest will not be collected. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows&#58; </font></div><div style="margin-bottom:9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;Observable inputs such as quoted prices in active markets. </font></div><div style="margin-bottom:9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. </font></div><div style="margin-bottom:9pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3 (see Note 3). A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value of the instrument.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses based on the difference between the proceeds received and the net book value of the disposed asset. Routine expenditures for maintenance and repairs are expensed as incurred. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated useful lives for property and equipment are as follows&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset group may not be recoverable. Recoverability of the long-lived asset </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">group is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset group. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. There were no impairment losses recognized during the years ended December&#160;31, 2022 or 2023. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether it conveys the right to control the use of an identified asset in exchange for consideration. If a lease is identified, classification is determined at lease commencement. To date, all of the Company&#8217;s leases have been determined to be operating leases. Operating lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. The Company&#8217;s leases do not provide an implicit interest rate and therefore the Company estimates its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the estimated interest rate that the Company would have to pay to borrow on a collateralized basis, an amount equal to the lease payments in a similar economic environment over a similar term. Operating lease right-of-use (ROU) assets are determined based on the corresponding lease liability adjusted for any lease payments made at or before commencement, initial direct costs, and lease incentives. The operating lease ROU asset also includes impairment charges if the Company determines the ROU asset is impaired. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Operating lease expenses are recognized, and the ROU assets are amortized on a straight-line basis over the lease term. The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The Company has elected not to recognize leases with terms of one year or less on the balance sheets.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds of the offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. The Company had deferred offering costs capitalized as of December&#160;31, 2023 of $2.7 million related to the Merger. The Company had no such capitalized costs as of December&#160;31, 2022. In December 2023, the Company abandoned its plan for an initial public offering and expensed related costs of $2.1 million to selling, general and administrative expense.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses and Related Prepaid Assets and Accrued Liabilities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses primarily consist of internal research and development expense, including personnel-related expenses (such as salaries, benefits and noncash stock-based compensation) and external research and development expenses incurred under arrangements with vendors conducting research and development services on its behalf, such as contract research organizations (CROs) and contract manufacturing organizations (CMOs). </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made prior to the receipt of goods or services to be used in research and development are capitalized, evaluated for current or long-term classification, and included in prepaid expenses and other current assets or other assets in the balance sheets based on when the goods are received or the services are expected to be received or consumed, and recognized in research and development expenses when they are realized.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to estimate expenses resulting from its obligations under contracts with vendors, service providers and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in cash flows that do not match the periods over which materials or services are provided. The Company estimates and records accrued expenses for the related research and development activities based on the level of services performed but not yet invoiced pursuant to agreements established with its service providers, according to the progress of clinical trials or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related activities, and discussions with applicable personnel and service providers as to the progress or state of consummation of goods and services.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company&#8217;s estimates. The Company estimates accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances known at that time. The clinical trial accrual is dependent in part upon the timely and accurate reporting of CROs, CMOs and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its estimates may vary from the actual results. To date, the Company has not experienced material differences between its accrued expenses and actual expenses.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock Warrants Liability</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued freestanding warrants to purchase shares of its Series A convertible preferred stock (Series A Convertible Preferred). Upon certain change in control events that are outside of the Company&#8217;s control, including liquidation, sale or transfer of control of the Company, holders of Series A Convertible Preferred can cause redemption. The warrants are revalued at each subsequent balance sheet date utilizing an option pricing method that back solves the fair value of the warrants based on recent financing transactions and also considers the enterprise value of the Company when considering potential exit events. Changes in fair value are recognized as increases or reductions to other income (expense), net in the accompanying statements of operations and comprehensive loss. The fair value of these warrants is classified as a non-current liability in the accompanying balance sheet since the underlying Series A Convertible Preferred stock is potentially redeemable. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred and Common Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s convertible preferred stock and Class B convertible common stock are classified outside of stockholders&#8217; deficit because the shares contain deemed liquidation rights that are a contingent redemption feature not solely within the control of the Company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of the convertible preferred stock and Class B convertible common stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur. The Company did not accrete the value of the convertible preferred stock to its redemption value since a liquidation event was not considered probable as of December&#160;31, 2022 and 2023. Subsequent adjustments to the carrying values of the convertible preferred stock will be made only when it becomes probable that such liquidation events will occur, causing the shares to become redeemable.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an equity incentive plan as a long-term incentive for employees, directors, and non-employee service providers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All share-based payments to employees and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards, or restricted stock units, are recognized as expense based on their grant date fair values. T</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company recognizes expense on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. Stock-based compensation is classified in the statements of operations and comprehensive loss based on the function to which the related services are provided.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has elected to account for forfeitures as they occur. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of options granted using the Black-Scholes-Merton (Black-Scholes) option pricing model for stock option grants to both employees and non-employees. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions. A discussion of management&#8217;s methodology for developing the assumptions used in the valuation model follows&#58; </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Given the lack of an active public market for the Company&#8217;s common stock, the fair value of the Company&#8217;s common stock was determined by the board of directors with input from management and consideration of third-party valuation reports. In the absence of a public trading market, and as a clinical-stage </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company with no significant revenues, the Company believes that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. In determining the fair value of its common stock, the Company used methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#8217; (AICPA) Audit and Accounting Practice Aid Series&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Privately Held Company Equity Securities Issued as Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, the Company considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1) the achievement of clinical and operational milestones by the Company&#59; (2) the significant risks associated with the Company&#8217;s stage of development&#59; (3) capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies&#59; (4) the Company&#8217;s available cash, financial condition, and results of operations&#59; (5) the most recent sales of the Company&#8217;s convertible preferred stock&#59; and (6) the preferential rights of the outstanding convertible preferred stock and Class B convertible common stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected dividend yield is based on the Company&#8217;s historical and expected dividend payouts. The Company has historically paid no dividends and does not anticipate dividends to be paid in the future. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Equity Volatility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Due to the lack of a public market for the Company&#8217;s common stock and the lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period of time commensurate with expected term assumption. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company uses the simplified method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No. 107, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are measured using effective tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a valuation allowance against its net deferred tax assets. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes. As of December&#160;31, 2022 and 2023, the Company had no interest or penalties related to uncertain income tax benefits. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to include interest and penalties related to unrecognized income tax benefits as a component of income tax expense. The Company has no accruals for interest or penalties in the balance sheets as of December&#160;31, 2022 and 2023 and has not recognized interest or penalties in the statements of operations for the years ended December&#160;31, 2022 or 2023. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its revenue agreements in accordance with FASB ASC 606, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). ASC 606 requires a five-stage approach, including (i) identification of the contract&#59; (ii) identification of performance obligations&#59; (iii) determination of the transaction price&#59; (iv) allocation of the transaction price&#59; and (v) recognition of revenue. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss attributed to Class A common stockholders by the weighted-average number of shares of Class A common stock outstanding during the period, without consideration for common stock equivalents. The convertible preferred stock and Class B convertible common stock are not participating securities, because they do not participate in losses. Stock options, preferred stock warrants, Class A warrants, Class B convertible common stock, and convertible preferred stock are considered potentially dilutive to Class A common stock. The Company computes diluted net loss per share attributable to Class A common stockholders after giving consideration to all potentially dilutive Class A common stock outstanding during the period, determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. The Company makes adjustments to diluted net loss attributed to Class A common stockholders to reflect the reversal of gains on the change in the value of preferred stock warrants liability, assuming conversion of warrants to acquire convertible preferred stock at the beginning of the period or at time of issuance, if later, to the extent that those preferred stock warrants are dilutive. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income represents the change in the Company&#8217;s stockholders&#8217; deficit from all sources other than investments by or distributions to stockholders. The Company&#8217;s other comprehensive income is the result of unrealized gains and losses on marketable securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s Chief Executive Officer acts as the CODM. The CODM views the Company&#8217;s operations and manages its business as one operating segment operating exclusively in the United States.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)&#58; Improvements to Income Tax Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state&#47;local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for the Company for annual periods beginning after December 15, 2025, with early adoption permitted. The Company has not yet completed its assessment of the impact of ASU 2023-09 on the Company&#8217;s financial statements.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_175"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Fair Value of Financial Instruments</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents classified within the Level 1 designation, prepaid and other current assets, accounts payable, and accrued liabilities approximate fair </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value due to their short maturities. Cash equivalents, marketable securities, and the preferred stock warrants liability are recorded at fair value on a recurring basis. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities measured at fair value on a recurring basis are as follows (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December&#160;31, 2022&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock warrants liability</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December&#160;31, 2023&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,962&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,962&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:31.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents measured at fair value</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,962&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,962&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,751&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,751&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,925&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,925&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:31.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities measured at fair value</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,654&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,676&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock warrants liability</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</font></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consisted of the following (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,742&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,751&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agencies</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,927&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury securities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,977&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Totals</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,646&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,654&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023,&#160;three&#160;of the Company&#8217;s marketable securities with a fair market value of $6.5 million were in a gross unrealized loss position of $3,000, all of which have been in a gross unrealized loss position for less than one year.&#160;When evaluating an investment for impairment, the Company reviews factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company&#8217;s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. Based on the Company&#8217;s review of these marketable securities, the Company believes none of the unrealized loss is the result of a credit loss as of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, because it does not intend to sell these securities, and it is not more-likely-than-not that it will be required to sell these securities before the recovery of their amortized cost basis. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, all marketable securities had contractual maturities of less than one year.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key unobservable inputs for the preferred stock warrants liability were&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated time to liquidity</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 years</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility rate</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2%</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any assets measured at fair value on a recurring basis between levels during the years ended December&#160;31, 2022 and 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents activity for the preferred stock warrants liability during the years ended December&#160;31, 2023 (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock Warrants Liability</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_195"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Property and Equipment, net</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; accumulated depreciation</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $8,000 and $15,000 for the years ended December&#160;31, 2022 and 2023, respectively. As of December&#160;31, 2023, all the Company&#8217;s property and equipment was located in the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_212"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Accrued Liabilities</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expense</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,289&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related benefits</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,744&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,803&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_227"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;Commitments and Contingencies</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leased office space in Del Mar, California under a lease that expired on March&#160;31, 2022. Commencing on April 1, 2022, the Company entered into a separate lease agreement for office space in Del Mar, California, which was subsequently amended to expand the office space leased and extend the term. As of December&#160;31, 2023, the remaining lease term was 2.3 years, and the discount rate used to determine the right-of-use assets and corresponding operating lease liabilities was 7.0%. Cash paid for operating leases approximated rent expense for the periods presented.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease liability as of December&#160;31, 2023, are as follows (in thousands)&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; Present value adjustment</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the years ended December&#160;31, 2022 and 2023 was $110,000 and $145,000, respectively.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. As of December&#160;31, 2022 and 2023, the Company was not involved in any material legal proceedings. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. Its exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at a request in such capacity. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of December&#160;31, 2023, the Company did not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</font></div></div></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_241"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Convertible Preferred Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has authorized 53,761,506 shares of preferred stock with a par value of $0.001. As of December&#160;31, 2022, there were 21,977,282 shares of Series A Convertible Preferred Stock (Series A) and 2,950,548 shares of Series A-1 Convertible Preferred Stock (Series A-1) issued and outstanding. As of December&#160;31, 2023, there were 21,977,282 shares of Series A, 2,950,548 shares of Series A-1, and 28,019,181 shares of Series B Convertible Preferred Stock (Series B) issued and outstanding. As of December&#160;31, 2023, the total liquidation preference of issued and outstanding Series A, Series A-1, and Series B was $47.3 million, $10.0 million, and $83.5 million, or $2.15 per share, $3.3892 per share, and $2.9801 per share, respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of preferred stock are entitled to receive annual noncumulative dividends at an annual rate of 8% in preference to any declaration or payment of any dividend on the common stock, on an as-converted basis when, as and if declared by the board of directors. As of December&#160;31, 2022 and 2023, no dividends had been declared. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of outstanding shares of Series A, Series A-1, and Series B shall be entitled to cast the number of votes equal to the number of whole shares of Class A common stock into which the shares of Series A, Series A-1, and Series B held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion Rights </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of preferred stock is convertible into shares of common stock at the ratio calculated by dividing the original issuance price by the conversion price. The conversion price is equal to the original issuance price but is subject to anti-dilution adjustments for splits, dividends and similar recapitalizations. As of December&#160;31, 2023, the conversion ratio was one-for-one. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exclusions, anti-dilution price protection for additional sales of securities by the Company for consideration per unit less than the applicable conversion price per unit of any series of preferred stock are to be on a broad-based weighted average basis. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation Preference </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of Series A, Series A-1, and Series B shall be entitled to be paid out of the assets of the Company available for distribution to its shareholders before any payment shall be made to the holders of the Class A and Class B convertible common stock.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not adjust the carrying values of the preferred stock to the liquidation preferences of such shares because it was uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of Class B convertible common stock and preferred stock and these circumstances were not probable as of the balance sheet dates. Subsequent adjustments to the carrying values of the liquidation preferences are to be made only when it becomes probable that such a liquidation event will occur.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of the Company then outstanding preferred and common stock shall be entitled to be paid as follows&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First to the holders of shares of preferred stock then outstanding, an amount per share equal to the sum of original issue price plus any dividends declared but unpaid thereon. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Second, to the holders of shares of Class B convertible common stock then outstanding, an amount per share equal to the original issue price for the Class B convertible common stock, plus any dividends declared but unpaid thereon, plus an additional per share amount calculated at a rate per annum equal to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10% of the original $2.15 issue price for the Class B convertible common stock, compounded annually, and which shall be calculated from the Class </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">B convertible common stock original issue date until the earlier to occur of (i) as applicable, the date of the deemed liquidation event or (ii) the fifth anniversary of such Class B convertible common stock original issue date. As of December&#160;31, 2023, the liquidation preference was $9.5 million, or $3.46 per share.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Then, among the holders of the shares of preferred stock, Class B convertible common stock, and Class A common stock, principally pro rata based on the number of shares held by each such holder as if they had been converted to Class A common stock immediately prior to such liquidation, dissolution or winding up of the Company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration Rights</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s investors&#8217; rights agreement, the holders of a majority of Company&#8217;s stock outstanding have the right to demand that the Company file a registration statement or request that their shares be covered by a registration statement that the Company is otherwise filing. The obligations of the Company regarding such registration rights include, but are not limited to, commercially reasonable efforts to cause such registration statement to become effective, keep such registration statement effective for up to 120 days, prepare and file amendments and supplements to such registration statement and the prospectus used in connection with such registration statement, and furnish to the selling holders copies of the prospectus and any other documents as they may reasonably request. The terms of the registration rights provide for the payment of certain expenses related to the registration of the shares, including a capped reimbursement of legal fees of a single special counsel for the holders of the shares, but do not impose any obligations for the Company to pay additional consideration to the holders in case a registration statement is subsequently withdrawn at the request of the holders.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_255"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Common Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has authorized two series of common stock, designated Class&#160;A common stock and Class&#160;B convertible common stock. As of December&#160;31, 2022 and 2023, there were 9,915,013 of Class&#160;A common stock issued, and there were 9,629,171 and 9,739,818 of Class&#160;A common stock outstanding, respectively. As of December&#160;31, 2022 and 2023, there were 2,744,184&#160;shares of Class&#160;B convertible common stock issued and outstanding.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common&#160;stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Class&#160;B convertible common stockholders are entitled to receive noncumulative dividends at an annual rate of 8%, as may be declared by the board of directors, if any. Class&#160;A common stockholders have no dividend rights. Such dividends are not cumulative, and no dividends have been declared or paid by the Company through December&#160;31, 2023. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class&#160;A common stock reserved for future issuance consist of the following&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,927,830</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,947,011</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B convertible common stock</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744,184</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744,184</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock options granted and outstanding</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,271,961</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,317,290</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A shares available for issuance under incentive plans</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,306</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510,254</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock warrants</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock warrants</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,495</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,495</font></td></tr></table></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_285"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. &#160;&#160;&#160;&#160;Warrants </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued warrants to acquire Class&#160;A common stock and Series&#160;A convertible preferred stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant to purchase 470,000 shares of Class&#160;A common stock has an exercise price of $0.21&#160;per share and was issued in December 2020 with an expiration date in February&#160;2024.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series&#160;A preferred stock warrants have an exercise price of $2.15&#160;per share and were issued in October&#160;2020 with an expiration date in October&#160;2027. The Series&#160;A preferred stock warrants shall no longer be exercisable and become null and void on the date of which the Company consummates the sale of its common stock or other securities in the Company&#8217;s first underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, or in the event of a deemed liquidation event, provided however that if the holder of any such Series&#160;A preferred stock warrant has not exercised the warrant prior to the closing of any such transaction, such Series&#160;A preferred stock warrant shall automatically be deemed to be exercised in full pursuant to the net exercise features of such Series&#160;A preferred stock warrants immediately prior to the closing of the applicable transaction, without any further action required on the part of the holder thereof. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No warrants were exercised for any of the periods presented.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_299"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. &#160;&#160;&#160;&#160;Share-Based Compensation </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Equity Incentive Plan (the 2020 Plan) provides for the grant of incentive stock options, non-statutory stock options, and other equity awards to the Company&#8217;s employees, officers, directors, and consultants. As of December&#160;31, 2023, the aggregate number of shares of Class&#160;A common stock authorized under the 2020 Plan, as amended, was 11,385,409&#160;shares. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the 2020 Equity Incentive Plan generally vest over three or four years and expire after 10 years.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The per share exercise price for stock options granted is set at the fair value per share of common stock as determined by the board of directors as of the date of grant. The board of directors determined the value the Company&#8217;s Class&#160;A common stock considering many factors, including third-party valuation of the Company's Class&#160;A common shares, as well as additional factors, which may have changed since the date of the most recent contemporaneous valuation through the date of grant. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for awards under the 2020 Plan is presented below&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Lives (years)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2022</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,271,961</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,585&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045,329</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2023</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,317,290</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,691&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2023</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,261,957</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,536&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</font></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,492,482</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,054&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share of stock options granted during the years ended December&#160;31, 2022 and 2023 was $0.73 and $1.07, respectively. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded share-based compensation expense of $0.7 million and $1.3 million for the years ended December&#160;31, 2022 and 2023, respectively. As of December&#160;31, 2023, there was $4.3 million of unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2020 Plan, which is expected to be recognized over a weighted average period of 2.7 years. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense was as follows (in thousands)&#58; </font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in the Black-Scholes option pricing model for stock options granted were as follows&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.8% - 96.6%</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.0% - 92.7%</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9% - 4.2%</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9% - 4.6%</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability for Early Exercise of Stock Options </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain individuals were granted the ability to early exercise their stock options. The shares of Class&#160;A common stock issued from the early exercise of unvested stock options are restricted and continue to vest in accordance with the original vesting schedule. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The shares purchased by the employees and non-employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding until those shares vest. The cash received in exchange for exercised and unvested shares related to stock options granted is recorded as a liability for the early exercise of stock options on the accompanying balance sheets and will be transferred into Class&#160;A common stock and additional paid-in capital as the shares vest. As of December&#160;31, 2022 and 2023, there were 285,839 and 175,192 unvested shares issued under early exercise provisions were subject to repurchase by the Company, respectively. At both December&#160;31, 2022 and 2023, the Company recorded $0.1 million associated with early exercised stock options in other long-term liabilities.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_319"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. &#160;&#160;&#160;&#160;Net Loss Per Share Attributable to Class A Common Stockholders</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s potential dilutive securities, which include convertible preferred stock, options to purchase common stock, Class&#160;A common warrants, preferred stock warrants, and Class&#160;B convertible common stock, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,927,830</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,947,011</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock options granted and outstanding</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,271,961</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,317,290</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock warrants</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,000</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,000</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock warrants</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,495</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,495</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B convertible common stock</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744,184</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744,184</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,228,470</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,292,980</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of convertible preferred stock and Class B convertible common stock do not contractually share in losses and therefore no additional net loss per share has been disclosed under the two-class method.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_336"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. &#160;&#160;&#160;&#160;Income Taxes</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) were as follows (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s income tax expense (benefit) to the amount computed by applying the federal statutory income tax rate is summarized as follows (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected tax benefit computed at federal statutory rate</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,192)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,731)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,153)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit carryforwards</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,788)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,472)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,916&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,003&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s net deferred tax assets (liabilities) are summarized as follows (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,975&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit carryforwards</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">982&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,269&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,044&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,282&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,784&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,810&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,727)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,736)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (TCJA) requires taxpayers to capitalize and amortize research and development (R&#38;D) expenditures under section 174 for tax years beginning after December&#160;31, 2021. This rule became effective for the Company during the year ended December&#160;31, 2022, resulting in a gross deferred tax asset for capitalized R&#38;D costs of approximately $66.0 million as of December&#160;31, 2023. The Company will continue to amortize these costs for tax purposes over 5 years for R&#38;D performed in the U.S. and over 15&#160;years for R&#38;D performed outside the U.S.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax assets and liabilities are recorded for differences between the financial statement and tax basis of the assets and liabilities that will result in taxable or deductible amounts in the future based on enacted laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined it is more likely than not that the assets will not be realized. Due to uncertainties surrounding the realizability of the deferred tax assets, the Company maintains a full valuation allowance against its deferred tax assets at December&#160;31, 2022 and 2023. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a valuation allowance of $26.7 million at December&#160;31, 2023 to offset the net deferred tax assets as realization of such assets is uncertain. The valuation allowance increased by $20.0 million during the year ended December&#160;31, 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company had federal and state net operating loss (NOL) carryforwards of $18.1 million and $17.9 million, respectively. Federal NOL carryforwards of $18.1 million generated after 2017 may be carried forward indefinitely but can only be utilized to offset 80% of future taxable income. State NOL carryforwards totaling $17.2 million begin to expire in 2040, unless previously utilized, and $0.6 million that carryforward indefinitely. In addition, the Company also has federal and state R&#38;D credit carryforwards totaling $6.5 million and $0.5 million, respectively. The federal R&#38;D credit carryforwards will begin to expire in 2040 unless previously utilized. The state R&#38;D credit carryforwards will begin to expire in 2042 unless previously utilized. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of NOL carryforwards and other tax attributes, including those obtained through the Merger, may be subject to substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, as amended, due to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ownership change limitations that have occurred previously or that could occur in the future. An ownership change occurs, generally, if the percentage of stock of the loss corporation owned by one or more 5% shareholders has increased by more than 50 percentage points relative to the lowest percentage of stock of the loss corporation owned by the same 5% shareholders at any time during the testing period (generally, the three-year period preceding a testing date). These ownership changes may limit the amount of NOL carryforwards and tax credits that can be utilized annually to offset future taxable income. State NOL carryforwards and other state tax attributes may be similarly limited. The Company completed a Section 382 analysis through December&#160;31, 2022 and it was determined the Company underwent an ownership change as defined under Section 382 on April 21, 2021. It was determined that based on the calculations, no attribute carryovers will expire without utilization as a result of Section 382 limitations from the April 21, 2021 ownership change. The Company&#8217;s use of NOL and credit carryforwards could be limited further by the provisions of Section 382 depending on the timing and amount of additional equity securities that the Company has issued or will issue subsequent to December&#160;31, 2022, including those obtained through the Merger to the extent the Company or Graphite experiences an ownership change through or subsequent to the Merger.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. As of December&#160;31, 2022 and 2023, the Company had no unrecognized tax benefits that, if recognized and realized, would effect the effective tax rate due to the valuation allowance against deferred tax assets. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes to the Company&#8217;s gross unrecognized tax benefits (in thousands)&#58;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior year tax positions</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</font></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy is to recognize interest and penalties related to income tax matters as income tax expense. The Company had no accrual for interest or penalties on the Company's balance sheets at December&#160;31, 2022 or 2023, and has not recognized interest and&#47;or penalties in the statement of operations and comprehensive loss for the years ended December&#160;31, 2022 and 2023. As of December&#160;31, 2022 and 2023, the Company had unrecognized tax benefits of $0.1 million and $1.7 million, respectively, which if recognized currently, should not impact the effective tax rate due to the Company maintaining a full valuation allowance. The Company does not expect that there will be a significant change in the unrecognized tax benefit over the next twelve months. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the U.S. federal and various state jurisdictions. All of the Company&#8217;s tax years are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and R&#38;D credits. Further the Company is not currently under examination by any federal, state or local tax authority. </font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_353"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. &#160;&#160;&#160;&#160;License Agreements </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company entered into a license and collaboration agreement providing an exclusive license (License) to certain of the Company&#8217;s intellectual property (IP) for use in the treatment of presbyopia in humans in mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan (collectively, &#8220;Greater China&#8221;). The Company also agreed to negotiate a separate agreement for the purchase of clinical and commercial supply of IP for clinical and commercial requirements at cost plus a negotiated percentage and granted a right of first negotiation to obtain a regional license on other products the Company might develop outside the field of presbyopia for commercialization in Greater China. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received nonrefundable, non-creditable upfront payments totaling $15.0&#160;million as initial consideration under the License, which represents the transaction price at inception. In addition, the Company is also eligible to receive up to $95.0&#160;million of regulatory and sales milestones, as well as tiered low double-digit royalties on net sales of IP in Greater China. Additional consideration to be paid to the Company upon reaching regulatory and sales milestones is excluded from the transaction price. Future milestone payments are fully contingent as the risk of significant revenue reversal will only be resolved depending on future regulatory approval and sales level outcomes. The sales-based royalty fee qualifies for the royalty constraint exception and does not require an estimate of the future transaction price. The sales-based royalty fee is considered variable consideration and will be recognized as revenue as such sales occur, if any.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the promises made under the License and concluded the License comprises a single performance obligation providing the right to use functional intellectual property. The $15.0 million transaction price allocated to that single performance obligation was recognized on completion of the transfer of the License in the year ended December&#160;31, 2022. no additional amounts under the License were paid during the years ended December&#160;31, 2022 and 2023 or were due to the Company at December&#160;31, 2022 and 2023.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with entering into the License agreement, a significant investor in the licensee purchased 2,950,548&#160;shares of the Company&#8217;s Series&#160;A-1&#160;Preferred Stock for $10.0 million.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_370"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. &#160;&#160;&#160;&#160;Employee Benefit Plan </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a 401(k) retirement plan to provide retirement benefits for all eligible employees. Participating employees may voluntarily contribute up to limits provided by Internal Revenue Service regulations. For the years ended December&#160;31, 2022 and 2023, the Company made contributions to the plan of $0.1 million and $0.2 million, respectively.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_384"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. &#160;&#160;&#160;&#160;Related Party Transactions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October&#160;2022, the Company issued 9,899,340 shares of its Series&#160;A preferred stock for total cash proceeds of $21.3&#160;million to significant shareholders that have designated members on the Company&#8217;s board of directors and are considered to be related parties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company issued 22,146,905 shares of its Series B preferred stock for total cash proceeds of $66.0&#160;million to significant shareholders that have designated members on the Company&#8217;s board of directors and are considered to be related parties.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A member of the Company&#8217;s Board of Directors currently serves as a member of the board of directors of one of the Company&#8217;s vendors, and has served in that capacity since 2023. The Company entered into a Master Services Agreement with this vendor in September 2023 to provide manufacturing services. Accordingly, the Company considers the vendor to be a related party. For the year ended December&#160;31, 2023, fees incurred for services performed by the vendor were $0.3 million, and were charged to research and development expenses. Amounts due to the vendor within accounts payable as of December&#160;31, 2023 totaled $0.3 million.</font></div><div id="i53d6782078384f7ab44e5c29cf9c0dbd_501"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. &#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through March&#160;21, 2024, the date on which the accompanying financial statements are available to be issued. During this period, the Company has concluded that no material subsequent events have occurred other than those disclosed below.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Completion of the Merger Transaction</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully described in Note 1, on March 21, 2024, the Company completed the Merger by and among the Company, Graphite, and Merger Sub, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub merged with and into the Company, with the Company continuing as a wholly owned subsidiary of Graphite and the surviving corporation of the merger. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a pro forma basis and based upon the number of shares of Graphite common stock issued in the Merger, the Company&#8217;s pre-Merger stockholders own approximately 65% of the combined company, pre-Merger Graphite stockholders own approximately 35% of the combined company on a fully-diluted basis (prior to giving effect to the Concurrent PIPE Investment described below and excluding any shares reserved for future grants under the 2024 Plan and the 2024 ESPP, each as defined in the Merger Agreement).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement and Subscription Agreement</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to consummation of the merger, Graphite completed the Graphite private placement financing pursuant to the Subscription agreement by issuing 3,559,565 shares of Graphite&#8217;s common stock at $15.03 per share for an aggregate purchase price of $53.5&#160;million (&#8220;the concurrent PIPE investment&#8221;). The concurrent PIPE investment is exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the Securities Act), and&#47;or Regulation D promulgated thereunder, as a transaction by an issuer not involving a public offering. The PIPE investors have acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends have been affixed to the securities issued in this transaction.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the holder exercised warrants to purchase 470,000 shares of our Class A common stock, resulting in $0.1&#160;million of proceeds.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-56</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>business10a.jpg
<TEXT>
begin 644 business10a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1^$17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   ###@  9
M ,0.  !D    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$X.C Q.C,V  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !Q     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M0!SQ/B6.Z58C.\8N#Y9D5<%-Z_?]!LW8QSFM3PXVKM%-_:HDS\FWS  =V/G
MQ_#GI5UM7LD?89CD.$^XQ&XG &<>HIB:Y8M$)"[JI4-S&V0",C(QQ0!HT51G
MU>SMX/-=WQM9L"-L_+P<C''/'-#ZO:0[!.SQNRAMIC8D9&><"@"]15#^VK#
M)F8;L8S&W))( Z=20>.M UFQ)&)6Y. ?+;'\NV>?2@"_14%K=P7L FMWWQGH
M<$?SJ>@!DTGDP/)C.Q2V*YD>(+3>S#34W,<DX&2?R]S^==%>_P#'C/\ ]<V_
ME7+Z)';Q_OIT+,QPK=D]Z\W&5,1[:%.B[73OH=F'C2]G*517)VU. 1R[M*D"
M3KM<'."/3Z<G\ZBDUC3I  ^E1G&,<#L<@=.GM6KJ:C$!#;OE(W>M<_J%L GF
MJN".OO6.*^N4J3J0G>WDBZ/L)SY91M?S+_\ PD%GL9/[-38PVLN!@CT/'N?S
MIG]MZ?M*_P!E1;3U&U<']/85Q-]9:I)?RS6ET(XS&JH-QX.&R<'*]UZ@]*K1
MVWB%B3+=QC:H'(7:6&,,,#/][.3CVKREF>*:O[1?=_P#L>$HK[+/0?[?L@^_
M^S8]V2<X&<GJ>E*OB&T0Y73D4[=F0 /E].G2N#6SU)K.-6NS*^]V)\W:2#]T
MY4 <>@&#3/LGB%2/^)A&W[TL054#;N.!]WIMQ[YSS1_:>*_Y^+[O^ 'U2C_*
MST!O$-I(-KZ<C#G@X/4Y/:G?VO9$?\@V+'T'M[>P_*N&TRVU2*;S-0O/.!BV
M[5"@!MQ.> .Q _"MR%\_*?PKNR_,YSK>RK23OL_,Y\3A(JGSTU:QT+ZS:RL&
MDL$8C."P!QGKVI@U&PX_XED/ ('RKT/X5SLJ".V59[O'S_ZQW"=^G&.U1VL<
M^#LOEE5HP =V[!P.1^G6O?/,.I?4[22(QFQ4*?[IQVQV^I_.D2_LD$(%@I\E
M=D>XYVC\:Y=X=356/VU,;O[H7"[A['MFGE+U20VH(K= "%Y/Y>G;VH Z:.\L
M(Y?,338E?  ( X )/'''))I[7UE(<OIT+';LY4'Y?3IT]JYRWBORCE[R-\D%
M"BCCKQ^/%+!;ZBDD1EO%90<R#8/F&!@#T[_G0!TT6I6\)8Q621EL!MH SCIV
MH2_MD+E+*-=[;GP -Q]3QR:YN.VOC!,L]R'=QA"IVA?R%2R6][YKM%=[59@=
MI .,*!QD>HS_ (4 =$-0@!R+1 2<YP/;_ ?E0;ZW8@M9H2 %!(' ]/U/YUSP
MBU$OO^TH0&!" #!7 R,X[\_G27,=U'YLRZ@D &2/,*[5!]<B@#I$O;="2EHB
MD]P /7_$_G20W%I  (;**,#IL4#^GN:P$2]ED7;>H44*KE=IR><]N#T[_A1]
MFU(1$1Z@#)TPRJ57@^V?3K[T ;C?8''_ !X1*>?F50",^A'(J4RVK"/=9QMY
M:[4W ':.F!6(D6H;)E^U*7*G8Q4?*Q/'&.@&*1K74FC ^W9.06PJCOVXZ8__
M %T ;@-EM5?L,.U6#*-@P#ZCCK2@V?R_Z%#\O3Y!Q^E<\5U!8CYFIPHX7^/;
M\I'4G@9ZC_/-:5DDJ--YMSYPW#:>/E&!QP!]?QH TG>VEQYEK&V,D;E!QGK3
MI'MYB#);1N001N4'!'2JXIPH <MO8*S%;&$;AM/R#&,DX_,FI"EJZJK6D153
ME04'!_R!3!3A0!/;F*("*&%8TST48%6:J1?ZQ:MT 07O_'C/_P!<V_E7*:>X
M-NH&<C@^U=9> FSG !)*' 'TKA88KV!LI!+SU&P\UY..Q#H8BG.UU9I_@=V'
MI*I2E&^MS9].3@=NU5+]U%NP.<G@>]-^T7>/^/*7.,?=./Y54FBO)F!:WEP.
M@V'BL<9F%-T7"DFV_)ET,+)34IO;S,G4F7[#)&TKQF4;%9%+$$^@'-8BV-K]
MFB/]NG)4C<[\.,IC(+=N/^^JZ>?2YKE%5[><;6W JI!!JHGAB*.994L9PR@A
M>&XSC/\ Z"/RKY^FI15K/[CTI6;Z&*!9I#';V^L0A1;)'\H!9PF>00WUR/Y5
M7>&WD'DVVM$W+;2%FD*[AM4#U]0<>K5OIX3MXUVK8S[<YQ\V">>?U-$GA:-X
M7C6UN$#J%8JIY''K_NC\JU3:>S^XAKT^\ELI!):(02=OR;C_ !8XS]#C-7(5
MR^>PI5L;A55%MI0 , ;#5I+2=5QY$G_?!KHRS!2K5^>2M&.O^1GBZZIT^5/5
ME%I;."R#MB. /W&WG=[^]5O,T^+.!(I=3&P]@#_@:VC:3-C=;N?JAIJZ:%&%
ML@.<\1=_RKZ\\,RQ;Z<L:<O@80]<C"]_P7K4LB:<9P7=M\QSLR?F(;T^O\JT
M5T["E?LAVD[B#'D9Z"G?V:&"@V0(4;0#%T'ITH RB=,\E8)&=5+$A7SG/ _S
M^-(D&EEV\N5WV+DHOX<_RK9^P9QFTZ=/W?3]*>+ <_Z(.1M/[OJ/3I0!BE-(
M<^6'8L'VMMZAL'@^_45/Y6FSV_EHQ=8%&0IY '_ZZTQIJ;=OV)=I[>5Q_*I#
M8AE96M 5;[P,?![\T 9$4>F13+*ID5P5(^4]?N@=/;%2K%IL%M(^]UCF0J[$
M<XR2<\<<L?SK5%EC'^C=.G[OI0;!69&:U!*9VY3IF@#-D_LV.-HG+N!)@@Y/
MS8Z9^AS1(NF6\T@<M&5(8N> O+<#\S^E:4>F0QL62R12>I$0_P *D.GQN6+V
M:,7/S$Q [OKQ0!C&#1Q@N[KQ@%LC/ 7TY[5.BZ7<W98.[32A1MYR/ER#[<#.
M:UOL:L,-; CT,?\ GTI4LT1MR6RJWJ(\'_/)_.@#.M18.L,,9D1MY= 1@Y'4
M],>GYTQ1I,YVIN(V'YTYR!L7'_H-:Z6BHY=;=5<]6"8)_&D&GP>68_LB!#P5
M$8 QU_H* ,Q1I3RG;([R KP.2N#P.G%:":I:LD;AFVR#*G:>?7_/M4R6,*9V
MVD:Y&#B,#(_*@Z=;/C=9QG!!'[L=0,"@")=7LF!*3;\';\H)YQG'Y<U=@F2>
M/?&V5R1^(J-;&!5*BUC"L<D",8/&/Y5-% L2;(X@B]<*N!0!-%_K%JW56)2)
M%R#5J@"*Z9DM)G4X94)!_"N3LKO6;^7RX+ASCJQ P/TKJKW_ (\9_P#KFW\J
MS=(@C@TNV;&?,!9O<XX_05YF,I3JUX14FDDV[.W5'90G&%.3:3=Q/L6I?<_M
M@>;C[NP5D7MWK-A+LGN'&>C #!_2MR_TV.]1<2,DR@[?+X"_6LJ&*2Y\-W;7
M#L[Q2$JS'., ?_7KDQ=*:?)!R3LVGS-WMT9O1G%^]*SZ;+J9W]MZE_S]O^0_
MPH_MO4O^?M_R'^%<Q<C5_.F-OEF#9C#,@C(QP#_%G/6HXIO$)FB66"!(ROSO
MQ\IR.V[TS^E>(JV(:O[5_P#@3._DI_R?@=7_ &WJ7_/V_P"0_P */[;U+_G[
M?\A_A7(7/_"0IJ5V]J%>VQ^Z60IM_@Z8.<_?ZD5*\GB$#Y(;8YD/X)DX_BYX
MP:/:U]/WO_DS%R4_Y/P.J_MO4?\ GZ?\A_A5A=7OF&1<O^0KC;!=5@OXTO)P
M\;@D@E<YQG@9Z#IQ6_"^&QV->AEV.G2K<E67,I>=['/BL/&=/F@K-&M_:]Z.
MMTP^N*5=7O#TNB?IBL*6.T>P55\SR?,/*;L@Y.??KFH;1;$RP-'-()%4%<_+
MD 8Y'T%?4GC'3#4[W_GX?\A3AJ=[_P _#?D*YAK>Q:1&6](VD!ANR.%*_0')
MS]:<L%C)(\ GD,FXIG^[^[Y(/;@YSZYH Z;^T[L$ W##/TIXU&\_Y[M^0KFA
M%I\:'==<!1RXSP"&YSU' ^@-$=M8[G7[7,&;Y02Q!!XY'H>U '2C4KG=M^T'
M=Z<4\7]U_P ]F_2N<@M].AD$B3AFA8;N,X).!G_/%:GVRW$9D,JA1W/U _J/
MSH T1?W7_/9OTIPOKG_GLWZ5F#4+3RWD\]=B?>/I21ZK9NI)EV$$C#@@\ '^
M1% &L+VY_P">K4X7EQ_SU-9WVVW$_DF3Y^>,'MCO^(I8K^UFD\M)5)ZCWYQQ
MZT :(N[C_GJ:<+J?_GH:SA?V_G&(/D@,6(Z*!P<GZTG]J688KYRG[O/;YC@<
MT :@NI_^>AIPN9O^>AK,&I6N)CYA_=$!LJ1U"GC_ +Z%.@U2TGD1$<[G^Z"I
M&: -,7$O]\THGE_OFLU=6L2Q7[0N1S]1ZBI$U&T=P@F7><X7OTS_ "H T!-)
M_?-.$LG]XU2CO;:09648XZ@CKT_G3H;^UGD6.*=&9@2 .] %^.1RX!8XJS52
M+_6+5N@""]_X\9_^N;?RK%T&^CGLELW8":,Y0$_>'^<UN7*>9:RIN"[D(R>@
MXKDAH@4@C4K0$=")*\K'2K4ZT)TXW5FGK;L=N'4)4Y1D[&WJ$U^H6"RA+-("
M&=DP4_'I5#4YXM.TA=-C</,P_>$=N<G--^RWFS9_;<.W_KK54Z)N))U*T)/4
MF2N/$5*\U)TX.[5M6M%UMKU[G12A3C;F>BUV>OJ<A+I$YO9;B&\>,RR;F&6Z
M * .N.S?]]>U)<Z1<SBWVWS*8(2@!R=[$89FY_+ZFNO_ +"'_01M/^^Z/["'
M_01M/^^Z\OZKBNWY'7[6CW_,Y%M(F\E$2Y 8&0,2#RKG^8Q4 T74MW.KS;?G
MX!.>1@9/^&,8XKM?["'_ $$;3_ONC^PA_P!!&T_[[H6%Q:^S^0>UH]_S.9L=
M/>VEDDGF:9MY,19B2BGMR:U84YW'\*T?["7_ *"-I_WW4XT< 8^W6O\ WW7H
M9;E\W6]K66VVVYRXO$Q4.2GU,>[BFEM]L#!7SU(_SWJ!;>ZC,A"0$*/W1"X.
M<]3^%=#_ &0/^?ZU_P"^Z<-)'_/[;?\ ?=?2GDG."TNL+^[M?0C9VQBG0V=U
M'Y8$<"E1RX R3@#T].*Z(:4/^?RV_P"^Z<-+'_/Y;?\ ?= '/BSF\^,&.#R=
M@#_*,MQ@CITIHM+\;P([5@6SDCDCGKZ]JZ0:8/\ G\M_^^Z<--'_ #]V_P#W
MU0!S\=E<);D*EN'9@7&T8*@=.!ZU(MI<$P*\-L4 8R?+T/.,#Z@5NC3A_P _
M4'_?5.&GC_GZ@_[ZH YLV-[Y9C6"PV,/F79P3V_P_#WJY9V3@LUW% S9)4JO
M0'_ZV/RK9%@/^?F#_OJG?8?^GF'_ +ZH H&UMW9F:&,LW4E>M L;7<K"%05.
M1CCVK1%C_P!/$/\ WU2BR_Z>(O\ OJ@"FMO""Q$29?.[CKGK0+2WVX\B/&<X
MVCKG/\^:NBS_ .F\7_?5.%I_TWB_[ZH IK;0!2ODI@]1M^G^ _*GK;PKMQ$@
MVG(PO2K8M1_SVC_.E%M_TVC_ #H I?8+0];:(\8^X.E2K:VZLK+!&&7[I"CC
MC%6A;?\ 36/\Z<+?_IJGYT 51:6^UE\B/:V,C:.<=*=%9VT+[XX(T?\ O*H!
MJR(/^FB?G3A#_MI^= !%_K%JW5>./:X.Y3^-6* (+W_CQG_ZYM_*N-TO29-1
M8L6$<"?><_TKLKW_ (\9_P#KFW\JQX=T/A'?"%+%"6R,]^?TKR,?0A5K1=35
M1BW;OL=V&J2A3:CNVD*-"TG?Y'F,9=F[[_./7TK&U32'T_$B/YMNWW7';ZU,
M+VY^W+&$CV; O^K'^KQZ^F*U%!F\),9@ ?*++@8 P>/Z5Q2I8;$PE&$.5Q3=
M]MK?>="E5HR3E*Z=OQ.'U&^&GV;3F-I6!PL:=6/H*S)O%5E'YA13(BQ;PP8#
M)[#V^IK>P#U%<]#?ZIYURKZ:CJKD(=I7*C?[<GY5_.O$I1BUJMO.QWS;3T98
MD\36$+[)!,K?/_!UVD@_JIIO_"5:9N5=TA+,%&%SU /]:C;5=0\PH-(8KM)$
MFTX^\!G&,\CG&,\4^SO]2FGABFTL1@E-\K<#[F2<?48_&M/9Q2NU^*)YW>U_
MP-2QO8=0M$NK<DQOG&?8X/\ *M&-MR^_>JHVCY5P,=AVJ2(D.,=ZZ<LQ3H8A
M)?#+2WY&6+HJI2UW03WWV>T\]H7^]MV,<&D;58(P2R2 #_9]\5<%(PE,D91E
M" _.",DC';TYK[(\$J#6(-Q!CDQC(.!TQG\*F_M%!"CB-LOG"DCL<5'(VI)(
M3'''(ADP 6QA?6EWZB 1Y88\@$8Q[=^G^<4 2)JD9* QR#< >1Z__J-*FK0-
M$\NQ_+4@ ]R>?\*C2?4V9 +954MAF8C*C(YQGZU*DFH;CO@5L*2#D#YNW>@
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MRKF=&U.!;9]/O>(7R V>!GL:Z&ZNX%CDCE#8)*8'4\=JP1;:,1D0SE>,$/\
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M?,2IR/8]:0VFBA<F&Y' (SGOTI_V1BO[O]?(7UVCYG(V=K)$6FN'WW#C:Q&
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M4T94                                  #VU@ !     -,M;&-M<P
M
M#61E<V,   $@    0&-P<G0   %@    -G=T<'0   &8    %&-H860   &L
M    +')865H   '8    %&)865H   'L    %&=865H   (     %')44D,
M  (4    (&=44D,   (4    (&)44D,   (4    (&-H<FT   (T    )&1M
M;F0   )8    )&1M9&0   )\    )&UL=6,          0    QE;E53
M)    !P 1P!) $T 4  @ &( =0!I &P =  M &D ;@ @ ', 4@!' $)M;'5C
M          $    ,96Y54P   !H    < %  =0!B &P :0!C "  1 !O &T
M80!I &X  %A96B        #VU@ !     -,M<V8S,@       0Q"   %WO__
M\R4   >3  #]D/__^Z'___VB   #W   P&Y865H@        ;Z   #CU   #
MD%A96B         DGP  #X0  +;$6%E:(        &*7  "WAP  &-EP87)A
M       #     F9F  #RIP  #5D  !/0   *6V-H<FT       ,     H]<
M %1\  !,S0  F9H  "9G   /7&UL=6,          0    QE;E53    "
M !P 1P!) $T 4&UL=6,          0    QE;E53    "    !P <P!2 $<
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M4RKPRT*G5D?M@*)C$AE/K(:=V$/OO ANRFU.N$8JZ;5W JZQ7W8X6OAJZQL
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M9EG6^U7*C$(QC8*I+ 1Y0E&A761#VZS>[*FZ"B0J8]72U4)@+)78XR)??H5
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M#$9&)3M6TZTE,B+&F,I]M:=HHN4PJI3UIW46=NM 70^Z:&D!A:*K*9R("4S
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MV<CO6T>,DQ;1'L!B%(GW"+.L;A?0VPC8VW":"G3Y)/<WUB?6S_ZV 1!2.&W
MB'>=?, 8 L38J\'TI\"(L"5?)-N@I@FL_"S^4]9*G6G0!*LFF$0(:%ML--(1
M"B(;@2Z^37N*PIE<*&MK6M)UZ,.?!7II2O;%DX#,V3*1#C#;2/(.LD8+S/)
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M95RVZ]Z.7JW#AU!%_$-4^6_2-XYW P#C$HE7T6DUKRQ4JE6J9,/=TMRKPI8
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MR:3EOE0;H%\;3GV)%4H)1WFGT#)V7VS5EP7$%P&'-;9*"J@N"O A7B*\\&S
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MBPV^O.?;UZ+B #=>'P;&LD?=-7?#$]G51J$X#I(:7;F5'TXT7CP,&OO[Z=R
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MNXY?+/7QG[Y+R*E"*CJ;)%#YTG*OZEE6S$HUCKWAWJ7N'\Z.$Y^QS%@T8*Q
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MOHT_7PL!N.+K6RHI8-&W*76P8:B0IT*Z;#ZBV#X9GO ODX3:7=\RYEA<$27
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M+MTCU'%M4 P D1$4^R(GNB9]$<(L(8#$65*>APSJMB7B+%-&?:!@0G$_)/%
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M5+U[*)LC3C/CU"R68=VGRMCKE*N08E@CBL5-?M"^J-*"W@$[3W3H7+F-FTA
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MLZ1K,1K/R1KZ9_1'?^&?[/P3:7O5Y2F<_J$:\\$,_E#(_/&G&/(_10NI4_\
MW!0TZNXOT!$@R?D&->)VUBMI;$0CH]QJ?Z-EC6=(2?ONO_J^\3CWLR5BP4.N
M-C1C/R%AZ80B)]XD?I,+QGW^A"ATDJ]2(;^B3,C$?HZ%^WC'I*-"[.!G_P"9
MGG)__+A QZ5T0$OUDUIQ_,7&+QMH+US)Y@RBI0Q:1L6>DN0AMET$U0J2'4B?
M$6\XW=,#VSQTNJ'6D=THZH=;;Z=25NZFGZ=NG'3%ZB*"(>F+ED<&$:F/3@MT
M$$=YCIJ,=Y1'"LCS!=*I4?9"FF06QYL<8R>T5*B2V@ R;"TT 8UGCENN[KOG
MFF^&.QC:\ Q4,.M-H&/(F#(HE<=Q+AA:S'@TUF+MG'1:6JAEKV&=%D164VL>
M8@\EP##B4S)1TRF8F?:,<93F>O:?.)PSKJ+[YK.%JV8^1BU )D>JS;)CMD(G
M?^3Q1OILA%?*5DVJ<O,4,>FPL6JT6V1.2D2C4--PSW3P"R:L6'ZI9- 3/_AA
M)01_^B)XV==75B8'9U@ZL$7O1V;M^I1[V--9CT<9*RK-XW$S37U'9&YT[E;'
MC!1U&/K"]>YFW45 91N=(1M+WLHR.697<]MFV-=Z 6F;..!OXA:LU5L:-*U8
M1HUM3=JJ"'41F=/NMPN+S]CERZUU9L9*O#),5I9O.N72:ENQD>G8T9U&-=1U
M&:==M@[3ZU6LEMMG<RRY"@6=DX]AO,9:4?G%/%2I3Q->M0Y>38SEEJ*(=9^8
MO=H[$M3NG+7MK"=K(L&#*>T,HZ=XR/ X;'W0O8Q5!]JWD#Y=K8^[A[-*U7MU
M*UYBZJ8R':B)_:*5H&O/H;IGBFQBX(;W9^P*?7/K=AR.0>61) IT11<I8IR-
MI>V8!#*]>9VJUGR/C;5RN/-%9=:MD41K& LT3(LA<$]I"LW4#6Q 'X6.JM&/
M$V.$W\@S+8K$KO5<-F^R=0+2%XVK9[=D5DL)<I%W,DFK:M*$MM%/47,"4EQ2
MNNN91G*BL[D4(R%T'M8S&MP@]E9>+I]H93'-2]-&TU<:A"9F9#:4TLC37>;=
M7D/=.\F=JK,%RDCVM>*"$N$-L=" B@MND-T4/?!<88Z&0S^26&"R7E$\MVEJ
MJN1*:FY4MLJ7V:Z7G>K37JN!&)[MHZWEY;)9ZI>'*5PP%"EVJ,?:QG9Z\P<)
M0EB;8,L%9C)->4&F!B)V  3.+V7\X[F4[-G[ZL98Z\XRC4Z%J7DM!+BK54AH
MUXP[:["*R,QIU-T\<F];(\P6V<R8/*JSXV[;3@7AA@M5F*#8,8ZR-DI4L@VS
M,>;TF>.5ZF*M9:>ARYS.O)@\K+6U\O2P5?HUV]=>Y9U+<3V97O1;N@-W% <?
MD,[=NYSDS.LL]KL$_9FZ^,0_'OJB0"O'V2M.-8K':!1$!M\'$QRL60L-1RA:
M:V)JV4J'*1<J U?G4=^7KU>TDM(@PQ9MC84SMG($60FWBX36$%LN9+(N1D=Q
M]HD;F1HTB")5MZU4.ITK$;_!KIP^BJ]GT+5S;:^^DX?<==Q^&<R\VL^JPED2
M$66S3FU9J=0NSFPYVCOF.8(K6,A<QPN<'+-W(2<W["II:GHUP@UU=5Z=E&PT
M8)@:]Y0,3QR[1IY'*U+J>4<\.>M>3K;>PYJO1PZU%<7TAZU]%GMC5I7.\X(V
M+UB8X *;,@6*3EUAE\SY;S#JKD%CB-<U\@6+\HT*PW!@,B"Z[0!\K K.UA\7
MKMD[66L+5D74.PMM>4'4=WXFH+EFJFRZRL-=+TU-S @3$&3'?D\:VSE'8NOD
M>1\A1L5<GE;7G[&7:C(0C)7*5-[%I!*VN4($NM8U;N&?#'/2<)8S;,P>0Q-B
M%6KE]YS@&(QJ\CD:1RAVMI00]:WH!UD-AB"ID>$JK9B[.,N<V\MTEV*%W)7+
MM>H]LQF%AE+]"HWLIATM9$&=E9+QZH]PCBMF5?1KI<R'JFUD*7E*(K$M"79B
MA6MOJM!LBX.HA@V6#MD=>^,KD0^^*AF<SR!1+"4;ERTPV9"O7S8M26H0AEVM
M)5&C+>F<,L"[9!-F(KKY;;DW6*_(]P[D12>,!F0N81+XT>H 9FJU:<B:41,E
MU)]Z6X>+'WJYCF.Z2N3;9U;N3*TU89=&9QECL,6[:5S#+@IE.1J=X(@]\0,\
M*S5MEBJGFBU%+ES&M6W:*L9685ETCMF%';?%ML-9(BVHJGIXIF)Y@A^1S]/*
M*6C[R*6+Z_8L@79 (=5*4:;SV9/J(R2[9#"*,++P+*3XYQMV#R V+F:7U5MM
MN.GN9A,0;F54GYN-EB6*6U>NU:X3$Z!Q.0;&4LU.1R/#Y:F*B8?-!7S,$9)4
M0&ZT^K5\ELU7YL+%VS)3YDM.:'V\MG4Y&KRC@7C9QUIE4'YB$9:TP_"$Q:&L
M\H2JH6Y:T[5D,Z\66V[&7J8MGWAMS#J"VA8H8^YALD[,MH[%RU&[(C2'(,0)
MMKID^X8UF.2AHY7F5V)!'.O^DBLW*]PP).&A=>,BU(/.B1[IK,_UTK(1,H7/
M&;KV%7LE?Z/,&*'J=7RA9JIR5NE7>?3@'6'!1@&STXAER%^'QMUXYQFNRKS+
M5/D%M7ME7EFMA*M7)52?*Z?8Z]95:Y?9)RY3.D5VD$=+J;"CB)Q3+)O9BV9>
M\'9XB:RWT*M2Q6&XL8MG-WLW1126?XLOM+_"0UXXRS<2H.V4QMU,.[&59"+5
M"KTP3>QE)TEYR4=3LJ2F1)J8TUUXR5GDF]S%F23R@P LY.;MB462R]7MX4;=
MFMUO*8TH8TZ@*;TGB)"N63(<9!P\R,KX4+N+T.;W,%TI:':2R%-N>9BZ]W'5
MK0=FZA*38BM: P9&EGI\95N.+/T)'D;?1WV'Y"Q&0CF,ZL9"K<=52ZR;:>AU
M6.K*=-79)HB(UEV-3DLA6H)QU4>6KS\ME@.WDS)W:SL]@QEX<I<&QTHFG9)8
M]BVPH-K"..5+N6LY! XW.8=^6LXEMNJ"MZNG:M&NN)-%$/GP[@_%X/2=._C(
M]+)<P1S;&=6/+F'7VGR+;Y>[57&HUM?I=D?2=BR8_*77M%R;N^"D#"!XQ%FZ
MZRGEYV-RU5S 2Y]7RI-O'-QXV!2!F#FUEW%UB*($C*5:[SB..7LG?R&<<UR'
M$OE_M&6PF4M.\MV=C4-KT;*;]N:8K3Y,NBCI)&)ERP=)< NW<;2R/WQ6NMC7
MW,JQ#.6H<Z*X+Q 8R<6M!TN@09*+^H6H,VLZI&'W3_9^#D]/3UPT_7T$\5K,
M3YS9"K$>T7KC0]?_ #>_C]!<6*KAB:N4B6KB?>38V;+2)_2T(%P_G><T][QT
MP#M]8>Y4]05VU#[%GU-%O@8[H9O!FGOH*?%PQ5&FSM$2:Y.SL@%D,R,SM BZ
MFDQ^<,?KCA8M(FRQO:;CI_V8SN.9]D;NY81Z.^!CB2*8!:@F9GT"(!'?^R(C
MBW=_):S16OL2'@7_ $8U_;QR38L8@+2GX?.G>LL2XZ_:L?6WX@K3!\ S7?H2
M1F8W3W:%Q5J1@N:(]UV.<.UVN8B&YV&<3Y1)A6#R/5[$6)G'[0[+'^LU+I[9
MX]T;F.[2=Y37SGEJV,LOZZU!3>N.NZDHM%%%KJD!O$2W+  @O#P^KA\5B[>(
MY1Q;:)QS&5ZKC[64Y@K,78LTRKJ*;+Z-;0%,CP(;O[]9'CW,N7LQ2M>4^2/=
M =AKCA0\JS,>G'OG'W56)7 G4Z/F!=/IZ,$>DGIQS&-A#JY'SSS*T!<LU2:C
ML*V-&#B))9_DG'A+V3QSO[G+^7<_:Y@S.8S7D6:>.:_'9&KEW)Z-R+X^82M0
M 1NAI#,=P^G=MQB[&*O\R96IRSR[BJN%M8;,6<6=JHI*[!8'-8RTH:#XF)ZS
M'JTW>@B]F>^^.CEJV2R3\>?*M^GA\MFG8^MTE;:V'NX_)5:M%U(_!;AZO/R!
ME)%KI/N@W\TK*6KF,Y<Q 8W*54O6X\B6&FO:R.,1NA+LI$Q,UPF6=%I[(TDI
MGA^,^]KM^.\BM#)\Q9/"93%66W!L@P*>6IY.Q:HY&VR8W]IKCX27J,Z<="C4
MK4D;I/HU$+KJWE[X^FH1'<6D:EIK/W-\^@?1^F?X?=YC98LX]W8N;*>/Q05%
M6J+!$,M2B$V+,V'P2B4S:S:J#+QZS(E Q?I9"M5MY)%C"KI,QJ;YUF+SMAU9
M)-I:V+DLJ-KMW*0PIM1T^GT2/:.3.]1=5?CS,0:VC>QJ<@$5(LB]-._^-I$2
MF4- S;XPF0:0S'&%R]^MBHH\PHLS512.R5FI831M7$RYAF2KB&=ED7] $E4W
M;I-L#,QA*Z48BMD\WBW9P9;VQU6E01V-79MBW+==N,=;&=ZSKJ0B)(A9(Z'V
M7%UL;7MT*QV<L5YMAU=AJR-S'=#'&B4D2&-H6#*^W<%99(@Z[)9QB*MC:PHY
M11F&O-QN:;9M/4R":4^<0O8/GIB)[XF9C6(XKEC48E1)P^)RN0[<=L@:65BP
M05Z?1/6LD%UBGMK^TCO* %!;2GCF8,G9Q[:-+,32H*J5GJ<H>PX^UL:X[!K>
M,19+OZ0,)DR6L+VK&OBU16=3R5S)8O'VPQV6[,B]14\AEN282Z.0T:@U6ZM3
MH,08F(N;MUX7DLU9JOR%W NN=>BAM09$Z1&!&!N=Y^#W%+%2"_>[%CIQ4J4<
M;<R7DG"X([T#C,OD+.2=;H+L2"+M6)JT3$/>-N]>'NF8GHB),XI402NUC[^7
MC"1*:&3&479IV+6CLRS_ $4=A3*Y(?1 .HLBUAY2)#Q;VLQF(SBVX5PXV]B\
MJ-BI5NYBKCK F-BRM>15J[HCDJ9+2<[]BHDEF,7LA V;TDBF H59BJ>0L>$2
M./QEU6@$P37,.62M(3&ILD8F]>3>9G9Y>RW9<^9@U-FP%CI^>P29@1Z8V+"U
M4Z)Q+RKJ9K'6T)@9JX>/59>A#E[9L6:>Z\T!HH#L_4?=<4.2J!K_  JU.Q.P
M2&>,Y7=7Z>3PEE=6.I2OXQ5EEBE%RI,T,@17:L>*%'!L/7WZSTGNHL=76&,\
ME,G+7>J>^AS'T7V%8>(GNA9KI6_.L[Y,Z@#WL[VJ#!/>S&ECU9*G6Q.8M.=8
MO)398M&03NHT"IKL"&ESK188LRWUUS$P(HQ%QV)/,NPVHXG+]9$*<54\D[*D
M/DKH@P=SJ<"+%I[XL,.(7./Q"M\AC,?8?D+F1[0-G(.G)W:X^219IVFM4,.G
M<OS)K%FRLH9F>H/IGY^.Z9C]7'IGCOF9_;P5+(JFS6,@(E]5RO$'O9WI8MD:
M?H+28[IXI@NLD!QPR% 1#2*@RKH3"(_(U3YN?]WCTSW_ '/3/=Z/N>F>/3/?
MZ?N=\S\_W>^9G]O&NZ=?EUG7CTSZ=?3[>.Z9C]7'=W?JXTUG3Y->[CNF8_5Q
M[Z>_T]\]_&FLZ?)KW?=/]GX.4_XX?\NGB2TEE1VD64Q^CT-7_P#<#^D/AGV:
M026PY);2%BRVM0T>\2C\I3ES\OZN\9[]C$#D CWKTL6A\Q[.LELBO=\I*9I/
MIZ8^CAI,6FJICFLWL<!S F9%'@5)3,Z3^K7V\% %$F4;K-MN@R>W^9:Q]@Z_
MIF9GOX+&XX]:VNEFQ'^OT_U2_P#[6OOR_+]$>'T\:>SC36=/D]GW/U>CC36?
MD]/LX[^_C36=/DUX],_/QZ9^?C]7'?,S^N?N0,>WB(CV?=LVCH))]PT,M'._
M1S:S%M2TU[^GU08I9=2!@ID!W3/%HK=)%B;R45[<L'O<FJ9MK#,Q,3'08PV*
M()$P,MPEKPZE13V93X=NT)C"ZCERN6D33,R+33\KV:=W%9:J2&V44SIG;D3B
M6"\9"T0))AJKS9$B%W1B)(9D==)GBK3LT$LKT8V4@B6+*J&SI[$M48- )#PD
M,'M*/?1.D<4TNQ5:58]<HIB&]/006DDB)28$23D8DULDA,O$43/?Q1JLQ-;L
M^,1-6BH>HH:]4M-U4>D8258MHZI.27.D=W%-9XFMLQ]==2H(=14*J)+<JKYI
M@=1"R[P4W>(]^GIG6SDJ]4$WKH@-IX2<=>%B !)ANZ>\06L-\!![0$9G2.!R
M:L77"\%AMM;XZGFK3]W7>I<G*E,=O/JDL!WR1:^F>'TZ5-=>I9ELNKA)RHNM
M$BR($B*%@0S,=->T(B?",<56LQB.I22BO7():K:BKI-9)PI@0Y:)CS0M@]GL
M[IF.(R98NO-X;7;1=JWPW.D:9M KJ=$7DIA@3!7!%!3KW]_%M*\4CIWD16M"
M9/;U*T'U11!-:9K6+=&B*I#:R(./%$3PFM5&4I0'34$&9;0CV;S(C+]9%,\0
M[L:I9Y19E]Q1)?Z3<F*[+TC,R,V"2,+WS'='HTGOX+$%11.,.2F:6A=&))W:
M-0TG<O:^>JOID/2/25[=(XL1BZ:ZG:V+=:()81V&J7"5L<QAF9F*X@(*2]['
M%JJS%TSK7L@.6N))?@L9(&+<%ML>UHL2LH_)\.FFFL<!D[-!3+X=*>T[FK(Y
M1.J)<*V #Y3_ *N6B>V.[T=W$Y<*"@R),)Q6 )H[G&/3-\I%D(EQAX2;T]Q>
MF9U[^,=T**%>21>&-D(F)J!:W=I6J==>F[=,FLM0DM"TW#$Q_P#%G^S\'*?\
M</\ ET_<ZU.PQ!^W9/A+]!A/A./UQQ$6*U:SI^5&Y)S^O;J'S!QYG'UUS\K&
ML9_-$+XTMV2Z7^P7YM/[0'WW_KU_[_=/I+^:/X_^*G^S\&U>\H=+M)P?3[/N
MVZ+ --W4C7WNOH]O'QI_9?\ -X^-/[+_ )O'QI_9?\WCXT_LO^;Q\:?V7_-X
M^-/[+_F\?&G]E_S>/C3^R_YO'QI_9?\ -X^-/[+_ )O'QI_9?\WCXT_LO^;Q
M\:?V7_-X^-/[+_F\?&G]E_S>/C3^R_YO'QI_9?\ -X^-/[+_ )O'?D]8^3LW
M^;Q\8_V?_,X^,?[/_F<?&']G_P SCXP_L_\ F<?&']G_ ,SCXP_J/\SCX?\
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M\]VW#7D^5^F:WK@\Z_M>1=TK#!ZK+>T.U++_ %#]@[U0/=K$_<UCTQQ!?/\
MKX?@Z^9N8%CGUG=OH[NK$5V;Y24"Q)$IGMB&#XH&>^(TFG5)S+)5:M>L5EW>
MZP2$@J;#9_VKI'J,_P!\IXYWQ\W;%8\AEK;*U >3[.19D!.NCIBC,[.@H+AA
MT>KK^+:R6Z)'CFR\ Y=%\ PB*%)5MTA4J%A\:>63B%L**K[8,FTH;109]<)V
MF)Z\9,L(G/6>7S#$J861?S$LJ]X[K8NVDEX^82K5Z?1G(JIC(,+;"(GSTRD<
MWY;#EZOG\L##H^7HL35*LIF),V'IS"W$]8WP,][>KT ='1$XX5*UY-7+[.8.
M9VV)R<Y]5Z>I83Y%=;+""69.JQ':=A3NU9->;4S/&&?<LY+,68J5^SXP YFH
MPV/*#C4:KE*(!F0[*256QYAA2R776<E$N:/',56%9)-L\S>MM&XS)/KE4LV.
MM596=:-M,I(6>/LI]36)AL>&.,VBZ/,K>;68/F5>03/E0\4;64K8J%"]9Q$U
M&:J'%#3&;,S(0<;Y/A5/?F45#S7(:#[*=JOLQ_DBQY5!;%Z2FO+A6%X@D=I[
M=Y">V>/)]$LK-&OSMB9JS8?=M_Z-LX=K+:F6WDQSL8%Z(D^LUBUL/9)1&T8L
MLFOS7=YK#%-\MU7/S*JDVC8L+) R)[$L5[F/I>0XZ\UER"H@R$>+2"5<=CZ_
M-7)UK'3LSS4](PN%DG(9GPC)2E; 5U^I$*0?O8&#\6(K9-^<'#LY>R-BPK#G
MDH#M09% 5W6QQ,]N[H(@22O#NG1_@TT2N:V7&^K$Y6QA[37\Q]N?,7[4XFL5
M?"054LJJ@-5C2S<[6Q(K.3+K1//5Q2LTK.Y;E.A:QAURRQJ;85AVKN]G%9'2
M3<1;Z8J3,+L+*9[,.A'PX&V6U;!96A.$;_\ J1JIQ$!4W#V>D$X ADNUA?\
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M;8U,G2&G JJ6V+ZHK)9I%1$0>+<K?'LDM>[CLQ5D%7TT[/*%RG3Y.E([/Z/
MH93JFD/>).LHE!\FQ<AM']D<0(Q B,:"(Q B,1Z(B([HC]$?=[_>EZ?W_=TU
MG3Y-?N5\>[(5%9&T!LJTF6E!<L+7ZPT5R.'- ._<0#,1I/R<6;KR(4U$.LN(
M=2*%(6363$>DIVC.D>WBLKI9/'MNH*S1C*4RI=M0"H>9UF=1JRV(GK$LC!G3
MU/9(B4P=A-^HVN!]-CU6DFD6>C8;!.0$]>[:4Z\6Z-?)4K>0IT/*4X]-Q'6.
MN2WL62Y(X7HR*[-3W;5#HQT@LA*:8/LHJONK!E>JZTF'')#!;5#O\](ZZ22=
MPSZ1F8X.Q;<C' #;2Y[7<JC&RM9*O+M\-Z< PA@MLEO7OA;8%FL<)-]ZH@+.
M@US=:2L+$G[V$D9Q#=WL@-=> 38OU$-(@!:G6DK81MUE0@!G!23-)Z<1&IZ3
MMUTXN8D,G4+)T%+=<I=H#M"%- F"9A):[=@23)C7IQI+-NX=0RE-M2VP$LIA
M>K-6[:F3AC:\/411MZD09AK[Z-9X<=6]5>""D;!HM*8*2'O*'$!S"Y'TS!Z:
M<2=7(4["Q&6D:+:6@(#,B32)9S$ )1(R<]T3$QKKPMM:[6>E[)6IB+*FK<V-
M9E:R Y%C(@2F0'4H@9G3NXKE9,]UJRJE52H9:^S8=.@J2J/$6@[F-GWJD@;6
M3 #,\-PRZ68MV*I4PM/J4>M0IS>7U4=HLRX-GFO.,V@6P?EXQ_+_ &RCC[%L
M+#<;C):"9<(N&7RA4S$:D^SK$>^:PRV04P6EG&S9JV6BH@MT>NIC04T=I"^O
M!R8 8SI.X8UB>+M(J&:*KR]%2K;=1QG6Q]$65T%60+.N&NU#4QM6LMNL#&L]
MW#<=7I9ILUK1TGWHH_Z,1:2,$U++4OU$DS/3/S4[6>']/#OQA<17^$>='1'@
MAGG_ !>:\W,,\>G@F"]$Z\=C"[6.UTH=V4;*BL= HUAO0@^ITBC28/;MF._7
MAXIOU'=C^%"NTEG9-.^>T0)ST--)UZFWT<*W9/'CVEI)1K=KQVAPSH2DZL\Z
MP9[I -2B?9]TU-B&J8!+8MGB UG&T@(9[B$AF8D9[IB=.&MQ>,J4FN"%L8A>
MARH9W"G=.LBD2\0I&87$]\#QWS,_KXTUG3Y->/U\>F?G^YZ9^?B/T>CC76=?
MU\>F>_T]_IX]/&FLZ?)]STS\_#%-$6*:!+:LXW P#B1,#&>XA(9F"B>Z8F>&
M-Q6+IT6. 5,8A6TY2$[@1!3K(H$O$*0F%Q/? \=\S/Z_P#_9^#:W>][?6U_5
MLK_<L,,"$'+42CF/"<"N!+;/MVSW3\G%/].(QFGZ?,>S@?\ S#_^4<6DJ F-
M.RD1 8U*2Z:N[3A8SZ8 8G]<#'&/_.[,S7]74[OY]?N^YK:\I8K$=)/,O^D,
MW1/(XVOJ./C\8JK\3-_O _-.8+V<>ZH[%Y(+%JSE^4K'WV\M*M8G%M)SQ3-*
ME4@4E78CK-ZVPBZ\;^I,QI)<J\N\P\V<U8KDAN&NWW9X<I;B]D.8F%U)JW<J
MA+'*4H)@ZM72%[9D(B8C6.6,?F,CGA"]F>8QPF?LY]W*=>[@<?TXH/S6176:
M]MINYG8UR(R^%Q)24S$SR,GF?F/,8[E8\[S!CL[S%0L6$WC[!*YQ%:UDE+[2
M"C%A1UY7N; QU(F8GCW0+7*^5RMS'/Y]PU:[S TWAD_O?FJP"MLMB@K*A(1!
M;,@*)=TMKMNYFG'/#<;S4=W%)N<OKQ;JN<R>5R>+NV+JHM+\K6:E&RVL]$[]
MD20@7F_#&NJ* W\GDM-7,N9:V5VZUKX$V23BTT7N]6F/"J/"/=^".[TZ?S>S
M\##\XW*SCSF#25>@X;!@@0F6R,MKQW,-4O;*IW#$;YWP>D:9:FB(E]O&WJR8
MF=L2U]9BEQ)?DQO*-9]G%4VY)^6S&-PQ5L57R<5?)E2Z['#2?,J0D.OJKJU1
M-Y&$+.=0G69XYC58JE"LK6Y34FO<LXZ9-F*R5I^3W+QM:M76KL[%"J"%C&KB
M D]L0,<R'C\55.OG.42PU6T!UZ\T;:*^:4"V*E>_I68R-98$HM A10R-!'AG
M:>7Z.=&\O [;C[5<)Q<8ZA2J.IF%A+#Z-6Q7;?J%5[FNL'$B)^.>7P=A49EB
MRY[OS4*PH-J,CFNTU;"B>!5B?TG!)*;H0[BZ9;QX&DFC7A%BOS!,5*3L;OQ;
M\K>-]7'E;R%-\%BE5V:.&DM>EGU6BX7IS%.1IU+.0R')V%P]1[B!S.WT<7?2
M^(:0ZI@;KD&+ATW%'4C20CC-#8PP7UYOEW"U&VJ]^K3M!;QM=R;=<G-0PH-Y
M,!BG;6)9TMCPD9TXS";%>K7:S?&&7:73EQ3V20W9B<<M55\38@(@@6)DB"AD
M>]XR]S)0-"D6!Q26C=9194L6\=G$Y!]1M;"TTRO%6:X36EK8L&%=D]3S0F,\
MS-PU;$8X'8+ UMV%NIMU+-BAFYR#L>_)+JQCS=9IKE6T:[0KK8(71.)D.'6[
M6,LL;=R%4YB_;Q+9H16I/5Y40FA2KI6[Q=CGI?C#E-WD<",CQD\EA>8F5;QX
M<\=BZ)8ZNP*9GWO93OS94ZH^Z6WKV8 F"  L)V1IQ+*E!HYQC<=NYOKYIE"H
M^*G3&;5_EY+BK&85X.MV.5NAXZ>>#74<!EZV/5=73KY:A8/J(79I>49H%7O*
MZX%U1JE5:4@$BR"(9#TSQR]59AJ5$L!?MV[G,*;:V,RZW+N!(K5"XMR>0*RM
MMT;C"!4JG;OF$R&%KR(QAZUR<KDYW1NL6*&PL53Z?I-<VRBXTI\.E,4S$PWN
M7:QN'=AF%G8R.3RP<Q/L8_(T2/=>$L+OE$VLD&BYCH!-9D]?K3(]XX?&V$M1
MF4(CG.JMD]:G5PS%V*K6"/JV95)^2BDB%AJBN:X):&:=2S-QJU9^YG*V25;Q
M2JLPPV-K*L*BAY7F-#&I:IC;Z3$#,"?2T#C(-LU11VGDWF7"&(V,6JFS*9$Z
MY4XHHQ]1#54?-G(LN-<Q<S["W26(+ X90W*N"QF,ZLNQ9X<3K$)M5=QENL38
M%;.HV+M%ZVND_$)$ 3$;M-VD;M/>[M(W;=>_;KZ-?9_\.?[/P<G,>F+"YC]<
M(3/%2V,Z]9($7Z&::,C]AQ,<8SN_(?'\X\4W,&#<O(DA;2B)8*-S]%"?ONG_
M +NNWB(8L&0-9YC!C!Q!CMVE$%$QN'V3[.*C&21F>19)&6LR4[CUUG]'M^3[
MC "=0IK&MK_OQ,FWYC+;^SA]RTT4UJJC?8<>NU25QN-A::SH(]\Z1P%#$<QX
MV[=9&JJPL);G:=\]$7 OK3$=\BO<41WZ<#-BJBQLUVR]"W;=?3MZ@EMUTC73
MTZ1QT(J(BOKNZ,5U]'7TP73@-FL3WQ.G&QR5N7K'@:L6!K'H\)Q(ZQQ3Y<M$
M@LG:JNR%*@VM+(*M3F(:X)E1(7TIF-(DA/\ ,B>"459$5YF3-9(7T9GWQ&0;
M=DS[9*8U]O%;*;UOQV4O5\<E^)J]O59L/9-8-W8Q,36!B2F,+6 VR'I\/'1B
MHCL^N[HQ77T=?3K*]FS77OUTUUX[HGYN.7L9T,5Y$SEH:AY!Z\GU:;IB=E=E
MA,%1BY>9YO'UV;.IH9F6@]_W-9]Z/\\_@X[EFYE$(SN643L=CCAG4LK'?&L'
M 2H)*5,A8,8)MD"Z<%IQ=O,$C"E5L6S /?&%91.(1U[MQ0&D:]VO&.#*XE^%
M'+UF6L<]UNM:K-!-+R@X'-5TYK-"G!O\82N06SSD3$1.3R]>Q%WR<M,S7!=@
M6,*RT453@>A+9J-:7PM:S1(B6PYG3@5V[M->075[5=KHBWTZRNG#H8?:4K<E
M9JF"#M(K(Y\ Q)=W%B_&12-:J8*L$Z&H8IK?4K)#EA8WO_\ EQA4S8_U._C$
MU!M.:S,LM)J$FE;8(-J").5:T3OJ,\8QL<(E&NYD OQ\/7+ZG::Y7"8JNTV"
M-6M>?2ZTFP%]XFB0L[=10_<O=,;2*LD<FB3M@@T=S.G,6HUJPQNSI5V68F)K
MJ>:V.UCIB6O%2O>MKKOR!FJDDH,FVF+VRP$@ D1D$%!%$1W#J4^&)F'4EWU3
M90#V&N1:$$%7X426& KL]F_^8[.;>C_K-O!!1RE5\C6FYKJ0 =,??V5,:(+?
M77Z',21@F>YLC/=Q%:IE*I-)-BT"]#1OJU1$K%Q?56L65 @PGM03*"U\+)X8
MU&220*966>X6K+6XX45#$&K S39<8K18 20R9\+)CCT<7Z5<#:&,7^-W(D>S
MQ;B-Y8]7Y3K*5;3L[/!6ZBULGJ%MBKE[W+]['X2WT]N4[94N!76YO158O5U=
M-U:M):=1H];H[HE@P&XXH8Y%%N1R.2&VVM6"Q7IKZ-'H]I8RU9G8,QVA4+4
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M>,?RKDFX6MB:R:=:]:HE<?D+M6D\'PE MV(J%8-2X:TNK(!OA<;IB>*X)QV
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M1G>_ @5(3H(5C^K3,A(EP_0D)&U.OB!KDNA[%N"]HFX,6%RS80H#D]D)@AU
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MI(HZ35>YY.I"-J:5!$PPDH4%[HYC3 D7T,N"ZT]W"1A;6$!JB!5U@=,YHDD
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M"U"MR R-XKQ"\'/ZW&%<"%MS]G,-%0"@5+JP5[*,KB7(;Q^T.%LT26%]L[I
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MM1GC.O*\S3@/:D,^2 ZKN,^F,3BP"(@3$)>X@2@))58J]P,AM)@#FGGAR%A
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M<UDIW34[^71E*2I8861.*<0(=]:U>06G!3?:I6#R7Q5S-391E*-QRJP3KR)
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M12EAER);$!0R!8>;(9LCIJ'Q@$1:;DK*5'8XF]I?^A>UV@=@EG?%<$UE]IC
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M!Q6#VV 1=L(V0&EP^IRA(48BTQ[M8FLTB[FS.K98JF6D2!(\K,]Q=C2!#-2
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M,IDW!:2?RN9>)W_=1O[D#S8WGH(0AN$.I"&H:A#H(;AN&X=/D]_I_2:25^I
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M4BK18"F/:G/-]]C(D07%#N33.$AQ6F8*(; 1' SH4.X:::+S+I RZEU<J=V
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M$#%,(:T*M,BHTZ 5=V<:QF)E!4SD8W#F'N1#L7US_]H # ,!  (  P   !
M     """  22002      "0""222"2              "2"2 0  22  2 20
M2"22022""                   "  2
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MDDDD@   DD$$ $@DD$ @$ D$$$  PDI0!M-M&"(  D@DDD $D   @@D@D D
MD$ $$  A)))))))),X$    $DD D$D@DD      $@D @  6S1VVVVVVV\ @
M$ @$DD @D@@ @D @ $$@$$   VX;0      X  $@DDD DD   @@D@D D D$
M$$  "'D*4CKO +_ $@ D@$ @D   @@D@D D D$ $$  @RA3MKA3VL!<@D $$
MD@D  $$D@$ $@$@$  D$  I=_P#7O3CW(@B(((!  !)!( !(!( )))(( )(!
M  %P.7)<82D@   )!()((   (()!(() ))!(!!!  -"R2,-MI!H(P)( )) (
M ()( (()() ) )! !!  ,%(P      @  )())) !)   (()() ) )! !!  +
M;;;;;;;;:N!))(! ! !!    !!(! !(  )(!   222222223W)  !)) !(
M )!!)((()((()    ,-W> 8$ETH*(()  (( ))  )()) ) )!(! !!  -G#,
M0&FN@B*((( ( ()()))!(!( )  )(( !!  #\92 XP3P:!@!))())!! (((
M!))()))(  !!  &/6T@#JRHP P (!))(!(( ( !()() ) )! !!  .G)A3[4
M CYA  (  )!)( ())((!() ) )! !!  -_SR W^B6["P !)!!!)!!))(()!(
M) ) )! !!  ,J><+LH7-T   )())) !)   (()() ) )! !!  "
M ((! ((( ((!!( !((!(!!!(((  )(!  (()!) ))!()!()(!(!!)( )((!(
M  )()(  (  )!!   ((!!! (!)()( ( !)!(())  )((( /_Q  I$0$!  (!
M P0!! ,! 0     !$0 A,4%181!0<9&!,*&Q\"! X7" _]H " $# 0$_$/\
M[6,T<61H2 V&@]2A0?A?A?XQH_+:?O7]<H4*%"A0H4*%"A0H4)1W"!6 D"D>
MQ:&++I)%1#@#@3GWM"=F"#LO 90 "K#!M'K<@#;M2-2ZIU1DHM;?Q%)BI)/2
M))P28_ 0-@:W&Q &QX&*P&_%D@ )6 P<E0N &I;P0DNCL6X<N-)*FN"EJ@0
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MEN4X5E$K1PJ]GI_$+HHTZT]45EQX7 Y*5P#2QIKFR\-VI85Y>8$#SA0!4*"
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M33\QI!<_34_:E^V,/;YM;<K\7$KU\8$&[1T99A%T8:XV=W5<@5H$^@XY8TG
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M"?-"L];[P0TX2#'3_LH,&#!@P8,&#!@P8,&#!@P8T37)L0,DG8@"<R0L.@,
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M@ N4]6GFK=Q:_+9%1^6@U(8NF0N1NYM3$@;W*,> 0:YP(1U3AA #@*?+5JE
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M)30%1T ;4H VJ3>::]A!HRE31P%#YCW;U*JU\-C/>/%08("C6@! 4!,-8/\
M?ZF'B4'HDWFH.0 IQ]D %EP\$"#W2EBL5CO-*;'6>U( 76@ ,@T5PDCV9I[=
M :II%NUD*@%=H;PI_%HH14PI(!.L:"J;&[#6=$\$KD1HK4L0-+2&@HCO$1>$
M!XG;QHL;7!+43\=D"?=<E.=K!_&D1@D#R(# XE8 Q:>PR#'0BR6FUEI= D1Q
M%1-NQ U]UZX>*_$%; 8\&I=P-!]@ZY]/$C_3D 6PWQ&(8[5]^N?,J47 )J3
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ME$B:M_)RY."7*A&^Q@0H!P[CO!'H</=04XG!5F:6;]$4(5+S$C7!'"**R64
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M*Q"(GU*UYLM3D *$(J:_)/72"QNU2#( 6$C!,(:UV.$"(C 'Q6 TZFFE'1]
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M]#]RI&1I,R+WX6,9&G54W%-EHR\_WKXRZX#6QCMH3B%5 &XDL+W.\%HY06P
M%,,B$((*" )A(6.(8(D742$VDB25LSDZMF""AIG%R;#55D*@0 N18F$#*:O&
M\I4WQ2W:4*!*$@NP/R7.VZ1$^SO%1M%0B<(8>U07Z'=WNOCFL 9E*,1.16J#
MCPA05#LKR#I:@,I< BDH+ 43AR4%W1<8R!5KX] TUHB(W!\@%6S*D]KR\G9
M86DD.6TF8L._<URW.UTAKP5R53<A(J)T"AG=GMTYA05'1:'8XFKSRS5YY9J]
M_HFKW^B=7C[F[V^R:O/#-7GAFKSPS8[G/IMV\_RK;2&V5H<!NQ)HC8T4C=:"
M?I=;P%/4QS+"ESS8@HAF,.B-[P.U0   CC75V.G+V  :CQ;(R$Y4EUS+4(B@
M4(% : Y$$#D1&$=5]+7/BT/.B?Y$-,-$3<:F8M3P&@HDKB4>V^_MB!<6C-RI
MJUB*=@0,9,VH8MFD87*Y'-,5 "O*V>*&(E1=()HNG21-1CBC7FX^3'68!<)M
MY/XXK;!4OLB&/1IM8(,A7%/*"3P8DP@10 41+$2FQ!F!QB>Q#3V<C5VXQ*H;
M[XXOLN1(3JBQJK>7^^S06,>9Y-KT<(A"&(W.9H-;441" =VN2[.?A0=:<M2'
M=J)*:33\W$PBY/D3AJY.RR.<,>H-PP:6^EFW3ZW\#MLF26Z0P1,U/5VN$^;N
MHF_ "M0#^-=QE $HX5.> ;/:"9R?5"AU  P(*&ZTY4ZZF9DN@ X+[F+HB85E
M;\?=/O4WT 58;2]5QYE$]]8C=VM*I+R C-;X_#ZJV.1(=RRVB[3"K*A..(U_
MPD .UW41,GF&W/\ B!F4: $B!ASL^R,0\KB!FK-?]*8[H%Y:>0(E(->O39Z;
MA0=2_,#7PS^;M[VP]$Q&E"KZ]VB@0$P]=\XWQ%%;$=2ZS(*F;5+X00&0"LO.
MDR%:9?4()I8&]%/T,\_B35UK*G98845#M(]8(B.C-N-*8=T:R1[/?-FIZ@F9
M*',_D0]!)O"&\T3,Q&]08T30['$U>>6:O/+-7O\ 1-7O]$ZO'W-WM]DU>>&:
MO/#-7GAFQW.?3;MY_C")CJ!@V.N4QN99YD5<$HUG,HI056\4)WE)+\7Y(< Z
M-(VMQH0A-ABQ^DO0K-&I4 D[4'<)$$^"X:^,N/1=.!B,*LBEA6TH4>HX>L,"
M03,:!&@Z =T4<@$M)C(B60#S%+R1$#G@8VO$>[L4+1KA%)+S7P[S2<<-@"@H
MRMG,$M',5H"T!  ,0 D:YED5C(J<99NB6QF6V3+1&4RC$MH ^#*X&B7 $"*D
MFC&$V&#"]#VBJ44*BJJVJN57*N5]&5.,=T[HG5&SX1B[#1%^_(K)'J+<XMU%
M CC3R-,+0*L- GNBF,X?023=61+@)^:VCEA4&HN#>S)YCUFK EDH! $--1-2
M%Q!4>CH\;3$5<P7"94VGP@QN50_"Z2,/6IKQUQ(18VCDOQ8"!U!L2N)\,)2,
MV&10"9DH%WG1%1K+FOAP?AD2LM(54@*(XT*Y*L25?<0L\@.M/#\F[#<$Q@P\
M2!X<?_HNLDII=A4P1]N+  $)9-"8F+J4.GY#8"2%F0LBEQ>L^:* (_1I31$*
M0;V3UX2)_#.;-4Y*D/P?4$-#VLBAN)8?Q-P8GVJ:$\8NW6,")FC$B[4\@IUD
M$QR$?^.LMG'D9^XSO5=6&XCVC?LG^?G7SW1ADF ^<B&A@#@P 76#MT%DDJ.7
M$>J>7&$Q$S&B5<N$O@Y1 %!:W;OFGQI$[NQ1^4.AZ<0%S#C]:,3WS:OWK(:_
M6(<# WW&@"6C0J9$ Q\<U<>@D0Q1RNIE_CH.6YDP2F.E!2@GLE">&:O?Z)U>
M/N;O;[)J\\,U>>&:O/#-CN<^FW;S_&Q:J4O5+?Z(Y$NE"0LOU($#'1+51%V@
M!: 6I'$&F,-ED& 2;/H;I0 X<]15$%H:A9(FH .&M5J%4EGHI&]G,#U/PT:)
MFT:@*0L$A[<ZJ-</)^7A@$H2OA?!2#/$.[P(0=. (M6]ZKBYF)"!Y<B3$G69
MSGVR:J)7"S->,>?:$I=EA)J,%AUS/\"EH!50 +56@#JJT$ ]!<ARK2$28HDU
M[NI(!-A0 (OT:0P&#8R0\98#4S_0(0R!F[ \)5D-8<1GXF%O$Z,M]&(4+X8^
M<E+SQ(H5=+60"$C 33RE&GO&A"*S(S0!I(<T Y"O-_%[_F:Q932?KOH=Y>:6
MZBESH)MI/J[S>;T,),Q# FH@)_2?-\.^A23PKCW*LM$KK]_R+:(J[&/^!L1;
M_P #&GLA%J3,GKT=QL(+S&ZR4XV \6F T,,)U1)1GSX/"B8R5%LY7UEP3S*5
M%S9"@+T8=P]+EAFE'.!)(/&NKEQ.HT2G2R;TIM(BVHV;F7-SUF<@2#G;T&E;
M0@$"D*+X+<J=.6>I*D(6,?*+S0W:)+*Q&,PTQ*[.&@3B;<<95:SG!+KWJN&Q
M-$!:BQZJ!.60%Y1K/>PJ^N?.*Z)\Y0!656MHA7KZNJ&2O"C5()]4<'J("0[A
MI9-8,A7)2@D_05H[8$_OT^'KI"J?*$@N6FQ4<'MHLI!O<,'VH"02D[9@@,U>
M_P!$ZO'W-WM]DU>>&:O/#-7GAFQW.?3;MY_C%BZ0?(P"U)&+8H6 0\$+:+3H
M($T3N3$LO;U LO I;72\H=:A.$FJ( D835L*F9P)2J62YLLBJ)]"- _[:7I"
M[<G' Z4&/=PE" T4D//$<)!$0U&-.&W@L3;Y;!0(%LH_62$/80A>:1/GU(W!
M(*05(>&>&2_3(8:O)I]#U7JQ)O@Q^VD\A>30 0!V1;8]0&E/6\QL%Z?4/8YO
MWGMF@]I-4T]=QS OS5\X!IN#2[&0'H2.B:D_8\HB!" &!P+G'-M<^-)EE:G(
MM[ $[#@>4B"NEJ3W:/."@1/P<@5#FR<-WL,9(DORA3"',-[P&IWO0?! U/$U
M*##.-@1NRJI!/19HT"P]!N&P_%\1HD-W?&1ZW "R<H&A&#J"J1*RA(!>@].V
M&@P.X.(+\0L@?%381DC[  ![A;EEJTIP=IGIS).!/?%@MFT+%&944$3LR+A=
M/\,-@-HG_%*5.\% J+I!DO8=#549SN,V4<P+L3H_U5:O:@C@%<>3%8 ;]$""
MT&CGV'\W5'/X"K'JLXH6K,5ENVRC_4OVLP$7,3LQ+;Q!$0PK!. FFFB1@"LX
MJW).9$=4&JH!GG08DIFE>CZODTMT;)1624TO]NK[(""MQ,BD,'*.FBNI?W)2
M<UTR876",V8L[EC)1\5# _9LE+ J@.BR4S-T'2RS7ID@*T?2.C(-5SO<RO2"
MB1)&^4!XL1Q5LO5*1S*V")[>+QR3'MT![9+/:$H)]Z!<7D.C"Z97LL*6H2-\
M0V5&;(U;!<U>>&;'<Y]-NWG^5;=R1HSQ1%*0ZHTF%<B,A,+B,8-!TRCB6Z0R
M+3%RVKECECW3.@(A= 6":, Q+Z+HIX3)8Z"- +0M9%R3-K(/5A6<"'^<H^:
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M/N;O;[)J\\,U>>&:O/#-CN<^FW;S_&@5:!%= *K#=(0IDK3EN6WF:2D6C+C
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MIH)5P\_5X4&0K^\!6Z1-HTG^=4KU\QZ=(C9L,G0:I@"MW)*;(4!\9VM7C0C
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M:N@'L)F"!+:4")@E;;0S)7IC_0XSIQ]!=Q7W3N*:8>2-J2%$%4VLZ9A5 J:
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M2MR.^9C= =!3.8T5#4&W%<T./DO#/V/!#L<P/[V.;.%]MYSZ)%*@"J@ 6JX
M.JN ZL#\89CLHFUZ&5].%6-E8 " %LZ@WW*'R\H$]999;/&@HH/$UX'U\M.Y
M@4S&K&=O.QMX4D!Z'#4ZV/S*RDXGU*S^#G^T=E$MQ7X39<S8V(!IK"1>D9Z1
MC.):!"=/ZT(XNUIQ*D!RL?3Y#5G@J:71U\X)=!W4E M5UB$$FW4P;H/Y0F 1
M*:3B1F.=O*BON)V9#EPI!$,CZ-( 2,8E+& 9%D.LQA@+#K3]4[4J&NPT*YO
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MYAM8PM3$K%%J," ?#9*E[HBL1I!+,-.3$ $?>"#9L_*++ZD*2J&TH4>HX8=
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MQYRT-QQ1^8*-;>7*^## ,#EAUR!5EN.A5LH#CQ.-W<H>%,FN&A( ^#XY>VS
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MCWUI?HO!JD>SN@R36.J*VJYH;J\ZQCPRT.G"^K]:] DH<Q]?*R^'/V1%\,P
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M22#2W0,AJYD(HYNIQ; UD=GYJL@F94SG  H';*3GF;9(;-[YR4M24N.$)-8
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M:UT455B#,6CH*J59I91ZZ$1:QRSW5$8M8,/0Y[J5E)?*ED0:@',XU4/EP?<
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M4# _:R IW<,A*=UP"5;FX"W?1_MD#;IJ8+;HJ0;;KXI VZN.0MNGA@3;HX)
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MJ6H%>OGM.T1GB/I).RD*0IGDSY+>[GS/2N(6(MG!-R1YC.Q2 @"WR&"W7(=
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JU15XF51Y35[I$E)IQN##FO;-.WO0%[/I/RB24('L4+8 3NKDYA76"?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>business11b.jpg
<TEXT>
begin 644 business11b.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1_@17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #. @  $P
M ,X"   3    1TE-4" R+C$P+C(X   R,#(T.C T.C X(#$V.C(S.C4U  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !V     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M!"V9!Z?(.:G3Q!>1KM185'HJ8H_MC#>?W!_9];R.QHK!TK7S<2^3=[59C\C
M8'TK>KNH8BG7ASTV<U6E.E+ED?#GC/\ Y'KQ#_V$[G_T:U8=;GC/_D>O$/\
MV$[G_P!&M6'6YD%%%% %W1_^0W8?]?,?_H0K[?U/[D'T/]*^(-'_ .0W8?\
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M (BBB@"Q8?!G7K;4;6X:_P!-*Q2HY =\D @_W*^IGQ) 8]SH67&Y#@CW%%%
M$<\1F9")G3:,8'?ZTP02JH NY, _W1T]*** %:W9L,)W5]@7<!^O6@02!6_T
MAR2RMD@\8.<=?Y444 ,-HY)/VE^22>.F?3GBG_9SMC!GDW("-W<D]Z** &&V
MF)!^UOP<CC_Z]'D7!"YNF!S\W'M_CC_/%%% "^1/Y3K]K?<PP&V_=/KUI3;N
M7R;F0KDD+CID$?US110 GV:0'"74B+Z =.O^-(UO.69A=N&/3Y>!Q]?6BB@!
M?L\NTXNY Q/7&1_.E2"567_2G(7'!7K^M%% %O>/>C>/>BB@ WCWHWCWHHH
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M
M   -9&5S8P   2    ! 8W!R=    6     V=W1P=    9@    48VAA9
M :P    L<EA96@   =@    48EA96@   >P    49UA96@   @     4<E12
M0P   A0    @9U120P   A0    @8E120P   A0    @8VAR;0   C0    D
M9&UN9    E@    D9&UD9    GP    D;6QU8P         !    #&5N55,
M   D    ' !' $D 30!0 "  8@!U &D ; !T "T :0!N "  <P!2 $< 0FUL
M=6,          0    QE;E53    &@   !P 4 !U &( ; !I &, ( !$ &\
M;0!A &D ;@  6%E:(        /;6  $     TRUS9C,R       !#$(   7>
M___S)0  !Y,  /V0___[H?___:(   /<  # ;EA96B        !OH   ./4
M  .06%E:(        "2?   /A   ML1865H@        8I<  +>'   8V7!A
M<F$       ,    "9F8  /*G   -60  $]    I;8VAR;0       P    "C
MUP  5'P  $S-  "9F@  )F<   ]<;6QU8P         !    #&5N55,    (
M    ' !' $D 30!0;6QU8P         !    #&5N55,    (    ' !S %(
M1P!"_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_\( $0@$W IV P$1  (1 0,1 ?_$ !X  0 " P$! 0$!
M   ("08'"@4$ P(!_\0 ' $!  $% 0$               0" P4&!P$(_]H
M# ,!  (0 Q    &_P
M    U017!^I(TW:"B$]8O(           (@&OP#."8X !'@A 9(6 FP2/!I
MGL  ?F0'-SDE0"!)\P-@DMCZ#%R%!*@C>>.  "7YL &D2-Y/(^PT@1O  )D&
M;@$&#D1.IDL\  !1">L7D    T^1@!_INPDD      08.1$ZF2SP
M
M                                %4ARO&='PF,EXQT8'($9&=;0
M      !R:D$3_#7A8"=?8 .>$HJ-BGC'ZG6Z5D%(1WL@ %=)R,DECM?/W!P3
M'\&0&"$L#KI-?G%"=4)S^FI#!3[3+261&0LO.G(_$XXC?!U5@IC.>,\8Q0SP
M^@ZZR9H!IHH/+Q22   .0(R,ZV@   5 ',$9X?B823F.J0WD     ::*#R\4
MD@
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MFB7>GM%,Q7V>X6GDPSGV+S"6)4,5JF]C<1YI>\<RY+HAZ>27<DS0
M
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M7QUOD=CFL+=C^RH<GV=?IP3'I%RI6V:O.Y(]0
M
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M#CXSK]."8NP.BDJG.5L[@3?8
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MO;+_ (K%.3T[?"0
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M/3M\)
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M[*CB61+\T25[%IYF
M
M                                                         *WS
MDK-HF'F3'7N2V
M
M                                                         !I8
MB*>@3>,U
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                           !I4VB>R
M  #1!O< T2;J/L       *32[(
M
M                            '-V2G/-,D+BP"*IOHS
M           JM-.'\$^R7H !1(7M@$0B4)[@   *UBRD  A^883S
M
M                                                      !047Z@
MH++P#GB+.C5I9J4WGL&L3:!])K,OK*S#29AY>B4*&QSZ"WLR$IG+F
M         4 EVYL<%/A;2>T4@EWQRL%@1K<N1*O"Y\J\-+F/EV)6N:1,++"B
MB$N>/&-#F2EPQ2D73G[
M
M                      YV2R<U^13+L"F<O3*8BV(HM.@L\\Y^#H9*B"P8
MP8@@5VG4D4$'0@:0*\R49CY/@               &"E4)K(L((1%SA[Q0"7_
M !SNG1$>"4EGS%[9RN%DAJ(DD16+\S\S]"B0O;*93+">IO(I:+K
M
M                                                      #GL+=3
M+#>1@A4Z7.E,1;$4OE[8*)"]LJD)ME-QT$E!Q>V4A%[8*(C["]$
M       TR;F/D*#C>A8L;C.:@Z9CE].H$TF5F&"%[9SX%^)B9G)0$=!QJ\V
M47%\)X)XI0L3\-RDP
M
M                    "L8LY ,:(1%@17Z3=*^RRD%:Q920F)$D(#1QXI=.
M5TEE(*[36Y:T                0#(J'SEH9L0IP/?-BEJ93X8V?67#E')>
MV15*^3URX$C45^&1%PI5X>>9Z1Y,N,#+LP
M
M                                                5-D>R]H^X
M                   K>(2%_@      -)&[0
M
M
M
M                                                    8(9V# S/
M           16-$%D!J\P\ W@>@"%)-(_0 $3B6(                !\!J
M<W.    1\)!@                            $?200
M   /S-!@&2FVP                ?B8.9\
M                           #BW.PTSLHD+VP          4'EVIG9$TT
MH5'EN!/DR0$?"08 !1.7L            YS22H);$YP  #!"ITN=    (2DV
M@ "$Q(DV@                <PY-L^ PHO*/7     (3$B3:!"8FR
M            #YBNLK6)S$E"9@    !4V6R        %3I;$ "LDKD.E$
M    J=+8@                                            <XQ]YT2
M%%1>V5+&!F'EZIS"$W2-)N,R@QXO**-S(S#2] _<UH4CFV#YB>A0.7/%C0!0
M"7_$(RJ MD*_B]@I\,:/B+M2B<O8           !0"7_  ! 4@L9T>V7'%.I
MX!XQDI(HAJ9N>>7;%.)XQAY> 4\ESIS?$IC2I>F<ZAO0M_*>399/0EB
M         4%%^H-"%<IZ1;2>T4@EWQS1%CQ((@X:C+KSGO-Z%SI5<7&E'YE!
M]A<X<Y9)DTF7D&?@              %,1:";<.? V^6P%,)LD^LMY*<3XC<I
MN,H[+T2))B)^QI4D(:&+N2/1"L_@GR1.-4&1GHD^SGQ+?RS8 H3)D&U":!1(
M9@?"?X6*E9!DQ*,S<JE)(FM2WLYOBTPW20T/4+F3W@
M                       "@$M8*WCRR]LK(-+$$#J/*""_<A<:<+-"A\M@
M*#2:I',M_)5%,9:>;-*52VHID+VP 4 E_P 0C->ECQ1.7L%5IK,A0=.I1.7L
M            YS22H+*2*QEA/$H8+EBJPND(Z%=IN,VF3G*L3/S0Y<.14(QD
M;B]@Y\3H.(>&GC"";9L0H+++R=QZ8             !047Z@_P *%3,2YP]X
MH!+_ (Y[SH0-:E89H,F<8P3;) %$Y+$VV3,*E2<93J=")%HC 6B
M      %,1:";<* R_P *X2!1O8A4='Y5&?"1U.B<HD+VRF(M$-LG/R= Q',A
ML07)0 UB;L+!#?90\7PE$Y>P 0:(N%@I2T7@%<1<*884\&L#=@(^EH9K\L<*
M'"^,HG+V"!Q"LDR63GZ@
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M!S[DZP0;+:"FDN-(*&)&;$ZR1YI(TT8X3_*)"]LH4+XC5IM$J_-ODZP
M                                    " !/\%9Y9@5T$?3=A9:02)VF
MHC#21Y!,G81B*]B0Q9  5S$="QTD.02)V@ @ 3_-(GFD@""9.PK*-1&^RQ<@
MF3L           !488J"1YMPSTWJ5L%DY XB0;8-G&#FDS^B1!8X0((H&SRU
M<K8+)RM@LG-.&GC=Q4@3W(-'UEA1)X              I#/?/@);$]C%RG ]
M\V*6IE:Q9218*[S/26QNXJ0+.2,A9.5;&H2418*5K%E)J\CL39
M     (8DH#+B"1.T$'B'9,8FL5''U$A2=96*>V;1)8'O$$B=IK\TB27*GSP2
MU0T"21,N()$[2"Q'@MP/'(6$ZP>"0T)5D,C:!#$N$*L#699L?F>:2 ()$[2*
M! \L**\3-2V(^P                                         %<!I\
M                     L?-P           C>00      (Q&SS9P
M -P%CX             (@$/P             "W\              P\JP
M                  !H(@@2')R@      $P"7X
M
M
M                                      //-'@
M       &0&X  #S:Z0                        /II]^GST #7=RCPO?
M                       !]KW:EJL #!C7
M !O$^\ 'X6+GAX+)@
M>EDH?HY*(      !'\X@P                        "?YU^@ $;\QCP
M                      /NH]W9C9GK45@",<FSSC[!B\+KI
M             _TNXPT^T_&30!K0Y$"'H                        +5C
MJ6/0 /XH]BG\H=TTMQ7HX
M    ]S.8R:/VI\YY7MF"      $?SB#                         )_G7
MZ  1OS&/                         'W4>[LQLSUJ*P!&.39YQ]@Q>%UT
M@                       ?Z7<8:?:?C)H UH<B!#T
M        %JQU+'H '\4>Q3^4.Z:6XKT<
M               >YG,9-'[4^<\KVS!      1_.(,
M       G^=?H !&_,8\                         #[J/=V8V9ZU%8 C'
M)L\X^P8O"ZZ0                       /]+N,-/M/QDT :T.1 AZ
M                   "U8ZECT #^*/8I_*'=-+<5Z.
M                          /<SF,FC]J?.>5[9@@    !'\X@P
M                 "?YU^@ $;\QCP                         !]U'N
M[,;,]:BL 1CDV><?8,7A==(                       '^EW&&GVGXR: -
M:'(@0]                        !:L=2QZ !_%'L4_E#NFEN*]'
M                                     'N9S&31^U/G/*]LP0    $?
MSB#                         )_G7Z  1OS&/
M       ^ZCW=F-F>M16 (QR;/./L&+PNND                       #_2
M[C#3[3\9- &M#D0(>@                        M6.I8]  _BCV*?RAW3
M2W%>C@                                          #W,YC)H_:GSG
ME>V8(    1_.(,                         G^=?H !&_,8\
M                  ?=1[NS&S/6HK $8Y-GG'V#%X772
M        !_I=QAI]I^,F@#6AR($/0               3--&&I0       6K
M'4L>@ ?Q1[%/Y0[II;BO1P
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M(   1_.(,                         G^=?H !&_,8\
M              ?=1[NS&S/6HK $8Y-GG'V#%X772    +3<9,@K-C:<O495
M1[^A8= E?5XK8R,6SO&R]]V+M4^4A;ALW-[6+D#)T;:UJNWG%3JG\I"_,AG,
ML?9XE3%O1*EV1<!B9M7&2B6 09-8V2B      ?Z7<8:?:?C)H UH<B!#T
M     ]XZ #GO/A.A4H<,-!T*G/469'EE?)=04?@        %JQU+'H '\4>Q
M3^4.Z:6XKT<     5&_1W(;<OG'KP%/?TIQSX+UNXWYG[+'[<M>UOF\;,_F&
MZB-^[ZU'+=M;L=XETFJGZ#Y1:M\^=7J&^D./VX?.77<)RL*OKLG/=AX7(2 T
M[89 :=L-0/TEQVWSYN[#_?GL2^BZC+3G6W"*G0=3E7S[; *Z>U<XESSC;]NZ
MYF!4;]'<AQ:?$N(^:>R8?DH<+.HZ38MQ7HXTYLV&@SUC1+2> ]4K4[ES.P#C
MO0:QN\<OM&X%U/\ OSVK/O\ RJV?YVZY53]!\HM6^?.KB)?1=1EISK;A%3H.
MIRKY]M@      'N9S&31^U/G/*]LP0  $?SB#
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MYSRO;,$  (_G$&                         3_.OT  C?F,>
M                    /NH]W9C9GK45@",<FSSC[!B\+KI    &24^W-8>?
M":;'D1'NZVN4;2MUP4FQ]]6+GU^>R&L7-;7*15EDX=R&(G4WY>#MVS7-2'(V
M9;JJ"RT(33AW_*]>1[Y/&#(AS,L0MF6      !_I=QAI]I^,F@#6AR($/0
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MLBXATKV(UX       #W,YC)H_:GSGE>V8( "/YQ!@
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M9P7K8B_:KU53[/6_;        ^ZCW=F-F>M16 (QR;/./L&+PNND
M  >[3[*2->FY"OTQ9B"  !_I_@       /\ 2[C#3[3\9- &M#D0(>@
M      ER:S-)            M6.I8]  _BCV*?RAW32W%>C@
M                              #W,YC)H_:GSGE>V8("/YQ!@
M                 $_SK]  (WYC'@     4HPY%UTR. *3H<B[&9' K%C79
MDWJ(&V+EB<BU[I5O&O6]R[&EZ*J[(]V0URC.*O)>W:*U8]V4=RB0]RG%/%0,
M2_Z!<S,L 1?M5ZJI]GK?M@       #[J/=\XN=]/GH B;*L<UFQ8K^
M    #]"4L6]H2_:Q&OP           #_ $Z L#DK!8,H :T.+$TX
M                "Z<Z50 ?Q1[#GXV^A=8<OW8
M                      >YG,9.O[O^8?1R,01_.(,
M        G^=?H !&_,8\     "D&%(NRF1_L] 4G0Y%V,R./X.=#'RIH7K>*
M>>^9XMME6>>Z#)G#>MPGLW.BN?%@U9N9Q5Y+V[16K'NRCN42'N4BH>)?G[(M
M;[KI B_:KU53[/6_;        &T(,G8$6^ /(]\Y[,]BX0S;
M             EO$O=%> RF34U "@DY^0                        ;A.
MODE$ #67,=TA[\=?07S1KP
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M (_G$&                         3_.OT  C?F,>
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MQ-MWSGUV*?0M3DOHNS1 Z3I^I]BQ.Z-7S4Q.:;E@N6@0/ZYH6R,'DIQ<IWH
M            \D[]/\6WWWWEH $?SB#                         )_G7
MZ  1OS&/                             &T(,G8$6^ /(]\Y[,]BX0S;
M     NMPT_3]Z@06FQMH6Z_N\]A[+L6[8J;43E85R&(G0OF6-DVZJ^YT:3,>
M[K&Y3BE=,X84C6]RF9T._5ADX?U&5456&0)-066A6_8F;4#EH0      $MXE
M[HKP&4R:FH 4$G/R    6B$S36!Z91<?F7GE)!>(?H4C%P1MHHE-\DSR111H
M;@)[FY"JLM^.?8Z.CG#,T,!      !N$Z^240 -9<QW2'OQU]!?-&O
M   #R9%FAWZYX+,WF&Z:/VO!2RYWMN]]1S\ .Q<^MQ^<NO53_0G)[6/GOK%(
MWU3P^Y#YE[+HO;<% #L7/KF_F'M-0?TEQZW#YRZ[4'](\?N#^:^Q1)Z-J/BR
MK$4>AZG9)P[I>>XB?5]WOEMD/$.E0LZCI.*Y").CDV]YUB9]%WUGPF^_Y![]
M5/\ 0G)[+>%]-IR^F>-7;?*W;ZL^_P#*[%.+=&K4[GS.U;Y[ZOH+<-?UCGL7
M-KEF\            'DG?I_BV^^^\M  $?SB#
M  )_G7Z  1OS&/                             VA!D[ BWP!Y'OG/9G
ML7"&;8     N$Q,ZGO+00):1;WW>>P]EV+=L5-J)RL*Y#$3M0W:(73(^GKU
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MH  $?SB#                         )_G7Z  1OS&/
M             &T(,G8$6^ /(]\Y[,]BX0S;      NMPT_3]Z@:3O6\2KI^
M[SV'LNQ;MBIM1.5A7(8B=5%E(=N.*FZXN4:SN4>WY[G%%6Q[5<0)=CX_4F(U
MW]2O.?&P2Y3T'8')<X>P8OY_0     $MXE[HKP&4R:FH 4$G/R     ?27]F
MOS<1SX'D ZP#F@,Q+_CEO+1B3I_)4J2[);GQE5);(4*$WR79DX,Y*!0
M;A.ODE$ #67,=TA[\=?07S1KP          \F19H=^N>"S-YANGQW:/RJIF5
MS'=-&[9@IR<HWJJ?Z$Y/:Q\]]8JG^A.3VL?/?6,4R$2O_L7/K*^&],J_[WRV
MRKAG3*Y>V<W_ !J\P3+P+,>%=.KI[7SBU;Y\ZN*J?H/E%B?%>C0LZCI,@]-V
M&%_4-+RW&RXG=%U*^?Y$[Y5/]"<GLMX7TVO_ +%SZROAO3(-]7T7>6IYV/VY
M:]K+.XO\*_+%.*]&S/&30          #R3OT_P 6WWWWEH   C^<08
M                  !/\Z_0 "-^8QX                           &T
M(,G8$6^ /(]\Y[,]BX0S;                 WY8N;ALW-BVZJW<C%
M EO$O=%> RF34U "@DY^0                        ;A.ODE$ #67,=TA
M[\=?07S1KP                                          !Y)WZ?XM
MOOOO+0   (_G$&                         3_.OT  C?F,>
M                  -H09.P(M\ >1[YSV9[%PAFV                 ,W
MHJW99N1=DV?\     !+>)>Z*\!E,FIJ %!)S\@
M  W"=?)*( &LN8[I#WXZ^@OFC7@
M         #R3OT_Q;???>6@   "/YQ!@                        $_SK
M]  (WYC'@                          ;0@R=@1;X \CWSGLSV+A#-L
M                      "6\2]T5X#*9-34 *"3GY
M      !N$Z^240 -9<QW2'OQU]!?-&O
M              'DG?I_BV^^^\M     C^<08
M !/\Z_0 "-^8QX                          VA!D[ BWP!Y'OG/9GL7"
M&;8                        $MXE[HKP&4R:FH 4$G/R
M           #<)U\DH@ :RYCND/?CKZ"^:->
M                   /)._3_%M]]]Y:     (_G$&
M       3_.OT  C?F,>                         !M"#)V!%O@#R/?.>
MS/8N$,VP                        );Q+W17@,IDU-0 H).?D
M                &X3KY)1  UES'=(>_'7T%\T:\
M                        >2=^G^+;[[[RT     "/YQ!@
M            $_SK]  (WYC'@                        #:$&3L"+? '
MD>^<]F>Q<(9M@                        2WB7NBO 93)J:@!02<_(
M                     -PG7R2B !K+F.Z0]^.OH+YHUX
M                             \D[]/\ %M]]]Y:      (_G$&
M                   3_.OT  UO,C@                        >M;JS
M*/>  B!+L0ZEV                        !]WBU#&3,FIJ &@RGT
M                    M>)0  ^>-=T)P/J?S1KP
M                       RS;,#N#L7/P      (_G$&
M          3_ #K]
M
M                                    !'\X@P
M      "?YU^@
M
M                                C^<08
M !/\Z_0
M
M                           1_.(,                         G^=
M?H
M
M                      (_G$&                         3_.OT
M
M
M                 $?SB#                         )_G7Z  1OS&/
M                        ]>W5NS&S/MIJ $()D?GLSV,\FKP
M              #[O%_^"R4^X,H 1[.0(T(                        "
M\<Z-#_0#YHMZ'OQW]!:RYCN@
M       RW;L!-'[4^<_:S6.      $?SB#                         )
M_G7Z  1OS&/                         'KVZMV8V9]M-0 A!,C\]F>QG
MDU>                        ?=XO_ ,%DI]P90 CV<@1H0
M             %XYT:'^@'S1;T/?COZ"UES'=
M                    !ENW8":/VI\Y^UFL<     !'\X@P
M            "?YU^@ $;\QCP                         /7MU;LQLS[
M::@!""9'Y[,]C/)J\                        ^[Q?_@LE/N#* $>SD"-
M"                         O'.C0_T ^:+>A[\=_06LN8[H
M                                 ,MV[ 31^U/G/VLUC@    !'\X@P
M                        "?YU^@ $;\QCP
M  !Z]NK=F-F?;34 (03(_/9GL9Y-7@                       'W>+_\
M!9*?<&4 (]G($:$                        !>.=&A_H!\T6]#WX[^@M9
M<QW0                                           9;MV FC]J?.?M
M9K'     1_.(,  EL26*LP3[/T(   L?)8E3AD!'([FCCS(X@      FJ1*,
M?      )_G7Z  1OS&/                           ]>W5NS&S/MIJ $
M()D?GLSV,\FKP                       #[O%_P#@LE/N#* $>SD"-"
M                       O'.C0_P! /FBWH>_'?T%K+F.Z
M                               #+=NP$T?M3YS]K-8X    1_.(,  M
ML.FTXI#5)VOE.Q#8T2:L+$@3M,C-TG-86T%%)A(-IEOIA!3P3U)UE8AK0M+/
M?(V$3CL**62@LM?-_E1ANTE68,59@  G^=?H !&_,8\
M          >O;JW9C9GVTU "$$R/SV9[&>35X
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MR1\W+7K,^%=-_6FJO_L7/ORJIL#XYT*%'4M(QZ;'L*XST0         9;MV
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M8QX                            'KVZMV8V9]M-0 A!,C\]F>QGDU>
M  2-CW;&,?*C/(LP8G1\SHJ]:GW+J?9,QKT;9%K?MBY&639F7#D5YY"+:AC)
ME/\ E85QV)G4ZY:#;9BIM0^6@S0AR, N41@DVA;GB9NXK5RDW,X_'*O
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M/E%JWSYU<5_]BY])O0]GSC%3H#]?T"R7A_2P      !ENW8":/VI\Y^UFL<
M (_G$&                      =,9S/'\@ G^=?H !&_,8\
M                  >O;JW9C9GVTU "$$R/SV9[&>35X    -YV+EIV,F5[
M3XLPXE_$:_,II]@I-C[ZL7/T)'1[NM;E.54>U.96%;YB9U-^7@R CW)'Q[N\
M;-RG_+0A*^+>V%;J\_UO&Q<T)?M0HFV      !]WB_\ P62GW!E "/9R!&A
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M>1A<A!^;'@O-CB3D:[.V#)T!(M3.AR(1S(\ Y\8      #[O%_\ @LE/N#*
M$>SD"-"       Z:"+!'0C&=&94P8>01+*S)SZ##"ODTL           7CG1
MH?Z ?-%O0]^._H+67,=T    J-^CN0RCT#:1M77LM OKV@VW?.?712C]2\1F
M_P IWG3VRX?%,A$D9I6QB6O.MNK#[SR^U;Y\ZO7GV;G?\5>8#E\?*WGNV;$P
MN1KK[5SG>NI9[7.;QMH/!.I 5._0_)=B87(V/<2Z373VKG%BW%>CBNGM7./U
MI]V%ALCG>(GPAZMH]N7SCUX5+?17(]IZ_E<KQ\N+^^ZM+SF^X"46@[3 'L//
M[ ..]!BGT+4]6;!BALW Y2;O*]XJI^@^46K?/G5P*R.[\P\V_:M)X#U2NGM7
M.+%N*]'        RW;L!-'[4^<_:S6. $?SB#       !8^0X-3@   L8(C&
MH 2X/W(@         $_SK]  (WYC'@    "--NJ!MBY;]+LXO3[I:FJ*-JN;
M=ZWNZND"G6)?P^GV[*;'^@I)AR+MID?Q?%)L.1>9-CTG0Y%V,R/AE/M6\:];
MW+L5YQ[FTZ_)57**=(E^YJ98$5;5<J;M%<<>[N6NF7%V@       >O;JW9C9
MGVTU "$$R/SV9[&>35X  !F-'OOTU:ONT#8ENK'*O/L\>'5Y]_GN/U>?9XV=
M;KU;<H^?UD5/OOT^^_3[9WC9=-.7@_EZ R:GW**/=8W:?4\>7Z       'W>
M+_\ !9*?<&4 (]G($:$      -]'Z@P$SX T:;./,-;ELA4V
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MI0                        7T'0H #YHMZ&GQE]$:[YUMP
M                                RW;L!-K[=^;?1R,01_.(,      W
MH=AI&<G:<CI?L>H;O.2H[/3AA+_B/Y9J;L/C*NCQ3TS'2U,R@YJ2OX
M G^=?H !&_,8\     5%1;UE<BULJKP"K:->FW>M[NKI%/<2_P"!XV#5Y"BS
M<Z.<A%Y\($F5MVB'-JY<#*L2GNT4G0Y%V,R/AE/M6\:];W+L"/=NJMR/=NGF
M6 !57%O21N43#O4        #/XE_:$*3_H!^+RBO-XZM'(Q0
M           !ONQ<Z0]>RNRK=8 I_.8P^8                        S(
MZV2>( ,)TG9(8_%WT5Y>*G
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M*S6)4>       "W J/          !F1ULD\0 83I.R0Q^+OHKR\5.
M     'D2+,:]YUF5?/ML&O,SCL.R<+>FIYX 5_\ 8N?6 <=Z"!"KJ.DRMY[M
MF40)0 K_ .Q<^L X[T$                   #???>62<^GN+?[Z C^<08
M    !* Z]2M8MU.1\Z1"')/8Y5SH_-.$ZRB LU,U,*(^&@STS8!*<UF<_P 1
MG       )_G7Z  1OS&/      &LZ??>,NJ\Q;QKJFH?89]53DGH?P893[_A
MF]7@P.GW/*O,)I]S:KS\#%J?<PJ\'X&->>Y9[X!JFCWQWHSOWS,ZO
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M/I[BW^^@!'\X@P      ;I-[G@D>#Q29Y'4TR9D2_-:&#&S3R#.2%AO(_0T
M3#/](=@       G^=?H !&_,8\                             9_$O[
M0A2?] /Q>45YO'5HY&*    +K<-/T_>H$%IL;=-FYZGGL1)5BV7%S:C,K"MX
MQ4VO:?&F[#OUOY"+)>->T_>MXO5Y,&)?U3=HEK%O09FQ_K\?X35AR*D\K"M[
MQ,VH?+0OX      !ONQ<Z0]>RNRK=8 I_.8P^8   %FY*LQ\P@IT!>Z46EY
M*02ZDS,J6)'&2DIRJXWB;3)+%-9>L<_9T,%!1LPC.      #,CK9)X@ PG2=
MDAC\7?17EXJ<             !#/IVE^Q&O28T79ZR.[\PL,XQT2O[L7/;&N
M)](K"[UR^V3YVZU0?]?<!NV^5^WP<ZQHTGM"VB(O2-/LJX9TRH_Z-Y%:)P/J
M4>=SUV6O.MNJ\[YRV2.C[+\%ZW([2-DKV[-SRT_Y_P"J@
M ;[[[RR3GT]Q;_?0 $?SB#                         )_G7Z  1OS&/
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MJX9TRK3O_*[8?GCK0%5/T'RC\:J<LQTS]:??Y]\LMX9TT
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M$!9">\;:-2$X#G5     !F1ULD\0 83I.R0Q^+OHKR\5.
M%<O;.;Z.VO!7%_-'9?#E6*F_HGDDGM"VCP9D>P#CO0JJ?H/E%JWSYU?1NUX+
M1NV8+4>R8>RKAG3*R^[<QVA@<IK;-XVS'A73:N^^\MG1R;>X$=>T#?FH;!D\
M"3,+FNY                ;[[[RR3GT]Q;_ 'T  !'\X@P            =
MZIPPF$    Z5B+Q24      3_.OT  C?F,>
M  !G\2_M"%)_T _%Y17F\=6CD8H     &>6ZLEI]'@5>8G7Y_7CQZO,NH]Q&
MOS,J*L-KI^_QLBW7JN[1_!M*U7AE=/\ IC]7F:45?Z>GXS2BJ9L._5MDX@
M   &^[%SI#U[*[*MU@"G\YC#Y@     ?0;M-/'E@&PC7H-B&NP;,/P-= V2#
M6QGI@0-GF&&VS2Q\(    !F1ULD\0 83I.R0Q^+OHKR\5.
M  ^*[;\B3:R2#)'Y5>:TSF+V1A,G]%%6*9")E>/E_#=M_!>H^2Y1DL&3_?GN
M 9C'Y/ E>Q&O8ID(F5X^7YM^U@^5@[*P>3                WWWWEDG/I[
MBW^^@  !'\X@P     6D%J)M4@B33(U'.:=+)(XJ**_3HU,M.<T[*3B@.BXH
M1)8EPQ"PY[R[\LE-HE.I24      3_.OT  C?F,>
M       ,_B7]H0I/^@'XO**\WCJT<C%                 W79KDS&O0)G1
MOA]     #?=BYTAZ]E=E6ZP!3^<QA\P                       !F1ULD
M\0 83I.R0Q^+OHKR\5.
M  &^^^\LDY]/<6_WT   !'\X@P     7:EBQ16=81QCG8"<C)8,;M+K#FX+L
M2GXJ4.YPC>5/E+YW#E$1;@4P%Z)QQ'345K%)0     !/\Z_0 "-^8QX
M                     &?Q+^T(4G_0#\7E%>;QU:.1B@
M         #?=BYTAZ]E=E6ZP!3^<QA\P                       !F1UL
MD\0 83I.R0Q^+OHKR\5.
M   &^^^\LDY]/<6_WT    (_G$&     "[4E"4+'7Z<2IV:%#)T?'.Z=-9Q8
MEEI:P5;G0B5:DGCDI.VDI />*O#K*.5$Z(RIT\HJC-=@    $_SK]  (WYC'
M@                         #/XE_:$*3_ * ?B\HKS>.K1R,4
M                ;[L7.D/7LKLJW6 *?SF,/F
M  ,R.MDGB #"=)V2&/Q=]%>7BIP
M          WWWWEDG/I[BW^^@    (_G$&     "Q$W*5FE[QSNG0 4_EQ9D
MYDA327-'B%$1T!G-X7>D0S#RW8T84.%GQ8^:V*Z3HJ.6,C      3_.OT  C
M?F,>                         !G\2_M"%)_T _%Y17F\=6CD8H
M                  WW8N=(>O9795NL 4_G,8?,
M    9D=;)/$ &$Z3LD,?B[Z*\O%3@
M           !OOOO+).?3W%O]]     "/YQ!@                  NL*4P
M     3_.OT  C?F,>                         ,_B7]H0I/^@'XO**\W
MCJT<C%                        &^[%SI#U[*[*MU@"G\YC#Y@
M                #,CK9)X@ PG2=DAC\7?17EXJ<
M                        -]]]Y9)SZ>XM_OH     "/YQ!@
M              $_SK]  -2SXH                        'K6Z]AQ+_^
M@ A=,CUUSXH                        ^[SVXW$SME6ZP!H,H&/F
M                   !<>3O !\\:[&SYK['Y>*F@
M                       #+-MP4@OH3D_^^@     !'\X@P        #H5
M*7#1H    .@$U04J@   &Q"^HYT0  "?YU^@
M
M                                                        C^<0
M8  +8S2Q&4F\>N5E$F#<1M@KZ-)$Y#=AT*'*B:X+ R(!$PMI-9@U 2B*Q"Q\
MP V29@?@5$%A!LDK-//+,C(#H;.(,   G^=?H
M
M                                                         (_G
M$&  #NS*]2CPLI)1FBS5A;45R$^SG2.F4J++ZCD6.I$ID+@3E=.P8II+.B,Q
MYI%0](U":G+73("ILM1(MFSC1Y+0U&6 G$&   3_ #K]
M
M
M    !'\X@P  =V9Q4$R3H1->& $-CU2E<[6R@PE*<SYVYE Y>2<6QU#D##I!
M.&$Z2"ML_DLD-;FH2 )TSG(0="Y,DBF:M)6E,1& ZX#B:/?,)  )_G7Z
M
M
M                "/YQ!@  [LSBD)F'0T:G,-(;'IE+)VMG%T=<A\QOPX^2
M^(F":S.3,[BSAA.D8K9!9,:W-0ESAZ9JTYM3ID/[*&S7QTL&O3.BC L$.4X
M G^=?H
M
M                          (_G$&                     "RHWD4Q@
M $_SK] !Y]5.D<G#                         ]>W5N#'R_W\] $()D>C
MS-8[\@                       #[O/;YL)D99Q;X CV<I9KH
M               %XQ=N #YHMZ)'R-WK"M)V0
M                    9;MV!EW]?<!^V;'      $?SB#
M           )_G7Z #S:Z= Y6"                         ,BLW-SXZ7
M^_GH K0R,2BO-8[\O0                       &3T>]%V RDLXM\ 0S.1
M0UT                        ?T=(1=P #RL5-AC\7?1>%:3L@
M                                   V)T349C_9?SS]LV.     !'\X
M@P       ">9ILC@          ":I%<Q(   $_SK] !YM=.@<K!
M                 R*S<W/CI?[^>@"M#(Q**\UCOR]         #=MFYK:Y
M1C=7@            &3T>]%V RDLXM\ 0S.10UT
M   ?T=(1=P #RL5-AC\7?1>%:3L@
M           V)T349C_9?SS]LV.     (_G$&       "TXOH.=8KR )$E[Q
MS,        ':J<L!$D   $_SK] !YM=.@<K!
M  &16;FY\=+_ '\] %:&1B45YK'?EZ         LCQTJ'LNQIZ]0/[).QKN&
MU>:1OV]LVJ_+]\W=9N1:DV?A]9M15(2/<T5?M_*8)<I      R>CWHNP&4EG
M%O@"&9R*&N@                       #^CI"+N  >5BIL,?B[Z+PK2=D
M                                          &Q.B:C,?[+^>?MFQP
M   (_G$&    =%19T:'.>HZ;#81S2'1(;4.>4N3-A%8IEA<*4@%N!QS%PYCI
M1<2C.J,SXYVB1A<J?.5I%$1UR'PDB#CI(D@   G^=?H /-KIT#E8(
M                   &16;FY\=+_?ST 5H9&)17FL=^7H        61XZ5#
MV78T]>H%P&)FQ'E6=O6J\2K\W;8N8Q53'>1:FM#D5<9.';-BIM>.0BV'X^5#
MZ78@G.C@     #)Z/>B[ 926<6^ (9G(H:Z                        /
MZ.D(NX !Y6*FPQ^+OHO"M)V0
M       ;$Z)J,Q_LOYY^V;'    $?SB#    .D\WB5Y%=)>$2X(HD2R0!'8N
M^(*%KQQ]G2V<99?V?46MG'6:S-[E\A*4U<0[-B%'9V>%#!*4YGSMS.3TB2
M "?YU^@ \VNG0.5@@                          #(K-S<^.E_OYZ *T,
MC$HKS6._+T       !9'CI4/9=C3UZ@7&8B=3GEX(N"Q,[P_?*R,E#Q"ORY#
M$3HCRK'A5>1$EV971;V?6ZH)SHX      &3T>]%V RDLXM\ 0S.10UT
M          2D(TGP@       _HZ0B[@ 'E8J;#'XN^B\*TG9
M                               !L3HFHS'^R_GG[9L<   "/YQ!@
M%ZIZI>65!&WS#3]B))( JK.G@IY,(*XCLE.:X@<=LQ5F<P8+MBP\CF;[(;'I
ME+)VMG*H=,I467U'&D1)   !/\Z_0 >;73H'*P0
M      ,BLW-SXZ7^_GH K0R,2BO-8[\O0       LCQTK6URG6%VC&:J;%\?
M*B7*L[=M5XC7YN^Q<K#R4/%:_+D,1.J-RL*X_$3M(7[<DXUV#4V/!.='
M   &3T>]%V RDLXM\ 0S.10UT        #;!9,#4!7 ;D+##0![YGQ5B"]<H
MH        !_1TA%W  /*Q4V&/Q=]%X5I.R      1TW77)%Z5L8$9]ZUB2NC
M;-_?GN!Y>!\M=&C]KP>G]EPP&X=:S.L<]B[ ^.="^.Y1";J>D9MBYLK^>;:(
MW;OK6FMGPLW>5;Q[,:^   !H_:\%M?7<M[,:^(\;GKN\]3SOJ6+OC2;&L,_B
M\4R$2/FY:\!N'6LSI[9<-8-QOH?V6JX8=/TKZ[=<Q^9[G"CJ>D";'+-W
M     &Q.B:C,?[+^>?MFQP  !'\X@P   "7)+XB:1E+.37I@IKLS A62T)@D
M$"/)8(>N8&=/ARXD,@>\6>&#G@&M#]R,):$5.$Y#>)\17V:[   !/\Z_0 >;
M73H'*P0                           !D5FYN?'2_W\] %:&1B45YK'?E
MZ       V1;JWU8NC"ZZ8Z2+4G(UW#*_-)WK>V;5>L+E'R^MR6:]17:)!6+N
MC[UNP^!)C))M1RD6@       ,GH]Z+L!E)9Q;X AF<BAKH        ^PRLL#
M/:($%WQ1R>X:T+VCG_,Z+8BF,         _HZ0B[@ 'E8J;#'XN^B\*TG9
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MI8NUZ]FYY9?POIH       V)T349C_9?SS]LV.  (_G$&    ?4?8>29"8\
M   #:!E)H8            $_SK] !YM=.@<K!
M      &16;FY\=+_ '\] %:&1B45YK'?EZ                        R>
MCWHNP&4EG%O@"&9R*&N@       #+3I ()GWE-YT'%$I=N4*%ZQ12
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M/@\:"HJQOSW)_?-O5TV"7[8C/;JVU5YGU7E=<>[K&GW&O/;/Y-G9%7@
M &16;FY\=+_?ST 5H9&)17FL=^7H    #;%JN9<.^!&B3:CG(M
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M\M!\FKSUZ?9&Q[L:9-K':O-MVJ\JHJU/=MY)35N>S7&J3:V3;KRVCV,TFT
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M.9XZZ#BS.B4J<.D0ID+""M@NU*%BOTZ;RO4K^*W  3_.OT 'FUTZ!RL$
M 4OP[]QTNQZ7H"M6/=E'<HD/<I&&4^U=QKTU[UO1]%5B$BU23#D7;3(_^%',
M*1>/-CTG0Y%V,R/XOBH&+?N8EV!27#O[>J\GG?M;CK\ I,AR,O\ ?+=Y5C[?
M0       &16;FZ,=+_;ST 5H9&)13F\=_     !=!AY]+^8@9%3[<!B9U?T^
M+/F!)IVR\'H/P.3J$RL+[RQ3'RJW<A%MPQ4VOB?%\WUDE/M;V1B@
M #)Z/>C# 926,6^ (9G(B:]                        /Z.D4NU !Y6*F
MPP^+?HO"]*V0                                           ;$Z)J
M,R/LSYY^R9'$?SB# !98=))2Z?45W'30<99V:',"="YA9'4KH.C IJ/S*]SL
M^.1<FP2A*0#KV-0'(V=NA1J9$4?G<F<"QTUD$CH+*HSY2G(L2)7$JRD$E$7P
MG"F>* 3_ #K] !YM=.@<K!     %3D6]8-?M;=K\ K5CW91W*)#W*13W$O\
M@>-@U>0HLW.CG(1>?"!)E;=HAS:N7 RK$I[M%)T.1=C,C^+XJ!BW[F)=@:5H
MJJHBWKP9L< "'UFO45-5CTBT       !E\>[M['R_P"P 5 Y:!3KEH0
MN@P\^E_,0)6Q;UCF/E:#OV\_MU5D9*)9+CI50N6A2TBWO6I]AK,L7+8B=33E
MX(N1Q$ZF[+P0         !LJU5TAZ]E=]V;H KF.3XQT
M        ](ZF2U$ &.ZYEX6_%7T;C>MY@
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MK:FH?0;"JIR3T/X,,I]_PS>KP8'3[GE7F$T^YM5Y_!A]/N9U>#^#$J?<PJ\
M_@U)1[L2KSVO0       R^/=V]CY?]@ J!RT"G7+0@     !NBS7I>]0,BI]
MDQ&NZ(OV]>7*=NVJ]17:,MH]_LP^OS<EFO3=Z@;DLUZ;O4         #95JK
MI#U[*[[LW0!7,<GQCH !=*1B(F'DF  WJ;,,.-.$QB(9A![A-,C6:D-]GK&;
MD-R?!:>49EN!3Z;[(3'R$N3TB'9^      /2.IDM1 !CNN9>%OQ5]&XWK>8
M            %/OTIQVX+YK[$*Q^[\PL"XYT'Z[=>@]PU^26C[+ZL>]51]!\
MGF+S3<\_P^0VGK^5U?GL5LK!Y,1JWG6=F8+*;/P.4JI^@^46K?/G5]4[!B<%
MR\"1VD;)_3T                 ;<Z[H,M_KK@GZW: !'\X@P
M              "?YU^@ \VNG0.5@@                            #+
MX]W;V/E_V "H'+0*=<M"                        &RK572'KV5WW9N@"
MN8Y/C'0  =%)&4S J'-< ZOBD,GZ9@52EO!S?'1R5*EE)4H7HE:9]9GY$ M4
M*.2Z TD1W)W$,3;AH@B4:M     /2.IDM1 !CNN9>%OQ5]&XWK>8
M      @5UW0=T:QFM_Z=L%5GT%RFS#A73:Q>\\OG#RG>H-]7T6VSYTZYS]_8
MWSY;;\Y==A5U+2;%.*]&@SUG1+*N&=,JC^AN3S3Y;NNB]MP5@''>@U>=\Y;*
MCGVUZ<V;"[HU?-QYW37;+^%]-                 VYUW09;_77!/UNT  1
M_.(, &0EKH-/%<Y=80D(4@      %OP!4"#)C,#5(!(TZFCC8 !9F?65@@
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M_1FVX&RKAG3*M._\KMA^>.M 54_0?*/-OVL]P^0'@3(]I7 >J
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M7;KI3:<)/CD&_P!7??>6RPYWMD?-RUZ36B[/XDJQ*KGVV
M ;<Z[H,M_KK@GZW:   (_G$& #;!V^G!87U$ES,3-S6IBY3P3X+(2HXNB*\3
M2!C!:B1;-G'+8#-#N0*/SG[!T:ED9S3%_P ?F40'3$<AA<,2C-%FK#TRUPK#
M-(E)X )_G7Z #S:Z= Y6"                           !E\>[M['R_[
M!4#EH%.N6A       6 0).L+M$3Y5G<]FO3]VB;,.1D%/L#YT:?$&3,F'(JS
MR</X_?).QKT)9D?9]NNX'$SJP<E#PJNF,LFT)'Q[L<)%H      ;*M5=(>O9
M7?=FZ *YCD^,=    !+0^XAZ 2#(^&6F4FJ209'P]PFF1H-3D@R/@)!D?"4!
MCY^1H0&^S2),L\$B*    >D=3):B #'=<R\+?BKZ-QO6\P
M !C\R/B.2A[.P.4&-S8T=]UUS?\ IVP9;CIFJ=@Q.UM?RV.S8WFWK?ARX^RL
M'DQ&K>=9V5@\GM' 975.P8G:VOY;6N<QFI-CQ$E]%V;[K5P
M  ;<Z[H,M_KK@GZW:   !'\X@P ;8.YLB :2.<HZ(BJ,U,7UE8!;,>\5G$3B
MSPW61Y)=D4S5ISJ R0E(=:QR&D4RS8N$.44Z_3GS(]G8><U!T(FO# "&QZ9&
M LN-OG(F "?YU^@ \VNG0.5@@                          #+X]W;V/E
M_P!@ J!RT"G7+0@      !O"Q<L\QLN-LFU!:;&];SW.+=7\^IO0I$$)T>:,
M._#B78G5"D5Q9"+:QBYM/F6@VYXJ;4CE85JN,F55Y.')&/=R*GV%TRP
M!LJU5TAZ]E=]V;H KF.3XQT                        ](ZF2U$ &.ZYE
MX6_%7T;C>MY@                                           ;<Z[H
M,M_KK@GZW:    (_G$& #;!V^G!4 =6A5$:G+ZRK\ML/W*X"71(\P YPCJ#/
M[*&RI(V<=C)J@]0X_3'211U_E/1/DY[C0!V'G-.=#1J<PTAL>F35-ZFJSD+
M!/\ .OT 'FUTZ!RL$                          #+X]W;V/E_P!@ J!R
MT"G7+0@        -R6:[=<5.JYR4.>T&3@=RG9]JNK;)PYH0[^(U^2RBWM2W
M:,FI]JOR<.U/&3*B<K"VW:KFS"D;&MU5#9:%_@     -E6JND/7LKONS= %<
MQR?&.@                       'I'4R6H@ QW7,O"WXJ^C<;UO,
M                                     #;G7=!EO]=<$_6[0    (_G
M$&            #Z38)K4           G^=?H /-KIT#E8(
M             R^/=V]CY?\ 8 *@<M IURT(        2PBWI'Q[N!5TRCC7
MH1S(\FH]W$*O-P6JZOLE$FA#OP(G1K@L3.BA*L^Y3[7)D8MW.&GPOEV(+3H]
MT6'GQQD6JZ\A%     &RK572'KV5WW9N@"N8Y/C'0
M    #TCJ9+40 8[KF7A;\5?1N-ZWF
M            !MSKN@RW^NN"?K=H     C^<08
M  !/\Z_0 >;73H'*P0                         ,OCW=O8^7_8 *@<M
MIURT(         971[E5-6J[M'^&?6ZO(J\^CQC57GM>>XW5Y]7C:%NO5]RC
MY?7N4^Y'3[DM/ME^.ET^9:#Y_H    #95JKI#U[*[[LW0!7,<GQCH
M                !Z1U,EJ( ,=US+PM^*OHW&];S
M                         VYUW09;_77!/UNT     "/YQ!@
M               $_P Z_0 >;73H'*P0                        !E\>
M[M['R_[ !4#EH%.N6A                 #Z?$^8,F-TBUHZ_;     V5:J
MZ0]>RN^[-T 5S')\8Z                        >D=3):B #'=<R\+?BK
MZ-QO6\P                                           -N==T&6_UU
MP3];M      $?SB#                         )_G7Z #X:J=0Y"*
M                    !ZUNO:<&3_8 (4S(]1^5A
M     #[?%WV%R&^[-T :#.: QT                        %UQ:> #YXU
MV+/ROW#&];S                                            RS;<#
M*'ZCXG^MV@      1_.(,                         G^=?H
M
M
M           (_G$&                         3_.OT
M
M
M      $?SB#                         )_G7Z
M
M
M "/YQ!@                        $_P Z_0
M
M                                                          1_
M.(,                         G^=?H                        /@(
MUDHP
M                                                          1_
M.(,                         G^=?H   -2'-6:]+K#]R1Q+   &HSDC.
MS@  K@*,3T"V0MY     !QR'5^;< *XC8YMTHQ.D<
M
M                                   $?SB#
M     )_G7Z   "GPK/.EL_0XUS9)T8E3YTD'(8=4!R]GWFJ2?I:N:%,1+C"H
M C$7WG$,=F1S1&&E]1"8K\/%.A4IZ+W"LDD449G5$<V!K@Z$CFJ/K.F8I"+^
MCFU/F.C ID-&F!'4F;^
M
M         !'\X@P                        "?YU^@   Q0H_*PBQ(QPG
M^;?*(3J:.*$NB/V+63E#.D IO-'G5*;3*@"D8DV:\+ #W"STY;2<!,0DP4,'
ME'0\5.DGBF,ZEBFDT,9,;P-_D_SF").ECAGQ388^7DE>)NDN5
M
M                                       !'\X@P
M         "?YU^@   K@(#'CFH"5A"HOV.4TL8*X3IJ.>(ED1".S8XT25!U$
M J (3%]ANHK[.>4DH;=/E(<&RB81K<U.0Y+VRF,O].?PF&8^3;*RR](H'+A2
MHHR L=*]B_XK?,^+G0
M
M        1_.(,                         G^=?H   /.(,'C$^3]R%Q+
MHU48P8:36(UGS&'&H2C Z*2:0-/F,$AP#09K$F.<Y)*TF 3*/.(8&?FPS3!+
M C&?<?J27(5$BC2A+\C&><2M(HF_S6YZ!N<
M
M                         $?SB#                         )_G7Z
M          "!1^1/H     A2;@-[
M
M                              $?SB#
M)_G7Z                        ##S,       #$#+3^@
M
M                                 1_.(,
M   G^=?H       .?\N#-^@    H$)-FK"WPS<        A29(2R(#&XR11S
MX$P"QLV #G')ND/BSDB0;6)F$:2PX
M
M               $?SB#                         )_G7Z   ")!QX'6
M23] !I$A.:<+J2I\^4B87F%<Q^9N$L-!2(7=D>B+9X!KLF01N,:-:%MA!(Q<
MC>6Z$-SQC89[)/,]PIV+B31)!@L /P*FRT4D& :F/L*WSZC<Q*\V<4[%Q(
M
M                                            (_G$&
M              3_ #K]   !K4H!+V3=X *$2<)6@7_E3A= 50DX2BDGP:G+
MLP<YA-,BF7I%:9]9K@_4N0-4D+#2)=(5OD@BC\L#-(%Y0!3Z6ZG-86P%=!=8
M>410/L,')B$ERF@MT/.-6E5Q<:5AEPP
M
M                 (_G$&                         3_.OT      &&
M%19:6> 5V'X&5$"SH+*@B9YD1. %(A=V4W%I92"3:-('YESIJ,A":^/K(;ET
M16R2Z/N/N)E'N%.I<$:'!4X6-&FS "0I.<'BE.I=(5_'\$("ZTJH+C0
M
M                                         1_.(,
M           G^=?H      ,?/H/8!@Y$@WH5.EYY])ILW(?J#!S.#SSQ#\CY
M#[#\C-#XSQ"(QN$JV+G3*33)M\Q\RD%?QOPD*###,S71])G@!Y!\AD0--&R3
M"2#19N
M                                                    "/YQ!@
M                      $_SK]         ,,(BDH39@       !BY#TDB;
M9   /X-2&W@      #59L8^X
M
M          $?SB#                         )_G7Z       :K,3-HF7
M@ _PK3)L&U0    :E/P-P@   U>8>;-,S        /'--F_  8.9P:?,?-F&
M: 'X&ES<)_)H\&:FRP   >>:/-T'L P ]0RLUV8&9@;0 !I\SLR4T6?&>R8L
M2,/T
M                          (_G$&                         3_.O
MT   '\D."8!]( *%"P\BR2M)I&G3<9#0BZ64'NGW&/GZ&<'\&FC<9466$F1G
M@FS3WC#C,#3AM\_4%#9801I)#$X341N<\ _ Q VL#51FQ\1EAJ$VF?6"L GN
M;( ( F8DS3G_ "R0T.?X6J@HI)MGC$E"JTGL;:)!&%E6):69J:<-O'[GAE29
M,TEV0.-(FO2Q,J])Z&N"-I=J"GDWL8$6FG.Z6C&5'NFI">
M
M        !'\X@P                        "?YU^@   @@<>1U<EH8 *1
M"[LPTJJ/ )0$=#?Y&TW*:4+22%I&LMH*FB7I^Q7:6IGZF!$<BX$IX/P)%D8R
MZ,%(I=T8V5'DF3X301(<AF2$,H-?F9&DC/SS3;A%,NZ/[*="XL T,0=).$OR
MD4NZ!2R73 I -_EAAK,I4)H$Y3>QJ8HX+P2J0EF0M+V00C,A)=E*Q=2?D4S'
MA%W8*Z"0Y) J?/A+"C<AS0E@9)DF$4YEQ@
M                                                       !'\X@
MP                        "?YU^@   ^ K%+*#(0 <_!*P@B=$!SHD_#Q
M";!IX\$DX"MTUL68D'"YX%-)<L1$,>(H&ZR491N3J,/+BP4!$HB!YT,E5!EA
M',G4;A)/%-)\!=*:0()D."8YAA;B>Z4_EP!5V2,*?R7! TNG((%W0*1R[@ U
M44IEP)$4LZ !3$7.E,)<\4\EMA[1",R$EV4LETIX!4L8:7=@JH)ZFX@8F4NE
MMY5&7=@%.Y<0
M                                  1_.(,
M    G^=?H      !3X7!D(#+",YCYN4WX:J/$)%'G%:9CY941'/,-W'\&C"9
MQXYN(I0.@TK0, -G%D *?"X,AH?J0U,M-9DT#:I(HJ<)6D,SQ3:AGYI0S4L_
M!3L7$@ %2Q;24'$EC$B51-X%1Q]9X98D4V$J#=Q.T%(Y/(CL>$?F6X A^>Z1
MX)2E<YYA;H5+&RCQC-BSX%<!K4UL7)G/N3,,A+*"ILMV
M
M      (_G$&                         3_.OT
M        $0"*!J4MC-R@ $/S\R8@                       *["39O@
M
M                    C^<08                        !/\Z_0
M
M
M               1_.(,                         G^=?H       (8$
MPC[2OTED:=)9      %<)KTD436     !%DE, 1;-V&<&NBNHWV3?(M&Q3VC
M8Q$HEJ"N$UZ2*)K    $.R11G0              *_2P(%<)KTD436
M( D_@   5^E@0  (=DBC.@
M                           "/YQ!@                        $_S
MK]   !BA3$7!FQ0 ?,4"$Q2S\IB+'2,1-XKF)KGG$DB/!M@_PUX0H-Z$U@4B
M%W96\;6-ND$RPD]DK>)7E.1-\M8 *1"[L HX-@EPQ1V78FEC?A202X-B&BS<
MI,H%(A=V5O&UC(C71+DK>)PFVRL\WH:;,R,)+)R/A)HC4;_*UC?9,0B21D)D
MDB"$IK8L@(BD;BQXS U@5[DS211!LT,6(FS"OL^@B\7.@I$+NRMXVL8H:_+)
MR'QJ4LD(U$FR/INPU"0<-%EY9%TBD63FES"C2A9,4V$D3VR>)$TB\63E>)-X
MQ4V<:,(TEEQHPA26!FV0
M                     "/YQ!@                        $_P Z_0
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MPR<TH61%6)8T5^FJ"[T^0S<
M                         C^<08                        !/\Z_0
M   #61LT  YX289'\G<1/+'2,1&PNP*CRS$JF-KF%'WEK) LA$7O@YS":9(H
ME^4_ERY2H7%D B-1FA:\:_(P$Z"ELN[!0828->&R2S(R,IM+5BH0EP::/2))
M$P <YA-,D436*8BYTYZ"Q@^,GL02(1$I22!*<I;)AD22?17D76$/#&ROTOJ*
MESUS!R11NP]@@.;T)_E,9) KQ.AHIB+G2FDR L[,A*3B\L'.833)%$U"+17(
M;4,,)1&Y"O0NF*;"T$JW+FBAXM1(XECQ2F9:6*&X2F<_4N=(1F0E89/<AB24
M-%'QEE9503H-F&X"!9\):J
M                        1_.(,                         G^=?H
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M@DJ0
M     "/YQ!@                        $_P Z_0
M                      ##"K(F.2Y  *R2S8                     %
M<!80>N
M                 #5YSH@                        $H"]X
M
M
M            &M
M
M                                         #Z380  !C)C0
M       !_\0 .Q   0,# 08% @4$ P " @, !P0%!@ #" (!%187&#<0(# V
M4!1 $S0U.& 1$C%P)TB (R4D)B&0L/_:  @! 0 !!0+^/S*;Q<?M'5&"JZHP
M56C* %W-<:),!F&KP,V4$^'9)".3$[)1#^WE!Z$\+?>J,%5U1@JNJ,%5&S^)
M)<]^68E@=P&EN98E2W6C+T.N6N.RN-2U'4X*T!&]VSDZ#E%WRZM6G1IU90@K
M3JA)?')&6^-[)T')[O5&"JZHP53.?0X^Z[5VU?MT]/+;'6GJC!50V;Q<@-#C
MDF%6IPZHP575&"JZHP575&"JZHP575&"JB\I8)FR>$W(\+'"3JB!6VD]_0IL
M5-R-#!PDZHP575&"JZHP575&"JZHP54<D;-+63QR*GKP.QE?>WE2Y8JD203V
M!^8S903X=DD(Y,3LE$/T)K/8F.VOJC!5=48*KJB!6VF$P"^37?5R*GKP.QE?
M>WE2Y8JD203V!_[*S'[158B\E565C"^MVBW<N6;F/>3+Q8=:RC[ZXG=[/M\F
M(Y(5YNX0EE<(RS9X8P-3BXF?R'S*-?=67KUY3>:(3,Y#:>(W(H[KCDGD$1=
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M9O)XC,<D.C* ;PX8V3B0%4> H'AO PL_WO)@O*7D^^+RCN.+/CN*9")(Q61
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MEM3L)#LDN_2@$JQ9%$))]=* 2IG:43"T>$J%0]FSMY<9.\WW&4#(GDN0O1-
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M?,A>ER?UTN3^AQ$7&#Q/*_LEC2QI&,,UD]8T-!DG#O>C\+POCJ;1$:+4813
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MYAP"N8< KF' *YAP"N8< KF' *YAP"N8< KF' *YAP"N8< KF' *YAP"N8<
MKF' *YAP"N8< KF' *YAP"N8< KF' *YAP"N8< KF' *YAP"N8< KF' *YAP
M"N8< KF' *3SJ$++_E?)/&HS;YL"RN; LKFP+*YL"RN; LKFP+*YL"RN; LK
MFP+*YL"RN; LKFP+*YL"RN; LKFP+*YL"RN; LKFP+*YL"RN; LKFP+*YL"R
MN; LKFP+*YL"RN; LKFP+*YL"RN; LKFP+*YL"RN; LKFP+*YL"RN; LKFP+
M*YL"RN; LKFP+*YL"RN; LKFP+*YL"RN; LKFP+*YL"RN; LKFP+*YL"RN;
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M9\GBYWU^;3J+J6ZC66EEKR$T9-)&:9!'W:+.WR.S;MV;0D;=CSL\DNB+!.6
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M W8>OWJ;-NW9M"1MV/.SR2Z(L$Y8#$'7\1O_ -F/($]DF5'B"#0;.]1F+O\
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MW-N7Y(R6&2VV:LL7E$P(<7W%).8+BK KO,XC2Z[.YRC)CE#,9NMV7UUNR^C
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M'%"&3/6@Q=@$ UDM?"W.:X_'%(.M3GBO!)W<0XJ0F$ZRFX05TFV#?YR@68G
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M *X K@"N *X K@"N *X K@"N *X K@"N *X K@"N *X K@"N *X K@"N *X
MK@"N *X K@"N *X K@"N *X K@"N *X K@"N *X K@"N *X K@"N *X K@"N
M *X K@"N *X K@"N *X K@"N *X K@"N *X K@"N *X K@"N *X K@"N *X
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M:<IO(2AK'"C'",.9&,9'Z]FS>47AT+HF XP4"A(RM(ZC$8?)D^7N",1XE()
M\2IXJ)& EP5,[Y%&E[28>)-3#'&Q"YSV99>OJ-N4?;8WY(;EK_/DO6;2BU(8
M]=:+OI93^0V]V:-@X4K:U$=,00T .V%3E_<S),(\P-D79_#(+W=0?U;(N7/
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MQ*8^.J'0\D!/DT_@CX-Y13<'),O&;>W+W=:S8>EUT23K&TJ0)!2)$L<E3)B
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M$9&7W)DQ)#38DE>'XL>$0EQL0+IRFL:$J<AXMBN-0/%H<PTC2/)\1#@:QB(
M''V:12;1=7"I;C.*&LGS+* >",9, 1Q:73YNM8K@VW9*F':&TWZ]&NUK<<6
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M@RG)Q<&D2ZRD3;NH&N+@["4TD@B-16QBBZ>-!XQ"8]D62!,;',>/6:,<3+H
M$HPFB0L.YIF<JG0XR9(0^1/1E)[X^-&O7<:5A+([BDPB]WYM^QL+IY]:R9IP
M;8B?,88+P6*R"]Z#7D6ZV'.PPN..62;JY"QK(;)%<HXVDCABN:]EJW.C'.YS
M(L59P_3<:YG)+*8L0^-I(?%)>!\E)H]!2*EF'-F42)HB9A=-G&$0=\;\B&E4
M7+AAV+ !)F62"<BXZFMZDI':LCHK$O)BYWU\BS\IZF6RF[?OHTB= D\<J^V
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MB2Z7G=^QD,[$H#&.Q4T3W+"5,TI*_HHT:MP5X]8])!ND\CFYIFI,Z.BEV4_
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M66+QF-Z6J/L+#3W'(])4]*$]A78:&1FCZ.='B+CB9HRL,5Z4[$EO+FQB:4[
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MQL[K'3J1M$>,9:;J^A3I,X>X]-]'KBN^*AIKOO$Y>CGFR4H>HG8#/*_\H._
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MI_6/M6?IV]4\V [2.+#'O6<XL?5\A'TZ^K:7ISZW>^HXX\.B;?Q#D^/O>1)
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MT9O&LIA_3:QUW=4(:.J0;C_3'=OM=&GET7G.*2=9;LK&?5I%5X:MY#LU:SC
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M_P!LE_R+-&9KO:)>FEHS&OJO!E'=-O$PF5::]J!^@J(:M)G1MC97CU)V?:/
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MI?@]M'M&J31Q*I*6>HG%4T3OPC5XJ8@X&75HF_.<<<=WU5IKIKPO6W1=$O\
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M;=%T2_R7;'65D9^B>)H(&'^[\4D@\WZ5?*<3-]G<<>'1-OXAR?'WO(D@ DG
M#>;3SF4X#8@W#E[)^6ST3AA,IY%&\^T.SWK*H4  8 >CVB6B4]_S\(J,\-U0
MOY;+N:H8;Z>G/+Z;+NC'*Y M3T\%)!%34T20P0H(XHHQ@J*-P [I)VL<2222
M?L9TUTUX7K;HNB7^2[8ZRLC/T3Q-! P_W?BDD'F_2KY3B9OL[CCPZ)M_$.3X
M^]Y$D $DX ;S:><RG ;$&X<O9/RV>B<,)E/(HWGVAV>]95"@ # #T>T2T2GO
M^?A%1GANJ%_+9=S5##?3TYY?39=T8Y7(%J>G@I((J:FB2&"%!'%%&,%11N '
M=).UCB2223]C.FNFO"];=%T2_P EVQUE9&?HGB:"!A_N_%)(/-^E7RG$S?81
MJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CM
MJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CM
MJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CM
MJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CM
MJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CM
MJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CMJ/MNY\=M1]MW/CM
MJ/MNY\=M1]MW/CMJ/MNY\=DB"G'''DV;O)2Q-+LUF5>IRX[>4G,+<#_K/S/]
M5N!_UGYG^JW _P"L_,_U6X'_ %GYG^JW _ZS\S_5;@?]9^9_JMP/^L_,_P!5
MN!_UGYG^JW _ZS\S_5;@?]9^9_JMP/\ K/S/]5N!_P!9^9_JMP/^L_,_U6X'
M_6?F?ZK<#_K/S/\ 5;@?]9^9_JMP/^L_,_U6X'_6?F?ZK<#_ *S\S_5;@?\
M6?F?ZK<#_K/S/]5N!_UGYG^JW _ZS\S_ %6X'_6?F?ZK<#_K/S/]5N!_UGYG
M^JW _P"L_,_U6X'_ %GYG^JW _ZS\S_5;@?]9^9_JMP/^L_,_P!5N!_UGYG^
MJW _ZS\S_5;@?]9^9_JMP/\ K/S/]5N!_P!9^9_JMP/^L_,_U6X'_6?F?ZK<
M#_K/S/\ 5;@?]9^9_JMP/^L_,_U6X'_6?F?ZK<#_ *S\S_5;@?\ 6?F?ZK<#
M_K/S/]5N!_UGYG^JW _ZS\S_ %6X'_6?F?ZK<#_K/S/]5N!_UGYG^JW ^639
M][A_\K*H4  8 >CT#0I-&U1$\\"N#+#'+J'D0;T$VKEU>;=FU;$#=MVBG\4V
M"D@BIJ;1Q(8(4$<44=Y8*BC< /F=ZY)VL<2222;>.K]P?UI_#K>.K]P?UI_#
MK>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]
MP?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_
M#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K
M]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI
M_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.
MK]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?U
MI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>
M.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?
MUI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K
M>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P
M?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#
MK>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]
MP?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_
M#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K
M]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI
M_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K>.K]P?UI_#K7_P"*!6WQ1FBI
MJ7YF12XBJ9:DU$L\?I0?44^JC.W6@!C(,%S!,ZO_ /Y@ZL5/?%E8,,1Y&> 2
M#$;''=[!]HV((.!V$;QZ);MHWV@GUG0MT_[7Q\H]'J>HGI)XJFFE>&>%Q)%+
M&<&1AN(/<(.QAB"""1;1+2V"_P"#@]1DAO6%/+8MRU"C?44XY/38M\9Y4(/V
M,Z0:/T>D-&:>H&KGCS-25:J#)3R$>MGB? ":$D!P 05D6.1+UNJLN:LDH:Z/
M5RQ[588F.:,DY)H7P&>)\#@< 00R.JR*RC[/%8J>^+*P88CR,\ D&(V..[V#
M[1L00<#L(WCT2W;1OM!/K.A;I_VOCY1Z/4]1/23Q5--*\,\+B2*6,X,C#<0>
MX0=C#$$$$BVB6EL%_P '!ZC)#>L*>6Q;EJ%&^HIQR>FQ;XSRH0?L9T@T?H](
M:,T]0-7/'F:DJU4&2GD(];/$^ $T)(#@ @K(L<B7K=59<U9)0UT>KECVJPQ,
M<T9)R30O@,\3X' X @AD=5D5E'V>*Q4]\65@PQ'D9X!(,1L<=WL'VC8@@X'8
M1O'HENVC?:"?6="W3_M?'RCT>IZB>DGBJ::5X9X7$D4L9P9&&X@]P@[&&(((
M)%M$M+8+_@X/49(;UA3RV+<M0HWU%..3TV+?&>5"#]C.D&C]'I#1FGJ!JYX\
MS4E6J@R4\A'K9XGP FA) < $%9%CD2];JK+FK)*&NCU<L>U6&)CFC).2:%\!
MGB? X' $$,CJLBLH^SQ6*GOBRL&&(\C/ )!B-CCN]@^T;$$' ["-X]$MVT;[
M03ZSH6Z?]KX^4>CU/43TD\5332O#/"XDBEC.#(PW$'N$'8PQ!!!(MHEI;!?\
M'!ZC)#>L*>6Q;EJ%&^HIQR>FQ;XSRH0?L9T@T?H](:,T]0-7/'F:DJU4&2GD
M(];/$^ $T)(#@ @K(L<B7K=59<U9)0UT>KECVJPQ,<T9)R30O@,\3X' X @A
MD=5D5E'V>*Q4]\65@PQ'D9X!(,1L<=WL'VC8@@X'81O'HENVC?:"?6="W3_M
M?'RCT>IZB>DGBJ::5X9X7$D4L9P9&&X@]P@[&&((()%M$M+8+_@X/49(;UA3
MRV+<M0HWU%..3TV+?&>5"#]C.D&C]'I#1FGJ!JYX\S4E6J@R4\A'K9XGP FA
M) < $%9%CD2];JK+FK)*&NCU<L>U6&)CFC).2:%\!GB? X' $$,CJLBLH^SQ
M6*GOBRL&&(\C/ )!B-CCN]@^T;$$' ["-X]$MVT;[03ZSH6Z?]KX^4>CU/43
MTD\5332O#/"XDBEC.#(PW$'N$'8PQ!!!(MHEI;!?\'!ZC)#>L*>6Q;EJ%&^H
MIQR>FQ;XSRH0?L9T@T?H](:,T]0-7/'F:DJU4&2GD(];/$^ $T)(#@ @K(L<
MB7K=59<U9)0UT>KECVJPQ,<T9)R30O@,\3X' X @AD=5D5E'V>*Q4]\65@PQ
M'D9X!(,1L<=WL'VC8@@X'81O'SS?L&^RTCD8LP3N^ =VW! =TH/K?ZC:2%X]
MI&(Y1N\/D0"Q &\G >O8QT\6 DQ9CZO>&& ]6TNIV&+';CB-NSM[?(E6 Q*L
M =Q(('SB*%I=VP#>3[7*?EC;@G)*">3#_4>]9T:-LK;^_P!D?/=VT;[03ZSH
M6Z?]KX^4>CU/43TD\5332O#/"XDBEC.#(PW$'N$'8PQ!!!(MHEI;!?\ !P>H
MR0WK"GEL6Y:A1OJ*<<GIL6^,\J$'Y]I5I5SL\ _D'#>&\*_WK@VJX-P?_P#Y
MY\^?7_:Y<OGLVSFZ1Z8QZ.WA1T<U"U1%4Q+-)4)49&A0S-$V6 POK2H7.!KH
M\W2XC?:">&IABJ()%EAF19(I$.*NCC%6![(^/;S+WK_F7=M9>&JU_!(3+J<^
MJUF! RZS))EW[\C>I;1^^/F[=<%Y<'X+KGF74ZW7Y=3*\6.LU4..;+CT@PQP
MV[[:0:2UUS5D=+2Z/U=ZQO3).:B!YE1':6:,PD1T52,RB)7)S@X2#H!L+<_E
M[_\ HR\ORU5_]3;G\O?_ -&7E^6JO_J;3>*554TBQ5&C$\$K %8YJZ2*1@25
M!5'NQ6()! (&T@BU]:47A=4]-#!HY67B)Z*&J>2&291!+(\JM3-DH)P7CU8)
M)9#T8QC7>?'$JTJ:6GJM&:BC-5,D2-45DD?3.J,RK)=L>?)G!(!Y!B,>965E
M+04\E763)3T\0Q>60[!Q  #%F9CL5%!9C@%!)PM+XHL<LKI<]QWA>BH<#("T
M.SJ@D5/5N ?.ZP1MAM(!V6N_Q0KMGJ!2WG25-S3DJ,:GHX%9L-DDF6*2+:>G
M> 1A>B=T%@0P#*000""#B"#M!!&\'B/,OC3JZ;LG-' DUYUJN8VAI,,B2#9J
MVF.(,F.S+"DI4XJ^5AEL/%%D@*M>>C=XT,#$ 2YV<G''<L]+1JQY!K=NWDVW
M7>U!?%,*N[YUGBQRL.EDB?TN:,]%&_'@PZ(8,I92"?G.D^D'.Y00UW!.&:VL
MCI=5K^#Y<\-1-K,^IGQPU&7+D&.;'-LP-WU7#Z"AKM7JN&4=-5:K-GU?"(4F
MU>?*F?)GRYLBYL,<HW<W2G2H:,F[\U":P5QJ<2*G4&(4W!L2 8)M86X1L&:/
M#)OZ+%:&NIKRI(*VDD$M/4('C8;^RC#SLB-BDB':K@J=HYE9/P6DJJK+K.#4
M\T^3-ESZF-I,N;!LN;+AFRMACC@=UM&-(.>.@FKN"<#U59)2ZK7\(S9(:>;6
M9]3!ACK\N7(<,N.;;@-(M(*RY'I5I;DJ;W%0LK.U.\JZC5E H;5TE5CK,Y(Q
M*=*<,>+G\O?_ -&7E^6JO_J;<_E[_P#HR\ORU5_]3:H\4FKI,HJM%ZBF+XY!
M45LD.?+AFRZR[%S88C'#=B.6UY:45]#0W160Z/5=:]YT[SS4\4DV:A(2G=8Y
M&2AE+%]<P!9(?,CT)VY9_%&KJ50]5HK5TR,V56GJYH59L"<H:2ZU!; $X#;@
M";02Z^"&;+EUT4<N7''+K$#9<<!CACAC@,>06EEB@C>::1(HHE+R22,%1$48
MLS,=@ &\FU5XHE'KVI[GNRMOAU\]&&AC;;M* 0SSE>R\"8GL8&U-XHM()E@O
MBZZZZ&;SSXSHNWII T5/.%[*0R;=F&&VT,T51%'/!(DT,JAXY8V#HZ-M#*RX
M@@\HM>NE]Y7=>%310:,5U?% RJE7%).(YLT:.2H2[IE&4L4.$K;5.[<+KTZG
MK[XI+HJ;AEN^2J+#--5OGC BDE#:AZ"%F#:O =$N_'$X8?4ND&C]'I#1FGJ!
MJYX\S4E6J@R4\A'K9XGP FA) < $%9%CD2];JK+FK)*&NCU<L>U6&)CFC).2
M:%\!GB? X' $$,CJLBLH^SQ6*GOBRL&&(\C/ )!B-CCN]@^T;$$' ["-X^=T
MB@NS=2-GK\?RY;2NSN<>(D <@^6_F&1V7(S8@'';O[=M^P;39:64\B_?'P8V
M:EE QZ%OO3M[H',@@?%),5R[^/'O8=VTU.\CY@5PP VD^ VDC,396PQ(QV>N
M.,#DLD+R=*-G*=@^7J6X)+RH>QB?!9E9#@PP-HX6E!*E1ARX^T#::)I$101B
MN&...&[#D-I('B7,Q7 G#9CV3Q@<EGA9%5R5*MN*X^J-X'-DA:(#,5Z+B&./
MK[.;M%(,G^+\;;\N2RXXC+CFQV8;\;59VH//!3CZ^[V_GV[:-]H)]9T+=/\
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MB"R4M.AJRF/1ED(&9$-KKNJAN>E2CH85BC4#,V UDS@;99GWR2-O).P=*@5
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MN"[FR10DX:P8@B#$'#75&"RU;IB8X\L2OYD]D18U5$4(B*$15&"JJC!54#8
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MXE3N)36/B1N:*DV1G$>6U63?A9$6-%C10J(H1%48*JJ,%4#B  P Y/(>*?\
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M*6TST:EOJG@K+O.2];OQ:#!LAGCS!]4)-F25'&LIV)RARRDKK-8EV>*## O
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MKS6H*%ZE:UJ*D:L08)5M3PFI08%<%G*:U1E8KL;<2-Q\A/!!4Q/!4PQ5$,F
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MEB?>I[S*PP9'4E'0AT)4@_8,_2M]Z>]Z+HY0]BP((Q'D9X,_1ITW&.J^/O\
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M(P4$J"Q"G#%@,=Y&^UQ7[2:0TDE;11U,4452]*RU21))K$BAE) BFF7)EF4
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MP$-ES?@*835+*00<T1&T6@ACIH8J>%0D,$:0Q(-RQQJ$1?64 >0\5#Z47?\
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M#.%"E?* /$P^D%7_ 'O/^Y4%M+])4T?H<(L&O&K#I2(=HC V/4R?:Q8C(O\
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M6]OLGDY+:^;JSW.]AA96%2I1\!(!B&]OW0^0(P)!WC8;8JL,;L,<B*5'VQ4
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MR_+D]'KEN6MOVM2CHT^VFF;'54\6.V64]Q5'12-T*]BY+DHKAHEHZ->1IYV
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M(Q"T+"76EMO-H6FZ%[Z9?&F)GP%:.0WE1/@+4"_!?(/!5LTC#F"E1I*4A#R
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MGB&I(LZ&G4*0I2#B#@21J/$1KXO[K4Q1*'$\25 C^<#CW+2OF=[[@VIWS/\
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M93@5?^'R%2#@GHM=)DJ4C 8K<24)Q./-RFZFXFXB3XU-O&HEIE1P)YZ/(RC
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M ((;>;>9:^HM]2BH-)X]OH\78XS9MM+8P&WC/+^_)S%)2L8*&/[\5@ D  8
M6<^:4?S?=\0=0QY+,C2K6XK9L'H]Y/=LUXVZIH[#T/N>MZXYBNA5V#W+1>A5
MV1W.8I(4"D[#:,2"M!XO^QM(\B/9'=LSY$CL>Z>9)\C_ )P]VS7D:/N1S'@6
MUAY/+POWZ]DJ"@%#8;/.9$ZNB.I/?]"S+>1.)Z)6L][]^/FO>1+[%H_D0[)[
MOT$M 6,JO^W7%G&RV<#Z!Y?WXQXF-)5'5B-:#T2>7KCD4/[C9MQ+B0M!Q2?W
MP/(1]#J4$)*E:@D$GL"R9L=2<2O+RI4#B.UB#Z&-L=_2DX#QEKEXQWUG5RY1
MUOHJ9#R8NM#@;5H'E>N/K>4>5[&SS=6A#J%MN(2XVXE2'&UI"T+0L95(6E6*
M5)4DD*2000<#JMNF[F2Z MVNT)I3E$<5FE14XK725K.T;5*@*4<$+.)CDAMP
MY,BS]3%WKPU.[%39JM*>T;[?!<;5B6)3!(+D:2V"-(RY@,1B%H6$NM+;>;0M
M-T+WTR^-,3/@*T<AO*B? 6H%^"^0>"K9I&',%*C24I"'D @AMYMYEKZBD:Y*
M_P"=WNYXESYI1_-]WQ$A>"0@;5]S^_99M.1 3V^SQVD)Z%P;4G7[GK]VR%9T
MA0XQ_P![*Z%78/<M%Z%79'<YBUI0,2>P.,VC \)9\M^YM(\B/9'=LSY$CL>Z
M>9)\C_G#W;->1H^Y',("@0=ALTK1+4TO9M!_?E'KV1X\Z5GH$=".YWSZ \0]
MY$OL6C^1#LGN_0:T)6G!7_;KBRA@2,<<#M''XF*^XTX @%86<"WR]<?7?N?H
M@PXQ.):'H%21V@H#UK(0AL94)"1R#]]?9/T7.8;:6"@@9]9;Z7KCD2>3M:MG
MFZM"'4+;<0EQMQ*D.-K2%H6A8RJ0M*L4J2I)(4D@@@X'5;=4NI2+KUMM-(EM
M:*>A<E=)!4I^F<(8:\"!%?Q)C)<4'DA"TX*;2E9^IB[MX:I=FJ,52DO%N0V<
MCC1Q4Q+841GBR6@1I67<!J!"T+"'6E(>0VM-(FOU&F09TF"_3'Y49MYV!)*2
M]&6L8EM93VTYDMN9"G3,LNYVD?42OQI\+\JK;W#W_$N?-*/YON^()6XZ5H3F
MRG5CLZW&.S;/)\[3^_\ /L52% @MIP(P_?A6CJ*2IM6H[1[H]VRNA5V#W+,H
M6L'*LHU\6/N&VA=\^5VU=^R4 .Y7<3TIQU'D[?9VZK;-0V6D>1'LCNV9\B1V
M/=/,D^1_SA[MFO(T?<CFR@,J5<>.'H$$^Y9L!*$@<@]?7XA[R)?8M'\B'9/=
M^@WW\> C9QGEZPZW=\2E)40E(Q)U #CM$B!@9E:W3M/2_6I]T\?8\TY4I,=.
M UN'H4\GURNMW>V0I2EJ*E'%1UDGS>W1-T2+<^*8<,MR;P2F\8\<\)N&VK4)
MDP#B\X8U*?4,3@T%*M,F2JA*?G3GW)4N4XIU]]U69QQQ6TD^LE(P2E("4@)
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M)@'%YPQJ4^H8G!H*5:9,E5"4_.G/N2I<IQ3K[[JLSCCBMI)]9*1@E*0$I 2
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MZ@?$I<;42$K0HC:$J!([(!U?*)$IN/J5BI9UA([I/$/7ZUN>)VJCJ">7-WT
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M'?EOM1HS+DB0^XEIEEE!<==<6<J$(0D%2E*)P  M W&*EO5$R\E=I=VFW/\
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MU\NP=C$X]D"T9I#32<HUJ2"I7&HD8[>3D',2PTAPN(0$J(P.&S;CLV ]BQ(
MQ)  VDZA950CI. *E_<IU>R*;)J$=1P.='74D8>Q*K;=8U@[#:7+;RNL8+SX
M9<<$Y<?38^M:+,:8:R*2LG,3P0G#7V5"S#Z7TE: H *R\+ '$ 'B)Y;/266=
M2U<+I1K5VN+T<+"I,<C@ZY2GW%$^M9#B'$YD*"AUO=&T>C9^4W'*0L+.88C*
M =G94+1I*&77'%!1"\<,H&.M6.O%0[MF);;ZBA 6"$YN$$@8 @<2CRV:DMNK
M4V M*T8XA8 V' X8*.SFLR4/E00E>"-JB !UL,%$Z]NSFX U(Z3 ]+CLZ 9?
MWZ:R\H2K/ADP.;'9AU[4T'*Z?*E8R^ACCW1\N(!!!&(.H@["+2XA9.=&MH]M
M!Y#UN0^@=>WS=F0XM0BOP9S#<J)*;4T^PZG,VXVK:"/72H8*2H!22% $;HFY
MW*N?*,R&')-WY3F$>0>$Y#<5K$.81Q^</ZDOI&!P="D_+?\ )_\ ];?^ _\
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M4A(U)T92U#PP&&]#AJ/B-PCY[JC_ +N2_P!)TBU\?GNO5_O'7/TG*YO^3_\
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M3I_-W&KP(I]?>H4S*J!>)G>V1S M;^:2LL!04""F0TI^*4?Z1;K(5B$BU\:
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M&QCM)V#'"R22 2,">+;AW.8MU#>TZ^0;;;X/$THCL_JFR9""<#B@]?9V^_\
M0+C8<&!V\1Y/[N464DH.56WN]<>)B2RP<JM;1VCI?KD^Z./LV2H* 4DX@ZP1
MQ_*)2I*,BV!F2G$K3M*O0XT]@XX]BR*DW_I$+0KK<(>X1VK*J+ &K.H_<X>N
M3W[-(=E2$R%IR-HP*?YO0A/+PM:CLVVGLJ=:!0,2V<<HVD';AUQJ]>S50;"$
MI<"DJ2,#@,0<-6/*.QAJLN87O&HR%%:M68C#*#JQX^V<,.O:F?Z?LH_Y[2OF
M=[[@VIWS/_ZBNXFSB$NH4A6Q0P[Q] Z[(=>@G1NH*FB3E4.ZD[.RDX:^3CYX
MQ\/+]C+K[N'KV9DO/O<!O!@ XE7=QZ;ZT=?$\8LE>\Y3FD2<J\V!&W*58A0X
MCR'KV1.:<<0V@*.8X8X8 :M77UG5UMO,D9HDA3B-CR%8=D[?12K!?HBT%K1L
MYCT3O"/8\KZVOT>;*9+[)2.B!"D]D<7H@D68FZ%(9?0L% P!PUX#8"#ALV @
M[,-7'9518 U9U'[G#UR>_933\U2GL@;&7@XZLV&P8[5'ZXX#BM#D%>++B2EQ
MH8;,!@-6OI2-F''Q?0! (((Q!U$'81:7$+)SHUM'MH/(>MR'T#KV^;LR'%J$
M5^#.8;E1)3:FGV'4YFW&U;01ZZ5#!25 *20H C=$W.Y5SY1F0PY)N_*<PCR#
MPG(;BM8AS"./SA_4E](P.#H4GY5_D_\ ^MO_  '_ *S;PGK^_2J/ZIT[X1;P
MGK^_2J/ZIT[X1:\5QKR76C,2ZU#:C,2'][-*1+BR"IW1K=RY6'7% 9$*.) '
M%MMN6?YNK\_<U7]!IYNY;?6->6-&NY>#(_5J2MJ729+YQ<EHB8Z-:5DYM_PT
M%25E)S28BEYPL"5GW8?G]JOWO3/T=&MN.W&9J\@WGJ:4NPJ;*T4"*<"'Z@TE
MMW3OI\YB!QM3:#Y*^4E7C;2D.W[NAND7RK*Y:Z6VU3HV=FE0U52G8,1R1F=6
MD22G?,DI2X^O6=3;(46V6[>$]?WZ51_5.G?"+>$]?WZ51_5.G?"+38;].FRZ
M?*2$2H,J1#DH"DK"'XSJV7DA:"4+"7$* 4DE*MH)%MQOYW+^_>C/YC5.9N;7
MSI,>!-N7>O+SAJFE#$ET^-0W)  =9>5M88<6 ^S)3AO26"ZK!+A>8J^XK7VW
MM-=V3"K=,>\<BN[Z9CR-$K6C29RF*[P2,'F'BEW JT36(1:[VY6Q=U:+Q7^J
M-.AP("TOH@!W3)?=;Q6A$I>3*X,R0I,.*)+DKR/4,6U[H=\EWRK>^6@MJEP4
M*C4QAS4O1E69V4ZG$A+TI025)!X#3;+9)+94JZEXY5U*Y#K,9.ET!4W)CYLB
M941T97V%*P.!(P6VHI4&WD-.%*LF!O%<JD;H^:]5R*E#$Z2E"ZG2Y*@R=/E
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MI76\W#0W":;)*=MJ9N74V=N?NWK<J[[=0WA.J+3:=!SN;;A:?^"O@ME\O.:
MI4ZEY :6O+H',F*_H&YU\:G<VIB;".FBO9$5"GK64L36$D]8Z*0UBHQI(25-
M*)2H.,N/,N4"OTR\M,8JM*?TT=[@K0K!+\9](!<C26P3HGVL1F3B4J24NM*<
M9<;<5]13J]&@GCV#LV::S>..<(JU@'NGW!LPYA2%#!0!'7LVVEO'#'6?W_?;
M:5Y&/NQW%6;\C1]PGN#Q#QSK2T.RK]^L-=EC0NH6.A.H^AJ/K:^SS?Y7^_G?
M,(!U$8CKV T+X Z%>&KLZAVCZW,C=$Y^_&>8KH5=@]RT7H5=D=SF/MYDYAT2
M>Y^^L69<TB,>,:CW_1MLUV1X\[G/0(Z$=SOGT.;HD9RO#$GEUX'EYDA *"KC
M3Q^CAA9DDM))[':)'T"XV'!@=O$>3^[E%E)*#E5M[O7'B8DLL'*K6T=HZ7ZY
M/NCC[-DJ"@%).(.L$<?RA3;:^B0A7W20>Z+!ED;&FQV$)'N<U332CBIMM1Y5
M(23ZXLE*4:DI2D<B0!W+)0A&.1"4X[<J0G'LX;;$!0(4 0=H(Q![(LE*4#!"
M4I'(D #M#F$ C @$<AUBV@9\Y:_%I[U@ -0U#D',4E*]2DI4.10![M@AMO%2
M4(1@#B4I"=6TXX"R7V5IS)<1AUR 1V0=8]&SJM^R4-HUM-]$1R>65Z.I*>OK
MX_$J0A?1)2K[I(/=L&61K#38["$CW.9@ 2<!B<,3QG#9CRX?0) (((Q!U$'8
M1:7$+)SHUM'MH/(>MR'T#KV^;LR'%J$5^#.8;E1)3:FGV'4YFW&U;01ZZ5#!
M25 *20H C=$W.Y5SY1F0PY)N_*<PCR#PG(;BM8AS"./SA_4E](P.#H4GY33Z
MQ5Z3I>=55J5,WQH]/SOG28>FT6?1:7>[K>DT>D<T>?')I%Y<,RL?!C>[JJO'
MZN5/X5;P8WNZJKQ^KE3^%6GUVMU5M#-4K%5J33:](VU/J$N8VAS ITB$2'G$
MI7E)3F "L"1C@;1:Q5X,=^'"JE1AQ)6;?,6+.DQX\C.C1+T[#3J&W<[?C:M(
ME69' .*=7-CR)$1YJ3%?>C2&5AQF1'<6R\TXG8MIULI6VL<2DJ!'+:9-FU%]
M4JH2Y4Z4L)"Y,R0[)?6$)"$!3SRUN*"$ )2"HY4@ :A:#>"O4QDQJ;6ZO3XY
M6ITL0:E,B,EQ02%.%IAYM&=02D*5ES$)2"=0MX,;W=55X_5RI_"K>#&]W55>
M/U<J?PJW@QO=U57C]7*G\*L\\](>=D2'7'WWW%O/OO+4Z\\\ZHK<==<62MQQ
MQ9*UK62I:B5*))M#JU5IS;[-/J=0@LR@$RFH<V3%;DI"5) ?0PXA+P"5K2 X
M%#*M0V*/-@URM4Q)13:O5*>@XXI@U"7$2<3B<0PZV#B=9Z^NTRH3ZBYIJA-E
MSGM?CLR2])<X1Q5PWEK5K.LZ]9U\V/)DQ' ]%D/QGD['8[JV7!V%MJ2H;!QV
MEWBO!4&BQ/KM9FLD$%F74YLEH@X8@MO/K3@<!CJUX#Q,&HU"F/&339TRGR"@
MM%^#*>B/%M125-EUA;:\BBE)*,V4E*21J%I$F1,?<DRWWI4EY6=Z1(=6^^ZL
M[5N.N*4XM1Z92B>8JHU!<)%-7/FJIS3A=;@*E/JA-NG$EQ$4KT"'"5*Q6E 5
MK.O6>; J51I;RI%,GS:<^MLLK?@2GXCRF5*0M32G(ZVUELK;;64$Y2I"%$8I
M&'@QO=U57C]7*G\*MX,;W=55X_5RI_"K3+QWAJ+"HM0KU9G15E*EQIE4G26%
M%"@I!4R\^MM10H!224\%0!&NU/K%7I.EYU56I4S?&CT_.^=)AZ;19]%I=[NM
MZ31Z1S1Y\<FD7EPS*QYB%K:6AUI:FW&U)6VXA10M"T',E:%)(4E25 %*@001
MB#C:?4JC5'DR*G/FU%]#890_/E/RWDLI4M:6DN2%N+#86XXL(!RA2UJ Q4<8
M%;K5*2XW2ZO5*:AU06ZB!/EPTNJ2,$J<3'=;"U :@5 D#4+>#&]W55>/U<J?
MPJW@QO=U57C]7*G\*MX,;W=55X_5RI_"K2I4J<^Y*FR7Y<IXA3LF4\Y(?=(2
M$@N/.J6XLA*0D%2C@D ;!:!5*E2G%O4NHSJ:\XC1..P)<B&XMO,%:-:X[C:E
M(S)2K*24YD@X8@66M3BE..*4M:U%:UK)4I:E'%2E*.)4I1))).).L\R#5JI3
M%%5-J4^GJ.U4&9(B*.(P.)8<;)U:NQJM.JU5JA"JE4ZA45).*3.F2)9!PRX@
MON.8'+JU<6K9S45:JMP5TMNIU!%,=)4Y3D39*8+BBI*R5Q X(ZR5H2LE39.9
M*5;0/$19<J"^W*A29$.4R26I,5YR.^T5)*%%MYI2'$$H4I)*5#%*B#J)M-GS
MJD^951FRY\DI2@R)LAZ4^4HU(277UK<*4C4D9L!Q<Q-2J+<-RG(GS44]U>E=
M@)E/IAN.C#!QR*%AA:^"GAJ05<$:]0^@[G7QJ=S:F)L(Z:*]D14*>M92Q-82
M3UCHI#6*C&DA)4THE*@XRX\RY0*_3+RTQBJTI_31WN"M"L$OQGT@%R-);!.B
M?:Q&9.)2I)2ZTIQEQMQ7U$R=:FT\7?('B97D8^['<59OR-'W">X.:HA(*CL
MQM'!45.JVDX#W>]9U&=!''M'9'[X6CKS(P.U.KT.+O>AS/Y7^_G?-4=)(3EV
M)P]B<3WN9&Z)S]^,\Q70J[![EHO0J[([G-5XP[F'0+V^[VMH[5GUE6#2-JL,
M>Q^^L]:R$A"0D<7B7UYR&D:R3K[WNGDLA.1(3R#Z"<;#@P.WB/)_=RBRAE)!
MXM6KQ,24IE60XJ;4=FTI)XT^Z./L_0Y 4"E0Q!U$'CL:=')QQ<3U@H8>NDGU
M[-,-LC!M.&.T[2>R?W'T40""",0=1!V$6F1@PH%)X"\<!CPD];E(Y#Z!Z_F[
M,AQ:A%?@SF&Y424VII]AU.9MQM6T$>NE0P4E0"DD* (W1[CBYE5;3&D(?IE1
M#KT!*W4&8PE"@'&)#>.=26RL!N2$Y'DZCE=2M/U,W.OC4[FU,381TT5[(BH4
M]:REB:PDGK'12&L5&-)"2II1*5!QEQYERDU)BLTV%5(J'VX\^.W):1)94P^E
M+@QP<;5L(XE)*FG!@XRXXTI#BOJ(DC4E8\J>[L[ED*"TA0X_WP\1*\C'W8[B
MK-^1H^X3W!S9*MC8VG6?<_?K62\I*0D,JU#E/O+;X5YRKMGWMD+RO9LI0%G6
M#U^UQ\Q>;?)R:E:L/2:^7BMA*Z=/L?>V<TPP#BN"KC&SUL.UQV;;2@<'7CY;
ME_NYD;HG/WXSS%="KL'N6B]"KLCN<UU(6A0/)B.L1:*D<)7'L'B7723HV]:C
MJ)'%UA[IXNXTT&QRJ.T^X/H-]_#@(V\9Y.L.OW/%0X>CP=='CGE4])^MW.SY
MIOOH81F5K)Z%/&H][E/NV==6\LK6<2>T!R#K?OM\WK[WWIUS*=IW\LBHR$J%
M.IP5@M]8U:5W#6U$:.&E=PU^1MYG% "M5JHW@J,BJ520J1+D*Q).I#:!T##"
M-C3#0X+;:=FLDJ6I2C]3&Y?N7FH&/>.\<?" ,KU-IKR=<X[42Y:#_(_+,LJ^
M:]2UC>N D@ # :@-0 V ?420% @[#;!Q@G+PV_WV\AZ^PV$EL[<1Z'>L9*?*
M J/:_O\ 6LUI,"7.,ZAQC^[DX^6TKR,?=CN*LA]L(2"3B$@'4>(6WPURGM&P
M?;5L/$3LY+,XN.*=/%L_?K#N\V0C,C'C3K[_ ._6LRO.@<HU']^Q;^5_OYWS
M%H"TE)_['ELRHH465[1T/>]T<R-T3G[\9YBNA5V#W+1>A5V1W.:KH5=@]RT7
MH5?=>YXA][#%"=OECR=8=_BXM>QI;+8VDJXS@>T.M;?#7*>T;(<2YCEXOH%]
M_#@(V\9Y.L.OW/%0X>CP=='CGE4])^MW.S\ID3- XEO19\R0KHL-I4,,,JN2
MW/!S_95^F/\ [5N>#G^RK],?_:M'DJ?44EE3> QQ))QUX8= FSBPVA2U;$C'
M^[T=ED/3I&*VLJ$8X;$X=M0)/7.RT8R<%"0 "",I&&*N7H3A@-7%R\EE2I#S
MJFXH "<>%@->'&<VH#'8,,3W&=^AP)>RJ;(.*N#JPY,N77CAM'+R6;<F&24K
M2=%BKRF"0G7E(7AK.SC./6VCS ??0PC,K63T*>-1[W*?=LZZMY96LXD]H#D'
M6_?;YO7WOO3KF4[3OY9%1D)4*=3@K!;ZQJTKN&MJ(T<-*[AK\C;S.* %:K51
MO!49%4JDA4B7(5B2=2&T#H&&$;&F&AP6VT[-9)4M2E'Z*AML/2XS,J08D9U]
MIM^4EK3F.RM:4N/ADN,Z71))7H]*WFPPSIQQM?RX+]R7*<H5 56%4FG%-S$Q
M=Z!+[1!6R4"5+!!:<:=;=THTF98"/&BI7,N]1)-XZU3Z+%.1V=(2V7<F<,,I
M!<D2%(!3F3'80X\4YDYLF7,"<;7TNW&NG6UT5BJ\]G8[#+DMW>6\@P^^G2IC
MA&^Y>D(84RZI>=.!=R9<4D^)W0+JT&B74N?4J7 WM-JD>.N>]OJ8]IU+IK#Z
MCHY$AUIK%U:E8,H; QRC@@#Q&YK3+BU)=6\&4MAA;33!I[4NH.4UA:5:;?+J
M7D.,:20T0P&V2]K"U$,/:]'56X#53J#5+><D4UN;*1 ?=&#CT-+RQ'<6,$\)
M;0222A!..);;)R)\1NEW5H-WZ+=&72(&])%3CN+G.;ZF/Z=28D!P'+)D/(;X
M;SAP92V.%AL"0/,G<OW+S4#'O'>./A &5ZFTUY.N<=J)<M!_D?EF65?->I:Q
MO7 20 !@-0&H ; /J,*$G:E)[(%@D#8 .P,.80%;0#V1C;1M](CTH[UM&WTB
M/2CO6R(Z1/I1WK  :@ !UAAX@)2GH4@=@ 6RIQS91FY<!CR;=NSFE*2<2D$\
MI QY@2D;$@8\@ YH2$[ !V!AX@)"=@ [ P\04(.LH23RE(MHV^D1Z4=ZVC;Z
M1'I1WK!*4]" .P /H!]_#@(V\9Y.L.OW/%0X>CP=='CGE4])^MW.S\JE_-T;
M_P!'^V5XB7+;4AUC!>?'+C@G+BE0Q\MCQ<EH\YIIE#:DN8IQQRA.&M1/&L<O
M);GBQ@#E=U]9'O[1)3;&DSA9SE.&4#BS;<5#ELQ+;D**4!8(&/""1QX<2C9,
MEM;RF %YDYL20,O!V^6Q];F.R66=2U<+I1K5VN+T<+<\F.E=[.5/O[-NMO#,
MVH*''RCLC:++6E S+4$@<9LJHQP=6D5UTI&'LE)/K6;G1W#AB4'BSC#'T02.
MV1S-FLZ@-ILN?'0<,5+^X&KMDIQ]#59$^.LX8J1]V,!VP3AZ.JSKR6F](0I2
M=708';L.L@8>CQBS;B74)<3L5R[1UCMU\QY]#"<Z\<,< $X8D^B19"LZ$KP(
M"AB K#' [,<">[] /OH81F5K)Z%/&H][E/NV==6\LK6<2>T!R#K?OM\WK[WW
MIUS*=IW\LBHR$J%.IP5@M]8U:5W#6U$:.&E=PU^1MYG% "M5JHW@J,BJ520J
M1+D*Q).I#:!T##"-C3#0X+;:=FLDJ6I2C]&4G_\ 47<JD4I7CU<NV$ICX\)U
M;D)M2X"AJ))F0=+3\2<5O(6M9&WF[DD"/0:+>#= J:<&8L9^+ !X*G$LY7))
M:*N#GE2-[P(ZA_I4OMG4JU1GR*I/F5*6O/)G27I3ZN+2/N*<4$CRJ$E65"1J
M2@!(U 6N]="\-Z7%)HU.<D-MG*]*64,0V3MRKD/%#97A@=$V5O8:PV19S<.O
MDAG2)D4-Y>&.]VYLH/8X8Y<7H#3&/%Y/EQ.W#$BLT*KW?EF#6(+T&1AF2ET
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M_,3<OW+S4#'O'>./A &5ZFTUY.N<=J)<M!_D?EF65?->I:QO7 20 !@-0&H
M; /J[??PX"-O&>3K#K]SQ4.'H\'71XYY5/2?K=SL_+)?S=&_]'^V5XB;\S.]
MA/\ 73:#\RM?S_[1?,INV1V6_P#\G,8_C!WLN]VU2\@3_P":G^JNT<@L,D;-
M&@=I(!'H'5S9DA;61IKR1SCVX#' 8=<GM6$*0O6Y)4#R#,O#K=$GUM5GH2VV
MEK,A2@E..7*=?6\D/<M3OF?_ -17<39/!J1S<9.'HMZN]V=7B)R2TZU)1MQ
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ME-N>$;E5Z4V:ELO*R()QP)UIPV6F_,SO83_73:#\RM?S_P"T7S*;MD=EO_\
M)S&/XP=[+O=LZV'6U-JV*':/$?0.NS;SL$Z)Y!4WCP2/7*3L(.TIU$'DUXFH
MQ\/+D\F7^_"T9Z0^Z5X!+&&&!':RGC5TQZ'#KX6GMN!;<A QT>&.K'#*K,">
MMRV346".$%I/)ACVB/= L])5)0M#*%!L)*G%JY$C-AQX8X<N)Y ,;4[YG_\
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M[0'(.M^^WS>OO?>G7,IVG?RR*C(2H4ZG!6"WUC5I7<-;41HX:5W#7Y&WF<4
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MM <@ZW[[?-Z^]]Z=<RG:=_+(J,A*A3J<%8+?6-6E=PUM1&CAI7<-?D;>9Q0
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M.QYIK0EQ)0L8I.T6DQE1U<K9Z%7_ "JZ_=VCC \W:U1:=>"G2*75(Z9$20G
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MX(?0->B=PU-2VAAI6L=?DC>9M0(^5_Y/_P#K;_P'_K/B-SK_ #17[_\ W/\
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MDGGG>&G*X3,FG1I*T* 4@F-(4QK!.'"3-4",I"QM(R@&HQQ#J$Z( 0(LR5'
M.T!E];>!VZQEUZSS-RN8Q>6[=XMSZHN:G8SLNFE6O1)=4G2% )PQA3][3FT!
M/"6Z\I6H&TR(_ ER8,I!:DPY#T:0V=J'F'%-N)]!:2,>/;:[-$>O'7J91F<P
MW[)0EY:1B68J/')3VP^11T.+&.HJ 3QVW9*XR_5X5V:?@BFW:BMQ]$WJ;$QQ
MIL% PVIBQ4QV$[=&YOA&KA8\W<&^>2K_ ($5^?P[7C^>&O?AFJ?GS_-_R?\
M_6W_ (#_ -9MN>WW?N;5L[N=VCSBANIQDZRE(.")C"=F^(^).7_3-9V24DH6
MWNIW(8AE%\+NI;>H-4R/2DQ<%,PWY."FY+674F%-*AEP 0Q)5HN"EYAM-W/G
MAH/X9I?Y\Q;=W^>ZG?[N1/TG5^8 2<!K)U #:3:[%*@;EMV7;W7A9"KPU!K1
M4VGKP#[(=3F:AIQQ++SHP>J+N!5%CIT&!=SM/5>K3JY49=5J+Q>ES'2ZZK8E
M/$AII.)R,M("6VD8\!"4C7MYFX-\\E7_  (K\_AVJ_\ &M3_  A-_.7+7R!I
MFXQ=**SJ1/712\$G41,A3:RK'5K_ (0E"B.F&.)PU\RBDU3<-K$=T%SG8Y,#
M.(UH$6;&J@*3CC@G3+!/!\;S-X%/16H_^8NN??;WZ3I_-W&JO'D+K-R:GPX%
M=BON1VE'47PP6IK2-H2M^'@Z%9=1AXXYB,:[29%!K%1H\KR:!*<8*L,-(@',
MR\D'RC[*FWD?6+%J93Y-6J$*F1$YY,Z2S%9&O#.\L(S*PQP0C'.XKRJ$J4=0
MMNNU"-2HE N%3%81*-$8D30, 7']$6H@=P \=+9>F/;4K7+;</#3J^@-S_=
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M"B.X?=^@GGLG!3T7<_OMM\3#A['7AUT(/]97N#T3\M?_ (P:[+7=YDSYF=[
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M>3;MV<TI23B4@GE(&/,"4C8D#'D '-"4IZ$ =@ >("0G8 .P,/$Y$=(GTHL
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MSB3Z'RUUU#*"M9U<0XR>0=>S[ZWUYE;/*IXDCO\ *>/S>O/>>EW3I;E3J;F
M&*(T9!&^)LC#%+#"3M)VK6> TC%:R -=Z;TU2]M4<J52<P Q1$B()WO"CXXA
MED':3J+KI&=Y?"5@ E*?J8W-=S5Z]#R*M5D.,7?8<X*=:'*JX@ZV63J4F*E0
MRR)"=9.+#!TFD<CL,,QF6H\=IMAAAM+3++20AMIM "4-MH2 E*$I "4@8 ?4
M*WY(C[M/='FL\]DX*>B[G]]MOB8</8Z\.NA!_K*]P>B?H52$+Z)"5?=)![M@
MRR-C30[#:>]S5--KUJ;0H\JD)/=%DH0CH$I3]RD)[EDMH224H2DG:4I )[.
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M +:T3XRMX4FZ#U/^VM$^,K>%)N@]3_MK1/C*WA2;H/4_[:T3XRMX4FZ#U/\
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MWT873>)I8;%U]^G4I*A8<T^R:TO%EA[)\6V'FQ[9\6,*?4US_!G[C]/\:?\
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MS/\ 1,5ZO:-]%V9_I9\6OH/S/]/P_P +KGZ,-3?;J[QJR??^!'T_W<SC=_\
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M:!5?&RH;!4+")<*I,Y7#.: DRD=N:?4J=F'9?BPU#VBY+I0V9#O-?"0]7>
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MKX70P^![R].4$5DHZ]X6XS U?7E-<@GV*F1<M1GT.FP^=<:QQ6ILUI/6(+0
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MHV7UUCL/T=5YY)U\IEV9#*6F6$,.L9J"M;NOI5 F:=6(BG6K\H)!0[+W&?\
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MFJNL!\[%ZITMJV]J?09W4TKV*O\ 5"HGFF250R.-E]FNH+*@-53-X\:S4O\
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M5V7:G+??\56<;D:J7J6N[U+-&^I=,)!74$>.W/\ ?/)?=5DOTSV*_P#\.?\
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M,_>RI]SV<]3M8S5D :[ W=4=P@Q@NC:RFIGURM+F8\Q@5%6JV\3$].VR/?\
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MT[U1N_(Y#HV(=QD3 H]DMBR%BF0+%D)B)1<O=C':>>$IW&0R<3FV7*ZAB"\
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MO'N_K_ZJ:=_-7CW?U_\ 533OYJ\>[^O_ *J:=_-7CW?U_P#533OYJ\>[^O\
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M .+U%^?_ !_7.:__ (O47Y_\?USFO_XO47Y_\?USFO\ ^+U%^?\ Q_7.:_\
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M (_KG-?_ ,7J+\_^/ZYS7_\ %ZB_/_C^N<U__%ZB_/\ X_KG-?\ \7J+\_\
MC^N<U_\ Q>HOS_X_KG-?_P 7J+\_^/ZYS7_\7J+\_P#C^N<U_P#Q>HOS_P"/
MZYS7_P#%ZB_/_C^N<U__ !>HOS__ $]G-.7F6%4L_A\EA;C:A+"TNKE:3J-A
ME8W*>H+ *>9))J'+%D#)J8.X3[OZ_P#JIIW\U>/=_7_U4T[^:O'N_K_ZJ:=_
M-7CW?U_]5-._FKQ[OZ_^JFG?S5X]W]?_ %4T[^:O'N_K_P"JFG?S5X]W]?\
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MN29B))-!(AMO/-!1MT,=VG75V2F 7WW+850D9^ "(6,-C^I,SX<H-WF=H]/
MYQ>7Q^:P3'HK19'XAO"ZQU)7$TC:];ES >!U+;VSY[#KJ2LF?"XG!5)@;&6R
M%6@MA1N"N\-%9../"96@))IQ'CR!.WCQ0TY8T8G5F:927;L-R%&A?;TR*5#8
MMV\D#%(99-3B55H5^FL5SU 0)IEN(L:+TI.G,CU+7EB(4JFCI *NZK34I-.@
MR&FQQ38%==X= 0,"!@\OPF.S.=Q/<<;E94-"SW_&6>O+J\VE^LT[EAZN9$2?
MKRE[>Q+8_-_0'Z@RV3#3^EJAL [QB,V+DU]IL]VE\KK(K(CF%U]QF"VC*Q0[
ME=*HQ6([2KK,NTH36@\GA7I=8/P $A&*J#;DCVV57NR9^P$MYW@\+DR"PLUQ
M:QV12,@C(4B(@%HA,E*7 8DNS6(R)+(\#:DTO;^B1,3M,>,3'IB?GQQ5T?K"
MUMF(Y48;,O+PRT>Q71O,+_WIZ!KV"G^J7@MD^4.4K_PE[3>I*(7\7?#8AGS7
M5W#OT;E-VTE6N5BGG0\/$9W$H-1L67<[G/?P%\V'@,\"^5-U(^,UK,1N-;)U
MAF(LUIG8HV>B30<3'Z3QVE<$OU^V75N7" CK8K&J(.^9.WR[;(KB8B(\PS8L
MLKU%3U["HFKI71V6U)FM0UH%NHWY2]B7XW'PQ6Z:"DT</2=Y09S#9=SVS73K
MRI)"Y[R*KQ4T_IK&6,MEKD[*K5XCS0';J/>TY%-6JF)W=9L,6A0^+&#Q6M=L
M':G2P=JX(RJAC;6-Q800QZ^%>[F@L/R?),Q$FG%5Q5MN4%!QRC3PG;+D5WG&
M*:\9'-Z> 6/;,"H%JM8#$RXC+S16M_,9D(#YTQ!9?25?/5M1QB20#,G5K,J
M375U6#0:#;9$'5^K"W0FU96)[AU>H+%A.HLAD%:5T>$GR9BRF+-G(RADA9C'
MTY?7&*Z.FQ;\A:>I*V["E=R0L"GN-GMFR97?1+:^>TZRE!^,>+DZ<LUQV(9W
M$KV\1MO/C$RW6'97J9':#I\%'9FI6FM8RG=TQ'6/'VL:QM+-&O9ALKI52MQ
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MJ$4-MK#UVN@SOQ"=>J3_ )H5_"8GZ+J'VFSW&B?H1TW]IJ?JZ$_A/_W>X_\
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MCF;^:Z23N(OZB]9X7-,@-5X7!-"T+/6V9.JMBE=_A<[3%A9\J<B$1L#R!T0
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M?SI_7 7CTV;;''ZTX,!^%[2_H UE]SN1_530W\)ON/U!^DR8PA6M8D9F90(
M QN1$4[0(C$;D4^$1XSP6"T'A+^O<OS$H68_JAC3:._-%0D5[=W)]/:=RK50
MJM'ST7&!/-QWJMV4855/P+H6D70N\FT%(\C=35'<\Q/A\0[P7F\A$)#PO"]J
M.BLKHRR?_MXIMLKQ'^_,Q]FNJ[%7?T/I,R?/S1LOECGXK9#'6D7:-Q(6*MNJ
MT'5["61N#%-"9$P*/?B>-*=GM*EA&8;.QA)MV;5>\>37Y2O6ZS^[N5DDU1Y0
M0$JZE)NQ24GSQL,?"8;"Z9I8O)9FY6LY/(ADTW+*J>-7S"B130O4FPUQ)MM)
MC&<B:]0BE90V#7A]3"*DVK*RKY6JG?IU,K4+HW% )&PP29Q%JJ#6&WN=BO+#
M(IF9XR5U4 3:="Y:6+(F5RRO78T(.!("D)((YH$AG;?8HGQXM6]+:'TAEZ])
MPU[3%5KZ84XPZ@A,6]7(*9D/.W&"C]G?B9_]&&EO#Q\ ;,_\41K7>?[D>/",
M=VJ=GF3TR-@IA>2IKM=+E@N4F+IW0VN(7,[M=2R-@HCV%=A;#Q4RN*MIOXZ^
MD+%2W7/G4Y1^@AGTQ,3N)@40:S@EL$3$AC)ZGPZ*%F_2L8U2E9)5AU0AN7Z]
M5G4"K:INF86TI#E>,0>TE!1N,Z>U/E%5$7\M6>ZPJ@#E5 )5VU6&$A8?:<(\
MB1F>=[)YI*=XC:(>-?LSTN:!<P4F0LYC5!S"RG_UT'Q(-IGS1_O8]'$9;4N@
MM(XO'3874BRU%UP]X<+"6OEJZP>S<A4R=^3E\WQF/#BEEL9V<:3MX[(UE7*5
MD5V %]9X0:FP+=9@P8,9B=C 2CWXB>%U;V@=(8JNQ-R>_6$V6(7853>VFMT(
MUFQHKLVP15-H ?1%TNY"@)B<WA-34J6'UA@;+.]8VHNS76ZD+>[FP*URQ:L*
M?1MQ-2^LGL@#.L<<O6E:_47V>:%I86WB<3&^K,WD*U^U-3NS/ZI#2FID:20E
M',K&JEX/Y\JPHF.@J9/BY<T/B:F;U&MM2*>.O1,UFK.TH+9'M?QOBJM+6#\5
MK\X8\#]A-S,9;LZTG3QN/3-BY:-5DQ0D=HDY!.LV-*(WCP "G]CC&:GS"*%:
M_=L9)358U5A-01IW[%5?3"U:N.B96H9/F>42>\C QL,?I"&JG:8],?,D/OB4
M>_$_XO3&TQ$\<X>!1X,7/L@+_P"S$_,E[_[$Q,1\)T7<E/-TP.<1EX#<T'/C
MW6UMYSJ#B]L7XDHO7T>?S"RWA,W4.GD*9\K%EX@P)]K>AGL75W#YZ7!N)C/S
M]XCX?.8;7^&[U4U I%>,N0'8C'J3)'TH57#OU3J.D6]_H,)XL2B.F(A+8FYH
M'M"INJGS;5+$U<M*C+QA4V:5FLY,#S"/2L4CL1&TF9E[*'Z@UQBZ%%90;S33
M+>4#,2W9]VU52@N7PAIBX%S,&2S]A+.S'LWL>41LK;5RF76SO%>$6IZF0+OO
M+"LE<R(E*#95B:=:L9*282I25//+R083-51I7G@LFE3:IO5J79 !)K%*F7*<
MM42?3?+1$R2(%;U#H?6.-+'95[+L52 ;U9++#):Z*]^B\MT<YSTT,K=1$>MF
MTY\8'4>MM3UM19FARVL+IFBL%$V^K<Z[&UY?8LO6+P'D?8"G108[OZ\R*HT$
MR?2=3.G.W[:<+/&C/W[K?YCX#Z'L9_I[_&/S>+=->_C;*[59GCMS!/BMD1(\
MZ7!))>K?E:EC%EYI3Q1=:R:](:Z17BMRN-,-9/*T^["-@JZLY0 ^H],(=7R"
M!]G-<3-9R;=:8I=#PGO7DY\LY?#QE)6UICYK;XLG?:/&-_-+3.$MEJ;696U.
M/-U;*F]R-1RNRJVVOSTEU^GU4CB4]6R+NFVTT36+2XP6G?+J<5JC3ZZ'52P5
MD\;M"I./-TT98DK..R"F=46U3V0XUK*>HEE<LKF<UK/$SDT GR5BQ'NT7V]<
M)<D3>967O*G#RKH15B.J,$YX(%A1P&D=0+[W8T9EL5:1!^)331;[_B#@R#;E
M J]S$O4&Y>3HA9$/>8XR/09SXK!26%QNT^8?=3*+MJ-BD"[U>ZTK:.W4J+J;
MQN/JT<^*CL58%E/*55\L,L8VSR]<52>P]91@JTB))8FY +-@+,YX/5.C=85<
M;ELATFY2B8KL=1O)*^J_%F^K?QUP^48<>[*UCI]4$]1K+#8L:BUSB<=064&]
MBZDQN@9B6[/O6JJ4%R[Q#3%P+F8,EG'F31TMH"HS4B!O+L9_)]YGD?N *M.3
M;Y 5=R)K6KI]V6O%K$86!^R$,1K[1F6H]QU8YA%AE%RG+X$V6KU2OMSUE*='
M=\G4<*^Y7FK7$#+>BO\ 1XF)VF/&)CTQ/SXXJZ/UA:VS$<J,-F7EX9:/8KHW
MF%_[T] U[!3_ %2\%LGRARE?^$O:;U)1"_B[X;$,^:ZNX=^C<INVDJURL4\Z
M'AXC.XE!J-BR[G<Y[^ OFP\!G@7RINI'QFM9B-QK9.L,Q%FM,[%&ST2:#B8_
M2'_G_P"[#ZF4T=K2N60[/]22WO@=#OD8NQ:1%2VXZ7*9W,=?JB",C47!LY5B
MZNIA]5-@\UV3]I6)=A;4\R<;8D<R%0Y.2- Y2E<FS )7/*-:[1.ZF5[6;+3,
MB6G57:]K_$7*>+,;2<'R#0I6[*!-XJL Y[\EFA\T6KQ5*FEELEPML6J[&565
MIQJFUM+:="S4P2GQROME9-<W,L]>VZ"NQ7K FL4E**]=?/RN8X8B\':3C\+K
M6<A;D\"R*EONV*3,(K]ZQYV:.1A]EPG9&^ASZ<5FH1W;O$-*"/)]HF"I4HGP
MLAB;3BY/'SB6^]14,\L<VW>BCTQS;1S3D<7V<6DZXU_DTDBQE8M(R"E, F=/
MRID*7)0K4J;]Y'"XS>X\UKB^8%(WQJ5FV&7L_J[/H0RVZ.8G9#,716=AL+&(
M$(:^6' "*U+B>40 8B- =DV%F5XO2>$KWK"(VD>?N\8G#"9;R?>*U&K=:>_L
MXR0F1&4^;^ETZ5U4Y]O0MM_K3?/?8TM8>>YVZ@1S,;B6L*69#'KB264G?H!-
MF;57(U[M*PBY3N(59JVJS0?7LUWA#$O0Y<DMJ6K(36P"D3&8(9F)^$D2B"$H
MF"&8WB8GPF)B?"8GWXX*]1&2I%.[51XS5F?\<HF?1/\ 8_8EX;3^A:$_A/\
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M1L'XJ<-C&P5YSJ>3^$D2B"$HF"&8WB8GPF)B?"8GWXXB*C1Y7Q+)J>,G6_\
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M>5T<D)T'RTB/IHI4JZ*=.JH$5JM90(KUT*&!6E*5P*UK 8@0 !@1B-HCC/\
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M,XU8C<R]P1GSB\2Z%)',8T:(F2ZZR(B)MEMBP[X3HIY67V#ZVOTBD9_LSO\
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MS@BB1+8US/50:7@MH+UC8[K2R=5U-N/BD@074C'.Z]'>2YCM-2>TD^R3#/:
M\U *2O3':EB5QUZE=2,J ;$2ZEMO0>EA0$F<XG-02 \X A=JRV8GS=N+&4GX
MGU3KL@BM.VST1D$&-&(*%P81C\,-C)A#HV5D;1(DHZ@Q^D.HSJT=-46C&3R<
M#YS"\"\GX_FB19<8,QSGL2J:BASH(B0BQ4Q&(J*HXZBJ$UZZ8\T1],D4SN3&
ML*98YS))KFD3&$1E,S\)?[/>SV_ZYZY3U+J6FSVOT@_#X=X3[9Z5Y#(+GUOS
MJM4NIU6K_0:SFA!,Q^G<Y;JS(A/3>85Z!'$D,R,]VO6%\RY ]CD>;ID8%VA=
MI_:QJ/X%] JS%2OC1!ZU9#4!TL91KM!12NPU=83J-HIK5*S\K?--GNPU10JP
M^,.KL_SMNF7,!9QE2^]6S(+F9+[FI0SP_M>C1@E20RD0VF1M:R[ <R5E],-V
M:9=<?9388L9:RA'E3^K&(RYJ+FKKR;6U;?*D1[LITWN" Q(# I$P*)$A(9V(
M2&?&"B?"8GQB?4[1^Q7,.V"_C[64Q$D7.:4Y!:Z%YE<#4:U^2\D.*R*?9[V;
MC6PG<3(KV+OJE%[&W+-"XB=IE-NFXZ]A4S'A,K<LPG;P\.-==K+Q%>:U+)4=
M.28F?FU6,Q&'*5%"IB)SEJ_;M0MDBZA30SJ<P\H]GG;/C5+[U60C'YX42!#7
M7DIZ%I#6RH&,'$:EK,H(]A&^1:SH['N&*P6."&9#,Y&EBZ0%,P!6K]A=5'/(
MB<B'4:/.4"7*.Y;3MQV>]C>%G^IVE,/4R=V)VF3>%8\1A^<]^:+(U@R=JUO'
MKGE)#.:9WX=VAUZ]9FM=>'7C&NL\L]/R@3QPE<)Z>[*]'$U[6HBJEX6+1.KL
M9"H62K68SN1MY7*762VS=NN)SF%,[[;EX L-^525P*4A$+4 +$1BIE,5;L,Q
M#+"XSV!EA%1RM$B ;/Q,1BE>16D=Z%^.5U=PB)$RHRS6?@=;X)8*Q_:!1L7;
M2TJY4EEZ?=66+\3$],"RM3(4WL7 #++:;ELB:RRR1R_:P-%#]8ZLV5BRMA$]
M&N[(3CL+6\#W*G'3=J*RM9).\OHUFR,UT,59S6H,G<R^4N&1ON77$UD\QD?3
M7$^8BNN3*$U4"NM7#UM"EKB!BMF<';<5.7+\L80W'&/S%/?9J;"?%8V(7S=T
MNP$OJ-\X))<M4W2O:;IU41CNT#']>^:H&$,OKJT[5*_M$^#LKC;42R CD-E!
MM@YEUAA'VE?N;2G^EU#PO#X),III)1YK./618_"U#DO77;2/7LM@&#2H+.&V
MVC[)-==BU7/LO[+ 4_7#U!Y=SK5+=8QK7($_*63;T^E;S+5MWQ>-CFIXM)"Z
MPJ%PFI>?;MO=:M6G-L6;-AINL6+#CECGO<R28US6$3&M81&9E)%,S,SQHJMV
M7@YI3C,&6HZ^ DN_6,<%6[.I$UPJ_%#K)Z@Z992NCUYZHR"F@P"<HV5["6UW
MI.5N2Y9*:I@SL0,6<"8&,^$B41,3Z>$Z5L9O)/TY7NKR%;#/M-=1JW%*L)%U
M5+)**WK=I_,M'349,YS C@2C]&IZ:TU3FS=LSSN<?,-/'4Q(8?D,@^!+H5$<
MT<Q;$QK"77KK;8:I1AA\.$6<A9A;<YG&K$;F7N",^<7B70I(YC&C1$R7761$
M1-LML6'?"=%/*R^P?6U^D4C/]F=_V ])S^UWG@W.,F-84D9E.Y$4_P#GPCT1
M'A'A^E;G[EL?Z(^,ZO3VA\GJX+KZ)V64%9!D4B2NR*P9W+'W8B7PPR'J2N?6
MYY8+QV^4OJ/Z6SWY X>CX#\AHJD]<KL9)V)R\W%*9/+,HN745:]>9'G'J#7Z
MT3YR')8,%%GX%\O&9R=EB7:@LN1-.^MT 45JY4F;M323N_NQ\[P<UEE@O*9E
M:M9_0YE?Z(SAVL,RN+YXVT>(T[7M1#DX^%3%^W<0H^8!85F],(*(B4M[TT?/
M;!QQV:_NW._Z?37J1IY3VU@RXX:K;:DN5D8^,6FQD.7WBGNB&R(%N!E B42,
MSQ7Q6'IIH4:P\JT("!C?YIC)]+7,VYFN9),87G&4SQF.\5USD<5C[>2Q-SE]
M?KV*:2L2D61$ET+8JFN]4\P3!PSEZJE&%G4VI>;+U],*I8; 5;Y39K(: G8]
MI;N')CE&KN:IW4MEHFP$,2DQXTIV@Z?4%*XZ\<WP1$(4^]0)%A+B%<1N5]!V
M:]^?[*"QDX,FMF>]27*CH]XDR\.57)U)(O[@^,\:@UMJA<V\)B7+3C<4^.:L
M<,)TX^DT.:1)%&L'>+:8CDM7+ FS=9N4P%* %+6, M:Q@  !C81 !V$1B/"(
MB-HCC(7%5%+U+C:C;6-OK7 V+'=5RWR;8*)'K)LB,I5U9+NS2%J]HZ@,A.1:
M3\E@+7DMSSGF;9J]('4'M+YIG2(JI%/G,FKU3F3.9G0ZZ!&%XZS I&HY6P+9
M9)$5B6P?. Q=(2)CXB6TQXQQ7Q6*KJAL*7Y0R'3B+62M1'KMBPWQ.8DY+HIY
MI777,*5$#'%G%9>FF]0MKE;Z[QYA*)]!#/LEM"?.4Y<BU1Q#%F)Q$\:\T!+V
M,HUIN6:T,GPEN*R*:2WB/A NMT;BS=R#'/%=?-X*#C4_T/9K[6V>,M]%U_[3
M8'C2W9GAVDIFH'U+&0Y9GUX;=Z:&-0[EV^)EN59MV1*>6>E787+"]Y1B\-46
MN16N+EZ5CWW)6!'S[-QWLC(RYB!6_10,]-  N(CA^.RM*OD*-D)!U:TH6J./
MG[%[$Q](,'9BRV-9"41/&C\ #WMQ :GTUD, #V$R:^-R&H$G*!DM_:;J[2BG
M^RDN7EZXT_4[2?W%J'[H<'QF?WJR']$=Q?S><5W[&Z?> XO&V/7:)9>\L"LW
M&5RW49(K5*<<I@0L,D&?C55Q$1&T1X1$>B(^='&*UWBUQ1S57+5JERW4]9:\
M36U]*XP@V^*J5BJ *L>#9!T"9E"4P& S)[=3*X;&Y!L1ML+;=-+FAM'A'(PR
M':/1,;<9'&9,S9I+0L/3-$3*%6G5; 57K(A(>4K^1ADN:'GECZ05Q,2Y70JI
M3KIJU:X0M%>NH$H2L?0"U+@0 8^<,1'%FLZND,U70T\-DX$1L5[0C)+0;MN8
MJ5@]EV4',ARSUA@7J4P>ZY,S;DM.6YQ#6MF9<ZI"@;18^2\[J@LCIE)>>?=(
M8R289S^FPR.1#U_P*M6*/:/G-;'^_>^ 3[5Z9]<]K^&[2_H UE]SN1_530W\
M)ON/U!_:"-FR/G^E:Y^8^<11^O\ G1\SZ9\[V/PEG(Y&RFG1II-]JT\X6E*5
MQN1F4_XH])3L(Q)3$<%C,83J>DZ;MZ]>=UNRKESYM^^/ZWWZE2?!$>N,WL3Z
MW^A]J'\-ON+QGPFDO^'R?VCR?&J__O%]S6']3LY_X#4?_4TUZFD/^!TQ_HF\
M9J@SP;?T^9HG>-B*G=JD:MO3)RMI,C;YE)[\:MI6P);@U!E&[%MN:+5MENJ[
MPF?-L57I>'O\K(WB)WCU=2]I.J*B\G7TVRVNK3<F+"43C,<C*6[?=CW79LRN
MRA=.&CR)8)LCUR5FJ8P6F]/TJ(R4*5D>_P!Y_3W];W*G<Q:ESMOS"*CC>=A+
MS=RP6G<CC-,II92RU5AE*GE%V@%=2Q8B4F_,V5#/,H=^=+(Y=_#?QB]^]6(_
MHW"HQX$QN*0N;28D>80P^?DKAEXQ$"NF,W]O9=';PDO#X34O9CFYZN/S=.U;
MH*.9CFZM?NN8J ?4YHEE;H6T+2,<DHNOYN8N(T-D5R:<-DFNS+.6 %N'H&#N
MO ]22%>54=1:.4C,/*"B+P$YCR)38,XO2:CQJX7R=.<DSD+)D,A,^TDM%"0G
M;I,I,B!CF+?]&ZC.K1TU1:,9/)P/G,+P+R?C^:)%EQ@S'.>Q*IJ*'.@B)"+%
M3$8BHJCCJ*H37KICS1'TR13.Y,:PIECG,DFN:1,81&4S/PE_L][/;_KGKE/4
MNI:;/:_2#\/AWA/MGI7D,@N?6_.JU2ZG5:O]"TDVPX$U,LRY@+!',C$EEJ;D
M4%[[Q&[,MY/&.>"'QVV@N4QTQA6FX<#5TT.2I*V**[<G<R60K7W\WL&O77IT
M5<L[E77.\<L6IY^,ICT.=%"]I.^V_6&2Z##I7L;W.PT/8=6N=AJDN*.8!MO4
M,QW@H+M"1C2$JL:IR;/,]B%JP[O%],>>>W0OMLIY=X@>3: 7$=,>-+ZD8R5T
M%7QHYCSR$/(^3B:-\VP(GU!J*=W\%\L\SZBMI$H$QQXX*O!!VGLQ[\;X;5O+
MEAZL7DE;IAC>7KS5RMMW2+:,F1#S\DQ'9_V-X0OZFZ2P]/(W8\"(K U3Q6(A
MI>GO0TPR%NSN/KOE-3=]YGCM'[%,RZ.3(8ZSE<++)ZAI&Z 4[K*X,$@'R7DP
MQ.30,;_%-ESN2.4BG/YW4"1JU^S&K?B_UBF!J9YLV\:(LV&5&%2M6S+CGG];
M<BNP8+TCJ?5K>:(S.4<ZJ!C FK')@:F*0R((HZE?&UZB#F"F)-<S[_&A];Z5
MQU+/>1\-I_%Y2O;*R*T)J1.!R#-ZTBP65<NE*BYO6^E+"GPY3X^0O3?TWD_P
MG'R%Z;^F\G^$XPM#*8/%XA>%MVK:CH-MM-QV4K3(GW@YB!& WCEC>9GT^'CI
M?6NE\8C./T_B<?C[]&U%GE!=#(SA<FXN[;.&*K1[U+-I6-2">?K7KD?(7IOZ
M;R?X3CY"]-_3>3_"<8O#93 XK$IQ>2G)@V@ZVUC635=5Z9]X.1@.5Q%X1S<T
M1X[;[]I7[FTI_I=0\4>S;L<Q>-ONP]Y9ZGR+^=U<K*&*B]2;;7REDLW<%4U\
MC>@BKXH=J58.\)E&-I]L/9N'5U)0I=/,8E4"5V\FHN&6L3=0GFGX(,/!\U.1
MWG(T3!:^\*9BS#AJ--9-;,78/JNP>63-[$D__?U)ZB7TW%Z''1LU9L;!WGJ]
M)7(BCVC]DNGM05C@8OO0RO97S!YT-K8C-X^^,[,$96MF7$E>!Q8D@CFS7:QV
M256Z=MX*O>NY;#;,35_J553<RF/MXWJW*^.NUL=M;K'BF10L<XRR#Z\V%?HM
M/36FJ<V;MF>=SCYAIXZF)##\AD'P)="HCFCF+8F-82Z]=;;#5*,,/APBSD+,
M+;G,XU8C<R]P1GSB\2Z%)',8T:(F2ZZR(B)MEMBP[X3HIY67V#ZVOTBD9_LS
MO^P'I.?VN\\&YQDQK"DC,IW(BG_SX1Z(CPCP_2US]RV/]$?&L/W;A_\ 07_4
MD2B"$HD2$HWB8GPF)B?"8F/3'&#5IY8T:>H!H1>H5XA-2!RY6*=E()".04]9
M"L@M41 A9@>2!$1VUG]#F5_HC.*?[ZY;_3QZG9K^[<[_ *?37J8W]Q']Q5_U
M,S^]60_HCN,_]$9?:S'^IIC]^;7]"G@ZJ]NI9PY5PW]'.ZETQW_8W*.-5X)L
M2K(4\LBZU)QRLZ;J_<RC:??0^D0LCYB6!O[*/4R65N% U<;1M77R7HZ59)N.
M/V9F!V@8\2F8&(F9XU-D"&81;RU2LF9CV1T:A,=M/OQ'?E1Z-MXF-YG>([*_
MW=2^WU+U=;_N')_]?#<:G^A[-?:VSQEOHNO_ &FP/&@<[>\W'.1B538GP!?+
MDKU6R13\ZH-M-EFW]C*-MR\/5[/*2"$V8K(:1KVYB?$+-C447(3/]Y6=79_^
M>F-HV\>.TG]Q:A^Z'!\9G]ZLA_1'<9_Z(R^UF/\ 4N?OKB?]//&C/H<Q7]$7
MQKG3.HKU[&6%7\SD:'<BK"5J)R?6V^*4OB>I2MKMK$8@^E#"GP&=O=_4?^%C
M/R?Q[OZC_P +&?D_C)HQ=[(71RC:S73?FM,KFJ+@"%]W0B-BAT\W-!>B-MOT
MT&1R(>O^!5JQ1[1\YK8_W[WP"?:O3/KGM?P_:7] &LON=R/ZJ:&_A-]Q^H/[
M0!LV1\_TK7/S'SB*/U_SH^9],^=['X2SD<C933HTTF^U:><+2E*XW(S*?\4>
MDIV$8DIB."QF,)U/2=-V]>O.ZW95RY\V_?'];[]2I/@B/7&;V)];_1-<81+0
M0[,934N*4YD%*TLR&EL/4!K('SI!9-@B@?.F(G;QX^2C"?2U_P"\X^2C"?2U
M_P"\XG4%W-XR^@;E:G**JK0-YK//RG$M'DV'D\8W]_PXTE_P^3^T>3XU7_\
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M!Z3G]KO/!N<9,:PI(S*=R(I_\^$>B(\(\/[60R.1#U_P*M6*/:/G-;'^_>^
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MSC5B-S+W!&?.+Q+H4D<QC1HB9+KK(B(FV6V+#OA.BGE9?8/K:_2*1G^S._[
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M_P ;CX[_ ,A_XW'QW_D/_&X^._\ (?\ C<?'?^0_\;CX[_R'_C<?'?\ D/\
MQN/CO_(?^-Q\=_Y#_P ;CX[_ ,A_XW'QW_D/_&X^._\ (?\ C<?'?^0_\;CX
M[_R'_C<?'?\ D/\ QN/CO_(?^-Q\=_Y#_P ;CX[_ ,A_XW'QW_D/_&X^._\
M(?\ C<?'?^0_\;CX[_R'_C<?'?\ D/\ QN/CO_(?^-Q\=_Y#_P ;CX[_ ,A_
MXW'QW_D/_&X^._\ (?\ C<?'?^0_\;CX[_R'_C<?'?\ D/\ QN/CO_(?^-Q\
M=_Y#_P ;CX[_ ,A_XW'QW_D/_&X^._\ (?\ C<?'?^0_\;CX[_R'_C<?'?\
MD/\ QN/CO_(?^-Q\=_Y#_P ;CX[_ ,A_XW'QW_D/_&XZILZY#[")#D$9_7;<
MQ\T_K?G>GT[;?"UZ4:S\AX)'*R<2G!%<[U;C_P!HNVO+5/KPO_V='=P6F=SG
MJ-V,?D]_FM_M'Q\GO\UO]H^/D]_FM_M'Q\GO\UO]H^/D]_FM_M'Q\GO\UO\
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MVY9J8C$5%4<=15":]=,>:(^F2*9W)C6%,L<YDDUS2)C"(RF9^$L:?T[J_P"
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MEEE.-KO=6Q=-2I)S!6(^:JJ!K;85/ 6KG95E[E'JKEV+'LZU767T8+UU=:T
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M5&=M>##(S!;4?(-26R4<TQ$#.KQ?,;#N4]WW'8O-GEX?G5'4U3INL/5LY+$
MX+5!$1$E9R.,;!,36'QDK%5]Y"5#U;3:X\(JU4.LVK+EUZU:NLW/L/<<+2A"
M5P3&N:PA!:P$C,R@1B9F(X')ZJRN)T/4-?5Z%Z"R.54._FE;J(;7I51(=BY6
MY3O"^;D?72R""#KXKMGPF1O!/+-1>!K24'YT<I]VU9;<$\PS'QO,^!>&X[<5
M_@CJHL8NZPDT,]BS;9Q5A\01]U-C$H=4NRH":-6VE1.!;CJS877<8*KUU,>]
M[ 2A"0)KG.:4 M2EA$FQC#F   B2(I@1B9GA>7U?GL5H6JY2W+K6TEDLHH#Y
MI^+ZT6<?3I3R<A"J<BU\<Q+LIK,7(R^=*]K>G<_=6LY77+%C6038C<0=:QV=
MS;4!.X\S(IND(+?IEX1,X35F,.C8*"94L@76Q^2KB7)WG'VQ];>K?;F'S'HD
MA"RE+)Y/4QV(QZ^M?RMZIC:2=^7JV[UA=6LO>?".=S0'>?1OQV;=CF(9'<\!
MB*^6OCRGSG-:N>&P[29O"I-W+F[-H)$F2QJ'>MP4=7])4>S[M!O?U&];J:<U
M';9[C^@$XG+..?<CT+HWF3_4GS:]@O)739B]X^$-+@%BF#(F!1N)#/\ Y\)]
M,3XQX\=9/,R@PO6V>DDE/]A=_P!@_0<?MMX_1L%_4+RUY:\I_P#O/R=W;R=Y
M/_\ R??ZW6[_ /\ PNGTOF^?S/5P^(N81E^KDJJ[EF^F_"6TTS;;69TZ,TFQ
M;-8*EL#WNMU)];W'V?%:_0L+M4KB5V*ME)<RG):,&M@3\XAG^['HF(GP]3,:
M@[KW[R33.WW3K]VZ_)(QT^OT;'2WW]ET6?WO%+4GD_R7WQMQ7<^]]]Z?=+3:
MV_>.[5.;J=+GVZ \N_+N6W--;&8S0&6U4A^-3>+(47W%J2UEJY7*F0U\)D@Z
MBPJ@Z9EXERV ]:B(@S^4WJ/Z;R?YJ<?*;U']-Y/\U.%U<AV9WZ-IHB:JUS-V
M*SV"92 $M+M- PQ(Q(!D1F)*)&/&.,;3H]G68U"-W"T\H^Q4?=6-*S9=:4S&
M-A."O1+JT5Q,R)BCF'#N@/"3QF/RG9KD,/.4MHJI._E[->9AKU(-JEV-.(Z\
M)ZHR0B4>F!DAYHGU+&5S%U./Q]4>9]EY; .\[",1$2;&&4P*U+$VM.8!8$4Q
M'#4:1T1G]4+2?*;QEE2)'Q]<%-6AEG0!;>9#P0<CXD %')P&*U-BLEH^\9 &
M^1V=149[>;9LRJK8K1O/@U]$*\!NQS4QP)@0F!C! 8S!"0E&XD)1X2,QXQ,>
M$QZA8>BJYJ;,@V4-J8F!Z"'Q/+-=MPN:#L<WFRJHJW(%! WIL'DX6>INSC4.
M#I,(8BU#S?,\V_L%WL7AU'/ZV(L^=X^C;Q'*X"^N[6F>1HQN%BJ[;>46ZY[-
MKMB/&!,=C"88J340G/Z#4S?DGRQWK+HQ7=N_>3^3K4[]OK];N=[FY>X]/I=(
M=^KS=2.3E+"9OH=U\L8C&Y7NW5ZW=_*%--OH=;IJZO2ZO3ZO25U.7FZ8;\L>
MI@.?!EF S99+G(<C%$J@XZ<=S2(31MQ9)L7_  &3KP,JVYIZFX4LUB; V:&0
M2+D,CTQOX&IH^/3>DX)3U%YRF@8%XCZF3R?2Z_D['W;_ $.?I=;NE9ECI=3D
M9T^IT^3GZ9\N_-R%MMQ;S?DGR/W7+OQ7=N_>4.?HTZ%OK];N='EYN_=/I=(M
MNES=2>?E'%KQ>BLEJR,@NT;CH.M*BE-<D" M[OB<GO+^J4CS2GVHMH/QY?E-
MZC^F\G^:G'RF]1_3>3_-3A<93LQR&-ET%*8OYJS3EL!MSRN+&F5\\!S#S<N_
M+S1OZ8XTCEZ79_ELT[4N/;>MX^K8MPS!D"<>U:+)IPELF$[OIP)-13GXF/99
M;E"P=D^RS*XY+#Z8-OY:W36;-I+I@=C3"Q(^42+EB>;:)G;:.*=SDZ?>ZM>S
MT^;GZ?74#>3GY1YN7FVYN4=]M^6/1P^Y<>JK4K*-UBP\Q4E*EQS&QC#F! !B
M-YF9X90TAIK-:P:K^RUH930V.;:30(T[]XEQ[QMHIYB\(CEV.5T=7:7S>D6L
M_LCX.ZE4<TQSO ZF/NBO;YI-)\P7AR\L2?"+M&PFW3M+%U>S68+D/4<;BQ3
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M%W_8/T''[;>/T30G\)_^[WPG9K_?83[I3XE:H6C/XT6.PMPO").8W9C[)?\
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M*Y3RW=2&(F1LD^YX=?4<1AW9MU;,[G6=*LKJ)PN%2PBHX6B11/01O ]6RWE
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MSAC:.7:PL*.T;B0T 8,['ZM/+W8*<7:KNQ65( )C$TK9I9WE8#YQ]VLUZSV
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M3R%XJ:J7MNQ3LU?<WDMV:R3 N9FRKQ#JB'*BFDYB).O2$C@"F//<VPZ($6P
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MCT="M5A2O,<8_"_^B_LJ LEJB^9T,EEJ<\T8LI\'U:#XGIA;0N#G(9(RA&)
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M+#2!-=(&YQ@L"*.JWH9+6.20,9K-0.XI&=C\E8KGB#3CDG$2QDP#L@X(L6(
M K5JOPG.>S+#(GN]??Q.?UQ?K5#\T7_)'SN&6K3)8UD_\0Q[P!'S(#Z!&/\
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MB\$+(Y@5F[K569"1YH(Z]"KD&HGYGI6!2\2]FH?3PRVJOC,Z"HDV*P=QS[4
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MQ,8G0N*YG9755M$NKJVEQ456 "K7VWB8+(Y/I J?8F-.RHO N,-IY'+/D^H
MV&CZ+%YLR^]8\?'9UMCC 9WY%R"_0$<:AZ(D?29B7-@?3T5Y:E)EM'I$/;"_
M6B,G/@/&%R^'[6,WB<?9KG",96L9B$T.A8=795 :^:0H86U1^ )7'[7CY=&H
M_IG/?E_B*F8[5<GE:L,%T5LD&6O5X<$$(-A-K--7#!$S@3Y>:(,HB?.GC%XT
MV]<\?CJ5(G[2/6*K66B6\LR4CU)#GVDBF-]MY]/':G.WCWV]&_O[3G[F\?\
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ME]SN1_530W\)ON/U!_: -FR/K?I6N?F_VQ?M/G1\W_>^R^$-C#%:UB1L890
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MZS4[BWR;::&S8(?/YJ-Z$-7M[6#K3-XVXM:^SZQZ.G:-$$J&)[K&3[MW:FM
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M3N1%/C,S,^,S,^,S/I]0:];6&J:Z & !*-099*A&(V@16NV(0,1X1$1M$>'
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M6L.9-C&',D9E,D13)%,S/ZI4,!@*#\EELD^$5*B(W(RGQ(S*=@2A(03;%AI
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M0VY<;$1U;#=HWG:  (!*06E:UC\):T7HNTM^L7KE>2R2Y%JM,*:/L1](,S;
MG=2IW&@,P]\2V5*EMBPUCWO8;GO<9-:YK2DV-:PYDV,8<R1F4R1%,D4S,_JE
M0P& H/R66R3X14J(C<C*?$C,IV!*$A!-L6&D":Z0-SC!8$4=5O0R6L<D@8S6
M:@=Q2,['Y*Q7/$&G').(EC)@'9!P18L0 !6K5?A.<]F6&1/=Z^_B<_KB_6J'
MYHO^2/G<,M6F2QK)_P"(8]X CYD!] C'^?>?[60R.1#UCP*M6*/;_G-;'^\^
M^ 3[;Z9];]L_1NTOZ -9?<[D?U4T-_";[C]0?#>V5O\ #;^!X]LK?X;?P/'M
ME;_#;^!X]LK?X;?P/'ME;_#;^!X]LK?X;?P/'ME;_#;^!X]LK?X;?P/'ME;_
M  V_@>/;*W^&W\#Q[96_PV_@>/;*W^&W\#Q[96_PV_@>/;*W^&W\#Q[96_PV
M_@>/;*W^&W\#Q[96_P -OX'CVRM_AM_ \>V5O\-OX'CVRM_AM_ \>V5O\-OX
M'CVRM_AM_ \>V5O\-OX'CVRM_AM_ \>V5O\ #;^!X]LK?X;?P/'ME;_#;^!X
M]LK?X;?P/'ME;_#;^!X]LK?X;?P/'ME;_#;^!X]LK?X;?P/'ME;_  V_@>/;
M*W^&W\#Q[96_PV_@>/;*W^&W\#Q[96_PV_@>/;*W^&W\#Q[96_PV_@>/;*W^
M&W\#Q[96_P -OX'CVRM_AM_ \>V5O\-OX'CVRM_AM_ \>V5O\-OX'CVRM_AM
M_ \>V5O\-OX'CVRM_AM_ \>V5O\ #;^!X]LK?X;?P/'ME;_#;^!XY[1+,1\1
M6'-,%/[?F$?"/UOCS>_X>$_"Q@M,Y+3V)T^T(G)%<OY-.1R9_P#VJP:N(M*3
M0#PDEC8,K1>W<JQZ1>Z^C_I_-?F_Q[KZ/^G\U^;_ ![KZ/\ I_-?F_Q[KZ/^
MG\U^;_'NOH_Z?S7YO\>Z^C_I_-?F_P >Z^C_ *?S7YO\>Z^C_I_-?F_Q[KZ/
M^G\U^;_'NOH_Z?S7YO\ 'NOH_P"G\U^;_'NOH_Z?S7YO\>Z^C_I_-?F_Q[KZ
M/^G\U^;_ ![KZ/\ I_-?F_Q[KZ/^G\U^;_'NOH_Z?S7YO\>Z^C_I_-?F_P >
MZ^C_ *?S7YO\>Z^C_I_-?F_Q[KZ/^G\U^;_'NOH_Z?S7YO\ 'NOH_P"G\U^;
M_'NOH_Z?S7YO\>Z^C_I_-?F_Q[KZ/^G\U^;_ ![KZ/\ I_-?F_Q[KZ/^G\U^
M;_'NOH_Z?S7YO\>Z^C_I_-?F_P >Z^C_ *?S7YO\>Z^C_I_-?F_Q[KZ/^G\U
M^;_'NOH_Z?S7YO\ 'NOH_P"G\U^;_'NOH_Z?S7YO\>Z^C_I_-?F_Q[KZ/^G\
MU^;_ ![KZ/\ I_-?F_Q[KZ/^G\U^;_'NOH_Z?S7YO\>Z^C_I_-?F_P >Z^C_
M *?S7YO\>Z^C_I_-?F_Q[KZ/^G\U^;_'NOH_Z?S7YO\ 'NOH_P"G\U^;_'NO
MH_Z?S7YO\>Z^C_I_-?F_Q[KZ/^G\U^;_  B+F;TLJI+0BRVM9RUBPM'-'4-"
M&X:JMS1#>06=A &6T$T(\Z*V#P=;H54><UI;%9NV2B(;<N-B(ZMANT;SM  $
M E(+2M:Q^$L8[LWM:?QF<O;USR^>MWT1C*IC,'8QZJ.*RG7R$^P25B%*K>W[
M/,1"&V+&I-"/>]AN>]V8U*UKFM*38UK#TM)L8PYDC,IDB*9(IF9X]W] ?534
M7YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'N_H#ZJ:B_-7CW?T!]5-1?FKQ[OZ ^JF
MHOS5X]W] ?5347YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'N_H#ZJ:B_-7CW?T!]5
M-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'N_H#Z
MJ:B_-7CW?T!]5-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ\>[^@/JIJ+\U>/=_0'
MU4U%^:O'N_H#ZJ:B_-7CW?T!]5-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ\>[^@
M/JIJ+\U>/=_0'U4U%^:O'N_H#ZJ:B_-7CW?T!]5-1?FKQ[OZ ^JFHOS5X]W]
M ?5347YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'N_H#ZJ:B_-7CW?T!]5-1?FKQ[O
MZ ^JFHOS5X]W] ?5347YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'N_H#ZJ:B_-7CW
M?T!]5-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'
MN_H#ZJ:B_-7CW?T!]5-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ\>[^@/JIJ+\U>
M)8V:^4UAD4B.9S@A/36&\'Y+Q/5 &IQJSB)-A M^0<(V+(+$*U6K\(?0A9.Y
M9Z<-(@7)>]SD ,*!^?RA,\,M6KF/8UD_[[9V&/> ([IYH#Z!&/\ /O/'QQCO
MXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'
MQQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L
M_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8
M[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XI
MQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C
M;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'
M&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^
M*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCO
MXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'
MQQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L
M_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8
M[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XI
MQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C
M;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'
M&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^
M*<?'&._C;/XIQ\<8[^-L_BG'QQCOXVS^*<0_*,KO!>TJ0B6&!G\]W44KS!_W
MN(F#GV4\L2)_H_:7] &LON=R/Z4TIJ?)9K6J;^=PE')6U4<C@EU%OLJ@S&N#
M].67"J)GS(8]IQ'I,N-5:6QC;;\?@\L^A4=?-+;C$J@>4K#*Z*J29X^,KKJ'
M]I'Z'F]6:CPN)U+E8SUC")JY>J&1I8VG6HXVW[GWD33*Y:9<(YM<EGDK@E2'
M)9-Y,Z1S6E\;C]/VLT>5J7\3C4KJ4[*Z(46)OUZ*I!%0D38E%GN]<5OZ]<CY
M6+F7?H.E\%<-RZF:U%A<3:96( LKK9+)5J;SKFU;EBX5N*5$Q+0@X&368[C.
MKM1T<WK=MW :8S^:IJMY+ G59:Q6*MWJZ[()TTAIUS:@!<*GI82Y* :LMCCX
M?0W\)ON/U!_]#?:7] &LON=R/P^/R=?.:$!&1I5;Z =D]0"X4W$!86+1#3#
MAD R(. 88P6_*91X\)S%+&T<'B;:P=1OZDMLQXWE',[.K5*U:]DI1(Q#5V&T
ME(LI,&U&/$M^,AH,*WEO4./R#<9W; *N9#OEE(=0^XK[JFX\(7!',E560@!F
M0B(S/ V+5; :<Y_8HSN7+O'+[Q$O#5,QT]_UC9!L?-+'AEBJ>E,ZQ8\T4\3F
M+06F_/%?EC%XBM)1'CL5D-_0,D7F\6\3F:%K&9.BWHW*-U)U[-=FT%RL4R!*
M.8"$PG;E8L@8$D!"4YM6FK^!HE@ Q[+GERUD*T,C)%<%'=NX8O)\\CW%O5ZL
M)VYE\G/N7+BL#5IXK4=O*5K%R7X*W:\G8RO7<E)'E;^9Q^'KU983MZRH)KK(
MI?T5F:^7CJ>5M#0>V_=YRV:ZW][O&G)1O_\ G^7]G@<3J[$-QKG0TZ5F""Q0
MR2$LZ9/H74D:7#&ZR-4R%JN+D]ZKH-@CZB\IB\2C%8=X"RIEM1/9C:MT#B)!
ME)05[60M(,9Y@MII%4./8/(O#AMNJ6E\^:HYNXX7+6XNG'O](<QB\17.8CSN
M2+'.7H6)GL,Z"IW:[ZERIIK&UK56TIB+-:PE73<BPAHBU+E,$@:I@B8&,B41
M,3'':']$ES_,O@Z6D<#;RLIY>]6HZ=;'4H*1C>WD;1IJ)+8N<42V;+0$Y0EO
M(7'4++:&46V_09ELU+?1OMNK3C4[SZ/;MM_3,1X\3;U)@R+$08!&>Q;8R.(Y
MF$ !#GJB'498TQ2J,E7IR]GFHAGAZB[XYW0<);5"X(SD]0=3IFJ'1$Q&EY'G
MY9VF.>1YOFMO'A>3[AC--5; @RM\%%RQ1LV%,'F%L4:5')7:X[;>%VO69.^X
MA(^=P[*S3Q6I*E4#;;^!B[9NV:Z%KEANFE>H8VX\ B)@HJ(LLCV4ATXDX[]I
MW$ G#<[%^7<N_P GXHV*+D8%<^1MJ[('!+85&K9!3 -;C68\O#;->WH[+-6L
MV#1QV7R 6WD([PI4Y3"XVGU&>Q#JVU+YO9L ?.XNX7-T+.,RN.=*+M&XN5/0
MR(@HYAGTB8$+4M"24])K<DS4P#G4&7[*-98?2X57U*&51F7/-%UC5F^NV,<6
MG\]CW&D1,0LM4NRF&&M1=-K-\-=[4]4XS5&4S-.UW!V+L63KU*M%J18@:K,/
MA:M(399AD+I5>1A=1C?7)W+!ZCHYO1"J6?P^-S5-5O)9X+2ZN5I)O5UV03II
MZ@L IX"X5/<L604 U@['/N_H#ZJ:B_-7AC2SV@>58$R=LIJ+?8!DIVWTM'CX
M>'C'J+R*\53T[0>(G6?JFR[&G8 I]L"BBI=R8+V\\6/I)!JY@T2T9B>&6JI:
M6SYKCF[EA\Q9&V<>_P!/RSC,/6*1CSN7O,$7H7!GYO%K%9BA;Q>3I,Z5NA?K
MLJVZ[.6"@6H<(L#F A,-XV-9"8[@43**=*N^Y;M-!%:K52RQ9L/:4 I*$*$F
MM:PY@06L2,RF(&)GA=VRK3VF^K',%34&3LA=Y/F98C$X[+]"2C^Q/-;P]#5
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M;9F8MHCFE1V*W>J#O$0>?C'!ZK9IO16F75)BP.6MIH4UT3")@6TYME"*+?3
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MS(9"FFS=NVF[1+;%AQS,SL(+7"T(!5=2E!7NZLTY4SMFHF:]4[K;A#73)<Y
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M3OD+=2#YI6<;+DYC;SHC>-RK:=PU[*L7[:5=7Q.C?V/>+;975K\WS'6<'/\
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M F&9;>/A<R6B-1KU+"1)LX2_3\F9-E=8R9+JVUV;%+(6N<!D$M7C!/T 4M
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MJQE$P+JI8NFM9KGT& $HT3,>$,2Q?L@GU-*=T@]T6;5EYB$G"ZJL?;[Q+-O
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MCK)W\(9$>F/ 6C'*6TP!@NQ78+4M'F Q]$Q_GB8GP(9V(2B1*(F)C]![2_H
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M'@%2V<_U8\$NGRMR'E/A&5;2X8ID?\8S[QA/S)CZ1*/\V\<<A[LKLF>[V-O
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M_P!QVO\ 0'QJ[]_:?VOCX3-1K[2)9;1]S)N=A\KAHF%4*)>95KIO=/NUB>F
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M Y7*C$^ 1XS2I3(LNL'>>6L+&<7<QF+MC(Y3(V#M7;MHY8^P]D^<9E[T1X"
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MJFHOS5X9>#%8_4M= L8_X&+QWK*UJCFYAQ]RMCLA:DH]@JE5LOGT2J/#@U-
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MO87GL9#6= .:9A2$)KJV2E8QD<(79IW*G0R-ZHAV>LY"K9RU:G8E WJFU)2
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M5&U;W>\?D%UI4-M0BY2+%6R'5AZE;VQ97!Y$Y9)B&X'7E="PRN,R:L%?>,+
M[6*OILNK=<MN=TT;U>!K#S>MCD+4[2/B/:5^YM*?Z74/'9=_#;_NCQH.KB%I
M%%K3&&RSW)$ABY?RV/KW[UT^I MD[%AYE$-B#6OIIY0%0@-[#M[,O)U:G>N5
MU1GK>0JWK]>L\D!;5M26A8.Y.I$JB\GE,8![(]<++Z9Q^GK^G=0YLE8Z\R+=
M;(XT<(R3G(]WMDJK8[Q<4L*1H9CQ$*]RP:[<M4N2^$T-_";[C]0?"VOW,_\
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M?.,R]Z(\! !@5K6(K6(K$1C]"7C\)KC*JI)B!16O!1S2JX", *:\9NID.[H
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MY9HV@],"^JTDLY9VCF#F"9 ]MC#8H\)XQB'JZF+Q,^6<KS#,K)%,PFO5+S"
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M96T5Y(E\L,%BZEO!:OT_DEA%JD<HN!X=-XIO4&^OU+2"A3NE92FS79"V1 %
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MS+WHCP$ &!6M8BM8BL1&/U1K4*%9]R[<>JM4J5E&ZQ9L..%J2E2X(V-890(
M,21%,1$<)U1JA*+FNKB/,#S'5],UW!L=2H<<P,R; *0OWPF1$9*E2+N_7?>^
M$*S9+]A:X]L<SW@"/^L7H&/&>"LV2_84J/:TK]X _P"T7I.?&?>B/[6(MVX(
M,>!>$>@K11\P'OPJ)\&,C^\#SN8@%:Q$  8$ &-A$8\(B(CPB(CT1^A]I?T
M:R^YW(_IL'H:Q#E%!J<DR6U9CZ#!@3! 4>\0S$QP5:QJO4KZQ#RE7=G<HU)#
M'H$E':D)']B1V_3&AOX3?<?J#X6U^YG_ .B+]5^JW>*\3_<ELQ[T?M?UQ?\
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M\;_Y5'X3CXW_ ,JC\)Q\;_Y5'X3CXW_RJ/PG'QO_ )5'X3CXW_RJ/PG'QO\
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MJF<S.9J5J^554AZ,;6HF-^T3C<EU.&7.FF@NM:">]5[%V0&>[GL%?66C57[
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MQ3+#: ^4<MCN@RT*@>6^*OT2;SBE4;.ED#R^9 S);VL7HW$>1Z-VYW^TCO\
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M"YFLE3Q=4[!B9@@;%YR%$X@6PQ5!<\B!E$;#.T$,Q,3&\3'C$Q/HF)]^)_\
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MA%LV\4]Q/45>N]7IV/N-<!W@NZ3(>-W0FN+]FOGWV:%W27:-I&S9Q YS'T[
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M;LO!D*8HG/?RLYH,1^4SI'ZYL/\ GEQV7:LU)V;8C32M'Z@J=_R6(U#@G,/
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M)GCY9>@/KRT[^4>*^1Q=VIDL?;7#JEZA93<IV53Z&U[-<V)<N=IV-9D,_/\
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MC(:>F[A&'58#H@$I;6ZPWA8M: RE +R'5BM5 NCZFOOWNI?;G&\=GOT.UO\
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M4NT>&Q6(MU3ZU6O;@D$[/U;) *[*Q,F55;,WCQC8B)C-'=IX  R9F>GL*(
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MT[;B[B<FJ6(;RRM@&!DI]:PHO.39K/ T/5/L6!/+)!(F7PC7O8"DI6;7-84
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MF=3W[W<V>MF^FQ=3'6BKP4"3AJ7J/48>WM.0J$.ZY\..R3LKPL]\OU,X&<U
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M[HM3>K2[,M'VZ2:6@,>_)9*[D!)^*5F)[NRTRXB*]E=KH$>-Q"Z[*[XBRS(
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M7>ZEK?PQ5<=39S2N3P-\\IALIAFSLB^2>A#[%865V/)*Y.*[$7*5E$M;T[$
MYH'-/%=KND<K0@.1-G/X_P#JB'O=29+2N6:QD1M/Q3D;(R7IB=YF<=V@]K.M
MWZ[U+AI \)337BGA,4Y<R:[ *@$BPDN+O%=5:EC4KL@-AHV3Y>G:TK@;.,J9
M!^2QEP79=UI%.%TW2QL$RG2OOYYB?,B*\C,^R(>%:D[(]<%H'45JC25J'%]&
M;FE<SD*R%BR]W5B&K2;'PUIQ8Q=U;"<;%)IDRP+YQ':%VN86CIMVP7J>D*)P
MZ]7F(A]=Y!AM.$P+ [B2[-FW4'?GFFR-U%5TUIFIW>FC=K[#9%E[)7#$1=D,
MB\07U[3N08F8 %*6"Z]=2:ZE*#C5-#$N*WH+L\U'<U-W0=_)M7/V.[PG$I3X
MI J.:0RM['>Q2TY*C*8B/4?IO4]4GU#.+%6R@H5?QMT!(57J#Y!D*L+$S"><
M&)<HV(L*:EAA,8C0?:]A,AI],$NC7U?0,K-%'CT%)8S#:D9$5PV %KM)J;1Y
MM0 @%C3U7VV:W=V@W\<0MQV"0GNFG:SH,63SHZ==+:Q& $RE4QV-18)8]\[T
MG=$[1X1'HCC_ '16*S)6:=O'ZZN7\)F\>?2R>&R ZHU7 V*K?FEEYO7K%/3=
MTU,W78KUGI\EX?MBTOD<6/36K)YW&_U=6H9B#+U[3>:)S2#TE;RMEDS[%ZCG
MJ<?!_KS4MW7^N^:65LA=A@T,64K-4%50YKF/<I9D-5K937I#(Q2HUV*!W$B4
M00E$B0E&XD,^$Q,3X3$QX3$^GB[J7L0UT_0%G(ESW=/6D]\TZP^;GCHK)=I:
MZZRYR54MX[) CJ,55.M6F*\3B]8=L&!Q&$< IN? ?0,;]E4[]>):O":;>'7"
M>F8CD.[2/@5:1DQ.EI+ E=*C3ZQS8NV2?:?:LESVK,SX)1+FS+.A44BLLIF0
M5SD9'=L]D?;#D,=3N6+%SR'JT)R51=JPUMAS9L'6RE1IV'-(GO\ (0663ZY8
M;:9X\-P^M>US3V,P%M7=L@G2>-DK5NL7MZS9Y$T\_P"*%S*6K[_W8E^::# V
M@>/TII\'11H]0S?9.&6[UMY=2S=ML$0 GO/WE@M2EBM"5@E0!'&*O5\M9TUJ
MW3K)=@=14QDS3/.#XKV0!J'$D;"P?7<BPJQ1L;O3)B;D/C&-[7M(!C8GD\JA
MBEV,YW?EY=NFW2J@)GI+J3D>\\VT]\\?#LWU5C=0JSE[!9X\]KS/ZFN7_+VH
M;4NQA*\GK73OKZ%952P-:M<R $J7>?;=)D8\9K"ZCN8:[:R6>+*(9A+%ZQ7&
MO./I5.1I7L=C60[J5CGE!1AR2,]3>9&.*/:L-S#? [6T^6*.G-B[Y:FP6-N4
M^<:\8Z:,IZE@)YIR(GR04]/FV&;F+RE1%_'9"NVI=IVEBVO9K.&0:EJR\" Q
MF8G_ )X\>+C^Q'M.C"XB[8FQ.F-4J*YCJQ%/G0#IHYE#O-]:%\XE%^$@H'7;
M+ Z_"%]M7:<K)Z>2\;#=*:/1-"AD)67,I=NX&.PLRH9$2F6T+=@=RBM8K,@;
M$=IF>,L$K3^J[5*=.8W$,M=;&T*5C($JM;K-Q]6M6A=>RA:EU+%L(Y"'FB(&
M2]35G:I9NX0]/Y[%,HU*:+-\LRMIUL&F"LUSQJZ0+YL8^9E>0<6Q*\W>3@/4
MRV!MON5JN8Q]K&V7X]_=KJD7$DAI5K'(SI-Z9ERG('$>^,QX<!2[-.V5%C")
MD8IXG65,G+IUAD>6FHV8_4:P2*XV^(:^-#?>5I1)R7"\=VM]J]$M-==3K>"T
M=0!(W127.M163Q.&'P.!<#+U7*"IL00HF5J(<=@<36&KB\521CZ5:)DX75K+
MA2PDCDB87+'GF<D;"DC.9(IGBYJSL5UM9[/<ED3D\AA&)[WIVR1'+"Z:>5P(
M1#)E@4K-')5U&914BFF!3'DS57;#I[#XAJQ5:;I+'EY2>$[PZ>JK Z;>LS"=
MN5.14DM]I4,1YU;3&"9>?64UMJQ9R%DK%BW>L<O>;,CX(K0R0':O54I([<TB
M;B:YD83-RRK9JL*SA\Q6&"MXJV40)F %(A8K6 &%VZC)@'! $)JL*0]0X7"=
MKNE;V%0M=>I>SE G9FN@-PCE[SIO,&T^GR;1;RUJ!VY0((CG/,/O:N3J_M/S
M-C&0>IM3G;IXS&XNG9E[<=B45:^5=5AD<H\XI@2@96E=%+K"W8K'ND"=1QM&
MFTE24K)E:JI)RN2$"D)()D)( *1VW$9\.*VM-,9VYH77]*!Z>H,6)<E_I#"U
M>45(;5?-@$1-4+R+ L[J70MIO(4A*O)=SM?TG6QD[@>4I8L#SDH\(\(^!:ER
M,B-YZBLFJQS1&]J=YGC20Z9RU7):@IZQK:HUEJC5=FZ&3SW1Y2(*TU:>3(8%
MDO8BK8=[-QLLW[#B)OJ6->]E6K;?9WJRZ;&Y-: )N#RS6S)N8^LN8Z!V7>O7
M 8F_1L.CK]P"S+'F6)U+VPZ<Q>(:/2LV=,8Z0RMA<[P92=?3^GG)(@G8EULF
MA)[R)#M&\GBM/+<ZQ<-;\OF+LB>1RME8R(DXP$0573S,[K45$*1#&%ZX]KWM
MP'T?XO[G=5<3J3L1UX6A79E"+N4TQ?1WO3%F\Q2S*PA!5[Z*<>)Q"2Q5SH"?
M2ILJUHBO'DWM/[6L8C31M";>(T=3(.^H"!F4N+R3I\3ZAQ)1W^,HA+.5T5V<
M@*&CIG35/N>+H0?()%+7V'-.6/MVWEY]BT]DR3&%X1'*I0K0M2@[)=5XFYAJ
M^/T'GJ^4RZ<C8O*NV*ZLUA<B08U=;'6T.=T,:\8&S8IAU25$L@),PXU/I+$.
MI5\CFJE=%5V18]5(#5D*EHI>RM6N/$>F@XCIUFSSR,3$1N4:6TME&U'Y#!XI
M5&VZ@;FTV- CF2KLL(JN)?G1M+*ZB_:\9+M!['-;1HG/9HF.S&,N5^KA;UEI
MBUSIY*UU?)8L05I]:YB\BN;;#>DD^U\>2^TOM;QU33+=@R&-T+2&M<R=;^RU
MV9$L)A&(&S$R#1;%^IR1YU)D&0QVBY,3PP::U(Z@&FJ&/LWG7:-"@^^2U9$;
M5&NH&]&RJ-T6KO.R&29^@BM:5P-G&5,@_)8RX+LNZTBG"Z;I8V"93I7W\\Q/
MF1%>1F?9$/&GL-:)3+.)P>)QE@ZY&2#?0H5ZKB23 4PE$Q12LC4LY#:2 )\V
M&X>U*Z>9I\]O3N9Y?7,;D.7V+)&),\?<Y13?1'-N')86/>JU<PI8;M#NX3*Y
MG%Q%-&7PUW(7)R-!0Q%=N2\HXS&L'(*'UAK0Z\6Q ;+3AYMWLZ][+=5W.SK5
MUR6MR U@)N$RKGS)O98K 437*VR8;<&5W:3W#%CR?%J6/9Y.R_:_I3&8TX-;
M\A@,;RYA@%X0R.CIG#%7:(^(]RR=/E*9\\MA.+6+QU_)9>[E+I9/-Y?)V&&[
M)9$QY3L16ZA(JQ,>'F<]AL0,V[5I@B<9K6_9GVIYK2V7S]F+F4Q62Y[^&M6(
M6*E[<LD UZZEK36KW,;DYKJ];0Y21!/$4,KVN:/QM(Q);[V#Q@SE6"7AS#RZ
M4Q$H8,;R)T[M0H+YKT%%NACK=O+93+V1O9[/7]HMY2V E 3TX(^A63+7DA!-
ML,$[#S;9>QA'_;]VE_0!K+[G<C^JFAOX3?<?J#^U3,5=.W:V.SMC'6TXF_<4
M;JU.^Q)A6LN6OSB%3)@_8L@9B")#QB4G.FO@>T1+B&*?P>C>HB8+Y.F5_NGE
M>"[US>N=6--<D;SRXWGV(3QK+<974&6M%E-2YKUR9R&19&T LWS+RJU!D@1+
M=C<QEBX:U-ML7'PO;9J'4&([AB-7:DM7]/6^_P",M>4*C-0:@N@WH4KMBS5W
MK7:K.2ZFLR.IR2$,!@C^IF(PNCL5Y8R=75]#*/K=^QN/Y**<+GZC'];*7*5<
MN6Q=K+Z8-)T]3F%<@#"&DED<K%5*ZV#O$\I@D!*-QF1G8HF-XF8GWI_^2.KM
M.465U7<_IC/X6FVV3 JKM97%6Z-=EDTJ>T*X->!.)2',%<%(*86P3[OZ ^JF
MHOS5X]W] ?5347YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'N_H#ZJ:B_-7CW?T!]5
M-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'N_H#Z
MJ:B_-7CW?T!]5-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ\>[^@/JIJ+\U>/=_0'
MU4U%^:O'N_H#ZJ:B_-7CW?T!]5-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ\>[^@
M/JIJ+\U>/=_0'U4U%^:O'N_H#ZJ:B_-7CW?T!]5-1?FKQ[OZ ^JFHOS5X]W]
M ?5347YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'N_H#ZJ:B_-7CW?T!]5-1?FKQ[O
MZ ^JFHOS5X]W] ?5347YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'N_H#ZJ:B_-7CW
M?T!]5-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ\>[^@/JIJ+\U>/=_0'U4U%^:O'
MN_H#ZJ:B_-7CW?T!]5-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ\>[^@/JIJ+\U>
M/=_0'U4U%^:O'N_H#ZJ:B_-7CW?T!]5-1?FKQ[OZ ^JFHOS5X]W] ?5347YJ
M\>[^@/JIJ+\U>-.:QS67TA:QF'\L=Y1B[^:=>/RA@<IBT]!=O 4JY<MBZHV=
M2RO9(L(><X%9?_0U[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7
M]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW
M[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O.
M/;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+
M^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;
M]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG
M'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%
M_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M
M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[S
MCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"
M_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V
M_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]Y
MQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!
M?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;
M?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\
MX]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@
MO[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'M
MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_>
M<>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P
M7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCV
MW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O
M./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8
M+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[
M;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?W
MG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L
M%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]
MM^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[
MSCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV
M"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>
MV_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]
MYQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[
M!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./
M;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^
M\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]
M@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'
MMOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_
M><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^
MP7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SC
MVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SA0DW<28 S'(OT2
M41/S/Z GI%R\W4W\T9WVY-O91/SYX]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O.
M/;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+
M^\X]M^P7]YQ[;]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;
M]@O[SCVW[!?WG'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ[;]@O[SCVW[!?WG
M'MOV"_O./;?L%_><>V_8+^\X]M^P7]YQ_\0 ,! !  ,  0,#! $#! ,! 0$
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MD!C6+MV M5,"H10(C2)HB:(\,X8K%]_*+545!G=F%]P(/A!5.]@D"<X[Y67
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M= E,9]W.;G_G!\1&" IMD.1TT]$;G?;?]>OKG$X$==$1'RJD0%6B849OX &
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MBI4%C>6JE><?8'Z?(*NG)<#8*ZW<L7*VH7O7VX)$]*PR84J\6Y$Z#CP=0%
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MQT>5 &!<&UE3?<[54*8%![AQJD,*&?8 !Y'JO^4>W(>P[($AVF *((C3-/Y
M7<G*2GM2)O\ QCS]D"U$9,!98>,MA03RT^#$@!7/STF7WQCTFJ]FQ?"@<0"?
M A:O#QB4 ".=JWG_ /  P/S_ 'P,/OT-R ;CZ'A1^Y9$R!! -B&B.B:,-2 S
M! O4$QX]K3F/CXZ/*@# N#:RION=JJ%,"@]PXU2&%#/L  \CU7_*/;D/8=D"
M0[3 %$$1IFG\@+N3E)3VI$W_ (QY^R!:B,F LL/&6PH)Y:?!B0 KGYZ3+[XQ
MZ35>S8OA0.(!/@0M7AXQ* !'.U;S_P#@ 8'Y_O@8??H;D W'T/"C]RR)D""
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MHC&I=9!#(=*:+.TI \OP%=Q/@"W6R1&E\8G?6%BO(TB1P#1:]S=^[A]I,O\
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MR NY.4E/:D3?]2]FS_ TB01B/\#L::3"KYZ(+5%Z=9]XFF>9+K$AB -ZTV_
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M! A<> K*N$@9D0I-EO2P6M^: ,,J@:YL6.L3,-@\-@E:&,+FL"    "@# #
M,"<ZM!*QY+Z)CW."(@(VLKR:.(+U&!-U VR(1<-6=D/'+BGM*V(&<M0=4"Q
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M7^P4   'XN"M&K@'*PQ?OA(<L_X!/)^>9??P G_NM_)_Z2=K@LJ2$9@&!;4
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M 01!$;$=$3D?#V>0>YX G]PH @!'04Y/(!#S^L5-'\9#[Z$EW\[4"4A ./\
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MC8I:VAQ%CZH*:I=SRK:Y!(X:N&]WJIB3'M^_86WYAP'X$(/OP&=I),&,#T(
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M=?P?L\^<1H_]="@*U$BW!_J.']VT::(B*.S3LY@" 4 Y]H\'DLJ2$9B.A;4
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M 3^X4 0 CH*<GD AY_6*FCZ$MH)4CQMV$\*&%EM<LNT9E?+;T2A/E 50 M7
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MM6G0 BFM9<%0(J%[:UT"WM0T.QF= *5="^I+K78A87>L&+$"A3' --3$:D[
M23T_ @_#^?\ 9E1BF21/J2:UV(65V0&MW N!) UX"E]C%BQ4Z<VU6W$898:N
M5SO)[&EZP2=:J5T2#B3@ #H6C &2D-&$!66[+FNE,;LI&@2[[W45#T9409V
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M,1)*E#3ZH53OVZ*%WCX7(.A\SUM9[Y%E_ BN%^//[!RVD]8*;QS#RQ3$JOA
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M*_\ 7.Z?P<,<,/INTT9#$Z6\$78"U+G*S!AE4<39>KH4 !4.EF)XY2=39Z^
M2<$IVDPL20L-6G []RFPLZ&SEH)VV15#3E2W9MT)F'-_6]D["]]5 E;DJ2+8
M0WK&-XP8^NYT0(@]3;!,TEFROC &!LP:6WMM4$=*U7KJ9)/G_'3A6&J22?\
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MXI88B25*&GU0JG?MT4+O'PN0=#YGK:SWR++^!%<+\>?V#EM)^,.J\\I+EG_
M)Y) "C P#@/42VU$[MQ-(UU1&?037"^3SD)"0R[Z:^!A11)8 50V''HC'WVR
M0G817VQX^:[(.<@[T['@E)CU =4SQM.=:A&$#K" BM4WC*2DAJS88*WD2N9
MPJ=?P81USMM85_3$Q<D@B$T]9L&=E<6B98E/-<GKV64N/ ?8K+H)\J5M+"PA
M@2.>F0*\,D4@9!4-O=%")1+:/ [K// ME07$0RO2QF 43S)F\#-G1_H.XRM=
M.(MXLE3/U=)&'(.N6'GP45%(H<& P3W5$4"-F\XZYM*&K^&%]MW\ !_[AO\
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MR6NL/JJK>=&P]BC"$!](>XS^%OPA\C"0+_[^  _]PW^3_)XG:>M5*ZI)Q)R
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M@S AR=<20. '!/4KTJQD0*G-XY^M$"+J24PP!A.'N&*X0?D4+H6+"+FQS:(
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M^4CSSP_$;)2'5P\"TV6^+C)VJLK?ZQ)L :>$XMEU94.Q=#*2;FF98:6)1IY
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M/<M(G/F#<8F'XHVT!8!IEM/)Z.[+>$"H?W+RI8S#UEL\5RU'1%0D9V8/G49
M"H@!;#>7B>;TS1A2E4#7:UD8JV%+G47G^NZ862U +-"@^4K'EG#5TZ+4SDP-
MS(=.DNK] &]TWT@NH.DHK8ZM4@2TS;';[Z 845OJXTP)R8+-)O!V4R?\@;
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MOJXTP)R8+-)@ $<4']Z(X@ 0$3MO_P!<[I_!QQQPSH/^ Q1X'( H1+^M0\8
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MA*X'CH/6B*&K<\DYP;*2IM^;&91:D%ZH>",RC8,H RQ^%YV+3RM)X:8':!Q
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M'6K(CED\[DY8ON=*<?8(3-&2')TRLFK2RR$01 >)ANF:W]LROC'94X 7E!H
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MP_($C^F($01&G(0"Z+3,AF6_/DNPHZ2\[+\ZOOZ$Z?"M2:_(7 ^5@'P4, *
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M6[E9S)9L"X8V5%7UG3*R:M++(1!$!XF&Z9K?VS*^,=E3@!>4&@ Z7WU6@$*
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M7/:GXR/.I4-=3 '(+;P34N2*@\   H/SN7WQ.GPK4FOR%P/E8!\%# "@# #
M/M6]:?CR0,?O.2M7;=@D(LFJD*)^5:";NA7D-#;;0H7]12[IE9-6EED(@B \
M3#=,UO[9E?&.RIP O*#0 =+[ZK0"% #[D\3Z$0*217K;, ++$RGY5&-GB2NW
M9\-?,5K>?*<]ZYSH:^ZK ^>%SVI^,CSJ5#74P!R"V\$U+DBH/   *#\'E][%
M/+06 6@M Y4/NBJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJ
MJJJJH3*$%7L?F(E/*LSX*& % & & =J"Q4+-I%-NR+]S)EEEEEEEEEEEEEEE
MEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEF(.<S">JO*E >)ANF:W]LROC;
M$UU][W%.IAX[KRK "! 'W-XGT=]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]]
M]]]]]]]]]]]]]]]E181;]LX*P;1#<,.P<KIR86ZXYD=WU6!Y<+GM3\9%UUUU
MUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU
MUUUUUUUUUUUUUUUUUUUUUUUVS1E_N$TZV- VH&I<D5!X  !0?_S92^Y?<ON7
MW+["L3,Y>MK:L%@/3M@"+T*Y1UO^R.7VJQ0LED/:*H;K3DG\>^54.H#:%Q5*
MVPY1:*[KX 2K/S\N1F2+KAVWF^@2D@HL<%J74K@(I03/=]>#\&H[.I0T. I$
M@D0W&5%@J:5PS%P1E\(26Y<0B-"R#I2=;ST1&3GK!_ZBIK4./D\QJCD.52\5
M!G$LMFT*$&]%;D#<'8NX\9O='^R2V7V]]^N5&>$JL8%!;900XCTP2, ?9_G0
MW[.965A270'2BKOTQ9RF5BY-XP6G4%2 K5:(=^8^WZ@+/Z;[+WJ(4,;F)'?;
M)A'NI88NX"9S""A8 (B1Q]86TRR BU'OY^6X,#;4J)"Y*-/1?:**$^I1S:F#
M5T<-1\2PE0;I=AP"EHZ[D367I1'L LKK.8C LI)KQ1A'M-D:=KLW/2)S9C?
M8BF\EH%7G"_6$/9'^RALON$_SFTB[F7 Z_A8D(\A&AF4*J;U&@*:DCD#7E5/
ML['>\)_R8>Q?2@$BJ ?$L=(XK$)G@:,Z=!!HQ#X(Z7:%!ZD<'-U3[<'VZ@%0
MY2(S(8^)& . '!#&P3*)%0Y4Q,01X9XSQ$ ;H'J=("H-*O9%DQ>*E:NV7G1D
M!5S!H)3LC%.@I&U"57(B=*</&P#I@M#FS'$Q.SZCM@K)]TT6$J@A%TI:]I^C
M)"-&S\EI%85D/XP:%&F<B<^"DBRFL "HK%4 HF)\I4CX#$(8W+C/<ZX[D.8D
M=]LF$.ZE FY-31>_>@%3=>9<6](/$LF"*R^<+@[6ZR?['96$OLX5A19HWOLC
M?HRNUO4T%B&5+#MNZXER[2U;!?;+@-'K@)C"6> H@NF%X@_0"KX!7H!8(H R
MN %BO@.DOA!G?*<>?.)F\U@5<4;E*R[37C*+B[@TA.9?34^/QX85[614RQC.
M#)[.Y&[3 :**;:J<7*@EG%BPB^X$1TPA.%;-T.D_PQI+W<@KS5-P*_UN,:9"
M""-.+_\ ^99KSUNYP\MTV17CW/)7PQE:2Q6P5<.VL2+@ =$7A'OAUE?,S4BM
M8%''I2ZLW^](KJ )S&HTE_1*6H:* ;*4T7;6F4 A9U2EP.041$L6.30>Y8EG
MD3QT(LHLL9/(-;7LTU[T^W6?U"OA1@QIVV&#WD"/AIF!@5(EHZ7YO+W>/3%2
M.Q' I]T@G"I[83Y?;>6\:+KQ[G@OY)H(,2*<H):/Q3&$1=,Q*P\@ U.SG$R+
MOYP YTX">4*:_-2,$#1+A$AX52#9H!71UWE>O<L,7EZN H_[&Y?;^4G.+;1D
MVWDH*CX/U(72,W$H6$>L/-ER+Q.D,H%1R7$R QL4$;QW')_&[WTK W:'U 9W
M('$;13"0AB1Z1_A3"JRT<)PCWBBN'\/XK",0(?L1D@<@ $2Y?LDNZ^-!4TI4
M:1\GK6)RHJITM(DW$MC2="^1\>@X\'4A8!1$I,97H:V<2\[;9$TRI?I:Z\K:
M^9_6>8P"91(J'*F)JK+XY#R&937)H.@X\'4!0   H,)9?G3(8ZL1HM1:F'A:
MB6*NCMIC(VR$A)4_)7Y*;Q!]@4Z'HRRC%U<I*)6W#C5\K=.9!D,GN?7N9P4H
MDIS'1J[]+4\D>8(3',@@%4ST^M:,'BW3GG3 %!ZMT_JK."Z"G1L!=N!U_P !
MNR6&BZX%\.@Z$B'II?SQ3?O(#&X#=4)3J!S.#W#TT20$Y13, 1"A ^5G=^ZR
MNYRPF V<DG%&Z-)46<<S=OCWJIB?AJ,&YO>L%WOE0_V0*!(CO<OM4U%N J!(
M*G04R<5SB>!6T>XB2P-'H+%17J3XJDFM6.14#C@#!:57Y]>;L$$F>)%++[=(
M "ZP5P"!+CPBY,<$8UC EC>;J[JZ-^\L-D1H\BZ7QIC^1TI%@  ?092#60C@
M#0_3.Q#5KBM[=WJ]0 %![<KR?M%!6"&RH2"80E CH@'SD!>"&,=;G/TZ=[45
M$W#([)Z"SZ4-#@/\:/47/H)>0>S@7EA4BO&* YC:LS["-*VK%H*!?\ B#P&
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M_:*<Q<NA_L3E]BDI?6P40F&:C$,WO;6O&(A!A*.OYDHJ1 FQVS:>@#;8A(R
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MO87(41N1[PCK(I !?:S[AB"'+7N2FM=1"KL*IG$LZ-V%3P-MS26$M4U#%VB
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M-Q%_+/<AKYCE,2A)=<8>QE6Q<8;?[2+;Z"!*]6A\1V"O0B/A]['SHLZM?==
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MYYYYYYYYYYYY[__:  P# 0 "  ,    0
M                   $ D               $   D@   $D   $$$@
M@@    $@       $ $       D
M
M         D @           D@   @$@@  @D @D$@ DDD @  @ @  $   $
M   @  @      @
M                                                       $$$
M@ D $$$$   $   $@$$   D@$ @$  $ DD   @@D D $@ @$@ $$ $ $$@@D
M@$ @$@@
M                                           @@ D$ $$D $$ @ $D
M  @@  @ $D$ @$D@  @$$D  $$$ $   @$@@@ @@$ @$ $D@ $D @@
M
M                              $DD$$  D  @ $@@ @@ $@  $  $$$$
M$$D  $  @   @@@@@ DD DDD $$ @ $$$ $ $  $@
M
M                  @D @ $@  $ D @  $  @@ @@     @$ @  @ $   $
M$$ $ $@@$D@@ @@D$$ @$$@$@D @ $
M
M     $  $  $@  @ DD @@@ $  D$ $D DD  D  $  @   @@@ @$ D D@
M$$D  D@D$D @$ $  @
M                                                    $   @D$$
MD D@  @ $D@   $$DD@  D$$D$ $@  @  $@ D @D$ $$D  DD$ $@D@D$$@
M   $@
M
M                                              DD
M
M
M                                  @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        D
M                          @ $       $
M
M                                        $  $@
M         @$  $  @   $  $@
M
M                           $ DD$    D$ @                 @$
M @  $$ D@D D
M
M               @$$$$ @D$$@$$                DD@  $D D $$$$@
M
M
M   @ @@@$ @@$ D                 $$ @@@@@$@  D$@
M
M                                                      $ @$DD
M@                   D@ $$D  @ DD$
M
M                                                $@
M            $@      $
M
M
M
M                                     @$           $$D@ $
M                @    $
M           DD                 $@
M                        $ @          $  @@$  $            DD
M    @       $                $@D      @                   $
M@              $          $
M            $D @ @$ D$ $@@  $@@@ @             $D DDDD$ D $@
M@D@              @$$  $ $$$@$ $@               @$ $D$$D@ D@$
M$D $ $@ DD$DDD @@
M@@D@@@$D@@@ $   D$$@$            DD $D @ D@ @ @$
M    $ $@ $$D@@D $@D               $ @@DD@$$  $D@D $  @ @$DD@
M$$$@@                                           D @$$ @ @ D
M@  $ D$ @              @D@$$  $$$$  D@              @ D @@D@
M $@$$$                @$$@$@ D@$$ D$ @D  $D@@$D @@D$
M                                    @$  $$   $@    D$$D$
M        D@$$$@ @  @@@@  $              $@@@ $ D  @@ @@
M            $DD@ @@ DDD  $@D D $@ D   D@
M                      DDDDDDDDDDDDDDDDDDDDDD           DDDDD
MDD@DDDDDDDDD               DDDDDDDDDDDDDD@              $DDD
MDDDDDDDDDDDDDDDDDDDDDDDDDD@
M
M
M                           $DDDDDDDDDDDDDDDDDDDDDDDDD@
M                     "  %;;;;;;;;;;;;;;;;;;;;;;;;;   DDDDDDD
MDDDDDDDDDDDDDDDDDDD  !;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
M;;;;;;;       $
M         ;  L                        $H $@
M      $  ^                                            .
M  @                                                      ;
ML                        $H $@                        $  ^
M                                          .      $
M                                             ;  L
M             $H $@                        $  ^
M                              .      @
M                                 ;  L
M $H $@                        $  ^
M                  .     $
M                     ;  L                        $H $@
M                  $  ^
M      .     @
M         ;  L                        $H $@
M      $  ^                                            .    $
M                                                         ;
ML     %98 %#  8   20     $H $@         $$$ D @        $  ^
M    ' 'HZ:08!9QB0    Q O%W2R.;9-          .    @
M                                             ;  L     %#9:**
M3\.'X!V      $H $@        @@@   @         $  ^        [IH%H@
M3D:7HH' 'X HW A"S:8@% X       .   $
M                                 ;  L    #IBD@HB@H*L O\ 0
M  !* !(       !)! ( (          !  /@      !*#0&A!0!0%QW> /P
M9N#6%J ! *?0       #@  (
M                      &P +     )I.140!0\P#-Z      !* !(
M !) (  (           !  /@      (/["0($*YQ@,OP!^ !#UT L@,(!3(
M       #@ !                                   (ZO@ +A124&]6!
MP(@       &P +    G;<\*TR%PH!0S0      !* !(         !(!!
M       !  /@    $M !7DO!@00* )00.D0 .FEUJ#A !@         #@ (
M                                  B P &V,@A:"1$P J        &P
M +           $.   (       !* !(                        !  /@
M                                           #@!
M                     (   !P[D!K02+> %0        .@ "
M %P           !& !(                        !  /P
M                               ,0(
M         D   $0\3U:"0,0 J        )P -P
M  /0                          !(  ,
M                  .0!                                   ,;AB
M=P-T);02!" %0       )P -P    !+L9@               /0
M                 !(  ,        !2O0 N       -  P@
M     .0 (
M       )P -P     !''$%ZQQ)&PV       /0          (!(()! ((
M    !(  ,         *1FTR#,@@E ] X"<"4( .             .0 !
M                                                      )P -P
M   .!2 184=:,JN"       /0       ( )) !( ((! (      !(  ,
M     !4O5 1/(J<P1D]^Z =?K%Z            .0  (
M                                         )P -P       0"*N ?G
M0 H       /0        )!(!()())(!(      !(  ,          *1>L"",
M@6 ; )OP(#D,BDP           .0  !
M                            )P -P     .!" 18+S>U^I>      /0
M      !!(!)() ) ()(      !(  ,          !4@5@01D#7\H!-Z. <AD
M.D           .0   (
M               )P -P                *F      /0
M            !(  ,
M.0   !
M  )P -P                 !      /0                          !
M(  ,                                           .0    (
M                                                 )P -P
M                  /0                          !(  ,
M                                  .0    !
M                                    )P -P
M     /0                          !(  ,
M                     .0     (
M                       )P -P                        /0
M                    !(  ,
M        .0     !
M          )P -P                        /0
M       !(  ,                                           .0
M   (                                                     !P
M                          #0 (                         (  \
M                                           P      !
M
M
M                                      (
M
M
M                         !
M
M
M             (
M
M
M!
M
M                                                (
M                                          !2 !L
M           +0 )                            H
M                           !:      !
M                              !2 !L                        +
M0 )                            H
M               !:      (
M                  !2 !L                        +0 )
M                   H
M   !:     !
M      !2 !L                        +0 )
M       H                                           !:     (
M       (        !                                     !2 !L
M                       +0 )                            H
M                                       !:    !    !! )!(! ((
M  !) !!)(                                 !2 !L
M           +0 )                            H
M                           !:    (   ((! (!)( !!(( (!()(
M                              !2 !L     "70 !&      ?0     +
M0 )         !!)(!()            H        .!$TF\+JA?P   !& L'.
ME5C!:2         !:   !    ( (!!((  !()  )!!(!
M                  !2 !L    !8+7.X'H*^  ,P      +0 )        )
M!!  (!             H       !$#0+1 <#5:!0* /P =N!2%BH! *!0
M   !:   (  )  ))) (( ! )!!!(! (!
M      !2 !L    ('9CDVJ<$JJ!X       +0 )        !! !)((
M       H       )H:-8(* Z @ [P!^ )=Q9PM0&(!.6       !:  !
M                                                      !2 !L
M   !EV"*2.:&R +MP      +0 )        )  !                H
M  !!)4:!!0-D% TH /P #.) %J!A )?0       !:  (
M                  !KHL . .6!"8:!D-<       !2 !L   %BDWA8LPV
M0*C$       +0 )        !  )!(              H    !:H ;-:8,/Z:
M0!D.!W6 %Q;:M1<( %10       !: !        !    ! (
M     !;,) !-  P ,@RN!!(       !2 !L   +@+'8..)FT +Q0       +
M0 )      !)))(                 H    _P"<"&__ & K M  S' WZ8#T
M_P"O0Z!@!8*        !: (      !(((!!) ! !                 & !
M(!LL  @!D!/P  0       !<  0          "6            +P )
M                       @
M       !<!      ! )!  !))()(                !0 ) ,2!R, ,@'0
M%P        ' !Z                         2 !
M          )0                                           #P(
M    )!) !)) )  )(               #K/)70#P&@!D!B -:        ' !
MZ   !P(-O,                2 !             !              )0
M           .P%P   ,@                      #P!      ! ( )()(
M()(                 !<#)J %@,$)@( !Y$       ' !Z      %<4PP2
MR.[T"P       2 !          ) ( ()!(          )0             (
MA^MA>@0)!!5@                 #P (       !! !))  (!
M                               ' !Z    !P+Y\JB44 )_@P
M2 !     ! !! !(!()! (          )0                OX]XC8-8EH
M                #P !
M                  ' !Z       " 100#52 -0       2 !     ! ((
M!)())(((          )0              *@QE"Q<;0!&D0
M   #P  (
M     ' !Z     !FZ0"+60%JGUM0      2 !     !   )) (!(!)!!
M     )0               +1JV(%C<<Y.&                #P  !
M             )                                      ' !Z
M  ,VXAP 8!I!!20      2 !           (!   (!!         )0
M          0 /!@XJ !A4                #P   (      !)((!)  !)
M (                                     ' !Z
M"R      2 !                            )0
M                        #P   !      (!)! ! !( )!!
M                          ' !Z                         2 !
M                          )0
M           #P    (     !(  !   (!!  ((
M             ' !Z                         2 !
M             )0                                           #P
M    !      (!!(  )!!)  ))
M' !Z                         2 !
M)0                                           #P     (
M                                               ' !Z
M                2 !                            )0
M                                #P     !
M                                  )  (VVVVVVVVVVVVVVVVVVVVVV
MVVVB !)))))))))))))))))))))))))(  'FVVVVVVVVVVVVVVVVVVVVVVVV
MVVVVVVVVVVVVVVVVVVV]P      (         (     (
M
M
M              !   )(!(!! )(  !)!) ( )
M
M
M  (  !) ! (() ! )(  ((  (
M
M                                                 !   ))!()!)
M !(!((!))((!(
M
M                                     (  !( )!()))( ))   (( )
M(
M
M                        !                            ,
M                   +  -6VVVVVVVVVVVVVVVVVVVVVVVWJ !)))))))))
M))))))))))))))))(  %VVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVV
MVVVV]0      (
M       )  )@                       !Z
M       +                                            '0     !
M         (          !(                                 )  )@
M         !0            !Z                              +
M                                        '0     (       !
M        )                                  )  )@         V #
MA*:(Z@     !Z                              +
M                            '0    !    !(!) ))  ! (!)!! (
M                               )  )@        &P#K-^KJV      !
MZ                              +
M                '0    (    !((! )  () !)!())
M                   )  )@        V!@!J#^(P      !Z
M                   +
M    '0   !    !(((( (  ) !!()!!(
M       )  )@       'A7K,Q=RV       !Z           !) !((
M       +      ! !:)]_P!(;4#7@    L!8,G_KC=(          !T   "
M   "  0 "0""" 2"0""00                                   "0 "
M8       4 "@3AH(P        >@          ""0" 00            "P
M     !@$>WWCH104! , + !C?7@#%A/@(!@      !T   0           "
M                                            "0 "8
M "=P         >@           0""""             "P       # @*,04
M"@"<"<@!8 8;CH!8 (0"LP       !T  "    "0     "0
M                                "0 "8
M >@          "0020              "P       #H \"#@.\!"0( +  :<
M7@+(!" /1        !T  0    2     00                       68P
M < <L"*@D X P@      "0 "8     1M@                >@
M"202""              "P    !+ ,C]*P*WX? #X<!5  7XI=8;X0 (C@
M     !T "  22 00 220 2"2002" 0 00          #M5$@": !@ 6CE, <
MP       "0 "8    !OLOP'/.#@          >@         "000"
M        "P   #@'@=H ;@$ 5( ?# 8!<#] ":CX#@"X8        !T 0  0
M " "220 20 2"0 2 022           ?@ D#98 ! "T"J@"!        "  "
M      (0'DHW;Y@          >@                             "T
M                                         !@"  000 2 2 020 ""
M" 2""""0          "\ $@8D#D8 6@1  !@        '  $     !!$*<%
M@$          #\                           "  )
M                             8@0  "000 0 220 020  " 0 2
M      '>(^V@'@- "T"H 7#@       '  $      (#H@@@4"@         #
M\     20                    "  )             <@8  4 9  4
M                8@"                                    H&34
M+ 8(! # "=@       '  $       @!D4/A@,         #\     0  2"""
M0 0  00"       "  )               #)&A@!UL"#/@
M   8@ 0
M     '  $                        #\      "0""2002   0  "0
M  "  )              #!KD0G1&CZS/0                 8@ "  "000
M       20"0    "                                    '  $
M                    #\      22 0""0"2 20 "20     "  )
M        6CIH8#XV@"%)                 8@  0 "  0  0" " "0 2
M2 2"                                   '  $      !#P "T@ <
M       #\       2  "0 0   22 02     "  )                <AR
M0&FG]Q\L                8@  "  0""" """"  0  0"2  0"0
M                          '  $       (P^:E:I!%@0      #\
M   "0 00"" " 0         "  )                "4#"CBYULCC1@
M           8@   0 "0 0"  "22  00  0202 0
M             '  $       #:4NV6&I9'2@     #\
M          "  )                                            8@
M   "  0 "00""02""   0"" "000
M'  $         .)#)B @@;P     #\                           "
M)                                            8@    0
M     0                                         '  $        "
M53%%/O8'C(     #\                           "  )
M                                8@    "
M                                  '  $         #B#5^CCA:F@
M  #\                           "  )
M                   8@     0
M                     '  $                 #Y     #\
M                  "  )
M      8@     "                            <
M        3  0                        "\ "
M     "  -                                            4@
M 0
M
M                                                "
M
M
M                                    0
M
M
M                       "
M
M
M           0
M
M                                                          "
M                             " 2       2         22
M
M                                              0
M                "00 0   200200 202 2220"20
M
M                                 "
M    0  2"2   "00202"00" "00 20
M
M                     0                             " " 22
M 0 "0 2"2 000"2220
M
M        "                              "202 " 0 "  " """2 "2
M0 0"0
M                                                        0
M                                  0     2
M
M                                           "
M                                   0
M
M                               0
M     "      20          200 "2"
M
M                  "                              0   2 000 0
M02  2"  """0"0 "
M
M      0                             "2  0" 2 0"00 0"0200 0 "
M2 0 0"
M                                                     "
M                           "  "20 02 "  "" ""220" 2"""
M
M                                         0
M               0 0020" 0200"2"0 2 0" "  0
M
M                            "
M     2         0    0       "
M
M                0                                 20  2
M"    20        0   2  0 2     2 ""0  2"02
M
M   "                               0  0 0 220"02" "0 0"0"0""
M     0"0 ""02"0"000""2   0"0
M                                                   0
M                     ""  0  0022"  0"0" 0"" ""2 2 0 0 0  "20
M ""  2""" 0   "
M                                      "
M         "0  "0"0" "  "00 0""2 "  0 2"  22 0 00  000"0  0"0
M"0 0
M                          0
M 200"0" 0 02 2 0 0  " 00     0  02  ""0   02"   2 "
M
M             "
M         "                           "
M
M 0
M
M                                                "
M                       " 0       2        2 ""0" "0    "
M             2      "        0
M                                    0
M      "   0 2 200"  022""0 " "0 0 00""22"   0"00"0" ""2 2""
M02"""0 002"020"" " "2
M                       "                              0   ""
M0" 222 " " """"0"2"  "  0"2" 0 2   "222  0   20"    " ""022
M"02020""0
M           0                                  22 "0 "" 20 "0
M20" 020"  0"2""  0 ""0"0"     " 00 202""0  " 2"""2 ""0"0
M                                                          "
M                                "  00  22 " ""200      "2 00
M   20 2"  "0 0 0 0 020" "22   """22 "  0"20
M                                              0
M                                                      0   0
M                     0
M                                 "22222222222222222222222220
M
M
M
M
M                                                "   "
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M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ V2_,6Q?_ !D#K/KP D)DV3AU.BD]0?\
MG#Y8ZP!KL_(MS;)>7H(LYX1W'(F?F?H6I_5/8^A^?!@-_B%('"P 1$'1K]H=
M! *D( F /IC8$J0!:P(="-?6K7X O;)" ?7JD D)DV3AU.BD]0?^</ECK &N
MS\BW-LEY>@BSGA'<<B9^9^A:G]4]CZ'Y\& W^(4@<+ !$0=&OVAT$ J0@"8
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MC!X0&"*!R6L,- Y)"_B";TDT4C59HS$\'C$78<8J! -'?)"(4D ^HR((FD"
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M9##4/12CYE2(ZY%1=?("YCJEV!B3*!*T'I,)7J9P@;I =%MM$? 'YPA#8,
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M !$0=&OVAT$ J0@"8 ^ ""^[C -.B)I,K/J*@U%A6!(A@@UX&_J2K!+F(6B
M%4#1/P!#)%%<5,A('@Z,&A3* EE4D>3A!-$Q#0%="DV*O" 3 4 !*C  "JH
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MEB#"DB%?B@01JTB( OB!"D2S(>&#(JF33,9T)JC1L=*[.3&&H%@"B(>==OB
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M69@%OF#U"*C4UBG-_J3'70F"-A*G:26_4'1K32D&3@=[8,%:8^!1%Q8:[/\
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M4V)8L4M-$0;$DZ UI..LL)I+!@6Z!/B+F!4"I)@HQXF,FD')'BX[!;;,M?"
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M:J<*OHFT15@"J!HP6!+RDIP+:3 EA>\$#=3 R$PL7IY6JGT,H9$F00 AKO\
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M\JB$1/,CB#H_G25E7K_D6[@6["'8$ =VN5;6WY\: 4&+\4"U0 O@A9@'0FX
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M\^*\#%)*4Z$BX8$-! '0FX DJRLM61],
M                              !<G68  W(P.K_^PASHL?03_O#H DCD
MW'A\M"P4X"=FQAK"(U"(0B;/S(5"($1&$3".R:," #T ;G'_ $%2'SUP#H7<
M@4B2,M60:04FA\$&U2"ODA?TP=8  <%!4K2%P4)950'"P ^O3.:^=%CZ"?\
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MZ(D%Z$JRQ=EI))ZFD+/R"2,4.& I0\D,1?*_DP@6&2B15X@7FU6B#)HY5=\
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M"G"RA89E,%!@F8EZRI3*_@ H" *"/YQ4(@1$81,([)HP( /0!N<?]!4A\]<
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MI=( (IYPYKI1<UAX9U&3SAX9-3B.]4O)HK4J8XF%SP BA*0#RY$T@9ZT3=H
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M> 8MRA^UVW= 4 ! 9=UNFZ^V" #Y\=-W:JD-@4AL"44L%_X1"J\'990'TR,
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M H4K'%KY  !# $'H#&NVOWKMK]ZAZ#$C'I*_ 3P%93?H<<&^6L^10%4 )5H
MRKL&G2B!@*4?@['J:@_F!<<BD:7"HRI.&8719ZP TN &2H6M"J;:>H3I5! L
MQ+3'5)F-M%$($TS"W"B#G33%8'HI$'K"^_A>94+ OJYC<"FYI(F3H3^X/?4N
M;<3")T)43<-;QHHQL E_\.5HT0+/RY/6+[^NF4 E9* WD)]C&\> *@"J@ 2J
MT %JN#0 @G A]R!Z(/(: 0$9$?L0?0%X'4[G&) N5$I+";-SJ'>6&)AD$108
M1$D/3P00$24@!"T%:@5I4D,E*DIA1,,DQM4E_ 8!BW*'[7;=T!0 $!EW6Z;K
M[8( /GQTW=JJ0V!2&P)12P7_ (1"J\'990'QHQ@LJNKFT"X"&0FA$$1$D2Q'
M".X^#<6Y#CU#@^SJ9O:GM%U["=L$HJE$ @*513#(*-- E"B D)T8T'$=A*WR
M/)A;0"U0$A=-P/K85"2& 50U>*E8)%.SD &BDT)6I$O9,[@OU>/!%J.SI%AH
M..(+T)J P  (!00204G"YT&,A0U1,DD2 C@%<0HDR&!"!R)#&0TE<H22%(@8
MM&'<>3A-6X6 !@0=&A)NM,$P 05 @3+8T* G6!HPW9Z6$8:"H1#Y( &63:%E
M A9*&]]0JJJJJJLJMJK:K:N?KN> K*;]#C@WRUGR* J@!*M &5=@TZ40,!2C
M\'8]34'\:@((ZX$!>A.O\3_C7^)_QIV1 IE%)WUO,,C%0U,:. 04!!Z8ZR[^
M;7ZWHBP$X4F",QIV 8E6/[=>W_!U+7*'[QTE =EG;4X(Q0LQF,!)2%(F"P&!
M<B;^YT* )+S!$( #L6(G=4FN!(F$9!U)8&5-C!II6%G:^P('V#2G44-D1A3*
M6 F$FIL,@ 0!M#\@@V$- B*&Q0,HG%/_ .NF0#9T3B!OUD]8K1L31)(<$S+A
MM,3)2@G2 %F3+(E%0@2KM<(".0),KS(\VFQX6RJ^4(D+VV<PJO@, Q;E#]KM
MNZ H " R[K=-U]L$ 'SXZ;NU5(; I#8$HI8+_P (A5>#LLH#XX:V7QBH P($
M*@!!19!BHW(TBZ9C):%$I"E9N2?#MDR#4UX@<8ZP/"HPDT'-%&&:8 Q*$! -
M05X\48Z2C6@P6VIIB,D$*00MTT"=:9DTN;0;:B9/':1TY!.CI*Q;1T)" ':L
M?!=.I@ C^2;@7$Z:<[OM=2$#%*FFR*( OQ@#!X   $:[7R\+LL-A&>=(.-T1
MJ4J[$$;H7!0PDU(8Z#F37^""W(V![4 %:2E8)CPX$#.AUP!(QR>'AD)WD(21
M(JY*=:=HB#(!091HVP$LE!;I2%.2!(\(&'R0 &63:%E A9*&]]0JJJJJJLJM
MJK:K:N?KN> K*;]#C@WRUGR* J@!*M &5=@TZ40,!2C\'8]34'P /O\ QJ6'
MH_'P^W_!TPDW$]9OP.@C$,E[BD?N(G1\1.IR4%"1%D!@S.:172<FTFX8'9ZH
MX^P(>0%%<@''J>NL'?>GH! >A(.MO2WR6H"I<AL5$QG+*L5H8"(T)I+%8@LT
MJ<Z"DB(,3"N, <*-_P"? ,6Y0_:[;N@*  @,NZW3=?;! !\^.F[M52&P*0V!
M**6"_P#"(57@[+* ^/&!,!  $(,B(HB(C#I%ASJ $U*%0=7:2#"N$JU "3 D
MOF(*T*3S,E HMAUG4;BR2!F0V5L"=*.830L$ BRD,WH$8&5/%1<R(3$$,%-S
M0EY)(ID**24$T$AC%@H@Y!04W@G!X$002>R;$'U$$=D$OP1=KY>%URHGGSB;
M3" C<*/)PV-'U)@E"'9 +1?.78X@04")D9\ 3E#RYCC(S!:&C\B #+)M"R@0
MLE#>^H555555656U5M5M7/UW/ 5E-^AQP;Y:SY% 50 E6@#*NP:=*(& I1^#
ML>IJ#^5]S)42$EVM\5EH"$B@67%'IKW_ (U+#T?CX?;_ (.LK[F-DPG0*=)G
M0@H!O(*"6)@($(L"!&&!R:?T)]M3@,RHT%38D&&;<Q,/2,@L4B/0#N;C&F@I
M56(V42GH,.720S5K2GD)L<1"98!@[[T&BVVV@@<"B7"MI4>Y44$-@ AQ(]-T
M[G\"R&14!S)>#<A&<:)9%WFWTRJVS" Y.TH;JA]TGWT(6%%X3D/V&*#)+"()
M13RK*_=?YL Q;E#]KMNZ H " R[K=-U]L$ 'SXZ;NU5(; I#8$HI8+_PB%5X
M.RR@/D(Q,&<Z$ 8O3":I;1>E3S5CHI]60"Z(HWRD,PB4+ JP$O/\HTW@>8E-
M(!N+TG*@K2T113D"6BTA'4,P545U='S1%$B[7R\+L%%1K0-1EE'TP]&H(&',
MW*D.&,1IK-^L.:.[#$ 2!XI"7G(H&EX<&)I)14 49RSM$5S$AJIF/@96":+[
M(C2""3"T$"2PTK@3G8HBYE=/Y$X 99-H64"%DH;WU"JJJJJJRJVJMJMJY^NY
MX"LIOT..#?+6?(H"J $JT 95V#3I1 P%*/P=CU-0?S$*0RA"P$H@F )S <>*
MA09:TPJ3#"I)H$)81"2&$1*4K;2)2B44@@E56  O!'A&9)NQ$Q)B8)C,''@F
MH&(;&,0F"-H*\!4*4811/1+-+$+'"Y_7B 0(* ,CB"&EPV*(U!+$E,C8S)IZ
MBHE*#!*6.GAWPYR-=\.<G7'=#8Z<K<"5# PZ""4P &;9!CC*T:=2T).2#<I9
M,RHS,_S8!BW*'[7;=T!0 $!EW6Z;K[8( /GQTW=JJ0V!2&P)12P7_A$*KP=E
ME ?(AGV?;3.JU8,@BFD*/<E<G-%#>8!X-QD.>I 4%(B.^D[J$@@ 3:  -@ F
M-'K '!@<!L #CP0<H54$(DM15*Z 7>@!3WR("@335XSD2+;V4RTNFE'RZ .$
M&*BQ6@3   ! !      0>"A 56Q4I>JVK)<Z%W" =Q(4JJ\!( #T'#82I"F6
M=.ER5\!!5V%+5*;N@EH @9F0W=UE?R( ,LFT+*!"R4-[ZA55555595;56U6U
M<_7<\!64WZ''!OEK/D4!5 "5: ,J[!ITH@8"E'X.QZFH/DCIB'(3!B3DV1'K
M$Z8"=W?]('MZ1I5**E5657*NZ_RX!BW*'[7;=T!0 $!EW6Z;K[8( /GQTW=J
MJ0V!2&P)12P7_A$*KP=EE ?3(P 99-H64"%DH;WU"JJJJJJRJVJMJMJY^NYX
M"LIOT..#?+6?(H"J $JT 95V#3I1 P%*/P=CU-0?,\ Q;E#]KMNZ H " R[K
M=-U]L$ 'SXZ;NU5(; I#8$HI8+_PB%5X.RR@/ID8 ,LFT+*!"R4-[ZA55555
M595;56U6U<_7<\!64WZ''!OEK/D4!5 "5: ,J[!ITH@8"E'X.QZFH/F> 8MR
MA^UVW= 4 ! 9=UNFZ^V" #Y\=-W:JD-@4AL"44L%_P"$0JO!V64!],C !EDV
MA90(62AO?4*JJJJJK*K:JVJVKGZ[G@*RF_0XX-\M9\B@*H 2K0!E78-.E$#
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M7=;INOM@@ ^?-9EKLE.90DK(#1">>$2J^.RR@/ID;_\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
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M4IDJ04/TQ_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ ^;;5"X@I *E3&FZ\@ %!$16JE6:?
M0_;>7S7G#R<=3K^= DD</E,(0;/ -SO]V411(2D<CP_,D[(D3NQPC24Z@K O
M7_(MS*IV7Y[)?^$JB_!V&$)H8ZYNVE#L"E,E2"A^F*P .@J+LU0:1;]UY  *
M"(BM5*LT^ANV\OFW.'DXZG7\Z!)(X?*80@V> ;G?[LHBB0E(Y'A^%>(4M:$#
MN"9&T1-Z6"*5)A4J)!B2I!C8^,3LB1.['"-)3J"L"]?\BW,JG9?GLE_X2J+\
M'880FACKF[:4.P*4R5(*'Z8K  Z"HNS5!I%OW7D  H(B*U4JS3Z%[;R^;\X>
M3CJ=?SH$DCA\IA"#9X!N=_NRB*)"4CD>'XE2H/()Q)_Z9[7HS[$ ]4!TEO;P
M0$L#@AF-QAQ.FI29@H]5 ^Z:2)7&:9_1KZ!.D4@@PB(CPC8^OA*&[P6)Q+@.
MJAJN9^__ %?VT1H"0%-7&PAC,QUTSA(*30V6D]_YD[(D3NQPC24Z@K O7_(M
MS*IV7Y[)?^$JB_!V&$)H8ZYNVE#L"E,E2"A^F*P .@J+LU0:1;]UY  *"(BM
M5*LT^A.V\OG'.'DXZG7\Z!)(X?*80@V> ;G?[LHBB0E(Y'A^'4J%<Q)#D&MR
M%NE/UEXBDH0#[PKK+G $ =85"!"U-%&Q%3#LDA$Z!@+0ZA$>H4&N^<Z.J%T1
M#60F9HE$B9%I3,HB/3$GV30,@>I#*-3C%VF,Z>M)$\&5U@+&\1HT@A<E24IL
M+R @A("Z;_2'8XU*8 (#0IPI*A"!H1/\ZB=D2)W8X1I*=05@7K_D6YE4[+\]
MDO\ PE47X.PPA-#'7-VTH=@4IDJ04/TQ6 !T%1=FJ#2+?NO( !01$5JI5FGT
M'VWE\YYP\G'4Z_G0))'#Y3"$&SP#<[_=E$42$I'(\/PRE1'JL>(_0F/&6=:4
MYW9ZXF;]]=\YT<LY7?NO"\]U^_\ -^NF$FX'K-]P3[QOJ8!L#RB$Z2)ZB;>
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M,D[(D3NQPC24Z@K O7_(MS*IV7Y[)?\ A*HOP=AA":&.N;MI0[ I3)4@H?@
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M.@6" G,0+0)U8HD#$F (-CHL6@3YD DDEI.8C-!3HHD=X"[*D--^"$J .JP
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M5 '*L!]W3-X,R$ZP:@U):R,!EA<%8 )5BLR@0AO,>41$J%2"D(AD%(;!3X4
M$KEV&Z;![X)4-9!JW+7Z#;9U57Y[(&6!J<$E!T:BJNDXE=GE 8"UM[K\A\6(
M*I)<H@2"V#ETAA/$OQ"*MFDD/@!NGS JX1*H0A"101D'[%BDGM>4DJ Q1-!!
M#T2YT 0$J"(OI1[D8D>8KX?OO:^7A==;.YH*!/G^*.=#3X4]T"DM:AQ'2^#
M X9A[& W5)-@$J'%@ (A QX<&80A(_&0UR<BT)&<41 -(%IB :ZF=B0X(*
M))*QZ.Q^N*4.,%FH6=^1.13_ $2TNP] Z ''[25-J[4%2J_0/;>7SIT' P;O
MM;O@W0 (" H# <>63#6 YY?C8,X*E?YYT)L6T$_82<,.E$;CT#2C$K5;N)@\
M*> @I2)@E=F85!"(W!4 54 "56@ M5P:&E!44+/01&X!Z:,4KW<OI%]_2=(
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M@DA2B9A08D&.FH/(K.)+'VF->_\ "(3T'*H;;+'6';1%V01A *_ICF3EUQN
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MW'D-T81R/Q+??7GF ?6?W!YCX]O6JE=$DXDX%)I_]3\U=@X@N9?+(?RWG_\
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M!YCX]O6JE=$DXDX%)I_]3\U=@X@N9>XB^[ZV(1IEMVI%B=/ +E,=R6P^%U?
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M$8@.,5>%@R1 *!MA%8N7 >= Q0I ; P#RY,N$O1HFZ)=J"YT(H8Q3 _4Z_\
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M "$_+!/^  H %0P ,JN ,K@T"808H S19!H/GQFR4[3^Y/R?08W\"<'@%4[
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M]!C?P)P> 53L!_3=QJ' O<"[I_;!W?$L #^0-L&0NQA9"!H.O;R"_H P!
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M$U!]@-TX' W]1'J&:CSI..&#>G?45!=S-F4@]!D(^P?ZK2=K,'V-IR(MIS\
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M&$BD"9/$)PRH&P*I Z33.9 ')0#!@X"ETY&V+;DLO>I[ZQVZN.9C8)I3Q .
M45"ZP1JO8&\1D@@;%)$R, !>!!"[H09!<:$A\$5FR 082$ 0(%U",T<Q "HL
M#=R#VX)A( H(B.$3<TZ-1YJ'";K</^ _'A^8O%8MD1C.C?\ /0R,M42 )1#V
MI"]X<.ZV$\(;@DR%4'@[XGJ+ @XVE;(W1@;Y!M3.0P/ Y.D*$L4*26&$D0==
M,.$I:AVZA!7@.!>C+<.-XUZR:]: ,99!LU\TH0& AH$P<O;3 ZWTIU6*<($.
M)7OHT,VF2*+@5!U9DUJ[*3W8A()"JZ+#W%#(MS-/46#H0_5>#(-6$L0\$$I
M1R3R+DDH0PDYM+GT(HZ"[0TR(.J;!*^+R^#-^U-8W91@KQ&$-83#+71!0K*!
M5 %\%H)&8 50"*(Z=5^EIDA%XY=FP&= BCG85$:.<XD'5APT6I>U$740"J:(
M=#+E X"JPQQ5DQ9=+I+TD125CF:OUN4/)^-&KNVU],8WD3;$+>+-$WP7L/DO
MR1& P5L4:FRH@L617&$Z"-!8&X!4(^R[]R7$J7@ %!%JE^433"@(B]J^2X?D
M$<"I!>5W\@%?2:^_P CL&SCR$8V  ( !L& ^FFB%P+]3L^9'64UFBT V VQ7
M+ER^(D69_P D'9<Y^OEW-$1A!%@ #\!RA\]"()D2CW'P(*!-P"/T<:HM),KA
MH/HL7)7=NOU^A_"[NMC$+ODW=R$S3U+0RZ@+M/F'X#/K3C2@4P!5=@"J^AH+
M%DB;*9P[_FC)U#1@&**5 \N-[.(,Z2X$DV*(2><.+<A)73J*QIY /7 9[^X[
M?!4S*_U?4\D$>A!]APG(\/J((AX*<6]Q;N']LG<' XA0.R/]-G/L$*[)5YVJ
M8TK7C(K4V:%ZJEC="]5%T-6LH5=K &V-;\..5"QB45ELKWT<1H,#L@B>2:RR
M-<E,K *PK*PZ(E B AV1HGKK+<G?+]\]   $   V ,!Y'0:-9 H[6!-L:# T
M2(Y$&"5N,7C1BT*[J2-$O87<HBA75,4:$F8(NIL86@      @!@ , &QX  /
M-@$N\ [Z1J\-6ILT+CCH&(8T!$E#,%"V&-O<03"0!01$<(FYIT:CS4.$W6X?
M\!^/#\Q>*Q;(C&=&_P">AD9:HD 2B'M"%U@3S>()HT?4@FC+F;L>!-GQ*LQ"
M8F%)$ZE).I\KFG+VR#0G5<=@J#T"P 3FT6LQK>T@!'71HT(H_#![Y-NY2G[V
M$0W=< &0O0,:@P(0X$L-%9SHB'8B^Q&_OH5SU%\B&^HH=E1 B@[AK/!8'"B<
M(69%A/ C/LE9C6^2@+#39DI #K *L 7'1Y""A6;0"(NIIT7'V%2BG#6Q?U:-
M#',Q/EJ44H8!.JP)YO$$.A]*Z)#B3@ =#C["I13AI8OT=FZLHT\UX"@,\&C1
MH4YD@M]&H@= !*D4IUI'8WX9"670MFU1/*457HF_U9FD^'.JKDQC1&@![$*P
M *ADV)U7[DABOB(!QN.K?P=U(HHT1D"$!QHVY2(H< .A%CX$93' $P[#W)Q*
MEX !01:I?E$TPH"(O:ODJ'Y!=!R5?N'T+]]  !@"!V#V!(MNF)?3CU7!YNMT
MY?5:CR,#R$U+S#_B?4OU:R5MJ[O+] ?",+DM)DR,/:RN4QN=/U^A_"[O!8$;
M#,%A7"'*?0HQ=(,&I#BL@IPAZ#:.MD0;\JY5]5?UX4P(+-A'%>3EV@,Y@#9"
M+W=U^JK[EM\%3,K_ %?4\D$6*5*513LG_P 39!IX142":@DMVNSYCN&E[YR(
M_4<GHY]V.@= H'"(Z< "VZ,V&+XRF<W.F^T+M9LIVK @K K[T"82 *"(CA$W
M-"V6K%#+"PWEF%L?CP_,7BL6R(QG1O\ H+0 #H1I[F(#Y8<2I>  4$6J7Y1C
M<"=M%U%/DEK3Q^Z ^6"OHQ]36R(!G9Y7F.'V!(LZ6JR"J&R&<HLWPX=24"+"
M]UFY:OF]$*6(A0P144H)=L"G0L&;HR&.5!R,C_NO_(TM61(B0<B&T,ULVL9;
MJB*LHW),&6 ^JN>GZ_0_A=W@LX2$G8*/^/<4TBN0EN""SUP>03GPY3H[DY3N
M9X-N]TH&"_LX[NZY> ]RR4[3^Y/R?09V\ *@"J@ 55P &578T! 45,A>7A?_
M ";D^).DR@V?X#C! P5 \ 1&PMCX'!NM54K\=3H.S'4M,4E.'H#)64RYS*QV
M ?++#HF4F $,Q"P:K3,      @ 8 , 8#!\DF70B>7KN/(F1R:O@HU.3LP*&
MT"!D, )N^1K[*?T:VRW )'^KT/J-7@F24#D0P;(;NK)T)#L"EL@.9G)K^J_S
M3"+1%0 *M28#1#<)"YBD SZ_F''6F"U/=)CWVS#=&K)?WYL_6%\[U=C%V3<-
MAYGY*.'58:9N1-X>R;OF,8=/U^A_"[O!9_"[M?COT\"M:;=F$'N5'/!CDTW<
M!_\ .,#[N[P']5_F@DE$#1-]M_3W')3M/[D_)]!G;P J *J !57  95=C0$!
M14R%Y>%_\FY/8,0F(EZ*0RVQ'-DQGH6+#;9SBB @,5W=MN=5^O4W> >:0<5S
M#.L'7"Y0;"^8@%,AL(%R"-"IR: 090Y09DAFJ$"Q788@U[:,Y01-I@RJ0BTH
MM.B(IV@0@K9(-PT%^ CI,H-G^ XP0,%0/ $1L+8^!P;K55*_'4Z#LQU+3%)3
MAZ R5E,N<RL=@'O;#CHCP-LM5:=V0-5V^-RGJD#CJ%A9,GRQV1YB*%& 2%#8
M@84.?O!]+9ZOO^>0 GJ=#( KSAYCX#2C@K.;CTL/6'ANQ4O&C_WR9A^%91,I
M, (9B%@U6F8     !  P 8 P&#Y,R:G=7['7X/S] Z'0T:! <EB)8I?-ZEBP
M=@T1@T=Q['DYT/E*P!>\ +UWWU8R>^8FU@77_A*>QY&^V-NH@$D2$:112.3.
M'HBK>Y0?5 OUZ((B4<([)V=%(>Y0@O=@7J@B)1PCLG9T4AZU""]T KX%%$W1
M7U45ZEBUC+[YB;6!?<,E.T_N3\GT&=O "H JH %5< !E5V- 0%%3(7EX7_R;
MD]J@<S&5D$J.&HY[4.$T"*6W!J'&5&;ZZ21*IO88WU^NMYH*L,Q@=LEYVYI)
MG2$B"VU-P)SHP)@!52$67%/G.F)> AK#M1@)D6$&*XT*R!W1]<)_%\M3)$ 4
M5V&!&,I&,6:3[@EA>QRKP KP:1 $9 7F8#U&A-Y"(IQ)-] \*]% H 5$  JJ
MX ,JX#2@*-T6NP-'>EPNA#6X$:<"/7= Y33(S:0X8[K5"BS 1I=F2A @H@(
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M,1%AJA8@&<F.Z+X\Q(*) P34-$ZX"HV.0@ R$"_!$3*3 "&8A8-5IF
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MX1:/)C=GB462;@&N@+94%VA40+HGO=2EB7:YOD_@53@2B928 0S$+!JM,P
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M XP0,%0/ $1L+8^!P;K55*_'4Z#LQU+3%)3AZ R5E,N<RL=@'P)APR XPN:
MF3 Z$6YB , $P6D]'Q#/"JD6!0(E$=& 5$4:1"4E"5*E;I$J4L]VB\H7EZ#!
M[8HE3G4<$-&3Z>4(*X6H @Z" XT;<I$4. &NVDFM+3ZP4#G3T'/+E 5"J*JJ
MM>@\= &(!\, @-IHT90(-XFES%]']["(;NN 3(30OD0WU%#LJ($4'<-&UB#U
M,%$F([<;? D3*3 "&8A8-5IF      0 , & ,!@^>\E.T_N3\GT&=O "H JH
M %5< !E5V- 0%%3(7EX7_P FY/@8REJS)E <,R')+$!H(W,?)H'^/6@F$
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M5R5KCVYP8">@3@^/#!64PYQ*QW!:8=."[-=0TQ"08_RR!@N2T4H:Q%J)X2R
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M*9&<9T@B)1PCLG9TBJFLF_SIOG?279)B>YAJ+F)>;#H*9DCBL#R[#>^6@ 0
M&6 0*U8'.>@^E$01@Q.&&<MW.E H %50 "JK@ RK@-*(P@B84!=HB4I8!QH"
M(VL!3NX6M;G-T7IP141,.0$9160+F+ TB(D8@!'#''N0"2Q/PCN(Y$B((TU<
ME:X]N<& GH$X/CPP5E,.<2L=P6F'3@NS74-,0D&/[B!;2.@R%BV+ 3A=!*0&
M(@@2O42\"(JF5G.0:7)C"LK"[=&SIAM,9DX?8KZIYIH0N( 9!#=8MU%-W8)!
M* 45 6!I@<.V#&4!A9+"[=&VEP&AA53>&6A4T\Z1#03" 4U-L.$HC-MK1#H
M) 6),N-R-'6KBCH[LM,8ZN@R ]8$"T22,]*0@5T\"*H>&-XK4$71[CTD4,Z_
M\MR\!P#H:<!.I]D%G)2 MD:BGL5C.BZ:0$CIRB@(^ 8W0_*!3$G(H( @6+96
M;]&UR$*#P030(I=&A45/5BOP>N >)@@$YM<6@LU+,.0+% 1"E"Q39Z.00RT
M"*AEAN:6L5-_F& X 02[3-E8, 02E(1!U<)];HG(]F%\,*NPBE5! JL RKK;
MD;#H%8'!8<=1?G&\\U-T$R'4:[HS)2GH)")&]P8+DM%*&L1:B>$L@,5(!\^B
M-U?P6NB"\A/R=CNLF%%PR(CN/^CN)A(BCX4:"F)E;P\K_P"S< B"(B"(T1R(
MF$39][WWTLLFN*FJJL'H4FV]B0?I4[</Q]--VA0 38%(X87)$'W0!)8GX1W$
M<B1$$::N2M<>W.# 3T"<'QX8*RF'.)6.X+3#IP79KJ&F(2#']Q N9HWP(&I
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MR '00&K$3HPE9E5\ZJ3<2(9PCJ!,X#IP8"8@$C)[3@'W%@N2T4H:Q%J)X2R
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M&;KE6M#:C,1:AZ%=G6F$^0Q>(+E')"DS8Y&N,%H"=9Y>LNH7BV.Z=S0;;A?
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MUXP,,<8&F= /ZL7L >.O[V/EO'IDQ!L(#4!$%9U)!@1Q]>$AN]A<01Z?FEH
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M@Z<BNT1JW2(#%&%T=Y/>8F*= BW0B9PR@1 % B((B)=-6T<42$75UH)@2Z&
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M/98RH+/4+R_H?5Q!52JJM5RJ[J^&^VX&WY >.7WQ@@^V4"@ 55  *JN #*N
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MV4 990%E9=J]]=S-L;<@<E<KG.D  $ 4$1'")A'"8=-&I4L(!005 %E@'!T
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M;><&(=E@ Q&8<$30I!@R01B0FAW+ZBY.)QFH''ZF@.]H)]8>?(X0%$HKAI)
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M$HD50.&06/=44HT R'*BF&;/3-2E/=S*0T[!JE2SE6@Y6L(T=H&6\/Y[()O
M,_+4NB7])'7+('$<8T;XP$KA $B503<6$9@U_N6M;]4A'EQ&6G.L<AJJ;[O*
M"X>$7?YR*2L9!(9I0Y@&KB6U_09L]Q6@*^X2\2R-I2M9$&!-F&$<HVBD@M#
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MT0#.AI0:_KF#67X+Q8:ZL#_H-J!U6@&UU:JH<:<:K&_[+!X4A9*S/[CR:*$
M*%*9N/HB3 P' PB,1<]*%"@0 MQTJ8Q4_-'N2[)>I!V8 $D  #'?,C!?B<Z<
MQLJE3G\9?2G(82=V,_!K?7A<V$]"Z2FO!6RE8T8OG!=$68C3.7Y>?#[Q020
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M&L)B=0 %1X\;!.E4.)-*4;E-^);PY14J%BN(V?V#QM5J<V!C>]ZYJH56DC=
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MC1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HSL&+4E9'+UV<52*YE*=7T
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M"Z#3C''B'<'H'\4($;(4N<> #<3\'"1$?DJ0 ?M1*0.%@ B(, ?_ /1;8H,
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MR]\1;'*^_P#O)\@\^1TZG4\MR+? +EEP!JV_2QH.O]I>C N;F+3L*43--L)
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M)3 <$S?WOV R23P<L_)_F]'/V%8M*OR> E;=OS,3\JS!*VL8PV8 .2O*$F,
M!P=D3S1/C8WR;>^#ZP55*PMJ.P%'_P"WFMK: *)^L$^X "@ 5#0 ;5= ;71
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M0K(*BU2[XKP\KVE/?)F<;5$^H457Z.LF!#^J:%J.,$"(61:84)+I6SB3T7[
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M^WBM+;$:9A/N?A\9:HE02Q#8"G@1N>?C_#I++&M$)=5 <J&:Q48KUSQDSEP
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MEX=\E@]8S$2O[ T/@[ J8$/ZIH6HXP0(A9%IA0DNE;.)/1?L DDG@Y)GYM^
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MO4<0_C1D>9*6*@%*($HKF^J+7Z38A?"TKNHW"?&\,<,LE(9:D):<O.@D+Q_
M(L+88 D:!0Z^:+F WK6;(L-[)3!]PEG2 ;63^]1L"O$>1DZ$3>0TFR>, RVR
M0E;@$J PW@"&,PEBH&Y,:(2D*PEI#P $QJE5R"B@#"8SJ]_%/V/DW4Z_0O.&
MS!O+]_J>[ORXF\OW^I[N_+GGK*-LO%/#*9W0O=C>_> .^<SVR.QE>RP 4J6
M>_=/!04'H"N(;FAFO!I#4_&#T#@^/9>/RAPU;;CZ\&&0V4G=?(PU"Y<#*%H
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M_%>_0]G@)N"'R!H'JO!L"YA'!BQL^XG^%J02A> (?B%H*U&X     !0 : -
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M!H)0O $/Q"T%:C<      H - &@-!H^]J%G: 6C%E#UA: ]#@@     !0!H
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MY3\3EYB2V.A!/O22Q+4(UM_G3BN$1P7,"OH^.%>=WP="@E"\ 0_$+05J-P
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M6<3B?"<)3P!$3Z<8:VOI_6@WXIEG,JO* X_2$"SM +1BRAZPM >AP0
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M%BQ8L6+%BQ8L6+%BQ8L6+%BQ8OTP&13B-L4H2#/;TZ  *%#$U%=@4VYW-CV
M6_UGD*%"A0H4*%"A0H4*%"A0H4*%"A0H4*%"A0H4*%"A0H4*%"A0H4*%"A0H
M4*%"A0H4*%"A0H4*%"A0H4*%"A0H4*%"A0H4*%"A0H4*%"A72"X2$Z0.X$B
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M89C1A+M\9L9OAZ)0X&C6GM0\0/-+RV#(@AH-3 $#\N?LLJ%E%I.9EP9'].-
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MD .Y7P?(.6WB!HO7:7NEUN$0,8+H?$_G;_E.&G?@O3<#>"_]1]D#PV9_3Y(
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M^JE$1 4&.^G!T'WA!#  %@#7[2$7HA(GH\@O&9Q# AT]I:-0:BEM3'9#1GA
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M#S7K+(QERY&', A1D:GP"PCRLRNF\-M8 ONA*-HB/"$$&'P=F40D68@!Q&M
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MF%6QW'[ D$4RC;SHE24.0.F/@3%?0$MZ, 9:4'$4@+\\5?:KS?4)=IE(T6^
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MH5P% A2$'%P*ZY"?-4R6N,FJN%].TE848MY=#38B4,_A+0MT(1 @(,)/SB7
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M5CN8*. 4P5.M5*Z)!Q)P #P=X'#"H-L"@=')/C4N?52B(@*#'?3@Z#[P@A@
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M26 WP)HO (^+)M)-#_P((NM$ !.?!6 DJA1 $"]U*EA<$J)"6N^M0,KU<8S
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M0:U+NPH-0I6%2%!CU9G!('   4'S(88?D*6 %6$#$E@-\":+P"/BR;230_\
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M*. O.K4*U0\5<'P/8VRGCZ7<V7CJ"A1 'FZ4BPF1SI9A/#)+ZL55W&=+@K&
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M:V35J[F"Y*'4A[7+$"*,<[U -X%CD]^$NA29,3%U66<F'K@QE7YD%#VVJ10
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M#@H_A6*N\$;8^]V@JF@+S:-*- *$WWJ($[@E,H&^8B4E<H*%55>L *L(&)+
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MC<Q5Z6Z+E&/E'9__ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
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ME"@;LH8,I5JZ1;<!Z9983H&,9\':+G1&J4OPD'6GT+3D0Z:M!V+XG1,D1+
MF.^9&"001MQDB8Q4_7@IDJ-%?$U"0PQH&P.5F*#R9<^9!>;BV&6_C8Q(P9 6
M4EXB9<!@VDND 1";^0%*@6'XLJME,QS4 7C8HL;L66TG"]D2.<ZC'D:$T&X&
MP& =:>) \DP(5H@,P4I8U(R>EM //,RUH5<\4 5)0_/-?+8Q7K=*C[8Q#43]
M2.S5]ZD#C4V)EOCB4[:D074R88;C>Y6/>FKE0GI_Y^/UH#(3]Q&; !<](UC?
M-,.3ER0S@81&(N>L9HUD O#Q/]Q 8MB*J.N/*&5!XZUHN5N!+$!-IE#>Y7''
M&846-I&%I*7 D@O1S,,[E</&BJW(R_RE^Q@C>JZ(69MXJ_%4DE9#LK,)=3L&
MI[@NZJ#BYOTP<W.@PK)<*5YP*NY!+<9$!TU:#L7U.B8!1EHLP)V.$EUB1AA_
M$1\#4^W5_8XL+T6_K@64+ F=#5#!^,^R]]"UM\M:"<P$7-ZR.C4)U=B>M-T*
M^T%:?YF 3KB1HB&0 IV9E !<:4?.N(-!  JJ "K6%!;WX=!@1CL3 7(W( -1
M([(D@P@VF-?O&&8U_L6QIA.GUA$PW&B$'0 C6FEL--(/*D@-/%T8P5C@3F[(
M8;,3;17+6;7=S;1]!J'0XJL61'%T;9&HE._3GE+H#C_J$*KBFOM!RMBL4+D$
MVN68!5K6HJB!-$5<W##D*'P;@"R,,;SC@  RYZY4O[X>.)&AU@ED$[S!'PCI
M,]LA$.X ,1P!<@&A4 '[ O+03XPJ$E*$:UB&DI$*JL+,9%;5G3P!D)T%DVO=
M%P, 5Z5#" <8P W*?X:)>_8OT8+Q5V6*%E.KXMK[8<C8J%C_ ('F=^">HTX"
MRLXTQA@:@<=8'+8)4L.U>9336S6=7%TWH<?M("(SQ@?$B5(^20DH75:YT!_8
M[U5"V;RA@D&<E2OH%-D&VB 2F*\+M;[&2?/8 -$@5AV%F7>HN I< B8\WD7R
M7JS$@ML;FRN0:6>9S.#$A:$HOL&"(S42N' 1O4!Y4#-2RSP>S?<VLP#!!'5:
MXB=4J80U/:6T=FZC'S/!@Z<P*LR +VPYC02ZU$6J)Y2"*2L;<Y<%E)T!&L@&
M4 9-D=15X0L'RTC6-\TPY,!( &07*A-2%4  EUJ(M$3P@  A3&>1/?OY4A\
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M 4W" FTU$XD1'I3Q[>B_$<+W8A=+! #4-_0O#Z"MK3P(!%R']V1.:R.\)/3
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M?TK24[C#A2\1( %@WO0,B*6[HXFT/C4 O-%X+8(P0,4R1OEBKW !6R*!^!H
M6]5#\G'$]Q13PYD*BA/D_8TH689HM$-)5\2<J@5-\4X5OJ>+S@?D"1]7  H
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MW,O0+[2]RR]A(8OED_=":^4H(^&)5/\ ]!C&@X':[HBYS1HE>'8J6J=-ID'
M=80>6F=78Q>'+U4'"C=UAFK[BAXJ8X132B.0TI5 E3E]@@C=N9:K[_X+.P..
M-J!,?QB2WY7KP&>,]A(JA5]\7TP#$S[,5.QRO5)U?4'1:=S'%K0NFP=*-902
MZU$VB)X2@"R_F4*^GVV+_@.%!^&>H-#VB@<J_NLC]W??G,%\;.]Z52LLK_'O
MA%IMD1(GD5I%@ZO>3++$MCZ,!,Z'\.-7,69,RFROA/(YV1&_B=*_8BHCRE7J
M7$[5874*9KE9'K7YIW4*(JCU$A_%!2/O&JE=QKG@-9+5NVQQII( L$WRCO\
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M\)CIDM"JZ;$,7E!B])4]Q1B]CC/M_B&G#QT*7&(4N!V#L&^Q^1"=OI520H8
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G(0L$$Y_TV)6?_80JGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>business12a.jpg
<TEXT>
begin 644 business12a.jpg
M_]C_X  02D9)1@ ! 0( 5@!6  #_X1<H17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #?#0  *0
M -\-   I    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$X.C S.C0R  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !4     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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MJJVE7#RP,=0VK!(TB*J?>RV?FYYXR/QKR/P'_P >=Y_UT7^5=/-<&%L")W.
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M5=O#>FEG*Q,F\Y(1L#.",CTZFM'R/^FLO_?5'D?]-9?^^J *UMI-K:P/%$&
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M-BV)0LI*\')SU'W<=1UR>*BN5\0I?-);M"]MF3",!G!*;>XSQO[C^5;'G/\
M\^\GYK_C2><__/O)^:_XT 9UH^NO?;;N*UCME/WDY+#+].>./+_'=5Q9;S9D
MVR[L?W@*E\Y_^?>3\U_QH\Y_^?>3\U_QH B$MY@YME!Q_?JW4/G/_P ^\GYK
M_C2^<_\ S[R_FO\ C0!+5:Z%L3FX_NXYSC&1_7%2><__ #[R_FO^-,8[SEK1
MR<8R=O3\Z ,368]/3PKK/V(Q_P#'C)D(V<#8<5\ZU]+ZO:27FAW]G;6A26XM
MWB4DJ!DJ0,\UX_\ \*I\3?\ /.U_[_\ _P!:MJ4DEJ9S3>P^2PUMX+>0SZ9:
M!X(2B)O3:H(=1D# )+(2 <DD5S7B%KXZF%U$1_:%C4%HUP&'7/N><9]JZL_#
MGQFT<<9GC*1@!%-T<* 00!^('Y5#+\+_ !7.P:4V\C !06N,D =!5*274EIE
M?P%]^^^B?UKK-0V?8G$B2.AP&6,#./QJ#POX#US1VN3<Q0GS NW9*#TS_C70
MOX<OY%VO;(R^A=3_ %KY7,<-6GC'4A%M:;>B/=P=:G'#J$G9ZG+&>RE)WPS@
MA_OL.0> .<]\?I6P.@QTJ^/#-Z 0+2/!.2-R\_K4G]@:E_SP'_?:_P"-<=7"
M8B=K09T0KTEO)&E8?\>,/^[6/XEFL(3;RWUI<3&W#W"- 5RH09;@L#C Z_3G
MFMZUL[J&VCC:W;<HP<,O^-$NFF=P\M@LC!2H+!"<'J.O2OJ:*:IQ3[(\.HTY
MMKN9&BR:>L]Q!:1RP2<%XI.,>X7/'4'\16[#_KT_WA4:V+H^]++:^"-PV9Y.
M?6IH89Q,A:!@ 1D[EX_6M2"MXR_Y$S6/^O5_Y5\X1EA*A3&X,,9&>:^F/$=C
M-J?AS4+&W"F:>!HTW' R1ZUXY_PJGQ/_ ,\[7_O_ /\ UJVIR26IG--O0OW5
MMXE96,]_I(>/ ,@RK#YE!Y"CJRJ#ZD<=ZX_Q%]N_M/;J(B^T+&H+1K@-[^YZ
M@GVKK9/A_P"-YEVR72N,AL-=D\CH?PJO+\,/%D[!IC;R, %!:XS@#H*I-+J)
MIL;X#_X\[S_KHO\ *NAU26"*U'VCS-A<<(<'C)Z]L8)S[4[PQX'UO1X+A+F&
M(F1@1LE![5N/X<OY%VO:HR^C,I_K7RF.PU:6-E4C%M:;>B/=PM:FL.H.23.4
MC%B&;-O/$?,QYAP/FX[@]A_7O6U6@?#5\1@VB$<\;E[_ (T_^P-2_P"> _[[
M7_&N2KA<34M[C-X5Z,?M(U+3_CS@_P"N:_RK(UN6S^VVZW=G<3>6ID5HPA4
MD*0<G..1['ISTK=@M+J.WC1K=LJH!PR^GUIKZ:991+)8*T@&W<P0G'IG-?5T
MDU"*?8\*;O)LR]#>R\J6&S26,(WS12]4//&/PK<MO^/A?Q_E4*V4B,62TVL>
M"05!/Z^YJQ;PSK.I:%E'/)*^GUJR2[Y*;]^.?K3?LT6<[>?J:** %$$8Z+^I
MH\B/^[^IHHH 3[/%_=/_ 'T:<L2*^X##>N:** 'YHS110 9HS110 9HS110
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M65H@!^@ !  % !4 ,@ I86-S<$U31E0
M     /;6  $     TRUL8VUS
M                           -9&5S8P   2    ! 8W!R=    6     V
M=W1P=    9@    48VAA9    :P    L<EA96@   =@    48EA96@   >P
M   49UA96@   @     4<E120P   A0    @9U120P   A0    @8E120P
M A0    @8VAR;0   C0    D9&UN9    E@    D9&UD9    GP    D;6QU
M8P         !    #&5N55,    D    ' !' $D 30!0 "  8@!U &D ; !T
M "T :0!N "  <P!2 $< 0FUL=6,          0    QE;E53    &@   !P
M4 !U &( ; !I &, ( !$ &\ ;0!A &D ;@  6%E:(        /;6  $
MTRUS9C,R       !#$(   7>___S)0  !Y,  /V0___[H?___:(   /<  #
M;EA96B        !OH   ./4   .06%E:(        "2?   /A   ML1865H@
M        8I<  +>'   8V7!A<F$       ,    "9F8  /*G   -60  $]
M  I;8VAR;0       P    "CUP  5'P  $S-  "9F@  )F<   ]<;6QU8P
M       !    #&5N55,    (    ' !' $D 30!0;6QU8P         !
M#&5N55,    (    ' !S %( 1P!"_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\( $0@!V 66 P$1  (1 0,1 ?_$
M !X  0 " 04! 0             '" 8! P0%"0(*_\0 '0$!  $% 0$!
M          0! @,%!@@'"?_:  P# 0 "$ ,0   !]_
M                 "$,6;R]V4&9,N+:CY_5&+ETMN\,Y5/9>Z+Y<X9G&S8;
MG8Z5'R9L-I9PI4;)L=WI!K9=:]I!L+J=EYN[;6^S6NF
M      #S\LRUFV$.WV&^"Y6#U2UTN)XTCREZ'3>T_/;?PSVT3/EMP8F>)96"
MJRZP=V/F74E36S[.SM? T&?2R;&]-;L,Y0I8
M                     \?,<GTQV>HD^!.\0YL?V^A9ZG19?FCN-;/TR)7C
M6[*P^*[NY,2"I5U[-!LL.Z/0SOSF]\/.AU/Z*==FR3!G\.9-GN-&O
M                'A)L(ONWKY7419/BOT&H]O\ 4SO'!FBB="]5H[QJF6R-
M&SV1I;.$R'3O6[/V"SP_,>+/C;=:;VATVSVZ5\:<EWI3*@SC"E@
M                                   "NF'-YD[6#.E^*,X4W-<N&.LE
MMW,%],9%G,LNL[KY>2S8569-UQ=-.Q;>::ZVIV/D/)L]>8]X\A,]GKW@O
M                    'FC3+!TZ%;[!E\X9..V-+8WMNM_%SUQSX<=SV=K%
MD6(Q79AL(-6]?L/4//$@[7;&(M[I[TZN?Y^XL]%MSJ_5^+FL9%S@
M
M
M
M                        #$K[/+G=:SZ         )_\ BWT>7/FG9@
M      :UI+_I7XZK0        #N3O0 <.M/)S>:OY4         L'\.^F2Q\
M\ZX        #6M)>])_'M;[0        .X.^
M(JSXOS.=CSFX         7O\<>A;6^<OKX        &MUMLOT8\C:W4
M    RTS< '4UI^67MN8VZ@        +]>+O1=HO/GUD        #6ZEL/T5\
MD?>7&        !EIFX                       !%6?%^9SL><W
M  "]_CCT+:WSE]?         UNMME^C'D;6Z@        &6F;@ ZFM/RR]MS
M&W4        !?KQ=Z+M%Y\^L@        :W4MA^BODC[RXP        ,M,W
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M^2/O+C CN-GQ?80<*CR+1*89%D0QM-?+.LV$;[*!8F/GI@70/D  RTS<
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M[I;;5^>>OG6<K;S9&*!<.7LLF..<ELS4IB,.7.>PA70CY@!EIFX
M              !%6?%^9SL><W         "]_CCT+:WSE]?         UNM
MME^C'D;6Z@        &6F;@ ZFM/RR]MS&W4        !?KQ=Z+M%Y\^L@
M      :W4MA^BODC[RXP        ,M,W                        (JSX
MOS.=CSFX         7O\<>A;6^<OKX        &MUMLOT8\C:W4
MRTS< '4UI^67MN8VZ@        +]>+O1=HO/GUD        #6ZEL/T5\D?>7
M&        !EI!YQ                        1UEQ^ O4Z/[         +
MC^6_MMC_ (3]/         UNI9/W1YEUNH        !/)8H '25I^3'K=!M
M        %T/*?W*PWQ'Z4        !K=2R/N7S/]Y;         )P)Y/D
M                    $6YL7YK.PYW<         +T^/O0-J?.GUT
M  #6ZVUOZ)>2];J         9R2& #J*T_*[VO,[8        !?3QIZ'L]Y^
M^K@        :W4M7^A_DW[RXP        ,W)%
M (JSXOS.=CSFX         7O\<>A;6^<OKX        &MUMLOT8\C:W4
M     RTS< '4UI^67MN8VZ@        +]>+O1=HO/GUD        #6ZEL/T5
M\D?>7&        !EIFX                   !MT<&M.9;=T=],BH $59\7
MYG.QYS<  -   :FAJ  "]_CCT+:WSE]?  !4% H5   #6ZVV7Z,>1M;J  #4
MT %"H   9:9N #J:T_++VW,;=0  T  !J   7Z\7>B[1>?/K(  "A45*
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ML^+\SG8\YN         %[_''H6UOG+Z^        !K=;;+]&/(VMU
M  ,M,W !U-:?EE[;F-NH        "_7B[T7:+SY]9         UNI;#]%?)'
MWEQ@        9:9N5AMR5[D8*<[&)K!F2ABR6IV.LO=JMCX5["/(\"9,^3%Q
MLL.K,^_H<%?5?1;6K/2Z#U"TFSH+(MM[CMIID3%=9&>/-QZ6LV*7[:V;CYP
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M<T59\7YG.QYS<  /874S(R7=7K]CENUU%$[)/SL]7>?4;*6=7L?&GIM-PLV
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MUOG+Z^        !K=;;+]&/(VMU         ,M,W !U-:?EE[;F-NH
M  "_7B[T7:+SY]9         UNI;#]%?)'WEQ@        9:9N
M              15GQ?F<['G-P         O?XX]"VM\Y?7P        -;J6
MS_1CR*NH        !EQFP .IK3\LO;<QMU         7Z\7>B[1>?/K(
M    &MU+8?HKY(^\N,        #+2N)PP                       1[EQ
M^"_3Z/[         +@>8?M5BOAOTL        #6ZEC_</FS6M         +"
MEF  ='6GY*.JT.U6@        %R?+/V^P/Q7Z,        !K=2QOM[S=]Y+
M        )[+1                        $59\7YG.QYS<         +W^
M./0MK?.7U\        #6ZVV7Z,>1M;J         9:9N #J:T_++VW,;=0
M      %^O%WHNT7GSZR        !K=2V'Z*^2/O+C         RTS<
M                  BK/B_,YV/.;@        !>_P <>A;6^<OKX
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M9:[U)RX;31)0  &6F;F&4K%V2R3:VYKBR1KDMR[%?UN;'F&.\
M    "-L62"L^"98L[&)L'?P7QU@R]M.BVHQ98JSXOS.=CSFX  >SFGFQTR9U
M#D\?+CG+6S?%#K^=O]JYLNZ^9X_;J!C,R( !>_QQZ%M;YR^O@ 8WT$"D_JSX
M''7<\U;SS)]IKI]U^:V<\\_2\5ZB'B?0:'(=+M+4^>/K@ &MUMLOT8\C:W4
M 'YT[97I[&P^06TA_HEPY?,6-)QW)AD#+;ZQV7  #+3-P =36GY9>VYC;J
M%Y<+J]-NI8V6IIY&GVSNP9'%DX9?;Y[;O6  "_7B[T7:+SY]9  %=?N/S:K?
MH/Y)Z)>(O2U(?6/P&^_CGT74KTE\>XDG!D_/;*SGP/ZN !K=2V'Z*^2/O+C
M 'G3K-C3??:2 [<GNCJ=CY5Y<<>[37_H/PY.PPY0 !EIFY$UMWB;*L]<I$*Q
MNKV/AAM(=X=5L,4V^JP^'-F>3%W(LB=(LB+96"K,K#ZQ0L_"LKBUU,_.I.YI
M4  876F:4J ,)5R&ZS:LNW+[>VMN Z=3N%0    (JSXOS.=CSFX  9*I9K73
M:FS8W'RXI7B2>FS8L%NI8*)(KI,C*@ +W^./0MK?.7U\  # ^PY[XR78_M]1
M+_S3ML0Z73;MN3:KAR_F]V !K=;;+]&/(VMU  !76E_QC11ELLM=;U:O61\V
M42XTFXL@  RTS< '4UI^67MN8VZ@ !,N#)$.2DA4MQ&E^6V5YN3'T>+-@TG
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M4N  RTS< '4UI^67MN8VZ@ -ZZWT[TVPB2S-@^SUL.X),X6N#EQ:1Y%4MG!
M %^O%WHNT7GSZR  (*^P\'#/U'A)[^+]]'G=<_./R7Z'TVQU4,?5>+LO\"^F
M=WK-F !K=2V'Z*^2/O+C  \^H,RC&Q@>BM]D_P &;YV;.!>G4;'I-A"HEBS>
MK4J)F$:2 !EIFX                       !%6?%^9SL><W         "]
M_CCT+:WSE]?         UNMME^C'D;6Z@        &6F;@ ZFM/RR]MS&W4
M       !?KQ=Z+M%Y\^L@        :W4MA^BODC[RXP        ,M,W
M                   (JSXOS.=CSFX         7O\ ''H6UOG+Z^
M  !K=;;+]&/(VMU         ,M,W !U-:?EE[;F-NH        "_7B[T7:+S
MY]9         UNI;#]%?)'WEQ@        9:5@."
M   "/LN/PCZ;2?8        !;OS+]GL/\1^E@        :UI8OVWYNUK0
M     "QQ:$ '1UI^2'JM#M@        %Q/+OVR?OC/T8        #6M+$^V/
M.'WDL         L&6G                        (KSXOS/]ASFX
M   7N\=>A+6^<OKX        &MU+9?HOY&74         R\S@ '4UI^63MN8
MVP        "_7C#T5:'SY]9         UNI:_P#13R3]Y<8        &7&<@
M                       $59\7YG.QYS<         +W^./0MK?.7U\
M     #6ZVV7Z,>1M;J         9:9N #J:T_++VW,;=0        %^O%WHN
MT7GSZR        !K=2V'Z*^2/O+C         RTS<
M     BK/B_,YV/.;@ !H  #4T-0  7O\<>A;6^<OKX  4 !4H5   :W6VR_1
MCR-K=0  #4 T    ,M,W !U-:?EE[;F-NH  :&IH  :@  OUXN]%VB\^?60
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M;OX\H &MU+8?HKY(^\N,  8SKYGYS=G!]+<&2DV1?);.TV)9R%+   RTS<
M                  VZ//:VZ=(FRP';Z>'H$G#;7)V4+U@BYXKSX_S.=CSF
MX  <NMOL#HMGYDSL5P+X\+0=C,.>)8+6["J\K%17=:KZ  +W^./0MK?.7U\
M 0]]1X^LOW?Y#>WR%Z(H+[)\Z6Y\U_::Z?<?F?<ZB5./R+O)0X+K@ -;K;9?
MHQY&UNH  /,'6;&@>\TTYTK,VNGTZE1KKR8_J?%D@  9:9N #J:T_++VW,;=
M0 'K9KI$DZS8PE*C=!!GR[.U])Y=ERX,B-[[:$3L&"S(@ %^O%WHNT7GSZR
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MF/L[,DQ6U          BK/B_,YV/.;@        !>_QQZ%M;YR^O@
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MY-B^S6E=;:XQ=;GRL59\7YG.QYS<  !FEE=BS)Q,F+J%>TMKK?;P[+^KR6
M"]_CCT+:WSE]?  &(=-I^UULCA3,?*BW]SK-API4;CY[>P@YN3AS  :W6VR_
M1CR-K=0 #:MNAZZWE74RW%?WM]G3W-G%?V^7'W-MP  RTS< '4UI^67MN8VZ
M@ -5):CYHPS8Y5P9(DSX^[I7';[<UQ7X7EL  %^O%WHNT7GSZR  .JV47K)L
M+O=3LN-FP=G!F=9.AJW;V&[G19  &MU+8?HKY(^\N, #2VL.5KN769MCO[7)
MCZ>EVY9=R<V/(++@ !EIFX                       !%6?%^9SL><W
M      "]_CCT+:WSE]?         UNMME^C'D;6Z@        &6F;@ ZFM/R
MR]MS&W4        !?KQ=Z+M%Y\^L@        :W4MA^BODC[RXP        ,
MM,W                        (JSXOS.=CSFX         7O\ ''H6UOG'
MZ^        !K=;;/]&?(RZ@        &7&;  ZFM/RR]MS&W4        !?O
MQ=Z+M#Y[^L@        :W4MA^BWDC[RXP        ,M*^G$
M          !UE:5OF1M0        #.>0W^4<]MP        -5,I^A<HJ
M     F@G, ' 4\JIL;Y         ,[XWH<FT.U         U4RGZ#RJZ@
M     $O$^FV;@!\FI\GV #:-T VJ-:T*C< !MFX;1N@
M                                                          Z[
M!FPB5'X>/)O&55MZ97XQ9,;RX^?9=S[K?FE?BK6C(#HCLKJ==;7NJVXO9?D6
M2WA8[^/FQ=E9?TU:;9R;+OK)8MKDU*XS5L5IS:)!K0
M                                                      #CX[\-
MR6<JKAX<O,D8.ZLNX]MW6W6]=9?V=UNW6F[2JM.92O75=Y1I6G7VUZ^K(:TZ
M6V[<R6;V._@WV=-BS9)FP<&V[<MNR&ZS&K;^ROLXEE^77V?5*@
M
M #0
M                                _\0 .1    4"! ,'! (" 00# 0
M  0%!@<" P$6%R (%3(1$A,8-4!!%#0V4! W(3 Q)#,X8$9P@"?_V@ ( 0$
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MB&GVKE%ZV^?PZGIVP*EM\XA--WQR\%Z3;<;IC[QEB+R2G+T;H)%6,'6\GO\
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MCG%22VPZT:-F;0MN=&C",2;%:*-O2NL+;A1&V6U7CD(;D0G+8QQPPP1WDUW
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M'3(M]KV8&Q[Q8XS QTM/2S=D&DDFF.YOHGF6]OB(!8>&$BGFVC/6TZ@H(U$
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M10 %W"D W2V,RC2JIZ>&Y(-*8Y-'-3Q7-O/:V-3_ &.*F:H]+DA1+U&N61M
MNNN63ATWX(H-#2WY/Q/<X$8L-6[6%SXGO.,QIPU/!)2 <=%XH34?]HA8V5KG
M99TZM^2ZSX8S5WJ,MIN 'XWI;,- ]LCE>6H=4-N3]9<0K%)"U/+9"RZHY+=B
M55[+^,<@ZC?8MI;EJOE0:EJXH7N*=)HY89#N(X^,"\1;N$?.._\ !FPOIVF4
MFO:0"Z?NGK=W6DC*_*!MB%E$5:";%Z30@^R;RBG:P^'2K'S XHHW2?,692HD
MJ8V0D=I124Z$CX-2LOG!_8SKV?.FGA]DA],:F3B+NO#99=+W\#<6\_[.>>SU
M%,T/LBJN4!BN]N#3TZR_B,I#>8_[QF6*LA6*70)(T,89NQ-%S6.3G9D_@WV%
MMF((!Q'KINJP,@7LA^MMRM=>TOAO?Q)Q0/,V:)52GAP-- S!NJ-:R)>1$&T2
M!!8BPU=JW>:F,/6M4"YX<]68[=EEG<[_  [ $8E><)[&@U:XAN"1I:5%D-OY
ML99OP8K))JG,5*@K3J&N;;<.,"."%+WTKS<@6-K6M<XB2$2(95+1AAQ%!-RE
M^M;<=:W9WYVOMA8?),[@EC;73F=(9Y%N8^&D@D@G\Z M&['W.W=BK#OFFM;M
M 9*LL1V#J/4)[M^[%=#'5TR,-,=1$40Z18EEWAJ% ]VMM,A&Y&Y/6Q02LU+6
M<=>%,:26$J>3RB6+>,[75P"R[#;S8HT=#4ZU*ZJEV6_>I L1\&*LZ\L$2[R<
M>I;0.=FID53^%A8?#BE4K30*PLRQ("#S!"C;%*RJTNH@7IYE%_$KL/PXI4=:
MBN9E(5Y*<H3[H+31J;>9@1YQ^P'X5.7BMY0[F._-HXM()9/L6<DKKY@7 M<W
M6&TO&*EWMI35N(QWZ!W%_=-VCL+V &(GD9Y@ZZ55E$9MV@44D_#9B1^#_P#%
M:[:49OL03CTQ;WH?C'YL>F+>]#\8_-CTQ;WH?C'YL>F+>]#\8_-CTQ;WH?C'
MYL>F+>]#\8_-CTQ;WH?C'YL>F+>]#\8_-CTQ;WH?C'YL>F+>]#\8_-CTQ;WH
M?C'YL>F+>]#\8_-CTQ;WH?C'YL>F+>]#\8_-CTQ;WH?C'YL>F+>]#\8_-CTQ
M;WH?C'YL>F+>]#\8_-CTQ;WH?C'YL>F+>]#\8_-CH7T63I915E7)6-1&EJA3
M!%B$P<&%)=5RZ6[5K6[KX_:L@^W$O]$7Z;'[5D'VXE_HB_38_:L@^W$O]$7Z
M;'[5D'VXE_HB_38_:L@^W$O]$7Z;'[5D'VXE_HB_38_:L@^W$O\ 1%^FQ^U9
M!]N)?Z(OTV/VK(/MQ+_1%^FQ^U9!]N)?Z(OTV/VK(/MQ+_1%^FQ^U9!]N)?Z
M(OTV/VK(/MQ+_1%^FQ^U9!]N)?Z(OTV/VK(/MQ+_ $1?IL?M60?;B7^B+]-C
M]JR#[<2_T1?IL?M60?;B7^B+]-C]JR#[<2_T1?IL'T+( "?3B78$_P"R+W"_
MOV#L2/ _7)QZ8M[T/QC\V/3%O>A^,?FQZ8M[T/QC\V/3%O>A^,?FQZ8M[T/Q
MC\V/3%O>A^,?FQZ8M[T/QC\V/3%O>A^,?FQZ8M[T/QC\V/3%O>A^,?FQZ8M[
MT/QC\V/3%O>A^,?FQZ8M[T/QC\V/3%O>A^,?FQZ8M[T/QC\V/3%O>A^,?FQZ
M8M[T/QC\V/3%O>A^,?FQZ8M[T/QC\V/3%O>A^,?FQT,Z*0]*LMGK9*N2CDAJ
MS %2-94*A U]RAO<^./VK(/MQ+_1%^FQ^U9!]N)?Z(OTV/VK(/MQ+_1%^FQ^
MU9!]N)?Z(OTV/VK(/MQ+_1%^FQ^U9!]N)?Z(OTV/VK(/MQ+_ $1?IL?M60?;
MB7^B+]-C]JR#[<2_T1?IL?M60?;B7^B+]-C]JR#[<2_T1?IL?M60?;B7^B+]
M-C]JR#[<2_T1?IL?M60?;B7^B+]-C]JR#[<2_P!$7Z;'[5D'VXE_HB_38_:L
M@^W$O]$7Z;'[5D'VXE_HB_38_:L@^W$O]$7Z;!]"R"Q/IQ+L"?\ 9%[O_C8=
M=+NOV+NM_'2Q7_R_X&F]JD^*?K7T'?J-FWWT7_*0_6C=EOBM_A.&[3><_I^N
M3R/F.#]:>A!]0*[[Y-^K7ZT/9;XK?H.)O;IONTOZQO\ @:;VJ3XI^M?0=^HV
M;??1?\I#]:-V6^*W^$X;M-YS^GZY/(^8X/UIZ$'U KOODWZM?K0]EOBM^@XF
M]NF^[2_K&_X&F]JD^*?6R2")&D.X73>W\Y@OZ3BIHY*5*=Y"I\H61U"]PC?A
MF_X<1CB3Q0#9I1(0>X<(*6O^-MBMA>AU\87"Q&967=9(PI:Z'X;6L=P=FMB>
MG>GHX*UB#%/*L*A>T&81-O\ ![*OR''D#^^1_*<244D8B)9;33<%>>S:#)<_
M!8>>_=B:D>"(3,R%2Y38^"ZK^%L4U.U3&)@1'">S))<:A]D!SL?<WM?F,5-+
M)2Z3);ANI9)1V"%[6_<R^Z4[CGRQ!2R31B4VBC>VAI-K@]DV[M7N0=R-\5-+
M+3,H>Q5QJ1U-U<<MOA!V*FQ!Y^M]!WZC9M]]%_RD/K9I5@AFG:Y6&*25@.96
M-"YM\-AMCHWTFH>E%/4U-#'/$E+/Y.XG"@E](>ZZ6;:S#'2'/Z3HUEWIG6QR
MR0^414NF$ OKF61E-F*C3:)K[^&,HS2CSNAI\PH).)!4+M?9XW]U%(ON70[,
M/PC;&6=-LLS6#.ZBG@JE7(HS)5*ZKJD XQM" QN?8&YVYC'[;&1VOZ79J._>
M!1\O7Q!Z)N2U%%65T=%F)BHI*6*11&I=FJ^-HTV>UEX#:]]KKCHSTPR[I4]:
ME!#4PF@%.9?*%47\I,P33I8\N VJ]N[&:^B7DF75LU#!3UN9/3,5J9*.-6BB
M*FSC4S#5H.Q(VO?? Z<9+)D4N?T_'J*>"2.&>FC3]U0RR,%"O&3_ #@=0)4C
MD>>.C?3;+.D]544E%!50R4T/&?RA54:=82PLQ.JYY'UK=EOBM_A.&[3><XJ8
M&II%B<J6:*"46\)X4G4><(XO\-\2S+  T@81D@&3FJZC8%N\+<@:N0OO8?L%
M$\CJ9]?L\90)'SZI5R9"G:D *JFE.M=[\L0L\D,3R)PY'16>/[!CS7\'K\Q_
M<T>7M2CREJAX14B_M0DF:.79=XO)HAQV,FTHZBZ203BO'D/I?_">7<#^;PN-
M)+'_ #M>GA7]S>]L5GL%='3P>S4[1ZGFM?2>&KA]8Z@#L3&(CUQ:]^JP_>CR
M/F.#ZQFTJSGDBLQ\R@L?T8-,XHX*VZ\*<H%'N@9(>,+^9=C\.-0#PIWS2I"O
MP,][$_!MBII9*5D#D,LBAHY%[+?9#X&0[,IW'X<.0E N8<XF;3H'MF[,OF]R
M>_'D#^^1_*<2T4D4:R,RE7J(*86O?74$A3YAI):V]N[#9?*M/-4ZT,<)B#6.
MY,SE%MW;$;XIH7J5:1>K"I(XS=DV-B1XJ#MJY$W Q4T<E,B2,5:%[@2J>J&
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M7*3HE7^#>S \R:Q2N2T",.LM6RD?"*.$'\^*&E-=+K<Z:* EI'8V61DYD_\
M*B/Y62R*#MBOK/*6M'U:>)6$*]_+>5_&23F?L195L!;$V_1NBN>TT:MYF55;
MY5)!QFH'DM!#;V)DE++[ECQ#&+COLBA1X#$CM)T6BXCEK566J')WTRU7 DW_
M .;"JH_BNV,]L*2AC'4C-)5.;"P+">10_G0*%'@% Q(QDR/+Y)/;.+S//>GC
MN/EL?.?6^@[]1LV^^B_Y2'UN9?4[,/\ H:O_ "\F/0>^I&<??0?Y>+'HL_\
MJB/OQ0_J:S'1S,,PZ U653UADFZ.=(*2EJG=5+)!),BLS*-],]/>TB#>:+K
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M0^\Q?DU^;' A]YB_)K\V.!#[S%^37YL&"'2WL,79;^#3P\V)?;IONTOZQO\
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MS+/\SS(R-&)Y5$@IET78K$KJ+[@R.QL.LV.B'26JSOTRH<SIXZ?-<HJ.!5"
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M ,L9#D:K?O9Y'S'!]?+KEX=.K'74/PE[[*?;6MX+'<L>X;XK&2CR^*EC%FJ
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M6:,+H1T:XY(%!%P;KJWO;'1#H_FE#79UGV=F%,SSN4,U/3G7'!&&+6U>-SL
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M;XK?H.)O;IONTOZQO^!I?:WN+C2=O''$@_B_]H?FQQ(/XO\ VA^;'$@_B_\
M:'YL<2#^+_VA^;'$@_B_]H?FQQ(/XO\ VA^;'$@_B_\ :'YL<2#^+_VA^;'$
M@_B_]H?FQQ(/XO\ VA^;'$@_B_\ :'YL<2#^+_VA^;'$@_B_]H?FQQ(/XO\
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M(398T8M)P)&[F9-Y%YK'>XZP!K)C5$+2JS45*"D113HVV>5M.P+$ ?S5"KR
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M!<V',[89E27@.=,O7'#/:O&;/^*>>%5FOI%[*SFW<J LQ\P ).%D1RP5@2A
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M*(U-5#!8&-/W14'^:A]C3SR2<Q]@"1C-Y2IAHAL(5XTR_P#/E%QJ'V21$ >
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ML@JO**D==(^$IX(EX&R;6X=N_GOC/.C&3=(UB&:TIF: ,()4EDBDBU[MI*,
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M-%7MO&ZQ^)<TJ[#X2+@#OQ2C3656M3KEX7!<]DPJEN$I[F23B,R[7XB\^[I
M\;4D$8*M.*-8)--B34/4RF!+^ZD6-HEOW6"^XQGBEZ&B*#7II+'3SU1UD[NM
MOL@K*;?",0.@IJJ74-,D'#CWW=G9;!1SV&[> &^^,B]LS?XN9?\ Z6F*?K5]
M5??AP4@3^;Q#4%[>&K2M_BC]BJ;]TY1![A:3,JZWC.:FFI%8^)2'B*+\A(<7
M,=;6EFT_NO4&YV4P0?\ ^>K^;%^#39E5(MD?.*04$3=4)!5U,<1C=>:QRR"6
M0@==4D&G2VP8-&^3(6U^59A613D@#5&E-QD06[.DFUQUB!N3B.'RK,*ZB1^
ML68UE)3N '91%(P36&V918+;9K7.JYP)GGRVHKTTQ/!2O6I'S22. @M'(3=M
M4D=V#+;2UA:V'5>)3Q&\7$C1CI(:8AY'43!=PL9M9%*]8HVYOLLQ]*TJ2 9_
M3H9?<@JKQK)60DNG,:N LC 6(-U!&.%,):+2>)%5ZZ5C:QCKD9I8P;#L3TQ8
M@[V:GMS).$<22SR(0U/QBD ]RT<-HV?5S/&D5V!OV"E@.^9!Z:YQ*Q.BCI*>
MLE4=J>.++A(D(N#HT7"IIL=KL2<,7\EFJM05Z>'REH@+Q/$NDR1@DEPX4^QM
M<AF%BHOM,3Y48(^HJ4M!4.W:8O,)BRKW!6T=>]S>VC3O>PX;:K*H*^R:M#*W
M< =]6K[ JU_# )XA"EI(M(M(R<,Z[[J!>[*!;KE$N?<[7PC:5E96 J%2U+K7
M7&LC,!K?GM$MW4:2"X%\01F%9XG0I+33:*G4XD=YI )>+JYR<8.)-5ASM8 6
MP;2>EO.S5\P[P?\ 9B#\(P6TT5;/:\L68P00@[*1)F+4_#?X&CV+=H6N#??'
M"D,F7%7&BMK7H)5([#^3FHCEC[[=5E9&)[B#C::6H0/Y*B35$,,EN+O3L\8>
M<"]^+)'UD324# 7N#B"1I88Y'0QNR@NA]RWNAOW7O8]XL<5ITTM',!UH<VAA
M%_L*Z"6*3Y.&K>%]_P!\F]JD^*?K7T'?J-FWWT7_ "D/K_PCY1CY/E'['/D0
M?,0?V-NX@^8@_O#=EOBM_A.&[3><_I^N3R/F.#]:>A!]0*[[Y-^K7]XN.5Q?
MSC]CY/E&/.0/.;?O)[+?%;]!Q-[=-]VE_6-];"0\-HB 49@Y'(ZE! -QX7.Q
MN/@PT7V!*^?K?-^C$4"1:R+L\A!=V[36Y#X O<!L+GQPITD-X$'Y-\2QB:K\
ML8D27F.D=CV=@S?#M;;?$<AC+D6.N*6(W\)4,;'S@-M\.((O)Y))8V8/(Z27
MO;2R*%!6UB.0/GQ+:4ERH#G<LNP8^)7EY].G IDUK(Y,C)<IJMI0D6+*![JQ
M(U&YL2+XUZHN$X#("66_:0FU])^&PN#<;86(!B2=0TL O<">3>)9>[N^#%&/
M(S4F/K>5"</KWT^44XIVTVMR076]^MSN-L1TZQRRS L6F6)&!M8"'B:;;=_$
M-]^X?L5"A_(*A?;:9JFED3QI:OASB0<K<*IIT##?JRDCD<6]DFD[YY>*W@&T
M(EE^"R#\-\2KQ8# VRM/25%QVM=',)HQX:686?:]N1&'&MJ)CSH:B6HCMR9Y
MHN"P?Q4+N+6-^^VV()6@JYJQ;&2:KGK&5NP))V+,H'/0">KO?Q)Q'"L5'+1
MDQRTDM&S'MB.5=)8=VL=VUO@PSDRQSBRS1Q10\0#M1P,S0AE-U)CUL UKV//
M;'!44JTEVT+F!S'43=S,7J)-)/>EZA_YVR]:]R9V=:>:"(GB5 B$<J?^SG6"
M\P8V*RQ)J5;;DM;LDX1%C1(T&E(U5$4=RJ+*/P 8O^ZZBK]U5)%'+&=XRD4
MI]-N\/&.N"3<G:V#&#'P 2L!TZHAOJ5#=49S>0H"!U=76MUKX*ZIVG]T\-/
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M(Q:]PP:HS&*KJSQ88I%FX7,23:NL\@Y$(G5B7DMR?L;5Q/EOED9TTD468,\
MYMK,+P=7LWB2.0?!KVYX6J\LCHJA4'E,<:&EGM[*JL!H1Q>S%=@NDJ=@&+67
M3+3%)DR.EE8YAFLZ39O7/NT8ZJ:5^"!.I$NP,Y9S?A=:)(ZPUM+EMJ5<M0I#
MKZXFX$*S.'^'A'4^D)=@RK;OI*CRJG28KPWN\<L?/1-"YCF0'O"R*P#=_/\
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M9<NNI'%6:&>&J;W<GE2%991_S%)U1:KA2J@W P8Y(,OJ,KHW_<]4W7FDVD2
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M&[[6QZL^C_O]7_5U=_I\>K/H_P"_U?\ 5U=_I\>K/H_[_5_U=7?Z?'JSZ/\
MO]7_ %=7?Z?'JSZ/^_U?]75W^GQZL^C_ +_5_P!75W^GQZL^C_O]7_5U=_I\
M>K/H_P"_U?\ 5U=_I\>K/H_[_5_U=7?Z?'JSZ/\ O]7_ %=7?Z?'JSZ/^_U?
M]75W^GQZL^C_ +_5_P!75W^GQZL^C_O]7_5U=_I\>K/H_P"_U?\ 5U=_I\>K
M/H_[_5_U=7?Z?'JSZ/\ O]7_ %=7?Z?'JSZ/^_U?]75W^GQZL^C_ +_5_P!7
M5W^GQZL^C_O]7_5U=_I\'IGT?TM[/5]EO_=]=X'_ /Y\'F?.?KD\CYL>23>"
M_CK\^/))O!?QU^?'DDW@OXZ_/CR2;P7\=?GQY)-X+^.OSX\DF\%_'7Y\>23>
M"_CK\^/))O!?QU^?'DDW@OXZ_/CR2;P7\=?GQY)-X+^.OSX\DF\%_'7Y\>23
M>"_CK\^/))O!?QU^?'DDW@OXZ_/CR2;P7\=?GQY)-X+^.OSX\DF\%_'7Y\>2
M3>"_CK\^/))O!?QU^?'H:YWEV2Y/5T^822I*]<TJB*GGJ!H* #K01R*#SV)!
MY;8]6?1_W^K_ *NKO]/CU9]'_?ZO^KJ[_3X]6?1_W^K_ *NKO]/CU9]'_?ZO
M^KJ[_3X]6?1_W^K_ *NKO]/CU9]'_?ZO^KJ[_3X]6?1_W^K_ *NKO]/CU9]'
M_?ZO^KJ[_3X]6?1_W^K_ *NKO]/CU9]'_?ZO^KJ[_3X]6?1_W^K_ *NKO]/C
MU9]'_?ZO^KJ[_3X]6?1_W^K_ *NKO]/CU9]'_?ZO^KJ[_3X]6?1_W^K_ *NK
MO]/CU9]'_?ZO^KJ[_3X]6?1_W^K_ *NKO]/CU9]'_?ZO^KJ[_3X]6?1_W^K_
M *NKO]/@],\@L?9ZOD?_ '=7>'_3XD(,DI'(R2$>8N2/^!IO:I/BGZU]!WZC
M9M]]%_RD.+#P'R#%AX#Y!BP\!\@Q8> ^08L/ ?(,6'@/D&+#P'R#%AX#Y!BP
M\!\@Q8> ^08L/ ?(,6'@/D&+#P'R#%AX#Y!BP\!\@Q8> ^08L/ ?(,6'@/D&
M+#P'R## :6V'9;N'V)PW:;SG]/UR>1\Q^M?0@^H%=]\G_5KBP\!\@Q8> ^08
ML/ ?(,6'@/D&+#P'R#%AX#Y!BP\!\@Q8> ^08L/ ?(,6'@/D&+#P'R#%AX#Y
M!BP\!\@Q8> ^08L/ ?(,6'@/D&+#P'R#%AX#Y!BP\!\@P0-+;#LMW#PQ-[=-
M]VE_6-_P--[5)\4_6OH._4;-OOHO^4A^M&[+?%;_  G#=IO.?T_7)Y'S'!^M
M/0@^H%=]\F_5K]:'LM\5OT'$WMTWW:7]8W_ TWM4GQ3]:^@[]1LV^^B_Y2'Z
MT;LM\5O\)PW:;SG]/UR>1\QP?K3T(/J!7??)OU:_6A[+?%;]!Q-[=-]VE_6-
M_OY54A[N$TH64$,=;;=06!L3SNUEVYXG+4\4$K(2*FH\GA4%>)(P75(RI?68
MH5WDDMH7D6N0,4=-Y74+!JT:DF;5:_M4,DW+X=%OPXUZJ>GE0:GED421G81P
MM%KXH;W9UV3ABQ]U>V/'X.?P>?\ 8^#O\/V)O:I/BGU]*L;506I.F$K[&=]&
ML LW&MUARM&.R3;4;D8%;2K/%#P1IFDX2.44@OI9E#+N0&"MOW=]L5E.D.<9
M:L8M!54M9,T.Y16581;>Y*AM12Y) /,XK9:6A9TDBU% AZ@!U&33H4?"S,%\
MY\,5Z1PY743!%24O"L6P)#;E]_YH(U=QQ-HROTNC2*.;CB,U)E'$+B9R@T';
M?D7_  @:; XKZ.^9'+Z+7[/HD3W4D%-(%)+'D).MPX^5VW%])Q7F!62EIU31
M3#0\HW::7D[%^]5MI7NVU<R3Z_T'?J-FWWT7_*0^N&*WHGTXB-75OTJ2GI5:
M:<M)55"K%#<OOU?<KX7\!OCH34=*,ZZ0P+'FM;4Y?05 FK)GED\G>!&V4AN9
MG]Q&=]-R18'%;)TGSCIMFN39;G%52 35#PAI95@2.(*=(TWMSV QTG7I;T6D
MI8:SI'-/+5*[I'3U,Q944Z=3Z@+!CLOC8^&*ZLS^/+^A/1N;,*BEJ\\O/F-<
MKGRL12REHX!(=U=(V(?X0@[(WR:2NZ/=-CT8],JS,\MK*#RJ+R^3C5$$H75?
MB67[%E-@ 01MM?%9F=?TMZ5IDV3UD])DV2MKS6MIG*FIE#=:!77N-C$G_P 2
M3>RC %@ .0%A?<[>)[SZYNRWQ6_PG#=IO.?T^OI8!.[:V*0Q1M-,X%R(T[E%
MQ=W-D07 U,+[7P]:LU1)!!&%2'3Q-/9BU"Z(\EKR3%;,X]R&5B%#J,4](9\S
MHUXA%,W5E N"\CLH (-QI1=1!%CJ([AO$5S:MS.F9>!#3K(M,L/L;1F.'C#4
MVY*Z;*#V]5W9F-QC)B'II:NN.N'+Y)8YF/4\I>)V$2%@+*TB@-*RCJA9'"V%
ML022U,DM;)U$J#^YX%&E(X+DA]/V<I-_YD8C4;ZB?WP\CYC@^N9@BEFY#Y3X
M ?"3L,4-,M+325M<JLQ(*P'<:OX*G6_:('7G;D!M8;$SS:5DF8>+:5%KLS65
M5'<-3 #P'FQ#2)24GE-2 \K,$([0XK+KX48[(2,#=N_GWVQ3>2YI'+$(^#41
MLR+L R2@:E5[6UPRCLO;GRY'&7PAJ3-:^07EHZE:.&-AJ16,BQ:V[NT2S#F;
M !QB:2.HR6CS@QB%WFDI98XQ[8RJQ5E&W6+(5 [PRW)M?"P"AH-50JM6UUV5
M#9O)XMNL.>FPZB';4Q=QJ6Q]?Z$'U KOODWZM?7+8$$\KB_FQ7=$NG"R5E6W
M2E:>D$D\]WJIU2&GU,XU'38!$L-O"PQT/J.E.==(888,WK:FAHJ@35E0TLGD
M[4\;\B&Y\>UD0[D;]V.F723/,TZ3IT2R*=J("5:>25'X;SU!0RR%Y><<,*!K
M*N[$<R2!C.:'IGT$6ES7T^>OIWG6*1&EFDCXANPBEBGOJCD 8:EW'/;'2/IC
M45G17(JG*7:BJ>D5='E\DP-S1,&1*I0>XZW 1KWL#;G?"QYAT0Z7='LM3-Z_
M,Z'/8FCJ8J^;C,DZZ[RQ;#2ETNO>+E6+6OCI/F^89UGU)T0Z.U,D$D4@J,YS
M"%M/DT2VO$''NE4]8#G(0GN3B&(00Q0AG<11K'KD.IWTBVIV.Y9CN3ZX]EOB
MM^@XF]NF^[2_K&]?ET2S5]%"XNDM73QN/%6E0-^8G$TZ&NEIPMFTO/MV50RL
MBCX.1M\ Q24KU&:T6I_W,$G6:*Y!D+<)T^#98Y%U<QKVQ 1G$F:I(. M*)?)
MA3GAE##&K[^-]5D\+ L7WQE$B>0G,J\J8J/B1R%NHE34PLZ@? AT<68+N([J
M""P.*8S3&6KGNIJ2&B@MI6"#W T^^/<R/>Q74(^2C_>7P]VWY^7R]V,QM(*G
M-H1H6C2C@%(^IECHWD2%UII?<RM,W'D$FIZ@DV)T6&3?5"/[C6?Y*HP?J;DW
MPU\H/PCTJO8_!??&8R-ZHLYC%EB@.76B ]CD>2@B=GE7DYWT*#U0HY:C?#I'
M0UG204NF&*BI8JVA68-.E(]7!2LUELQ9(7FDDC4J50Z3;2N*A":*<)KEK8T$
MM'4E@9FJ%925F>ZJ\-0FM'1NH&9&0+; ^3X/#$WM4GQ3Z\D*"S&P'?\ _/,^
M YG%!0[BNJ_8EB4M&K?P*OMK<>ZJ'7JK&+Z>0-RS"NJO*IQ(HT)$@BA![:H.
M9+?9/VGM87VQ3(:JNC4W=:8"HD)N?9&NL"=_6[3Z?L;'PQG4BR.M"/:J9"CV
M]W/)O*Y^+M&AM<(HO@5JK' U7"*IJ/\ V?W)9CLBV'-F)\>9)!6]\:JB*S2$
M29WGDS:BHVIX=)U% +$@(.%$H"WNS[AQB.CIYJJHRY)'\K@B>19&MY/,8PVM
M5/:OJ4IXZRFQ5K^O]!WZC9M]]%_RD/K^FV1YITAR89;E=5#2R-51R5!GDECC
MEIT22\1,4<C&\A1M)&DZ=^6,GS7/?0\SJ'(LR6G>@J9H7G2-4<,D[!/*X9PB
M3-H^PD[E(" VQPJ9&-1PH4;27:;AJ'TVU,Q>VKL[G$ DZ>>B"96NV7T\VL]Z
M1Y?0MIC4=WL\@6_BTCOW''27HO3](HJ,B>2@KLNEXM!6P=N$[=0KMJ0E5/,%
M2-MB0<]HZGHY4$KF51GO33I!'Z7TDFE8S14;VC>:-%-HY''L<;DJ$ =Q:Q.,
MDDSC**J7HET5ILN>MH(169YF68\4I45KJI:).%U[*S"&,M<;,3I&YZ(=)7Z1
MT=5Y33BES#+JEJ2MA0WCX@Y/'S(5NL-))L5.Y'KF[+?%;_"<-VF\Y_3Z^E_V
M/,K=K@P>?3Y3%J_!;GBEEB+U%-$NB-*@FKGT@EZF94D()[;F.$PBW5C1.&J
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M$LNX[SN-_7'LM\5OT'$WMTWW:7]8WKZ&=:6KAJ'4L(27 7GK56X9W[A)I)^
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M?'%?RN:LVXM0L22@@&-XXH%IPC1FZLC1+9U-PV'B1D$0'#@#I)P(B5C)C.I
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M@?S1HC"_!;$?^R5WQ(#^'C"W_GC+2=%4/<+6U C^%3I=_P"V:4?@MBD[4_\
MT=9_EI,0:!)4&+=RR<8>#:.K_P"&QPS3^2R K[!Q8RQV]M$<W#'CNID^#;&5
MG@Y5Y2 #(NF*(G?07:1FDM]D%6R^!:_,#%#)Y4OE$]^')))I4'V30LC)Q"QN
M"[Z2X%K $ [WQ-"<NS6&-7O'-4+%(!V7UH)8)PON78:0PY6<WW4'&:_5]_\
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M]KCGA?\ T9E\BN_%J:B*2-6?VQFJ">-4FYU#2I98R>UL.0Q9Y'CIX-YYSIC
M%](]U)87V0?*UAORQF?"HZ6++(=X8)H)<Q8=9IM+AG1COJX9Z\@Y:P>02PJ$
MJ)\WRZ:E):$1J0Z&Z+'PN1(V[?6_\5[;XK65JRI9""AF<J1R._,><W\_KO0@
M^H%=]\F_5KZ[S[CO'CB6E3H-TY%5FE(]1EGE%1/2R",.'AJ+E94U64RP,Q#1
MZKCN/+'3WI+E?2Y\JHLAHYIZJ.63V?R<)++QE5$IHU6\C*&&MBW5!W4<VQE_
M_H7H]2>7L$]+<LC-22VRF"&[K<]]QI'BVV.A5))TNZ9U>?5EW@I9GKVOR,K-
MIHX=_<HO7T]VE;=_['22JFZ9]((NA^72%<KH'6HSVKC-]10^T@C:RGJ*.^1B
M>26QGD5#D?3GHW-F*)%D%/E;TF7M(MZ:EJ$N!KV*J^K4Y)WZX;X<="FBJ^F?
M2W,,K'_H:58T62-2M/-5:B6:(;#?K-L!U2-O7'LM\5OT'$WMTWW:7]8WKD1I
M'1%W9V5%'\YC8?G.*QS2QS4=*%:5=23R,2O&E0VX>JQ*4Z/X+JDMJ-^J,(@I
M8Y:B4F6727FD[]* GAQ*39(UWTH+7-V:[L28/J3F!\:K+3\J5V,L]IJ/OCF7
M^=FQF$KT-,F7TWU2S"W&<\J:G%F*D<[HI662^S2-!#8#6<9C3!<IZ/1TB,U-
M254@S)5YO,7J'$TBWN]]= ^K_D.;>QG&;20S9[2/3D-PLF6.L=!934&&@7KD
M=IC+'46.]V#O[O?_ '@KNFH*S*'4H]B1J0\U:W-387!VPR*ZE'570\U8 J;&
MXN#L=P#Y\([QMJ1F1K$:E)4V8%6%QONI(/B"1BW51/<QG4B^Y1BNC4HY*='5
MN-].W+#=:1YFZTLNGB2'=Y-"A$UN>LVE %6Y-E  VQ<F0RDGBMIU2>[.@!4N
MW,Z% 5=^J  -L..(_$DZ\@Y.W6;\8[_L3>U2?%/[PI*-J4E6\5V)'@;<_P .
M'GFD 5Y&91N%)ZM_&W*_PX!*MJ4V:Q&H;&QYB_.Q[\.S2$M(2Y;M%R6+;6W)
MY[;8+N55"[%$[*$G2O=U1R&WA@;,'&S+?2PV87YV//?OP\DDAO([.0+ L2;
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M\A3?0X]7'2G[:O\ D*;Z''JXZ4_;5_R%-]#CU<=*?MJ_Y"F^AQZN.E/VU?\
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M_6ES!X[=KI&\4,4[]8C+VMQM<]W\%;]!58[A2U 'K#=/P&*;^8YOO.4^]?\
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M\9%NZ:LJ5J6C$?FC(VIK&-X]VJAP>10D<#AI9X9XZF,LZ@Z)H@3QC9N$L?\
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M53>02<.N"AN"!B"5)]HJ^>(WCEHWD0\NJ]5 1?R&QL1W&XQF-:,NATQ@-6U
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MIFAJ9G8K)$6!=(^%CSX8;PE>#S;++<I7PB9/F1S?)8U1*K+N,58JVNK%9HI
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M0-K_ +#2_GZ7_>Q\H&U_V&E_/TO^]CY0-K_L-+^?I?\ >Q\H&U_V&E_/TO\
MO8^4#:_[#2_GZ7_>Q\H&U_V&E_/TO^]CY0-K_L-+^?I?]['R@;7_ &&E_/TO
M^]CY0-K_ +#2_GZ7_>Q\H&U_V&E_/TO^]CY0-K_L-+^?I?\ >Q\H&U_V&E_/
MTO\ O8^4#:_[#2_GZ7_>Q\H&U_V&E_/TO^]CY0-K_L-+^?I?]["[ [7ZT_\
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M+^?I?]['R@;7_8:7\_2_[V/E VO^PTOY^E_WL?*!M?\ 8:7\_2_[V/E VO\
ML-+^?I?]['R@;7_8:7\_2_[V/E VO^PTOY^E_P!['R@;7_8:7\_2_P"]CY0-
MK_L-+^?I?]['R@;7_8:7\_2_[V/E VO^PTOY^E_WL?*!M?\ 8:7\_2_[V/E
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M2#<TU.<K2XZLB5O15)E53>X:IIZAC<V-^7'#U\M'-!7"-*O.E1*3+GDONTD
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M2.^F_*?P(O[0WC 7*KZ9@OY3;$'R.VU-1!#.N<9,JSPQ3*&:IN%E19 #YSS
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M]F)JZ7:.MVDFGVAJ,K,AS1F>4FY-/_&%3=]' T\!%]S?'AFWS;,^#V7.1_\
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M?E/X$7]H;ZD3MI[=??#$'T/3?U:G_P E/^1J;Z(A^^+^OZE^23^F79W\!/\
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M=J%YY#W]5.JA')SQX8R*$&*:N(XU+:(F[^CPDJ+7XA7DU,1WD ^3&:_S9_\
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M'51J9;"3M]@CB?+SQ&BQ(D<8TI&JHBCDJJ+*/Q ?OQ+&D\>YE&J/6)-/$=<
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MWRU)14;"Q#"^^E(Y7!PL2OF$%/Q6%LIJ*J6W%PT67P5&N._HA(Y*J>IQL18
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M+RC58<$]#XZ=M/;K[X8@^AZ;^K4_^2GC;AY:U=^_\391:U],3*"6::,<9M?
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M9?\ IK*?CF/F9;7_ %IE_P"FLI^.8^9EM?\ 6F7_ *:RGXYCYF6U_P!:9?\
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M/-3PY4(':HKJ.B82"8M81U<T,C"Q[2J5]?'S,MK_ *TR_P#364_',?,RVO\
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M/(,I(\H!!(_&.&,K\('@MK'R_+:?P?O69A,*>E2./+Z-GGJ-*H2.MZ)[L6/
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MR2&*1J^H0ZAZ<]9]/"Y'DQNZK+ZG,):!!/'7%GB4MI-+)(AC:U[#@K:>.H<
MW/AC+J0T5*D+$-(6>69AR,LK:GMZPX >QXWR1WTWY3^!%_:&\:$PB:$U"N].
M)8S.D9 =X0P,BH3P#,EP">_!S#Y'[:6&FFK*>7):J*GAA=!%444AW2!//>B[
MREF?AUI1UWYL<;1^%+8K9K9.?9/P>122FJBGIS4Z)5IZ9*H%:B=I9[35%3(I
M('#0M^UP QL!%X()\B>FVSGJH\[>J>1IBM3%'# !ICCIY:<NCAAUY-\H;6>
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MU"0W[Y&7N.(8XY^FQ1RJ:K+^-3 +$:!:[QN"0ZCM!QU'4,48Z&M"S5.819?
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ML>%[<+XC18E58E$:IV50!0O?U0+6X^3"Q1HSNJ(KR=M@H#/[8CB?QX8!E*,
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M<?,IV!^P$?\ ;*_XSCYE.P/V C_ME?\ &<?,IV!^P$?]LK_C./F4[ _8"/\
MME?\9Q\RG8'[ 1_VRO\ C./F4[ _8"/^V5_QG'S*=@?L!'_;*_XSCYE.P/V
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M)4-3<Q=$@J&U)D5&5&-V@P@G8&1P@**CP^%EA(7!PN+P_]H " $!  8_ O\
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M)&T>H-=C-.N:450;,N543M/L\JI_O&\9G<!=3;KK9BOZP&\ZJ;E[J+AO*=
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MWP=- 0E$5-1%=**2)?E5,-5&OY;S7+E,,<&;<%&HZ(SJ4].EBM *\956ZI?
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M'I3?@#]F/2F_ '[,>E-^ /V8]*;\ ?LQZ4WX _9CTIOP!^S'I3?@#]F/2F_
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MU4<Q'.IKE#?CMJ.WEQ*<W%]%=L\**345]AL6W%L;RBE\ TT MM- +;;8)80
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M.T8WL2=I4QF7X&G_ %!X'WJ?1TV8Z-LG$DR-A-;E"TI-BVVWL5:-VVD"0N.
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M0*"5&J,:+$JS,F56B-AJ,M/ 5X2S&-MXGG%G-DL4FE;'BJ2GNM@&VQ0&VQ$
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MLP\\U-ERCD1ZLD34+J&V1$@:S!110%JRDA<WBX5%Y4547OHME_[^FJOPD/\
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M4"-0X+BMQZ3L44CAL.(RJ[2VN_\ VT[:HF(51;'2,R.#Z#^KJ3>/[EZ9.^F
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MT2"RZ[*F)"D\$;)D]#L=']GH=E!RE'95QQ$5+IOMAN#LZI#E2&77X352I4V
MM0;8#:.<!X2T"2'!#C[(>JZ>-IMBJ1_0JK4Y84N;'&0_ D QLXP 2$ZZZ @U
M*XWJ9;KN3NXIM0FU2344G$3$-W@9+4:F_M7$1IBGQ&U,W$TJFEMNR".LK)B?
MLBE1Y%,:V\Z!.AR(4]AG2IBZL60 .$T:"NAP-0$N[5?$9]IV<5/DFRT%7]#9
MGH0#S^E 9=J.RX,!ZR1L^/H!WJ9$A;L1J6\YM*76J.^_#%12\:HTYP-L"$F\
M@D175<LM[&UNW+[&S+\#3_J#P/O4^CV)5?A(?Z9KV(G?3Z?8KW>'I9O[)(^I
M/!^_/^9?8DWX07ZM/8B=],![P?Y4]B.^]3Z?R.HF]5;.R?\ 97&89M5H-8IL
M-ZGU(&9<ZGRHL=TSJ<8P%MYYL0(B!%,41;J**J;L?])&1X)U%EV3PV5$CM$^
MZQ)=2TL'8C:[9Z)+N1&;-U;4BOIW+BF4=S+3E!I$)W:ONNQY4>(#A<1R2_(E
M(BNF :D8C,IJWKN+G)3*'$WL4V(U&$N134$X[B^ZX:D:]_&8X5.B29\QZ.RC
M,6(R<B0ZJ2F25&VFD(S5!15W)R)?$N+6*9/I<DJQ(=&/4(KT1Y6U:91'$;>$
M"4%5%1"M;=C+ T6CU.KE'E3R?&FPI$Q61-IA!5Q& /0A*BH.JU[+C+5*%%@U
MZD4Z"_%:F 375QBBV_"DH2(3*FFZZIQ'!35NOA,G_F;,FNPP6'3YYTN=+<8:
MWB"-/Q26)*!G_<&NI!2R$I"EL3LZ9ONU6:@V^,>$9B;[?#3VDJ7,(%5!?=NH
MHU>X(9Z[%9,5#,67*$_6Z=4'YA,FQ%?G1WHLUU72C2@B+MXSK)EQ"+2BJB**
MFETQ2\PUK*-3;97]'I].IU.ENK#8!P#<<?81'I#*O$M]<G0IZ>(* .,EQZ11
M:I4WXM^$LP(,B4['_P!GMAU8&0(F^.BCQD3C;N7&6(LMAV-)8HL!I^.^!-/,
MN@P"&VZV:(0&*[B$D147\G1.I++#TBH1Z[7OT5ALG9+R3&8LR.K3((IN*ZVY
M9M!15)1LF&(E,ROFR54DBM--,RZ#/I47;"T(WD3J@W'CM,B6\RU*6E.**KC*
MTTXSM6E4BO3JW7(],#:O*58";PM8#"V.0,1R6FEL>J.@VJBEUMB'4VZ%6(-)
M8RU6(K,NI0G8;C\IY^(2MK&<3:Q]S:;+A"-F_P =6Q405<)'I40XU<;@U HT
M9QE&WDDN39+B+LGD0=L0EK;VJ6(E"^Y<9)EL,Y^F-P*J\54DYFCN,QHAG37V
MU5MDF&;(3BZ5D-CP1$ZF)JIBF,S4.52ZL+TZK5.IQ9PP73I3L61&:5M?1!.H
M"ZI K>P4MMKMQ++?&2*XY1Y\P*+%J\6HTUEA5J<5)[SFSFL0G-#CQMHFDVFT
MVRLN*K8EBI5^/2*G38,?*U2I#'HC$*%/JDJ2NU1!@G^DBRQHLVKP 1NGU,;8
M"EM4]Y)@Y>B-^AX1RX0DE$:,PX.@Z]LCFHB33JU77EQD:)OV\.DU6HR47G-L
MK$9A)M.VFJ0Z@[^VB]SV-F7X&G_4'@?>I]'3MUFIS6<OTQ\=I'62WM)3S*\C
MVQ4FQ:;+E!73%23?:V)U>B9QA5%J"@JXR3( 3A&2 +39,2)";0E7<A6Y%PP^
MUFR$NV89?4!BJ9-[5L3LNEWM7M?MVQ4\J19;(!1W)'HA5'446&(T8M)/:.6Y
M+S OW5541,3LRY4S.QFB!2)"QJN(Q'83\0A) (P!Q2VK2$J<=+(0KK#4E\5%
M]9;5)H])C+(J%7D@I1VELI(TB7'6>A%,D1>*-K\Y,/MQGN$1VW3!F0H;/;MB
M5A=T773K3C(E^3IZK\)#_3-=/+I:4QV244T!7 =1-2Z45;#I5=W)B)3O0>1'
MX4:AMB.XA85*ZIH3N6Y<>A[,<ZA.&VT; M#;2ES0([$JN*F_2(K;M[\-QJM3
M'J8CJH*/:U<$=6Y%<0@;) [I(BVQ&<1HILF>XC4&*RN^02VWZM]@XP[]]]26
MP5$JU+<I%2V6W:;5X7VWF[7XK@V35;?V^14Y4Q IS,8ZA49YH+<5HK$ *NE'
M'%LND57N]I"7D3":DTE9-27O9>VE^W;ID[Z?3T\JH3748APF'9,EY44MFRR*
MF9:112*R)S1157M)A]C*62*E7HK"JG"WGG(RN"G^\2.Q%EFV"\J;725N5$P[
M09%,?H&8!8??8AO/(^Q,2,"N/-,/:&B1\!%25IQH544)4Y%3$J*]D6H)P>4_
M&1PYPMB[L'";U#JC^VTW[>Y<4#/$FG2'I&9VH:4>@L.(4F3,F-JX,?::>:V*
M+K<T=P4%2)$6-D?.^3)62J[4X:3Z.#DYJH1YK*@3B KK0@C;RB!=3XRB8JVX
M@GNQ0Z<W3GJ]F#,,L(U/HL1T6Y!-D2-\(/BFHAM"$ XO&55[2*J,.264CR#9
M;-^.A[1&'2!%-K:637LRN.JR7M?IWN\/2S?V21]2>#]^?\R]-%I%)C'+G2ST
MMMCR"GMG73YK;+:<8W"L(IAM:WG&%3Y3B>D-L 0(7ZJ./R8ZG9=UQ#$#*U.G
MLU^=4@:*,,4% A5X]+8O(JD W2[FI#44!+KAE:UF^'3YSR):,VP#@:U]H+CT
MEA7++NN *G<PR[+<:G4N42A'J4="0-HB7V3X+O:<4=X[U$_:EBB3,U9LC9:F
MYET^@E..&[+=>VB7:628$(QA<N/&/B)J%-6I;8D9>FBCTMHVT8*.BD,L'_4Y
MLISNJWMIM="W8HSM2JC)UFK,I(.BMM+M8+-D52D.ZMUE5 MIWG=.UT\WX07Z
MM.G2*0',GD.K@S*HFS%>:KI^U4NT*(I>YAAEW+LD!D.@TVH.DI$KA((V0V0%
M>7];#E+*F.R#;;8/4+J#=7@UZ=.E=X\F+E0Y IW2>LG_ 'MX*NNPW&[RUA1X
M:'K<D/\ M4%;<G=W+;]^(U(K-'<H\F<UMH*J^+X/#O5$511-!*B<WE14L2(N
M(H[ IDV:\C4:&V5G#WV4^W9+V1-V]<-&ZWLG" 2-J^K9DJ74-7;T\E^F3OI@
M/>#_ "ITSTF0:-,1VG'WG"YK;30J;AKV["**N[?A^#E#)U2S&U',A66XX[$1
MW2JIM&X[464^+:VXNU$%[J)@,LU*E/Y:KLC6D-EY[;Q93K8J91A=5MDVY&D2
M(0=;'7I5$75NQ4:<]D>H*D"=)@\(*:+0/+&=-K6.ICV^G4B77=BF]$N?3WVV
MZL(! H[;@N27YKIN U&%VR#R-$9GIXH(NY<4;*N><CR\E2\S1N%9=D.SFIS$
MT2%3!IY0 .#OFB6V1=4;-1!P!4QO3-I!=K-9K4P(=+HL5Q DR;D@F[=4+2V)
M*()Q5UN$@IV\0Y,V+P*6_&9>D0]IM>"NN A$PKEAUJVJZ5*R75.G=]ZGT^PI
M=39:V<R>TPU+,2+2\D;7L2)N^SV@(9#M-.M1L*JJ(G]E)JXL_P"T)4=F([((
MS)>#,*I RV)*HM!K+6:-H.T*Q'=43^VOEFG0JE5''V60"H2UAPX[3A6=F/F
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MH,1P7'31D.+MFV&Q,[#S4+3O+45\<(ILH)32+I)1U"0%W#;-!,%]\*=,G?3
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MVI:E".T#(*7ZRB"(BK[N!"=#CRQ!;@DAH'=*_P"'4BV_=@66&P9:!+ VV*
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M#K33QN.-BC31$PXZ6LU$R1=27O9"3=?"(JW5$Y>[[O[_ /[HW__$ "T0 0$
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M*73U-AI$-M2XU%>:!0K\#799,H]@WRLN4D"UIWKXEIKF'U>*[_,2$'HB+AN
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M?O\ @+/(BGD_.]B-_DW5?*2:8+_9]C ][NSU<"NLT_RP)Z(;:'#,W;7*3KZ
MN!#.-''PMB^FKGE]W<5'P ]()3(4(H"&PPKM>D82P/PB887VP+XQ7B5 4N<A
M(IM'<]B#A-,WC_:&.T>#L :SC-D+&2C0C09\"J$V%C#P'Q6TPJI+>PT;71>L
MW<.0=.F P0@00,(K%8(KFAB0(7-+FMP##:P+6_=P365)O^(A!CMN#<=E))V:
MSN9H$X&1D\&;;T7Z%O3=$2Y&"IH)D,,25W%.;3A!R"WO@Y*=.?1C2F=TY%"7
MGA5AP4:$(QLC&XD/!ZW/&SZ%7O71 8 8'%7'=S:CX&O.]GJ3EVU@%*(/*BHY
MJPZNH:B#[ 5BR+6Y"+1=990SCFR0N .2+I.[B@8)Q:(]U,*N%PCH$O#'6R=7
M$S7UZ8Z<R%>=O!6=*.D**MD35M^;C_D!U->K:+Q3',#S028CN06$N5ON@LJ^
M>C*I;QWZ4;6TJ V+!M#C:+F-I9KE$0Y1$40L'L07 (PEQ%U40$]Y9R(DQXQF
MP7;(Y@&[4Q_O,('**CU@^WJ/#[,.#['[>I6ZL""ZXP4BQQE\1T4U.%F<=9D
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MK>(/FXPZK%;?;[^]!/.:^(UA0MV<Q[%5RS"].WNIQ%JJ76;=M6EN[^$443?
M#Q.* -L/<))I,:O/-%'N7@MI4F)C_LABSO"EML8U]I=TP'\"8Z9ZCP^S#@^Q
M^WJ[PQ)*3!4U F4B@I[,+RGN#![WX:5[V,Z>NJFL(-K:;2N;G)C7-G394)0B
M8<IL%]&JGH' LNL;+1J5ZVU,,2WZ\/S<U:G[/U,33F3[_J)XKO\ ,2$"YF[2
MA9M2 [N*/:JUXF"+Z- 9%N_:@P'M"8T39!P+]!^%..N,A#WL>D/0#FRGJ9'*
MM5$\HV6 N:>;VTT=VNSYUXGZHZ=['RX[W;+P*(UT$NZ-^I/7(,)_E(-M>[_L
MYBKB6<IM=#!;Z(T?)@S2 P>KK. TQUT=6H:P\X<+P> X_'"]KN>*@?/U%ZK7
M4\./4>!W/6DT5.+*%(PNP5#'A 182VSJ2 T8R;V>[,^4"VK;BUG.@7;!C&AC
M</0 1(D2.N "Q H9.UM,-'=UA#@ZZ#WGFH."$$#;</.W>WU:4^@><!_->KR_
M?^)FO.]GJ P%4'MH!^B7KAS8TZQ.*1T5G+SV,=^A"#1K%ZDS602$)K45=X$(
M<&=:V7_H>KQMGERM%;J4 U2(-3<Z9Y SAQH4F.7SL<L:#-Q2"EXW=X"89D"@
M#@ @949EF]9*6ZPN:CX.)L37GCADY )EH="(#1).F-D_12J$8U-Q4\N*N97;
M1M@P40]3%0$F%>>035U-7U'A]F'!]C]O5<7/+> ZG#<TN,LL*YP$DU[(R#>?
M(:9#]LIG7+E.$#QV >V->?<[.M =$E@7!_I$W(Y6TL.HC>AHXF<YA5."8=B?
M'6TU2FN_7>*[_,2$$E6@#B6QA#8F$B<<N1+(.$WWSE?ZYEL[_P#Q>3L!"DB,
MTG#G%P^4%A' 2!Q(<9"[*(9(] !3@NW-1!M.:3C=BYN,L'8FE4D2[IFZ^=>
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M#H9=1])KD;MA"P'I->=[/4HO8S!VKGL2AK*602P]T/$X20<#@PKH! .]K$!
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MN)I_Y%%DD0Z:3YUXY:&WQIN3DF,:E*L?>@[>F&;P8M 2((]O@TVJX5UW04;
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M(=-TF_ UFQW>ZMJ:@Z;(UI+.3S&%/H9DR3Z0(9MH2.$GK\OW_"0O_G%S2HB
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MC49QD)K%I04=]-6L#;6(2R$U2TT <F@#);=4X06D%IEBT+1IUO QBRH0W$
M.  NV&MO5]_4>'V8<'V/V]82C!H@LLAR>#UCVZ4;QAWA$6%>,\;FO>8JOR((
M+/[QZ^X:%I% [\XNU5I30GE#5.4YM#X; 0^1XKO\Q(08I.HQJ#RJZ"M&1-=X
MM6G(!"(60](@D+88M*!*:,5/QTZM)_5T(MS4RX *?FQE6KL+^->"FSRU>2S(
MF7-Y9A6K8 'K8G:*I!9$%6&]U^;>>'[,^\S6*WI'<)H VL!89U)%M7UX831
MRE-&EFBF$>A:M#QR/,$5[(X39$Q]2Q<Z0Y,@0@*RPJXJTY@@@EZ<(O\ -:6]
MYL@>/%'#&@$3%7<53U?4>!W/D))]8NHH4O15GN9(>]D@NKKH@C3"!"]>1%3=
MK#,+ZU6*W$1U0&YP].#)E-@69V19CNV*!ATM!+Y #^7[_P *CU#'HHJ+QE%.
M,.JODF+BD2E*8'?L]FN+;"K"TR8S&P@2\XC W(+=EWZ:8R6,N40 U$9F,2T3
M^*->=[/5 48PL I?IRP%RT\F7(FBC)<C3!YH@N<P#66>V+Z(!H.:7;%HEMRT
M2^79H(2[T+P*4&-*A;<31T'#1.GP3?"E%IJ&TYD\VIV:EDO10#A!_7YN-$$!
MJ\1D&3M1M#)LS9.V^*C8P8KN\?J4.(Y#[LNZ#81('%FNEY<,FX K4HFS<"KR
M J<PM@04 V .@7&XQHL:.#D]&Q#$)G0)".K+5$)4B])X?9AP?8_;UL3<6WA-
M'V-UICTB?I*UNC8#5Q[Z*G2W-0+T7:#DR,+3%-&S [3 AA70T[-&%*?WO]&4
M>,T]_P#?7XKO\Q(0';RJ10T^AU7LL3]M=P 3@N='9@X"6PH8!$45.^"-Y]HM
M_BM#F+QA-:.8(=Z@@SKSCU&H,W4& E[(YT-@G-1&42&B\,+(MJ@S#=6@HMX-
M3DZ$";L'3YMZQ$! DW)B(^KFS+&+'1:EP*8KS=RB*<I\R:@P>GUF@K&74>;W
M#KMWSS;+-!V (Q!S]&JP*<MFQ.+E"4P1U1U$)O$6,"L@HK;A5-(]#TG@=SY"
M0P"EE.Y5[&C6&<8O^J?M9<S1P.GP_#D#,N(Y,VC898CT<V*P84=\FM8"/ZFP
M>_%8PLI-$.Q"2*=O7Y?O^&DUPY<QSJ[KURNMP59$4O2F=!A*Z3<FUT0[0"@/
M<@VZY&KSQQL @"CV]A>J32=,8:^(D3I(X.=X=)W(;)J..K9TQ)RX"*2!)KRN
M\WJ**!+X9-!P8FWVX1(BO4%=3#)D-_5$N;&(V. U,'&N3]ATV.L(?:#(E2"
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M4V5S!V,3O.I(2(" VHA,WP5 P31-C)NS?Q->=[/43Y_Q4*A*8]I_,@@"C:A
M@"[9K?*;J"=,)G1TO9ZDTAPUBN;A(9N1JG"10%2%O<] E 2C=QJ-\R"%+9Y,
MVAQ%9I^0#)(.E^;C,,<!8,BYCX/?'>3!XFIX:57A4&6[LF[0DR- Z0P7?@*"
M2"QLJZ]N<>MP4V=F9<-!!Z ^Q@VZ@-K1UE(\$[+DG C.@QJ0J#V1>H!O;U'A
M]F'!]C]O4C_A E!R!H")SB:D%FH\2)0RJR"[<=KR;/! L:\RE+GMFWWL[PW
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M*DF2/                        :7'>[P;MWL
M                         #GM\YY1)(H                       #%
MX%KN)P(A@                                             #P3_3Q
M1=X#                        +VC&Q4U:![
M
M
M
M            ;;;;;;;;;;=DDDDDDDDD@$DDDDDDDDD  %S;;;;;;;;;<DDD
MDDDDDD*DDDDDDDDDD                        %          0
M  /         $  7         &
M           H         "         !X         @ "X         P
M                                        %  *VJLBW  0 "R,:"&
M /S$($D-4 @D  7 $_=T*"( &  15;[+8    ?72+-$
M          H ";=7=QX "  B1Q[58 !A"J\HMXT]L@ "X .BL0H<  P %V_:
M2E    %_U%BN0                          %  .VS[Z2  0 "KB0RZ
M(-LX0!U_E-4  7 $5-:0PH &  N9US?8    &C0(6,
M         H         "         !X         @ "X         P
M                                      %          0         /
M         $  7         &                     DDDDDDDDDDDDDDDD
MDDDDDDDDRVVVVVVVVVPVVVVVVVVVVX         @ $.VVVVVVVVVNVVVVVVV
MVVW         $$DDDDDDDDDDDDDDDDDDDDDDDG2222222222J222222222?
M           U22222222262222222222          @
M       H         "         !X         @ "X         P
M                                #Z  %   @DD$   0    *)   /
M$ @\@  $  7    $D   &   "( (       EE@
M  L/I4H  'Q#"H  "  &J: 5  !X  KE"X   @ "X  FR2,   P  $C"YP
M   #HUF          8             %SYYE   L:J$@  0  _Y!0P  /  &
M$==X  $  7   R/Z0  &  $ZEAW       JJ5    ' 7$!=[
M     H   N\^F  "  !%PUI  !X  1"'8   @ "X  %37I   P  &?Z]0
M   D73(    31H$H O%#.D8           %          0         /
M     $  7         &                     VMJ$"0""I2]^
MIT  H  %+W68  "   <)$^  !X  P,F,   @ "X   ?&2   P  @ J+0
M '\^*    #-@H@;O]#<+-8        A.D%   L2$;   0  ( ]5   /  "&:
MS@  $  7  $2CG   &  '=0K9      6J0U                        !
MOB0H   \O]E  "   YTIH  !X  BXW_H  @ "X  P9YL   P  #UA8(
M%#"1#                           %   MGG;@  0  "'.7H  /  &1EM
M0  $  7  $J).   &   9+$R      ,L:M
M  H         "         !X         @ "X         P
M                               %          9)))))))))#DDDDDDD
MDD@  7         &))))))))))DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDUMMMMMMMMMH_P#_ /\ _P#_ /\ _P#Z         ( !E;;;;;;;;;9__P#_
M /\ _P#_ /\ [0        !                        !0         $
M        #P        !  %P        !@
M                 *          @         >         (  N
M ,                                        !ZH !0   V&"@  $
M!B":0  #P !$,4L  !  %P !$4B8  !@  'OEG@     !>LD
M            'PY-:  !=2#^   @  ,!=V   >   H]U@  (  N  !V;'0
M,  !Y@2:      .(YP    52.                !A3[10  /C#C>  $  (
MEN_\  #P  $,BH  !  %P  $B%X  !@  #F-\      ! "0    &K%3N^%FP
M   $  &X .     *  !;DIQP  @  !XAJ@  >   E(!@  (  N   %U_P  ,
M  -U.>F      #_G     1HD3DS1SHG/*74O>K.0    !0  )IAP   $
M..   #P !###"  !  %P  $,,   !@   0.       (  X0   /[]#4IR(I;
MLO2AI6*%8 "DO8*   @EK2   @ !Z9T.0  >  *2!QP  (  N  &JQ\   ,
M   I]0     ! N<8                        L)/S0  (8KCJ  $  !,/
MRN  #P  (-,)0 !  %P !Y)H^  !@  .ATH@     #WJ!V
M         *LF**   4(8"   @  !<)#0  >  !DK'\  (  N  )2*>@  ,
M!Y9F&     !LP&;P                          !0         $
M   #P        !  %P        !@
M            *          @         >         (  N         ,
M                 !))))))))))))))))))))))))TDDDDDDDDDC)))))))
M))-         !  !4DDDDDDDDDY)))))))))H         )
M           *DDDDDDDDDE2222222222')))))))))   JDDDDDDDDDB2222
M222223))))))))))                        !0         $
M #P        !  %P        !@
M          *  !!!((   @  /_SB   >     (   (  N  !!))   ,  !^.
M,       ! 1                        !J/!!0  /LP"   $  +)))^
M#P  -$A   !  %P !%DFH  !@  S24C0      GUR
M     %A-I:  ![0>!@  @  /U]*@  >   A;O   (  N  )N'IL  ,  !%M?
M<      (1EP   !$<3UK$=             U[8!0  &H;WL  $  .\BK,  #
MP   (S>  !  %P !!Q!L  !@ !LD530     !?5(    +>'[EML8"D@:6D
M        *          @         >   (     (  N         ,
M      !      !A"7Q;[ P9AH?W0         !0   $/.P  $  !KUWR  #P
M !ZE?4  !  %P !(X5L  !@  *J C0     & [>0    !      "    "
M   ">)$*  !;=.2   @ !R-QPP  >  !@&#   (  N  !!]ZB  ,  '4=MN
M     3C@^                       !3(0C0   5'0@  $  )_V@.  #P
M!PJ1>  !  %P !VF-V@ !@ !1..L0     .);BP
M  'N9&*   -'>,   @  (4890  >  !1N*@  (  N  "LZ+0  ,   *O.X
M    (\\0                           !0         $         #P
M      !  %P        !@
M     *         !MMMMMMMMMMW)))))))))   N         %MMMMMMMMMM
M))))))))))))))))))))))))))))))))))(B2222222227)))))))))'Y)))
M)))))(  .2222222222Y))))))))(U))))))))) (  ( !0!V   !
M
M         "\\LO6/NMY=)F[Z-P
M                                      !O"75)M2,." /#5\<
M
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M)%P3P(FI2NB< , & #   # #0!H#0?$\]M[N<-3YD;CI.H1*K$PRSF17=7H
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M7?ZK@1OJ]RT#CV_:8LE. 0%XL>2ZV U/#4LK>!Q24*0W@5<.LBV*'#&],'5
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M\I]V?E/NS\I]V?E/NS\I]V?E/NS\I]V?E/NS\I]V?E/NP_86H-AP*"*<)O\
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M:!0&EH"%TD\O*Z\HENP<I% 2@$E0FQ!3+;00M+T>""$8Y@$I%'46WG:_30%
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M?S_OO_ P@BA *,L 3T81U=CB@U:)"([]ZA ';3#'S=$<R2"VFSF!J@+4IB$
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MWH!K IY7 !1B0<J<(+!2A-47">Q%J+!3<22=*OH4A!9?%A!'2/;4%(,(Q<*
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MW)0&TU[&['"2T0["!Z+9TG&IXO80R* $#4:,.Z8:3AD*<([#0&Y&A<%R>?9
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M$=K(1+0D0[(S9AHBH:*QMJA&>-98DUE!IDNVDW.+L:!08 UBWY!W]H-N,"1
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M60 PIDX(K/M 9(!HU@$UG21A(66A-23 Q0Q!4VU("HP.=X(2CL3.&*!;G3(
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M2Y#D49@E(%/(+6!K%U!NSA#D$$<@09         T &@#0! U)D& 6!%VT!0
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M2L.$#NL'$']D>*C;:HA PKH@52;T8;@!7(D0\XCE"@"L5$0#?[E+E<1:0-Z
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M6;\3WCLYR?5^OQ((B")$2B=D=)Y.""M#2/0L = @<A<?\PH4DB[40BW@[8<
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M;4GH="DQH@#;&<%%4@(64DIX8C01/"MUTNZIQ T)K %$:7&-7(IA$8[P0@A
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M54"S' ++4?"ZH!( NLOSY_SVZXD<)ZRZP8E:S06@6R.(/A](0TT\FD^E^?\
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MS$!+5# M#C^FYM3L6H3IL@0DV0,1$!BJ$4*1CB<'"0TK-136CA'/:MQLYD!
M9!<(>:,XH #05B@2=(,D($6S;"$"0.1)W:UM82"($.G3)L342!8%RR L6#ZF
M.M;"CLZ4^[X+LS@>A^/L(A0(E0HJ%12H7E.<2H4J:QM*5+:D@<@E#U-*(SL+
M-#0[2#>[ Q8MJ:(JFB6(G0VNHA-@-":+/E12< -4 9I)R!"-:0>LZ0X8EC=&
MM!.V-'J !U.=4&[M1%(P,AR@/C8ZA@0W#@RC2/,$H7(=CL# YV4D;F@&N:B#
MX0TT"W!THD@HP!41_,.UG3FADPIQ@L?/8XR:I&B<@(7$31HW:,]13 O_ #T
M&LC4U2B,4,PZ[RN 3ABK%5UH]*ZD<M;H]L)]MX=3D-(:VPEGX8^W84XPPL1F
M:ZJ3001[B+D6L^V3)K(QE0=>&$C[N9:Y9$T@J% @0J145B24.E7YSBEL^$QJ
MI9T"3$6<.RM>,AU1AH!K XM0A!H"00.'-*!T-Z1":+140P1@H(P[="AF"9,S
M>H +I<LEWV+T,S>H(2*'ZQ&79?\ %"<VQ_?(IK!)=7BE/3JOW?7R/9_ ]R%Y
M\%V9P/0_'\O&A(_R/9_ ]R%Y\%V9P/0_'\O&A(]ZRA4 :K!= OZ7_P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ -M_U0%2XBHB*(GZ0V;-FS9L
MV;-FS9LV;-FS9LV94P8\ M=7H%U@@=0'R0D_I$_4L'= B^0EPD=L_2'_ /\
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M7I*L 7[/D>SPJ'+/TN[SC.\9[R?WE/G7T[Y[CV1'V?TB%Y3Y_P!_UXWP79G
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M<O0"PH\S735H"E)8H@C$3CF:+#E2*P<,T)#NRXA/$<PL9FRB,9( 528@5*W
M@"$:K-J[_2 @"H$4'('9TZ'H]OUKC1[A6M3BD=Q&#0J@BU5(04K:)R4>U%3
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M.#">Y'-!"_%R%X:1[)B";N^%+&A]][PQF,B"-8 J#Y47$QHK"3>N(C5T:+X
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MC>I0TQ2A>EZ3!OM+LJV%#IJ6=DT7'LX"*JL'BDOQ4W-(VP@.)7D-3H5#%R.
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M&T37F_(:$BMZ@DC]!VX@'2%1"DOSFQXQ #$6TK+G00N4$[C@<(LO4/$^1[/
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M@[$%<O<[+&$B,?2EO6@E01:7#U8IDA<F#L*%UT?=,2A @=HF50U0A6BZ!:7
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M!V&N0$%"3*=OCA&MLE6$!I<BJTX&1YNJ2%FV#U(2Z'SQ2"%YL<DA.Z",X$L
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MM!7(=E&T4HTTD+Z&=0I0P] 8/E4?-\RMSGB2-K9=4J=S(TKL)'"'RL84FT4
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MDM4D+"Z-U46T:F+28N8$L;5NK[.2Q/+]8VA.D1! NSD\N;5C"TA=6"%BAWY
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M*Y$4(B. F<,   @   0"& OXP95<(; B/&(O7*.W"PQ(-0L")U)VBV[J#:@
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MUC++!O'/.K08J,17E52O+Q4!M8VB*<9S2P?X&:F;6*W .9(W1S<@4(:" 8
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MIDDL#3F F<;U^B@X4)SOQ(L4Y1X@ZJ2[+FR#3N-^>"@]DR,\!+P?C(,(,9"
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M_P P#8\<X-* [$\A/]X(E$3XRDNYQHP],1^[^@CQ_P!_8Q_W+U2^+;\<Y/\
M7/Q^>OFYX3L1/)Z-/^'Z_4"L,A[?[/\ W]!)9KOCC\Y-SEXUO_[D=@IX'X +
M^X& K#:XB:?LU8FOC/F_T_\ F4]_]/\ YD/?_3_YE);KO\\98Q%2@B3L *?)
MK%#;]A=YX1^!%\"OZSV_G\^<^=)V(GXIJ_'KPH_.?%_L_P#<$J LVS<.V>WS
MQ@4B1:+3FH2>^L!6&W)I1 TM%U1KX9@+P7^I=$RM',L4AMZ-KVQ3]BTL,D5V
MV---X0<4)D^+C%2DY&+,"FCN?D4DQ12#(Z)0E2#C6PI+H,6CUJ.4%CI_366
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ME32LZ/.W^'+_ (5'VG0QN$"U!88=&$E$/O"EG=96X2SJL)D!X?V#\([<3QT
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MH"83A5!H P,*K88VEPVGG'QHA@:@G#JX>FK^1\B31M+/S"CYO @WGCU(_P#
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MAR/3X<CT^'(]/AR/3X<CT^'(]/AR/3X<CT^'(]/AR/3X<CT^'(]/AP)83O\
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M@% B91<:)!?(Q*J]=ZRJL+9#@V?LTRC&]$S\P,(X"<#,*2_^&*>A-6@00'[
M0S.>Z4JQ]6[QA(]KD+1VC!0\\+)4(6EC<P^3+FR5@F@G&":'>A\DX"R$MXPH
M,YS'^:G$"0G(()2<<M=_3CX4@J%J7_VT+LE&N,!IGK0HYXL:$^62]8 H+ A_
M?C019BL\"X'V9K3"G!697JF(CB6. ,3C7.;.D/E0SMP $\*=DPZA%0E_4O1
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M![](<LG6.M-*C#BZCU:[^4#E5@!RJZ -JZ#>4S&'$ZD0M-0 BF!#4'#<@&5
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M(M:I_61L$RK?E9D.035@&@],D6-GM)$X::?#8DID'QP$3#A!DV2]2Z  4(V
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M4#"5@\"@ GD&@ 3-9,(?MD\/EL:REMGF"Z^.@H-Y4U\L*^+ ;98D6PR^9W<
MF@#_ #U1P2!QEB-"2W'=7=A0E%]S;;X<Z"BR+OLL^;F[.4 & :A1NR$78+<-
M+M<Z/2//*:'&=P%%'F"(HW:M"/98%@0B-QLR3 ?:\6X?>_U()/H'L"BQ<<V_
MP7C%I>= ZNN.EM$'D*K\! HFXN#M?<XK! #BIC9$# D7J*V4&VAONCCS_O#
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MIRZVX[,V$DF^2Y2^ J7-W'#0H 6J/U&;:GD-@Y!WFMJ0X\:N20,,/3NE)0+
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M:?9C^7$686[95ZZUE/A;,2-7"*:S>:K(+#U(YM#O (N7G+&152M3@<!4_P#
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M+KJ!_P"IADL2*,JXK0VH.PPMH"BOF'P%"(((IE=^"OCA>N!4E_N/H>P1Z?\
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MR-:"Q7KPT',EE&M!?.;0IKKJX0 FBJ1GB,T["V<FNAM_$P9)#! 0?VN3A=D
M6ID%G/3("QT&2@&EKS^"-W<:MK$$>U_C;NN#@(&2CHH$A!) J (?X3IV>3*=
MGDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,I
MV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDR
MG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3
M*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y
M,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=G
MDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV
M>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG
M9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*
M=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,
MIV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GD
MRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>
M3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9
HY,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDRG9Y,IV>3*=GDS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>business13a.jpg
<TEXT>
begin 644 business13a.jpg
M_]C_X  02D9)1@ ! 0( 5@!6  #_X1@H17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #?#0  *0
M -\-   I    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$X.C T.C,T  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   "<     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M@RNQ+J@"H3DLRKQ^++^=3-K-F+&XNUDW1P$JV.N[.,?7/%2-I.GNH5K.$@=
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M)+2%@Q).5ZG@?^RC\J4Z78,A0VD14YR-O!R-I_0 4 6@=R@CN,TM(JA5"J,
M# %+0 4444 %%%% !1110 4444 %%%% !1110!#)Y'F#S"F_:<!CV[TQA9HF
MUO*"J<X)'!Q_A4%UHME>:E!J$R,;B!&2-@V, ]>*F;3X6Y)?=G.X-R>,?RH
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MH>'=-O+A@TT]M'(Y P"Q4$\5HTAA1110 44UY$C7<[!1G&30DB2KN1@PZ9%
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M5<MR;^]8[FBBBH*"FR/Y<;/M9MHSA1DFG5G:]J!TK0;V_6)93!$S[&Z-@=*
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MJWQ?_P"18M?^OH?^@FK/PG_Y$S_MYD_I6GV"/MG<T445F6%87C3_ )$S5_\
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M?$*'PGD'QE_Y"FE_]<7_ )BO1?!W_(G:1_UZQ_\ H(KSKXR_\A32_P#KB_\
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M8Z 9)J]3)88YE"RHK@'(##- &=)-I\,[1/:QC:>OE#TSGZ5=%I:D BWAP?\
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M4%)/1DE,10 ! 0   J!L8VUS!#   &UN=')21T(@6%E:( ?H  0 !0 5 #(
M*6%C<W!-4T94                                  #VU@ !     -,M
M;&-M<P
M        #61E<V,   $@    0&-P<G0   %@    -G=T<'0   &8    %&-H
M860   &L    +')865H   '8    %&)865H   'L    %&=865H   (
M%')44D,   (4    (&=44D,   (4    (&)44D,   (4    (&-H<FT   (T
M    )&1M;F0   )8    )&1M9&0   )\    )&UL=6,          0    QE
M;E53    )    !P 1P!) $T 4  @ &( =0!I &P =  M &D ;@ @ ', 4@!'
M $)M;'5C          $    ,96Y54P   !H    < %  =0!B &P :0!C "
M1 !O &T 80!I &X  %A96B        #VU@ !     -,M<V8S,@       0Q"
M   %WO__\R4   >3  #]D/__^Z'___VB   #W   P&Y865H@        ;Z
M #CU   #D%A96B         DGP  #X0  +;$6%E:(        &*7  "WAP
M&-EP87)A       #     F9F  #RIP  #5D  !/0   *6V-H<FT       ,
M    H]<  %1\  !,S0  F9H  "9G   /7&UL=6,          0    QE;E53
M    "    !P 1P!) $T 4&UL=6,          0    QE;E53    "    !P
M<P!2 $< 0O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_" !$( JH$7@,!$0 "$0$#$0'_Q  >  $  00# 0$
M        "08'" H!! 4# O_$ !H! 0 " P$                %!@$"! /_
MV@ , P$  A #$    9_
M
M                                                "W.V.BQ^BZ6N
MP'R(^.CSD'Y_3&CUT_1DSY;\@%(9Q3>5OMM<E//>G,XQ@]=<PO'<  ?,I?.*
MLQD#\F/WIKD'Y[ 8K^NF5'EOA3[>>8GCOZ3(%LMM;8[8R;\]P .B=TMYMBP'
MIID#Y[W"US9/?6]FFV#7MYYR^/H !^2RF^M78SZ6%6XR  +)[ZWATVL_OK87
MTUSE\/3@P;]_/.7P]  /(SB@<XNKKL          *0SBK\9
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M:;:W4UVH;.*ZQFV>VM:8SXIP>D=["W6^+BZ9\C+KGHG0*PQD
M
M                            6;WUK[7/[/-*SQFRF^M<:YJG&:6SCKY5
M[KFB=L6SVQ6VN;>;8NEKFELXKK7/HX>+E6N,TSG'>P\[+UL9I_./R>D=W#R<
MNN5EC.-GIKW#TL/N4-MBI\9J##N8>'E<77-)[8NSIL
M                             !COZ:T3G7\9SWL*CP\7+R\K<[8KW7--
M9QF1X[X^^FMB/3$B'-Z8W^NMQ=5B=\>QAX65,[8RW\=[&;ZT?G%T=<^?E2F<
M>@SZ6'U*7RHK;&5'CMCQZZ_MFOM62GEOC=ZZ>4>F?0MUG%1XS7&,Y$>>P
M                                            %D=];CZY%N=L7:TS
MY.5O]L51C--YQYY?33:QV^MP-<UEC-+9QZ1X!Z0+7;XO7Y[6[VQWRI<.H#@I
MW+OX>H6YVQ=?3-L]\"H\9IG./+*QQFJ<.H=@Z)1&V+RZ;
M
M
M                                                     4-Z:=;.
M/KY>E>EG"HREBEBLBB2YA1I?PMT5X=D^)C0>6>Z7-+C@Z.VOZ**UV]0]H_92
M9WBJBFC@J0^90Q7A]R@2SY6YZ)ZA<(
M                 $"MG@[8^WG-C4K!D.89'DE^RK#%LRU,-"]QD$8Y%NSM
MGKEQRX!: [1D&"Q,GQ=_3/DQ_9X!;XJ\IP\TKPJ8L85*7\+&GR*W.\?$H(N2
M=DOL                                               ##F0Y/ VU
MRDC>VC"X!312)6A[!:DNB467T+#%S3JE;%#%7E.%MB^P*/\ ?R^V%2>/K:L_
M1Z!4!09W3Y'T/D5R6:+H%<@H(^!X)U2]@
M
M
M
M                                    !9 [1X!D$?H
M                                                 Q[/D7C*F
M!;4MT6V,TSZ@        %D#RRX9<
M                    LZ>."_0   +-E=&-QE:=X         H\LV=0R?
M                                                 +4%RBBBX0
M            !;,N&6R+K
M                 'S8@4L\)ULX$M4%*9'<G2
M                                       ,")/AB!GXD7%\O38PJ5@
M  ^+&J[=JST]L"?&K3F8?!V        "P/5SP#VB#Y!LD5"PU;IN
M                                         !'?*Q\+=CAQ<OQ]=FFF
MV,  #XL:KMVK/3VP)\:M.9A\'8        ,=.OGUU;;7^3@V@Z59:RTW
M                                              COE8^%NQPXN7X^
MNS33;&  !\6-5V[5GI[8$^-6G,P^#L        &.G7SZZMMK_)P;0=*LM9:;
M@       #@QX/4/<+L                                       $=\
MK'PMV.'%R_'UV::;8P  /BQJNW:L]/; GQJTYF'P=@        QTZ^?75MM?
MY.#:#I5EK+3<        4"8W%[2C#)4
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M0=*LM9:;@       "-.7C8=[#$B[_-Z[*M0L8
M         %O=L6!]-;MZ9O+IL   !'?*Q\+=CAQ<OQ]=FFFV,  #XL:KMVK/
M3VP)\:M.9A\'8        ,=.OGUU;;7^3@V@Z59:RTW        $:<O&P[V&
M)%W^;UV5:A8P        ,%9/AQ^ZO 7VYO?/6+[@
M!\3&OUUOYYY][&0   ([Y6/A;L<.+E^/KLTTVQ@  ?%C5=NU9Z>V!/C5IS,/
M@[        !CIU\^NK;:_P G!M!TJRUEIN        (TY>-AWL,2+O\ -Z[*
MM0L8        $(-DA<"93A&<,9VSIUJ;                     &%WMYXA
M>VE;ZYE7Y?8   ".^5CX6['#BY?CZ[---L8  'Q8U7;M6>GM@3XU:<S#X.P
M       8Z=?/KJVVO\G!M!TJRUEIN        (TY>-AWL,2+O\WKLJU"Q@
M      0@V2%P)E.$9PQG;.G6IL   ?,_1U#N@   H8I<LT72+Z
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M       !&G+QL.]AB1=_F]=E6H6,        "$&R0N!,IPC.&,[9TZU-@
M     8*27%1_IH,E>/HR&Y>@         "VVVL0?9Y9J^&^>'AZ    1WRL?
M"W8X<7+\?79IIMC   ^+&J[=JST]L"?&K3F8?!V        #'3KY]=6VU_DX
M-H.E66LM-P       !&G+QL.]AB1=_F]=E6H6,        "$&R0N!,IPC.&,
M[9TZU-@  6N]O*.*7C^3]$J\'*>IC(  &M_;J]8OJ\!+9 RLI$+)@
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M;YN>'H   !'?*Q\+=CAQ<OQ]=FFFV,  #XL:KMVK/3VP)\:M.9A\'8
M  ,=.OGUU;;7^3@V@Z59:RTW        $:<O&P[V&)%W^;UV5:A8P
M (0;)"X$RG",X8SMG3K4V  !C-V<VO';(#D_>&T72[-4VFP  &M_;J]8OJ\!
M+9 RLI$+)@  #@'!^@    8A^VD<G3YY^<V^;?CZ    1WRL?"W8X<7+\?79
MIIMC   ^+&J[=JST]L"?&K3F8?!V        #'3KY]=6VU_DX-H.E66LM-P
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M[PVBZ79JFTV   UO[=7K%]7@);(&5E(A9,  "-"8CH>K!$"\_-[;)M0L0
M PU]M, ^CSOMY[2H<OJ   !'?*Q\+=CAQ<OQ]=FFFV,  #XL:KMVK/3VP)\:
MM.9A\'8        ,=.OGUU;;7^3@V@Z59:RTW        $:<O&P[V&)%W^;U
MV5:A8P        (0;)"X$RG",X8SMG3K4V  !C-V<VO';(#D_>&T72[-4VFP
M  &M_;J]8OJ\!+9 RLI$+)@  1H3$=#U8(@7GYO;9-J%B    %N=L8+^_G?G
MSVRU\MP   ([Y6/A;L<.+E^/KLTTVQ@  ?%C5=NU9Z>V!/C5IS,/@[
M  !CIU\^NK;:_P G!M!TJRUEIN        (TY>-AWL,2+O\ -Z[*M0L8
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M0+S\WMLFU"Q    #'CTUC'Z?+.+PWS=\?0   ".^5CX6['#BY?CZ[---L8
M'Q8U7;M6>GM@3XU:<S#X.P        8Z=?/KJVVO\G!M!TJRUEIN
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M>,@'/Z2+<_J   !'?*Q\+=CAQ<OQ]=FFFV,  #XL:KMVK/3VP)\:M.9A\'8
M       ,=.OGUU;;7^3@V@Z59:RTW        $:<O&P[V&)%W^;UV5:A8P
M      (0;)"X$RG",X8SMG3K4V  !C-V<VO';(#D_>&T72[-4VFP  &M_;J]
M8OJ\!+9 RLI$+)@  1H3$=#U8(@7GYO;9-J%B    $9G3Y>3E*3R^H    CO
ME8^%NQPXN7X^NS33;&  !\6-5V[5GI[8$^-6G,P^#L        &.G7SZZMMK
M_)P;0=*LM9:;@       "-.7C8=[#$B[_-Z[*M0L8        $(-DA<"93A&
M<,9VSIUJ;   QF[.;7CMD!R?O#:+I=FJ;38  #6_MU>L7U> EL@964B%DP
M(T)B.AZL$0+S\WMLFU"Q    "&[M\/()8.3VN1KD   ".^5CX6['#BY?CZ[-
M--L8  'Q8U7;M6>GM@3XU:<S#X.P        8Z=?/KJVVO\ )P;0=*LM9:;@
M       "-.7C8=[#$B[_ #>NRK4+&        !"#9(7 F4X1G#&=LZ=:FP
M,9NSFUX[9 <G[PVBZ79JFTV   UO[=7K%]7@);(&5E(A9,  "-"8CH>K!$"\
M_-[;)M0L0    P(Z/.F<L@?/.3GEN   !'?*Q\+=CAQ<OQ]=FFFV,  #XL:K
MMVK/3VP)\:M.9A\'8        ,=.OGUU;;7^3@V@Z59:RTW        $:<O&
MP[V&)%W^;UV5:A8P        (0;)"X$RG",X8SMG3K4V  !C-V<VO';(#D_>
M&T72[-4VFP  &M_;J]8OJ\!+9 RLI$+)@  1H3$=#U8(@7GYO;9-J%B
M     $=\K'PMV.'%R_'UV::;8P  /BQJNW:L]/; GQJTYF'P=@        QT
MZ^?75MM?Y.#:#I5EK+3<        1IR\;#O88D7?YO795J%C         A!L
MD+@3*<(SAC.V=.M38  &,W9S:\=L@.3]X;1=+LU3:;   :W]NKUB^KP$MD#*
MRD0LF  !&A,1T/5@B!>?F]MDVH6(          1WRL?"W8X<7+\?79IIMC
M ^+&J[=JST]L"?&K3F8?!V        #'3KY]=6VU_DX-H.E66LM-P
M!&G+QL.]AB1=_F]=E6H6,        "$&R0N!,IPC.&,[9TZU-@  8S=G-KQV
MR Y/WAM%TNS5-IL  !K?VZO6+ZO 2V0,K*1"R8  $:$Q'0]6"(%Y^;VV3:A8
M@         !'?*Q\+=CAQ<OQ]=FFFV,  #XL:KMVK/3VP)\:M.9A\'8
M   ,=.OGUU;;7^3@V@Z59:RTW        $:<O&P[V&)%W^;UV5:A8P
M  (0;)"X$RG",X8SMG3K4V  !C-V<VO';(#D_>&T72[-4VFP  &M_;J]8OJ\
M!+9 RLI$+)@  1H3$=#U8(@7GYO;9-J%B          $=\K'PMV.'%R_'UV"
MZ;8^R>J7  !\6-5V[5GI[8$^-6G,P^#L        &.G7SZZMMK_)P;0=*LM9
M:;@       "-.7C8=[#$B[_-Z[*M0L8        $(-DA<"93A&<,9VSIUJ;
M  QF[.;7CMD!R?O#:+I=FJ;38  #6_MU>L7U> EL@964B%DP  (T)B.AZL$0
M+S\WMLFU"Q          ".^5CX6['#BY?CZSN4VQWN+ F3H /BQJNW:L]/;
MGQJTYF'P=@        QTZ^?75MM?Y.#:#I5EK+3<        1IR\;#O88D7?
MYO795J%C         A!LD+@3*<(SAC.V=.M38  &,W9S:\=L@.3]X;1=+LU3
M:;   :W]NKUB^KP$MD#*YPPLGR7F  (T)B.AZL$0+S\WMLFU"Q
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MU-TB7>  ,9NSFUX[9 <G[PV?*79L/M-KO&3  !K?VZO6+ZO 2V0,K*1"R8
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MK%]7@)-XSOSMXND51X>MZ([K $:$Q'0]6"(%Y^;VV**A8L-#- J
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MUB^KP$F\9WYV\72*H\/6]$=U@"-"8CH>K!$"]//Z[ ]:G *]Y?;[XR
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ML-@:!E_8QD7>C^JLN?V       C3EXV'>PQ(NQX^DYD+*#@OW%=WK:;
M  0@V2%P)E.$9@<?3+)%]X[>F<A(KOY ,9NSFUX[9 <GTPV#H"7])D7DC>NK
M/'U &M_;J]8OJ\!)O&=^=O%TBJ/#UO1'=8 C0F(Z'JP1 O9X>LW,+)\9#(&)
M[N_KL       ,;3I&#<EQ1.3L4+C^>\QT1)<'!>2-Z_0UV ^;&N/;J_U,X$L
M<5(7Q\?45IR^U?\ +[@      6,Z?""JS0G)]2;J%E/5QD7,XNBI_#U
M  P$E."+.;C!<OSWF)B)(<%Y([K]#38      "(F>B<+I'C&4G+[R81W<.SK
MF]4;V "P'5SP;66%Y/H3@PDIWV1='@Z*B\O4 0-6>#L[T>(D*C^S,KDZ14/E
MZ72X.D 8 RO!%M-1@NYY>DO,3(\ O1&]?;UVKHO*      #&PZ0
M                                                    *Z+S
M
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M(  #'<H4I X,L"@R_P
M                                                       64*Y/
M4/1/H?HY/H?H
M                 &(Y29W#Y% %-%W#,P]D
M                                         I@I\N.>(>L?4\8ITK [
M8     ,2O73PLXHW9GES[^DR
M                    !C"> 4B6++AE0E0%NB[AF(     #$KUTP1Z-+U>:
MXFNV+/MIZN,W<TSU2G\XE3Y?;D
M                    ^!T3T#JE)%8'W/R?@[0     +9[8CSZ/.G,XJC#)
MSRWQV]-;3[XL-Z:W5TS-KQ>_W
M                             !U"FLX^1]CUCS#IY>IAX.5PM<@
M                            #@Y.#D  _)^@   #\GZ /D?4^1]0 ?DY
M.3\GZ                                                  !2.'Q
M9^F78QCR&:>9^;'IG<.\>QG%/8S4C%#LU"?@]C.*6QGW\X\UGIX=X[93Y]BI
MLX[1;K&:]8MPS>'.* 9_6'JYQ2>,U,>>?3+G"L\XHW&?).\7%S@
M                                      #QSR3\XS\#L,&>N>VQZF7G
MX>.?%GVV*=9^AX)7&<<8?3+I@\G&>B5/G'3/(QFN,XIK&1^&*IRHK&:FSCP6
M>IATBL,X\%GM8Q5>5%XS]#TSW<X[H
M                       !P<@        '!R
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MPY6/XY!:J&K(BLL1;I 9!D$<U*D4LG<0@)BDA+ 8$W<(L# BIRFU) ,A/HT
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M/DZQ">39XID_*4I9*2AW!-+2206#S)'%)DHYZ$$Q'900&9:, $ 0 *O;F7=
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M%1OM>>'B*UQ3#WN%QO#MU2'YDO9^-SMPJ89^BXY\^2%DD!J+/C<]G&"B5LB
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M+V?C<[<*F&?HN/$OV*C=:[Y2M41<E$\G$8U:_3[2+A/*TGY.)#2-$9J_CC^
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M1HB+OJL+S4=]?51]O51]@L<4P-6/X">JHQ6W7Z!<F9TAAY^.._ =G;RJ?O\
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MY^)7L5&^UY:0%#!K_!Q%:XHR&LZ2/Y^!X=NJ0_,H, <!5ZD!MZD!M*FRYT/
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MPDD0Z+29&7I!IHHRX>[MPN^23N*E19H=3%#G+<H%LD51Q3)<N="A9<$IRT/
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MD#0QS<W:2635^K.MA9Y226*@I*H=&2(NR+60H)$"P5G1T,ZY_1DJS5%E'/(
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MA>[S?F%A96PL?RM#VC8&V9T.G^6 T; ?JPV"+#:8_1OS*Z0_RR![(L9?*UE
M0%H90T"'4,*1C]&YFS2R=A//2PC#8"R=FEH>V=,- 8Z"#&/)A2(ZZ9D_FM97
M(<XL=!!^A^K#2<[EL'^VB8QA$; R3M$(<PPVJM_41Y%H:8M\VS1-#8>C9H:
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MZ<=06525:<9Y#NZ;5<'*JAY=\CN@BZ,.#RC01;.XKG5]./"90KA<&)GD%?\
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M%<ZOIQX3*%<+@Q,\@K_L5VU$KW=Y9.&113=&&HE6\/;T^3J+RT8:C*-!W>.
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M,XTY_P"S/7"E+*DP(/C0S\A+M*(Q.3[FE/8=_O8TG4"E2*":/'(R).M*P3"
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M8F)I+ D1AM$&!(HW>K D90P44T4=QRCT+%153_AB2<I;I%0A3"B(!:G*6"U
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MT1^+,2"MN;7(SEGFD7;5><Q(JI)^&+S/ACM.;*KQJSC2#+"FYE.72B3C0C3
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MQ!#OR9K!%87PS>)Y1H'O#5=F R>RG<+I\)UM>Y-VIR"MN;7+J/=(\MK]QU/
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MFFMTN =%Y#LB,K,/4PRY:VV9CNK-BHJ+;4YJV6[:;\)GK))MPIU/?3WX@2&
ME[, [G+ ;V_):PD-FB<L.2N^^&\T5-QH)5/8DC6M%@;&1#12,A&ZZ1=;T$*>
M=51,9USGF9Y@,IT)'$IT5B*#;SS[CBK'81ZZDX:-;-M?TSU<V)5?RK&H]-HK
M3KH1(S_%=<I6O"9 Y1ZWC3<A.)LF]7)$L52AUZ&W3\S42_&0:W,R0$E:,Q;5
M55IQIU-+@(1"J6(5MBLY:R]$@5:;QF6S!18K320F8[Y"K[KA. TJ("(.M\Q!
M%\^)N7\X4B+/JJM@$6-LVV70DR;)$,7(BFU+CN*O)1O>?P3Q!K.:J7":I4YU
M-$16(NR5/#XL3D9UQ^'(4/!20NJ_P%WXA9V%A7EJT>,M+@$6DG94D-6S<).9
MMA4+:FB<P]&K"YRC1Z,-(V13FJ7LXNW<@#<U=%DW.,J.A%7>X+I#RA;Q6J_'
M9"#6J-$EC,C?E&6Y;48G67F]6]67;:M!;QWBJXE4[+<"!4)S![614.+QX[<5
MA4L#-Y#K<5'#5%4=:D1= X+(>?HS3=2<)YB.\# QWFIK#:O<7>!M5:=;=9!P
MFW@LG)3G0L4LJ]!B,3V'FQRPVRK6B5"&J$L$W]#YIJ.1R3UJVMN=$3?B8>?Z
M?#I]2&=IAM0U94#@\795'"V+\@=>W5U-Y(MD3D]/ECA2MEQ< (WE?T[(6Q34
M1.:^2@BB752W)CWVV:#[G>2)2MTMC1HC5JKB7*D(TEA-L5%"(E3\F@ F]<>[
M%_R@<13-GOA,XFE2T\=1C07O?[S[3E(FO9(G%>C<O(W8RS[[[;C/$UV7&+[;
MB>U/B>TU<J^PT>%OM;&6,Z1HKDRGTW91Y: *F+#C$OC3>V1$72V\EPUKNU)9
M<3J926ILBMU>GK 6GNQ#!N&;XH#I./+W)Y&TU;)&%,B+3N'&:GJHV<9ZN4ZM
M5)J*ZFEUF*E'..P3HKX!/BUMM*\H1(4)$7&:+*B_SK#YO00X*W0./N4Y9E0?
M_&F=[K>SC:]R(0KOM;GPT_6\Q56KL-$B\5W,HZG2!/*;AB)<Q:+*J?"3GQ3(
M>4A<I5/66W3I3].0FB@P6V%XO':-O>P#ZHJ$ZBH7<[:N6MVY</.>8Z[FJ7%C
MF[2SD2#CLR;@<SCS)@HML1^Z:2-U=H2 0W15M7-_^AS)V18S,::=2U6.BDG/
M9(Y62_[UQDS,$EISWMCQJ<1/"-T4H%6>DOMHO-M$:<%4'IOC/4S+DPY3,&%Q
M>1M8[L4P,]BX*[-\0/0MU%#M92 [71+KF>BP%19DVHU1(J:K(X^RS3GVV5+F
M3:DVC=UW)JW[L3LJ9PCSJ5*B5"3);<2$\ZIDXC8.1WF@':MO ;7)-1V9"J(I
M#IQG)B%1*E"BT^E5$VJB^@K$D,JPX+8D:+W.6>\]@FOD(2ZDMC.EE1?QNF<W
MH\[&8Y]78?*F5 Y\&3*CM*\Y"7WRVS;R@/*)I2;T&(\K>A(BJEL98HN3(TJ:
M$1PFTEG'<:5TY3K*N%LS1'&H\<&KJ;J!O55MBCY4S#7JKE_)D2%3&.,P#>:!
MUKBPB],/96VQJ^*M$I:]B(W0.?%$:RC7:MF"*#K22Y]2?<?CI(60WI9A.N@W
MKL'*=T7&ZHE[IC*EU3^FC[#B"EDT_P CN;HM[UEC/[3?*-PJ<V*)TF=-FB*?
MO5<9GIV;')-/?DO166K17WOQB*X<=QEP6P4FMY:]HYI:T(O+YL!$S1)JU)J[
M=.B/-Y@I;1NQ7F9 [2.R^+8.DX0-JC@."V-A.RN=&*%3/<[S36LS4:3(8;FC
M):E-1R9-5XTV[&>Y&AD.4DG0&E?!7@@Y&R^\T8T=#C[0R58K4S1MI\E_9H:[
M.,.ADB02W\FW.F'*/4LZTBH4H6F[4XD<T$D4>X W:F H$.E!;5#&WGQFOW-)
MSVSFQFJE[W@X7+;&2#D68R*+OLS(7:H/, DN[?C,F7LZQ9E/20^%I:17'E!R
M+K ;M@BN.,/@J&!M(>]=^)=!I%'J1P&V5=CUE0LRHMCW19;:V*,AER6+JIE\
M(!QG5=RDC=1MS72]2WX]S[F158IW[_\ VB#&2[JB;IG/^L9QE7,L%AV5%I,1
M(M0!E%(X[;P-N,R=(W+9ZD(''$3N?(4N=,(],S'[H"5%8Z"_0^,/.*;VE$-H
M']EQ)62*^G:.BNC<HWW8J-*H!U!ZDYMB'+!*JB)(8E$TB-7#9M[-6'V@5=W.
M-T51P'N2(AV+-GY&Z[5)6OBRL*'/LD<UR23FU*I*FZ^*S1(R(+--RTD9+;KD
M&RVAKYU-S42JN]56ZXSZMT_+U+V:GXJ"C;E9AE:E3IM#@IO_ '8K*);^D5;=
M_P"%3$_-KM(D5.B5=Z:^#[0$H&Q4%UOM"]I46I4=SX!VN-O@EB%%IU J%/H<
M.I-2)%0GM[W)_%Y(1HS9!=L45HI)JFI2/3>R(.,G=04_L4Q"#-5<J%"I*UR+
MM)%-CO2'Y+G%9NF&HLHJBVXFHR,A(45L=U[8$J>+DB6G/4*G1ZA/EJOYPJ]&
MV3*_&PTVOG5<4W-]-9EU:EU&?Q&*VPP<5S2TX02W%!\!V:,(!:4-!1PM*(ME
MOBK"U0N-5^I1748,J.U&FL3S;TLR7:DEE78N:3+0Z[M$'3I)%MC-%,K2RX=(
MS*^;$%-[;PL+'V4N7'$TY(O$K: =K$3)>;%-KT.JUEZ337MNTU(=;5DRLJ6-
M$&]M^%K=2(QA4Z5 >D;(=H[HXB"<D.<EWX $D56YF()_-SG.9(*?"\ZXR@:+
MN<]X3&^Y;&X1)N^1<92$M*[Z'N6W_P 071B:JVW5:B[U]-%,95]ZFSDR:2BU
M-8K7*.1':FS@D(V*?E#;;-71;3>6FR;\--YGS#G>B5B*!-OPXCTER(\0J5N)
MBRR:1T5+"K<C9Z2OOMBH9FRD[7?Q\B@3&*TH[0"8=VB&.AL1<VB6/:"9IO4?
M"1<.?JS^RN/= B2FVI,:1#ELR&'$0VW6CJ[HF!CTHJ8?*GK(7*=:/5&-"+8L
MN 6T&GR_@J3"KJBD?A!S+J1<4Z%2VR?EQ@;J3;#>\Y PI3QN- B>$2@JJ@].
MG"1\W9@SI0*O$)P3CP7)2PW4OR>+M,,N+'/H,'M":M^K&=L\>YRN83K#5.E0
M48K.AP]39[9N6VC;>EXE#4\G+/2J6-+XJ=4SYGW,[681>?V=-9FR]K(11[BC
M(Z7=L;KBZ5:'0C7@JB#C-^C5IXI&LCGY1!XT>G:?IV\/]*^,TWTJ0+F#3S*H
M]T91;>;@-IT!<:= FW )+B8&BB8$G2)"JHJ=*8SGERGNK'A5N,<7?=-K29;O
M&6%;_2!%)E%Z!(PZ<4YMYK9SZJB56==+&A2!'8-'^ICZ!MT8K*72_&JQN_\
M#8K359J5:RQF"&^D>74H49UV#.D-@B.'H:;=)'FU[FXXNR%Q4OREWJ-#RM7J
MMF7)A"^DN1.:D PD8(IF,G8R%+BCC<O0R!#I5Y"LHJBI;W0(Z&B*_#S"S?\
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M[:;6;&A1V93FV+4[K? $<+:%O.Y<I>?@.JQ*+2XU3<VBN3V(4=J6:O?E=3X
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M2&FM5([1]&R34JJJ\G>JWQQH,IT-'D74A<09LA>=&U39HO\ J8%ML!;;!$$
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M:;BN6_IQMJK0*3/>7>KTB"P;J_*[HUK^\L*S2*7!IK9>$,*,U'0OG;,14O\
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M6I\.I1D,74CS8[<EG:#X)[-T2'4-ULMKIAN%#C,1HC(;-J,PV+;#;?Y@-"B
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MY$V8ZNJ1/FO+KD2Y!KO)QTU5?, V =R8]V)&-6OCH7T\^Q2GQED<W_R^UO\
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M(UB>M#)-8N)J1<,+58>:I#_%; =#2J<51O:+N<XDZ#>VO^<FK3;HQ4&H$#,
M@X#/&&\QMSS9<024@V(5$W051)+EH3=R57HQ0LG!RH^L:]70'P4IT!Q.)1G+
M=$R:*<A><&>:RXXI3N+QW9&46N*3Y3>V;@Q&9[BS.+Q[HCK[SQ- B7040;GR
M;8I5%K<N+5XE>:G<1FL14A28TJ V#SK3[($31L.-.)H<1=2&EBW6QGE@?R3>
M80<%.C7)@1WGOXN*M_C_ +0O5^?4JE&D/1HL96HVQV2#%$A!4UBI7+5RL4RO
M1:K57I%+D\9::>V&R,MFXW8]((MK.*N['O:[*D0K2HLQN3&T;9I^&\+[)#K1
M1W."B[TZ,-.%GFONB#@&31,T_0Z(&A$V5H]])HF@K;[+NQ6Y[3KIN5R6S,?
M[:6C8C!&06K;]*B"$M^G%&S0:&S5*/M$%QFR#+:-L@1J4GPT:U*K9>$-[7MN
MQ5*[$S76H$JJ*".BT$-P6F&D[C%95YHR!AOG0$YRY177'&9>::M5VMD;?%)C
M<06=1*-G;L- >L-*H.^W*6^*[)0C?]_Y229;3R"K8VCC&5L$MO;(!Y2%?G7!
MT]C,F88V7G#)2H+,D$C(R:ZG(;4E6UEM0S55NR+FX544)!PW1'8^QA1T9XEQ
M4E8>@.1K<7?ANCRF7653DDG/O0KHJXB3ZQ7JOF,Z<6TIK-3-GBT1ZVGC6R8;
M!'Y2#N%YVZCSBB+OX,VY>?:>;9.H2*A$?T+LGH=< G'-DY;0KK$G;@;?.'<U
M7<6(%'CN..L0(PQFW';;0A'I*VZ^_HPU2XSKKS+3LEU#>MK594AR02+ILED)
MQ43XN"GUV0XXX[2XTEB%&6W%VG9>D79=N?;[%%9%?@@96WX=:0R:5QLP1P/"
M;4A4=8WW:AO=/CQ$I412)J*!)M'+;5YUPR=>?=5.=UYTS<-?.N,UYCDM.,A.
MEQZ53 >!0<6GT@";5_26] DRW7R#]$$+F).$WB<<17%NJ):V$> S)40DLMK<
MI+8-MP4('!(#%>8A)-)"OQ*BVQ-CT]R0]QV6<DG)):W&V[EL(C:]$>*)*#(]
M"+@*M!J50H=6%E(SDVG&'XU&%=0L3([HFU($"WMD2(;>^Q6Q/;?JE3JTFI):
M5-J#Z.';9DT QV@$68[8"2V!L=Z[R5<0Z4P9N,PV=B#CEMH2:B*Y6W7Y6(-'
MXS)V$"KC6&W.1M">&6Y+V9;K;/6XH[M^G#-6B3YU$K++7%O?&FF F_%OJXM,
M9<$FI+0ERF]::FUOI),5B%*JE3J4BN,N,SJA->0WM)LDP(QVD06(X- 2Z ;"
MU]Y*N*71S=E-E16XZ4RIQG=A4(;T9I&@D,O"EA,A2SHV5MP542&V&ZE4,Q5J
MM/QVW&HK<MUMF(RCPH+AK&C V#SQ"B)M'=6G?I1+XJ--);).A28M_,KS1 )?
MN547&6%JH2H$_+4]@W6%;V>J=2$<AV7:)RXSPV=%P/#$D5%Y\-09+KK+;4Z%
M/0F;:E<@OB^V*ZO@D0V+IMS<-:K&U=D3JTZPKSCUNX1XS2-QX;%O!8;Y1VYU
M,U5<1)'&9=-J=/(R@U2GFC<N.CJ:7FEU"0/1WD1-HPXB@5D7<N#KU4JM0KM3
M8BN,,2IVC1!BKRW@AQ&!1MLWM/=7$0G7$1!YMV*A5Y;#D9_,%6F51([PJ#S,
M4SV<('17>)\7 %45WI>W_P!=4JGRJR 2X3JL2F@B3WMB\F]6S)B*X&I$Z-6*
MF]"K /A1V&I-21(TT7(K#Y*#+ALG'%U4<(2TZ )5LJVM@=5> $(@!%<@U)L5
M-PD$!U'#0;D2H(I?>JVPBIS*ET^1?[?2!C0<PS1BRGX;CT.BR)#'&(Q[-X =
M!;%H+<ML3GV(=?>][9?$IS3=&D$]%?V'&51UM%N(HUO(O@KN7?B)5J>1G#G-
M;9@G 5LU"ZCR@7>*W145.\UZKFB,L27Y5>JK[Z[5!,6!VYAK\$=FRFEI/A<V
M\L3LSSHXMS\WS"JI@0(A,TW\G28:I;<+,-!/3^>X96NN&)^9J+*#(E!XO(BR
M(34>1&=JIE;WSK3:*CXPZ?=!C@(D(N*3SB+9+ XVJ$!B)@0\Q"27%4^)4WIY
M)-I'%:U-F4_8\<][J6_,:960&T:0G&]UR'?;$R*W!S!QR!&8EOPUHTA)7%Y+
MNQ:<!F^HD4_X)OYL/S:9QC9QIC\!\)3!1GVI4>VU;-H]Z*.I/[45:I,,(Q'8
M63,&.%R*54YSG<VP0ENKDN8X Z4_.6R8<";OJL^-.JU8<7PCJ50;-^0BKS]Q
MN+"7YD:QEWT0_:7^\PZ*R;3=,E5**68-9D+CM)CEMW8C(B*ZUEN@VTYJ($1I
M3W]&'8U#E,4V<+8#"?>C<9C-;-1T@XQ<=32@.S72J$(K<=Z8?R[5H^5:739X
M<6J=6@2ITN2<-53;)"@O-@+3SX7%">>,6M5[%;$>*UN:C,M,-WY]#0( W_<*
M>25BMJ 1ED-C+JLFZ]T""P2"9W6W<V=2):V*GG.IMDU.S9+XU&9.^N)0H]V:
M/&W[QU1TXR2?G/7QG+]NJ_\ :9_M1E\I$D$I5(J/OI*IZLJ?OA*8#\00SVB
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MEPZM$&-O9D)#V+:1D&PO#)<2XEN5-7+WHJXS[G+BYQZ=5YQC&14L)./2CE$
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MKP8_%$D,-'H?:>C75!)M=UTZ?B[P3KG1X(])E\$4^-5Q[XSD)9$DP;$42^P
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M2:A4 )UBGQ@=4E=1@;;=TSTMM@JVN5UW)BAT+-D^G5NFYE)V/!J,*%Q!^+.
M;@PZRBJ+@N+9-?0BWZ.\4>0W%?G4JFUZ%-KT&.)../TYM=ZJR.]T&CL9AOW;
M[8G4NB-MU>IOQ/YLAP*>X,FFOM)M E.%L6T@I"TJ1EK2VG2B+?'N2UE XY4S
MJ<$VFS54XQ);16&D,N>QJ J9>:ZX=S5-JU"J<*#LY%3H3%.5C8Q#,1<2/.U*
MXX3&JVHO#\)-V(51:14;FQ69((O.*/-H>E?DO;\/-;ZL,J^D%BSRM!M4_'HB
M;G+:^;X\>YIE?:$W#S%-I+%1TJH[:)'CLN&PJIT.)?=Y[+T8J5)][8;#,>FO
ME!)EAMLXC\5@CC.M."*&*@8#J6]S34A<^,OU"5JDRX]1IS)*MU*0<&2XT._G
M57$;1+X=S+[ZT!!B0^/OY;&G*6F*TWM'6/?%2UD^VTBJ16TW14'HQ2JXVWL4
MJ,1N0K5[[)Q4LXW?I0'$)$7I3R2K4)XMF-2ANQQ<3G:<5+M.)\QQ!7Y,,Y<K
M>2J_-K=,:2#&?IL?;T^IBUR(SXR4Y+0F*#KU<WQ8S-FRHTMVHYFKDLZU*H\1
M=9M<S<:$"IJ529:74]HU<J]L4*K)DJI3:?4(.WJC40Q.I4J2JIH:.(O*-O3R
MM2)?X-A7%#HM*RI6*9&AUJ!59U;K,7B:0VH+J.JU'0N63C]M"Z+WW;L5&>L2
M0D$LJQF!F*T?%R>1P+M(];0KGG&]\>YH[%B2)+</,KSTIQEHW C-+&!$<?(4
M5&PONU%9+]X]TN6_$D,Q9:T'BLAQHP9D[-J9M-@XJ:7-&I-6E5TW2^,Y\;BO
MQ>,9OJ;[&W:)K;,&7(=;U(FMLO@FFY<5">L60D$LG-,#,V1\6)])L<MBCUM"
MN:45=%[V3O#CNDCV8$>@$N9:4OI%.DEYDQ[X5FCU9UN.7\W0&HIE':_ZYZZ)
MM'O]R+\F*KL:?.8<$$;%E]@@=<WBO<PYR3Y,1A5%0DA,BHJF]"1@45+>>^[!
M@^TXR?'YA:7!4"TJ:6*R]"]"]XDPOY$U.J4E :*)5*7)A.*:J/=1>CR'V"$A
M+<B#T;U5;XHF89&79F6:7ER)*3C$\XO':J[)11%A BO/69&]S1PMUOCMCW0Y
ML^"[%BU:NA)IS[BMJ,MA&4':MZ#(D&^[NB OQ8R]6VX;ITF)E>J0I$Y%;V34
MIZ2AM,DBGM=1CO32VH^<D[PWM#<'9[QT+;?Y_E3 *V[+>7;-HHJ2G85O<K=&
MGSX?9;)Y\B4237RS\(=R?$EL-IT[(=W^K@!,5 M;NXDLOAK^'NY\28==R)F)
MMQIYT8TBEL^^,26RAJC+@.-^"IC95U=*^"F,\YWFT=ZA,5ZE% IM(>1..O"T
MQ_2Y#0>";BMB@HJ:S(RW);?0HTR.]%D-M/;1B0V33H*K[B\H#1"3=OWICW3'
MI,5]AJ97X+L1UUHVPDMC",2<8(D1' 0MRD-TOWBFUV)&6:Y3E(7X@VVCC!;]
M;5]RN-+O1/-AJEPJ7/:5Q]EQ^5-8V#<4&RU$HJOA'T#IQ1'!;=-EFGR6S?TJ
MH"5]VL^9"+$866C=)*K3C46Q4E0!>N163X(ISKT83Y.\4&D.1)(Y:RRVM;FR
M'&C&)-J:Z4B,":IH>5G<2(E]%G5Z<9CC167)#[M.<!IAD%<=<+4/) !NI+\2
M8H#+S9M.M4:GMN-."HFV8Q6T("%=XD*[E1>9<5-J=$D0W3S'5G1;DM&R9-&8
M:'$$T15 O@ES+WC-50J.7JI6Z5F66U.BUFD1N/28J""BL&0RB[41;O8+6'2@
MKOZ,L5N#0*E0:1EEQZ1)JE6C\2EU'::;06H_Y4@*UBU\E!(ROT8S!.**^,)W
M+%.9;EJT:1W'1?N38.VT$8IO446Z8]S1Z-$D/LP\Q*[+=9:-QN,UH'NCY"BH
MV'Z163O$FHA3)M85G1^(4]M')+HF2"2H)<X@BJ1\ZZ4YEQ)H&3,DU2ERZLVL
M.=6ZI3FZ9'IL5_D27E+2AON:%5 1-6]?!\WN8T:EQ9$MBB5ZG@\3#)N(VTT"
M;20[I1=FVIZBU%N2^,U18C#LF2]2W 988 G7G3VC?);;%%(B^)$Q067FS:=;
MI4,'&W!43 Q9%"$A7>)(NY47\/-$6''>E27H3(M1X[9.O.$DZ*2H#8(I$NE%
M7<G,BKC*\FD!IS#ECWKJL&,]W+;N166E?A$J^ ;B!I1"LBK<%MJNC^7J-DBO
MQ,PU*.=/D.3V-C3J=MPV,F2LI>28-@1D"IS;BY5M]"RY3V'Z@_3ZE1]OQ9HW
M3<,7]I)?TBBEHUJJJ2]&]<5UEILW'G*!4FFV@%2<-PJ>\(@(IO4R)4%!3>J[
ML9<C2V'8LAJ%I=8?;)IULMJXMC D0A7Y4_[0I-&"D9AJTR%%CS)GO/3@F-16
M)6O8JZ1262U'LS70V!E9,,U:F2A>A/*X&IP3CN-/,DH/QY##XMO1Y#!B0.LN
M@)BJ<VE459,?BSX,L-,.A/)6>*2=LBJH,*+JN:FK<O6V [TT*6#+;LV:_*+M
M LW\];\G_6MC:JZVC5K[13%&[>?7?3;]^$/:!H+P2U)I+Y"O9?W8U 8FGG$D
M)/XIBZ*BHO2F]/\ L%S0_E]*/'C/4;+P')KL&J/,NNM\=Y,-R%(BM'LD+NX*
M1D)*&\$7&5*3,>F5LZE[H3-<S+*88<C-2GI82')2N,P^3%IJ*#+.@BT:!':F
MIF2K[HT6'%G#&<RS08D!(K4FRZ$-LVH*MBNIQL-Q(Q<PW:L9*::I+XTTZ+4O
M?AD.-<1F2(T:*L$JOOV;TAMTG29XPNLG%+PK6Q7*:[0UDT./[H=0;A'5*;6J
MG3Z+2SA,2&7F:=3+5"= .43K$7BVTC1S,E/D\T:F384]*3_ROMN,LQH%7I<;
MW@*!)?NPQ+(IL:C.2+;GG$;36K:Z->C!4K+(&U']T:.Q1V1;NK%"J<%O92ZH
M WNPP5#UIW/_ -X-L.ESKB'3XVK80H[49K6NHU%D$!",OA&5M1E\(E5?^P1V
MIU>4,."RH"X\H.NV)PD!L1;8;=>,C-4$1;;(E7HP]&I4F0^]':1YT7J758*"
MVIZ$5#J$**V:ZMV@"(TYU&V_@D5&<YLHD4-H\Y92TCJ0;V3>N\DP#@[Q,1,5
M\XDET_W+P0X9H_M9VVV*MQWG&4V (9[=\ 5J/=%Y&V(-HO)"ZX=KB,N'47$<
M1'7GWG08VUMMQ5DS5N/MM*(YLA'4B6PYL7FG=BX3+NR<%S9/!X;3FE5T.!=-
M0%8AZ4[[.I4ZJ/MS:=*>ARFTAO$@/QS5MP4)-Q6)%2Z<^/ZWD>HOXRO4<N44
MZ[3<R;8VICNV8%18DK%..R(BJ\;4Q-1$K[D1="WQ%DDT;!2([+RL.?E&E= 3
M5L_T@OI7XT_MHX\LR/3ME5J*?'Y>CBL/346?QA_:$#>R;YRUD(VYUQFY(_N@
MY;S34(U J4R,% =IHR8"-0W_ ,8,(,V2XH[71I<5!023GOCW+ZRS6ZU+FUV1
M1Z=6^/U!Z4Q4VJI2%=<)R,XJLM.,/ )QS9 "'I4KKBO/9CS+4(GNAK/E,R:
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MP;JMD3G5=R)P[U1.C?N_M/&88/9.SI;,,7O^A1S41N)^EH D#]-4P#C1RPD
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M=VQ@=W25G0*CI:W:1.ZKJ--]RW(OF_[!+_VF_\0 +! !  (" 0($!@,  P$
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M,D2(%,(<:5;6HS+>/).-AM[(2GBT ,G"Q&;%9<4.>A6C,$7%15U+B$YRD'Z
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MUV# 'E?$U.L5844B:TK(1O'CV4A6V?F F).9!H.,2/!S]!RU:BS0*RMIINO
M+W1S@KX"8B4(+'.<)I!H5J-W?IOK'UT5_'A"C 1**F"_=SWEXJ5<UA]F=O48
M@F"Q%Q$I'P"1DP"52I@""A:(/L"Z(V>#-B9 U)4H%/(K%!+T0B6)G4[*&7O\
MGXB#4K+EBUT)@P3H*( 3.#5RUP0:>Y-IQT'][4H!JH0, 7E)(P@C9!'B>28>
M^N6C0)4-D,"[L @V(_Y(Y$9%N<[^4?((TF 5VA)7>+.KD9* (19,SM7^<U:P
M9/%RU]RD""680C(0L2GYA"40[4.%C"UF<RD4RS&"(.^K[[@ %$Q@,0FG@;3
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MHS"]39V8Y;"SL>9!+9" >'[3>(#2!UF/G $'^K*(2$[9O)2DJWRSQ3;9 :!
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M^M)!ZM?<02XZ)M4Z[P!1""LU;)S5/&/$BN7/;S,.BIW-F<]JGO #=K7 3/\
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M/\#\?(2SIGPUI)M,I(2^FY<81U8H%P)A"&^<(HP@B8KP+(N%Q% HI^0<4!
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MV@ , P$  @ #    $
M
M                                               /P!)"0 $N"
M(@!  */P!V  %)0$.   AP  %D1*  #P          &             !O0)
M@-!P0:#2!W#1A_#E)C$+24U:5<,'?@UBZZ:@!.\82"<YO +W87\_(0
M       EFOD+_P 2_P!='0L!_"W3UW$M1?"CTH'_ +!@C?T*)A4N]V+*A<]L
MYNU@U9%0            !Z!GF.,R;**=EB^XAQD6WG$E7B#CX)FKGQC^UT Q
MX7IW56^1WG,&<SZZK@
M                                                          +:
M@-L #M#_ (#S+7_1#4RO<@
M         #<<@P:F(4F"?_<R0>B8JG=
M                   "QY@@Z? GTQ(&6S5,V'2FJ@
M
M
M                                                 #4"2"  0"2"
M 6@" "2"0""                                                #
MP"20"2"220 +R0 0"22 2
M          " 2  0 000 ;P  "200"
M
M
M
M                                    0
M                                              0          "0
M                                                  "0    00
M       "
M""               "0
M               ![9@
M                    ;8@  #\!@        /9$
M                              <"   #\!@        8"8
M                                        <"   #\!@        8"8
M        "                                         <"   #\!@
M       8"8         "                                 ";<
M<"   #\!@        8"8        "2
M   "<3    <"   #\!@        8"8        "2          "2
M              0P    <"   #\!@        8"8        "?L
M2"                      ?$    <"   #\!@        8"8        #@
M,         2"                     #1V    <"   #\!@        8"8
M        #@,                                 "0    <"   #\!@
M       8"8        #@,         5(                      *$
M<"   #\!@        8"8        #@,         4!
M    ,\    <"   #\!@        8"8        #@,         4!    "0
M ""0          (L    <"   #\!@        8"8        #@,
M4!   ""     00          "@@   <"   #\!@        8"8        #@
M,         4!   "0     2           4?    <"   #\!@        8"8
M        #@,         4!         !;<          .<    <"   #\!@
M       8"8        #@,         4!   #Y)   !@4          .(
M<"   #\!@        8"8        #@,         4!    P>   !@4
M    *(    <"   #\!@        8"8        #@,         4!    P>
M !@4   "      <8    <"   #\!@        8"8        #@,
M4!    P>   !@4   0      6$    <"   #\!@        8"8        #@
M,         4!    P>   !@4   "       <    <"   #\!@        8"8
M        #@,         4!    P>   !@4   >U     #,    <"   #\!@
M       8"8        #@,         4!    P>   !@4   8"      8
M<"   #\!@        8"8        #@,         4!    P>   !@4   8"
M    "H    <"   #\!@        8"8        #@,         4!    P>
M !@4   8"     *,    <"   #\!@        8"8        #@,
M4!    P>   !@4   8"     >$    <"   #\!@        8"8        #@
M,         4!    P>   !@4   8"     2<    <"   #\!@        8"8
M        #@,         4!    P>   !@4   8"     *D    <"   #\!@
M       8"8        #@,         4!    P>   !@4   8"     -\
M<"   #\!@        8"8        #@,         4!    P>   !@4   8"
M    8     <"   #\!@        8"8        #@,         4!    P>
M !@4   8"     &@    <"   #\!@        8"8        #@,
M4!    P>   !@4   8"     44    <"   #\!@        8"8        #@
M,         4!    P>   !@4   8"           <"   #\!@        8"8
M        #@,         4!    P>   !@4   8"           <"   #\!@
M       8"8        #@,         4!    P>   !@4   8"
M<"   #\!@        8"8        #@,         4!    P>   !@4   8"
M          <"20 #\!@        8"8        #@,         4!    P>
M !@4   8"           <"2  #\!@        8"8        #@,
M4!    P>   !@6   8"           <""  #\!@        8"8        #@
M,         4!    P>   !@4   8"           <"   #\!@        8"8
M0       #@,         4!20  P>"  !@4   8"           <#^!@#\!R
M       8"80       #@.0        4!"   P<   !@4   8"
M<#L0 #\!@        8":        #@,         4 I8  P>2  !@6T  8""
M          <#L0 #\!P        8"=)       #@,0        4"6Z  P>)8
M !@0#  8" 0         <#L0 #\#;        8!@!@      #@9;
M4" .  P>@8 !@0#  8"           <#L0 #\"@<       8!@!@      #@
M*"8       4" .  P>@8 !@0#  8#P!         <#L0 #\"@<       8!@
M!@      #@*"8       4" .  P>@8 !@0#  8!(!         <#L0 #\"@<
M       8!@!@      #@*"8       4" .  P>@8 !@0#  8!(!        2
M9*Q;23I)):2222222)(Y)R2222220)'+&2222222-+I820Y-I>23I-(22%(A
M(P        "2    20         "2          20         22    20
M "2    "2
M                              20"    0    0"    00    "
M      0   ""0   "2    "0    0           0"     "    "00   2"
M   ""    "0    2 0  ""    "00   220                020    0
M  2 0   "     20    20   2"     "    0     "0  "0 0
M
M                           2220
M                                     "0"0
M                                                  "      ;Q@
M                                                         "2"
M       .=&?.
M       0"20      !)_7(
M                           ;YEB@
M      ""          "  0
M              =#Z'['=Y%&9)HB]"(_:*=X
M                        4K-+G/<)WDU>E39U$9D>;(
M
M                                          #_Q  N$0$  0($!00#
M 0$! 0$! 0 !$0 A,4%1\!!A<:&Q,$"!D2#!T?'A8'!0@*#_V@ ( 0,! 3\0
M_P#XK-%1+!K/2A97PV?DQ/FD@VXD.7Z_%*!71)]6^;>."BE)B0V[1]4(@$L1
M-IG+K^*""@N!3$$H8:T\B0SARU\GQ\M+ L+ L&+RI[EC.;/+ N1?T"1",8Q^
M(X&XQ")YC_N4_@9 CB7#&+<'0+F..L 1-UY:8S0R#J?A- 6# _?*F"I$,;?R
MDUX&R03'S7/?M1LDDQI?AF[R0^<.# R&+SC/*,OOXQ_)-%<Q,&V/7J6HW )C
M":  N))^;X*)PLIC&)IG0S<I,2[@ N<9>,:$W\2DLS!G$88/S\\6=A$WF>D\
MW3\E K@$N=&*E!BXGGVZ""@N$L>]L8*&\7Z6TE_5YH(49 8C2LDZ_P!BI"1?
M!20K &CRX0L)6&G7_G\:;R#"8T,IB^>*3K&4#,9)96O5^X$71(6^8AG[B_"$
M4(OBQ^E&&$A$8O?2_?JXT:$Z?N.[0L"%T(M+:<]ZX%CQB_)P=.OU5A"1E8<+
M0:=<5Y%-0 (ADWMGK_V: - 2A9( 1@7.<YM3)'99BQ 3SHN '-'EZ5 8D3,0
M3I_DYSE1"A9(@C&:%9"BA;(8EE_E! V;#9<<;,9]>T*8 1)EB!OSSMKWJ,)&
M8ZXVLU$!=S)DB:8"" X$P8NJ+>QARNCB2$@<(C'$_5];TPL1O<TGKUO'Z*.!
M)M=POGR#6_2E$2"X&!O3YRX2Z8MC]]II<OB5OE-OESH",B3IE.=3@2$W8Y7O
M'P7QY4M8'(6PSBT.I^J+"%*7P"6[AY^Z AD+%R6!Q"-XD5AA?4G>%1KB$&DQ
M,O(_=02V1*)"!+,8$_>$TP=,),8W+D9S\81<%S"%3.3+K--%,X!HXOBF6,DQ
M!!8,J&8EL>J(B<SE.,VI$9)-SE CWN58X7"8F_+*-6_PXC$'+%;1AB>?G&D4
MQ07YJ%)(1DML_<4VHF<(7"2[RTF,\J<;G3"9F?\ *5D")8^;!_)QH%&.J<7!
M7FM2823I)6_WP(40H3%XY.6>M%@!-(T8+FN>N%6,$L(MTQG]320U%C-<(^_]
MH!$!=!BYCG]2IYJ-<@8G[-XSP(*2Z5,KY\LM*($Q!#3'<Q]6HW, ^[MJ#Q!*
M07&\6PME%I^:>0%RVNEL2]L\/N7 (R8)ZDX\F]*$$03SF?K2*9Y#> "_VSX_
M[*&RZQ&&6%3C$MUL8,:-N;SF=,9_WI5PEL'3 Y\^35Q9$F5V9Q^O-(5D8EC+
M'&WQI3L6(Q&+S<OK_J!B$9B]DQ?EIP)#=3XEFP=?U0$PG,YQI)XB\U'A"7M+
MC%N= 3!H@SG&Z_.%" (GR8UV56II/[J3$)G&&.K$MJ#3#A#"'OYI802<N\(Y
M3F.%+T))OB4!(1:]KWRZ.(885<A [ZVRBDP#="$0$SGBY<ZF(U RUU-+7F;.
M=1 "-&,W0;/@QC"FT\F!OUC7S0R<3!S/[0D8PC-Z^+9T&B L#C%_OM<I)A Q
MC./&>= *3*%L(<6_FAX97"P76V$299=:AT 8Q%M(F9YQ-N60A%O@9[UPH883
M@6E)R-L&=*RP%S&YC;37+&*L(%UBQEK&<WTPIL:[A:$=$YDWZ5@ D2-H2;3?
M6SA\4T* 9L&D3SS8QRM;WC&>&-^6?Q78&&)%R3,/@TS*!%F]C-F(G]9WFLP3
M%IQC+MARHD&0QT(O#R;\J:PE4B$?W/F?FEDR**$B,&>>,UL^N%V(OCG;)1-)
M(8F\L/@YV!EI,,&!B=+_ +K$#H6GHLE[$,7\36)]ONNX'R?HJW($=F=_\I"4
MPAM&5,!BORL6^:4&B*X3/+KVJ-%0##%ON<<XT^JP]?@T"TLJ*8EW;X6A,K%I
M;,9IH&?W30(8PF\&-L";'WT!Q(NN$SDQA]UWA3!\N17@>&F#,6#Z63_M)12
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M-&H>80VQ)F^OSTPH @ -  OC;"]&  Z$'UA2+ /4F@R 1T* , .A'BG&!ZE
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M&R":)- %@@T*72I>;DWWN] !!8TX ,@#J$;Q?ND$A!-&@   # ,*5NA^* "
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M6.HA;G0H !,E;\\'?Q0Q I8(RF]LH8\VI%!"K<QP?[E2"&*QT"ZX/>)G&E!
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M58Z3AUQH&!/9.B7* 9B4P56.DO?'G2BN95A2[6"8N;=Z3C&\BD B2-DH  6
M@B@ !@4A)=,HC/ET=**2;*JDX2[GG_\ STZ)@99#@PIC09<0(%Y K[9!1),1
M;T*@%T'_ -IN>C[>+8<BNV\G_M%K! A$"#$?FH6\!86$O!.?MG2R4M#65!+\
MR/\ _!8X/1HB1 &@*&6E;H_5;H_5!L45 +#:Q:V[_P#O40R!6220IE(5N']U
MN']TL&(HL(L(BMD8?0P/1\5L6KCL6I[-D0-$A$T2MP_NMP_NMP_NFJJJRK=;
M+KF\_P#TW;^/LFCT,#T?%;%JX[%J>S[]^&TZ/_3=OX^R:/0P/1\5L6KCL6I[
M/OWX;3H_]-V_C[)H]# ]'Q6Q:N.Q:GL^_?AM.C_S2:6!2R<X+MAY5)GWZ,^_
M;*L-$U_<AYJ(A DFX/1[?Q]DT>A@>CXK8M7'8M3V??OPVG1_YJ2D642(N3_/
MJF,4$JQ-\(.5+#)S&".%K[B@C#T>W\?9-'H8'H^*V+5QV+4]GW[\-IT?^:&;
MKPR%,G(_M*!-8B&!E.G)T2@FRW"KKI\>EV_C[)H]# ]'Q6Q:N.Q:GL^_?AM.
MCV;4[.Z9,X>;6SOW6SOW10D21B2!"3<Y?^$%V9EA>,$!;'I1L077$6CB9THR
MG6Q-3;?TNW\?9-'H8'H^*V+5QV+4]GW[\-IT>S[GXX[UH_\ ![UJ]BA24,.8
MDGQ-')?"4)A%V7S\Q_::@0I*:?=_1[?Q]DT>A@>CXK8M7'8M3V??OPVG1[/N
M?CCO6C_PED!ZE79\F.]0T F>+W]+M_'V31Z&!Z/BMBU<=BU/9]^_#:='L^Y^
M..]:/:&0)33Q(B(=,9^*_P!Q3_<4D4BU-R6B#&?_ ,X>%EY8?>%",PC##&OI
M=OX^R:/0P/1\5L6KCL6I[/OWX;3H]GW/QQWK1[=[@_\ YH2.)N@]%SZUH&*I
M2;3FVC(^<:A$K&0ZS_SZ]+M_'V31Z&!Z/BMBU<=BU/9]^_#:='L^Y^..]:/;
MO<'_ /- #@/..]() Y2HPK,$_>$RT4!E;KK_ ,W/I=OX^R:/0P/1\5L6KCL6
MI[/OWX;3H]GW/QQWK1[=[@__ )HC*5,+FN1\X4,LR2%VR27/$<J 3+K,S&^+
M)CE6IB7Z^CV_C[)H]# ]'Q6Q:N.Q:GL^_?AM.CV?<_''>M'MWN#_ /FA7&-D
M^&8^8H,O"Q95CSI;+.BVE7/,+%R19EUC1J(9Q?JN_/H]OX^R:/0P/1\5L6KC
ML6I[/OWX;3H]GW/QQWK1[=[@^T"A\@V%@6)36*V']UL/[H,.@;;R3:%]L;+
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M2#[Z]:571F908'M..7?*I)#.,GB__P!K_\0 +A$!  $# @,'!0$! 0$!
M 1$ (3%1\$%A<1 P0(&1H;$@4,'1\6#A<("@_]H " $" 0$_$/\ XKF 02W
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M1K0I'*%I 15'!%>C-*J55U57U>R+M.BMYRTE )8LL6%&8XQK>D)<W:3>)&>
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M_-!=9S'E$_NF8M9WK6(CA6O/VZ4DB:]D7^/TZ^URHB-VKC/KN>;_ .U__\0
M*A ! 0 " 0(%! ,! 0$!     1$ (3$0\$%047'!,$!AL2!@D8%P@*'_V@ (
M 0$  3\0_P#BLKJ7WM*8$1EX4A:/724U00:$9P2'T*!8B8:4W4Y6_57 )$@4
M,,8P&DEX&,/EWD1A.(R(M(7 !%:%L!PO\@,G-M8&S#1YHR$%2'C@?X@&Q>4@
M@@1%'^#_ (87K?:?:W*8ZE2#L#>I?+N@T"TRQ>2D/IZ1X+>"FI5RCP&*HQ%[
MSYL@AT+_ #A9+XG2959!"Z,%1B9 #[$"4*4'\ #_ "&)> R@ *H&:<?"P("\
MCX5U6"^A<4C5[5AJYU3Q^B/-AP,=LBL$& &KO@)8 4D!#PX.J :Q8B*HH]64
M-)B'S!YM()1_RU7_ (GU82XYL8!, 0 %$*(B(BB-,>(BPP/%M4Z3@142^@S_
M (94XT0,?M68%&8?T!>-QBZ,^F570>&3"$%L@ (V>GX>?^_Q7_08M1X58%@*
M^&&S>!=T^F$2:,*R97T,\&RI4251[U$5[;2C0*%_D6(6C@@'@>E6QQ:5 W^4
M/3"@TPS1\MI^X)5FX(JRK#^)Y86R>@M T,*H+!XKP'BXNM[ AX^&A71_+54:
MJ2[\6,$" Q.7CT*NQQB!!]NR'G6D(,HD2:9@B";$H^H_>!2U3&:$PO!8@3<V
M?-E11.=MF8_@L-(P0-.8QX#*H .).1$<68P1%NLN]LH*X- W3B[)!='T 6;F
M &"=.N#?*8)<JPPC^A7EKX622R*)%1R/#F+8(?C,, ^#_P#"H1OW#D:/X?V$
MNF(8-E\'IQ-@P:MAH CA5J'OU\\?CE6^-"G-"M,8/ OVIJT7.\-0$*@ L\0U
M*%(05H\/$@$78$+PYL>>2=%Y8,(KPTB"Z.)1X_"_N$"K6&#+1C/'!B>^HJ#(
MMK0=DY 867$P?K[+P5D#^8\:26KX22>)5N8F2AC/6#D%E;D)PYJM&A>I4XZW
M[ZE$.7@)'RD#DZ,CS'6"H!@O.-Z[0I,,(DZ.CMBF+1FX+94"7@D5RI+;FK@P
M=#7 C)K%JM"4F(]FS< _-(GKY)K?%WP(D(;1#V;RZ/I1W,/9)M4W[#LOKI.X
M BE?H5T!A:J1B0W=/:L=6OH'R*YYTA"<&T Y!.2YBG?CLR3!,1"@TI3Z3V44
M@S]!PUH]=L\1WZ)?: 9B)^*G?8HA8B-R8"HZ6#W4% !68,&/M=-N3D])RF/8
M4[*K0F O':XFKN@9:'0S"!LE^.TO5B%QCPC@[&!!F1IHR*@2!N?TCG"Z&"B(
MJU% J7ED+$UE&?E*?EY0/Q4Q"[@4E!9ULIP<>+*1,T%D&N)'CM:F4K6)-Z"U
MW"#P_7+IE<#U&#45Q.#V-/!9HR+I@!'9'&HVA0TPLV,$'0W5X)0212J%:58
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M,@.631H<Y#'OR@UVH'#!1V#SB(%5HD%2)D2##)4R@O$ 13GF8A0 .J@ 65=
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MSJH_Z]#QOQV^"\B[Q!%9=@ !CQ;-03I4R,B2JTPT7A\.QQ%0Q,$\\)K=:,:
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M1FPS3.";7"X7\#5X\.KL0,%2,!"<BX1_LO4/!TE>)@*V$L2:_&\MFL
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M(3ZIO1)UY.@_%XZ8?H5RF2*Y5,*\#$7V%=P2XHJTN1E<]Z/9$@+# #"'</\
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MQK)+Z50A' !,ZM9O $EL\4,3FOQ*KM@-#EP&"]X^FG4!,R18S(=_J%6%"_\
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MQ'"W02MNG"TI_0\DGS"*0H)8*"BH90)\-D$RC_6R'%=#IQY2:H IX# ;HL(
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MQZ'1Z*'7+/$IW/ZV2\-\9P6"*]@@F*^5K@8]E7YJK<<2%</5B[ATX<>$ EF
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M0L\B'1&'1HE2D_AA(LJW*"81*9=1I8*<JD_F6CX4) (LH(QTCO%U[@[*.,]
M0H.5^+81VK2*H,:C;@FNXF&#P?IEIU7J\D;%JV_ST@0[R< 9P. 8&MFRD09
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M/ Q6!A$ &":<Z:-B<TR=@0S4W0PC0-!'":_H:G%WZ?PIQ2^EZ4]3_3*/"/\
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..)]I^.O"_R+/Q9_9O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>business14a.jpg
<TEXT>
begin 644 business14a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1L>17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #$#@  9
M ,,.  !D    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$X.C U.C(X  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   "6     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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MQ;&<R$%0<L222<^Y-,#'_P"$MA:Z6"/3[LEKDVX<F,!MKNC,/FS@,AX."<C
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MP64<:VS2!H8V5LAE &2QX^8UV'BK_D4-:_Z\9O\ T UY1\(?^1PG_P"O)_\
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M "*&M?\ 7C-_Z :\H^$/_(X3_P#7D_\ Z&E$?@82^)'MU>5_&C_5:+_O3?\
MLE>J5Y7\:/\ 5:+_ +TW_LE33^)#G\)TWPR_Y$*P_P!Z7_T8U==7(_#+_D0K
M#_>E_P#1C5UU*6[''8YC4$0^-;4NPP88V*B4+DJSA2P*D\%^,%<DG.X#CIZY
ME[:]D\:BZN-+:6UC7RX;A3& HPI#'Y]Q^8R#!4XX([UTU2,*^??%'_)3;O\
MZ_4_]EKZ"KY]\4?\E-N_^OU/_9:UI;LB>Q]!5A>-/^1+UC_KU?\ E6X"#T(-
M8?C3_D2]8_Z]7_E6:W*>QYI\'?\ D9+[_KT/_H:U[17BOP@D2/Q'>EV"@VN!
MGUWK7M*NKJ&5@RGH1WJZGQ$PV%HHHK,L*^?-)_Y*C#_V%3_Z,-?0=?/>EL%^
M)\+$X U4Y_[^&M:>S(GT/H2BF)*DGW&#<9XI]9%A1110!XC\7O\ D;X/^O)/
M_0WKUWP__P BWI?_ %YQ?^@"O(OB]_R-\'_7DG_H;UZ[X?\ ^1;TO_KSB_\
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MC1<HJG]GO/\ G_\ _((H^SWG_/\ ?^012&>._%[_ )&^#_KR3_T-Z]"\/_\
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M1E0                                  /;6  $     TRUL8VUS
M                                                           -
M9&5S8P   2    ! 8W!R=    6     V=W1P=    9@    48VAA9    :P
M   L<EA96@   =@    48EA96@   >P    49UA96@   @     4<E120P
M A0    @9U120P   A0    @8E120P   A0    @8VAR;0   C0    D9&UN
M9    E@    D9&UD9    GP    D;6QU8P         !    #&5N55,    D
M    ' !' $D 30!0 "  8@!U &D ; !T "T :0!N "  <P!2 $< 0FUL=6,
M         0    QE;E53    &@   !P 4 !U &( ; !I &, ( !$ &\ ;0!A
M &D ;@  6%E:(        /;6  $     TRUS9C,R       !#$(   7>___S
M)0  !Y,  /V0___[H?___:(   /<  # ;EA96B        !OH   ./4   .0
M6%E:(        "2?   /A   ML1865H@        8I<  +>'   8V7!A<F$
M      ,    "9F8  /*G   -60  $]    I;8VAR;0       P    "CUP
M5'P  $S-  "9F@  )F<   ]<;6QU8P         !    #&5N55,    (
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MW],>LP\7ES8]MC-,/LQ1<YK6%)SCW6N;?;*KAW2SN^/6X5+&>IG'MM<WGTV
M       ' Y@          X%'VUXZ[<"GGT*X5 \J=4]H?+./AC/ ',[ATSX%
M"*Z5,        ' Y@          \UOK@/)<65L5W] K!\#MG KQ0B\IXGH\:
M)X>OE\9^A\CTAXXN.>"+A'NP        <#F     ?@/T
M       ' Y@  IA]#O@&.94"_@   .@?,J8                  .!S  !8
M0N*>V ,$9/A^N,YTQO:   / GC"^(   *.>,+DG(             X',  $6
MLU&7+\?3/^+[P-?FU0/;US/W5YT   8,27%C_P!?A+/!2@   \&>6+R@
M         X%J-]?$Y9(>>P UP+=7L@^7WF\K<T!K\VJ![>N9^ZO.@  "&VP1
M&$$GQ;.-,L@   Q#[^2,^8CIR:W->CTV   IAY8]B=L'P/"GL"H@%O#UI5@
M #@62WUM-OC,GQW &N!;J]D'R^\WE;F@-?FU0/;US/W5YT   0VV"(P@D^+9
MQIED   $>LKP0GV.&VB:79?8^>X  'R+#%TCU@.)8T]X>X +*'J"X8  !P,+
M/;S[#.9WCN -<"W5[(/E]YO*W- :_-J@>WKF?NKSH   AML$1A!)\6SC3+(
M  (]97@A/L<-M$TNR^Q\]P  +,='C$7/1,L\%*WTYO<>']/.%JQ0\H$+)Y.\
M?2*;G$&EEA)$HF0S+C^P#R14BM@X'C<X\1MB]FFP UP+=7L@^7WF\K<T!K\V
MJ![>N9^ZO.@  "&VP1&$$GQ;.-,L@   CUE>"$^QPVT32[+['SW   QI[.;7
MAMD!L%U2>RIXNH6M]O+6:N5<G2K,UG+&]PHNVNK%=JS,?7I>2B(D0,=CW)=
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MX>D!9PLH9'GOP6(+/%XB^QP.8                             !P.8
M           !X[.,0_;2^OGM5"K87.UV             X',
M  &$/OYU3&?@>@PRQ\MP            .!S *84DIK/$KS'6*>SVV.P4P^YQ
M.V<#XG69^S'8.HS6V*V?H                 !P.8    .)R   !Q.0
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M/DWQ?".E6(]7Y-TC!-/;$\JNYHD]$1A&-+1/PTU*()_7ZM#\MH1'NY,!#ZG
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M<'GWUVZ#SMF>=IF>=O\ &ESZ^\J?[MD" [Y.KK.UX_\ D*BZPU!]=@_[RVP
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M[W!_1G[N,'['QG@D_$<P9S&2H;^.IBZM+U]54'-A*_37K&Z-IEW:\?E\/_\
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M\]_P_+G]R<7K <AYKIV+MNPO=:P<%L<]C0W1[ZSH6THUC6=)XS,Y;D#F8_?
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MO4<#,C,Z>9UKEFO43K ]6RY:%[I]0[VD(ZS\T:ZSQ"5V$FTD#:A8, CFL92
M/@8G64D42(LCT)F-(GS)?;L(JI'2"=8:"51,]T1+&$(QK/='?W\)4-A),L*)
MZ %H23D!LWN5$3\(L>HO4QU&-X=_I1Y@TYLUXMD'5&K+E]I)<>M@HW=60C3Y
M4#M_7Q:,+U,PH[NVD%E)Q4V1)'VF1.>AM$2DNIMT@9U]7 F,P0E$$)1.L$,Q
MK$Q/SQ,=\3\3S<A^%N9')9RO0#EB\FB=A=>54P2I<7Q&0Q$X_)PW(M-K*\2#
M(>$M.-L8ZWIEQO8E.5HKB>4V9NA>MSV06;E&F2 7LKCV2T!(6Y)MV6([^.9<
M\ 9?'9<0Y7LU<9CY9&/;:5B<:-]$5@$@R*1/JTV"4M%0*T7(,&3\Q]9-:]CZ
MY>Z<-X6T$E5(,=_ASIG;0P%Z)KL?NKE:7IHPR@3ALZ\92K?.ZX:6;OUL>_(;
MCLOQL=%E8R><05H8EK%!8G=)@N((B(9GS,FQ%!],O>RW3J58Q[D$Q<D,RYQ2
MH5FTR$>S(B2D W%WDPH%B9;;=6*DANZR4M@;/48#(!DQZ.X( B5'HQZQ$=?,
M.WC,5<-OO=FL9<KVN73J+H@RI;-F6I96%@%NUDK 5*L*@[16:S/@^A\-OY?0
M5G,/IV>51G(JR!FY%3)5?>P4 J" 1H,Z;K:IJKV 8IUE<FHC\Q=F:B'0VWV8
M#AYE%;'=-A3Z'0^"8U@"Q[MQ;BA:(T'2>,8<%=^&NWPMUV;N@JN97&K+HZ:)
MT,4[&]TEU/2DM\>8W(8RO<N95HX:NNA:Y;[;C+2Z[V%)HSO3_P!F=(+3C>V;
M 0IJA/I,[HG'W4NS4%9YQS*KN/83)QX8BW<RYPV:4KV*7N&M95=[F23>]A+;
M >8ZQ R8314%+_(=O$K ,;+*Q>N*T.U5),]#?'_2CTM.,G>#MBK/;J#%UU27
M9V1*:*[/P<1I8#O:)'.NWIZC([9\R6U<8NWFKP+P-2X=;M48ZM>?!6;A[H-:
M54UBRUU)'O:M2M9WP,\U.PIYJE[T\O8!/+Z<>3%U[;\94N[%DH F,E([5(97
M+>&UA1LAC(*%$<:&2PDXTTT*1B2C3YM)^;R\N6!!RZM1F4-]]6)//#7-U5:4
MI;B@%FZ+.K-MWIE-8E=.)&+):IDO?W%32Y,M*K'3EM!EBV.<R=BI+1&"E36*
M)5H<-)2NL-B*YJD $8Q;KXD%YN.I,N 8=(QM'665@27W=,H;)Q(:1MGT?F\N
M,O$Q@LQMXFI7[S6<]6:3ZKJ\Q:QU3X:8$#F4V!D>@[;WZ',<<O+O,R]%(HYS
ML]6E$XMM:MDLM1L8VBV:^^,?\%O>J@MOP6R$E)0DQXQ9Y:'>^/9]MKM*^D\C
M69K@W!M'1A@(F?HQNDMVG?Y<([&UYBYV;F2O%\%:35.Q@K2J?6LB.JES:,.G
MN*!ZFFGI<2&'P%_%G1Y$SN*S LQK*DV[[Z5==+'AJ$>^M@+*K+XM)ZX?":PX
MBMZ37J%9R]O&OY9K6'%DF'86C+)>I,@EA#$52:AA2RFO:N.D) H="U_]'2L8
M;#3GKT,4(X^+U;';UD6C&=IM_ QTH]+;/>?J'B]S'7Y8Q^"QU:Q%-65SV:%]
M KB\LC&6:C*V,060 ]QMBNZ%RDFB.Z=A:\.Q&5YAJ4\E5;71<0:[>E9EE8,4
M3W17E*4'!CH]C!5$S D<%W<90L=S!1<.&1VK)$<LKC7I^E_G=UE:8;3G;.VT
MF6(GNT/TAUL*P>37<=5!;7(E-FJ^$.UZ-D47$H:RJ[2>E:6!(/\ TG/^^[G)
M'OEC^WV<ZW*C<V6.R"D^8 R\+(=O5ZG1'I=T;>IW_)X]U18W,<)\^CB1QQM4
MTNPQCZ8(.+DP$R4$P>HOHZZ>N?2XRA'D*U.CDO<[J<F_Y91=H3=J9!=Y=S9H
M*F5(Z0ATI*&2.H^C&DP[+9TL58O!BDX>G;H6\_9>54&0UW7]^+MA2DM,%&NI
M77 5S$MIS!:1_P _GI;]=P;NG^5Z6\>KTM?^DZ>[9^OU=^G"9CMA5]EC7J Y
MARS<K9KJ,L]6_9O_ %\-@EOB7FER]&",KB7B+40Q>I*&$[2UF-VO5]?!Q,V1
M*$69" 86\60^(2'5C273T]9@I^6,]_JUXV=0RJB/6$C*2.6%J'0(Y^4L-.K'
M?NU*(]0QP[6;, 1]( >+)W,C>1-"2C:M6@R(",Z%$;YB-1X(I%D;5OC8*)V+
M/KI%4[MT]H^"W,]$=8'=I&OH\(2T!$C7U6SMF.F(20$)#):B32Z1*UB/1(^Z
M=D\,$)+6;VT2;$MVUBVS)1J43,1Z6W6=(_9'#9Z8CM9IMA33.(W'H(>CL/>$
M!,'NVQ,Z3(ZZC*Q4T#B#DBA<QI,64=*!/=(EN3+).!F8[I[X]7".OO,-C.T3
M%:1."$F:E/\ HA8C _(F2+UB):]W6CJ'7@:X2N%R4")2[K&,#.I'$PG7T9F!
MG]'"#8+ $A43 TVB,RAVZ)'6=-#V:QK\K3ABQ#8O?&UAIF>G'4D2_P!4">X-
M&#,%.D3&O?Z,0$*.)*NV#VKF)ZG3?M8LXF=L[P7Z)3K$LC3=\KAO2@9[.V%$
M8K)G6F?3^"VS,1(KE8%N[H=)#,C$:\*$UG"CEVL=.=P_"NVDPY*0$=D+[@*9
MW3H([.^&""XD8:40SHLV"'I=,=-),R/T=Y#$@.L3!>EH+AL;I+K'L^"V@"](
MD8@_4<=_<4Z%\TQK_O*9TC6?7/SSIZM?V?$Z1$1'ZHT]?K_W7__$ "@0 0$
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MWS#6ST7;55(+//K&Y"\Z^[S8YH%*DI*;JK'T)$?GY3YO( G2K[GV[YFSM_\
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MKJ"+AQ0R2QD8R.G2WP4K@$    6^77Z;]V+:U=.[Z=X?_P OTUU>P!
M     !Q$[J'7AX9*        !           $9)((!9  ((        !
M           (!B) (         !     !(                       !
M ) !(   !(                  !   ) !<         !             !
M   &P!>   !H   !(             !"@ ,0!>   !*   !1    ( )( )
M !-  ,0!>   !*    (0   ( (( )   !&@ ,0!>   !*    (0  !"@&4 J
M0! !,0 ,0!>   !*    (0  !0@,& 8@!(!-  ,0!>   !*    (0  !0@,&
M 8@!4!!P ,0!>   !*    (0  !0@,& 8@ (!+0 ,0!>   !*    (0  !0@
M,& 8@ (!*@ ,0!>   !*    (0  !0@,& 8@ (!-P ,0!>   !*    (0  !
M0@,& 8@ (!)P ,0!>   !*    (0  !0@,& 8@ (!)0 ,0!>   !*    (0
M !0@,& 8@ (!/0 ,0!>   !*    (0  !0@,& 8@ (!   ,0!?   !+    (
M0  !0@,. 8@ (!   -8!6(  !+H   !8  !0@,/ 8H )!   -EQ:>  !&2
M (8  !1@,*09@ $Q   -Q!4*  !(B    \  !0P," 8H %A   -Q!4*  !(B
M    Z  !04," 9J ,1   -Q!4*  !(B    Z  !1<," 9J ,1   -Q!4*  !
M(B    Z  !1<," 9J ,1   $3XM=)))C[)))G')))V/(P9.;!VA     !(
M(   !( (  ( )      !(!   !(!( (  ( !  !  ( )(!! (( !!
M                       !              !JKP            !
M          "%P            ! !2!:"2;91:*                  !
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MWU_P?]ZB3:L(*!3:@=8EZA$DE)-R2VO^#_O06178$(BDM:]6B7$/<%U_P?\
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M3 N<Z[+D(PCA0L"G>RNA:4"&CS*&3:R*.[&HHHW*-L# S(E%!NA&II.=3 M
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M%)%)9%Q=YQ>^A004'<%!^3OJLE9;.UYG.J\NTW=N/CVUB2)@8,;%)MA$FFH
M8,%K#.5RJJ]]8]AM*DXEFE,*'"O_ '0ILI\,_K2FZ<3*N+9\7/SG5<Y<[Y<_
M/.L&3V5G\;:K$K'<[,VOQJN,N-L[=\<9SJC4&S6G[VZ]QR1R[.Y\/'2MM:;-
MR3;/MK<*C:5S=[S>]U7#6F!K@X.-9%K7"UJ<+WU6!6&QV+O/G5>79-W9W/A[
MFVJDBDVRXN\XNE*XH)1/>;D]O^NJR5AD+@7=FE4!5#85A\';2J JAL+@^.-*
M2IFU7'QQ^VJYRYRYW>7G62Y.:W^=]5SESOG?YY_?0#1#M1;.+O\ K"4NU+\7
M.LH!1*I!,#8]E,[)-!: =TNAW#$]B'&>\*\ [3!J%*F:9B".BA3A$51X4$'(
M*&]$@9@Q$9BQ0X%9DQ*[(29+**M#NN:42;&*U0(295<3(9F+8?.G,V2"?)CB
M2LHD))H@[F$HJ]B9$NVS'95(%PC[I)8[ +V( UM3,1!-DL!FUQ7<OUJ)& 4-
M-IR;5E"]RZ0B0%PT$2,FTK0V6;:(&_. C29I3;.QW(0!7@I>108;R+\<B:.^
M),,=I1L6!9$VNJ8$-$E*A%&* ,T!'":%51 - ,V%,14:1(XT0D1"GE"^L7A4
MS_B@5 %5@&578#NNCJ2L$Q<LJ!8+/9_$?0 7^C\-=K@V.+O_ (H'E$(I8%A4
M,5"[Z ()I"$F=EQDOXF=441('<9QIP.X_P J_P"H\+Z;(KDB#9=-V@63954)
MDWB'^8?;L F4%1A[ZA0Q.B5J6B/;?\UII%\8#(BFAN9C0B)" 5P**QDQ_B+S
M3<$HVJ!?:WVTR8_L&A*'O)[^GSW'Y\=IKS/#\2$<%0=P8J92+&CNMKPF"2U
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M4(UG#P"PBB3^!<QD09Q5$F(0)!%<=DA!! @0?*][RG/3\>+22A>T^2#Y%*'
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MQ$L1,(F1-S@)@3%V\MQE)8Y!ZP*G]2"O* NJ1M*"UPC8'R#Y07VDPC5 XFM
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B1MYT[O+#&1%$H! 0!35%!>3YS8>,JI@S6A%5]*WG3NS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>business15a.jpg
<TEXT>
begin 644 business15a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1L>17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #$#@  9
M ,,.  !D    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$X.C Y.C0W  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   "6     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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MQ;&<R$%0<L222<^Y-,#'_P"$MA:Z6"/3[LEKDVX<F,!MKNC,/FS@,AX."<C
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MP64<:VS2!H8V5LAE &2QX^8UV'BK_D4-:_Z\9O\ T UY1\(?^1PG_P"O)_\
MT-*(I<K8-NZ/;JJWE_%9&,.DCL^<"-<],?X@?C5JN-\>^+I_"J6!ALX+G[09
M,^;GY=NWIC_>J$KNR*;L=9;7"W4 E174$LN'&"""0?U%35A^$=9DU_PW;:C+
M!'"TA<>7']T;6(X_*MRDU89RVI&9_&=H%DO8U01X&_;"XRY;'S@$_=SE6XXQ
MD@CJ:YB_1D\<6;K!<GS(%4NB*R':S'!)0[< L3\RYX S73T %?/OBC_DIMW_
M -?J?^RU]!5\^^*/^2FW?_7ZG_LM:TMV1/8^@JPO&G_(EZQ_UZO_ "K=K"\:
M?\B7K'_7J_\ *LUN4]CS3X._\C)??]>A_P#0UKVBO%_@[_R,E]_UZ'_T-:]H
MJZGQ$PV"BBBLRPKY\TG_ )*C#_V%3_Z,-?0=?/FD_P#)48?^PJ?_ $8:UI[,
MB?0^@Z***R+"BBB@#Q'XO?\ (WP?]>2?^AO7KOA__D6]+_Z\XO\ T 5Y%\7O
M^1O@_P"O)/\ T-Z]=\/_ /(MZ7_UYQ?^@"M9_"B(_$S1HHHK(L*\^^,/_(I6
MG_7^G_HN2O0:\^^,/_(I6G_7^G_HN2JA\2)EL+\(/^12N/\ K]?_ - 2O0*\
M_P#A!_R*5Q_U^O\ ^@)7H%$_B81V/G_XC?\ )0M0^L7_ *+6OH"OG_XC?\E"
MU#ZQ?^BUKZ JY[(4=V9'BK_D4-:_Z\9O_0#7E'PA_P"1PG_Z\G_]#2O5_%7_
M "*&M?\ 7C-_Z :\H^$/_(X3_P#7D_\ Z&E$?@82^)'MU>5_&C_5:+_O3?\
MLE>J5Y7\:/\ 5:+_ +TW_LE33^)#G\)TWPR_Y$*P_P!Z7_T8U==7(_#+_D0K
M#_>E_P#1C5UU*6[''8YC4$0^-;4NPP88V*B4+DJSA2P*D\%^,%<DG.X#CIZY
ME[:]D\:BZN-+:6UC7RX;A3& HPI#'Y]Q^8R#!4XX([UTU2,*^??%'_)3;O\
MZ_4_]EKZ"KY]\4?\E-N_^OU/_9:UI;LB>Q]!5A>-/^1+UC_KU?\ E6X"#T(-
M8?C3_D2]8_Z]7_E6:W*>QYI\'?\ D9+[_KT/_H:U[17BOP@D2/Q'>EV"@VN!
MGUWK7M*NKJ&5@RGH1WJZGQ$PV%HHHK,L*^?-)_Y*C#_V%3_Z,-?0=?/>EL%^
M)\+$X U4Y_[^&M:>S(GT/H2BF)*DGW&#<9XI]9%A1110!XC\7O\ D;X/^O)/
M_0WKUWP__P BWI?_ %YQ?^@"O(OB]_R-\'_7DG_H;UZ[X?\ ^1;TO_KSB_\
M0!6L_A1$?B9HT445D6%>??&'_D4K3_K_ $_]%R5Z#7GWQA_Y%*T_Z_T_]%R5
M4/B1,MA?A!_R*5Q_U^O_ .@)7H%>?_"#_D4KC_K]?_T!*] HG\3".Q\__$;_
M )*%J'UB_P#1:U] 5\__ !&_Y*%J'UB_]%K7OB3Q2-M216;G@'GC'^(_,5<]
MD*.[,SQ5_P BAK7_ %XS?^@&O*/A#_R.$_\ UY/_ .AI7J_BK_D4-:_Z\9O_
M $ UY1\(?^1PG_Z\G_\ 0THC\#"7Q(]NKROXT?ZK1?\ >F_]DKU2O*_C1_JM
M%_WIO_9*FG\2'/X3IOAE_P B%8?[TO\ Z,:NNKD?AE_R(5A_O2_^C&KKJ4MV
M..P4445(PKY]\4X'Q,N\]/MJ?^RU]!5\^>*_^2E7G_7ZG_LM:TMV1/8]QLH+
M6.[WQS;Y-A4#;CJ02>!WP/R&,54\:?\ (EZQ_P!>K_RJ33_^/T?0U'XT_P"1
M+UC_ *]7_E46LT5?0\K^%8@_MZ[:X5F1;<$!3WW#&>>?Q[X/:O:;+R1;XMU9
M8]Q."<\DY/\ .O$_AA_R&+W_ *]__9A7M&F_\>G_  (U=1:W(AL7****R- K
MYXT_:?B4@?=M_M-L[20<;ST(Z5]#U\[V/_)25_[";?\ H9K6GU(GT/>;$6?G
M.;:)D8HJGTPO XS[U?K)TO\ X^'_ -W^M:U9M692"BBBD,\1^+W_ "-\'_7D
MG_H;UZ7X?.I?V/I6U6$/D1??V8V[5].<8W8[YQDXXKS3XO?\C?!_UY)_Z&]>
MB>'Y'_LS2EWMCR(1C/\ LBM9*\49I^\SJJ***R- KS[XP_\ (I6G_7^G_HN2
MO0:\^^,/_(I6G_7^G_HN2JA\2)EL5_A7>?9?"4X\II";N1@%([+'Q]3D 5Z3
M7F7PNNWM_"\RJJ$&[8_,/]E*]*B8O"CGJR@FG-:A'8\"^(W_ "4+4/K%_P"B
MUKVZU-E]I011R"7D!F).>IY.>>IZ^M>(_$;_ )*%J'UB_P#1:U[+9?\ '^GU
M/\C5R5XHF.[)/%7_ "*&M?\ 7C-_Z :\@^%IG'BJ7[.'+_96^[MX&],YW=OI
MS].M>O\ BK_D4-:_Z\9O_0#7CGPR9E\33E20?LC=#_MI2A\+"7Q(]QL?M7DG
M[5]_=QG'3 ]..N<>V,\UYI\:/]5HO^]-_P"R5Z/IC,UNQ9B3N[GV%><?&C_5
M:+_O3?\ LE3#214OA-;X>P2R^#]-=9_*168G$S#.)BQ&WIR 1GW]*[ZO-_ ?
M_(G67UD_]#:O2.U$U9A%Z!1114%!7SYXK_Y*5>?]?J?^RU[_ #I+(@$4WE-G
MD[0W%<3?_#&PU'6I-5GU.]%Q)()2$"!<C';;[5<)*+U)DKG0Z?\ \?H^AJ/Q
MI_R)>L?]>K_RJS#I4\,OF)?MN'K$M-U+1YM5TVXL+B_<0W$9C<I$H.#Z4KZW
M';0\A^&'_(8O?^O?_P!F%>T:;_QZ?\"-<OH?PYL_#]S)/9ZE=EY$V$2JA&,Y
M[ 5TD-C=01[$OSC.>8EJIR3V)BFC0HJG]GO/^?[_ ,@BC[/>?\__ /Y!%9EE
MROG>Q_Y*2O\ V$V_]#->^?9[S_G^_P#((KD(OA?I\.LC55U.]^T"8SX(3;N)
MSTV]*N$DKW)DFSI=+_X^'_W?ZUK5F0:7<6[EDOVR1CF):G^SWG_/]_Y!%2W=
MC1<HJG]GO/\ G_\ _((H^SWG_/\ ?^012&>._%[_ )&^#_KR3_T-Z]"\/_\
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M1E0                                  /;6  $     TRUL8VUS
M                                                           -
M9&5S8P   2    ! 8W!R=    6     V=W1P=    9@    48VAA9    :P
M   L<EA96@   =@    48EA96@   >P    49UA96@   @     4<E120P
M A0    @9U120P   A0    @8E120P   A0    @8VAR;0   C0    D9&UN
M9    E@    D9&UD9    GP    D;6QU8P         !    #&5N55,    D
M    ' !' $D 30!0 "  8@!U &D ; !T "T :0!N "  <P!2 $< 0FUL=6,
M         0    QE;E53    &@   !P 4 !U &( ; !I &, ( !$ &\ ;0!A
M &D ;@  6%E:(        /;6  $     TRUS9C,R       !#$(   7>___S
M)0  !Y,  /V0___[H?___:(   /<  # ;EA96B        !OH   ./4   .0
M6%E:(        "2?   /A   ML1865H@        8I<  +>'   8V7!A<F$
M      ,    "9F8  /*G   -60  $]    I;8VAR;0       P    "CUP
M5'P  $S-  "9F@  )F<   ]<;6QU8P         !    #&5N55,    (
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MW],>LP\7ES8]MC-,/LQ1<YK6%)SCW6N;?;*KAW2SN^/6X5+&>IG'MM<WGTV
M       ' Y@          X%'VUXZ[<"GGT*X5 \J=4]H?+./AC/ ',[ATSX%
M"*Z5,        ' Y@          \UOK@/)<65L5W] K!\#MG KQ0B\IXGH\:
M)X>OE\9^A\CTAXXN.>"+A'NP        <#F     ?@/T
M       ' Y@  IA]#O@&.94"_@   .@?,J8                  .!S  !8
M0N*>V ,$9/A^N,YTQO:   / GC"^(   *.>,+DG(             X',  $6
MLU&7+\?3/^+[P-?FU0/;US/W5YT   8,27%C_P!?A+/!2@   \&>6+R@
M         X%J-]?$Y9(>>P UP+=7L@^7WF\K<T!K\VJ![>N9^ZO.@  "&VP1
M&$$GQ;.-,L@   Q#[^2,^8CIR:W->CTV   IAY8]B=L'P/"GL"H@%O#UI5@
M #@62WUM-OC,GQW &N!;J]D'R^\WE;F@-?FU0/;US/W5YT   0VV"(P@D^+9
MQIED   $>LKP0GV.&VB:79?8^>X  'R+#%TCU@.)8T]X>X +*'J"X8  !P,+
M/;S[#.9WCN -<"W5[(/E]YO*W- :_-J@>WKF?NKSH   AML$1A!)\6SC3+(
M  (]97@A/L<-M$TNR^Q\]P  +,='C$7/1,L\%*WTYO<>']/.%JQ0\H$+)Y.\
M?2*;G$&EEA)$HF0S+C^P#R14BM@X'C<X\1MB]FFP UP+=7L@^7WF\K<T!K\V
MJ![>N9^ZO.@  "&VP1&$$GQ;.-,L@   CUE>"$^QPVT32[+['SW   QI[.;7
MAMD!L%U2>RIXNH6M]O+6:N5<G2K,UG+&]PHNVNK%=JS,?7I>2B(D0,=CW)=
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MX>D!9PLH9'GOP6(+/%XB^QP.8                             !P.8
M           !X[.,0_;2^OGM5"K87.UV             X',
M  &$/OYU3&?@>@PRQ\MP            .!S *84DIK/$KS'6*>SVV.P4P^YQ
M.V<#XG69^S'8.HS6V*V?H                 !P.8    .)R   !Q.0
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M/DWQ?".E6(]7Y-TC!-/;$\JNYHD]$1A&-+1/PTU*()_7ZM#\MH1'NY,!#ZG
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M<'GWUVZ#SMF>=IF>=O\ &ESZ^\J?[MD" [Y.KK.UX_\ D*BZPU!]=@_[RVP
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M[W!_1G[N,'['QG@D_$<P9S&2H;^.IBZM+U]54'-A*_37K&Z-IEW:\?E\/_\
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M\]_P_+G]R<7K <AYKIV+MNPO=:P<%L<]C0W1[ZSH6THUC6=)XS,Y;D#F8_?
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MO4<#,C,Z>9UKEFO43K ]6RY:%[I]0[VD(ZS\T:ZSQ"5V$FTD#:A8, CFL92
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MD8@_4<=_<4Z%\TQK_O*9TC6?7/SSIZM?V?$Z1$1'ZHT]?K_W7__$ "@0 0$
M @$$ @(" P$! 0    $1 "$Q$#!!42#P0'%A@5"AL9'QP?_:  @! 0 !/R'L
M*!, 3N:AJ,LHPUE&=<1+(W" A% X>B B+5*$.!2P%C#;Y$71T()7QK?40YE7
MBRK$B,%>E>^'>6X826D*?%0* %1@!M5= &U>,#G,8]PH0/L9G.T)'?0,<[8:
MP=0X'IQ5(MH7 0 $!040TB;$TG0>WR;S4C"'$K\/*K%$XN6_@SCX.S3BXKX%
M7UG/XP/U)$)(0$O1!B"0#FV84:#*7%Q.#H"@&L; %-G5LN&#J<7%_%%]8R0D
MPDYS+ &@89\F(H _F.1'#XX-I:$BYMN75Z0K<Y9BLMZ'O/99YSP>N!:@1O.G
MRH4D7A9"\W+1!KN@2G,66$X1\_2>B#RVJUGQ.!-=*3GZ[!<E8JE,LQ*O\VB*
M:AJE5)K)H1!<PO3-7<"JM1G'FK0N E5 LL:AE)CR)C8(8CD(>2?"!E*3Y74V
M,@91X8'(C%0-SIO /X4.2)1,S^'DI*V1L%I7UA%F"[&UW[:?G6X'N:H[^CT(
M(59")J?N3YRA'LI@ER)T)>=&1M-=DZK:,#-B:S4&HSL1SR!CC>H=.<VT T+]
M4EW) ]:M"V=8O LC#\3)T&!2>-H 6<0927AD4*T-E:8EHJ!DY)I5S7KMD],.
MII1<##'BM6RR"-_7*X%Y*J8T34%"^"EX B)E$*3">#".UBUH>!;9-K@"HID-
M;XS&>"FDS*M,[DRPRZ5$@.12*M]56=\YI,L%<&V1U4>6\" @X"HYI*!77/&7
M5)#%*9'0+#^)@1A#D4 VC*+Q;0.NP4H$"P"9*_MU&UV>+,G)2-B8X@GO;:\R
MF[5UU[JTL\R;57R3G95M!J7AGD%+&YM;0A4H*)$XC5>S*WI[C^@0D\ S0\KV
M3J$_6E(VEE%'(_V5&4PZ>3Y%C:_%F)D)V FC[W#; >+J]G^?4_?_ !(CU0KC
MBV_109V1R;!S<TU>G(N U-W@MXXWD!3%2RH%P!V"G)>H*U9%8%+)G<41@$)-
M+BQ>K$(BR0)E0=C" _6!H$5&BQ47.1!9N'9P6@;?>))/(.N.SW::3!T$:TA=
M$:0HGDX6A(FM4!&W5--<,N<$0!&<8(!6"3J0N(D1 =& :PU=8]P6"@"0 +B=
M^;4A7?=NNRL_5_C_ !U0Z$H4Q5);*]=C]Q&W3/' J@8T>_D^^<J$B=!.PUGO
M/\TWDJ*7K4"[X#2-B$8VFNG8I'!J)0<BY!D;G0&I@,!7G*H&ZE=Y*UG/3+,_
MDCNIL[WD*I\F'@!0&B+%S_DU)]WA;9'7%?<<UV.$;S;DVS6U"Y\E9P*"$F!&
MTBZ ( 1I %!GA9G(DSN- F:O#-C=:#$7?@T-!NL* *Z*!01B4$ Z;F<G*V&V
M37N\V G&+A%$< ">!C(I2^15<7<;G3$_9-M#[Y(5$*Y+< \&NWB9QAK%U,N$
M#C=S:L/0X(?TN* ! [$( QL010I["58AA/$U51E154B+I!7/:FC8/($#YX.)
M&5*32#7?>)!AP% 07*0;1S&\X8PX<X6)H" P&;^CY<D=4VPPT<,QFJX2"X0P
M(@99@5<_BWPJW\F'04>'0"   $#1U?R#A4+%"'928/+K-$>C+\E(*+L$VH>+
MWQ%,3C7I)-^I\\E(AA\@SIQXP7"K6%Q@8')H)C -J-3X1UJ: 8!$8&0B;4!3
M1"4(E1@QIFKT.G9VM/E!7GC '6(C*@%,W:.1^% ZB;) ,:\Q&ET@=6C"I%2V
M(PC ,LTJVNG=+^0,SF"3CC;[%]5+$%A>;@VQA=& _P##/O&%L3\P>#[$,OF)
M,*NVH?\ )BL/4(Z& S(@UAL/;+OCP!<FOPW\< 'S$52!R@ *LQV%&_[8@2A*
M@NS$->9<U.S)-"=N>RSL<WH^$!WC2;X@1U4 G#%"6\..]I=L3+/)8!,8Z"Q$
MR.8P+TX-]=Y!I;)J<9J[PA Q1"NB^=C$42@XGO8UC^O_ (5$8+DA&D#^<6RY
MEJ8 \A<Y^=J@1$$)E:'-B"'7AN/\9%-\=&54*-J4AJ=1ERB<H^X!5'W3@5Q;
ML!/Z6;-2HL[(0I8.C8.P2'X8_CNL+DJ &*F'TP8K-V?N65.A**'8]:)=,%91
MET4 BD@)-QH? H8(KC#O2&-YLR=@4+-! 9F$$K$)F+GDVDBWE+?G: 6:%QT^
M0G5MW4"1,!J(HZ0RH)>31CHMKKE(=E02R/NW&;B63$CP(=Q+%C9;^H!)0T,0
M->$)KD;M56[+P<=^@$]%$;9F%*T: >E<400/N9,G16C6I:2%"88AP,3U(3;L
M\E:V:%!*YY83^4F)G;@M8:>Z0-^$]S_]RG%WZ_R+\]" P -RT(70<N<D-SJ@
MDT!H$_ U>1Z2Y="X1QRZ/ETKET #3-?8:&;\*,O2:UHKDBBIFDC 1]1M'^'?
MGR9*#&%4 ];&2()#DMX>7#8(5ZSO-2:44VC8&G TFKM:\)=:&@[)4\#[E5!B
M8@BKYK,<,"L)T9=F/!ZA(A"QT=P1[KN:G5I9HQ$ + "B,2['8_P[/S'YF[K9
M,^3$$1-8$NHZL3F ,)!%[V\@/X]!;K.-=DXP7ZZI:J_.@ T[*]H@ZM9R+!CA
MHM#+6I0" 9^;7<?/]]6<I[N$&+DW7'@2GKTX=^<4^;R )TI;(P-6*8'0$\LL
M0*/:&L"4YKI#(KCH0<=@X:JE&ZJ*K44,V(;6@4:+W.[(=;KS!M4PB?\ >KU6
MYC=_A >AQQ?ER1'7@;D7@K!VU9I$"HC'TZEP^_.QYJDP28:Z#2A4.0LU""_-
MP+XO,E!(VU4UBXVF%6<@_P ^O,,I\WD 3I5]S[=DR.F:)7RT B"E@-F(@1L2
M/"3#(T857MA[!AU8*J'0$ $ 4$0=(FD=)B;7=^*R:,1VV >M7,1GR#LE\"60
M,@G=7PL$&'.>A./RV.!V,]')'P9P&%Y W* ZY8UL:6M@(W\XI\WD 3I5]S[=
MDR",2CKU'Q8W'QT$G5"<L+Q$VRUY=4:L.E6C'MQNHN.3E#^PR\)F.>,!!_!F
MB=>/UD_H^"IY-8H'$I=K#,B+> LX1KX4@D#!"A:DR^4Z.4Q6[,HK0R='*L2/
M/_:^]J A 2MIYHAHV=&GYQ3YO( G2K[GV[YFSM__ $WH^.0#Q?&^T:>$B?Y'
MWS#6ST7;55(+//K&Y"\Z^[S8YH%*DI*;JK'T)$?GY3YO( G2K[GV[YFSM_\
MTWH^.0#Q?&_X*I)F06A040<9:Z!HLB3(!Y#6NCBBZPF1SP>JH<TF>WRK/)9C
M3_.*?-Y $Z5?<^W?,V=O_P"F]'QR >+LW^B!QQ ,P>%V=(,"POR2T*'NVR4?
MGZ4^;R )TJ^Y]N^9L[?_ --Z/CD \79O]$#A''T4_?6LMG0%P2$P:8V''.W_
M #Q3YO( G2K[GV[YFSM__3>CXY /%V;_ $0.2BGC7,8;(N^)5/[T[5IY9S\]
MRGS>0!.E7W/MWS-G;_\ IO1\<@'B[-_H@<3ZP,Q9H4+3IC#.9^Q94 8F?\\4
M^;R )TJ^Y]N^9L[?_P!-Z/CD \79O]$#E"M+;,B;O(,$3Y)=@VZ-@]/YY3YO
M( G2K[GV[YFSM_\ TWH^.0#Q=F_T0.!>2ZN0EVQ;:,D%$J%54(14_/"GS>0!
M.E7W/MWS-G;_ /IO1\<@'B[-_H@<V!_"0)28VKA!I;';T0C8D.$[13YOHBI\
M\\4@I%0\X'18NJ**D^W =D"0H$( @(= "JZ#;K'%[#OA!J6Q*6%PTJ7R3XB3
MR@"CV%7W/MWS-G;_ /IO1CG7P"=?0-+R>N>IX>G2#U65L0I Z >+LW^B![!0
MH<\46(41DBC8/=I& -I=+<PEUWH ]>73RH<4V=1YK],OHN1O1 *,(9VO@B(*
MWV 4HL]SU\U](<V6P!0(@QH]I&GC[<-_</=)/#=A5]K[86G;X\IL0&&@+(:\
M$'T<:)M/NK.W_P#3>C'H0>+##$,[@NJ1W%K8.<[(SK >+$%D 9BD!;^#0:I\
MQ^QAVZJ!AUZ6=@M42>.-)LUEQZ@-!Y1Q+ETZ/8*-FE+PA$>S*)ZFS;7ZUGF#
M]TQ4/&GKOMI&/<W Z5)Y#QG_ -?.T!N:"RJS]]@$PVTD>%*'^%(_Q@!Q(Y\7
M(-WX"%CNM>785?:^V#]C0I74 SC<7#-,RVF8<O*GL61#DE_.+&E5-)<Y) HM
MY-DDB'5?_IO1C@@BT01(FG\XLUJ<AJ5/'GJ!XL0"6%D&:S))L'Y08[;N0!HB
M_ WT<9\+U:N+%,Z],@Z>8T6.5>E>CV2B5X?T]][OUX LGTWM[)%4:/LO]83D
M2+  J\L\X+ EZ9YGEPY[-G=O2&Y!&P:-6<W"#.R[2^D %-(]?_TWH^(@&!XL
M B=MQ 3PUC[P,$I@/C3S\.B2*GH4_P#'/]S)Z_ST>R42O#^GOO=^O %D^F]O
M9(JO]M_SIN^E]]W9C7?_ *;T?$0# \7SM0>G'[[UZ/9*)7A_3WWN_7@"R?3>
MWLD57^V_YTW?2^^[LAKO_P!-Z/B(!@>+YVH/3C]]Z]'LE$KP_I[[W?KP!9/I
MO;V2*K_;?\Z;OI??=V0UW_Z;T?$0# \7SM0>G'[[UZ/R=H.DMB^"[R<H#YF*
M2#M]1![8<X);1#+:%.AAFYK31L.5$8I33"^NF(EG?*QII7&],=8]+JDCM(%)
MY >.EKA_@X$>2/Z/GBQ8L6+$Z]9!2R\:MS]S#I23B1BWL<!'.(0W)_:Y7&7'
M@DVV^D_OYXL6+%BQ S;5I A*4!#W Q0%$3&P(QH'M&13!88<8L(@?W (\)S\
M\6+%BQ8GR?/8CS#DM$W3!6GL#99SYTSEN7$X7N_0-M?O?3$WY&<#DVQD*C:P
M0= /TF9MW':%-"\%<+*^&TU=38V^SIB'V;>8W71Z&*QDP0&*8F8C& ZX0+1]
M,VF?+T 36&BG7%3).$ !P!!%!0KS@7VDE,\B?M*R8YI*>D%RB+>>"K_!DK\T
MD<3D1G:POY>6> @0^!#SSDJ"'WR(D(JE89X])0Q)G#]K=+T4!5@;5X#VXC]B
M@RH8%$KV)\!]NH>2VUTC^A]8-*;'8_#RN:3ZQU&VM4@V8K6H*V*1$1^&EA*4
MNT;XP8VZP\A"N D93NK2+8_#GC;(;0^'6!OIB%!C158%68U$/@?95%^W_O X
M,8K\!1%7'@^(3X/_ "EET^( 4%BW$8UKM:!\2O07P]G(L+XI[X PUBW.VBAL
M&$K)3X.H)#UJI:A*M&\8C/A0IJKS<7(ZKE.-TJ&S*T1NF#31Z(^P15=F!0 9
MPA(=1  Q&G1^;)L/;%3<8%QF*PBTOQDP$9!%03_QYB=\'J@\Z=CR9*#. 4Q0
MQS!,/''XOKWFNR9](JE(TEI-D\_KSF_53>QESA=LW "^/$3=J'6$3\&IJB?Z
M10T@4K!R,KG-*,0"0CKP_7Z.6AY,#H6XU$.PJ;-R," ZEW29I]!7RA3RBM[8
MW=/(A.*NI!\D99S8G%'P48FI;"UEYIAH&^!4?I@U9@K.8H HA.MO*(Z8D[;R
MQ6W W2E;)'JV"1CP]54@V;@S,(.$;RB D^8:/E/[$F-"8-.LGZT_N'(/KM!7
M]D+B[ @1"PX3N^5S9K_14 'J3AVL+YF3;**#/&Y%^^G_ ..V,$'HHAG>KPJ;
M=+_GG\YMPWW_ .DY5&.42&^"DP130NK8XTQ0];:03DXK[33+U"!<+R1%/!9\
M"5(I!_+?SW6@#\(M,Z=J5SRFLN$7 G"92&(KF&W2EZ>2T!,/99Q^8"/06Q^#
M'\-<:6BB/Y&N!;%DA0FF1BXNHR9,=LJLL1EX1H9;YHT8.*!H*%II-(!X]%H6
MV?S#:7C-_&+INU*1HGK<L(";-4;$:)22<4-OTI8"$VND;H2+X4C#"*T@<)HV
M4(I*9)=N$L+1+0@V-(,A1S<AU+%6@5Y6W"%'Q$5XSD.)]T2HCJ4VDV.;%\58
MSD(R65)3E#&7NA./$8!(T+>7@2Z]$(RQ>;AKW=Y-A 6%*,=:$,"URF!-&#%M
MTQ%!:^2-T$0F!";_ +:_^O\ AGMA!",@/8.79EXNNR/M)8 JJAJJJOE:_P"*
M<__:  P# 0 "  ,    0     #X%!   =@H  H   Z(       $    !&"XE
MKJ"+AQ0R2QD8R.G2WP4K@$    6^77Z;]V+:U=.[Z=X?_P OTUU>P!
M     !Q$[J'7AX9*        !           $9)((!9  ((        !
M           (!B) (         !     !(                       !
M ) !(   !(                  !   ) !<         !             !
M   &P!>   !H   !(             !"@ ,0!>   !*   !1    ( )( )
M !-  ,0!>   !*    (0   ( (( )   !&@ ,0!>   !*    (0  !"@&4 J
M0! !,0 ,0!>   !*    (0  !0@,& 8@!(!-  ,0!>   !*    (0  !0@,&
M 8@!4!!P ,0!>   !*    (0  !0@,& 8@ (!+0 ,0!>   !*    (0  !0@
M,& 8@ (!*@ ,0!>   !*    (0  !0@,& 8@ (!-P ,0!>   !*    (0  !
M0@,& 8@ (!)P ,0!>   !*    (0  !0@,& 8@ (!)0 ,0!>   !*    (0
M !0@,& 8@ (!/0 ,0!>   !*    (0  !0@,& 8@ (!   ,0!?   !+    (
M0  !0@,. 8@ (!   -8!6(  !+H   !8  !0@,/ 8H )!   -EQ:>  !&2
M (8  !1@,*09@ $Q   -Q!4*  !(B    \  !0P," 8H %A   -Q!4*  !(B
M    Z  !04," 9J ,1   -Q!4*  !(B    Z  !1<," 9J ,1   -Q!4*  !
M(B    Z  !1<," 9J ,1   $3XM=)))C[)))G')))V/(P9.;!VA     !(
M(   !( (  ( )      !(!   !(!( (  ( !  !  ( )(!! (( !!
M                       !              !JKP            !
M          "%P            ! !2!:"2;91:*                  !
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MWU_P?]ZB3:L(*!3:@=8EZA$DE)-R2VO^#_O06178$(BDM:]6B7$/<%U_P?\
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M3 N<Z[+D(PCA0L"G>RNA:4"&CS*&3:R*.[&HHHW*-L# S(E%!NA&II.=3 M
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M%)%)9%Q=YQ>^A004'<%!^3OJLE9;.UYG.J\NTW=N/CVUB2)@8,;%)MA$FFH
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M3<$HVJ!?:WVTR8_L&A*'O)[^GSW'Y\=IKS/#\2$<%0=P8J92+&CNMKPF"2U
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M4(UG#P"PBB3^!<QD09Q5$F(0)!%<=DA!! @0?*][RG/3\>+22A>T^2#Y%*'
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MQ$L1,(F1-S@)@3%V\MQE)8Y!ZP*G]2"O* NJ1M*"UPC8'R#Y07VDPC5 XFM
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B1MYT[O+#&1%$H! 0!35%!>3YS8>,JI@S6A%5]*WG3NS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>business17a.jpg
<TEXT>
begin 644 business17a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1E 17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   "]    !0
M +T    %    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$X.C$P.C4R  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   "<     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M^S[+_GSM_P#OTO\ A5FB@"M_9]E_SYV__?I?\*/[/LO^?.W_ ._2_P"%6:*
M*W]GV7_/G;_]^E_PH_L^R_Y\[?\ []+_ (59HH YW4C)::BD%OHT4\4D9<.L
M((7;]Y2?4\8_&LB'5[RX/F_\(RL4)B7Y6A^=7+LN1\O/0$CM79W1E%K*8/\
M6[3LXSS5"&759 ZR1+'\Y7<.PVKR!WYW4 <])J\R6WG+X<WM&"7A6V.\_+GN
MH'7G@FNCTZ&VO=.@N9=,BMY)%W&)HUROZ4RSDU(7R)<*S0E<AL#CC//\JUJ
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M9#"0"V>'R,Y'M^)K2W-ZG\Z2B@!=S>I_.C<WJ?SI** %W-ZG\Z-S>I_.DHH
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M3M1'JM\SJC:9QNVLY;MM8DXQ_L@#_>H NV#Q7MMYQ@B7+$8&".#ZU:^SP_\
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MZ  $  4 %0 R "EA8W-P35-&5
M]M8  0    #3+6QC;7,
M                      UD97-C   !(    $!C<')T   !8    #9W='!T
M   !F    !1C:&%D   !K    "QR6%E:   !V    !1B6%E:   ![    !1G
M6%E:   "     !1R5%)#   "%    "!G5%)#   "%    "!B5%)#   "%
M "!C:')M   "-    "1D;6YD   "6    "1D;61D   "?    "1M;'5C
M      $    ,96Y54P   "0    < $< 20!- %  ( !B '4 :0!L '0 +0!I
M &X ( !S %( 1P!";6QU8P         !    #&5N55,    :    ' !0 '4
M8@!L &D 8P @ $0 ;P!M &$ :0!N  !865H@        ]M8  0    #3+7-F
M,S(       $,0@  !=[___,E   'DP  _9#___NA___]H@   ]P  ,!N6%E:
M(        &^@   X]0   Y!865H@        ))\   ^$  "VQ%A96B
M  !BEP  MX<  !C9<&%R80       P    )F9@  \J<   U9   3T   "EMC
M:')M       #     */7  !4?   3,T  )F:   F9P  #UQM;'5C
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M  $% 0$!              8#! 4'" (!"?_$ !@! 0$! 0$
M   ! @,$_]H # ,!  (0 Q    ']_                4BJ
M               #\-O=P[@X;H&KM38$M6/9-Y899(9=9ZSEUM$R*Y"-UXUS
MMTSM+%TKTSM'&IG&D>DY-Z8[)X[USO-H=S\.D*LX+]&/U9\G7A?OS_1[S]0
M                 -)[S@JP-F*,^?#/RX9*561;&C.F>M.6X392-F9NOM3?
M?/7,/7.8CX9 LS9>:"[(PA&IS/USU%RWHGIGKKCL
M                        <H@
M&\2>@            '*QJLYI+LBY-S&G[%@          'YSFG2.F;.BSEX[
ML.JP               " G,YN0T&;R(V8XZQ           -'%0P)8&++@VT
M;,                !QH71FS792.N2;            Y /)E30YUX;H
M             (V8,PYB2?&7,R           "-&&,N8TJ$U
M     !Q>9,B!ODWF            :=-5$.+4[Q/H                 (88
M<OSX3T            PIB"S(8;P   !J0
M       G9RKTYZ,-Z'PA)-SX0H@\;6K+      % K@      IU4@
M      ="8UI;>?QWSK*),B+K X_1;4_..789CD_8W4N0     6Y<       I
M55@              ;@QK3^\_0 #X?3Z#R      6Y<       I55@
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M61]*YNP  \&@B1D4-DD-,F69?&;*1AB\*Y:&)+$ORZ/9FS8@
M           !AC4)E#%DB(R>##F2+PCQE26EP1(JEV6!7/)N4R(
M              !2/A:F0!8'DR(!CC(@       P9=EL43('@^F1/H !9EL5
M3Z794/A@B_+\    L2Y,44S(E,R(  ,6<-%N;)-,&]R%%(HD*) ;+-;G@K&R
M3JX     XI)>4CGPZC-$DF.C#:  !#CB4PY=FZ#T1DU43<[R    -2&N2@:T
M+$V4=;@  %F8(K'@S13*AKPEA?%X6YCC(E S     !&#/D6*A5+DQ1)2_  /
M)'BN7I3+DI'@QA)0   "D8<MRD9LBQ.   6!QZ2DAQM0@I4+HO"B= DJ
M                         +(P9?EB>S(% \F,+,GH
M             /)K GA9E<J%J6AZ+PSH       !KDBQ*R/ N"X-J@  BYK4
M^GPV:52L0<JFS0   #4))B"$Q(T28E9E@ "D?GZ9XU\98VB:Y-L$=,&=W@
M     '/QA2\-4$Z, 0T[]  !ASD@L3,$D+LAQ "9':@   !RV9@B12,<98VT
M;?  !;&"+XRA4 +8N06Q<@       %J70!:ET            43Z506Q7/0
M!A#C FI C91$38A"2-$L,.6!W0                            #5&GDJ
M \EJ7@ !1*P                           !-\N>>C\GLNM"W-\UR%$G-
MQUI"-AU(S2,8,V =C:7                           -Q8:4VX%REU; B
M_K4T7U7L8HCAT]7.9XBJ=GZ9D                          &XL-.[
M                               ;BPT]L
M          !N+"91#B7GLP1F"J1\D         !J@PALPU\3@C9*#.%^  #5
M16,R2@OC$EF?20@   &M"0$&):8\S)(R[ !]*1^:Y6*1BS)&SR,F(/T,,B
M      <6&PC+FH"<&N#,FWC>(  /S )(38W2<Y$F((;Z.I    #ETL2.DB-8
M$J-XFY                 8(SH!CBJ7@ -7$;-KF7/H(F2P\F(,P5P   #%
MEV7(,47I<                      UB:D+XU<9$BQ9'DOB*F?.]S,@
M    &@.F0                                 -IXLGE^E0'P\GL%L5"
MV+X H%(K%8 %,J ^'T  %,J IGL^@%,^%4'P\ J'P^@          C)'%DJ8
MI:9YB^L&+,V6X*10,T8HD1$EK(EN:NDQTOJSS+DJQQ62BOTS*1A;U*QBEO4S
M)CC'%^4ENDQZI+ZK(KEM+F;)4          >
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M/#$R:K-DJ;?7>/H-W#ZE2C1(FTFDF2-BN7N:8]7,),ECD@E"YDRT2:1>Y)Z
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MT!;Y]\'QV^<1%OTV4V4DCN/< P=('+&V+$ *,G\_RGP0MB[>E<>/)SX_S.L
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M;Z_3]T/U"^/;L!V^D7J%14@,OG!^<^,UBQP<C!4CMCY3XQRI 4!/"CQW@ZI
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M+(R"KLS EL6X>,_K YA%$@I+"_R5B:)HFKDUUO9D:TM;21F \>3./:F8<ZG
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M.K+2"&OD0[#-]Y-CLCQY<68'I@R)3QQB#+#"UA!-1S0\@45!D>BY8S9*KO\
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MCVRRO\^J_%8]LLK_ #ZK\5CVRRO\^J_%8]LLK_/JOQ6/;+*_SZK\5CVRRO\
M/JOQ6/;+*_SZK\5CVRRO\^J_%8]LLK_/JOQ6/;+*_P ^J_%8]LLK_/JOQ6/;
M+*_SZK\5CVRRO\^J_%8]LLK_ #ZK\5CVRRO\^J_%8]LLK_/JOQ6/;+*_SZK\
M5CVRRO\ /JOQ6/;+*_SZK\5CVRRO\^J_%8]LLK_/JOQ6/;+*_P ^J_%8]LLK
M_/JOQ6/;+*_SZK\5CVRRO\^J_%8]LLK_ #ZK\5CVRRO\^J_%8]LLK_/JOQ6/
M;+*_SZK\5CVRRO\ /JOQ6/;+*_SZK\5CVRRO\^J_%8]LLK_/JOQ6/;+*_P ^
MJ_%8]LLK_/JOQ6/;+*_SZK\5CVRRO\^J_%8]LLK_ #ZK\5CVRRO\^J_%8]LL
MK_/JOQ6/;+*_SZK\5CVRRO\ /JOQ6/;+*_SZK\5CVRRO\^J_%8]LLK_/JOQ6
M/;+*_P ^J_%8]LLK_/JOQ6/;+*_SZK\5CVRRO\^J_%8]LLK_ #ZK\5CVRRO\
M^J_%8]LLK_/JOQ6/;+*_SZK\5CVRRO\ /JOQ6.KJK&#91=[A=3 E E@Y&:;Q
M\H'O9O;JFYNNJ:IKWX]F<N_(JKPF/V>++R .Y0W3+"6MJO-DZZ=.^0D+I&&U
M[.-QT5'>:NCNS'LSEWY%5>$Q[,Y=^157A,,RFM)ESR^2J6Z9!_9ZNU6M0[HR
MR.7H^/\ KF.9LUW]FNFF/9G+OR*K\)CV9R[\BJ_"8_9?H,H?M$L/RAY'\C5G
M6]%V_P 1MZ+9LT15TW\FWSMFW1</JLP%R/4V0QC,^'+I(?,T1DW">O%6$;H]
MO:GG:Z=Z8B6E91Y8G5T\#),.8"CK%#)CD^H4:NAM=M=]FK47_+'LUEWY%5>$
MQ[-9=^157A,>S67?D55X3'LUEWY%5>$Q[-9=^157A,>S67?D55X3'LUEWY%5
M>$Q[-9=^157A,>S67?D55X3'LUEWY%5>$Q[-9=^157A,>S67?D55X3'LUEWY
M%5>$P[_LUEWZC/\ ]BJOYD__ (F/9K+OR*J\)CV:R[\BJO"8]FLN_(JKPF/9
MK+OR*J\)CV:R[\BJO"8]FLN_(JKPF/9K+OR*J\)CV:R[\BJO"8]FLN_(JKPF
M/9K+OR*J\)CV:R[\BJO"8]FLN_(JKPF/9K+OR*J\)CV:R[\BJO"83_LUEWY%
M5>$Q[-9=^157A,>S67?D55X3'LUEWY%5>$Q[-9=^157A,>S67?D55X3'LUEW
MY%5>$Q[-9=^157A,>S67?D55X3'LUEWY%5>$Q[-9=^157A,>S67?D55X3'LU
MEWY%5>$Q[-9=^157A,>S67?D55X3'LUEWY%5>$Q[-9=^157A,>S67?D55X3'
MLUEWY%5>$Q[-9=^157A,>S67?D55X3'LUEWY%5>$Q[-9=^157A,>S67?D55X
M3'LUEWY%5>$Q[-9=^157A,>S67?D55X3'LUEWY%5>$Q[-9=^157A,>S67?D5
M5X3'LUEWY%5>$QP084."#J"OX(44$0.]VW<_BCL&S<[1-7;=5T35>S%E&A%X
M)DFOF B'_P#E231R#"37[-I'-[?[O?\ 9B9]%L_(ER3Z0R E5SJI,NF.:POC
M27*#,0[KB42QTU9(ZSJ$4;1[6ZC\["5/TK6&?D#79/RO#R6;)K[1PY5N"OCC
MN7L?7(X9[SRBA6CZ[S%#M5W8K,?2G#G#SB9,U9'HDR-LA6$TCY@:LXY:N)&:
MH:^Q80C"6+DXU:895?HJ,1:*W)67EM+#_P##BQI6122X]G*L'3Y.\([!K''#
M8(C^=53=)1K%<UCG:(N>P5A[;R/8?1)=VC(XCYIF1XV8XT=41L27F$(9?E83
MB*.0Z"B!(33A5=-&U]O93[N=+L:>/?WAKB7(G2F&'!3?'BB-Z2,,81(,41NJ
MJ3M75[EP[Z9DR:3KOVJ;FY+)+%GE/]CD$VK9EQ*-1=1P^3U4B>?NU5IW,]'B
M^NA9CLLK5]QE#+!(<\&2_P!J4G-()QTCJ(\4R0WA:]'.=HU^[T;^[3%5<P9U
MQF>-(H,O^2<KMCYPRO((?0:2;&C+2Q_)W63R(0LF).8U(CGN!]5C$0#G,<)S
M@!<X1%W$$YPFJHB._O$&OF/=]KD5?Z5__@'_ .Y/Z=/[?_SB?]/]H?\ ^ ?_
M +D_IT_M_P#SB?\ 3_:'_P#@'_[D_IT_M_\ SB?]./62_ S'K)?@9CUDOP,Q
MZR7X&8]9+\#,>LE^!F/62_ S'K)?@9CUDOP,QZR7X&8]9+\#,>LE^!F/62_
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MK#F<T[ /;(6-): _!J1&+L*@Y%<.MN[F3 BCG6J4D%LQM5%-R*%\Q7'#Z4S
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MH5K-[W8@5S"F.ROA18+#R';Y!FQ , TIW_WS$0>\COM>JK_B_P#SB?\ 3_\
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M((+C1:0E05"7:A;I?;T]2?<HT.5%8 2ED5<93T* 7.'EN XVF:(+84FGI?\
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M0N"I/[L20[ OV[1!X-K_ $E]5VF(8VGG$-:VH0L/SN"=+1IE"P&RX(\[ E-
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M1I)0!:E *UJZ2T(N2I-2=_F1[UHERJ$;46#,\8%2PY6L4TA%W9#MO6MFY8
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MS\-X@D=!($<,NK]&)D 4?S.7(9!#=0&\("\H0.6+]0#""+'GZN64LTD-=5R
M\V8H'P(Y10#CH:JKG"XYTAFTBK&URUE:E872K#7@!OS=HBDY4=B\T+%XE/+(
MFPEDT5JB$_2YE:Y@))"&48(6SM*=Y0"7Z=9"2P)\);?U0T8,@'5!,,QUA-(K
MC\QTG0$YI\CK;!'=KPUR@Z;G(!Q<JAI=@)7SFL!P3=0#0=V8(UDQ&@Y=M^MK
MB.#IK5:9$VL+ [T,EC$KQ10(T_(V4C@L0+_9=@/B:4!$$"A!(0+!J_9!3P9H
M'-#_ -$2?CUT_MIC'"J_NGK52NB2<2<"*0+1HSA$"P8  4?%)ROWXH:C&Y
M   H!@ , & -/F/02:P)-AD;C$ 4BI&34,]MA80E.U/E+9'_ #)/94"X08\
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MV*_A94)B"2KV;0A<_-QG_<<IY^J(QL7!)#3K"A2K_P S_P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
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MRV6RV6RV6RV6RV6RV6RV6RV6RV6RV6RV6S__V@ , P$  @ #    $
M                                      3\4I]XXHE$1E;?$P
M             X%3';:!:"HR21V8
M             ))))))))))))))))))))))))))))))))))(
M  )!(           !  !                 !((             !(
M            )()            ()                  !!(
M  ()(                   (            )(                  !(
M             )    )))))))))))))))))))))))))))))))))))!9!)6))
M))))(I))))))!))))))))))))))(P']];P      @
M   Q))(        @                      P           @
M             P          !       $              !P(  ((()))
M !((    ()!      !!    (!))! !!(!   (!!(   ) !!    !((!    (
M)!) )(!)(                         !!!(( ))!(
M        ( !( (        ! )(     )(      )    ( (! ()     !((
M(  ))()(    (()    ) !!)))      !(((  !)))      ((   !(((((
M                            !!!))
M     ! )         ())    ) !      )    ()  (        !())   ()
M!)     ()!       (!                       !( (  )! ( !
M                       ) )  !                             I-
MLL%%L@                          !(A@IDD-@
M       !                                  !
M                  ! (          !  (    (((     )!!( !)!(!
M      !(((    !!)(    ()!                 !    !(!! !    !(
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MH6M$!:@ #[G\02(2)"3*1O\  (@$: . 02B=$9FCMI ,D "$, @E;B" "$S
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M?^Y)MRK,PNDD&8!Z.26=$(<A. 2YG@#GEO4)@+ ;(E$ (\G>31^60Q87 )Q
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M::]IDY0D0AP$$F7)+U_]1@M0<D=W NQ=3(%RPD48.X9NT) A@0 L&)'#EF
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MTA * $$2((HC-1C:<P&D.9'#+(2.Z+E!0"FNX) HJL-O\+S=HB#SH!NFN?\
M42PVNI1II2T"W";,2)";U9A"8<PF!? 1LG0K0?F^?/GSY\^?/GSY\^4/ .&
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MX\+/'M<<HGY "BONW9OO9U  P7X*;E;DGPTK[;R"9$G>"G8*!L='^?\ 5#(
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MB9 2\X5 U 0.C_H2*1F])D7-.)*;%'QN%KR3Y-QOQ*DR5UW;</)4(YPGD$.
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M6ZK)*&Z9K*O7SB7=F*4!#G6K+"/5#1[F+E@$DL1"50%P9B9-A1E1&P>=E>'
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DO=#Q-[H>)O=#Q-[H>)O=#Q-[H>)O=#Q-[H>)O=#Q-[H>)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>business18a.jpg
<TEXT>
begin 644 business18a.jpg
M_]C_X  02D9)1@ ! 0( 5@!6  #_X1C$17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #?#0  *0
M -\-   I    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$X.C$Q.C4V  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !M     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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MB.2?TKC"222223U)KU#X7Z;8-H&K:G>6D#NES#!'-):FZ*@GYE\L=,@CYO\
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M=E95-U,1*XDD'F'YV'1CZGGK4LVD:C;Q&6:RG2,1),69" $<X5OH>U4PI)P
M<YQBF(FN[V[OYA->7,UQ*%VAYI"YQZ9/:H*OR:+J4,U[#)93+)9+NN5*\Q#(
M&3^)'YU1P3C@\]* $H!(.0:?%#)/*D44;/([!551DL3P />IKBPNK6**2>%D
M67<$SC)VG#<=1@CO0 V.0,<'@U+.F;8-_=/\ZIX-7+602[K>3JXV@GU[4Q'=
M_!#_ )*&O_7I+_2N\^/O_(IZ;_U_#_T6]<)\$@5^(@!&"+64$?E7=_'W_D4]
M-_Z_A_Z+>IZE=#P>QU34-,9VL+ZYM2XPQ@E9-WUP::VHWKQS1M>7#).XDE4R
M$B1AT+>I]S5:BF(NC5]366>5=1NQ).-LS"9LR#IACGG\:I444 %%%%,04444
M %>S_L^_\?VO?]<X?YO7C%>S_L^_\?VO?]<X?YO2>PUN<#\1_P#DHFM_]?!_
MD*V=$\6^';3PE!I=_9/)=1V=W&)T3YE:0MA,]U((Y[$5C?$?_DHFM_\ 7P?Y
M"MS0KSP:WAC2X=;CBN+J)Q&R/)*OEH\[[V^4CD(5-+H'4L?\)-X,A:5+2SBB
M,D9(F%EC9B161,;L[PH8;QWP>U1/X@\%3ZDES<6?FPO=2R3J]J6E?<TA5S(6
MY7YD^4@]#5VTL_A_<V=Q?O!9Q0KY*2(\\_R9,N_8 <EB%0C.1FJ4'_"O'DE1
MX8DC2VAR[R39<E"9"F#_ *P-M&#\N*!DLOB?P9!IVJQZ79_9I[BVGMP?LV3(
M650I#9&Q<@Y7'4YKS*O2[ _#9Y8S/ %>> 3E)I9A%"YV@Q97GC#L#S]X?2GV
MK_#7;;Q2VD94^2'E>>;> VX2$X(&5 4].I_"@#S&BO1Y3\/+>TMY(H(KF1+5
MVV/-,#)(%7 D'&#NSC:0,?A67XPD\,-I%K%H"VH>*ZE#D&3S2C'<O7@J.F3S
MP/>G<5CC*W/!G_(ZZ)_U^Q?^A"L.MSP9_P CMHG_ %^Q?^A"@#Z(^+O_ "3+
M5O\ ME_Z-2OF_P .ZI-HOB"RU&"(RM!)N:(#[Z=&7\5R*^D/B[_R3+5O^V7_
M *-2OG;PEKD?AWQ';ZC-&TD2*Z.J %L,I7C/'?-);#>YUK_%7=);,=*4B*Z+
MMEQDP@,(XP<<%-Y(/J!3V^*%G*L@ETB=W4.()C<#>Q> 1,TOR_,Q !R,=?:L
MK7/%NBW^DP6UII)2:.6)\O'&H0("&P5&3O/)ST[5JQ>.?"T,K-'H4S1N9WDW
M0Q[@9&5@%((P!@@9SP>E%@&:U\4(-6T?5+)=.N(3>JZ "<>6,R!]Y7;DMVSG
MH!3])\<3'3K<6^D:F\=E:B"5[64;+;Y=HDB^0['..22>IK,UKQ?H6I-HHM]$
M6VBLYDDG6-%#,H !4-DY!P3R!6T?B?I=M?6\NGZ6\$(N(I9T6*,>8%613CDX
M/S)W_A/K0!63XL213(T.GM%"K22&!)0%+M.LBMTZ@!ES_M&A/BG]F5A:VMTK
M-<B5I'F!9D\XR,AX[ABOTH/Q \/QV5M%%H*-+"'S+);QY9BC@/UQDE@2,8X^
ME><RR--,\KXWNQ9L  9/L.E%@N>BVWQ,L+9X9UT1S< 11O\ OALV1^8%*C;P
MP$F<\\@5QWB76AKVOSZDL;1B3:!O(+G  RQ  )..N*R**=A7/4O@T!+\0([@
M'YFM) X]^.:['X^_\BGIO_7\/_1;UP_P1?/CQ5]+67^E=Q\??^13TW_K^'_H
MMZ74?0\N\%^)M,T2SO8M4M5G,;+=V(,>[_2%4J ?8A@?^ UNR^(? TU[-$]L
M'LXD4PM+;%MP9G>55 (*ME@ QX&W\\OX>MX5MR]UK;V_VN.<;1=,X41;&Y4
M$,V[ PW&.:VT\/\ @34!"+66()%;M+=W$<S@1A#&PR&;@N/,7 [XX% $&GZ_
MX&T]#<0QNDL\!22-8&#(# 49-W0Y?G/O5?6O$/A*XOO#T5O"DFEVEW/)<01V
MS1@1.5VC!)W$ <X/)'O4T4_@S2].M]=T];=;^W@9_L:SR,[R. H!+' V[F/
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M*O7=IMA2X3!# ;L#C/K5&@ HHHH **** "O9_P!GW_C^U[_KG#_-Z\8KV?\
M9]_X_M>_ZYP_S>D]AK<R/B/8R6GC?41,A"3L)4)'#*1_CD?A7 /;_9;MF1U4
M;"5RP&#BOJ7QAX.M/%MBJ2/Y-W#GR9P,X]B.XKQS4/A5XHBFVK9?: . ]O.
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M=')21T(@6%E:( ?H  0 !0 5 #( *6%C<W!-4T94
M              #VU@ !     -,M;&-M<P
M                                    #61E<V,   $@    0&-P<G0
M  %@    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)8
M65H   'L    %&=865H   (     %')44D,   (4    (&=44D,   (4
M(&)44D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M    )&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &(
M=0!I &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P
M !H    < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #V
MU@ !     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB
M   #W   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0
M +;$6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP
M#5D  !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /
M7&UL=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
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MKF                 !%)N#6<IZWNC6WT       Q5OGJRVQPBTSL#:LED
M  *F(4["2$<1IU$E/A&$T.HDQQ)X?"2G83LDQR1,4R<G1+CL(D$G!5<,B:WS
MRRTVHX[7UK<      =1@3KEK%VQP^OG96T08   /I\/A]            !]+
MA1.35+[$,M-H^.]<1(     Q4OGI>Z.?7UIG(Y?0   ?3X ?3X
M  #N,O<[[BL-]C>6W8     6[FOG_P"KFUMZY=8    !R*W),<3K.)*2=G$Y
M$J.DG9P.HEA/#X2(G)\)>3DDQ,SZ=1'%/G4 "8FW/#;>7S=,]2    !C)?/S
MT=/-B)I3Z     #Z?   #Z?        #X?0 "MXG>IS=&UW'?L   !"FC[IY
MM,^^$,        ?#Z             9\YZ>C+DZK@Q8   #'ZU/,!V<=D[0
M     /I4!W$.0)%G80Y*"9D2?24'TFQP).3PA2#)P2,GY*"+(@X@D(  ,O*7
M].?'UU[%@   , M<O-KU\E-                       'PVI8[>A'EZHH
M '2>=OJY-7FV7T      'P^@      ^'T    'P^@  R4K;U*\79<.+   6]
MFOE%[>.Q]J@       3 C3N.HXDH)P?#X24FIWG02PG9U$ 38DQ.25$X)<=I
MWDQ*4.L  &:&=_47Q]DQ2  !B5?/RS=G'(9          #X?0#X?0
M   ?#<3AMODYNH  :<=^?1!T\_T                   'P^@   SVST].7
M'V=@  /.7U<FL?;(         3(CB&.9S/A*B:',A"$)J<25$Z)<19T'>09-
M#K!].DDP  !O)Y^C='S]   E2/)AW<6.]J@                        =
MAZC./KS<SU %H[5\B';PT](                        ?#TC\O5LFQV
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M-AU\F>.>NP7+75CMANXY^GS1=?'NOY^CSO\ 5R[Y^;IT;]'/OJYNGS(=G)#
M          ^GP   'T]AG#W7?K8 >4OMXL1[T 'JPX^S&2U+(7KO YNGS6=?
M'M0QVIF6&MZ8YWIG-GIA'IGNBY]_,MV<GIJX^SSE=7):"T    "8D<=1T$:0
M!&' X'T^G41QQ/A](PX%+   &T+'7T5<O6 *8F/&3W\$  9'UMZS.'M\X/7R
M;%,MKN5G3UT8;MN;HPBTSIJ8P]TIN-Y]_,YU\GIKY.SSM=7)96T
M         >@_EZ=KN.XIY'C"]#@@0 ?#TX\G7;B8U*[8>F3DZ]5F^.Q++73O
MOAJEVQ](W+U6JF+N5G#S2F0]+7YK;0KT\UE;5HF0     ^'T         ]-_
M)UY^Y:@<#QG=_!0\P ,S\[X_VKL<SUW)\_1Y#.[A]4W'V4:C#W2FJO;#8-EK
M>F+9<YWQ$O3'6],!]<[53'T     ["<'TAR+((CB!(TASZ=IS.9%$P*"/@
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M"SO=6+>6#LX_1]R]-H9C1#T\^9F=Z_B=HN.W$IV8PJTSU2[9
M #Z?   #;7AMZ >;J%D;4\?W=P\T@ 79B;Z4M=R+>AOEZO+[U\>U+':_%;::
M]\/1+R]6@7JYM;FN65=+;M.?HTX;X9]YZT%,6(M771KD          !]A\D
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M             /I\  !MKPV] /-U"R-J>/[NX>:0 !\!] !\/H  /@/H
M       /H/@  /0=R].U['<"$1XP._@IV0    XGT^@  ^'T         $<3
M0^GT^G,Y$65(6])0  934MZQN+N &*5Z>3[MX>20 /@/H   !\/H
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MV\/)(                      'TYG6  ;:\-O0#S=0LC:GC^[N'FD
M                #Z=D3U3   ]!W+T[7L=P(1'C [^"G9
M       30G!VG:1A7,38J8Z0 934MZQN+N &*5Z>3[MX>20
M         !VQ/5,  ;:\-O0#S=0LC:GC^[N'FD
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M'FD                      ?3MB>B8^@ ]!W+T[7L=P(1'C [^"G9
M                 "-*R)DFN88[3'P RFI;UC<7< ,4KT\GW;P\D@
M                (?9GN.A  VUX;>@'FZA9&U/']W</-(
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M<!D?6^5E+ZF=L0    !/#(B+8ZS62@RFI;UC<7< ,4KT\GW;P\D@
M               ?2.K: M4#;7AMZ >;J%D;4\?W=P\T@#X9_9:8(:YWLK:/
MACM>H%90Z#.S/2)3K?UR   &W7';4IMC"@          [8GN(28 ]!W+T[7L
M=P(1'C [^"G9 "\M9]!_-U:,^CF]5_%V^0KNX?1=R]7FGZ^3:[CO)D:J]L=C
M.6VN+7'85EKE[336SMADW32^M+7@B?.5U<W:;6L=KD5G4MOCM&QVBC43OAM.
MQVN-6<0-*;$<M;E5G21T\]]J6NM%KAUG&B]+)6K4,3+)=Q54,Z<]=76V-@;5
M N%$UW$V"M4934MZQN+N &*5Z>3[MX>20+VUF!+86C*NE\1+TRHI?&VU)3(
M ;#LM,)M,Z*E=^LY!5O@]IF     !<.)N5$XY6J+VUG(:MQC-:EI;0   (N+
M=,QU(&VO#;T \W4+(VIX_N[AYI '%'K/XN[";3/%>]*JB<8+Y[$\M=;FN6UK
M':J$ZE-L)<39.P;+361ME7,3GKEIJSVQKR)V(9:YZYZ>3SMXY:
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M6NN#7'8GEKAU?/4QOC8ZT;@\-[D5G:;CMYSNODM%:+'37<?AO;&T:IML0
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M:[CN!"(\8'?P4[( =I<>)MG,         5;#=+S]&L';&R=JTO(
M <BN29&9.>GI6X^P 8I7IY/NWAY)        Y(XI                 ^FV
M[#??[S=(LC:GC^[N'FD #T6\O3YV>KFZ               "*+E5FU=H
M ')/H.Y>C:YCN!"(\8'?P4[( 9E9W]$7-U>;CJY+X5ME)2^JC;&SMHOO6UYJ
MS:NT5O$WDK;)NEM3FV.P3/6K8:C-L9+++:E]B&6N!6F6=.>F8^>EN9B(//OU
M<NU['>V$UP!TSV69:XU7I@YI0       "K"+,J:7]1G%V@#%*]/)]V\/)( %
M[JS>*M\+],P   +K5G=-AT: ^GF    %20SWSUUR:Y34R9I;%&]0
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MM7I3FIG?6WMEE9G>I(G6=OCNAYNBDICR[]G'?ZM\3;T         "&VO';T
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M_N[AYI 'TWW\W1H6Z>?H         !DE2V:=--36V(K^)V^X;:0^C
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M                934MZQN+N &*5Z>3[MX>20
M   !MKPV] /-U"R-J>/[NX>:0!Q1ZMN+LU8[94E,7#BUN;4UDZY[H>??&Z],
MFZ7L?:NY+#?7CKEB'>F]CGZ<-KYV?M&=F>GE?[./D?3U(<?99*U-3&^&S7+;
M&ZU,Y\M<:=*9=YWQPM6C9C.?/34COAF9EIKGVRSWRVT7]/,     !Z#N7IVO
M8[@0B/&!W\%.R $T,J:7M+-;2VC+.E\7;4O[6TJE1LQ(49!5O3",EJVVYX;^
M9'KY*7D                !E-2WK&XNX 8I7IY/NWAY)
M           &VO#;T \W4+(VIX_N[AYI 'PRSI:U,Q!RF4)9*V$Q>NLTU*IX
M4C*I(9&UOA??/(VMHY-LYK7L3BE>OT%^ZVIJ8IE%T(F>Q-S8MAQ?._E;8VWK
MFEGI96U;=36Y\6MQ,5_$V(M4     #T'<O3M>QW A$>,#OX*=D       +W5
MM3LQ;.8                 &4U+>L;B[@!BE>GD^[>'DD
M            ;:\-O0#S=0LC:GC^[N'FD                         #T
M'<O3M>QW A$>,#OX*=D                          ,IJ6]8W%W #%*]/
M)]V\/)(                          VUX;>@'FZA9&U/']W</-(
M                   'H.Y>G:]CN!"(\8'?P4[(
M      934MZQN+N &*5Z>3[MX>20                         !MKPV]
M/-U"R-J>/[NX>:0                         /0=R].U['<"$1XP._@IV
M0                          RFI;UC<7< ,4KT\GW;P\D@
M              #;7AMZ >;J%D;4\?W=P\T@
M >@[EZ=KV.X$(CQ@=_!3L@                         !E-2WK&XNX 8I
M7IY/NWAY)                          &VO#;T \W4+(VIX_N[AYI
M                      ]!W+T[7L=P(1'C [^"G9
M        #*:EO6-Q=P Q2O3R?=O#R2                          -M>&
MWH!YNH61M3Q_=W#S2                         !Z#N7IVO8[@0B/&!W\
M%.R                          &4U+>L;B[@!BE>GD^[>'DD
M                 ;:\-O0#S=0LC:GC^[N'FD
M   #T'<O3M>QW A$>,#OX*=D                          ,IJ6]8W%W
M#%*]/)]V\/)(                          VUX;>@'FZA9&U/']W</-(
M                        'H.Y>G:]CN!"(\8'?P4[(
M           934MZQN+N &*5Z>3[MX>2>1].!\/H
M   !MKPV] /-U"R-J>/[NX>U-1%1$\3-3M3 (DJ)$4N0(
M     !Z#N7IVO8[@0B/&!W\%.2^G)'%/P^@                       &4
MU+>L;B[@!C1>GFM[.*=PC4_2#)/,4]*E"D2!                      !M
MKPV] /-U"S-J>5;NX:T3%@ @2F)B#14"9W$R,H0H8Z0
M  >@[EZ=KV.X$*CR2]_#S)L1)UDN) BG)4D4V<0
M#*:EO6-Q=P QPM3S>=W%R   .!2!;8IX                     &VO#;T
M\W4+2S3S#]_%R )>BUUHH:U>)4D34$36%9JA,$CJ3;0H$^
M     ]!W+T[7L=P(8\JG?P2.8   $N* +>$,                     9F4
MOZH.+M &.%J>;SNXN0   !\*(+3D&                    #;7AMZ >;J%
MI9IYA^_BY EA8>^<ND!4D34$3;^U:MK-.3%21-YJWILLX2X
M     ]%O+T[/\=P(8\JG?P2.8 XG2=AS/H!!%JRA
M 9OYW]1O'V@#'"U/-YW<7( 'P^@ 'P@"S)3(                   !MKPV
M] /-U"TLT\P_?Q<@61M2D;0 *DB:HK-M+U^ C89#TTB" +)%/@
M       ]'_+T[+<=P(8\JG?P4Q,4Z6W*?.@K@I<J<N 5(?04:6=(<
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MM>&WH!YNH6EFGF'[^+D4],6$O0 "I(F_%+BG$6&TH+E5M5U9J1(@2PA+
M             >C_ )>G9;CN!#'CU[_/M-*JBZI-CO/A*RGRW!3Y/"[A4@)&
M6)(4                  &;^=_4;Q]H QPM3S>=W%R!:FU;>36K8M*$2F8
MY%7Q:G9B"1DC33B6&)(                  #;7AMZ >;J%I9IYA^_BY$*8
MY7SZI "I(F_%+CZ8RZ9\ 7&K:ZU; 4X6(.(               !Z/^7IV6X[
M@0QY#>_S^F58'T  $(6F(4E9?,CP4H6//@                 !F_G?U&\?
M: ,<+4\WG=Q<@4O,4^@   #Z7$BW,D98(X                  &VO#;T \
MW4+2S3S#]_%R!::U;>6J *DB;\4N)$BP&E!6-9N!%JKB0!:@MT
M      >C_EZ=EN.X$,>3[O\ /Z9   "4EHSN*/*X+R %JBW
M     !F_G?U&\?: ,<+4\WG=Q<@6HM63S%21,&2"8JN)ZRDIBL8GX6VM7(_/
M3N!:LMN                  ;:\-O0#S=0M+-/,/W\7('26"O233 %21-^*
M7E*++7K(IB=1.0E+\0 "%,=R%               !Z/^7IV6X[@=)Y5^_@IV
M8   IPLP7L.TQ]!D23('08^$M                 !GEG?T]<?: ,?[4\UO
M=Q<@6HM6#15L3 )IB:UM$]10TQ7T3\+16KD=33N!"&.Y#
M   V]8;;\N;J% 37RV]_#] )4BQ-Z2Z0J2)K&LVNO7K!-(G(&E^\  %KBV@
M              /2YR]6Q#'8 >9?MX;+WJ  *-+-EW"N@6.*4+M%P@"@"T0
M                -FF6OHXY.L 6^FOEP[^$"U%J\"LZS+BD;17]9Z2WUJW'
MK;X64O3(VFG< 6G+=@                 WH\W1N;PZ!"'E8[_/D,@!*T6*
MO663%21-01-N[5GT3)T5'$WOK?L  !+#'<^               ^'JTX^S+G/
M0 :*NKDP$VR  MX6G+@EV@"V9:\N"7; .HQU((                 WG<_1
MN>Y^@ ?#S'=O#:&]1:BU:?F)[$PI)IBHXGK*;F*HB10=JY(9Z=P!(BP
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M  +737S.=W#(Y6HM6B9K&IZR$1'IXD B8I$GF,DL].X %GBA
M     ;W^;HW&X=  E:/-5V\5F+U $E10%H %4Q-81(    I LD
M    3 ]8W%VY+4N  ,5=,_/)U\<)*B2WY5Y<<     '48V'6
M   "NH>L?B[;UUN  !J_WPTW=/-#G0    "//H +=%J                #
M*VE_55Q=DU2 !BK?/SU=G'+I <88^Z9\ "\E+U&D    24Q]
M !\-Y?/T;HN?H   &N+;'2CU<O4       #'XD@              !4</3/R
M=><6>H   ZS2?T\NN+?'Z       4866               !>NL^IKC[;SUL
M  !@=KCHRZN66R D2(20YE21/T    $&8W@             V\X;;[N;J[0
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M    ! RI0            '>5]6<G*WO#6WT       '$EB(0      ^'3(
M        =T)XGM
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M#H)F2*$63.5/$R(4D\)[*&!%G$F1TG>2>$;*&APE-#L((D<)M*8$O(PY$<
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MPI7$Q$'>
M                                       #K
M
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MK+$EWN8!C+%0]C_Y!AO).Y4FA43=G5<^.?N>VFP!2N'\MMS/]"00PPPXS^L
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M ^,@+QGFI'U:Y+P]*L?3V\//M$\W\++].P_Q]NQ_'FVC^1^)_P!AX_,>U%*
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M "+GZPOK/DYSC&"S"S@<@Q@+!C.!8X!4D#P6J3&YT:<40 E4G4<@#BC<\X3
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MA-)&482<=0O8A"1*VX*HPIE2%ED-XBLE-6 '%-99!G<Q. =T)LHU"(I3HI,
MHX303T"V@D 2411!YK5@1H0] *I.!6F.;R3DRENP<9EO+$3EN3B.3MO9S!-
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MFFMWQ/&C.R#N<G"8;9G)AK:$\@MI^"Y6D L F1@3"1I0(DPVS/6&MOQ- TD
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MD2H92X+;G^(3XA>)2DH Q'LHA-<]+DSXH=N1"Z!- AL]SJG$N))Y)!Q]MTV
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MYJV<1N%R97MK]E6 C$\+C^:I[2X?"Z2$.)Q>1W*=.<B9R[T-C50!5NZK;_\
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M18J[S^XJNZ4JUB!(NL1<3>9T;1_\E?>@]PN)1>XWDJZT(N<[$9_I68VZ[L3
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M$7.=B,^TD"09B]%[G8C/L!\Z!A.OC<*/Z$.<+B423>9\E9C9KX.[$P.T0YO
MQ'3S2_ [0H<V@83KXW"CS=F-FO@[L3 [1#F\#$=/-+\#M"AS:!A.OC<*/-V8
MV:^#NQ,#M$.;P,1T\TOP.T*'-H&$Z^-PH\W9C9KX.[$P.T0YO Q'3S2_ [0H
M<V@83KXW"CS=F-FO@[L3 [1#F\#$=/-+\#M"AS:!A.OC<*/-V8V:^#NQ,#M$
M.;P,1T\TOP.T*'-H&$Z^-PH\W9C9KX.[$P.T0YO Q'3S2_ [0H<V@83KXW"C
MS=F-FO@[L3 [1#F\#$=/-+\#M"AS:!A.OC<*/-V8V:^#NQ,#M$.;P,1T\TOP
M.T*&Y(9J0S4AFI#-=^70,)U\;A1YNS&S7P=V)@=I1-3*F5,\S@8CIYI?@=H?
MD3"FIRY; PG7QN\3J59DIC)3Z*?169*SF+,;-?!W8F!VG.(&(Z>:7X':'>)I
M%Z=PT\E#ED#"=?&Z;SJ>;P\;=?&[$P.TYQ Q'3S2_ [0[LY[@O3N&GDT5J >
M4P,)UW3>=3S>'C;^<-V)@=ISB!B.GFE^!VAW#NB].X:<M@W'=-YU/-X>-OYP
MW8F!VF\=X\L@8CIYI?@=H?DB^B01$J!RF#<=TWG4\WAXV_G#=B8':;CD+T0K
MAN!$%&[E<#$=/-+\#M#2;MX7TFFL@9\G@W'=-YYO#QM_.&[$P.TW#1,JT[EJ
MF<E;RN!B.GFE^!VA^2+]]O)X-QW3S>'C;^<-V)@=IN3DIJ:FIJ:FIJ:FI\J@
M8CIYI?@=H=PCCNB^DTR0$N3P;CNF\Z\WAXV_G#=B8':;CD!-5550$U555 35
M55>5P,1T\TOP.T.Z1+<%]),Z!;RF#<=TWG4\WAXQNQ,#M-QR!4U6"!4U- J:
MGRN!B.GVI=<=#O$2I%Z.X#RF#A[[KQ)SM>;PL>ZX3!'3<<@%(*00"D%((*04
MARN ,1[;AL.\1*@7IW#3R:)&@#E,+ -V,).GGS> ,1[;SQ)Q%+D#)5E60,E6
M59 R595N5PA)@ZV[D42<>MN\Z@7IW#3R4.5WV("0 R&[%;-L^(YNQM5H&]&;
M<[UI<A2*6\L K$#,[L9LQ/+Z?(L5AXJSE<%LW3X-^N^]M5TN:PFUG3X#?<*P
M(1L,J'*:F5,J:F5,T3*F>506_N]-TVI[:I(W2JJJJJJJ ERIC:K9>N_$96'4
M<T F9"],;5$OD163^(=^:,;6/3BKK-Z(RL.HN5UF[;3:ARF$S]Q[#S\F)#G:
M+^9 3L"ALJCJ;_E1(<K1=EES)K2XR":T-$A\B)#K6B_Z[LE(*04ARF'#G\3K
MN S^6^'6M%A^J((L/+VM+C8F0PSJ3>?F/A<6^GVY@R&YW09IK0T2'RGL#^AS
M3F.;IGRT FP)D*5KK3EP'S2T.O"=!_CZ(M(O!Y6&N-P38/\ ,]@@ +!\YS Z
M].@N%UOU1!%_*Q#<ZX>J;! OM/M\YT)INL1A.'552.!Y/(FX(0GGA+5-@_R,
M^@0 %@L_0[-AX+8LZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8M
MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8M
MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MZK8MS*V+.J#&C@/T
M<IWK9,R6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6
MQ;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6
MQ;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6Q;U6R8@UHN _1R&2D,AZ
M*0R'HI#(>BD,AZ*0R'HI#(>BD,AZ*0R'HI#(>BD,AZ*0R'HI#(>BD,AZ*0R'
MHI#(>BD,AZ*0R'HI#(>BD,AZ*0R'HI#(>BD,AZ*0R'HI#(>BD,AZ*0R'HI#(
M>BD,AZ*0R'HI#(>BD,AZ*0R'HI#(>BD,AZ*0R'HI#(>BD,O_ ,="\:T_GK1G
M1P/;?LMI_+]P\-%P[E#BL_SC0#:K0OM-9[^:'#5<<J!QT07Y.@TYH+@5^7[F
M5LI(W[DZ/9&CO/=X'MN]*,Z/R]6+/2BR:X*2_+U^31X;V5'Y?*C[JWC=^<%^
M7K[+_*_+U8%P7VI*L4I>M'#N/*R4J.![+/[T<!N!9K\ZT9[O=9:+[T2_)T9J
MQ2^LMTK[T27^:;*/LK%EUIZ;EGHLE(;GV_4^/E3^1.B>_-"S>FITS4]V>]/Y
M,]Z=$Z)KTIFITS^7.B?TEN3^1/<GN3^=/?G3/?RZ*>E$_P#W>GR25DZ9?.E3
M*[<EQW)4RW>'R9;LJ9?(ENRIE\B7R.JEO2LFI?*EO@*7'Y$J9?,D:9?IN-'$
MT<:/19:[V2_S3DOSZ(<=%P7"=''UW?1!<$;Z?SZK-9_==;*<J/2C@* LUDL^
MRX=_"S7!9+THX=U.VB7TW0KUG1QGN>5U5Z/BC[4<"N/HLU?]%.^GC3G:O\T&
MC[K+O1P"S[+AW\+BLM?LN-!7"@J\SGN<$>&BSU7HLEZ4W+K9^=T%P*R7&<_S
M1<.ZZ4YZ>0N"]%P[[GI1DN*X%<9KCN\.]'&^CKQN_P H7K-<.ZS[[G!?9<%Y
MI/#_ /H$E)27VW);P4IRHRI/!2ME^3W)4<:)*2E1)20"E1EKN2W#PTH_/\^*
M>'>G-<$;Z,]*)=U*ZCA0%G2>%%B^ZR[_ %IRZJ4U)"^F2E0+UG3?+T7_ (LZ
M?\K/2GC*G)24EP71<.ZDI7]%)26>BE1P/;>E])T'P%]UDI6RUHLNH/A<*>-$
MJ."/#124J)42HE1P*RZ[V:X!27!!9K)2H%]RSHX_IC\BZF=$_E]5.W>GNS^F
MY/<G1/Y$Z9[LU/VHFO%,Z!\R=$Z9[D_F3W9J>[/<)G1.B=$]R=$]P[L_T,__
M ,W_ /_$ #T1  $" @8( P@" @(#  ,   $  @,1$B$Q,E%Q$!,@05!AH<&!
MD;$B,$)2<M'A\#- (V*"\01#<&" D/_:  @! @$!/P'; )L!.2$)YW+4OY+4
M.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5:
MAV(ZK4.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5:AV(ZK
M4.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5:AV(ZK4.Q'5
M:AV(ZK4.Q'5:AV(ZK4NQ"U3\$6N%H(_HMAN=99B4((^(SZ(,8/A'",ZT8;#\
M/E4C ^4^!^Z<QS;1_0;"<:[,T(+!;,]$&-'PCRX00#: 483#NEDG0#\)GFB"
M+1+WK8;G98IL%HM]H]%9PIT-CMTN8J3H1%8K'7WH!<9!,A!MM9Z</?!!K95R
M^R(E4?>,87V>:;#:WF<3PX@&T33X,JVUC#?^?=L@[W>7WX>^&'UV.QQS1!:9
M'W36%YD/$X)K0T2'$7L#^1W'[\D06F1]U#ATZS='7DK*A4.(Q(<ZVVX8_GW,
M.'1K=;Z<1<T/$CX%.!:9'W#07&036AHD/^^)O93',6>YALIGD+594+.)Q63]
MH>.W!9\1\/OQ.(RF.8Z\O<0F41/>[TXK&9\0\?OMVIC:+0//BL1M%U5ALV6B
MDX#%658<4C-DZ8L/KM,;2<!Y\6(F",41(D8;4%LS2P]>+1&TFG$5C9@MM=X;
M1( F48_RCS6N=R_?%,BAU1J.ET?Y1/F5KG<DR*'56']WZ'Q SF<%KW8"2:X/
M$QXC1$B4*A6=Z:21,B4^ /;28?,;4 5%WALOBEKBV0J6O/RA:\_*%KS\H4-]
M,$V2*B1*!E*=2UY^4+7GY0H<0O)$I531(:)E:]VYH\:TR*'U&H]#H>Z@)^2A
MO+]P &_@D82<#B-J&),'.OSV7Q0VH5GHM<[ ?OBA'.]H\$UP<)A/B%CI2FM>
M?E"AOIDU2DB0T3*,<[@/%,BAU1J/0Z'NH"?ES3'N?ND!OX,\47$<]A@DUHY>
MNU&=-TMP]5#ATZS8$8+#95X_=$421@H;J3>8J49WPC,IC"\HP!N)FB)&6\*&
MZDWF*CV3_:B'ZI=E1!$I5*%4^6,T]U$3\LTQI>Z9LM/ G"3B.>S#$F-\]F+_
M ".S3(0<V9)M6I: 3,U5[M$(2;G7]E&O^ 4.'3!)G;):AN)Z)D,,,P=TJU'-
MT>*A@!@YUE/%&)5B"N9JWIQ,5U60R311  X)&NY'UV160.>R\R8XZ!!8+:RH
ML,-K%AW*$9/'.I/AAQF2?!1&4#*VI0+79*.;H\5#: P<[5$%%]7(KGR3B8CZ
MLA]TUH:)#_LX\&CCV@<1I%HVXHD\\U">&S!L.]&(P?%Y)QI$G%0#>&2B7W9J
M!=)Q/;1&'MY@*!:1R4447TMQK&:,84:KW10172-@%O[R3W&(ZK(?=- 8T"8_
M*!!L(/ 8PD\\P#LBP9#TV3#:XS-I0:&B0L49TFAN/9,;2<!^RT13-[LTV(6B
M4D(^+?)-<'5C\J,V8!&ZU,B@-D[=9)5Q8F9Z*,_X1XJ$RB*1M/0*DW$>?!(E
MQWGLLOMSV7"D",406F1M"$>JMOBGQ"^54@%!972W"SGHCWAD% M=DHS9@'#T
M3(H#:+IU6*N*_/T49_P#Q^RA,HBD;3T"I-Q'GP:/8W2V\WZAZ[;FAPD?#DC!
M<+)%:E_()X#72&ZW-0/B.03[[LRH-TYZ(]X9*!:[)$ U&M:IF"BND* \?LF-
MH-,0BN57[S0#HKC7XIS3"((.1374F@^? (]X9; 0VWNI.)4%M1=X#083229F
MO):AN+NB?"H5SF/10W47 Z##8=R<1";4!,V?=0F4C2-@ZE/<7NHBR<@.Z="+
M1.<Y6\E">7 @[N!ON/R[C9AWV_N[9B.HMYFH*MQQ)0@#>3/DGPJ(F#,>BAO+
M3R-NB/>&04"UV6@PV'=).HPFU"1-BALI&9L%O,X)[B]U$6 R 3H):)SG*U07
M4@0;1^]."Q[HS[:67F_4/5':<0T3*$2&=\LTZ*T65GHC,GF5#;1;+?:5&;(T
MMQ]5#?0-=A6M9*V?*2<:1F5";)L]YK\-#W46SW[E#93,S8*SFHEQR@?$,E'L
M:H-SQ/ (]X9=]@(;45TF\S4@)F6* D ,!H$<3,Q5N(6M9CZJ)$#A1&*8)N Y
MZ)@5FP(DQ7^G(("B)#_M,JB">*?<=DH%KLN!ON/R[C9AWV_NY'8C#V<BFF3@
M<"@YIL(45XE1!F2@)D#GHCWAD% M=EHLK-B),1_0<@F@-  3:HM?S'NGW3/!
M0+QRX+'NC/MI9>;]0]4=J(PN%1\%JGX(0GG=YID(-K-9Z:" 1(V)T$B[6.JU
M;_E3(,JW>7WTO9$>ZRJP5BQ-%$ :'0G-,V?E"&]Q]KJ9E"H2PX!'O#+OL!#:
MB,>YU0J%E84.&09NW6:")@C%.@GX2#T*U;_E*$)YY9IC SF<=$0/=4T5;ZPH
M;* KO'H-$2%,TFV[U0BNJ,_$IC: EY\#?<?EW&S#OM_=R.RZ#\ODM6_Y2A">
M=TLTR&&<SC]M$5CG.F!5)0F.:3,;M$4/=4VS>H;*(F;3Z:(D*=;;=X5"*:C.
M7,U)C* EY\%CW1GVTLO-^H>J/%H]X9=]@(<7?<?EW&S#OM_=R/%X]T9]M++S
M?J'JCQ:/>&7?8"'%WW'Y=QLP[[?W<CQ>/=&?;2R\WZAZH\6CWAEWV AQ=]Q^
M7<;,.^W]W(\7CW1GVTLO-^H>J/%H]X9=]@(<7?<?EW&S#OM_=R/%X]T9]M++
MS?J'JCQ:/>&7?8"'%WW'Y=QLP[[?W<CQ>/=&?;2R\WZAZH\6CWAEWV AQ=]Q
M^7<;,.^W]W(\7CW1GVTLO-^H>J/%H]X9=]@(<7?<?EW&S#OM_=R/%X]T9]M+
M+S?J'JCQ:/>&7?8"'%WW'Y=QLP[[?W<CQ>/=&?;2R\WZAZH\6CWAEWV AQ.S
M8?<?EW&S#OM_=R/$CLQ[HS[:67F_4/5'BT>\,N^P$-EQ#1,V)KPZ<MVC6LG+
MPT.>UMJ!F <=M\2A*J<PFFDT.QT.,@3@$R)3,I2J]X2!;4I@V5J(2ULPH3W.
MF#7+?[X[#[C\NXV8=]O[N1XF-B/=&?;2R\WZAZH[1BM!E7H<X-$RFO#[-@D"
MT@9H$&PSR45SF@2WFU0G.<#/P/N7Q2UU&0W?V1L1[PR[[ 0V7"DTC$*$9/'.
MI/=1:3OL'CH::30<0G^W$ESD%4!R",<;A/F:D(XWB7-<TR+2,I2\?QH9$INE
M*51WX*/:W+NH?\;?%.C 5 3]$8P<"")3!YJ!>.1TNC 6"?1"/B/)3$ISJM1C
M#<)\[$(XWB7,5H5V(QI.D14#*<^TD8^#?-,B!]5APQR49X/LX'LH<0,!$M\T
MXR:72G95FH;Z4P&T9?O).BT7%LK#*<_PC'P'FF10ZJPI[J G*=:8^G.J4D]U
M 3E.M,=3!,I2,D^(&<SA]UK_ /6K--<'"K9&E]Q^7<;,.^W]W([!<&WMZ#@Z
MS0(C"9 UZ"]K3(^X?$##*4ZD*P#B-#C1!."9$ISJE+WQ( F;$U[77=)<&VK6
MP\?WR6MAX_OD@X.$Q9[V/=&?;2R\WZAZH[(42^[-0HDO9/@>RC7/'[J!8[-/
MB!G,X?=:\_*$R('\CA]E%?/V96%,B41*6]/=1:#*<\<E#=2%DD^(&<S@M>?E
M'FF/#[+=X3X@95:</NM>?E":\/%7DGQ SF5KS\H3W!SYCE_=CWAEWV AM1!1
M>99A1G4@W*D?%.9_B&(]KS^RAOE#=RL\5!$W3P]5'-0"A,%&D1,GHHS !2 E
MN4(S81@H5\>/HC8<BH-_P/HH]K<NZG*!T\RH+022=VY1& M-58$Q)0+QR.B*
M9,/.I06@S)KE4 G0VNW2YCT47V6!K:@2H+1*D:ZU&8*-("1GZJ :I8%.KB$?
M[=UJVW9!-JB#DZ2C@2!D)SM\%!:TM,P#6HG\;O!0/CR'JHG\COJ08P"4AS.]
M77R&YRC7?$*!8[-1KGBH%QV?9 BE-U=<RC%AFUGI]U",GC U;)TON/R[C9AW
MV_NY'8B";#B*PH!K(Q'HHIDP\ZD#(@X%<_%7XF9Z(D"LV(QQN!38S358B9 G
M 33(E,RE*J:)H@G!,B!\ZI24:_X#NFW1D/1&,T63*=%#F.%A]5 ^+P[Z'.HB
M:8^G.J4DYU$33'4YF4I)T9HJ%?HM>/E*G,33HS14*_1",#:)<]A[C$=(66#[
MIC0T2'B=,:QN:9"#FS,PGM#3(5J&),'.OWL>Z,^VEEYOU#U1V0G_ ,AS46'+
MVA9OY(OI,HFT&U0+'(>T^O>51;*5$*[$JW.48"0,MZA %M8!KWA1K@^KL5!N
MG--]M]>\S*HME*0DFL:RSSWH$4INKWE&*PB5$]%#,GC U(^U$S=+K)46BJ03
MA1>1S']V/>&7?8"&U'%0=A4F"DX#]DI3JQJ1JF%"$F9UJ*TN;5:.H3(E"HB8
M]$^)3D *NI4-E%LC:;>6Y5PW\PG1IBB!;^U*#?\  ^BCVMR[IHI00,4UQAGU
M"?%I"31:H%XY'0]M)I'DF/,,D2S"=&^42S3@7PP92<*Y8ID2A415U"?$IU 5
M>JA-HBNTE'^7_GW6_P 5_P"S_D?51A-F14.(& @CFGF<(D;Y*!\>0]4_^4_4
MOPG?R'ZE$%)I\U#?0G5,%/>7[I *!<=]79$&&_TP*UK/D]%#=3G5(C:L[Z'W
M'Y=QLP[[?W<CLW(GTG]Z*,9N P[J(V3&<JCXUH/_ ,)Q'LJ *R["I1S8/%0X
M;:()$R:U%8&R(L/J@9P3])"@7C])42X[)0+79*-?\!W40RA-Y@*"P.F37*J2
MB0VT20)2]% ^+P[Z(MP^'JH%C_!1KGB%!N._=P3?9=[39RW%4H+K1+PEZ**Z
M3*M]7@H98*W6[MX40PR/9J.4E!,VD8'1%?\  /'[*%0:)EPF>@0B&G>]F?A)
M%XD7"3I<UK_]>OX332 .*)D"< FBF_J??1[HS[:67F_4/5'9"?\ R'/1$90/
M(V*!8[-/:6.F+)S"U_\ K7G4F-+W3-DYDJ,)MR,U#B4!(CFHQFQIQ(]"H-WQ
M3FF&Z?B#V6OJLKZ*$YSITA,8IS3#=,6;EKA\JAOI3JE+R41I:Z>XF8*U]5E?
M1$DNF;3_ '8]X9=]@(;1 -10:T6"6@L::R!I+6FT!!K6V :"T&T30:T6 (-:
M*P)(M:ZT35E0L1:TV@(,:+ @UHL$M):TV@%!C18T:"UKK0$&M%@&B@V<Y"=N
MB@V<Y">B@SY0I"4I58(-#;!)4&DSE7HH-G.0GH+&'X0J+92D)( "H"2D#:)K
M5L^4*SW#[C\NXV8=]O[N1V8XK!Q"ABD\>?DGBDUPT0Q)@YUJ,V<G>!3(H  =
MNWI[]81*S<.:#90Z.^1\RF.H.GX$)\4.$A.NV:@6NR4:_P" [IXI0A+< >BA
MOH3!L*B1:0DW?:H'Q>'?1$$V.'CY*&^@3@5$B4JA8H)DUV?V6MANO-3Z'P#-
M428(&^T)C@VIS0?"Q&)#W,!\ FT9 M$I^&AT&D2:5O):C_;I^4!-TN:;#H@M
M/M3."H-P&B,ZQOB5!;)L\?3WT>Z,^VEEYOU#U1VJ+;:(\M! -HF@ + !EHH,
M^4::#?E'DI U2$LD !8 ,M%!GRCRTT&?*--!GRA46G</+^['O#+OL!#B[C_C
M=EW&S#OM_=R.R6AU1K36-;8)?O/1JV?+U.DPV'<@QK;!+06-=:$(;!NS36-;
M8)>:+&NK(]=!AM-H[(0V#X;<TUC6V"7GI,-AM'94&2E10:&U 6_N]&&P[O*I
M"&P;J]!8UUH\4(;!N\]D0V S KS/WV##83,BO,_?W\>Z,^VEEYOU#U1XKOS4
M>\,M@(;0(-A'G_4)D"38$8^#4UTVAQDV?/\ ;5,&PS_M1+KLMF'?;^[D>+QK
MHS['2R\WZAZH[6L?3ESLX$' V$'(^^CWAEL!#9B.HC.83'47!V"8^F"92D4Z
M*UM5XK7_ .O5-<'"8T.=1$[4Q].=4I<TYU$4I3K3'TYU2DG16M,A6>BU^+>O
MX0-(3LS3HP%E:$<;VRZJVL:'O#+5K_\ 7K^$R('\C@HS_@E@9J&\,G-LYJ)$
M#A("2AQ P$2G6B0!,U!&.-P\TV,"9'V?1.-$$X+7C>V7C.:8^G.J4OZD2X[+
M9AWV_NY':<:+2<$Q].=4I>Z<9 G *")N).[U]XR*'&4M(<:5$ME5.V?]:/=&
M?;2R\WZAZH[1BR?*COE-1'T!.4ZUKZK*T(^(\DZ,!=K]$V,#>$N>@1\0M>?E
M3'A]GDGQ*! E.I&/@$7 "D48^#?--C VB7HHCRR54YICJ8GYI[Z G;R3'4A,
MB2,8?")H1\1Y*VL+75UBI:_!O5:YLI[\/W<M>?EZIK@X3'E@GQ SF</NM>?E
MJ3'A]EN"B1*! E.:,? )L;YA+FHCZ(QI33'4'3E.WJF.IB<I>]CWAEL!#9<
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MU-764W5J9YJ@#>;O>7$42L$T6U GCC.\EVEFZ=F60BCGCS)E19*JAK=]&J5
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MBW/_ &=MS,)P.55E$<D3-W$Q5RM&//:2W<<5NRDU539K74<D,)?+=Y(LDM0
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M=E?W0VK:F$F6-)J_,**:0KQ">$-13.[<K3,L9Y,;8F3;BEJ!G>4Q5^=UL68
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M-RIX-H9M5CP-N.-G)J[:;.,RI\XSJDH<TI*VNGJ*6HIZZ81RZ::1C#$\>K5
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MAF-/4:NO!),Z[Z6G=>*[UW,;"R]4VQD+Y?$L%/GN8Y#G+01C3''52Y@L-65
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MU"K#SR;\@'L /=C,MA,PJ8Z:LGK&S/)M\P1:O>1HE52Q,UAOU*"58KZI%+E
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MJ:M<RGRN&GJZ2O,$,$YAE<Q/!-N$C232=+)(5WG$AB>&)IX$6,YEE&7U=1I
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MJ5OZN/J5OZN/J5OZN/J5OZN/J5OZN/J5OZN/J5OZN/J5OZN/J5OZN/J5OZN
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M\7]?&KW3ZOQG"?>+_9["9/*"ZU]*<?Z1<?:7(0T>[GS;I&<S\+,QK7\"Q_\
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MHOW?'; J:G@X]KC[ONF\_</IKK[I67\8PR>Y9E_$;?:'+]G\F@:HK\QF6)
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M.S.06XG1Y-_Z?I=2/Y(G\7'^'0_NA[34A2HDCOLS0SK9H8GYYK+&>*R2KPI
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MJ8C*NF2404JT$\R2I$Q7PDZH>O+;R#9+]ML%X;PSO#JC$B^)(5N%=3]UP;%
ML-DFJ&O/<7W4<'U0+>ZUVC7NO?LQ/7P5$5/&KSBFI6B#JZ4[,MZB0G4&ET'Q
M-.Z!'C8I](T4]1D\-<(R.LLLD\B'K=P"@?TXS6*0@I25B0PV%K(:6"4@]YUN
MV):."H2FIXZ2&9GW2R2F21Y%TKJZH6RW8D'N%L5 ?=2UL->,NCETF.%VDD58
MII$!.FRMJ=%/$BP/'%)%/5K4QUSO3:MPD;P5&Z>5)$L2&CZC JX)'#K<\5L\
MM4U1I]<]"RHA :*:?C>UV!T^*>J!P'#&745.Z4[RY<E=4S[M6TH;1K'!'P0%
MGU7)N$4#J\<4\#3++4554T25*4LCF.!4,C.U-%JUS #2--DXZB+"V*PRK454
M4-(:F*>:BEH_"*=)IY"R*AN2K*RB^G5<<+X@EGJX9A)5Y?OX1"(T0-5PGP#W
M+]0V'A-6L<>&)I=['!HC)WTHU)'W,RW75][?B>&*:E>:6IAJX)W#S4,E&4DA
MW9\&651)&ZORXLO#CQQF,T=7##T2LK8::+HX<2+3NP43L2#UK:>I8CQN)Q35
M)729X4D*]Q8<0/-?EC+7IC"D]7FG1&)B&[$9:JN= MQ&[#><^G"99TN-TGIF
MJ^EF!1-"(G$;Q",'=MK9T*N?$&H$-SQG:2NDE3E8EW<P0()1T05,+.G$!A?2
M]N!M?MQ#F,U5#,#N&J*40!$$<Q13N9;Z]::[W:X>UM(OBN!F1*.DG2-(Q$#)
M+J@20ZW)ZJJ6X6&H\;FV&S:.IB1-$E1%1-"#&:>.YT22WWF]=%\<=5&/BD#%
M8U5[6*:/,*7A9C32(-47W3QS I?M#I?%%1RLT51-2M6U<L%(]4T8:33'3Q1Q
MJP%N(:5Q;J\KMC,) C=(I9Z6.FJ)Z62F2ICJ)X$N8I5%F76\<FGA<!A:]L4%
M.*J&;US>2$NT 7HDD<>_:2,*?"+NT= CGQM+%N8QF,-9)TI:.A&81RK&(Y#'
MX;7$RKU2P,758 7#<1PQ35?T34&9X3+1+EE2D:0S, =S4;OBT"MK+.=$@4VT
MW&,SIXJM*6"D:G6(B!99&:6ECE(;4;: S??&]KBV,IEZ2:67US>DG$**4>6'
MI,9E&NYTG=W$9N./FP S:V"\7( U'OL. OW#AC*VIC#'/69F:1B8QNQ&35W.
MA;<1NE;A;41SXX2@J9UJHZFEEJ(I=TL4D;P/&LD9"=5D82@J>8M;C])FI)2R
MQSIH8H0' /N20PO\1]0S1SU%+*P"R-3E!O57Q=8D21;CL8 ,._$<2&2)HG:6
M.H1_#B5[[R36P;49+]?4"I[N Q*[22SSS)NWGF*F30+V1=*JB*"2;*@X\3?$
M(AGJ*>2"(0K-$R;QHQY,@9&C?OXIP/*V!!)+/(0^]6=I/#K*.4BM:RD=@"Z;
M<--L1U4E14U$\0=5>9T\5Q8KH2-$'?< $GF3C=.6"ZXI.K8&\4BRKS!X747\
MV$D$DL$\8*I/ 0'"MXR$,K(Z&U]+J1?B,;KI=7KUZ^D;Q=]J_(W>G[C=Z?-B
MN"O+55-5!NB\S)J8 '0@T+'&H&INP<^)Q%O*FJFCAT-'32R*8D9?%Y()'T>3
MO':V',=3501RL6F@A=1'(S>,>*,Z:_*W;I?%*ZW3HBNL2+XMG30;\+FPY<1Q
MYXEEWDJ/+$D):-@ND(Q8,G#QKGMN/-@R3S3UCF)H0:C=]6*2VM L4<:]:PN2
M">'/"$5=8T4?M=.TB[I>X7""5E'8KR,,'>5=6\!?>&F9XS%?5JM?=[[3?R=Y
M;LY8,4H.FX8%259&4W5T8<593Q!P)I*BHJI4!6)JAD.Z#>-H$:1BY' L06([
M<2A"QWL\D[:K>/*;L!8#J]W;Y\35<-?74CU"PK*M.:?0VX#",VEIY2"-;>5B
MBDEJ*B>6A:9DDE,6J0SQM$V]T1(ITJ_5TA.0O?%)7.&6HHV)1D-M8*D:)18Z
MU%[CD0>1M<8J*R/,LP@EJ=.O=FE*JJ#JQQ[RE=EC'/3JYF^)*.HJZJI$C:C-
M*8=\!=2%!CA1-(*]J$\3QQOXJFJHIF01RO2N@WR+XHD62.1;KY+@!QWX-"4+
M0-<M=FWC2$ZC,9/&WNOKZ[W#<L+42U556R1!E@-4Z,( PLV@1QQC45ZI=]3V
M[<(DA8!)H9QIL#JA<2*#<'JDCCYNT8J:A2VNJ,9D!(TC=+H73PN.'.Y/'#1Q
MEB&EEFZY!.J5R[<@.%SPPU1!4U-#/);>O2L@$VD6&\CECEC9@. ?2'MPO@TD
MD]3*&E29YI) TS.CJXXE="BZ#JJBK;D!BI"U=9#!5LTE131/&(GD<!7<,8FE
M358:@D@4VY8HYM4FJA@>GB%ULR.J*2_5XM9!:Q4<^&*B=];&II11RI<:-T"Q
MX<-08ZSQU?%AJ2-*S-%E0PKO9*8;A=&B-#[1X,=K6=^'&^(::^IP-4SDZC),
M_%V+=ON0?<JN*=W+ TTN^33:Q;25LUP>''LMA4D+HT<BS0RQ-IEAE3Q70\1<
M=S J1P((Q#6355545D!\%42-&&2,^/$%BBCBW<@X/="Q]T,1Q/45$"QR"6T!
MBM(5\591+%*KH#UM-N?/#%ZZKJPP "U'1]*6[5W,$/\ 3<8Z1'45-'4:=VTM
M,R R1CB%D66.6-K>2=.I>PX-)JETO*L\DI?5-+,KJ^MW93<DJ > &G@ML4TS
M%@U+(TD=B+$NAC.K@;BQ[+<<".74I5A)%+&=,L,B^+)&W8P^,$<"",0ULM55
MU53"LB)).\?M<BZ2FB.*- .WJ@$MXQ.):?I=:M)*6;HJ21"-'=]X2K;K>D:^
MMH>1DX\5MBCDEI9*6"A+[QWDB/3 .,$06)VO&L@6<[P+Q&FV)81+)#O$*;V$
M@2I?RD+*P##L)4XA6+,\P,43:MRYI-$G&Y$A6D5VU'QCK#'W6)335M;1QSNT
MDT%.\6Z9W\=EWD,CQ%_*W;+QXBQPFY<I014>X2GU:@9S-O#,;\==KZF))8MB
MGJ26UTV]T 6TG>KH;5PORY6(Q)5W;>21+"1PT:4)86%KWX\>/J2O'F->K32&
M20WI26/=J:F+:5'!1?@,250S"N260!>J:8A$%NK'KIV*@GK&QXG"E<PKHW"Z
M7=7B\+YV1H3&&[+QHF(1%),!$TCOU[](>0=9I[CK&_$6M8^;$-Y986@E$T<D
M.C4' (^R)(I''W.(Y)ZNJJMTVN-9FB"*XY/IABBNP[-5[8F J:J*&H+--3QN
M@C9W%F:YC,JZNT+(%/=A42LJXH]TL+1HT6AT5=/EQ-I+#QC'IQ#N'FI7@B$$
M<L##7N1]C<2*Z.M^/64V/$8$$LD\I#[Q9WD\.LHXB1'4 *5[ JA>RV(:N2IJ
MJB>GW@C:9H[:95T%=*1HOGN &OS)Y857+HR-KCEC.F2)QY2'C^(@@]HQ*TDT
M]1++$T)FF92ZQ-S6,(B1IW\$XGG?"4A+[M!$H((U^"TZ;FUO)X\,3*O%FBD5
M1WDH0/Z<4T,\]4(UBBWM%O$W&L %E+!=X4U<T$N@^C$S)45%.M3]410L@24Z
M-%^M&SH=/#P;+>V*:!99HC2:=Q,A3>KI&GRD9#=>#73C@/*7E/1FI6UE;21N
MP9BUE'7N.8L/-A6Z9621Q^UP22+NU[!?3&LDFD<MX[8J=!8]*G>=]1'!G55(
M6P'5ZO"]SY\04:RSQ]&D$M/.C)OXY S,'!*%#XY%BA!'9C<2LU0"A1VETEI0
M>#:]*JO'S*!B2&"IK9T0Q&FHI)H]RFB5&MJ*+*RHH.E99F46M;EB*=9YZ6IA
M5D6>G*!]V_%HV$B2(R$B_%>!XC%7&6GEZ;(DTSRR7DWR* )4=0I5^ /#D>5A
MPP[25]=5:D,:[Z1 (U;F5$,<5W[I'U,._$4TU965?1R6ITJ&B*Q,1IU7CB1W
M-N ,C-^/%2T=14"&J,K/2ZH]PLD_MDB>#W@)YV,A0'DN*<05%5334T/1TJ87
M3?-#>^[E#QM%(+\1JCX'B+8J*-GF;I9U5-0S U$KW4ZF?3IOU0  FE1P4#%*
M'+CHE1%4QZ2.+P@A0]P;J;\;6/GQ4SJ6U51C+@VTC=)H73PX<.=R>.$$<]1#
M+%/-413QF/>(U1[:MGC:-D8<-+(>';?%<#/4RMF"(M1)*ZE^HACU)9 %)!Y
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M X=58$Q-ID'N6L&L?YI!^/"SM,@B9M(D)LI/$6OZ0<"2-M2-Q#=XPH%5%UR
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MPPIYDD9;%E'!@#R.DV.D]_+$$6\A"O'*QC:^^?3:S1^3I6_6O@#ID/%M%]7
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MRGGU=%"2I/3II2ICIEC!TVX2:XSK/'3VXS" ;Z6,='>":2EZ)--ID5YH=U(
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MS< ./:>P=OL0CM*H#:KPRO"U_OD(-N/+"00KHCC%E7_Y/$D\R3Q)Q<\ .).
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M6IRTU4CF,E82K*H$<88<#?@+V%N>,X6?=/4Y;&\B2(A6.4&F,\1:,L;$'JL
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MZXU+P\;PAY\.6(\O+ONXQ3@/PU_0[HZWX6XE!?AB>2&',X3.(][+0F%HZHA
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M1S73D\^?SX9[KX>_9K/=5^\8X?N0_K[/EE_#W?NO+/3\>?/Y\,[\?#I_6_\
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M&'RF44(YE?!!<F36!P"A][Z+,F+=4E>\3<#K&7*"1'R&;L.K.^CO?H,C 2%
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M!*X;.F2*#(RU,_0VTD(F.#(4G7>7ZN?9#!C5OTJJU-\-?U.1/H#\?Q?C7?\
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M1(@""%B-B6-Y!=)T9U0^<+=K&QQ#)&%.M"AE=<CG!UGB#;C%T%%D IRUU)N
M-&9%U#E5W<#9EJ+&1IC4FR#&Z:]6%!5$>D6+QHT@5]LMZ(,>E=%816Y2A2KE
M<9&Z&T>RX)Q]L]<>*WJ93;5N*2?+FV,0@;97F=57B&O')S-=U=@7I+1,PLX0
MJ/0M8)D.,-&MP*H.B@)P604@D<$PB4KI@Q!OZ%8W!$VG:#*Y3B@\"$0*</\
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M-NG8X\+%RWGQ/3"$9RIC8X88"!1BOJKN&=#RI5N$$\I6/^*$G G&<BK>8>Z
MVU\4?&;7_8P).4F"$/1[=-'29!K)YO<RV@AK:%6TP.3^9^A%PS\9!%*B([=,
M7+]L9E/CF'''/*J_8BL)?=2<A?&)T7 _>7(&L)C@",X=J];0!R#7?.:[W96@
MEHN)H8P*"'L37<2BLVIR7(M':*"O$M)4WDJ/=57$M$Y'IYG>T49QV6Y*]U2O
MFN$N6B!%96#C08LUFN!/K\8$LN-3$]O;H#6%EO)_SA*?1_\ 6&S/P-_B._CN
M3>\@OI!?R;UX9H#Y1@\)\?\ FC@LY,!?)4BFNB2VPG":SDT":.?/P/SLB?0'
MX^4[((R41W'LA>C(/GL>_&SL,BR8!X)26E2SWFT-3E411!^..1(4+,&$!DD<
MI 5L.EK9P'B>N5 2%QDLL2@1S(CU8V)J8#DU;Z[,W<&,BX>0;J =/G#N,@^"
M2Q)MUW@BW 9]FH=KLR?X@KB&8IU"ANKP;4 D]?-%P@I\PH&%MM@87^CI!A\1
MC*GVAB7"H1!=&\#>B\Z?OZS"LR7_  & $& IWW,G5@MQ+GH#J%5&2"W&MP&2
MPJ2C%B"4OA]^ 43#-AQ#Q NCN:!R4V[X80A).R%!?AP@7&#[>:+["3"D&0!:
M9%M)S*'/=I94Z\/5^"@3 T[8V+=\))Z<3#F/["O7Z1M'P\1,VC?.OF.0'#;<
M<QW"LC)YM4!MID3S9203].C>F'?6EXSUZ9(C>B1UACSOS=,FB=9>VSU^_P M
M5%[-T/F3 EE6"-25FSKCF+ERZARI5>7# SUP5P9DLD@\9+)%T=\^"AMD^FAH
M[:'4F')*[&Z8H.%=F=^$K:O,9A!*G4I5#0H$;')6AP+D$9Q4*.,J'.K:--.I
M/19?,'FO5EC8DN.#F>?33OBCMB]Q2PI&) *J9E&(=*B#R/\ C3C' U//IISQ
M1VP.+E4U,1/AJ;8FY9OUF(=Z2@Z9*F4C.T@\DP\F3,WPF0PU*E2;P0%W^5<9
M0NR27$R-BE4MRA5Y7_HZ3J;\,B.;_LI/,OJP.4N>5PA/G]\^V!Z.I_-6;-Z!
MC'2N5](ADR85S*EW]LB4.\/-$&V'+,QT >3D>W&*56DCI9[_ #$^@/Q\IR1?
M*$#;4F,=@N\E;HF4J5< /@HEB*(FD2Q-B:R-F[Q^>KCE)K)K1.RS/U,XNJQ%
MT+4)-"0D!L<)3 QE"04 <*&*TZ4C0S+UPZN?P;2:S',VJ-H.1P,JR#7[NCAD
ML,YF:I55R:6V2O->(T*8\<%0HO-UR#OV\=PE-6"V_2I."K6>UD$5R=DA@>>D
MH0SNO@8NY"X,Q5^ 44PGD(;4-(C"VTKO Y9V .[)4UPNLC4B'A$&&:=5P #P
M( 8<48A_C467!4M9E@CGJ24I4*IM;<>&!UE!1.D(X@1BIPR744<10!&$Q]#>
M\R0I*2JW\EPIMWEV\H9L7 @ T5\8)SY;=$1)88"+-Y=E%1PM0'TSOJI\]?9N
M,DZ?^*?)\T]L0K"Q^:>)V3S)VQANE5U/S=?D1>S=#^3AWVMU#?V,\O#[]'/'
MI@RWB39TGKT[L*!V!])LWG:Y>,I^$A%0"\T 7)5:X"%DP?\ (@.4K=,# $!$
M,+ S4]F:VDM@B&U&&%+@-6DS5C6O/+3TU"K&.B9_YW-AHZ"3R0Q:>;Q9768-
M#E3>++3X[V!&^KIF1C'B@42HZQX.(^8GT!^/^*(E/J%]S\G\%$L>_;H\<\.S
MX?ZO!46*DYJ9]FS&E\?X/R(O9NA\I"A8(/4(/D7Y8RW@&>4*@<@B<_QW-%CG
MF_@ -2T-@*["% !@N-)>D8"(DY(_3]_?]YVGQ>B?!Y[X*,S9-=7G^QUWWQRG
M7Z0V;QE@"KT\#9>2F'L@M/\ 0@P2I;RFC=_9?'X 0DY?V@U'M&RU'BP1+A 2
M4T-P(%=6-A11EKF#4D1^3/N*5?V*>-8<53A@YA'1CAG"&_>W)Y=5=)X\V(,1
MXG8_W 5C3B8CD$<MY26&%?"8R-B9ZH91;KQ^\^CG B)6:W,>:GJ-R"Z!]N$1
M71:@ZZ#'S[TN"HPT:6L9PGQ2-[&D@1)NSPOWT=$;WQ?1BC,+D^F.H':-&6'D
M:24'$\(!MR+)\14EB+*IA6<1)FU 5M1*G2<<TT9FXVI$S>/8+5943Y0$TFR-
M!*,F<'L)MS)Z81(08XK=B36(9>DC5D1:LR(2,-M.F>2K'L)MP"1-ISH'&19&
MPA_P[S\,VGCUD\V'4N4+?&#J!0WFQ087A?))RD2Z^8GT!^/F/LE;P:BFB&6Y
MP^.U&TC#$@'C/I'H69S(1+!XK.&-U[% )>, @9]-NR0C2-$SE 1)BRT00 /C
M)27<? ;)HN8B.<Q1 8?SO'Z6PZ$5IV_X_1H>=_I^^:_)T[C/G/A/.=%T?#^K
M5_(B]FZ'RK N'IMB2B4R&2LN?,W]%/I#&F:KQO@;S  G.=1:7@-[O8CR<QD9
M9#L]B9-G"MS8E2^:'+BMJU01BHB1DJ1YM(VP3"PN(Q%6#-TF*U]^Z/0ZO%(;
M(G)O$PY@>$25VC&)+!T>Z:C51M-XOL?7K4-$J29 A+1V(WD=F"D7N89HP3A#
M@3!0F!)!BD&D<IJ6%XUXL?5\SS@C2,<L@!32<2Q&@4##5VE!=ZP%#1ED_$DJ
MB/3C&X@.#=+43%K]N!G#$EE&>"+IE!H)P3.1--/BE,R5B<E RWWG>M/A@ HN
M.<2C7TECHX1AI&@ ZP*"Q5#BBF6%7"I*>L+H3E(6N-=8V@88N#5O*><9J0-H
M"0$.%<2O0!JF3'? ].7CV1!BS)/#*^MAU5U1$025<7'JYHL5K!)(C/5P"':M
ME><H9R:.PG#'KU9ID8JQ 8D.GVKAPRZNP!U*D\_ CZ7]U[\.,\.2/%W]/",_
M\?'A/?WSE_2&S>,MI"A.$07EN;&-V'&DZ@;%,<^&WT^D67+.'$!.<8&!#I+8
MH ;'FK'<.:NC&0/%\(>C3)G)D3\FB^5<&"=BB3)Z3QB!6)1:1%V(KQP?$:=M
MX1%3Q@<=2-WZHR L_!;CW3%-OY@,M $A6EMCG;J @A8PD;X@/8N+50SB'@LQ
M##8-V02OP@)<O2]TE(H0)PES%3NRAE<A>#J:A 8!(W@YQ> +6E8#X4H2E=<)
ML\/NCD&\%&!;@'Z :P$EEP)-F2C/F2<G3(12U2PO#T+Z(HSII7"8!HQ+0C)"
MBSO4K\ENI[ N.CI%M$F A 9=8I&OC5*2 886>8@,D8! 8^  '_%+!.A[*=QC
M%N;W^W)99&&\8:!3P6#PC\S!/H#\?('@3OL$2X95<C#GLLAXS<]!A1QV$;'+
MT0',#A'1FE,'5-G@T-;+6 )T?8J"BJ0DWET,9S1= ADUA<&S.!17]2,H8%(,
M L0!+0 ;5 '+D;!R1Z1/)<4DS8T<OF&.-$*A+D0,.D1?\@CV?5A#\F-2AM$Y
MF.R5_>B)UU0Y6$'N#V09HA$ "Q$HE<(F3ZE#1DJX.G?XWJAH$9(D%3,G' 'I
M#6*I -] 2RD)4<YI?.^$Q*@\+@,),M2B5K&VX-<CY:)NL$L$@J?,D"3F$8H7
M $K@_38Z:&Y'@5@+,9RF?9<5-5F#F!F<@ I&$$2?@_O:%3<)&"1C$<8'[L3Q
M:/)-F ?^5BGC85_?[S7B6?W^SK?7/N5CI\DB]FZ'R[/#X]B51@ZD]/"(@,9W
MQ,B.\*[-OAC,9OS7?6\$99@^\\W3)UT1PC TT3!Q;R1FRL#%)1# :9R.1 74
MU*$# &%P\7\>ZG@R@HYR@]8$=L4/.'R;A;;M:;V1.DE$'#9R4_N)B=*Q7]I[
M*Q'ET&&#%QJ4B1 I E2Y&$/<A%.HN 42LU,'2N?(LB-ES@& L!1R\*PL8%R$
MTT&B,,E(M'9B;87O>@4K(DJ&L#A;AQ/!GB5EP9T)FY.(%C* "3D4#:Q/#V*I
M6&3,2$W"1)1(@BK@[RCYRQ2&=K6&(<0>YKSAN[B-GG(UL2&C$EYPA[CO&B%$
MJ]>O()I(ICHK]"EPO!R2LBA>;S-,-+EE$3J2)P03+&388R^&=J #$+$E8_7H
MIR%2@F-V4XR&TS.<P6_3\>23Q[G]=')\;I]^]?3LV;P8(H+6"G-*Y8,W&0\L
M^S*PA(DR]GO:T6<X[KS,I:N[8%15:>B2DE^%H>$)G($B2-:T VPDD>*1\-QU
M84/I=3Y5"X-JH=B?_+\P:Q@*"G'I;T&LEEI+';8J=RGCA S^1PS3LH95D0C
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MDZ>_"R^O\Y9LWCK^6\*(Y$F$=))=C1> CPJ?F)] ?CY0&O'B0+:KRBX?TO\
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M$\2^:E6$I6JF:BZE%+L'3+K_ *HLRJ#[8$=(L,ABHL@*\,6N^Z:D0,+BPAB
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M01ANI)KW '+C$BD9","PF(> 6F7[0P:K-+P,)"1F@$)H&;*;^'X3#3[_ )^
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M9O<B?0'X_FZJ+V;H?_<6;-[D3Z _'\W51>S=#_[BS9O<B?0'X_FZJ+V;H?\
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M7H#\?00/NQ?89R6)^;)[JCSX7>A_\^N86TOY&KV](_'R+;+0/5%/N <ID09
MFG1L)IY 7;&#&E*CU5M?D"/0Y6+M56P3/5\ ,OAMT 6]7H9!V,\(-!V>#LAZ
M9-)A5^T\(O#M<04(0$(;$;$_E;(X2D2) B> P?OAA[TD/D4O9,,NC92=32=4
MG\9)E6$Q<.981$Q\S7H#\?202$D>'6'1UF'RB>7@CM8O +)_"3=3\_Q]7MZ1
M^/B+\A.0%0ONM RXM2[CI7@ ZNW:OS!'IU'2H#V1,GV41*^8#I;'>W*CZ'1X
M%\X +560)9()2<N5R9 >!Z0)$<,(XRA="U\AZ\8]2^*_+%[FSD_AFT+4-C
M :.>K]$<)=8>*'YQTCXG@D)Z"?<,87J_#Y$#;J%O7>=QP3>P]VH*NH ;'?\
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MQ-9 ((&  D_* -TVH'Z+0**-QW#XQ=13P]GA/UEY44MO_$.&OX/T_P"7'?:
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M%^@63PL!Y]CI1OLYUR=HV@2)U!,!$1^1<&J^;=O.5O.^P=]@%A))>#J[P$3
M   4 0!T T?3[/G[K_L_M -JM '*M!SBINI0#< 1Q2!,!)-&>* 2#  "#Z3-
M[T!$JJD1,LM3%MKIP$!A"L&&F3_@BT@\> %^/^^&Q*:MT'IGW>M'PD" !.6<
M@W+[],=>*U(6KI&4(D8G)1LD\%OK;&X.DXRHA*4]?KN _B:G?^ -;G6'17-;
MHBJR)T(B'R#C=0#VB_2M+.,56Q%"'OBN!0D4F6#"%!)B%"_C(R[$IJ9%3D/!
M9G-<IK+!0OX2%8$P   $ % % 4'U 8>3?:DI0G%AU$@#;5(H8UKM8"PY0>HQ
M3#\+).I]6#VB'_LDF-O 6O@%OEA262V4^90H48MFWGQ %*T?6)@5G;4051I7
M-,%?JPHAV!D30-VRM(J-"<@'\#H$EUXF4T+\,2!>@RN%R3^)3'F<M0@$BM %
MN)#-INVD&%!!%"\2)@*/(J]3S!JY%DP__!4*A@4'U!LYXNAUREETP9I9)F5+
M&- >*!A*'L*&S(!L+H-2$%3DX,RX90$S&/KF#\_6FC1HT:-&C1HT:-&HA,J>
M[_Y^?/GSY\^?/GSY\^?/GSY\^?/GSBZ?P3\9HIZ(*X1H^.4<O< VJMM*.!P]
M\ 6S)A"#=38AR ?D,8*.F%FZH!_P*OG1_%"C:!R:G[-:LM@EEM7G%C]M#GIX
M,)\?J8L6+%BQ8L6+%B98P@).VUY_]3%BQ8L6+%BQ8L6+%BQ8L6+%BQ8L6+%$
M:2&'J$G@/?&3*D:+T,'%YN-F%12'G AU A.@ !X'_%X&?5ZY?T8DX<36%#0R
MMPB:!@*9Q7G".]M/-NWT\6+%BQ8L6+%BMA$"J"%9LZ?];%BQ8L6+%BQ8L6+%
MBQ8L6+%BQ8L6+%BKA2(X>Z4\6,A(]-*1MKTN(VFHQ06C-W;<+E>!FJ/^% @
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MN0N$SL&'WBDY)ON,GQN+$!T,1I>)@Q X'0X3[D,*)N@/66"&TAR P5ZB&0X
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M,XV&KP% 2288%AX"/, M$V&+"O3&Z4L4#1'9] P*9J-B$=Q2XX\H82+9DRX
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MU<*@F 8,F5J(48&\[F566M)R*\,<%IMS9CGM0PUREGEITX-[39'JET:4-I(
M!E(1]#EI?Q"7:"CK$;QY<B:1$=#(T28,!X5V'JPVFL.VPC;%Z+Y(,C ^R*I)
M4PO$<'X)%, I)(,2.(<*,O:%A-4 <F5ME%@D&8EL%<XAO[%-GB^V\$8@IC2H
M%%" 0I"#$QA*44<(2%)-7"QIO'TI$M!#^CAR% 32%+6V%L3&9Q-[ZH;SH \K
M<(+G<"3)0B!NFF!$!G2"FPEB 8RM'% 1+!CG([,E$F:+">(Z8 SKB2J#1NI
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MMXCG2##VSELU36[2!)WR1"P31OJ$N"TN3SIU1I#,X$L7836'E%$[4CT2,NN
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MR_)X;4"^8>K+.3Z12E(QD# #A!1-)D+A%00@SO0$EF'D^"#= 0&19H@)S!*
M2H>/R&O,,28!# L>B68-X,J1[C 025"I^5]4BA*4P M5@Q $ "BQ&Q'D37Q
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M#.$*39+49)._#*JXT$1D*QFL@#8F]2RAP1#""91@>*$@29( J<0T^\33[!Y
MIH%DUF4[,3<+#V1@!;+PQR993T(%86M:ETVK8]S<T@K'4"(7:.BECH@X3"JX
M](#LXE )8\J7*.(6(!H*5BD'2@A$C$6:)*"F4'EAD1,K$H*+@=K@0-+R2M7V
M!V*#TJ7@M7.>G) 5'G)&1G8D(<E&PA5!-I)U),[]<3T<.J,#HXV;$VD8$2<2
MI,/DCS-L6A&O4F!<'&1 JO JTDQC6^RA@"%(T&B]X19I/\+-0(YCAC849'9<
M_8E%4&U&MX! @<, K.(OV;8+DN=%W&*S<J5D262KE9!2JH)'@)9V- 3AU[TR
M89 BTIJR8+92@2CF\0F)A1)&.XP]TPJ !A7T@\]*5,D!L%K)0$BO<T)Q A%%
M@#RP;RTX5.('#@0= FJ R0""3(T$@09RA"&29%(J,$F86,-NO!% <8_!NFMQ
MR59/N-%,)D^[:5DU6IDXP^ <F"2X<64$88?O$Q0Z$JP5+B,),JTCB*&G .;=
M5,4 @ LVA:"POWM5301H&TO"ULIKM-S DR3!"UVL=.HE$9A&B<YX *C*9W8=
M6\5\P(C%DH*#D3@URK:8>J(##<\9'R=&R8B[5V8 A<WE8F#M#8$*MXG(]8TB
M0%VC0D*608X5\,KB0)<-X>]U$AB,G)D$@E,N(XN('HKNE)C(G$-JQ(<224C&
M+D0E#2V=&QM&L#H+(!A4H!R=(84I3TRNT-,@4K&Z!01=*'/J\C"Q<->89*8:
M1L.*R#G':.P$.9$!@"H@B;-\!JEPJ8&2$1_6RC*N9(3&,8'5 8NV<+HRZEOE
M.*<^A4N,LQ3,$=@"*P BQ5@LQE/QV6IM.*0^/)"ME2X@ +$,T*LI)AW,=/!A
M:<W4BU!<;F3;-:VC)^.Z(2F.-&1[Z>0O1P=R6_&[#W[7.2+D2X&(X$)9(%)(
MZY*]($1%M((+6X6R&'B*(O3(("<KM9?::YA#*JCF#/%4,)6,8H=MMY)D:,@3
MHA34V,,N<X8# $R*[CUFLA,4BR0*KFDC(OC;@$ BF1A@! <>C=:[$SHBD7?.
M,I(BE8=9(#!2A$YR/RAU(ZUGU58ZV9%(?20Y7!@G7-HVD ([JQR.24"88/;*
M0VD%C'E.N#8'FLFM+.LG)_8S]P20KI$IPF#BB4Z8!186! R#X9O9%)TP"IIS
MG%2!%W6650$%7BHAM+36MH)3;D?:6!!#Z*MI8&YIFH)E$+]%HE-7Z,V%X146
M ]@9/^KEPF;+3XAF\+N#4%5*$6*7<53L4I1!@PPA74 T\1RVDZ FY$($$%BY
MBYHRPEJP<U8$U-07"*66H35T0@#9\(1,;O$"E7G25L9)X6,,IW*TVMZ<"IP5
M>P!ZSC=2F4C!<0H2R.J189E(G)D-4'&U)R._97>AE@P),TPE "S<G/*L(V[9
M=)Q Z*;PY:P=:S@.!270G0R3*&1. ,CN*L@C)PG($  8S5#:<FD)8/#-/3@H
M#0JY,)RRF&/VFHD+H8I3.[*H2): E$T-,5G=7"B;1*)P7$8]2&2+RTQMO' @
MIRK:94<(2SBX7V;S#L'#&D!:#=G",D5HFB5T8]"*F#9NP5PA&)R&O;R:%PQ$
MXJS@7B0-F!MY 0>3(IE0HBO"&2[UR3P2H42+3'6 3CH<H#UN!E/ @44U]G>=
M%R =!!DYW,$,A20PG1R8]+ \]RT:-UIF5L.>YU=F*MCFGC+JMOJ8BIMQ6G$;
M.BE!4@$$W@7_ &E%N E(G)H 3R/AC<&" !*T9M]6$P#805F@Q(Z25-T4%MDQ
MD373<<D0F$UR!)G4*44F"A>B4IB98'BF,0R)DC2.%[ML-UQ6)ST!C)O8&WNC
MI96P@R9Z<3')(3 01"46B6.KKT(+E$PE%M#H0+B2;-(IALV3WHC1/&);X)2!
M&$]5>$D4SAKX@BI58"TW4$TO'F]M%^F#-(0YS.!!(!REF,$BBX"E125E5?J\
M;,X%B&5W&@2& 5)(C()U&BE=*!5$"1A0D'0!DXI!( !B43(\6[%%(08F7!FN
M%8:*2)C-'#I9@]H.6D-$("R((662(6<IW$8R4))J)A.#?BAQC"'51.$%AA0H
M1N(BN ?(X_J]) Q+V&]IE0R1WPF8B3HAD@!9@B?G$S0'29^:< H=4+M4\M62
M(Q-VM@"" 0Z&R0S4<-4!!FSEE)ICG]"(-HX=,ZEB\FJ]F#8%17F*%3(NAWSW
M0 E5 "HREG K,6VL$TGJR?9F@G$8%=2EAMQ66(9>9RCNP J1B5&Z!!M/<6%2
M=1@Q(5K4V)%L0*[QZ)]:2*EL)/"C,<<O*!M[O9H+0P>?$S4B"4(8F(F\6&!V
MSB%9+=-D1"0!GE+3"83$C4R$&8%#$FK";>\J\/+JT=/S4UE5G#?7R.F<+L -
M DL5F6/S<-"4@3&3>+):(<K&K!0XB!4$F0A-/1ZX(3H[!,%BDGR"I"G!Z%B(
M>C40 @)&,"\PMQ.IZ08>S(?-52!(A$[T!*N74L(A$ \26,!G-YM).PHF! &%
MD82^"3_@7A+! PS<T>B!JP1D"#%,1Z^-;?;I!$)$Y!0(.E$2/H26U<XR#);I
MHO5$IC"C; O1"Z52 HAG!6C!<+"(F%T,8*[(,C,G7J)BB!PN%S8XI-; D,X)
MP\K34$F"2*YM%5RGO:$XT4'25B0QET7)L-^XQ9L!<&Q6W@T"I%G-LT>*\*)A
M"L()%9"7-<XPC#9:YB?$WLL;(S"E4,08@%@1"J0$C(LDB=F1$!0#NB>J2S2
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M2,E%'B;YR7)M,"J[2MJE!-*I(0K#^<:2P F(C58"O_YL_]H # ,!  (  P
M !    "=MMOMOMM]MMMMMMMM]N8P       'O@   700&"0"0@0< "2 .>@
M     "$P   2R@  2$ 4 @ "@  3P     !EP   04 B@20" "@0"P  !\
M    @      %#""2 2 2403 0  1L     70      @   @"0"    B  "*
M   80     "F40"02 $"@0" @  !@   !4       2 2@0"200 0"00   ,
M   0@       DPD04    $     "0   !P      "@22 "P 0  $ 2   '@
M #P        "@226206R2"0    !\   ?@        02060""$ 0     "4
M #P         $ 2 0"@04$2    2   8          (  0 2 2*0 "
M .@          0R 4"4  0 $@   <  <         6@""$" 4 400    4
M0           2($222" 800L      #P           6BB 0$  0 D@  #P
M<  0 0&:>, @"P&"4   0B4   "   @ .VO6@]#@   2020"8 2"2    <
M   7XUB".    "2266 BB0"$   #@1@  $^B$/\ :<  $ D   H A    $@
M$  "L?&0G&8     M@@$&!FD@   X    '(-VH>7       @( H(H%    "
MP  @F8$ BS?8   $@D(  @%@     $@ &P@&G8>=@     $@@.D @    #
MH "JNCT[\4       % ! I (H   ($X  %XO( XC/@     $ ($ D@   8 ?
M   ,E$@?##       @D$4DBD   X &X \G$>"[1(       $HH((!)   # K
M  !4K=?@+X@     $( HA B   ' #X  X(E?3 ;         D)D$$@  '  7
M 'XHSP47C          (!!%L   8%8  8(#;$F\HX      H@!%A    X ?
M &@C+86C?         F@DH!   X "X %/8I%@;8         !(( DH  # K
M  $     $@       D@@$I(  ' #X    $@  $          DH@V$  '  7
M  @    @           (%D$   8%8                  %%%%=   X ?
M                  D6NM   X "X                    %()4  # K
M                  H)%P  ' #X                    $"RO  '  7
M                   %(-(  8%8                    $!+@  X ?
M                  $% <  X "X                     )IF  # K
M                  $H?  ' #X                      &#  '  7
M                   !!X  8%8                     )@0  X ?
M                   !:  X "X                      DJH # K
M                  -,@ ' #X                       4  '  7
M                   &   8%8                      %S  X ?
M                   AX X "X                       %P # K
M                  D8 ' #X                        , '  7
M                   )@ 8%8      $@               *  X ?  ;!"8
M   XX     'X(     $M X "X                        . # K  C@X
MO<    $           1 ' #X 'GZ?'\ZQCX <$$XS&'[XGD &0'  7 '\(7
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M6,Q,6 !=2+@"" %@    0G 5@ "                      0O@!\  0
M      /K@          2@  +@       !@                TD"L "<
M            "8     6, /@ 8>D@< =RL"-]/QK,        "0 !<  /
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M8/V)((_"\V8         !&!6                          . 'P  !V
M(X                  $  N    (. (                   P*P !0
M       P .          P ^  T[.@'XV                 !P %P
M                    &!6  %6@-2)^'C(TQ?1)P'X      . 'P &V"L^W
MWC                 .  N                           P*P 'W/14$
M/QH_.4(_=Q YP     !P ^ !.2(H#!"                 !P %P
M                   &!6  ^T *6S$$A (^+SFWW4      . 'P *.(V 8_
M>                 .  N                           P*P (W' 1XY
M^.X )VP](O       !P ^        (                 !P %P
M                  &!6                          . 'P
M                 .  N                           P*P
M                !P ^                          !P %P
M                 &!6                          . 'P
M                .  N                           P*P
M               !P ^                          !P %P
M                &!6                          . 'P
M               .  N                           P*P
M              !P ^                          !P %P
M               &!6                          . 'P
M              .  N                           P*P
M             !P ^                          !P $Q((
M              &!7 :8;8                     . 'X/(
M             . !%Y,                         P*P   Q!(
M            !P X#3.!                      !P -    )
M             & P # !$")                   . !     (
M              !H    )                      P& (P ('_  0
M             < "  20 00                    < #0     #
M             !@, <  < >"0                 #@ 2  0 0 0
M            #@ : 2!@"?P                    ,!@    /A0"0
M            < "A00 22"0                   < #0 %V =&
M            !@,     (2("0                #@ 42 2""
M           #@ : 1A-MR<0                   ,!@3@  "@" "0
M           <  B   20  0                  < #0 -MMMM@
M           !@,     ,#P "                #@ 4    "
M          #@ : ""  "  0                  ,#@ 0  >"0  2
M          < 0   "0"2 0                  $ #  4QD\W
M          ! . #\ , :                   "@ <  "" 00 0
M         "  $  +Q;K( "                  , 4 !@"0-P   0
M            @  0  " "                     8  0"
M         3@"    0!@   "               >  2 0 0
M        !@ !@!B\0"( "                 #< 4  3L>     0
M       "  "P        0                !@  )@<!B,
M        , !H #R20                   "$  "<00     "0
M      #D   "     "                   3@ #, (VW@    0
M     "0   "        0               !L   ".       "
M      >   #\ ,                     .     0       0
M    "X     9@      0              ">    #J        0
M   ">     #_ (      @             'F      &#@     @
M    #       ?%*222222P           O(        AVVVVVT2222222222
M226X         >^VVVVP2222222222222FD        C2222226
M  X
M         $@          D)@H @  $     $@   DD  @           D E
M      @$ $@   DD      D @ $      $     RROW?R62^Q2?R*CN>"6Y#
MURV[>*#P,E9>F7*P0_8E;R12R3CJNZ73RZZ<R'C,7:JL!KMU&376:7*1WR;3
M?13F0   !%MM\-=M)-%K9W]\MQP+->?]I6<R-L3IO1O8I&]/EG^[JO.,XAY+
M7UU1#%YU-AKV-@$;ODWXO+O5Y)&P1]-P8,    @(L()$)%=AA<+,-L#%MME
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M7T@
M                                   )))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))__$ "P1 0 ! P($!@(# 0$!      $1 "$Q05%A<8'P$)&AL<'1(.$P
M4/% <(#_V@ ( 0,! 3\0_-P!S0]ZW+R%]<?XTZ0^@?-=G]J[/[5V?VKL_M79
M_:NS^U=W]J[/[5V?VKL_M79_:NS^U=G]J[/[5V?VKL_M79_:NS^U=G]J[/[5
MV?VKL_M79_:NS^U=G]J[/[5V?VKL_M79_:NS^U=G]J[/[5V?VKL_M79_:NS^
MU&N'H/S\T+E3F-N>UNG&O)4$GRSI_P +<*>8>NW7Y*?8!&6Z;Z6"+;YJ3FYL
MQ;A$=YFE7*O-G^$O;&8>.@W*QY\-XSWPFMH\M>_W;'C;ES^_U4,2%M;_ !W:
M_P",==;7B/'GWWTYT"S&EWQ[Y^#Y\.]^-JMD9/4X.,8]X\.X[[WT\/FN^^_U
MV^O?3Q R+<4Z5@$MA3[S38ZMGHKS6=;% 2'$F$Z-XXZ_\"Z&<.XDLDXS&)]*
M:;=+Y%MY%N-ZRAZK\.5*MUEW?X;).H8WB+^5WDO+:<<(GOG4;7X:Z:=;1^'?
M>O?!\>^_*K1K/IWBH[\_KVW_  !<$^-MXYS?R/RFT>7#?S\4CT];^/HP*'EB
MO8"[]^M"VV$C)F)C-]BA9(<'',R<G^6TK.Q=WOMS:ER#&DRG=;G2*54JKQ9_
MA+=YYUWW;OVG>_6_?,:Z]V[Z3X3IDX]\*VTWJ-O+7]]/PUQY5WW^NOCG/?>O
MG^&\>O=_=VVKO'?Z_#/,.%P^3VY7KA_GY,68;I["W//-/P/6'N_\KA(#S> :
MO J0Z%='%P7V-+M[?REW&F-^7'7N*B>:8<O#4?W!-#UX/OH_&U6WW;XWSZ'Z
M?$MZYOFK=^W[FCN_^7X%=W(XZ^'0>?X6UWZQ[5;2>O=^?A.C^SE^_2N^/EV<
M:O>.^==L_'2.OA]PQIM/IB8F]:1I,]?#GC7\A3"G*U0%EB(^8,\\^=@ DC<3
M7^0:;M R_1V#3MW8&.;O/'R/YG5+<)[[CQWTVJ.O+G'CWWW^XMGIW[9_#7;X
M_+OW^_'EU[[VHXXU_7AGH;'?O1W\>==G*\]\_P D92-3Y-3A0HN&(U+:JV73
M3-S^)8%<%VG5MFL<WW&V;:UFZJ[K+Z_RS:'SUY<N%(:,[\'YY_KPL\._/AK4
M?AR];?/X/EWWOS\2+38W.MWO'C,YXWUZ[^&_'NWA[>WAWL?JOWY>?GRIWWY_
M/GU_.&0ZYE#=+PQ1A1$G_=G^+(!;!E?6[I4B. :!L'_!;KN^AZVUYTSKJ6UQ
MQ\K9*[V]:F'9\F_M-<&$ODWY1/6=.,VWCI/J1[-7VTG[\OGPOS>/^?%6]-/3
MU^8IS:Y:^.>^/7QR_7UCRBFTWF/-Z=\_#,>]^F^.'K7'26(O,=)\+7S,ZX;:
M/Z;R^&?N<_OWM%Y\.6.-GRTJ>%_3_>TU\/<;^Y^]/SE!*W(QQ3,:K9<YFC"2
M/</'^(!DP%K-_@:^4JI1257C['#_ (/2W&_O]5S)G#?2UN56TWU[CV^JGKSO
MI%6C6>&-./.>S\)-3RZ]-3H>$)DCPZ=]^WC/?7+OX\N^5U?!SWUZ;>&'EJ?%
M<8MZ<J>44^?+\UNY;G+]A8Y4,DF&Y^>*9+VL*:M>GN<_YQB]-^'+'ZU^O#N_
M?U\4B9$YU/6T7TY4QH16_?I]3XY_1QK+;I-)%GP[G\N^^_?PBPZ/</@<;^'R
M2?=OG^ PZE]":VT>/OB@""/IP=NW^!1B#J\#==J1).S8[[Q'_#I&CGCSJT6L
M\;G2#O>L/OJ,=8SYU[=_K7]E[G/UCM+>$[WYR^LSUK7;U^O/3TJ.O+ZSUBN_
M+OK7</?K7F:Z1K;,YCI7EKK\?<>!QOQUZZ/''Q29BX1?GS[]/"SO-LX9VP$1
MCCX-XS;":\'@'P3B.?WRJW7WVC=RO#Q\^O>-3;%;&_TQZVZ_P)JJ$)L:2:6H
M1!+B2?P3%= ZKO&QJTJB2LNKYRQPG_BGOG^'?'QM:T;WGK'[\9>[^6W2K>GF
M_'BLYI(U'D^&<'3ZUH8N5W^\^/#CWYV\-Q[>_FN^^_U^<@OEFN'971,7MB+V
M_)R<Z7S@L]29\M?^*>NE6[[Y>O"OWQ[YTHN(Y=V[MOR\;<N7[^_PMU[[GT\9
MX>7?^^/?>_2?"+>YK^SVY7\'AC3OA6>] ^ K]O&]7\O3M:;Z1_!$CF#0#I\.
M,_P7&OWX_0TWF^/^7O[HB69/-.FL;VMG6O?%H>?3W\<$YY9\IGP]>>7FY]:]
M+][VUM^O'OC3;%A,QU]<=7PY6J]IU._6NYUKRC1'/>F]1_OGZ$V*]^^/I-9E
M[\L<_FL_$]>E^VG9[^9K[GEOWIZ?PZEB6>IF[A>#;\U I@!5X%)I&!P-;[Y[
MG_FMWCCF^WK4=\)CWWJ7_;^]=G?GUJ.6)SW?AX3WWRJSP]O:??Y\?W4=>]>]
M3?PS]_+^ 3MU[]_'WUK/3_/2QVU,W;];X[CYO_#""Z#QV>OXFCHUU<'K2)25
M55X]VX?\@]=+]VZ59X=\Y]^7A/>?>K;=_P"?A;>/;[]^GCW/?Z^N^^X\+,Z>
MT\-N^E=XJYN/DUGG:W#?GOY[U_G?Z]:Y5QBWIRIS/7_; \HBHBW7;27WZN,_
MP9I9Z;/33TC]_D&N1 W6Q:U=_OK_ -#?/#AAG3YKOOO]5-HT[US5N[^G&N^]
MJG9IOH=D<O2N51?B6[\JG_=>^YBM6XWR?6C_ +7>_OCI'O6OGFS-L;VS^FBT
M\<^43TTI@QC:+GEDS%CE:73RWGT]?#T+X[]9FOU:W'N;XW:NDO+C;&-_TUR1
M&Y&F_KT1.'\"$,J3IIUQ1&8 _E$1F>5P;\%M_P!*RR_56WCVTVZ^$N)M5N^[
M>OCG]'&N^^_CPWGMX]W_ #Y]2L=YTK#;U^:,QO$>X]XEIO#T\N/O]0'YR";*
M68AUMLQFW7\9T'%QIL>B\IX_D:!5T/=X45E9V5O-SSCVI<PN\GM&.OU038LN
M$-TV-=O %8!5P%UZ5"*#,A.-6$YERU,=D.XGLCSY^@:+>8+.8?'A<A@S8WV!
M]]/2F&#C%(6+21.#=ZVB"01)##P31\_!V3"8]SRQK>G[(94L.PZQ>>GC\=WU
MJU]-C/2?UUJ&)T=?"SPMSO\ OK4;7Y=SXQ.+^_EWZ>,8XXKOON]?KUKONY41
M5M--.&J<K>]</KR5TZVVHVL2WYX&>'>*X3;SN3&.=[\AHQ.HVER.2.'L[_PR
ME8%ER?8(E_)6=8)&ZV)T@+PWF$Q^)30A,6M=-N%0W^GU4-_I]5#?Z?5%(3!>
M4(?-&J1$"(A@O>]YM%0W^GU4-_I]4 E*B#BZ7T]J,%*^0&5:",Y-$#I(^?'A
M0+$XF;(L&\YN^W@L*P$[!IU?]HXN1:PMNM@U/X/\K.@6BT^O''KUZG+A'EW$
M:UWW%=][O%FMHVN._1;>?Q2:-<[\^]&_.HN0S)B+V[_S4LR9C[^VN?3]]Z<;
M=.5O9Z5F9;YQG]QKK7?1^ZVCKP^YZ1[S]=9C]</;'?U3;KWZ?Y7?/OTUKNW\
M,XYM9PW],?E+9D4.G'#G\2A,UR2[TTZT$71YGUCOA4"V>1,XL";3=I>(MG1Y
M-&$Q,V[*AO\ 3ZH2A527TQPXT8"5\N:Z%0;IUL#A$CUWX4QD2S:PDN_.^>'@
ML"P9;'W1A>MT,:KB+:$^7\9QO7>WC;2W#SQTCBM=^=3N3Z-O\^H;UO\ ?<]*
MF/:LQ&?3S7T_SPS+CAOR]+<XV\&)MCP[]J[^N]/"[B\WX\>]?X.5*ME(>*67
M\&=Q!R+'# 3QG6?R#<MSD!2.YYTQ '4<#[=*$R U(!TL>5W29HC,"?NIX" ^
M!//W*.%W6> &7:9M-2!)6VYUT.RI-E)O##'#3%X]<T"20]]'9WJ6C8(QN<<Z
M>51<,=92=?+I0(5=*SG6_"B+64C>Z#C@TYG&>#5//!QHF *0[&K?0]6EE5RW
M?X(CWJ>MH[ZW_P!K/X3Y9C3QC;J:\8W/4UW\,7//PST_RLZWVX?KYK-V=9T[
MYQUO4/3[QY[_ '_ _P"3OI6]2)YX?QD&T#D!ZWOV'X=UQ:4@H RK[4&"* "Y
M:,$YUJ>-"]3$^Q;G1@_Z#I=MU]*40&977E\G<E?ZC0A ",C.+Z\MM:T&]M4Q
MGRUY^=.G6&$%(@T\\_)3@R%&\$FNL4#,$LH!S@.E*ELAS=A[&G2LI3@T#0Z>
MO\9;_*M;3?;H:<CRWC:_<6,Y8TFNO3EKZU;T[[OQLU&O>I]UO-]KX<;;>[BN
M]NG?6]3O?/KW-1KZ:A;/W7-]/3SUT.50_7&F&Y;<TYEL.TL5GOK7V?YU\]JX
M:ZG':MI;&>7"V5<'ZKEB=;YX]X8/X'"-WUAD]W\7P!/D5E7=6^;O<</P!C"R
M\KM]XMJ24P"Z!Z%/%WD"!8W5,O"U2,:"06DXZ+.P<LT*'-A]'S&A)*#,K>_*
MD5""+,V.^\OJ7O0)AODVRQPS13*P -C=YO\ FM)C<Y594&,Y]9Y: K!=D&[=
M MK4YA,3J+M\!;YI'S-@Q&@CN_\ -W_O94?OAS\,\/;ONU)'V8KO_=^]O">$
M^=N_CP]]\=\_/P=S%X_?IX=]GN]LZ]''$]BN]OG_ ';3^%&=:P;#TPPOM,SX
MJ$< OI4K*Y5?R(&J0<9DZ0U&,;":IPW=,T )DY; -[YXA>H5O")WW>K1MJ"-
M)N60>3?%" X'SO\ JE);%\U_7OIX3(O97V8;<,T#=".B3\4,QN X,P^3%",B
M,IED#80,IF_6:LKRC!M-N(K <)IG!8+X[,V&QYM%A- !0:%K==YOFL -+B$]
M^Y_%'7ZF.G7P[YW]+>WA,YWNQ_G<T]]]^7CWS[Z5WWW\5CO3O/EX,9#MTGIZ
M5:>'L^6CE\BKQ;6T3,\]>KKQ_ADXSB6==WC^-[YEIYKTVX?B4(6 @;=2G42L
MH'T5,(L8)W&3?BZ4:.A;BZ!QJ[*Y96^K?//_ "H%S>;W;3%"218(M &ULYUV
MK<.IZ<.^=+P8V2XXN/QGUHE46NR2T<XOIMM3YC"1-G?KPV*6"LV#BQIK$^F;
MU#;E59Z2R[KN^^N:2_JLAQ#TFT[^2 13PQ)-_P"7ORJ>$SJSWYUUZ=]\*;9M
MS]/>M=L\N7UGUJ8OBT_=ZSP[].GE7+-SS]^RMV FZ&-._JKS\.C\<3>]-L/$
M?N,/":SYX]OUK7<:QJYTU_5==>O?K6<X9G6_7/']UOW'\#CC0Z1,=8/Q<)MV
M_?XL;E3TU]*G@!S])[E3)C+,),%K'EZT4FX."+8.AJ_0";%8\2^;N@^':MVO
M4O>@*VMAX)MBZX+TV;!!4A+29,2XS6"MPWW6T\=]"I"#+)>-U<UL;7U@@)5+
MQ-^4R!_E($I$2L,'-CO;_AY<7E$^=O#I'?>M1'?7YK/#O!MW?PMIUYU,@.F.
M$[UC/7'[A]2N^_.F-.^]/6K3P]I/A\X\'T+$YU?]C^!6L2#SCZEC9\7#/<-%
MPY'Y6\;!PDW.>S15^J3P[MB]J#B> (WWY?51.B2 T$!?7>;3-8K-WRP/GH3Z
M4Y7 /,L^O7>BQ=$QQA9\OGP"-W:,Y+!W>:5N<NV\#WG])0BC48_W&M*D6\8)
MCOWX%)<UENF^-W0ZQFL2P!6S98W!F-:& 78DNN57WXM1\(@2^;B/#?1*VI(Z
M&YY8^#^/E?W_ !G33ORKE_F;>7ASH?+OU[Q->W#T3N_"HBT7F<,W^YQY:U.>
M-O69],^=Z?KSU]?X,+9^M_GO!XX/)]JR>;[_ )7P9;!NN*WO"_-S4P&P,&]@
M'U8X%-Q-ZAR1$LCULT:_26=> 4:5 )+R)K&I&SQHM<A1U$HTT?:@B)NTWH7L
M+UH&@VF"0NF:"-L0!U&.6/W4%<#D8R!+QWS1ENX)9&)LVLIIZZ!!:EDT$VYZ
M^_\ P<M]=OGTX;5+'QD[XY\.MMM.=?[R[^:7S=?<Y[=9FAY\28TZFO'6L8VD
M<>>H][3C$_OA?ZIB9]/\CTQ6.MQZOE$=MZ^;..#\:;U\W_S]?FXZ?\3L.)1@
MY'X0PX(-R8#-IWAVI4L ,! !L5)8Q+#)8T8&/ULT#B(9(;0B8UUQ2.P$G VO
M"ZCZ>':MVO4O?P 1-#$E^KKSJX+)($$8!%V=##164* .19U]VGY7R&0R"#:)
MC6K!+)(SM//2)^Q! D)H.D<_+_AG$RQQ]J"<?[RKVVJ)QY:_O2>>*[]_NL8>
M3BG_ 'STX41AZ/'CP]M-9Y^'!GA;+UO#];5_FG?I;FUST+=;COKYI.W\'9\'
MCW;:L#D>WY*.9F\, ;M+)?LB7QS[TI>TFOJ36PVGO-@ " +<"I9,+<0:]:)4
MZH85:\8<P?IPD&*<,Y'7;72E(8-U/:9[NE"+H7=W5ZM$0P4FUUA8X8.CX.6A
M=&0_?/I1C8" :#]#G/G#B>;KYO7=X^U!X%SJQ'LT&?0 <79^*8J- /._Q'\L
M6F>FO[KO]UW[_5=\N^]JN?IR=,UV^$Z/1V_6YUX(3WGA7O\ %H[_ ,HVWUXV
MT,[9F-*X]?\ >N_\'9\'X8/)]JR>;[_E"J:IXZ% A@+Y4F9)7KCE:+5"V+K8
M.-2C$)(B8NC\8XTFQ-XB1[U;Z01D;D*HQC2C6W :JF M+1@[^_=H$ E #B_!
MFA,=+H+IY\BG>XJ9N ,QG!S^"C<-#)L;6::"-BSL W>%(BU9[8+Q\GGG_AYX
M[[^-R9C/#7G;?H>5^=_K;II6,>?/?;6WN4<HX5TZZ\MH]?*'&?1]L_NFVSBN
M<QWR+>;6B3#HYZ93T^ZY:Q;CW];S\]Z6\OY-.PXE8'(]OP(8Q@'B73J?/"KX
MQ")]>\\G%*()-84<X2SC/[J'0+BX51+&;<;(Q1*8$OE698B5?-7OXKM6[7J7
MOX 5 )5 +Y>0P<=*?K="5JKH>P<*7,-&@;<O7-Z'& D&T,QKB>-!&KPV<9]F
ME8U3Z$K[6U]'_C[X^59SG=GUSWZ8[ZVGI7'OOZK/.2,1M'"-*],_YWBN#;X\
MT/.N$7^IGO2*F\O+3:,<#'&O;'O#?X/5ILO??IR_/L^#Q[MM6!R/;\FAF2!(
M4Z,>C0Q(=,VF>=".0P!GDX\THE!+9)N\TCR]:Q0)(&'WM04!#@H\<$<O6Y7#
M[X7V'E&:D$4&R[,6P:98?9KUI[[]Z@(K"5*[M,8,&FK2G,^AH'*I1$81$>3-
M11%,(DKCPY-* "LP! XOUYQ2(LI7F]P</YIG-^.O?.?#W[[UGPQA^*RV(X?7
M72L][7K//0#/E\UQB]R+>AB_O=BU<,S<X.(Z[<!YEYO'^_>>7#^#L^#\,'D^
MU9/-]_RB"9I@K;$Z\+O2C+-W(BQ???P8T%PFY?O-/+SK:3TH8F')D?)HRRO8
M<M6#7T>$K7L,#'-W?!Q1T6+!JXSUQI42+:R*N5GT_5Z @66R(;(Z9WXU?7#-
MA92TQF]+(("89@>.[_QM_>9OU]'SF2H;ZB;R<G;%CG)7V?<\OKE.65O>_/?M
MK2)@-=CBW8S/W>N?<\]/C:L6=<.AY9UW^*+R:F73$_O-%^3OHZK-XOT,4N8U
MR+Z7-\-W&O\ )IV'$K Y'M^ HB*(B)FU'$%$,;CS-.9/*AM'63T;_P"\X$LJ
MV#YQYI4$8[P;O;08SG+2I69, ME8:FFJE1$U/KP:(Z$+!JM)<%\1-\&0GRI=
MXX8)\O""!-T"Z#HFIFY?A4U@+.X^AG=C.<Q(1 M),&_-UC_ES'E/MY=WRB<F
M^CB=2N/??;I6=CAWWM7?/OH6\.^_U7?+ONY;3T^OFF+)KG%N%NNA;&OY]GP>
M/=MJP.1[?TWOZ=\9^_#E.IM/=JY6[Z5WWW^N_P!]?NN/'EZ;=(H(;9R1<G,;
MSYWF>&K]1;68?;2D1OG\^SX/PP>3[5D\WW_J/FU6TK)QG.!Z:>T40YT(.$:<
MK:<ZS9[O?IOSJ+Z=\9BG32/4F?/2>V+P0S[YY3:!QCIM,8F)\]#M*<MH]/X]
M.PXE8'(]OZGE,???6N/Z[[CP]^^U\.^^^5=,9[[TZPPLG$UM)+QU>K^?9\'C
MW;:L#D>W]/.FF8[FN^?.N);-L]EZX_?GVU#$Z88^><3M[5WKWY5&U]1Q8F8[
MR6H>N&%+:#;C)+3<.2>3])]OY]GP?A@\GVK)YOO_ %6QK.=-<R\L1]<],-K$
MJ\SZS7???W02AY3WW-=&99TG3?WX5;&\+P3:-/C2O7]>L0WQZ5H8R>W(-(T#
M^/3L.)6!R/;^JMUU^*SSW6W6V>-!-NWO%=\^^/ZKOT/EMRO7OQXV\SKOI1+K
MKN[:V2YN-C0ILIM^79\'CW;:L#D>W]3RSM'MF>OK7?\ G97'TZ7_ 'SM7G"W
MWL]["\JQ'F0X?CT]IY<,VA,PC^^L4 C9GA+YVC]&CG\NSX/PP>3[5D\WW_JS
MC/O&<<"<6^:A XX@[C&''6H&Z8B#SPS@^Y,-><D.XZ1TB:M/!LSI;)PDQJ-7
MQF8)P"3?J3OOO6F2R_$LXC$;W_CT[#B5@<CV_J\_OY@7WK8L?.O+D^L5'GMO
MZ9]]*MS[[W\\>KYVA[X<(HS97_(#7DZ:3%ZRG<'[VRD_EV?!X]VVK Y'M_5?
M[Y=_5-]BWGWKCSKUX?7Q/K%-NN':T\3GL^OSGGO;@1/34I,YUQHC9L;9_P _
M/L^#\,'D^U9/-]_ZS2-)GJ5!&9F\Y29Y$QPOU:YEXLSI:W+V2]=I)T<\XLM^
M#5[<#_+XS=(>E#,EI2" /4\]GR/X].PXE8'(]OZPC7]CWI]%:YXSK\PT3?DS
MR_7O4Z<;:].7#6OWZ_5)8]#E_LQSS^79\'CW;:L#D>W]7GKW>MYNW-'.:Q.(
M<SH@0S%N6I.UT['EVWZ173]ZD\S:D<NN,:<OR[/@_#!Y/M63S??^NWV?,;Z[
MQL1O>(UF"0MQ()D]_P!U?$XGIPQWYUK;2XQ>U])^>A0A>-SK_%IV'$K Y'M_
M71^F]\6OMC]7.^^[8YZIC/G>W <;47$'28ZVBW"'F/ _'L^#Q[MM6!R/;^LS
ME[X]M3BU\.SMQGYAKE'"8QQS?N&U&Z[::<L6XYI&&WWG3?.TA^79\'X8/)]J
MR>;[_P!?Q[Z]^LUY&/\ =7RMCA1O$FIB/+?RX8G!$1C:]].+IC/7^'3L.)6!
MR/;^N[[[OX<KOV7.FG'>;#I-K\?3#.SZ9I(7N)O'3\>SX/'NVU8'(]OZV7=X
M7Q\QGSZ5B9$C,>\:_NR243)&9(^.]:BS+!>"]TX:7C2<_EV?!^&#R?:LGF^_
M]?\ -GB=Z5%AV8.'"-GE'6M,:IU@S;1N7WHN)PG49.63GE>O\6G8<2L#D>W]
MAZ]Y_P!H]Y,Q/O,^4\"M#T=YX[L1/$_'L^#Q[MM6!R/;^N\^%^[7;5GMMIEM
M&VVK7-&5CRQ#N]+VU<\[Z:[QKP_'L^#\,'D^U9/-]_[$V+01TSUZZD4B30-=
M9O$WDG4N6TFD!0GK_#IV'$K Y'M_8'^<ZQ.'KI=B./H[-0I&7,SKMQ=Z?CV?
M!X]VVK Y'M_7G>V\,;QN7JW#%LVEU@R>V] 01+6YGI";1C\>SX/PP>3[5D\W
MW_L?WWTTJ)F/-M;SC6A)+/#'?&8VT_AT[#B5@<CV_L1[B>_C3B,ID<,!N9UV
MF<XWH0NW?=OP[/@\>[;5@<CV_L!^,%\F./OKI1D:1DF[F<;[XTM--OW;\.SX
M/PP>3[5D\WW_ !%Q2%NP09WIHB1*$9)--+]-'P04" F)O'*.X? U8P,2L7\F
MD1A5"ER<V?S)3(!;B<Z )442Y<_7A)[$!.TM&Q(!#QM\_P B$(@F 6W2D("D
MD$13>] $M"YB8TZ\+T2KR2Y9,VF<<_Y;Z=>512,S?>;YY6YSTE(4V?X-.PXE
M8'(]O[(83@XFA)JI +JK>W?S^'9\'CW;:L#D>WXMA=J!YA(3?_:X)"9')SJV
MB8E6F@BR*1M.O'\"1)"[ L&[%*(19@(QHWT=*R!N L&S[YVHHMD5.MGA.W#^
M$"B=!BR\?>?*DA39C_G03:9MQOMW>U#4B+$E^$-_K/X=GP?A@\GVK)YOO^-W
MX@3R6$Z\;5/)>0-/W6VQZ%T8<L7]2:89)O%S6&N))&MFY8C&(X6H@+:$W%UO
M'"@LA5F-9;X[XNM(!$=A/K.3EO1Q2AJ(7EI,<0YT$C!N;EXN>L5G6&ECYRH)
M0W0\V*6SV$1&43,N*]$]J]6<];<W2@@!28B7KMOKIQI(- PD,#O+/I7:MSQ"
M%DS1+\1[\*8)E0;)$MM1>/GK%)2HE%EYX;SN4P$[,!+/&4QPH$N-A(OL,Z\:
M"D",I$AMWUH!*J20C/&:2,#L2CK-$7$L3B-I/J?IH3$Q:E&006$767OG4"))
M@"85$G/?:D4D@)&T$Y58??2@:9@;C@F?6H$B.P2&=;<#;Y'@FHQ",NFV+[^B
MP\"S$XCB;U,&!,Q$,\VE06"9B?DK6 )1$0Q&7WZ41)J$M4V-=EB-FU(P:4^Z
MTS4.,3ATY._3\()+P^9;2C:?\B_<X_@T[#B5@<CV_!= * LIAYI3<$,21<3H
MO$S6H95 -UI42'$7GGX/"*9<ETO&8),?Y2(HY&&X^HI^:P#!B$6V\SZ1UH:A
M(3O#$QIREY^"@H296\0+CIO3!(D2Q$1'%W_FCC*B\"-7O-I)*!DA*!"3?6)9
M#5,>+Z 4NSMYGO7"\Q3A>8H2A(3:]IC1??\ A6#.0SS^N44(;8>X_7CV?!X]
MVVK Y'M^.#R?:NPXM1G,%FY.>=[[UFIZI[U)) 6E>7@'NQJ:58SG3USPX7X)
M3@MU@8.>W>E-&0F/4E$O><<(I\? (B6TNYOCUJ<D$D&;.VGFU#DIDREZ&D<A
M*]^!K7^ 9Y;=:@ERP3')X\/*A+LO,\/NMF2^A$ZD3Z7BHI<.##24EC*UX'?S
M3!93?-S]QTSTJPJ33B%4]*R>;[_]!(BT<968F9Q/"9S:D1A\>SX/PP>3[5D\
MWW_%PZ4!G@&^"+]*1K1Q:-9[SQBD0X$XX;:STCDR\PPLYL\>]F)MQ)P"<1C3
M3:\TI<* '#EZ\:FD %"TKNC<(QUIHBR"Y(X[:1^Z-1!.PL2.>;>:]C[UY^#S
MK/WV5Z)[4$F V1E#]WYE]%<<DC(&AS_RY1+()"K9F(VO%SK-=JW/ ADD31$X
M,[?,U+RP@S EC:^>&U2<0)8:@[_<6J:,%EHU@QL0'KFAE$ *BBKI;2)UZ4N0
M1)+*.3UD(]+6(!D#&)-7[I\ GY$U<;YP&",Q&(MQI3G66\,2\<ZTN9 H2P=,
M4!$FP*$R;<XY6Q7H?A6?.^S2AM@^1-*"3+ V(F#N..*&Z,B^4S\UWW$CK&>-
M86LO>L_-0$'#%Y)-G>ED]+AE"V2/2A%D;LR=QW'$;:ZT#E(P0ZD26WQZ?AA'
M9_7E>]"%ED=9^,F<_P"T(4\N7YZ=AQ*P.1[?A/%B1=8A\_>IB9</*STSVU+(
MDZ4W#OE1-X$>$FM)"ZDB:R:5TF$C<6TT>&E(@)T B5N\NM("$[$L</\ %#=J
M,&.L$)QA<'!7A5[82#LNM $)"!:)UO3BL*B: 2)(L)6?FJZ'N5$2CA97K&.7
MM4F %E+19,9SQ=.-8<WL\#&63++?!/K3LQ<+6B"=::.@PLO"F81 L@V[][4/
M*A2TRKT-$B.M.BF(D3GO\]*"E1(PQB3-!B!=$;-TTY-Z,D'%\'IOR8TB](BC
M9&$U'CX!+!EL4XMHG@C <=]VV"D9L8&QIU??&8\2)T+"[&LT(!(A9U"2SO47
M@E8"<%KSQFC07!%Y9YW^OX9LFF>OD_'.L&64N6OC''IP7;Q[/@\>[;5@<CV_
M'!Y/M7K?S4'16%T1K.7IPFC3$LD67#@^D5ZI[]E+#P!SC+O>[5I?#-VW C8T
M,7VJT@U4XA,G4DIC$%J5"Y@F#I1T&@P@3+>#6")VZ5GYJ,EN#S:<D+A!O8GI
MF@LD,RK/&_I4 EI++&TLS+&[RC-*3AD!:&KS]J "09F6_.]^39UHDI$!&=3.
M^;G)S5L"X=5SZ^=369(R/7&(X4J.5#Q21>L>=9/-]_\ HT3HWUD'4Y3]%Z;!
MU"_K?CAU??Q[/@_#!Y/M63S??\E'82'!+)\T-BF&.*QU:$B5T)Y,OI^Z1:&0
M#S*MFAT:MWG@BA8LA%L 0"SHX["K5D 9Q#'++?7U"BBC. -)=-:&&M$D."*\
M1B PZR-)$G"DR/+1-2@.>)0$2VA;[216?OLKT3VJ<\*YP<^AUQ0E"<YCM)Y5
M&D92!B>;L<)]Z[5N>$R87<A9:"!(,%R'1[FA)8EB0<4Z[W+<IE\2A):!F3@\
MEDVHHQ 0.49TGS*-)&"; US[IBC>Z0#:[#,<.-'>XJ[NE9.?VH(%B0.>8ZGM
MY"4()#.&+D9;8M3$(8/:_>*SYWV?!1CK[GP4;&PBG:8AY6H)B!AB1,P_93"H
M%RL;&>M:+,HYUFYA2 ,)B3[Q5Z(IO<8ETN3$:TR@T,+>>7%>;0YX_@<]].,/
M>-F:PODPVOBUW-^[S^6G8<2L#D>WXD6NGF8D.<E2B0IWQV6H*I#Z$#5VBQ4P
M U#M%GG-WM<M"$W2LV##M=MN<+4$:]C@0-N=*3)5%E2)XPWB_G,$Q9@EBRH8
MM:/U1G"!!U&?)UXUVK<KL.#7JGM6?FH) (DYS;WS[9I.6!5UB8[A^*8'1*[D
M<YN[Y\ZPYO9X/3>Y6?.^S6#LM3!G!=Y#+Z<^5%TN(!-MC:<6FF<J=A,SFWJM
MQOI$F01$LS%YTEXS!%0:@1=8SMRQ<OFG0I362/"<WSPQ?)B9O<_<QW=?"6#M
MDOPB>77A&Y'F+?('OB@-"PLWFPF#SM'Q4A+$RRQPDRVS4MGFI>R9).)AVIC<
MP;P97D'E11C""+>(M.UVNWGK_"1-\:T,7'O9F)FV/? ,F3FX3.[YZQGP[/@\
M>[;5@<CV_'!Y/M7K?S0HB*(R(PC07[%9[/WQWKU3WK4] 9)>/6*\QU,-MGGF
M:UX-0@B)>'OI00KH%WD3SBG$@L(1TG;G3/9">O;6+D?)FIJ3 '#,8&;YGI18
MFP[7&@SKNSTJ)E*XL@0W5E,3$WOI-20X S",9.>GESTW.9F-+%IWP7F' 3 Y
M&%)&TL;.22UPFC;U <D0<6V?\IDHBUM$ILFU^/\ E: 1"\XF>LUD\WW_ .@R
MYZ:[SPCCPMFA#%YR>F-6^CTUH1<P[YG4>]]O#L^#\,'D^U9/-]_R1"0DW..2
MC883,,9/ (!"P:1M2JJLJRN_/P#@1SGWFLYIM,&9+&W'P?EI9ASS,><UE43,
M3:9D\M/T4++$C#N8\JF9@YCOE2J4RN7>@>.0-O6<\O8J"EHA-+F&V?N=Z,AP
M,PXGQR/P'QL\:'ABOBV>^4> L-*8F;SQ[QM5E5-O\BW"LUP21$Z;>5N5O#6=
MD)I&WE;P@L=G?W.*#A7F-\YJ*FAB=*!@=D1I'@# 0(C2-O >!QH*V[>6=RN$
MR)X3/O[4K(H(EV6?>A$HMS;;E5B)>D^W?G**4KNWV^CR_'?IM[9TS^J)NDO)
M:\=Y-Z$R@Y9X-M,\_K\M.PXE8'(]OQE;E27T>&G'C10;-B/-Z3R\BH2P(/-F
M:@4@3%F+PZ3F.%:=A1CAGUVSZII$9#A<)+KL>5.T:E*7U3.=>ABB I< !<+[
M77?-"FE!Y$G,G:AC&]DXZ</>F$UK U7B];%>J>U9^:C@@F=IL5V(OSTB::0"
M0OA'ZF: ,2$ .K%UL/+?UPYO9X 2L"H]2VL9#-+( J19A$X>F:1(E2 /5XO
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M!P"[9<3L:3NTT5 "(ZFD;)Y?.4X(!>)RSOW>;>Y?E)/I-%147 Z2::3_ +1
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M?*SYRUL NUL1-K4:!5T/=X4+=3:%OQQQ^L40X&4R&Z;<?.*BUA4"X*"@2F7
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M.U(BB(F1S^"')[UPO5^ZX7J_=<#W_J;8$#/ -ELVU+G\9XFJZ<W'C3J")O\
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M-S31HAF<"H3&="^\8Q?2IL['P]EN=]Z<!Q'U0VNR;YN>>OK1$!>+>(S0!HB
M,YVU^"G!R^7]5-TT5/6SY^E.TR';Z^D5D%K+:QF+R\@X1QIA168XKI-I^=8X
ME.%R9;#*8AF7CAVIL3)(P;:S?<C._1A%0',B,LXB?7A1$,YM L'&\F-M;UR,
M:,Q=ME?/I_13\^O\2JR_\7>C[U*^^.1IT_A5<Z$=/Y.[D^E*N?\ O&+V9M"$
M??K2KG^>8_P?>KN;OY2Q&DSU_P"&4(^+\N^'\XI_GJ?BJY_F"6.?G%O6HM.N
M8X8]^D=* XFP+BZZ&QYLG&TK:3:%EYV,;U@MR"UQGVS:/FDL*,0QOMPB1G]>
M$$.2-TW-(G]TA8)E!S:_3YK7DC5B)^O/T:(F_?>M!NWF(]UX?-6<268OF+W(
MVVI+#O/HTD>0^8/S0E#VJ0ZO>@F;+< F&\_5_/2HAT2X68OPBW[J+":L)LZ;
M6?BG/?7IM4% 1(>MKV[Z4!@D;D[\6Q/-B-<ET-TH)G@+46D%MD2)B\VM'&C#
M686$(%Q#FVMK\J2%-GO>F P1"<M''95F8DREQL7X>[O0D&%GB%ICSL^C4+F4
MBT@N^]RB4V;01,-]<8Z:YLTD1Q+D]V?NA).9TD(C6^;QM]ZC4)R=1Y7\N- [
MX5,;02SF<Q%RF!.&<+,FXP%M<T1"I. O&[MPCK5NI2>5O**@E"8)E8E#8T\Z
M@1<1&7,H;%[E(#'(F;2]-V(]:+'5&$'3RWHF8%">4&[BX4MV+20^D^I2JRW6
MM;5*^:49Z)YB5&LX"&$YX3KNG-KTV4VJ"8OJ3QY;9_56TWU#FUM-* 9G07RJ
M)%)LEIT;6M=GTJ!,A-TCEH\*0 WEGD0UHXN3UBYMZWJ F9RA#MF;4 L)B3QT
MSPI #,I+<-;19TOSK*(9 B,1(YD:L0R#&T[6T;G;4",3(+P3X?UU8A:[-YSC
MAY&G&D"8E!S,GH6R:U";DV;=//E1&BT8GB:Q\5! DYA-9X6^/.D$4DAPLZXP
M7)UJ$((LS?,/?>'Y/<I A+<);$+T2W-*0!9G",8RZ_K6H(.B^JD!,S P>NO(
MVJV@MK_.]J@&?1,ZADYCBB108"4DWP,6G&L4X:2PS>[A(R1FV:A")UO.<\".
M[:^$229F$M!,PEYOB(8MO74Q!9,ZWV//>D""MQ88FV[@G?TJXC"$.?*1@([F
MH0DDG%0,L!H<>.E^&*2TF\7OQV*&"(-=]2-$]=:PW#HT;CTO3>'2>@T67GY5
M95H1C,8,SM?6H&'$H0_#G;37-!/DOD4$A.)ET!HC"2[-YQY;ZT$L;^^GK46X
MS >\^E0,$S<%2)-\0<9MF*=.)\I\4D/0]2F(E,PZQJQHZ\L4=9 [3.CM?/I3
M ''!1ZVTJ,N,>E03E-P=)#6UBV]6TWXN%M/3G>BPLJWR$&F]0+G1$:SB^ELT
M2!A9XA&V2_I629B-08?=F,>5$3(Q@].&7?2B0L+F"0ZJYZ;.*@%FX$QJW")T
M;YVQ0$Q.0CS8^=/:Y\/LTP!,W);EB>7!Y4D*;58"9EAS@;[,O6/<@"6;K&"Q
MKKY5#58T,G#CTJ+3J,/68XZ7SSJ%H(^B\VS.NM0 S-H$)QS;AUX14$Y0_<-
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MGGKZV_AQ4WEZFC[U+?6<\:G$ 1S^5I9T#S^ZEMP(Z;-:R4LS8OF)WG>*58X
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M9)-&D&!8S2'F8AX8<J1((F(XG\BT6!BL#[_3>L). "]+6TM[_P WMIOS[?\
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M[_C#<Q/P[%OQ60BQA@.BWEY"<:7;"<E[_H5(O#*2)WF>X5)F;PC9'B<<J<$
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M:8LCR8.S\5P6")C&<X=-*B+$1C,S?0J-R@B8QG.'32LM A,XDS,'BEH3"8.
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M"U*$QA$6<KVJTE$5.*(Q,6F0X34V'X <C *"88LD#.4NKQHP60@SL@_.=_\
MI<X!X?%YPH=S/?CWPQ]=GQ?AB.9YK <CQ^4IL4KDW'O:ER*2707:0&%@P.)!
M[\N$4%))"B:PY^:CG-JY%CVX?-"FZ5"]R5@PDQXX5&F2+:RG&UIUNE^%,X0-
MC%'7X#JUD,J\1$%Y+8MO%#.B%SP3Z3!I'6)A9EC,AKF^U8>^ZO>_.H1QE#Q%
MCW>F.-/1'1K-O#,7AM4JPA"N,: +CBO:MJT?1#8G&3%QPFD@D8$41,])Z7US
MI4#&78*\(N'2GQ(0S"$<8C"QK---S*8P2(SZ*6P[.!A(;W5D0>P-Z<X0!2\A
M($\<=PUC<GC6[K1O<5)(7N/)(G[YY9J 18)&,1#*09R3RHFD@9U<-_JL=%[7
MY*<>G@5[9Y*<1B(#6)DYPV\7LK#F!,(F9]-1N)6NMW-;!(6(R;M>P%9\0@JD
M8')/:.M6IL8PA$\\8Z4,B4,(6AN VN%DSQB\?B[ZUBM8;7:88O?'O^>GOGRK
M$\WS^%F1N(G>M;-F-)^U1C@)RNW>(\YU/@N="\EW1][8U%<, 9LX<H.6'&I5
M9 3FN/8AZYDE+.7$L;LI?E4 Q<5P&8(;29VEO?5@,2"9 B8T&<*=[*B)O@D,
M\3PUOG"MAQ*]D\UA;KT2!,E> 'S'[J"<%#),3+DXV$R:(&<6"PRB(PDG'%PP
MPQ<GEZ/?>"MSQK$H"B3*H1JP>_*^=(FQ <IUZ8E6@*M=L803DYL<C%'U21A(
MO$6P@GBM\I,5E9$!K&LZT*0BY0)G.5K1UUIE%<*;V8L:'##V/3'ZG;OTC.K!
MMH))XFB\,L:295W/,8Z845T,AJ0+WC&;E0U=E+*Q"8LQI>B=PFTX 6Q7YI@D
MF5Y<W\A_)((9QO9Z;/B]=MT5B>;Y_'$<SS7M?Q2"(@B0B2)26;WEY.F5B3K7
MLGBH/9CB8S#RPC,I,<+J:X3CEIF8UE&2!91F#"Z]B[Q24,QC8A'M),Y9ZBC$
MF"1F C.5L>= )@HZU8W-XHN,!S0DN+-,$S.=(P.W4@VO;K:.'$MP Q667",$
MBTV@C%BH*8E:20VAY##[<+>O22.0Q,<R3C6-%7"#(R)QG)UQM3LS808&9C2S
MAPRH0)MF(W.J9<BLQ8.$6M$<(@.'_3UW_O+G48_%LL]:/L[;Z8>FSXOPQ',\
MU@.1X_(! 1Q&E9%82>B2DN*YY4  !  !H>BLJ=8^HJ^&=8ETQ9?0N"T27.N.
MN"5*PE(F\QSG/O2L-0DF,./>HA)%B<C&#K0  @8&12).XQ?XF@H$LBYPQ-\3
M#)[4[)J(DT]<1S5+]\8QM--S(XD^9CI?3T<ESK >(X>^M+R),&+G5E]_-85Q
M679S,SW].*29SG&>]8XTLRR7PL<+%K;C&EI1,C1PMSO4U%*)C.,*5&5,JXSK
MZ*R,F9SG7T4EDQ6(EXQ'S[UQF3$9Z\^.-Z-1!90UI @!R23GSK:/W0 @ -"Q
M^.][TIWA?O0PQ$3<G.<1G.7>?XZ>^?*L3S?/XPEP@>9^MXU &X73+;)XJ0,Q
M>I<]ZEB)8F8RG"8UJ.WS;1CASTIP!,6 RR4.<3WHVG("]LAOEPIA%A;$5-VV
MM@X!-/K4D7S(T88C$\4\P6S@,;,\G]4Q,2)0+#@$N-F;>:]D\UA;KT4.(0UB
M3'%'V.5&@+H8B;B@0D(22^L%U.+G[UBY/+T(02P#JFV:Z'?A= H$A$B8)*:L
MW)J& @99B5RUB)<V7E<E-C$\ 3[%(+\F# Z1<O:/=OJVD@WS0\APH:2V2<<6
M!YC8NF%L*31*DR%1SQ'F:S12]28E!F;SS2:D( 38,' TUP<K$^B"@E,7?-2T
M=U(Z<3"8]XHF@)&8%HRES-:_QJ  "P8&140#C8MAEQQ%Z5(,N[:PM[LVY?Q\
MK4Y8VO;Q>V?IL^+UVW16)YOG\EE2K=4+.MST @!,P@D]:D0!90 3A@4@B((X
MB">]7IO\B.V'M0 0 !@! ="O?@X/.E667D\9]9I,)!@(0QRB,V@( T '8BD$
MA!-$DJY-_DB=8;;MI0 0 &0$!R*01$$<1)*O3=X@^S:@ @ - @I!(031)*O3
M<Y'C#?&E$KI$*%M@3&!I_P!.NYX59PPQ)]O%].U7G(>\AVUT?39\7X8CF>:P
M'(\?VNGOOM[TD\\F<'95I;)#.\P>/Q]\^58GF^?Q*AA,Q*7YB-(K,2%E;=3'
M3X/1=7,SQ.X>WI^SO9I:4G)3N$'M4U'Q77NR]H]'I%=11]DGK- (&$BYE)F)
MF:168D-U;JM/73$3(MT2@  L  <"Q3:C+F2O:!ZC0" LA9E%L&9)SCM4CC(F
MZF,,5U]65NN*+=K AA]S02BAB;LJ87F3*0;I13"+D59RS.15V8M[I]A!OHQ*
M6F15?9M.X]+T2Z)'N)/)M2TDW*2G9L]=*PP_ !!#(R7Y,/:L?3"D4E8L/L .
MA0  $  &@6#^5FR83?##K]GUL^+UVW16)YOG^SSCBG*TYQ \;\-3[\1TC']-
M88N O;!M,VW>MGQ?PQ',\U@.1X_)8%+@ 5UM.6>G_(&$"5WGI238C*5EYQAR
M/>AQ*+(C018U,8E ) 3$B-\RRX?[$_\ 1O>_BM);O/&]N/6N* T<3!\_%_Q]
M\^58GF^?^*.7<_H_ON</WVKYQHQM_LSU]=MT5B>;Y_$I%9"-F4Q'[U_H?;.]
ML*2A;& 6#%@5M_'OSVQW:(XE_-_>/8QPIXQURU]IKD=/5_#$<SS6 Y'C\1OB
MY1+6HF!;K'$B@ 4 O>9%]H]Z<@08@P#I.O(2BZ]G"3[@5)F3!&R/$])N-B6F
M)E#&_6U':PUY,S.491XXE96 $3&,WF'"*@HO B9F2=/NG )8Q:6DW]CWM0?I
MXS+JSHQ,AG0@9L3;CP:60O','RM(0;%*/19#V]Z$ @B2)F>D-!5E ,8U;1YI
M4V,<;_I[U8B89E>>26:"$*1XC,M+DT% :(;6#*^N= &@1R##"##XI *4K(9!
MGRI @ ,NC'=O@411TDNHMR"=S%!ADVF9EQ@([1JU(I,)B8GK>A9; L"DTO$%
ML9SPK3R"7GA&!KQ;?\7SSQ_?SVY^,'V_65;#C^/OGRK$\WS^0HDV6PF9SZ:4
M-A2&+,S/2T?Q<7QZY>\4C)0-W"7SCRGJ?Q+ N,"QK%ZN/++,CAPCYX<?1F&"
M6+&$NDTJX%ER!"+ ></^;9\7KMNBL3S?/XA*&K%8!2"-OC$X?-\:0!(P98R6
M<'2H0<]$FP9,QGRMC4S;#5-N,9\J0@6YMNC-SR+X32@0%P7#BS#'>E@7&!><
M$T$ML!2%99L8$6Q9JY@CFS'8O02V)BL>9&7'_*< RE*QFD8.E$!?8O+ .$8$
M\[7>P.R(,&*I@<<:2;$<5_8MRE]J3!FN,S)UP@^^P" +,8AXV>G^4,,A&!,P
MD=YD>^E$,)+!@RQDTW.%.Y#,#,R&+E;Z:,HF46P\B[13$9JIC61CSTH0"")(
MES?"U&$)<*,ML(MG'OI-*FQ'%3[%&!-T89UF</=>T427$<T\;Q\'.IT<%8KC
MSR3&H(;F1N=6&F%[Q:LR'4^8B=YT,W Q6(9,X(TD0@F9B,.#0 76"98!T+2Q
MT^:%0@+"&0XHWCK:@.U@#-BV/$OEWRJ,R@B8P)C#A0P\1(F<(X&O\7QAX>YQ
M+37+*_*M[WYK0Q;Y?PQ',\U@.1X_&P0(2#%G"<*)P29$D;:44D$B ,$#T\PT
M+-X9#+)8OPS6:%HD2!"03EB01#PI 2@*,X82//*>/I[[P5@YUTO>L7?C]U[5
MPO%O>@X3.& 3.*7QQO6'C$A@$)]X+8$Z&=&N$H,7.#.%AGGK2Z=MC! SLI?O
M42062 29C#?*_!Q6F4<!SA,.7H05PI!B>0D]6+4QW;DV$G&+\;7L^[DI"TY-
MK]*,H+!9>)B)M-+J@(@,6XTD*0) ,1$*$O6D]2V0+$->=+;L1+C%@Y!E>]Z@
M:+=@/()2-YTT)<0+ \8,]Z43E91+H[-P'!@$!A0RF]2\4L8(F-?W_P 7QO>%
M:^W;#OQ[85!EXB^<&^'[T_'WSY5B>;Y_!8%<"[48"1N+#CA-^]1?4D3>8G3G
MN]8.;PHJ@62,6!.+\"4+$AK"NV!I0<'0H&*F7/*B<SP*V'3_ &]O04E5!GCC
MR@G"G<6<$=U\4BWZ:,WF"+\;"C$T,XXD;QSJ,F/0,'=9Z4"ZE,+)."S=L <3
M.:C-%T5E&'<O5U)!L,0%AXWG@>(G(3":.E(!298+0:O7Q41L4D+,#@6F_#'G
M0%%&JA[7[VPPIV$Z$+\#5W%* JP%U< U:<1"9V#ICO6D0"W!;G<P[1QKGOH:
MP-EJFDE; B7CRLWJ4P@8IM-[&OQ::?\ F#L^+UVW16)YOG\<1S//HK9\5+2"
M0!( %^:N67.*)1!"! I>8,T2:?"(2P0!BW:?U5HH! 0"V8OA:>M.4JO 7*7O
M'*^.1C0,&(4@!$&$3"FD'.^(L7\\RMGQ:C$)-D@2VAMI?'&K1L%#BS/"+ 4R
MP 1!QO!P)C*A$B,@()A<YS>+6U6C&2N0\0=T7QTI&6%L:"_=B*4I$@0S6+SF
M#I0G42K&D*AXIAI.-XD"I82&"S:6RN>EM9LQBD*,,$86>WM3(:RX)*<K+STF
M@8P;^5U\4TQBJ (E\2]XAUSFB$) 4:P3?AKKA3C$$H!&$EL2+7PIP6H8<)''
M'&_&<(H@*F$8H,1V(J>1,(B.XO9XT2!= '&2(8Q@SZVK>\JF60L@8)0 <,.L
MT'C"P8#*,<+?J@J@6H&$&^C#YH@ )8$DBB2@$ :"#M_&SVUT^-X8UO[\1]UL
M^+\,1S/-8#D>/Q21-1.]J0E&\(68P8G7*;4>QP,$LYD-KQ/!;TVFZ$1M)@C?
MF)F<*-$BR3"P]64XQQFK!(!)&+UTUPQ]&(Q AJC,&4I;KB9MC ($PR-LGJ)X
MI@0B6\SHL6CYKV#Q2\"8#94%NC!.>.FE%DTEV 1=@#R)=&Z12,LH+;"'/+)[
M7M5N(MB$$S)$\3K4&U.H +Y!/*[D:M*"@3" CQCV?02F(M%BYWW:CMD 2E*9
MMA?]135TA0QS9KVWRU[)XI) F!8+QA/+#]9H 2P88P$,I9UQ*"3@88JPPYC*
MZ<K 1 -D#F&2\97UM2Q I!D"G0)!G59TH   8 MC#ADZ\9K:M'_CYUYF-[36
M,X7H<1E%RT8.O#\??/E6)YOG\%$-)> 3&$736<:/# 8!PG-=O'&D,H((8(O:
M>48<JP<WA2W!(D"@D38B=1?JL/#A$"3@A!U;^*8N6L<%DGJ$/F)*7!!3@7F+
M1@]SG0DAD"Z85V9+I#A@Q-7$M'<S9X6PJ2-@U6 FU\Q*(8= #DB<,Y*("-H0
M;1K,N.=\:<0F /,96S07RYUQWY$W'+AQ>-0(8!)S.V4]J8Q6)#&TI?-1JXBV
M"8\K1QM6&-![N?!B^=+"<1'%<>.%OFU P%"3C9@N72\5 R")2(@+V)#P9RI6
M.1.0&$Z2Z7.&*I#+:9 0]/:H,7 !!<8R?/:E><>=2XYP05@^40&4N$\/.%3"
M,5B^&&.!0( #(]V<Z;!L8\8,=O\ EM@9SAQS.];/B]=MT5B>;Y_'$<SSZ*V?
M%6-NM3!UT>^\E;YQ]%"<:[IGRDSJ12B$E$),2"_M\4;>),O0C6&ZUL^*MAQ:
M@ F$!BF3&<7G.],3,!#<,A'373*@QP O MU?*P 5GC#NK+QNTZXA,Z'-TQO[
MX12LKDF7.3CC$N=XSBI,8CT!AU).M2 Q;A"):3A[-D=32V,FHC, O?G:B L)
MD0DZ[PBMDTIL6JL3;8K8<2MGP5'9<$229F&<Y&B/-X0GQSP=.:@2BXD %B)M
M?/CH5O>5>V?*MGQ49'5G>2DG#H!N0ER@$%($<491M;)(X?Q[WO'G4VY:;G3Z
MO6SXOX8CF>:P'(\?E?#6$WGN,UAE+%S>;C\4?!!A)AR=N6% 8=3[6]OP;D5U
MP7G%W/%[10:OB*1C&$N-20064-<*;E"XL0KJQ%_@JZ$A@I/F?3#.&"X\I(8X
M32@B)J3R;YF3RT]8$&)"3?7ATH1()LDWB-)FLM^\:]_W+>@8,)E&I<(-T,WT
M491-Y"PZ6+8\#Z    6 L%)RIUP7G$33<B=<4Y+ATI ()$A'.EI-1$S+'_(8
M_O</'#6U7</XOO\ 'WSY5B>;Y_!%Q)9PSCCGR&BF*MF3$<[9C;"$XU"5DBFT
MQ@!SE9=+5AZ8YQ#WIF16P<;XP.=,2"2!! ;W0?\ 76:Q<GE2U@Q)S5B<<GI6
M8 +#BMQSHP\@EXKKU:E@A" R#CA)/7G28BDN(#.SGRM>FM*5@YJ!)?6\7F[$
M7J5!,6+JXO8]WCZ(MF60T<>.I-N14J\R7'515\7#7.BJ$3D6S/=:Q[F<<5GJ
M>].PI @YE[+PY89ZIQ#",<C"9O,?MH< E;%3E8)C5$<XJ'&^ 1%F!RTY4>G)
MD0#@CEI%R^M!2$FZE!<PB^O2D"B(@ ,30[<CI1$F"ZQBAEUK'L;8Q7I.FCTJ
M^,,'@FW-D]-?^;>M;/B]=MT5B>;Y_*>1)3,$SC,QK0\$!DD$,:!@!,P$$U#Q
M0PA,=^5 0 &18X]VD1<") VR+T ((! &1#!0$6X@345-7EQ>#Q@=*    + $
M'M28N%A06-*    P @/1*5'6-XXO&AT,= 'JAPQ^/2'M&$@QRH6 &,!'IWO$
MOWQI.0.L3RY)Z#H$,$ 1_P FD$1N)":C2,J1$@##B=:0"((V1N-(RXD* 6I!
M(01Q$D[5,S[,'8M0$ #0(J#6"P@8-+T   # +!28N%A06-*    P# JZN:I?
MJXMJ'@N0">>;U?X]>5N-8QVXNGUVK9\7\,1S/-8#D>/[=>RMD3#7>>/X^^?*
ML3S?/XLR,ZI[HL]3YD! PD,JKUF3HU*XS&ZX<U]J6FYJ*/6,>LQ0B9R&5GO,
MG2/F@L 2I+&&)X\Z4HF1 8E(DSCHX8U< 7>3!@VVMZ(R"ZBR>,B:6DFS))0Q
MR;?Y3O4&5$"Q 0I@,X6FF=LK.BR>1:REO2%O"893'DCWJ,,26)6[Q5:@68$%
MQX2C00,"[BSBRO6N9)A#2LI&[<XN T](CJRO=6.D>C4RNHH]82>M*B33-+G,
MPL3TRYR@B9)$<*MQP29+/!4H!"5B:E H(P?M@\G_ )M[]ZV?%Z[;HK$\WS_)
MS),QP>#2$K:@)U _J,_WE^N6-;/B[?PQ',\U@.1X_@<P&$H3RFA!*$U$3N?F
MZPL"5F*7B'6FWM[D_P!-\3SAOO\ C[Y\JQ/-\_Q((B2-D<$T:59MO< .PP<@
M*   , (/V\6_]7L^+UVW16)YOG\D& @E=+#&.,](G*/^9&)*0'!;"\!3GA38
MQ@0"(PLY0KY];2+) Q8R_=$3$<$26##G(&.<'_)O>^5;/B_AB.9YK <CQ^*
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M%8GF^?[;9\7X8CF>:P'(\?WFGOGRK$\WS_;[/B]=MT5B>;Y_MMGQ?AB.9YK
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M._[^/\R3*8TLQ]P8:3-6(@Q8L8V?]]&=0MI>=Q1?W.UJLXF"E[[FL*O=F<0
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MJCZX=M\:02,M^*S+8.-M'_.MO_-W_\0 +! ! 0 " @$# P4  @,! 0   1$
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M^B<G48YPJ6(SI7D3AWP:A-)I(\CX3L=GLR4=C1B?1[($EX&B  :()LPEVU6
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M7(==LZTDXL&J169R?T"K0]30=NEN17;#>?@=V/Y*<2YJ7 =U=C0\@6MQ)+Q
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M>2C.G6I8"#8APH8V0WD6UB(J#,/RI 8L4!SFYR(@B(E$V(\(]CDNUKLK;<P
MCC=;+Y\S9!(3D6?B"H4HX1B=82T$54&Z]B$)K2AFRJY!8OYG^-K75H+XH8QT
M]]/?MY/"4>G%5'@UNB^X3AJU>+0B@PD'BR/2-GPNW8./AU3OL>)Y'I-/(N#0
MZX'.@T0BZU !"/I-*-#IU'6O [6=PP?#R(]T91ZWK^DC'-:Z>&OL$7D]K5V
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M$>^N8CXKMSR(1SEWRPX O!RA  @\MY*EG=!D3L39ZC&,'J#AI$"D)R,F]B(
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M*%?K!20#F #@;[7[ ]66:X!BS 56I6*=PA$N2/D5!=A -QPSGQ%JU8HE!O\
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MA)9072-8(%1 T0T\Y*2H7WQY%!HSAW*,!#54>1GYTN,!4^ 0 V% R.. 'O0
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M5U!2RFU0")"A.:(=A"H&W6AP;.VHU3E+9 \C8J+[DY'VR^BC9-E<>B#"%I[
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MI:P;(NR$""! E)P'(J@P5UNFEMWIZ(R=(G7[L&UEO L"[.7.^:O$5;'(SD1
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M0@ .:!HL@\2"AC$!4TITP9O0&J@""P>!J-0 GA0)&X@&YB.B"!0DSI 39/\
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M(,H0^4F(0TX#'LY-T$"X.?Q;T),.C1=B""*HN G%$:O2Q"[8YTA&+#$QX//
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M'P1)HTU.26\QZE'#I&>'%B"B]YXS X5\;+ /(=0#GEC<<.0Y G"*$:+E"&Q
M:/-EAY M67U8XB?T#2($CLI%&9)67Y39A';M#I*.$/?*F 6N7V?) 0O!02*%
M(<U(?7H;F;"1L3^2;!R4X_T)##7CH9^"1N)/-2 :1F)>:C@)A(&"HQ6*$V!<
MP#I6YPGHF<T(?%$U"G8&Y1^I0*6MB[A.2#IM$[,YWUBK!1-J[:-G83I% N#4
M)J)M>H2EG##C3^41D4VBTI5!!K<<8[-#FY6? 5>*WB"(E'2/">'"L&404$QG
M=P(!:KJ1  )N@   $$1!'D>,[WB_<%[B&:KLN-4_2421_7]"LXXP8!PQH ?W
M06UV86PAL C:&T%N:-2:8T+P HD@&=X\\=$A.ZM%WB5G%7"#H*\:+O()3=LH
M\0H%7#)R=,@,VQ= ]L5O_*610H!JKZI_NO,]=L"!I3"0?(34&;7ZH&:&!&T2
MC6MO*JJM55=N/6MV6>UH_?0[PA^0 [;A-B8"V8NT%I]%$8\(S"1PM@H(VJNT
M*! IPSW_ ))?=6=XE1VH;8'G,P:K@WVE<IOPY5@.(\" R _L-*"M,:?<GLVT
MO(H7#*HC< TK?D9P-< ;(*%&:HQ(BQ'#<U*.;PXFUQFF[U$PB"H1$".MTG>4
M%>J%]7)YF'>KJ@2(%RHN,Q7GB$0W"XQH;EJ0RGM3AK#AHO CJ,@,H $Q6G3Q
M=['_ +*G+%7PK7P85KX,\?;602*[4APWCD.YP0UQ@-MAE&@.@7;[%;2&0#)0
M"J.;?;?_ $67^%X?;O.::IA4" .6A@ A30\\=(+!R@RPP:O@'L(3QD#MI"C9
M49,/Q@+WB#5ML6%<JJ]/\XQ&ATSMAC/\:U:*JLP.<&*D5%SY3BO )%XP--@7
M0D18@),_DXEAPP]R7BDB?EM+]7_!GZB)L )2LI=-03!S%P?^GE>R<AD9%V7I
M+6^NIUZBL4MX^3$^37EP)VAM7_V %<KF$3+@I).D6T0<MQ0::WY*M[2".(&&
M7J6P5F.1DMUQ.PTWFAL2@R/*M.YS$*S&59*HG!J,T.,&$U.7'] UD<C?F"-N
M4QDM66243R)\DQ9AX;3I(T:GS*@7N#W$/^6:GMQZDGC>+J8?'"K[;M J$
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M;,*EK)38#J)PNT^I)%'.>?!_48,O=')"2Q@[F?[IH82BJAD[0;XVW$+3@.6
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M0?AY$:OV?T67^%X?9L1%$1$41&B)$1!$1$$;D5,!X5$F%2"XF_4"$I0 MI$
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ME3(<Y7[?Z++_  O#\0%8TWHE?-P29K.2P58:4EMIRN6BSJJ\25D/!]8/(/\
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MJ#_%D+$W&A8XNZ<7)%4(7AO7]R$9%-/)F_"^PO\ P9?C,)Q3P-^$.*'*'O\
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MJZ$7 3 :$27@"N&Q\M^[+^Q^P62E0K#*6H([*+$:6M#V$9-C*\P:5^L?@C<
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MS]_AD6CZ28Z0A!>12!B71="5A,Y9Q$HB>1I^AVM^KXY3Y'0T( #J!($BNBM
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M-]NQ'BW'H0O673;J08VP.D$CS]IO81XZ/.>$\C]0% "H  VJN@#:NC/XDR=
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M/B0'%00L OL!X,UOWGF+ZW.0Q ,1 #?&G35N+ &VG6H^RFD0$$@O_P!N7KO
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M7-C$<!)*-TJ7H3(&$NT'S4Q 2?-I-XAUE+O%Q<*8B;"&E04]</Y6 A2, M
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M&SMAJ39H=5Z>@9Z&Q9N"P Y@Q]-05QU;<3!-F+J$(=,!MPV@^O"L&&"??95
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M\9!SQ-& =.@M]8"BLP0V@)80:.N-FJ0;:F5\GJ2Q0"P'J' 9Q'D;2 +8@@&
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M((-8T4(8A34\'YQ/ ZL,"NGS/44:OA'BAK>=!TW$T"A4&VS!2PL7Q"A@
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-?+\N5\ORY7R_+G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>business1a.jpg
<TEXT>
begin 644 business1a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1VH17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   "]    !0
M +T    %    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$W.C4Q.C X  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !Z     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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MH0I$J 1OM?&,-D/DIG'R]>:F,OC4QW@6"W5T+>1D*0^%8J,[^A.P'(!Y/UH
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M?+;N#@,5; Z\;2:C/B*!'*21L&"E\ @Y &?SI5N ))4.BOA&8!A&,,H) (_
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M;"N#G!VN&(_"H](T_3[/2(FU)UCEF(\L;L,!T  JQ<>"[.XNDN3Y+2)]R1X
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M6B 'Z  $  4 %0 R "EA8W-P35-&5
M    ]M8  0    #3+6QC;7,
M                          UD97-C   !(    $!C<')T   !8    #9W
M='!T   !F    !1C:&%D   !K    "QR6%E:   !V    !1B6%E:   ![
M !1G6%E:   "     !1R5%)#   "%    "!G5%)#   "%    "!B5%)#   "
M%    "!C:')M   "-    "1D;6YD   "6    "1D;61D   "?    "1M;'5C
M          $    ,96Y54P   "0    < $< 20!- %  ( !B '4 :0!L '0
M+0!I &X ( !S %( 1P!";6QU8P         !    #&5N55,    :    ' !0
M '4 8@!L &D 8P @ $0 ;P!M &$ :0!N  !865H@        ]M8  0    #3
M+7-F,S(       $,0@  !=[___,E   'DP  _9#___NA___]H@   ]P  ,!N
M6%E:(        &^@   X]0   Y!865H@        ))\   ^$  "VQ%A96B
M      !BEP  MX<  !C9<&%R80       P    )F9@  \J<   U9   3T
M"EMC:')M       #     */7  !4?   3,T  )F:   F9P  #UQM;'5C
M      $    ,96Y54P    @    < $< 20!- %!M;'5C          $    ,
M96Y54P    @    < ', 4@!' $+_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" $K G # 1$  A$! Q$!_\0
M'@ !  (" P$! 0            8'!0@#! D! @K_Q  < 0$  04! 0
M         @$#! 4&!PC_V@ , P$  A #$    ??P    %!'"669<QQ'C6<VZ
M. C!09M2=0EQYRF]1FS%F4,*<QUR,F;(6=0RI'B+EG%A'.>>!?9?15I:IT"6
M'5/IU#E/T:Q%^&OIL09PZQDBE2@3<PJXMLP9:0         !YLFM!!3(%8GL
M@>/YM0>>Q[6&EI5)6Y[AGFH5P=8EQ]("5$6,>GQ3II\00MXMDL$HHID]XCQQ
M,>5X;!&C!NJ5&20N8^&E!N*:''O >+98QSE8GN:>9A+#6DFIG"J3W4+6
M       *C+<!%S(&8.(BI4)L:8@QIT"< AIDS/@ H<R9+"9$.)P")&8,J8XQ
M!C2=  _!6!E"<G*"#$Y !6!8)W@            #S^-(3U0/&(N$CIZUGBV2
M8N0KXHLVK,0;C&DY;I$#*GKF>!ALP562\_9CR#FTY196Y:9D#6(M<FQ1QM 7
M^:C&P1H(9TN YS7\VI(0=8Y2"%G'H*;-             K BQ9Q0!.2#&QQ6
MI%#J'0,J3$U[+Y(>4\7R1<E!71?)7!^R8'*1D[I+#/$5(,08ND@1EB6&<*U+
M6,,?DCI#3K'Y(.3LJ8NH^%OD_
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M&0.F=P 'T'P 'T%$2I=4:Q<Z1R$G,N?  #Z? ?088S!]!7Q8)\!]
M      -;YQQT)?@CI:!#"#$Z,V6V3(      %$2I:4:Z]G2)"6L3\
M                &N$X['PD          !1$J7O&H               %,E
M!&4,N?#\G;,"3$[)!"1F.)";.   UPG'8^$M<"&G>.X?2NR0D\*X,L3XCQ$S
M*'"7D6:  "B)4O>-:?*X.0QIB#N'>.H<9U"=G&0PRQU"6&R(       .,Z0.
M<Z1@?.=_F>VT_:V%C!DH!BCMGZ.\  #7"<=CX2QY]/V<9^3C.8B/FO0RWO\
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M^C4=QO0P3 RYQK,CK9MW+>@<[6^=:JO5=WN)MN!])MSY=F960*(E2]XU
MKORKI:Z]-Q-8./[VG.:W,;P[UI:S)P'5VW:<K5%CH,%B=#ZD]%XSM-F\G]
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M"*TE>\:@ #Q[//VULJ,R]=E;$]PO)NFVRR]CAL7:X^=W$IQV-ZI=E"):G?\
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MSH     UPG'8^$@   !!O).HG/K?+@    "B)4O>-0   !!?(^IG7KG+
M         ##\UL,;H,Z5>B:$     :X3CL?"0   'PK_ ,8ZZ?\ LG)?J=
M   *(E2]XU 'Y/H/H!7OBW76%[3R( 'P^@         H<KHZ):Y2I)C9DSX
M  !KA..Q\)   0DUC,N<A+BK3)&Y!]   !1$J7O&M3E('X(X3 CIV2T2O3*G
M$8 EQ%R,G=,\747"          ? #Z    "@I1OV,@   /A]/A]/A]    *7
ME2Z(U ^'T'P^@   ^'T
M   __\0 ,A   00" 0 )! $$ P$!    !0(#! 8!!P ($1(3%!46(# 0-C=
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MOD20UD%>NDC$ES],)VR!LM#B4T[FMA8/?**Z\'UJIT8$&H_2 Z2E6C&YUF
MZCM7- L2Z5*%01%4U)M)FH:B%Z]LM-@BAS5?O%)#P:)MZ*.-Y*B=;A+#:&01
M?T=>*XFR:YZ/U9:3==\LSR.PHE9-%=5$Z)* [E."J_\ QGN*/(DZ=N>JK76M
M3[*K%@:MLJO%:[K 0%-1M>:MJ@.ITG=8RZT&^[#H*JB!,#& 5\/56Z&GZP+%
M'=C!-8!Y>A:(J4NC_KGKS6:R9^A(T)$#!\^&5@\6M#:'904L&U_KJ@4ECD^?
M#%P19L2:'MV4"\?^D^Q5\4\/*C"S7LNNM:=L'%+U_4M?04V4"NP*<;0IJR G
MS_T(GP0A<.="(L<ERXT"*&-"K$,A68"2,>Q2L)Q7[O4;8^_:ZO%DH6AQ/T/6
M4#5X_LM]QK]$!QI+,R-^WMFPEQ&Q(=DW!8 U7*EK[JV@#BC?1R!&-F:Z#%MI
M[>LUD9(F"^L:.<V>QT<T;$N(6FL[)V,(UX*OEZDQG YR8T3 VHWTD8FS=G*U
MCK2XE]CWK;HR25Z19WU3K/7Y[=-J7 UE;]P>KHQ&!,B%=Q[ &R9,W:-RV]'W
M/L(_1=>P#0SI.;Z"GI>X9P"V&^D=)WIL6%JW3MBVHNV;ZD5N+N\1@_51!&Z[
M1J^O9=EN=;L59/[ UYI27<R%'O>M;EN5ZT0;INA[5@JR[/JNP=Y7>QUAHN<V
M! *=%FO2!.L&Y>OH^U8TC;6O-=WZZ[,"7%5PZ0$^A;'LT@[JCSK8]9V*#VQ=
M[7$5>=EVX:_L385XN-AV=?1U$V+?+FZ8TY<"%]UM^T;IM=L16#K2EC1@,*-K
M@AO2FLV'INN*<1&V32>K[:84.A*'#*!4P]0):CUX8K3>G-;-549I36H=934&
MNS5:%4"J!3MGUB9A5W7-''ZZIUPTWKN^%CNHR8:KTS6X"I4 #I36]4D:MH3.
MMZ0]T?=1OO#Z76Q=BSIW6ZZK4M/Z[HQ:YZ^J&P88F@U0(=;U1KY *EZQH^O5
M3*=72%GL  5: T^BU(I5JYJ'7=3A"^CYI\//:U_4&2]8TQK6FF6=44)BI2Z)
M5IQ&SU2NW,57-2Z^J8ZN5P/4@H2FURNEK'3*W;)%SUK2=@)EZ5UE-KO\'ZM]
M.B-0U"D(UIJPO7[8>T?JRRF[CHX?=-DMZ;ULS43FF];V,C5ZP$IH/_SE_?E,
M5^8U/J)B%>R<,8.L=E8EXVD28'3[L:K#A>TVFJ"*=:"!U]5G,"A,NQE "Y%\
M;A.E;C::RT+/V)!SY8-QL F,SLHJW%L&T)(J.,/F2ELEV1RJ'T&K(#Y'MJI[
M8^YV%QD3=K3)A[!9-S['"NA]<:FFC5A@P[J39B,;'*M0+!M*4,@'#MDCF%R;
MMZWA[(1F+=29N-0V"<FO"SFQY$*8YL6P9'B9N"(SEJD/PZRU<+!'$QMG3II.
M+L1]=II9HW91?J0VP!?M1,0F3>,0Y):Z6:L,BC=@183=IEA2@,T:4=*G('JP
M9;;:EP/LPT1X5N1LE5"5PL]=?(7<@HI,O-D'J+68O$;?V*_&M'ON5>F6<2.H
M-F'3G=8G'8<C7)R4_P#Q<9RF=3[.3DM:V.HB":K= Z)%(L<JP2J+:93C.MBS
M#;6LC:&8];LF3'R.X<RT]0CTH(YK<^M!75YDQF'6+?!F'*18['R?3;42DQ=>
M6"([#UL:@S6Z/9&ALFM7"9-C:V-1)HRMW$/#C52VPX[NN#ZVRFL3)?DK7QZ8
MW!J5N'RG];7"4Z;JEOL ]RE[&APXNM3T6O+H-L7%KHG ()P\/?+!R-!.EFT4
M&RLD8^LC46:+K5Q#054BQKL;]"M#W&M:E&6$:S-XCKK=Q<)RJ/9)LC%:N."D
M6MW&'+],6_S*#KRQCN.:M+R(Z:+>!*(&L#<&LD-56"9!9UR?98_C(SX['7U>
MZTFY=>$.7Q(TFNW5]$V=:8PLRY>JTVB/;P$R3/M(\5/E&66F!%PKYU]VZP8A
M<1819W@^[UHH[*V !CLP[,.?E1[E7I,N39AC)"O7T,<&JO5:0PY=ZTW'<,C&
M<EM@!80I-O%/JG;!$QV19:"9B<;,PGR9#8),;%Q=*]F.3M<5BN^LJ[XEN^5=
MV.Z?&1Q4G8 N*17;0*'8UUK<J4Q?*N_GUS7.Z(V(6+3#O8ITJY<Z\QE%UKJV
M1A6"8BC[J-?CLWBM/1X]N 24.W:LLQ8!T83@>N*YW+3J7FI)2'$G3G9;$:+L
M=:X[MXK+4<G8F!L_UU6?#>MZ[EL[;8P$L[<*^TARYUUO$'8 >1&?O=6CN0;"
M+)3D68&X^YL 2R^&O0PC-G6(4-FHNM<<FB;,&-NS;*J*<QL2IJ41V '@1WKD
M)A.YNM=[@83@F1_L."TFPTFN-R)\+60^%+L5)@V22'I487-8U]X=TO4FB\U-
M63@7 JC U#E2[N;7ZJH(1Q0V4BH&MU#^3J!&G-MZ_'L'RE0R2.2:&W('IUR4
M&SY&L8CSANI0S U%"B-K(42"3F)K1*1D2(0*7P-^3B--8(LGZ'$.SO1\;TTS
MK,='>G4MN5QNH9; 1 ,I!)6K65\?I<-P='HYH\]G7B? &*BLH)Q2VL#BNL)'
MA2&O_/>  ,T"^UK4;!3.IC!%^10TSTM4.(RYBLI3"CZRQ&CC8>1X^P_>O!M0
M9'-2=80GGSM.''VH6O(\9!2A>8<6$2LK.U8U+CJI_9:>UJT[ST)"2/@5-4*Q
M$->QISK]+3A_%3CIBV/7Z;$4Q4#4HJ(H\BN8(5:.2*BZFP/;_CQC#'H_O"A.
MKDQ<NH") &L^R_&BH,7"-W(NZ]L(QD@!,S&0XRT6B/+I5AG%IJCA.D5:MSC!
M0F3LQZ4.>M!%YSUB=QRM$CWF_P H;\G1]AGGI;]D<;P_:RJ" PA="2(YRW$W
M/4UM@P\VPCAU=Q(A*S(+$.W(N)QI(<V3&S[ 3+B;75#LF<0DW$F=0R9E#9*K
M?<>Z/K(637J+"7&28MLEI%E+U->R?L#[3?J.XS8<5W,B+8?O6R$LB 0V\&9C
M$>QRGC#ETL*1Q"7<Q^7C%PE9?L)N%)+VTO, NW$I%L4 \;B"LV8VXY"-D88@
M1<[.6>59B[3XB3(;US"(7*?GUD55*=V >23#%3LIJ(>M"1+MH.M&;$2LB2T>
MZ6B39HVP+)+3';<:8_<#?DXG<P0^/@\#5.]65C,&03'1(4J[UZ'(6>@,K>LU
M<CP6[I5'G8DN+.C\?CL24_)8?O5^3'BHE'($6<S91,M;=HK3D.#/A$XOQ^7Q
M/,/KBL!_,_\ H _Y-333F:^]1R3Z%T&RO)>J3K(%NFV&(3:H\^8B%23 AV=5
M2[W $,E %?-8?O4P,9,BU4(C)BO4$X38]'%2!0$'=$+_ .P#?D[]>P_>O_0W
M>9)ACV[J?@-R[J5%L/;&FI<C7@XYB!82CU"+DT#XY"\S1$)JZ%,LGC%C>K$N
MZ'<3RE^?1)G6^>1$B+@:GV'W!OR=R3.3(/S=@E(L<I9+/%4[<R^(X&\3K!R%
M?K(T&)7 M(ED9^'K&1LLUJ7-V'.C3T64PP4D6$Z.M0>\S15=EW\E"E$[85%R
M*J6(%X/NL/WKRVSGHO)UG6(5&N!^2L#:SSL:'L8C)5.N)H7-8NAQQ4 \0?HE
ME+>7"C-^F!6%7 E%X?+6?R;UF7P8(; D(<(VLD0# ;>8+'_T,I2KCL2*_AR)
M%>QAEE//+X&&BI*"%BQ&8&8[D.(]@H%AEXO=HZE-MKYY:.[&8D53GAHW?>X-
M^3N/1(LA7A8O>.,,.X7%BN-^#B=:H$%:<Q(N73L\9 2A$9YOPD3MLAHK13"4
MXRN'$=QB'$PM$2*VAEAF.CW6'[UXXVV\CP$'N^[;XB/':5B#!2C$2+CG@(/<
M]RSEH>2#RI;D.(]PH$A&&LI2KBFFG.>7#^SX2+ES$:.E[]6R-MN#L8PG'TD$
M1\3GJ:N];)85)S\ ;\G?!8FFW(>,=7U?*#(O,6:NYXP4&2L_!8?O7X1[+2#7
MT4M",.V "QQ-B +XS(CR,?K6#_7</7. (>),W(VS)KU,RI54HJL8UV[,Y*_D
M2F+![V.0\UC9-8M'N#?D[X#_ /A\-W:)!D%85M+LOUZDJ4NJ4=6,:XGR^2)N
MPJ:L%ODO&S6=@5FU)]MA^]?A@_[B9,BP([]P+G%&@"U+S6J"OBZ;57LR-?W<
M>U&V1=JT]7=\P9*AI4:8C?IV#_72B6,<F'!=>:F*(DG))[P7!1(T=Q+@6B!G
M$BP]Q)B5"Y/2-;;& YH6UB0]8PK!+QOJ&_)WP'_\.<3;4S,/P*]%E8(RW9-A
M\'P9,/'D28EA'*5(M#34@13[TX[0-C5WE!VU,;Y!GQ"4?ZV'[U^%F2S%)VA\
M7)P6M! @MWQ,!+=L6E_(ZY3H\=4IE^:4/P$S=:PK U =O.O9M-V5"/,_I6HD
MWAFRV?O.3K4B [.+$R;G=+7AGL0W]>6]!^.?!>5KG1 ]G'5RRG:!-(5NJ7V%
M4:"JISOJ&_)WP6DJWENR6=QZ3-MGERI9&>07EE:\1',#I5$M3-F@FPWD3A06
M%M(^I7 ]39Y>G5.\1Z=2G:FOZV'[U^"1(:BL33W<3R-@8D(*W J\TM2WE+C]
M?*;:':S,7%%V@4XXZ'DFZZIB;0;ZT?CEM/@)4@5"6-'_ *!.?@?&)3^\>-(R
MB5(ZN+B]O/B);"T*2X@*2>"SQ)".<%$JK*C.RDJ0O6Y=P3)]@;\G>\P0S"CS
MI^)#I9KP[TC'5Q<3KYB5*87CJ6FLFGJ\2C/QBXXA5YT)<MM+F-9FGHJO98?O
M7X+,8CXY853",$CW?:F([?'6E1TQ)3RE24\U)9\(D&@K)9DF)-P&W,HQ*J9=
M)87^@0(1!<39>V&Z]&6Z=F-$U2LC9..OBG.YSAS.<#W,)PM*5XUM>85=:3L6
MDN\61KAMDK!=JTP;*1-'_4-^3O<7+0PL+9^UO)L/OF9+Y7$B;R6A6%9=[KG;
M[:1SW6RM"5\UUL <%'IV'2GN/R:Z?8DM/5$HRZEYGZV'[U]]DL\:$N?LENWV
M:H8LF9$S*N\D8XB1UYF.*1Q*L+3%?=@3!^TJC)BM7:H3,F@@PVWJXHZV5^=Q
MQ#39_9CUX.-1W;2;$K9K[]@KT$P,FQW$+2PE/.SGF<8CJ1GMX=[2$O8PXU&>
M7W :Y$.S2$K34?J&_)WMG38HV$2V5.N$\:.=/E8^6Q&(4<61@6*E#2\:>(>%
MR>SGF,8CX3_7AWM(Q+_KCMON(2*N,^4R 0ML%];#]Z^[;FQDT$)8C$_RP!7F
M(\:CRH4]-YKN!LE<?M+PWU<FLN.-)>9RKLJSS*\X4YU)F13!$4[J8XY8K;\2
MEH;QXN+SQ<7GBHO/%1>=((V2B:X:#DX2V)/D9:Q.Y:;U)*38J3<!.89GP_%,
M<4SQT?'5EV.^SAASMYCJZHH$<\6,0X^(D3ZAOR=[>E"?EP:>VXTY+%$F89NP
M/^'<T4203"2 [3K6QP*HSJV.KBF>.CHZLOL2&DH<[UEM?]O2Q#QNRI3A"?K8
M?O7W;-L:CNTX.,OL5DG@D,JISRFY[(")6'<'/ISF+G'%L\=C(7A8]">2E.L\
MD9ZGG5\Z.X1UGXS/^"TE/&DIXA".)0CE\<[&6UJY=+40)[#F3TRHFB3WEK>Q
MD]W:6T2%8Q";=YY!!=YFG#7>+U[$<Y.U9AE4^LP1Z-4UA+1_V!OR<I24XS-B
MXYXW&>=_)5S^Z5S80(<7+$VXU7K=4-R\7$M+[]K21;RXJJQ93&V&RR3JD=<K
M*6XB'>>G1SW%T4>]R5JES*B%-4.YIVNML&O98?O7BW6F^9G1N>+5GG>RU<ZG
M\\;J(/Q?2.(O5_7>G"ZFXSTC_D(Y1!ZHO]^K#DDFCBYY;'%DR?'"\O'))?"T
M><07'1@S,Y5#E%PXJ*1+O9^$S_@M<:XWQ/+]C^Y<QU(N0>4,NBY"VX&L2WA'
M24K$BQ.0$);6Y$8RHS#:Y(L\]/)]@L#V#JW'\4Q#3MHJ%HC K&BXCE<;LHIS
M+$V))^@;\G.--O)\OC8YF$YS,>=CF?')Y8B8M@K9@Z+!50\5Y!XA+<4SKTDI
M@@.L"783EM;ETL4A3S..YC<=/PF,3;>9ZK(8+3TZ_;:=M5 M<0,81<!RN-60
M4YEF7&D_2P_>O'8L9_/@&N9AOXYEF>GBU3$X'F*\0YTI ;\_76J^TT[)F+\:
M -)\B"L(DP)@MY67!+G%"H?'80Q')#K<?$H\8P[6L]JHTB]"70K=L&+XR<%O
M\2M*T^]YEJ0CRN!SRV%SR^)SP$7G2/4<!5F+>+9(9*O>H"69J5QJ0]W7$/KS
M;Y1!G"DX:7A;?)"<<E]741['75ZN8L9M(T[(Y,E&0N(NR*7W@BPR)&*A-F3A
MP;\G>WI5AW42X,Z<U#5'@R2#\U#D.GN]TX!EY5ED@KN0RG7X*F&T<D)QR9U=
M1#N^NG58V;*8&GI6)A$F$Y"V12EK$'YKO*M+DS1-A^]?=8Q3E7NY,C/;9'-0
M!+<UW#DT-*SBN Y3S(CQ<28KN48X\C')&,<(=GJF=GE9J5BKH=T79VDRKF.$
M*%7JM$%5PV<1(^2W5J%<*U'!% A4R*=8<ZD.,AD9A9@15>H78[<MU<=V*\^1
ME1\2'.3G.$E=:Z>QD571-,\P#31!T1@B(H]IX%UG5*W.J(G$.$&_)WMV136+
M[3A@Z;'>+C7H:WN[Q'$L*@L5J1VG(;JWU1HTP>T\0DM9D.<G+Z\D,]MRLQU#
M0$.DJFBIPTT'22K]"MG .NJS5'ZN(P,@6'[U]W23H;N);HQ<@?(8[EV%%4Y.
M!=M^N,MIB15#(OA\NDVDXG*>5(<Y,7C. (Y1DW7FEGSDVD$(JB3K,/A'5NNC
MN:G5(45QAKN&?DONMAERY:J@7$Y/)D07Z,UFV3Y24X?_ *V$Y?0OAA?_ ![B
M_P"F:KK4#%NG"E9%J,ET)9BL1"0\AR>##%,MTVL,X0A#2 WY.]U]U>/M+]IK
M!(5D^U)@S:\R0LL:NU@BT\'KK(7F7T.8,+_M'W.35Y[59$*,D*<)<.&%*:CM
M0R$$@B?7P9-35/K3.,8QC%A^]?=(CL2V+9J#R+AD2_'?@%YPK-2#-#PKR.O*
MY/9XXOBW/^3DKX15GNJL,6.@:Z!^!A3"8X?Q26GVW:957EP0@D:Y\UDKL:PP
MKI3,MKUMX<>3F*_N%JY*1ASDA:I++SF$<3'>(R!(AH:P,OE4J$"=<3]NDT6H
M+KS/U#?D[WVRL,V")<:;V<:U=BL(95Q:N2D=ODI2I<=YU&%,09!>2.&1H<:+
ML6LU. _9+#<IE*JGIJ'];#]Z_!L>AQ.[LU?\L=&R&Y 1:N.*X]G,;,Q+O?//
M1<I!5_$U8]0YF46W#A;=; EKK,B16847]&WU1)UDK3O FYK[OC%3$\=E8ZEO
MX[#-;D3L#H+$6/8;8RZU4JT>MDZET$73X_L#?D[X+K3\&43:MY29'R''&ES$
M<?DX[+CV<H9K+DKD2+'C1+#;$3T4NHV"XRZC21-0B>RP_>OP.M-OM7W7V&&P
M(YVO"'9*V^+EHY(D(RKN9D]R'6H,-PH2A@VB)F87F:]U(3*\B1(L"-^F>K@X
MRU8PF ^$L3G,*@2%X\/*CYFVFN0.9=N%_=J71^>6H:+'!H?M#?D[X3M4'',%
MZTY5Y&(T]2<CWU<[J3%Y,MM<'\1'NVPWZAT?VVU0X40=&]MA^]?A<;0ZBST>
M*^\XCNY7@YW&Q\GKDRXT!J9>V&L@=67VW/TG4E:I^?U7O_Q#L,R0!71]!(.N
M='Z,I3/1SIW:$:FU\&RTTTPCWAOR=\5BC1YC9+1=$F.+Z/T=2H_1TI6%B-74
M$)E"$-I]]A^]?B?_ -_8J95[8W*T#7<\3T>1KG!O1_UW 4(JM; )_7?_ /C(
M#.,A?D#?D[XC.<8<^2P_>OQ/YQZA_<GQ$SX8<7@1#^0-^3OB- 4&',8ZL?'8
M?O7V=>/<^ 0^9_:NHAF>N#Z@%2&"MM1 )%F15S7:[HI98M:A.14E4P;\(;\G
M>^Q0FIX5@:8A<6>+]\++'6;.V<P/LHRQ78A'E6.S#U_#8?O7EI<EMK\WND4:
MY>"D48H&4EV0"<+O<%6.W9ER9]V77;!.FRZ]%L)YMIRQGDHBE;.2)+/7B. >
MF7" 0<M-J0V@^4BRDF[#+CS;1:&N 'SC93_HA,.6WL3]<Y%DNV[_ -3_ /_$
M %X1  (! @0"!@0'"@@*!@H#  $" P01  42(3%!!A,B46&!%#)"<2,P4F*1
MH<$'$!4@,T!RDK'P)$-04X*BLM$T-6-S='6#L[3A%B4VH\+Q)D1456!D=I#2
MTY/#Q/_:  @! P$!/P'_ .VQS/E]OYQS'G_*W,^7V_G',>?\K<SY?;^<<QY_
MRMS/E]OYQS'G_*W,^7V_G',>?\K<SY?;^<<QY_R/T?Z.UO2*>>"C>"/T>(2R
M/.S*H#-I10%5F)9O"PYG%33R4E1/2S "6GEDAD -QKC8JUCS%QL>[X[F?+[?
MB>C_ $:KND<E3'1O!'Z+&KR/.S*+R$B-!H5S=BK;VL+;GAB:%Z>:6"46DAD>
M*07O9XV*,+\]P=_CN8\_BLSZ*9EE654F;U#4[4]7U78C<F6'KT,D76 J%.I1
MOH9M)V/?^>]#)YH<Y^"EDCUT.8:M#%=6BCFD6]N.EU5UOP8 C?#,SLSNQ9F)
M9F8DLS$W)).Y).Y)X_?IZ"NJ_P#!:*KJ?]'IYIO]VC8_Z.=(+7_ >;]_^+JO
M_P#3B;+,RIQ>HRZN@'?-25$0_KQK\3S/E]OQ/0Z>>',:OJ99(M649H6T.5N8
MZ222,FW.-P&0\5;<8)))))))N2=R2>))YD_?@RW,:K>EH*VI_P!'I9YO]VC8
M/1SI !?\!YO;_5U7_P#JQ-EV84V]305E/_GZ6>+_ 'B+\3S'G\5G%342=&NB
MR23RNELV[+.Q'P-6D<6Q/\5&2B?)4V&WWU5G.E5+,> 4$GZ!OB+(L[F%X<GS
M20'@R4%4RGS$5L/T?SV/U\ES9?$Y=5@?3U.)8)H#IFAEA;Y,L;1GZ' /YOT1
M_P <K_H.9?\  3_>RCH[5YF.O8I242[O55#+&FD<2I<J"/G$V]^*"KZ#='7'
MP3Y_6I;\C")EU#Y,D^F'B/XM6-^&*;[JF=H N3="HA&-D:JFDX<KI#'#;W:B
M/' ^ZQTZ07EZ)Y4T?,1S52O;WM*X'T>6(/NRQ A<^Z+UE$OM2PZ*R%?$ADB:
MWZ.K$6=?<RZ6C3)3Y+42R6NE33Q4E7<\ -0CFU?H.<9O]QWHGF0:3):VHRB=
MKE4+>F49)_R<K"95Y#1/MQL<=)?N<])NC.N:HI/3<O7AF%!JG@"]\R6$M/X]
M:@4?+_&YGR^WXGHG_C&J_P!3YO\ \#+][*NC-37IZ552QY?0#<U%0RQW7O76
M0+'D3>_LJV,NS7H/T==>HHI<^K%MVXH1(I/S9:FRV\8H\4_W5ND(%LHZ%TZQ
M^R:N:5MN_3$D%OKP/NL=.$WGZ)Y6\?,0SU*-]+R2"_EB#[LM%LF?]&ZW+[[-
M*B)6P#W]F)_H4XCKON9=+ELU+DE5)):ZM#'25ESY0U%Q\UCOSQG'W&.C=>&D
MR',I\KG(NL$Y],I"W](K4(+[761PH]DXZ2] NDO1<L]?1&:BOV<QH[U%&1RU
MNHU0'PG2/C;<_C<QY_%9I_V=Z+>[.O\ CH\0P2U$JPP1M+*YLJ(+DG]^)X#%
M)T:RS+E2HZ29A#!MJ%%&Y>9N=NKBU2GZ$7E<XRSIWD.3KU/1[HK-7,+#KF2*
MF5SWE@DTS?[2QPGW5NF]AZ-T0RR./V>OEJBUO>LD8O;YN%^Z_P!*(3_UCT/@
M=?:-'52*;>"RK-?Z1[\4_P!U;H;F?\'SC+SETC[-%F="DL7_ /(JR+;NU*,3
M=%/N:]*(C+!1T"E]_2<HG$# \1=8#U7O#Q>_&>_<1J$5Y^C.:1UZBY%#7:8*
MG]&.H3X"0\@'2&_RB<9EE68Y/4O1YI15%#4IQBJ(RA/SD/JR)W/&S(>1_-.B
M/^.1_H.9_P# 3X 9V"1J79B  HN23P  W)/(#%#T;K\P6)\[JIQ$B*$HHR!H
M1191+:T-/M[(#2]^DXA@RS+QHHJ6&Z\2@#N2/ESMJ8GW%1[L#.3!Q@B-N3,Y
M_L?WX3I%!SR^"Y]9HW*W_2VOQ^5@5=#6C1U.@G87*L!?WV.,PZ.TSDMU"!CP
MD0:#X&Z6_8<4>=]).B\@2.:6NR__ -EJ&9BB\_1IMR+?)%U'.,8H?NK4,B]3
M,\D!86:.J7L&_%>LWC8=][#'23+.CN>%ZS+EBRZM>[7@ %)4$[]N)>RC-_.1
M:?G(V*JDGHI3#4)I8<#Q5Q\I&X,I[_IL?Q.9\OM^)Z)_XQJO]3YO_P #+B)9
M)I4C@0R2,P"*JZRS<@%%]7[+<=L4?1FIK2*C/JJ:4@ ^BQO9(AR623\E%M;X
M.!21S:^(DRZA&FAI(1IYQH.7RI2"['QU 'PP,[,%KP1'P8N?[&UL)TAI^#9?
M"-7$Q.5!\3L=^/''I%%7C1U6@GAJ*L//@3]&*_HY3,21"L<G*1/@S?ENOVKQ
MQ0]).DG1F00RR2YAEXX13N341(.)AGW+*.XETY63E1_=3RZHC,$TACUC2T-8
MEE<'BMSJC<>!/TXZ29-D&:LU9E 3+JI[LT,?^!3,=S9!^1)/./L;[ISQ44\U
M+*T,Z&.1>1YCD5/!E/(C;\3F//XK-=NCO1;W9U_QR8R2DS:JED&7,U.K+U<]
M5ZB1QD@V,UBRL?D1?"-[L4?1G+*%1/7$UM0=S)57",WS("=3>!E8D\;<L)6)
M3V$-.JHHVL!&+?HJ%'T7PO2!%[$E)32CYQ?_ ,5EO@9[22V#48C_ $7^JQ7A
MYXJ*&CS*,ND*$<T=48_;]F)LEJ:&3TG*9IZ&HC.I332,I]QC![:GFHO?Y!QE
M?W2LQR\"+.HI&=-A5TJ[26XZX=@&[]%O%%.*[ICT>Z44GHF81TU?&1V1(--1
M"?E1L=,T3#O0\>_&=]'8Z9Y)\JD>II-VZIMZB$<;=D#K47Y0 <#U@=S^9]$+
MOGB1J-3-19D !QN:*8*!XDG&19'!E$+5%4H>N"#4]QU=,".U%&YV5UN.LJ!N
M6^#CYXS3/6""*"1$6Y"J0VG_ &<((>=SWR$#GI;AB"JJB&>9ZR1WL1&4*I$.
M2JJA$!/%K6'+E?'659W5 @_RKL'/DFH#S.!721[3%HK[7>SH?]IN/(D>[$%4
M;7!W'[.\8RS,$JAZ)4'MG\BY^5\ACW'EBHH;W20))&QX'@/ GDP]EK@^.,[Z
M.#M/ .T1J7Y_S&VMK^3(+:N#B^^%FJ:-RJ2.EB;J?5X[W0[7[^>*K-)JR!8)
M4C.AM0DL=8VL0I/ 'F-[V'XG,^7V_$]$%:;-YH8UU/)E.;(HO:[O12*H^D^6
M,GRFER2D,DJAZO3IGG)THHMO%$_K)&K=DLO;J"#[.V,USV5@(X9%&QZN/23P
MY04PV8GY<MP#Q0XAJ:G03*U9-(QU$,K )\Q!V$ '.U@3P%L"2KOJ5%0=SR,)
M#^I=5\SA:YU.F4M$3_. ,I]TG _K ^&(:I@+@[\_W_9C+JY:Z/T:8CKU'P3'
MVQS0^/=W_5B>AU QRA)$)-O(\FMV7'>+>-\9YT<TZG@%VMJ%A^4%K^X2CP[,
MG@<15532-I21@![!W3]4\/*QQ6YE+71Q)+''>(DB0;O8C=;_ ">=M]^?XG,>
M?Q4.3OFV2=%R;I2P?AEIW'K'57IHACOMUDEN)V1;L<25%+E,4<%-&L*QK\$H
M +B^^H+S<F]ZB3M/[L5>:5=7,5CFD"ZB))*56ED4=SU!!.L_(B"*O$ZL&HF;
M9(YW/?(= X>T7-[_ -' FJX]R 5_R,C7']%[:O+$-=K/KW(XJ1I=?>M@<4N8
M24\BLIX?01_=BT=="M13LHOZRD[K)S7^E[.*[*(ZQ'UHO66-R>+6]EQ8$GY+
MCMKWD;8S;*9:"36FK06[+>TK#?2UN# ;JWM#QOBGS>LI[=OK /EG?];C]-\3
MR]?-)-H2,R,6*1BR@GC8?7[_ ,Q)MC[G61L\\F<3'2$CEBI0=B>M1D>;Q'%4
M]S'NOGL[^E-0*;0TALZ@[-+WL?:T\!?G<VPL::P^A==K:K=JW<#Q'C;SO@.!
M_%1>X@[^=]7T''5HZ@WZEV/8C8E@^]N-KI<[#5<'!'$$=X((Y\P>6*1UBO$W
M8D5W)7EH9C;J^133PM>W/"2%&V/"Q!''P(]V*+.8IHQ%57238=<HN)+?SB\0
M>]A<'C8$XE1*B/L=7*EA=EL?*W$=][<=[XZ695Z-**E%LLILW=U@&Q][+Q^<
M/Q>9\OM^()MYX^Y[D!59<UG $DT$L, :X*0RJ5,@YZI;&QY1CO;&<5+R5<E-
M>T-&QB50>R73LLY[S?8'D!A8T#Z]"ZSZS =H^&KC;PP)!_-1V[K']NJ_UX,2
M,!I;JY&%Q"Q+:O<UNR3[*OQ[[X8 J00#<$6/ ^\'Z\44BHJQ-=9$[,B-L1<\
MN]/D$<K8CE:)PRDAE-PPXBW C%+G,%0@2I^"EYR*+QR'Y3+[)/,[B_#$T2SQ
MW&B1;#M)8W-O#=;<>6^.E.5^AU/6JMDFNWAK'KC^E?5[[_B\QY_$TU-+6U$5
M+ -4DKA!W7/$M\U!VF/AB:@3(.CU$$(<4,4@X^O/5-KUD?.:]QR'##%IR[S$
MR-)=I"QN6O\ OL.0X8B"1 !8TL/5%K*/<JV_?EA2LA"F)=_:0F.WB>*V'NQ)
M&J]I'$B$VO8@JUN# ]_)AL;8J18Q2Z21')J=E';"6/#GIU6UCNY8BD5UNIU
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M*XV(9_AZCEQ]4'Z\13R0G5%))"W?&QL?TE.Q_?;%-T@JHK=:BS@>W$3%);Q
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M9CPNJB]R,5TAIXH85WEZM41>?6O=W/N35OX #'2FM4=5E<+ZA$1)5-?UI3N
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MY5%@/(?"/43Q;W?% V[P=X.XX]+&7T<TGH[30$]8])&1PR*1>+0]+F)O;AM
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MLK4E-$!#4V."DJ*QT0B3L[3!TA<F1%!D=(.CT_ 8-3948'6%E,/A1<+Q_]H
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MT*A($8%Q_P I#$U\?F&4+7W)6\.HN4[/+ WB/)A+K6/Y;#JA1WI!9DBO)3"
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M97VC:S#KM9,:5U!D;=FV<TU?XI2F]'7OI,Q&G%O)9"PNI0H5W6[EIT[55ZR
MECG,GX L!DBGZHXH93%9"K=Q^45#\=:2R.G<5/H:-VTCCM\(XL<K+RE4^8:E
M%>2LXF#GQB:#2$%VC#33I$1A$3K]*/X8KY3.8C&V""&0B_DJ=1TKF9B&0M[E
MG(3,3$%IIK$]^W!/Q61HY) 'TC=0MHN*!D1!2LF5S8,'M(9VS.NDQ.G?[VA]
MU.,.X[%DTL=;KW[^.N4^OMZ\(LX^S6:,.V!U(W>:!B)[</H<IXA6,5;=XBZV
M6OM7+K^^C+=VVU]JP0Q,P/4;,#J6V(DBF6<J#E*D\QJQ\95F(@Y\8&.)@JBY
M(::=&6&(:Z^I1VX #8 FSLL2(8(YCU@(F=2T^SBURLG*56<PT:2\E;Q(G/BT
M47$ JM&&FD*,F+B)U^G'U_PK5E<SBL8UH2Q2\AD*E,V!$[9,!L-61#!=MPQ,
M:]N!M8^Y5O5B[#8IV%64%,>L0U)&$S'QTG^"S>N."O4IH;9M6&3HM-= 2QS3
MGX M8D13]4<5,UA+R,EBKX$RG>K%N18 6&HB64Q$S$,683V]1GC+<OT<K4M9
MK!#6++XU1ZV<>-L.I6FP.GEZP>8.\ZQ][)%,"(Q)$13I$1'>9F9[1$1ZSQD*
MO+7,6)SC\40#D%XRXJU-6628AU)5,CM,EL$3&2"2 HB=1GAE.SS'@J]M3.DV
MJ_+T%6%M_P FQ++ L _T2&)^S@6+(3 Q@@,)@A,2C42$HU@AF.\3':8_AK6N
M8,I4Q->[=1C:K;9R /O6=W0JAI$ZM;L+;'V3]Z_F/F:[-#%5FUTL>*'V2ZMI
MHI2 JKK8PI(R_-TB-9F>*]NN?4KVD*LH9H0[TO 6*/:404;@*)T*(*->\1/^
M&?(CCL?9!-3-\U7*N2656H\G)A52-JW6$L=6G1AQ)U32R8+22F.W'RR<TT?E
M-?B:OR;\Q\P>S,/["Q5N+ZL7U;4U+5QRNHJH-58(KK$&ZM(S?VTXPN7B^6!S
M?,W*=6S.2H(6\L;D+E*)*Y4K/GIGTG3+5):6WT$IX^5K)6>:;60H-K\S4E<N
MN16A5.Y7N52?EXLB16R;=B8$TG$)#U#69UX^0;-6.=@SO+O.C.5N67\HGA:-
M2IB\9D,;7]F^#OKB;;K56G$>(L-D"9:&/RB"D>.?G\L7>8,8KDS/W\-B<'B,
M!RY=PYQC7,5U.:;N8O5\@N;_ $I(BKI8E,%,*TD>&Y+F'&3ALW<Y/NNRN,F=
M?!WIQCXL*'S%[OJ1)KC<4PLAB2*8UXR&.QG(F%O<GER[S:MW,#N9!KWAJ./)
M>/M>R>C)$RI)NZ:NI'7Z0_G\?(7R#RH_)8J.8>3/:=W*X7&XW)YNQT&V%KQN
M(3F+%:A#1Z,NM$38=TVIZ<QW%G,L<ZY;.\OWZ_,V)PG*',X<L82]S)GUY G=
M7%LP:;AX=66KA7D3L2X.GU@F8-L1)_+-\G?.5S-9!=/Y,,SS!C'<SXC&8CF&
MKK0V-1<3B7OJDAXV88C<PV"(!,;8,AX_Y+?@><K^!#+8HZ6.E%2HQ?+]NMYK
M&41+C$;;KT-6MB;7NU"@>G,[RCCF'&<M\Z,Y5N#\FN%G(9].*IY*[;2HJ0]-
M%>U^#(*S:E3W-&8(%@2U3Y]>*W/3LM-VY\FORB6\)SHJI3KK3S/RO6?5K6;+
MT N.E9J2X9AE?H1TI8]FI#,\<Z\QX_*M/Y-\*%/EOERJL BMELM"UV\MF.I*
M1<<(W#53'5)4BW73<'&+J5.3<#STZ?D^W^PN8[R<=CI%=VW,V_$O U]>O_B@
MD9W=0M-)C7C#<Z8'EC#<A#@>;0O\^<F\K6*>3QF7Y>M,KT&VVVE)'\,4@*Y"
M0;22!3ODH7$1\JORG<KVRN<E\MCB.4N3:OAQ/&W,U<;6]J\SVM5@]R<?XD02
MLF= R<D#CW;->6EY5O,?,O*O,-)MC.VN8<-RWB%XB9K==&4P;L-?>UV+ZT@E
MD6%B K8&H V8D?'T[M6Y1VL*+=1ZK-:15NALBY!&!=.1*#VS.TAF)[QQ3YXP
M/-?-7,7*=CG(,+/M?DW XGD^[1.X]14\=:KVV9:;*EJD%V)2IAR!L8<$,KGY
M4^4,!\HS^4\-RQC\'=IK7AL=DF=>YC:[5H4=D(*O798ES+C(,VE$@"QVZ\?)
M?C59K'\O\Q<Z<XYKE+,<YG2K,743A'H7%I%-HA15<O!;".X@/41/2Z/6W*S5
M#/<VKYTNU?DQA8YJ*=2A8\/[3Q9JJ7Z]&2KQ<3N*2.)W,2Q)GYIGCY'O!<ZY
M#!!F+>3J8R4TZ;%\NVJM>O-C(5^N8A<;D8:M;4VO(J%#T]V^1XYHQG+7.K.5
MK8?)M@9R6?5BJ>2O7$*]G#MKHLSX9!VK?1>YHSJ*A-:I\T3Q6$[*7\V3\IU[
MY-[/,Z,?4,O#TEP[Q];'NZ..G)O@O#UXL].N6R6LT9J49+E_FM/,.8Y7]E#>
MIY_F7%X/$YC'9'J#'@;*<)=MI=4NKZK*C&>\U5.TMD%''R;NYLY=N<U82.5,
MU%G"T,3[;LV3EUR*Y!CX8OK0ATBXIW>[@9/0M-./EVY_Y(P.?^3GDE_+^/;R
MGC,M6F@_VU7957:RU/$62>%54CXF/FDO;86D2+H[5<AW;G.]:YGOE9RW+U%.
M?R&'HU\3R)2O4X,^F #"KUAH-6P[-\=-Z;)B'S"'G'Y+>8.<5?*)C<E\EG,G
M,=?+3CZ-'*X2PBA:":]\<?))FK9VSTNJ1''5K;)")*#Y.^47%?*-0NXRC:10
M#Y.CQ6.FL^C8S%A+Z7CAGVF>7WFRVPM!)*)GIEM4._\ Y3/.6+I=?)4L'R"V
MK7<N6!7?D:E6N+[0#(R2:,V.LX=1W0O;,Q$SQR@R\[F/F?ESF=?4SY9O!\MX
MNEC5.0+5Y3EVQA[[K3:5<SCJ ](CTML&L6G!!S!\JR_E+* Y5YEMTD<O.P6,
M>G(U5Y&K7;X^[*A=.GBQ&NE8[14N?>BP]X_)35YCYT5S7BOE5HW77L46%I8Q
M&!M*QRL@ XIE:)<:$^(4D"<>YHK9+P(S AY)P/+.0IX&[SSS.GE]G,]]"[-?
M!5S@-[Q4_P#!BLGU/==?4(%;=-I:,7\H/R1Y#Y0RYF5/R;7^;J/-U;%X^MF<
M--'4[F%R":A>%)>4KK;7AAEXA";:')*"G9QBLJW*^.5GT!9K4_9=&E[)"M9O
M)-'C*PQ9R</.>MU;TRQ4^1>@S/'RWIYU^3O-<^6+',L#BHPW+AYME*97:%RB
ML@]18X[1DGI,&)*97U((>GW^2?E^ID[G*65YG^47)4*-+*@O(-Q?+U_PT8NA
MD460:6VJTWVO">0X%@K.%]UCR_\ )-CN9>8;=BMRV><RG-&$Y>P#^9>8[5B[
M:E2Z^/R-JIBZE.BJ 4P:C9<4+G7=$:10":MS'Y!/-S\7DL]3Q_+Y\T93E=:(
M-.0Q6#?=C%NRBV]=&013=U!8D-D!'B&Q04WG7)\PYO!_*YA*=FSS9RY4Y:R/
M+C8I6R35RU&F34/!+1989:A[MR]RIV[-O&!^3R]\I4<Z5_E%Y=S3$Y*MB<92
MR/*.5KTG.J9:J-#>LL9U1'HA8WK<L6QL&0WGR1\EZ<G8QWRF!SAD,1S]DE(5
M-FC@.5VRZ_D8$T>'$LK6-*4,A738U;MFFZ)X^4[GW'?*1C^2JGR>YG,X_%\F
M'B<;:5;1@@AO]V[-W\,ZV5C\'1("4>+Z@*@!&(X^2O%8GG$/D]K\\?)N.<R<
M>!I75AD(L9"'%BTY$?-9M#5'P4,=&Q$D4=0XC=\M/+E_F*IS'D_D[S'+%?&<
MXKQ>.VY"KELJA;:EVI*GXX[M81(2GI&2V=:),R4#.'XOD[F[G!>0Y;Y,P^;R
M^)Y<Y/P%[&8ZU9Q8Y#Q6<R^3M(=-:TDTM)%9+%UUR>P2+< \K<TY84CD\E4>
M-_PX=-++-*[9H,>"_1<6/#=>5CY5DR0#RC'^%\O9K,8_Q>2Y5N'D,%8\3;3X
M*VSIP;>DAZE6->D'DL@X.W8?7CFO#T\/TL=SM9OV^9:_CL@?M&QDUDJZ?49:
M)M7K+(HVTS0(:ZK@9[\8[ X>OX3%XFHFC0K=5SNA50.Q2^K8-KF;1C3>UAG/
MQ*>.9G5^65UIYOI6<?GU5LAE45;E6X]5FR"ZBKPUJ1.>A3"91579J.@G S,<
M<J8BYB>KC^2+.-M\LH\;?#V=8Q"(K8\^HNT+;702,#MN&\6:;FP9=^&9[.\J
M5;64?(%;L)M9&A%^0V[9R*,?<JU[\Z",3-M3I*(B"F>"Q/0$<<5*<=X4-P!%
M*4>&Z 2$P0#"/=CM*"&/28GAO(>/Q?0Y6?4OT6XSQEYFZMDY=-U?BVV3NQUI
M>WS18@PW>[(=(TP_*62Y;K6\)R^N%851V+T6\8$?_=,H%D<FJ2TC>46]6;1W
M[MHZ/Y+#E>K]SUF[&2=4*S?-YY(8@1R/M$[99*+PC$!%H;<.@/)OV]N,HW'\
MO$IV;P-KEK+/9E\W:??Q%S^^4V'6LBYIN9$"'C-WC!6"P%\  Q&%Y1R7+J[.
M"Y<B(PB/&Y)=G'1\?#Y)-M>1C?Z,UM3U=!W[MHZ?=-C<9*,U["I\M^-F[?=/
ML:A"8JU)4^RQ$ROH*_")7XD]OO&EK.M_EGY*IY7P.-YFMYM_-JN9$9;,>+/.
M)6A]NC)6F]!RXAA]$AFO)2O8"]D[L-RECCZP8U$^)MRN%G>OO.77;AA&NWK/
M,M@R12M,+5N+9KPO.\T8-M_*JJ!07;3F,UCCBJLV,!6W&Y"H$Q!-9.LCNG=I
M,S$1Q;Y2^2,N7L#B.8IR*N:5<U%GN86/7D*2<?#\<VW?M2AM= '/2/5)LZ9[
M8*#DZ'R?'6KY;%*HLK90;E<"3EGVR)N0?8KEO#2P\R(0F2Z80L8+4(GB]D.6
M^6:]'(W*%W'P]]W+75HK7EFM]>NJW>>%2LW=HU=2$ZAVB8XQ/*(6 NG3\6ZY
M9 #6FQ<OVFVK$I4TV&NN,MZ20,S*% .\B+6>+#CY3&/$W1R$I7ELXFFBX+8?
MUZ5%62&G0(V1[WP:$PT?=G$KF1XSW-='']'.\S)IU\W=\3;/QBJ"H15'P['G
M61TU# ZUTJ(]-3DI[\%R6WEBL[ER<A8RHT7V;[F(R-J9)UNM>9:*_5<6LQNK
MV5Z!,A&@3,<3G>5N7XQF5/''BF6_:&5M&ZFQRK#(<-V[8!KC:A4E9,9L3"Q'
MJ[>W%6ES=AE95-%\V:1=>W3LU'%$"95[E!]:TKJ0(PP0= LVAOB=@Z%S+C,9
MX?-%@J/+17)N7G:X7&C7"G4Z+[+$>Z&JB/$=/Q+-GO&G,EKF>6BY;JV,)G\M
M8SN4HW'6[@/R]J1EMY;+-AKJCM0&5S48B$Z>Z@-9UNLY2P@XQV1A87;)W,AD
M+3UIUE*2L9*W;="53,]-0G #KVCC$\Y6Z'4YCP=.S0QF0\3;#P]6Y#(L*\,M
MXU&]2&L\SD,,=WE*.W&0Y?SE;QN)RJ)K7JO6>CK)DA/9UJS%/7YA&=RV 7;U
MX1R7DL)5O\M5:M6G7QEOJN%*:00NI*WFR;0/0(QT[(NBP/>>KK,ZYBC@>6T4
MUY^FW'99YV\A<OW*+UDIE0LE=MV+X(D"F(6JP C.TAB" 9C'Y*CR94&UC"6R
MGU[V6N5@>J8E=IE*W?=3?:&1&?$O0QVHCJ?EC3FC.>QD-R'.=:O3YF.RVQ;K
MY6K53X=*74K+FT@"$^0H2A?4CY^Z>/;_ "YRRG'Y4!>"+'CLI:&F%F)AX4:]
MR[8K4A:)2)164O49D?3C)<BJP>WE?+VV7LAC?:&3GKVG/398SQ<W)NKU=746
MU5@ C9I P,S$\J9:SC.I?Y)!B^67^+NC[.!U9=1D=,+ JM;D)6'X8#YC;NCS
M3,\-PG,^)JYC&.(3FM:$O(T-=CD-60.KO#6=KD,6R(F8@M)F)S&,P/+J*5?/
MU6T<PV;-^U?OTW+-1UW9*Y:?D.EL8>T LC 3.X-"B)XH<O8"IX'$8Q9*I5>L
M^QT5DPW%'6M-<\]6,,M6,*>^FNFG',6<P]#PF3YKMKO9ZQXJV[QMI/4A;.D]
M[$U]O69Y:RTA.[N/&"MY['^.?RUDPS&%/Q-NOX/(+V[7[:STB_38/N[$-5V^
M9Q5^ZS U\FVCN\%;AUNC?JB<ZF",ACWU;@*.8U)4.Z<EWVZ\8WE5W*U?V)B+
M-BYCJZ;N3KOJV[>GBK(7T75WY?8VCUF'9(F:1N].%\J?<G5]A!EE9TZGB\EO
MM95*S2%N]<\9XV\718:I"W8<LESMD)CC,9+Y.\#BL+S5=Q]BM0RN3/)Y95-C
M ]R&VU<>Y% #A<LJ43KB8!"_F]N.:?E$YUNX/(\Y<SKK5"CE^@VEBL=2K@H6
M="+,E89:O$BN5IQSK[J(W'U#GAG,.9Y1I6LH]@-MM"Q?JHOM#3:S(T:EM%&^
M?:-2MUVD7TIGC \P9BKBK/)F)Y0;R\>$@[E.VNR+[#:+Z!T>AX5=7JKA9IL)
M8K9,!&D\7.1D<L5T\M9&PBWD*2K5];[MFLU;D/M9(;49)[%L2O:3+9>4=GS)
MF)5E<ORX%B\N@C&&U>0RM.+E"JH45ZV252O5TY-:4@"P\>%B8$!C7RCI2Y<Y
M<I^S\/C^M%2IU[-GI>(L-M-]];:^P>Y[F'[QI:;M(T&(B/\ \.!%.Y;H-M9W
MEC'G:HMZ%L*V0YAQM.T*7;3Z9LK.8O? S([M8[\<L>&SV8RU'F#->P;N)S5E
M=\QZV/OW59+'6>DNVAE,Z7X6HF-K-JM,]J6I CY9Z-7$X/$6L.F\>3S<\P9'
M'->S(VJSL4K**ZY4G54I"TVYF'-$AMJA:Y!3"'Y1+F8R7+'L/EW(='&D2;]/
MH"?+V!R=;Q5V&VQ.I/CR)W2J.LMLM/PTPB:Z1YOEE*AD<GR[B<;F*4UZN9PM
M+(*R=ME-=5J<RKQB&*<F8FTN7H8)B>Q9 2IRR^9\?C;'0P#N8,86#;9"&=*_
M5QI8JYX[?M=%F_2TR(;4&HW,*HGH[3?D>8Z.#L'9LXK'XD,.S*3 9++W!I!5
MOK.O9<ZO5E@-.[3B&68@E+QZBD2XR='(U(ZF/74>O*U,=E\;C;R[DV!Z"Z^9
M4%I5RH=>?$ +;"R4VNZ##J=(>8.6&V3M<WU,VK X"R_0FWJ_,IF_E_+LB!VL
MC&TBM^.F!VD>"M;YW%/&=JXZGXIE+/X?$9#.Y#VQEE5TSRGCKLYO*8ZA)/'K
M.D*/3Q@U:W7:%NS(R32*KF&IH9=D<CY+)>*PU^\-*S;7S#B,6G'H3:*$(!MJ
MXOQ-FY7F[CR U273AHGD0SV.P=JW]S&>YBPY8A]Q=8G8%"G6<3?"WN?&Z+"9
M3DD[%-]X)U:Y0$%C,5S#3Q +Y@QEW(XQF*;:)E)F.\$5G'Y#Q.H62Z5Y9*O5
MN@LC6Q<U8B09/XWFF<]?E^*RV6YVJ\JYJ0!1X/*8VWDD5.7;S(B%]-X51=@K
MC.YN%N.?)-\)U,3CJ@)LY"CRCRSE\Q9R./SETLE<R^-BR-.K.&JN"HUHJ-K;
MUKJ+%KH6%,]AEP&22BB":N'QN9RF M4\Z[/H7>0%DZEFQ2JSC<):4DIE0Y#K
M=;;O9%910?&?Q*ZF.1A>7RQ8LN&Q[,A=/*X=&1!:DCM37\*QOO6L)D-6:P6N
M#%A\<QJSEIK</9PK.:<&3--53BTKJYW"(G2-Y;_ Y"FKS',W[01Y51'$'<QC
MLYS.7)=K/N0-BYN0Z]S#6@L0K'HW(.KAE6NYJKLR+%420@RZVV>7F7;&%RKO
MNO\ 9[CPQ9S&^  >7<UDH;:QEPPN19TIDL:EWKU'J9X@!ZH!LY>SU['8D.6N
M:<A0H445K%@LWCARYRO$V[IL_ ;D//HC;K512RCU]XMMBAG'+V>R.+PB<'G<
MRG!^%JV+AY:JRWD'XRGD>L<>#:AME:Y;2Z8N2EN_Q+# E<<BXJI:HJQ%V[E7
MY"M8+,J999CL78M!N;B<A1,E*#WB5%,QXP5-9# #I\8#F&UCL4'*W,F1QV/H
MUTV;)YZDG+N\/BK]QA:T;/7,DE:HH$'4P?\ WQ:-+!X?E,G5QU*H=S(U,>BH
MRP^R08W*W\>5FVUFU0>)&LMBZZ@*4^?>]FZ!7SHIN(YHRC:','--:E?HT4/J
MIKU2+PBDM*PJ=M7YO=<[2&?G<<O8ZK";&37R5RSGLM<R6/S=_P!H6,O2(@J(
M]B5FQ5>\JKVNO6MR@)@"%1VC-BLM7KTE!6P=7.Y3E^]2SKL\H'"QAU&NI5?
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MW!U@NW<-9?NM7,390ZK[(J) O"^R%=2QDMUBUN "5$=69=6BWC!M6+(O;:C
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MQ@MCHN QZ*>5H8JD^:E<E6D^*@E6 [0=9Y#M)R$MD?S98L3D>_?MKIQ\GO\
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M[=QZQV\TSVX?F)*P^XU'A538=+%4:Q$HW5Z*](BNNRU"6V(\TL-2^\" C!%
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M_2#2>)V%-A6FDK/3JQ$_FGV@_P!1Z3^EPS7U$87I,:3$Q$QYH^$\*C\T=O\
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M"S_9+]?%F=>\@0_N7I.OU3KKVX3_ "8?[N,966,R)6E <_HF40?[E[IX$!]
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M^5YI_L3^#WC #^.8C_OGCRG+)^I8&?\ 5'3^GCR57S_'Z:OZY[O]GCL%=?\
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M3Q^%/17_ $6-B6?\TO>S7[)&./<)MVYCXP(U5?Z[MS/_ ''[>)BJNG1'O&Z
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M9:0_#1:8\FG;4Q^/!.Q%Y=U6LSX')C"G#\=M?(5PC7ZA"R@OM?$<35YAQSJ
MGY9C(UX90;_$MZ-HLB?A$M OT(X\2&/15:7FZ^+=* UGZ725+*T_ZD<8_ T;
M-B*:51^$)=TK8#7"3DH<$1*VDSZ01&DEVX4F#:R%+%?4><M<>R--S6%YC87J
M1SW*>_XU.07MH<PT0D*>2$.SE?.\%?&.[JTE\R?RE<IDE]I(":EM.0L59ZSZ
M?SI)<>MK'.B/.HN\R(ZZQK&V"\O%7(48'P\+G;7TC8+I8'4*=(B?>1YI+Z^W
MI&G#/$UO"A0Z;&,C0MY08R(QZ::SIZ^G#]L;??&>H]IWE.I%]LS/K]?&W3JA
MJ4ZCV9YIW3,CZ3WGX?NX\I:Z?.CT(?UC/>.+?\C/^^.(_BQ_NX&?A$,UGZHV
M?\=..C&L*(]UAOP355^4/]OS0^LYCA )'943MJ5!&)D04H=&N_\ 8IUC[6']
M? A&U2$+@8W3 B !&G>9TB-(CO,\,\#=K6^B6UOAW W87Z6R9T^R?2?AQNR.
M+H73TVPRQ52QL1]0M(.H/^B4<:+P]88^K5T_[V3P"UC   P "/:!$8TB(CZH
MCCGC^;W)O]?/??\ MS'=*AS(I4*)\QI6RB ^;6R C'<PCRHM1$L7'NS@U:0#
M(;3,?!G/C*9C^$5A+M+$LC7K5"CS=MX2'FCMZ)M58$JQ"GPRM(Z:9W3!!VCX
MEY]?6==>">C&&WP^T'Z&L)&9]--Y#N^/V\97JU&UA?AKM49<2]N]VS3YA%]7
MKQ#6#XE^GS@[PJ?CH$]SG]*/V1QJ!:Z>OUQ^N/6/V\3_ "]7_K*OX)+X0L]9
M_:.G]/&K=8IK.;-QGPBNN?*O7\YTQL&/JUGTC@7$.E>9VK$?FKIITAIQ]6^(
M%"_MF>-QD"4J'N1E + 8[=R*8@8C[9X)E&W7M@!2!E7:#8$H^!;9G3]OK\.)
M9D,1C[;9C27-JIE^G\OMZT?L/B(7B*PQ'IW;/]9D\1$1I$=HB/2(CX<?)[_*
M\T_V)]^ZK:2NQ6L+-+T."&*:I@R)K8!:B0$,S!#,:3'#[6 AC\%,D[PD:G<P
MLSWGH3WFQ1'X1.K4AY3W@.^'(LK6+'";:%Q8QT9.1TAJQTD1</\ C(B8TUWZ
M>D\'2=5\2$$L)G7:6YDS&[TTG4OCVXFP8^]O33MDN8C1)0#.GI]90)SW^WMP
M!#.FPM\#/<-VDC^L>TSZ?NX]]$K_ $O5<_Z<>G^EIQZ\6/\ U*O_ -*V>)X%
M?Q:9#_H]2?\ LUG@K\A^'92(JT%SK!#6GYS/KCK%Z?YN-?2>)NL[F<2E1S'S
M^^MET?QV>0?T0^W@/'7JM263 KBP]:I.9G2-((HF>_Q].)$H6Y+![P4"Q; G
MZXG42&?VQ/$,+!8X#B==4(BKW^V*W2&?VQ/$NHT4UFD'3DPW;MFNNWS$7QCX
M?C^B>U5Q.IT;>GF0W3YI?$D-^:Y?QCS1YQ&>+XRGPD'OK9*O(ZQ0O:P2KR_S
MJCYTDB#R[&=0?G3$9G$;H\4E5&3F>W4.5K8R0CUV]]1^N(B>'_RA?P:Q.QH_
M,;'SAGZI_.&?I#/:>'(8,1NB5E,3Y9^T?CZ_#U^WB N@*STB!L"9=%FG;3=.
MDJ+] _7X%/ T\>!/:V=.Q20#'Q(BUVQ ^LE/8>)Q5,HZI##<OD/H@,=^F)?F
MQWA8>I3JPOL_!)C,Y=X0"ZU,HZ%.OZB-B[,2N#9/O7PGJGKH,P,CP%=K#D'L
M@*N'Q\%TS.?FA(1Y[)Q\3=,C'>= 'M#+M^1G*W5B#%K+<JI7B=\5X*.S&R6A
M.;\W=&U?EC<7\//'\WN3?Z^>_$;U0M>4K"4TWE\UD>I5+'YR'>G?7I'/4'Z0
ME;6H)J)<<A*VCI.)RBB[J9'J*'SJ(3':)D8'R2'&=QBYT;4O",P?SYV+$3F?
M].9F/T9'BQ_ZNS_L_@WA.QP_-9]<?FL_."?JGT]8X-<Q %KV+U#>LH(2C28F
M1WC^O3C;;"$-GT9U)Z3?KV,\NA?YLM"^K6.(I4!EDE^49)3*U!](S/TB(CX_
MLC6>)QE4H"I6T;ELA/DZA1'<(+T](T ?\6/FGOKQ%?%P.;R[P'J16G90IA$>
MYKG;F/>=..YQ7%FXY+S]N%5VL9:8\]*N*IQLKC/U]/728#Z=BP1;8[R4<,.P
M8MR=[IE;E<^Y2(:].LGTW0O>6]LQJPYF8T&!^\^3W^5YI_L3\2VVE.W&6CU=
MTA[XF\<^[MJCZ%1ISHP?F+.=)T4SR/R-S2#HI +*QC\LR'*&K= O3P[!G4OC
M!QMGX\5W)F)62:>DQ]BMLQ^R8_@T_?\ ;QN7W4<Z2G7YIS\5?5$_$/3XQQ-A
M8"S<KI-412!F SN#87S-8F2U@H\VL>:.)D2V3])4D0L&?S27KKK^S]7;CVMD
MQE6,KSN6!_/ME'T1^/3^!E\8\@]_1%_/W:^*08^X%W8J])<>:5(&"8=A@Z I
M:PF1UUG3CV=RG4\'54,)7D+8CU=@]HFM4[B'\=^\OCTHGO$V'.>=7J:9#+V"
MEDS\216D_P K8T[:#[I&NI=]!FO3KCL164"%#KKH"Q@1UGXSI'>?C/\ @7BJ
MHK'))62]K-.E?K3KK3L?OF4-G\F4R)>[,M$Y1'BL?;J-6A\K7J\%"<?@E]$_
MEE!K^#V(\ZQG34EZ:WM A@*LL'5);Y#3Z+0TW!/USI(?I<=X/_5F?]W$Z=OT
MBT"(_?W_ *.-J(EQ^D::[=T_$C_7WG3O/PXZEW1*(C5C[?U?YI$SII^;NB(^
MN9G@UXR J4XC\,R]B(B3$?G0J9VP6GP@=$AZE/!8?!;XHQ/X5=U]Y>/Z7O/7
MIS](_I_-"(#U\'A*DN@"&+5T]5XZC$_2L6--)*([PA>]Y_1#X\08SX_+L#;9
MR;AB"[_.347WBK7_ $1F39ZM,NT1]YSQ_-[DW^OGOQ++])0'<Z72N5)T@,E7
M&.T?5%M,?D3GYX^ZF8T7(EF*K;%)FO1MF"M\,@/+"LE6G0H<GYD61T(P\K.^
MG%IL[&!%-OO4EJ!%$CVVS[Q9?HD/ZB+CO!_ZLS_NUX+3RQ^<4P.G[^^OZ^-E
M498<^49VS(#^E/YVGU#W*>(=D)&O7C22;:\S"_B)F=H_9K$1'PUX,:NW&8D(
MW6LB_0&V!'UZ<EIK]A]EA]"->W'LO#@2<2J?,?<3NEKW8R9\W3F>_?S,GN40
M.@\0K$5IBHMD#;RSXD,?4_.C?_Y2^(]*Z=QZ_/V#J4=.I$V;S1B+>3L1'B;$
M_FCIV17B?FH7Y?B<F7F^]^3W^5YI_L3\2Q+@%BF@2V+.-PF!QM(2B?6)B=)X
M:,KBSBFB:Z]AH]3H+;ZX[(?$D3Z)?_%[PX?/>HP]LJ7>J163>+RI68L]RFU$
M3U@F8]V9Z3$1 LG7OQHQ1A^O_LGYI1]L%/'H?^I/^_T_IX'>4#I\T==2F?XL
M:S^KCIUU.E?Z,2),G[2_Q:Q^V8DI^SU%V0$+%HM.E0KQU#,OAU2^><?HQH'U
ME,<!<S,K*SI_<["HT\LQ\V6C'E\GUZ=)7Z1=N"N7"F39.U2XUF &9\B4+[S/
M]=A=])UX5D^9P?B\7.UB<;/N\C?'UCQ'TJ-8H^CVLLCX*B8+A-.DA5:J@(6E
M"1@%K&/A$1^^9]2GO,S,_P""2QX=*VH)E=Q.D.C;&NP_@U?Z!ZZ?1D>%9BU+
M,?6RD"\,JG>5(6LCRJO3IMKNG\X^F#?HL(M8CJ!.-RZM.S5M!9SK/KNB-D=N
MT1OF?KXC7"*)GU%;#IC]<R4LG7[-([_9QU#C$XJN(_E',$S_ %Q,>7]DF/Z^
M#D[3.8;6Z2V+T#'K/M\XIGH:1I](FS_FYXBMB\7?O5=8@*>,0:\8N-=!FU>9
MTZYB/QDF"H?S(X5;YTO""XT+V'B63YOT+N1TB9CX&NH,:]XBS\>$X_%4Z]"D
MB-JJU98K6/VZ1\XI^D9:F<]R*9^^YX_F]R;_ %\]^*EA1X6[IIXI0CY_T;"Y
M\KQ_C:''P+3MQ=%PS1!U-YJR2Q+V4?F#<<S/D0]?:309+[3N#>.I<;Q5CLH$
MQ&URGBHR]>\EI =^WS2GMP/]Q%$4S&N^T&P._?U9.Z?J_P!_!,<S$8BO'H;#
M$V=H[^;RA/V1OC]O$RMK.8+<$109S"\>MDSKKJ7N=(G\V'E]D3WX$:&+OY"O
MNCIKK*.IAD?FDVY8Z:&:? S87Z QPJ[SI="W(Z'&$QA&%/Z]MR[H#[,?G+0*
M G\\X]54Z%9%.H@8!->LH$I6,? 0"(&/^WUGO]]\GO\ *\T_V)^*);0%BSB1
M,#&" AGU@AGM,?9/'@L8J"BVEUWP33F%B=60\E5GSE$?5\FXMHE&FX1GLW'H
MR U;E8I"QA\N/2L+/X#(LB&;/J( .&1\PYCOQ MQ59GYS$VH$9GZ^GJ!=YU^
M'U<'*\+57.GD-UE<S,_G$.XIVQ^;W_[.(C+YS'T([25:AI+RV]]@Q\_69^I4
MS]4SP57ENG(O=Y?'60*Q?=_(51W/.?JWP _YGCQKJ3<:E\Q+<OS%)*803\:]
M#^^F1I^3'IH3\.H/"[A#.:S<=_:E\ GH%\? 5>Z:D?I^\L?Y[2=/\&;_ "9_
MU9XH(L*6]#:*P:EP"Q3 D>X&LXD2&?C!1,<$^I3O8!Y3)2> R#Z ;OK\/JRN
M,?HJ4N./=\_<YK5_DO%J/M]6^1B>(/(Y;F;)EZSU\D$07\;\'*>_V%'Z^ .M
MRU2>X--'Y'J9)FL>A1%TW*"?Y-8<"I*UI6/85J 5@,?4(#$#'[(_$<\?S>Y-
M_KY[\7CJEM*K-6SDTIL5W@+4N4:GP2VK.)$P*/42C3@G4%Y7EYI:S_</*6*J
M=T_'P[)<H8^H%PL8^$1''_V_YSA7^2\6J>WU;]NO]'$,OY#F3)G$ZSXC)#$%
M_&VU]W[C&?MX Z7+6/-P:3%B\)Y%T%'TA.\;]D_R<!'V<0"P$ &-! !@1&/J
M@8TB(_5^(^3W^5YI_L3\7CO_ ,OO_P#25N!#/X:GD"")A5@PE=Q,?YFXF5V5
MQ\=HMVZ^L3Q/LGF+F[#1/^+1ER>D?L 'A,Q$?:9?KXTO\[<X7@_,.XI8_P!
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M6>1>Z8WGY8[_ /XJ_\0 *A ! 0 " @$"!00# 0$      1$ (3%!46%Q$#!
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M%<^GD[F<CY(5/C@X+[M<UC$!+0)("=U)6>RQD-,!#&3<,:2PBNW)A)?UFA=
M/IG% >?20==YAR*K)2,F-5(VNZ'@HV,."F=YBTJ="F])O37$! &%2;)!D[+I
M%#@ :6\!@*RJM@7.78W@W?G?KFZB">>,F$U;U<$[HI6$B?!9S3R;'ER#("'8
MY:FII[8M[2Q!W@9!; ^K$R^Y^-11J<@7EXF)%ES]IQDK>L'Q %;.Q*C9N@0*
M_12DX-<8C ^G<5_G"@&Q3+"<LL4,@T&Z?1RZH3<R1A@@;U'I^,;);'W.BG+U
MPM> CB1E-B<&F1P+ $M95[UV.2-G,^THR>^Z1/A!H-81?P,4Q#:%==, "9"(
M>%:K1".=53JHP7ZOBV'5F@2:6[BM?9K4S%;"GCF.%TAD]&L=@6;PXRBLOIB%
MZB.2FG<2),83$/4]]""8A@#-K<55%QTH0B8.>4W@'&6+.94L9?V==_IN6GSK
MP)S<"&SMFJW\H %*]<F<%KF/X<.T(+S3V=PX72D0'A=/+>)^CF$*KBJ*7%C8
M\]FC;1F96BZ.)R;I>,;I,"2SA&R!]1,LT783QT#16 PL<?%64(N%N]M9G)X-
M\AZ0KIBS+Y%YH)VQ351P$^/6TI:$G"(*0G23P[TI.<VT8WT_XQS/(B?.]YK-
M9IA&K:,B=$T[2Y9J@GY VA3"LB43>&=! NMT=1[)'<?*E*8+5CD^JQPZ&(S0
ME<554@[SBQU0IX/(V@H$&#\P!1++P!L*](%IF('K,%!J'WG,PI" A#E$7^2$
MSPNIW@+,\E83U:5X<DA>R 9\?;C -.>>W>:,^VT+I1(_&?2*"O,9P/U  4#!
MUDU.SDP4A/W3;#ETGWDZT-DX8@4^4FKY\&L$Q\>WLF",13T0YIM4A"9@R9C'
MA0)T8#^0<42Z0%C=0VF)$]F/54AU;:U:NT$A[*2 M+2QUG@INRXIC ;A3L_L
MN@0K)DCE>JK_ .=#18V,4]8"7U*N .,..8F$A</=S+E52==0/-GR!2K5_/R#
MO@'04P"A2=J2U.N1N)(W'07O,#]V#X#"5NVE2YW<=N B_@"XM")WB>%APYL:
MN9 <RDHZFG3%^<1AF1S/ C+:=ZS6QX0M[C%B 8*/3W9UX^7OYU8@T8\& +EI
M:@N,!]#O_.8'B1GS5;4.NJEY)N/85.9/0.\468*.[X<-!\=/7<Z\YK!5O^PS
M48>)&\T:E.0YV)^5RHCP\;F6V'4(3B)V;\YF/J R#V)].9@_MB!_/-E]1VWS
M?GD/.,K<#*<)>F"KKW0*QN,''P;%% O26-@;)B9K@":UDH.*U&CR$W9,9N!V
MS##RC%,,*@[B0#%(QAQXEIMN %NKYHH2+B:,;3!+?C!B:&;33L)PUB)#<>HF
MLJ)KB<IM7OJC4P!A"C%/HB%N^+&[[ S3.6<KOM*"^B])8XA6H*"UT@#-AW:U
M'T12T8;!QQ0?PA[IHD080V^+GL!XR_5099Z9P8<A% [(RO%KZE8<]>+MF2X+
MW",#[J,*WVF$M%)L:W>O@%"%4XCCVR ,P&P*HTE06CXD!50PJ' M&]OQ3I+-
M,PZMI82H-"%@6(U)DVFU<P*@;QA(T6 +)*L7&[25W4QRPP1>=[%50M"(5N;+
M$?DU02$=DLH0&=$;_([S/I];/.8_0"TBUV&%M.#T<-4[P",\L7?C.84H#$1
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M?;OIIQM%RD.?_P#0]>2:\N((']&F1 2LZHW2Z:U-S.R4'W_.,[:&E+U6X)N
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M_P 8(X^B@LZY;_L></R$_@@?@/E@P=W>W:2H27J&%' -"/!((#E(A7%*0>8
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M8#\9^XH<?U81R/[!AO(/+_=MFZ\B$L1U"G"8S_4&<:XV@8HQ.U%M'&H5ITN
M1D:!%K[! U)'K-])K-D>FGQE7:3X1NGED>JY,[8VO"W?D>%R>G.0T'AFL WU
M(6;A][Z\8Z-+"7Z[?[0]8T=( OPPD=[WAK(>;=MDA>%#87=["45)2K.V(V\X
M< *E!7C>I*(KB._%X?D94P?F+V+'"KU@*N&D/8_0":4:P=LU[5=&\0T#Y?\
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M8X'2SFU'M/O$\.1]D/=,_#O.?:^?L&+M#PTJV^\#RN(/92;L\#L7BM7+^V(
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M/F H(B4=(\)X<XMMJ.(QP3S6Q,;@_P @Y?8O0J$;845=NAXAPI)[9UYK5L1
ME!X1T_<QO$W06]FO9U&&S$;+C0>\=))H:,7%O.!6IG6M(>4H< /I6%]4[ #Z
MFEP\$:A(+42>4AL@2U%2*TW38Z]S@-DB*KEZRX!Z>'1$=)G)=P*;H]_1'IKH
M#$U$&BCCB=VI$8F=%>7KX,M(^(CH"C1[QUQO"]@\<<V^B&.A?+:9I;/5L#YR
MPI+&G:P25R^(*X<Z(4/)1 / 9R%6>OD<80"O8H2M9VEAQMD;DU)P,5V]AFJ!
M73&;8>$''G:G9U\Z)SS6.9&0+,TA1H6PN6WDA>-;$F04(/W>N(BQ.QPO<8@T
M'T+KJGA^?3%["")GST_8 8"D02CA2<>RT@P5!:2N.U;V]^KHPV=?HW?2YI2H
M%A6$>:Q\#(FO' ". SNK0@:F[1>0MO6V"*=;S.- _G 3R^97=-+@>1R$N6+7
M.;='.]G&<12*#HC('V*>4*]+H1]I?"$?.2]N^G]P'W<.%FU"A+RD4Y&W>,L@
MC>/M3<O@PXK;HKU$[=ROLPF<1N84+A4%0X#7DYI=0I/VE (II!@5Y**D2/.'
M5EY,"H%/0X;Y5:N2_1IM (8PJ<>1\G52N=MX3$PB](<1M6I\Z4H?N'5Q2=.^
M<-$"<E/+N:8P$N3F%QXW03$';;"0 !IU\OLN<-PN(@F$IGAMJ!+&-&SHH#A2
M$Q(JL;0%#8Z_<:7Z#GQS2<3(3)=&AT>QW@W/4!464S,7S8==)'M-"/DK7+*Z
M&8N5=1L!.%'#6,!#YL;,NZ1,$N>6H1,M:A!,335R)]SE\($WV8GH"WH[;I'
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M45N@F7^6B"3R%CEE#_Z-60G\WD!(C(L\8("H:=.[XEFY%48M.C%-C+0V[M@
M-X..#!5MZ#VJ'$ZZ.#: D4ZEU; $80O:6.II>V9)3$ZB*0N<VP(&<7O$Z=*Z
M8YL^-#.>4B:$FP1/$C,PI6)B0X;CZ5!Y!]R_-1KY94% UTK&Q\N"U!3AFSYA
M>'5534'?=P=/_JO_V@ , P$  @ #    $     !(  )  ))!) !!  !(! )
M) (!)(            (!  !((!!()!(!) (((()) ()! (             !
M!(   !  ( ( (!( ! (                   !!!!!))! (!!!(()! !( )
M()              (( )  (!(((! !!  )! !!!)(
M                           !() ()        (!  )( ( !  !)))!)(
M )(   ! !!!)       )!!  (!( !!(! )! ) ( ! (  ! (()((  )!  "
M)())(!((((+ ( (  )((()(  !))  )) )!! +) !!(!( )(!$() )!)))!(
M(( !)) (        + )(( ))(( !$))  !! !  !) !))) )       +!!)(
M))) )! $()!))!( (!!(              *)!()       $!(
M             *           $                 ( )( )   *( )!!)
M(   $! )((!          )(!] !!   *()) 0!(    $( !(,!!!
M   F!J@   *    @!+8   $    $!^,           AAKG,  *   !0&4&>
M $    , ^SS0         H6_D.N *   !9#:?(Z $    *B-JH+
M':J#_P" "@   !TI)[M@!    <IMR!.L       !#Z!=3$ "@  !V":GW, !
M    +V]=>A        6V4CM)& "@  >YF"PCS !   !^L!Q\_        '4F
MR/B6 "@  (>9!]I+@!   6:N)()5@    0"1\98RTF!@"@ #A9,S%_8@!
M8IWS+^$     2"0)/A'DA$ "R"!5E'JJ;P ! 0"2N8#*$"B    " 0%ZPP^F
MS_BP21P@=AA7)_A""0?E>M\!*W     0!G 9N65  &@ "\[%12*K?=   ,)I
M=  83,     "),CYP+!7R@ "!GV#6[?Q]   8D$20/CXS@     *;Q["EDL2
M@  "[Z6X3$=1   #21I=-&GX      "A\1B'E "@  ""OM\@O@!   "&ST)^
MCX        ><BSZ< "@   4 VTTL !    #-=!7"         #ZK:P@ "@
M "XRLS  !     '.*)@          N(U   "@    +2D@  !     5@@
M        8     "@    4     !     (             "H     "@   "8
M@    !  20 <  0          2""    "@  " 0"0   ! 22""  2
M     "0    #@   " "      " 0   "
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MH<>1K,=+P*FRQ0-U0?NG$I@Q!7PEGTGZG+E[:T9BM,X%X%XXHW$*]@0LP+$
MM%X(;*-B0"V>&P$!R4FF.3&&BXJRW0X\086<F??P)RYAPF 0*0RG]6.WF838
M]MTP)"P$@J7'#QF+X8":IJ*VI?A/M_+MY$D!_;_+1'("&]"0MI<PP^%02' )
M496<8AF04H$WCAY>"4P\$/"L].8U!.P+1:E18-F%;PH@E(%9C*BP8-<;Y@4D
MK%0X&A,S@MPAM$T"PBL" _$/X/7RXA;).'O1H-H@94,\&/H*F8(:YF(S%G@
M= =AA/%R&&U1XQ,GA-A!ERS #%#7,0SID)48PL,G[.334J_4MN3!60&3AP&R
M'A4,1:XNC%.'G:IA5C RKD&9Q*EH7QBD6.%):Q_28UX+3*.,P#*R E5 ..'
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M,A2#2K4DH8%D-"BE7Q!(&,2+D%0 <1#]0+OL,2DN+F<,8M @KIQIT/8G"F)
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M:J_5S\#^#U\:**/)\ M7&=&/W\*DL<!6D,7%87.- \S@26L,:;VN#M*7'-'
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M%A=]Z_UQ_!Z^-1#9@RZ2>/JS][P!12(([R%8);"Q"\94B5@F.X&N[-)ZG*;
M:A")UG:Y%CJ;X(60@/HPS[F/5.6DNE05:"F7*L7*])%12&H$. 4  C<@0@D)
MA_X7\.);CSHE/VT?Q=&^*IO/UIG*_P"^O%UQ(H:P90^ PH%7B+12PT*0%?4+
MB6],5K,=/0(ID5&*3:Y.:#6X-.7@9H;).L2+TW-<<0*U MAL4*+D"L 2<1T^
M0 P  5&4&?.8VE2=J.S439'+P1/!1Z'< @*B<'6BH8ULB?,1@;Q7'.PR>MF)
MI]:ZY;AD!0V&S9B>C:<'"=/NTH5Y&Y@9%340 LBU84"+0' ,$0<A0IEC% HO
M")[W3)Y6.UN4Z-<EQZ40/HQ' JBT  EEH$0("$@I<W\*EADG+L=!B$F>+!0&
M8($Z#-)K'F:80#@$P<!T 5QB$X:'92%W2(6X:'3C+J&Q) M)?&%#7 ,@831E
M':!R-O;CA]OXK\_CB&C!PT3N/77>>\\B80 D()NPK&4)C/(A+ =HE28*$AW7
MD%V"PU1'ZP)YW<YYFO)41V83:W?_ ,KM @'2Y3+Y3S/Y"%!$V,L'"BLQ"D$N
MM9@K=&("&SAX'8?PFS2:ZP]<5?@1@UHCB<1>*?ET1 0 %1E) 5(!" LZ:RQ%
M:.!2V&1PJ%Q231+$9,/<EP\!H!J0Z<'6.[=O )"%",CI*.2)X+P-)(?8RD"U
M!:NH7AV0(* D1CY 5R\?P>OCEX5@N1P M+ 0R>P37$(-SP4V)3(+R$TWC+!@
MP!@SM-E3>_/'P(B=&9^@5U[XW"E9;T! 0(#(00RH@S,HB27LA,6):6BE''.+
MHH@4=H='= 54 * @+&:76IFN_P#63OZ<H4NPJT.JF'#ID; 9TLB!LP0_@A-
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MAHZ8,N,I&QK4QKDH60CKPQ_S<WDY1;A3Y:^B^*I15:JJJ[5<J^7Y#^#U\O\
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ML? @0!#!4-'QX6"0_]H " $" 0$_$/\ ^12A!D ^L7Z4^O\ 8$@:B_-A]_\
MEOV/G^Q^T_'_ ,M^Q\_V/VGX_P#EOV/G^Q^T_'_RW['S_8_:?C_Y;]CY_L?M
M/Q_\M^Q\_P!C]I^/_AR9ITK&R,,(<.)=II55P69JG1E?B_L?/P9XZQW9@9BC
MY* "A)_W"0(JA1^-]I^/X5I4;M5Q:TEG.7_<M$/4AI2,Y"Q9P*V\_P"O #%
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MG8A]G^'['S_.(]Q70&U]#OB4[E6>BP%%KH9ZJ6.W>AC]K' &@98'AA&!H(
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MK2!//7#*A,!T2F4@%0$MX>#0$1E(23!E!<MB@>0P3."2LD8<FN-"#I19!HA
M@ $QPGR_?WKW.'&11JV5Y&,%RLLAX/%DVE,C8E>F/E:I%(+YU9%DC?D*R>P1
M.[:CL"W*("@+@1DA +:"9]?GV)5H9B.&"GIC:!6I7"W>4-]CN>/X?L?/\XC.
M WN4V@=@2W#WXXXY]'J@VS;64<.DDX1&"A1-H1/.KI'JDH(0<&G3=W!V==<#
M^5;&9-"P*W$"*<,-*K)%#9%@@8@8*?/Y?O[ZZY:'@0!TND2X;I.>,J);GR^F
M?@4G>WBZ@E"B!0[*2B'CJT,82+)TH)@X-<LRB+P5PU''7_7&Y*0(*FH!Z(?
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M\ K*BT*YA$1N; DO463L=)6Y8\3>E%0E';3L $)'8ER<%,Q;8BB&Z,O@%KI
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M4 3C0&WK*O>5;G/^R,@"SIC\O5 "3TX !  'H$/Z4 Q48HB1$[$PG9Q:F#M
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M@I]:K6!;+EI#@C# %];7KAC 2,M_,]:84XHS^C>L; (RF#"B$S2<5]8J-O\
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M T=:X%+^21A[Z<,[]-!$D@$M5SGB[)<I#2([GM*MR89DWK1FGSA=:N*QS?\
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M%07J"J'"N*(@TI!:(QZ4TSIW"B!3 "J53JPJ[T8@R@U2@QB4O&*4W%//R J
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M5\-58&[G\*2=<MVOJ=4F82\7[PJ9N;D-@OQ98!8N#Y?-_MQ3+)Z.WW^LF H
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M*_L4/*8(U<1KZ&3^# (R"@ \0*(^$9_!&O["1!O*0EHP4 #_ ! -@\!
M'PH"K VKP/;CLG+[QXMXD$J(8W&4QT_:(SV/]L\P4UU[]P/'G!$$1$HC1/8F
MD^Q^D]OM%A,C_4DV=@,Q'Y-;JGZ%4W!M4 89NJ%K($]UIGG-F2 %%L!B3A3@
M\K_"&'GY$?R8!$#P@6=PA-X#0RL\9Z +;V$0FU"!5"]5VNB#<JV3+$(.*BB+
M&[0GA4QD^AL[89(>@!&))?:E@T%ZL'285,6!R%P$*D [P>L4A6Z<*"10 #^
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MEM_'*REUY) &!( C//H#6A @*PHOZD,P"!@HZDN%!B!LDV:!*"4",<2KH-%
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M(]8[T2\=US[HY=1"R CFN-+^SQ@-$1, 'S_7G*!QSP:"83A9'M&^2;4/(G#
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M/*R[?T^ZVHF@8096 K%NWV@'8JW=.=+Z%4*IBJF70F>O& \A"CE8"O(\BN;
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69LX^KW(6PJ OE"POHK/5??\ XQ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>business2a.jpg
<TEXT>
begin 644 business2a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1*:17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   "]    !0
M +T    %    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$W.C4R.C W  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !V     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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MP?EQ[U)!JOB-+UDGM%DA:[15*6S B$JN6Y;'WBV<G(QT.16^-3LBKMYZJ$+
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M 4444 %%%% !44_*#YMO/WO3@U+4%V 8<$ YSP3UX- $"VT@;=]L)'T%!MG
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M2"&MB0...GTH >ZX 4);8ZC+TC0+D );\]<M2,\;\J;7:#CIGBC>C8&;7U)
M- %2[14G&%C0$'[ASFHC,L2#)VKZFEOBOGQ%3$25/*#O3&B,D)5@#D<'WKFJ
M-\SL;P6A4ED1KB)$,C1/N9_+1B 1C R![GCVJ]'+$6$,9 D[+C! ]<&H7E:"
MW+A&("YP 2?R%26\:SQK)*%<N 0>H_"H3&T6UP#\V>*UM/\ ^/;_ ($:QQ#Y
M> K.<=1NS_.M2QW&T9@Q7D\$"MJ>YG(O5SUSXNM;6:6-K:X?RF*DQ@/DC/0
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M\8'3MG]?PH S-1O+.>5!&\:$#G+ =ZK)<([D?:8$5>  X)-=3]F@_P">$?\
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M2<YD;<,MD8Z_2M];JT10JW$(4# &\51_M"PR1]D/7^XO3.,]?TZ^U6[86MU
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ME]#>2.IMKD1*!@@C.?\ /%%% $36NH!F,5XH4YX9 >I'MZ9I/LNHY)6\1<@
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M1T(@6%E:( ?H  0 !0 5 #( *6%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
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M+"X.DZS6!8FP#!&;)R;%           *%0 4@ :L("2PEI.  5H
M                    "A4 'C;"Z(RF1-C2XVS6\8BMH2^SLL<]*,#$\R
M                            4*@ \589:MRQS%3/&Z/LR<L')G9]*LI?
MRU2/RR2@                             *%0 :KQ1HRZ\"ZLQ!0XQ**C
MQ<IL%9)0                             %"H ,&9D%2A4'$Y'$Y$=B24
M                             !0J "&1FRIS!PJXBW*G [B/DSH
M                        "A4 &K<;%TSY96W:1Z6]3-UA)>Q,Q4&R>CH
M                             H5 !JZ7$2<#I+RNJ6XLP\57K+JRW-]T
M                             !0J #5N-AY=I?U;R\:LHO3A9PCC5W&[
M\@                             %"H -78V'I<KV%^8X[BYK%1F"T.LW
MGE                              *%0 :TQL8,RG1509$LB[$N/LZL+N
M79                              *%0 :WQL;.Y+RL1+=)QI'.KXLBUQ
MN[\X                             !0J " RQD2=E=:W*=9;2\K,H6!W
MFVJ                              H5 !KF,>6)Q)$1LR)2+>KR+"KXV
MK0                             %"H -88HJMQ9G3'%N<CM+$YRY&,79
MO3(                             !0J "'QG*[S@#KBA4[:XQ'BREG^4
M                              H5 !J?&QE,JO2=5EU+V&/J/)L$Q,N-
M-_90 >-2-F&/;1+0                         "A4 &J\;%3@EZH[S I(
MJC\N6CEE.$N],H /'!!RA[.)D                          4*@ U;C82
M9*K],-&2K+F,EQQ<)B%Q7/OSWD^APSF7NG$X[L5$?8RS/'+RW=U59=^6,E[.
M>>]V@                       "A4 &J\6%7M.PM$YU>2XDR5EM+VD-U;,
M?\Q]#W73VXSIFR 8W-39-MG-V;\+?#/-9Z,DPS/I<VU/6XP.)#2W)*9<
M                %"H (!C<2F),I73%Y7,Q!DCB=Q!-&V)?&_1]^<QG+OBF
MG?V>CQ7%F<8P[MYM_P"-Q^6OOF,O]/DVEZW&!CSX>'83L^R@
M        *%0 :XELDZXQUO=&0LO# 2Y6SJBR(YIVZ^^,^FR%QR6O.)<F^5[N
M?CCC&.C"8]>F'].$KV:\UKUROTN;8_J<?EF;H]S=7H+C[<KLT=V<Y)TXY:6W
MZO1?3P7EQN<E_0%F>"C9IMLVR              "A4 &J,;B+.Y>N+RKI+8X
M1V5;2Y-(OHVZH^.^FD&6&1EPW/LY6:GV-J5,>K1F-FGCLU8W=KSO?S;K]3B_
M.MR^E@OF/KOJIXWMY?/3/>O@XIU[M7S?[N/[#_2_'SW/7BC*@ \"'(](&Z0
M  ?/0^?!ZS/J^         4*@ @$8\QYV%VO=)B[<PF.EN+!$^?;K+X_Z63[
M,;_.831G>:9WYS6/5AM'/3,=FNRSF5:^7I<NW/6X_EW\A]W"?,]'U#AEY?\
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M]^>NNO'BFL/SSZK17RGW\,]7?K+[CY&'?5_*?H?Q\N6 H5
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M NES/"WTACM"X:2EO_//DE,1C_F_7.<8P!9*]+99M-8)!(/!#Q_7J-;#9?F
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M<&Q4Z]@=VGUIWC<>$RX/6X$4Y$<"V#[/%]E^+C]#3+O2U29R+-PR90-=*C9
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M]FK]/5FF.TQ?()5;5--$Z@%1<*>M,:23HNQTE&&ZM+R/5>GP[!KW*: !@*H
MU5/C2J4SY.[8_P C_,,V6)$3\D]@:'18?UL'0;8& .BTVHY:*!;J6/-XH6U-
MX&D.U$.QT54$%[J536AND'0H<0.<0,!I]ZB6".-C6@.OD3&PQ>"%)M;O8?3C
M$4)TT& Y,^Z=EN<;0<9D)I!K32?.HL*'$EZ.%7 <^U2DL'"&UC15HJ>;:I>&
MXO -;(*EQ4=C0:/,FBE/H/95I"?*M=>.R N3Z08AWQIM&U0[;)HIZ;>W\X_
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MX +W@!U4UB*^HH5EP^HQV!65^$J++:+(Y:?;J@^UZ55/::N2VP*MPHC:@T3
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M5=F4L?;X>2A"1LR&GP)'V'#;51728RS\YE57,=4J^45D55IJ%2DI]*H%:;G
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M%Y(ENW5WMS]<:9#S;""0;FXZC8+T]B(M(D*+9$'5=%[IAVFTPR 9;A,3)Z"
MM,1!7Y1PU^HY$L;LQW$%6Q%2?NMA1>%DL-OQA0+-/MLN,JED;$=!:KH/N]0W
MMZIAAND2JA26T"2Z\Q3YK[,6Y&VC0#&<WHK:(NLE1IL0LEK(F$,:HQ.;Z0X>
MHPP;,U&ZV;EQ$;,5]?O+M[:E2V%66R##G^:5AU9#*A?W2)6VB0[]5B&W:R]\
M:=LW21AZZ-V4K*3"H9:B%.?_ #X_ Y7Z&OZW$FBUDZLS/B:-]MJFF^ [C8NC
M9P'-*W D7"0*:Y6G9*WL)4EUM.2HB]1.6]<(B,5'G_XJG]9CDQ-_B1_K,?@\
MW^)'^LQ^#S?J9'^LQ^#3_P"('^LPY2IWF[4UH=9-^6F2:?BA(Y94PS):B2U:
MD--O-JH-BJMN@AA<5=NBZ23EZ8_ Y7Z&OZW#B;;C9-JB$+B(B]0ZD5-)$BI9
M?T_</NM,E)=:9<<;C@0";Y@"D#($XHMB3I(@"1D((JW)42ZXIU1?R5F*-'E9
M\<\.Z@IRJ,14;,(2H\1&Y2!-57F3<><LY$W41(YW]YO5X@NONNTLO#:I5.#F
M!F:K.ZL>GNO,MU&(C3A;L:<ZPZS%%=+V^B,F F8:J-FV!%DPHE:CN2&(LM6E
MDLBW)?C*+NR;C6I284N@RY*GK?\ T)\I[<?/M_*7+X0@>["J]^R8=,)"(!"H
M6O\ IQTN753^/.ZX15<023H[_#".(\@K;X_E8=7?3VUT+J_*P'6FHDN*7PLK
M=1"[+=?JP.EQ%W#^.%:W!1-6OOV+$_:,55AK=3FGO:P^.-GWG6K(=BMRY+=$
M3T/OU6^&G#OXQ+9%U#^C45O=Y?\ 9<*0M;)D/94N/-;(2I>YJJ\QY]^6&CU$
M_P 3N;B';;;)IOWAT^Z*V0-M?X2>N'"&6['W.D4;TZ4<,$N2-E[W3[Z<K)S[
MKB53Y+(#5)C@4MF).C/NQ'G9"]3XN@&@XRQP>D;R'=D1LXB%RP#7!F2[;0^S
M<Z2/2B:DW$'I0-*"I+J7T%, .DFWD&Z-KUD@HMNZ(H6OR]Z^+#;2J<[BO4J\
MU1/F3MC1U(@E<2'[X+J=B;5.8*/^[UY8*RC,$+JVW(VFB---].\RE]SDMB-N
MRKWY<\$Y)BQ8@<(Z+;;3YR9.H76-7$N:&VA5.R- A*/.Y>GV*FC/ON4^DJ];
M_P ,D;M]*AIP_4' ]FU&725N2F1<\",=M"7NJER2WP3Y\:9$=6_WWHN-6.@4
M)?3".D;:674@(G*WP+##C#>IZH4@A: >Y/:A:$1_?*JJJ8H;=033-;I<)N0G
MJC@, /.]NJR)J^>_V)G\)G_H4^Y>I/VP BN^,2^*F]P"\FUG),\FT<1[W+1Q
MFJWKL>F%JU9EO3I29SS)F@FXX<)%J4*MU(:O"H5<9U.>8PZ14FF)T?4H:GVU
MZ4 R'%%RJ<Y*D5);E LU&.&1_B9\J;=&=;FC1Q.W;6M]%^5[?X'*\>'4)-*C
M5#.=+C5:?Q52I]%;IB,RW'FLQ5"C*-6ATQ\Q:'<A.-&KZ-B1H"JBY"B9;K4]
M^K0?%3.K=%ENS:K*R[7J93:.M3BTJ!,J)>85"@2 ;=IC4BK*XXW)=-1/I0\4
M&O5V/5,O4/,&2LQ>29/FJ\V[3HE*G4YE9U68118\SJ$UR4XRIM[K<$8XHJ(6
ME/\ *#;5;6GSE_\ Q3F'"$RZV]%KX15<)42_*_QQJW"][5:^!=0R2RW5+]\?
M?"$>GE]&-6X?>]KX:?UK[,4%!],'[0DU+@"0UZ,7)PK8J#HN*2;-]!=E]H'Q
MP""!,JYU@3 W)U%_'TV4B_?J2I\/AA+BEC1$ON:M:KU?\5?IOZIZ8,CNA *J
M7XUD%>7.UE4;=1>ZE^6& W4%WN];VJML@V2BIJ.K0CAJFF]B7Z.> --+ET]F
MXWU:]1H**B\T3T1Q4]VW/#K#S.^W(!P%9/FV6H-M4OW%-/XX*)IS45QLP*P=
M4@-1_D]-S NLXPC[C42J,(4HVK] I-200-J*H[TV470 F":<-J7",Q63 EM7
M0XTG2JZB55U(?WLP5MP.2IC7H44TZB'\9/A9+\S7M:^+J.T3CSDA1U=B<._4
MJ>NFR';E^*G:^$OS)>0D/8.2\U7U_>KSY\NV(XW5;1)-R+N9[[.LR]5(RN2K
M\_V$K9&W'18;QN.**ZSFB38#<DYD*,VTB72-L36'Q17AFD*.>AM$(F!"OP5%
MPOD5'&HS+:6^(D!$BA^^<<*YE;OI ;KVNF'HE>H%-#+[6Z8NQHXH;X)]Z1B3
MQ)6<7ER<3XWP@DEL$SDH8@U9UUL.(EFV"18W-77F$=Z''[H+8(7(-2GZ8ISE
M<KB3WRCJE4C2U:>+BMTE$H;\<0T-HS83 ]:*?-+8H50>'4U3HW$$%OQ@<N"$
MO;3?]/V7Z?3T@JV<6*_\H9)P]9 J+S1T.7)+<L<DI262Y7B.73_E\$@^6((\
ME58A]_X_!/N.TL(X\D3A#W'"3O;Y1R'!$!TO0*V5>%.WT(N_S7'+RI _U1S4
MO_+XZ4I2I_JCG]?A=L*/=/18;O\ [1A31J@G;_Q-Y+?5Q&$(VZ,-_7A';7_E
M& C(U1=1<[\([_[1B#$>CT+@Y$V,R\X,9Y";9<=$7#55D6'2"JMUY)W7%AS!
M1E]>52AKR_C<7&M4HD^*3XRI^G<Q^W=*_G"+_6XOYU2K?Z_%_K,*#E9HY@26
M(3G1"$D^"HKEE3#?[,41$9^]?+87LN5O9^TZ.7+IMRPA^=47<1%$3X^'K05[
MBA;ET1?5/7%O/J/_ #C$_K<<\P4;^<HG];C]OZ/_ #C$_K<?XPT7^<X?]=AP
MZ=/ASQ:)!=*'):D(V2I=!-6B+2JIS1%[I]SE>%,S=/\ M#S!/DQMXLOY>>@K
M6WT?\KRBS,B"M5CFFTKDFI2Q_P# L)U.&8U2).@++\1Y;=3EY0EA"9"GU*@-
M'4%DY@>!MI(3:98"G36Y[!HFZXU!0@<XEQ<94K-0<1V=5,OTF?,=$ ;1R3)A
M,NO.(VV@@"&X1%H 4$;V1+?X4MY;;D^:*?RIS&E'AO\ 3C;5Q$6U^^%47!73
MWYX"RZM?:V/OH_IPJ[H\OGQKW!LB7[XUJZ-K:N_IA7$<32A:<$2."NE+K9<3
MM+@JILII2Z75=P.6+MC[5OI0M1=5^5DOR5%OSO9+HFG#2!%:)^2?#P^LG61(
M 4U*0*(#B(C8F3;;>K6=ANF.(JDQY_4J.*P!+%B"0]D2.RH[R+W7<4UMTX4
M =KOVTW(EZF[]RLO93YV5$O9, _" "-Q$:>B:S:9<Z;[FM$,6G&^W2%GM6DN
M?/'#<"_'E*FL^)4-EIOLKH.-F22;<DV@1"ZDW-.!N6M=1*1_C:;=*>FFZWZ4
MZ41,+4::VV,E0$948D$/-&6[Z6R,;*U*:&Z1'BNG/;<N!7'5'=NX*6-AQ%;D
MQSO96I$=4W&S"RB7+3\%5%1<=]IM 1!M8C<<)5Y6[(""GKS5?6V"[,@/=S79
M56_HB)T<NZKS15Z4PC-R50CR"N?)5$W6"[?!%NFKU^G[#\4VT<-!4VA5;:ET
MJA!?]^"JG\+3A8XD9"8B76J731RT*B(B(0]E^/?%KV3%^6.7;X_[L:7+<UL*
MKZ_1CI5,:[=9(@JOKI3LGT?9-U'M+:4NGHH7[])XTBB<2B<U3U^E<:@[<S5/
MHPVQN*(D=BLO8;\\"V'0PWV_?+CEBZ+S3"^F"LO;O\^%&_*_+&H2]J"=/QP@
M21U.DA@E^Z*0JB+]5\1K]MUIE;WMI>5 *_\  ON(OS8>@2F0<=]I'-U134+@
MJ0ZPY?P#^=%PK>@G.'<X8C0134X-U2Z?BZDLM^R(MEQN&%G4ZM*)[._HENWT
MKSNO/"ETC:R6LEE]%],*3:>VU6&WP7UMAL]Q09Y"::;W/5:_UJMN7IC7?7J4
MKE\X^G_;UP;C2;KY.FK2%V%'"]FBI\R<L,:]6\(7,17V;;JC=16__-\^-;EN
M5[Z;\^>,SZW0:U5*&J(ZX(E^#'^6J+;'X5&_CVOZ6/PJ/_'M_P!+'X5'_CF_
MZ6/PF/\ QS?]+"YG8H%#"NK)?F\?J0S&;*0DD3&VC>*.U+>0BUR6V1?6Z]>
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M^O\ QB7GW7 ;OAAXB:@+4C@PZ&V[?X;K>9 ,D[+I)5&Z"MN6%3];KQ',?37
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M4&:NJTW,,FHLI1'(46AN4\910G.-U($G4^R$7AB(SDHIO-D&VMZ93W),0::
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M#FX.J8$2H)%G-I+7HDL;Z*3GO?Y#_\0 *Q ! 0 " @$# P,% 0$!     1$
M(3%!42!A<1"!D5"AP3! L>'PT6#Q_]H " $!  $_(?Z-Q6.O%E8>X&8WK J>
M:#F0AO/;23(%W2MMU+SK-%(35]EG925,5O4_()75IC5@<"5 12VM)C>*.4^H
M 5@*]*06BI,[Z6&?%!]DY]G:FZ Z'I=N&Y,;QZBV)+-X;K+IOW]4Y3OTFUGK
MMZT##=H (8-0PHC9WKLZ>O#B 9PC!5HW;H=G1O(.WWO<6+?4&"HJ"ID):\6;
MO3.0Z_ TU>Q7!^TYDN#O 2V'#X-]@FLVZT?K+K'Y@I%;A;>3W<V"/ KB]>'Q
M@ .CDHM(XJ6.V+? -L^%!79=,((95F_OI<%:**->ISPPOVC#30-0WB(PWS>+
M/B,J]:E^R,7Q522;%&:11R#)<D[6C%Q*Q1,0004GL<BS3L)IP!"NH_D&5]C>
M(CE$(V@A8;2G+O&)<(K$SMAL3H<XEN[F5G2@<1J8!X0HCY,-IBT)2%)*;:QG
M^=T3M]!,X<R*4(>1: L$:V$<ORD3(*B0AMKHQ@D+.2!'<&@C>'$HM*+Z[*.V
ML&TF02+G[(&F$!#U9$8Y$HH-5P1-1F+:C '([Q,RWG T]%&KY,8F6Z:WAOP!
MX#)H*;X@0BH'A)R9_.P9\E"3:ZP ( $*!V(FD38G.%+71KV%5$0-8?XM\+^A
M;$9D[ GT&@L$RUJ,O5$-J\"I3T7>-@D$<#PK &D;WA1($/ Y#*"-;-8*I2 Z
M\*0?9QDN2'MFEO$ZAT_T7C^D$(1Z@5L/U?DR*MPZ&,<.7B-EW2*8;,_\8.9E
M&;:!1/*M+!H"8L27H-HBS&6.LSQ!FO2A&QBM2/UN(+2W5?@&#N]\C&6[59RG
MU@1IQB 200M8)?K7NB^(3JCM5).?X%1-)RT9":\O-SQN6=[8*R",=$HK3L3I
M,GQF7M&8BD&$\V\)=908]G0#+0^J:M++$@$(Y)&$2A"J\AH3$B+6:8W0,X,@
M?5U3C(O';L/$(BS] >C*TZK,SBQS1#)J%,];Q20J1/QRC"C&FK DQ*=M&DP/
M04G!ZNF2G $)>IT6Y)-[E3>,GDS3&_XJS;>L&G?:NJ"3;?'=1J./W>*T%O7U
MX+[R#AG39P@MF9(IG?!M?YW8BBT:I"Q4-#YS6[H=X%#C,>,!N^$*ES_R>>$,
M1@,9E&E@5-4(]T:#*A'EL[5G-[R5AHF Z>P,DP!QDI$I&#W!03_Z(\%BSK(&
MB!:HG84&??PO3EN^#'E,3BKE^F!>F2;R"<@,.QZ"7P-[B$,;09DA-(6NP?&#
M$Z;?C5*M!QQESDWRO*FB1[X+-E3J?4M!&&2R/*D$NSV!QV!O#<* N9 :S#B6
MX.>PN.^B8V#8N\/*W.VM@@- 8T#BICMU*QJC-1XCEA&\-S3ES5CND-"+F-8(
MYQ&I$H>"D Y+"P1E&SD91(8V[_8(-%=@G"$@]94^#"M\#PD_1:7D,\'-+R&Z
M+X%Z7).+)$X\1/\ 1S;W8]=X_I%=U-;R-84G4&))Y2G[C/O(&AD4MA.#0@5!
M*1+G@I\G=YUCHA#6+GE2FI5 K0JQ<3%JJ#?,(_ J8 9RS0HM^_T?$]3%=7(H
MNS;WBN+C82#=J2&<E"5&D3:301L"X5<4")*%A0,5DX:RTYB4-ON# HKMQ=#W
MQ?8%L:(7?-5'\UBK^Q2#C;,C(V.%>4S '/R"U&8*\:LZ,8G!4R4  5LAH9QB
M?[7P%$@33C5_METCV:!?:,]P@ZC ;SHV_K_V9;J+>' Q)KDL1-*/4(+%@:&(
M(H!>D)H6JX?'1G,A&*=IL:Y5H!UC7PZ"]09RUJ(KW+'?N=[P4$.!<(?O]P8)
MA\;Q&)Q B$-9VG-A_D4&\[0_1UP+.:O4&A-;SG%NNM'6\(GISSX(>G8DU$#H
M)8U9YN7>"[?NX1(,"'@/_*(EP39^ \'!Z$'C'</9< 5:@"C ;QRH<KE07U2F
M6C<6/U<6Z 7L5M<%,87(H(ZB&"XE7.A^\V)=%($4]L:- .-%@1I8C4S<J6['
MG>KO0Y=T6[F\WG<EAN+ACA&$HI9^UD1  0!01$=(FD=)G=MM]_F^^[S?I7)V
MC(HQ\@);&V4*:N.RD=X>(9X,;!@  $"9]AJKMRL;FG..KX&J+3A L$$X,JE8
MP$VBU/!$XQ,L(J%0Q6TT/&.DMRM"KSJ+""&336#A,E%M5(TR)2!J?Z2!R&%<
MY11ZR[5[OV.]_P!%X_\ CGC^Y<NLVK?7N,MQ4^Q5T!+XJ9F9'.UKUWAJ!^9<
M6]U!G<LS:J Q3P&(Z@(;58+"%2OXSXL-LRPL]* W_16HNK(CK@3!S,8N"\1#
M>.X&J2P\>95Q]>R/S)6PTI$=X]1;#>&2-"X1YWHGQ$BUT6.U;F9*!B(?<L@6
MU:$5QS'<][[ EE&CA(H_3A:D4B.>UL11:(@(J%ZN3-$D8]HT$[,J2#/$)@$!
M=%9T3J/57-*>%S12.*.ZF4^.85?+'39,0&S,HGN=R5(S?8H3E-[O)H'$/W,,
M/-NZ!/@:#%)ME+3+>-<5JDOA$RHJM-8 EW4!42(J93_*S,UF:J8%SVF_XUJ"
M#.3K_"^']PUZ7C^B._7>1Q4H=KNB_5;2+][<"8DK.*N?-XGD"3VU30X?9_JT
M:J=C:GZ)5.&( 80.E8(R*'9^$DYDRP-0D2:X P!+"-_G8-,+5<;3+&922ZFA
M:X3:EU:6DHN!3E!NAYG+M[-]@4#XHQPUC?$O %0O*4"!0U^7RVQ$R:KE-#D5
MN(>WKIR!/(<6&4TW%RL7L80[X4&E8!00?EB].@&16DCG6?4Y]"@)%A]%1MX6
M5'<5]0H$1V-]8W:A]R%"^UIB]5*@\E5:%$>;/Y-3R_2>F;!!6NM//.% 47;E
MV+IU;FG;($RHJ()X@T2B5\IS'<HYK%!AYK:>KM&"<W@5J_##KP<BD90RSJ-3
M9AKZN)LQ6[L&UX(PI3]C_P"(L[8'$>=S$:N;FV-P!+)0.<+JN*8G]P\>FGG*
M>3\Y3R?G*>3\Y/Z^OI6Z @MJ"??E=6\J3BDRM^W&F4-DL089[22,-:'TJX.4
M\GYRGD_.4\GYRGD_7GCTOQXV=,4I#70!HSPJ0V-H?CG"X_L#@X[Q);&NUTX7
MG.L;4RA==)\Y/<,MGGYIBP\H(-*^T<Y&K/)TOP6<Q#O(Y_+ZR)$/@2?F3%TH
M?UYX]/C"?)RCW,-M[B=D)[?XQN2#\DDX YR 8RJ+G\+G>(*@H[T"R13?4HYG
MW<VS@#8_;VZQ'@Y(F$ G<)"3_4YX0%EW/.#Q:+MN?'Z^">/2][>]O7< 3FO.
M6:N%$HO>7[&).:-7MX_?&.V2;ST^['A7:7GEGN89LU%I.OWWFR$Y-Z3K[Y;Y
M"K8[/G(0A1L.SYRA(T*V'V7]?!/'ID(?/A[;\9[+F\=Y[!G/IOG)=,]@RMTW
MSK.B$R/3\9)H+YGZ^">/2_@'KYQM1@9YOOARCX&\TI'IKO\ ?)G A&[EUH.2
M?_<,#.H:R^R.@U>W+'OFNL6!'DQW]\&?:HA[_&%(L(:DO(OC]>>/3R*#U.<;
M05Y+'C>#K>:F(]_."+8RNC\YQF7=DR\]X&"52J\<L*Z5SS8/.2@J52&[YQ3N
M&H4M^^2;':]CCO"!XG'RO/>%=M;C3F^/Z\\>E-5=5,@0C9K(:_?  L7;R]'Y
MP*=IOOV,0U%)71Y_G-P%OVGCXN5P*=Y;_P#,B)QMZ<3VR&KKN_OG'4V5WX85
M%5G)Z!ES;A;Q?R?KQX]-_(.EAKSVQ1(\C-#"DN'Q[9X'1S7OOOB_J,]KH'\9
MO"KI=O9P7K$FDCQDT9#ARKDVLR/L;_;$&%0YVVN4R@F!F O)#)H*P?9_7GCT
MO8+\T$\>I4#Q'RZQTK*5Y?;K&:B-*_\ X8PX03_Q]Y(MR'H/.LL@%]V].,O=
MV*],-Z/; 3Y^,&O<8X7-^'*50N'*\8^R0O!L+YXGZ\\>G3H,E@6S<E-';RD\
MX -(N6=.L8$137HZPHMZVJ==8LC+G1^S.H572NC6/\I_P3K-R-2]3LXQ@1[?
MXUXR%Y%7B%YF3KC6G,+-'Z\\>F<432[P"K511LKK#=O9[^& PATI/],A)B4-
MGK 8@P[ABD3A]'CWRF"CVNOSET +[$Y&+GEL=!9QWC(^2*;>6="C10I>._UY
MX]*=:%/+RX8<  ZAN8E/7<1U^V7T:HT:A[8,97=V7\8-K!!&W3%T)7>6'/>=
M,$;EO>;SQK[AX7&I0%06=GWS:@*V[M_&;9PZ-SOO/UYX]+??*(X<,'WAB\]X
M*)78X[ZF;Q!0P!>MX(^D_8N:81O+?GK.*08UT]W6(\?)WE<2AVA#0]&<IH3O
M_G.H1-N=Y[[R&"3#=&^WZ\\>E$",E%]AFNQB*W-X_"*<]/=S1 =+=?SAE6,K
M5SC8,4;Y[9L3^IR]?#E^: (T/\L",,9[OSG6^HK<^7C*XL $=A=]N)G-*DT@
M_G[?KSQZ6H E6;_VY $@9;G[YH-)>'&:;<LX8B^T'_N(DGR GYP;A 9(7C>:
MOA#_ +LCU])N_?%^;!90%T?&."%?#C#+[IV*)^O/'IL^3>;8S&9=OR3[XX*<
MC8#??G W9JG*M=^,A>1@[=G.>TP S@^,/LV';.=W@#PP/M/.2RBG0OSD! 6U
MZK+YP S02.6^<HJAS4*/Y](P=!VH*R3"*,0@W:Z>&T53,YTQ5=Y^Q1B"L#)?
M5'@BHL2#/U9X]*!N5(O!]LL/-RVPRH$B=O[.-7) :T_ZS;K:)_Z,!Q@&IQX^
M<1!H16O0&..WO!O/OA@FBGG^<0HT0OEAPXE^QN-*&TEDGW]+.1LN?=_O;$C5
MU1A[V&F4@L(U!X!: &O;ZQ@4)@<IA#QB(?JSQZ7)JS[+,"R8E'3>+C'?A"J<
M?G!I7@:/G#E(;)J?;O(G,VN7HQ\RW4U#M@3D5; GIYQO\'9QY^V"+:3Y(_9P
MK*.\C$C]S"1K7!.IV :=9=2&4;JU($Y'0QM)9C"ILZ'=GF<6 X/8#I@!M5SH
M:5^+AXI5HZ313!S_ /:?#% R1[,861E'[<!JB$-+$=]59/FFJI?(1,X/IW29
MPZ(*BF*Y-\ +WHB\),)BA\ FIP6740.QPX=./ =QAO!*#9'O.+)% 9Y>5.&C
MU^I/'IW*TR791^</T6WR>.'+C!KYN3CK$2:PYTT^V(FZ3+%Z<XD,#CMQ>/&3
MZ5LQUUK- Q_@1\8[=4_\MRH^ [Z9K6\X[1//IQXQJJF<+,I1)Y-Y0_&[@44
M$D#<L#$5BS!4XX5X6R.182>TZ*01)&IVY2'80064^;6.Z,!4-5@G+%(7"!1
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M'*- ;AVA0@4F&2R,D'9(GM?:EEY)!+PI$URNOK/T7X23A,E;[W@B8 \8W/\
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M  ! ))) ! !!()!)!           !!!(((!)!   ()!((()(!!()!  )!
M                                                     )!!!)
M!))((! !                 )       )!! ())!() !!)
M .VV^VVP                                &,9W$EP
M                   )H<<Y#0                                #^
M!3R70                                !!(!)!0
M                /GL%GL0                                -^*F]
MS0                                (WS@_80
M             -NX=J:P                                ,]LM$J0
M                               &&KW3CP
M          $.57S"@                                !'17C"0
M                            "J2C:[0
M       .J:*2&P                                &( N@D@
M                          \+O+&  )(
M    'FI?-[@  (                             '!&XTVOR5",40
M                      /$'4#C3=,S<;@  (
M %^'Z60L4Y,?,   (                       )_-;JV=[@!\_6^%:EF@
M)                  %(ABW.2WESX0!^(+>   !    !(            &2
M0P475@M1T(0'('B!$;%GO#?T3<8> !       -HLDN\I1.ZR(P?Y;^ \E4Q[
M%X>8&\^.](SX    +;_V(^125_)AP+D'* CLX(UN+V'9;*Y$(&C0
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M.GTR .+8@99 E(C@Z2P1#&ZL-I$9BAYJ D93$144-UI-54K8@#26!4K&<%
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M9S"X&<E/Q7Z"88GK&-JW/G4%'"/M[9ZW9C3)\%3O\S%VT^6]0D:&3JQO//\
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MKS)\<Z(E,;8SU,U-3[[:$0I7=Q<;^?3VTX3':MCGUK2"7Q<*/B,Q/ZU H5*
M^9_#W#&=,!'-P3:7DN:SHA)$)MGB]XSY[U/-MD1$^C-/-G,:;5 P)QL5[8?'
MF,!Q7+'GUS^]6P&)J8;#O='#E-_X&@ISOV=[Z@\^)8;?PYO+YU"DFUN?[WG>
MJB]0@'8B9WG]]^FH)#8(BLO)G:6>GG2+.[3:0SWS?G5,PX,SCRW'K^M5*$#*
M4<GODS7Y(6:P8Q-_V_,[:Q*R2 \0U$D;G9'FB*B GWR>_>^FHJT5<(LKVFX^
M/X&B9]_$?9G;JM8J;?$O]^VH)Y[\8MX/;C46$V62"P>G/KF'A$JY:^([N/3=
M*U&_4%U'XAKFMM!65DW^]\^ND'XWIVYC._6@ ABR'N)\6Z08B.IF^?3"1^](
M,$UB!IJ2?0DTL;@A$NX)KAOR9IG^!(P1@"'O-1[?K?05IS7I<SUCW\:D$#4U
M.QG:+GFM),BB"N7X\];=(I#ELSDQ@ZR+Q>V@BI8N&,?VW7KJ+(H,DOX]?GK4
M3Y<WB-L9P_K+.TS)PFW.Q'$SC?0I%>*../!7,_.E2IVG//K<<YWO34/8@VD>
M*]/X'-AS/W\^VJ]I)_.=28F^/\3&=3<=#]^/?4E](9,_;^,B:DJ\_P")XO/Q
M]V'4GP/HZ!@/JD^WMO\ P,6=,>:;ZQ\\Z1+/4V50ZN\]7&E*HHU&2RG;C$3O
MJ+B8B$[Y=[G[OHL5O,;R#QB6/FHT%NDDJG&0C&#&33(IBY_J/N\\&F47C%;[
MO-^<WHF4X/W'SOAB>S00IWN>+=_2]OSK'*M=5C\?C4 3FY-QD)ZB3T._X&%1
M,_4]<_O3+$Q%3YF$(WVX/-Z%E%(R3PN/U?I)I5;0(I5;;SH!)B"=^>.O/!O,
M@DI%%C^N<\9\ZQ:J#O5[X7"4,$X6M.1EB9CCQ$9Q^;T2+BV7SMS/M5WI$M9E
M#B0OTQM[ZOA(+,^,]\>KLC!<44VB:S.6SOS_  .0R73'3N_<^VJ)FJLD\R=O
MMZZ6I,D7U N]D;3GQ.EB8S&<VU"9\?ZA2AJ/S]=7\^9G?-$^P:N%6LQ\,\;Q
ML>VA4+D2SM/?W#Q&K@Q/3#42_O&_$ZF8)8,'WTCWTDEDL\LQ@/UM&VDPRH9%
M@E0;I-IIWO0H58G+XGX;UHH9$N&*E<EF\8<W6DC>^?OVJ\Y]V>"%WD_.'YC1
M0HQ$R<\'[XTP!O*026BXH#!!;O2$0-RWQ,2F&?>M((,%V4;:R*/WSJ"20095
M8D_*2- 2!G,LN)ICT'029)VPM]F",[\\A@ 84$L"U9HN-_\ UTG!<W!_WXY3
M2D4GJKS[=1;OI503+7,',\\^OA319D-\\7GU]7;4H0(A++NXZBYNO;2FN MW
MJ_%\Z$TD,Q^1V;IZ8]Y"D7-9]]^H*SJ>!<R\$2CQ'BX<;"C=S4$YH]^X(C0I
M&9'QQ\S:1OWHB284G"$H<YHO/NZJ@3 E323=SUYU@HK>*3U?L>FB1L2#-?C;
MQ>JHDFT)+^-X^WK@231*H.])=J;'335W>6.);-*$[0VWF[V(L/UH<-@DQB("
M.YZ[1.A(I9@.!EV//S<1J(]86>PKT(/L_P"')<0VR2ED\^T(;_\ KM!WQS._
MKQZYUN,!8;.^>GBJZL'&)2MIS&=KK/IH2%#$OEBW'DG4BE%C>9._;?QG"AF;
M^.OO#I8LWE)F*/WQZYS,B@+'QQ^XST3J2IWB/.9YXOQB]238SXYVK.-^&-M(
M"<W$?:A,<G$SJ"4! DSDQ+S&9W=<HHL=XX.:TD&$ W:F4DR6F O$\Z<*,&YP
M(ZQ.Z\[ZJ;D$P$-U #E:,U>D5I2+:4 7 EO+P&@)Y E(W(X(&.^^;8H;T+20
MR%N(S=8F=,$&0+&YN>1,5XU 50$A:M4.^SB?.II"WF.(/L]\:GFL._YW\?WI
MC#Y;OS<=<G_KL0D,2/O_ -ZU3^?<C'BHU 2LDOYY[>CTU,"-X/,W,5^<[\",
MU$.#.V0YBS_NJ68H)F*1"5^ ,^<$B2\;Q=.POM[6ZF2";G.?BB*JB.5T1#PN
M\GYCOBL&I3/!$DY9Z'!G\:D8(B2;AA<1GTQQ&HC!NUV2+T+M&D=$2@0)$PYV
M?S5TZ8"!0@J)'XOJ=&"$2TMD!K$[S[V3HS2R06PG-6YEG.VT<-P!-(B=BXD4
MK&G@04AL5F6LQMQF=M*RDXA3$++A*%[89U$<Y4IA(G<N;GR=:$"O!$8W!6]Q
M;^-.Y*::,<(S>82><: T-,0Q<[D38?V[:5\P:2A>5;*49G%:[GW[T9#!(;<Y
MW2:_?&K.6&0RP0(MXJ70W]U+P3.:]&FXU>@CS"_$_;F(=42@8O?$QF_)3I,&
M:20)J3L#/@RZ',AX5OC[L7IUP99!W"C-F#?2X4 .<21SN:[GW[T*@I+<D8]2
MO_+ B>&;P%S^>:\:@&<@9M]I9@-H\9U 2;.U;U7N!J CT(NX2\P)GN=] 3,9
M7/H_[(7?K5R[")ZP?''?IHR/6/,\:@-K"X\;SLQG9\NE$I4+=O%_,?%:) RI
M)>?$?&<NH;X3'KLY9M"/RZ<WY,H3Z;=V:2A" L.=O[AJ&YYM ,@G+" '..-Z
M-24@D)<TY9K;:*- FI(JQJ0SS5\.!U$I)[AW8]<.)VU0,6G X06V, %K)O$H
MV!4=DB99-T_>E J=+\L<_CYU.^B?=C+]1T$#//W[SHIIXFFY@YO#;S&76P+=
M@@GC]*>/-:B(<*3U)VDVXK.A2,!S8"HMIEF,2Z4Q(F,JKBY3<J<AAG"P4"Q/
MH$<"[&U:GQ0F F3=S96^/72@L(!*!N4\SXF>31,#D80#:0[/.!:EIB,$H%I8
M]G94S@Y5+Q$H$1 E".&(GO\ \U!1XZ_?V]11;ED,8QMQ6YJF\TE\=_WQMJ*#
MC[SXZ\5 (YK 7]G3)G%OX+/#SVZ *\KZ3\_.@L^#\?Z^=;;<RS?CJO7.LEG)
M73B?8-^=!$YLS,OS6H5N,&(#$=2Q>WC2$5L0,5/JS_W.D0UL$&Q8*[FH=6$"
MSE;"YQZ&WM%SB6"$VJNDE-ACWT)1$<[G!#^7H:F*8)J12V2Q1-7"1<:D89BH
M21 "IY6V-190,C$3:XX(#+O$$:S>.?L<</I+H5SC;F)?,5'S1C_!A.:X^;W]
M^?\ $CB&21I6! 8$,S#H,[5-QP@4;S&V=]0=1**D*&1'Y&73T]X0M)@DD&AK
M.SI-B^!)&9&N+YQ.HRA[9,9)8-V+;\ZP7&P1$!9C$"@P(U,*4T02YDK,I:0G
M^2\RU(:B,@:$8B8SE\0Y*@$1NV>/?>1(*$!"D$L&/[IT JF.\-I5S6-%B*)#
M!O#WCB#F9TZTC;E<P6?UCO2#8C&^[]KO?8:2%[FU'DS/G)U(7#V#%[3Z/]:E
MD!!9P \6[\[<Z/Y R&,>(C8]^DF$C0@P#6Q8[E2UD(1G"$?5CIJ'TD ,>NHF
M'_7KEV;=DY=NK+8J>S)J.2*=:0XHH92 S^CK=ZM88D@YJW_1O0"4#N)]<Z%P
MWA?QJY/V$@<Q(DQW_P#R*"#N+[9U.>O^Z,IJ,[V_[DWGK=0SJ;#%2SMY\?9V
MDY/?4G)])_%Z6+:Q\_;TH9=3'*6/]_8WC&IJ6L3>+AOK[&D'4[. E:X#$WC2
M21BA2H"(E[P1=>D!&P"#H$ [K,&L_;TI"3>&EB3KO1HQ",S,E<2R/XB?*SF4
MP,4K+ 8G<Q.K[8<DMV,%FP2I?!K:-MXSO'&6CSH514P3A<!YGWF=.2 G<C&?
MKB?\KN!Q967LG]='^,XTE@4);24]F-"1%2,N*P0 PJ18B]*PP,E0T7%8ZWC-
M0["1))$,+'B=SMO41D-I S$RJ)ICN:S&!!4$@"84PY(O<QO"+1-,7.WF?9AT
M(PC5&6V9@J[6O7^4(<F;)D(6(<0XX'2P(#Q)%DF2/3O,*L1*P %J66"N7TTV
M\-0I"-%;9])G,:BRC!)RPG+,L1G-YG0F C +-\[Q'CG?+IW@JJG$;^?O>L:2
M2,3J:+&1AAA@ZCN'_1RE@<K!<4Y$V_X!0*%5$@KB)BROT1!9@&ZI)H09]W.D
M9X*IG)4 .,]YQ>D]+,S$J(XQF9K?G38DGL%GO_JF<ZBJE4QS%1+XXK1C+,21
M PP8F:3QJ<.D!,F9(O58+NHSI>.I)QF:XK#MM-QHBE 4B"HIR.!K%&@]!(B$
MF;$&2;+##.APRD2SQ"'&'B-^M.!4E321A5J=E(NG/^)#*'KJ3D]S4CA'_,AE
M#UU_S']ZDY/<T7B_%_\ U,AN!(V=SYTRZJ*^W&U'DJ$*O/;X]HYF>MQ)'MJ&
MB9(AE]OW/G4=J>?OZU@DVO*[^DL>\&K1;W;M'[N:\38RGN/CN\^-)(&(NL#U
MJ/@OQ[YT?H;DR($@03FL>-)8<0PR;T9=&H;4AFRF>G4W(T:-L!N.MXBD1#/-
M:6.?:8?Q^^=7Q0"S\4*U?$$NJ@K!P7$YI3X>;T.<>-_X\K/]:\?OECKE_P!K
M7_4?G2JLS('5_/\ P"4!VX,K)FJLROS_ ),E8D)D*&HDS""P!+IN5HJ#'.[[
M.="3.(.9)()A)]6&M!(*\4;F1,>(E\F\;_"]AHH0AB@+AF'5:HHC23,PT?7>
M/+HL-R!00*"XS'^87Z@J%E!$A+>559V9(5$L<8CY^.7Q,(!%3L9\&ZR: D)%
MG5C,SWF]_&B')/%>.N)O_P" 1C&W1Q.^A(G7WTF/;0Q"SB9@N>,]]:K @,#!
M#:AW@L*C2E@I'Y"4@#-8GC5E<A.+#$RZ26"R:TQ 3VY@,L\_5DBR*P%DDX$8
MX>M%0X HH@X" ^=_$Z.0&9RYYSK?B2-.04D($B809FYSSI^.PCI55 <77>=C
M0@L4CK*2B?,G]2R*RI4;WO?LQ00"S#"E1M74GG:=*:-+<((KD=B,LZ+P;$QA
M3*,>T^VFX-N*N9"6>?C3P:8GG19?NTFOIE<@)L"W</OKB?D_LU(RF!$HI$]>
M)>=K7SUH5VD &6=SS&AHM:+<4<%GI1IB63P%L1@#:R;&=%Z@1_ C E9:,1H\
M:3%21AD*)C!4>?\ \>__Q  K$ $!  (" 0,$ 00# 0$    !$0 A,4%188&1
M$"!QL5 PH<'10.'Q8/#_V@ ( 0$  3\0_HA4Q(AY9/+#@A]<!!=\?DAC5&(I
MDY:9(%>T+%$Q,8,+A$ ))LQ$43&/^@ 12Q!,515U!,J)M"@:%)&!&I!0C(S
MA"5!B>/8FFW%0-U89Y7&37TPH:6$<1,=C4ZM(<$<]!J@J.=6X^".#"WR;::
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MK[B''*+P8+/*ZS)J7: 46-@'5Q3I^:W9-L(I5#!F-2.7V"HH$ HBTRW(9_G
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M&TAHV;=3\XZ,91H?/HZ#@N *^* 2Z @T.Y.'W>'XD&O<FWHY4AD/J]"S*CU
M>9WFLZ&IT!'#[>F2<$P46J(0A'7'C^>YO;]GVCLH:#8AV?\ ,R![2)2BDUM
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M1F36LU?:@&+*QFC*^+6"I0QNTGN44PW_  95$SY!UG/(HY:<) W!1[ICR"?
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MB-]$&%!'1-Z09<9C"!.HH4TC1HEM"L9244V0*:PQPZ<4@1!:I2UB9^P,@.:
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MC:(O8\3CU%RN,$Q>VP=#6*M\2'<@<\\VX:!+B!V.C \^<#R4+E$XMDY/;*R
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MK8@5USZJ-]S#;RIW"V =VYWEWG>LHE3T]8NL*OV 8.&/*;*&S AB''7U[Y*
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MN88  %@ 55@0JJKY55Y5?MF35'B:FS@+<ENT&6MB10,&@Q-WC*5H$'\/+/\
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8Y/DRGD^3*>3Y,IY/DRGD^3$5L^?7/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>business3a.jpg
<TEXT>
begin 644 business3a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X19H17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #$#@  9
M ,,.  !D    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$W.C4S.C(U  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !W     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M&]BH;Y1_=!;&>O!XHT[Q3>7WB&U@GTDQ0S0*RS,,K&Q:0$!QU+!%(&!UY]*
M)[_6M8M_$E[;11I]FA@1X?,7:DCE6)4MCU [\9I+/Q9J%_>:>;?1Y#87BB1)
MV.,(3CGT..?QKJWC21"DB*ZL,%6&0:55"J%4  #  [4 <I=ZUJT&JW*0JTRQ
M7&Q;?[,<&+RPQ;?]?\*BO/%6M6$9>;1XVV6QF<HSX!\MGSG;C:" IZ')SBNQ
MI&574JRAE(P01D$4 <A:^+=3>XA%SI/EVS2E&N$#LI3:IW %00.6!S_=]ZZZ
M*19HDE0Y1U#*?4&EVC;MP,8QBE P,#I0 4444 %%%% !39)$BC+R,%4=2:=3
M)HEGB,;YP?0X(H 8+FW(W>8@[_-P?R-!N;<$9E3GOG/;//IQ59M)MY)5EE:2
M1E(;+-U;UX]N/2HSHEB&)^93P>&Q@@8!_P#UT 7$N[61 ZS1E3T.<=\4?:K8
M.$\V,L>< YXS_C5*'0=/BE\U$)<X)).22,8/Z#\J$\/V"1-%M<H^X,-WWL]:
M +ZS02,%62-F89 !!R*DP/053@TNVMY?-4,9"02Q/)(S_P#%&KM !@>E)@<<
M=*6B@!-H]!1@8Q@8I:* $P/04;01C Q2T4 &*3:N,8&/I2T4 0+!:V\K,D44
M<D[?,54 N0._K3%>RFDCN08'DV[8Y.,@'!P#[X!_"I+BW6X506="IRK(<$=J
MSG\/Z<Q (8!3PF[@<8Z?UZ^] &DL\#D!98V)/&&'-2X![5E6FAV\,Z7,C^;<
M*<[\<>W!SC\ZU: # ]*3 ]!2T4 %%%% !1110 4444 %%%% !1110 5#)=0P
MMMD< ]<5-6-JG_'W_P !%3)V5Q-V-'[?;?\ /4?D:P-1T33=1U":\>]D1Y=F
M54<?+T.#WI:*S]HR>8MZ7:66E23&&\E=)>?+?D*<D\>G6M/[?;?\]1^1K!HH
M]HPYCHHIXY@3&VX#K4E9VD_ZN7ZBM&M8NZN4@HHHIC"BBB@ HHHH *K3:A9V
M\ACFN8D<=59@#5FN$\2_\AR;Z+_Z"*NG#F=B9RY5<Z_^UM._Y_8/^^Q6#J&E
MZ#J%[)=O?QQRNT;%HW ("Y.,^^>3]/2N8JI<:E;6TIBE=E8#/W2>*V]@NYG[
M1G?:4NE:2TPAU-6CD((C:0$)UZ?F/RK2_M;3O^?V#_OL5YI;74-Y")8) Z'C
M(J:CV"[A[5GID%S#<H7@E210<$J<\U+6!X2_Y!DO_74_R%;]825G8UB[JX44
M45(PHHHH **** "BBB@ HHHH *QM4_X^_P#@(K9KE_$&MZ9IVHB&\O88)"@(
M5VP<5$TVM")R45=L=6-J&C7-[>--%J#P(=OR*7[9]& [^G:G?\)5H7_05MO^
M^Z/^$JT+_H*VW_?=9<LNQE[6G_,OO+&G6%Q8M*);V2X1CE1)R4Y/&<]*OUD?
M\)5H7_05MO\ ONC_ (2K0O\ H*VW_?='++L'M:?\R^\ZG3I5AMY7?.T,.E6/
M[3MO[S?]\UC:7J%IJFF7+6-PEP%=0QC.<&G>3+_SS;\JN\HJQJI75T:\^IVE
MNVV63:V%(&.3NZ4AU:R#!3..1GIQZ57N'57Q);1OB->&0DM^.. .]4XY(8"T
M@TDCSVP2W.._3'K6I9OQR++$LB'*L 0<=J=6''K$T1$::9(8U0$!3C;P>#GO
MP.!FMM22H+#!(Y&>E "T444 %<)XE(_MR;GLO_H(KNZ\3^(C,/&EV Q V1]_
M]@5T8:-YV,JSM$V\CUJ VEL9VG,:^:V,MW..GY5P6]_[S?G1O?\ O-^==OLC
MFYSOX+>"V4K!&D:GJ%&!TQ4N1ZUYWO?^\WYT;W_O-^='L@YSVO0-2MM.TIFN
M&8!YB!M&>PK4B\1Z=+*D:.^YV"CY#U->=^&(II_"H\M'D(NWS@9_A6MBQL[E
M=0MF-O* )5))0\<BN65.-W<WC-V1WKW,,:R,\B@1XWGTIT<J2C*.&^AK$EGT
MM-0F4VDOG3.L1=5!!()YZ\<D]@3[U)!>:?ID"[(;A!,@EVD%CC''<^@&*Y#<
MVJ*Q_P#A(K8X_<7(Z$[H^F3CM]?I[UL Y - !1110 4444 %%%% !7B/Q;_Y
M&N+_ *]E_F:]NKQ'XM_\C7%_U[+_ #-:4OB//S/_ '=_(X&BBBNL^;"BBB@#
MU[X02QPZ+J;RR)&OVA>68 ?=KT7^T;+_ )_+?_OZO^->$:?_ ,DRUG_K]AKD
MZP=/F;=SV(8]X>E"'+?3OYL^J1+&6VB1=V,XSSCUIV]2Q7<,CMFL&2UM[B*(
MRR7" 01AS%@#L1VR>F,>],9=))3%Y.N6P.,!CDMU(]^WTKG/<1T)=00"P!/
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M3T5D:%4:=9@8^SQG@#D9[YJT!@8HHH **** "BBB@ I"R@X+ 'ZTM(0#U H
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M0U]04D]&24Q%  $!   "H&QC;7,$,   ;6YT<E)'0B!865H@!^@ !  % !4
M,@ I86-S<$U31E0                                  /;6  $
MTRUL8VUS
M           -9&5S8P   2    ! 8W!R=    6     V=W1P=    9@    4
M8VAA9    :P    L<EA96@   =@    48EA96@   >P    49UA96@   @
M   4<E120P   A0    @9U120P   A0    @8E120P   A0    @8VAR;0
M C0    D9&UN9    E@    D9&UD9    GP    D;6QU8P         !
M#&5N55,    D    ' !' $D 30!0 "  8@!U &D ; !T "T :0!N "  <P!2
M $< 0FUL=6,          0    QE;E53    &@   !P 4 !U &( ; !I &,
M( !$ &\ ;0!A &D ;@  6%E:(        /;6  $     TRUS9C,R       !
M#$(   7>___S)0  !Y,  /V0___[H?___:(   /<  # ;EA96B        !O
MH   ./4   .06%E:(        "2?   /A   ML1865H@        8I<  +>'
M   8V7!A<F$       ,    "9F8  /*G   -60  $]    I;8VAR;0
M P    "CUP  5'P  $S-  "9F@  )F<   ]<;6QU8P         !    #&5N
M55,    (    ' !' $D 30!0;6QU8P         !    #&5N55,    (
M' !S %( 1P!"_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_\( $0@!) )P P$1  (1 0,1 ?_$ !X  0 " @(# 0
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M*3XSA7I-SE@                  CAECF@PQR3W.:#&'*.2
M<,',                   !JB8\K EYB",G!+7*F),34BIL*7J
M  :YF!*@(^2DB)V7                  BA\CF'U,2>A[DB(L<T^1(CZ'.
M          .&1HXAZE4EP$T                   ,<5$8TL0G@
M      !K02\YI:Q]0                  "ECJ2+>,<=Q(
M !UP&HI<!V/%M@                $:U,7RXX     Y^3MF]C(
M!B\G3C=NH    'UXYS&+(              !KQ6(W'8NH    $VD,]Q3FZ
M       !HU=*Y3TIH@    3K3V.PRAVD              #7BL1N.Q=0
M)M(9[BG-T         #1RYURGI72 'EP/#D "<Z>QV%T.T
M :\5B-QV+J!\S@\AS>'U !-I#/<4YN@         :.7.N4]*Z0 T$A9#C.?E
MP["IN-\.0)SI['870[0              !KQ6(W'8NH$/[<],<MLSKIQ-.O'
M:_&:_@ FTAGN*<W0         -'+G7*>E=( 5U@R27)T^'',GR=0!.=/8["Z
M':               ->*Q&X[%U \'R!['T !-I#/(=K+A-?&)%LY81(YX63L
MC9+BX      :.7.N4]*Z0    $YT]B\X:0BVQA%K1F[9,/(\HP!-3V
M     ->*Q&X[%U     FTAGXO3B)Z6$3B0SXN<W8>5B7\>Y>(     .H'TNE
MZO6")     N",W=P(&6KK>UALA 2F!JTY<)K^;$ET           &O-8CL=B
MZ     3:0S\3IQ$]+")Q(9X].;O+(^<8Y) 27FT!]0   #I7]1H^I=CAP
M +KB]W?*LSE=;VL-D("4N.K3G-,D>I\3@G!+#,F         ?GFM?R?7.>&
M    W:C/2>UBI^]8W%U&7S=XIN9<09HA9ES$DS+0    !TK^HT?4NQPX
M%U1>]W$>;W'!Y\8G>CLT)';D;-EBL2&'S/4VX)&         ?F>O?QC6&S @
M    ;\0OJW=Q5?I8         #I7]1H^I=CAP    +JB][OR\?\ 0@
M        /S/7OXQK#9@0    -^(7U;M_K7T'P^V(9SIM?/'O2HQYD#W/F<$R
M0    .E?U&CZEV.'     NJ+WNXKS.Z8/-C$ZT]BQ=':'H<@           '
MYGKW\8UALP(    &_$+ZM06Y5Z!W:F.QR"]BW$K/T17Q/#"'W.:1HWT,@
M =*_J-'U+L<.    !=<7NY3%DH"9CAV&4RR3SSZV;7&N!M*6@
M?F>O?QC6&S @    ;\0OJU"[E6H'>J0[&X'V/M$K/T3)C.'J8TQ1Q"PCR
M =*_J-'U+L<. /)X/)X !=<7NY3%DH"9CAV&4RR=E?GULSYP#[G.!@C.@
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MXKOK #?B%]6[N*K]+          =*_J-'U+L<.    !=47O=^7C_ *$
M         !^9Z]_&-8;,"    !OQ"^K=W%5^E@         .E?U&CZEV.'
M   NJ+WN_+Q_T(              #\SU[^,:PV8$    #?B%]6[N*K]+
M      =*_J-'U+L<.    !=47O=^7C_H0              'YGKW\8UALP(
M   &_$+ZMW<57Z6          Z5_4:/J78X<    "ZHO>[\O'_0@
M      /S/7OXQK#9@0    -^(7U;NXJOTL         !TK^HT?4NQPX    %
MU1>]WY>/^A            # P$IZ]>0!T&W'Y7KW/#@    ;F17HW;17/>@!
MRMK!EI?1     Q,3O<74S@#JC]%J.MD[%@    6O';?<QY==P!]LW3-3<:
M       !XX  >>0&NY)R#&=*N,6;(EH@'C@ !YY     >.  'D'H:VE@$>.*
M5Z9,O@FX!X  //(             #7,GQB3BD8."6$7"            #XFN
M!(CP0\RYX+#++
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M9ZAC>T*%5%G,:F0K9UD>'RV49A*I$ZKFUDL! -6B,'5*FFQ3)X:%L\J5IX@
M#<^Y;E6PV9>HZHR(UW,5N<;9-++ID4>\1R8>957-3S=CHI$J-DFT867[6<ZX
M,!W^N;BAU]9&>I9JJ^HSY2@1V_EJ]$ML*$O3K"MJT&%>L86><ZUL(/8]$I?%
M25W\-BD6$TU*3N(&@5=:@F\/$VN,;&HOA:VKB".:@_A&E%K?-@I*@PYUV"HX
M2UQ3+XMO]-&!MDVW$-U@\*#J?J0M#!ZN>IGHE:5X5*[Y'2\ZD/$8BU4I%QX
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MPI#CLZ_+Y?/XW'5_.= L5%*&H[XFRX'#GQR</Z>Q00YE1Q*,QDRJ,LLT_*&
MV.G3OGD$'@:M.)61B4TEZZ-0"2--8""Q_1\RT''S]9'Z]9'Z]9'Z]9'Z]9'Z
M]9'Z]9'Z]9'Z]9'Z]9'Z]9'ZCD(LKG\7+-AX.?J8[7J8[7J8[7J8[7J8[7J8
M[7J8[7J8[7J8[7J8[7J8[7 A!R<OGS/R_; _F?%>MMNH?IMKZ;:^FVOIMKZ;
M:^FVOIMKZ;:^FVOIMKZ;:6=MNH/GS/R_; _F?%>NX?M^F_W+/<'SYGY?GRY<
M>''A,AY-<9D/GQ_7PVW^P#^9\5Z[A^QUY8^JXXTOF< K=,A2O_/L6>X/GS/R
M_-@RA\ 05A6<<I-%0RT5:.EUHKO_ -;^8'\SXKUW#]DI05)TKTH9MERA0^?[
M5GN#Y\S\O[-L>/CMMCQ[<=^/'??[ /YA OFB2>H).NH).AI3--SY'+:.^Y+%
MX92)2P%D-RR6(.@F8#C$(-/N/7</MK/<!IVGC"G\BD]?R*3TJLTH]GGE80WF
M0G1A<$0>BF>'UVW^1,_+]L#^8;_R'D _,,I7 V1(5QMEBM8D]MAW4<W+ ,6R
M@<_[EPG"T%XZH/ZZH/ZZH/ZZH/ZZH/ZZH/ZZH/ZZH/ZZH/ZZH/ZZH/ZK]A,R
M75M[B\JX_+<05A\9)H44EC,L(W-BHL.8/"_'F?E^V!_,-_Y#R ?F9I)Q@8^9
MPV/DX7^44E?R3PS\^+ASCSL5BRA.?!9>T[!P_5OP]F[._O;KCOMM[B\JX_+(
M.JH*F3FQ;&R\3 %SEI#$#BQR#,!%;YF]9CC]FN#D*PYD8A%^&X.#5':^MF_7
M6S?KK9OUULWZZV;]=;-^NMF_76S?KK9OUULWZZV;]4*Q'BSC+$89>;I^/KI^
M/J$+Q0LI16QS2.9+Q\MQ*D*"2Y5>0I0G,BC>6L-=#<./$L8_K[5V=_>W7'?9
M)(@DYW\=#=?QT-T"68H'+R@M'-FY5>3AY%X!S#$2Z#F,GLU?L>>)DKDIAY3*
MHYE,8C8EL-^&[=X^WX=>]_BW9W][=<=]_/=N\?;\.O>\AF7(F;J]4UU>J:@F
MPQ3(0/@Q.7;?;EM,F1A\7;?;EMKERVX<8<N-/B^U=G?WMUQWV2L-,$3OY5K[
M7\JU]H$WK;+DY<^'#7+GPX;<,N++\EV[Q]OPZ][VGMM_(GZ>.OT\=>&O;;J=
MOSP 9LB;9Y9>=S,<81@Q*X<S;=)#A.1;-&;QI0X! Q<'[6+[-V=_>W7'?=I_
M[ \O#W_EBDF1N>E1L+9B@;[ E].(R2X'X[MWC[?AU[WM/_8?EX;.YS#*+&SH
MI,=/AY<T;#MER1,?+%+P9N4(R+G3-@P38I_[[5V=_?9]-_OKCONT_P#8'EX>
M_P#+2@PB?)R8^&7'^QA?3#&CQO/D2A<"/Q';O'[-]N6VWZ>?ZM\&?CS^SPZ]
M[V6LL<M]Z1:]=(M>O#T$,BV/)L26F@M%SSS*\BYLA22LF8PV6NE_W^51.Y8X
M])S9\?'CQX\?9NSO[SX\=^7(MBEG@KAO$PB?_@+8C WF&+>=<=]V%7[D6<_X
MN?\ 7\7/^J64F-;(F<H[,U$([KEGK(J3U.?@-$PL8RM)>),C-'"!G'/^^EO)
M&R@OANW>/G7L83,=B V$0+EBA0.#F#HI@5GQ?\&;S\.O>_Q;L[^^S.0GRL6:
M?/DXN,Z=QS[[[\M_.N.^_LP08D:1\IV[Q^R1-F2]9YDR5RXSYW')]GAU[W^+
M=G?WMUQWW\]V[Q]OPZ][_%NSO[VZX[[^>[=X^WX=>]_BW9W][=<=]_/=N\?;
M\.O>_P 6[._O;KCOOY[MWC[?AU[W^+=G?WMUQWW\K<E"X[^J0=>J0=>J0=>J
M0=-B6V36CH%TUT"Z:Z!=-= NFN@7370+IKH%TUT"Z:Z!=-= NFN@735'+YQ?
M;?5(.O5(.O5(.O5(.L4Z-GY^WFFQL'/U2#KU2#KU2#KU2#JV0)LRY]&-FNC&
MS71C9KHQLUT8V:Z,;-=&-FNC&S71C9KHQLUT8V:15AB'.'JD'7JD'7JD'7JD
M'7 A$R<_FS'785+BN,>1Q8FLOB"V"6,+X:2WE\4UBLF:(+ RTR46^5RY;<>(
MVPXV\'BY!<@_J0IU8>/- .3BL>?QY1FEKD-BV7V/@?Z7,IRIA+,KPI94@DB)
M 7D-=I'/9%*1 O.N<V&,MAI$ I\K)PVR<$U7FP-HJ(,W'%EF3AD<UEVD,DQ*
MDE#N8"RY)Z<*S!%?_P#4.Y.4&5>%@9!DCE8<[:-UAQ_X #4T9I8AHSF0H5Y+
M1U[A9$O+$VLGAD)XFTV2(DV^7#SPG:?(D,KQQ7B1DP;B-(=R.; L#Y,_0-:"
M.!@S/!##SRV7MAS[M3;P+C&7 7YP'AE(<)UFX8<4N]RHT:197/;"M'S)DQGL
M.3@P\; E<M0K*X3)$:R)<KCQ8C4WBGM!F;A.O9F)'RM$F)NPNI[( @-?[Z?G
M<9F/)%,LT:N9)2=P8X)4U'8F$[.%R\+]*RRHEE39D/ V'R)J%8>&=%D6'+A#
MY]@S NW*PIVT8J=FX9>=SGX-8WD_GWPNIB;(VL";F#[/$W'(W?\ ;CQFNY<7
MO-L&2.Y<G@P1@RF$WC7.#W^UDS#)/CD82IKBU3&\P%/2Y[,1B\=M]N/NSH,4
ME%G+X<CDRIX'/&RIBUFG\E,!RU 7A(W'%0E*%&XI2]PQXE,!'DQTQ:B$)JN"
M(3]@8K;&14P!67.##B4C=>#;QNF@>\80MAP>5=6@LXCP2%C'RL7)B65RO8,7
M"E8 @N-J0C*\KCL#%;;9D]>S;80@V.0S+87/$R* '-CV4P&V2&H+\#GS5@>0
MAA#C8_/FI@,N>6CK,_!,1E8ASJ$GD:</)7!<R>$9 CP8R>O0^'1R]O)9@X^8
M6@KH4;K$G@,.'(AJN32C*QFK-:%4 ,6("8MXH&1/ Y8Y)>$%<7)17>4O&#%8
MN,<&*B2N2P"Y0LB>O9LN!17L&HJ@O0N,Q;#3^4M+6I^*8L B Y@XQ([Z6"#S
M?#(F!<G+F!$9<'0R]M(X\=N/'V/_Q !5$0 ! @("!!<-!P(%!0     ! @,$
M!0 1!A(3(0<4%18P,30U-D!!45-457-UDY2AL=/4%R R4%9Q<I*RL[31TA B
M,V&"HL%2@2,D)9&50D1T@)#_V@ ( 0,! 3\!_P#K.7FP2"<K\C2[MZ_,:7=O
M7YC2[MZ_,:7=O7YC2[MZ_,:7=O7YC2[MZ_,:7=O7YC2[MZ_,:7=O7YC2[MZ_
M,:)<0LU)-_S'2Q<;2:E+2#K$@&EV:V1'K"EV:V1'K"EV:V1'K"EV:V1'K"EV
M:V1'K"EV:V1'K"EV:V1'K"EV:V1'K"EV:V1'K"EV:V1'K"EV:V1'K"@=;)J#
MB"3E *%?B!?AJ\YR2'\/])Z1I:8YK5Z".C)(3-+&^#^?$"_#5YSDD/X?Z3TC
M2TQS6KT$=&20F:6-\'\^(%^&KSGOJCK=]#^'^D](TM,<UJ]!'1WK%=R*G&47
M )4!4W6ZZO4(5EWCEJRJ%: Q"N+0FLW9-:4#+J 2HI_ZK76_FCC(4%ANU2M:
MA; B^"$6P;%5Y!-5NHY59">]A,TL;X/Y\0+\-7G/>"NL59>I0U_<K!K!\$D?
M>-67158M20JM58M202*]454(!"@+U\UU7[X&J=;4&N>]A_#_ $GI&EICFM7H
M(Z.]#SR14EUQ(&4 L@#S"ELJ\+95236D5G[IUQK&ENO[U2U"W\.^?O>?7[V$
MS2QO@_GQ OPU><Y)#^'^D](HX\4*M:AJ4PPK^D<],,*_I'/1ITK400!>KYQI
M*8YK5Z".C)(3-+&^#^:1$P=:><;2A!""!6:Z\H&F*C^QM_NIBH_L;?[J048N
M)6M*TI3:)!^[7JG\].+\-7G.20_A_I/2*/\ XA\P^V'\,^B>D:2G3SB(]82L
M@7-N]>_I\U,,/;(>;Y4PP]LAYOE3##VR'F^5,,/;(>;Y4PP]LAYOE3##VR'F
M^5,,/;(>;Y4PP]LAYOE3##VR'F^5,,/;(>;Y4PP]LAYOE27/NJCH4%9(+HKR
MM8_E2,S6_P"D/9'VRK\5[T$].G%^&KSG)(?P_P!)_BC_ .(?,/MA_#/HGI&D
MI[G@O>VO9R26YOA=]'0:1F:W_2'LC[95^*]Z">G3ED-D]D$//)JRS-XYMIN8
M1:$(3$.!*4)B' E( 4  E(  JRA3'=9+NS,.4N_53'=9+NS,.4N_53'=9+NS
M,.4N_53'=9+NS,.4N_53'=9+NS,.4N_53'=9+NS,.4N_53'=9+NS,.4N_53'
M=9+NS,.4N_53'=9+NS,.4N_53'=9+NS,.4N_53'=9+NS,.4N_53 OGDWF4_>
M9CIC%13*9>^L-O/+<1;AQ@!52B;X!-7G-%LA:K8D\U,+IUU<WRIA=.NKF^5$
M-!!K!.55?TE/<\%[VU[.22W-\)OPZ#1V7-O.+<+C@*S60+6K*JUJ8E-;*[^W
MY4Q*:V5W]ORI#0:(92E)6I5L #;5:GF&G+*-$,YX2C?B7<DP(=$C_!L1[V'T
MM/<\%[VU[.22S/"$WX=!\064:(9SPE&_$NY)@0Z)'^#8CWL/1Z=2>'<6R_-)
M>RZV;5;3L9#MN(.LI"G I)_(BF."1;LROE\+UM,<$BW9E?+X7K:0LSET<I2(
M./@XM:$VRD0T2R\I*:ZK90;6H@5WJSJZ2GN>"][:]G));F^$WX=!H[,H)EQ3
M3L0A"T7E)-M6+P.MK$4Q6EVVD?N^5,5I=MI'[OE1B-AHHJ2PZEPH *JJ[P-X
M98&G+*-$,YX2C?B7<DP(=$C_  ;$>]AZ6=*4++)Y42/\ZO5.L*6ZOZE?[FEN
MK^I7^YI@.$F<S2LD_P"F#+O_ /=-:2GN>"][:]G));F^%WT=!I-\\8KTD^[1
M]MCGXL3O;?M'3EE&B&<\)1OQ+N28$.B1_@V(][#TLZT6SS_S5] ^W ;SYFG!
M@^*:TE/<\%[VU[.22W-\+OHZ#2;YXQ7I)]VC[;'/Q8G>V_:.G+*-$,YX2C?B
M7>]*%"HD&HY7YTM%UA-J:S54-4UY57GU*%EU*E(+:PI *EI*36D#+*A56 *Q
ME][@0Z)'^#8CWL/2S223B(LHG+S$KF#S3D8LH<:@HEQM::A?2M#2DJ'Y@TQN
MSW<>:?\ 'Q?4TQNSW<>:?\?%]33 EEDQ@9M,EQD#&0J%RX)2N(AGF$J5AEHV
MH+J$@FJ_4+]0.DI[G@O>VO9[P9='@N(94%)=@TM&'06XA+8AW?OI3>6!;_F:
ME4C;1+,45-$IAW&%(2\TA#-JE2;9,*M-]5M55?U#53_#>3=1;-OJAW"V5H2M
MY+"G*BNYHJ%M]ZY,UWPV%+UJ/-%EUQDD*+:BFV&4:M7O);F^$WT=!I,I=&O1
ML0XU#J6A2DVJ@47ZD)&JH'+!IB3,=JK]9OZZ8DS':J_6;^NDD@XF&<?+[1;"
MD("22DUD*->43IRRC1#.>$HWXEWO+$&8"(LDE#,SN>$EQ: Z'34VHU*+2'";
MUHX\&T+!O%*B#>-(N#AHJ82EZ<+C(2!AK(W()F5S:&@6(2,.%XC"<1 AAM"A
M!79++=S65LK21;J-M?CXR,@):W-;)8)&*<%9-:RE"F686)<E]R<#Z&+1 )A6
M*PY#.J0IM+J&RDJ%1,3"L3&#;@DO14+-(MF4RJ9/*1AN-:AXK##T&B8.)6BY
M-JN:7I@NM2PV(2&6HVJP7V[B\XU;!5S6I%LDUI5:FJL'5!U#WF!#HD?X-B/>
MP^EI[G@O>VO9[U3CB@ IQ:@,H*6H@>8$U"A<<4 E3BU)&4E2U$#S FH?VI=%
MVUM;KM@*@JV5; "]4#7755>J[V69X0F_#H/B"RC1#.>$HWXEWO7HN*B+2[Q#
MSUS%JW=7%+M!K)MB;47A>%'HN*B%(4_$//*; 2A3CBEE &4$E1-0&L*"-BTK
M==$2^''P4O+#J[9U*LL.*KK4#J@UU][@0Z)'^#8CWL/I:>YX+WMKV<DEF>$)
MOPZ#X@LHT0SGA*-^)=R3 AT2/\&Q'O8?2T]SP7O;7LY)+,\(3?AT'Q!91HAG
M/"4;\2[DF!#HD?X-B/>P^EI[G@O>VO9R269X0F_#H/B"RC1#.>$HWXEW),"'
M1(_P;$>]A]+3W/!>]M>SDDLSPA-^'0?$%E&B&<\)1OQ+N28$.B1_@V(][#Z6
MGN>"][:]G))9GA";\.@Z;3)IDI*5)AP4J 4#=X87B*Q>+U>5KTQ$F>UQRB&Z
MZF(DSVN.40W74Q$F>UQRB&ZZF(DSVN.40W74G^!G9W%3J:1#%CD6XR]'Q3C:
MTNPA2M"WW%)4#AC*4D@CST[E>"!Y,QO&0G:*=RO! \F8WC(3M%.Y7@@>3,;Q
MD)VBG<KP0/)F-XR$[13N5X('DS&\9"=HIW*\$#R9C>,A.T4[E>"!Y,QO&0G:
M*=RO! \F8WC(3M%.Y7@@>3,;QD)VBG<KP0/)F-XR$[13N5X('DS&\9"=HI@9
MV 682B?.Q$RDD1",*@'VPZ\]"!-NIQ@I3F@WR$JJO:AIB),]KCE$-UU,1)GM
M<<HANNIB),]KCE$-UU,1)GM<<HANNI$2V-A6[J^R$(K KNK*[YRKR'%*YLDA
MY;&Q3=U89"VZRFNZLHOC+O+<2K^]55,1)GM<<HANNIB),]KCE$-UU,1)GM<<
MHANNIB),]KCE$-UU)O8O/GXY:VI>IQ%HV+9,1"55A-\?CZE,:-D6YB^/A.T4
MQHV1;F+X^$[13&C9%N8OCX3M%,:-D6YB^/A.T4QHV1;F+X^$[13&C9%N8OCX
M3M%,:-D6YB^/A.T4QHV1;F+X^$[13&C9%N8OCX3M%,:-D6YB^/A.T4QHV1;F
M+X^$[12 L5L@;C89Q<N6E"705*,1"5 5&_FBF(DSVN.40W74Q$F>UQRB&ZZF
M(DSVN.40W74Q$F>UQRB&ZZCLHF#+:W7& EMM-LLW>'54!^272H_V!/\ [*?_
MQ !.$0 ! @("!Q,*!0,#!0     " 0, ! 41!A(4<Y2RU!46("$P,3,T-4!!
M45-457*3L=$3%R)04G%TD9*B$#)A@=(C)+-"H<)B9("0P?_:  @! @$!/P'_
M -LY3LN)**FM:+4OHEKI^T7?+>VOT'X1=\M[:_0?A%WRWMK]!^$7?+>VOT'X
M1=\M[:_0?A%WRWMK]!^$7?+>VOT'X1=\M[:_0?A%WRWMK]!^$7?+>VOT'X1=
M\M[:_0?A#4RR\5JV5:U5_E5-+]TWL++QI; TX0\8@2I\T2+FF.0=[,O"+FF.
M0=[,O"+FF.0=[,O"+FF.0=[,O"+FF.0=[,O"+FF.0=[,O"+FF.0=[,O"+FF.
M0=[,O"+FF.0=[,O"+FF.0=[,O"+FF.0=[,O"%8>%%(FG$1-=5 D1/>M7J!_9
MG>N7?JE&[,747O3>U"[GA?',;5*0VC-WE>\?4#^S.]<N_5*-V8NHO>F]J%W/
M"^.8VJ4AM&;O*]X^H']F=ZY=^AJ7B7Y14O$ORT5&[,747O3>U"[GA?',;0S=
M5TBVS,NW43@&5;U3##2:XD.D/I)K!IDJZ\(#BS4\RTX:B-SN()NDB**DI."A
MUUMH:<*:R:6M#4T0$VKMNXVV"VJB6D0J[Y-7BME174%51MM--51%/A30TAM&
M;O*]X^H']F=ZY=^@"V4QM/SUI:^_@@K?^W54.W ]B,AMG%1*U-"KUN)%_:'2
M4?)FOE+9RW#R1$BF%:IZ0*GY:];W0X N":"M7I$1VM2C;B-?I+7^5/RCQE6N
MAHW9BZB]Z;VH7<\+XYC:$I:6,E,Y=DC734B;%25>-5CR;=9K:#6XB":VJ5F*
M:R$O"B0K32VE;8+Y/8ZQ3T.*UXJJN#0TAM&;O*]X^H']F=ZY=^AK6*UT5&[,
M747O2)F=-AU6T$52I%K6NO3C-)WV _WC-)WV _WB5FS?<4"$41!4M*OC1/\
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M+9G6#]"T,33LX^KX=:PP^&R.G-ZBGV69G"VK2+MYT_*/5("4,"8F"@9%8_\
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MQZ1'7XR9?]+/K\9,O^EGU^,F7_2SZ_&3+_I9]?C)E_TL^OQDR_Z6?7XR9?\
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MF?HB(WF?_9'5>[3<%BI:4#Z[USNMJ61R!@3](E$[Q][N_5^,_5_OFEOK5?\
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MR9M(''ZW<O+%%,=L>,U-08!U?#5G8_+UW6[E;M7#JD%I0VJ@'+5+5/K81;&
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M(&/I\8F>OQ9S_P#X1>_8=?BSG_\ PB]^PZSC<EB<ECU,PP@MEVE8K 9^<27
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MBR&7R063KRXK':<\;,,<(M,B7W)+AOL.T>G62K/I*L(S" KY1=C=PWDA6\I
MV.Y)<_N>.$S\9_"F>7KU-E*;E1TTZ-"9I9/(58\GC52FC7XILB/;KKDH =OX
MTD6Y3OT(QOL,0,;S,SM$;>LSZS/],^L_>?_$ "L0 0$  @$"! <!  ,! 0
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M<P9CS[)K4!<R&EH/!*3G6CE773;V\!<'-)DH^P0$G3EJZ?\ ^ :BS=8LJ$9
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MAFXIK3C::T,C  NTJKCM SD$\*N!F'T$I;#1HG&O@+20+7@'9[A39%N_1/\
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M P$  @ #    $ !((!! (    !  )   (( !!     (!()  (   !! ))!!
M  )()!((() )!)  ! )(!(()( (  ((!()((( ! (((  ! ()!)((  ))))
M()!(  )))        ! )(!!(!(!(! ( ) )) !!                 !)!
M(()!(!!  ))  )()!)!)                                  (
M                !(!(                                 !!(() (
M           (((                   !(((!            !(
M              (               !
M         !)                 !K;;;;:P          O_ /\ _P#_ (
M             <     (          5MMMMML               <     (
M         , !^  0               < 0U  (          , 1Q\ 0
M          < (TP (          , !7P 0               < 1K  (6X0"
M      ,     2_H2            <     ) ."2      <DDDDDH  "0
M       8DDDDDM ."0"0    (     $  22"          (     ; :"02
M   (     3@802"0         0     ,          (     0
M    0     /$P202     (     1-X0            0     .@ 20 0
M(     '@              0     - ( "0     ( "I  '@ "0"
M 0 "%@ -;("22     ( 66( $I2"200         0 "^( ,          ( 3
M:L 0               0 #J@ ,          (     0               0
M    ,          (     0               0     ,          (
M0               0     ,          (     0               0
M ,          (     0            #?_B22222+_\ 8     O_ /"22223
M?_P          /\ _@"00  #_P#X     _\ ^DEMDLDO_P#@
M  2"2             0 0
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M%BQ8L6+%BQ4--,880F2-4+>6,H2@QIJ2"3J3)]P6+%BQ8L6+%BQ9T?D<)B4
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M2ZTHI&66(NY;2N,T       ( ( "P  6#M!%.DV:U4M84CU8+MV_JYH4%2@
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M!#7N15I$<-^3_-OY0E%"B_*;0F,UK-W$@%A$*3,2SV7""6<3!""\=2$S''2
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4\M7#$KT@4*S*>%H+6 WH.%>X_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>business4a.jpg
<TEXT>
begin 644 business4a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1B 17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   "]    !0
M +T    %    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$W.C4T.C4Q  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !R     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M&9A/(QYV97! '3C=U[C\^MHH Y75&\37-Y-:VJF"V9L><BC*KN3!4YY)!?/
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M@4M-C#"-0[;G &3ZFG51(445#=+*]K(L#;92/E/O0!@:OX8_M76/[0:22)Q
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M-3;C (P#T'MC.?\ ZPJ>PCU)6_TV:-E /"+CGC']:$FNHF_(OT4450@HHHH
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M>*/[%TG&?M QZ^:*00K LD(TDF(D@A68@X+ 9X[C'Y_C4*VEO+'+NT*<;0%
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M=$TH=9\<9YE'2HIK&.%G9]*:;:X;<)6//&2 ?Q_*GQ0+>HJ'3]L4G +2/M(
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M*JVVG6MI)O@CV'&, G%6JLD**** "BBB@ HHHH **** "BBB@ HHHH ****
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M;7,
M      UD97-C   !(    $!C<')T   !8    #9W='!T   !F    !1C:&%D
M   !K    "QR6%E:   !V    !1B6%E:   ![    !1G6%E:   "     !1R
M5%)#   "%    "!G5%)#   "%    "!B5%)#   "%    "!C:')M   "-
M "1D;6YD   "6    "1D;61D   "?    "1M;'5C          $    ,96Y5
M4P   "0    < $< 20!- %  ( !B '4 :0!L '0 +0!I &X ( !S %( 1P!"
M;6QU8P         !    #&5N55,    :    ' !0 '4 8@!L &D 8P @ $0
M;P!M &$ :0!N  !865H@        ]M8  0    #3+7-F,S(       $,0@
M!=[___,E   'DP  _9#___NA___]H@   ]P  ,!N6%E:(        &^@   X
M]0   Y!865H@        ))\   ^$  "VQ%A96B        !BEP  MX<  !C9
M<&%R80       P    )F9@  \J<   U9   3T   "EMC:')M       #
M */7  !4?   3,T  )F:   F9P  #UQM;'5C          $    ,96Y54P
M  @    < $< 20!- %!M;'5C          $    ,96Y54P    @    < ',
M4@!' $+_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P@ 1" $6 F\# 1$  A$! Q$!_\0 '@ !  $% 0$! 0
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MHZ+..#I,VZ0 C)LTG!K,Y7/VB/R2-J')9U8=2D)->G)1V(<"'7IK$_H+*@
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M,#4GK;?@  5];&Z1J'U5X   -=\YVWRM5@ #6_KV-A>-'>MWR^!LO<]>
M%"H    !'SW,D>)>ED?1A"],R#%GF9@    PA\&=,<9(\BR+$^C/ QAY&8
M !!B<F+,H##F8($3PJ8L^#+@    %"H    !HPYJ-@FNS.GF9DVH08C9C#R-
M<G59TJ   #31S"3\@!DC(&+-YD/(T08F!JPZ+.J   #CXB)(R*%V6IMLL2%G
MT0L]S+G09NX    H5       !J(YD,@=.FRP        0(Y:+<Z?-E@
M  '-IK0SYU\       4*@       YB.-3<!L$[&        !HTXH-J$K.R@
M      #G0YR,X=C$V      !0J
M    4*@                                     %"H     ,25*E"^(
ML2 R!\&,/4R(    !B@?9\%\1TR1EP8L^3+     Q1BR4F*+X@QL &,/@RP
M    *%0     :#-/%@8@D!M8@Q'#(D2(F==F]@    :0-&%T14SIMXA9@S"G
MJ:M.L#HX    Y.-;%@3,GICB'EJ8PQ9\G7YLX    %"H      (@2<PQPD;2
M.BR8@       BIG"APD2TZ/-@       $()N:6->F..GC/       H5
M  !&S\[#<AL(Z1        !BS@$DAL8ZH        .'C2IOLV\;R      !0
MJ                                      4*@
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M,.A3]          0(_*0M3IX_00        X&./S;YW:;M      !0J
M                                 4*@
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MZS7-XJ0H/0     >-/[+#7]JN51^7@LO'LKEO8D+)WMNX !O'N7,^I_JKAX
M %"H  !P=\%_4,7U:;   \JO.?-RUW9<%):\FHZSNT;=UN9E\;F       #'
MW[>D-J@9W$9\$E\''7[4RB\W;VMS(      $/DL. S$=F\6_#I/"C>=C=)Z-
ML^5Q[H &\NY<SZG^J^'@  4*@  $?UZ5\;5P
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MPY@C*FSS"%P>Y&#P.Q        "A4        %"H         !\E2H /(]0
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MWK#L;+1VCULWUWL6[-;4FVY*PPV\\'Z@RLE +/L"[@>KOAS/@%M:FOBD&(@
M7XD5:O7RY'4K0SDET"8FL*2O;DEH@E;E*75H\;,9U])4@^7YKV0L;F/B5EN&
MAFGJLE<VD5RW4BFMSX?8CJUX9>8U*N%DF "&N[*@K7,;E5>4K T]I/O'-@0,
MX:?2_P!78Q@Z*A65ENG4[3U7NH53*]V+!,6?.ZZZQZ^F6*.>*./"&/OKK+JM
M6KTZ\:LMQ7\E -6Z)D=1IU(6Q:S"VJUA&QL5*P(C3* @QO&XKKA#KM87.R$*
M+7Z-55X%1O\ Y6_UXXPKX-$<!M.AK4C.KZY'OBVU_A,H@09$8:TLS(ZYJD[
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M-&GV[V:L!DQ"K P!T.7:M":E2JCZLZH,GER25W*.!3 UKT%"I6LSK(:>K(I
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M!Z+2]DQV86C^&D;XJTRC(U?+Q/+1LF:]K9K6O=%Y>O+#=$\.NBAM4FD. O\
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M+M[FKO)2?/C>%V]S5WDI/GQO"[>YJ[R4GSXWA=O<U=Y*3Y\;PNWN:N\E)\^
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MEK^<NTZ&DK5@#8.3Q%-^0+4<LQT7Z+;3G,NX_&=NN$7K#G6%<WVH.6\1Q_\
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M]M@+T?<_@NO:KY$#I9C&8F\ZQ4JV9#YQEA;EGVK#M5W-[!KR9MA8.8IQ!/8
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M?+NV+R&Y!B2W[Z:"7,6.Q3&Q1UE4O5>11QU?)LKY,A3*\G9PXX[SZ%6F+IR
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M)86W1,<@ZCI-6HLJB,7=RXDEUF](2_-_,J:JE:R%.PNH^:]IOV4O8N5P*B/
M+KT_GK\E7=CEGW!0W2[ZGS%F69[M_P"4!;\6YD;)C)34&8^W@.LKCLH2*>I;
MM*HC'8;Y1;HLKV,O>^4KLULA.2O5\OCJ[G017*PI,12QY! 3 B&G*=*FUVFK
ML?- *61V=!TD56?.XV+<KAU;2X)FQ(9?JWU\/3TQF>51M9*M:Q6M0PM+'!98
MAU"AE--H#.9?CRA-- #=NNL0LF!1]M1;FO@3Q&2^8J/;,Z0LWLEC2--(Z+,[
MC9O/67=9,8XZQGSYM,2K3/<*8F>F_(]KUBIH+)6E8MEF1J-R#<WC54S<KNJ
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M<I7!, I[?+W=N=PY>[;?UZ0VSI_$/9617JUR;0KG*J]3CXJ0W#T76XCXX_\
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M=JYM]E6\CW*]^7KY1]\<UL(=X_6-]XZ_,[WU+?W=15+.L&T7J-8LCM8*/O\
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M9>.6Q,-?E*,C++BO:KA)>M<<@VN^]"ABTZHHT5F._P!1H2PV&M<_H!,.8_\
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MDT-?5M@=:U)BIH6*;&JWYJ,#44BP=H+:0*"_H*P:HQ<97%6LG5J&HD>0%1C
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MS,J9;LL ]J(%NN%%W6CO$33RKEMR64G':>LV,;4$$V39G;&/IJX=Z0K!]O?
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M!QF#P(J1=X8KGO\ E2+F?:&0/4Y$4:8 NMK]$S0@Y_-"VO) I"PM>R<*O>1
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M?X<^?X<^?+Y";3XP#[SU,A]6;C%!?/@E!]+F)X$SJ@.^@ QL=G:CJ]U%-_\
M.K:__CHF-'EM<6/^X/7<7Q51@%1 JG $#.;4?6 I"K ^BZ3M9$-,V,@X=QDQ
M;*S"@JT04Z'R?0;1'GAO9#Z3F9%IRT[.:6-&?44Z*8\ISZ&1.F\9X^J*]0C(
M:P7(A;":A)@+&K\,E%$)_!9X1<4VBKL((/ J>'XJ[O8\I_SQJ T7[ "H-!-W
M0Z_&@HV>//$B:@@$KI_06MV #I/QI67#J5"!"T4'!3N* R6/, GA*&$R(&$T
M_P#*L5HH_,MX\?7E-^HO:'N"#W+2_.&L"P4ZGROGRA;4=  +Q<@M%=8\5 8
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M5\]8SY_ASY_ASY_ASY\'-!T*PJ#Z A^H<.'#AQ,D$&P8_"4J ZA@QZ-#4"(
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M]@?%55T)4_E=N._#&%TPHFLA9QC:#RBP>#&D -G_ -E?,CC#LZ.K.%98+<\
MPXCC?7%GE*!)Q/<C"'I79/Y&M\^/'=#; #8PN/#?-+C=<I%PEXP0@=<:%,"%
MBY;]R770%8/JL%6\1=0=+^9C S3Y^6_[^<US?,+[!'@\ !I*Z-VQ DN%)8[#
M=J!2F<R)"$=YH3L41^KMMZ.=,DU1O-NM6<'64K=S'_$9OW\\#&7<-!AE?2C0
M*X9,R%0#\ @[D<  R$"M/P'11\F<@[4Z-AKP:,@TBH*'3Z"%T7DS];(%?8UT
MK2=8*A V3"C(2$HI:#:Q;6MJD2D*5J>"70* X38PU];2D"UQVD47^E'0(6TD
M-T=1PHV9E<L'72!)"%  <F[502:?[ 8@_5[1>?P(V!B_T;8%F2%9;*SF?5I3
MKOE+I2]T+QA2W=0H/%2)EE<9*08#$8S"N"CE]P@X74:JU4MLB'>.XY=%4"O1
M@'P9S.W,,3 7KOD@I^V3"C-C/98?JS3G,"#@9<=(C$<"586F':-\R4=1+& 7
M'&5WE_#&]7M0T&X\(W.:=[\\(([DRA(:B>_"=G 9I$W1-I\@]2Y8$^0&A<<-
MDCL&S$\F--A?5TO/O.E1$VD>'HBTJAZ\*7*>?H_E7&;B=Z#@CBO\@@8U-X[=
M>JL<>Q>KM@S]8(;5:!#.-8G,_:]SA!'$L/.WY"^'-X;42GFZ(-1/L./NF3 Z
M^D,BAC>)UOC& U.L,FZ.X(<C=!#?C&%2<.*=!1Y9+;*A;<*8R1T$-V9N(!':
M,V#O.KSJX,]8' TM/,H4NH W/FZ"CRR,==&-/D<]:LL1+28OPL +MUJO<EUA
MNE:<FFO!HX"%Q%;^Q&J\Z':B8,5DQKT"C@L* PRIZ/=!!7$;2Q=A%P%P$:^#
M(/3>^C7<DI5EPHF+A+32<59^Z*) P@M PJE(LE",4'B:VE8*< 059JBI=VU!
MRKB4MZ5K,8C[>37=#SO3W#XN$U%+*Q?SK%EZY4#6LG2<5KX4/YG<?/V39J$^
MD&>$?)]J894RGQPJ<V(U^")NM! )-G0[6V#<Q<#I'@<,$J>O3ZX>X6+J!&,9
MTBE''CYA6.@I$BE WI T]A-DD^H IID3W /Q(?X&&<$=X*"6)2FB/4$YY:L5
M M"%.VC[^KOG]Y[<YU6R S#><5J[^F B@24ZS5TU+I%K?R7K!(8T73B1^4A@
MF54D7G5>+OB[E^%DBW#-61--:2,>Y(+9,(L]E-J$2)Q+,VU:BS$U6\<\W1A.
M6+-3 .*UB;8:7V) &8&$UJ.4,4/-/2K1^<%QA0@6W#A,##L2Q]@3W.]EEO+S
M.SPM")0$*8;[V0QZ/BTH#].E&0RCTD55R,\$UUO1+N,W6F4'4Y@.!S,$_P (
M*A!H?DF$#PQ@<\_>B/!SGI%[HTE%OP[_ "4R;1A$6J$==^=Q]&KWTK,]KI;R
M,$O"7X[S4@Q6A$6YYE%K=GY@^_X(#]"(]>3T-791;C<1WD\=1'3CC?LZO[M8
M6%!2<P#Y^S / /7A.O5_Y^_VP)G1@!%%$3B/$P     " '  \#Z/T@,@$K,H
MZ+"2F? @B((D1Z(_2?9^F%X.)QV>R^R@S]D^;__:  P# 0 "  ,    0$ @@
M@DD$DDD $ $ D@D@  @DD@@D$@DD $$  @  D DD$ DDDD@   DD@@D$ D$D
M @@$  $D@$@@              @    $            @  @   $
M                                      $@@@@ @     D$@@@
MDD$DD            @ $ D@@      D@DD    $D@$@$@           /^_F
M_P"X    !_\ ?_\ Y(   '__ /PNL           ) !! )     !    )
M  (  ((           !!!()!     ! ! )      ) ( !!!
M!          !          )                !)         !)
M (
M                                   (  )      ))( !     !(
M(            ! ) )         ) (    !(!)!((            !!!
M    !))         ((               )!         ()        !)
M
M                               (          (
M      ( !!(( )    )  !((!  !)! (() (         !!)(! !(     !)
M( !!   (!!)(!(             !          (          )(
M
M                                                           P
M  WM. :     !U_ZQ2      1LYP  0       @  L #+      !B2/@?
M   <D*   0       @ !GC[WL     !MAM?L     !L0MP  0      !?_\
M_P"3R7__ /\ _P#_ /\ @]'?_P#_ /\ _P#_ ,TCO_\ L       .2222222
M22222222222222222222222(     2 02  "2""""00"""2  00 2 200 0"
M02 0   "2"  2   2""22202 2""2  00022 2 2 000          002"""
M022"0" " " " "00                               "
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MOEJ -)9_B#__Q  I$0$  @$# P,$ @,        ! !$A,5&10<'P,&%Q$"!
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M]L D?@9T#[J]>O7KL)E&O0$S8!2+@8F+# ! %0(@(B().KAW^C5H99<,M 5
M$"UTF0T+4$(B39%#E*#(LJUE](H4V7173HUS*4>EAZAZ^@P24+/5KUZ]>O7K
MUZ]>O74" @ I!00 54 5C4)P[PTN41 &D=/HKP7@WQR6):KRDA6 *<!*K,-4
M\<%0(;!9>+//U=G4Z!II?I7:I:/V-AEC)9IPYF5B+O[XVG7Q@SZM>O7KUZ]>
MO7KUZY%/8VLJ*P@KH1#MSI*!#$ 0I+^BOJX=XT1J*$!(00 JM Q)8.,& 1;X
M$$!2R'CQ%$;8X*+:!LL^ZO7KUZZM,9F4]]+ 6M6/P/';?N8\LZM.)/JPE"UI
M)@AK! ZLA1 #"<VHD*=T85W<L2&(6CP3%-=-ZT14F+;6D?#Y^H45Q1Y405PS
M8I6J-&B.:0.6XPRD]NK0$%R!) "ZR':3* PB<HT6&ICSHQAAZA^FQ 5"E/JJ
M"6TMR5_H>BG!N"3U+BYID4C<J6T:0QS$9W%X0N/B6R@5=:\V 0,_<P,03GUN
MT,$ED4[=4+J-(!9'?+9*-%0)@5HA*RQ,<A@5)CS^S0S7>HRGU*"L?]E4:9.H
MM%%_0GD@56X"H1\8FVT3??M<FCN84:_$H8)&&C%]G?[J)*Z"_%L+5;@1G!2,
M8/'<HTJ[=Z.9>[(NS@NUWD<:7XH/QVW[J+NLU5^T=1*Q2*LPDP(  Q &I2P2
M5$4.'#$+T$<8X,$N82A%R6VJ &W ,59N/2T!)10>!$I>7M[MRGE1B(@Z+O 1
M3RN<P62+ %0!=91=]:K]>J@HIII[1,"GPBZW3F%8%)"X:* PQS-V9 (0_EY.
M"9$*+\Z&JS!#)"PO:->[0I%SDJ*L&-&!&S94CV!P@ E#9HXIUN5$.ECI+<ET
M7O7G,HNZR8OY]6B[K)B_F,;I@TQ#F@.XNM#9H<O-7:,VLL*( =%6+2J@007;
M*_0<T^,@&K@4%!P51KZ490ELC Y4H J$01$_&!HUC%V39+-SDEFYR2S<Y)9N
M<DLW.26;G)+-SDB 6%"6C@>Z#7O';8:SR@&V2/E:4)C7<()0">443^(1C!<P
M)+FZF,MZDCZ>F+G8G'?"MH.]J!+%FYR2S<Y)9N<DLW.26;G)+-SDEFYR2S<Y
M)9N<DLW.26;G)+-SDEFYR2S<Y)9N<DLW.26,404@506H%!H*&0!H;$@%;-#$
M,)ZMV@EF'Y4-@0Q%7Y?%5*P$F!2BE<9;I8;U_P BUMH.*%!=J($2+-SDEFYR
M2S<Y)9N<DLW.26;G)+-SDEFYR2S<Y)9N<DLW.26;G)+-SDEFYR2S<Y)D=[H2
M"ZH%147#)L*CD([Q43,P_F,JH)F!.*HS/ABJ%3!HT-(50Y]9B$Y18R)H7SX/
MN,U6N '( HEFYR2S<Y)9N<DLW.26;G)&-".Q^!O01O!:L/+0RK_G@8,&#!@P
M8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#
M!@P86O%O$#? 6 87_$'_Q  G$ $  @$#! ,  P$! 0     ! !$A$#%1,(&1
ML2! 06!A<?!0\?_:  @! 0 !/Q"7&DK#]&*N5".]QH/Q36E9A4NH-#55!*?%
M!<6DVZ>"Y8B!C.!OCHO\*W%]B0<Z.0!0M!71I@L8/^]T^\8MPC"K)%6;I<@K
M:((7#43I9S*:-%^> :" EJT&F@IF,#Z?$KOL; '!CY^(7 "!F2\"G-118P&2
M*>GD511N[$L)MM,=4C$]02+G)>MQ8B G-.]3%T=6G*X"K@8W@.,3XG+.7D /
M!@@\A7MV>%0QA>'NKNI=-75737$!.F>:<8FL*5PEK5=J)E5Q#4^-3ET(1P-*
M8*(2\K!\2E0;EC&R5'E5T,E7=PK79 )X[\:,?IJ9D$ -!9"\']6%0&.U%*?=
M']/3)FUF+</1Q@5\HNUH\<YSG9"5%4?#=DP)QA@;Q6[AE9#I7"4%Q40OG>[(
M>XP4@%4*)C[(H3("5&,(/H2 ]K91M8T[**T4:]"PNH^\K"7=E&JBL;U8"V(J
MU3#GSM/:)*N$TTHT55<ON47&LE+[D"DC*.R&EPH&>H#YN ND626V;7XKN%WX
MY[X(B!\L:,AA1UBT:7T[:P/P,6PU\T4#89\BH.)9P!LV2'"VJ!UX'EI.,HM,
MLH%R[7X\.*8['34"-&GJFR6GY:](V$P\^PD@E&)(71F,EJ,C*=,(!6)$A1;)
M%SNXL&: 4L#]YAZ!'-(Z30#.?,@4-U)OC@ 6J,T<'#;]0+.>*H SK!$(CA;!
M99A@6WC!"B/7M.*H#(5'<TYIKD4CF*%(%8W  SLK:-!KGODHQBGTY*G+IXT3
M))UZNAR)"T<@A%"2:H3BOXJP@-JF)1%^0/0)H^UL.Q \<H]0D; R6ID9!">]
M#TB&+\*_,LL=$!+5@YUKW!6N3%VX^&\4"%A@!0BYB,%^ZJ $E3'$1"K*QSA[
M&]V]F@I#[$>]J$IDZ#YC_ '6RFB:53KWIK&=*%R@[_SDH%FGC2<8AZ?6M=)N
MAY[H $EU)QVA#SD.+^D?ETFR5?X.A%VJ$D$Y5?G;2_I@9)D_ML09G\*Y4%W3
M*Q=HCQ;45@Q$W@J3N^:Z\AB&A)>(\86$ C9MQ\413"Z>A59.4%/853A/9T.L
M2TZZ$M8YW="G,9I+W'RL01T6^GXPF1B&"5+B+EOTG4&,'&HJLA38%GEQX]H4
M]%*3:(7.:T.WU4$&4PY7H65/#P_WZ(A90+.0C.DC-RL-L4"@ K*_"!,J-#W3
M ^+6$!XKI8.2.A(P1 1ACCDRQ$E]$GP5 $*,["P?7ADDSWO$O6O4M?NF3%A*
M$W5EJ0')<F1BT7>]M/-\U$9_M(60/'X.JO>$904[%@U2RB)0Q2BNX(#"CS)%
MKO*68&8PZRD8DG;D D@$M3HHH,G-L)HI;_7G9#WP\<+#%.(U0RK5YK8<L+V&
M_-2E7B\%AEKLG9CY;,@>O%, A1IITL2HF31NCVAT$K"QVH:^,B1![9Y3CIO:
MK1FC7=54G_HZ(_K 3B&06&:'=FU.-$L"T2NN2:M\0:5NO-&:C,4JUFCUC9Z0
MX=ZTZ&>4F4#:" .%"=M8!01Z<2>M(J ]#0+'CU0WBJ*Z_NM8YCQK(.4?G5P^
MJ2@S0'$%S(M'Z$?:9R'RT7@+8]^HRE!9)=>K()&8A%N.F"\6&B_(E917R*-8
M$P<7L\^DCVO8MPRA0#GFE<RU*LA5!K#/O2-/SR7$Y3.FP)(B7-?@V/X(7,8M
M:<9'_ ZETVE+Z;YSLS:82=76T%MU[%JL)Z'1Y8)Z66"SE:9+G,4:44^P1''"
M;.H40Q!Z8Q.M"$47FV]V]GV>RX%+;%7U, ^Y!C^U$$QU]2[;BD Y%;/WS\X]
MTB'I$@S&Z/K[IT@V<,TW0I+TNVDZ?)%9/(^A87'5?3A]T!T'I+GBZ5.>R=:%
MW8J08&+Z0 * -@ M5QRMK_JV_NF]V]G\.WNWLZH(]5#^HR/?+P?*]1L-3/M0
MWM3<,M*@P-F96@QCBSY'TN>R AZ'E(4 26*0B:IHU?4".792_P"T1>F]]0D!
M%35_E#B+J)54YDNM2@&R%2A:8X8:/_B&0Q!ZG8:>AF#>+:*]AQHB"= I[D/U
MW(<,OS0@Z5O:CFAH "6M=8R)LV'"(%#6',^@WX6SIH$RF@PVG1-B2\2IZ"@?
M?^N8ID!J>/B\;18$@>+M-:,U@'(UWABSVUA\@!Z:+:V"@AEJ:<H-VV>C[Q:6
M>]))6F74D^0+V%!OI.=T1P1;7*"\!@\PPR77 QD85$A"\KXH6 3S9M<828)(
MJ,0W^(;/L2,WMHM!YT)@7CH+:@Y(Q05AT\0]B6FWP.T=96++F*1S0@#_ $]G
M6?'.6VFI^24VP=4?]F/B+\3[MXVTSM"$[*1HN<1TM[M[.H%NP+ZRCHLP+A3P
MOJ[P-5,))DMGCLA+ /\ '= TP 3=RBX9L;OE(;TWME(]+0RH\0_KU-+7J%\J
M!;F9J'SNE-H<_P 2O73)N"(VLAA*]:3-\4LFP@RIR1]X+GGFI(@'E_H55F^X
M!!IQ/_1YBB_)SV]73T2_@2 7IHI07KJP20PWKKT*<_-,]FG-<VGPRSLF+(L\
M (,+U=H[W:V$@/['8N!XI_P;XM,9L4*U]L:C"\=IJWV=J80"M:_ZS)V:]JVG
MS&L+!>_I8S8QC<RAL!SI4->_RIWJKI'=?*B/A&N'G:<0A52,$DZK1K-+&G?U
ML.\$*5%5($:BF,&\\\:Q!!Q&14'/3*\%HQPJHIEAP,)3P,?O.O'^@5&2S0*J
MVQ<0]9C0E+56W-E_!28+;K[M3J21"/*9=H6:(''<TJW3WNWLZJ-3^<CQC<Q
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,)"U*"EA]+>[>R?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>business5a.jpg
<TEXT>
begin 644 business5a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1,B17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #$#@  9
M ,,.  !D    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$W.C4U.C0X  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !9     @$#  ,    8 0   P$#  $    &    !@$#  $    &
M%0$#  $    #     0($  $    > 0   @($  $   #\$0        @ "  (
M /_8_^  $$I&248  0$   $  0  _]L 0P (!@8'!@4(!P<'"0D("@P4#0P+
M"PP9$A,/%!T:'QX=&AP<("0N)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R
M_]L 0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\  $0@ 60$  P$B  (1 0,1 ?_$
M !\   $% 0$! 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%
M!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()
M"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$!
M 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P !
M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:
M)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ]_HHHH *
M*** ,7Q)<:G;VD#:6A:0S 28SPN#W"MCG'\)_#K65-JOB1WE2.SVQH2 _D$E
MP4;&#N!SN"Y.T 9[UU]!.!D]* .5M]4\2B6 2:?$82H+_(V\895(SG&2&+?\
M!/K52'7/%DK1S-I"I'Y4N8FB(9G 0H#\QV]7!ZCY>O(KL8[B&9BL<T;L.H5@
M2*DH Y&'5/$US?Z4DMBD$+S_ .DE$8YCVR<Y/W>0GR\GGKBJ7V_Q0)]70+.S
MQW:_9F$6(WCXRH!7(.,\YQGN*[NB@#C+/4/%S/>@6,4CKGR5GD*+]_')"<?+
MC@;L^HZ5K:A=:Q%J"1P0YBD2'!1=RJ_F'S<GTV8Q6[10!S]KJ.I-K\J36\YL
M'4&)@F-AXX8%<^O()]P.]6XU#Q-'J$B1V*-:)=$B4<LT6WA0O'.[G.>GN:ZJ
MB@#CFU?Q5/ILLD>F1I<1[2J;2IE/F 8!).T;<YZT^?5_%$AD2WTZ*-1 KB5X
MF)+<%@%S_O#&>V>>E==10!SVK7>M17?^A1NRA(C$HB!20EOG#D\KA?\ )Z5E
MGQ-KYB1H].C;S>8CY+_,=K'9C/LOS=/FZ<5VM% ',PZIXCGN_).G0P*S >8Z
M,PCZ\'D;N #D8 SBJT>M^)8M,A\W2Q+>F-6?$3*N[:^X=>S!1^-=?10!RL]]
MXD6Z&(XD2-U61Q"S(R;N2!NR.".YZ5)!K&JZAH@O(K/9(+E(PB@_.JL [#_9
M)#8]1@]ZZ:B@#EKF_P#$C:+*4LU%\MS;JOD+C=$Q0R$!C@%0SC)/\.?:F3:G
MXIM8)!_9\$SQ[%#;22<@DDX/..!QW.:ZRB@#C+G6O% =FCTT*T3'"+"S))\K
M87=D'.0!NP ,]ZG.OZ]+'</;:9$XAE,0(!;>P!/&#T^ZN>QW=A7644 <>FNZ
M]<O,4TXF.&Y=!Y:$'"NRX.3\V0 <C K>T.[OKW31+J-L+>X#LI4 @$ \-@],
MBM*B@ HHHH *#10: "BBB@ HHHH *RO$Y*^$]992018SD$=OD-:M9/BC_D4M
M9_Z\9_\ T6U %NUM((K-1##'$7C )10IZ>U<4;N[4D&YG!'!_>&N\M_^/:+_
M '!_*N'U2+R=4N4[;R1^//\ 6O#SI24833\CTLN:;E%D?VVZ_P"?F;_OX:/M
MMU_S\S?]_#5:16:,JC[&/1L9Q6)<:1?O+,8KUE#EB&\Q@1E .F<=<G\17A1G
M)[RL>I**6T3I/MMU_P _,W_?PT?;;K_GYF_[^&N;LM(U2WNEDFU1I(1*KF(@
MG@1A<9/^UEJ?_96HQI*8=3=)'W'!&Y0>W7/KVQT'%4V[_'^8K+^4Z'[;=?\
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M^%=)10!@:<NG7$Z-!8S(>!YC=N,X//\ LC\<5IG2[,NK>5RH ZGL"!_,U<
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M.G(XJ(:AX,CA/E:7.9&#+F4LVW*$ _>P2#CT_I1IV#YF9_PFGB?_ *#^I?\
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MX>>SOC$;AYFD8Q,2,<8YP*ZVBDY-[C44@HHHJ1A1110 4444 %%%% !1110
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M4D="(%A96B 'Z  $  4 %0 R "EA8W-P35-&5
M            ]M8  0    #3+6QC;7,
M                                  UD97-C   !(    $!C<')T   !
M8    #9W='!T   !F    !1C:&%D   !K    "QR6%E:   !V    !1B6%E:
M   ![    !1G6%E:   "     !1R5%)#   "%    "!G5%)#   "%    "!B
M5%)#   "%    "!C:')M   "-    "1D;6YD   "6    "1D;61D   "?
M "1M;'5C          $    ,96Y54P   "0    < $< 20!- %  ( !B '4
M:0!L '0 +0!I &X ( !S %( 1P!";6QU8P         !    #&5N55,    :
M    ' !0 '4 8@!L &D 8P @ $0 ;P!M &$ :0!N  !865H@        ]M8
M 0    #3+7-F,S(       $,0@  !=[___,E   'DP  _9#___NA___]H@
M ]P  ,!N6%E:(        &^@   X]0   Y!865H@        ))\   ^$  "V
MQ%A96B        !BEP  MX<  !C9<&%R80       P    )F9@  \J<   U9
M   3T   "EMC:')M       #     */7  !4?   3,T  )F:   F9P  #UQM
M;'5C          $    ,96Y54P    @    < $< 20!- %!M;'5C
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M&S!9)DTMXJQ>AKB;6F(3; O(\TCW8/&\R,:T&22QC,1<YJ*9S,<DV>[!G\
M  @1     +:.LJI3">)<Y@YDT2A;Q7SD4@O,%#)XII4CJ!+G23I+'>#F6\6.
M6J;&%/)LD3I.1.&%"ZS()*%5.@X'2<2)CTHYELP.9Y.@JQ-    $"(
M                               ! B      "U#7HV8*P
M                  "!$      'FJ;HF4(-+.(^DJ?050          &S73
M6F<I;2PD                "!$      'G>>B -(>(>DK!P'*@
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M=!, '$\\3T0!"#".D=D]?CT         !D;8N(W;EMB
M$"(  !89H0=QE(Y%M&2C$9Z( &'-.;!D*"J         $#,NY->SU=3
M            "!$  &%3)QT%%)HH97R=-$CT0 -*N*NC<<:XR\         =
MLV7Z'_0_DR8J)0                 @1  !JV8N.)6R?*82IL4:GGH@ :M\
MM;MP/HC9X  $8( B0B    N[+;!O=W?S$,-F-2=+D*&785TH)C@R&6H2)>1,
ME>)8D2AEMER'63);1VE\G84DI!33O,IF'3:H @1      !YWGH@ 8,T7LS5;
ME?>  $E-EZOY[BVG^R\,[O$S;77.6Z\9ICN9L8O5GW*CFO'K/>'Y!G[#\A
MR_M[ -O>OM!#') E2C%=('04HDR^S'!6CD4<R 66704DMXN JY89V$Z7Z6L3
M!S+0*\7<40RH 0(@      \[ST0 ,>Z]RS27B7I   2<SQA3*;'>UJKJK(FX
MPOUKGI4SE!4),RLTL_(5FN( &R'2&G]C.C-1C"!KP4TO@R 6,:_F>2UR8-DC
M%YB$NHM\S$39CXK!;1;Y4"8+H-PP    "!$      'G>>B !3;;6>>OSUZP
M        &X'8&@,N;<P(2AU'(',[RE$Z=1,%..)4S@=AP.\ZP<26)HQ\9#.\
M     @1      !YWGH@ #2GBCHVDVFO        $(1W'[(Y[N;)K,
M          ! B      #4 U^/1PN0                             $"
M(      /-0R\;@DX#R=N=#XYW>A        'HK;ZKW9LMR
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M',LXNP[R3.\[CK*83AU%5*81*T6L5LB2Y,@ZB3)@JH  ! B      #0 W_
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MK;TU AD/?LRK'_B]W#F!?8B,"@S>R2*3=)T:.-W7(#=<@-UR W7(#=<@-UR
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MF0,\XFP>*F68)W%W[L:% 8@I3]#;GRETER'G O\ ;EC;/$8'$A4:9#V(Y/\
M6%(>::_?+''/%%NW;8_ZO#C:_P!_;GRET)(^I'_6@*'\_%5++].^W?MSY2ZY
M04;EEP,;7 QM<#&UP,;7 QM<#&UP,;7 QM<#&UP,;7 QM<#&UP,;7 QM<#&U
MP,;7 QM<#&UP,;7 QM<#&T'$(!F_\R3&\8Z"56)"8WDF_B!1K+)&ICD<*L9&
MTG4K]NASS-S.MN?*75U-&#1SSP;7/!M<\&USP;7/!M<\&USP;7/!M<\&USP;
M7/!M<\&USP;7/!M<\&USP;7/!M<\&USP;7/!M<\&TV7LY;_RV\\"N%?6#5U?
M5B7='"PD&._]>QQ'%XZ8P:Y / -]INEMSY2ZRQ#R3OU,,+J9I)V22_E@803]
MO6BAAL'90TH7!F(_+)#BI&)(O,&,*/<>(PDH99"@.0N4;<^4NL]0\+WZ@%'U
M!GH:DN0 R%F$@>,XU/')$8,F=WR0>=.<U9%+&\<?VDZ6 *\\$>>OM,8\'##Q
M!TR';&11#*['2?,\IXWM>VP -WCV3V;)AI@/-O1$U;''S[9(%@7>;)5R#NYK
M8:_PV%AXG<_:MBJ.S44Q9+8Z*H5>59C@PZ9LW[S.=I9N4-A)$6@_9"* 3':(
MF[<G(O;4[S$N7DWTMN?*76>(>,?^KE;T[=2='\A\&,2EL=AFRY.SAFL7Q![J
MI<\5OHAU/).SFL?VC,3I,=.]COX_K^2/I$Q_6$H>89Z22+BY2CA%A2<D2B(M
M)LWA#)CGQ09Z<J&'OR0N+"!@EI @;-1IK\2S:-8\Q:(M]<ADVK>$L$F:,*&H
MN_\ '4;R8F0+<OGP,>E8%%1D>J\,&V,KZ[%NU<8F+]P7BHUPW2@D>;&+:[&X
M(DH".(89 &.>#J%CUE0L.& U$X>*38(:V"XLT(2Q3;&@+<U0N(#!+OZ6W/E+
MK*4?/!?LX00=H!]:0H"]%Q6/AF8,&,C@QOK&#-2V>NH>H<;:[A[(YP:,>RQZ
M*@HJA^L!0_\ '0O(?9I4TFA>^+*8S%8:5-F@*\G,.$3D(0>EI41Q2M;E!=1V
M"+/F0-Q,Y(@R-OFKN'OI@V0A+=%-J&$/6RKV%.B.><G..VYN(E)";-F7Y9G(
MUI(6C2KHQ)L%BT[=X"&Y1PX.CI87S)1@M);I?:VY\I=7B7GM.Z]OJ0I'R@O1
M5!!Q:[5K=2S5M;/-LV4S500<6\.-K^W#_4>0AYUVC3+&R26--1S%E9 8-;**
M(I*V3;MT</*2\"J""]6QQM>Z25[W23RI1!%6UV3.^'DI4WB@IN0LFG:WVMN?
M*7Z/X\6L^X^;KCYNN/FZX^;KCYNN/FZX^;KCYNN/FZX^;KCYNN/FZX^;KCYN
MN/FZX^;KCYNN/FZX^;H,VR9B_P"IM37YF7.G!O?C/(/D1S$_\7M\,TEVTFW9
MZTPUQ;MT6C?IVI6[I%A[D3KW(G7N1.O<B=>Y$Z]R)U[D3KW(G7N1.O<B=>Y$
MZ]R)U[D3KW(G7N1.O<B=>Y$Z]R)UV9TGI&<?U9S\]?IVC1OKM9_2[*HWP#.L
MCV$_$$G4V8#R*6Q0V;!'8@AQA')7<FT4V$-:M@\E1+/4MB@5B2DZ'/6)#8R:
M8=_-$!.=YTP3Q!25 XY0V4P<X*SMBF+<SUDN@WV(&]I4V2BJJ<DS<&Z1G8YR
MZ93=+-LKL4 D3D!\BP)Q.2RR2L+3.2(Y1:<.3SOZ3&;$@Y@?,),*B[^9F"HM
M+9RBH=&5S(@3J<_/7Z;(&7,0*U^^W0((=GS$UU=&8G134S5@B6TW9DV4CYE(
M+#8 4G#,'KXJ;B!. 3,,)CVGY.1,VB$FR9L-23ES(I''B<5,]>SH-]!K/J[B
MF:Q#+5P7U3G6HL@XQ@R&#<5%& YCE D'*. =NF:8P5@,(IP 0U;N->L'SM:%
MH/+2&*6>WA<=)B5VD48LV[_7HYZL.@XT:/\ \8QM-G>%H8#Y'&B!@R+A[$6]
M2@J+*R4%'-S!,(Y='0<-L)?X ,6X5A$_;S/TD!8YMDY!P8B-P"1]%A[)&#K;
MB,=NTJ<_/7Z+HX.$"C/(<3Z!56B!><3F $X<YV+$&HT]MJ(O$'>X):\A>OIQ
MA"A#[< (P)*;&U_>.-=H@,-LVVY&%Y,\VB!&E9LJ%=23I?\ ^:[&>SP7K=1\
M(/MY%(WQ68$4XD1"$GH B2DA8R >R0L/>S^3/@N7)Y24:S.3$'@28G%Q2(.2
M2F6TZECB\$1G$B<BE)B:]<_GZ^3)!::+&<I_*B%IK(B3P#-G9;POC<<E$:,,
MR @J9D+MO 3TGE@XVW;K-C^O<N\HO)#+=HRDAHPZ RZ4E#WT7X,KR/NDBTPM
MD?!@5!\MS.U.?GK]=P#?:MF?0$,LR99)+!%+KFU;*X),VB&"J22^#IDS?8>D
M:]S2,C&9-RQ9/:LV;6Q5&CEU7+)F]3P;-TJ49M%FV8<0JGB/88.TA8U"O*2M
MDH-'+4J.'KKTX!A7E6;-K8^F;V1<,63O/TZ%8-T$KJ-&BR5Q8V[>S%E9W]:<
M_/7Z]IH;=I/_ *&G!ONFS/ZVX"Z$1V>CVBM++V;N$7;?K+=<Q"<+?C_JJOQ_
MU57X_P"JJ_'_ %57X_ZJK\?]55^/^JJ_'_55?C_JJOQ_U57X_P"JJ_'_ %57
MX_ZJK\?]55^/^JJ_'_551K4T#B)7^M>ULK+1N/.+XXXX8_W?_\0 3Q$  0,!
M P0-"00&!PD      0(#! 4 $1(&$Q0A%A<B,4%15%61DI/1TS)04F%Q@:&B
MT@<5($ C)$)B<L$00X*QL_#Q,#-$8'!S@(.$_]H " $# 0$_ ?\ R7@Y.9-2
MX4.4*-"ND16'O(.O.-)43Y?";[;%,F^9H/9J^JVQ3)OF:#V:OJML4R;YF@]F
MKZK;%,F^9H/9J^JVQ3)OF:#V:OJML4R;YF@]FKZK;%,F^9H/9J^JVQ3)OF:#
MV:OJML4R;YF@]FKZK;%,F^9H/9J^JVQ3)OF:#V:OJML4R;YF@]FKZK;%,F^9
MH/9J^JVQ3)OF:#V:OJML4R;YF@]FKZK;%,F^9H/9J^JVQ3)OF:#V:OJML4R;
MYF@]FKZK;%,F^9H/9J^JVQ3)OF:#V:OJML4R;YF@]FKZK;%,F^9H/9J^JVQ3
M)OF:#V:OJME[&I\*MIB4^*S$;9AL%Q+(("G7,3A4;R=>!2![O.V14G2LF:6J
M^]3+:XJO5H[JD)'9X/S&5TK2\I*LZ%8DB4IE'J2P U=[B@^=OLQDYRC3(Q_X
M:=B2.'#(:23[L3?2?PU>MPZ(AIR:F5FW58,XQ'6\ALWI SRDZF\14 C%Y1U"
MS^55)C23&=5*3@>;8<DZ'(T-IYW#A0Y)P8 =T-8O3Z[2\JZ/#DO1GER3HRVV
MY4AJ*\Y$B+<NPID/I3@;.L7\1U&ZS%8@2:C)I;3ITR*TR^M!3<E;3Z$.(6TK
M><&%Q&*[R2H6C5>#,G3:='<*Y-/S>DW).;2IP$A"5[RE)N(6!Y*AA.NTS*JF
M0I<J$XW4''80092HT)Z0RR'&PZE3BVP<*<!OO(X%<5FJE >:9?;EL%N0TE]D
MEQ*"MI9PA82LA5V(X=[4K<G7JMI#&>T?/-9_#BS.<3G</I8+\5WKNLN;%0IU
MO/M*>90IQ;"7$%X)2DJ/Z/%BWAPVIM8A52,Q)8<#>?9SX8>6TF0AO$4XG&TN
M+PC<DWWD77&^VDQLVV]GV<TZI*&W<XC-N*6;D)0N_"HJ.H &\FPD1U/*CI?:
M4^@8E,AQ!<2GC*+\0'M%DS8:UI;1*CJ<65)2A+S96I2#<L!(5>2DZE ;QLJ0
MPEU#"GFDO."]#1<2'%CC2@G$?<+&3&2\(ZGV0^K6&2X@.D>I%^+X?@<6&FW'
M#J#:%N$\00DJO^%I+QD2'WU>4^\Z\KVN+4L_$^=OLNDX9]3B'^OB-O)'_8=N
M4>AT?@J=.%391'7*EQ6PZ'7##>+#KH2E02V74[M*,92LA-UY2."U=HDM&3D^
M*R_/K$R1)AN8GUAQXH;D1MPA*0A"4MMM8E84C$K$M5Y-JV[49L]J _1JJY18
M:FUNZ'':6Y4I#6%;:5J<>;P0T+ )"25NE&O#N<-5H]5?EUM/W?5E/5&6P]!$
M-UENCN-(S>:-49+@QNH _2XT*.,$@C?,BAUIVM52J0F]'J,9ND:"\NY$&4#3
MT1ZA&UZBTD^3>-2D) XQDU1)%'K55"D/+8<B4\F:YK3+F%"US' H\)>6K5P;
MUE4:LRJ]E$MB6NF0Y>@)SQAM2-+2(F;6J.MQ8S2F=TC$$DXE>JR<F66J]1V=
M#5)IE-HJFT//I#C>EIE8TES]DN'&M>'#A23>D @71:!/%4#<R-4A,%77,%6B
MLP5,J:SA<;<7.<7I> IN2Y%P$7;POU&!39D>L.:-1I&:6Y4ER)=1B11(:SS;
MH28E19?+L@+4H(0TZSJ2K?!O4*31I26Z#'30)%.J$.:W*GU=XMH:5"2MQ3S:
MEAPN.%]HAHQEH"6[M7E*M282Y-:<I,=UA^C4.4]58CC2PZT'9R,4&.5(O;_4
MG')#R ->(#>N%H5%GH<ID;[F?CU>'5=*J%?4MLLR8R77%O7/!S.R-);4E&CK
M0$INNX5718"YL:H,PZ(\Y4GJ_)5%K:5-I:B!J8@JQ/9P.LEI(4,TE!2YG N_
M$ +2Z!/759R9L6HR'9<]EZ)4X#$!>:9!1A_67UAZ'F,)O:;!0L:N$$_=TMC*
M/.Q:3(E%RJ(>D2ZE%B+:0T $N28=10^)#5P&<;CJ:4G%JXOP932=$R?J[_"(
M+K:?XG_T(_Q+_=YWR"DZ-E/!!-R9*7XI]><:44#M$(_VQ (((!!%Q!U@@ZB#
MZK1H<2$@MPXL>*VI6)2([*&4J5Z1"  3ZS_0S'8C)4B.RTPA:U.J2TA+:5.+
M-ZW%!( *UG6I6^>'\7VC2<QDX6;[E2YC#0]:6\3RA[-R/.]'DF'5J;)!NS,V
M,N_B =3B^%]COZM[@]G!^6^U.3JI$,'E,I0ZC39^+GG?>UV1]IM80A"-#@'
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M:PK'+J=UG_!MM85CEU.ZS_@VVL*QRZG=9_P;;6%8Y=3NL_X-MK"L<NIW6?\
M!MM85CEU.ZS_ (-MK"L<NIW6?\&VUA6.74[K/^#;:PK'+J=UG_!MM85CEU.Z
MS_@VVL*QRZG=9_P;;6%8Y=3NL_X-MK"L<NIW6?\ !MM85CEU.ZS_ (-MK"L<
MNIW6?\&VU?6>74[K/^#:9&,.7)B*6AU49YQA2V[\"E-J*%%.( W7@[X'GC(2
M3I.3%/UWF.9$97_K=44CLUH_*NN!EIUTZ@TVXX3Q!"2HGX6?=+[[SZO*>=<=
M5[7%E9^)\\?9?)QTVHQ"=;$MMY*>)+[6%1ZS0_*Y42=$R>J[W#H3C2?XI%S
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M@^*/J2V0?%'U);(/BCZDMD'Q1]26J. LBB(B9C\"=Q%7OW +"0B>,)#^6/\
MM^YU,NV:'P"2KZ5P3_1>_<<LK[1> Q_-</L&:-@1KP"BJMF9+CND70JJ)O#
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MQM]JQV R[1JVC -=VP#>HR$=WCMB=-?'AU>OA\6BO9T[A"<?44FQM\(ZR@5
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M9L2DJ\O?3KN=*#C0T2UBR/HG'@2]=A1X3'"T5U*0A(0M24K%2E /@(+6$0
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MAMG%VUWBQ6/?<@F4J=]]VGN6ON5JR"*TM0)"73=[EQS<]Q)WX9QA2T5I B.
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M1&YBL5<PX]SY/=![2\Z9@=GNNP_8.V9M5[N3QV0]<7,VK(4G5^X18OTTT;J
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ML%<WQJ7:6<'=H(5L&E)VD:M.Q79&R'9&5(Z^4O>B=K@- , 2NX[(M9">L)]
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M=.U:;70SI-:E9"O5*6L4GI@91(1"PB%_@X@1T#PF/)X>7PF8\-/"9CY?QO\
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M*,73/HKNNG&;;MF;WJY=1* R1VZUE]GP4O)HH>YZM9*P$MO313R-C+=\&/#
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MM)=-6)E,5HZ8IV$SN1/K'NTDO#7CG(J]EM;.9"O@IP4@J36=C&Y=5RPNP<>
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M,"I45M8:;+=%ERZ=OF5F)5C>=<]R]>LI+#%6R@(P89"DN^X!;CIL3UIJQVA
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M@PEG"DND-&J<ARU^_P#60Z 8TXW ]9I-&769$'4@&#FA^+8=R-@Y;1<TH@X
M63RM]:';X,U+@X8:5T/; 0<VL0VSCQ(^AGWE"T H_"Y8DT2IT==@_EF+2*FQ
M3Z6<^CP0/GA.%FAX@J#0EXG=U.':<^1?AA*>@4O)SZ)T>UF\",: <TCX"R&W
M6TB8[X(Y+J0JS7(5&(&4<;_Y: IC?.B<=U_%"'"'*9O#N(+,#!"D>R,]Z;(\
M$#-5O5GW]R4B;3(LRIG>9* 9P[;3Z.GAE=[2.2MLV0O_ &C$8\K, CM.?-7%
M6XW&0J)4@/(,>J,"QY[WRZ]KD<3DS[\C8*<$]*@FW(T$&]+FPY -HQ:A0HN
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MYUXS_]H # ,!  (  P   !      "2 02 22 0"" 2  0" 200""2 20
M       "" 0220" "000020222""2 " 0 20          2 2""220"200 2
M220  200""022"
M     "2                                     "!K;;;;;;;;;;;4
M                         <          #@
M    0 (Z>X(.*X  \"""2"2"20 2 "0 2          < 1Z^&)'47( "  "2
M2"02""0  "0"          8  8   58  !@        "
M *@          @                     "0   422222222223@
M                    I)))))))))4@                    " 0 0 "
M         <@                     2220 !   ![,    ,""220 200"2
M" " 00          !@  H 0*L  , " 202" 22   2 "               ;
MXT0@  $ ""2   2 2020               8         0 0 2002 "2""
M              <DDDDDDDDF
M                             "0 <DDDDDDDDF@
M        "               2"02" "0"20          """  2 -U6KY1
M  0" 20 02 """          ""2  ,@;,M97A@3 "   20""2 20" 0
M   """  ! "      1@  22 0"2"02 0            "   @       $
M                       ""  $DDDDDDDD
M                                  #_Q  K$0$!  (! @4$ @$%
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MC,!A>(T.<N1W8VF95^"FC9(X#0E@430+G?U!P3K"FG&VR ,L*/7H_F#,@S%
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M6(,-]XOYBSW]=$DD(WF@>)I37D7'''''''''''''''$-4CE*C4:O?_6__\0
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M;0S\^+Y:<@E<# \^N)=,#BP <O 5=P$9< #!+D"#?*&/^,C#Q4WLD_2MLN&
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D]%.K$1>HGRD$4B=C3+7NG[-DMF[AJ7)*ABKG5@'OF[M]D__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>business6a.jpg
<TEXT>
begin 644 business6a.jpg
M_]C_X  02D9)1@ ! 0( 5@!6  #_X1<R17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #?#0  *0
M -\-   I    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$W.C4W.C P  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !Q     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M(Y.[E!U]: *#MI".$>W@5FZ P#G]/<?G22'24MW9K.$J%)9?)'0$CG\C4]W
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M@O=>(0&%%)VEB')QZ]^W3WH_MA?R?B/^SW_-^!ZM5:ZL8;P@R[N!C@XR/?\
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M<&%C:V5T(&5N9#TB=R(_/O_B K!)0T-?4%)/1DE,10 ! 0   J!L8VUS!#
M &UN=')21T(@6%E:( ?H  0 !0 5 #( *6%C<W!-4T94
M                  #VU@ !     -,M;&-M<P
M                                        #61E<V,   $@    0&-P
M<G0   %@    -G=T<'0   &8    %&-H860   &L    +')865H   '8
M%&)865H   'L    %&=865H   (     %')44D,   (4    (&=44D,   (4
M    (&)44D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0
M  )\    )&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @
M &( =0!I &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y5
M4P   !H    < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B
M  #VU@ !     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'_
M__VB   #W   P&Y865H@        ;Z   #CU   #D%A96B         DGP
M#X0  +;$6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #R
MIP  #5D  !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G
M   /7&UL=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
M         0    QE;E53    "    !P <P!2 $< 0O_; $,  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_" !$( D8%) ,!
M$0 "$0$#$0'_Q  >  $  @(# 0$!            !P@%!@($"0,!"O_$ !T!
M 0 !!0$! 0             % 0(#! 8'" G_V@ , P$  A #$    ??P
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M]?R#BBA-!?X\P#YDIGHH3V6D/*8\I"WQ;0\UBQ)9DKL0D>Q9<D   X',
MI<6B*+D@EC2DY?,HT;2;H6=,8>=I^&H%$3^EPJN:$7E([*"DA%]2FY<\I2;8
M>>!G3T9+!GX4<.\2*2D8PID7T*)F[%F"LA-Y68ML4O+VF]E$#$%]#4B+2R)%
MYI)'9)A\#'&#+(%$"UQ#!:LH&7")9*:EPS[D+E9B8#^>8]IR]I6TPY= %#"\
MA1LO,4\+9%<C63N%IR@Q;0F I:75*FD_%0R^!2HVLS9)948Z9/Q]S7SB=8\:
MB,3^I U$H^227'*G%FCOE/#RL+''L84#+"'AD>AI>,@<M44'+U&X%&3\+"'
MB(VHW U4WT@LN>   <#F           8<R!V      8<[AW
M          #7#8P                 :T9T[    !KYL  , 9L^@
M   !P.8
M                            .!S                   !K1LH->-A
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MR*0F.+V'F&69,4?$[1@2?2B)ZYGD:=,LB3B5^,N241P= U4GDJ63P7L
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M(I*FGH45#);*CD]$F&JF&+2%(B4S<P<3@8TG$O       #@<P
M                =4[0                                ,.94Y@
M_#'&2 .J=H             X',
M      $-74E:UWU0                                      !P.8
M        !$Q@2=P 8LR@ .H<CL@^9'I^$CD<$C@    C D\
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MM78-]W^4           X',             ZVCF@+XV]:EGZ0\_VWT?GP
M                     !2++;;S%7850              !A.4DX/\ DSU"
M=?KORO+='H                      <#F             :'X_U=,_RS^D
M9V^P?*[)?=?BX                         I%EMMYBKL*H
M    A'Y.].K+\">W6H_1/P>8/IGSL                     #@<P
M      #\HJ7^;_T!:+] O#,G/Z0                         I%EMMYBK
ML*H               ^.KDJ/^;/T';G]*?GOZY[
M .!S             !5W\_/<[-_?'B/WV\0
MI%EMMYBKL*H               %5_P \?>+4?H=X.
M   .!S             !5[\_O<[,_>GB78W<(
M  I%EMMYBKL*H               %5_SQ]XM1^AW@X
M    X',             %8/@'W*ROW=XIVI#
M  *19;;>8J["J               !5?\\?>+4?H=X.
M    .!S             !6'X#]PLE]U>+]R2UP !P-9Q2$?ZL_JV*1R-V'8\
ML;O.Q"[%DTN=:                  "D66VWF*NPJ@               57
M_/'WBU'Z'>#@ #'VY8VU>AC[5Z+%X]O[78MDRQDB;?/[OGA^S6P
M      <#F             "L7P+[A9#[F\8[LIK #4+-RLD=Z'5GG_9(?B>]
MZEF7XT8''NZ[AD.W6FY;,%,DCQ-DYGS.U\WY1OVS"                 4B
MRVV\Q5V%4               "J_YX^\6H_0[P<#\(IQ3-6XCU"L?/^PZUJS?
M[3'UZ5UK#OZ/KSG.W-L>>+F*0XFR\SYC;B=\EDG;YX             #@<P
M            5D^!_;K&_</C?>E]4?,J%I=S"L?W<W9N>R>WS4=VZ.O:4E^X
M-OL[6KF-BG1U>DK9%^@5>A?2-;TNDRE,UMYKR_T5ZKY^G.2X@
M    "D66VWF*NPJ@               57_/'WBU'Z'>#C#TRT6C?2^O@FIIV
M>7UO8YV/-3:Q6A+_ &QY_ON:&R[FLUIZLD;W]7(7TG38_JLI;L6WF/,O1CK/
MGR=Y+AP            .!S             !67X*]ML5]N>.Y"9U!6Q)8''N
M831V:_PO9:A&]#U-*2ZNEO[/BOYVY>AO1W"7A<[.\G]Y2#[N*9\Y.6]ATJ-[
M"2\<E>^>\G](>H\"WS/$               4BRVV\Q5V%4
M "J_YX^\6H_0[P?@5+2VT6VPI#=)"</V&+T)?5]3=Y:&YF,>;G7)W-S1XS,)
MVISE>]*0.R62OFKRWL.G1O82ACW[YSWE'H]T_@N\YXH           #@<P
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M^EZG:O2;<K+QM,-B.V68Y#U2D>2SM^/SPUYJO>M/>I.WS=GMB$
M X',             %:OA'VKJ?;/C^ V)VNO >G1_P ;&Q#U7.0ITO+]/4WN
M.#-RK3]I7KW4R.KM3]SV[ZF^9;?WU]NF_5]O\?3[=VW-*O=^"+9;D/6R<X*P
M>32PU*_8RE:              4BRVV\Q5V%4               =2M*<?GK[
MOC/O#A(!X#N].Y^#@OK^;B^:@OG'27SI7[*%W4OMR.MLV:Y60]._-]CK8-ZF
M/:=OVO2,>V;6G7;+K:=+<=ZSSG!3G?JXNCNU?<           X',
M     %9OA7VC6OL?S6#(OU6I$-J_2WC]"D-##:<CHUN[\;J[+36RU*?6E,7O
M:72NM] /.):]_$Y=7QR--?0>ZSW9V8W>LC_8C.O-</ZG3G 27=B
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M!4DJ_2LU7'T*0DGT+@_2/J_+]VK:              *19;;>8J["J
M       -?NI7[9M\]N6]$C[A.@SG2QOU@H70;\FK;NKKE7WT]S]LS?6M-8KM
M;173R-CI;&##;VEZ">7S=\^(I\;<O2MV<&D:]RTW7/T/?EOT;SCTMZ7SG-@
M          X',            X%1=G'4W5D82^$O=("^J_/9 GKYGY73B5DP
M]:X577Y&-^-:=M7\JUC!*23I4_+G _=S4]3/'-^28V[OXLN7Q;/1;,4[>]3K
MT^:]'/6?%;&[L.              *19;;>8J["J             !B5*?[=G
MGM&3D9\SZ''<UQUC8J9R?-1^@TV,,KA37Y.,^%]G>LR?)=@<,E(FG15\U<GG
MU/3'R'>W;2KD\6;8-?9X6[40;V_4'U64]3O5O#YASZ(           X',
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M;.'%;&/E@V,;HS/PN=VR_&WY9NAXGTZ[^+N_T7(           #@<P
M    "/S^8+)2>,E(VR62Y(Q-D*W1S7%M^G*>FV6ZM<1(44\T['"X;^)^'X?$
MZE]=/;O4NNZ]:YJF'IR,9T;J]R-E]+;VQV4QE<OPS8_;28\_N_UT*
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M/5K9')4KUE]KY/C?=/N>*RP              *19;;>8J["J
M!_+A6FDZUV[[.>0I&)W'-@EK<TH3P;$614O_ $=X[MC5Q%*^?>COUJX'I,?@
MS=57HWTZZO79.G6_K6W8^N3%TRQ3/Z6QPDGJ%)+)4?9;>SH>$]GNKY?F
M       #@<P    #J'3!^    '\W%::'JWR/M9]VVM*,J4M3(1<)74@./W_2
M?%N>GS'YT14KH' ]#A:9.I;=T*.DKTKWQKDZ=,F.78QDQ]N;7=S6CK:V\9&3
M?>)IU8N]_HO$>H<CS_Z              "D66VWF*NPJ@      8HXGX
M?(_EH4SFO=)>ULYK9T-74LE(Q5?K;H=C9/\ H?Q9IM/A51C3W*M\M,]6$D\;
M97H'2NN^5;^DR8VEV,9,?;GUB3CXWPSORUMSM4OL'K17H[Z;YW?O8C0
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M8BO+M8"<CY2Y6^Z//9(OZ*%L'V/(YN5TN_N8-]V\$HY+=UM258V.E0
M    !2++;;S%7850           !U#^0123\&3+TE8TV-#/7ZGUV-;(Y=6*=
M;?O'SDO?+\S/H2N'Z*^.87H=';<FG+7$=#K5+^JOZ];NHR8JS+A;,N#MS:TV
M-%NSQ=EV]>Z&'L=PN2QL9MZ?,\[._7\UWI+4^V]K[MOZ\O[&+>[4F6-FI4
M      <#F           ?S4*0-AR2+?L^J/Y#?3V)D-3Q$_77Y8D'<CX^CI2
M?<.U-UV#.8,]K_/^PR.#)A*7XQ=\E?A=?TU^)MS8+'FP>//K5-C1K\^E3&AJ
M._BP,;(7,X&OTKK\:Z\AZNEN\;DX5MQDOJ]OKXF7O2^:N_GQ;]0
M !2++;;S%7850            /Y0EO3PYM]KNPS>Z>U#]>MF];6G'4?*6ZU]
MR^WY\^X0']W^6]7)BWNFO)'$]'T%WSK7X5OZ-+\1;FP>/-@L>?5J[&D9,NE3
M<;I&38S</LVSXET<VOCLFO(."/D6(S=S%37I?6[78P\T>H\Q>^ZS9P
M #@<P          #R14\>:5E_'LW/^&_:HZG8"@7VQX]VKJ:GI[]D,&Q*-^M
MMNKN6T\V[/3*[^HVR6]UC=@R:OSK=CV7"V9<#CSZ]3/JF2[1)Z)T>)Z;6M:8
M]9.?X[5YJLBZG-N1GZS2$C5/M8JOLY'RM#4N#QTG:#V?SR]<OH2%2H
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M@M1YSLM,;MO(/GMV[[4OIV_DMH[7P*Y6Y($N1<2'$[.RZF38>ECKKXP
M      I%EMMYBKL*H             \;2E^6NR8)*(XKJ(2F.,W*F.6=?/T[
ML-^_S\]NI]]^^-35IY[!>>]=U;<G4OOZ-<F)KDBJR6W&[2PK+K%<NJ]!#Z'S
MW9X.ZZ[W/\_F/4H?T-Z;S2?[:]8J_;D@2Y&5:2!H9=MQWR5+:=NL=0
M !P.8           /P\U:H%^>.\BNDY"?ML35G<YN5KK)+T]BT7,[\X0>_K$
MAH_MU>W'274IEQ]<F/KDBZV6V:[2P[-KK/HW0PF@<[W&PM2[,9$;%ZYP?IC(
M\OMU  Z5$;J_:MNSJ[0           "D66VWF*NPJ@            #YGE56
ME:&Q#D;U>*U=^KV_S5G[L&U6XKB?G_[-'?VQYEOD=G^V+/V-#?Z=,^/NOQS)
M%U)79ZZ>&9M99]-Z2!CWFN\DG%&6PMCY0]9\Q]),\1DP =4CVCD;;5G0
M    <#F            "MGSKWM$I"E*O5Y:*-F&K]MP=U^.Z_P!!8/5ZJO65
MQN5KLAI]#+3O1<QC[<T6TE=@D87$,N!U]_4.@AH^Y;T&YD/S.Q=YI74[;RBW
MU+<72ZN6*9FS)&;K=K@             4BRVV\Q5V%4              5.J
MH+;M52YOTN%=[G8:SQ?HWPW77F^(>]TG[+\YZM6-OKKDEI=#*[T3,8VF>*Z2
MF=F.>Q=N;!6[6G2>KIG+=[>V'Y3L>GPM\.F\VLK;73*9JZ8)RR>:#VN["
M       !P.8            (G^=.^B*0P4Q]\Y.HO,>DUODN6N3Q'46OCH[I
M+NLNZ-;NI=DQ=UVB3T+F8J:C26P\]'>Q&+-@]FFLQG3S'&Z,ZRNC*OIGEWH/
MFBJT:W0T]UNIQN._TLD>!F;+H              4BRVV\Q5V%4
M    "MU7GY9OU,YOT6O>_P Y?OA9^U7Q1W>A?9?G'4K=TJW]*[+BKVD3T+E8
MR8C"9P=R!F\,OU_+?K.CTEH(WG=TZK!8/T'R>[E,5,-3K*S:_0=ZFMZE27G^
M_7X           .!S            !$_SIWW9W\,8>_<-0W!+5VY/U&*XO7]
M#HB#ZE;^I2[J77]&N7H5OQ2[1NPY?N<QUFA:TQ@K=W'6[DIZT7/6]'YWT?A/
MGAZ."(OT#$TRR-O<AZ8R_EL]9HX              4BRVV\Q5V%4
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M6*CH?M=2W/N?/Z9<M]"Z-$]]FK]&V'1^*>M?0^,;9=A            X',
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M;T>LFZ6\[]>^I\"LQN<Z                *19;;>8J["J
M   .!5VY7W\^/=X%^Y>.P_)S^6C,7=QX,?;?][,O[LT^^S?PZC3W'HN+AK5Z
MFK?(_0.*Q[]JYWR3UZZ7P^8LT<             .!S            !$_P Z
M=]V=_#)_OG#@##%#Z[%;[-O(ZDK@M26[6#9^-^/)[<9EMJ+B_!.5ZY[UG1(W
MLK1ROG_HE/>37.WN5^H                !2++;;S%7850
M   !4;\^/=J^_H/XI#=NQF]62P>M*]O!GX9<&8VHKK9M>&]#L*^<]ZWU\6];
MV7\U](IWRNS&Q#_H             !P.8            (G^=.^[._AD_P!\
MX<  5 Q;]'<4A#5FYI&*0Z>&1^^&2V;7D[(YHVS&_P C;_?Y3=+L(
M           I%EMMYBKL*H                 JQ^>_N]I?T(\(I+BD*489
M&'[-W1\4A\<,EVL$E)F+;LAM05G9#C[;[4!EZT               ' Y@
M         B?YT[[L[^&3_?.'    _ ?H                    !2++;;S%
M7850                !5C\]_=[3_H1X0 /P_0                  <#F
M            ")_G3ONSOX9/]\X<                          4BRVV\
MQ5V%4                 58_/?W>T_Z$>$                     <#F
M           "I?YO?0'9W\%J_P!$O!@                         !2++
M;;S%7850                (]\6Z^HOYH?0EL_TD\ DGW3BP
M        !P.8            *7_EE]*=J0P7&_3WYR
M        %(LMMO,5=A5                 T;R3J*K?G?[S:+]!?"Y ]FY(
M                    <#F            #YX;OVKGEM
M           %(LMMO,5=A5
M ' Y@           ADB(WXG,R) A/9^GX0$3Z?I^ 'Z?@(Z- +"@
M          I%EMMYBKL*H            ADW<A0LP?H/TXG2-7-V/T_"!">R
M-"*#=B;#]                 .!S           !30[!7,VPYGT/@;T:,;X
M5*+/FRGX4U/5L\TRTA5LLH7?                  !2++;;S%7850
M     !40C<K67(.L1Z;$1F2,1D6&+>'C<36? DXB0PAZFF1
M    .!S           ! 9-1&!'YOYH)O9H)'9+Y&Y.Q78^IL)I9#Q/QUR4BQ
M0                  *:9;;6XJYY4            06<C"D;$@D8FW%82U)
MK9]"X!3<Z),AK!L)I194V$                 X',                 &
MO&?.0-<-C                                   !%A*8/B8PS(
M                 .!S
M                                         !P.8
M
M      .!1GX4^G
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MI5?T#E9\Y"?V^-W                         /S*NK]J_-X
M
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M%HK$:).A0Z*+"7#J/@-=O\_Y4.CJW<2JH<(DSC $P,@XQT_(5T(K&$5V3S9
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M=ATEG46L[]3R0:J9Z.A[U%8U:C"XO\$CAU^1U@A-;2*-*(;0XGHAWIYVA4I
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M:I1##3&9XZDM6(OVE.</R;DK,:I0&H:2 T+<5P>(;>+@MYQ%8JA!5)2IP_\
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M#?%F6UL&_*Y;1['$[.Q0\L)4%@*0H*2=Z3<'RB! @<T,C_LR;_.&+?JJVPF
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MYQ!DWT/:G5J*VW,)RRMBL%?1-[Q.HU<K)(&Q(<!/SLH'M >T!!2% @BX.T$
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MJ)M*&=<K%JTG67">89"-'*I49FMZ6,3$X^\S)N38E6UKNEC!,3"4ZL;L*4I
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MC\X*3ZQ")N6<[!]I7@6(!!W$'P'Z>_"H%L=X<5_X0WKX)TQ1#>C4D\]-DO\
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M#Z@(ZYE)?YAGKAS^DF1Q!^:T-#_:)CXP0YI,2;!'UF1L7!X,NA\8@2\O,?\
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M7A"%N*"4)*E'<! D2 =M,2S)^JM94OR-I5KX3 IZEWV#\O,'ZJ%D+\25A-_
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M_:/Z/#$UV!\0B60$MMH':I \=HJLN\MP+;;*TE&4VWCQ04E/%4"E0Y"+'QB
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MNGBH W(-HPVU_!),<KSBG%>-6_R"-R4CF'TF"G-:YOX(40-_V"&^,DVY^72
MDI.L)W]D8XV4\HMX]T:[-'@AO17CA1O#_8*YHF60\K1:1E)W]/Z8ZT;&]] C
M8RPO=_U?? ZS'\Z3XX#LB.51MTQUY)IW))_O1\8RXW-']O#:/C9'(S]B?OCX
MY7VK0_;RP:U,7T0D>/\ 5"JS-\A2/V\4?&TZK^<_;RQU_-JLV9A38=.0K&N4
MZE)\%[ ]$*G)I24JVJK[E:[E)T,5N9=%.?SK4<P L3]8VC"I IS)YIA9/]^)
M9P.M:&]C;_G&4\T6/,?QYCYP>/U0?QSD,(4"="?&(4I(.I/DA S)!'E.D 9>
MR\&D)T-[PYFV2N:U^D0[V/\ 9$?A4S=3ENI[3V9,NHE)NO--50MD@%A,LZXP
MAPIMQ%S"4"QT4=/@_!3GZB[@S$$O-+=5(R=;ETTS:9LB0]*N.3J&2=Z0Z&5*
M2- I1Y3&8DP\4];.YCIEUZ((D!RJ\OZH2[(H[$+\6:!/,)W(7Y?O,?&:1N:/
MCR_KA54/]"CQV^Z#4<V^68\:0?T0J:"O^ZRWF_UB-LRK?*,>($??&:5.^43X
MEJ^Z W(*_F%I\"_OCK6GY@GY=-T*4-1VO)XX,G)V!2Z\,PN+IO$ZJ2I[*W%S
M*B7$.-(3L[<92#:,/N!$I3E<@:'BU,,K#S2%)\'ZHRJYHRGF/T@( ^4\9AT:
M",2=47!F!6TG%%<EZ>X_=3$HA*IJ>>2+76B48"G2D:<8@ \D84ZH.$<<2ZYC
M#%:EZEL39^6-V)YB_8EZ3>RO)2H;E6*>F&R#KSZQ<I!(U3;Q@\OB@J&1(Z+_
M &PC4PI4/=@8F%6F7OSH4K2%G]Z?^<'H^$0#N_).:W/X_'$G*"<I\RZRWF?D
M7-L^E'&)EG3;-D'&NVO4\F4QB5E76)4D&Q4FYL1H/#%(JWQ>V65I*FBK,,HU
M!.^)3& DWR6_E&%6SH7<:?H4(EL;T1X#.ZJ75RI4+CRB$8DHSG85)F_2K+ZX
M15:>YV$]+*__ )$PEYASL7&5_FJ3^@QD3_R-XR<Q\L$$;Q^,L?.#Q^J#^.<\
M-]E#HL8EM6_'"E%)'-;]9!\6L-Z[O'"[A"^5-C;G'AAP[QS ?;&(</4G%=%G
M:#7)83=.GF\KK=\JT*&J'F7-2V\TJRFUC4$<T3_4[D);JR\&[<],FG*Q)*4A
M,\4(ZZ3+32&'<V7L"XA+V3F)3FC#.&Z3A&BR=!HC!8D)-)RYCF=><7JZ^^NP
MSNNJXRE?V1H(28?UE7Q_FE>J";QN_>&#\(\,7W$V.7,+;NRW[H9DS-4IJ=8:
MSJDW.M9L-)*S91*F7B@"X OD4?!&*Y9Q+;"BA03M"25)(Y+<L4VMF391+N(4
MMM&B2GL@#]T2.,W)%U7%+DNH_-KOY4GD,2^/**X!M2ZR>46S#RB$8MH2]T^$
M_G B&Z_27;9*C+^-8'KAN<E'>PF)=SP+1]\60K4>+*1!;YCY8((W_1B]%=&^
M%#,$F,?UFI5W&.(:A57'%S1JDXQE<O\ (LR[[C++"0>Q0VA(L+#GY8ZEE;J=
M!Q_A6<I3BT/O5F0D'D(O9^4GIIJ6F6G$CLD;-PKL=Q0%<D9-FM0&H"E>LQ?B
M$]!]4*-FP>B&S!,.FZ%>")E?\)?-^W4/)I&8_!>+_#R1?76+Q?X&*8K9I?GW
M>LI4BZ<PO,/#F89WZ_679,-5UJG)6FEM*DT*&1Q]1#DT\G_.*/%U/\V@6Z8F
MZP9N6<34BDL]EF4AL:?EV M?HAU[#BEJ&=YO4\9I5T^(+$)D*1,_]7J^51W)
MF&[?:DP<-39UEWY28')D<L3XC"\/5EL$]8N+ WEH9]/[,+9FF#9;3[9'.E:?
M%#<[--]A,O)/0L_?$KB:M2Q&2=<('(OC"*;U07P4HJ#*5#<5HT,2-1EJBPE^
M7)*%"]B-T'?^,,?.#Q^J#^."#Q5^/[(=&XQ)*XRD'E'VB%@;O#"!D(MN$.GY
M)72(>-@(OQ?'%6_E6(_KS2/\))? D1.+R24PK_-Y?[VD:1<0#%_@)B_PH2IQ
M24(2I:U&R4I%U*/, (3(RTD-I5'"7+713Y<@OJYNN'.Q93SC5<'$+[3>RE$F
M19[5B4.7,>3.H\9P\ZEQ4JPAR5!JRMH!<#/8C7DMV1//:%3V'G%6+#R!]9I2
MA_JJTA$I09GYBINL*.Y+Z$J'E!O'[FGEZRT]*/@[N-D/VZ0O"];2"I,F7DBY
M)9(7NZ!K:'9.=8-G9:8;(YVU"$S#S9XCKJ#T*4F)6OU:5(+4Z]8<BE9A]L4S
M'\P@I14&TN)W9TZ*B4FVYQA+[0.18O90MO%X/T6M.9-^40D\523XC'X274JI
M=(8F>J)2WC++GJI*2M4IF3Y)R:GDO$3DNH'Y,JV!+S9T*E9D\L?@R]2.ESDA
M3^J?4ICKN91.5&6I-,V8V,J_).F67./J5?:.WN6 G1%[GC6@"_VWA2[-*';;
MH?T3E\$-\I\D$Q,+R-+5S)/1N@KS+6OZRE*\IO&A_;[82HD#2_3??;E\<!5_
M58[Q\-QXXN8)Y/@99=F'4,LH4XZXH)0A(N5$Z?MR ;X E*.;6:GJDC12CQY.
M36-X2-S[J.?L$GGM#[[TRZ77G%.N*[)2SZOJCH&EHOF5?M4Z)_*/*K] BLE4
M],,TM@ZW"G+<KBOK?DMIY.<Q)8*DIADHLHK  VV8W*^@;@(FNIO44I4N4F&'
M#O#:U%*CT9HF)6N4-PHF&YN5(W$YE-&W*E>J;'Q1)8MJ4JI)VBC;MFUE)\AN
M/T1)8WITT W4VFG+Z9IAA*5^)U'_ .0CXLPK64YVD,MDC3<H:_EMV4/&F)W
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M3F.Y00#=1MX(IS(9DVFP-PT YAI!!&\$>$$>OZ+'-"D6U&[U1^%$/_=:X?\
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MVBUO#7QQ.X?+T_,.R.(I>7=+[\LHC8E190X\TZA*=GER6R&X4E5XKV,L,/\
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M+E-$.V;'L8;;M& GPMIC.DTO20=($N*5*JHJ%3?F5ERH H;-1F$R_P X16_
M5'=5QZL-<EW)Q*;IT_7'B5*K:F6Y'/I:(0Q&)$CM$-IELD61(+>F^Q#IOA_.
M#/*_"K3D$.>3:7$SM)JK[;2=-[_-]23F,A&^#C<76NF^R143%4=O&@9RI(.T
M]]X6KPSF.1U.!4$85=P.+;:M:M*&)(BVP],S#ROTK+LS:NZ*:6=)5*+2)+IT
M,4,.; *I;2+IZQ14VF^^&.3'/U8+,<2=4PH0RG)C=2<ASWT3F$F)4@4EEQ)1
MFRA[4S5&W=?1,%#&3/Q!,_7TQE'_ %8H/[*BXSS_ *MU+^Y7&97<P4ZL3TK+
M4%N/V):AN*VL8W2/;<[EQ;7UIIT*7!;IBDY>A4+-;,NL368,=V3&I0QVW7RT
MB3JMU5QQ OQTMDODQE_.V6\SYEIU)G;.',@0JW4X]-:J4$MJP2PF9(1]$MGH
MO"K>AU0L2+J6X<ICK@(PWEXJA*"X]&HLM;-V+:Z(A%-30@^(DQG;E/S?FG,;
MN6,O,3Y',9-9J#M+YR^+DQT&X!R>:J,&(EF&Q:TB9@(]+%5BY6S5&R+EJ 2F
MVKE9[ ,LQR,AB\XFL?YQES'D'4;<5"%M.Z%!L2TIZMYSA9\R_.<LZT%?*OQY
M -JG.&4>F6J4&4C:W9<,4:)5\.RVI-?IQ*4&L0(U0C*O'926A<02^Z"^DO*B
MXSO^+F?UV-C.WX^@_L],56'5:=$6I-P9+M+JVQ;2=!EM,D;!!)0=KL5,1%UI
M24""_1O;%?R<;Q%3JC27JF#*JJ@W/IK[#2F"<!5Z.^6M=R+LA3BJ8KU)REF?
M,<F>_F2I4NDTIRK3I4$%?=-D$;@29!00%@5U IM;-C3KM8<9XSIRN9I^B1>;
M1YL.(-5G3R8E65ING@DIIF)'<ERWF6!YG=FZWO9,5290<S/Y9H<!Y!4XU2ET
M2E0C<N3,,'::!5";(V::G%LZ@I8CV>L46%1<^5.1F>AR-F[:9,=J;$^GZ]#T
MBF5*0//6Y#.^[4GI(6E'&D0D+&0*YE.OU>D,UFHG(&12:C,ICLB(_2N<,@^4
M-YHB0=2*K9JJ Y?==,0JI!SU.HE"@-<RI;TVN56FR:OS<CVLCG$!MZ=-+:*K
M12YKV@R#0"V;7#/)SRGRY55ANSVJ4^51>27-I[LBP1)L6H[SEQ'%(%)'3<U@
M5T(#%4]C*V3([QM4Z2R_6J@V*JB2GFGD8B [U&#'3=!.IPK\43%!J$>GQ7LP
MU>FQJC4JTXR#DPRFM"^D=AXD4V(K(&("TTHH2HI.:BQ2ZEF++\.;.I,QN8Q*
M0$:>>V5U2---M$67$(K$3#VH;BEK)JODCZ'*U5J!M*E467.PM1ETO:,M1(^R
M:/F+S&IMO[&"]$/!1,95S$YG273LHT2=3@:&;5ZC&D5V'390<]4^: ]*J)/B
M#C3CM2>V+YW3N47'^2SDSF-TMYF0%.J%8VK$=YVH&FI]EN9)[3!B1!72Z_N,
MC$U$D33=W.$?E=A9@2#IDSZ?#SE)K+K3.I%=4J;542/(;!>BZ$-#- U$VF@5
M)*E4::46FYUIX2J4Z1-ZX8U88PO0YB-$O>\H7 515;-GM$WH&"GY@Y8:7E^H
MEK/L2>>)5-=#K%O8T0$@AU"B$YT?#7C@>3#/E4+,#$N8]2F9;TAN=(A5%H25
MDF*@W?G<.1ILJN&:])#0KHHX.=FG,:UR#F&J5^I9=C=DJG.[$4QVHFZS"V4\
M!:A[-EUEO8PU)A-G85TB.*5FO,6=.RN4JAEG_-]"6MUR8D+G2,.Q5YC,;&GL
M<W:$Q[22Z+V#=?$O(/)I6&LLT6))DPUJA36J64H89*W+J$JIN=.-&UH7-V8O
M;S%!4=1'I2/FC_*? S=30DLMS8[.:7\PM"KI:0:E0:MIE;)U>CMH:=J6US&^
M*%GK*C3<2M9AF+1I!F*/A19\82Y_I$D4#/HH<7:71 =%21514Q&SC3^5O8+.
MVCK%/=SC5HTI=F:IVR!36R@QU(N#3B!9+:A1+8D,<J%7.IUM:D\,4''(L@HM
M/9$6VOJV+NE<Y+4\BN=L ;":ZKHF*VDSE/I65*(S/=&B:LR%0 EP=5V'&X]'
M%R:'0LA\](3(D)431;%.HN9\V#G*BO'&*4'9@J_$EP)#B-N/0Y[ZK,CRF>DH
M@ZH](;&WI*^&)+?M<AEMYN_'0Z"&/YB3'*!^)4_7HF,\:B%/\[TWNE1/^IGX
M]^,M202 F;#J#H:X^RY\[3$8Z?.U;Z9- [HV*O<"4D# 5!JH5"F5&/I&GS84
MN3#F-0.S0A'V4ADVGFQ)E5'H&B**VX8S7+K=:JU8E,5=YMF35:C,J#[()3@)
M :>EO.N-BA=+2)(FK?QPYEK*&<,P3*G68;T9QVK5J;-CTZ$VZS(D3A*H/26H
M9MHRC?.6FED:'#99Z3N*36:MGN?5X]2>/9/)6JC6:4Z^WVQV#)A580V>H-_:
MF %0OLG$5,9@S4C2,.5;)K[LEA%NC,H"1J2 _<;4"(.M (;[\5[+/)K64R]!
MD+%F5ZK%(.$C6R%QJ*USQAIZ8BGK-4;B-[3=K(D%,0:5FG,\ZOPW5CR7F)M4
MEUJG52FNN:'3BO5'ZKCNA8T2VP('$36*BN*;6Z0TU(K69A:&AM2$UM,B[&&2
MY+?$536D=LQL-T0W%1+VP.=FL_3Z3%E[1ZELOY@J='2>V)+98D&DM<V".IIL
MVCE(V)HG=*-UP/)=RINNS7'9Q4EN7-0%J-.J7V!MV0VB#*B/[D%P]1],#0R1
M<4S\#RY_?IBB4R@;)<TUZ&CD=QX=H%-@,M@V<U6EZ+CCCJ[*.*W'4#A$FY,-
M9K>Y8(5/J,EE)S-#D9[D0Y:H8;5ELX,7_,[!N(J=I>($;5=+J#;$_D[SV8RJ
M_3V9#L"K)LM<KF+B-3(<O8]I=>"^U9D,[G@1R_ 2+%,_ LM_WR8!FJ) >@'
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MN&(,S+PD=(HL%JF1YSC:MN5!Q93DAY]!+I#'13%MA#1"Z+AVL:8R%^-:'_\
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ML4Z=FMBHNOTN.[%BK"G+$%&G7-J:&*-GK77U[L1:<R-XL2*S#:%SIKL&&A9
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MHT[\3*#7^0/E J%,G!H>CN]@DLJ+=MYIP:JALOLG8V7FR$VS1%%<=C)F6O\
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MFJ:D0E4;HJ7Q2,L4_D9Y3I,*C1>:QWY:Y=YPX&T-S4[LZF(:KN+W*(EK8_\
M,ERC?_(/_NF*WGEOD;Y42J==H],HLF*:Y;YDU'I3CSC+K-JEMMJXKRHYK)1W
M=%-^,U5B'R-\J+TC-M29JD]N0N7-E'>8CI&$(NBI"6S44U+M%(KXRM4)O(WR
MHL.Y2K@5^ $9<N:)$H&'8Z,RMI4B78Z757M>DKIQQEO.+_(WRI-U#+$:I18<
M9I<M\T?"J (.E(U5%7=3>FX:"1/'BK4"9R+\IC,6L0)-/?=CKE[;MM26U;(V
MM=3(-8HMTU(J8C9%G<A7*-5J#'I$>BFU/3+I')C1F09!QW14Q07^@C@FWI5M
MQ$(%141<=B7,K?\ 21=RJ@[),J'7\N]C^;=419J3>R91>K9K(WAT;XF9&A<A
M/*)2*#+HDR@@S3ARZ"PX4R*Y$-8Z'4R':B+I&A.:E-SI.*2JJXCY(J'(1RBU
M:A,TN/22:G?0\1OL1FA:;<-6ZF.A]-"."XUI5L[*"[L=C$RW_P!)1,LZ-E]#
M/T09<YGS;_U7G_/.R?-[='3SB^G=JZ\0J33>0OE%CP*?';BQ6==$<V;+26%-
M;E6(R7QD1*JKA[+56Y'.5*'#>ET^:K\!<M\X1RG3&IC0IMJD8:#-I!/=?2JV
MWX_\R7*-_P#(/_NF/_,ERC?_ "#_ .Z8GYCR_P G?+ID.J5<@*LKE2?EIB)5
M3!$1'I,*5.?CC)5$Z<AH1<*R7WIB'FB!R.<KTFM,0Y\6;/J<R@3IE:.H*VKD
MNJ2G:EM3=91O1&;:V;#0+I%OQYC=J_)1G]9:Y*H20X5-D4N'F:@OQJJX;-=A
MS0GBU'%U?J<5;><)S28/-;-5Q J6:LA<O>?DI4D)=+IV:JCEEVE1)+?M;QPH
MDUAJ:ZVMB;*6CFDDU65<4!*CR-\J49,NU^#F&)S-<MIMI4#5LV']I42[06KI
M:+%NW8RGF.5R-<J+4S)TBI2J>PPN6TCR7*G%"(Z,O74E/2  A-[-175>^[#3
MI-FR3C0.$RY;:-$8H2MGI54U@JZ2LJI=-R_:<Z; Y,\X9HC"RTYV5HW8KF)D
MZBJ3*<[G,/:VN#EV]._<JXS37*+R*\J3LO-4OG,@9:Y;5NG-;=^2L&G[.HB0
MQ2??)PD<N2J >+%0RI6^17E.9A3U8/G,-<NI+BR(KX2(\B.KE2($<;<;3NDL
MHJ0KN7%*R]3.1'E)YC2(3,*,KJY?5TP9&VT=4:FB*ZX5W'%1-YDJXJV=6^1K
ME1*I5BE0:1(C&N7.9ML0'"<;<:M4MKM34K'J)1\6$HE3Y&N5&+&&H4^H[6$N
M7-MM:=)"2T';:D0[,R#2>Z]N&,J3)_(YRI1W,H9ACYC@#%7+>F1+CLNL"Q*V
ME1)=@HNJJ[/2=TXXROFN3R-\J3<[*G9'F+#*Y;YK([),HP[SG545<[6B7#9D
MF_CB#5)'(URMT/,-+0AIN9<NS:%3ZQ% N+*O)4U;DQK]+FTD'&K[T1,0LPUK
MD_Y>,[U:F;1:6]F>J9>.-3R<'23C$"#4(T57M*JB/.@9(BK;"I_D3Y1DNG%/
MH?NGE2]4MN\N[$J! Y&N5&>[4*G.K%2J507+BS9\^>\KKKKRM5(0L":6FA1.
MBV*)AQEWD.Y0W&G0)MQL^P! XV8J)@0K5+*)"JH2+N5%Q]#E-Y'>5.;2VY4U
M^(U4%RV:PX\QXGNQ[2MU$=45A3(6M=RT+9<9AJE$Y%^55]_,,G:J$YS+AM4N
M+MGI*4VF(-216H:/ON.J*K<BTW[G$:+7.0SE.!^!(&72ZM39-$@UBDRA^ST^
M<U5=HR1)T7 WM.CT3!=UH,[->0N7O/[=+D!+IM,S54<LNTJ-(;6[3SD*'-8"
M:XT2"3:R]I8A151<9:[(\C?*E&^A?,U/S1"YFN6TV\RG-R&VH\C:U$OJ<TDE
MKT6/HI;$1BM\AW*@S*IK_.Z36*7*HD&L4F5:RO09K55UMZT1$=;+4TZB6,5P
MZ&;<B<ON>$YO(9I[>9*CE=Z)2G)#1-).CP8\QF-(G1[H<=^6+NS--2)?>B<G
M;O(]RJA21I4:D\\!<M<_V,79Z'-]1V.T+9IJZ%M^*?E>?R/<JD:%39M$G,OQ
M%RUSDW*$ZT[&!S:U$F]+VR07M(HN]5"V/_,ERC?_ "#_ .Z8J5-IO(WRI3&:
ME7*O7WBG?0WK&36)"R'V 1FHBBL-KT&[HIJG=75<27:IR:<HN5ZD_),JC3J;
M49>78\V5K[:LJGQ93##Y&2=,@"SB=:H6\\[Y/Y%LXMY/#*K&6*+$IT:G1#)T
M)G/ITN0DZ5'-]#,T$)%W"<5"(W"7'_F2Y1?_ )!_]TQ/F99R/_T@,DPZM,=G
MU2AY;JF66J3)EODI2'F69,QXH!/W7:<T4$U$I)9<5FJ4#D6Y5MI7(T!B8U-D
M4"5J.!ME68<ERIK)D2Y9O$Y)=>-;EW*(F/\ S)<HW_R#_P"Z8S M/Y&^5&1]
M$>8JGF67SM<M]IEU1S:O,1]G4A[0VOM>NYVXKB3(C\@^?6'YIB[,>::RZVY*
M< $;!R08U)"=,01!$C550=V*]RAO<CW*D,F;08=.GM*- =AQX-()^3SAIIB>
M<LW;.'M!%'-P] +XAY0RUR>9QJ,Z'6H=1FG'",W)A4^*2I4@9>5P&V9,F,91
MD%]UL5UJBH6(T")R&<H;,2''9BQF0[ (#4=AL6FFQ1*I9!!L4%$\28J%6RMR
M?<O')^_5WEDU6-E2HY:9ILZ0O=2%I\N<^Q&D.+=778R-J9+J5+XF]B>1#E3E
MU"JO)(J]=K$NASZS57DX%+F.52^@-^R8;0&6K]$<<H-5#DVY3X68@S@Z_%KF
M4IE)@5[+^UA,HY1YSC\P8\H"5!?.,02(]]F2$))O9S15^3#ELSQF.(T;,"JY
MLG9<E=C6W$L78^''GLPXSRCT5D"WMM*V0DQE[/+W(YRI!4LMTVJTN)$;^AOF
M3[-7V>V<D:JDKVT:V?:]!(*WZ7#$*MER/<KV7,RTYHF(69<M3:#3ZJVP2WYN
M^O9(V9L82Z0LRFS$26XVPUF:I\FG+=G7,<9AV+"JN::CEZ0M.8?LCHP(<:HL
M0XYNCT''MDKAAT;I@@/D0Y12 Q42%>P-E$DLJ+_G3K3$@\H9*_Z0F1(\I]Q]
MZF9?K&77:6ANDI%S:)4YTL8@ZE5=+)(*+P3$VM!R/<K^8<R5)L&9N9,RSJ%4
M*JXP&_F[)=DA9AQE+IDS&; 2/>5\9LKL3D;Y47I6<*A%J,]I]<N;".[$AA#
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M]4YVV^T3!DZ=2DFKR-FB$+;]]LUN]K,<<EDJ'"D28U-S'-D5!]EHC;ALG3C
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M]9Q93H*1BB]I*]L9$Y0>;%FW,%*RB.4\]TF(\TE1J44B;E]D*8X\0M29U.E
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M<USC+='J:32P*]TCF!!L1  1!$!1!$13<B"B;D1.I$^VW_>X_P#QX9_KI/\
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M>L(C=W27R%L_*J8;E3P<S'5!LO.JD@\V;/QQH W:!+\%=)\_N\"VV M@":1
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MM\;+M*O)<D-JOX,.SCJGW)@:8&-3X<6#'!+ Q$8:CM"GD;:$13XOMY_WN/\
M\>&?ZZ3_ 'I?;>N_A=#_ &S"Q3/Q?#_5V_M*GXQ8_N@_T'_[W'_X\,_UTG^]
M+[;UW\+H?[9A8IGXOA_J[?VE3\8L?W0?Z#NPV[)"9=W);I..-W36J^)%OI1,
M,T]U46&\YI'=TFG7%W*B^](EWHOCW?;>N_A=#_;,+%,_%\/]7;^TFMG<^^>Q
M:+WBV4E+SHB;L<Y5T]OKVFUU=/7[[5X\%M][\8]DX?OT5+@7GMQ_T&>NV91W
M7#<9>1%420EU:57J(;[T7##FS(8T=T'7'514&[:H8@GC)51.'5]MZ[^%T/\
M;,+%,_%\/]7;^TFQ;5$?:+:LWW(I6LHKXM2*J7ZL;#F$G:7M[6MO/J[G3]U>
MUM^%!VW.'RVCUMZ"MK""+UZ4Z_'_ *#6(4)/$2(J?$N+"B"GB%+)\2?;>N_A
M=#_;,+%,_%\/]7;_ -*JOFA()5(J8#"A!%T6%D'(E,Q0#:DBB'3>15)4X)CG
M;W)6#\86T>-N!FNF/S2:4==H\<A#:O6[EK4BD71Q)S%D.&S-J^EZ/'I%;,J;
MS>K1GD:ETZJKO.*[&76A\=Z#;<6(Q36VV9A,-+*:9/6TW)5M%>!HUWF N:D
MNL41?8R+!C16)(9KS2W091O$8E&8.!,E[9A W$[KC".D^CI)>OZ2C9*&+'*%
M4LLU.N.3%(^<MOP9;,<&0#VM6S%Q5)5Z2*F[^1!S*=/IU3JBS88''J<LH<9(
M)O(DUY'1155UIG433?AENQD?*K<2.Y'S0S6W)<DS<VT8J7&:>;1@430:.$:H
M>O@B;OM/7?PNA_MF%BF?B^'^KM_7=8S8]#.>U2&FGG(K1HVXZ!R&F2T$5TN*
M.:D3KM;KQ2Z]2WAD4^K0H\Z*Z*W16GVT-$7Q$%]!IQ$A5%WIC+,24T4ZJ9IK
M<:DT^GM."#B-.. $JH.7OICQ-JTA>_-T0'PK?2R"B #LH6'5C-NEH;<?0%5H
M'#\$"<TH1=2;\0'LS0X5/KAM7J$.G2"EPV'=1=%B02(K@Z-*W\:K])DV-%BL
M21S+F>-0Y)/$8K'8?9=<5YG1W3J*VB()]'?[%"'+E-IL^,_4Q;S Y4)A17(-
M*T=*1! 47G,G7N1I;);?BCY,R? I,NMU*G2ZS)DUN2^Q3X-.BNI'NHQ1)]U]
MY^X (I9$157%.RC7&VH^;)% <KLIF"IO4P6&90Q'=C)<TFO;2%1 QU:;JO#[
M?9J</<#84QPUXV *Q (EMUV%%W8:1BHSZA(".UHA0*+57YD@T;'M3#7-10W%
M7<B:T2_7CE1K]2BR*!.S95:KF:+3$<5F;2HDV7%2*V^3)(K4PV@VCZ 2*)'I
M7??'(K I58FT:95,TT2*=1BO&CPM.T*0LDEZ6EXU91W9[9#%'U!U14A3%1SI
ME6JY@IN9<O)'J0U!VM5"<-3V<ID9,6IQ9+QQ7F9C9N(YH:;TFJ$%D2V.1L(4
MYRD3JKG6F$D^-97H?.:'.<DG'UW%'=@3P,FJ+H,A/JQ4,ZY4JN8*;F7+O-JD
MDYZM5"<W5$"6P$J)5(DEYR,\S+:<<0]#32@:B0V1+8R%D.-4)5%@YEH\S,F8
MYE.=YO.>@0FHVSI<*1W;*29#Q<Y<#M@L@-NZP>>LB5&JTV9EV1!E5*FS*M.J
M%,KU+.;'CSH<QF<\_H?)EXG([[*@:/"@VZ6[)DH45 D<F];D"B]T@NSX;B(O
ME1%WXS'5\\1.4"J!'S%5J30Z5E^!6THE,IE*DE"9/;4MQGG-2E*V3\LG#5&C
M-&Q'=C,F6XS&;'LH18<&J9>GYK@2XDR$ZZX;$^AH_,3;3&6EV,F*X:J8 3@*
MI<<9D=@278DQ'*0D>0RZXP;;A5>$(KM&B$T&Z]-$7I#=%W+AJ56:WF61FJ1&
M;>?S'&KL^.ZQ/)I"UP8S3HPFXS+FYE@F#0FA1#5555Q6EJ4U\J[E?E!@Y1FU
M:&X<=RHI1LTT^-S]2CD.S*5%<!)(B5M>N_=8KIB1 8T"HD)B2B8DD!U4(214
M421=Z*BW1=^,I2(-0DQZJ\]DD&)ZR'MJDE^MQ6VW'WMIM7&]H0J^)&NT;U"5
MT7!RI=<S,N;'05X\SLUR>R^U4234KT>&#J06XH/>UQ>;*",HC=^O%)J$^6Z-
M:IW*-0,M5*=%,XRSGJ/G*/37Y*;$AL$UMM%="^@]1HNY;8Y(OP;.'ZA'^T]=
M_"Z'^V86*9^+X?ZNW]=YC14144J2BHN]%1:S NBIUHO6F)&4YCXQ<EYE@NYH
MRJ_(- C4B<TQSC,=#VA6%MCC5(87L+9N@/!<!RIU)DD*M9WRE2\H-/C8X&4X
MM8[4^ +[4[6GT*:ZJ6)6E:%=R8H->5]_L#GN,&5ZLTX^X46+7XB$[0I@-F2M
M,%,95V"XH(".$#-]1E@M+TA,N\EM,>J<UJ.\ZT%2S748Q\VBO[,A%]JF4Q'7
MU9<U"DF2RJBML-YZSQ4*O4IF8'9<BG4V)5IU.I="I@RGF8,2''@O,:GT9 7)
M+[RF9/D261!QRC<GDFJ3JO3J'0&*[E^;.>5^HQ(%4C3 .FR)6YQWFC[%XSI]
MLV9<5T7QEZLYVK%<K<R5#/F+3=:J,2)3(*/NC&;8&*^V;LK2FTD29!NF3JZ;
M(()?E)Y.Y55G5B!0:"U7,O5"H/;>I18%5B3!6FR926-Y8;[%XSIV<V1(G@WQ
MR54:E5)^'5L[3(% .MF9/RX,5TY+TZ2TZ\IJLQ8S1-QG#5=+BHO5B-*HE:S5
M2*W%>9?[-A79TV1)-LT)T9T:8ZY"DM240A>;V+:=+H:;8-&E17=F6S4^YVFG
MHJ5NK5:^)R<LY9VI>=.RE06;69,NN1Z,C?.W.8.T.52SY@U3QB['8BXVI J%
MML<D4#+E>?)N1G.DL0<P<X&;***420A2@DJFEV0K.I =5-Q;U2Z8J^?<J5.O
MP,S97;8JPS'JU4)K=6V<M@942J19+QQG69K9F+FS:;4%6X6QR,R@==C+4<YT
MEV2VP\XV#@R*6\\3+B 2;5K4O<.:A6R*J8ALS(LTPJV3*E6)J!5ZHSKG=EE;
MUMJU* F&]&[F[*@Q??HOB#2#ASUA/<GLR>X"5JK":R6ZNQ& D?&8CP@C*VV2
M.(VI=-14L1X<="%B,T##*$9N$C;8H(HKCBD9K9.Z(E)>M?M[6,MTYV.Q,J',
M=D[*U; >;5"+*/7H12WMLDB6\)4PR.S;UMMM@I" IO$4%;;O)BOY>@N,LRZI
M"YNPY(U;$#VK9W<TW*U@7ACDP*._%#Z"J_3ZI4MIK[>Q$I,B 81;)[8KKHD.
MNR:$7KQF#+T%QEF7587-F'9&K8@>V:<NYIZ5K O#')D4=^*'T&5Z#5*EM-?;
MV(U(DP#"+9/;%=>$AUV30B]>,P9=@.LLRZK"2.P[(U;$#V[+MW-'2M9M>'7C
M*M3H=39I&<<G-(-+J#K*R(,AIZ*U&J--GL[C<@S1:'>*[1HQ%P-]\0J5GV;E
MVEY5C38D^I4O+*SGI.83@O!)CQ)<J;IYK3^<-@Z\TTBF[I$56R8H><6G8P4R
MEY6J=#<C=))"OS);#[1-HB:-B -JA==[6Q6IG)Y+H4FB9AJ#U8F9:S#SMIJG
M5B7OGS*5,AW(&9KB;=^(X.A'5(@7?B:]G&ITR;,ER!=C0Z1$)B%2F$#2L9M]
MU><3%,NF3KR"J+N'<N,S-$JBCKE':4AW$*.5B"&H5ZB2]Q\N&<OTRL91DPFX
MS<6%F>HLU#LU'AHV@-'(@-?4<J:PU84=U(+QBCCB75<3.3A)DJU0%^7+KI:2
MGOY@D24J#E<<3N"?6>(NH'<HV M]5\2<IU2L92B0WZ<[39.9:>W4"K,UE6%9
MU##>^I(LB4GM[J*2-ZC)L;VQ0\I39"*]"J62:,_*BDN[578<97V"*R[0!/6!
M+]D1%P67H=:RB4-&UAL9LE,3UKK</3LVWW:</U$[4A9MJ=U[(WDVJIOQ1<B9
M=D@A4NO9>K$B=45+:3G*?6V*M5)3Y-IOE3"%TAZM1"*K9+XR+FAAZ.$'++5>
M":RYKV[JU2,TRSL+)IZ! JGJZN'VGK<:#%D3))RJ,H1XK+C[Q(%7AD:BVVA&
MJ"**163<**J[L4X211(8$1"%4LJ*D=M%14ZE1>*?7=5R_3W6&)<XH*M.2=6Q
M'FT^-*/5HN6\&21+>$J8AY?S*P;\:*[!D(4=TF'A=BH(N #P],6936TC2!2V
MU8=(%Q2:)1EB0DIE>R_40!U"%@(5'DBX3#0MIN+9"@-)W/CQFV#*KL(*G3&D
M* Q#EL.5B+F>*3;]$;BPP-97/2G\V$6Q;4E!P^K5:,.8%21F6O$Y7,TO$B7>
MJU31')#)6W:(P*,4 [D1;LF[$VFY$FY<JF59,R5-IM+S+SYB5E\YKI2)$6++
MA:N=0.<.&ZRTZB&SJ(46V,YY@S#4VZSFS,T*0[5IC#/-X,:-#A/MP:73F"N8
M0X@$6]Q=;KIFX5E7&7ERG4,N5BCU*&4V/$S+SYF717Y#SI2&8\F%J27!5V[K
M+3J";.H@15&ULV5.NU5JLYQSDT8U.H-,K&I\9IN*Y&I]-I[&\VX,-'%6YJKC
MKA&X6]<9<R=.J*0J[EL8DNF5NGBI\PK,!\WXTIH'+*ZS<M#S16VK1$*XC4V=
M6,G4:*#S'/:_1XTZ359<=HQ5T8L"9]10W98HHD2D:,ZEV=]V#$#TNJV0@YIO
MI<4;">G@MBZ6GX,2*0\]R>U9B0#S'9F5%J4=[8O:A0WJ0&TB&XV!;VT/9.*F
M_<N.3*ATZH-/ADG,4>L5"1*0FUE @R2D#$:"XM)MI"[!I>@VTB#U8S1E6FNL
M,3JU3N:1G9*DC 'MV7+N*"*2#9M4W(N^V.39(TB*'T'URFU*H;77V]F'3SB.
M#&LG=J97'79-.*9G(7HZ4Z'E.70G&%U<Y64_4%E"X.[1LD#<N_5JQ1<^Y+DT
MA:K HTW+U0I5=YR,"=3I<EJ8#H/Q$5YF5&?;Z.[20*H]>(?9KF:U78!S_L?M
M.9<X\/FVV[;LD\'7TO'_ *$N4ZK0H]0@O*V3L64VCC+BM."ZVI NY=#@"8^(
MA1<(B;D1+(GB1/9YE5X,>H1$?CR>;RFT=:YQ$=%^,]I7PV7@%QM?!(47_0D<
MR/9:HKE>$A<2JG CK-V@[A=VNBZNCX+JW<'BA7]DVG!0VW )MP"WB8&FDA5/
M$2*J+ABGTZ*S"A10V<>+'! 99"]]( FY$NJ__P"O7NG*]/YL>Z<KT_FQ[IRO
M3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<
MKT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'N
MG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ
M[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/Y
ML>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3
M^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<K
MT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG
M*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[
MIRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL
M>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^
M;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT
M_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*
M]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[I
MRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>
MZ<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;
M'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_
MFQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]
M/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IR
MO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z
M<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;'
MNG*]/YL>Z<KT_FQ[IRO3^;'NG*]/YL>Z<KT_FQ[IRO3^;Z1Z2^>S8CM&\\XM
MU0&FQ4C)41%5=(HJ[D5<?_JR-_L-5_\ Z.*A7XM>8=I%+=:8GS$C3A&.Z^EV
M@)LHPO$I]6S;)/&N$%,V1;JMNE#J8I\)%"043RJJ)@)U)G1JA$/N7XKHNA?W
MJZ>Y+QB5B\F!J.8*BU389.BP+K@NN:G2WH ML-NNDMDNM@L*;UMB/5:3*";3
MY8J4>2VAH+B(MEZ+@@X*HNY1,1)/%_(2I(-$^3$=UX6 [MXFP4D;'RG:R8JD
MJIY>>H)P)HQVM>UV4H30U5 VXB>VCZ$21NT7<#3UHGTKT9_-,9M^.ZXP\',Z
MFNAUHU!P;C"45TD*I<55/$N)+N7*HW4VX9 $DFV9+.R)Q+@BI)995;I[VZ86
MN5H9A0DE,0[060??VTA'%;Z#CS Z.U%J+:;MVY;XRK.HF6Y==C9DT.=PZ+K+
M+FS4&M#.T09;HN=!'#V:*F]5PV:B0*;8&H%W0*8H2@7W07TEY4^M#<,D &Q(
MS(MPB I<B5>I$1+KAC+E(@5N?SB;S%NILQ YAM;K=U55U#&**"3BND@ELTU[
M/J_DO'YNOR8S#"J&6I%$:H[VB.^YMK/)M3;V3NV$4YPB#M%V2:-))[&7*!"R
MS(JT6LFT,B:UMKM(Z^C)(QH%6M; ]N<VRVT)U<?I9TUJ.<MR)%>D!%;]L?)H
M%-&AX[SM;AB=/J5!=H;D2;S9L2VNRDAIU7;VZ(YK9[A[=IU*FGKM]93:=2ZI
M%FS:;?GT9DB5R+9S9+M$44MVSH=>_P"DEUZJI)6#"V>V2(T+S_;31L=#9N-"
MO25+W<&R;\4^NTY'T@U)G;QTDMHT_HU*/;&Q-P16XKP,DMUXDUNGTDZS):>8
M:&(.TTBCJJBON[%%<V3=NEIZU3?C+F9\STVJTY:^ HD"-&&0_'D;/:$AB\]&
M46E'>VI=L5%1"!%PS(;OLWVFW@U)8M#HH8ZDWV6R[TNN_P"F<>=) :9 G7#7
M@#8)J(E\@HEUP<VAU&/4HK;JL&_&55 7A1"5M;H/202%?A3$F8]JV45AV2[H
M34>S9!7#T#=+EI%;)=+KUX=J]$&:,1F4<,DGL!'=VH !K8&WGQ4+&G2U\;I;
MZ3,&6)66)-.A4E'E8JA;;2>Q<0!21M!%N\I%UQ]C?<BZOI6IV8:BW38KSW-V
MG7&I#J&]I4M"#':>/N45;J-O+B2_ERJ-U-J(X+4@FV9+.R,QU"*I)995;COZ
M**G\LN0M-0[.BTV\I<V;YAH=BMS!^J.<;2^Q=&_U/;7<;]>,R99EY:D4V'1=
MOS>IGMM+^PD"P(O:Q1O5*$MO'V-TV8%JZK_3W7<B;U7Q(G%?@P.7*;!K53-9
MPTXJA#B"<(9"GL^*N(2LB5[N*@[A4D14W^P_)<U;..RX^YI2Y:&@4RTINN5D
M6R72Z]>,QYIRO3*G4BR^:1R@RXZ1W7I! +EQ%AZ21,@!:G%2Q[K:>O$2MSZ4
MY1Y+YN@44]>DD;*R/,[7MFR/JU[_ &'<NMU.,=<9;5UVFHI<Y!M!$U,DTVMI
M,%[K@2?R>9:!,RU(I<6B$:1Z@>UL]H?V*"_M!$-3X]M9V-^AW2=?L9=I]/RT
M_6FJP[ID2&]MVGMPM;%G9"H[>R[3MJZ-*?#@5LHZA$M*\1NB+I7RCP7R_P E
M6_Q5/_5G,2XF;Z*E1J#DY767NQ[<O3'V:)HUEO3I>#BO5?*5-;IM.F2&1-L(
MP12<>CR!;4G #K2]D7Q8RN_4LO4J8]+ICG.7GHH$Z\O/98W-RVK5I1$0KW2R
M>+%3R;2'GBH%1;=O"(U<!E2822P6^]CC%<$/NE;5$*^*/D1V6+-!R\VY)KCN
MW%D><$WK=;$R5!VH(K3*>4CMPQF?DTFO@94V9(G44T<0P>C:^WMM$BJA= FW
MTW^$2=7L9BIE.S>]"I=+JYN2YDLMK(%M)3@,P(BVVC;9 V6L0)L??J7#$G)U
M*S9$R73*(G-JA77]HKTV<R()(T&RVZX@HYJ!L&]&NQ&9<$P>4J]F6)G*F2(L
MA^GUZ,AHXV]&C.RU:<-UMIPA<:9<$D=U*VX@:3TDN*U5<OYG#*U$I<Q8T..T
MEFS/3K:9=0!VCZDVH././$2)M-(C9+8SA1<V59^2[2:/+188&G,69D9Z.RDF
M,T*( :QN:**)[8NY.&,X]G*K,JG,:NPS$YVZKO-VBYSJ!N_<BND=WDQRK0:A
M5YLN'1Y%5&EQWG5-J"+-1G--)''P$!ML &W4*8Y1JI,K<Z14:8^^E/F..W>B
M6CZNTEX/2WXI^:JSFIQ<LTEZ8CL)U=4NKBP!D\LEU+*0MD2(&U)4Z/1%-ZXJ
MDH.4:GY I<2035*@KSA')8#?0XX49APG$-$17''7%1%+2#=DQG07.;US,65V
M4<@U*.SJ:F1''M@LUUH #:\U]OOH#:-VVJ7OBGU)GEDIK-1E/MD_E^<>QV0D
MXB$R++S8Q''-/<--C9;HB+@$(M1((H161-16345DW)J7?9-V&XF6<D,RIM8Y
MP]4:S"I/.G8##97>]J:-1D2+JNU54T@A*F_!0,KB^W-B$"UY)H($]Z::>WN:
M5458W*VP@]%L1TVU7P?X_I/]B;CDG["U273>>I":E\U<T;=M&HM@<\:=)?CQ
ME.C95K,B$=4@QA2+K^HGI4AQ6MK):)%$]*+J6Z+W/!<99#,>9_HGI>9)8QGF
M#OLVU)]EE\6@-+L&PL@'&B;5!-$TJ.&LD4.OQ,IQF60=JM?DH2F!NM;46@(&
MW7&T%M1LC0H;AGO-!3%-RQ4LX0\^46LV::J3(N[>'*/7LT4WFFWDZ0H)M$KH
M*)H0J*WQ7HDSE"C\G?8V<]&@TF0+T830'"$!,Q#I*B"*N.OFNK7<$T6Q [.U
MJ)F"H%M2.J0=B49]I7%V*-N,H@NZ6[(3B](BOJQ0^3_);C42M5K9F_4'$ CC
MMO$0MBUK0A:32#CKCNA7$$+-V5<4-[-&81S9EZLR4BR=KO<8<Z.T1HW$VS1M
MBJNMJ);-Q (2%,4W+63ZT[$&IT:%L8CY(M.:.4W+VTUQ@T(%<9;':B6DE0VQ
MLF(L',-76N55LGBD5)=7;MHXI /2WV;%=">1,9;R[E&LNP3JL)AIN*9(L!9#
M[CH%(?9-" M )JN0K;3N3$/+KV:&LPR,QL"$$Y;>V89>DN;!'6P<36P<9Q=0
MHBJT0]T"INQEH,RYG^B:E9ADM,28Y75MI7'@9>!D22[)LJXAM&TJ"2)90Q_D
MUR+.:HI1FC<J5673M^UMHZ\HN*A$TW'%4L+*"ZX9;RLF*-E+.E7',U)S'I&#
M4"WR&3-S9(XAJFVZ#MFW67",50D,%3?C,V3\KYD=@Q^V=*46TC4N$P#:NN16
MU0M#RF8B*MIM-_1(=ZXR_P G\+,<:G53L?&<S%FV8A*H$Z*J"AT'G&];?;C-
M 5U=0"*BERQ1J7-SQ"Y0:%67VHLAYL7^<P'7W!9!P3?:;=!0<(5T:G&W&M71
M0[+B94'U^IX45^8ZJ<=E':)XK>51'=Y<52N4/,S>5*/#DG'I\*/<=H8IK!IT
M@3:.KIT[5YU5'42H#:"EL9VR54:FE+S9EIHWG*S'33SVGQS<&9&=%G0FT,0V
M2N#9'6WA4AU(5^S;%>V- @5&4U/H>E;3GW()MMO:N";-QQMS?_-XS-4:=)=A
MSHE--V-*8+0ZRXA#TP+J7'T71\[NQHM-8FNQ8JG:94FX3KION27T'MAZD-EI
M'M5P;$=R8>SA/99D5R++6BM]'0S*FJHHS)-L;)80/:.@%D70MDWX',X\K5,D
MU32,H\J:'B%!*R\V1DHJ0U=%%L3::;<$=NE\9=K^6*[2\HN372:KTN>XRRS'
M1L2;/FLF3=0[>-Q$2$R$K:^COH%'J.>(.?*+77FV'CCR6YBQE>=%GND4G([S
M9DA@.TT.A?=B'E?*5;>B=D(<9EB*Z:+3VG'P<VLHV20@4VQ%315$K$FY+XB0
M<P59:Y56E=634BU=NUGJ!.EOLVG13R8C4NKU6;)RKFIK33X\IY2BP)#]A#8(
M6X$:DCL[)Q1Y$ZL)0:/5)<3+65&$6L,Q75%B?('VP)*)N-"?-&0W]RTN.5:6
M_,EUMZ@I,>I,*02N@!M/R1 &P%-2B(@-Q3>0A; U-.6&FTBKNR"1,O3BYHRW
M9S2(J!MI#L?@-V+Q$M\<F5,B5R4VU/?I+552,0M,5$G*G%8D&;8)HT/ 1CI"
MPZ"Q)Y.\C5%J@LTP7"J-51/J@B:T;=4<L1 TRK@-MML:3<)54SM9$IF1\[U4
M<QT^O:!IU4M]4-.NJ0LEK5$=45=%&76G5/3J$P*U\9MREE[-;]/BL.2C4Y);
M5JG08[C ?48*BJVXKCS8(K=BL2])$OBH\G&<*IV?TQBDQJ@:ZW05&6Y0$+JH
MAJTZR[8FW+JV8V%;8JCS1JVZS3Y;C3@[B!P&#(23RBN],9^K4JN3WJK3I#R0
M9Y._5$5$:9+M)^#O)5^'!YV:SNZQ$I;;[K,/5:5/9BEVYR0Z@V=+J 7M>I$M
MT<2\W0<T,T6)1VG6684(.:G57J>R#LMYTA1>D>KPU5I3N( "7QF&OG+.-F"C
MZH?9*)VAXR$VE"0FBR Z39Z7%!$15WVQ&S9&SJ40&8CK\"GJ2H_4F(FT4WI3
MFA1<<>4#0-OKUB*<$MBOUM))T[,M%DQ84B?!^IR<4W0L^"#N:-QM5%T0L.KN
M43#?*)F[,O.,NQ*-,D-44=SLMID%1F5)<1$$GG'!W$ZIGTKW3N<3\T4K-3>6
M:<U)>:IE,C7;:=)G?L2THI$B=R3T@G%,E7HH.,W4Y)TFFYVR0;<E^;3"YN51
MAM..M/":-(@(XFR<UH"()Z1<L/#"9F21_P"49M]@-7V7LS[44RR;T5&+RQ7W
M^A>O&4*,]6#<S=FADJC-K-7+;E28#[M@MJ$]XW4$)6RV8MFHBIVM3)O^4:GY
M_I\E\ JM+1)"NL-K;:JR4AD";445=BXT:)K1$-M17%)H.3Z\_!9J],@'&C.E
M> "RXYFY)<8)%%3 .FFZ^L4MB)DU<T-5^9F5E@*?*F-[9N*<MY6><-HZEV"C
MJ#BJ*[1K1TM"JB(F7*7F;,WT34S,3@ X#ER $<>%AS8(::V'&'#$@4%T&.Y1
MMB5DVC9HB9*I=)1&Y]<?UJ[(EZ <<!HV6W7!%O6C0MAH4G!<4SM9,,Y+J^9H
M>=*;4VS2GUR.CFV8E(T;H-F3C3;ABYH5LP<U[,E @.VI,9MH5'SG(IT*!-DD
MY*E$KQQ6@ENLQX\-;;1I"W(6A1Z(I=>K&=.36OUC;UJFP9"TZOWU/QGQ)IO4
MKB().!I?!YM2[8*HH7QF1FG9I<I\FD2A<KL@=I>MLMU+2\T=BOVUQ%-==^/C
MQ)9:<-AQYAUMIYM=)M.&"H#@%U$!*BHN.42!FNH/SZSDUR4\P_,<VDE]ES7'
M8%2/>2!*1M0'WKGBQF"%G*HRY1I22S'3BGEOYDR)N/I'U?8%"Q@G"W#'*!FB
MM5&;)BU2K,M42'(=(F(<"/-&ZL-+N#41(%TXB&(6:Z9FU*;1Z-3U?I]$C(C9
MO4Z.ZNIUY4#9NF2J1:'M6H4M=-R8^BMB2=-K:/L0WY4/M2DXU*1EUP$WZ$>3
M>0IN2^[')=/G/N2IDP8[\J2\6IU]XX**;CA=9%UKC+63:!4XE!?F4JGR*I7Y
M72YBR\P.R;;L#JM]!%<<<1LG%N MZ>DJT2!,SY"Y0*'6)3,263:/\YIYR' 9
M%T2D- X.S-Q"LAF#C:$FD2MA?,MOBW8S/3*7G:13X=/F&3DN62NO-=O?;CQH
MA(FT: D%=IH)$L WOC.F6<Z2^R<G*$9^:E1NBNN-17-D^T;EAVJ'=MQHS36B
M$2$J[L53,%#S.WE:CPYKL.G0F+MBZ\V#;R,.*VBN.6;=:5UY\C34Y81TI;&=
M,H3ZFE)S9E=2655V!T\\@Q77 F1G!8T#K<1HF5,;"Z#B$27OCLW&S"Y'R[&J
M<EF9E]->SER>:L_5"V71>Q-IO2_0Q6_Q34/U5W%=KP- _);K[L>$T[?9%+?8
MCBTKEE15 >Z(4WK;'^4(<XH-XA58* @@C10!N?M&CFEU;34C*CO#BYJQ0LQT
M9L*=4*E5G:+6*@#2NM4XXS8*;[**)BTDI330I(NC>+?2MBF.IRN4S-5,-">J
M=*5S7-,=FJ[&/'ECM43:*FMUG2K:!PLN.4*E3:K,D4VG1YA0H;CEV8RMN(C:
MM#U**+NQF*%3,[R*=#ILUS5+E$KLG:$XX+$5AP4VK;5AN6DD1/$6,\TC.+O9
M.;DAAZ5S[=MI L&\T['=-$3:=L:16W537I-4+N<3<U4S-S67X#,UYFG4T0M%
M=)KI(R;0@J&V%T;)V1M2,KJJ6QG:GYKJ3\EVF TWS':7APY02WV'^:-]RV"J
MWNT[K6M;"1ZK C5!@%5P&I30N@+FE4UHA<"MUXS8B<$JS*)ZG!5&$VT[4YD@
M8-/1Y-33;QB1$^073:;$!4A#N5*VKHWP.?Y&<!EBVPS4IM!<0399A/:#WLJ'
M-ET@7;&VA!02^@E5,9(S5EV;+HDJL50FI80W5#4;#$D'HZKX;/.6;HB\4M?$
MRJYVKK=1=J[$5^+3&!TL4BZ*X38(*"W=1,!+0G$=Y$N_$*=0ZE*IDHJNRT;T
M1Q6S-K9F2MDJ<0542Z=>*-GR?G 'V9BP5<HS8CS9@)30NQQ>8T(R]M LCRC8
MT(KZU+I8C\IKF;&V(KRL2_H>C!HBQX4@[,ZF216G4X(8%=S2M]HI8R;+H+#+
M.8<ZQFU;-P1<;@KM.:O&TVY<%-R2BBUM$, %;V54Q"S75\U!F.GE*89JU*?[
M8VPKZ^TAK'<B[VT>C[/9FB;E'')Y)R?49,'Z(H34AN$CEH\B1+=;;8"6"]%P
M0)S2NKHJB;T5,.OY@K;-?S57:FK-->,?J6FHK*')TMV02")=- ""-J9#=-.Y
M8V86.56EYEEJXTY,RR0R#;0'%N;(BY&;9L*=$U85D@XMKNQ2:ZR"M-U2"Q+V
M2[U:)P>FW?KT'=$7Q8<_%D/]@P\<I-*FU67)IU,;FK AN.79BJW)TALAMNTC
MN3R8S'"IF=GZ?#IDX]<N42N2-H9NC'B1W!':MLZ6KF@D@I>ZH6,\TC.;_/Y>
M1VY3[L_H[5P(1R&9#+KB:4=TN1U4'534HGTN&)M;=Y4*9DS0^[V-R_:0&IL-
M[8N[".X"B2=':/$Z1E=51$Q6:JPTR_F2C5"-3)-29CZV!B2;VJBL(.R1P439
MW449U$#A-\4Q1IC'+'3*@4I]@ZC0I+G;P:-4)Z*Q&E C;CR#J;1&132N\,.O
M'W#+3CI_>M@IE^9,5J?EK,C>5,OTN4L6$#%Q)\^DK2.$VFU=(P1''3,]F&I!
M ,9QY.*M54I^;J(T;D?,#":3*/&-.<LN[#1K5QM4T/)I,@=LY=4Q-J</,2Q*
M32:X U>E:25*JYLW%UJ7!/AQ5\P[%)!P6/J=@E5 =DNELV!<)-Z-ZUN=M]DL
MG'$K/ 9N::8EQ9C[&7S!.:R(*"XC@HR@;!J[>I&M2$XMKJ>K?CE2J,&0Y#J$
M6:+S$AE=+C#W-HJ*0+U+TB3S+BB5R+*>E56HU:3!F5N2'.3I\9#+0:W%00C]
MJ;,Q5!LMDU*.*8\URP4W,,5^YU*D&YJEHBM*6RC1Y8(6H35-1LH*@@K;%6HD
M?.+T?,;<5Y][,";7:.QME&<YLO2VGM+C37&W:^%L41BEY[I65*:,#95:H3WF
M(LE^>U;MK#SMGG$>'[&V8Z215*^I,-Y$KN9(N<8%1:>6#5HSS<G0\W&=F"22
M0N6E6V'6W6'%/0>A15-]\W93RYFI^GQ&I$Q+R2VK%-A,FUOAMJBJV[J46Q4+
M%I(MZ8F<G6<:OV? H;TN-4#76XVK4?G8F+BHA[)QE'!)IS5H<%-*VOBOPLHU
MX,JY?R\\D=7VMSSQDX^VR3C@)MG2D+'=/2ABRVV'!27?F2IY]6%5W::Z$?+\
MD7$YQ/>?-&&EE;,0U1M9(]K+M^C4*]2X7,Z\K5,8J=BDCE30\@:45;1MES58
M>NW!M;[K7=U;\4^O.-"Q*(G8D]H+[))L541U6K[]FX) Z*>#KT]6*"LRJSGL
MGYD%&1@NNJ4**\Y]3.:!X";+Q-.AOOTUZL4?*&7ZM+A4B@LC,S+S)U0"46YX
MXKRIQ1 5IJW#MI=:8Y66GYDNJL4*!+DTFENFILMO,S-+8,MIO2X]KW;U'=B1
M4G.5JGY:JO.W09R[-(H#":%Z*%=M(C;9+VM-IK+HKM,<F45G,+_.9RL#6),!
M6V8]3=61'%QS0TFSV9(9""AN4.EUXC<FN1I;=(D PV[5*P5E>0B8%YP6RL2L
MMQP(=6A-LX\JIK0,47+F<ZRF::+F(FVH\TN^8YNO(PCH&2;7M3Q(+C+A&! N
MH=*IOS!E#+.9WZ?&NX@)(+:1*?%!IHS=CM*A:7;KT%&Q=);*F&.3W-U:7,D>
MJLF<6:YTG&3YL]+:= RLX($,=QIQDU)$72H6WW^FJL9@-H_(I\MEENZ)K=<9
M,0&Y*@IJ)42Y*B>-<3X.9J0$&8[4U?:;?6%*(F=D(ZM;#D@435X*FB^3%7HU
M"@I*GR>;["(TL>/KTO"1V)TV64W;^D:7Q3<MT_(\$&:='6+'FR9M,,Q0WG7=
MJZ(U)472KJ\!7<B;EQ7<^9A<"OYYFPY?,8,9P-DT^^/<[=_8M*Z5A#P666QT
MBI=UBIUCE&"IPJY/J3[PQHT]C4+1KK)QYR.4ALMHX2Z$1VX@EE1,97S'R;Q)
M]6;BR%[+1Y$Z*CX"A(A%KE.QA-EZ.9AH'66T#?9+8 B%6U(1(@6UP54NH+:Z
M7%=VY53Q+C.KU>IAT]NJU)'Z>1/Q7N<-;>06M$C/O*'1,5LX@+OX8E9\R'&I
MU8*IZCJ="J*,=-YU$VY-<Y4&";=(=I[:T;1JMM2+NJ<G.]!R]1:=(B+'AP(3
M,3L@PZ:*VZ:/15=!&S:,D)5>(E6UA%+WJT/)4&G9@H-7E+(9)]^.WS0UZ+;L
MAM]Z.X#C8:0-&E?%P0%=R[L9XCYA?:E5=:7+[)NL[V2D.RX9.BU=![6&K0'1
M1-(INQ7AR93J=6:/F"3M1DR)$<&XG;'28=?:=>9=!QC;F)HR#XF(HOB3&>YF
M9X7;:U&>V4]N1%<9J4UYZ0\\XR+;NU 7#=U)MVF=Q;T3ACE!HE0HSD:J5IUX
MJ9$63!-92$QH14<:DFRWTMW;7&\,4/,,$H,WG-1VT4G6'E1F2J(*ZX[KS72&
M_ U5.O%53)]&HV;:%5)"R&8\U(6WAK<M&I)KC&S5L3T%L73%X1%2%%3%75^+
MEB)G"6ZJTT&F6FH\>(9"I,2R9:)EQP!U(R%G&]_;'%ZH\&HY$RMEMP93;LG,
M\-(##[@@N]46'(=D$B]V@*REU3B&(D/:[=V)!8C;9S[,XPP+6U<Z^V$.HNO>
MN)<1JAT2O,NO/<UGL/Q %AEPBV:$+\B(9[,%3<3)+NXEUUFJY@?CG6J^XCCT
M:(6IF(WM#>42.R"3I.&JJ@)H!.BA%QP5)H$$JC4%J].D\V!V.RNP8&4CIZY+
MK+71V@;M>I;[D7')I#I=(<ER:"49:LT,F$WS/0W'0M1/2&Q<LH%[2KG#=C(U
M?I]+.32*0$)*C,21$ 8RM.ZG+MNR ?/2F_M39WZL9$DT&F'4&:15G9-1,7XK
M/-F5DT]Q#5)+[)'T&75LTAET>%U2\7/^24@3*FVRVW/I%0V6B5H:V-PVZ<W=
M0V^B8.DWI(1< [I;'/\ -F6\M4"D-1B (3#,(II2[W;?9<B$_I^Z4GDL*[@5
M>%0B5+(&3LRMRG9"0ZOHIZG!9>(D95'9+T:4I1VR2Q;)3Z/$EXMT>K20D379
MC\YQMHU<8A[<&AYHR:HFH0V:F2HB(KKAVW8HV=LF28[68Z&@)S:26S"6VT:F
MWH-44-?2,":=T@X!JFL<48L_0X.7:#17TD%#8>8==F.W'4381GI**3J)L]3K
MK:--D=A)5Q0LU1Z89Y<A4IB*]4=O%0&W&XTYM0V)/I**RNMI<6%3I<>/L9,S
M-"IAOT.EA&2?/1^*(QU!7]5V7'QD';4/M;)\<9(KE*I9RZ52=CV0EI(B-C'T
MRD<*[;S[;QV#?VIL_CQDN30:8=09I521^>8OQ6>;M<Z8<U*DE]DCZ $MFT-=
MW"^/\HW)Z<654' )N?291@TLA"#9.;(G5!DP?;MK W65!40A)>&*7G'E%:B4
M>-0=/8VBQG6GG%,"5P478&\V+:N+M7'%?)PE01011,9HS3+IALT&H0I;42H*
M_%(7G'.:Z!1D'RDCJV9]VR*;MZ\,4S.^3RAG7J:VVU(I\_1L)[;-T:5-JBM$
M2-DK1MNZ0(=*H8JF(LG,^5LL9?H<=MP9+ L0'9<AVUVGHI1#D*#@.(F\W $1
MOT26UI4*0FIB9'>BO#XVI#9-.)Z!+BI4O)D*GYEH50?-^*XX]'9=A&2:1=>:
MDOQU1P1TH8MD\!Z=71OIQFZL5Y]N=FS-4&8VXS'-%:8VP/&C".EH$G7GG!UK
MN:!  46R*2U.%F*G'394BJE(9:-Z,^ILJT Z]45Y\$WHJ64D+R8S)2:7'674
M)U/-F+&$VVU=<54L*&\;;0^<S%/+CZ'*C *-6NQ];9YBKT<RVLMZ44<=JTZ<
M?M@N M]K9+])4Q5,FYDC%1*G(JSM0A*XY'D;-QM&2CNFL1YX-F9 H&.O7ION
MPQEB/E?+,@(J#&C9E>&F.(,<%L"GM"20YI#HZSAJYIZB5+XRC)I<>FU%ZA#J
MJV6V32%3JA*-6C<>CBXK31"2@32BZ3:[-Q5%>(KE&MM<G=!RM"I\^.4N%0GJ
M<#K;;4EIPY515'Q%TM(KL48)\D"]T15Q1LV,4LSR]%99%^H[>(@-D+#X$FP)
M])2V(A3HLKQ]B#*R^RKN8Z%.;DT\0<:8==:-4VS8//&VV)-$@/MZC%-0KOO;
M$^=F-E6LRUV>4BHHXXR^ZTPT7:&R>8-QLE<)3?/296(^..4B4M,9I\ZL&^YE
MYV=)C.17WBDR#;-WFKLDP! -#LZVG4BCQQV+J>0,I0I1NM[7-D=*='>T@5U)
M'&'RDZ3\).;7+?T4QR3C3HKM:AY2"CL5:J\XBM:>95&,\\ZH29 /FB- 9IH%
MPE$;;RW8D<H?)YS2?)G"0U&C23!HW5<04>V9/$VRXT]H U0G62:,;HI(MDI^
M>N45J)3$HVGL91(SK;IBXWJ5I3V!O-" .%ME+;&XX8BEA1,9RS+4:6<:B52'
M/;@SUD1#&0X],I[K8HRT^<@-0,NEVQH$31OWJF)&;EIA_0Z=.%@:EMXNA7>Q
MS+&G8;?G7MHD-]A;=>]M^*G'9'6\_ E,M!=$UN.,D(#<E04N2VNJHGC7&>LN
M3:*XQ6JN^Z=.@K*@F4D2::%%1UN24<-XJG;70X8E98F4XV:ZY3ZFR$!7HQ$K
MCY%L1VP/%&Z=^.VLG6J8F4"L4\H57=6N[.&3T9TBYVR@Q^VL/.L)M"W;W.CX
M5L9ZI^8J<=-EO/\ .&V3>C/J3*\W'7JBO/@G214LI:O)BETW+4"FU*AU>))&
M#4=O'"528S[SS+[+R2'65Z);4P5MN1I$MUUW8K>6(0!5\RUB1&F26HSK8-*X
M#H=I9>E$P!(RVBW,U#6O!,4O*M?C%%?*BN4ZH1M;3ALJ[M$7IM$XT1#J0D43
M(;XG9>RK!IN8J+*?==A3B>C-%!5W=MG&I+\<P.W2-L=N&I-0KOTXK$ROOLSJ
M]F4]55V2ZXX,*KA+%U*@[52-UPG2THG2TCN3 4UZ,ZO)ZQF ZN,E9438FRB;
M5L.:[99&V.S<-SM")H0BU<+TBJY?>CQJ_E\OJ-N3NC28R$+HQB722 K;@W;U
M"K9(1 >Y;I2VJQE+*E&I41\.RDIQBG.K48Z)I<V(17'W!<+NVTLRFNRDMKCB
MAYIBTHCR]#BQFWYZ/Q!!I6X[P$.P)\9*Z2(4Z#*IXMV,DYD@4PY%$I3;"5"<
MC\4!CJ#\DBNTX^$@["8KVMH^.,BU.BTLYT&D/ZZC(%^(TD9.>QW;J$A]IP^U
M@1=J ^%N.'L_9$8I]5>G#_G.A5%&+..;(&G%9YSI8,'D; NDZT;;NHD)4*R3
M*AG*@Y=H=/6,@08,-B(L]F4B^VB]%5T$ Q54/4\J\-(C95QGFH5NEG!AU:01
MT]XGXCJ216<X[=!CONF':R0NVB'BXXSCF>;3#9H53CNA!GJ_%(9!%S&R(RV^
M4@+[)SVQD$Z/E3%=J^5:5 KE+S))N[(=DQVN;179:221YMYYET'6U4ANT+Z*
MEEX[L(JII6R*J7O9;;TOUV7=?KP=1RU%,Z'F1N$-?=:DQF!8)MT1E*^V\\VX
MXB@ OM[%MSI)X]V*',R%!-U6Z)]#E1"-(BQ32 V MMJ:R'F$,'&T47-"J7DW
MX^@R@PN=U%J#3VQBMN,M*[(%X'I2[1]QIF^K6JJKB7MNOA,KNP""O?0U)@]C
M]K'4N=&1Z6MLCJQKK=.EMM'W6'<I+1G$S"525]*;SJ#K5KGFUU[?G/->XZ5M
MO?JM?')WE^G49R35Z(S'&J0TE00*(01-F2$Z[)!ARQ]'M+CGDW8RYFW*YQ$S
M'1($*-)IL_9[&7S5L4%!(D)DC#IM&VYVMT+6<&V^&_F7*N6*!1(PFDQM&(#D
MJ6=NUNQ5B.2% Q<LJ:C;$4U;EW87S+^C&<GZ_2SIS54FMNP#-^(]S@$?E&I(
MD9]Y0Z+@+VQ 7?PQRBU*LTLX]!S'"F1(<Q7XAI)&1(87HMM/N/@NS$R[:T'#
M%2H^385.S'0:A*<E1'#>C-N073$6MNZW*?C*CFS!H7!!7P/9"26[G&99^9)K
M3^9,W-R!G$PNT:BC(VIJFO2.MPG75-S2F@;((71+JN6BHT"7E-^J'+DUE)4>
MZ-$VC6ID=LDG6HMMJK91;(5T0[;\52,P.T>D4Z8PR%T36Z[',&QN2H*:B5$N
MJHGC7%:R=F6,5$J,RK.3H2N.1Y*-F#3'-WCYH\\&S4P(2'7KMOMCZ &Z?2RI
MFP6FAF/GD;H4XKHK>I74E6T+H0^9*Z@='RXI&7\DM4>M2V9;\NOLU005JH*^
M"*341I]-EIUH@W=<;70*>/%#S%5<KT3($6BR&Y+_ &'6(V_/)L]=D:@OO@1N
M>UF;I!9M2W%C/M>J%*.-2:RS-&FRUD1#&23KB*V@MMR#>"Z?SK86Z\9L7,-,
M.G=D:D#\+6_%>V[2$XJFG-7WM/%-SFE?)CE,E9BI11:%F493462<B(8RF'I<
M@R5!9?<=:[2:.=N;;MY\5.)D7E4R>&6793[CZU*6+<RG$EP,QBN,N=O !LI(
M;8NJ*%IQGRHI*<J,12CQAJK@DG9!Y94ITG^E==1CI>)%WV='"^9?T8S$UF.F
M'37)U1;?BB;\1_:M(W923FK[Z#OZCTKY,'26I 19S#PS*>^ZBJTDAM%30[IZ
M2-N"J@I"BJ-[V6UL!D.?3Z7$I>R:@2LPK+C+SF"QI%!79NG)+4 HA+S0#>3<
M6F]\9*RIE2"Y6'*#4]O,(7HL=;.,OJ_)^JGV1L<AU; "D27X8C :6,([($GB
M(6Q0D^!4Q#I^7J>52F-55J0;(/1F%%D6S13U2GF0XJFY"OY,4J@T>G'-JT?L
M)MH8O1FB#FD5MN1VQ]YIE=F:*FYQ;^#?#668=/)ZN#2Z;'6 CT821Y@@VH;8
MWAC]"R[]K9>I5QD>&VK=)S?E.*2@Q*< FE<YV\_S=Q^.K[8FG:W&W V@7Z)=
M=H66\U0J=0:(Q(9>J-1%^*9U!6-R.@W'?D&1\3!L@8!3+4:[M..33Z':6Y-I
M&5^9,2Y"/Q&N;,QI;!:S!]]IPU5L"<79 ?BXX[',/A%J4*5SZER';[)'K*)M
M.V12%MX+)K1%4%02LO#$&B'E3*D<(AL-NY@DM4QQN1'8(;ZQ;,Y!;1M-)$D4
M'"^X5;X:;T--Z %%!@=#(E9-6R#P0U7TIXL'F_L6?T.+!C-)4]O$T;0*1&C$
M.PV_.MSX$'M%MU[Z=^.4.NU"EG'I5;"8E+EJ_$,92NR-8:6VWS>;U#O[<VWY
M<9N^B&F'3NR549D0=;\5[;LB4C4:<U?>TVUCN<T%OX8Y4GZ_2W(E$S6[4VH,
MI7XCG.XTRH3#0A;9?<=;NP\!V>;;7?94O=,3*-EZ@4'-M&D27'X4N4D#:Q-I
M8=3B3'([HV014V15YO7<@[I4P#,:/E?Z,7)0N3&Q9:;A/4]'%-8IBC/-WI1!
M9@KH+2 JV<U)K6DN5')N7,CA FMRI=:IG,F9,I )%54&#(?-PNC=L31M$)45
M2W*F"9/I";2LG]T)!H+XT7%7:R+#@9CH%7DK):8>>CM.PG.ELR<"2]&TDT):
M%V3C@NB**0HJ8S%FS-LEF1F?,3$D"CQSUA&%]%)1-RP@KIEH#2%VVP$4VA<<
M9G9S#33IKD^M!*B";\5_;,(T8JXBQ7GD'>J;C42\F*KEY]U6$J#&EN0B:MA(
M!=;#NGPD$TZ2=8JN'LBPJ?2G:4C<B-%S 4J,HL1'4+4#2*\DFYHNEM#B]K(K
M:K=+'*+ERH4=QJM5M]"ID194$RFHC,85,70E$RW<@+V]QM<4:C4>E4L:U'J$
MMVJTNL.19"/P2(R;8:T$]$,GB6YZG@THB6)%OBA5FJ93H.0H]&F-2Y4BD<T:
M?J*MN@\J;."^^CA.:=E=Q6[ 9]UPP]G_ "13HE;[(Q>:O17GV&BC:F&V7-H,
MAZ.BM]I;,#:<(KW10QES.'T/T[-*,4R*Q4<IRY3*18TL!+G" C[C4=YAPS5W
M5M+ZTLHD.G&7<U2\G4G+M%:;?.2Q0GH0PJ=M*9/C"VZR+PO.22==;1TF&G6^
MFEC5!54SAF:=2SCT.IA.2#/61$,7]J_')NS+;YR U"!+VQD+6WX#-JTP_H<[
M%G&*I;>+HVA4UV/HV&WYUO<) OL+;[WMOQ6ZMR>QH5?H^8'MM(IC[S++S+FT
M==#6DEV.':"?=1MQM]5(#42;Z\9AI'*/48K;M9,'Z5%B@V9T=YHT>9VKK5@)
ML7!$=@).]KOVY5+ 97@Y8RU4X\=59A9B=2FN(RPI*HJ>W,)!Z?NXQD-[=.V(
M#-0""W4!CM\_[&M;&$4O2FV-D+#T27K5$OXD2R8V5*9VU=I4IJHT@4-MLS='
MHNL"XZ;;8[1OAM#$$,45<5JMYM8<9S'6IF@T??9DOC#9L6LW8[KS7U0ZJJB(
MYJ06[*B;L<IM:*FA#"M17TR_+E2(QQI,E9HO,[0([KS[8:4UEM61W):U]V'J
M35.3_*)2WR$2S8PE.8=#I75T70>YT-_"7FJJJ>!CDNI=-C'7?H8LE6F-R(S0
M,?5C+RH"2WV7#9;%"1O0AEI'@BK;$;E%R <9ZKC'::J%)E$#:2=FRC)*R;BB
MT2/MB(N@XXW8TV@N>#BDYHY1F(E$@T$@.#1XSS+SSCC+J/"G:''VQ:-Y$<<<
M)Y35$T("<<5[-<BEFWE^8Q)&/4=O$('"-MA 1&1?62EU$DZ3(\,9=S:S3#/+
MT*-LY52V\1 :/L=4&+*P3Z2B[:\V/08+NK\$54^LJGFB!#<:K58$PGR5E2'
M=%PVS*S!N$RW<F@]K >'VXET:JLD_3YP;.2T+KC)&"$A61UHA<'>B;Q),0Z+
M2628IT ";C,DZX\0 3A.JBNND3A],R6Y$O&WVF421%$D421>"BJ65%\BINP4
MM_+HMNF:N&D29,B,D2EJ559CO VMUX]' 4VB0&*?#!=6R8&VHUXFX7=.&O61
M*J_;7O ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO
M ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\
MRN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK
M_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO
M ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\
MRN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK
M_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO
M ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\
MRN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK
M_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO
M ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\
MRN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK
M_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO
M ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\
MRN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK
M_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO
M ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\
MRN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK
M_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO
M ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\
MRN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK
M_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO
M ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\
MRN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK
M_P KCO ?6O\ RN.\!]:_\KCO ?6O_*X[P'UK_P KCO ?6O\ RN/_Q  L$ $
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M$,4A.<]LS<T?-G2S7!4:^'S781U[ 0$F,8:_6WH=*@13"=$692@'^% B@C7
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M@)O*88A/OT$(16BL6PM&,K106$R7!-WD,)6,>2>+"N]7\,,7YT4EAVQ?AO\
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M8&:!V!8,-.\*/\=],&S>.%7IIQ<YV06;".I==?A28GM3@5ZX*(/N:(R!"7L
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MKO[M(E29QR=BV0%'#X9@ 3+V$+J[>PD'HH,;&878)+$AME974Q/H\F9I454
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M(/7Y,-Y^!^^_MB8$*$H".9%PVU.R_O P]LWCB3(GJ9LR0FW(>P(>9&!Y!##
MAW@<R&<FG3_99 ;^N8\@??/09"R?#]C $A7[SEP"PL:T/(TE)J<F^SR'8AX^
MSQ6!H@QS)]%I/'S+\RH"J $JT ;5X##5/TML>?%K[)A5&,!#$%25:X\F##[L
M#'H+#VV.2,6'HR-IRAA#S.!\-=6D[NHVWCQRS[)/KCB(498&WP+->F-I+D$(
M*1/7X6)Y!-@K?" G?.$NPA 'D5P.6)224@_9Z9"($:"*],3*[$BT%Q>IDTY
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MJ325]')PXLVI$;M)\A;M,YDN_=D@>_ZAQY*P<CPU^YXUA*15EYJ538++K+>
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MK!_S/_6)R?;$?7CC&F(3KZ8Q-9%Q\-A!!+LHS[8RW2QYB/9^S -13)/+;]W
ML=&)( %<KEGKL*I$'4OJDY"2 )44M=ZWU\T_F4YL<$/6,3&,2WFV[_\ &_#B
MJ0J5_HGX'!I8V"[3.\4NL4Z'4 .#+(NZ6^V5P[,91N_)U\9:P@4WE_V=@>-Y
MH=BF<DKVH0=$REM9AR3OS[,4(AT-@ZRFD7Q'O#WK"=A5[I_<S<*17DH>8G"Z
M=/?;++9 E:W>')]N3-26W_4<W7_MRLJ24]'\ S24>)(^AQ]M,3_*YH-/?_,]
M/>1_C'U\&3]C/WQ9 V037\SYIJM"1( 05,]8:Q=$ZE<#K*8X^K6($ 4W6!:0
MBIH,=0 PJ.C=%OK/ZB(QUE*R2OUS(&[U3%+(_P!UZS2_OQ\&A6^!K\FQ/L;*
M18\/)$ 04B3$21+,GCL)/PHXQQ&N,<ADY-FI%>_-E@Y?,(!951H0L?\ QCKJ
M(T(-!VR[@1.N17 &EL,0$YXFJ1E1>=G.0M34BTB2)YY5O""2NE(J]^JUR0^]
M91NGS'C>4:=^EX?W.'!TL3SUFU,<Q?\ ;UR,C3X_SDR=Y/)KI],@XT[O )H.
M5'[&$F3VB/V<3?UKU[\C$_PS]F.^M7OKAW^AEX-G/T=E$("DD!S@GU,'ZV.#
M7!EO+R=8QBC>-0PGRSA345#32Z^:?S(R4XP/<-D9ZS_3;/*&?)> &2!_NX#_
M -_ '(!80#,AXHG,\>H;#8.AH@0,&<3F$I"CB^_QI96:O>VS"2):GO+K)-UJ
M>'#$H.$5"$SA>F'HA=X\D.0[*UIN)&+GQS28-,L<8(&Z3RWR'#)SLO\ L8,C
M,DL36E8NQ/TS?A],=/[?^\W%],<,C\[^V?RDX^F&AHU2Z]4S41O^W^N:&Z6'
M\.7(NL2_CBYG]"OYQ&X9M#$SNR)G;XSKUQ3AZ2ZIVX1%FF6D'8TPZC"O),2P
M,/!WDW!JNR#RM8YB, 4,"=WAFKBPD4!(7W&!R)_>ES=EGZ:1CN$J119V"B3C
M.??9\8:1_P"P&0?]O //[L$?A0J#\%_FT,F,XS4V0E4X0-#=+!/Z", &R4/]
M<O)&4X5IE]K DRJZ\ & [\[ *LO?L&(G+:*)XR20*O8,C1-WNK($9D1G"MNI
M(DB'1<[RB5.:J..;+\"FT[,*:X%<8[>2\X]M*O:)'TUC<G;V_P 9(V_$->F<
MEQW+AH+^KMC)A,%/W/\ VH8R^]<,2!G?W31G]LCQ_MA*$Z4_=DP)"99441(Y
M)A6FI'EP+M0E)(P1#<8<F"*!,P*0<$=8A.;<0('0 &]C#9/3;]GFD(IHGHLB
M6;U!7T!<%\*%^J3Y9^8,)D_OT&<"X,*SX4_SE>&_^,E]3%"(WI*%66,ER0[M
MO1NPGA!9);C\]#1P1S@#DB"-MFKH+!IRNC<@#.?&>.-8W0R)[+_.1F69F?[Q
MEPC]6L%,-/L(_?$(DR9Y9<XSXSQ9NK*_$Y_3]LWY%.:0\SDI4B4:7P=8H32B
M4:"5;XT/&0SDUQ5O&X3US?D $EI:P2"$FLF_40DL 6IT^[>!@,T%Y-K+2X]
MQ(? :.*!O/< ^8,YQ_$V3_@M,.*1VOEF_1X0I"?5- ?<M!FI[YXX@?:)<_JI
M&..D(^C^-[69,,#[#C&UN,XK:?>,9Z@&=, #IC;(+-)WZ%*R=X!'+*1K;,[Y
M"5VP;!D#<1'H\84QR(WZH.CD0^Q6&I3KX +I"DZ,\SQ6<#G<F7O&3C390CT8
M4'OCG>&-XPQ5=N2..]9X,\/P;O;-O6;LF$\X*D5-C?,]G3O)HD!M24(!=$2#
ME<"P+,U K#.LX\<<994@4'L)P'T@9L*?0(\X9""XY-RGRU4^,^L%)]2.L/\
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MQ&@$.P1PR%-L&)0]H+:$-LD6P4G K]!/=R$1(%H5PV1%)6!(28+MZ/4.]'C
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MDB;-E9,#D783QI7@R28[/QRNAC.&;()>4!XC%0&FW/$?[8\93(@[NO(BL-S
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M\H*8F6F0J8N+ZC-B4CR5I! ^4R,,.>94TH0JMHW^B/S/ K$)TL%YV*G(8ML
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M^'X!"XWK<T)D9J[3U!&-=!B>3-*Y5$S)7%9NKQ 3>8DHC"UCP,B4&PJELI"
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M7# #960;;B'#%[@TF,G%CYE'E"UT:D!%0G4312P #@7>1;CB.<$,]'DD&.$
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M  ,    0                                $           $     @
M     @ $           @    @     @    @$   @$   D     DD   D
M  DD @  $ $@   D$D @   $D    D      @    $@$  $ @   $     DD
M@  $D@  DD@D DD DD@  D @  @D  @ @$$$$$@$$ D$$@$D@  @D $D$@D
M D$ @$D @DD    @     D$   @ @  @D@$@ D   D$D D@ $ $@$$  $$$$
M$$DDD$@@$  @$@@@D$$$$$D@$$ $  $@DD   $     $$DD$D@@D D@ D  $
M D$$ $ $DD DD@ @@ D  @@    D  $@@ @@D@@@$$ @D@$$$ D$@DD @
M@           @      D
M       $  $           $
M                                             @
M     $ @      $@                            $D           $$D
M       $           D @DD$ @ @$D D $ $                     D
M@$ D$$@$@  $ @ D@@$$@@        @          $$$D$D$$ $D@$$@D@@$
M                    $$ @D@DD@D$$ $@D$@D D  D        $
M      $ @$DD $@@$ @ @@@@                     @   $ @@  D  @@
M  $@$ $$       @                           $
M                 $   D $             $
M                   S
M@           D  @ $@  $     @             &X         D@ @ $@
M@$D                   $             $$ $  $ @ $DD$@$
M    W           D D@DDDD$    @ DD            @          $@@@
MD$$DD$$@DD$DDD            &X          D@@@D$@ D   DE\,L"
M       $                                         W
M            @ */\Q            @             @@
M           &X               !G                      $
M      "                           W                8@
M               @             M8                         &X
M             "T                      $              H
M                   W                "
M@             &                          &X                0
M                      $              "
M    W                "                       @             %
MP  %BQ;0                  &X                0  &\>8H
M       $              D  8&X#64H                 W
M      " $FL9\%;0              @             # !JX=PO#4J
M           &X                0%0@5-.HT=             $
M       \ O0BL1OMW)@               W                " P\[>,[9
MOXX            @             #:&'M<*$B\DSQ              &X
M              6Y,S[8;VQ::0           $              (#;LGOBO
MR[=18              W                &?\ .8?Q"1Y&20
M (             !8"0HKAK!I*:-@             !N
MY;)OF26]2L2/           !              %:@XX)(/,I,N
M     -P               ,*!K;^?\Q?-B            (
M)Q/-&3###?2U8              !N               #0'1+_ XG_J\X
M        !             'GJDELN2M31D$P              -P
M      "LM4:-T#BKO0@0           (            (] >S296M:B V*
M            !N              .0\NK1IJ [O$AL           !
M       +V%KZQ7>Z=&680              -P             !<,4R4(,(@
MEB[6@           (           !ZT+HRI &_4MQ2*              !N
M            !ZW0;2P Z [-X0T           !           !$#4R'  ,.
M#M0]9P              -P             +J"ANT),H[==2N
M (           &],=D9B8A30P=8D              !N             "P!
MYUV+0A2S,; *           !            Z^4C];;I]<@MSU
M     -P            !)Y1(@5LPU#0G[,            (      !))( /C
M X3:0O!M9/$&@              !N       ()))  -2()YA\!![Z,]7@
M        !      )!  ! &P6Q1H7CQI\'E<               -P      !(
M!!!))&'W2!IYU%-2L04            (     ((! ((&)09"9 )>R]MD5G!
M            !N        !((  'S2<H. T[OD[K8BM          !
M      +;?+CX9@><1?0#W_J0           -P            (AFDDN9L]".
M1!-,%T-0        (           &U!0_35/](JM 8=C.B           !N
M            &-+82)!#(R'!%T*1JU@       !            9G3#H?1K!
MD&1NV^,R*           -P             8';2$35'! 7YCZ,'R0
M (            P%NF/JDZ",[4TJCXSP          !N             %;%
MR$U!@YG#+,0G8/:@       !            %^>&\1+!?264"Q5E#0
M     -P             %!R6KQ/V=),,V0>D5P        (           !(
M1,50:&QB1/-H  A0           !N             !&Q[S0+%(#41<(  +@
M        !             ,4JA<7Q;<^(L,H              -P
M      $>RY"F",:6VB)B           (             =/G8J51]2DD>$0
M            !N               -8"_=@8(.K9<1P          !
M       #-9UFP-51*1+RP              -P                1\XR.DB
M<.IV0           (             8#H&Z*5-4:4=               !N
M               (P$,':V.>4Y            !             #!+0J!DI
MG4C+0               -P                -O5 4?AM>?0
M (             8! V8DW.-\R                !N
M!$V1H[9*Z2             !             #  %??%+OK0
M     -P                 *>X9WT,(              (
M8   8O3WH                  !N                  123*U>
M        !             #     (                     -P
M         " !                   (             8
M            !N                  0                    !
M       %P                          -P                 &
M                (            !(                          !N
M                #.                    !             .
M                    -P
M (           !!    !!!                    !N            !!)
M((  (!                 !            ))!)(  (!!
M     -P            !!!! )!!                   (           !(
M  ) )!(!                    &            !)!(!!()!
M        !
M       !                       (
M                                                     !
M
M                )MMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMM
MMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMML0 ;JC!@,,)L-& U@,!@!L
M!@!L-AA@,%AQ@AL,-@!AL!L !^6\,-8Y@QA@", -A@,',,,-*L?@!@!@)](,
M   ,=1[88H)Z)\PR19S-.P>8!K@C]JE*!U)-SLL$./@U)7V<#1 /C (1(8W^
M <.'-(A%9^W'<X2Z+ :SF4F   / 4^;HND'Z+Y]^/SR)E(4I-4,A0'[,K@W\
M'C0?TJ([F'1'9-]?S^_8ZJ5)'O>:TA]MFVQ<R! ':/GG1  DDDDDDE@DDDDD
MDDDDDDDDDDDDDDDDDDDDDDGTDDDDDDDDDDDDDDDDDE\$DDDDDDDDDDDDDDDD
MDDDDDDDDEK;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
M;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;9_\0 +A$! 0 " @(! P,#!0$! 0$
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MGRW:\(MCGKN'SZ,BZIG@0N ]MHS"8$/#N\2T*1&6HL8HNS,_6W>]^3_+P0O
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M.$JQB^$9$U[7$F^%H+-0Q<RBWL&/MX*0JKZX2(2G06:E9#A2K ^ 1R?+XXH
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M68Q=MX,(6N<SIS]-LR^^5&F$TF$^)KA]B,"9I-<, #R/&C)>%*)8%&@P0*/
MR(DI<V(F%,CNMY-!8Z/!J?/5_$YN)N>E*L^*N-N*X;%,0F-OF'P_PYZ7JZJO
M6\=_9\WC=0B*@GSK  LR[9R2_P D#JY9G>_Z_P#$_#FA\'X_K$%+?._'[XO7
MUY/HXW5[9Z\![G"/74LEPR[W,^&<82%M;<&9^W^2\*1C(_CZP(4U>N,2!3WP
M/+X_C,3A98+MG[[#2?7),FX;AAC%BXA9\:WP =$=QC&Z;UG[\J2ZD@_XS]_I
MP5S/"ZQUZNKK/C/(Z&\ZN4]47#LO1ROB9[V_&<=]9,_%;KZXG^?V_P!AA*XQ
M%LR]_P#?CJ<_%ZQK/]OKP4<;];^G_7(!^"=(G6SJOQCA("!)Z4@ @P>'F96
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M$/ N"U@P6,H!AD+(Q2)$!]E1Q\3?%"Z%E'L-*$4WC]^'#+*P==6"3JS?+IW
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M&$Q,LFH:UPM55\UQ=L]?7\?Z"C11-(Q/J<C!#44&-&=.W/?)K61QA/R:/B/
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M$1HR89'@N& !A%+EM(F80!],!T&WI_/#"= &FQ5T.;ANO'!AC#A(%'&%P67
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M[>#]3_@_'^M*XST=0W;?Y\\124[#HMN;X)R\*<K+)H0(.&B'R(HX2U'4#LK
M,PY0Q&T<#A$E!D1.D8C>G@T*#H"F]@XUFZ[G$-AYNWU_F[R<%?O]/?SFGQS<
M6+Q:Z^MZ\Y^AV+D$YUD 4M. (LLPX.+<LE)124X9!NI@%PX!4QQ 6'#O-P'Y
M#9P5#I9SMR($.@:?&%=!7B;E:FB:TLNY*!SP38PL;*[J"W*NUAPP#43=&*7
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MJ"0;-$%=T.JH%%"8U@ $,!+II0\F HH'*7Z)&ZU[G)-!B"G9B#,ZI]0Y5AS
M!9,P?6<X[QP ;VH1A8"BABC/T.,M25JE+"J-]A3LX<5BD0R!18G@+\<1@P!
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M*?8@\<DV<655K(E1@*@XT<1915D0"(Q(G_X:0W!3<3Z1M-ZY%W526U&A[7<
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M.,UQ?=$LJ"?*\&[0[@6B 0MFU::D84T(Y4PIH.GY)GV3)].+B& X"A-6$2S
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M @%$1$42<>@9ZB4& E[4%X7:OBR05:A6P$_=/L_S\V?=_/[#,A;?8X[L2(0
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M[XHJ#.S0XN3>,^/7OBO!&R$6<*U1Z3TMXCL(]5N>[^?I&\!06HKN%%9@"/\
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MK,JL9Z\8-1@)/ [<C U7Z4F]  X)LVJ/<PV^O# 2%:ZZ.Y7)6/NX_= 4 56
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M2>@=KX#O_/$A\!=<MU>FO;VX$B QXJ#"6D]@G'8=Q?.+$Y9#VSB0A  F( @
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MI#*",; "W@\ D<C=6'>L/H<@Q*&F9/3SCQO">G-#AWD'.]XSDC..!(@@H$R
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MRPHK/$%%<=!UQ*1(((1+?"*+@F4A2^5?._S]?[\?NY[-4KY\'^?T_G\^W"J
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MY_&<JZD('PP<YS;W]9QNO.5O\^>4LI>4SDP_CWXBK!WFF;CSUZ]^EX2XPH6
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M8><L_GC7+(P5Y<QL\0(Z,7+ T3:N;E7M617&N)0FS:/H]#>I,X[KN"T 3/Z
M#:O(N337*\@BPT#KL'H&B&,C/7@[Q].(M%/$).P$3TZ'/'&*!J:0"%P]3=.&
M9U"*BE5JBPQKB]SFEZX0(&22ZQ*_L671>FHR[?KP4)P(K-(L=.S:;X3!<3.
M.'UK'EA(XP7;YN3ZL\'$H)0&08(X 9.KYO\ 3_9_GYL^[^?ZQO6_M]>/8[<O
MCHUU[<N4P*O?LPDNYL-O&2C!I];KTC<^GF\ L[/I0R5DZ\8P<83TYC-S$],9
M\Y<\A@:R#%)[MJ>\]\/ZQC<L]YX-]Y;SJ8P1ODQ;'),+3OTY,-B&<_Y-?' (
M0<=??%UM,ZQCF%D/Y>]]TIYN.87F,H(KN1&\'9FPY552:CYW^/+G&''+&2T
ML4/4'0'8&<<%V!LEF>?IC'MSOL95$[7UU_)BRT ?#_?SZ8=^.*@L#9N9N&[U
MW_9_3>N(:$' 2%HQ37 D/'T!?L&(1Q@U?'&"(QEHY!-QKVE9O#MF(N%SAI8:
M\!U#F-Y9T%3)4&K<5CT0H2),.AT^5J>WYXK+<=G1^I'T/'&=97?.H3V8)YYG
M/A %LURU;!+HIP"C223(*X>PJ^C.9J(P1.A*YMB-F+P0]D? "F%S/I]>4@ 4
M JR$<S+B\?&<TH00F8^GO2\&<*E(Z))[W]K&(S^;SZ7[\99+@Q.PGTG;GAMP
M ,:"JGCQZA[\0!(/J-%01'_$<\.!&Q0HEN=DMSZ>.#*&+)B]&8RM7/ \"##T
MN+@F\_&L\40%)Z^QZVZRYUZ<=P &K_C?^,+Q8XZXH2EL&B&1K)Q/!X!-A&5>
MT#4U%_?,1U7<!F+1QO QVPY-!'&^^O.N(G5_REKY<IKZS(ZS[?SQG^7@5SO'
MX_GB8ZX"%)$8%*!Y\NYMCR=N5[Q=WZ>V_-O)?O\ 8O-A[]YW0?#/.LSBHA-M
M+RZK@Y2M/%E@@"XM<G97 %<XXP.KK>2P+D$F"!W>75LTV%4=+0XF6GC[,Q&H
M!99DI>H<DP@ G4,8]&7_ -_6QK'2L?71_DX10).RQYQG\,Z>(0>",3?0?Y.)
M;=S5Q5>8UU.IQJXUJS!@IH$=COG7,!G /;V^<QOC^I^S_/S9]W\_UJB>N'V_
MG\G!H^0N=!VOR8\YZX2$@X4!QL=/A/,OCF0P1</E#U_'G)<E@R(])'=+E%].
M4&BV00'@VZM;=X<<NJ*Q[6>/'F_ZZ8BWZ;\?Z-<]5Z67+OOE;R0+!3P]=?7&
M_OP1B7 P@OI4#APQ& 4<HMZVIZLYYDCO\#V7P1W/\T;^?G7^?AP\%,#C'?\
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MX#H^_P!(?U_V?Y^;/N_G]AH%KJ3#3^6>_7)K!*2.?U=/H?1O#,@KV8L$/8M
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MY%%Z+0:YF  @>45RMR)(=-,O*  X<02Z+13IK)3$422S5<(+8#)#'%UT,,+
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M11$[HJX8 XH%&?=[JY:CCZ$L)+#2!40#XJ!0 *J@ %570!M708Q0_,/M4W2
MV0:]!@U1$$!37^H'**(G)2VD*YQVB%DM.463ECX38#$"R:^B9M@:<@]*@:6>
MGF,II,J*\=*T1G]I?YC$JTB26%DYA>8U9#C7^$',):"N=11OT3DDRRR$#^8D
M!.8?[%-6XD6D D$##F-4Z5@T   $(0GQ0!^Q$K Y0 *H&&%/AWWFR/24F!4^
MT.+V, ,\1W81*6SI;Z77-OZ>8HDVYI@8_@$G*83T[H:N5,UYLV&]:EYA@.#.
M?><+?S?'HSYAW>.DJRN_ WE_1=)0Z2@@4W_8YGM_+_;"-<$^+Z'1TV))5I.H
M+4=I)"Q;1 'TUP@GI#">'J(-,N Z*8)1L$*&:^F-TH> M",E%3I!AC>*@T U
MGK;:A85Q$B'ZCR^C^@4>.&()D@:@3YL@PQMU;1'5,1L2_6.\XAB+8ZM7P8:^
MR^>,DQ<M7.%.1MP!:8U!$E]@9PT&:1S58^VFD$2,J <6Q7"$*%H,6D&3'P8
M14V51]X4/2Q=I0PE/,P*TA$GD\9DH#!PT]0K *J-H6_&.R\@ CI"F&:6TNWT
M9"HFMOW!DADB N2S.Z$L%I,'B.]L8O\ 7>)-2^B/B$4K=8AE"S9*FK%L]=
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MM[AR"T?HXTA[<)G+6.;C?-2HQ%I:KLN>9Q(727&2O%$B8&W0 ;<YKX<1Z^#
M[DB>&,@NF TVC_2;IG:M/DW'("4;?,<?, ''^Z(1+#"L$2L3(246BXU6Z%KT
MCSU>L-4-9R13QPG$_!C008A).+5Z[K9+7DRJLY3DBL<R,M9P-?4KCP.W?L*@
M"9^;0=G*Y/UJ%SB3RY=Z A5GB<?2\LQW07R RQ;55'M:6H$4C9IQCI@\2B %
MX %0HVBJJN+P*LM49RS$WGD*.,YB,YJW<#/D?# 8Y$:<!*%UR)3L*9BLHC@'
M$51J[X"TZ ;8*K'^!Y1P&(R*A@T9&W4"$$D?!BU=RO2 8>CVA2,*!A$[NG4C
M")LTRCE!]X%K"F,T OO!B%36=S SVJS#J(Q=8"ZF')$4JU.\;&N?EZ6]@.]3
MBQZ$5C.6H@J>U5>_@G- AHMCQ%@Q*#"&GPHQ2,8 57_V<WX=F Q^V7"+H*E(
M*DU3PHHI&*<*8 F9D,8<@-!  MA\"A- TM#2TO,NY9=X 8C(H$)L&%2F!7"H
M-*C#X?L'7A<C-7J:\2"R(7OP(^I<YL5,%5]B^P8*!30/U3J8DE3R>V*.Q)3D
MXA(X_4K4@[? 0AOE94HB3X2-$X+/5(T1!6F@BD&*+_)O=<'$CL3 F854189O
MZ[\/H;']6=EYL"F\VH&GD%SDA3,USDVA SD0<$(+DK&AV8G$T_C4\OW3V609
MWK'8Q5Y&Q $O1*E"89XYCT03*_0D*Z7;& ;A=% QB;,7R]RD/C"+$101)$HB
M2(Z1.3#[A1:9%PI$*$9_1'>CD37I_ HI8$ 3\#GYTJ(#2UPD@O@+,+Z>)GLP
M'0GP%.31+.%H ZQ1'(M<J.Y5"<@XT#@"X-XP>KJJ-*UE1%$+IB-% 879:NF!
MKO16'=916[5["WDJ@HO"%$4 :^%5L/-K[" :3J[M:W>V]X1A^,*M2+B2+!SJ
MV<BSAR[!8,7B%L:5E6&2^$:WH)HH(2HBQ04L4%*&<%\VJ+LPV14D4'-]Z[*;
M,(1H58&W *#$O,_B4<*EKP/X#'@1A2P;+E0E"VJV!.D_XK9 *F(#HTBTV+$&
M%=+)Z0^ S7M$Q\Y$ )K@8%4IWO<=J.A\")^)N&+H#CX57Q!RNO*'Q&)_H1LP
M(UD<1]'0J<@R&UH%/O!GXO,($>"-+UPA2+'<HG$O3.NIU9CV#9;<AY/Z%:,\
MM:HL.BLFML;;^5O.H.HXF/)]"#P]F1G0L J\7S\ .F=6N;B%3T#I50 5T#%A
M+G-2830H^QQICK6 JOYEEE)"#I35L$@+WT!A! -  62KRSJ\=8"K283, D B
M[" 'Q([I$C#M!5+RG= G'QFT#=C1"R4*_P!CF>W\O]H3*M_ DF$9YAJ[FB@J
M.X,3,L"(\8!*C)"2 \(W-V-P=ZB%&]700W2A>\($8=B^#CF#PV:E1-VX7?%J
M0O!PZ_%!R6X6*+],8)@,D32XUECQ *G<23'"C@L[)5N)&B,W),^IQ;4%S#X1
M@ H%ME<8$<OJW^N1 ] #02B'842A1-8<%8<NE_>[KB <9@=!N];L1\#!!&-4
M$N3!AWG9DO""$E.=XX0    @&@#@#H,,*-(-SPD&3$V/6?\ OK._- WH%(-/
M@1X)R%/RLY.EM"^C8TODG"FPZOA&N$I-<7UZ$@#+=*4<VIES8()-:!"5$!ZL
ML98P,2DF<T[E*VG,^H7Q!;/P/+;#L@2/H8H$01%$1Q28QAAJ,*VE$O !S"#H
M"/='6[E<-.V6: @6PL&KZE+C2!$'2XV*)&RU;!/0$8.G@34AN[ V@!+1"<TQ
M#D^/<6U*EM[!F%"7,:!0^ZZHC2+'S%>1-W)_E@J6$H2T[TVH/6E8KO.,_&,+
M5+L0+N"U'2HYG65N#2T!>.A$,AV-I8JD!H@N;$=!P:L!284@3^"(D][UV 3V
MZ6W<1*9GT-;M!HYCR(9Q)\Z :H*A9FB,B)EO%UI[P4-6K!S@00;5Q\'0VV-8
ML&83]-I#TEJO-0:8;+,C#Q+\OX804K!%;JA"K#&"C@F6X'BTP"+)2TK@E.I&
M,?3@5AT('Y_D/8BBE4MN5FS1SZWR*6BPB^]'!DW33/$F)D9C@#=8UFH3'-EX
MSRDV@6!5-A\=\S'0@GX]<1DFL05$I'0F-8&/\H/<+4!F<\>VNS#Z#9"L%TE4
M,(F1! JL+\'<?>4:\1 B:\\)I<O>(Q,*.ETEPM><QS(LPWUQ5:LL64:T"A2Z
M<H/[83)(D0$OV70%D.-&)&$"M,1\>E$2  $HQE.=7:Q?P'*6M(B*W)FJP>Y$
MP&5 1U NTK@44Q!9BEQ;(MP+M50!O (DPNW>.:SY%!?P0R!3HUNU =,Q6%4-
M1C _N^&711@;%\R2W"]D,E:FO0I4W[> T;@4YPL#?&BL#&_0"/=WP0="0P_!
M;D<M_?'THL,+Z2.RYM@IJ !1DQ> >_PX.=J96W#"; ')MZN_P,"2V*=25.CL
M6KM'F-]JP%"6^'3M2\%LV*[\FQ+5'$Y0 N3L-A"2$Y3V;"&T:!3^V\I/Q WN
MJ=.I\XY@5#5R3>Z-H#[5 R"9?8<C:@8>V++%T@>V##U"A A<2Y:BDD=;@U/
M&1,/+)8>3Y90HQZ9^+6T&Q\.6>( 7(PE($JR#"^[*WU?6N!! _A"'@X
M 3(4WK6>0VUK,JO)-Q*BH3-("/@&7&;C]9H /P'1H@N=!*N[N<%#754A-"2*
M189P43B>]& P6RYI9D#/3S)^!XYI\Z;Q%[JYJ3!.2 /N_<&A#A*PK?Y)!_\
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MIDI *XJE?R<R^3)H< &%,P,N'<$9/@*<-BSWUR0B+I0W7;.O45"B"'^6]#
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MGPRDVM6!),&DQ%$<&J[?Y8^:U3V.@IIM\P?-_*0.B%@2B:XY,,\7UY88(X
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MNRO#DE<@2GVP(?69=.&_,J=(W<%$GCY?F>W\OSC3%4B17:9&5C0%X+W(PM(
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M*1Y2"W+J,0I.$8L(,!(1 #HJG%PSG  0*((B*(TS5W6$L/8 E1.<"I(=$PJ
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M&^@0J"R2C0\HZ7N)#%3B!)=!0PQT1<T2M7>W[W>0^9YGM_+\TZ<+J-=42Q1
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M$;HGBA;6F^?&KAST!NJ$DZD6E(,#Q1JZITVBQ"39"/+P-%2.K6:H:D/UUT^
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MJH.IWLH[WZF3 :FZZH\+>.>^,Y^VL+6^K0;IEZ[P?ES5"Q.YP!>14<@"H/1
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M=>O?KG @AQ!LWI-^_<XQ:@>8P^SUT6/#QBX(#CFT("B-&I,:F*#9 E6)]!1
MF'77*($T(Z&DZYPN0+<W4#@U&B$23>;8/^^'6]#_ -]0(5V(K&P7<TZN QQ!
M-/RJ0!JD%D^M'L 8(!R'0 !\SS/;^7^X8\V80B-L"D(O)_8J1'+ERY<I<E[_
M !<>/;C#S&_4N.O'(+UB)DF&[H: \H2<X')C@H@ KF-]/@,"+!7J@X%5@H2H
M4Q(]5GRP-B# @; MW6D:!1*A2J -=U-WI53 5!4+,#VEMD1BQ1T[N1J3%I1
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MV=3$K;/2\>OQG<FQ]I7#XZP$1XGCTX[QO?T/XX$VLZG^]?ZSLG4^U_' 0.'
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MZ^_TQ>"(4B6UON^MZQ1&+E"*]^>DG!?7(H@=L*(_6VF0\X-E)/,T6!NDII7
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M%5$K$"$-?)<SV_E^;,N<(7#T=R-!9. )IV0YFM,9!0*"$.]T'5E4" [A:Z6
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M'KJ1>?CNY*$ZTA6J%,11A HSB5.KCZX@0?\ @+=/A"/6DADS 8_(1.F#VR%
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MC#NN9NEWR5HHB7_@+I\_8&9PA5:,H4(IBR4.5=8IIQ 7&R%W-1SV)HD:C(*
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M'5D-4R$G"I&H!H8"'J*RZ]&; 594$:3Z" U$ .G#/Q#.MDH0(: 1HR$A3[[
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M-+'^$G,&;C7\084&/B-4(=#ZTS?2SG-$HQ"S:PZJN_T_F>W\O_Y+S/;^7_\
M)>9[?RY^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7
MC\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+
MQ^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%
MX_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"
M\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A
M>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/P
MO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X
M7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\
M+Q^%X_"\?A>/PO'X7C\+Q^%X_"\?A>/PO'X7C\+Q^%X_"\6Y;Z/Z!N[%P%+2
MJH<!P2E0_D@9@L9HG6#Y@35 ;Y.G>F*+WQ4$E!4^1($<1!N_?M:P]PUO1T%0
M[S:P'PT?#]LB\%^$7@7(\S7G$3D3WPNEJ=0RM>TC$ZPH.L\]Z('FALG'PZY]
M,B\"_"/,9YF O'A?H%?V,7 "W8H=@*HQ&?3GN/*.K4$)G!23(UTY6':K!)VD
M)GR>LP8X!&9@"4)#8)%:3(G(GT^$3DF1>!?I\43D3WR/,UY^$>9KSB)R)[Y$
MY$^GPB<DR/A^$3DGPB\"X&8@NR_@DZ4XG*C5!-R QKN5(IRBFMC&:\^F1\/V
M^$>8SS/@B<B>^1YFO/PCX<: U@A9!5-/:"BH;R.=0SEI8><@$SQYC/,S5]#[
M*!$E:'$TC >M(12H"AP 4$8IO(G),CX?MD3DF=>U73SZ^V]M#$I>>TIVB(+I
M+BCX?MD7@7X1\/V?A'PY%X%^F1>"_%$Y$]\CS-><1.1/?$3D3W^,?#OC7.16
M1OCO&$NG(B:1L,!Z*9$Y)D3DF-:PZ6TYA6Z(B@QA<ZFM;+1.D H)8"[(*'E2
M!<K7C0].DE7:)#D9(2H$PF)!E(G(GO\ "/A^WPB\"XP?M49^$JP*)!=8 [YF
MF'0 .I@=@]1;IL"Q:+#*PD=O79[4L+8\QGF?!$&@H6>7UQB$E3E\%0"A2#,?
M#]GX1\.1\8VM1@+&5T,M#!! BP(CF ,&A"&1YC/,R+P7X1>"Y&6,\]9'F,\S
MX1.1/ID?'PCX?A1//G<T(0\'(3D=RY>'+VRC2XT?#]OA%X%^GPCX?M\(O N(
M(#6H,N5-I"Z,2\DZK7+;EA6"(<I4\C']_IXPLQ\9 68-5!%@_P EF)586SZV
MP _RV120[[HQ4<B<B?3'[:5'RAEPD4FV9$Y)D?#OC61.29%X+\(\QGF?"/,U
MYS=$%!>B]N$' 3%XX<VB1@<?#]L9692\Y?D1I4!G*F)]V@B-!$IO(G),CX<B
M<D_L2$,YZ@..H,>1<=;/!/#,5U 09BNVHW'*?@2):$=F>E>*D$/[+48:>6$C
M,,"W"C'>U#Q [*%0(D[%R5'6JI]WP3K,)-AN\GU SE_XRAOAG*C:9G2F&KK"
MZR)'JRL[L:&E17]V=9NR:YXQ&.$UNU89TQZ[@^:DC3C#O6**BGX)!TJL? OD
M,3MZWLX"*J2\6_68'NV9RHLZ.I?7?O6:C]+/3M," ))!OD!X"&2 %, 8O-4"
MKF6;.U',G2=^:!(LB5[X$ Q ).)HY1 T'HIA7\G015YVT[!L(I9L<WJMIR93
M%KX4_=<6#0HNEZ0>&BDD:SZ1Z/'ZJK$0>F+@,W+6M% <-#*O8TD)FG%A@^H7
MB1(64S%4$(.^>&E_\S! UZ0'TF.&J]&M_G_-KQ6G!80I&P<6""V(Y@6, 0O'
MZH=]95C*'\YPRD]%"$XH3-V%04H0>Q> 2^YM@%@U45?\HWZX[&QLF +#5,Z7
M-,*0H(8F%84G]H*?WDE4\5EV8 4+[N@Q9CON]K4[+QD $'LCVA= S+%48$8+
M6&\E;<S"69B9:G^D+%KQ>"BHQ2-2&I&R',_@#:_7KM;?V@L/0X6,<>.LL:&*
M@LW2\X(\$B SG80%I.D"8,6DNL3L(-P+;AXY 7VRG) 3*B0WCZ3#"&(GC@-L
M!PD8M'%X( J[P,G'J$Y_NCDQ%F1^8D6+LLF=%AHC1)3%!2VFKVPK #;7"KI-
M*V<E0*U;"8D?OJ,!ZQ_ FS47@2HB*L,8V_\  G]"87*] ?>R<,PH!+AT%7B1
M6.B*)XITE-UDX@Q0ECRW%ADC-V8O2"'6ZK0@%C,P-"'O8$P 9P\C 8R1;F7
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MXL%91<HB9\NR]@F,L'+<5(IW?-!2P[K4AXN8BQDF *K.)0^EI<\";C1$X?%
M QR+9%EHC=;,[?AUI]6O/"TV'EZ"Z5QA4=?P@;H36F[:HC>B>R\ <)4%HF!L
M/UX;OHMS6'(4VC*BK0<MIQ$K;@C+:2VOT7C*2W&[/RT?4R&K6\:(K:':V=,K
M XQ'"TJ"C@9=<L]R"H2#4"##'"ZH">72,SG0$.3K(9WX=.5HA3$S@[ETQ,-$
M@/!)P!VTW96$H0P[W7FVH X4!!A7N@$*^\SX3A"';VG:+"2!EFIIVX&*%^XL
M$9I5@WFR:LZ8H,[*CV^&Z*K0+ +709B,RZ+ 34&*N>^QF"J47GJ+$;?A^HRB
M[-2V8S$'CBJO3]T<(5_1C^)_ ( ,E#%2SUUHWU/2T#.DEH _7T"H"LNP)!+D
M%CYF'A.R!!(&^^EQ:(Q@X-B44JHU3>+4.*Q&?],3F\BBTO*J.0Y8HWB#(&F^
M'JMC.5U!%KK8!!TJP%GH7"1-[WE6K<0 >_S<Q+AEJ/P1\N7=PF8*UT5BT&;3
M8)D-B>L&XH##%NTQA!G088WYJ O3"B2VW2&U7_DK0XS69$&Z 3@4\ADW_K6A
MWH<U$9;<#&SBC2M8@%==O"V42$L6+F$V8U1C&R8"Y)FUX(X9PO9H3TQ@)A %
M 8 = %T/>F:G <;&KX! X.<=WS8"\I^;E@%%KOJ'4%F6_'F%D+ACJKTI:4D2
MP(VQN+I)QHS8/-;<A_<![*;;0G_DM/T^&:>9:"*1,[*]1NM<H=!Z&2YF1S C
M;B(6<N[TXCREB/<?"EQVN/G/K/SB-UDY@ AC;3<J[5*LY/<'4F/-(0U"VJD&
MCC?MD@I3;/01GAAYAR69XH#)+Y@HQ%'GAYUTJ$Z.5-%UTIC#[$1&K? Z$)18
M^(Z87-0^I0@(Q[ 7T%TE!,=!_KV4MG \,3*$ K60U.O^B<-$V@/(Y]4&]'>L
M=!B]'\5&K@:N6<]PN"F4#80FC\P5!W0[3"]L([Y[WX@5\#/789**N2-2I 5'
MT+*RO^K/0AP.";=&=#S^W;2VO[P!6C+=:HPLM%!L!S>T LCZOP)G)Z*2D-FW
MRS.Y0CNG372$B$T),I.8L<SG#H Q*! X!.Z,\A?Y^IA;60A$[MG@HY4,0R="
M2Z''-)"[-..\TH8;6X1@T3P^8.#3XI&6,1$Y"8?IB(FHL"F]RT.6. :Y!&J&
MS9DAWN'%..LD6(6RU7R8U+V]!&#'"F9RIU_RQ_ADDB8+_14RH&8@@244X.Z0
MA K=$%1&>$J@S78EQ68C%ZRHYF-/:)<#FOD8+1#/!7%3\T&6S+D/(%"T])3%
MWOH@5L,$>S^B>&,Y"HN1AV9 .UGBKLP;+LE T@AEX>2R)KSO4LEJ0&U &6;;
M.*3/(>]Q/.QV5JE+,VHCY1VGD;!<DT>Y8); %2\#:;12BRB#J M41>-DJUZ9
MEW+K2'&5$84JRJ]T,0GQ-"GE+:9(D'&A(V[V-R2G6YG@3ZK('H_T4?CLP\%U
M*+B:2->-S,"+-XQ%(D<6M'R0!1$Y&GN81>Y]1_9+&N#?U>VI.TAHX(]D*9(]
MLOA69LX ,_11ML^>D]-RT@=.;KE94WN"[#2)'HN<E!B!#1T&=?JE#E#Z_P#X
M/Y\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^
M?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GS
MY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\^?/GSY\_/>?/GSY\^?/GSY\^?/GSY\
3^?/GSY\^?/GSY\K=#KQ_ZS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>business7a.jpg
<TEXT>
begin 644 business7a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1:017AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #. @  $P
M ,X"   3    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$W.C4X.C V  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !M     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M#ZTV6^\7QVS%;&WEE)XVJ!@!V'3=SE0K=1C-=1;7"75M'/'G9(H9<C!P:EH
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MM?\ 5-_UT?\ ]"-35GP7+_:);:)8G9&9CEV7J<_W<=QWJSON_P#GA#_W^/\
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M<P
M    #61E<V,   $@    0&-P<G0   %@    -G=T<'0   &8    %&-H860
M  &L    +')865H   '8    %&)865H   'L    %&=865H   (     %')4
M4D,   (4    (&=44D,   (4    (&)44D,   (4    (&-H<FT   (T
M)&1M;F0   )8    )&1M9&0   )\    )&UL=6,          0    QE;E53
M    )    !P 1P!) $T 4  @ &( =0!I &P =  M &D ;@ @ ', 4@!' $)M
M;'5C          $    ,96Y54P   !H    < %  =0!B &P :0!C "  1 !O
M &T 80!I &X  %A96B        #VU@ !     -,M<V8S,@       0Q"   %
MWO__\R4   >3  #]D/__^Z'___VB   #W   P&Y865H@        ;Z   #CU
M   #D%A96B         DGP  #X0  +;$6%E:(        &*7  "WAP  &-EP
M87)A       #     F9F  #RIP  #5D  !/0   *6V-H<FT       ,
MH]<  %1\  !,S0  F9H  "9G   /7&UL=6,          0    QE;E53
M"    !P 1P!) $T 4&UL=6,          0    QE;E53    "    !P <P!2
M $< 0O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_" !$( /0"/0,!$0 "$0$#$0'_Q  =  $  @(# 0$
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M&>)B1@C)UEZ%<'A(63<\A'28F((T3TWG)@    #@Y.#D 'R=0!P#D    '>
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M?<_-<QG$!,N9DV )@   8$K$N@C!%2U0 #K-7>EL]IN:K*2(U#3[)37
M        I N\ 'YB3]5LOZU-H->@[,/#YU\?YUL])8@")9V_--C'P[&%Q6XP
MS9@3"$^)$3$  'E-2F=OF-,F98QM$  #4CI;/;?FJRH")PTVQ<UR
M  ,&8XEH*0+O !1%?WVK'4<%M357EZ^*+R>8,5YU)!)9 "-MGQ3O/#-&<:'6
M9@QAD#"DU)F  #RFK3.U[ A!-P  :E=+9[:\U600I&&GVIFN          !7
MI41:!CR#&S  *PK.XTAZ/D]O]+?L&:KDFKIX:/1D4MF *[Z6KPD^EY=[U5'"
MWV)9X+ ,*?1BB1F(.PO L0&/-=&=FV!"";@  U/Z2RVNYNMJ(@T-+LQ-=
M       ".FM9ML=12I=X .#\#=;N_P!?=KA,7L]!L'J<W@HZZ22VH \Q0Y=A
M&SM.HQA)B3'C/L])AS)'<"!$9+C!"";@  J3=FZMR:X*;3B$-)+YKL
M    5Z0@OD%(%W@ %%U_T+47M_E&YW-==9?BGQT=1)I;8 5(:3EZEM$?,V52
M7 6^   "%FOK.TC$+,26X  "/%%=-9[+<S61&&EETUT          (H:Q&U)
M""!FR0 !4%1]#T$^B\)OAR,$3]=%=\'#2>6V         '44>S>F,:>9S-6-
MCP  >(U:Z>TVRYBKB,-++IKH          8$UW-B3%E=EZ@  T,L>VU5KN(_
M2SU>65!QTGEM@        !"BAF=KF!"";@  &NEON63#'E*CG9=-=
M   "&E1FQP*0+O  !"-_-![&S4-;ZV&]Z.Q>OZ         'F-*&=X&!"";@
M  'A-7NIM=@^0Y&637(          BIJ^;7GD*V+O  !\9QK]<;FBLNUG><I
M-WY^CO+S1         1XU79W)8$()N   "I[7:J'Q4[(5NYYCUDD
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M?O"V-:&]J32  K(Y*=+"    ,%'79V2Q CN[HP/I*_GWZ\,_C4RLL*:K;?\
M4:IU^0#4DVV (Z1PWM *Z(>S,&*-9VW8 I N\ &N3.QK  TV9W)8 J$[BV "
M@"VR2 &F>,[F9P !'3[,T=H .@[P#@ZSM /*=Y]@%-ER  I,NP \!6A;0  (
M434 Q1E0 5@6> ##F8 !BS* $#)@>P A!-P  #2XW//H I0NL B!4QL0 4>2
M<LD U2-J#M -0S;P K@K V6     !AS'$I(N> S)G@>4]1YCI/>=)Y#(@
M       $-)D> P9\$N .H[3&&3!BS*          K8@C-.DE+<8JQG&F5(F2
M4F)%S( MIBR0          #5QFO2;&4.@@1,3P$2+W8@+/E/43]B\@   #X
M                       !P<@   X.0<'(   !_\0 +A   00" 0(%! ,
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MGGAM\\-OGAM\\-OGAM9YX;?/";YX;?/#;YX;?/#;YX;?/#;YX;?/#;]\V9C
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MEK6H)*Q;Y?WKEKA-B9-T>'1!M\S+E.W("Q&$%VRV.YY&'6:U ?%GO^^>1SD
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M_P#MY_Y^-__$ $\1  (" 0(#! 0("@8&"P$   $" P0%$1(&$R$ %"(Q$!5
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M(_AV]7Q-^2R-)OJ#M)$W[G30?O[>J;9^9R)?JY5F!R?N&_7^'9\;?3YU2?\
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MC_+TZ^CW]O\ Z[:]M?:O^/H]_;_G^';I_+_/M]7Q/\O1K_/^'_5/_\0 31$
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MA+O(=.[EALN\AKNC:@(W5U4KQ;CDV7/^\<_*XS5@.94@?,;1@K'&IYA%!\0
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MIURVQK"GP:\U*2YAEXB.*46L(NQWZ4BS+K71-'P#J.$D3 /&^88#_AT__\0
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M(U#3MZ>RF4L?ERK-XF_C\_I?'Z5G KN(FK%?"\*V59G 5)':M7+ D0B<RUK
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M4 Q?$XZQ Z&D>D=*:JTAF;6,TMJ$,H&IJ6N<4C3JXJ6&6ZF3Q^&"C.9[TVR
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MI\9'XH,@_")_0MIC>/V^/NP_='^'C[L/W1_AX^[#]T?X>/NP_='^'CR!<_\
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MR)=\5@3.MS]+:@3$Q(S,3QF<CA4/S5BX6'U4G-D>02[#%?)]>OB2QM<V,"A
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M.#R8H2424'9&HTZOE'GRBP*B';>>41Y>-,Y'\;.%Q\GO\>JNN"G;_MZH'O\
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MYF%2E?\ S@YC]OB(KZKPDS/X-NKK?_Z>EX^JY?&6=_AV]^J[?_Z;2\>4Q/\
M9._SYHY2JNY4DP9*6\N,FN=P+TD,[C/P\_#;>(Q-6C9<F*S7J@NH:(/J]+D9
M%/#J>OC&T<O/Y= _W^I?\C/\U3"W#(L"!0V'3NS?JGMRF9G?T[?C\/DRZ$9/
M.X]678D"L5R05+'8ZO3@!?B6.$YJY.Q8CC9" +EU#=QB06WQ.G;%4[]$J[J[
M&Y%S+N09#VS88PK[I*Q#IL3UQ,##IM@27 \1VLX#*5#KXC'T:AX;45BWUD7:
MJP56.OE+=B0E67!WJV+TVDSU0GE!QX@AF"$HB1*)WB8GSB8F/*8F/A/C\H,1
M8NZ+UB/W>JM,&-*\V?\ AY:KMV6;K%_M$9!+)(?2+0CP6.]K&#][Z?$>*?:7
MHZJUB:OH((NYW C#LA@+2H/E[QQ_=4TGZ@Z8P11IW&9/5@ZMI:@N6ZNF-9(6
M+:5E8=(L?A\YDE-8J-0L S$2,$=YTMB$;7(2_/8O"X;'HR.7RJK]L1NW#H4:
MM'&Q7[A]BPNK<=)FVU7174JN<F9D9D"UE/C"Y.EBR/*9[*>XJF*LV12M&64Z
MZF\%NZM;H&K1G&WF&]*&DY:1Z2N;1&,VJU0FGE,'E4X_)TZILR"N==U"_%BD
MP$+?9K.HN78")K+L#ZU$GF'G]N__ (+FOY?X^W?_ ,%S7\O\?;O_ ."YK^7^
M/MW_ /!<U_+_ !]N_P#X+FOY?X^W?_P7-?R_Q]N__@N:_E_C[=__  7-?R_Q
M]N__ (+FOY?X18&Q?BF%.RIJ?=&<]5ACJI(9P]W<9X+6\>6^\<]OZWC[=_\
MP7-?R_Q]N_\ X+FOY?X^W?\ \%S7\O\ 'V[_ /@N:_E_C[5__!<U_+_'V[_^
M"YK^7^/MW_\ !<U_+_'V[_\ @N:_E_C[=_\ P7-?R_Q]N_\ X+FOY?X^W?\
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M#VGTW;/-'*];BE75#@"5RV7R/)43S6LA:<"N8+PFOD\@JJ^PMCDID6L:Q2B
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M@DFU0/7!1,1Y,2P# HW&8GX^4_HM_'XV8&Z^:?0.>GLLDWZKR9LV8673!1'
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MERY<N?_:  P# 0 "  ,    0$D$@ @DDD@  D$$D @$@$$ $@ @  D@DD$D
M$DD$@  @D  DD@ $ D$$D D $$   D@$D$@                $
M     $            DD D $@         DDD$D@D@D@        $D$$$$ $
M@          D$@D  D @      @ $ $             D @  M     $
M !   ( 6               X H  D@    @@     X X   DDD@DD      H
M E  $D @$@D %    _ P   @  $       $* X          )    $ 0  .D
M@ D     D  O "  [:$ @   A%H  B 0               5("  /P $D
ME%H   $X           @   388  ;5@D$        & X          $$@  $
ML&  \?D@$@@      '8X          $@   (*K  D $@$@$ I    %HH
M           'AQ  @D @    H!@  $X             D  $P8
M$PH  $ @          $D@   G"          ,     %H          $@
M.?          $     F0                GCH         E     %,$
M      $D     D[P        --(    4$$D@      $      Q-?@
M@LH    0@ $@@     $      LB"@       @      P)    $D$D $ @
M /SLK       ,      P G](       @     "Q;PX      @      X   N
MA4P(  $      '#SE,       )H    0 $   &&2U  $$DDDD@DC3A(D@D@@
M (M !  @ ! !( L "  $D  @ @ $  @   $@  %    H      ( %   $
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MU9C]>(Q6&28,[NOY^#66'ESI^\GP\PC"!T/MGB>TGU_AH>[ 0+A[T"    K
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MJN57:O5?C-ST+C13[&>F==M_"[[%MRJ\*W3IEC/M>.;]I@-@9%9& ?/@3P:
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M*'*]-^@AKEJ I?@6UHHB.5X".#Z(>P\F8GHB,P1N$D.U;.8FL5+3_$17R$=
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MEWAUBD#0Y<8&GL5G32>+\\17/*"#PFO"$ZA>#J8-O[?Y_P 0GV>(FQ/4GRH
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MC&B)-SI^;Q'3NF/P?"]..@]4]-?N/_R7_\0 +!$! 0 " @$"!0,$ P$
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M+"S5[ES/'MZ,J#*\=']GD!7-6W6O:B:L06^HT%&KM)*PTK,B%9#W\%SO(3<
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M+"!G\O(ESZ%7D4NMH.JVS)#,Q\@/WY='#,2!>M/ N4C949:L (V7B"@J6BZ
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M0! )AB;@)^O^?G\^G^/TEDD5SE.&F MI4F?U11HHFD8G[G&11-+1]E)R=5-
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MO3RI]G1Q*VT<(?%Z3<E7DF0V]$" 5+\QUJ^.EG>C#9CTEE., O3P 0WY0&V
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M[??Q9KF4@5FK!>D$<[X];:DT!J:X0&&(KA$?!U H6F1]%)T0=\?E\,6@ O\
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MG&,4B Q?D ''SVX&QWD!4UTCQ[IQ(J-4%2H*12M>=Z2".%5)EEX8IC\?IEP
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M+JC85H*!O1X]\ERKTI(NR!"T(&#"KAWK]E9=!U EE<[L7V)RCW@M2*L#,VD
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MX/?V7X/?V7X/?V7X/?V7X/?V6&$A! 0LH!$T *,2_![^R_![^S)/M66P&JK
I"K4 6@E^#W]E^#W]E^#W]E^#W]E^#W]E^#W]E^#W]E^#W]E^#W]G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>business8a.jpg
<TEXT>
begin 644 business8a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1<P17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   #. @  $P
M ,X"   3    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$W.C4Y.C0P  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   !]     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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MIZPJ6;PVDL?F6Y=D6$R'S<C$;8^Z,9Y-='5"YU6&UN'BD1_D7<649 '<_J*
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M"A=Q@OL8SGS3TIO_  FL7]R[_P"_Q_QK+V\.YS?7:/\ -_7W'5W6D#,BPZ9
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MC_A%-5_YYQ_]_!1_PE>J?WX_^^*/^$KU3^_'_P!\4?N/,/\ 8O[P?\(IJO\
MSSC_ ._@H_X135?^><?_ '\%6]+\1ZA=:G!!*T>QVP<+79UK3HTJBNKG30PF
M&K1<HW.3T/0+^PU1)YT01@$'#YKM-'_Y"UQ_UQ3^;57JQH__ "%KC_KBG\VK
MIA34%9'H4J$:,>6)<UD/]GC=8W<*^2$&3TK&\Y_^?6Z_[]&NKHJ[&UCE/.?_
M )];K_OT:/.?_GUNO^_1KJZ* LSE/.?_ )];K_OT:@EF?[5;_P"BW/\ %_RR
M/I7955G_ ./VT^K?RH"S.>\Y_P#GUNO^_1H\Y_\ GUNO^_1KJZ* LSE/.?\
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M^CQ<_P"P*GHH C^SP^9YGE)O_O;1FH9O^0A;?[K_ -*M56E_Y"-M_N2?^RT
M6:*** "HV@A=P[Q(S#N5YJ2B@!L<:1($C154=E&!3J** "JU]_Q[K_UUC_\
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MJ9%D(^900#]>O\J '4444 %%%% !1110 56OO^/=?^NL?_H:U9IDL2S(%;.
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M;G1R4D="(%A96B 'Z  $  4 %0 R "EA8W-P35-&5
M                ]M8  0    #3+6QC;7,
M                                      UD97-C   !(    $!C<')T
M   !8    #9W='!T   !F    !1C:&%D   !K    "QR6%E:   !V    !1B
M6%E:   ![    !1G6%E:   "     !1R5%)#   "%    "!G5%)#   "%
M "!B5%)#   "%    "!C:')M   "-    "1D;6YD   "6    "1D;61D   "
M?    "1M;'5C          $    ,96Y54P   "0    < $< 20!- %  ( !B
M '4 :0!L '0 +0!I &X ( !S %( 1P!";6QU8P         !    #&5N55,
M   :    ' !0 '4 8@!L &D 8P @ $0 ;P!M &$ :0!N  !865H@
M]M8  0    #3+7-F,S(       $,0@  !=[___,E   'DP  _9#___NA___]
MH@   ]P  ,!N6%E:(        &^@   X]0   Y!865H@        ))\   ^$
M  "VQ%A96B        !BEP  MX<  !C9<&%R80       P    )F9@  \J<
M  U9   3T   "EMC:')M       #     */7  !4?   3,T  )F:   F9P
M#UQM;'5C          $    ,96Y54P    @    < $< 20!- %!M;'5C
M      $    ,96Y54P    @    < ', 4@!' $+_VP!#  $! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" $: D # 1$
M A$! Q$!_\0 '@ !  (" P$! 0            8'!0@" P0) 0K_Q  < 0$
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M?@W[            !Q-*C=<Q92Q?H!49;@      !41;H
M    !79'R7D .X[3N,Z1PR1UG22PCYX25$Y  *?/$9,[R:E?F/,^<C"%M'N
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MW)G^VDE*:Z1T#XI&>    %4EK        '(J4M@\Y#3-'C/09D]I^GC.\[3
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M4C,/BU0     H^JWNGV9D<VT *\C8#:>3Z&:4MUTCH'Q2,\    *J+5
M   .14I; !4Y@SQG,R9E2-'2>(P1M4 #YA^8?.E_VV51%\W5\9SH     _*4
M^JGN?V7D<VT *\C8#:>3Z&:4MUTCH'QR,\    *I+6        .14I;
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M3.&#-ESQ%V@  &JQJ@6 30WD   *5+J        -&-'J-D<FE:VU"
M    #B?AP.)^F!)$<3D4J7:   8L]I^@[@  "E2Z@#'%-$))>>X]IC25%=EI
M$\ !_/GQ_P!"[:[_ "MP]#Y)=1L8               4D7:        "E2Z@
M#"E.$B,62L\!XCR&!+A)0 #^?/C_ *%W@W^5V,Z'R2T2SP
M"DB[0        4J74        :$1_6[+Y="X-N!                I(NT
M       %*EU        'SSC.SS&M- ;D2_ 2S+H@             "DB[0
M      4J74#!%=EB'K,B#''H.PP1(3"&= /Y_.0^@LQK36&LV*.TND_H#[OY
M;O+=YL              4F78        "E2Z@5P5(<"8%;$;,(3\BYE3%%XE
MZ@'\_G(?07[I]#XZ9*7T^A_H$[OY;O+=YL         "F3&$+,,9XQ9(#%&V
M)29=@  !C330CANJ2L   I4NH   ' Y@   U'UIBP\>Z!<&U 96_"
M  !%R"F4,,=AP)48,M@I,NP   %0'>6&94   I4NH        ^84/Z&T^A'%
M7Z-]!Y+),FH              *3+L        !2I=0 ->RJR?F5(F34KP[#;
M<Y@ _G]Y'Z!E6O*\%=8HSLOZ,O0?DRQMB)              %)EV
M I4NH $1/TYGF,J1\[3D3<  _GYY#Z#\6ETV%Q[%9:TS_1GZ#\EV/L1(
M          I,NP        %*EU        &O5FQ;EN4"29-/MK0   # X-+/
M9]T         4H76        "E2Z@       #2&#XZ8:4./P_0    :><AY=
MOSW?M%\3O9         4F78        "E2Z@       #XA^7?.-?\QYS;<MT
M\HV9#&X]?PX\7.M85I1.5R[,RW97&XM?+YMK#8=2(:D7"M*)S&7:^TWLGUA/
MM^:        %(EW         I4NH        ^6?$^0=$+R/MORYK/MYS-MQ'
M4C?7?EQ6+5RF79]=V7R6XO5=DZ*68?#JT-!<9M_UOJ'T#[WVP        ",$
MG        !7!8X       !!R<      %&PG(7E-]>
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MJ-L7A',$)5=[$(I*$Q=#'[998#AS%$8P]DB-8EFJ,4 ((K1".K8(QI@,;1\
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MX7JV6-\?BFNBM>EG;1M\%5DD,/CJ5_9&B/\ 88.>"SDCBNKT3EY7OYE_W[*
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MJ+=!Q?8AA%Q2_NO82R*2S_Y#_\0 61$   4! @D'!0H)"08'     0(#! 4
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MVS(;ZLGV>ES.V9#?4.#D>>[C591<I%$U037E7RJ0G14*JF)TS*W3@4Y2FL,
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M@4H@8X] =0=/3 PT\&;^A3_A#S$IL1*_ 0T""20A](":4"_=F$!%7H P2 I
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M+)*)D>02.UKG'$$CR":UZO:B,?IFO#<QE'7PY%C((YIAB[/B=),X!""8R7$
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M\C&.7\G#M*H[0Y6/T]=+VY*YCLO$YN:9HO5,T_'QDC55?R)PC8A'FU,*1'(
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M$G\W'B3^;CQ)_-QXD_FX\2?S<>)/YN/$G\W'B3^;CQ)_-QXD_FX\2?S<1?\
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M:F7$J)2AD(MA.+964R=-E6-C93S-8-\J=/FE-(D%VA""S4_2,0V,8UK4_P"
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M?ZO'BM/0O]7CQ6GH7^KQXK3T+_5X\5IZ%_J\>*T]"_U>/%:>A?ZO'BM/0O\
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M?4O:E63 ;#L8JYC-6L_"AY^,P%2A-1JP.Z_Y%(%0\7/2CT@;T%I (D'AE4^
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M><[./BT<K6(R12U6DYQG7K#H2 .,UJ8W(4 ( V[C05,_+J6J]/'P6%5K*%,
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MM3*&H 2*' PUE4B71J Q<RK8NS^RAWV7^^ZTUG;H4UAH)J!HZ Z87.0<=P
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M       (                    !!(()((    !! !    !!! )((
M     (((( ()    (! (   () ((  (           )!! (     ( (
M!)())(            !)!!(     ! )(    )!!))!    [;;;;3;;;;;;;;
M:;;;;;;;;:         !10P             (  () )!( #K;;;;;;;:$ P
M            (!()))()(!%@       !T P! ((    !!   ( !  )    9)
M)))))))(4 P! )((   (    (        !6VVVVVVV@ $ P    (
M( ! (  ( !/[;;;;;5@ $ P             (  )))((  U      /@ $!R2
M222222222222:222222223R2222220"2> =MMMMAMMMMMMMMM-MMMMMMML_M
MMMMMMMMMGP     (        !  ((    !@(               (
M! ()!))   H(             !     ((   ! )       J           !!
M! )    (!   !         *             ((!(   ()   !  !  )   E(
M                        !    !)   L                (
M!         "                         !         _^
M   (        ! )   !) !H(@                       ! !(!! )  O(
M@          !()(     !   !    (    9(P         ! (!     !!
M!        !OY                        !   ) (( !5,
M            !  !) (  !@U                        !         =M
MP    0                  !        ![8;33;:T
M!        !@C=LH(2,         (        !        !TZUB=?:0
M   (                        !
M         /_$ "H1 0 ! P(% P0# 0        $1 "%1,9%!8&'!\!! 4" P
M<8& H?&Q_]H " $# 0$_$/Y\Z_S09T:4FTFB\_:GSY\^?/GSY\_4QH!C"2VV
MF=5$UUWV7GSY\^?/GSY\^?/GSY\^?-G 5C4Q#;XATNOLI\^?/GSY\^?/GSY\
M^?/GLMQZ/43"'M[2#!@P8,&#!@P8,&#!@P8,&#)HG40W$5)'6(@(9RDR48
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M-0C<%$-P8:AP[-0X=FH<.S4.'9HNB_A:O&Y>BT!0QV%@9BY3[8
M '"[&]:5=*%J*$"]F                    (=%(*M,%0L"6]<^Q
M            !+1GLY"2DDZZ+ &C6NFEM5,BGM
M#14NHPC QBB"4JE:JKH766Q8_5ODM7DAR&KR0Y!CHVK\TE:5R65M2Z=!.6+N
M@D&R/(]L'U -&T5K1=&E 'NRCT",8!!2YR/J\D.6U>2'+0?QW<+9V\(7NUJL
M(*#P+"W3 M#KR.VBVQ]/BG)>WD<?4Z=$Q';:8R"LV5=.1'90T%0! I8 %+ 6
M"I$Z&V#B0$T0)5L<F7#H@C3=@'(H=EU18$ 9-B2X%0ZC=Y&B@20RM:9YB %(
M:DE3(1*M>O(H>D>O!(QS=2*Z%?X2O^$K_A*X"VGB@3 2P<B#;]8K15O^B8F6
M8(8;J0PW4"H0)0G2EBOE12#.X@B7D36;OS"L%U,!JL4TG49^?>_?F %,6V=$
MG!?5<3,\QDY%1.OMN!85 %*0PV1HR;9II/$8;RVM0KB>'M*^V 0" K^O Y.E
M%"2'0>1+!>:+<$X6)02V/H(D2*#^()*<H*H5557[18;2VQ 0Z-&'S32.+^,^
M>O>&+,L^IPYM,]#/126I_GU!PY%K?L<1Q]8Y8.'#AR\2K#ISR&1C(3!08@(N
M/&!='S8$%O>U'= E*F++*##/7A&Q52Q0%"&Y\#KO1 J8LDXS/+8'4Q)R50,E
M>3UG]R7%PK*%:G$.)-JG2T&RXQTVA XH_&$N>W#8U+BABU(UN3;<P3$F((J'
M]#<,PF80Q550D79G5$I4A\R'(WW'):*0+!8^G#.]6N.G&2!(+)(:4$EAHFVZ
M&'RV^8&@*@RA+4LUBWL>B,;_ !F 'P002#IAB@C1 ^EIRIHNZD*L23IB:1^%
M+(@:3KJPDNK.067K/ 7U!K-J)*TQW/1#6Z L0C1M0OF!1$+G,]>%JRB+"2M7
MC6N*EZ A\!4%D;)+@!!BI=F2EIC0O$"01!X#<J>*T!86!"6$0%,QP$:(L:Z3
M2?/5J6B1<>'(4%._SLQL0Z:884DY&N"XC1B$@<"VB+TTY0__Q  K$0$  @$"
M! 0' 0$!       !$2$ ,6%!46#Q$%#1\" P0'&!H;&1@,'_V@ ( 0(! 3\0
M_P"^;G8/"VIXFH-(O-S"W,+<PMS"W,+<PMS"W,+<PMS"IVM9B%%DH. LN$G-
MS"W,+<PMS"W,+<PMS"W,+<PMS"W,+<PMS"W,+<PMS"W,+<QDIK $!* F.)B5
MQ2MN;F%N86YA;F%N86YA;F%N86YA;F%N86YA;F%N86YA;F%N84VOY_\ T_GZ
M3/GSY\^?/GSY\^?/GSY\^?/O+[-_,FAWK'/A-0!%DRD'-_7P/W?,! 282+H)
M!2"0EHNL;O'R)S2<2ZT6+B,7'(*9#HL8>#$-_1$B1(D2)$B1(D2)$B1(D211
MFUJ1$L!+!,$L'@[]XYO@?N^8#+ &8+D0*'8"@D%PDXKPWAI OK4DB63 A&+$
ME.&%?1:WA[OWCF^!^[Y@,&BP"<>PF7;D?29\^?/GSY\^?/GSY\^?/GSYW4.:
M%=-"T*DD+<8[]XYO@?N^8%3[:AB+>0A"%$&GZ V;-FS9LV;-FS9LV;-B 0 (
M(B)(B4B6)2?$[]XYO@?N^8"DHG3B(*H  E6#)\,@8%.BB!\R!. XQ&D)") L
M0:+G;'IG;'IG;'IG;'IG;'IG;'IG;'IG;'IG;'IG;'IG;'IG;'IC^<.#F;?&
M\=^\<WP/W?,#F,?+/!(2 @!%DK!MR,58.P,L,(/$N#.@-P9Q50!\QT_/]'QO
M'?O'-\#]WS 1MMU-RB(001)#,S\_'CQX\>/'CQX\>/'C6_!^%G*LHE 0)D%P
M-HEB8GXO?O'-\"^- 0*1 A@QHCY>_?OW[]^_?OWW%S% @K-:9$!)A)^CW[]^
M_?OW[]^_?OW[]^_?I !I%C2I )"#)4H_1;]^_?OW[]^_?OW[]^_?O 80@4)E
MI02($H&%5Q!H)0<(6_2;]^_?OW[]^_?OW[]^_?OW[XR#QR(K#!"%+J3%55U6
M7[OF6G[[Z(1-/WWT0B:F!&P4),RZKBJP2]4EBM4Y R7KKT/I!Q\K01-I-3_,
M?GM1$  "2.)7#7H?3]]X]BYNA]/WWCV+FZ'G/P7\Z%UI9NLT&# J2D!&I#+T
M/J$:), 2B$IJ-+^!8L>&2@P#H 0'G"]"$ZP,K0"RK53-X>I- H "64LA 2&N
M/(PZ6@Y1!(XL6)SW_D]".((>)5 )2):I)&G"HZE@8FPG,$#:&)BFG6CA(+!A
MD KP]_Y/0FK_ *AM63H2P9W+ZYW+ZYWKZX%91,"T#@'0EDB^^#^A)N>$9#G_
M ,XAS_YP@%G0\.-\6<T;()B8F">1T(2B0#B&OPEQ6&B\$XT""D"+65OZ1RR!
M+W$")2!T/V?YT*B4>7U2(*&1A!L3GC 2*M]4M52":# 2B21&A3P:(B5&<T/V
M?YT*BH3 4<:$HP<"?@OW[X       - "@. ?*+$OMA('>.B51"SSF%;TYJ%_
M-4*JW.P<=@^(($[!QV#X G8..P<=@X[!QV#CL'$?EKTW$!59)1-(-)I]ON;*
M==4<;SDZ_OOP$"-KZ"%J)4 FHDA+/>UBT:-." P>MY&T1)*P4H+&'/>E<"@#
MJ@!B8Q2E"BF&;3"0BP@M ?!L& S5D!"1<4@G.!_*#B8&##0DI%RV' Z:;D5H
MT N"#$0MD/('A+#&<RT+7)0'B^H\B7VPA,^B3*?NT2U.BHD#!X ,?]?1-54,
M@*D3D2'J'Y,Q," A*E\W8*.,&-**&'5='')9@"C4&3A*"S9P8P@,-E2DC/ %
M!1)UVIW!T8#[O.=-03&H@1A2B)$3*$'P:"@. 8J IS22\&3,FT:'# S6+1W9
M9(#(.8Q195#8'2F4TI0)T9,L[$,J$8)J $HI60EFK+ 01!P8@"$ 9HZ1)(7M
M4-Q9LS"7)G: XH5% 8'=AI;A$Y)RM$-CEJ8.(7$II$"\BB3H:S#F%GB@]=A9
MX.D7_\0 *A !  (! 0<#!0$! 0       0 1(3$0,$!!8='Q(%%Q4(&1P?"A
ML6#_V@ ( 0$  3\0]2#_ (")>!R@ 50(BG&HDO6Q$B:*LD21A3J! ( JT,P4
M_*=$,9L9DM2GA 743E)HEI86[Q\/1PUP4*'%OP:#G<\)RS,#]R#F.Y':EHE7
M8KQ$":BL?#%,!8AZ&C75M,)X#0TP@.4 5+08 U H-P2E.1>D\HK8$%.!S/1H
MW) ^\Q2L0H,KW81%)JMDVPU6TN4#1BBUG1 F"NJ"%<65.')D>8@.Z2RICF8,
MG26=,_NZK\W)?6%JA*-L );IVX(DS Z%H!!)=3R/SVD'.$X*ZBT:B: :)!K.
M)N%)D4LAD?8X@Q>M@3 ]K0LY %VX5, ;! GG:D\5)>:-;O%G33-2G"(XDW!1
MB+*3AO-^ CLH"850,Y0-8JR1)&%.H$ @"K0RZUJX)_"VF5P&[R.MP_W@*)TB
ML4^2Q*I?P 0(J*J:BHK"H"(I!MO>OOL("P:1KMN3^R >),"%:XV<\<2O$TIF
M)I ;E6O5L:^+YXLG_P 0:Z0-7V9(%8C->$+<7:N%JY?6)FS/DR9%U9 TP<"K
MHSB)"DFE!"U#6,%4!1&BD&"=F' T0-AA7#[X>=FZM9>[&K  'D]RK"P'@MQK
M0 Q3!1GXTU+>GUP 0N/FP@]Q6.+RO:LN18<>CS&1P\CP:8P8"%8+8(T((1M
MR-QEK\J)L40;$(DH#51*1(9YY!RUCR65F(NNYDEGRMMQ@B82' '7 1<JJ&RA
M?6#WUA46 R>C% *QB@X4AKZ7H;IQPK&*VE0P^J?@TH-'"I3C?/?-ES]$H2"!
M$CE*FL,:XHQ2C5^%^K#\B$J^VP93)\XN.0U^QM(]I8OE K>UT6C36 9-(4'1
M/$5?S/N"2K_CQ6(7I2R$^I31D+N_VD'T&!\,Q4<V+DL(B-JZ5/SCE"LL!^3.
M%)"#;<#\3S535_-0U'ZA KYZHD!(LXM-1.W>>]9)<I-R?-/=4K:CG4#'):H)
M>H895GV3>:M:FJM+6]1D5I6 J(9/NM=%+\3T9V-M$ZW+':-U/TB;#()90]1M
MHB I?QE#Z>NZ)77..0TB2X3/KLWN7SALGSF[@=H_>[E1FE/Y ]\_2.,)*/#_
M $ JJ =:Q!'L.R[V1",(_&118JI,3),RX^2I")#;&2]N%XQ@^/JR"W>.!1,*
MB"X:W@!#K9"D'7/68H=26/G%#RI*>;%,E72:I-8(!"W(R>US#,-64K&TWB!,
MKIL)\,@,' 4M,S#8GFH$' DF?VZNAH- $J>"0A8GUZIP'^36UU#?T1R<*W%T
MM]-,6+9S><A&HR>V111!A!1\<907:RLSRU;/ZK0X WK_ ')ML&9T$OP+C&"J
M).';-I-\JEA'\M2?[CK+,UO,]1X)BP2TXPQJ'&_4PC7S5S381X.O4VFZ*F&3
MT+IS7X,P"^PBO-"S@W@AAV6_#UCHNH$E=Q[U?7F+C2"MZ(LS'V24>D^SZV"J
MFN)5#Q6.+442GHE< Z$6@)E"#+2^*XOI4J1JF$&8W<COF#GX*8<G?DP/>@N
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J^&:8-'06^"J\K$4HCAEJ4!96^&P0TMAL.A*P$4    * P : <@_\A__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>business9a.jpg
<TEXT>
begin 644 business9a.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_X1R417AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   "]    !0
M +T    %    1TE-4" R+C$P+C,P   R,#(T.C T.C U(#$X.C P.C,S  $
M : #  $    !          D _@ $  $    !      $$  $      0   0$$
M  $   ![     @$#  ,    8 0   P$#  $    &    !@$#  $    &
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M\RM@ZDYN4963]3S\ZSJ#(5-T^",'\L53EE>>9Y9&W.[%F)[D]:],_P"$?/\
MT!;7\E_PH_X1\_\ 0%M?R7_"H>%D]V8O+JLMY_F>845Z?_PCY_Z MK^2_P"%
M'_"/G_H"VOY+_A2^J2[D_P!F3_F/,*[[PI_R H_]]OYUH_\ "/G_ * MK^2_
MX58ATZ\MX_+AT^.-!_"C@"MJ-!TY7;.K"8.5"?,W<=13OLFH_P#/F/\ OX*/
MLFH_\^8_[^"NFYZ-QM%.^R:C_P ^8_[^"C[)J/\ SYC_ +^"BX7,.P>R73X
MT3 %VZGON )^F2.*F62QD+1^0VSYB6.,= 3WSTQ^8JW86%[]@@VV*8QG[XZ^
MM618WXZ6*#_@8H6B%'16,QIM-D0QF,L"-I7RVZ#Y?Z8_"EFFTUR8Y5#!OG^Z
M2#D$Y_+=6E]BO\Y^PK_WV*/L-^?^7%/^^Q1<=S)-QI,,@R C*,_</ R?ZDT1
MS:4<^4N2G[S&T\<XSS]*U3I]\>M@A_X&*!87R]+!!]'%%PN4(=4L%@7RG(C
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M?/R\\_3B@#6HK)\O6&?'FQJH/)..1CMQZ^M6[%;X>;]M>)B6^3RQC _SC]:
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M6QX\T8C(6[/ ;B G@]*AN? >G7UY;W-PF#M(G1&(#GL<CO5Q/!FD1@!%F
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MQ''3*#C_ #DT 9\,IN90T.J;UC52ZJHYQU)X[X-5([B9Y9&EU9XE)^6/RQD
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MSM001;Q9'0[!QVH:RM6&&MH2-H7!0=/3Z4 3*P=0PZ$9%+2*H50J@ #H!2T
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M  4 %0 R "EA8W-P35-&5                                   ]M8
M 0    #3+6QC;7,
M                  UD97-C   !(    $!C<')T   !8    #9W='!T   !
MF    !1C:&%D   !K    "QR6%E:   !V    !1B6%E:   ![    !1G6%E:
M   "     !1R5%)#   "%    "!G5%)#   "%    "!B5%)#   "%    "!C
M:')M   "-    "1D;6YD   "6    "1D;61D   "?    "1M;'5C
M  $    ,96Y54P   "0    < $< 20!- %  ( !B '4 :0!L '0 +0!I &X
M( !S %( 1P!";6QU8P         !    #&5N55,    :    ' !0 '4 8@!L
M &D 8P @ $0 ;P!M &$ :0!N  !865H@        ]M8  0    #3+7-F,S(
M      $,0@  !=[___,E   'DP  _9#___NA___]H@   ]P  ,!N6%E:(
M     &^@   X]0   Y!865H@        ))\   ^$  "VQ%A96B        !B
MEP  MX<  !C9<&%R80       P    )F9@  \J<   U9   3T   "EMC:')M
M       #     */7  !4?   3,T  )F:   F9P  #UQM;'5C          $
M   ,96Y54P    @    < $< 20!- %!M;'5C          $    ,96Y54P
M  @    < ', 4@!' $+_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" $? E4# 1$  A$! Q$!_\0 '@ !   '
M 0$!              (#! 4&!P@!"0K_Q  < 0$  04! 0
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MB:4.,#IDUL6,V2=B&KS1I>C8Y6G=X!"1           D$\$ (P   "G*@
M $@G@     E$TEGI&    "$B         -9DXRHL9:#(":8F7XO!3&#&8D91
MEQ,",^)!EX  !J8O9?"V$9$5!3EH(R]$0,%,O*DOQK$OA+,O,2+,9&32O,B
M(2(        %"?-TQLV^:6,S+&7,%O-@%B+>22L+$49D1;B^'TF/0  <-&#E
M 60LA$5Q?RR%27 JR\F%&+&S3+C11F)LHU&49BQM$QDZB.L@"$M%G%U'AQ,5
M?0     MI<SP  'AZ        #TLBMZ4   \/0 0DDJ "23@     0T\[MDM
M@P7 A=/YDI5>[P     TK:QZ37.?P*@      IN_9>A5/N\   !Z<EP.E]+R
MFQWS*D;:6DN)2F0$1X>@](3TH2N/       :MC8#LR2G\;P(73^9*57N\
M  .>\*(XAXG\@PUJ      /*4^I?</L6]9,@   !Z?*'E'S+]"][[3?9S<=)
ME>5YBY6F%EG-B%U* A,&,B*XZK      !JV-@.S)*?QO A=/YDI5>[V$E27X
MIBXEM))2&1GI..>\*(XYXS\ET7FW7>[UCLXA3P]5]   !Y2GU+[A]BWK)D
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M;"Y&!%6=K    U;&P'9DE/XW@0NA[EZJ]W0    !J5ZVW3Q        15J
M  /34JNV5              !K7 ANW)?:+O3SH[%CJ0     &GZ^MQ4\P@
M         'IIZOK<%/(              J_=S=V1GU0      .>K6/C&M\_\
M      !M:4V3:\KL@    'STC=QS:Q)  #,+V!U%)Z7;B<2">5P  !3$9.
M  !"1       Y5PH?Y7\3^0H:U      '?N^=I[_ -\[6    !^<W2_I# HS
M=@ !T=(:E]N]W^9N=RA,-*4@(3,C,C 2$K37!D!WF    "$B!X889 8Z5QE
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M9@:B-D&)&RSK,    A(@      :-4W7Y\^       F5K,KZ     T:;R
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MF\@ 8\60SL L! 9$6,JB(MYD!8"_EL,+-CE"5X .0\75>.M7^4NFY3JU-YM
M"K]7YKU;_.-45NT]+05=.RG6-I9>W        0D0      -&F\@ <I@NYS$;
M3,1+R;<-1FSC6IDA6F+&S#1QEI";+.EP ?%C5?E'FF ^;<\N['E5R9RB]+5O
MJ_@&/K697IW%K,3GN1L5+2U$:IQ=/UU8UCZ];?\ :?8DWVP       "$B
M   !I$W<   0D0 !"1      &E*6M20W%NGY7J_BH'JGBH 'J@O/O/KO60
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M::\,Q,A*$C!CY.+J"@,S+H 0G__$ "\0  $#!  % @4$ P$       4#! 8
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M6N +VBN-/)7UK@"]HKC3R5]:X O:*XT\E?6N +VBN-/)7UK@"]HKC3R5]:X
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M?B BE\J<I1'.TFHMFJLJ58]>;=KQF@X(JFT.'!BYB&F,S0%UF$   OY3I;0
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M?E*A@,!@_-\8UD]*QL?#-2+789XKE,@#LKQJBX5+#'20(Y. JD,)$OS]91M
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MO@U?1V4'D&:]DR/PBU 4W(/T#=59I^0?H&ZJS3\@_0-U5FGY!^@;JK-/R#]
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M<<+Z(]:U ;R.%]$^M:@-Y'"^B?6M0&\CA?1/K6H#>1POHGUK4!O(X7T3ZUJ
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M&A#VIOXIOID_LCS@^Z:2]'OO8W/N3PF@LH0QTTE#D3":AR$,8I E]L0"1?\
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MS_SA,Q4RF*5PV*J)B""@C6)@P 0,0#"49&K8Q"7C%Q3BTM ,90*@B0QDDR2
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M^*UUP=8B-L,2!L6)#RT&'YJP=ZYC7YC!,YAP_HVOS%C*XD9V\44V&,(94,N
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ME2)*0,S.#WK=YIG:OCW%K&7R>.RLY[+Y=/-,<D49RE3F"LCM_1R\(MN^P;+
MN#P0:];#)B)A81Q[H]K%,YJY'YBY.I*])U<CA:4\R8;N7+BO;3C7WNQLB\8,
M8W75[!+?J!2J2]SKDW 6.=TUK7*N+SF2S&(Y9PES/\TG9I(L=U4IV;?8JQZA
MDHR<J8,HL]P(0\$K(N:,'D^4,QBU8G*W:]/(S1A56C7J0$!CN86E>=*>8&:[
MI1545;2"T.-(W?F$<SFOD#.\L<NO-G*'+6?R>;3CZSM V9;)T*F+-=S*04$4
M=5[4K]Z$(V+T+E7!YGT'CZ=KH,]T=N-?:)]JK76#W<N8 VU0=Z,R]X83D++W
M5W>C1-,*9-@XX1G]>7Z^%Q_,_,?,E?*T^Y'F3(T\[BO1M7E.\GMPKKQ&'UAB
M)BX]<C4J0FI7*#+CE!-C+SA>1^7(M9:RW%7FUN9'<R3Y,<ZI^1FBNN@(":K?
M<]8"?8V*UV'QE'X[FG*9WE?GCE/*<L\].YIR[[O,>]R9'%Y''O[,EVSI$*1$
M+3TRM'<*$Y%V@X7DO,YODD^0<'0=AV6Z%/(ES%F\/VLU*=8TN%=3&6$JF(FT
ME[YG;N.'%KKC\'8QON9\P\I4LS%R<WF:^=+F9V)[DK,T#QZ6!B^]#=L1=ANB
MB@2D#&)@N;B]S3-<G^@.=LZ7,-AG,U>^>4P&1M=,;TU%U5-KY-)@'O2[+$P$
M0$:06\S]U7+Q=PC8YW]S.GRCCVFVU6*<TFO778LVZPU7C3HL:MAAT7W&@,B.
MR=->.0^:^2LARJ?,^#]SG$>Y_P R8O/'D)PUM..4J8N8Z[4J]V)#87'@==74
M!83H.]@\<^X'(Y/E>US%S;[H>/YPBXE]ZKC22J5LN;P]'FVJV6070KB%@=NW
M=8UUX]T/GA[<=.(YIY?P^+QJUO<5]=B@A*W3;3-85*5)+G82[#B*--0'CDJB
M=SEEO-G).>YCR2:-TLA:Y9S%#/6@<5*Y82BI?KG J7[XE$[=S!\?(<9BYG,)
MR5B,UEK2]8Y-7D^C&.KKB*]:[<RC)?>:MG58#>DK:+>G.Z!'3*^Z-[F5WEEE
MKF;$4\5S#A>:^_35D\> +J7Z5K'*>V#@$I@TFN(F>K.XNKHOFKE@<QB,ASMS
MKS?6YOSEUW<T<*%KOZ]AU6ILKVK$)2E,PJ21JQA3K"@VZ>YUSG7;CAQ/*G+G
M,6)R:VO>-T[.6Q=JG6FHD:I*8D6N"6DQZ2$-9$#GPXY'9B\MRZCGKD'FKF/.
MXX+)7+7+^1I9Y\RRG:=%15I#>CI'475/9N9 3NZ;1]VWEWGBQC$9KF'W-<=C
M;%K (M3B:(WT4@J+JE<%;K?9K8N',9L*P8,TA<> ^Y31YAR?([.7_<PSM!]>
M,<S*CDLE0IAT MV"=1Z,6U506@*@=-9RQC66-8B..8HP=3W.^8.7>9,X_,C9
MYQ5G"RV$&_8ZUVB%7'&-/)HTDA3+V*+U&6A:\<W^Z%S#.-I^YT[W/\)R?V5)
M.1O6ZX)96IM3.,KTGG-#86P>DVPR%>9BX$2+C/<Z6;%^_@\9W?)WN:.R=9U5
ML<JCDK.2=:17M"-A2W,L*KK(X@BZ=H)B!@8XY/19R_H;D;EV+>6LLQ5YM;F1
MW,<C(8YU3\C970NB(B2[7<=<)=9V+UD"C*NH<T93/<K<]<I97ECGQO-.8?=Y
MCDGHE>+R&/?V9!;92F% (6GJE2.NL#F&Q \N\KY+-\CGR1RU7*A%NE2R)\P9
MO&H3T:%9R'"NIC6JC;U+";#YF!U*&E/CS7[F\V,'Z?S>=R.2JNBW:]&0BUF:
MF07#['8=P+80@H*!JLB&;1@I'S1S=9RUV@C!<S^Y1B.1(;3>YN2K92B..D[7
M;LJK050&TI()[G>T=!)2]TR/+I<R87W,;.+Y8U-&<QZ<^SF7(6:P;<9=%5I@
M4,9;28K98-?6%WF'8.HR+>8SR-$O<WK9^[SQB>78:WN*_..0HIK.L34FIVP5
MTNAEA!KMR42JM'2B8*>/=JHU+6 %WNA<Y8//X.7W+@K52QMMCK Y&1QQRBQ(
M%'3! V0(OA,'CW/.9H/'>@.6^7N9,+G4'8>N\X<WC&8^(HK76)9AHPMY,>@@
MCQ 2GPXM^X]RASM<YAQQ9D*>%Y-;[G^;H\T2)9N+?:Y'+O4..3CZEB9NS95)
MM><"/O2NH"J^ S=*K?J,Q-;'9&C96%BK8$*RU.4P"B08&X?#^J"CQTXMY#W/
MLQF<:J,;DET^2\CE[=WDH\BZN?8-[6SW5K&+1;VL;-!OG#4.GMB!XM<T\S)]
MSW/9+F#(J_&#F1^5SEC.5,)O'J8W 5YQ5>C22I?Z*N.P&2*@:>P!TYU]SKNL
M%Z=YAYMMYRB[O+?HX:3LIBKH#9?Z/ZX/Z5)D2 56A!]..I,3)1[EO,ZG8V,?
MR9ROFL-E@-[XM,MY#&+IH*DN*LK:F&C,L)K4$(>(K*?#@/<R[K ?C!'-/IF7
M=[<]%]IZ9](;>X]'=QUNCX;.TV]3R]33S<<I<^ W'^AL'R9D>7[BB<[T@5ZV
MYS%DA,5I2=?1D;C.RLXG714\>YW,LKC@N7LQ?M<PA-^W0R#:-M%98CC&U$F7
M<;DSKJZMI&FC/'CF[E_EN@6,L\X8:]B,CF[-BUE,HP+59J%2RU=<UI)03(9V
MZR4LY&-T;M"CW+,7GLGR.SEWW,>8<=;K^CV94<EDJ%&"4%MY.H]$;::L0A=,
M-BV2TVLLZA&ON[8WD:SRK4Q6<]T'F'&90N9$Y$;M.+<N4W(XN:R6IM;J;25V
M]@8"&"#0/S3Q[ES\;>HV<)R+R/S'RY?=98]-^WDLTJZ7<UJPH:KM2N6R,H.T
M)(5Y1%NWQQW*V>;0=DJE[+V6'C7.?4D+V0?:3L8^O59)0M@[XE,1!:Q$E'CQ
MC>>:U['IY-?:PF:YFQ!ML+M7LWRZ%@<>P:RZ\U[ S,US)K;*R&2?[V?EUM\^
M-O8\N2(R.1YIQN%%K^[5S7E<>BG:M%5[:*P#U8;:AXVR+<"!Z,>,Q[N%^Q?Q
MM7%^Z;RUC<+AW*98?<IV*F.BJQN0JS74L4PZ(F(39<3%Z_ GCW-^7<VWDX;?
M('.W+N16['W,G"+?+.#K G5G6QTS.7,H*>B(+K$.WWX9UXYJSUVU31ROS+[F
M#^1RE+G>ET7W6PL19BM->*TUU;(/6;6XYC9*X@MT<A\I\[9OE&>1_<\RF,R5
M.Q@DY <]GO02Y1B$VUV%!6Q\ B=E@Z[FRS62\Q[9X]U3 <HYCDZ>5/=+R62S
M;FYGTF&9H6<D,S;QR1KUG5>C9T"MWA$PDJ]^!'4\L^Y)S%RG<Y8+F+W/^6CY
M;R-#-LR$8JTNS136?8J6JE8K$RHA;M%B%=2"66H;2&<[RKBCH)R^532%977.
M51%B;E:R[<Y5>PZ VJ.%ST"F9VZQ'CH_G0+.EQG+;:X8'S>A5\X.Q'HAG,T>
MN(>=7WO6*O4AI%;W=308Y$]SW)7V#[K7++ZN=Y,_%W'Y7)K?DE9QP"FO?B@M
M*I;4LD3 M="28B)@#"(W<@8_"Y6KCN>^3\RGG;O,FH[./R/,]R2M9564V;VR
MMCF]&'K@R 4! QMGP]UCW3/="MX(^8+?N;Y#E?%X7E4;K,=4QT2-IK66;BU6
M;-IS5QM'HZ+@V>8O>X'W)\7S-E.5ZON>X$.7.9Z_H]%\.:+XT:D'C<9<4Y45
M*I5U/96?92[5OZ:5]2('CW3.IE\7CKV>]TVK[H?)UI77NJ2Z@=LJZ,U7.NC9
MU!L[6 @K4 6AZL@96=^U[HM[D\:<U4(Q^)Y61?9MLA,2Z_8R&0%+='1NCLX4
MP!U&18.R8995B<;[E?,_*]FJM2,5SSC+Q6L98Z6U]@+%>O;&S#6:L@=$2N($
M1*)B2+W&JRLOC<B'(G-6=YCSYM9:KK$,Q%792P->46-R*THG0;#:VID;O++-
M@^[ADJ=G"C7]T;EGEW#X&'V[0,3:Q*<>NR62$*#!0F9JLZ)H*T11([@#6=/<
MNYH:_%SCN3?<W_%++ %FQ-IF3[1B>I27-2%MI[RCWUKD,T_Z'YN.<["K/+M[
MD3G'.WN9G--EX.9:F0M)GIU5HA'8'7%NV#:5C<2XW",%Y?Z6386$-.($F0([
MRB/5!'INF(^:)GP_#(E$$)1,2,QK$Q/KB8GPF)^>.($8@1&(@1B-(B(\(B(C
MPB(^:/S75Z8=68VRW8/4V_Z._3=I_JUT_-E*U@&\MQ[!$=Y?Z1:1YB_USX_G
M1(@$B#60*1B9"9C29&9\1UCPG3YOP2)C!"4:$)1!#,?LF)\)CB! 8$1C01&(
M@8B/5$1'A$?T^GDROUL>B^ZXBJ&3L5Z3G'2R)XML+!K8WZVQ$ V;M9<B/ FB
M/ V<Q?QN#%M^]0KQD<OC%C9.C:96*4MBUTB,^GOFON[BONZ=A:VB01-_(Y"E
M0HQMUN7;2*M6-_P-;#S!7G_R/-YOFX3<L\P82O4L*BPBT[*T55WH(X5#DN-\
M+8J63"X8!2&^=NNOAQ3JW[].G5NXJUEE9:U=IU\9T*UFA6@.Y<X (WSD%L3(
M3($ '.[X.M$!.NRG>H7<C&2&]2BL%:G%4NK$$^&O0P+4'W-<65TB.KV+ZJM[
MZN-S&+R%FL('9KT<A4MOK@S]&;E(:9J$]?(1C$%\W&4R-CF+#S6PL:Y/H9&G
M893+=LA3E*<1@XS\@**(,S\HQ,^'%*^[/X9-')>&/MNRE)5:]/JTJ/-\+L3K
MX3"B.8GPX31=DJ"KMG;V]-ERN%I^^"D.C7)D-;O@#D=@3N@"T^#/%?'WLOBZ
M=^WIVE*U?JU[=G6=L=O7:T'.U*-L=,"UGP]?%]V#OTLP>,RPXB\BOD**V5W^
MD1QQL.7V #I0V2),ZZW-FRI#6D(3&./.8<<@1-"*)9.D-R31&KQBM+NM))CQ
M:.S5<?"TX;<IYO$6ZB'#6?:K9*F^NFP9" (:Y3B6MQF8 *C*#(C&(C4HXN6G
M%#VTJZ;3*"&I[V:[K05 ="3,9A75/;U"T"9$AB=T:<>AO2^+]+R._P!%]_5]
M([=N_=V75[G;L\VO3TV^;U<7+& O4\W..RRL1=36R%!9H<=T:1-*7V "4[MY
MHF)UN=,@J0UF@\>A_2^,]+[=_HOOZOI'9MW[NRZO<[=GFUZ>FWS>K@<8K-XA
MF2.6P./#)4SNE*)(7P-472^920'#8@-5R!06FV?S#L10Q>6SV0J*2_()Q*$F
MO'+L"1UQMV;+ZU<+-E8DQ%06'8-<0P@!9K(J%G)WJ^"G)1^35,\^OB;LLUVD
MB:]IP%+P+RD"Y/QF-)F"B9"G8RF.1;8.]=5UVLJPP=ALW @V0PAZ:V'K S&P
M#+U#/#<@>?PH4$.&N^Z64HC42\A@A0VS+^B#B$A*%D<'(S$Q&D\4W7<[AZB<
MAI-!MK)TD+NQ.FDU#:X1LQ.X?%,G\*/VQP%*WG,15N-:*%U;&2IILL<8B8)!
M#'"TFD!@0K@=Q"8S$:%'%;'7<OC*F0N?%*-J_51<M:SMCMZS6BYVI>$=,"UG
MP]?"\?9S>(KWVNBLJD_)4U6V6)$#A 5S<+C=(,64*$).18$Z:$.ML\ADJ(7*
M^.N9)6**]33DKRJ:&O(*=5[EL:3(40!,1MW^$SZ^'-LRG'55(Q3ALW+] !,L
MK6BRI)KBQ+*S0UA<18%?<3.ZMU \>'9&EF,7;Q]>618O5LA4?31*HU;#K*FD
ME4KCQ/><;(\2TXUQ67QF3C9U/YOOU;GO>[I[_P G:SR;_)N]6[R^OA6)=E\8
MG*OB"1C&WZJ\@X9\8E5,FQ89$_-(KG7A(309UWXCF/, $7L:2(7RY=KTVI.Z
M-J::SM%968&;836B&#<-!K(8I4+&5Q=7*7E*;7Q3LE2B^WJC!#":_7ZECYX@
MD"8'IJ$S'CQZ//,8L;_4A/8ED*D6^J6S:KMI;UNH757H&S=/4#2/,.IUH<J;
M*UK<RO# EZTM)@*::M=XK82FBLY&!,EL@9F0+3(Y&QS)ABK8DEAD9KY*G9.H
MQKHKK4Y:7$:V$TMD+.(+6)\/">/):HGC/10Y:,R.3QY493-HZWS6.ITHD-W>
M;>TU]ZAW5B0A]DN9N7XK57Q5M6)S..A->S.NE=[>XV*?.DZ*9(GX3Y?#A25V
MZS'/K=ZE0/43'4]RP[M004DRMN:H>N,2K<Q<;M3'6CC@:#@O8W-Y.,@I]<Z*
M5X&YC:-Y;70SP8+\C EIJ*IK6 =(&,#-WF%O,.)=A\>8JM7:=^K<4MYE C7W
M5VG'7*2C1.O4F-2VZ1Q 5VU7X\L5Z57EDY"BVHQ/7));1!\NE0P,LFYL[/34
M.MU(D>'7ZF<P]JC78*;%VODZ3JB&F8K!3K"W$E;"88 (&<$1$(Q&I1PUF*R>
M/R85VRAYX^[6NBET>M+2K,9"VQ\ZST+_ %?T=]NP6Q%9+;#SVF>Q20EC"V+$
MF'M 9G: D9>H1F?#CDVQEKE8RY=J<\P1>C<Q8*M;S^>JVZ!UOYK\TMQ\/ZAQ
MIT)][+S%&J[&.L72S@.YQ"M>H(W5%U<WS%<RM2OE<=G<5%>S3>#*[W'5W74S
MU$2N=(XP/5MV[N:Q-FI=WX"K=QY5<B%%]5UFD&:Q<4+-3W]RNUMRN90R"'1@
M>&"R64JT\_D*G*.:IM76H,HW:@6^8*SJ<J6W'HQ$VF5(A67FHZO7ZL%VIO">
MF>#OY.W1Z=''\X=.LG%YJPG!NYBS>+R%;&8[J8@=R:]-%E)V%""X+JJ7$(8O
M=5IQD4!VN(]U?'  4<Q"UQS5FUVN7DITQ>@)FB ]2(@1I0 I*(F('CDVIBLE
M7Q0XCE//\OW[%7%9A)5#R."JTJD)A6+$[*0OIZL[/@2$.CSSKQD>7/1..PEQ
M7*K<+3O#6MNKV+(@L0K49KX@[:<8]B8<3;\5&@71EE0S@S!',"VY12[7+:L%
M8P=5%7O,<Q5VVYDFS(XRQBGT;ZGK[GLK/6]Y7#$O\!0-]F2EBZW*. Y>I6GT
M,U<OK]'NOLL5Y?.&44K#JH]_@%0^(#R1LT&QE.6;5I5S(1A@M7K-0K. LKQS
MBF(R>-O8OTM6962QT*=AA-C))91(LB9CF'#0T!&USLKF6ED8J9'M[=%_,]+,
M,3*HQW>(M4JRW0P7H%;&+B*S7=2-.;Z!LHMNYWG,L^DF8G+>_5_2N->MSWSB
MMP/&E5:$+F=8'WCU',<<PNQ&0J)3D.7^7%5@+&9JLNUEL!GVY056 7B"Z<%3
M%555L@*%PR ^ N8C/Y)L!B57N5L;A:%:R-^Q<.W5STY*R5F:5"Q42B43';R%
MALE,3U8610,*,<C/:5N=\5G*UBO0BGB@PU:RLFF:XPLY^QG.VEJ[4M@4NG4$
MVB3M7.=Q76 %NY[1S/3R'9Y&*]O'OSE7),3T0Q\VT6:*5L%@/0"V&,=JUN[P
M;R]';C+>;6<Q1SG%7([P4>>G-#:[;T;Z6]/)JS&)6'2FEM -;T5-4P5.O;IK
MRS/="_&>&AB\N!=!G.?I$K/=>B8*+1862"1UW].9IS/CLXU_E\T=$2S5?+Y!
M%MZ*R[57(XS*U,?5Q=I#2N554;F/:NC7:A]:X3DMEZY0Q4K9&3S3\?3SQ<P8
M*AC3I2-^?0C*O=];'M?D<1678P]SN@L6&T5,L=T-@9IV%Q6;-TK671=O_B%A
MN5JV1]%YPFG9I(R0V5C+<5U4U>L]&UAZ$T-DG&Y<P/('HC(N7^*>,?3NXK%8
M^Q7=-BW1IHFW1;E</.-:]#4.%AO-!L588:G[I(&HL8%V9#--I91?79%:W3KE
MD\B>1]'9;'7L,FD6/"R4.F<&#"3!.2GJ;5&7NC5_1N,S3>99QM,LCVV0KUTO
M_%FA4=%]5O&]\.,J6I-]6*06;<Q+-*X,V./F3!:UN8SYFKU4KYFMU<DDJ4KQ
M%3&1Z538QOI"5XRQ6/(8WT6NX1$[X-1^YD^Z'4[^M;RW,<)BA>?B<OU[Q4N6
ML/CZC[;RQ136:.1IV&+W%/1/W^"\T'QS_BT5*7,+><DO.IEK2+]<*YLPZ<>F
MEE1MXSO(#&6$2W&LH*LKD& 1]H[K'Q:1:NUK%6SD_<XL,4W'Y@@;7Y955'*=
M0)Q?CTV)F4K+XP(^'KTGF'**S&+JXUT<F9*%9*AF:F+R-GEK(6K-RMF-,08U
MZ[:W;)[MJG!&B=ZVK201F.9!M8=%&SRUCL;W."5E,P+;=;(6W$J_D*>)"H=M
M26!((5O)-8ERQI2R 5E:[Z57,U\MS18SP9]E6X/;H>X7(&Y6LXD\CWV' (K8
M^*B'HE:JTC9J>^=.*GI-/5CE3W3,1IV69TF[S/FD7<0.OHO3INKB1/9ZJY1L
M9XS&MW'TK\RLOQ;+&.JTQIT5QBO1TVBRC;.%/..R2V5[,U#K_DW1[9:WUYEN
MG/I9CF"AA3YEYAC)8_-/I9*N:W5\9B PMDK+L<O98I9''&U%;=)>]S(#,-G6
M]F^8[G;<P<S2#LA2'&9[ITJM>M%.AC0=&,W0E:1.Q)#'Z>Z]NDD4S.6Y>JVF
MTL,/+PT,71SE3O;07ZEVF^E6HY7%8DK!8KM464L/,Z6(<5(X#PM'QFW;AI>F
M.1/Q?]&VZM\R"[Z8?9.JYE2@^K*3J%!=5;"5J?3G0H+2KGH93[&ORG9P@GZ"
MRO4!QY&JU:AK^BOT79K:N&?Y 22? 63$\L9 3]*MQN S_+=S'55WT-JJO\PH
MRN-LUW7:":KJB:M0:SD"X7(@U=%3H681C=+^,7EZO+WNBUC4VAF+N.7D^9^:
M\9F<<G1F'VVZY5$6=6-3T@<"QLKT/;QSIU\A85Z;Y4Q&.H!F*^^R_*XV];LG
M#PP6&["LDE$I-9TL=MZFA=$ D>+5L'KQ_=\N8VG.,OU,H8LL8_F>OF7XBZS'
MXZTGLLG1KG2L.25A4+M$)">A#QE+)(KX1-S&8/#,P[ZMQQ94*?-&+RUFU>G'
MX]U$:]#'5;5;' 3667=W:6:D#*A*Y<P=A4UK/*5*D2UT;](FV\?E+SY)BWT:
MZYA%2TL%M(]VA2H(T&=/Y%N^X2)5.NVRP0TWD*@DY@=9B-TZ:1K/ E'+62T(
M8*/RO&>HHUC_ *U^R>/U9R/MF+^]<?JSD?;,7]ZX_5G(^V8O[UQ^K.1]LQ?W
MKC]6<C[9B_O7'ZLY'VS%_>N/U9R/MF+^]<?JSD?;,7]ZX_5G(^V8O[UQ^K.1
M]LQ?WKC]6<C[9B_O7'ZLY'VS%_>N.YN8"^A$-K(EAW,9MZMRRJG6#PM>MUEZ
M4C__ ".-?#C]6<C[9B_O7'ZLY'VS%_>N/U9R/MF+^]<?JSD?;,7]ZX_5G(^V
M8O[UQ^K.1]LQ?WKC]6<C[9B_O7&OXLY'7U:]WB]=/V?&N/U9R/MF+^]<?JSD
M?;,7]ZX_5G(^V8O[UQ^K.1]LQ?WKC]6<C[9B_O7'ZLY'VS%_>N/U9R/MF+^]
M<?JSD?;,7]ZX_5G(^V8O[UQ^K.1]LQ?WKC]6<C[9B_O7'ZLY'VS%_>N/U9R/
MMF+^]<?JSD?;,7]ZX_5G(^V8O[UQ^K.1]LQ?WKC]6<C[9B_O7'ZLY'VS%_>N
M/U9R/MF+^]<6&5>7,F8UKUO'.W6<:&EJBSI6 C=:\1$_"#CREZXX_5G(^V8O
M[UQ^K.1]LQ?WKC]6<C[9B_O7'ZLY'VS%_>N/U9R/MF+^]<?JSD?;,7]ZX_5G
M(^V8O[UQ/_Z9R/CXS^5XOQG33Q_*OV1$?U1Q^K.1]LQ?WKC]6<C[9B_O7'ZL
MY'VS%_>N/U9R/MF+^]<2)<L9"1F)B8FWBYB8GUQ,=UXQ/SQQL3RK=4&NNU=G
M$@.L^N=!LQ&O'ZLY'VS%_>N/U9R/MF+^]<?JSD?;,7]ZXV-Y5O,'6)VLLXHQ
MUCQB="LS&L3ZOV<?JSD?;,7]ZX_5G(^V8O[UQ^K.1]LQ?WKC]6<C[9B_O7'Z
MLY'VS%_>N/U9R/MF+^]<?JSD?;,7]ZX_5G(^V8O[UQ^K.1]LQ?WKC]6<C[9B
M_O7'ZLY'VS%_>N/U9R/MF+^]<5%7<+>HJN61JA98^BU8-,2(=XIL&S;.V8U@
M9TG@3'Q$HUCC._[+N?\ !+A']@G_ (0_G;EIN[I5LGRN]FV-Q;%<UX0SVQX:
MEMB=(UC6>)^4O7/_ %./M^/\Y>QQ]OQ_G+V./M^/\Y>QQ]OQ_G+V./M^/\Y>
MQQ]OQ_G+V./M^/\ .7L<?;\?YR]CC[?C_.7L<?;\?YR]CC[?C_.7L<?;\?YR
M]CC[?C_.7L<?;\?YR]CC[?C_ #E[''V_"G!KL<L&AK&D[6#!CK'S3I/C'YJ.
M.8*%SO>X5S?S))]&M#%Z,N[QT+JCKX3X^'"+]7J=O8@B7U0V,T$I"=P:EIXC
M/SS^!P5K=:R=<MCP0]3227^BT0(I"?"8\WSQIZ^.H>7QHAU3K[RNUX'KKC5B
M==_Z4(F)(/A#$Q,QX\3D(NU)H0,E-V+"NU@1+:12_=TX@2\LSN\"\/7Q8N*R
M%1]:J,G9<AX/% QXS+.E)D/_ +>/S<04>(S$3$_-I,:Q_P"\?@UCQB8UB8\8
MF/VQ,>$Q_KCP_#ZI_#UK)PE>]2]Y1.F][!2H?")GSM,0C_7/CX?T#%?[:I_[
MF<5O[(?]T<9W_9=S_@EPC^P3_P (?SN;_M\!_>3#\3_7_0,?_P"!J?\ +K_-
M1QS5Y2_6S.^H9G_K \8K^S;_ ,PWAR,8=!:7T+J6&\[(70LM0P*\U24,I&-\
MCN-I1(?"'U<<O6J?+V1Q@X# V*/,.W&=%MI[DU*Z<>J%Z3ES"\+<C-H98L5[
MG]7J-(..=\DK (MW_2=7\78.BLUD^]@\90;86.W9VX6(W7VZ:[*[?-N]=K!T
M:[+G:5*<$I".LVXP<C6M7W176/OK+#.XLF CYY(M!^;B[D^4L3D,<RI@,^I]
M\,:6'=D'V@3Z+H5J\@FQ<?7>#+(M-.VK!:+9,MD>&>',/IZ<[3+&FLW?BY'+
M?6K=6'QN['9V'=#=!X]\>3VDJ)C848LJ[.:79"QE<RK-V+S[,89G+WI#*UBA
M+)/M8F %"\5VNEQ3PU;L&)GCE:C45FZF,HXU]7*J.,W-Q/,"HKK#7L6]Z=.!
MAD4&+DZ$/U*?+(%&=9D,IGALIY<Y>KTK=-3MG>L3<]*VT8I;E]6[^@"UM=UU
M1YDE#=..9 K5<C4O!6RJ\.WKY!MJV15(*O;HADQC(U?R@B4JN^-1<HC5)K(2
MG,#7R',\UT\IA?QXQEKA07-$=_$N$]V]EF>A3UJ27;ZLF>CJV>%X)-ADLR-&
MIS2RT3(_FUE6K%>WA+.DR2%WLVNJ0IVP/9EDAB=\:<9*U3/FJO<K<JYIG,S\
MJUL+',Q75-(\43RE'>1:[B4,Q^E0:?3%D^H886!CFD*4KP'?^ERLS8G+?C)B
M)M33BP1-VQB/2/I8J_Y":NGLDOF214\I5H/L<P)RJ7LREJLE:@:>),K%HO1_
MOY*4VIZ.#1*G36,]=8_/XK_;5/\ W,XK?V0_[HXSO^R[G_!+A']@G_A#^ :]
M^R:#D5L,^UMLKH6X^DIEFRM)(KK-D;=S&1M]9[1\W%C6V,16^&6P]C/RCM/R
M8MNEK2W^33T-^C_)Q8N6V0BM52RQ8:?J4I0[C(M/'PB/@QK,SY8B9XKY.O94
M="TA=E%J2A:B2V-0.29MV:ZZ3![2$O+,04:<+&6K@F_HAE@03=(U]ZC75GAX
M^37PXNV7L';CZ-K(V% 0E8BK40RPTQ3KOGWM9;/#0BTC7@W:,0@%5'0^SL2E
MBKE<+*S R/3018(,W[=K/+X^OB5)%Y0%K(4VOV#%=+L<($WJ,DO@-WQ%<Q@H
M9,3\&/'@]C%GTYVLV, NF6FNA[9G9.GCH6GAX\0:C!H3ZC68F$Z>$Z$,R,Z?
MU_@S?]O@/[R8?BQ8JT[-A%7QLN2HS77C22U:0QH$;8F?'YHUX%%1#;+S@I%2
M EC"@1DBF!'QT$8DBGU",:SX<.93H7+85OC!UJ[7"G^T)8S$>J9T]>GCZOSV
M/_\  U/^77^:CC/X*.IWZ^:N:'EJKWK9WD,_2?MVSZN$)O9"E2;9\*ZK-A2#
M;YH#R"91Y=\P&Z= WS :[ITXZ^1N5J*9.%PRTT$B3)UF '=/F/2)G:.L[8DO
M@Q,\"-O.8U$E77;#?:#2:KMW2L00[AZ#-A[&:["VEI/A/"Z$96A-UL!*JG=*
MZY]4.JL1#=KO8N>H"OTAA.X0F/'CPX^?CY^*-#WJKWSGIH5E+A8,<*VW7BL%
MC #.P7/.?#=.Z?$IX^?\'^OBQ16W=;IKKNL)TG52[6_MRF?5[YTCTTG7R^/%
MQ_133L6<@FG:.MC3&SD,@Y4N4/O%?JY ^CO838ZHK$621CM+B1+H6ZKA("&=
MCT-'U&LAG<LXUU$PG728D2C6./ZO#_T_9_0,5_MJG_N9Q6_LA_W1QG?]EW/^
M"7"/[!/_  A_!7Q=?#V;G+K%B_+,IW\?7LY Q;Y,1(VWI)%&=L-O.7N99#2J
MN5C+9F+M*NVNBF^F\*E:[M=<ECYL9'M.NV:N.E6\NV .B++AMMR8D*"'!8EE
MI:CZE2QS!D)6JU!^CH"P%6*I](+(Y"\*AL> K[=3X*/?0X2M]:MS-B,;E\AE
M$8]G:X\;0YJN746NF<G3AF$R/6?378(4G7OZ),&5]"AT4HK4K=;%)K5*%C&3
M^+793[\FO:MU.NI?4_+U.Q@ZS::Q,J@ %TY^B6!I7LA?1S3-?FMEQ$67>F*%
MY%%; 8N;86 BPG&L5N&DNJKK@[757$6W8ZOEJJ+6#>S#,M*$;PTN6AQ;&#UO
MR:7T+NK*Z;6U#H(FP8L!1<;%X^ICA)ONAL"C7NP:JJ^9* (Q*09H$:]36&PL
M156G79H&D\35P:JN*A_*=;'7920*&YD:>2QEH4VM!/J]>LK)5YML!OQDA;O!
MIC.2982ZI-^REHTV'CNFKH(A,L77Q:ETZ\NT]\V29/VBUFPO+'&;_M\!_>3#
M\<R!;M]NNYRYD:J (B@'W&;82N!CPEDQNVS,?M\>'XZUDK-I^3*I7?G**.E3
M3BV@!VZ.]S!M5NH6Y-ZPD9;TXT3,>/%"OBL^>(H<O\U6<LY5@7@68QQBO:NO
MVO4&S(R#*ZEOG<2" S\9F..;\FU=)7<X[)MPJ+U==A<76V>K5 $F)AU=OFT]
M7S:Z<7*C1P8*L\G+L$5?'H0Z>:MR]T Y:H8#](GR#,+B..9/1X\OL[7'85G+
MD^BJAR>1F-F3D9)/OS!#7=#? =-1\>+MC$=MV+ET6#V@=.OURHUYN=,(B(#\
MKZVHQ$1!:Z?FL?\ ^!J?\NO\U'',TZ3IZ>YI\=)T_2A\_JXYI_F-^:'F7#5<
M?C')6AJZCDT[%0ZETW,&:%;N'#D.YCWJ?-X]R(C/+MZQBKV43@*%S#6Q4A=B
MQ-IU/';,O0K&W6W5;*FTS;.EA?B73A<L/BGB3Q:JI9_+669LA!!EB^6HNVLF
MK#,L!K!3*W1C$J5))6-FY"Y'X4VY75R\-9SG7S56DM5'\4&8Y+*XQ=M6Y'OE
MW.W W&D+(-BZM0*IE7F=;[C'('25R@U>.[>[:J)].][=8HX&LY6Z\L.WE1GK
M 06GS\&G%1F3M9'DIZ,HV<A:;9=GX;3)+NHU\]#)2)6HZU:%>2-OJ$=.:)QZ
M\OL7R]6?R\L,ODI6/,4#D9=8K05OQND2L=U)9,K+7X/OK=W++,?&R_6]+&=D
MM.G2N6.6;]6J]_KT&,BU0^ EXSZICB^K^>JSF5\37MUQBU6-]P<G6.Y;KW7Y
M6\QC@K#8AMNG"D/0V//)A CF:E)>:C"!>P=_'UZW>91#VS3R*LG7>KT@G(GC
MS;-)KU5;&H6A4Z%Z2V>,*#Z60IVT&AMO&8_N<H'O8-$:M\1R"LE9IGN!A0FX
MZPEFR&28KDHSN2MXR]0RL<I8U6&15R=[:C+T5Y(DP@XMR;K,,[.2[QM@@AG:
MF9QU=]1V8IVK"$\U5;L23W+!-(N4V5[3%]%P=-7I/190&GOTSI&A%K9QT8VU
MCV(R%WJ]?J$FWU+3V)L5&FYW53*"7J0[/-.A#U(+3^@8K_;5/_<SBM_9#_NC
MC._[+N?\$N$?V"?^$/YW-_V^ _O)A^)_K_H&/_\  U/^77^:CCF3#@)]_5YH
MYEL-*4C"^D>0'3:[7<4^>-1TCBM3NY*E4MW)TJUK%A:G/G7;'3 IB9U+RQ\T
MEX1X\"[*7ZF/4QG2!EQX($V?Z [YC<7SSIZH\9TX*M?YAP]1XK4TE/O( Q4\
M(8AA>;R@Y<P:RF=#"8*/#CRQ):^K;X^OQCU<:[9\?"/"?7^SCX!?NSPN6[XA
MKU5PV*:V>JZ= W0H#D UCS-/12_69C'&LC,1^W3PXCREX^KPGQ_JXUVSI'A,
MZ3I'$>6?'U>$^/\ 5^WC3:6O[-)U_P#;BMW+85W=I-&OJ)3U+3]>DKRQ.DGM
MGS%H$:>)1Q'EGQ]7A/C_ %?MXB-I:SZHTG6?ZN)EDP$#IND_+ ZS QK,^K4I
M@8_;,Q'KGB_24<G:Q?:]^K8R)K=ZHG5M\R,#/54!%Y9+;IH>V?#AX)ZA%6=-
M=L2EH>^B ,G9O >L&U@^^JWJF=1@]PE$6Z*F;[5'MYMIVGJGNERU&LR.TNH
MR7DDMNGFTGC7;.G[=)T_]^(\L^;U>$^/]7[>)\I>'K\L^']?[/S.*_VU3_W,
MXK?V0_[HXSO^R[G_  2X1_8)_P"$/YW-_P!O@/[R8?B?*?K_ -$OJX^"?[I?
M5Q\$_P!TOJX^"?[I?5Q\$_W2^KCX)_NE]7'P3_=+ZN/@G^Z7U<?!/]TOJX^"
M?[I?5Q\$_P!TOJX^"?[I?5Q\$_W2^KCX)_NE]7'P3_=+ZN/@G^Z7U<4/_ U/
M^77^:CCG;PG3TSG_ !T\/E"O\_'.-4<%:RWXU4Z-?&74C7.K5)5&:71R3G-
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M?'Q['^U5?X^/CV/]JJ_Q\?'L?[55_CX^/8_VJK_'Q\>Q_M57^/CX]C_:JO\
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MGN*,*3JM1N+>SKEM\BRT\L^/AQ)%,"(Q,D4SI$1'C,S,^$1$>N>.[[NMVO\
M^YZZNW]>W]-NZ?PO+\+U^'KXEM>PAZHF8EB6@U<3$:S$F!2.L1.L^/A'!]M<
MJV>G&K.A84[9'[3Z9%M_]>%V:KEV*[AWJ<DX8I@_Z0&.L%'^N/S#7O8"DI6;
M6M84""U+&38PRGP$ &)(BGPB(UX!JR$UL 6+,9U$P.-PD,QX2)#,3$QZX_I7
M,7]K@/[RX?B?Z_S_ #)_WL9_]MS\YSS, R8_''.>, 4Q^E7\\1IQ^B;]$?\
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MS]2BLROE\A7TY4:_$HR"T)5:%"\>RF61ENU<.@M[0,6@HA'$0&9'EM/.</6
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M8?\ %X^%D_8?\7CX63]A_P 7CX63]A_Q>/A9/V'_ !>/A9/V'_%X^%D_8?\
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MQ/,F0LA<"HN<:/+Q<O6IHI[S2 UC+0D81&MH7;>I[U/BH9N\PW46\/B;>7=
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M TMQV(I!UQAEJ9V)DQCSK@W#V^-Q[65ZW,N Y?OY-A(Z"7Y"]C.[4-:6A8(
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M2LCKX%]ZGM!Z05,4;'$ H2NBUWU2FW!!<,$T[H(NC(<.-0S23Q97>WS9M$[
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M1WVPNSFGR)L^]*#A\K ZA;^DA_H26D:B''O7;RW\@0XB92T+EH<$[ACLA?\
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M1&[U:O7KUZ]>O7KUZ]7?Q4XKF4 .$+</=K+2RRK+TOBSYIKP)1%S+8&6 /H
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M2 0"20    0""0"2 2"0220          ""  00 " "0   0 202 0" 022
M  0R22222 222"222222220:222"2222"222220R$     #D       T
M3>0""  22       >0@     !       -@   " R2 "220       !R$02 2
M2 $^&P   !L    3:22  "20       .0B"0" 0 QT]@   -@   ""02"0 0
M        !R$      (      !L    0P002 2" ""0    .0@     1
M  /@   " 2"0 "  0200   !R0DDDDDE9)))))))$DDDDUDDDDDDDDDDDDDD
MDR5__P#_ /\ _O\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ L       T_\ _P#_ /\ _P#      -MMF0"   "
M    %@      $     "2222 0"""2      "   "  P(G@    @    !2  4
M     "        "000 $LR5@   $     )B 00022                L
M     @    #"0 0  0""              5@      ,     40""020"0 2
M            B2222220@                            0
M                          #_ &VVVVVVVV    Y))\@  D$$
M     !8        8    ;;?@D  $@$@      $  @D@+#_0     #    F@@
M$ @ @ D        $@ @ !<#]X     8   #@$ @$ @                +
M       #    R @    @$D             %G_\ _P#_ /\ _P#^@   "B2
M02" 02"20          !K;;;;;;;;,                           0 "
M"2 002" "  $3;:/'Z$               "   022"" 0 0 #=R7@X>9
M            0   0  0      "F2&22$\             ""0 "    2
M 00      2 0 0          222"""2   0  00"20 "00"" 2"  0     "
M0 20""0"20  2" ""2 " 02"02" 2202"    20" 0"0202  "2002" 0"2
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MX:W6G$N==C#D0)$B1'CR4+J@"%N:%L K!'\/O__$ "T1 0 ! P$'!0 !! ,
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MZV^#T?K:*FL.9A.N"4$)$;HB)Q!A]O-9\Q4F%',R (8,H6%P4+7T>#&!8#@
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M^5XQ^5XQ^5XQ^5XQ^4 R \0!]I8&#BYCD!*2#20D&]U(['(+\@4LI0BP7_\
M4%BX82,D2!E-D5 L,L"+#*$!50J=9PP"@L0K.P*U+JR=<J2!G/CP<J)*$#AB
M 06Z8EN[]CAM KK4*U ,(+-F]J0 E@CKA$">77V]A@=#ZV^&T"$0VHB,2IBZ
MV9J+J^#, $A WY]NZO<%WH;ZAG /AV[%BQ8L6+%BQ8L6+%B(2_V $)VB.Q"
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M0%: M[9.RU=L=:.!A[86]'Z+LB;GN\X58!GP@M^&>@)^:AO(8 *@"J@ 6JX
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ML$(/H&O-.7+ERY<N7+ERY<N7+ERY<N7+ERY<N7-6(U90BUW5'W,X,&0HP!H
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M H,*$2Q$BJJRJJLJY56RKN]>1(D2)$B1(D2)$B1(XUGOF[ 6U=U;6[U/L/\
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M0M4 W5 RP<"4A!06 -T9+JS)-_@#XF@+.$H',A69VW@E#QQ=C'O(<!%@@5
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M"0U1WEAN"&=&\*1M*8V$,#K5'P7FTW>$5V0*\P=T%<":')2G)*-91VI= DK
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M43S%>$7\(2"DT1R2>Z_.!O%ZA%J:"21(B!K>P^,[V#AY8AKP<T!U"1@&>%K
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M_E "EZ0"<")0]6I),9Y2PS] 2621J0?"8#'H+H%03%VLX$&]ER19LMM!X/$
M)^*](=H<>4$""*""(AUJF1TR5!EAL!WJ_KB+,2BO!0#XNZ82Z-/,,3N<%U+#
4/^M^G^IZWZ?ZGK?I_J,:I[_$_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>lenztherapeuticslogo1a.jpg
<TEXT>
begin 644 lenztherapeuticslogo1a.jpg
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M444444444444444444444444445%-,D,;R2.J1J"Q9C@ #J2?2O!/BC^W?\
M CX1>=%KGQ&TJZOH\J;'1I#J$^X?PLL(8(?]\J/4U\A?$[_@MIH=D9H/A]\/
M+W4SR$OO$-VML@([^3%O+ ^[J?Y5\G_$S_@J?^T'\1A+%;>)K3P=92#!MO#=
MDL!_":0O*I_W7%?,'BKQMXB\=:DVH>)=>U/Q#?MG-UJMY)<R'/7YG8G]:PZ*
M**************************************[#P#\8/'/PMN/.\'^+];\,
M2%LM_96H2VZO_O*K ,/8@BOJ3X:_\%;?CWX&:*/6-0TGQO9+A3'K5@L<NWVE
M@\LD_P"TP;WS7UQ\,?\ @M1\/M:$,'CKP9K7A:X; :YTR5-0MQZLV?+D4>P5
MC]>M?7GPM_:Z^#GQG:&/PC\0]$U&\EQLL)I_LMVQ/803!)#^"U[!11111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111115'6-:L/#^GSZAJE];:;80+NFNKR98HH
MU]69B ![DU\H?%O_ (*E? 7X6M/;6?B&X\;ZG'E?LOAF#SX\]OW[%8B/=78^
MQXS\6_%K_@M%\0?$0FM/ 'A32O!ULV56^U!CJ%V/1E!"QJ?9E<>_>OB_XH?M
M(?%#XT22GQIX[US7X)&W&SN+MEM5/JL"XC7_ ("HKS:BBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO;/A+^V9\:/@FL4/A3X@:M;6$> NFW
ML@O;0#T6&8.JY'&5 /O7V?\ "7_@MAKEB8;7XD^ [/58N VH^&YFMI0!W,$I
M968^SH/85]L_![_@H=\"/C.L,.G>-[;0-4DQ_P 2SQ)BPFR>BAG/ENQ]$=C7
MT=#-'<1)+$ZR1N RNI!!!Y!!'45-11111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111111111111111111111111114,
MTR6\3RRNL<2 LSLP"@ 9))/0"OF/XT_\%(O@5\%?/MKCQ8OBO6(LC^S?"X6]
M?<.JM*&$2D'@AG!'I7P5\9/^"S/Q'\4M<6GP\\/:;X(L6RL=]>#[??>S#<!$
MOKM*-CU/?XD^)7QI\>?&+4/MWC;Q=K'B>96+(NHW;R1Q$]?+C)VQCV4 5Q-%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>J_"/]J3
MXK? B:,^"/'.JZ-:J<_V?YWG6;'WMY T9/OMS[U]U_!G_@M7JUC]GLOBEX(A
MU*+@/J_AM_)F"^K6\A*LQZ_+(@]!7WG\%?VVO@S\?/(M_"OC:Q&KS  :-JA-
MG>[C_"L<F/,/_7,L/>O=:***************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M***********************************************\[^+7[07PZ^!>
ME_;?'?C#2_#B,A>.WN9@US,!U\N%<R2?\!4U\ _&_P#X+4:99&XT_P"$_@Z3
M4I<%4UKQ(3%"#_>6WC;<P[@LZ'U6OSZ^-'[6WQ9_: GF_P"$T\::CJ&GR'(T
MBWD^S6*C/ $$>$)'9F!;U)KQZBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBB@'%?2'P/_ ."@OQM^ RV]IHWBV76]#A( T7Q$
MIO;8*/X5+$21K[(ZCGI7Z#_ O_@LE\/?%PM]/^).AWG@746PK:C:;KW3R?[Q
MVCS8\GMM<#NU?=W@?XA>&?B7H,.M>$]?T[Q'I,I^6[TRX6>/./NDJ3AAW4X(
M[@5T=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%?,G[0/_!0[X,_L]_:+#4?$(\3>(XLJ=#\.
M[;J9&':5]PCB(.,AF#8Y"FOS=^//_!7/XL_$QKBP\%16_P -]%;<N^R(N=0=
M3Q\T[* G8_NU4@_Q&OB37-?U/Q1JMQJFL:C>:MJ=RV^:]OIVFFE;^\SL26/N
M36?111111111111111111111111111111111111111111111111111111111
M11111174^ /B9XL^%.O1ZSX/\1ZEX:U1,#[3IMRT3,/[KA3AE]58$'N*^^O@
M)_P6:\8>&OL^G?%;P_!XNL5PK:QI"K:WRCNS1<12'V7ROJ:_2/X%_M:?"K]H
MRU5O!/BRTO=1V[I-'NB;>^BXR<POAF [LNY?<U[%11111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111114%Q<
M16L$D\\B0PQJ7>21@%4 9))/  '>OB_]HK_@JM\)/@S]ITWPO/\ \+)\21DK
MY&CS!;&)A_?N\%3_ -LP_H<5^9/[07_!0[XS_M!?:K&_\0MX9\-397^PO#Q:
MVA9#QME<$R2@C&0S%2>0HKYDHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHJS97UQIMY!=6D\EK<PN)(IX7*.C
MY!5AR"#W%?:'[/?_  5<^+OP@:VT[Q3.GQ)\.QX#1:Q*5OT7OLN@"Q/_ %U#
M^@Q7Z>?LZ_M_?![]H_[/8Z/K_P#8/B:;"_\ "/Z]MM[EF/\ #$VXI+SG 1BV
M!DJ*^DZ*****************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M*******************KW5U#8VTL]Q*D$$2%Y))&"JB@9))/  '))KX@_:4_
MX*P_##X0_:M(\#E?B1XFCRFZQFV:; WJ]P ?,QP<1!@<$%E-?EM^T'^VQ\6_
MVE)Y8?%GB62'0F;*>'])!MK!><@-&"3*0>C2,Y'8BO!Z****************
M********************************************************4,5P
M1P>U?6_[-_\ P4P^+WP!^S:=?:C_ ,)[X4CVK_9.O3,\L2#C;!<\O'P  &WJ
M!T6OU2_9M_X*&?"/]I'[+I]CK'_"+^*Y<*?#^NLL,LCGM!)G9-DYP%.[ R56
MOIZBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBD)P"3P*^-OVGO^"G_ ,+?@)]KTC0+A/B%XPCRGV'29A]DMFY'
M[ZY *@@@@H@9@1@A>M?D]^T5^V[\6/VF;B:'Q1X@:R\/,<IX=T@M;V"X.1N0
M,6E(/(,A8@],=*\"HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI0Q7!'![5]B?LS_\%//BM\!/LFEZ
MS=-\0O",0"?V;K$[?:8$':"Y(9EP  %<.H P .M?K)^S=^VY\*_VGK.&+PUK
MJV/B,IOE\-ZJ5@OHR!D[%)Q*HZ[HRP QG:>*]_HHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKYY_:8_;D^%W[+EK+
M!XAU?^U?$Y3?!X;THK+>-D?*9.=L*G@[G()&=H;&*_(G]IK_ (*.?%;]I!KS
M3/[0/@WP;-N4:#HLK)YT9[7$W#39'!7Y4/\ <!YKY3HHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHJS9WD^GW4-S;3R6]S"ZR130L5=&!R&!'((/((K[V_9=_X*V>.OA=]DT/XG
MQ3_$#PRFV-=0WJNJVRCOO.!<#':0AC_?QQ7ZP?!7]H/X?_M#>&EUOP)XCM=:
M@4#[1;*VRYM6/\,T)PR'K@D8.,@D<UZ31111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111111117$?%CXR^#/@=X3F\1^-_$-GH&EQ
MY"O=/\\[ 9V11C+2/C^%03WQBOR:_:I_X*X^,?B.]YH'PGBN/ WAQLQMK$FW
M^U;E>F5()6W!_P!DE^ 0R\BOS]OKZXU.\GN[RXEN[N=VEEGG<O)([')9F.22
M2<DGDU5HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKHO _Q \1_#+Q+:>(/"FMWOA_6K4YB
MOK"8QR =U)'WE/0J<@C@@BOU(_93_P""P5CJWV/PY\;;9=,O>(X_%FG0G[/(
M>@-S H)C)[O&"N3]Q0":_2S0/$&E^*M'M-6T74;75M*NXQ+;WMC,LT,R'HRN
MI(8>X-:5%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%1R2I#&TDC!$4$EF.  .I)K\_?VN/^"LGA/X5M>>&OA6EKXW\4INCEU9
MF+:79M[,I!N&'HA"C^\2"M?DG\5_C+XR^./BJ?Q)XXU^[\0:M)PLERV(X5SG
M9%&,+&G^RH [XR2:XFBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO;OV;_VP/B5^RYK
M*W'A#6FDT:20/=^'[\F6PN>F24R-C$ ?.A5N "2.#^RG[)__  4(^&_[44-M
MI<5P/"OCDK^\\.ZE*,S$#DVTN )AU.  X )*@#)^IJ******************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M*************************************\A_:(_:D^'W[,/A<ZQXVU@0
M3R*WV+2;7$E]>L.T461QG@NQ"C(RPR,_C1^UK_P48^(?[3C76C6LK>#? ;$J
M-"T^8E[I>QNI@ 9?]P (./E)&ZODRBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBI
MK>XEM;B.>&1XIHF#I)&Q#*0<@@CD$'G-?HA^R)_P5I\2?#U['PQ\8/M'BWPT
MNV*+7X_GU*T'0&7)_P!(4=R<2#D[GX6OUK^'_P 1?#/Q6\*V7B7PCK=GK^AW
M@W0WEE)O0GNK#JK#."K ,#P0#73T44444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444445')(L,;.[!449+,<  =237YW_MA_\ !6/P_P##?[=X
M5^$36OBOQ,I,,VOO\^G63=#Y>/\ CX<>H/E@X.6Y6OR.\>?$+Q)\4/%-]XD\
M6:U=Z_KEZVZ>]O)"[MZ*.RJ!P%4!0.  .*YRBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBO6/V??VG/B!^S+XI&M>!]9>T21E-YI=QF2RO5'\,T60#QD!E(9<
MG##-?M'^R%_P4*\ ?M26UOI$DB^%?'P3][H%Y,-MP0,LUK(<"4=3MP' !R"!
MN/U;11111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111117"?&'XU
M>#/@/X-N?$_C?7;?0]*AX0RG,MQ)C(CAC'S2.?[J@\9)P 2/Q?\ VRO^"D_C
M+]I1KSPUX:%SX-^';91K"*7%WJ*^MS(O12/^6*G:,_,7P"/C*BBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBK-G=S:?=07-K/);W,,BR1S0N4=&!RK*1R""
M 01R#7Z:_L9?\%:;O138^#_C=-)J&G<0VWC&-"T\(Z 7: 9D'_351NX^8,26
M'ZL:#KVF^*-'L]7T;4+;5=+O(A-;7MG*LL,R'HR.I(8'U!K2HHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKY6_;&_;^\$?LHZ;-I<;1^)_'\
ML>ZV\/VTHQ;Y&5DNG&?+7D$+]YN,  EA^(_QR^/WC?\ :,\;3^)_'&L2:I>M
MN6WMUREM91$Y$4,><(HX]23RQ8DD^<444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444445])_LB_MT>//V3=92#3Y3K_ (+N)=][X:O)2(CD_-) W)ADQ_$
M0>-RM@8_;W]GG]ICP'^TYX-7Q!X)U47/EA1>Z9<8CO+&0C[DT>3CH<,"5;!P
MQP<>L4444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444444444444444444445')*D,;22,$1
M0268X  ZDFOS%_;D_P""JT.@M?\ @;X)WT-[J(S#?>,$ DA@/1DLP<AV[&4Y
M4?PAB0R_E#J>IW>N:A<ZAJ-W/?7]U(9I[JYD:2661CEG9F)+,3DDDY)JG111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111178_"OXM>+/@KXSL?%7@O6[
MG0M;M3\L]N?ED0D%HY%.5=&P,JP(.!QP*_;#]B;_ (**^%OVH+2V\.>(?L_A
M7XDHGS:<7Q;ZC@?,]JS'.>"3$26 R06 )'V/111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111117/>.?'GA_X9^%-1\3>*=6MM$T+3XC+<WMV^U$7L!W9B
M< * 2Q( !) K\6_VXO\ @I9XB_:&>^\(>!S=>&/AP28Y<G9>:LOK,0?DB/:)
M3R.6)R%7X<HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHJQ97D^
MFWD%U:S26UU ZRQ3PL5>-U.596'(((!!'((K]5/V%_\ @JHM\VG^ OC;J"QS
M';!8>,YB%5^RI>^A[>?T/&_'S.?U&AF2YB26-UDC<!D=2""",@@]P:FHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKS#]H#]HKP5^S3X$F\4>-=36TM_
MF2TL8</=7\H&1%"F1N;IDG"J#EB!S7X5?M<?MG>-?VM/%7VG6)6TCPM9R,VE
M^&[:0F"W'(#R'CS92.KD<9(4*"17SW111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111117W5^PG_ ,%*=;_9[FLO!GCZ6Z\0_#@E8H)LF2ZT<'@&
M+/+PCO%U4<IT*M^T?A#QAHOC[PUI_B'P[JEMK.B:A")K6^LY \<J'N".X.00
M>0000""*VZ**************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M**********************************************^>_P!KO]LSP;^R
M3X/^V:LZZMXIO(V.E>';>0":X;D>8YY\N('JY'."%#'BOPB^.GQ[\9?M&>/K
MOQ;XVU,WU_+E(+:/*V]G#G*PP)D[4'XDG))+$D^<44444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444445]+_L9_MQ>+?V2?% 2$RZ[X%OI0VI^'
MY)<+DX!F@)XCE 'T8 !NBLO[M_"+XO>%?CGX#TWQAX-U2/5=%OE^5E^62&08
MW12KU1U)P5/L1D$$]M111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111111111111111111117R/^W-^W
MSX?_ &4M!DT72/L^O?$J]BW6FE,^8[)2/EGN<'(7NJ9#/[+EA^&OQ"^(GB/X
MK>,-2\4^+=6N-<U[49#)<7ERV23V4 <*JC 55 50   !BN9HHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKW[]D#]KSQ5^R5\0(]5TMW
MU'PS>LJ:SH+R8CNXP?OKV65025?\#E217[[_  E^+7ACXX> M*\8>$=234M$
MU"/<CKQ)$X^]%(O\#J>"IZ'U!!/9T4444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M5\0?M\_\%$M*_9ML;KP;X+EM]8^)EQ'A^DD&C*PXDF'1I2""L1]F;C"O^)7B
M3Q)JGC#7K_6];U"XU75[^9KBZO;J0O+-(QR69CR2:RZ*****************
M************************************************************
M************************************^G?V&?VT-8_9+^(0-P9M1\!:
MM(J:SI2')7L+F$'@2H.W =1M.#M9?WR\*^*-)\;>&],U_0[^'5='U*W2ZM+R
MW.Y)HW&58'Z'H>1T/-;-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%? W_!0W_@H
MI:? 6RO/A]\/;N&^^(L\92[OD*R1:(C#J1R&G(/RH>%X9AT5OQ<U+4KO6M0N
MM0O[J:]OKJ1II[FXD+R2R,26=F))9B2223DDU3HHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK]"/^"6G[;;_"7Q9;?"GQEJ!'@K
M6[C;I5W</\NEWKGA"3]V&5C@]E<AN SFOV@HHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHK\_?^"BG_!1*+X(V=Y\.?AS>QW'Q"N$,=_J49#IHL;#H.QN"#D#D(#D\
MD"OQBOKZ?4KR>[NIY+JZN)&EEGF<O)([$EF9CRQ))))Y)-5J************
M************************************************************
M*********************************************_<3_@E]^V(?CY\,
MSX(\3WWG>._"L"*99FR^H6((2.;)Y9T.U'/))*,22YQ]R444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444445\&?\%$_^"A5O\ =-NOA_P" ;N*Z^(]Y'BZO$*NFBQ,.&(Z&
M=@<JI^Z"&;^%6_%2^OKC5+ZXO+RXENKNXD:::XG<O)([$EF9CR6))))Y)-5:
M************************************************************
M**********************************************************[_
M .!?QDUSX _%;P]XZ\.R8O\ 2;@2- S%4N83\LL+X_A=2RGTR".0#7]'GPJ^
M)>B_&+X=^'_&GAVX^TZ-K5HEU QQN7/#1L!T9&#*P[,I':NMHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHKXI_P""AO[>]G^S-X<D\(>$;B&\^)NIP93HZ:1"PXGD7H9"
M/N(?]YAM #_AUJFJ7>N:I=ZCJ%W-?7]W,\]Q=7#EY)I&8LSLQY9B222>235*
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MOTX_X(X_M--H_B/5?@MK=W_H.I>9J>@F1ON7"KF>!<]G1?, X ,;]WK]<***
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M**********************^4OV\_VW-*_9-\$"RTTP:C\1-8B;^RM-8AEMTY
M4W4X[(I!"KU=A@<!BOX.>*O%6K^./$6HZ_KVH7&K:SJ,[7-W?73[I)I&.2S'
M^G0# & *QZ**************************************************
M************************************************************
M***********W?!/C'5?AYXNT;Q/H=RUGK&CW<5[:3C^&2-@RY'<9&".A!(/6
MOZ4?@E\5=,^-_P )?"WCK2"HLM;LH[GRPVXPR_=EA)_O)(KH?=37=4444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444445X1^U]^U=X=_9-^%\_B'5"E_KUX&@T710^U[VX ZG'*Q)
MD%V[ @#YF4'^?OXH?$[Q'\9/'FK^,/%FHOJFNZI*99YFX5>RHB]%15 55'
M KDJ********************************************************
M************************************************************
M*******_6'_@BS\<C>:5XO\ A+J-R2]JW]O:2C-D^6Q6.Y09Z -Y+ #N[GUK
M]1Z*********************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************\\^.WQP\,?L\?#/5O&WBN[\C3K%=L4"D>==S
MD'RX(@>KL1QV !8X521_/7^T9^T)XH_:8^)^H^,_%%Q^]F/E65A&Q,-A; DI
M#&#V&22>K,68\FO+J*******************************************
M************************************************************
M*********************]C_ &0_C$?@-^T=X&\923&'3[34%@U YX^R3 Q3
MDCOM1V8 ]U4]J_I#5E=0P.5(R"#Q3J******************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M*************************************************Q?%WBW1_ ?A
MG4_$7B#4(=*T738'NKN\N&PD4:C+,>Y]@,DD@ $D"OP%_;@_;$UC]K;XF->*
M9M/\$:4SPZ'I+M@JA.&GE .#*^ 3V4 *"<%F^:Z*********************
M************************************************************
M*********************************************_HO_89^*G_"X_V4
M_AYXAEE,M^FG+IMZS'+FXMB8'9O=O+#_ $<5[S1111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111112'"C
M).!7XJ?\%.OVZ/\ A=WB:;X9^";_ '> M&N/].O+=_DU>[0]01]Z&-A\O9F!
M;D!"/@.BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBOU_P#^")OQ$.I_#'X@>"9I"7T?5(=4A5CSY=S&48+[!K;)
M]W]Z_2FBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBOS=_P""JG[;Q^'NBW'P=\#ZAL\3:I!_Q/[Z
MW?YK"U=>+=2/NRRJ<MW5".[@K^/-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?>G_  1K\9OH/[4>J:&S_P"C
MZ]X?N(0GK+%)'*K?@BRC_@5?MI1111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111111111117S7^W-^UWIO[)OPGE
MOX6ANO&NKJ]MH6G.<@R ?-.Z_P#/./()_O,57C<2/Y_?$7B#4O%VO:AK>L7L
MVI:MJ$[W-W>7#%Y)I78LSL>Y))-9M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%2V]O+=3)%#&\TCG:J1J69CZ #DUZ7X3_9?^+_CC8="^
M&/BS48GZ7$>CSB'\9"@4?B:]@\-?\$N/VD?$6QF\!QZ1"W_+74M5M(\?5!(S
MC_OFO5/#O_!%OXQZ@JOJWBCP=I*-U1;FYGD7Z@0!?R:O2-"_X(=73!7UGXNP
MQ'^**PT$O^3M<+_Z#7>Z/_P1)^'4&/[4^(/BB]]?L<-M;_\ H2/79:;_ ,$:
M_@/8X\^_\9:C_P!?.J0+_P"B[=:Z>Q_X)-?LXVB@2^&-4O3ZSZU<@_\ CCK6
MW:_\$N_V9K3!_P"%;><W]Z76]1;]/M&/TJ_#_P $U?V:X<;?A?9GG/S:E?-_
M.<U/_P .W_V;SG/PMT_\+R['_M:H)/\ @FG^S7(NT_"^T _V=2OE/YB>LZZ_
MX);_ +,UP"5^&[0MZQZ[J0_0W!'Z5A7_ /P25_9TO,^3X>UBQ_Z]]9G./^^V
M:N6U3_@C/\"KX$VVJ^--./;[/J5NP_\ '[=OYUQNK_\ !$?P#.K?V5\1O$EF
M3]TWEM;W 'UVA,UP&N?\$.]5BW'1_BW9W7]U+[0F@_ E9W_/'X5YKXC_ .",
M7QKTO>^EZ[X/UN,?=CCO9X93^#P!1_WU7E7BC_@F1^T?X75I'^'<FIP+_P M
M=+U&UN,_1%DW_P#CM>/^*OV=?BGX%#MX@^'/BK1XD^]->:-<)']0Y3:1[@UY
MVRE6*D8(."#UI***********************************************
M************^D?^"=7B-O"_[:7PNNE; FOY+%AG@B>WEAP?QD'X@5_0O111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M5+5-0CTG3;N^F#-%;1/,X4 DJJDG&<<X%?(G_#U'X2?] /QA_P" -K_\DT?\
M/4?A)_T _&'_ ( VO_R31_P]1^$G_0#\8?\ @#:__)-'_#U'X2?] /QA_P"
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M"3_H">,/_ &U_P#DFC_AZA\)/^@)XP_\ ;7_ .2:/^'J'PD_Z GC#_P!M?\
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M+AFF4GY6&<@<YZ]:XS_AZA\)/^@)XP_\ ;7_ .2:/^'J'PD_Z GC#_P!M?\
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M\/4/A)_T!/&'_@#:_P#R31_P]0^$G_0$\8?^ -K_ /)-'_#U#X2?] 3QA_X
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M-4?\/:M(_P"B;7W_ (-D_P#C5'_#VK2/^B;7W_@V3_XU1_P]JTC_ *)M??\
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MW_@V3_XU1_P]JTC_ *)M??\ @V3_ .-4?\/:M(_Z)M??^#9/_C5'_#VK2/\
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M%%%%%%%%%%%%%%%%%%%%%8OC3_D3=>_Z\+C_ -%M7\_-%%%%%%%%>C?LW?\
M)Q'PP_[&C3/_ $JCK]VJ****************************************
M************************************************************
M****_#K]K;_DYCXE?]ANX_\ 0J\DHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHK]*?^"3/_(F_$+_ +"%K_Z+>OO>BBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQO_ ."B'_)V
MOC'_ *XV/_I'#7S?11111176?"SXH:_\'?'&F^*O#5V;34K)\X.3'/&?O12+
M_$C#@CZ$$$ C]I?V?OCQH'[0WP^M?$FB/Y,XQ#J&G,P,EG.!\R-ZJ>JMT8$'
M@Y ]/HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK^?;QA_R-VM
M_P#7]/\ ^C&K(HHHHHHHK](/^"2G_(O?$G_KZL?_ $&>OT HHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\7OV]
M?^3M/B!_UVM/_2."O ******************************************
M***************DM;6:^N8;:VB>>XF=8XXHE+.[,<*J@<DDD  5^Q?[$_[,
M,/[/7P\%UJD"-XUUI%FU*7AC;)U2V4^BYRQ'WF)Y(5<?2-%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?B#_ ,%0
M?VS&^/'Q";X?^%K[?X"\,W+!YH7S'J=\N5>;(X:-,LB=CEVR0RX^%:******
M************************************['X=?!_QO\7-2-CX+\)ZOXGN
M5(#C3+-YECSW=@-J#W8@5]@_"K_@CK\9/&7DS^+;[1? 5DWWX[F?[==@'N(X
M28S]#*#7V#\,O^".'P9\)B*;Q7J&N^.;H??BGN/L-JWT2'$@_&4U]8_#C]GO
MX9_"&.-?!O@70?#TL8P+JSL$%PW^],09&/NS&O1*********************
M********\G^)?[*7P@^+_G/XM^'>@ZM=3??OA:+!=G/_ $WBVR?^/5\E?%+_
M ((O_##Q())_!'B;6_!ETV2L%SMU&T7T 5BL@^ID/TKX]^*G_!(_XY^ 1-<Z
M#;:7X]L$R0='NA%<!1W,,VPD_P"RC.:^2/&GP]\4?#G5#IGBOPYJOAK4.HMM
M6LI+:0@=PKJ"1[CBN=HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHKNO@.6'QQ^'90X?_ (2+3MI]#]ICQ7]-U%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%8OC3_D3=>_Z\+C_T
M6U?S\T44444445Z-^S=_R<1\,/\ L:-,_P#2J.OW:HHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHK\.OVMO^3F/B5_V&[C_ -"KR2BBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBOTI_X),_\B;\0O^PA:_\ HMZ^]Z******
M************************************************************
M**********_&_P#X*(?\G:^,?^N-C_Z1PU\WT4444445ZA^SM\?]>_9V^(-O
MXATAFN+*7;#J.F,Q6.\@SRI]&')5L94^H+*?VD^&7Q(T+XM^"=,\5>'+P7FE
M7\>Y#P'C8<-&Z_PNIR"/4<9&">LHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHK^?;QA_P C9K?_ %^S_P#HQJR********_2#_@DI_R+WQ)_P"O
MJQ_]!GK] ***************************************************
M*****************_%[]O7_ ).T^('_ %VM/_2."O *****************
M****************************************_0+_ ()O_LK?VA<P_%KQ
M39_Z- S#P_:3)P\@)#71![*<JGON;C:I/Z/4444444444444444444444444
M444444444444444444444444444444444444444445\&_P#!4C]LC_A2/P\/
MPZ\+7WE>./$]LPN)X6P^G:>V5:3(Y$DF&1>X =L@A2?Q)HHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHKJ_A]\*_&'Q6UH:5X.\,:IXFO\ @M#IEJ\V
MP'NY PJ^[$#WK[@^#O\ P1J^)OC!8+OQ_K^E^ [-AN:T@_XF%\.^TJC+$OID
M2-CT]?N7X/\ _!+WX#?"A8)[KPVWCC58\$WOB:3[0A/?%N L.,] R,1ZFOJK
M1]%L/#^GP:?I=C;:;80+MAM;.%8HHU]%50 ![ 5>HHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHK(\2^$]$\9Z3+I?B#1[#7=,F&)++4K5+B%_P#>1P0?RKY"
M^,/_  29^!OQ*:>ZT*QO_A_JDF6$FAS;K8MZM!)N4#_9C*5\,?&;_@D#\8?A
M_P"==^#[C3?B+IB9VK9N+.]"CNT$K;3]$D8GTKXP\8>!_$/P]UJ32/%&A:CX
M=U6/E[/5+5[>4#UVN <>AZ&L&BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBO2_V9M/.K_M'?"JR7.;CQ7I4?TS=Q FOZ7:*****CD5F1@I"
MO@X)&0#VXKS/]G;XZ:3^T'\-K7Q)IX6UU"&:2PU?3-^Y]/OHSMF@;N0#RK$#
M<K*V!G ]0HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHK%\:?\B;KW_7A<?^BVK^?FBBBBBBBBO1OV;O^3B/AA_V-&F?^E4=?NU1
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111111111117X=?M;?\ )S'Q*_[#
M=Q_Z%7DE%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?I3_P $F?\ D3?B
M%_V$+7_T6]?>]%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?C?_P %$/\ D[7QC_UQL?\ TCAKYOHH
MHHHHHHKZ!_8__:JU+]F_QMLNFEO?!>J2*NJ6"G)C/07$0[.HZC^)1M/(4K^Q
MOA[Q!IWBK1+'6-(O(K_2[V)9[:Z@;<DL;#(8'Z5I44444444444444444444
M44444444444444444444445_/MXP_P"1LUO_ *_9_P#T8U9%%%%%%%%?I!_P
M24_Y%[XD_P#7U8_^@SU^@%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?B]^WK_ ,G:?$#_ *[6G_I'!7@%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>\_L>_LU7
M?[1GQ*CMKI)(?"6E%+C5[M<C<I/RP(>SN5(S_"H9NH /[-:7IMIHNFVNGV%M
M'9V-K$L$%O"H5(HU 554#@    >U7:******************************
M***********************************\X_: ^-^@_L[_  GU[QUXADW6
MFG1?N+4,%>\N&XB@3/\ $S8&<' RQX4U_.;\6/BAKWQF^(FO>-/$UT;S6=8N
M6N)FYVH.B1H#T1%"JH[!0*Y"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBG*K2,%4%F)P !DFOJCX#_\ !-GXV_'1;>\3P]_PAN@2;6&J^)M]L'4\YCAV
MF5\CD':%/'S#K7Z'? W_ ()"_"7X<^1?>-;B\^(^L1X)CN\VM@I'I C%F^CN
MP/'RBOMCPOX1T/P3H\.D^'=&L-!TJ 8BLM-M4MX4_P!U$  _*MBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBN7\>_#3PG\4M%?2/&'AS3/$NFMD_9
M]3M4G52?XEW E6]&7!'8U\,?'#_@C9\.O%RW-_\ #?6K[P-J3?,FGW9:^T\G
M^Z-Q\U,^N]@.RU^=OQV_8)^-'[/8N;O7_"DNJ:#"23KNA$WEIM'\3$ /$OO(
MJU\\4444444444444444444444444444444444444444444445]!_P#!/_PZ
M?%'[97PHL@N_RM86^P/^G>-[C/X>5FOZ):******_%#X?_M,77[%/_!0'XI6
ME[)(? .K>*+VWUBR3)\N%[AWAN44=7B$F>!\REUZD$?M'INH6NL:=:W]C<QW
MEC=1+/!<0,&CEC90RNK#@J0001P0:N444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444445B^-/^1-U[_KPN/_ $6U?S\T44444445Z-^S
M=_R<1\,/^QHTS_TJCK]VJ***************************************
M************************************************************
M*****_#K]K;_ ).8^)7_ &&[C_T*O)******************************
M********_2G_ (),_P#(F_$+_L(6O_HMZ^]Z************************
M****************************************************_&__ (*(
M?\G:^,?^N-C_ .D<-?-]%%%%%%%%%?7?["G[8C_!?7(O!GBR[9O NH3?NKB1
MB?[+G8_?'I$Q^\O\)^8?Q!OU?AF2YB26-UDC<!D=2""",@@]P:FHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK^?7Q=_R-FM_]?T__HQJR:******
M*_2#_@DI_P B]\2?^OJQ_P#09Z_0"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQ>_;U_Y.T^('_7:T_\ 2."O
M *******************************************************Z+X>
M^ =:^*'C32?"_AZU-YJVI3"&).BKW9F/954%BW95)K]MO@+\$]&^ ?PUTWPG
MHRK(T0\Z]O2N'O+D@;Y6^N  .<*JCG&:](HHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\*?^"FW[7G_  T1\6CX
M6\/7IE\ ^%9G@MFB?,=_=C*RW/'!4<HAY^4%A]\BOBVBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBM+P_X<U7Q9K%KI.AZ;=ZQJETXC@LK"!IYI6/\*HH)
M)^@K[P_9_P#^"/OQ(\?_ &74_B-J$'P^T9\,;%=MUJ;KUQL4^7%D=V8LIZI7
MZ6? 3]B/X/\ [.<=O-X7\*V]SKD0&=>U<"ZOF;^\KD8CSZ1JH]J]ZHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKYA^/W_!.WX+?'[[3>7OA
MQ?#'B*7)_MOP[BUE9C_%)& 8I"3C)92Q'1A7YI?M#?\ !*'XM?" 7.I>$T3X
ME>'H\MOTF$I?QJ/[UJ26;_MDSGN0*^*[RRN--O)K6Z@DMKJ%VCEAF0JZ,#@J
MRGD$'@@U6HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK[E_X(\^"
M_P#A)/VM&UAT)B\/:%=WJR8X$DA2W"_4K.Y^BFOW#HHHHHHK^?+_ (*6:6ND
M?MO?%"!1M#W-I<?C)96\A/YN:^SO^"1O[81UK3Q\$/%E]F]M$>?PS<SOS+",
MM)9Y/4H,N@Y^7>. B@_I_111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111116+XT_Y$W7O^O"X_\ 1;5_/S111111117HW[-W_)Q'PP_[
M&C3/_2J.OW:HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\.?V
MMO\ DY?XE?\ 8;N/_0J\EHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK]
M*?\ @DS_ ,B;\0O^PA:_^BWK[WHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\;_\ @HA_R=KXQ_ZX
MV/\ Z1PU\WT4444444445^@/_!/O]L@:;)8?"SQO?8LW*PZ!J=PW^J8G"VKL
M?X3T0GH?EZ%0OZ/T44444444444444444444444444444444444444445_/K
MXN_Y&S6_^OZ?_P!&-6311111117Z0?\ !)3_ )%[XD_]?5C_ .@SU^@%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%?B]^WK_R=I\0/^NUI_P"D<%> 44444444444444444444444444444444
M4444444444444444444444 $G &2:_6C]@7]E<?!?P7_ ,);XCM-GC3785/E
M2+A]/M3AEAP>0[?*S^F%7C:<_7%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?#O_!4K]K7_ (43\)?^$(\/7OE>
M-O%\+PAXFP]C8'*RS\<JS<QH>.KL#E*_#FBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBM7PSX6UGQIKEKHV@:5>:WJUTVR"QT^!IYI6]%102?P%?H;^S=_P
M1T\5>+/LNL?%[5?^$0TIL/\ V'ICI-J$@ZX>3YHX>/3>>H(4U^G'P5_9P^'/
M[/>C_P!G^ _"UCHFY0D]ZJ^9=W&/^>L[9=N><$X'8"O3J***************
M***********************************\4^/O['OPH_:2LY?^$R\+P/J[
M)LBUW3\6^H1<8!$JCYP.RR!E_P!FORX_:0_X)'_$CX6K=:O\/9_^%C^'H\N;
M6&(1:I O)P8<D38&!F,[B?X *^%-0T^ZTJ\GL[VVEL[RW<Q36]PA1XV!P592
M 00>"#S52BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOUS_P"")/PY
M^P^!?B+XZFBRVHW\&CVSL.0L$9EDQ[,9X\^Z>QK]-:******_ __ (*K1"/]
MM_QRP_Y:6VFM_P"2, _I7R[X9\2ZIX-\1:9KNBWLFG:MIMS'=VEW </#*C!E
M93Z@@5_0_P#L>?M,:;^U-\$](\6V_E6^M0@66MZ?&?\ CUO%4;L#.0C@AUZ_
M*X!.5;'N=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%8OC3_D3=>_Z\+C_P!%M7\_-%%%%%%%%>C?LW?\G$?##_L:-,_]*HZ_=JBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOPY_:V_P"3E_B5_P!A
MNX_]"KR6BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOTI_P""3/\ R)OQ
M"_["%K_Z+>OO>BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQO_P""B'_)VOC'_KC8_P#I'#7S?111
M11111110,J05)!'((K]2?V!_VQQ\3=-M_A[XSO@?%UG%MT^_G;G4H5'W6)ZS
M*!SW91NY(8G[7HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK^?7QA_
MR-FM?]?T_P#Z,:LFBBBBBBBOT@_X)*?\B]\2?^OJQ_\ 09Z_0"BBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQ>
M_;U_Y.T^('_7:T_](X*\ HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHK[7_X)V_LJ_P#"PO$4?Q(\3V>[PUI$_P#Q+;:9?EO;M3]_
M!ZQQG!]&; Y"L*_4FBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBN7^)'Q"T7X4^ ]=\8>(KH6>B:+:O>7,O!.U1P
MJCNS'"JO4LP Y-?SC_M!?&[6_P!HCXN>(/'>OL5N=2F_<6H<LEI;K\L4">RJ
M ,\9.YCR37F]%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%6;.RN-1NH;6T@DN
M;F=UCC@A0N\C$X"J!R22< #DU]\?LQ_\$C?'?Q06TUWXFW,OP_\ #LF'&FB,
M-JLZ^A0_+;Y'=\L#U3O7ZJ? O]FGX<_LXZ%_9G@/PU;:4TB!;C4'_>WET1WE
MF;+$9YV@A02<**]3HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHKPS]HC]C+X5_M-V,G_  EWA^.+7-FR'Q#I@6WOXL# S( ?,4=E
MD#*.P!YK\F/VG_\ @EY\3_@+]KUGPY$WQ"\'Q;G-[ID!%Y;(.?WUL"6P!U="
MPP"3MZ5\8D$'!ZT444444444444444444444444444444444444445_1;^PK
M\)_^%+_LJ_#_ ,/S0^3J,M@NI7ZD887%R3,ZM[H'5/H@KWNBBBBBBOP*_P""
MJ%R+C]N/X@(#_J8M-C/_ (+[=O\ V:ODROIO]@3]JZ?]ECXV6M[?SR'P5KA2
MQUZW7)"1[CY=R%'5HBQ;@$E6=1RPQ_0)9W<&H6D-U;31SVTR+)%-$P9'5AD,
MI'!!!!!'7-6:************************************************
M************************************************************
M****Q?&G_(FZ]_UX7'_HMJ_GYHHHHHHHHKT;]F[_ ).(^&'_ &-&F?\ I5'7
M[M4444444444444444444444444444444444444444444444444444444444
M44444444444444444444444444444444444444444444445^'/[6W_)R_P 2
MO^PW<?\ H5>2T4444444444444444444444444444444444445^E/_!)G_D3
M?B%_V$+7_P!%O7WO11111111111111111111111111111111111111111111
M111111111111111111111111111111117XW_ /!1#_D[7QC_ -<;'_TCAKYO
MHHHHHHHHHHHJSI>J7>B:E:ZCI]S+97UK*LT%S Q1XI%(965AR"" 017Z_P#[
M%_[6EG^T1X2&EZQ-%;>/-*A7[;;C""\C& +F->F"2 RC[K'L&6OIBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOY]?%W_(U:U_U_3_ /H;5DT44444
M45^D'_!)3_D7OB3_ -?5C_Z#/7Z 44444444444444444444444444444444
M444444444444444444444444444444444445^+W[>O\ R=I\0/\ KM:?^D<%
M> 44444444444444444444444444444444444444444444444444445ZU^S+
M^S_JG[17Q.L_#UIYEMI,&+C5M05<BVMP><$\;V^ZH]3G&%8C]KO"OA?3/!/A
MO3=!T2SCL-)T^!;:VMHQ\J(HP!ZD]R3R223DFMBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOR)_P""P7[57_"1
M^(K7X+>';S=INDR)>^(9(6XENL9AMR1U$:G<PY&YU!P8Z_,VBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBOI_]EK_ ()]_$[]J&:VU*TL?^$7\%LPW^)-6C98
MY%SS]GCX:<]>5PF007!K]@OV9_V&OA;^R_:PS^']'&K^*-N)?$NK*LMX21AA
M&<8A4\C:@!(X8MC-?0]%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%?)?[4__  3@^&/[22WFL6UL/!/C:3+_ -N:3"-EPY[W
M,&0LN>[ J_3+$#%?C]^TE^QO\3/V7-69/%NC&?1))-EKXATT-+83YZ#?@&-C
MS\CA3P< CFO#*************************************]S_ &*/@FWQ
M^_:7\%>%9H#<:0+L7^J@KE!9P?O)%;T#X$8/K(*_HT P !P*6BBBBBBOYY/^
M"B6L?VY^VE\5;G=NV:E';9_ZY6\46/PV8KYRHK]D_P#@D?\ M9?\+!\!R_"+
MQ'>;_$/AJ#S='EF;YKG3P0/*!/5H6(4#^XR@#"$U^BM%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%8OC3_ )$W7O\ KPN/_1;5_/S1
M11111117HW[-W_)Q'PP_[&C3/_2J.OW:HHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHK\.?VMO^3E_B5_V&[C_T*O):********************
M*****************_2G_@DS_P B;\0O^PA:_P#HMZ^]Z***************
M************************************************************
M*_&__@HA_P G:^,?^N-C_P"D<-?-]%%%%%%%%%%%%;O@7QSK?PW\6:;XD\.W
MTFG:QI\HF@GC['H58=&5@2K*>""0>#7[/_LQ_M(:+^TCX!CU>R"66N6@6+5M
M+W9:VE(^\N>3&V"5;V(/(->R444444444444444444444444444444444444
M445_/KXN_P"1JUK_ *_I_P#T-JR:*******_2#_@DI_R+WQ)_P"OJQ_]!GK]
M ***********************************************************
M*********_%[]O7_ ).T^('_ %VM/_2."O *************************
M***************************TO#7AO4_&/B#3M#T:SDO]5U"=;:VMHAEI
M)&. /;W)X R3P*_:K]EW]GO3/V<_AE::%;^7<ZW=8N=6U!1S/<8^Z">=B E5
M'IDXRQKV2BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBO%?VO/VB+']F'X%Z]XSN&CDU15^QZ19R'_CYO9 1$N.ZK
MAG;_ &8VQSBOYT=<UN^\2:U?ZOJMW+?:G?W$EU=74QW/-*[%G=CW)8DGZUGT
M4444444444444444444444444444445V7PM^$?B_XT^++7PSX)T&[\0:S<<B
M"V7Y8US@O(YPL:#(RS$ 9'/-?K;^R3_P29\)_"_['XD^*SVOC;Q0FV6+2$4M
MI=HW4;E8 W##_: 3J-K8#5^@<,,=O"D42+%%& JH@ 50!@  = !VJ:BBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL[7-"T
MWQ-I-WI6KV%KJFF7<9BN+*\A66&9#U5T8$,#Z$5^:'[6O_!(.QU5;[Q-\$95
MTZ]^:67PC?3?N)3U(MIF/[L^B.2N3PR  5^6/BWPAK?@'Q!>Z#XCTF\T/6;)
MS'<6-]"T4L9]U(!P1@@]""",@UBT44444444444444444444444444444444
M45^Q_P#P1Q_9];P;\+];^*>J6GEZGXI?['II=<,MA$WS,.X$DP.1W$*$<&OT
M9HHHHHHHK^9S]HKQ,/&GQ^^)&O(^^+4O$FH749SG]VUS(R@>P4@?A7G5%=?\
M)_B=KOP:^(WA_P :^'+C[-K&C72W,)).UP.&C8#JKJ65AW#$5_1]\$OBYH?Q
MW^%OA[QUX?DWZ;K%LLXB+!G@D'$D+8_B1PRGW7(X(KNZ****************
M************************************************************
M***********************************Q?&G_ ")NO?\ 7A<?^BVK^?FB
MBBBBBBBO1OV;O^3B/AA_V-&F?^E4=?NU1111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111117X<_M;?\G,?$K_L-W'_H=>2T44444445^@7@K_@EKI_B
MSP=H.N-\1;FU;4[""], TA7$?F1J^W=YPSC=C.!G%;7_  Z3TW_HIEU_X)E_
M^/T?\.D]-_Z*9=?^"9?_ (_1_P .D]-_Z*9=?^"9?_C]'_#I/3?^BF77_@F7
M_P"/T?\ #I/3?^BF77_@F7_X_1_PZ3TW_HIEU_X)E_\ C]'_  Z3TW_HIEU_
MX)E_^/T?\.D]-_Z*9=?^"9?_ (_1_P .D]-_Z*9=?^"9?_C]'_#I/3?^BF77
M_@F7_P"/T?\ #I/3?^BF77_@F7_X_1_PZ3TW_HIEU_X)E_\ C]'_  Z3TW_H
MIEU_X)E_^/T?\.D]-_Z*9=?^"9?_ (_1_P .D]-_Z*9=?^"9?_C]'_#I/3?^
MBF77_@F7_P"/T?\ #I/3?^BF77_@F7_X_1_PZ3TW_HIEU_X)E_\ C]'_  Z3
MTW_HIEU_X)E_^/T?\.D]-_Z*9=?^"9?_ (_1_P .D]-_Z*9=?^"9?_C]'_#I
M/3?^BF77_@F7_P"/T?\ #I/3?^BF77_@F7_X_1_PZ3TW_HIEU_X)E_\ C]'_
M  Z3TW_HIEU_X)E_^/T?\.D]-_Z*9=?^"9?_ (_1_P .D]-_Z*9=?^"9?_C]
M'_#I/3?^BF77_@F7_P"/U]&_LK?LMP?LOZ/K]A;^(I/$0U:>*=I);06_E;%9
M< !VSG=[=*]WHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\;_ /@HA_R=KXQ_ZXV/_I'#7S?11111
M111111117>_!+XS^(/@/\0+#Q5X>FQ+"?+N;1R1%>0$C?"X'8X!!ZJ0K#D"O
MVG^#/Q@\/?'/P%I_BOPY<>9:W V36SD>;:S #?#(!T9<CV(((R"#7>444444
M44444444444444444444444444444445_/KXN_Y&K6O^OZ?_ -#:LFBBBBBB
MBOT@_P""2G_(O?$G_KZL?_09Z_0"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOF#XN?\$^_AY\9_B)K'C/6]9\
M3VNJ:HT;30V%U;) I2)8QM5[=F'"*3ECR3]*Y'_AU3\)O^AA\9_^!MI_\BT?
M\.J?A-_T,/C/_P #;3_Y%H_X=4_";_H8?&?_ (&VG_R+1_PZI^$W_0P^,_\
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M^'5/PF_Z&'QG_P"!MI_\BT?\.J?A-_T,/C/_ ,#;3_Y%H_X=4_";_H8?&?\
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MHHHHHHHHHHHHHHHHK\.?VMO^3F/B5_V&[C_T.O):********_>_X,_\ )'_
MW_8"L?\ TG2NQHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\
M;_\ @HA_R=KXQ_ZXV/\ Z1PU\WT44444444444445[/^RW^TKK'[-OCY-2MQ
M)?>';XK#JVE!\":,'AU!X$B9)4]\E2<,:_9OP7XRT?XA^%],\1^'[Z/4='U&
M%9K>YB/# ]01U# @@J>000<$5O4444444444444444444444444444444444
M445_/IXN_P"1KUK_ *_9_P#T-JRJ*******_2#_@DI_R+WQ)_P"OJQ_]!GK]
M ***********************************************************
M*************************************************\R_:$^.6C?L
M]_#/4/%&J%9KA?W&GV&_#7=RP.R,>@X)9NRJ3R< _B3XZ\;ZS\2/%^J^)M?N
MVOM7U.9IYYFZ9/ 51_"J@!54<!5 '2L*BBBBBBBBBOJS]@O]E@_'#QO_ ,)-
MXAM2W@C0I@9$D'R7]R,,L ]57*L_L57^+(_7)55%"@84#  '%.HHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKY8_
MX**_M-?\,W?L^:C)IEWY'C#Q'OTK1MK8>(LO[ZX'<>6AR#V=H\\&OY_R222>
M32444444444444444444444444444445O>"_!.O?$7Q-8>'O#.D7>N:W?2".
MWL;*(R2.W?@= !DEC@  DD $U^O?[&?_  2E\/\ PO6P\7?%N*U\5>+5VS0:
M%Q)IVGMU&\'BXD'O^[!S@-@-7Z&JJQJ%4;5 P !@"G444444444444444444
M44444444444444444444444444444444444444444444444453U+3;76=/N;
M"_M8;ZQN8S#/;7,:R12HPPR,K AE(R"",$5^7G[9_P#P256;[=XQ^!T"QMS-
M=>#9),*W=FLW8\>ODL<==K#Y4K\L]4TJ\T/4KG3M1M)]/O[61H9[6ZB:.6&1
M3AE96 *L#D$$9%4J******************************_<K_@ES^R2WP#^
M$K^,?$5C]G\<>+HDF>.9<26-C]Z* @\JS?ZQQQR44C*5]O44444445\B_P#!
M4[XB+X!_8W\4VZ2^5=^(KBVT6W.>N]_,E'OF&&4?C7X(T445:T^^N-+OK>]M
M)Y+6[MY%FAGA8J\;J0592.000"".A%?T0_L2_M)V_P"U!\!=%\3R21_\)#:#
M^SM<MTP/+O(U&YPHZ+("L@[ -CJIKWVBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBL7QI_R)NO?]>%Q_Z+:OY^:********]&_9N_P"3
MB/AA_P!C1IG_ *51U^[5%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%?AS^UM_R<Q\2O^PW<?\ H=>2T44444445^]_P9_Y(_X&_P"P%8_^DZ5V
M-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?C?_P40_Y.U\8_
M]<;'_P!(X:^;Z***************^G/V*?VN+K]GSQ3_ &+KLLMQX"U68?:8
MQEFL93@"X1>N,8#J/O  C)4 _KSI^H6VK6%M?64\=W9W,:S07$+ATD1@"K*P
MX(((((Z@U;HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK^?3Q=_R-6L_P#7
M[/\ ^AM6511111117Z0?\$E/^1>^)/\ U]6/_H,]?H!11111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111115'6M8LO#VDWNJ:E=1V.GV<+W%Q<S-M2
M*-069F/8  FOQ>_:W_:2O?VCOB9-J$;2P>%].+6VCV3G&V//S3,O]]R Q] %
M7G;D^'4444444445W_P+^#.M_'GXD:9X2T1"CW#>9=7;*62TMU(WS-[ $ #(
MW,57J:_;CX;_  \T7X5>!])\*^'[7[+I>FPB*,'!9SU9W(ZLS$L3W)-=3111
M111111111111111111111111111111111111111111111111111111111111
M11136(4$DX Y.:_GU_X*$?M*-^TI^T-J]_877G^$M!+:3HH5LH\2,=\X[$RO
MN8'KM" _=KYCHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKV[]F#]D;QY^U9XJ_LS
MPI8_9](MW4:CKUXK"SLE/.&8??D(^[&O)ZG RP_<?]E[]D#P#^RCX7%AX7L?
MMFN7$:KJ/B&\0&[O#U(S_P LX\CB->!@$Y;+'W.BBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOEG]L;]@3P1
M^U=ILFI;8_#'C^&/;:^(;:$'S\#"QW2C'FIP &SN7C!QE6_$7XZ? 'QO^SEX
MVF\+^.='DTV^7+6]RGSVUY%G E@DQAU/X$'A@IR!YO111111111111111111
M11111111117WA_P2_P#V+9/CAX\B^(WBNQSX#\.7*M;PSIE-4OEPRQX/#11G
M#/V)VKR"V/VXHHHHHHHHK\D?^"V7Q5%]XL\ ?#JVGRFGVLNMWL:G(+RMY4 /
MHRK',<>D@/<5^8M%%%%?7G_!,_\ ::/[/?[0%GINJW?D>#_%S1Z7J6]L)!,6
M(M[@^FUV*DG@+(Y/05^]E%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%8OC3_ )$W7O\ KPN/_1;5_/S111111117HW[-W_)Q'PP_[&C3
M/_2J.OW:HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\.?VMO^
M3F/B5_V&[C_T.O):********_>_X,_\ )'_ W_8"L?\ TG2NQHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\;_\ @HA_R=KXQ_ZXV/\ Z1PU
M\WT4444444444444445]N_L"_MD?\*]O[7X<>-+W'ABZDV:7J,[<:=*Q_P!6
MY/2)F/7HC')^5B5_4+KR*6BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOY]/
M%O\ R-6L_P#7[-_Z&U95%%%%%%%?I!_P24_Y%[XD_P#7U8_^@SU^@%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?FK_ ,%'OVJ?[>U&;X4>
M%[O.GV<@.O74+<3SJ<K; CJJ$ MZL .-IS\$T444444445/I^GW.JZA;65E!
M)=WES*L,,$*EWD=B%554<EB2  .I-?LM^QM^S-;?LZ_#A%OHHY?&.K!9]5N5
MPWEG&5MU/]U,G)'WF+'IM ^@Z***********************************
M********************************^/?^"GG[2/\ PH?]G>\TG2[OR/%?
MC'S-)L=C8>& J/M4X]-J,$!'(:5".AK\&:**************************
M***^V?V'?^";WB+]I*XLO%OC!;GPU\-E8.DVW9=:L ?NP CY8^QE(QV4,<E?
MVJ\ ?#SPY\+/"6G^&/"6CVN@Z%8)L@L[2/:H]6)ZLQ/)9B68DDDDYKI:****
M************************************************************
M********\[^-_P "?!?[0W@6Y\*>-]'34].DRT,R_+<6DN,":&3&4<>O0C(8
M%20?PZ_;(_8/\:_LFZVU[()/$/@&YEVV7B*"(@(2>(;E1GRI/0_=?JISE5^8
M***************************]^_8X_9+\0?M:?%"+0[ R:?X:L=L^MZT$
MR+2 GA5SP97P0J^Q8C"FOZ!OA_X"T+X7>"]'\)^&=/CTO0M)MUMK6VC'"J.I
M)ZLQ)+,QY9F))))KI********CD=8T+.0JJ"2Q. !ZFOYOOVO/C%_P +Z_:.
M\<^,HI?,TZ\OVAT\YX^R0@10$#MN1%8CU8UXY111117[[_\ !-W]IC_AHK]G
MNPCU2[\_Q?X7V:5JV]LO,H7]Q<'N=Z#!)ZNDGM7UC1111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111116+XT_Y$W7O^O"X_P#1;5_/S1111111
M17HW[-W_ "<1\,/^QHTS_P!*HZ_=JBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBOPY_:V_Y.8^)7_8;N/_ $.O):********_>_P"#/_)'_ W_
M & K'_TG2NQHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\;_
M /@HA_R=KXQ_ZXV/_I'#7S?111111111111111117Z2_\$_?VR/^$@AL?A=X
MWOL:G$HBT+4[A^;A ,+:NQ_C4<(3]X#;U W??=%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%?SZ>+?\ D:M9_P"OV;_T-JRJ*******_2#_@DI_R+WQ)_P"O
MJQ_]!GK] ***************************************************
M*******************************************************^8_VX
MOVHD^ '@#^R]%N%_X3;7(VCL0I!:TB^Z]RP[$<JN>K<\A6%?C]--)<S22RNT
MLLC%F=V+,Q)R22>22>],HHHHHHHHHK]$_P#@F_\ LK^2D/Q:\46?SL&'A^TF
M7HIRK71!]>53/;+=U-?H;111111111111111111111111111111111111111
M11111111111111111111111111112'"C).!7\]__  4&_:)/[1O[2&NZI8W)
MN/"^BDZ/HVULHT$3'?,.Q\R0NX/7:4!^[7S1111111111111111111111111
M1113D1I&"J"S$X  R2?2OU%_8*_X):OJ/]G_ !"^-.F-%:?+<:;X/N5PTO=9
M+Q3T7H1">3_'@94_JU;V\5M;QPPQK%#&H1(XU 50!@  <  <8J>BBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBLKQ-X;TKQAH-]HNN:=;:MI%]$T%U97D2R131L,%64\$5^-G[=7_  3&
MUCX,S7WC;X76EUK_ (#),UUI2!IKS2%ZD]VEA'][EE'WL@%S^?\ 11111111
M11111111111111117MG[+/[*7C+]J[Q]'H/AJW^RZ7;,KZKKLT9-M81$]6Z;
MG(!VQ@Y8@]%#,O[Y_ /X!^$OV;_AU8>#?!UC]FL8/WEQ=2X:XO9R &FF8 ;G
M; ]   J@  #TFBBBBBBBBOEG_@I!\>!\"_V7/$DEI<^1K_B,?V%IH4X<-,K"
M:0=QLA$A#=F*>HK^?VBBBBBBOIW_ ()Z?M(']F_]HS1[[4+KR/"NO8TC60S8
M2.*1AY<Y]/+DVL3UV[P/O5_04#D CD4M%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%8OC3_D3=>_Z\+C_T6U?S\T44444445Z-^S=_R<1\
M,/\ L:-,_P#2J.OW:HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHK\.?VM?^3E_B5_V&[C_ -#KR6BBBBBBBBOWO^#/_)'_  -_V K'_P!)TKL:
M************************************************************
M*********************************************_&__@HA_P G:^,?
M^N-C_P"D<-?-]%%%%%%%%%%%%%%%%%/M[B6TGCG@E>&:-@Z21L592#D,".00
M>017ZS?L,_M@1?'#08_"7BFZ2/QWIL/$CD+_ &I H_UJ_P#311]]1U^\.-P7
MZWHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK^?3Q9_R-.L?]?LW_ *&U95%%
M%%%%%?I!_P $E/\ D7OB3_U]6/\ Z#/7Z 44444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444445Q'Q@^*VB?!3X>ZKXMU^;R[.QC_=P*P$ES,W$<* ]6
M8\>PR3@ D?B+\6OBEK?QF^(&K>+?$$WF7]_+N6-2=D$8X2) >BJN .YY)R22
M>0HHHHHHHHHKZ&_8O_9CG_:(^(JR:E%)'X,T9EFU2<9'G'.4ME;^\^#DC[JA
MCD$KG]D;&R@TZSM[2U@CMK6"-8HH8E"I&B@!54#@    #H!5FBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBODS_
M (*6?M%?\*"_9MU6#3KGR/$_BK=HNF[&P\:NI^T3#N-D9(##HSH:_ JBBBBB
MBBBBBBBBBBBBBBBBBBBBBBKNDZ3>Z]J5IINFVDU_J%W*L%O:VT9DEFD8@*BJ
MH)9B2  !DDU^R'[ 7_!-&R^#D>G_ !"^*%I!J7CK"S:?HS[9(-(/4,_427 ]
M1E4/W<D!A^A=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?"'[7_ /P2Q\'?'&2_\3_#YK;P/XWE
M+2RPJA&FZA(>29$49B<GJZ @DDLK$[A^07Q>^"/C?X#^*I?#WCKP]=Z!J*Y,
M?GKF*X4'&^&0961?]I21V.#Q7!T444444444444444444445]0_L:_L'^,OV
ML=<CO0DOA_X?VTNV^\0S1_ZP@_-#;*?]9)V)^ZG5CG"M^YWP=^#/A+X"^!+'
MPCX*TF/2='M1N*CYI9Y" &FE?J[M@98^@ P  .YHHHHHHHHHK\+O^"K'[12_
M&;]HB7POI=SYWAOP2LFFQ;6RDMZQ!NI!]&5(O^V)(ZU\444444445^]O_!,G
M]HX_'S]G&PL=3NO/\4^$2FCZ@7.7EB"_Z-.W<[HUVECR6B<]Z^NZ********
M************************************************************
M****************************************Q?&G_(FZ]_UX7'_HMJ_G
MYHHHHHHHHKT;]F[_ ).(^&'_ &-&F?\ I5'7[M4444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444444444444444445^'/[6O_)R_P 2O^PW<?\ H=>2T44444445^]_
MP9_Y(_X&_P"P%8_^DZ5V-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%?C?_P40_Y.U\8_]<;'_P!(X:^;Z******************TO#7B34_!
MVOV&MZ+>RZ=JMA,L]M=0-AXW4Y!'KZ$'@@D'(-?LC^R/^U)IG[27@</,8K'Q
MAIJ*FJZ<IP">@GB!Y,;'MU4Y4]BWOM%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%?SZ>+/^1IUC_K]F_\ 0VK*HHHHHHHK](/^"2G_ "+WQ)_Z^K'_ -!GK] *
M************************************************************
M*******************************************@NKB*RMY9[B58;>)&
M>261@JHH&2Q)X  !))K\=_VW/VHIOV@_B";'29W'@G1)&BTZ,9 NI.CW3#U;
MHH/W5[ LU?-U%%%%%%%%%=3\,/AMK?Q<\=:3X3\/V_VC4]1F$:ELA(E'+2.1
MT55!8GT'&3@5^W/P2^#^B? OX<Z7X2T-,P6J[[BZ90)+N<@;YG]V(X'8!5'
M%=]111111111111111111111111111111111111111111111111111111111
M111111111117X*_\%/OV@3\</VF-3TZPN?/\-^#PVBV.PY1YE;-U*.V3*"F1
MP5B0U\@T44444444444444444444444445L>%_"^K>-/$&GZ%H.G7&K:SJ$P
MM[6RM$,DDTAX"JHZ_P!!DGBOVZ_8(_X)YZ1^S/IEOXN\71V^L_$ZYBYD&'@T
MA&'S10'HTA!(:7ZJN%W%_M:BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBN0^)GPI\(?&3PM/X<
M\:^'K'Q'H\W)M[V/)1L8WHPPT;@$X92&'8U^6G[3O_!'?7_#;7>N_!K4&\2:
M:"TA\-ZI(J7L(ZXAF.$E [*VUL #+DU^<_B;PKK/@O7+K1O$&E7FB:M:OLGL
M=0@:":(^C(P!'Y5DT444444444444444459L[.?4;R&UM8)+FYF=8XH(4+/(
MS' 55')))  ')K]*_P!C/_@DOJ/B1K'Q?\;(IM(TGY9K?PC&Q2ZN!U'VIAS$
MI'_+-3O.>2A&#^L6@>']-\*Z+9:/HUA;:5I5E$L%K96<2QQ0QJ,!550  /05
MI4444444445\Y?MW_M+P_LP_ '6-;M;A5\5:H#IFA0Y!;[2ZG,V/[L2Y<\8)
M"J?O"OYZI[B2YFDFFD:660EGD=B68DY))/))/>H:*******^J?\ @F_^T1_P
MS[^TIHSZA=>1X7\3;=%U7>V$C$C#R9CV&R7;ECT5I/6OW_HHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK%\:?\B;KW_7A<?^BVK^?FBBBB
MBBBBO1OV;O\ DXCX8?\ 8T:9_P"E4=?NU111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111117X<_M:_\G+_ !*_[#=Q_P"AUY+111111117[W_!G_DC
M_@;_ + 5C_Z3I78T44444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M5^-__!1#_D[7QC_UQL?_ $CAKYOHHHHHHHKJO!7PRU_XAZ=XDN]!LS?G0+'^
MTKR"/F3[.'5695_BV[@Q'7:&/:N5HHHHHHHHHHKK/A9\4-?^#OCC3?%7AJ[-
MIJ=D^<')CGC/WHI%_B1AP1]""" 1^TO[/_QYT#]H;X?VGB31'\BX7$.H::[!
MI+.<#+(WJ#U5L88>AR!Z?11111111111111111111111111111117\^?BS_D
M:-8_Z_9O_0VK+HHHHHHHK](/^"2G_(O?$G_KZL?_ $&>OT HHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\_O\ @H_^U1_9=K-\)O"UYB[N$!U^
MZA;F.-@"MJ".[ AG_P!DJO.Y@/S@HHHHHHHHHI41I'5$7<S$!5 R23V%?KO^
MPE^RROP*\"_\)!K]H%\;Z[$K7"NOS6-N<,MN/1CPS_[6%YV GZHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK
MP;]MOX^#]G']G'Q3XKMYEBUR6+^S='!/)O9@51AZ[%#RD=Q&:_G4EE>:1GD9
MG=B268Y))ZDGN:CHHHHHHHHHHHHHHHHHHHHHHHHHK;\'^#]9\?>)]-\.^'=-
MN-8UO4IA;VEC:)ODE<]@.P R23@  DD $U^YW[!O[!.B_LK>'4UW7$M]8^)F
MH0XN[]1OCT]&'-O;D]NS/U8C'"X%?7]%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>9_&C]
MG/X=?M":/_9WCSPK8ZX$4I#>,ACN[?/_ #RF7#ISS@'![@U^:O[0'_!&/Q#H
MOVG5/A%XBC\0VBY==!UUE@NQ_LI. (Y#_O",>YK\^?B)\*?&/PCUMM(\9^&=
M3\-:CSMAU*V:+S .K(Q&'7_:4D>]<G111111111111117TS^S7_P3[^+7[2C
MVNH:?I!\->$I2"WB+6U:*%T]84QOF.,X*C;D8++7Z]?LM_L$_#+]EF&&_P!*
ML6\0^,-FV7Q)JB*TX)'S"!/NP*>1\N6(.&9J^E:**********K7MY!IUI<7=
MS/';6L"-++-*P5(T499F)X  !))Z 5_/S^WY^U5+^U-\<+N_T^:3_A#-#WZ?
MH4#9 >,-\]P5/1I6 ;D A513RM?,U%%%%%%%%%?T(_\ !/?]H+_AH;]FCP[J
M=[=?:/$>BK_8NL%FR[31*H65O4R1F-R>FYF Z5]+T4444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444444445B^-/^1-U[_KPN/\ T6U?S\T44444445Z
M-^S=_P G$?##_L:-,_\ 2J.OW:HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHK\.?VM?^3E_B5_V&[C_P!#KR6BBBBBBBBOWO\ @S_R1_P-_P!@
M*Q_])TKL:***************************************************
M******************************************************_&_P#X
M*(?\G:^,?^N-C_Z1PU\WT4444445]N?\$HQGXQ^+QC(.@'(_[>(JA_;X_8Y_
MX5KJ5S\0_!EECPG>2[M2L(%^739F/WU Z0NQZ=%8XX#*!\4T4444444445ZA
M^SO\?M>_9W^(-OXATAFGLI-L.I:8S%8[R#/*GT8<E6QE3Z@L#^T?PS^)6@_%
MOP3IOBGPW>"\TN^CWHW1XV'#1NO\+J<@CU'&1@GK:*******************
M***********_GS\6?\C1K'_7[-_Z&U9=%%%%%%%?I!_P24_Y%[XD_P#7U8_^
M@SU^@%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>"_M??M+6?[.
M/PUEN[=XYO%FJ;K?1[-\'#X^:9E[H@()'\1*KW)'XQZKJEYKFIW>HZA<R7E_
M=S-//<3,7>61F+,S$\DDDDGWJK1111111117W/\ \$Y?V5O^$PUJ+XH^*+/=
MHFFS$:+:S+\MU<J>9R#U2,C"^KC_ &"#^G-%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?C-_P6.^/0\:?&#1
MOAGIUQNTSPG!]HOE4\-?SJK8/KLBV8/8RN.U?GA111111111111111111111
M11116OX7\+ZMXT\1:=H6AZ=<:MK&HS+;VME:H7DFD8X55 __ % <GBOW2_8'
M_8/TG]E7PNFNZZD&J_$O5(0M[>J R:?&>3;0'TZ;G'WB./E KZ_HHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHK!\8>!_#WQ T271O$^A:?XATF;_ %EEJ=LEQ$Q['8X(
MR.QZCM7Q7\:/^"/_ ,(OB 9KOP7=ZA\.M2;)$=JQO+$L>YAD;<.>RR*!V%?#
MWQ:_X)*_'3X=R33Z#8Z?X^TQ<E9M&N5CN OJT$VUL_[*%_K7R9XS^'OBCX<Z
MFVF^*O#FJ>&[\9_T?5+.2VD..I =02/<<5SM%%%%%%%%;?A3P3XA\>:LFE^&
MM"U+Q#J3_=L]+M)+F4_\!0$_I7V/\%/^"1WQF^)#6]WXJ%C\.='DPQ;4V%Q>
ME3W6WC/!_P!F1D/M7Z)?L_\ _!,[X,_ >2WU&;2'\<>(X=K#4_$069(W'>*
M 1KSR"P9ACAJ^LE4* !P,8 %.HHHHHHHHHHHK\R_^"M'[9R^&]'F^"?A"^_X
MFVH1!O$MU"W-O;, RV@(Z-("&?T3"\[SC\BZ**********^X/^"3/[0)^$_[
M12^$-0N?*T#QO&NGL&;"I?(6:U;ZL6>+ ZF5?2OW(HHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHK%\:?\B;KW_7A<?^BVK^?FBBBBBBBBO1
MOV;O^3B/AA_V-&F?^E4=?NU1111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111117X<_M:?\ )R_Q*_[#EQ_Z%7DM%%%%%%%%?O?\&?\ DC_@;_L!6/\
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MD#G8OWF/H,9RP!_%'Q7XIU3QMXDU+7M;O)+_ %;49VN;FXD/S.[')]@!T '
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MG.[G(B4[CQDJ""?Q*^)?Q-\3_&#QGJ/BKQAK%QKFNW[[YKJX;H/X411PB*.
MB@!1P *Y6BBBBBBBBBBBBBBBOW3_ ."3OQL_X6E^R_:>'KR?S=9\%W!TJ0,V
M6-JP+VK'T4*6B'_7 U]JT444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444445B^-/\ D3=>_P"O"X_]%M7\_-%%%%%%%%>C?LW?\G$?##_L:-,_]*HZ
M_=JBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOPY_:T_Y.7^)7
M_8<N/_0J\EHHHHHHHHK][_@S_P D?\#?]@*Q_P#2=*[&BBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQO_P""B'_)VOC'_KC8_P#I'#7S?111
M11117V[_ ,$H_P#DLGB__L G_P!*(:_4.BBBOF']M3]DFU_:&\*G6=$BBM_'
MFE0M]DE.%%[&,DVTC=.N2K'[I)!P&)'Y"ZEIMWH^H7-A?VTMG>VLK0SV\ZE)
M(I%)#*RGD,"""#Z57HHHHHHHHHJSIFJ7>BZE:ZA87,MG?6LJS07$#%7BD4AE
M96'(((!!%?K]^Q=^UK:?M#>$UTK698K;QWI<0^VVZX47D8P!<QK[D@,H^ZQZ
M ,M?3-%%%%%%%%%%%%%%%%%%%%%%%%%%?SX^*/\ D9]7_P"OR;_T-JS:****
M***_2#_@DI_R+WQ)_P"OJQ_]!GK] *******************************
M************************************************************
M********R/$_B33?!_A_4=<UB\BL-*T^!KFYN9CA8XU&2??V Y)P!R:_%7]J
M+]H;4OVC/B9=:Y/YEMHEKNMM(T]FX@@!^\P'&]\!F/KA<X5:\@HHHHHHHHHK
MTC]GWX'ZQ^T!\2M.\*Z2&AA<^??WVW<EG;*1OD/J>0JKW9E'')'[;> _ ^C?
M#7P?I7AC0+466D:9 L$$(Y.!R68_Q,Q)8MU))/>NBHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\C_^"UGQ
ME_M+Q9X)^&%E/F'38&US444Y!FES' K#LRHLK?285^8]%%%%%%%%%%%%%%%%
M%%%%%%%>U?LF?LRZ]^U5\7+#PGI6^VTN/%SK&J!<K8VH(#/SP7;[J+W8C. &
M(_H6^'/P[\/_  G\#Z/X1\+Z?'I>A:5 +>UMXQT Y+,>K,Q)9F/)9B3R:ZBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL?Q1XITC
MP7H5[K>OZI::-I%DAEN;Z^F6*&)1W9F( _KTK\I?VRO^"M=]XDCO_"'P3DGT
MK36S#<^+I5*7,PZ$6B'F)2/^6C#?S\H0@,?S0NKF6_NI;B>5Y[B5S))+(Q9G
M8G+,2>22222:@HHHHHHHHHHHHHHHHK[6_P""37QI/PQ_:BM?#MU/Y6C^,[5M
M+D5FP@NES);.?4E@T8_Z[FOW2HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHK%\:?\B;KW_7A<?^BVK^?FBBBBBBBBO1OV;O\ DXCX8?\ 8T:9
M_P"E4=?NU111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111117X<_M:?
M\G+_ !*_[#EQ_P"A5Y+111111117[W_!G_DC_@;_ + 5C_Z3I78T44444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444444445^-__!1#_D[7QC_UQL?_ $CA
MKYOHHHHHHHK[=_X)1_\ )9/%_P#V 3_Z40U^H=%%%%?$?[?7[&__  LC3[KX
MB^"[+/BNTBW:EI\"\ZE"H^^H'69 .G5E&!\RJ&_+L@@X(P111111111116[X
M%\<:W\-O%FF^)/#M])IVL:?*)H)XST/0JPZ,K E64\$$@\&OV>_9C_:1T3]I
M+P#'J]D$LM<LPL6K:5NRUM*1PRYY,;8)5O8@\@U[+1111111111111111111
M1111117\^/BC_D9]7_Z_)O\ T-JS:*******_2#_ ()*?\B]\2?^OJQ_]!GK
M] **********************************************************
M*****************************************_+[_@HM^U3_ ,)QKTOP
MR\,7F[P_I4W_ !-[F%OEO+I3_J@1U2,CGL7'^RI/Q!1111111115O2-)O=?U
M6STS3K:2]U"\F6"WMH5+/+(S!550.I)( K]G_P!D7]FVR_9Q^&D5C,L<_BG4
M@MQK%XG.9,?+"I_N1@D#U)9N-V![M1111111111111111111111111111111
M1111111111111111111111111111111111111114,\\=K#)-*ZQ11@L[N0%4
M 9))/0"OYK_VGOBY)\=OC[XW\<,[/;ZKJ,C68?JMJF([=3[B)$!]\UY;1111
M1111111111111111116WX-\'ZO\ $#Q3I7ASP_I\VIZSJEPEK:6L(RTDC' '
MH!W).  "20 37]"?[''[*^C?LG_"*S\.6GE7?B&\"W6N:JB\W=SMY521GRDR
M51>.,L1N9L^]444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444445\@_M1_\%+/A=^SNMYI.EW2>._&L6Y!I.DS P6[CC%Q<#*I@@@JNYP>
M"HSFOR _:._:Z^)/[46M_:_&6LG^RX9"]IH-AF*QM?0K'D[FP2-[EFY(SCBO
M%*******************T_#?B"_\)^(M+US2YVMM3TRZBO;6=>L<L;AT8?1E
M!_"OZ9?A#\1K'XO?"[PKXTTW:+/7=.AOE0-GRV= 6C)]5;<I]U-=A1111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111116+XT_Y$W7O^O"X_]%M7\_-%
M%%%%%%%>C?LW?\G$?##_ +&C3/\ TJCK]VJ*************************
M************************************************************
M*******************_#G]K3_DY?XE?]ARX_P#0J\EHHHHHHHHK][_@S_R1
M_P #?]@*Q_\ 2=*[&BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBOQO_X*(?\ )VOC'_KC8_\ I'#7S?11111117V[_P $H_\ DLGB_P#[ )_]
M*(:_4.BBBBBOS;_X*!?L;_V-+?\ Q2\#V/\ Q+Y"9M>TNW7_ %#$Y:Z11_"3
MRX'W3\WW2VWX#HHHHHHHHHHKO/@G\9O$/P'^(%AXJ\/3XFA.RYM'8B*\@)&Z
M%P.JG P>JL PY K]J/@S\8/#WQS\!:?XK\.7&^UG&R:V<CS;28 ;X9 .C+D>
MQ!!&00:[RBBBBBBBBBBBBBBBBBBBBBBBBOY\O%'_ ",VK_\ 7Y-_Z&U9E%%%
M%%%%?I!_P24_Y%[XD_\ 7U8_^@SU^@%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%?*'[>O[5 ^"/@G_A&/#]T$\;:["PC>,_-86IR&G]F.&5/<,W\.#^
M1S,68DDDDY))Y)HHHHHHHHHHK](_^"</[*O]BV,/Q8\46F+ZZC*Z#:S+S#$P
MPUT0>C.,JO\ LDMSN!'W[111111111111111111111111111111111111111
M111111111111111111111111111111117S7_ ,%$/B[_ ,*;_9)\<:A#-Y.I
MZM -#L"#AC)<Y1RI[%8O.<'U2OYZZ***********************_9#_ ()1
M?L8CX=^%8?C%XOL-OBC6[<_V':S)\UC9./\ 78/2293P>HC(Y^=@/T8HHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHJ.25(8VDD8(B@D
MLQP !U)-?)/Q^_X*=?!?X'_:;&RU=O'GB./*_P!F^'766)&':2Y)\M1D$$*7
M8'JM?F#^TE_P4F^+O[0RW6EIJ(\$^$YMRG1="D9&F0_PSS\/)QP0-J'NM?)]
M%%%%%%%%%%%%%%%%%%%%%?L__P $:?B__P )=\!]=\!W4^^\\):B9;=&/2SN
MMSJ .^)EG)]-Z_C^A-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%8OC3_D3=>_Z\+C_P!%M7\_-%%%%%%%%>C?LW?\G$?##_L:-,_]*HZ_=JBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOPY_:T_P"3E_B5_P!A
MRX_]"KR6BBBBBBBBOWO^#/\ R1_P-_V K'_TG2NQHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHK\;_P#@HA_R=KXQ_P"N-C_Z1PU\WT444444
M5]N_\$H_^2R>+_\ L G_ -*(:_4.BBBBBH)[>.ZADAFC66*12KQNH96!&""#
MP01VK\G?VZ/V/9/@EKDGC#PI:._@349OWD* M_9<['_5M_TR8_=;L?E/.TM\
MD44444444445[-^RW^TMK'[-OCY-3MQ)?>';XK%JVE!L":,'AUSP)$R2I[Y*
MDX8U^SG@OQEH_P 1/"NF>(_#]]'J&CZC")K>XCZ,#U!'4$$$%3R""#@BMZBB
MBBBBBBBBBBBBBBBBBBBBBOY\O%'_ ",VK_\ 7Y-_Z&U9E%%%%%%%?I!_P24_
MY%[XD_\ 7U8_^@SU^@%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>=_';
MXS:)\!_AOJ7BW6VWI;CR[6S5PKW=P0=D*^Y())P<*K'M7XD?$CXA:W\5O&VK
M>*O$%R;K5=2F,LC#(5%Z*B@]%50% [ "N:HHHHHHHHHKZ4_8A_9=D_:!^(']
MHZQ;N/!&AR++?N00+N7JMJI_VNK$=%XR"RFOV%M[>*VMXX88UBAC4(D<:@*H
M P  .  .,5/1111111111111111111111111111111111111111111111111
M11111111111111111111117Y)_\ !;'XM&]\5> OAM;3?N;"VDUR^C4Y!DE8
MQ0 ^A54F/TE%?F'11111111111111111111117V-_P $V?V/?^&EOBM_;GB&
MS,GP^\,2)/J D7Y+^X^]%: ]P<;GQT4!3@NIK]WHXDAC5$5410 %48  Z "I
M************************************************************
M*************************************************:S!022  ,DF
MO#OBM^VQ\$?@PLD?B7XA:0+Z/(.G:;*;ZZ!]&CA#%"?5\#WKXK^,/_!:[3X(
MY[3X7^!)[J;E4U7Q1((XU/J+>%BS ]1F53ZCT^!_C9^V)\7OV@GEB\8^-;^Z
MTN0\:/9$6MB!G@&&/"OCLS[C[UXM111111111111111111111117V#_P2M^+
M_P#PJW]K30M/N)_*TOQ9!)H4X)^7S'P]N<=V,T:(#V$C>M?O/11111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111111116+XT_Y$W7O^O"X_]%M7\_-%%%%%
M%%%>C?LW?\G$?##_ +&C3/\ TJCK]VJ*****************************
M************************************************************
M***************_#C]K3_DY?XE?]ARY_P#0J\FHHHHHHHHK][_@S_R1_P #
M?]@*Q_\ 2=*[&BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQ
MO_X*(?\ )VOC'_KC8_\ I'#7S?11111117V[_P $H_\ DLGB_P#[ )_]*(:_
M4.BBBBBBLKQ)X>TWQ9H5_HVL64.HZ7?0M!<VLXW)(C#!!']1R#@CFOQQ_:\_
M97U/]F[QKFW$M[X,U-V?2]189*=S!*1P)$'0]&4;ASN5? J**********^F_
MV*?VN+G]GSQ5_8NNS27'@/59A]JC&6-C*< 7"+Z8P'4<L ",E0#^O6GZA;:M
M86U]93QW=G<QK-!<0N'21& *LK#@@@@@CJ#5NBBBBBBBBBBBBBBBBBBBBBBO
MY\O%'_(S:O\ ]?DW_H;5F44444445^D'_!)3_D7OB3_U]6/_ *#/7Z 44444
M444444444444444444444444444444444444444444444444444444444444
M44444444444444444444444444444454U'4+;2;"YOKRXCM+.VB::>>9@J1Q
MJ"S,Q/   ))/85^-'[8W[3%U^T9\2'DLY)(O"&DLUOI-LV1O&?FN&4_Q/@'!
M^ZH5>N2? :*********['X1_"O7/C/\ $#2?"7A^'S+Z^DPTK [+>,<O,Y'1
M57)/<\ 9) /[=?"'X5Z)\%?A_I/A+P_#Y=C8QX:9@/,N93R\SD=69LD]@, 8
M  ':T4444444444444444444444444444444444444444444444444444444
M44444444444444445_./^VM\5O\ A<_[4?Q#\313>=8-J3V5BZG*FVMP((F'
MH&6,-]6->'T444444444444444444445UGPM^&VN_&#X@Z#X-\-6GVS6]8NE
MMK>/D*,\L[$=$50S,>RJ3VK^C#]G?X&Z%^SE\)-"\"^'TW6]A%NN;LJ%>\N6
MYEG?W9N@R=JA5'"BO3******************************************
M*********************************************************^5O
MV]]>^,GPR^'*?$KX1:^8?^$?5FUW0)[**ZANK/.3.H9"RM$<EMC+E"Q)^09^
M'O!7_!;+XA:;L7Q5X \.Z\JX!?3+B:P=AZDL9AGZ*![5[;X7_P""V?PWOE0>
M(? 'BC27/WO[.EM[U5/U9XB1^'X5Z?H?_!6[]G75L?:M=UK1L]K[1IFQ_P!^
M@]=GI_\ P4J_9LU)5,7Q1LTS_P _&G7L)_'? ,5K)_P4#_9W=<CXKZ&/J90?
MR*5#<_\ !0[]G2U'S_%71V_ZY1SR?^@QFN8U?_@J9^S7I6X)X^EU"1>J6>C7
MS?DS0JI_.N \1?\ !9/X%Z.C#3M.\7:[+_#]FT^*)"?<RS*0/HI^E>2>*_\
M@N%:HLD?AKX42RL?N7&K:R$ ^L<<39_[[%>#^.O^"P?QX\4K)'HW_".^#HCD
M*^FZ;Y\H'NUPTBD^X4?2OF3XD?M(?%+XO>:OC#Q]K^O6\IRUG<W[BU'T@4B,
M?@HKS:BBBBBBBBBBBBBBBBBBBBBBBBBBM+PYK][X5\0Z7K>FS?9]1TVZBO+:
M4=4EC<.C?@R@U_3;\,_'5E\3OAWX9\7:<0+'7-.M]1A7.=JRQJ^T^XS@^A!K
MJ:**********************************************************
M*********************************************Q?&G_(FZ]_UX7'_
M *+:OY^:********]&_9N_Y.(^&'_8T:9_Z51U^[5%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%?AQ^UI_R<M\2O\ L.7/_H1KR:BBBBBBBBOW
MO^#/_)'_  -_V K'_P!)TKL:************************************
M************************************************************
M*********_&__@HA_P G:^,?^N-C_P"D<-?-]%%%%%%%?;O_  2C_P"2R>+_
M /L G_THAK]0Z*******Y+XG_#+0/B]X)U+PMXELQ>:9>I@XX>)Q]V6-OX74
M\@_@<@D'\6OVAO@%K_[/'Q N?#NLHT]H^Z;3M312([RWS@,OHPZ,N<J?4%2?
M,:**********^W/V!?VR/^%>W]K\.?&M[CPO=2[-+U&=^-/E8_ZMR>D3,>O1
M&.3\K$K^H8.:6BBBBBBBBBBBBBBBBBBBBBOY\O%'_(S:O_U]S?\ H;5F4444
M4445^D'_  24_P"1>^)/_7U8_P#H,]?H!111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111117YS_ /!2#]JGSY)OA)X7O/W4;!O$%W"WWF&&6U!'8<,^.^U>S"OS
MWHHHHHHHHHI\,$MU/'##&TLTC!4C12S,Q.  !R23VK]A/V'_ -EZ/]G_ .'P
MU/6+=?\ A-M<C62_8@%K2+[R6RGMC@MCJW'(537TS1111111111111111111
M111111111111111111111111111111111111111111111111111117DW[5WQ
M0/P9_9Q^(?C".;R+O3])F%G)G&+J4"*#_P BR)7\V!.:****************
M******_9/_@DC^R7_P *]\"R?%[Q+9;/$7B2#RM&BF7YK73R0?- /1IB 0?^
M>:J0<.17Z*T4444444444444444444444444444444444444444444444444
M44444444444444444444444444444444444444444444444445!<6\5W#)#-
M$DT,BE'CD4,KJ1@J0>""."#7X#_\%#/V39/V7OC5/_9-JZ>!?$)DOM%DP2L'
M(\VT)]8RPQG)*,A))SCY6HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK]
MQ/\ @D+\5&\=?LLCPW<S>9?>$=3FL I.6^S2GSXF/MN>51[1XK[DHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK%\:?\B;KW_7A<?\ HMJ_GYHH
MHHHHHHKT;]F[_DXCX8?]C1IG_I5'7[M44444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444445^''[6G_)RWQ*_P"PY<_^A&O)J********_>_X,_\D?\
M W_8"L?_ $G2NQHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK
M\;_^"B'_ "=KXQ_ZXV/_ *1PU\WT4444445]N_\ !*/_ )+)XO\ ^P"?_2B&
MOU#HHHHHHHHKR[]H3X":!^T/\/[GPYK2>1=+F73M21 9;.?& Z^JGHRYPP]"
M 1^+7Q0^&>O_  ?\;ZEX5\26AM-4LGVG&3',AY65&_B5AR#^! (('*T44444
M44445^DO_!/S]L?^WX;'X6^-[[_B90J(M"U.X?\ X^$ PMJ['^-1PA/W@-O4
M#=]]T444444444444444444445_/EXH_Y&75O^ON7_T-JS********_2#_@D
MI_R+WQ)_Z^K'_P!!GK] ****************************************
M*******************************************************^<_VT
MOVGK?]GCX=M#ILT;^--95H=,@.&,"]&N6']U,_*#]YB!@@-C\<+N[GU"[FNK
MF:2XN9W:66:5BSNS'+,S'DDDDDFHJ*********^^/^"</[*O]M7T/Q8\46>=
M/M)"-!M9EXFF4X:Z(/\ "A!5?5@6XV*3^E%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?G7_ ,%H_BA_
MPCOP1\)^!X)=ESXCU4W<Z@_>MK502I'H9982/]PU^-=%%%%%%%%%%%%%%%%%
M%%%%?2/[!G[+\W[47QVT[2;N"0^$=(VZCKTZY -NK?+ &'1I6 4<@A=[#[M?
MT'VEK#86L-M;Q)!;0HL<<4:A510,*H X     JQ111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111117BW[7'[.6F?M1?!/6O!MX(X=3Q]KTB^D'_'I>H#Y;
M$_W6RR-C^%VQS@C^=3Q/X:U/P;XBU/0=9LY-/U?3;B2TN[288>&5&*LI]P01
M671111111111111111111111111111111111117Z"?\ !&7XH?\ "+?M":_X
M+N)MEKXJTDM#'G[]U:DR(,?]<FN3^%?M)111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111116+XT_P"1-U[_ *\+C_T6U?S\T44444445Z-^S=_R<1\,
M/^QHTS_TJCK]VJ**********************************************
M**********************************************************_#
MC]K3_DY;XE?]ARY_]"->3444444445^]_P &?^2/^!O^P%8_^DZ5V-%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?C?\ \%$/^3M?&/\ UQL?
M_2.&OF^BBBBBBBOMW_@E'_R63Q?_ -@$_P#I1#7ZAT444444445X!^UU^RSI
M?[27@@B!8K'QEIJ,VE:BPP#W,$I')C8]^JGYA_$&_&_Q'X<U/PCKU_HNLV4V
MG:K83-;W-K.NUXW4X*G_ !'!&".*SJ*********?;W$MI/'/!*\,T;!TDC8J
MRD'(8$<@@\@BOUE_89_;"B^.&@IX2\4W21^.]-AXE<A?[4@4?ZU?^FBC[ZCK
M]X<;@OUQ111111111111111111117\^/BC_D9-6_Z^Y?_0VK-HHHHHHHK](/
M^"2G_(O?$G_KZL?_ $&>OT HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKD?B
ME\2M$^$/@35O%GB"X^SZ;I\1<JN-\SGA(D!ZLS84#U.3@ FOQ&^-7Q?UOXY?
M$75/%VO2?Z3=-MAME)*6L"YV0I_LJ#U[DLQY8UPU%%%%%%%%%>Y?LB_LVWG[
M1WQ,BL)ED@\+::5N=8O$R,1Y^6%&[/(00/0!FYVX/[0:/I%EX?TFSTS3;6.R
MT^SB6WM[:%0J11J JJH'0  "KU%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?AS_P5\^)'_"9?M7OH$4N
MZU\*Z3;6!0'*^=(#<.WUVS1J?]S':OAVBBBBBBBBBBBBBBBBBBBBIH+>2ZGC
MAAC:660A4C1268DX  '))/:OZ#OV!_V8XOV8/@'IFE7MNB>+=8"ZEKLN/F$[
M+\D&?[L2$+C.-V]A]ZOI2BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBOR?\ ^"PW[*JV5Y9_&[P[9XAN&CL/$D<*\+)@+!='_> $3'U$7<DU^6]%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>E_LU_$IO@_\ 'SP#XQ,IAM])
MUBWFNF'>W+A)Q^,3./QK^EM6# $'((R/>G44444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444444444445B^-/^1-U[_KPN/_ $6U?S\T44444445Z-^S=_R<1\,/
M^QHTS_TJCK]VJ***********************************************
M*********************************************************_#C
M]K3_ ).6^)7_ &'+G_T(UY-111111117Z9^ /^"FOPN\*^ _#FBW>@^+GNM-
MTVVLYGAL[4QL\<2HQ4FY!()!QD X["N@_P"'JOPF_P"A>\9_^ 5I_P#)5'_#
MU7X3?]"]XS_\ K3_ .2J/^'JOPF_Z%[QG_X!6G_R51_P]5^$W_0O>,__  "M
M/_DJC_AZK\)O^A>\9_\ @%:?_)5'_#U7X3?]"]XS_P# *T_^2J/^'JOPF_Z%
M[QG_ . 5I_\ )5'_  ]5^$W_ $+WC/\ \ K3_P"2J/\ AZK\)O\ H7O&?_@%
M:?\ R51_P]5^$W_0O>,__ *T_P#DJC_AZK\)O^A>\9_^ 5I_\E4?\/5?A-_T
M+WC/_P  K3_Y*H_X>J_";_H7O&?_ (!6G_R51_P]5^$W_0O>,_\ P"M/_DJC
M_AZK\)O^A>\9_P#@%:?_ "51_P /5?A-_P!"]XS_ / *T_\ DJC_ (>J_";_
M *%[QG_X!6G_ ,E4?\/5?A-_T+WC/_P"M/\ Y*H_X>J_";_H7O&?_@%:?_)5
M'_#U7X3?]"]XS_\  *T_^2J/^'JOPF_Z%[QG_P" 5I_\E4?\/5?A-_T+WC/_
M , K3_Y*H_X>J_";_H7O&?\ X!6G_P E4?\ #U7X3?\ 0O>,_P#P"M/_ )*H
M_P"'JOPF_P"A>\9_^ 5I_P#)5'_#U7X3?]"]XS_\ K3_ .2J/^'JOPF_Z%[Q
MG_X!6G_R57MG[//[3GA;]I:PUJ\\,:?J]C%I,L<4XU>&*-F,@8KM\N1\C"G.
M<=NM>PT44444444444444444444444444444444444444444444444444444
M444444444444444444444445^-__  40_P"3M?&/_7&Q_P#2.&OF^BBBBBBB
MOMW_ ()1_P#)9/%__8!/_I1#7ZAT4444444445\C?MT?L?1_&W09/%_A6T5/
M'>FP_-#& /[4@4?ZIO\ IJH^XW?[IXVE?R;G@EM9Y(9HVAFC8H\<BE64@X*D
M'D$'C%,HHHHHHHHHK2\->)-3\'Z_8:WHM[+IVJV$RSVUU V'C=3D$>ON#P1D
M'(-?LA^R/^U+I?[27@<-,8K'QCIJ*NJZ<IP">@GB!Y,;'MU4_*?X2WOU%%%%
M%%%%%%%%%%%%%%%?SX^*/^1DU;_K[E_]#:LVBBBBBBBOT@_X)*?\B]\2?^OJ
MQ_\ 09Z_0"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBHY)4AC9W9410268X
MZDFOR%_;J_:F;X\^._["T*Z9O ^ARLMJ4.%O;@95[DCNO54ST7+<%B!\NT44
M4444445O>!/ ^L_$GQAI7AC0+1KW5]3G6""(=,GDLQ_A55!8MT"J2>E?MK^S
MW\#M'_9]^&>G>%M*"S3K^^O[_9M:[N6 WR'T'  '95 Y.2?3:***********
M************************************************************
M**AGFCMXGED<)&@+,[' 4 9))[#%?S,?'3XA/\6/C+XV\8NS,-;UBZO8@W5(
MGE8QI]%3:H]A7"444444444444444444445]W_\ !)K]F%?B]\9I/'^MV?G>
M&/!;I/"LBY2XU(\PKSU$8!E..C"+/#5^W-%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%<_X[\%:/\2/!NM>%O$%HM]HNKVLEG=P-_%&ZE3@]F&<
MAAR" 1R*_G"_:(^"6K?L[_&/Q+X#U@,\FEW!%M=%=HN[9OFAF7M\R%20,[6W
M+U4UYI1111111111111111111111111111111111117]'_[&?Q*/Q<_9;^&W
MB9Y?.NI](BM;J0G):X@S!,Q]R\3'\:]IHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHK%\:?\B;KW_7A<?^BVK^?FBBBBBBBBO1OV;O\ DXCX8?\
M8T:9_P"E4=?NU11111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111111111111111111111117X<
M?M9?\G+_ !*_[#ES_P"A&O)J************************************
M_27_ ()+?\BK\1?^OVS_ /0):^^Z********************************
M*********************************************_&__@HA_P G:^,?
M^N-C_P"D<-?-]%%%%%%%?;O_  2C_P"2R>+_ /L G_THAK]0Z***********
M^ O^"@?[&W]N0WWQ2\$6/_$QB!FUW2[=?^/A0/FND4?Q@<N!]X#=]X'=^;E%
M%%%%%%%%%=7\+?B?K_P=\<:;XJ\-79M-3LGS@Y*31G[T4B_Q(PX(^A!! (_:
M7]GWX]:!^T-\/K7Q)HC^1<#$6H:<[ R6<X&61O53U5L88>A! ]0HHHHHHHHH
MHHHHHHHHHK^?'Q-_R,FK?]?<O_H;5FT4444445^D'_!)3_D7OB3_ -?5C_Z#
M/7Z 44444444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444444445\'_ /!1K]JG_A%=(F^%?A>\
MVZQJ$0.MW,+<VUNPR+<$='D!RWHA YW\?F?11111111117ZO_P#!/W]E;_A4
M7@\>-?$EGL\8:Y"#%#,N'T^T;#*F#RLC\,W<#:O!#9^P:***************
M***********************************************************\
M2_;4^(7_  J[]E3XG>(%D\FXCT6:TMY <%9[C%O$P]P\RG\*_G$HHHHHHHHH
MHHHHHHHHHHHK0T/0[_Q+K>GZ/IEK)>ZGJ%Q':6MM$,O-+(P5$4=R68 ?6OZ.
MOV5/@'8?LU_ WPWX'M!')=VT7GZG=QC_ (^;V0!II,]2-WRKGD*BCM7KU%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?GW_P %<_V8U^)7PF@^
M*&B6F[Q'X/C*WPC3+W&FLV7SZ^2Q,@[!6E/I7XMT44444444444444444444
M4444444444444445^S/_  1:^(G]O? ?Q9X0EEWW'A[61<1KG[MO=1@J,?\
M72&8_P# J_0^BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL7QI_R
M)NO?]>%Q_P"BVK^?FBBBBBBBBO1OV;O^3B/AA_V-&F?^E4=?NU1111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111117X<?M9?\G+_$K_ +#ES_Z$:\FH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK])?^"2W_ "*OQ%_Z_;/_ - E
MK[[HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHK\;_ /@HA_R=KXQ_ZXV/_I'#7S?11111117V[_P2
MC_Y+)XO_ .P"?_2B&OU#HHHHHHHHHHHI"-U?EW^WU^QN?AUJ%U\1O!=CCPM=
MR;M3T^!/ETZ9C_K%4=(F8].BL<?=90OQ)11111111117I_[._P ?M>_9W^(-
MMXBT=FN+*3;#J6F,VV.\@SRI]&')5L94^H+ _M+\,OB5H/Q<\$Z9XI\-W8O=
M*OH]RG&'B8<-&Z_PLIR"/;C(()ZRBBBBBBBBBBBBBBBBBOY\?$W_ ",FJ_\
M7W+_ .AM6;11111117Z0?\$E/^1>^)/_ %]6/_H,]?H!1111111111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111117B?[5W[1EA^SC\,I]58QW'B*^W6VCV+G/FS8YD8=?+0$,
MWKE5R"P-?BSKVNZAXGUJ^U?5;N2_U.^G>XN;F9MSRR,Q9F)]22:HT4444444
M45]F_P#!//\ 96_X6;XH3XA>)K/=X5T6<?8;>9?DO[M3D'!ZQQG!/9FVCD!A
M7ZIT44444444444444444444444444444444444444444444444444444444
M4444444444444444445^?/\ P6?^('_"/_L\>&_"L,FR?Q%KBO(N?O6]O&SL
M/^_CP'\*_%VBBBBBBBBBBBBBBBBBBBBOT-_X(_\ [-__  GWQ6U#XI:O:[]$
M\)'R-/WKE)M1D7J.Q\J,ECZ-)$1TK]FZ****************************
M************************************************************
M*****************J:CI]MJ^GW5A>V\=W9W430S03*&22-@596!X(()!'H:
M_G2_;*_9YN?V9?C]XB\'!9#HQ<7VC3R9/G64I)CY/WBI#1L>[1L:\/HHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK[Z_P""-/Q"/AO]I?6/#,LNVV\2:'*J
M1_WKB!EE0_A'Y_YU^UU%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%8OC3_D3=>_Z\+C_ -%M7\_-%%%%%%%%>C?LW?\ )Q'PP_[&C3/_ $JCK]VJ
M************************************************************
M********************************************_#C]K+_DY?XE?]AR
MY_\ 0C7DU%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?I+_P $EO\ D5?B
M+_U^V?\ Z!+7WW1111111111111111111111111111111111111111111111
M11111111111111111111111111111117XW_\%$/^3M?&/_7&Q_\ 2.&OF^BB
MBBBBBOMW_@E'_P ED\7_ /8!/_I1#7ZAT4444444444453U+3[;5]/NK&]MH
M[NRN8FAFMYT#I*C JRLIX(()!!Z@U^0W[:W[(]U^SWXJ.LZ'#+<> M5F/V64
MY8V,IR3;.W7& 2K'[R@@Y*DGYDHHHHHHHHHHKW_]D']JC4OV;_&VVZ::]\&:
MFZKJFGJ<E#T%Q$#P'4=1_$HVGD*5_8[P_P"(-.\6:'8ZQI%W%J&F7T2SVUU
MVY)8V&0P/^<5IT4444444444444445_/CXF_Y&35?^ON7_T-JS:*******_2
M#_@DI_R+WQ)_Z^K'_P!!GK] ************************************
M*******************************************************P?&GC
M#2?A_P"%=5\1Z[>)8:1IL#7%Q._\*CL!W8G "CDD@#DU^)O[1OQXU;]H;XF7
M_B;4/,M[)<P:;IY;*VEL"=J^A8Y+,W<L>V /+Z*********]2_9O^ NK?M#_
M !,L?#=B)+?3D(N-3U!5RMI; C+<\%F^ZJ]R1V!(_;+P=X1TKP'X7TSP[H=F
MEAI&FP+;V]O'T50.I/4DG))/)))/)K<HHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\:_\ @M5X[_MC
MXY^"_"<<F^'0]#-TZ@\)-<S-N7'KL@A/T85^==%%%%%%%%%%%%%%%%%%%7-)
MTN[US5+/3=/MWO+^\F2WM[>)=SRR.P54 [DD@ >IK^C_ /95^!-G^SC\!_"W
M@> 1M>6=L)M1N(^D][)\T[Y[C<2JYZ*JCM7KM%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%?"O\ P5F_9O'Q9^! \=:3:^;XD\$[[I]BY:;3
MVQ]H4XZ[,+*">@23'+5^(-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>R_
ML<>/C\,?VI?ACXA:3R8(=<M[>XD_N03GR)C^$<KU_2'11111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111116+XT_Y$W7O^O"X_]%M7\_-%%%%%%%%>C?LW
M?\G$?##_ +&C3/\ TJCK]VJ*************************************
M************************************************************
M*******_#C]K+_DY?XE?]ARY_P#0C7DU%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%?I+_ ,$EO^15^(O_ %^V?_H$M??=%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?C?_P %
M$/\ D[7QC_UQL?\ TCAKYOHHHHHHHK[=_P""4?\ R63Q?_V 3_Z40U^H=%%%
M%%%%%%%%%%8'C3P;HWQ$\+ZGX<\06$6I:/J$)AN+:4<,#R"#U!! (8<@@$8(
MK\9/VI/V:]9_9M\?/IESYE[X>OBTVDZH5XGC!Y1L<"1,@,/<,.&%>,T44444
M44445]=?L*?MAO\ !77(O!OBN[9_ NHS?NIY"3_94['[X](F)^9>Q^8?Q!OU
M@AF2XB26-UDBD 974@A@1D$'N"*FHHHHHHHHHHHHHHHK^?'Q-_R,FJ_]?<O_
M *&U9M%%%%%%%?I!_P $E/\ D7OB3_U]6/\ Z#/7Z 444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444445^4__!0C]JK_ (6EXJ;P#X9NP_A+19S]KN(6RNH7:Y!((^]'
M'RJ]F;<W("D?&]%%%%%%%%%7_#^@ZCXJURPT?2;22_U.^F2WMK:%<M)(S!54
M?4FOVG_95_9UT_\ 9Q^&=OHZ".X\0WNVYUB_C'^NGQPBGKY: E5'?YFP"QKV
MJBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBOYXO^"A7C@^/OVROB??!]T5GJ?]E1@'(7[+&MNP'_ H
MF/U)KYTHHHHHHHHHHHHHHHHHHHK[M_X)'_L^_P#"T/C]+XXU*W\W0O!,:W<9
M=<K)J$F5@7GKL >7(Y#(GK7[=T4444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444444455OK&WU2RN+.[ACN;6XC:&:&0!ED1@0RL#P002"/>OYR?VP/
M@'<?LV_M >*/!923^RHIOM>DS29/FV,N6A.3]XJ,HQ_O1M7B]%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%2PS/;R)+$Q21"&5P<$$'((/K7].OPE\9K\1OA
M=X/\5H5*ZYI%IJ/R] 984<CVP6(Q77444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444445B^-/^1-U[_KPN/\ T6U?S\T44444445Z-^S=_P G$?##_L:-
M,_\ 2J.OW:HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\./VL
M_P#DY;XE?]ARY_\ 0C7DU%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?I+
M_P $EO\ D5?B+_U^V?\ Z!+7WW1111111111111111111111111111111111
M11111111111111111111111111111111111111111117XW_\%$/^3M?&/_7&
MQ_\ 2.&OF^BBBBBBBOMW_@E'_P ED\7_ /8!/_I1#7ZAT44444444444445P
M?QH^#WA[XZ> K_PIXCM]]M<#=!<HH\VTF .V:,GHRY/L02#D$BOQ7^-GP8\0
M_ ?Q]?>%?$4&)X3YEM=HI\J\@).V9">JG!R.JL&4\@UP=%%%%%%%%%%?H!_P
M3[_;(_LN6P^%GC>^_P!#<B'0=3N&_P!2Q.%M78_PGHA/W3\O0J%_2"BBBBBB
MBBBBBBBBBOY\?$W_ ",FJ_\ 7W+_ .AM6;11111117Z0?\$E/^1>^)/_ %]6
M/_H,]?H!1111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111117QS_P %!?VJ?^%3>$V\"^&K
MS9XOUN$BYGA;YM/M&R"V1TD?E5[A=S<':3^4M%%%%%%%%%%?II_P3E_97_X1
M+1HOBEXHM-FM:E"1HMM,OS6MLPP9R#T>0'"^B'_;('W91111111111111111
M111111111111111111111111111111111111111111111111111111111111
M5/5-2M]%TN\U"[D\JUM87GF<_P **I9C^ !K^7KQ=XBN/&'BK6M>NO\ CZU2
M]FOIN<_/([.W/U8UD44444444444444444445_0Q_P $_P#X!K^SW^S+X8T>
MZMOL_B#5D_MK6-RX87$ZJ1&WH8XQ'&1TRA/>OI"BBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBOSO\ ^"Q7[/G_  G'PATGXH:9;[]6\)2?
M9K\JOS2:?,P&3W/ERE2!V$LA/2OQGHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHK]^_^"8'C@^-OV+_  .))/,NM'-UI,WMY4[F,?A$T5?5M%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%8OC3_D3=>_Z\+C_P!%M7\_-%%%%%%%
M%>C?LW?\G$?##_L:-,_]*HZ_=JBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBOPX_:S_P"3EOB5_P!ARY_]#->3444444444444444444444444
M4444444444445^DO_!);_D5?B+_U^V?_ *!+7WW111111111111111111111
M111111111111111111111111111111111111111111111111111111117XW_
M /!1#_D[7QC_ -<;'_TCAKYOHHHHHHHK[=_X)1_\ED\7_P#8!/\ Z40U^H=%
M%%%%%%%%%%%%%%>,_M/?LWZ+^TAX DTB\\NRURT#2Z5JA3+6\I'*MCDQM@!E
M]@1RHK\8O'7@?6OAMXLU/PUXAL9-.UC3YC#/ _8]0RGHRL"&5AP001UK"HHH
MHHHHHHH!(((.".AK]1_V!_VQQ\3-/M_A[XSO0?%MG%C3K^=_FU*%1]UB>LR
M<GJP&>2K$_;-%%%%%%%%%%%%%%?SX>)?^1BU7_KZE_\ 0S6=11111117Z0?\
M$E/^1>^)/_7U8_\ H,]?H!11111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111117E_P"T3\==
M(_9[^&>H>*-3*SW?^HTZPW8:[N6!VH/11@LS=E4]3@'\2O&_C35_B+XMU7Q+
MK]VU]J^I3M/<3-W8]%4?PJH 55' 4 #@5B4444444445]1_L)_LM-\=O'7]O
MZ]:[O ^A3*UR''RWUP,,MN/5>C/_ +)"\;@1^O*1K#&J(H5%  51@ #H *DH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHKQ#]MCQ@? O[)OQ6U=9/*E&@7-I%)G!62X7R$(]PTHQ[U
M_.-11111111111111111117TE_P3Z^ X^/W[4/A;2;NW^T:#I+_VWJP9<J;>
M!E*H1W#RF*,CT<GM7]"U%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%8GC+PGIOCWPGK7AO6+?[5I.KV<MA=PG^.*1"CCV."<'L:_FG^,_
MPOU+X*_%;Q3X'U8$WVAW\EHTA7:)D!S'*!_=="CCV85Q5%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%?L#_P1)\9_;OA1\1?"I?+:9K4&HA2>0MS#LX]LVI_
M$^]?I/111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111116+XT_Y$W7O^O"
MX_\ 1;5_/S111111117HW[-W_)Q'PP_[&C3/_2J.OW:HHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHK\./VL_\ DY;XE?\ 8<N?_0S7DU%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?I+_P26_Y%7XB_]?MG_P"@2U]]T444
M444444444444444444444444444444444444444444444444444444444444
M44444444444445^-_P#P40_Y.U\8_P#7&Q_](X:^;Z*******^W?^"4?_)9/
M%_\ V 3_ .E$-?J'11111111111111117S-^VA^R5:?M$>$_[4T>**U\=Z5$
MWV.<X47D8R3;2-Z$Y*L?NDGH&:OR!U+3+O1=2NM/O[:6ROK65H9[:=2CQ2*2
MK*RGD$$$$&JU%%%%%%%%%6=,U.[T74K74+"YEL[ZTE6:"X@8H\4BD,K*PY!!
M ((]*_7[]BW]K6T_:&\)C2M8EBM_'FE1#[;;C""\C& +F-?<D!E'W6/8,M?3
M-%%%%%%%%%%%%%?SX>)?^1BU7_K[E_\ 0S6=11111117Z0?\$E/^1>^)/_7U
M8_\ H,]?H!11111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111116?KFM6/AO1[W5=3NH['3;*%
M[BYN9FVI%&H+,S'T !-?BY^UI^T=?_M'_$R?4@9+?PSIY:VT>Q?C9%GYI6'3
M>Y 9O0!5R0H->)4444444445W/P5^$.M_'+XC:5X1T),7%TV^>Y92R6D"D;Y
MGQ_"H/3C+%5'+"OVY^%WPUT3X1^!=(\)^'X/(TW3HA&I(&Z5SR\CD=79B6)]
M3Q@8%==11111111111111111111111111111111111111111111111111111
M1111111111111111111111117Q)_P5\\7?\ "-_L>W6FA]K:_K=EIY4'DJK-
M<G\,VX_2OPRHHHHHHHHHHHHHHHHHHHK]G_\ @CC\#_\ A"_@CK'Q$O[;9J7B
MZ[\JT9EY6RMRR C/(WRF8GL0B'TK]":*****************************
M************************************************************
M*********************_(W_@M%\"?[)\6>%?BSI]OMM]6C_L7571>!<1J7
M@=CW9X@Z_2!?6OS)HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK]#_\ @BKX
MO.E_M >,/#KOMAU;P\;A1G[TL$\>T?\ ?,TI_ U^S-%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%8OC3_ )$W7O\ KPN/_1;5_/S111111117HW[-
MW_)Q'PP_[&C3/_2J.OW:HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHK\./VL_^3EOB5_V'+G_T,UY-11111111111111111111111111111111
M11117Z2_\$EO^15^(O\ U^V?_H$M??=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?C?_ ,%$/^3M
M?&/_ %QL?_2.&OF^BBBBBBBOMW_@E'_R63Q?_P!@$_\ I1#7ZAT444444444
M44444445\4?M[_L<#XFZ;<_$+P99?\5;91;M0L(%YU*%1]Y0.LR*..[*-O)"
M@_EL<J2&!!'!!HHHHHHHHHHK=\#>.-:^&_BS3/$OAZ^DT[6-/F$T$\?8]"K#
MHRL"593P02#P:_9W]F#]I'1?VD? ,>K6?EV>O686+5M+#Y:WE(^\N>3&V"5;
MV(/*FO9J************_GP\2?\ (Q:I_P!?4O\ Z&:SJ*******_2#_ ()*
M?\B]\2?^OJQ_]!GK] ******************************************
M**********************************************_-#_@HY^U5_P )
M)JDWPI\+WF=+L90==NH6XGN%.5M@1U5" 6]7 '&PY^#J*********EL[.?4;
MN"TM89+FZG=8HH8E+N[L<*JJ.222  .I-?LA^Q;^S#!^SO\ #E9-2BCD\9ZR
MB3ZI.,,8!C*VRG^ZF3DC[S$G) 7'T7111111111111111111111111111111
M1111111111111111111111111111111111111111111111117Y>?\%P?%'D^
M&_A3X<23(N;N_P!0E0'IY20HA/U\Y\?0U^35%%%%%%%%%%%%%%%%%%;_ (%\
M'ZC\0_&F@^%](B\W5-9OH=/M4[&25PBY]!E@2>PR:_IC^'/@;3OACX!\.^$=
M(39INAV$.GV^1@E8D"!F_P!HXR3W))KIJ***************************
M************************************************************
M***********************\7_; ^":_M!?LY^-?!J1"74[BS:YTSCD7D)\R
M$ ]MS*$)]';UK^<*2-H9&1U*NIP588((Z@BF444444444444444444444444
M4444444445]3_P#!,?Q9_P (I^VM\/F=]EOJ#76G2_[7FVLH0?\ ?P1_E7]
M-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%8OC3_D3=>_Z\+C_P!%
MM7\_-%%%%%%%%>C?LW?\G$?##_L:-,_]*HZ_=JBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBOPX_:R_P"3EOB7_P!ARY_]#->3444444445]W>
M#O\ @EI=>+/".AZZ/B1#:C4[&"]$!T5G,8EC5]F[SQNQNQG SCI6Q_PZ1O/^
MBGP?^"-O_DBC_ATC>?\ 13X/_!&W_P D4?\ #I&\_P"BGP?^"-O_ )(H_P"'
M2-Y_T4^#_P $;?\ R11_PZ1O/^BGP?\ @C;_ .2*/^'2-Y_T4^#_ ,$;?_)%
M'_#I&\_Z*?!_X(V_^2*/^'2-Y_T4^#_P1M_\D4?\.D;S_HI\'_@C;_Y(H_X=
M(WG_ $4^#_P1M_\ )%'_  Z1O/\ HI\'_@C;_P"2*/\ ATC>?]%/@_\ !&W_
M ,D4?\.D;S_HI\'_ ((V_P#DBC_ATC>?]%/@_P#!&W_R11_PZ1O/^BGP?^"-
MO_DBC_ATC>?]%/@_\$;?_)%'_#I&\_Z*?!_X(V_^2*/^'2-Y_P!%/@_\$;?_
M "11_P .D;S_ **?!_X(V_\ DBC_ (=(WG_13X/_  1M_P#)%'_#I&\_Z*?!
M_P""-O\ Y(H_X=(WG_13X/\ P1M_\D4?\.D;S_HI\'_@C;_Y(H_X=(WG_13X
M/_!&W_R11_PZ1O/^BGP?^"-O_DBC_ATC>?\ 13X/_!&W_P D4?\ #I&\_P"B
MGP?^"-O_ )(KZ6_9%_97E_9>TGQ'9R^)4\1G5YH9@Z61M_*\M67&#(^<[O;&
M*^A*********************************************************
M*********************_&__@HA_P G:^,?^N-C_P"D<-?-]%%%%%%%?;O_
M  2C_P"2R>+_ /L G_THAK]0Z******************_.'_@H)^QO_9TE_\
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M4444444444444444444444444444444444444444444444444444445^+_\
MP6G\4?VE^T9X3T1&W1:7X;CE8?W9)KB8L/\ OE(S^-?GO111111111111111
M1117W?\ \$?_ (.CQ]^TC=^,+N#S--\&6#7*,1E?MDX:*$$=.$\]@>Q137[<
MT44444444444444444444444444444444444444444444444444444444444
M44444444444444444444444444444444444444444444444444445_/G_P %
M&O@Q_P *5_:O\76EM;^1H^NN->T\!<+Y=P6,BJ.@"S"90!T"BOF.BBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBO1?V=/$W_"&?'[X;:Z7\M-/\1Z?<R-G'R+<
MH6!]BN0?8U_3'11111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111111111111111111116+XT_Y
M$W7O^O"X_P#1;5_/S111111117HW[-W_ "<1\,/^QHTS_P!*HZ_=JBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOPW_:Q_Y.6^)7_8=N?_ $,U
MY/111111117[W_!G_DC_ (&_[ 5C_P"DZ5V-%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%?C?_P %$/\ D[7QC_UQL?\ TCAKYOHHHHHHHK[=
M_P""4?\ R63Q?_V 3_Z40U^H=%%%%%%%%%%%%%%%%%%0S0QW$;Q2JLD;@JR,
M 001@@@]0:_*']NO]CM_@OK4OC3PE:,_@;4)OWUO&"?[*F8_</I$Q/RM_"?E
M/\);Y#HHHHHHHHHHKV;]EO\ :6UG]FWQ]'J=MYE[X>O"L6K:4&P)XP>'7/ D
M7)(/U4G#&OV;\$^,]'^(?A73/$>@7T>HZ/J$(FM[B,\,#U!'4,I!4J>000>1
M6_11111111117\^/B/\ Y&'5/^OJ7_T(UFT4444445^D'_!)3_D7OB3_ -?5
MC_Z#/7Z 4444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444445POQE^+6B?!'X=ZIXNU^7%K9)B*
MW5@)+J8_<A3/5F/Y $G@$U^(WQ7^)VM_&+Q]JWBSQ!/YVHZA*7V*3L@C'"1(
M#T55 4=^,G)))Y*BBBBBBBBBO?OV-_V9;G]HOXCHE[')%X/TEEGU:Z7(WC.4
MMU;^\^#DC[JACUV@_LOINGVVDV%M8V=O':6=M$L,-O"H5(XU "JH'     '8
M5;HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHK\"?^"I7B(Z]^VUX[C5]\.GQ6-DA]-MI"S#\'=Z
M^3:******************_=7_@DS\'Q\-_V4['7;F'R]4\87DFJR%EPXMU/E
M0+_NE4,@_P"NQK[3HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHK\XO^"T/P='B/X2>%OB/9P;KSPW?&PO74<_9;C 5F/HLR(H]YC7X
MZ4444444444444444444444444444444445+#.]O-'+$Q22-@RL.H(.017]1
M7@WQ GBSPCH>MQ8\O4[&"]7'3$D:N,?]]5LT444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444445B^-/^1-U[_KPN/\ T6U?S\T44444445Z-^S=_P G$?##
M_L:-,_\ 2J.OW:HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\
M-_VL?^3EOB5_V';G_P!#->3T44444445^]_P9_Y(_P"!O^P%8_\ I.E=C111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111111117XW_\ !1#_ ).U\8_]
M<;'_ -(X:^;Z*******^W?\ @E'_ ,ED\7_]@$_^E$-?J'11111111111111
M111116;XA\/Z=XJT6^T?5K2*_P!,OH6M[FUG7*2QL,,I'TK\<_VP/V5=2_9O
M\:>9:"6]\%ZI(S:9?L,F,]3;RGH'4=#_ !*-PY#!?GVBBBBBBBBBBOIO]BG]
MKBZ_9\\4?V+KDLUSX"U68?:HAEC8RG %Q&OIC =1RP (R5 /Z\Z;J-MJVGVU
M]97$=W97,2RP3P,&21& *LK#@@@@@CL:N4444444445_/?XB_P"1AU3_ *^I
M?_0S6?11111117Z0?\$E/^1>^)/_ %]6/_H,]?H!11111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11115>ZNH=/M9KBXE2"WA1I))9&"JB@9+$G@  $DFOQU_;8_:?F_:%^(AM=*
MG=?!6BNT.FQ<J+A^CW+CU;&%!^ZH' +-GYQHHHHHHHHHKI?AQ\/=;^*OC;2O
M"WA^V-UJNI3"*)3D*@ZN['LJJ"Q/8 U^V_P)^#.B_ ?X;Z;X3T1-ZVX\R[O&
M7:]Y<$#?,WN2  ,G"A1VKT2BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOYO/VR/$'_"4?M6_%
MK4-V]#XFOH$;U2*9HE/TVH*\:HHHHHHHHHHHHHHHHHKH/ '@V_\ B+XX\/>%
M=+7=J.MZA!IUN",@22R*BD^P+ GV%?TW^#?"UCX'\(Z)X<TJ/R=-TBRAL+6/
M^[%$BH@_[Y45LT4444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444445Y_\??A?;_&KX+^,_ ]R%QK>F36T+OTCGV[H9/^ R*C?\!K^9^^LI]-
MO+BTNHF@N8)&BEB<8*.I(92.Q!!%5Z******************************
M***_I!_8SU[_ (2;]E'X27Q;>W_",V-NS>K10K$Q/ON0U[/1111111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111116+XT_Y$W7O^O"X_\ 1;5_/S111111117H
MW[-W_)Q'PP_[&C3/_2J.OW:HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHK\-_VL?\ DY;XE?\ 8=N?_0S7D]%%%%%%%%?O?\&?^2/^!O\ L!6/
M_I.E=C111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111111111111111117XW_\%$/^
M3M?&/_7&Q_\ 2.&OF^BBBBBBBOMW_@E'_P ED\7_ /8!/_I1#7ZAT4444444
M4444444444445R?Q,^&NA?%KP7J?A;Q)9B\TJ^CV.O1XV'*R(W\+J<$'U'.1
MD'\7/VBOV?\ 7OV=_B#<>']75KBQEW3:;J:IMCO(,\,/1EX#+G*GU!4GRZBB
MBBBBBBBBOMS]@7]LC_A7E_:_#GQK>X\+W<NS3-1G?C3Y6/\ JW)Z1,QZ]$8Y
M/RL2OZA@YI:********_GO\ $7_(PZI_U]2_^AFL^BBBBBBBOT@_X)*?\B]\
M2?\ KZL?_09Z_0"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOSY_X*0?M4_8;>;X3>%KS
M_2)E#>(+N%_N(0"MJ".[##/_ +.U>=S ?G+1111111110JEF"@$DG  ZDU^M
M_P"P3^RP/@GX)_X2CQ#:!/&NNPJSQR+\UA:G#+!SR';AG]PJ_P .3]8T4444
M444444444444444444444444444444444444444444444444444444444444
M44444444444444445_+KX^UO_A)?'7B/5]V[^T-2N;O=Z^9*S9_6L&BBBBBB
MBBBBBBBBBBBOM3_@DM\*_P#A8/[65AK-Q#YFG^$K"?57+#*F9@(85/N&E+C_
M *Y>U?NI1111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M117\^W_!2+X3CX1_M>>-K:"+RM-UR1=?L^, K<Y:7 [ 3B91CLH^E?,%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?OU_P $N]=_MS]B/X?AFW2V37UFY_W;
MV<J/^^&6OJZBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL7QI_R)NO
M?]>%Q_Z+:OY^:********]&_9N_Y.(^&'_8T:9_Z51U^[5%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?AO^UC_P G+?$K_L.W/_H9KR>BBBBB
MBBBOWO\ @S_R1_P-_P!@*Q_])TKL:*******************************
M************************************************************
M**************_&_P#X*(?\G:^,?^N-C_Z1PU\WT4444445]N_\$H_^2R>+
M_P#L G_THAK]0Z*********************\Q^/_ ,!] _:%^']UX:UQ/)G&
M9K#440-+93@?*Z^JGHRY 89'!P1^+7Q4^%_B#X-^.-2\*^);0VNI6;8W#)CG
MC/W98V[HPY!^H(!! Y*BBBBBBBBBBOTD_P""?G[9']O0V'PM\;WV-2B41:%J
MEP__ !\(!A;5V/\ &HX0G[P&WJ!N^_*********_GO\ $7_(PZI_U]2_^AFL
M^BBBBBBBOT@_X)*?\B]\2?\ KZL?_09Z_0"BBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO
M?VQ/VF+3]G/X:R3VKQS>+M5#V^D6K?-M8#YIW']U 0<?Q,57H21^,VIZE=ZU
MJ-U?W]Q)=WMU*TT]Q,Q=Y9&8LS,QY))))/O5:BBBBBBBBBOMW_@G5^RM_P )
MUK\7Q,\3V>[P]I4^-*MIE^6\NE/^M(/5(ST[%QC^%@?U#HHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHKG?B)K1\-_#_Q-JX.TZ?IEU=;O3RXF;/Z5_+S11111111111111111
M17[)?\$6_AC_ ,(_\$_%WCB>+9<^(M6%I"Q'WK>U3 8'T,LTP/\ N"OT6HHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\O?^"VGP
ML%QX=^'OQ'MHOGM+B;0KV0#)*R*9H,^@4QS_ (N*_)FBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBOV]_X(VZT=3_ &2KVU+9_L[Q->6V/0-#;R_SE-?==%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%8OC3_D3=>_Z\+C_ -%M7\_-
M%%%%%%%%>C?LW?\ )Q'PP_[&C3/_ $JCK]VJ************************
M************************************************************
M********************_#?]K'_DY;XE?]AVY_\ 0S7D]%%%%%%%%?O?\&?^
M2/\ @;_L!6/_ *3I78T44444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4445^-__  40_P"3M?&/_7&Q_P#2.&OF^BBBBBBBOMW_ ()1_P#)9/%__8!/
M_I1#7ZAT4444444444444444444445X)^UM^RYI?[2'@<Q1B*Q\7Z:C/I6I,
M, GJ8)2.3&Q_%3AAGD-^-GB;PUJG@WQ!J&AZU92Z=JMA,T%S:SKAXW4X(/KZ
M@C@@@C(-9M%%%%%%%%%/@GEM9XYH9&AFC8.DD;%64@Y# CD$'G-?K+^PQ^V!
M'\<-!3PCXINDC\=Z;%\LKD+_ &I H_UJ_P#351]]1U^\.-P7ZXHHHHHHHK^>
M_P 1?\C!J?\ U]2?^A&L^BBBBBBBOT@_X)*?\B]\2?\ KZL?_09Z_0"BBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBN9^(GC_ $7X6^"=7\4^(;H6FDZ;"9I7ZLQZ*BCNS,0H
M'<L!7XD?'KXU:U\>_B5J?BS66,?G'RK.R#;DL[=2=D2_0$DG W,S-@9KSRBB
MBBBBBBBO7_V7OV>]3_:,^)MIH,'F6VBVVVYU;4%7B" 'D*3QO8_*H]<G&%:O
MVJ\+^&]-\'^'M.T/1[..PTO3X%MK:VA&%C11@#U/N3R3DGDUKT4444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444445Y1^UAJG]B_LO_ !;O0=KQ^$]4V'T8VLBK^I%?S74444444444
M444444445_2)^Q[\-1\)/V8_AOX7:'R+FUT>&>ZC(P5N9QY\P_"25Q^%>R44
M444444444444444444444444444444444444444444444444444444444444
M44444444444444444444444444444444444444444444444444445\\?M_?#
M,?%;]D7XBZ5%%YM[9V!U>UXRPDM6$Y"^[*CI_P #-?SO4444444444444444
M444444444444444445^PG_!$?5/.^#_Q%T[=_P >^NQ7&WT\RW5<_P#D+]*_
M22BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL7QI_R)NO?]>%Q_P"B
MVK^?FBBBBBBBBO1OV;O^3B/AA_V-&F?^E4=?NU1111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111117X;_M8_P#)RWQ*_P"P[<_^AFO)Z********_>_
MX,_\D?\  W_8"L?_ $G2NQHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHK\;_^"B'_ "=KXQ_ZXV/_ *1PU\WT4444445]N_\ !*/_ )+)XO\
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MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\N?^"BG[5/\
MPGWB&3X:>&+S?X<TF;_B:7,+?+>7:G_5@CJD9_ N"?X%)^):*********LZ9
MIMWK.HVMA86TEY>W4JPP6\*EWED9@JJJCDDD@ >]?LU^Q[^S3:?LY?#6."Z2
M.;Q=J@6XU>[7!PV/E@0_W$R1G^)BQZ$ >^T4444444444444444444444444
M444444444444444444444444444444444444444444444444444444444445
M\)?\%E)"G[)6G@'AO%%FI_[\W)_I7XB444444444444444445_3-^SYX/_X5
M[\"?AYX:,?ER:5H%C:RC&,R+ @<GW+;B?<UZ%11111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111111117GW[07@T?$/X%_$+PSL\R35=!O;
M6(8R1(T#A&'N&VD>XK^9BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOO#_@C/
M(4_:RU4#HWA6\4_3[1:G^E?MQ11111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111116+XT_Y$W7O^O"X_]%M7\_-%%%%%%%%>C?LW?\G$?##_ +&C3/\ TJCK
M]VJ*********************************************************
M***********************************************_#?\ :Q_Y.6^)
M7_8=NO\ T,UY/111111117[W_!G_ )(_X&_[ 5C_ .DZ5V-%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?C?_ ,%$/^3M?&/_ %QL?_2.&OF^
MBBBBBBBOMW_@E'_R63Q?_P!@$_\ I1#7ZAT4444444444444444444444444
M45POQB^$/A_XX> ]0\*>)+;S;.Y&Z&= /-M9@#LFC8]&7)]B"0<@D'\6/CA\
M%?$/P%\?WWA;Q##^\C/F6EXBD17D!)VRH3V."".JD%3R*X"BBBBBBBBBBOT
M_P""??[9']ER6'PL\;WW^A2,L.@ZI<-_JF)PMH['^$GA"?NGY>A7;^D%%%?S
MW>(/^0]J7_7U+_Z$:H44444445^D'_!)3_D7OB3_ -?5C_Z#/7Z 44444444
M444444444444444444444444444444444444444444444444444444444444
M44444444445\E?M\?M4?\*4\%_\ "*>';O9XVUR!@LD1^?3[4Y5IO9VPRIW!
M!;^$9_)0Y8DL22>2311111111117Z-?\$W_V5_L5O#\6O%%G_I$P*^'[29?N
M(05:[(/=AE4S_#N;G<I'Z#44444444444444444444444444444444444444
M4444444444444444444444444444444444444444444444445\'?\%FN/V3=
M)'KXJLQ_Y+W5?B1111111111111111175_"7PH?'GQ2\'>&@GF?VQK-GIVWU
M\V=(\?\ CU?T^#"C &!2T444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444445_,5\9O"/\ P@'Q>\;^&0FQ=&UR]T]5QP!%.Z#'MA17
M&44444444444444444444444444444445]V?\$:V_P",M;_W\+WG_HZVK]O*
M************************************************************
M****************************************Q?&G_(FZ]_UX7'_HMJ_G
MYHHHHHHHHKT;]F[_ ).(^&'_ &-&F?\ I5'7[M4444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444444444444444445^&_[6/_)RWQ*_[#MU_P"AFO)Z********_>_X
M,_\ )'_ W_8"L?\ TG2NQHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHK\;_\ @HA_R=KXQ_ZXV/\ Z1PU\WT4444445]N_P#!*/\ Y+)XO_[
M)_\ 2B&OU#HHHHHHHHHHHHHHHHHHHHHHHHHHHHKQW]IK]G+0_P!I#X?S:-?!
M+/6[4-+I.J[<M:S$=#CDQM@!E[C!'S*I'XP>/? >M_#+Q=J?AGQ'8OI^KZ?*
M8IH7Z'NK*>C*P(96'!!!%8%%%%%%%%%% )!!!P1T-?J/^P/^V,/B5IMM\//&
M=Z/^$LLXL:=?SMSJ4*C[K$]95 Z]649Y*L3]LT5_/=X@_P"0]J7_ %]2_P#H
M1JA11111117Z0?\ !)3_ )%[XD_]?5C_ .@SU^@%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%><_
M'GXTZ+\ _AMJ7BS66$GD#R[.S#A7O+A@=D2_4Y).#M56.#BOQ(^(GQ UKXI>
M--6\4^(+HW>K:E,9I7Z*HZ*BC^%54!0.P4"N<HHHHHHHHHKZ-_8I_9?G_:&^
M(@NM4@D3P5HKK+J4W*BX;JELI]6QEB/NJ#R"RY_8NUM8;"UAM[>)(;:)%CCB
MC4*J*!@* .     *L4444444444444444444444444444444444444444444
M44444444444444444444444444444444444444444445\'_\%F(_,_9-TL_W
M/%5FW_DO=#^M?B/11111111111111117T7_P3R\-CQ7^VA\*[-DWB'4VO^G3
M[/#).#^!B%?T.T4444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444445_/=_P4@\+_\ ")_MJ?$VV5-L5U>0Z@AQPWGVT4K$?\"=A]0:
M^:********************************^[O^"-$?F?M::FW]SPM>-_Y'MA
M_6OVZHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK%\:?\ (FZ]_P!>
M%Q_Z+:OY^:********]&_9N_Y.(^&'_8T:9_Z51U^[5%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%?AO\ M8_\G+?$K_L.W7_H9KR>BBBBBBBB
MOWO^#/\ R1_P-_V K'_TG2NQHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHK\;_P#@HA_R=KXQ_P"N-C_Z1PU\WT4444445]N_\$H_^2R>+_\
ML G_ -*(:_4.BBBBBBBBBBBBBBBBBBBBBBBBBBBBBOFK]L[]DRS_ &BO"/\
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MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\2/\
M@LGX=_L?]J[3=15,)JWAJUN&;U=)IXB/J%C3\Q7P=1111111111111111111
M1111111111117WU_P1;B\S]JKQ&W_//P?=M_Y.60_K7[7444444444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444444444444444444445B^-/\ D3=>_P"O"X_]%M7\_-%%%%%%%%>C
M?LW?\G$?##_L:-,_]*HZ_=JBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBOPW_:Q_Y.6^)7_8=NO_0S7D]%%%%%%%%?O?\ !G_DC_@;_L!6/_I.
ME=C111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111111111111117XW_ /!1#_D[
M7QC_ -<;'_TCAKYOHHHHHHHK[=_X)1_\ED\7_P#8!/\ Z40U^H=%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%?%O[>O[' ^*6ES^/_!MD/\ A,+&+-]90K\VIP*.
MJ@=9E X[LHV\D**_+%E*L5(((."#U!HHHHHHHHHHK=\#>-]:^&_BS3/$OAZ^
MDT[6-/F$T$\?8]"K#HRL"593P02#P:_9W]F#]I'1?VD/ ,>K6?EV>NV86+5M
M+#Y:WE(^\N>3&V"5;V(/*FOQ4U__ )#FI?\ 7S)_Z&:H44444445^D'_  24
M_P"1>^)/_7U8_P#H,]?H!111111111111111111111111111111111111111
M11111111111111111111111111111111111117YQ?\%(/VJ?MUQ/\)O"UWFW
MA96\07<+\.X(*VH([*<,_OM7C:P/Y^4444444444Z.-YI%CC1GD9@JJHR6)Z
M #N:_7S]A?\ 9;3X"^ _[:URU7_A.-<B5[O<,M90'#+; ]CT9\=6P.0H-?45
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%?%7_  5XM/M'[&^I2=?L^LV$GYNR_P#L
MU?A911111111111111117Z3?\$1=!^T?%KXD:UMS]CT2"SW>GG3A\?\ D#]*
M_8*BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBOR5_P""X6@^1XK^$VM!?^/JRU"S+?\ 7)X' /\ W^/ZU^8-%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%?H=_P1/M/,_:(\:W/_//PM)'G_>N[8_\ LE?LU111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111116+XT_Y$W7O^O"X_]%M7\_-%
M%%%%%%%>C?LW?\G$?##_ +&C3/\ TJCK]VJ*************************
M************************************************************
M*******************_#?\ :Q_Y.6^)7_8=NO\ T,UY/111111117[W_!G_
M )(_X&_[ 5C_ .DZ5V-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%?C?_ ,%$/^3M?&/_ %QL?_2.&OF^BBBBBBBOMW_@E'_R63Q?_P!@$_\
MI1#7ZAT4444444444444444444444444444445^<W_!03]C;[*]_\5/!%C^X
M8M/K^EVZ_</5KM%'8]9 .A^;H7(_/BBBBBBBBBBBN\^"?QF\0_ ?X@6'BKP]
M-B>$[+FT=B(KR D;H7 ZJ<#!ZJP5AR!7%:A="^O[FY"[!-*TFW.=NYB<9_&H
M********_2#_ ()*?\B]\2?^OJQ_]!GK] **************************
M**************************************************^;_P!M?]I^
M']GKX>&VTJ=&\;:TC0Z;%PQMDZ/=,OHN<*#]YB." V/QSNKJ:^N9KFYE>>XF
M=I))96+.[,<LS$\DDDDDU'1111111117W=_P3C_97_X2;5H?BKXHL\Z38RD:
M':S+Q<7"G!N"#U6,@A?5P3QLY_3*BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOD/
M_@JU9_:?V(?&LF,_9[K3I?IF]A7_ -FK\$Z****************_6+_@AWI'
ME:'\7=4*_P"ON=+M5;_<6Y8C_P B+^E?J-11111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111117YK?\%NM%$_PK^&NK;<FUUJXM=WI
MYL&['X^3^E?D!11111111111111111111111111111117Z4_\$1+$O\ %/XE
MW>.(M&MXB?3=.3_[)7Z_T444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M5B^-/^1-U[_KPN/_ $6U?S\T44444445Z-^S=_R<1\,/^QHTS_TJCK]VJ***
M************************************************************
M*****************************************_#?]K'_ ).6^)7_ &';
MK_T,UY/111111117[W_!G_DC_@;_ + 5C_Z3I78T44444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444445^-__!1#_D[7QC_UQL?_ $CAKYOHHHHHHHK[
M=_X)1_\ )9/%_P#V 3_Z40U^H=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%1R1
M)-&T<BJZ,""K#((/4$>E?E)^W=^QV_P;UB;QOX1M&;P/J$O^D6T2Y&ESL?NX
M'2)B?E/12=IQ\N[X^HHHHHHHHHHHHHHHHHHHK](/^"2G_(O?$G_KZL?_ $&>
MOT HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHKC_ (K?$[1/@YX"U;Q;X@G\C3]/B+;%(WSR'A(D!ZLS
M84?7)P 2/Q%^,WQ<USXX?$35?%VORYNKQ\0VZL3':PK]R%,]%4?F2S'EB:XF
MBBBBBBBBBO:_V3OV<;_]H[XF0:5B2W\-V&VYUB^08\N'/$:GIYCD%5] &;!"
MD5^TNA:'8>&=&L=(TNUCL=-LH4M[:VA7:D4:@*J@>@ %:%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%?,W_!2C3_ .U/V(_BC#C.VUM9_P#OW>P/_P"RU_/A1111
M1111111111117[)_\$3=-\KX ^.K_'^O\3&#/KY=K V/_(GZU^BM%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?!?_!9C2OM
M_P"RCI%SCYK'Q3:39] UO<H1^;C\A7XET444444444444444444444444444
M4445^I__  0WT_=<?&._8<JFDP*?J;QF_P#05K]6:*******************
M************************************************************
M*********************Q?&G_(FZ]_UX7'_ *+:OY^:********]&_9N_Y.
M(^&'_8T:9_Z51U^[5%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%?AO^UC_ ,G+?$K_ +#MU_Z&:\GHHHHHHHHK][_@S_R1_P #?]@*Q_\ 2=*[
M&BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQO_X*(?\ )VOC
M'_KC8_\ I'#7S?11111117V[_P $H_\ DLGB_P#[ )_]*(:_4.BBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBL[7M#T_P 3Z->Z3JMG%J&FWD+07-K.H9)8V&&5
M@>Q!K\=?VP_V4]0_9O\ &7GV2RWO@G5)&.FWS?,T+=3;RG^^HZ'^)1D<A@OS
MU1111111111111111117Z0?\$E/^1>^)/_7U8_\ H,]?H!11111111111111
M111111111111111111111111111111111111111111111111111111111114
M4TT=O"\LKK'&@+,['  ')))Z"OR _;G_ &I'^/GCW^QM#NF/@?0Y62S"DA;V
M?E6N6'<'E4ST7)X+,*^8Z*********VO!?@[5_B#XKTOPYH-H]_J^I3K;V\"
M?Q,>Y/15 RS,>  2>!7[9_LY_ G2/V>?AG8>&-.V7%[_ *_4M0"X:[N2!N?U
M"C 55[*HZG)/J=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>'?MOZ;_ &M^R)\7
M(,9V^'+N?'_7-#)G_P <K^<BBBBBBBBBBBBBBBBBOV[_ ."-=B+/]DO490,&
MZ\47DQ_""V3_ -DK[MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHKXV_X*U:?]L_8M\13$9^R:EI\P]LSJG_ +/7X0444444
M44444444444444444444444445^O?_!$/2?)^&?Q-U/'%QJ]K;9_ZYPLW_M:
MOTMHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK%\:?\B;KW_7A<?\
MHMJ_GYHHHHHHHHKT;]F[_DXCX8?]C1IG_I5'7[M444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444445^&W[6/\ R<I\2_\ L.W7_H9KRBBBBBBBBBOW
MO^#/_)'_  -_V K'_P!)TKL:************************************
M************************************************************
M*********_&__@HA_P G:^,?^N-C_P"D<-?-]%%%%%%%?;O_  2C_P"2R>+_
M /L G_THAK]0Z*********************************Y;XD?#K0OBOX-U
M/POXDLA?:3?Q[)(^C(PY5T;^%E."#V(_"OQ=_:._9\U[]G3X@3Z!JH:ZTZ;=
M-IFJ*FU+R#/#>SKD!E_A/JI4GRJBBBBBBBBBBBBBBBBBOT@_X)*?\B]\2?\
MKZL?_09Z_0"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBO@O_ (*.?M5?\(WI<WPI\+WF-5OH@==NH6Y@
MMV&5M@1T9P06]$('.\X_-.BBBBBBBBBBOU6_X)[_ +*O_"J_"B^/?$MGL\6Z
MW /LMO,OS:?:'! P?NR2<,W<+M7@[@?LJBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBN!^/^C_\)!\"/B/I>W=]N\-:E;;?7?:R+C]:_F5HHHHHHHHHHHHHHHHK
M]U?^"15I]G_8UTN3'_'QK%_)]<2!?_9:^TZ*************************
M************************************************************
M*********************************^5/^"HEG]K_ &&OB3@9:/\ LZ0?
MAJ-MG],U^ 5%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?M?_P1ATC^S_V5]=O&
M&&OO%5U(&]56VM4 _-6_.OOFBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBL7QI_P B;KW_ %X7'_HMJ_GYHHHHHHHHKT;]F[_DXCX8?]C1IG_I5'7[
MM44444444444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444444444444444445^&W[6/_)RGQ+_[
M#MU_Z&:\HHHHHHHHHK][_@S_ ,D?\#?]@*Q_])TKL:******************
M************************************************************
M***************************_&_\ X*(?\G:^,?\ KC8_^D<-?-]%%%%%
M%%?;O_!*/_DLGB__ + )_P#2B&OU#HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHKS3X]_ OP_P#M!?#Z[\,ZZGE2',UCJ"*&ELK@ A9%]1S@KG# D<<$?BS\
M6/A7X@^#'CK4O"OB2U-MJ-FWRNN3'/&?NRQL1\RL.0>HY! (('(444444444
M44444445^D'_  24_P"1>^)/_7U8_P#H,]?H!11111111111111111111111
M11111111111111111111111111111111111111111111111117A_[67[2%C^
MSC\,Y]24QW'B74-UMH]BYSOEQS*PZ^6@(9O4E5R-P-?BYK>MW_B36+W5=4NY
M+[4KZ9[BYN9FW/+(S%F9CZDDFJ5%%%%%%%%%?8G_  3Z_96_X6QXM'CKQ+9[
M_"&AS#[/!,OR:A=K@A<'K&G#-V+;5Y&X#]7*************************
M************************************************************
M********J:IIZ:MI=Y8R_P"JN87A;Z,I4_H:_EHN[:2QNYK:9=DT+F-U]&!P
M1^8J&BBBBBBBBBBBBBBBOWE_X)-Q^7^Q1X5;^_?Z@W_DTX_I7V'111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111111111111111117S/_P %)(O.
M_8C^*2_].ELWY7D!_I7\]]%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?O9_P $
MJ-!_L;]B?P9<%=CZE<ZA>,,<G_2Y8P?Q6)?PQ7UY11111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111116+XT_P"1-U[_ *\+C_T6U?S\T44444445Z-^S=_R
M<1\,/^QHTS_TJCK]VJ******************************************
M************************************************************
M**_#;]K'_DY3XE_]AVZ_]#->4444444445^]_P &?^2/^!O^P%8_^DZ5V-%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?C?\ \%$/^3M?&/\
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MHHHHHHHHHHHHHHHHHHHHHK\-OVL?^3E/B7_V';K_ -#->4444444445TMO\
M$WQC:01P0>*]<AAC4(D<>I3*JJ!@* 'P !P *?\ \+5\:_\ 0WZ__P"#.?\
M^+H_X6KXU_Z&_7__  9S_P#Q='_"U?&O_0WZ_P#^#.?_ .+H_P"%J^-?^AOU
M_P#\&<__ ,71_P +5\:_]#?K_P#X,Y__ (NC_A:OC7_H;]?_ /!G/_\ %T?\
M+5\:_P#0WZ__ .#.?_XNC_A:OC7_ *&_7_\ P9S_ /Q='_"U?&O_ $-^O_\
M@SG_ /BZ/^%J^-?^AOU__P &<_\ \71_PM7QK_T-^O\ _@SG_P#BZ/\ A:OC
M7_H;]?\ _!G/_P#%T?\ "U?&O_0WZ_\ ^#.?_P"+H_X6KXU_Z&_7_P#P9S__
M !='_"U?&O\ T-^O_P#@SG_^+H_X6KXU_P"AOU__ ,&<_P#\71_PM7QK_P!#
M?K__ (,Y_P#XNC_A:OC7_H;]?_\ !G/_ /%T?\+5\:_]#?K_ /X,Y_\ XNC_
M (6KXU_Z&_7_ /P9S_\ Q='_  M7QK_T-^O_ /@SG_\ BZ/^%J^-?^AOU_\
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MWQH_Z*3K_P#X$_\ UJ/^&OOC1_T4G7__  )_^M1_PU]\:/\ HI.O_P#@3_\
M6H_X:^^-'_12=?\ _ G_ .M1_P -??&C_HI.O_\ @3_]:C_AK[XT?]%)U_\
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MQH_Z*3K_ /X$_P#UJ/\ AK[XT?\ 12=?_P# G_ZU'_#7WQH_Z*3K_P#X$_\
MUJ/^&OOC1_T4G7__  )_^M1_PU]\:/\ HI.O_P#@3_\ 6H_X:^^-'_12=?\
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M%%%%%%%%%%%%%?C?_P %$/\ D[7QC_UQL?\ TCAKYOHHHHHHHK[=_P""4?\
MR63Q?_V 3_Z40U^H=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?F)^W
M]^QO_P (/>W?Q*\$V./#US)OU?3;=>+"5C_KD4=(F)^8?PL>/E;"_#5%%%%%
M%%%%%%%%?I!_P24_Y%[XD_\ 7U8_^@SU^@%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>5_M&_'C2/V>?AG?
M>)=1V7%\W[C3=/+8:[N2#M7V48+,W8 ]R ?Q-\:>,=6^(/BO5/$>O7;W^KZE
M.UQ<3O\ Q,>P'\*@855' 4 #@5BT44444444444444444444444444444444
M4444444444444444444445K^#_\ D;M$_P"OZ#_T8M?T$T44444444444444
M4444444444444444444444444444444444445^1/_!;SPO\ 9?B%\+_$@7B^
MTN[T\M_UPF20 _\ @2?UK\S:***************_;/\ X(Q7_P!J_92UN G/
MV7Q9=Q8] ;6T?^;&OO6BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBOD#_@J[?"T_8E\81$X^TWFG0@>N+N)\?^.5^"U%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%?2'_!.OPM_PE_[:/PNM"F]+?4)-08XX'V>"
M2=2?^!1K^)%?T,4444444444444444444444444444444444444444444444
M44444444444444444444444444444444444444444444444444444445B^-/
M^1-U[_KPN/\ T6U?S\T4444444444444444444444444444444444444445^
M_/PO_P"2:>$O^P1:?^B4KIZ*************************************
M***********************************_#;]K#_DY7XE_]AVZ_P#0S7E%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?J1_P2E_Y(?XI_[&.3_P!)
M;>OMBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBOQO_ ."B'_)VOC'_ *XV/_I'#7S?11111117V[_P
M2C_Y+)XO_P"P"?\ THAK]0Z*************************************
M*JWUE!J5I<6EW!'<VMQ&T4T$RATD1@0RLIX(()!!X(-?D9^VY^R+<? +Q0?$
M'AV"2?P%JDI\D\L=.F;)\ASUVGDHQZ@%3DKEOERBBBBBBBBBBBBOT@_X)*?\
MB]\2?^OJQ_\ 09Z_0"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBL[7M>T_P +Z+?:OJMU'8Z;8PO<7-S,<)%&
MH+,Q/H #7XL_M8?M&:A^T=\3+C5LR6_ARQW6VCV#G'E0YYD8=/,<@,?3Y5R0
MH->+44444444444444444444444444444444444444444444444444444445
MK^#_ /D;M$_Z_H/_ $8M?T$T444444444444444444444444444444444444
M444444444444445^=G_!:[PK_:'P%\$^($3=)IGB+[*Q Y6.>WD)/TW0H/J1
M7XU4444444444444445^Q7_!$G5/.^"OQ!TW/-OX@2XQZ>9;(O\ [2K]'J**
M************************************************************
M********************************************************^&?^
M"QFI_8/V18(,X^V^)+*#ZXCGD_\ :=?A[111111111111111111111111111
M1117WK_P1I\'_P!N?M1ZMK3QYAT/P]<2H_\ =EEEBB4?BC2_E7[9T4444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444445B^-/\ D3=>_P"O"X_]%M7\_-%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?OS\+_ /DFGA+_ +!%I_Z)
M2NGHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHK\-OVL/\ DY7XE_\ 8=NO_0S7E%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%?J1_P2E_Y(?XI_[&.3_TEMZ^V***************
M************************************************************
M*_&__@HA_P G:^,?^N-C_P"D<-?-]%%%%%%%?;O_  2C_P"2R>+_ /L G_TH
MAK]0Z***************************************Q/%WA+2?'GAK4?#^
MNV,6I:1J,)@N;:895E/Z@@X(88((!!! -?C-^U7^S+J_[-OCQK%_.OO#%^S2
MZ3JC+_K$!YB<C@2KD CC(PP !P/$Z***********_2#_ ()*?\B]\2?^OJQ_
M]!GK] ******************************************************
M***************_,O\ X*.?M4GQ1J\WPK\+WF='T^8'7+F%N+FX4Y%N".JQ
MD9;U< <;.?A.BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBM?P?_P C=HG_ %_0?^C%K^@FBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBOE3_@IYX/_P"$P_8L\>A(]]SI8M=3B_V?*N(]
MY_[]-)7X!4444444444444445^JW_!#G6 8OC#I;-RK:5=1KZY%VKG]$_.OU
M2HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK
M\Y?^"VFL>1\#/ .E[O\ CZ\1FYV^OE6LJY_\C?K7XXT44444444444444444
M4444444444445^LG_!$'P?Y/A[XI^*73/VBZL=,A<CIY:2R2 'W\Z+/T%?J)
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111116+XT_Y$W7O^O"X_]%M7
M\_-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?OS\+_P#DFGA+_L$6
MG_HE*Z>BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBOPV_:P_Y.5^)?_8=NO_0S7E%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%?J1_P $I?\ DA_BG_L8Y/\ TEMZ^V**********
M************************************************************
M******_&_P#X*(?\G:^,?^N-C_Z1PU\WT4444445]N_\$H_^2R>+_P#L G_T
MHAK]0Z****************************************XCXP?"7P_\;? >
MH>%/$EMYUE=#,<R<2VTH!V2QL>C*3]""0<@D'\6/CI\$?$/P!^(%[X7U^$L8
MSYMI?(I$5Y;DD+*GUQ@KG*L"#TKSVBBBBBBBBBBOT@_X)*?\B]\2?^OJQ_\
M09Z_0"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBOEO]NK]J5/@/X$_L/0[E1XWUV)EM"C?-90'*O<GT;JJ>K9/
M(4@_D+)(\TC.[,[L2S,QR6)ZDGN:;1111111111111111111111111111111
M11111111111111111111111116OX/_Y&[1/^OZ#_ -&+7]!-%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%<-\</!O\ PL3X,^._"X3>
M^L:%>V*+C)WR0.BD>X9@1[BOYD****************_1;_@B;KGV?X\>.M&+
M86\\-_:L>IBNH5_E,:_9*BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBORG_X+C:]F;X0Z*C?=75+R5?J;9$/Z/7Y7T444444
M444444444444444444444445^[O_  27\$_\(E^QKH=^T>R7Q#J=[JK<8) D
M^SJ3]5MU(]B*^RZ*********************************************
M********************************************************Q?&G
M_(FZ]_UX7'_HMJ_GYHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK]^
M?A?_ ,DT\)?]@BT_]$I73T44444444444444444444444444444444444444
M4444444444444444444444444444444445^&W[6'_)ROQ+_[#MU_Z&:\HHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK]2/^"4O_ "0_Q3_V,<G_ *2V
M]?;%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%?C?\ \%$/^3M?&/\ UQL?_2.&OF^BBBBBBBOMW_@E
M'_R63Q?_ -@$_P#I1#7ZAT44444444444444444444444444444444444444
M445Y#^TM^SKH?[1WP_ET340MIJUMNFTK50N7M)B._=D; #+W&",,JD?B]\0/
M .N?"_QAJ?ACQ'9/I^KZ?*8IHFY##JK*W0JP(96'!!!KGJ*********_2#_@
MDI_R+WQ)_P"OJQ_]!GK] ***************************************
M****************************X/XU?%W1/@;\.]5\6Z[)_HUHNV&W5@)+
MJ9L[(4_VF(Z]@"3PIK\1OBE\3-;^+_CS5O%GB&X\_4M0F+E5)V0H.%B0'HJJ
M H'H,G))-<I1111111111111111111111111111111111111111111111111
M111111116OX/_P"1NT3_ *_H/_1BU_031111111111111111111111111111
M1111111111111111111111117\SO[1G@?_A6_P ?/B)X82/RH=+UZ]MH%QC]
MR)F\HX]"FT_C7G-%%%%%%%%%%%%%%?9G_!)/Q%_8?[9^@V>[;_;&EZA8X]=L
M)N,?^0/TK]W*************************************************
M************************************************************
M**********_%[_@M1XB_M#]H_P *:0C;DT[PS'(P_NR2W,Y(_P"^40_C7Y\4
M444444444444444444444444444445_2W^S/X'/PV_9[^''AEX_*N--T"SAN
M%QC]_P"4IE./=RQ_&O3:****************************************
M************************************************************
M*Q?&G_(FZ]_UX7'_ *+:OY^:************************************
M****_?GX7_\ )-/"7_8(M/\ T2E=/1111111111111111111111111111111
M111111111111111111111111111111111111111117X;?M8?\G*_$O\ [#MU
M_P"AFO****************************************_4C_@E+_R0_P 4
M_P#8QR?^DMO7VQ1111111111111111111111111111111111111111111111
M111111111111111111111111111117XW_P#!1#_D[7QC_P!<;'_TCAKYOHHH
MHHHHK[=_X)1_\ED\7_\ 8!/_ *40U^H=%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%?-W[97[)]C^T9X/^VZ7'#:>.=*B8Z?=MA!<IRQMI6_NDY*
ML?NL<]"V?Q\UC1[[P]JUYIFIVDMCJ%G,T%Q;3J4>*120RLIY!!!%4Z******
M**_2#_@DI_R+WQ)_Z^K'_P!!GK] ********************************
M**********************************K7EY!I]I/=7,T=O;0(TLLTK!4C
M11DLQ/   ))/3%?CC^VE^T[/^T/\1&ATV:1/!>C.\.F0\@3MG#7+ _Q-CY0?
MNJ , EL_.U%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%:_@__D;M$_Z_H/\ T8M?T$T44444444444444444444444444444
M44444444444444444444445^#_\ P5D\#GP?^V5KU\L?EP>(=.LM5C & 3Y?
MV=R/J]NY/N37QO111111111111117N_["OBC_A#_ -K[X3Z@6V+)KL%BS9Q@
M7&;<Y]OWM?T8T44444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444445^!/\ P5*\3#Q)^VQXY2-]\.FQV6GH?=;6)G'X.[C\*^3:****
M*************************]!_9^\"?\+.^.7@#PFT?FPZOKEG:3KC($+3
M+YK'V";B?85_3/1111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111116+XT
M_P"1-U[_ *\+C_T6U?S\T444444444444444444444444444444444444444
M5^_/PO\ ^2:>$O\ L$6G_HE*Z>BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOPV_:P_P"3E?B7_P!AVZ_]
M#->4444444444444444444444444444444444444445^I'_!*7_DA_BG_L8Y
M/_26WK[8HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHK\;_^"B'_ "=KXQ_ZXV/_ *1PU\WT4444445]
MN_\ !*/_ )+)XO\ ^P"?_2B&OU#HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHKXR_;S_8Y'Q:TF?QYX.LO^*SL8LWEG"O.J0*.P'650..[ ;>2%
M%?E:Z&-BK JRG!!&"#Z4E%%%%%%%?I!_P24_Y%[XD_\ 7U8_^@SU^@%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M?GI_P4@_:I^SQS_"7PM>?O)%4^(+N%ONJ<%;4$=SPSX[87NPK\ZJ********
M***************************************************U_!__ "-V
MB?\ 7]!_Z,6OZ":*********************************************
M*******_*O\ X+>^ ?\ DF'C:*+_ )^]&N9,?[DT S_X$&ORKHHHHHHHHHHH
MHHHK:\&>(I?"/C#0M=@SYVEWT%ZF.NZ.17&/Q6OZA[6ZBOK6&Y@=98)D61'7
MHRD9!'U!J>BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBOYJ/VHO%@\<?M(?$_74?S(;WQ'?O V?\ ED)W6/\ \<"BO+J*****
M************************^T?^"27P^/C+]L#2]4>/?;>&=,N]5?(XW,HM
MT!]\W&X?[N>U?NO111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111111111111111111111116+X
MT_Y$W7O^O"X_]%M7\_-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?
MOS\+_P#DFGA+_L$6G_HE*Z>BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQ<_:@^&/C+5/VB/B)=V7A/7+
MRTGUJY>*>#39G1U+G#*RH00?45Y?_P *A\=_]"5XB_\ !3/_ /$4?\*A\=_]
M"5XB_P#!3/\ _$4?\*A\=_\ 0E>(O_!3/_\ $4?\*A\=_P#0E>(O_!3/_P#$
M4?\ "H?'?_0E>(O_  4S_P#Q%'_"H?'?_0E>(O\ P4S_ /Q%'_"H?'?_ $)7
MB+_P4S__ !%'_"H?'?\ T)7B+_P4S_\ Q%'_  J'QW_T)7B+_P %,_\ \11_
MPJ'QW_T)7B+_ ,%,_P#\11_PJ'QW_P!"5XB_\%,__P 11_PJ'QW_ -"5XB_\
M%,__ ,11_P *A\=_]"5XB_\ !3/_ /$4?\*A\=_]"5XB_P#!3/\ _$4?\*A\
M=_\ 0E>(O_!3/_\ $4?\*A\=_P#0E>(O_!3/_P#$4?\ "H?'?_0E>(O_  4S
M_P#Q%'_"H?'?_0E>(O\ P4S_ /Q%'_"H?'?_ $)7B+_P4S__ !%'_"H?'?\
MT)7B+_P4S_\ Q%'_  J'QW_T)7B+_P %,_\ \11_PJ'QW_T)7B+_ ,%,_P#\
M11_PJ'QW_P!"5XB_\%,__P 11_PJ'QW_ -"5XB_\%,__ ,11_P *A\=_]"5X
MB_\ !3/_ /$4?\*A\=_]"5XB_P#!3/\ _$4?\*A\=_\ 0E>(O_!3/_\ $4?\
M*A\=_P#0E>(O_!3/_P#$4?\ "H?'?_0E>(O_  4S_P#Q%'_"H?'?_0E>(O\
MP4S_ /Q%'_"H?'?_ $)7B+_P4S__ !%'_"H?'?\ T)7B+_P4S_\ Q%'_  J'
MQW_T)7B+_P %,_\ \11_PJ'QW_T)7B+_ ,%,_P#\11_PJ'QW_P!"5XB_\%,_
M_P 11_PJ'QW_ -"5XB_\%,__ ,11_P *A\=_]"5XB_\ !3/_ /$4?\*A\=_]
M"5XB_P#!3/\ _$4?\*A\=_\ 0E>(O_!3/_\ $5^EG_!,/PSK'A?X,^);?6=*
MO=(N)-?>18KZV>!V7[- -P# $C((S[&OL>BBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQO_P""B'_)
MVOC'_KC8_P#I'#7S?11111117V[_ ,$H_P#DLGB__L G_P!*(:_4.BBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOSK_P""@O[&VTZA\5/!%CQ\
MTVOZ7;KT[M=HH_.0#_>_O&OSSHHHHHHHK](/^"2G_(O?$G_KZL?_ $&>OT H
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHKY^_;(_:9MOV=/AO))921R^,-65H-)MF ;8<8:X9?[J9! /WF*CIDC\:-
M1U"ZU?4+F^O;B2[O+F5IIKB9B[R2,2S,S'DDDDDGN:KT4444444444444444
M4444444444444444444444444444444444444444445K^#_^1NT3_K^@_P#1
MBU_0311111111111111111111111111111111111111111111111111117QY
M_P %6_A^?''[&_B*[BB\VY\.WUIK,2@<X5_)D(^D<\C'V4U^#5%%%%%%%%%%
M%%%%%?TF?LD>,/\ A/OV8OA=KC2>;-<>'K))WSG=-'$L<I_[[1J]<HHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKF_B-XK3P'\
M/O$_B64J(M&TNZU%BW0"*%I#GV^6OY@)IWN)I)I',DDA+.S<DDG))_&HJ***
M**************************_6S_@B+\/?LWA'XD^.)H\F\OK?1K>0C[HA
M0S2@?4SPY_W17Z>444444444444444444444444444444444444444444444
M4444444444444444444444444444444444444444444444444444444444U@
M&!!Y'0@U3_L73O\ GQM?^_*_X4?V+IW_ #XVO_?E?\*/[%T[_GQM?^_*_P"%
M']BZ=_SXVO\ WY7_  H_L73O^?&U_P"_*_X4?V+IW_/C:_\ ?E?\*/[%T[_G
MQM?^_*_X4?V+IW_/C:_]^5_PH_L73O\ GQM?^_*_X4?V+IW_ #XVO_?E?\*/
M[%T[_GQM?^_*_P"%']BZ=_SXVO\ WY7_  H_L73O^?&U_P"_*_X4?V+IW_/C
M:_\ ?E?\*/[%T[_GQM?^_*_X4?V+IW_/C:_]^5_PH_L73O\ GQM?^_*_X4?V
M+IW_ #XVO_?E?\*/[%T[_GQM?^_*_P"%']BZ=_SXVO\ WY7_  H_L73O^?&U
M_P"_*_X4?V+IW_/C:_\ ?E?\*/[%T[_GQM?^_*_X4?V+IW_/C:_]^5_PH_L7
M3O\ GQM?^_*_X4?V+IW_ #XVO_?E?\*/[%T[_GQM?^_*_P"%']BZ=_SXVO\
MWY7_  H_L73O^?&U_P"_*_X4?V+IW_/C:_\ ?E?\*/[%T[_GQM?^_*_X4?V+
MIW_/C:_]^5_PH_L73O\ GQM?^_*_X4?V+IW_ #XVO_?E?\*/[%T[_GQM?^_*
M_P"%']BZ=_SXVO\ WY7_  H_L73O^?&U_P"_*_X4?V+IW_/C:_\ ?E?\*/[%
MT[_GQM?^_*_X4?V+IW_/C:_]^5_PH_L73O\ GQM?^_*_X5<55C4*HVJ!@ #
M%.HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHJ)H8W;+1JQ]2H)H^RP_\ /*/_ +Y%'V6'_GE'_P!\BC[+#_SR
MC_[Y%'V6'_GE'_WR*/LL/_/*/_OD4?98?^>4?_?(H^RP_P#/*/\ [Y%'V6'_
M )Y1_P#?(I5A2/[J*I_V0!4E%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%(5!&#TJ/[+#_ ,\H_P#OD4?98?\ GE'_ -\BC[+#_P \H_\ OD4?
M98?^>4?_ 'R*/LL/_/*/_OD4?98?^>4?_?(H^RP_\\H_^^11]EA_YY1_]\BG
M)$D>=JJN>NT8I]%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%1M"DGWD5C_ +0!I/LL/_/*/_OD4?98?^>4?_?(H^RP
M_P#/*/\ [Y%'V6'_ )Y1_P#?(H^RP_\ /*/_ +Y%'V6'_GE'_P!\BC[+#_SR
MC_[Y%'V6'_GE'_WR*/LL/_/*/_OD4?98?^>4?_?(H^RP_P#/*/\ [Y%'V6'_
M )Y1_P#?(H^RP_\ /*/_ +Y%'V6'_GE'_P!\BC[+#_SRC_[Y%'V6'_GE'_WR
M*/LL/_/*/_OD4?98?^>4?_?(H^RP_P#/*/\ [Y%'V6'_ )Y1_P#?(H^RP_\
M/*/_ +Y%'V6'_GE'_P!\BC[+#_SRC_[Y%'V6'_GE'_WR*/LL/_/*/_OD4?98
M?^>4?_?(H^RP_P#/*/\ [Y%'V6'_ )Y1_P#?(H^RP_\ /*/_ +Y%'V6'_GE'
M_P!\BC[+#_SRC_[Y%'V6'_GE'_WR*/LL/_/*/_OD4?98?^>4?_?(H^RP_P#/
M*/\ [Y%'V6'_ )Y1_P#?(H^RP_\ /*/_ +Y%'V6'_GE'_P!\BC[+#_SRC_[Y
M%'V6'_GE'_WR*/LL/_/*/_OD4?98?^>4?_?(H^RP_P#/*/\ [Y%'V6'_ )Y1
M_P#?(H^RP_\ /*/_ +Y%'V6'_GE'_P!\BC[+#_SRC_[Y%'V6'_GE'_WR*/LL
M/_/*/_OD4?98?^>4?_?(H^RP_P#/*/\ [Y%'V6'_ )Y1_P#?(H^RP_\ /*/_
M +Y%'V6'_GE'_P!\BC[+#_SRC_[Y%'V6'_GE'_WR*/LL/_/*/_OD4?98?^>4
M?_?(H^RP_P#/*/\ [Y%'V6'_ )Y1_P#?(H^RP_\ /*/_ +Y%)]FA'(B3_OD5
M-11111111111111111111111111111111111111111111111111117)?%;P/
M#\3/AGXM\)7.WR=<TJZTUBP^[YL3(&^H+ @]B*_F,O;*;3[R>TN8VAN+>1HI
M8W&&5E)#*?<$$57HHHHHHHHHHHHHHK]T_P#@D9XX_P"$J_8\T[3&DWR>'-7O
M-,(8\A69;E?PQ<X'TQVK[5HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHKYE_X*1>-O^$&_8Q^)%PDFRXU"UBTF)<X+_:)DB<?]
M^VD/T!K^?&BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOZ#O^"</PW_X5G^QU\/K
M62+R[S5K9M;N&Q@L;ES)&3[B$Q+_ ,!KZ:HHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHK^=G]O?X;M\+?VN/B5I"Q>5:7.IMJML ,+Y5T!< +[*9
M&7_@)':OGVBBBBBBBBBBBBBBOU._X(@^/%6Z^*'@R63ETM-8MH\]E+Q3-C_@
M5N*_5JBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBOS?_X+8>//[+^#O@+PC')LDUC6I-0=0>6CMH2I!]MURA^JCTK\=Z******
M***********************Z+X>>#;SXB>/O#GA6PYO=;U&WTV# SAY9%C!^
M@+9_"OZ=]#T>T\.Z-I^E6$0@L;&WCM8(AT2-%"JOX  5?HHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHK\A_^"V7PT_LWXA?#_P >018CU33IM(N7
M4<"2!_,C)]V6=@/:/VK\SZ**************^OO^"5/CX>!OVR?#%M)+Y5MX
MAM+K1I6)P#NC\V-??,L,8^I%?O5111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111117XG_\%E/B%_PDW[36E>&8I-UOX:T2&.1,_=N)
MV:9C^,9@_*O@>BBBBBBBBBBBBBBBBBBBBBBBBBBBBBOLO_@D_P###_A8/[76
MC:G-%YECX6L;C69=P^4R!1#",^H>97'^X?2OW=HHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHKX[_P""K'PN/Q&_9"UZ_@B,M_X7NX-<A"CYMBDQ
M3<^@BF=C_N#TK\&Z**************Z?X7^-I_AM\2/"WBRUW&XT/5+7445>
M"QBE5]OX[<?C7].^G7]OJVGVU]:2K/:W,2S12KT=& 96'L00:M4444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444444444444444445_-A^UA\1A\6OVD
MOB-XK27SK6_UJ=;63.=UO&WE0'_OTB5Y-111111111111111111111111111
M117[#_\ !%7X5G0_A/XT\?7,.V?7]233[5F')M[92693Z-),RGWB]J_2&BBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL3QMX5L?'7@W7?#>IIOT
M[6+&?3[E<9S'+&T;?HQK^8KQAX8O?!/BW6_#NI)Y>HZ1?3V%RF/NRQ2,CC_O
MI36/111111111111117]#?\ P3W^)G_"U/V0OAUJ4LOF7MA8_P!CW()RP>U8
MP*2?5D1&_P"!U]&T44444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444445Y5^U-\2Q\'_P!G7XA^+A-Y%SIVCSFU?.,7,B^7 ,^\KH/QK^:R
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBB@ DX'6OZ3?V3_A7_P *4_9Q^'_@YX?(
MN]/TJ)KQ,8Q=2YFG_P#(LCUZW11111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111117X/?\%6OA/_ ,*U_:WUG4[>'RM-\66D.MP[1\HE(,4XS_>,D3.?
M^N@]:^.***************_6;_@B5\41<^'?B'\.IY?GM;F'7;.,G)99%$,^
M/0*8X/Q>OU"HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHK\\_P#@L]\4/^$;^ OAGP5!+LNO$^K>?,@/WK6U4.P(_P"NLD!_X":_
M&.BBBBBBBBBBBBBBBBBBBBBBBBBBBBBO>/V&_A'_ ,+L_:F\ >'9H//TV._7
M4=05AE3;6X,SJWL^P)]7%?T8444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444445^=O_!9[X3GQ-\$?#/CVUA+W7A?4C:W+J/NVMT%4LQ]!,D"C/\
MST/KS^--%%%%%%%%%%%%%%?4G_!-/XJ?\*I_; \%RS3>3I^O,^@77. PN !$
M#[>>L!_"OZ!*************************************************
M************************************************************
M******_"_P#X*W?%;_A/_P!J^ZT*WF\S3_".GPZ6H4Y4SL//F8>X,JH?>*OB
M>BBBBBBBBBBBBBBBBBBBBBBBBBBBBBOU0_X(F_"$F;Q]\3KJ#Y56/P_I\I'7
M.V>YQ],6PR/5A7ZL44444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M45P'QZ^&%M\:?@SXR\#W(0+KFF36L3R?=BF*YAD_X#($;_@-?S0:EI]SI.H7
M-C>0O;W=M*T,T,@PR.I*LI'8@@C\*JT4444444444445:TW4;G1]1M;^SF:W
MN[659X9D.&1U8,K#W! /X5_3-\$?B3;?&'X0^#_&UKL$>N:7!>NB'B.1D'F1
M_57W*?=37<44444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M445B^,_%5CX%\'ZYXDU63RM-T>QGU"Z?^[%$C.Y_[Y4U_,AX^\97_P 1/''B
M#Q3JC;]2UK4)]1N2#D>9+(SL![ L0/:L"BBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBOZ,_V)?@Z?@9^S#X#\,30>1J9L5U#4E(PPNISYTBMZE"XC^B"O=:******
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M****************************************_ ?_ (*<?!T_"/\ :V\4
M26\'DZ5XGV^(;0J/ES,6$X],^>LQQV#+ZU\GT44444444444445^SG_!&GXQ
M?\)9\#=>\ 74^^\\)ZAYULC'D6=T6< #OB99R<=-Z_C^AE%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?$G_!6SXQ?\*W_ &6Y_#MK
M/Y6J^,KV/3%"MAQ;)B6=A[$*D9]IJ_#*BBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBO>?V'?@P?CQ^T_X(\-30>?I,5V-2U,$97[+;_O'5O9RJQ_605_1?1111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111111117YZ?\%E?@S_PF'P/T+X@
MV<&^^\)7WDW3*.?L=R50D^NV98<>@=C7XQ444444444444445]:?\$P_C0/A
M!^UEX<@NI_*TCQ2K>'[K<V%#2E3 V.F?.2)<]@S5^^E%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?AS_P5R^-'_"R/VFO^$6L[CS=
M)\%V:V "ME3=R[9;AA[C,49'K":^':*****************************_
M6[_@BK\%_P"S?"OC/XI7MOMGU.9=#TUV&"((]LD[ ]U:0Q+]837Z=4444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444444444444444444444444444444444445R7Q8^'=A\6OAGXH\&:I
MQ8:[ITUA(^W)C\Q"H<#^\K$,/=17\SGB_P +ZAX'\5ZSX=U> V^JZ3>36-W"
M?X)8G9'7\&4UCT44444444444459LKV?3+RWN[65H+JWD66*:-MK(ZD%6![$
M$ @U_2C^S;\7K?X\_ OP7XZA9#+JVGQO=I'TCNERDZ#V657 ]@#7IU%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%<?\ %SXD:=\(/ACX
MH\::J1]AT/3YKUT+;3*44E8U/]YFVJ/=A7\SWBSQ/J'C;Q3K'B'5IC<:KJUY
M-?W4Q_CEE=G=OQ9C6111111111111111111111111111115W2=+N]=U2STVP
MMWNK^\F2WMX(QEI)'8*JJ/4D@#ZU_2K^SS\)+3X$_!/P=X$M-A&BZ?'#/)&,
M+-<-EYY!_ORL[?\  J]&HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHK\1/^"O?P2_X5W^T9;^,[*#R])\:V@N791A1>PA8YU'U4PN3W:1J
M^$J**************_5S_@BO\<?/L?&/PFO[C+0D:_I2.?X6VQ7*#/8'R6"C
M^\Y]:_4RBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOS
M>_X+.?',>'/AEX<^%MA<;;[Q%<#4M116Y6S@;]VK#T>;# _].[5^/%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%?:'_!*/X&GXL?M/V/B"\M_-T/P5%_:\S,N5-T
M25M4]F#YE'_7 U^[%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%?)G_!3/X%?\+L_9:U^:SM_-U[PL?[>L=JY=EB5O/C'<[H2Y"CJR)[5
M^!5%%%%%%%%%%%%%%>I_LQ_&BZ_9]^.W@_QU;ES!I=ZOVR*/K-:."DZ8[DQL
M^,]#M/:OZ2=-U&UUG3;6_LITNK*ZA6>":(Y62-E#*P/<$$$'WJY111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111114<DJ0QL[L$10268X  ZDG
ML*_G-_;2^.C?M$?M(>+_ !=!.TVC"X^P:3D_*+.'*1$#MOPTA'K(U>&T4444
M4444444444444444444444445^\G_!+7X$#X.?LOZ7JM[;^5KWC%QK=R67#+
M RXM4SZ>5B3'8S,*^Q******************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M********AFA2XB>*1%DBD!5D8 A@1@@CN"*_G$_;"^![_L\_M$>,?!J0M'I<
M-T;K2V;HUE+\\.#WVAMA/]Y&KQBBBBBBBBBBBBBBBOW,_P""3OQ__P"%M?LX
MQ>%-0N?-\0>"'737#-EGLF!:U?Z*JM$/:$>M?;E%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%?)'_!3?\ : 'P._9CUBTL;GR?$?BTMH=@
M%;#K&ZG[3*.X"Q;E##HTB&OP.HHHHHHHHHHHHHHHHHHHHHHHHHHHHHKV#]DO
MX&S_ +17[0'A+P2J.=/NKH3ZG(F1Y5E%\\YR/NDJI53_ 'G4=Z_H_L[2'3[6
M&UMXE@MX46.**-0JHH&%4 <    "K-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%?FW_ ,%FO@'_ ,))\.O#_P 5].M]U]X=E&FZHR+R
M;*9OW3L?1)FVC_KX/I7X]T44444444444445]/?\$[?VA!^SW^TOH-[J%U]G
M\-:]_P 275BS81(Y67RYFSP!'*$8MU"[P.M?T%4444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444445^"G_!3S]H7_A>7[2FHZ;I]SY_AKP>&T:Q
MVME))E;_ $J8=OFD&P$<%8D-?(5%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?L%_
MP1F^ /\ PC?P]\0?%C4[;;?>(9#IFE,Z\K91-^]=3Z/,NT_]>X]:_2:BBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBN8^)7@'2_BIX!\
M0^$-:C\W2M:L9;&X  +*LBE=RYZ,I(8'L5![5_-1\4/AYJWPE^(GB+P;KD?E
MZKH=[+8S[00K%&(#KGJK##*>X8'O7*T44444444444445_0%_P $Y/VBA^T)
M^S;HLNH77VCQ3X="Z-JQ=LN[1J/)F/<^9%M);NRN.U?4U%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?.O[>/[1*_LU_LY^(-?M+CR?$FHK_
M &5H@!^874JL/-'_ %S0/)Z90#^*OYY))&E=F9BSL<EF.22>I)IE%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%=A\(_AKJWQD^)WAKP5HB;]3UR^CLXVQE8@Q^>1A_
M=10SGV4U_2I\/? ^E?#'P+H/A+0X?(TC1;.*QMD[[(U"@L>['&2>Y)/>NDHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\D/\ @LY^
MSW_9/B;P]\8=*M<6VJ!='UID' N$4FWE;W:-70GH/)0=6K\QJ***********
M***^M/\ @FG^TA_PSW^T9IUMJ5WY'A/Q7LTC4][82)V;_1YSV&R1MI8\!))#
M7[Z444444444444444444444444444444444444444444444444444444444
M44444444444444444444444444444444444444444444444445^$_P#P5+_:
M1_X7A^T%-X=TJZ\[PKX+,FFVWEME)KLD?:IAV/S*L8/0B+(^\:^+Z*******
M**********************_4K_@C+^SL;C4/$/QDU>V_=6X;1M#,@ZR, ;F9
M<^BE8PPX.^4=J_5ZBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBO-_VB/@SIW[0'P9\5> ]3*QQZO9LD%PPS]GN%(>&7U^2148@=0"
M.]?S:^*?#.I>#/$VJZ!K-JUEJVEW4EE=VTGWHI8V*.I^C*16311111111111
M1117[\?\$W_VFO\ AHS]GNP35+S[1XP\+[-*U;>V9)@%_<7![GS$&"3U=)/:
MOK"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOF?\ X* _M,+^
MS/\ L^ZKJ5A<K%XMUK=I6B*#\Z3.IWS@>D2;F!Z;M@/WJ_GRDD::1G=BSL<E
MF.22>I)IE%%%%%%%%%%%%%%%%%%%%%%%%%%%%=%X!\$ZM\2?&NA>%-"M_M6L
M:S>16-K%V,DC!06/91G)/0 $GI7])WP5^%6D_!'X4^&/ VBK_P 2_1+)+82;
M=K32?>DE8#^)W+N?=C7<4444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444445^-_\ P6)_9S_X0SXF:5\5](M=FD^* +/4_+7"QZA&GRN>
MP\V)1]3"Y/+5^<]%%%%%%%%%%%%%%?1_[!?[3+_LP?'[2M:O)V7PGJV-,UV,
M9(%N[#$V/6)]K],E0ZC[U?T)6UQ%=6\<\,B2PR*'22-@58$9!!'!!'.:GHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHIC.L:EF(50,DDX 'K7\_O
M_!0W]J$_M,?'R_N-,N3-X-\/;],T10WR2JK?O;D>\KC(/!V+&#R*^7******
M************************_3O_ ((V_LU_VMX@UGXS:U:YM=,WZ5H(D7A[
MAU_TB=<_W$81@C()DD'5:_6VBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBO+?VE/@CIO[1?P4\3^!-0VQMJ5L39W3KG[+=)\T$O
MKA7"Y Y*EAW-?S?>*/#>I>#?$FJZ!K%J]CJVF74EG=VT@PT4L;%'4_1E(K*H
MHHHHHHHHHHHHHK]K_P#@DU^U./BQ\)6^&NNWGF>*_!\*K:F1LO=:9D+&1ZF$
MD1'T4Q=237WS111111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111111111111111111117PS_P5
M4_:H_P"%*?!O_A!M#N_*\8>,HI+<F-L/::?]V:7CD%\^4I]Y"#E*_#VBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBNG^&WP_UCXJ^/M \'Z!;_:M8UF\CL[:/G:&8
MX+,1T51EF/8*3VK^DKX+_"O1_@A\+?#7@;0DVZ;HMFELLFT*TS_>DF8#^)W+
M.?=S7;T44444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M445^/7_!8C]FEO"?CO3/C!HMKC2?$)6QUD1+\L5\B?NY3CH)8UQ_O1$DY<5^
M;E%%%%%%%%%%%%%%>B_ 'XT:U^SU\6_#OCS07)NM+N TMMNVI=6[<2P-[.A9
M<XX.".0*_HZ^&?Q$T3XM> ]"\8>&[K[9HFLVJ75M+T(!ZJP[,K JR]05(/2N
MIHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKG/B!X[T7X8>"=;\6>(
M;Q;#1='M9+RZG;LBC.%'=B<*%')) ')K^<K]I+X[:S^TA\9/$/CO62T37\VR
MSLRVY;2T7Y885[?*N,D8W,6;&6->7T44444444444444444444444444445^
MK'_!&_\ 9D\F'5?C9KMIAI/,TKPZ)%_A!VW-ROU(\D$>DP[BOU0HHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK@?CG\(-'^/'
MPG\2^!-=3-AK%JT(F W-;RC#13*/[R.%8>I7!X)K^;OXC> =8^%?CK7?"'B"
MW^RZSHUY)9W4?;<IQN4]U8893T(8$=:YFBBBBBBBBBBBBBBOT@_X)%_M;?\
M"$>,)/@WXEO=NA:_,9M"FF;Y;:^(^: $]%F X'_/10 ,R$U^Q%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?D-_P5V_:W'BKQ%'\%?#%[NTG2)EN?
M$4\3_+/=CF.VR.JQ9W,.1O*@@&.OS0HHHHHHHHHHHHHHHHHHHHHHHHHHHHHK
MT7]G_P""^L?M!_%[PWX$T12MSJMP%FN-N5M;=?FFF;V1 S8[D #DBOZ0? /@
M?1_AGX+T/PGX?MOL>C:-:1V5K".2(T4*"3W8XR3U)))Y-=%1111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111111111117Y:_P#!8K]ELWEK
M8?&WP_:9EMQ'IOB-(UZI]VWNF^A(B8GL8NP-?E#111111111111115FRO)M-
MNX+JUFDMKJ"198IH7*/&X.596'(((!!'((K]_P#]@']K*#]JCX,07&HSQKXX
MT$)9:Y;C ,C8_=W2J.BRJI)P  X<#@ GZ@HHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHKYI_;R_:NM?V5?@Q=:C:31OXTUD/9:#:-@D2[?GN&4]4B!#'
MC!8HI^]D?S[ZCJ%QJU_=7U[<27=Y=2M-/<3,6>61B69F8\DDDDD]2:JT4444
M4444444444444444444444445^TG_!(W]ET_#/X6W'Q0UZS\OQ'XNB5=/65,
M/;Z8"&4CT,S .?54B/<U^@E%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%8GC+PGI7CSPIJ_AO7;-+_1M6M9+.[MI!Q)$ZE6
M'L<'@CD'!'(K^<;]IKX#ZK^S;\:?$7@35=TJ6,OF6-XPP+NT?YH9AVR5X8#@
M,K+VKRNBBBBBBBBBBBBBBO9/V4?VD-:_9;^,FD^,M+\RXL ?LVK::IP+VS8C
MS(^> PP&4]F5<Y&0?Z(_ GCC1?B5X-T?Q3X<OH]2T/5[9+JTN8NC(PSR.JL#
MD,IY!!!P0:Z&BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL+QIXRT?X>^$
M]6\3>(;^/3-$TJV>ZN[N8X$<:C)/J2>@ Y)( !) K^=_]K;]I76/VI_C-JOB
M^_\ ,MM+4_9='TUVR+2S5CL4XXW-DLQ'5F..  /%********************
M**********^C_P!@_P#9?F_:D^.^FZ-=PR'PCI.W4M=N%R!]G5OEA##HTK84
M<Y"[V'W37]"%G:0Z?:0VUM"D%M"BQQ0Q*%5% P% '     %6:***********
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M************************************************************
M*************************************************^(/^"IO[*?_
M  O3X.'QGH%IYOC3P?%)<JL2YDO+#[TT''+,F/,4<\AP!EZ_#:BBBBBBBBBB
MBBBBBOT._P""5/[:0^%?BN/X2^+[WR_"6O76=)NYV^73[YR!Y9)Z13' ]%?!
MX#,P_9JBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQM_X*N?MH#XE>*)/
MA!X/U#S/"^B7&[6[N!_DO[Y#Q"".L<)'/8R9./D4G\Z:****************
M*************LV-E/J5Y;VEK!)<W5Q(L4,,*EGD=B JJ!R220 !U)K^@W]@
MW]EN']EKX%V&D7D48\7ZQMU#7IUP2)V7Y8 PZK$IVC!P6WL/O5])44444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444APPP1D
M5^"__!2;]DYOV;_C7-JNC6?D^!/%3R7VF^6N$M)LYFM?0!68,H_N.H&2K5\@
M444444444444444H)!!'!K]OO^"9/[;"?'_P,G@'Q;?;OB#X=ME"33OE]5LU
MPJS9/+2I\JOW/RMD[FQ]TT44444444444444444444444444444444444444
M44444444444444444444444444444444444444444444444444444445\._\
M%,?VV%_9[\!OX'\)WX7XB^(;<@2PM\VEV;95I\CI(V&6/N"&;C: ?PZ9BS%B
M<DG))ZTE%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?HY_P $C?V3?^$[\;2_&'Q)
M9;]"\.S&'1(IE^6YU #+3 'JL((P?^>C*0<H17[&44444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M44444444444444444444444444444444444444444445Y%^U)^SWI'[3?P9U
MOP/JFR&YG7[1IM^RY-G>(#Y4H[XR2K =59AWK^='QIX.U?X>^+-8\-:_9/I^
MM:3=26=W:R=4D1BI&>A'&01P001P:PJ************V?#/@_7O&VJ+IWAS1
M-1U_4&Y6TTNTDN93]$12?TKZ%\%_\$U?VB_&T<<T'PZNM)MF'^MUJZ@LBN?6
M.1Q)_P".U[O\)_\ @E/^TE\.O&6B^+] \3^#?#>O:3<+=6TTNI7+LC#JK!+9
ME96!*LI.&4D'(-?K_P"'GU630=/;78;.#6C AO8].E>2W6;:-XC9U5BF<X+*
M#C&16I111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111117BG[6'[3OA_P#94^$]]XKU
M<I=:I*&M]'TG=B2^NBN57U"+]YV_A4=R5!_GJ^)7Q$U_XM>.M:\7^*+]]3UW
M5K@W%S</TR> BCHJ* %51P%4 <"N7HHHHHHHHHHHHHHHHHHHHHHHHHHHHHKT
MW]G3X$ZY^T=\7M"\"Z"NR:_EW75X4+)9VJX,L[^RKT&1N8JH.6%?T8_#/X<Z
M'\)? 6A>#O#5F++0]&M5M;:+O@?>9CW=F)9FZLS$GK754444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444444444444444444445^9?_!7+]D'_
M (2;0_\ A=GA:RW:KID2P>)+>%<M/:CY8[K ZM'PK'GY-IX$9S^1=%%%%%%%
M%%%>W_LZ_L=?%']IZ_V^#= 8:.DGEW&OZB3!I\![@R$$NPXRL89AD$@#FOT_
M^ ?_  2!^%_P]AM-0^(%W=?$36U 9[=V:VTU&ZX6)3O?!XR[X;N@Z5]N^$?
M_A[X?Z/'I7AG0M-\/:9']VSTNT2WB'OM0 9]ZW:*********************
M************************************************************
M*************Y3XF?$KP]\(/ NL>,/%6H1Z7H6E0F>XN'Y)[*BKU9V8A54<
MDD =:_GP_:V_:B\0_M7?%:\\4ZL6L])@W6^C:1OW)8VN<A?0R-PSM_$>!A0H
M'B-%%%%%%%%%%%%%%%%%%%%%%%%%%%%%.52[!0"6)P !R:_=S_@FE^R#_P ,
MW?"7^W_$-D(O'_BF..XO5D7Y[&V^]%:\\AAG<XX^8@'.P&OLJBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBJFH6%O
MJMC<V5Y;QW=G<QM#-;S(&22-@5964\$$$@@\$&OY_/V]_P!DVY_95^,US9V,
M$S>"-;+WNA7398)'N^>V9CU>(D#DY*LC'EB!\RT4444445-##)<S1Q1(TLLA
M"JB EF).  !R23VK]0?V)_\ @DZVJ0Z?XU^-]K+!;N%GLO!X8I(PZJUXPP5&
M.?)4@\C<1@I7ZHZ+H>G^&])M=+TFPMM,TVTC$5O9V<*Q0PH.BHJ@!0/0"M"B
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBJ.L:M9Z!I-YJFI7<-CIUG"]Q<W
M5RX2.*-5+,S,> H ))/0"OPD_P""A/[;UW^U-XX&B>'IYK;X::).W]GP,"AO
MYAE6NY5Z\@D(IY5220"S"OD"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOT%_X)
M2_L=_P#"V/'@^*GBFQ\SPCX:N0--MYTRE_J"X8-@]4ARK'L7*#D!A7[1T444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M444444444444444444444444444444444444444444444444444444444444
M4445XW^U9^S?HG[4?P;U;P9JNRVOF'VG2=29<M97B@^7)ZE3DJP'568#!P1_
M.YX]\#:W\,_&6L^%/$=@^FZYI%R]K=6TO574]0>C*1AE8<,"",@BN>HHHHHJ
M6&&2XF2*)&EED8*J("68DX  '4D]J_9?_@G/_P $Z[;X0:?IOQ+^)6FK<^.Y
MU6?3-)N5RNC(1E793P;@@YY_U?0?-DC]#***************************
M************************************************************
M**********8SK&I9B%4#)). !ZU^,G_!3#]OP_&+5;OX7?#[43_P@EC-MU34
MK9^-8G5ONJPZP(1QV=ANY4*3^>M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>N?
MLO?L\:[^T]\7M)\%:(&AAF/GZEJ&W<EC:*1YDS>IY"JO&YF49&<C^B3X;_#S
M0OA-X%T3PAX9LET[0M'MEM;6!>3M')9CW9F)9F/+,Q)Y-=11111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111111111111111111111111111111117YZ?\
M%5OV+V^*WA%_BQX0L?,\7Z#;8U6T@7YM0L4!.\ =981DCNR;AR505^,5%%%%
M%?IY_P $F?V+8O$5U%\;?&5B);"TF9/#%E<)D2SHV'O&!X(0@JG7Y@S<%%)_
M6RBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOR<_X*:?\%##JS:G\'_AE
MJ?\ H(W6WB/7K1_]>>CV<##^ <B1A][E1QNW?EU111111111111111111111
M1111111115[1])O?$&K66EZ;:S7VHWLR6UM:VZ%Y)I'8*B*HY+$D  =2:_?_
M /8+_9$M/V4/A%%:WT<,_CG6@EUKE['AMK@'9;(W=(PQ&?XF9FZ$ ?3=%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%(<,,$9%?A__ ,%.OV+3^S_X^_X3SPG8>7\/_$EPQ:"%<)I=ZV6:' X$
M;_,R=AAEP JY^&****];_99^ .I?M+?&[P]X&L/,AMKJ3S]2O$&?LEFA!FE]
M,XPJYX+,H[U_1OX7\,Z9X+\-Z7H&C6D=AI.EVT=G:6L0PL44:A44?0 5K444
M444444444444444444444444444444444444444444444444444444444444
M4444444444444444444444444444444445^7?_!2;_@HR='_ +4^$OPJU3_3
M_FMM?\1V<G^HZA[6W<?Q]0[@_+RH^;)7\FZ*************************
M******_6?_@DW^Q3_8]I;?&_QI8XO;I#_P (Q8W"<Q1,,->D'^)P2L?HI9N=
MRD?J#1111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111117+?$KX<Z!\7/ NM>#_$]BFHZ%JUN;:YMVX.#R&4_PLK
M,K#D,H(Y%?SS?M6?LSZ]^RO\6]1\(:P'N;!LW.DZIMVI?6A)"N.P88*LO9@>
MH()\9HHK]HO^"/O[/(^'WP;O_B7JEOLUOQB^RS+K\T6GQ,0N.X\R0,Q[%4B-
M?H-111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111111111111117Y>?\%&O^"DPT<:I\*OA+
MJF=0^:VUSQ/9R<6_9K:V8?Q]0T@/R\JOS9*_DV2223R:2BBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBOLC_@G)^Q7-^TY\0_^$A\1VKK\./#\RM?,P(&HW PRVBG
M^[C#2$<A2!P7!'[L6MO%8VT5O;Q)#;Q((XXHU"JB@8"@#@    "K%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%>!_ME?LJ:+^UG\);GP[=^58^([+==:'JSKDVMQC[K$<F)P KJ,\88 L
MJU_/GX[\#ZW\-?&&K^%O$NG2Z5KNDW#6UW:3#YD<>_0J1A@PR&!!!((-<_78
M?"'X;W_Q@^*7A7P3IF5O-=U&&Q63;D1*[@-(1Z*NYC[*:_I@\)^%].\$^%M'
M\/:1 +72M)LXK&T@'1(HD"(OX*HK8HHHHHHHHKF?''Q&\*_#+2#JGBWQ'I?A
MK3AG_2=4NTMT8CLI8C)]ADGTKY4\>?\ !6S]GWP7(\6GZIK7C&13@C0],8*#
M_O7#1 CW4D>F:\BU3_@MYX-BF==.^&6N746?E:ZU&&!C]0JN!^9J32/^"W7@
M>:5!JGPV\06<6?F:SO8+AA] VS/YBO:/A[_P58_9[\>RI#=>(M0\(W+D!8O$
M.GM&I/O)$9(U^K,!7U1X5\9:#XZT>+5O#>M:?K^ES?ZN]TRZ2XA?Z.A(/YUM
M444444444444444444444444444444444444444444444444444444444444
M44444444444444444444UF6-2S':H&22< 5^4'_!0K_@IJ=4_M/X8_!_5"ME
M\UMK'BNT?!F[/!:,.B]0TP^]R%^7YF_+BBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBO7/V8/V<?$?[47Q6T[P=H"&&%L3ZEJ;(6CL+4$!Y6]3R%5<C<S*,@9(_
MH9^$OPI\._!/X>Z+X+\*V8L=$TF$11*<%Y&ZO*[ #<[L2S'N6/0<5V=%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%?#'_!2O]AQ?VAO!TGCOP=8K_P +'T.W.Z"%0&U>U7),)]94&2AZ
MGE#G*E?Q"DB>&1D=2CJ2"K#!!'4$=C7WY_P1K^$Z^+OVA-;\:W,0>U\(Z8?)
M8C[MU=;HD/\ WZ6X_,5^U%%%%%%%%8OBSQ9HW@;P]?:]X@U2TT71K*,RW-]?
M2K%%$OJS$@#G  ZDD <FORR_:I_X+#:A?SWOA[X)68T^T5FC;Q;J4(>:7L6M
MX&&U!Z-(&)!^XIYK\W_''Q \2_$KQ!-KGBO7M0\1:O-]^\U*X:>0CLH+$X [
M*, =@*YZBBBNP^&OQ:\9?!S7X];\$^)=1\-:FI&Z6PG9!( <A9$^[(O^RX*G
MN*_3K]E#_@L!9ZY<6?AOXV6L6EW<C+%%XKTZ+%LQ/ -S",F/W=,KSRJ@$U^F
M6FZE:ZS86U_87,-]8W,:S07-M(LD<J$95U920P(P00<$&KE%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%4-6U:RT'3+O4M2NX-/T^TB:>XN[J01Q0QJ"6=F8@*H )))P *_'+]OS_@
MIA>_&!M0^'OPMNY]-\#9:#4-:3,=QJZ]&1>AC@/.1PSCKA25/YYT44444444
M44444444444444444444445T/@+P+KGQ-\8Z1X5\-:=-JNNZK<+;6MI"/F=S
MW)Z*H +,QP% )) !-?T&?L<?LHZ'^R;\*;?P_9^5?>([TK<ZYK"KAKNXQ]U2
M>1$F2J+QQEB-S-GWNBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL[4_$&EZ*N=0U*SL!C.
M;J=(_P#T(BL8?%3P4S%1XOT$L#@@:G!G/I]ZMC3O$>E:PV+#4[.].,XMKA)#
M_P".DUI4444444444444444444444444444444445GZMK^F:#$)=3U&TTZ(]
M'NYUB4_BQ%<\OQD\ ,VT>.?#9;T&K6^?_0ZW=)\4:-X@7.EZO8ZD,9_T2Y27
MC_@)-:E%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%?E+_P5+_8-\AM2^-7P^T[]T<S^*-)MD^[W:^C4=C_R
MU _W_P"^1Z]_P1F\#+H'[,^M^(GCQ<Z_KTK+)C&Z""-(U'X/YWYU]^444444
M5RGQ,^)7AWX0^!]6\7>*]2BTG0M+B,UQ<2GGT5% Y9V8A54<DD =:_!C]LS]
MM[Q;^UIXL9)GFT;P+93,VE>'T?Y1C($TY'$DI'U"@D+U8M\TT4444445];_L
M3?\ !03Q7^RKJD.BZK]H\3?#>>3-QHS29ELB3\TMHS'"MU)C)"MS]UCN'[@_
M"WXJ^%OC1X)T_P 6>#M8@UO0[U<QSPG!1A]Z-U/S(ZYP58 CTKL*********
M************************************************************
M******Y3XE?$[PQ\'_!NH>*O&&L6^AZ%8INENKANI_A1%&2[L> B@LQX -?B
M%^V__P %"O$W[4FH3>'=#%QX:^&L$N8M,#XGORIRLMTRG!Y&X1@E5."2Q 8?
M']%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%6+.TFU"ZAMK:&2XN9G6.*&)2SNQ
M. J@<DDD  <DFOW(_P""<?[#,'[-7@\>+_%MI'+\2];@ E5@&_LFW;!%LA_Y
MZ-P9&'<!1PI+?;%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%?B5\;_ (R>/],^-'C^SM?'/B6UM;?Q!J$,,$.KW")&BW+A
M550^%4   #@ 5Q7_  O#XD?]% \4?^#JY_\ BZ/^%X?$C_HH'BC_ ,'5S_\
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M1?'OB?1]+MY;<0V5AK-S!#$#:PL0J*X5<LQ)P.I)[UXE_P -'?%G_HJ'C/\
M\*"[_P#CE?3/_!/+XO\ CSQM^T/%IOB'QMXBU[3CI5U(;34]6GN8MPV8;8[E
M<C)P<9&:_4.BBBBBBBBORD_;P^,_Q!\'_M-^)M*T'QUXET33(8;-H[+3]7N+
M>%"UK&S%41P!DDDX'))-?/W_  T=\6?^BH>,_P#PH+O_ ..5]!?L&_&;X@>,
M/VF?#>E:]XZ\2ZWIDMO>-)9:CJ]Q<0N5MI&4LCN5)! (R." :_5JBBBBBBBB
MBBBBBBBBBBBBBBBBBBOPPUW]HCXJP:[J,<?Q-\8I&MS(JJNOW0"@,< #S.!5
M+_AH[XL_]%0\9_\ A07?_P <H_X:.^+/_14/&?\ X4%W_P#'*/\ AH[XL_\
M14/&?_A07?\ \<H_X:.^+/\ T5#QG_X4%W_\<H_X:.^+/_14/&?_ (4%W_\
M'*/^&COBS_T5#QG_ .%!=_\ QRC_ (:.^+/_ $5#QG_X4%W_ /'*/^&COBS_
M -%0\9_^%!=__'*^AOV"?C)X_P#&/[2V@Z7KWCGQ+K>F26MXSV6I:O<7$+,L
M#E24=RI((!&1P17ZK44444444444444444444444445^.?[4'QU^)7A_]H3X
M@:=I?Q"\5:;IUKJ\\4%I::U<Q11(#PJJKA54>@&*\O\ ^&COBS_T5#QG_P"%
M!=__ !RC_AH[XL_]%0\9_P#A07?_ ,<H_P"&COBS_P!%0\9_^%!=_P#QRG1_
MM)?%J)LCXG^,2?\ :UZZ8?D7KH-$_;*^->@.CVWQ'UF4J<@7KI= _42JP/XU
M[%X#_P""HWQ-\/RQIXDTO1_%=J"-[&(V=RP]FC^0?]^S7V#\$_V^_A?\8;B#
M3KB]D\(:]*0J6.M,J1RL>T<X.QN< !MK$]%-?2]%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%8?C3Q9I_@+PCK/B/59/)TW2K22\G;OM12Q ]2<8 [D@5^$_
MCWXG:]\0O&NM^)=0O[A+O5;N2Z>..9@B;F)"*,\*HPH'H!6%'XAU6&19(]3O
M$=6#*RSL"I'0@YX-?MO^R[\8H_CI\$_#WB=I%;4S%]DU-5Q\EW& LF0.F[AP
M/[KK7K5%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%<!\>[ZYTSX%_$6\L[B:TN[?
MPYJ,T-Q Y22)UM9&5E88(8$ @CD$5^*G_"\/B1_T4#Q1_P"#JY_^+H_X7A\2
M/^B@>*/_  =7/_Q='_"\/B1_T4#Q1_X.KG_XNC_A>'Q(_P"B@>*/_!U<_P#Q
M='_"\/B1_P!% \4?^#JY_P#BZE@^/GQ.M3F'XC>+(CG.4URZ7^3UV/AO]M+X
MV>%I%>T^(>JW(7JNI;+T$>A\U6_/K7T'\,?^"JOB339HK;Q[X6LM9M.%:]T9
MC;W"CNQ1BR.?8%!7W-\&?VAO ?QYTLW?A'6XKN>-0]QILX\J[M\_WXCSC/&Y
M<J3T)KTNBBBBBBBBBBBBBBBBBBBBBBBBBBOR\_X*'?%[QYX)_:'ETWP]XV\1
M:#IPTJUD%IIFK3VT6X[]S;$<#)P,G&3BOF;_ (:.^+/_ $5#QG_X4%W_ /'*
M/^&COBS_ -%0\9_^%!=__'*/^&COBS_T5#QG_P"%!=__ !RC_AH[XL_]%0\9
M_P#A07?_ ,<H_P"&COBS_P!%0\9_^%!=_P#QRC_AH[XL_P#14/&?_A07?_QR
MC_AH[XL_]%0\9_\ A07?_P <H_X:.^+/_14/&?\ X4%W_P#'*/\ AH[XL_\
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MUNV[V.W.U<XZ[1Z5]YT444444444444444444444445^9O\ P4@^+7CGP/\
M'K3-/\-^,_$/A^P?0+>=K72M5GMHC(9[@%RJ. 6(503C.%'I7RK_ ,-'?%G_
M **AXS_\*"[_ /CE>O\ [(?QP^(_B;]I+P)IFK_$#Q1JNFW-ZRS6=]K5S-#*
MOE.<,C.01D X([5^OM%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>._&C]J[X:_
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M/WY"/O2-R>@PH"CQ&BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOUP_P""7W[
MI\+PZ;\9OB+IVW5YD6?PYHURG-HC#*WDJG_EHP.8U/W0=Q^8KM_3BBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOP=_:#7
M;\>_B4/3Q-J8_P#)J2N!HHHHHHHHHHHHK]4_^"57_)O?B'_L:;C_ -)+.OLV
MBBBBBBBBBBBBBBBBBBBBBBBBOQ;_ &]/^3M/B!_UVM?_ $D@KP.OK#_@F3_R
M<Y%_V![O_P!DK]<*********_'/_ (**?\G9>+/^O>Q_])8J^:Z^EO\ @G3_
M ,G8>%O^O:^_])9*_8JBBBBBBBBBBBBBBBBBBBBBBBBBBOY[_$7_ ",.J?\
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M"'_Y6=0_^2*/^'?/P"_Z$/\ \K.H?_)%'_#OGX!?]"'_ .5G4/\ Y(JOJ'[
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MJLQ_!A7Q7^TA^P[XV_9[M9-9\R/Q/X35@K:M91LC6^3A?/B))0$\!@67) +
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MD/\ $+2[70_'WB73;*+R+*SU.YMX(MS-MC25U5<L23@ #))/K6!7UY_P3Q^
M_@7XZ:YXVM_'&A?VY#IUM:R6J_:Y[?RV=I QS$Z$Y"KUSTXK[;_X=\_ +_H0
M_P#RLZA_\D4?\.^?@%_T(?\ Y6=0_P#DBC_AWS\ O^A#_P#*SJ'_ ,D4?\.^
M?@%_T(?_ )6=0_\ DBC_ (=\_ +_ *$/_P K.H?_ "17HGPC_9^\ _ D:J/
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MY.<B_P"P/=_^R5^N%%%%%%%%%?CG_P %%/\ D[+Q9_U[V/\ Z2Q5\UU]+?\
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M*******************JWM[;Z;9S75U/';6T"-)+/,X1$4#)9F/   R2>*^
MOVIO^"M_@KX:?;-!^%D$/CSQ(FZ-M59R-*MF]0RX:X(/9"%.>'/(K\G?C#\=
M?'/Q\\4OX@\=^(KO7K_D1+,VV"V4G.R&)<+&O X4#)Y.3S7 444444444444
M44444444444444444444445]7_L,_L)Z_P#M9>*%U+4!/HWPWTZ8#4=75=KW
M+#!-M;Y&"Y&-S8(0')R2JM^Z_@7P+H/PS\(Z9X8\+Z7;Z-H6FPB"ULK9<)&H
MY)]68DEBQ)))))))-=%11111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M1111111111111111111111111111535O^07>_P#7!_\ T$U_/517Z8_\$F_^
M2>^._P#L*P_^B37W?1111111111111111111111111111117XM_MZ?\ )VGQ
M _Z[6O\ Z205X'7UA_P3)_Y.<B_[ ]W_ .R5^N%%%%%%%%%?CG_P44_Y.R\6
M?]>]C_Z2Q5\UU]+?\$Z?^3L/"W_7M??^DLE?L51111111111111111111111
M11117\]_B+_D8=4_Z^I?_0S6?7Z.?\$DO^0/\3?^OC3_ /T&>OT$HHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHK\.OVMO^3F/B5_V&[C_T*O)*^TO^"4__ "7C
MQ-_V+4O_ *56U?J=117F?QW^/7A;]GWP9/KOB.\7SV5EL=,C<?:+V4#A$7KC
M)&6/"@Y/8'\5/BC\1]7^+GC_ %KQ=KLJR:EJ<YF=4SLC4 *D:YY"JH51WPHS
MDURU>W_L9_"67XP?M!>&-.:$RZ7ITRZKJ+;<JL$+!MK>SOL3_@?M7[8T4444
M44444444444444444444444445^87_!47XR?\)%X^T?X=V$^ZRT&,7M^JGAK
MN5?D4^Z1$$?]=F':OARN^^ WPMN?C1\7?#/@^ .(]0N@+J5.L5NN7F?ZA%;&
M>IP.]?NQI]A;:386UC9PK;VEM$L,,*#"HB@!5 [   5:K\A?^"B7P6_X5?\
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M*P_^B37W?1111111111111111111111111111117XM_MZ?\ )VGQ _Z[6O\
MZ205X'7I/[/_ ,<M4_9[^("^+-(T^TU.\6UDM/(O2PCVOMR?E(.1M]:^F/\
MAZ]X]_Z$[PY_WU<?_%T?\/7O'O\ T)WAS_OJX_\ BZ/^'KWCW_H3O#G_ 'U<
M?_%T?\/7O'O_ $)WAS_OJX_^+H_X>O>/?^A.\.?]]7'_ ,71_P /7O'O_0G>
M'/\ OJX_^+H_X>O>/?\ H3O#G_?5Q_\ %T?\/7O'O_0G>'/^^KC_ .+H_P"'
MKWCW_H3O#G_?5Q_\77RW\<OC!J/QV^)6I>,]4LK73KV^2%'M[,OY:B.)8QC<
M2>0H)YZFN"KZ6_X)T_\ )V'A;_KVOO\ TEDK]BJ*********************
M*****_GO\1?\C#JG_7U+_P"AFL^O=/V:?VMO$'[,=KX@@T31=-U9=8>!Y3J!
MD!0QAPNW:PZ^8<Y]!7MO_#U[Q[_T)WAS_OJX_P#BZ/\ AZ]X]_Z$[PY_WU<?
M_%T?\/7O'O\ T)WAS_OJX_\ BZ/^'KWCW_H3O#G_ 'U<?_%T?\/7O'O_ $)W
MAS_OJX_^+H_X>O>/?^A.\.?]]7'_ ,77U-^Q7^U)KO[3FG^++G6]'T_26T>6
MVCB&GF0B3S%D)+;F/38,8]37TS11111111111111111111111117X=?M;?\
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M^A,\/?\ ?<__ ,71_P /7_'?_0F>'O\ ON?_ .+H_P"'K_CO_H3/#W_?<_\
M\77H_P"SM_P4/\6_&3XS>&?!FH^&-%L++59I8Y+BU:4R(%A=P5RY'5 .1T-?
M?%%%%%%%%%%%%%%%%%%%%%%%%%%?SY>*/^1FU?\ Z_)O_0VK,K]%/^"1_P#Q
M[?%/_>TO^5W7Z&444444445^.?\ P44_Y.R\6?\ 7O8_^DL5?-=?2'_!._\
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MHHHHHHHHHHHK\6_V]/\ D[3X@?\ 7:U_])(*\#HHHHHHHHHHHHKZ6_X)T_\
M)V'A;_KVOO\ TEDK]BJ**************************_GO\1?\C#JG_7U+
M_P"AFL^BBBBBBBOT>_X))_\ (#^)?_7S8?\ H,]?H%111111111111111111
M11111117X=?M;?\ )S'Q*_[#=Q_Z%7DE%%%%%>J?!O\ 9C^(WQTNHAX7\/3M
MIK/M?6+Q3!91@'#$RL,,1W5 S>U?IY^RW^Q7X6_9UA35KB1?$7C21"'U::/"
M6P(PR6ZG.T$'!8_,PST!*U](4444444444444444444444444444445\%_\
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M&3AE((R?6OS,_:,_X)R^+OAM)=ZUX#\_QCX:7<YM40'4+5?0H!B4#^\@SZJ
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M'1@GK7Z;?\-6_!S_ **7X9_\&,?^-'_#5OP<_P"BE^&?_!C'_C1_PU;\'/\
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M]^9O_B:/^'3_ (V_Z'?0?^_,W_Q-'_#I_P ;?]#OH/\ WYF_^)H_X=/^-O\
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MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBK%K:S7US#;P0R37$KK''%$I9W8G
M50.222  .M?K'^P/_P $NT\.-IWQ$^,VFI-J:[;C3/"-P R6QX*RW:]&?H1"
M<A?XLM\J_IX!MI:*********************************************
M************************************************************
M****************************J:M_R"[W_K@__H)K^>JBOTQ_X)-_\D]\
M=_\ 85A_]$FON^BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOQ;_ &]/^3M/B!_U
MVM?_ $D@KP.OK#_@F3_R<Y%_V![O_P!DK]<*********_'/_ (**?\G9>+/^
MO>Q_])8J^:Z^EO\ @G3_ ,G8>%O^O:^_])9*_8JBBBBBBBBBBBBBBBBBBBBB
MBBBBBOY[_$7_ ",.J?\ 7U+_ .AFL^OT<_X))?\ ('^)O_7QI_\ Z#/7Z"44
M4444444444444444444444444444445^'7[6W_)S'Q*_[#=Q_P"A5Y)7V7_P
M2M_Y.&U[_L5[C_TJM*_56BOF#]JO]B'PS\?-/NM:T6*W\/>.U4LE_&NV&]8#
MA+A5')/02 ;AQG< !7Y+^,O!NM?#[Q/J'A[Q#I\NEZQ82F&XM9AAE;J"#T92
M""&&0P(()!!K&KU_]F+]H[6_V;_B!%J]DTEWH5V5AU;2PWRW,(/WE!X$B9)5
MO7(/RLP/[2^#_%VE>//"^F>(="O8]0TC48%N+:XC/#*?4=B#D$'D$$'!!K<H
MHHHHHHHHHHHHHHHHHHHHHHHHHHHKY4_X*+?&3_A6?P(N-#LYO+UGQ6[:=&%;
M#+;  W#?0J5C/_77VK\BJ*********^L_P#@F_\ &C_A7/QM'AF^G\O1O%J+
M9D,<*EVI)@;ZL6:/W,B^E?K;111111111111111111111111117GG[17_)O_
M ,3?^Q7U3_TDDK\(J*_6;_@F#_R;5-_V';K_ - AKZZHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHK\D_^"G/_ "<S_P!P2U_]"DKY+KW?]A?_ ).N^'O_ %]3
M_P#I-+7[4T44444444444444444444444444444445_/KXNMWM/%FM0/]^.^
MG0_42,#637Z"_P#!)*YVZI\3X,\R0Z<^/]UKD?\ LU?HW111111117XX?\%$
M+I+C]K3Q@B]88;&-C[_9(6_DPKYNKZ6_X)TVSS_M8^%G7I#;7TC?0VLB_P V
M%?L51111111111111111111111111111117X$_%C_DJGC+_L-7O_ */>N5K[
M\_X)*_\ (S?$?_KSLO\ T.:OTDHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\G_
M /@J1_R<AIW_ &+MK_Z.N:^/Z]N_8G_Y.H^'?_7^W_HEZ_;*BBBBBBBBBBBB
MBBBBBBBBBBBBBOF/_@HMX+;Q=^S!K5Q$ADGT.[M]515&3A6,3G\$F=C[*:_'
MNBOV,_X)]_$2/Q]^S/X?MVE\R_\ #[R:/<J3R!&=T7'IY3QCZ@^E?2E%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%4M4TNRUS3;BPU*T@O["X0QS6
MMU&LD<JG@JRD$$'T(K\ZOVNO^"=_]B6]_P",OA5;R3648::]\,KEY(EZL]L>
M2RCJ8SDCG:3PH^ 2""1C!%%?4_\ P3S^.LOPK^-5KX=O;@KX<\5,EC*C'Y(K
MHG$$H]"6.P^SY/W17Z\T4444444444444444444444444444444444444444
M44444444444444444444444444444444444444UE# @C((P17YD?MX?\$LX/
M$@U'X@?!?3X[35OFN-1\(P*$BNCU:2T'1'ZDQ?=;^':?E;\F;ZSGTV\GM+J"
M2VNH)&BE@F0H\;J<,K*>0P(((/((JM111111111111111111111110"5Y'!K
MZ*^"_P"W]\<?@8L%MHGC2YU;1XL :1X@_P!.MMHZ*N\[XU]HV6ON;X/_ /!:
MSP_J7D6?Q-\#W6C3'"MJ?AV47,!/JT$A5T4>SN?:OMOX3_M8_"+XW+$G@[Q]
MH^J7DN-NG23_ &>\)/;R)0LA],A<>]>NT444444444444444444444444444
M4444445X]\6?VNO@]\$3+%XQ\?Z1IM]&<-IT$QNKQ3Z&"$-(/J5 ]Z^)_C!_
MP6LT'3?/M/AEX'NM9F&535/$4HMX >Q$$99W4^[H?:OA?XR?M^?'/XW">WUK
MQQ>:7I,N0=)T'_0+?:>J-Y>'D7VD9J^>2222>32444444444444444444444
M444444444444444445T/@?P'X@^)?BK3O#7A;2+K7-=U"016UE:)ND<]SZ!0
M,DLQ 4 DD $U^UO["_\ P3AT#]FVUL_%OC%+7Q'\2G4.LN-]MI.1RL (^:3L
MTI&>RX&2WVU1111111111111111111111111111111111111111111111111
M111111111111111111111111111111111111111111111111111111111111
M11111111111111111111111111535O\ D%WO_7!__037\]5%?IC_ ,$F_P#D
MGOCO_L*P_P#HDU]WT444444444444444444444444444445^+?[>G_)VGQ _
MZ[6O_I)!7@=?6'_!,G_DYR+_ + ]W_[)7ZX444444445^.?_  44_P"3LO%G
M_7O8_P#I+%7S77TM_P $Z?\ D[#PM_U[7W_I+)7[%4444444444444444444
M44444445_/?XB_Y&'5/^OJ7_ -#-9]?HY_P22_Y _P 3?^OC3_\ T&>OT$HH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\.OVMO^3F/B5_V&[C_P!"KR2OLO\
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MX6_Z]K[_ -)9*_8JBBBBBBBBBBBBBBBBBBBBBBBBBBOY[_$7_(PZI_U]2_\
MH9K/K]'/^"27_('^)O\ U\:?_P"@SU^@E%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%?AU^UM_R<Q\2O\ L-W'_H5>25]E_P#!*W_DX;7O^Q7N/_2JTK]5:***
M_/7_ (*5?LQPS69^+7ANTVSQE(=?@A7[ZG"QW.!W!VJQ[@J>S$_G317ZY?L!
M_M,?\+K^'7_"-ZY=>;XQ\.QK%,\C9>]M?NQS\\EAPKGGG:Q/SXKZNHHHHHHH
MHHHHHHHHHHHHHHHHHHHKQS]K/XPCX'_ OQ'XAAF$6KRQ?8-,YPQNI051AZE!
MNDQZ(:_$-F+L68EF8Y))R2:2OUU_X)S_  <_X5K\!X->O(?+UCQ8ZZC(67#+
M; %;=?H5+2#_ *ZU]5T44445E>)O#MAXN\.ZGH>J0BYTW4K:2TN83T>.12K#
MVX)K\(_B]\-[[X0_$OQ%X0U$,;C2;MH5D*X\Z/[T<@'HR,K#_>KD*^Y_^"77
MQH_X1_QMK'PXU"?;9:XIOM.5FX6[C7]XH]WB7/\ VQ [U^G-%%%%%%%%%%%%
M%%%%%%%%%%%%%>>?M%?\F_\ Q-_[%?5/_222OPBHK]9O^"8/_)M4W_8=NO\
MT"&OKJBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOR3_X*=?\ )S _[ EK_P"A
M25\EU[O^PO\ \G7?#W_KZG_])I:_:FBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBOQW_X**>#7\)_M0Z]=>48K;6[:VU*'C@YC$3D?62)S^-?,]>M?LH_$Z+X0
M?'[P?XCNY1!IJ7?V6^=CA5MYE,3LWLH;=_P 5^XBLLBAE.Y2,@@Y!IU%%%%%
M%<C\6?B+I_PE^&_B#Q=J;*+72K1YPA./-DQB.,>[N54>["OP4OKV?4KZXN[F
M1I;FXD::61NK,Q)8GZDFH*_2/_@D]X)>U\,^._%LT6$O+JWTVWD(_P">2L\F
M/8F:/\5K[]HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK\"?BQ_R53QE_P!AJ]_]
M'O7*U]^?\$E?^1F^(_\ UYV7_H<U?I)11111111111111111111111111111
M17Y/_P#!4C_DX[3O^Q>M?_1UQ7Q_7MW[$_\ R=1\._\ K_;_ -$O7[944444
M4444444444444444444445^9O_!4'X%OHOBS3OB?IEO_ *!JP6QU7:.([I%Q
M%(WL\:[?K'ZL*^$:5':.170E64@JP."#ZBOUS_8;_:TM_CIX2B\-^(KQ$\>:
M3"%D\QL'48%  G7U8<!U'?YNC8'U91111111111111111111111111111111
M11117'?$3XH^'_A5#H5SXDNQ866KZI'I,=V^!'#-)'(Z&0D_*I,97=T!8$X&
M2.QHHHHHKS+]ICPO;>,OV??B%I5TBNDFBW4R;N@EBC,L3?@Z*?PK\+**_;C]
MC69Y_P!E_P"'+2$EAI:J,_W59E7] *]HHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKQ_]I+]E
MOP)^U)X-.A>,=.S<PAFT_6+7"WEA(1]Z-R#E3@91@5; R,@$?AY^UA^Q3X]_
M9-\0%-;MO[8\*7,A33_$ME&?LT_4A)!R89<#E&/.#M+ $U\]444444444444
M44444444444444445<TS5;W1KV.\T^[GL+N,[DN+:1HW4^H92"/PKWSX>?\
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M_E"U<OJ?_!<;5I,_V?\ "&RMO3[3K[S?^@VZ5QFM?\%L/BO<9&E>"?!]@/\
MIZ2ZN&'Y3(/TK@M>_P""NG[0VL*WV35=!T0MT-AH\;E?IYQD_6O-?$'_  4*
M_:*\3;OM?Q6UF'=U_L]8;+\O)C3'X5Y3XH^-'Q!\;;QXB\=>)->#=1J6K7%P
M#^#N:XRBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBM'0="U
M+Q1K-GI.CV%SJFJ7DHAMK*SB:6::0G 5$4$L3Z 5^K_[%/\ P2>M/#;6/C3X
MVVT.HZHI$MIX/#+);P$<AKM@2LK?],E)0?Q%LE5_3*"WCM88X88UBBC 5(T
M"J ,  #@ #M4U%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%5-6_Y!=[_ -<'_P#037\]5%?IC_P2
M;_Y)[X[_ .PK#_Z)-?=]%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?BW^WI_P G
M:?$#_KM:_P#I)!7@=?6'_!,G_DYR+_L#W?\ [)7ZX444444445^.?_!13_D[
M+Q9_U[V/_I+%7S77TM_P3I_Y.P\+?]>U]_Z2R5^Q5%%%%%%%%%%%%%%%%%%%
M%%%%%%%?SW^(O^1AU3_KZE_]#-9]?<W_  39^-/@?X3:7X^C\8>);+P^]]-9
M-;+=LP,H19PQ& >FY?S%?:G_  V5\%/^BCZ+_P!_&_\ B:/^&RO@I_T4?1?^
M_C?_ !-'_#97P4_Z*/HO_?QO_B:/^&RO@I_T4?1?^_C?_$T?\-E?!3_HH^B_
M]_&_^)H_X;*^"G_11]%_[^-_\33[3]K[X,WMU#;6_P 0]'EGF=8XXU=LLS'
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MOX-L^HL=+TUF'(@1@TSK[-(%7ZQ-ZU]]T4444445RGQ2^'VG_%;X=^(/".J
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MP8)%!)_WF _&OU:_X;%^"W_11]$_[^M_\31_PV+\%O\ HH^B?]_6_P#B:/\
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M]&([F]N+A,Y"RS,X_(FJE%:WA/PGK'CGQ%8:%H&GSZIJ]]*(;>UMUW.[']
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M$0UW_H":C_X"R?\ Q-'_  B&N_\ 0$U'_P !9/\ XFC_ (1#7?\ H":C_P"
MLG_Q-'_"(:[_ - 34?\ P%D_^)H_X1#7?^@)J/\ X"R?_$T?\(AKO_0$U'_P
M%D_^)H_X1#7?^@)J/_@+)_\ $T?\(AKO_0$U'_P%D_\ B:_83]@2SGL/V3/
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M%*A5E/H0>14%%%%%%%%%%%%%%%%%%%%%%%%%%:F@^%]9\57GV71=)OM8N?\
MGC86SSO_ -\J":]G\'?L(_'_ ,=-&-,^%/B&!7QA]5MQIRGWW7#(,>]>]>"?
M^"-?QL\0[)->U/PSX5@/WTGO'N9Q]%B1D/\ WV*^@? __!$?PG8M&_C#XE:Q
MJ_0M#HMA%9 >V^1IB1[[1^%?17@'_@F5^SOX!\N1? J>(;M/^7CQ!=RW>[ZQ
MEA%_XY7T/X3^'_ACP#9_9/#'AS2?#EK@#R-)L8K9,#MMC4"NAHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK'\0>$=#\6VWV;7
M=%T_6K?&/)U"U2=/IAU(KQSQ=^P?^S]XVWG4OA1X=B9\DMI=N=/)SWS;LAS[
MUX_XE_X)!?L^:[O^PVGB/P[NZ?V;JQ?;]/M"2_K7E/B7_@B%X1NM_P#PC_Q/
MUK3,_=_M/38;S'UV/#FO,->_X(B^.;?=_8OQ)\/:AC[OV^RGM<_7;YN/UKSG
M7O\ @CQ\?M'W?9#X6US'3[#JK+G_ +_1QUP&K_\ !,G]I31]S/\ #6:YC'1K
M35;&;/T59RWZ5Q6K?L2_'O1-WVGX1>+I,=?LFERW/Y>4&S7'ZA^S_P#%#221
M??#CQ=9;>OVC0KJ/'YQBN9U#P;KVDY^W:'J5D!U^T6DB8_-16.00<'K11111
M14D-O)</MBB>5O[J*6/Z5N:?\/?%.K,%L/#6L7I/06]A*Y_1375Z;^S+\7]8
MP;#X5>-;Q3T:'P]=LOYB/%==I'["/[06N,!;_";Q+%G_ )_+3[-_Z-*UW>B_
M\$K_ -I/5MID\"0:8C?QWNLV0_,+*S#\J[_0?^"-'QRU-E:^U;P?HR?Q"XU&
M>1_P$<# G\17I7A[_@A[KMQM.N?%?3['^\NGZ-)<_@"\L?YX_"O3_#7_  1-
M^&]FRMK_ (^\4:KC[PT^.WLP3_P))3C\?QKUKPQ_P2A_9S\.A3=>%=0\02+T
M?5-8N.3ZE8FC4_0C%>O>%?V._@?X+V-I/PI\)Q2I]V:XTJ*YE7W#RJS _C7K
M&FZ39:+:K:Z?9V]A:K]V&VB6-%^BJ !5RBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
MBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBJEQIMG>?\?%K#/\
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C%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>picture16.jpg
<TEXT>
begin 644 picture16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %# BD# 2(  A$! Q$!_\0
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M/AMH?PYU?0-4T.Y\9^$HK^SDM=0\TV-U;W,K/\K ;D<9ZXYZ5U?C'X._%#Q
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M_B"#0(=0DDN);J^5XA&0^"5\PY'([5]BV,E]IMYXRTM]#U)VU._FEM[J.%3
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MQIUI=S133VL,TT)S'))&&9#Z@D<?A47]N:?_ ,_D/_?8H_MS3_\ G\A_[[%
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M9>_]B%#_ .G"2O::\6M_^3S+W_L0H?\ TX24 >TT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4457NM0M;$J+FYAMRWW?-D"Y^F30!8HJ*VNH+R/S+>:.>
M/.-T;!AGTR*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G?&
MWC:Q\$:4;JZ/F3OD06ZGYI&_H/4U\Q>)/$E]XJU:74-0E\R9^%4?=C7LJCL*
M]U\2?!=?%6K2ZAJ&O74DK\*HC7;&O95'85X?XPT)/#/B:^TN*5ITMW"B1P 3
MD \_G7EXGVCW5D>=B.=[[&-70>"_&E]X)U9;NT.^%L">W8_+*O\ 0^AJRWPR
M\0K9RW7V6%H(4\R1EN4.U<9R<'TI/ASX0A\<>(&TZ:YDM4$#3>9&H)R"HQS]
M:Y8QG&2MHSGC&2DK;GTKX9\36/BS28K^PEWQMPR'[T;=U8=C6M7 >#?A/_PA
M.J?:[+6[EXW&)K=XUV2CW]QZUW]>W!R:]Y:GK0<FO>6H4445984444 %>"^+
MOV:]3O-9AU+0?'6N64UUXG@U[4!.UNV50$;$8PEL(NU41B5 %>]44 1LCB J
MDG[S;@2.,\XZD#&:^>?".G>)[']KW4X]?UW3M7O&\#0F.:QTIK-$3[?)\I1I
MY"QSGG<.O2OHJO%K?_D\R]_[$*'_ -.$E 'KWDWO_/S#_P!^#_\ %4>3>_\
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MP_\ ?@__ !5'DWO_ #\P_P#?@_\ Q56Z* *GDWO_ #\P_P#?@_\ Q5'DWO\
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M^#_\55NBL30J>3>_\_,/_?@__%4>3>_\_,/_ 'X/_P 55NB@"IY-[_S\P_\
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M_M[3_P#G[C_.C^WM/_Y^X_SJ_M'I1M'I0!0_M[3_ /G[C_.C^WM/_P"?N/\
M.K^T>E&T>E %#^WM/_Y^X_SH_M[3_P#G[C_.K^T>E&T>E %#^WM/_P"?N/\
M.O@G_@I1>P7OB[P.T$JRA;&YSM/3]XE?H+M'I7P!_P %,/\ D;_ W_7C<_\
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MGS1U]^;1Z5\$_P#!3/\ Y#O@+_KWN_\ T*.NK#?Q485OX;/3_P#@GOJEI9_
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M'? 7_7O=_P#H4=?>U?!/_!33_D.^ O\ KWN__0HZZL-_%1A6_AL]8_X)W?\
M)OK_ /89NOY1U]/5\P_\$[O^3?7_ .PS=?RCKZ>K.M_$D73^!!1116)H?CU\
M>O\ DXCQM_V,$G_HP5^OFF_\@VT_ZY)_Z"*_(/X]?\G$>-O^Q@D_]&"OU\TW
M_D&VG_7)/_017H8KX8?UV.2A\4BS1117GG6>5?M4?\F[^/?^P8_\Q7PS_P $
M^/\ DX>'_L$W7\TK[F_:H_Y-W\>_]@Q_YBOAG_@GQ_R</#_V";K^:5Z%'^!,
MY*G\6)^G=%%%>>=85\'?\%-?^0E\/_\ KG>?SBK[QKX._P""FO\ R$OA_P#]
M<[S^<5=6&_BHPK?PV>I_\$[_ /D@#_\ 87N?_9*\Q^-G_)4O%/\ U]-_Z"*]
M._X)W_\ ) '_ .PO<_\ LE>8_&S_ )*EXI_Z^F_]!%=U#^/,Y:W\*)]NZ#_R
M ]._Z]H__015^J&@_P#(#T[_ *]H_P#T$5?KR'N>@M@KY8^*W_)1-9[?O5Y_
MX"M?4]?+'Q6_Y*)K/_75?_05KAQ?P(Y,3\*.SEWW?A>^U:+5M#-PL'V:;5A:
M2I/(-N-@)X+D<9 S6/\  '_D>G[?Z%)_Z$E:MY-?7OAEVUW2=%TNSL;;]S#(
MK-.FX84K$I^4DX^8UE? '_D>G_Z\I/\ T)*Y_P#EY Q^W$^C****]4](*_/#
MQ9-^S.OQR\<CQ'>ZTA4 RNMW<B)[SS'\Y$5!O!!QU)7GY:_0^OD?XR_$^Y\'
M_M$>3:WWA_PI8V@TU=1>^M(S<ZQ#,926,C8Q#"5P=O.6/(K2!+/<_P!GF_L=
M4^"_A2YTSPZWA/39+3-KI#%B8(MS!.6 )W##9//S<UZ+7G_P#\=:C\2O@_X7
M\3:M!%!J&HVOFR"!"D;?,P#HIY"L & /8UZ!4/<H*XC7_C/X2\+^(#H^I:A+
M;7"RQ02SM:3&V@DEP(UDF"[$+%@!ENXZ9KMZ\(^,/B+5?$GC%/"%YX1\3R>"
MK9H+J^OM,TX7 U60.'2W1@_[N)2JF1B,M]T<;C2 ]WKQ:W_Y/,O?^Q"A_P#3
MA)7LT@9HV"-L<@[6(S@]CBOGCP?I?B33_P!KS5(]>UVUUB[;P+ 8IK>P^S!%
M_M"3(*[VSWYSWH ^BJ*J>3=_\_*?]^O_ *]'DW?_ #\I_P!^O_KT 6Z*J>3=
M_P#/RG_?K_Z]'DW?_/RG_?K_ .O0!Y'^V1_R;/XZ_P"O6+_T?'7R#_P3E_Y+
MAJW_ &!)?_1L5?6W[845RO[-?CDO.KK]EBRHCQ_RWC]Z^1O^"=:R-\;M5$;B
M-O[%EY*Y_P"6L=>A2_W>9R5/XL3]***J>3=_\_*?]^O_ *]'DW?_ #\I_P!^
MO_KUYYUENO@#_@IC_P CAX&_Z\;G_P!&)7WIY-W_ ,_*?]^O_KU\#?\ !2I9
M5\7>!_-D$A^PW.,+C_EHE=6%_BHPK_ SW/\ X)_?\FZV7_81NO\ T,5](U\S
M_L"1W#?L[V1CF6-?[1NN"F?XQ[U]&^3=_P#/RG_?K_Z]9UOXDO4NG\"+=%5/
M)N_^?E/^_7_UZ/)N_P#GY3_OU_\ 7K$T+=%5/)N_^?E/^_7_ ->CR;O_ )^4
M_P"_7_UZ +=%5/)N_P#GY3_OU_\ 7H\F[_Y^4_[]?_7H \E_;$_Y-I\>?]>2
M_P#HU*^+_P#@GI_R<$W_ &"+C_T)*^R/VOXKE?V;/'9>=77[$N0(\?\ +5/>
MOC7_ ()\J[?'YQ&P1O[)N.2,]TKT*/\  F<E3^+$_3>BJGDW?_/RG_?K_P"O
M1Y-W_P _*?\ ?K_Z]>>=9;HJIY-W_P _*?\ ?K_Z]'DW?_/RG_?K_P"O0!;H
MJIY-W_S\I_WZ_P#KT>3=_P#/RG_?K_Z] %NBJGDW?_/RG_?K_P"O1Y-W_P _
M*?\ ?K_Z] 'X^_&G_DOGC/\ [&&X_P#1YK]AK+_CS@_ZYK_*OQX^,X8?'KQD
M&.YO^$@N,G&/^6QK]?;.&[^QP8N4'[M?^67L/>O0Q7PP..AO(T:*J>3=_P#/
MRG_?K_Z]'DW?_/RG_?K_ .O7GG86Z*J>3=_\_*?]^O\ Z]'DW?\ S\I_WZ_^
MO0!;HJIY-W_S\I_WZ_\ KT>3=_\ /RG_ 'Z_^O0!;KX)_P""FG_(=\!?]>]W
M_P"A1U]U^3=_\_*?]^O_ *]?!_\ P4M65=<\!^;()#]GNNBX_BCKJPW\5&%;
M^&SUW_@G=_R;Z_\ V&;K^4=?3U?+?_!/6.=OV?W,<RQK_;%UP4SVC]Z^F?)N
M_P#GY3_OU_\ 7K.M_$D73^!%NBJGDW?_ #\I_P!^O_KT>3=_\_*?]^O_ *]8
MFA^0OQZ_Y.(\;?\ 8P2?^C!7Z^:;_P @VT_ZY)_Z"*_('X[AA^T-XT#'<W_"
M0298#'_+05^NFFPW?]G6N+E!^Z3_ )9?[(]Z]#%?##^NQR4/BD:=%5/)N_\
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M:?\ \_4?ZT :%%9_]O:?_P _4?ZT?V]I_P#S]1_K0!Y5^V)_R;3X\_Z\E_\
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M ,D ?_L+W/\ [)7F/QL_Y*EXI_Z^F_\ 017=0_CS.6M_"B?;F@J/[#T[@?\
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M16<ENT:JTL@'F;U!S[#G% &_1110 44UF"*68X &2:\WT#XP7>O>$=1\3?\
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M!(Z&NSH ***YKQMXUC\'QZ;%'8S:IJ>IW/V2RL;=E0RR;&<Y9B%50JL23Z4
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MLYIEO+)DP24^3+D$';\P'/(ZYT];^$-_J'A?XA6$,EFM[XAU1+ZWF8'Y558
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M )**8945U0NH=NBYY-.9@JDDX Y)- "T4@8, 0<@]#2/(L>-[*N3@;CC)]*
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M9D0;2 V6'&>F: )**;)(L2EG944=68X%(LT;;,.IW?=P1S]* 'T444 %%%%
M!135=7SM8-M.#@]#Z4Z@ HIN]2Q7<-P&2N>:=0 44C,$4LQ"J!DD]!1G/(Y%
M "T444 %%%% !1110 444BL&S@@X.#CM0 M%%)N&2,\^E "T444 %%%-5ED4
M,I#*>A!R* '4444 %9FLV<MQ):2I"MTD+EFMV( ?(P#SQD>]:=9FN%Q';\S"
MV\S]\;<,7VX./N\XSC.* *HCO+2]$]OIJ[&MP@B655",&)Q^O:J/_"/:E%9W
M,.^"<W061SM( E#@L2">01Z8^[3KJ:Z_LNT:1KAIHMQ:$QR;I?[@9D'!QCVS
MUJQ9W-]9R>=<EQ:O+)OC:,DQ*%+ YZGD8].:!B6NA7$=PC31PLOG2NXC&U,%
M %PO;W]^:(?#C):Z5&%6'9$L5XL>,2*%S@^OS#KZ$^M+K\=V\C/9M,#);]5R
M5#>8F#CUP6_#-7K&\DQ<V]V6:6,N5*QE2\8Q\W'?G''I0!7U:UFN-2MBE@LD
M$>V1KA642%E.549Y [G\O6H]>M+_ %&%?*CDV26[+Y*S",I(1P6/<#D=ZIV,
M=])(J0RSI']J8B>1'(V%#@;7P1@X'/&:T)+R74-!?>SV]TNU9=D;Y4Y!(P.>
M0>W3- %1=-U;[80K>1 (2@=)2>0J[>,_W@>W>K4EC=ZAH6+A!]LED68QL>(C
MN!V@^P'YYJ@DVI[EG@22)([8XB9&<2,)2!][D97GUY%:>L#^T-/$MLTSODQQ
MB,LHW$[=S>RX)H ;JFGW\TE[);S,I9(UB3?A>#E^.Q(XS5+^S]7W0;6DR493
MYDORQ9W8Q@Y)Y'7/05/#]OT^Z=O,DEM1.L961"3LV#+[OJ/I4'B2:\FD@DLF
MF$30,R%%?ER1MQM'7&?O<<T )>:9J>K1L)HO)7*;5,P)&(Y%8Y'3)9:FMK?4
M;.YMY1;2/"D"JT33 [2%QA>>23CK^=+9W5[87,LET[FS:XFR&C)\M0?E(/7!
MHU!;Y==A^SR.X:2,E</M6/\ C'3;TR>N<XH DU'2[G^U)+^V4M(%B  DQN57
M)9>>!D5%_9E_<^3+.BB3.6!D!('G;@,^RXJ3PZVH0P0QW9>53;!\M'AE;.-N
M>_&.M5;/4M7OI5B"R6Z-)S-)!RJ^6QQCI]X 9]Z +&K6NJS:HKVOR0CC>)<?
M+M.01GKG';\:CN-,U.&VDB@9YE<1GYYSN#8;>0<COM[XZU%=7VIW"P(RRPN6
MMSY<<#$."RF0EOX<<C![#OFK6J)<1WLQ4W'V5_),OE[B0N7W;<<Y^[G'.* *
M\>GZM;KN#?OKB14F8,,!3$@,GU!4_7-*NGZK]HD ,@A\QF$AE!D(*.!CDC@E
M<=/>HH9-6A\V>,S-'''F..6,LTJ^8=H/<';^/3-7-8%['JPN(3*8HX% 54+*
MI9\,V!U(7G'M0 +9ZBV@F%E9+D2<+'+DLN1]XD]^<X/TJDVDZQ=+<1W#[5EA
M91LE.T I@(><Y#<YQ^-:6E76H75]B;*VBQDJS0E3*=Q )S]W@=/QJ#[;J\<+
MRE/,+B7;'Y)'E[9 %/O\N3COCB@"V\=S<:3-;0Q2VDRHJJQD!/0$X;GIZTP:
M5>?O8TNFCB6;=$79F.PJO&00?O;NN:K0WVJ2S-M#-;QQ2NDCVY5IF&W:"#TY
M)[<XIT5QK$<H,C>:BM#E1!C=O.'Y_P!GK_.@"0Z#']IN)S9PN(T"V\1QAC]X
ML?JV/RI)/#Y_LNPME +PSK-(0=H+9)8\=>3TJM97^HWVH0++#.D*SALM&5P"
MD@(/J =OYBEN;B_M+J[DCC<J'E*NX)"KB'!'.#_&<>QH (=,U21%1WFB7?%Y
MI^T9+X)WL".@(QQ_*M*1+F#6FFCMC-#)"D98.!M(9B<@^S"L6"^U+4+AY;:X
M9HX%G59/(P)"/+*@CUSGWZ]*U=/O9H[^Z6[DE DD001M$0HR@) 8#GG/4]J
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9** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
